<SEC-DOCUMENT>0001641172-25-000632.txt : 20250325
<SEC-HEADER>0001641172-25-000632.hdr.sgml : 20250325
<ACCEPTANCE-DATETIME>20250325172319
ACCESSION NUMBER:		0001641172-25-000632
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		101
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250325
DATE AS OF CHANGE:		20250325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanara MedTech Inc.
		CENTRAL INDEX KEY:			0000714256
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				592220004
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39678
		FILM NUMBER:		25769388

	BUSINESS ADDRESS:	
		STREET 1:		1200 SUMMIT AVE
		STREET 2:		SUITE 414
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76102
		BUSINESS PHONE:		817-529-2300

	MAIL ADDRESS:	
		STREET 1:		1200 SUMMIT AVE
		STREET 2:		SUITE 414
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WOUND MANAGEMENT TECHNOLOGIES, INC.
		DATE OF NAME CHANGE:	20080611

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MB SOFTWARE CORP
		DATE OF NAME CHANGE:	19960805

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INAV TRAVEL CORPORATION
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:SMTI="http://sanaramedtech.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_034_SMTI_sanaramedtech.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0000714256 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_064_Integer_5_Integer -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0000714256</ix:nonNumeric>
  <ix:nonFraction name="SMTI:RoyaltyReceivable" contextRef="AsOf2024-12-31" id="xdx2ixbrl0076" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0083" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0136" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0139" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0169" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0170" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0369" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:BackendFee" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:AccruedInterestIncomeExpense" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireLoansReceivable" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0569" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_us-gaap_RoyaltyMember" id="xdx2ixbrl0590" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2024-12-31_srt_MinimumMember" id="xdx2ixbrl0628" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P2Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_InternalUseSoftwareMember" id="xdx2ixbrl0662" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0688" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0690" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0792" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0798" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="AsOf2023-12-31_custom_ChemoMouthPieceLLCMember" id="xdx2ixbrl0902" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:EquityMethodInvestmentsEconomicInterest" contextRef="AsOf2023-12-31_custom_ChemoMouthPieceLLCMember" id="xdx2ixbrl0904" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="AsOf2023-12-31_custom_SIHealthcareTechnologiesLLCMember" id="xdx2ixbrl0910" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:EquityMethodInvestmentsEconomicInterest" contextRef="AsOf2023-12-31_custom_SIHealthcareTechnologiesLLCMember" id="xdx2ixbrl0912" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="AsOf2023-12-31" id="xdx2ixbrl0916" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2023-01-012023-12-31_custom_ChemoMouthPieceLLCMember" id="xdx2ixbrl0935" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2023-01-012023-12-31_custom_SIHealthcareTechnologiesLLCMember" id="xdx2ixbrl0938" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0941" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0944" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-12-31_custom_CRGTermLoanMember" id="xdx2ixbrl1055" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-12-31_custom_PaidInKindInterestMember" id="xdx2ixbrl1058" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-12-31_custom_BackendFeeMember" id="xdx2ixbrl1061" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-12-31_custom_CadenceTermLoanMember" id="xdx2ixbrl1063" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl1075" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="AsOf2024-12-31" id="xdx2ixbrl1083" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="AsOf2024-12-31" id="xdx2ixbrl1085" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="AsOf2024-12-31" id="xdx2ixbrl1087" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="AsOf2024-12-31" id="xdx2ixbrl1089" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextRef="AsOf2024-12-31" id="xdx2ixbrl1093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1307" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1309" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1315" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1317" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1319" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1321" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1345" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1347" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1351" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1353" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1355" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1357" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1359" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31" id="xdx2ixbrl1361" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="xdx2ixbrl1363" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1365" name="SMTI:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2" xs:nil="true"></ix:nonNumeric>
  <ix:nonFraction name="SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2024-12-31" id="xdx2ixbrl1367" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="xdx2ixbrl1369" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1371" name="SMTI:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" xs:nil="true"></ix:nonNumeric>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="AsOf2024-12-31" id="xdx2ixbrl1434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:IncomeTaxReconciliationIncomeTaxExpenseIntangibles" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_THPMember" id="xdx2ixbrl1505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-012024-12-31_custom_THPMember" id="xdx2ixbrl1512" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2024-01-012024-12-31_custom_THPMember" id="xdx2ixbrl1547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2023-01-012023-12-31_custom_THPMember" id="xdx2ixbrl1550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-12-31_custom_THPMember" id="xdx2ixbrl1577" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31_custom_THPMember" id="xdx2ixbrl1580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2024-01-012024-12-31_custom_THPMember" id="xdx2ixbrl1584" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="xdx2ixbrl1586" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2023-01-012023-12-31_custom_THPMember" id="xdx2ixbrl1587" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1588" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2024-01-012024-12-31_custom_THPMember" id="xdx2ixbrl1612" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="xdx2ixbrl1614" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2023-01-012023-12-31_custom_THPMember" id="xdx2ixbrl1615" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1616" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:ExecutiveSeparationCosts" contextRef="From2024-01-012024-12-31_custom_THPMember" id="xdx2ixbrl1619" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:ExecutiveSeparationCosts" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="xdx2ixbrl1621" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:ExecutiveSeparationCosts" contextRef="From2023-01-012023-12-31_custom_THPMember" id="xdx2ixbrl1622" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SMTI:ExecutiveSeparationCosts" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1623" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2023-01-012023-12-31_custom_THPMember" id="xdx2ixbrl1629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="smti-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_UnvestedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SMTI:UnvestedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_UnvestedRestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SMTI:UnvestedRestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SoftTissueRepairProductsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SMTI:SoftTissueRepairProductsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SoftTissueRepairProductsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SMTI:SoftTissueRepairProductsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BoneFusionProductsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SMTI:BoneFusionProductsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BoneFusionProductsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SMTI:BoneFusionProductsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RoyaltyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RoyaltyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_InternalUseSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SMTI:InternalUseSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_InternalUseSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SMTI:InternalUseSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_InternalUseSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SMTI:InternalUseSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:AppliedAssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember_custom_CashClosingConsiderationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:AppliedAssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">SMTI:CashClosingConsiderationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember_custom_StockClosingConsiderationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:AppliedAssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">SMTI:StockClosingConsiderationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-01_custom_AppliedAssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:AppliedAssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-08-31_custom_AppliedAssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:AppliedAssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AppliedAssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:AppliedAssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AppliedAssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SMTI:AppliedAssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_us-gaap_ConvertibleDebtMember_us-gaap_ExtendedMaturityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LoanRestructuringModificationAxis">us-gaap:ExtendedMaturityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-01_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CustomerRelationshipsAndOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">SMTI:CustomerRelationshipsAndOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CustomerRelationshipsAndOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">SMTI:CustomerRelationshipsAndOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AmortizableIntangibleAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">SMTI:AmortizableIntangibleAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AmortizableIntangibleAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">SMTI:AmortizableIntangibleAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SMTI:SeriesBTwoPreferredSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SMTI:SeriesBTwoPreferredSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember32609109">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SMTI:SeriesBTwoPreferredSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SMTI:SeriesBTwoPreferredSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-012022-03-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SMTI:SeriesBTwoPreferredSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_DirectDermatologyIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_ClassAPreferredSharesMember_custom_PixalereHealthcareIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SMTI:ClassAPreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:PixalereHealthcareIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-30_custom_ClassAPreferredSharesMember_custom_PixalereHealthcareIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SMTI:ClassAPreferredSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:PixalereHealthcareIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_PixalereHealthcareUSALLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">SMTI:PixalereHealthcareUSALLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-012024-09-30_custom_CommonUnitsMember_custom_ChemoMouthPieceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SMTI:CommonUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_CommonUnitsMember_custom_ChemoMouthPieceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SMTI:CommonUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_ChemoMouthPieceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ChemoMouthPieceLLCMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ChemoMouthPieceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ChemoMouthPieceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SIHealthcareTechnologiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:SIHealthcareTechnologiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SIHealthcareTechnologiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:SIHealthcareTechnologiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_DirectDermatologyIncMember32609359">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_DirectDermatologyIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PixalereHealthcareIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:PixalereHealthcareIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PixalereHealthcareIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:PixalereHealthcareIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ChemoMouthPieceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ChemoMouthPieceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SIHealthcareTechnologiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:SIHealthcareTechnologiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SIHealthcareTechnologiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:SIHealthcareTechnologiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_OfficeSpaceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SMTI:OfficeSpaceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_OfficeSpaceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SMTI:OfficeSpaceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-17_custom_CRGTermLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CRGTermLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CRGTermLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-04_custom_CRGTermLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-042024-09-04_custom_CRGTermLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-04</xbrli:startDate>
        <xbrli:endDate>2024-09-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-172024-04-17_custom_CRGTermLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-17</xbrli:startDate>
        <xbrli:endDate>2024-04-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CRGTermLoanAgreementMember_custom_BackendFeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:BackendFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-01_custom_CadenceTermLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CadenceTermLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CadenceTermLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CadenceTermLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CadenceTermLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CadenceTermLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CRGTermLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:CRGTermLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CadenceTermLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:CadenceTermLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CRGTermLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:CRGTermLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PaidInKindInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:PaidInKindInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PaidInKindInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:PaidInKindInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_BackendFeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:BackendFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_BackendFeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:BackendFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CadenceTermLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:CadenceTermLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CadenceTermLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:CadenceTermLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-262018-08-27_custom_SubLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:SubLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-26</xbrli:startDate>
        <xbrli:endDate>2018-08-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-07-31_custom_BIAKOSLicenseAgreementMember_custom_RochalIndustriesLLCMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:BIAKOSLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:RochalIndustriesLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-07-31_custom_BIAKOSLicenseAgreementMember_custom_RochalIndustriesLLCMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:BIAKOSLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:RochalIndustriesLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_BIAKOSLicenseAgreementMember_custom_RochalIndustriesLLCMember_srt_MaximumMember_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:BIAKOSLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:RochalIndustriesLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-07-31_custom_BIAKOSAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:BIAKOSAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BIAKOSLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:BIAKOSLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BIAKOSLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:BIAKOSLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ABFLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ABFLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ABFLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MaximumMember_us-gaap_ProductAndServiceOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ABFLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-31_custom_RochalMember_custom_DebriderLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SMTI:RochalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:DebriderLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:DebriderLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-01</xbrli:startDate>
        <xbrli:endDate>2020-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:DebriderLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-01</xbrli:startDate>
        <xbrli:endDate>2020-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:DebriderLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-01</xbrli:startDate>
        <xbrli:endDate>2020-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:PrecisionHealingMergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember_custom_AccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:PrecisionHealingMergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SMTI:AccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-04_custom_PrecisionHealingMergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:PrecisionHealingMergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:PrecisionHealingMergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:PrecisionHealingMergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SMTI:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:PrecisionHealingMergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-07-31_custom_ScendiaPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ScendiaPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_ScendiaPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ScendiaPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-08-31_custom_ScendiaPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ScendiaPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-10-31_custom_ScendiaPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ScendiaPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-08-01_custom_ServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-202023-12-20_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-20</xbrli:startDate>
        <xbrli:endDate>2023-12-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-202023-12-20_custom_LicenseAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-20</xbrli:startDate>
        <xbrli:endDate>2023-12-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-202023-12-20_custom_LicenseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-20</xbrli:startDate>
        <xbrli:endDate>2023-12-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-01_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-01_custom_LicenseAgreementMember_us-gaap_RoyaltyAgreementTermsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-12_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SMTI:TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-312024-12-31_custom_TwoThousandFourteenOmnibusLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SMTI:TwoThousandFourteenOmnibusLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-31</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-312024-12-31_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SMTI:TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-31</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SMTI:TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012023-02-28_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2023-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SalesAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_PrecisionHealingIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">SMTI:PrecisionHealingIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_AccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SMTI:AccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_PrecisionHealingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:PrecisionHealingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-04_custom_NonaccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SMTI:NonaccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30_custom_PrecisionHealingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:PrecisionHealingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandFourteenOmnibusLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SMTI:TwoThousandFourteenOmnibusLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SMTI:TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SMTI:NoCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SMTI:NoCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SMTI:NoCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SMTI:NoCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-07-31_custom_ConsultingAgreementMember_custom_MsSalamoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SMTI:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SMTI:MsSalamoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SanaraSurgicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SMTI:SanaraSurgicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_THPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SMTI:THPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SanaraSurgicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SMTI:SanaraSurgicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_THPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SMTI:THPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-162025-01-16_us-gaap_SubsequentEventMember_custom_SubscriptionAndShareholdersAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:SubscriptionAndShareholdersAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-16</xbrli:startDate>
        <xbrli:endDate>2025-01-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-162025-01-16_us-gaap_SubsequentEventMember_custom_SubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:SubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-16</xbrli:startDate>
        <xbrli:endDate>2025-01-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-192025-03-19_us-gaap_SubsequentEventMember_custom_CRGTermLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-19</xbrli:startDate>
        <xbrli:endDate>2025-03-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>SMTI:Integer</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000566" toRefs="Footnote000577"/>
  <ix:relationship fromRefs="Fact000567" toRefs="Footnote000577"/>
  <ix:relationship fromRefs="xdx2ixbrl0569" toRefs="Footnote000578"/>
  <ix:relationship fromRefs="Fact000570" toRefs="Footnote000578"/>
  <ix:relationship fromRefs="Fact001590" toRefs="Footnote001638"/>
  <ix:relationship fromRefs="Fact001591" toRefs="Footnote001638"/>
  <ix:relationship fromRefs="Fact001592" toRefs="Footnote001638"/>
  <ix:relationship fromRefs="Fact001593" toRefs="Footnote001638"/>
  <ix:relationship fromRefs="Fact001594" toRefs="Footnote001638"/>
  <ix:relationship fromRefs="Fact001595" toRefs="Footnote001638"/>
  <ix:relationship fromRefs="Fact001618" toRefs="Footnote001641"/>
  <ix:relationship fromRefs="xdx2ixbrl1619" toRefs="Footnote001641"/>
  <ix:relationship fromRefs="Fact001620" toRefs="Footnote001641"/>
  <ix:relationship fromRefs="xdx2ixbrl1621" toRefs="Footnote001641"/>
  <ix:relationship fromRefs="xdx2ixbrl1622" toRefs="Footnote001641"/>
  <ix:relationship fromRefs="xdx2ixbrl1623" toRefs="Footnote001641"/>
  <ix:relationship fromRefs="Fact001625" toRefs="Footnote001644"/>
  <ix:relationship fromRefs="Fact001626" toRefs="Footnote001644"/>
  <ix:relationship fromRefs="Fact001627" toRefs="Footnote001644"/>
  <ix:relationship fromRefs="Fact001628" toRefs="Footnote001644"/>
  <ix:relationship fromRefs="xdx2ixbrl1629" toRefs="Footnote001644"/>
  <ix:relationship fromRefs="Fact001630" toRefs="Footnote001644"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 12pt"><b>Washington, D.C.
20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_90F_edei--DocumentType_c20240101__20241231_ztnzilVqVDk1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000012" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--DocumentAnnualReport_c20240101__20241231_z6cvPUTSQWPi"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000013" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">ANNUAL
                                            REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the fiscal year ended <span id="xdx_904_edei--DocumentPeriodEndDate_c20240101__20241231_zlxTkd1ukNz6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000014" name="dei:DocumentPeriodEndDate"><span id="xdx_90E_edei--CurrentFiscalYearEndDate_c20240101__20241231_zxjeccETmMYe"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000015" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90E_edei--DocumentFiscalYearFocus_c20240101__20241231_zEjY0T47pIUd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000016" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>or</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--DocumentTransitionReport_c20240101__20241231_zSc3vCTH9arf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000017" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">TRANSITION
                                            REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from ________ to ________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Commission File Number <span id="xdx_901_edei--EntityFileNumber_c20240101__20241231_z1V1j71kbxm9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000018" name="dei:EntityFileNumber">001-39678</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_908_edei--EntityRegistrantName_c20240101__20241231_zjg1gCOf4x54"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000019" name="dei:EntityRegistrantName">SANARA MEDTECH INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of Registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 49%; padding-right: 2.65pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;<span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20240101__20241231_zVztP59gGaG"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityIncorporationStateCountryCode">Texas</ix:nonNumeric></span></p></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20240101__20241231_zaLa3lQ79jy4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityTaxIdentificationNumber">59-2219994</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">(State or other jurisdiction
    of</span></td>
    <td>&#160;</td>
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">(I.R.S. Employer </span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">incorporation or organization)</span></td>
    <td>&#160;</td>
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 100%; padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_edei--EntityAddressAddressLine1_c20240101__20241231_zzVmd9bRDgrb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000022" name="dei:EntityAddressAddressLine1">1200
    Summit Ave</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20240101__20241231_zR8gC3OYD4d2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000023" name="dei:EntityAddressAddressLine2">Suite 414</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressCityOrTown_c20240101__20241231_zaR22ohHojZ9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000024" name="dei:EntityAddressCityOrTown">Fort Worth</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20240101__20241231_zcfOLXjRO008"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000025" name="dei:EntityAddressStateOrProvince">Texas</ix:nonNumeric></span> <span id="xdx_902_edei--EntityAddressPostalZipCode_c20240101__20241231_zWudkCUVgSD5"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:EntityAddressPostalZipCode">76102</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_906_edei--CityAreaCode_c20240101__20241231_zgFZfJp4NaVf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:CityAreaCode">(817)</ix:nonNumeric></span> <span id="xdx_903_edei--LocalPhoneNumber_c20240101__20241231_z67UNoFT0aGk"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000028" name="dei:LocalPhoneNumber">529-2300</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&#8217;s telephone number, including area
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Securities registered pursuant to Section 12(b)
of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 36%; padding-right: 2.65pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;Title of each class</b></p></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 24%; padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 36%; padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_edei--Security12bTitle_c20240101__20241231_zezmQwfrs2v2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000029" name="dei:Security12bTitle">Common Stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_908_edei--TradingSymbol_c20240101__20241231_zqKfyqPLszFa"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000030" name="dei:TradingSymbol">SMTI</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">The <span id="xdx_90C_edei--SecurityExchangeName_c20240101__20241231_zuWiNrtmGyGd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Securities registered pursuant to Section 12(g)
of the Exchange Act:</b> None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#9744;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#9744;
Yes &#9746; <span id="xdx_905_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_zzllSTLg0Kh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000032" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. &#9744; Yes &#9746;
<span id="xdx_908_edei--EntityVoluntaryFilers_c20240101__20241231_znIbdUvFSxR3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000033" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. &#9746;<span id="xdx_901_edei--EntityCurrentReportingStatus_c20240101__20241231_zezFxQDbHQ4j"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000034" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>  &#9744; No</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). &#9746; <span id="xdx_907_edei--EntityInteractiveDataCurrent_c20240101__20241231_zuE9dwGqDt8l"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000035" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9744; No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif">Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company
or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 20%; padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="width: 20%; padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="width: 20%; padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityFilerCategory_c20240101__20241231_zgdEQ1Cjw5Fl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000036" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="width: 20%; padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="width: 20%; padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center">&#9744;</td>
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center">&#9744;</td>
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center">&#9746;</td>
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span id="xdx_900_edei--EntitySmallBusiness_c20240101__20241231_z1cpkAumPNi3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000037" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></td>
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span id="xdx_902_edei--EntityEmergingGrowthCompany_c20240101__20241231_zgOwcCmTOtwl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_90B_edei--IcfrAuditorAttestationFlag_c20240101__20241231_zCOM5VqMnSt8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000039" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_902_edei--DocumentFinStmtErrorCorrectionFlag_c20240101__20241231_zomPYhX4O3gf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000040" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <span id="xdx_90E_edei--EntityShellCompany_dbF_c20240101__20241231_ztUJCte8GEkc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000041" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June&#160;28, 2024 (the
last business day of the registrant&#8217;s most recently completed second fiscal quarter), based on the $28.22 closing price as of such
date, was approximately $<span id="xdx_908_edei--EntityPublicFloat_iI_c20240628_zuAAKhnq3fI5"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-28" id="Fact000042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">118,175,765</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of March&#160;18, 2025, <span id="xdx_905_edei--EntityCommonStockSharesOutstanding_iI_pid_c20250318_zJNZkDdmgal2"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-03-18" id="Fact000043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,901,903</ix:nonFraction></span> shares of the Issuer&#8217;s common stock, $<span id="xdx_90B_edei--EntityListingParValuePerShare_c20240101__20241231_zGrOcWyK87Y9"><ix:nonFraction name="dei:EntityListingParValuePerShare" contextRef="From2024-01-01to2024-12-31" id="Fact000044" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> par value per share, were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">DOCUMENTS
INCORPORATED BY REFERENCE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--DocumentsIncorporatedByReferenceTextBlock_c20240101__20241231_zs7yCpivtweb" title="Documents Incorporated By Reference"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000046" name="dei:DocumentsIncorporatedByReferenceTextBlock">The
information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated by reference
to the registrant&#8217;s Definitive Proxy Statement on Schedule 14A relating to the 2025 Annual Meeting of Shareholders which will be
filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Annual Report on Form
10-K relates.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"/><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="TOC01"></span>SANARA MEDTECH INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Form 10-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Year Ended December 31, 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 0.75in; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 0.5in; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section4"><span style="font-size: 10pt"><b>PART
    I.</b></span></a></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 1</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section5"><span style="font-size: 10pt">BUSINESS</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">4</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 1A</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section6"><span style="font-size: 10pt">RISK FACTORS</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">18</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 1B</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section7"><span style="font-size: 10pt">UNRESOLVED
    STAFF COMMENTS</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">39</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 1C</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section8"><span style="font-size: 10pt">CYBERSECURITY</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">40</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 2</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section9"><span style="font-size: 10pt">PROPERTIES</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">40</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 3</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#section10"><span style="font-size: 10pt">LEGAL PROCEEDINGS</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">40</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 4</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section11"><span style="font-size: 10pt">MINE SAFETY
    DISCLOSURES</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">40</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section12"><span style="font-size: 10pt"><b>PART II.</b></span></a></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 5</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section13"><span style="font-size: 10pt">MARKET
    FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">41</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 6</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section14"><span style="font-size: 10pt">RESERVED</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">41</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 7</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section15"><span style="font-size: 10pt">MANAGEMENT&#8217;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">42</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 7A</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section25"><span style="font-size: 10pt">QUANTITATIVE
    AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">55</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 8</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section26"><span style="font-size: 10pt">FINANCIAL
    STATEMENTS AND SUPPLEMENTARY DATA</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 9</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section49"><span style="font-size: 10pt">CHANGES
    IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">56</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 9A</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section50"><span style="font-size: 10pt">CONTROLS
    AND PROCEDURES</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">56</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 9B</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section51"><span style="font-size: 10pt">OTHER INFORMATION</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">56</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 9C</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section52"><span style="font-size: 10pt">DISCLOSURE
    REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">56</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section53"><span style="font-size: 10pt"><b>PART III.</b></span></a></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 10</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section54"><span style="font-size: 10pt">DIRECTORS,
    EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">57</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 11</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section55"><span style="font-size: 10pt">EXECUTIVE
    COMPENSATION</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">57</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 12</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section56"><span style="font-size: 10pt">SECURITY
    OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">57</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 13</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt"><a href="#Section57">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">57</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 14</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section58"><span style="font-size: 10pt">PRINCIPAL
    ACCOUNTING FEES AND SERVICES</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">57</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section59"><span style="font-size: 10pt"><b>PART IV</b></span><span style="font-size: 10pt"><b>.</b></span></a></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 15</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section60"><span style="font-size: 10pt">EXHIBITS
    AND FINANCIAL STATEMENT SCHEDULES</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">58</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#160;</td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><span style="font-size: 10pt">ITEM 16</span></td>
    <td style="vertical-align: top; padding-right: 0pt; padding-left: 0pt"><a href="#Section61"><span style="font-size: 10pt">FORM 10-K
    SUMMARY</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">61</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Sanara, Sanara MedTech, our logo and our other
trademarks or service marks appearing in this report are the property of Sanara MedTech Inc. Trade names, trademarks and service marks
of other companies appearing in this report are the property of their respective owners. Solely for convenience, the trademarks, service
marks and trade names included in this report are without the &#174;, &#8482; or other applicable symbols, but such references are not
intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the
applicable licensors to these trademarks, service marks and trade names.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Unless otherwise indicated, &#8220;Sanara MedTech,&#8221;
&#8220;Sanara,&#8221; the &#8220;Company,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; or &#8220;we,&#8221; refer to Sanara MedTech Inc.
and its consolidated subsidiaries.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="Section3"></span>&#160;CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This report contains forward-looking statements within
the meaning of the federal securities laws. Forward-looking statements generally relate to future events or our future financial or operating
performance, including topics such as our value-based wound and skincare services and Tissue Health Plus platforms. In some cases, you
can identify forward-looking statements because they contain words such as &#8220;aims,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221;
&#8220;contemplates,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;forecast,&#8221;
&#8220;guidance,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221;
&#8220;predicts,&#8221; &#8220;preliminary,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;target,&#8221;
&#8220;will&#8221; or &#8220;would&#8221; or the negative of these words, variations of these words or other similar terms or expressions
that concern our expectations, strategy, plans, or intentions. Such forward-looking statements are subject to certain risks, uncertainties
and assumptions relating to factors that could cause actual results to differ materially from those anticipated in such statements, including,
without limitation, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">shortfalls in forecasted revenue growth;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">our ability to implement our value-based
                                            wound and skincare strategy through acquisitions and investments and our ability to realize
                                            the anticipated benefits of such acquisitions and investments;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">our ability to meet our future capital
                                            requirements;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">our ability to maintain compliance with
                                            our debt obligations;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">our ability to develop and commercialize
                                            new products and products under development, including the manufacturing, distribution, marketing
                                            and sale of such products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">our ability to retain and recruit key
                                            personnel;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">the intense competition in the markets
                                            in which we operate and our ability to compete within our markets;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">the failure of our products to obtain
                                            market acceptance;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">the effect of security breaches and other
                                            disruptions;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">our ability to maintain effective internal
                                            controls over financial reporting;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">our ability to maintain and further grow
                                            clinical acceptance and adoption of our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">the impact of competitors inventing products
                                            that are superior to ours;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">disruptions of, or changes in, our distribution
                                            model, consumer base or the supply of our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">the failure of third-party assessments
                                            to demonstrate desired outcomes in proposed endpoints;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">our ability to successfully expand into
                                            value-based wound, skincare and other services;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">our ability and the ability of our research
                                            and development partners to protect the proprietary rights to technologies used in certain
                                            of our products and the impact of any claim that we have infringed on intellectual property
                                            rights of others;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">our dependence on technologies and products
                                            that we license from third parties;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">the effects of current and future laws,
                                            rules, regulations and reimbursement policies relating to the labeling, marketing and sale
                                            of our products, and our planned launch of value-based wound, skincare and other services
                                            and our ability to comply with the various laws, rules and regulations applicable to our
                                            business; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in">&#9679;</td><td style="text-align: justify">the effect of defects, failures or quality
                                            issues associated with our products.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All forward-looking statements speak only as of the
date on which they are made. For a more detailed discussion of these and other factors that may affect our business, see the discussion
in &#8220;Item 1A. Risk Factors&#8221; and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results
of Operations&#8221; in this report. We caution that the foregoing list of factors is not exclusive, and new factors may emerge, or changes
to the foregoing factors may occur, that could impact our business. We do not undertake any obligation to update any forward-looking
statement, whether written or oral, relating to the matters discussed in this report, except to the extent required by applicable securities
laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="Section4"></span>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="Section5"></span>Item 1. BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a medical technology company focused on developing
and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic
wound and skincare markets. Our products, services and technologies are designed to achieve our goal of providing better clinical outcomes
at a lower overall cost for patients regardless of where they receive care. Through our two operating segments, Sanara Surgical and Tissue
Health Plus (&#8220;THP&#8221;), we strive to be one of the most innovative and comprehensive providers of effective surgical, wound
and skincare solutions and are continually seeking to expand our offerings for patients requiring treatments across the entire continuum
of care in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reportable Segments </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Historically, we managed our business on the basis
of one operating and reportable segment. During the second quarter of 2024, we changed our reportable segments to reflect a change in
the manner in which the business is managed. Based on the growing importance of the value-based wound care program to our future outlook
and how our chief operating decision maker, our Chief Executive Officer, reviews operating results and makes decisions about resource
allocation, we now have two reportable segments: Sanara Surgical and THP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Sanara Surgical</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Sanara Surgical segment primarily markets and
sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Sanara Surgical&#8217;s
soft tissue repair products include, among other products, our lead product, CellerateRX Surgical Activated Collagen (&#8220;CellerateRX
Surgical&#8221;), a hydrolyzed collagen that supports a local environment for surgical sites to aid in the natural wound healing process,
and BIASURGE Advanced Surgical Solution (&#8220;BIASURGE&#8221;), a sterile no-rinse, advanced surgical solution used for wound irrigation.
Sanara Surgical&#8217;s bone fusion products include, among other products, BiFORM Bioactive Moldable Matrix (&#8220;BiFORM&#8221;),
an osteoconductive, bioactive, porous implant that allows for bony ingrowth across the graft site, and ALLOCYTE Plus Advanced Viable
Bone Matrix (&#8220;ALLOCYTE Plus&#8221;), a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable
bone fibers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Sanara Surgical segment also includes an in-house
research and development team (Rochal Technologies) with an extensive pipeline of innovative products under development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Tissue Health Plus </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our THP segment is focused on value-based wound care
services. Through THP, we plan to offer a first of its kind value-based wound care program to payers and risk-bearing entities, such
as accountable care organizations and value-based primary care companies, with Medicare Advantage payers as the initial target market
for this program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">THP&#8217;s programs are expected to enable
payers to divest wound care spend risk, reduce wound related hospitalizations and improve patient quality of life. THP plans to
coordinate delivery of community and home-based wound care for its managed patients. Community based care spans a variety of
settings including physician offices, skilled nursing facilities, assisted living facilities and senior living facilities. THP
programs are intended to integrate science and evidence-based medicine protocols to standardize wound prevention and treatment. We
are preparing to launch our first pilot program with a wound care provider group during the second quarter of 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Summary of Our Product, Service and Technology
Offerings and Development Programs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sanara Surgical Products</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Sanara Surgical segment markets and distributes
surgical, wound and skincare products to physicians, hospitals, clinics, and post-acute care settings. Our products are primarily sold
in the U.S. surgical tissue repair and advanced wound care markets. We believe we have the ability to drive our product pipeline from
concept to preclinical and clinical development while meeting quality and regulatory requirements. We are constantly seeking long-term
strategic partnerships with a focus on products that improve outcomes at a lower overall cost.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>CellerateRX Surgical</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CellerateRX Surgical is a medical hydrolysate of
Type I bovine collagen indicated for the management of surgical, traumatic, and partial and full-thickness wounds as well as first-
and second-degree burns. It is manufactured with a proprietary process. CellerateRX Surgical powder is sterilized and packaged for use in the operating room or other sterile environment. CellerateRX Surgical products are primarily
purchased by hospitals and ambulatory surgical centers for use by surgeons on surgical wounds. The majority of CellerateRX Surgical
products are used for a variety of surgical wounds, including those associated with orthopedic, spine, trauma and oncologic
procedures. Additional surgical wounds that may benefit from the use of CellerateRX Surgical include cardiovascular, gynecologic,
urologic, vascular and plastic/reconstructive related procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CellerateRX Surgical is used in operative cases where
patients might have trouble healing normally due to underlying health complications. There is always a risk of complication with surgical
wounds. This is especially true in patients with certain comorbidities, including obesity, diabetes and hypertension. These complications
can include surgical wound infections, dehiscence (where an incision opens after primary closure) and necrosis. Surgeons use CellerateRX
Surgical to complement the body&#8217;s normal healing process. By supporting the body to heal normally without complications, improved
patient outcomes are achieved, thereby reducing downstream costs related to complications (such as re-operation, longer hospitalization,
re-admittance, extended rehabilitative care and other additional treatments). Surgical wound complications have become increasingly problematic
due to the high rates of surgical patient comorbidities and the financial strain on insurance payors as well as hospitals that suffer
exorbitant costs for readmission of these patients within 90 days of surgery.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>BIASURGE</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BIASURGE is a 510(k) cleared sterile no-rinse,
advanced surgical solution used for wound irrigation. It contains an antimicrobial preservative effective against a broad spectrum
of pathogenic microorganisms in the solution. BIASURGE is indicated for use in the mechanical cleansing and removal of debris, including
microorganisms, from surgical wounds. First sales of BIASURGE occurred in November 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>FORTIFY TRG</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FORTIFY TRG Tissue Repair Graft (&#8220;FORTIFY TRG&#8221;)
is a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet. The graft is 510(k) cleared for implantation to
reinforce soft tissue, is terminally sterilized, has a thin profile, is available in multiple sizes, and can be cut to size to accommodate
the patient&#8217;s anatomy. FORTIFY TRG is provided sterile and can be hydrated with autologous blood fluid. First sales of this product
occurred in the fourth quarter of 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>FORTIFY FLOWABLE</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FORTIFY FLOWABLE Extracellular Matrix (&#8220;FORTIFY
FLOWABLE&#8221;) is an advanced wound care device that presents small intestine submucosa extracellular matrix technology in a way that
can fill irregular wound shapes and depths. FORTIFY FLOWABLE is indicated for the management of wounds, including partial and full-thickness
wounds, pressure ulcers, venous leg ulcers, diabetic foot ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds
(donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence sites), traumatic wounds (abrasions, lacerations,
second-degree burns, and skin tears) and draining wounds. FORTIFY FLOWABLE is provided sterile and is intended for one-time use. It is
a 510(k) cleared product. First sales of this product occurred in the first quarter of 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Other Surgical Products</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TEXAGEN Amniotic Membrane Allograft is a multi-layer
amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement if needed. BiFORM is
an osteoconductive, bioactive, porous implant that allows for bony ingrowth across the graft site. It can be hydrated and used as a strip
or molded into a putty to fill a bone defect. ACTIGEN Verified Inductive Bone Matrix is a naturally derived, differentiated allograft
matrix with robust handling properties. ALLOCYTE Plus is a human allograft cellular bone matrices containing bone-derived progenitor
cells and conformable bone fibers. These viable cellular allografts are ready to use upon thawing and have fibrous handling properties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Tissue Health Plus Services and Technology</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through our subsidiary, Tissue Health Plus (formerly
known as &#8220;WounDerm&#8221; and &#8220;United Wound and Skin Solutions, LLC&#8221;), we are seeking to simplify skin health, starting
with wound care through a refined business plan. Through THP, we plan to offer a first of its kind value-based wound care program to
payers and risk-bearing entities such as accountable care organizations and value-based primary care companies, with Medicare Advantage
payers as the initial target segment for this program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">THP&#8217;s programs are expected to enable
payers to divest wound care spend risk, reduce wound related hospitalizations and improve patient quality of life. THP plans to
coordinate delivery of community and home-based wound care for its managed patients. Community based care spans a variety of
settings including physician offices, skilled nursing homes, assisted living facilities and senior living facilities. THP programs
are intended to integrate science and evidence-based medicine protocols to standardize wound prevention and treatment. THP services
are not expected to directly involve telemedicine or virtual consult services, and such services are no longer a primary focus of THP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We anticipate that THP&#8217;s customer contracts
will have three-to-five-year terms. These contracts are expected to incorporate a mix of value-based pricing methodologies including
episodic, &#8220;per member per month,&#8221; and &#8220;fee for value&#8221; pricing. We believe this approach is aligned with the financial
goals of the payers and will help deliver outstanding clinical outcomes for the patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our vision for our comprehensive approach consists
of three key sets of planned capabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(a)</td><td style="text-align: justify"><i>Care Hub</i> &#8211; This virtual
                                            patient monitoring, care coordination and navigation center is expected to help doctors and
                                            nurses support their patients throughout their wound care journey, from prevention to treatment.
                                            We expect to have Care Hub staffed by wound care certified nurse practitioners (&#8220;NPs&#8221;)
                                            and registered nurses (&#8220;RNs&#8221;), incorporating care delivery best practices from
                                            partnerships with Direct Dermatology Inc. and certain physician-led multispecialty wound
                                            care groups. With NPs leading Care Hub, RNs are expected to be the wound specialists, providing
                                            patients with expert review and support of the overarching plan of care on each patient&#8217;s
                                            journey through the process. In addition, care navigators are expected to serve as a primary
                                            point of contact for patients and their providers, coordinating care, managing appointments
                                            and ensuring seamless communication among all team members.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(b)</td><td style="text-align: justify"><i>Managed Services Organization (&#8220;MSO&#8221;)
                                            Network</i> &#8211; With respect to patient-side wound care, our plan is that THP&#8217;s
                                            programs would be performed by a network of third-party providers who will be contracted
                                            through managed services agreements. These providers would include podiatrists, wound care
                                            provider groups, primary care physicians, and home health agencies. The providers in the
                                            THP network are expected to leverage THP&#8217;s standard of care, patient education and
                                            tools to deliver optimal patient outcomes with high predictability and efficiency.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(c)</td><td style="text-align: justify"><i>Technology Platform</i> &#8211; THP&#8217;s
                                            technology platform will focus on scaling workflows of THP&#8217;s Care Hub and MSO Network
                                            through automation and integration. We expect the THP technology platform to enable enhanced
                                            patient empowerment and self-healthcare. We anticipate that our platform will leverage our
                                            technology investments and partnerships with Precision Healing Inc. (&#8220;Precision Healing&#8221;),
                                            Pixalere Healthcare, Inc. and others, by leveraging modern technology including artificial
                                            intelligence and machine learning. Our platform technology is expected to manage program
                                            economics, standards of care, patient monitoring, wound assessments, network performance
                                            monitoring, and revenue cycle management. We expect that each of these components will work
                                            in concert with each other, constantly improving economics and care delivery.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are seeking partners to facilitate commercialization
of THP and share in the cost of development of the program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>SI Healthcare Technologies Joint Venture</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2022, we established a 50/50 joint venture,
SI Healthcare Technologies, LLC (&#8220;SI Technologies&#8221;) (formerly known as SI Wound Care, LLC), with InfuSystem Holdings, Inc.
(&#8220;InfuSystem&#8221;) focused on delivering a complete wound care solution targeted at improving patient outcomes, lowering the
cost of care, and increasing patient and provider satisfaction. The partnership is expected to enable InfuSystem to offer innovative
products, including our advanced wound care product line and Chemo Mouthpiece, a 510(k) cleared oral cryotherapy device that SI Technologies
currently has the right to distribute and sell in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Tufts University License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, we signed an exclusive license
agreement with Tufts University (&#8220;Tufts&#8221;) to develop and commercialize patented technology covering 18 unique collagen peptides.
As part of this agreement, we formed a new subsidiary, Sanara Collagen Peptides, LLC (&#8220;SCP&#8221;) and issued 10% of SCP&#8217;s
outstanding units to Tufts. SCP has exclusive rights to develop and commercialize new products based on the licensed patents and patents
pending. SCP will pay royalties to Tufts based on net sales of licensed products and technologies. Pursuant to the exclusive license
agreement, royalties will be calculated at a rate of 1.5% or 3%, depending on the type of product or technology developed. SCP will pay
Tufts a minimum annual royalty of $50,000 on January 1 of the year following the first anniversary of the first commercial sale of the
licensed products or technologies. SCP will pay Tufts a $100,000 minimum annual royalty on January 1 of each subsequent year during the
royalty term specified in the exclusive license agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#9679; <i>Drive additional
market penetration as well as geographic expansion for our products</i>. We are actively working to expand our geographic footprint across
the entire United States. We also intend to leverage our comprehensive product, services and technology-based offerings portfolio and
relationships with key constituents to deepen our presence in the surgical, wound and skincare markets. We believe the breadth and flexibility
of the products we offer allow us to address a wide variety of surgical site needs, wound types and sizes and offer significant new opportunities
for sales growth. In addition, we believe that as we continue to offer new products, services and technology-based offerings, our salesforce&#8217;s
ability to reach additional customers in new and existing geographic regions while penetrating further in existing customer accounts
will be enhanced.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#9679; <i>Launch new
innovative products.</i> We are actively developing additional proprietary products for the surgical and chronic wound and skincare
markets. We expect these products and services to deepen our portfolio of technologies to improve surgical site outcomes and treat
chronic wounds. We are focused on offering additional products and services that are more efficacious than competing products and
services and provide a stronger value proposition (lower total cost to heal and less time to heal, leading to reduced costs to the
healthcare system).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#9679; <i>Seek and
establish partnerships and product, services and/or technology acquisitions</i>. We plan to continue to seek and establish
partnerships in the United States and internationally to provide innovative products, services and technologies. We believe that
partnerships will be a key driver of our growth in the future. We also intend to selectively pursue acquisitions of businesses and
technologies that complement our existing strategy and footprint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#9679; <i>Seek and
establish partnerships for THP with Medicare Advantage, at-risk payors and other types of healthcare at-risk models</i>. We believe
we have assembled the products, services and technologies to offer a comprehensive strategy to help improve outcomes and lower wound
care costs across the continuum of care. Looking ahead, we plan to leverage these capabilities to partner with value-based care
models to aid in the treatment of their wound care patients who currently are a significant cost for the healthcare system and
challenging population to heal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#9679; <i>Aid in the
treatment of patients throughout the entire continuum of care</i>. We intend to continue expanding our platform to aid in treating
wound and skincare patients as they progress through the healing process in all care settings. We formed THP to hold certain
investments in technologies and operations in value-based wound and skincare services. We believe our service offerings will allow
us to collect and analyze large amounts of data on patient conditions and outcomes that will improve treatment protocols and
ultimately lead to more evidence-based healing formularies to improve outcomes in the future. We anticipate that this data will also
enable us to participate in the creation of new standards of care that promote patient compliance and enable direct dialogue between
patients, clinicians and payors, resulting in greater satisfaction for patients, their caregivers, clinicians and payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Competitive Strengths </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#9679; <i>Attractive
markets for surgical and wound care</i>. We believe the surgical and wound care markets will continue to see accelerated growth
given favorable global tailwinds that include an aging population, extended life expectancies, increasing costs of health care,
recognition of difficult-to-treat infection threats such as biofilms, and the increasing prevalence of diabetes and obesity. We
believe there will be growing adoption of our products due to their clinical efficacy and cost effectiveness for all key
constituents compared to traditional wound care products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#9679; <i>Comprehensive
solution for improved wound care outcomes</i>. We are dedicated to offering a comprehensive portfolio of products, services and
technologies to improve wound care treatment outcomes. We believe we are the only company that will be able to provide a
comprehensive solution for wound care which includes a wound and skin specific electronic medical record, coordination of virtual
consult services with expert wound care providers and dermatologists, propriety diagnostics and highly efficacious proprietary
products allowing us to effectively treat wound care patients in any care setting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#9679; <i>Wound care
products for all care settings</i>. Our wound care product portfolio allows clinicians to personalize solutions to meet the needs of
individual wound care patients in all care settings including acute (hospitals and long-term acute care hospitals) and post-acute
(wound care clinics, physician offices, skilled nursing facilities (&#8220;SNFs&#8221;), home health, hospice, podiatrists and
retail).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#9679; <i>Innovative
pipeline and proven clinical performance.</i> We have a robust pipeline of surgical, wound and skincare products that we expect to
market in the near term. We believe the efficacy of our offerings will be proven via statistically significant collected and
analyzed clinical and health economic outcomes data, resulting in expanded adoption of our products at a lower overall cost to
payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#9679; <i>Proven executive
leadership team with a long-term track record of value creation</i>. We are led by a dedicated and seasoned management team with significant
industry experience who have successfully executed our strategic implementation to date by launching new products and technologies through
investment in new areas of growth. We believe our management team has the vision and experience to implement our future growth strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Market Opportunities for Our Products, Services
and Technology-Based Offerings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">According to a study published by the <i>Value in
Health</i> journal, roughly 15% of the Medicare beneficiary population has chronic nonhealing wounds. Chronic wounds do not advance through
the phases of healing in a normal progression and do not show significant progress toward healing in 30 days. Factors contributing to
the chronicity of the wound may include pressure/friction, trauma, insufficient blood flow and oxygenation in locations such as the lower
extremities, increased bacterial load, excessive proteases, degraded growth factors, matrix metalloproteinases, senescent/aberrant cells
or inappropriate treatment. Examples of chronic wounds include diabetic foot ulcers (&#8220;DFUs&#8221;), venous leg ulcers (&#8220;VLUs&#8221;),
arterial ulcers, pressure ulcers and hard-to-heal surgical/traumatic wounds. In each of the various wound types, the presence of biofilms
is a frequent cause for chronicity of wounds and the removal of biofilms is a crucial step to commence healing. Biofilms need to be eradicated
to prevent further deterioration of the wound that may result in additional negative patient outcomes. If not effectively treated, these
wounds can lead to potentially severe complications, including further infection, osteomyelitis, fasciitis, amputation and increased
mortality. Chronic wounds are primarily seen in the elderly population. For example, a 2019 study published in <i>Advances in Wound Care
</i>reported that in the United States, 3% of the population over the age of 65 had open wounds. According to the same study, in 2020,
the U.S. government estimated that the elderly population totaled 55 million people, suggesting that chronic wounds will continue to
be an increasingly persistent problem in this population. Four common chronic and other hard-to-heal wounds are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#9679; <i>Surgical/traumatic
wounds</i>. Surgical wounds form as a result of various types of surgical procedures such as investigative or corrective, minor or
major, open (traditional) or minimal access surgery, elective or emergency, and incisions (simple cuts) or excision (removal of
tissue), among others. Traumatic wounds form as a result of external forces causing tissue damage such as lacerations, puncture
wounds or tissue loss. Severe traumatic wounds may require surgical intervention to close the wound and stabilize the patient.
Surgical/traumatic hard-to-heal wounds develop for various reasons, such as local surgical complications, suboptimal closure
techniques, presence of foreign materials, exposed bones or tendons and infection. In the United States, millions of people receive
post-surgical wound care annually, and the typical operative patient has comorbidities that create challenges with post-operative
wound healing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#9679; <i>Diabetic Foot
Ulcers</i>. Diabetes can lead to a reduction in blood flow, which can cause patients to lose sensation in their feet and may prevent
them from noticing injuries, sometimes leading to the development of DFUs, which are open sores or ulcers on the feet that may take
several weeks to heal, if ever. Diabetes is associated with pathological changes that contribute to poor wound healing. These
changes may include peripheral vascular disease, neuropathy, excessive inflammation, and a disrupted cellular response to wound
healing. According to the 2020 National Diabetes Statistics Report by the Center for Disease Control and Prevention, in the United
States alone, over 34 million people, or approximately 10% of the population, suffer from diabetes, a chronic, life-threatening
disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#9679; <i>Venous Leg
Ulcers</i>. VLUs are the most common type of chronic wound in the lower extremity. VLUs develop as a result of vascular
insufficiency, or the inability for the vasculature of the leg to return blood back toward the heart properly and, according to a
2013 report published by the International Journal of Tissue Repair and Regeneration, VLUs affect approximately 600,000 people per
year in the United States alone. According to a 2023 report published by the <i>Journal of Vascular Surgery</i>, Venous and
Lymphatic Disorders, chronic venous disorders are common, with varicose veins occurring in &#8764;40% of the population. These ulcers
usually form on the sides of the lower leg, above the ankle and below the calf, and are slow to heal and often recur if preventative
steps are not taken. The presence of a VLU represents the sequela of progressive end-stage chronic venous disease, often related to
a previous blood clot. The risk of VLUs can be increased as a result of a blood clot forming in the deep veins of the legs, obesity,
smoking, lack of physical activity or work that requires many hours of standing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.4in">&#9679; <i>Pressure
Injury/Ulcers</i>. Pressure injury/ulcers are injuries to the skin and underlying tissue resulting from prolonged pressure, or
pressure in combination with shear or friction. Constant pressure on an area of skin reduces blood supply to the area and over time
can cause the skin to break down and form an open ulcer. These often occur in patients who are hospitalized or confined to a chair
or bed and most often form on the skin over bony areas, where there is little cushion between the bone and the skin, such as heels,
ankles, hips and the tailbone. Annually, more than 2.5 million people develop pressure ulcers in the United States according to a
2019 study published in the <i>National Library of Medicine</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Published Studies on CellerateRX Surgical</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An animal study model by the Indiana University Center
for Regenerative Medicine and Engineering and the McGowan Institute for Regenerative Medicine was published in Advances in Wound Care
in September of 2023. The study, titled &#8220;Hydrolyzed Collagen Powder Dressing Improves Wound Inflammation, Perfusion, and Breaking
Strength of Repaired Tissue,&#8221; demonstrated the effects of CellerateRX Surgical powder on resolution of wound inflammation, perfusion,
closure, and breaking strength of the repaired skin. Moreover, the study provided translational research validating published clinical
case series and further highlighting mechanistic effects of hydrolyzed collagen. Future empirical and clinical research revealing the
unique support hydrolyzed collagen provides the wound environment is currently ongoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Several research findings involving CellerateRX Surgical
powder have been noted in scientific literature. For example, in November 2021, Dr. William Hotchkiss published a retrospective study
of 154 patients in JSM Neurosurgery and Spine, in which patients underwent spinal surgery and CellerateRX Surgical was utilized in the
surgical wound. The study found a lower wound dehiscence rate in a high-risk patient population when compared to previously published
wound complication rates in the literature. Another retrospective case study regarding the use of CellerateRX Surgical was published
by Dr. Alex Gitelman in November 2022. This study of 54 patients undergoing spinal surgery demonstrated no incidence of surgical wound
complication.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a retrospective study published in the <i>Journal
of Surgery</i> in October 2023, the impact of CellerateRX Surgical collagen on surgical site infection rates in elective multispecialty
surgical procedures was case matched 1:3 for a total of 5,335 patients and demonstrated an overall reduction of 59% in surgical site
infection rates. This reduction was most pronounced in the clean cases with a 69% decrease in surgical site infection rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since the acquisition of assets from Rochal Industries,
LLC (&#8220;Rochal&#8221;) in July 2021, the acquisition of Precision Healing in April 2022, and the acquisition of assets from The Hymed
Group Corporation (&#8220;Hymed&#8221;) and Applied Nutritionals, LLC (&#8220;Applied&#8221;) in August 2023 (the &#8220;Applied Asset
Purchase&#8221;), our research and development activities have included internally developing additional proprietary products, services
and technologies for the surgical and chronic wound and skincare markets and actively working with third-party research and development
partners. For our internally developed products, we seek patent protection for our inventions in order to protect and differentiate our
products and technologies and establish a defense against third-party infringement claims. With the aim of optimizing commercial and
regulatory success, our proprietary technology and innovative applications thereof are protected by product, system, process, and method-of-use
patent claims. We believe that our granted patents and pending applications collectively protect our internally developed intellectual
property, both in terms of our existing products, as well as our anticipated pipeline of new offerings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2021, we acquired certain assets from Rochal,
including intellectual property. With respect to the assets we acquired from Rochal and products developed following the Rochal acquisition,
our patent portfolio includes, among others, eight issued U.S. patents, including U.S. Patent No. 8,829,053 entitled &#8220;Biocidal
Compositions and Methods of Using the Same&#8221; (expiring December 7, 2031) relating to BIASURGE Surgical Irrigation, BIAK&#332;S
Antimicrobial Skin &amp; Wound Cleanser and BIAK&#332;S Antimicrobial Wound Gel, as well as over 100 issued patents in foreign jurisdictions.
Following our acquisition by merger of Precision Healing in April 2022, our patent portfolio now includes, among others, five pending
U.S. patent applications as well as one pending international patent application. Following the Applied Asset Purchase in August 2023,
our portfolio also now includes, among others, nine additional U.S. patent applications, five trademarks, four 510(k) clearances and
various domain names.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2024, our research and development team submitted
11 provisional patent applications covering innovations in proprietary antimicrobial technologies and hydrolyzed collagen, including
novel formulations, treatment applications and key component advancements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our pending patent applications and new filings are
representative of our ongoing efforts to broaden our portfolio as we continue developing new products for the surgical and wound and
skincare markets. We intend to further grow our patent portfolio by continuing to patent new products as they are developed, to defend
intellectual property as we believe necessary by actively pursuing any infringements, to pursue the commercial opportunities our patents
provide for our innovations, and to continue to develop our brands and trademarks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sales and Marketing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December&#160;31, 2024, we employed 40 U.S.
based field sales representatives. Our field sales representatives are recruited based on their previous industry experience and professional
performance. We constantly evaluate new markets and sales opportunities to add to our sales teams as warranted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our surgical products are sold through a growing network of surgical specialty distributors and Company representatives
who are credentialed to demonstrate the products in surgical settings. Field sales representatives are initially trained
through an internal learning management system, &#8220;SanaraU,&#8221; which gives them further product and surgical specialty training
including wound etiology, operating room etiquette and credentialing requirements. After completing their internal training, new hire
field sales representatives participate in field training with experienced field trainers to get insights into best practice as well
as real world training. The initial training period lasts approximately eight weeks. Field sales representatives are supported by regular
updated training modules on product information and best practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A key component of our sales and marketing efforts
involves working with physicians and clinicians to champion our products in their facilities. We work closely with surgeons and health
system stakeholders to demonstrate the efficacy and beneficial impact of our surgical products and successfully navigate the hospital
value analysis committee approval process, allowing our products to be sold in those facilities. If our sales and marketing efforts are
successful, the clinicians then advocate for the use of our products when medically necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Manufacturing, Supply and Production</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not own or operate our own manufacturing facilities.
We rely on contract manufacturers to supply our products. Our contract manufacturing strategy is intended to drive cost leverage through
scale and avoid high capital outlays and fixed costs associated with constructing and operating manufacturing facilities. Our manufacturing
partners have internal compliance processes to maintain the high quality and reliability of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reimbursement, Clinical Validation and Clinical
Utility</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not promote our products based on their reimbursement
status, however, we are mindful of the benefits of a favorable reimbursement coverage status to increase patient access and support our
research and development efforts to supply the highest efficacy solutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We anticipate that our THP strategy, once launched,
will provide a significant amount of patient data to help us measure our products&#8217; effectiveness on improving patient outcomes
while simultaneously reducing healthcare costs. We believe our reimbursement strategy, including establishing the clinical validation,
clinical utility and health economics of our products, will allow us to drive improved reimbursement coverage for our products and technologies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The surgical wound care market is served by several
large, multi-product line companies as well as a number of small companies. Our products compete with primary dressings, advanced wound
care products, collagen matrices, surgical wound irrigation products and other biopharmaceutical products. Manufacturers and distributors
of competitive products include Medline Industries, Inc., ConvaTec Group plc, 3M Company, Integra LifeSciences
Holdings Corporation and numerous others. Many of our competitors are significantly larger than we are and have greater financial and
personnel resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With respect to our comprehensive value-based care
strategy, THP plans to offer a comprehensive wound care and dermatology strategy to expand cost-effective, high-quality wound and skincare
to all patients throughout the care setting continuum. Although novel in its comprehensive offerings and solutions, there are existing
competitors for each of the verticals in which THP plans to offer services and solutions. Any clinical wound care or dermatology physician
provider group that has incorporated telemedicine into their practice could be considered competitive. However, most of these groups
are not offering value-based care contracts to payers, integrating prevention into their programs, or enabling continuity across the
different settings of care. Examples of large wound care specialty practices may include Vohra Physician Group, Healogics Specialty Physicians
and WoundTech.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Government Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operations are subject to comprehensive federal,
state and local laws and regulations in the jurisdictions in which we or our research and development partners or affiliates do business.
The laws and regulations governing our business and interpretations of those laws and regulations are subject to frequent change. Our
ability to operate profitably will depend in part upon our ability, and that of our research and development partners and affiliates,
to operate in compliance with applicable laws and regulations. The laws and regulations relating to medical products and healthcare services
that apply to our business and that of our partners and affiliates continue to evolve, and we must, therefore, devote significant resources
to monitoring developments in legislation, enforcement, and regulation in such areas. As the applicable laws and regulations change,
we are likely to make conforming modifications in our business processes from time to time. We cannot provide assurance that a review
of our business by courts or regulatory authorities will not result in determinations that could adversely affect our operations or that
the regulatory environment will not change in a way that restricts our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>FDA Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our medical products and operations are regulated
by the FDA and other federal and state agencies. Most of the products we currently market are regulated as medical devices in the United
States under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), as implemented and enforced by the FDA. The FDA regulates
the development, testing, manufacturing, labeling, packaging, storage, installation, servicing, advertising, promotion, marketing, distribution,
import, export and market surveillance of our medical devices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, we market certain products for use in
surgical wound care regulated by the FDA under Section 361 of the Public Health Service Act (&#8220;PHSA&#8221;) (42 U.S.C. &#167; 264)
and 21 C.F.R. Part 1271.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Device Premarket Regulatory Requirements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Before being introduced into the U.S. market, each
medical device must obtain marketing clearance from the FDA through the 510(k) premarket notification process, the <i>de
novo</i> classification process (summarized below), or the premarket approval application (&#8220;PMA&#8221;) process, unless they are
determined to be Class I devices or to otherwise qualify for an exemption from one of these available forms of premarket review and authorization
by the FDA. Under the FDCA, medical devices are classified into one of three classes&#8212;Class I, Class II or Class III&#8212;depending
on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurance of safety
and effectiveness. Classification of a device is important because the class to which a device is assigned determines, among other things,
the necessity and type of FDA review required prior to marketing the device. Class I devices are those for which reasonable assurance
of safety and effectiveness can be assured by adherence to general controls that include compliance with the applicable portions of the
FDA&#8217;s Quality System Regulation (&#8220;QSR&#8221;), as well as regulations requiring facility registration and product listing,
reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising and promotional materials. The
Class I designation also applies to devices for which there is insufficient information to determine that general controls are sufficient
to provide reasonable assurance of the safety and effectiveness of the device or to establish special controls to provide such assurance,
but that are not life-supporting or life-sustaining or for a use which is of substantial importance in preventing impairment of human
health, and that do not present a potential unreasonable risk of illness or injury.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Class II devices are those for which general controls
alone are insufficient to provide reasonable assurance of safety and effectiveness and there is sufficient information to establish &#8220;special
controls.&#8221; These special controls can include performance standards, post-market surveillance requirements, patient registries
and FDA guidance documents describing device-specific special controls. While most Class I devices are exempt from the 510(k) premarket
notification requirement, most Class II devices require a 510(k) premarket notification prior to commercialization in the United States;
however, the FDA has the authority to exempt Class II devices from the 510(k) premarket notification requirement under certain circumstances.
As a result, manufacturers of most Class II devices must submit 510(k) premarket notifications to the FDA under Section 510(k) of the
FDCA (21 U.S.C. &#167; 360(k)) in order to obtain the necessary clearance to market or commercially distribute such devices. To obtain
510(k) clearance, manufacturers must submit to the FDA adequate information demonstrating that the proposed device is &#8220;substantially
equivalent&#8221; to a predicate device already on the market. A predicate device is a legally marketed device that is not subject to
PMA, meaning, (i) a device that was legally marketed prior to May 28, 1976 (&#8220;preamendment device&#8221;) and for which a PMA is
not required, (ii) a device that has been reclassified from Class III to Class II or I, or (iii) a device that was found substantially
equivalent through the 510(k) process. If the FDA agrees that the device is substantially equivalent to a predicate device currently
on the market, it will grant 510(k) clearance to commercially market the device. If there is no adequate predicate to which the manufacturer
can compare its proposed device, the proposed device is automatically classified as a Class III device. In such cases, the device manufacturer
must then fulfill the more rigorous PMA requirements or can request a risk-based classification determination for the device in accordance
with the <i>de novo</i> classification process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The <i>de novo</i> classification process allows
a manufacturer whose novel device is automatically classified into Class III to request down-classification of its device to Class I
or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA. Under
the Food and Drug Administration Safety and Innovation Act of 2012 (&#8220;FDASIA&#8221;), the FDA is required to classify a device within
120 days following receipt of the <i>de novo</i> classification request. If the manufacturer seeks reclassification into Class II, the
classification request must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the
safety and effectiveness of the medical device. The FDA may reject the classification request if it identifies a legally marketed predicate
device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk or that general controls would
be inadequate to control the risks and special controls cannot be developed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Devices that are intended to be life sustaining or
life supporting, devices that are implantable, devices that present a potential unreasonable risk of harm or are of substantial importance
in preventing impairment of health and devices that are not substantially equivalent to a predicate device are placed in Class III and
generally require FDA approval through the PMA process, unless the device is a preamendment device not yet subject to a regulation requiring
premarket approval. The PMA process is more demanding than the 510(k) premarket notification process. For a PMA, the manufacturer must
demonstrate through extensive data, including data from preclinical studies and clinical trials, that the device is safe and effective.
The PMA must also contain a full description of the device and its components, a full description of the methods, facilities and controls
used for manufacturing, and proposed labeling. Following receipt of a PMA, the FDA determines whether the application is sufficiently
complete to permit a substantive review. If the FDA accepts the application for review, it has 180 days under the FDCA to complete its
review of a PMA, although in practice, the FDA&#8217;s review often takes significantly longer, and can take up to several years. Before
approving a PMA, the FDA generally also performs an on-site inspection of manufacturing facilities for the product to ensure compliance
with the QSR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Clinical trials are almost always required to support
PMAs and are sometimes required to support 510(k) submissions. All clinical investigations of devices to determine safety and effectiveness
must be conducted in accordance with the FDA&#8217;s investigational device exemption (&#8220;IDE&#8221;) regulations that govern investigational
device labeling, prohibit promotion of the investigational device and specify recordkeeping, reporting and monitoring responsibilities
of study sponsors and study investigators. If the device presents a &#8220;significant risk,&#8221; as defined by the FDA, the agency
requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials.
The IDE will automatically become effective 30 days after receipt by the FDA, unless the FDA denies the application or notifies the company
that the investigation is on hold and may not begin until the sponsor provides supplemental information about the investigation that
satisfies FDA&#8217;s concerns. If the FDA determines that there are deficiencies or other concerns with an IDE that require modification
of the study, the FDA may permit a clinical trial to proceed under a conditional approval. In addition, the study must be approved by,
and conducted under the oversight of, an institutional review board (&#8220;IRB&#8221;), for each clinical site. If the device presents
a non-significant risk to the patient according to criteria established by the FDA as part of the IDE regulations, a sponsor may begin
the clinical trial after obtaining approval for the trial by one or more IRBs without separate authorization from the FDA, but must still
comply with abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent,
and labeling and record-keeping requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Device Postmarket Regulatory Requirements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After a device is cleared or approved for commercialization,
and prior to marketing, numerous regulatory requirements apply to the various entities responsible for preparing a device for distribution,
including the manufacturer (including specification developer), contract manufacturers, relabelers/repackagers, sterilizers and initial
importer, as applicable. These include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">establishment registration and device
                                            listing;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">development of a quality management
                                            system, including establishing and implementing procedures to design and manufacture devices
                                            in compliance with the QSR (unless a device category is exempt from this requirement by the
                                            FDA, such as in the case of many Class I devices);</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">labeling regulations that prohibit
                                            the promotion of products for uncleared or unapproved uses (known as off-label uses), as
                                            well as requirements to provide accurate and non-misleading information and adequate information
                                            on both risks and benefits of the device;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">FDA&#8217;s unique device identification
                                            requirements that call for a unique device identifier on device labels, packages, and in
                                            some cases, on the device itself, and submission of data to the FDA&#8217;s Global Unique
                                            Device Identification Database;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">medical device reporting regulations
                                            that require manufacturers to report to the FDA if a device may have caused or contributed
                                            to a death or serious injury or malfunctioned in a way that would likely cause or contribute
                                            to a death or serious injury if it were to recur;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">corrections and removal reporting
                                            regulations that require manufacturers report to the FDA field corrections and product recalls
                                            or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation
                                            of the FDCA that may present a risk to health; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">postmarket surveillance regulations,
                                            which apply to Class II or Class III devices if the FDA has issued a postmarket surveillance
                                            order and the failure of the device would be reasonably likely to have serious adverse health
                                            consequences, the device is expected to have significant use in the pediatric population,
                                            the device is intended to be implanted in the human body for more than one year, or the device
                                            is intended to be used to support or sustain life and to be used outside a user facility.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We and our research and development partners and
contract manufacturers are subject to periodic scheduled or unscheduled inspections by the FDA. If the FDA believes we or any of our
research and development partners or contract manufacturers are not in compliance with the QSR, or other postmarket requirements, it
has broad authority to take significant enforcement actions to compel compliance. Specifically, if the FDA determines that we or our
research and development partners or contract manufacturers failed to comply with applicable regulatory requirements, the agency can
take a variety of compliance or enforcement actions, which may result in any of the following sanctions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">untitled letters, warning letters,
                                            fines, injunctions, consent decrees and civil penalties;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">customer notifications or repair,
                                            replacement or refunds;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">mandatory recalls, withdrawals,
                                            or administrative detention or seizure of our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">operating restrictions or partial
                                            suspension or total shutdown of production;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">refusing or delaying requests for
                                            510(k) marketing clearance or approval of premarket approval applications relating to new
                                            products or modified products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">reclassifying a 510(k)-cleared device
                                            or withdrawing PMA approval;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">refusal to grant export approvals
                                            for our products; or</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">pursuing criminal prosecution.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any such enforcement action by the FDA would have
a material adverse effect on our business. In addition, these regulatory controls, as well as any changes in FDA policies, can affect
the time and cost associated with the development, introduction, and continued availability of new products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>HCT/P Regulatory Requirements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Some of the products we currently market are regulated
as biologics, more specifically as human cells, tissues, and cellular and tissue-based products (&#8220;HCT/Ps&#8221;). They include
(i) TEXAGEN, (ii) ACTIGEN, and (iii) ALLOCYTE Plus. HCT/Ps are regulated by the FDA&#8217;s Center for Biologics Evaluation
and Research (&#8220;CBER&#8221;) or Center for Devices and Radiological Health (&#8220;CDRH&#8221;) depending on the type of product,
how it is manufactured and its intended uses. HCT/Ps that meet all of the criteria described in 21 C.F.R. &#167; 1271.10(a) are regulated
by the CBER under Section 361 of the PHSA (42 U.S.C. &#167; 264) and 21 C.F.R. Part 1271 only (&#8220;361 products&#8221;). Although
361 products do not require premarket review by the FDA prior to commercialization, manufacturers of 361 products must register with
the FDA, submit a list of HCT/Ps manufactured, and comply with current good tissue practices (&#8220;cGTP&#8221;), among other things.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Federal Trade Commission Regulatory Oversight</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our advertising for our products and services is
subject to federal truth-in-advertising laws enforced by the Federal Trade Commission (the &#8220;FTC&#8221;), as well as comparable
state consumer protection laws. Under the Federal Trade Commission Act (&#8220;FTC Act&#8221;), the FTC is empowered, among other things,
to (a) prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b) seek monetary redress
and other relief for conduct injurious to consumers; and (c) gather and compile information and conduct investigations relating to the
organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority, and
failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or judicial
penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or products in the
future, or criminal prosecution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fraud and Abuse and Transparency Laws and Regulations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our business activities (and the business activities
of our research and development partners and affiliates), including, but not limited to, research, sales, promotion, distribution and
medical education, are subject to regulation by numerous federal and state regulatory and law enforcement authorities in the United States,
including the Department of Justice, the Department of Health and Human Services and its various divisions, CMS, the Health Resources
and Services Administration, the Department of Veterans Affairs, the Department of Defense, and state and local governments. Our business
activities must comply with numerous healthcare laws, including, but not limited to, anti-kickback and false claims laws and regulations
as well as data privacy and security laws and regulations, which are described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal Anti-Kickback Statute prohibits, among
other things, any person or entity, from knowingly and willfully offering, paying, soliciting, or receiving any remuneration, directly
or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering, or arranging for or
recommending the purchase, lease, furnishing, or order of any item or service reimbursable under Medicare, Medicaid, or other federal
healthcare programs, in whole or in part. The term &#8220;remuneration&#8221; has been interpreted broadly to include anything of value.
The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers,
purchasers, formulary managers, and beneficiaries on the other. There are certain statutory exceptions and regulatory safe harbors protecting
some common activities from prosecution. The exceptions and safe harbors are drawn narrowly, and practices that involve remuneration
that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify
for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory
safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be
evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted
the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals
of federal healthcare covered business, the statute has been violated. The Patient Protection and Affordable Care Act, of 2010, as amended
(the &#8220;ACA&#8221;), modified the intent requirement under the Anti-Kickback Statute to a stricter standard, such that a person or
entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.
In addition, the ACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower
to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes
of the federal civil False Claims Act (the &#8220;FCA&#8221;). The ACA further created new federal requirements for reporting, by applicable
manufacturers of covered drugs, payments and other transfers of value to physicians and teaching hospitals, and ownership and investment
interests held by physicians and other healthcare providers and their immediate family members.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal civil FCA, prohibits, among other things,
any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by,
the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent
claim to the federal government, or avoiding, decreasing, or concealing an obligation to pay money to the federal government. A claim
includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. The civil FCA has been used to assert
liability on the basis of kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or
Average Manufacturer Price, or submission of inaccurate information required by government contracts, improper use of Medicare provider
or supplier numbers when detailing a provider of services, improper promotion of off-label uses not expressly approved by the FDA in
a drug&#8217;s label, and allegations as to misrepresentations with respect to the products supplied or services rendered. Several pharmaceutical
and other healthcare companies have further been sued under these laws for allegedly providing free product to customers with the expectation
that the customers would bill federal programs for the product. Intent to deceive is not required to establish liability under the civil
FCA; however, a change in Department of Justice policy now prohibits enforcement actions for knowing violations of law based on noncompliance
with agency subregulatory guidance. Civil FCA actions may be brought by the government or may be brought by private individuals on behalf
of the government, called &#8220;qui tam&#8221; actions. If the government decides to intervene in a qui tam action and prevails in the
lawsuit, the individual will share in the proceeds from any fines or settlement funds. If the government declines to intervene, the individual
may pursue the case alone. Since 2004, these FCA lawsuits against pharmaceutical companies have increased significantly in volume and
breadth, leading to several substantial civil and criminal settlements, as much as $3.0 billion, regarding certain sales practices and
promoting off-label drug uses. Civil FCA liability may be imposed for Medicare or Medicaid overpayments, for example, overpayments caused
by understated rebate amounts, that are not refunded within 60 days of discovering the overpayment, even if the overpayment was not caused
by a false or fraudulent act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The government may further prosecute conduct constituting
a false claim under the criminal FCA. The criminal FCA prohibits the making or presenting of a claim to the government knowing such claim
to be false, fictitious, or fraudulent and, unlike the civil FCA, requires proof of intent to submit a false claim. The civil monetary
penalties statute is another potential statute under which drug and device companies may be subject to enforcement. Among other things,
the civil monetary penalties statute imposes fines against any person who is determined to have presented, or caused to be presented,
claims to a federal healthcare program that the person knows, or should know, is for an item or service that was not provided as claimed
or is false or fraudulent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Health Insurance Portability Accountability Act (&#8220;HIPAA&#8221;) also created federal criminal statutes that
prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent
pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, a healthcare benefit
program, regardless of whether the payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit
program, willfully obstructing a criminal investigation of a health care offense, and knowingly and willfully falsifying, concealing,
or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or
payment for, healthcare benefits, items, or services relating to healthcare matters. The ACA, as amended, modified the intent requirement
under the certain portions of these federal criminal statutes such that a person or entity no longer needs to have actual knowledge of
the statute or specific intent to violate it. The ACA further created federal requirements for reporting, by applicable manufacturers
of covered therapeutics, payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests
held by physicians and other healthcare providers and their immediate family members.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many states have also adopted laws similar to each
of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third-party payor, including
commercial insurers, and some have transparency laws that require reporting price increases and related information. Certain state laws
also regulate manufacturers&#8217; use of prescriber-identifiable data. Certain states also require implementation of commercial compliance
programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance
promulgated by the federal government, or otherwise restrict payments or the provision of other items of value that may be made to healthcare
providers and other potential referral sources; impose restrictions on marketing practices; or require drug manufacturers to track and
report information related to payments, gifts, and other items of value to physicians and other healthcare providers. These laws may
affect our future sales, marketing, and other promotional activities by imposing administrative and compliance burdens.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If our operations are found to be in violation of
any of the laws or regulations described above or any other laws that apply to us, we may be subject to penalties or other enforcement
actions, including criminal and significant civil monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation
in government healthcare programs, corporate integrity agreements, debarment from receiving government contracts or refusal of new orders
under existing contracts, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations,
any of which could adversely affect our ability to operate our business and our results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Telemedicine Standards, and Related Laws and
Guidelines</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have entered into a professional services agreement
with and made a minority investment in DirectDerm, a dermatology telemedicine company based in California, which has an exclusive network
of dermatologists.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The delivery of telemedicine services directly or
through contractual relationships is subject to various federal, state, and local laws, regulations and approvals, relating to, among
other things, the health provider licensure, adequacy and continuity of medical care, medical practice standards (including specific
requirements when providing healthcare utilizing telemedicine technologies and consulting services among providers), medical records
maintenance, personnel supervision, and prerequisites for the prescription of medication. The application of some of these laws to telemedicine
is unclear and subject to differing interpretation. Further, laws and regulations specific to delivering medical services utilizing telemedicine
technologies continues to evolve with some states incorporating modality and consent requirements for certain telemedicine encounters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>U.S. Federal and State Health Information Privacy
and Security Laws</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are numerous U.S. federal and state laws and
regulations related to the privacy and security of personally identifiable information (&#8220;PII&#8221;), including health information.
In particular, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its respective implementing
regulations, establishes privacy and security standards that limit the use and disclosure of protected health information (&#8220;PHI&#8221;),
and require the implementation of administrative, physical, and technical safeguards to ensure the confidentiality, integrity and availability
of individually identifiable health information in electronic form. Our affiliated network providers and our hospital, health system
and other provider clients are all regulated as covered entities under HIPAA. Since the effective date of the HIPAA Omnibus Final Rule
on September 23, 2013, HIPAA&#8217;s requirements are also directly applicable to the independent contractors, agents and other &#8220;business
associates&#8221; of covered entities that create, receive, maintain or transmit PHI in connection with providing services to covered
entities. We are a business associate under HIPAA when we are working on behalf of our affiliated providers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Violations of HIPAA may result in civil and criminal
penalties. A single breach incident can result in violations of multiple standards. We must also comply with HIPAA&#8217;s breach notification
rule. Under the breach notification rule, covered entities must notify affected individuals without unreasonable delay in the case of
a breach of unsecured PHI, which may compromise the privacy, security or integrity of the PHI. In addition, notification must be provided
to Health and Human Services (&#8220;HHS&#8221;) and the local media in cases where a breach affects more than 500 individuals. Breaches
affecting fewer than 500 individuals must be reported to HHS on an annual basis. The regulations also require business associates of
covered entities to notify the covered entity of breaches by the business associate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">State attorneys general also have the right to prosecute
HIPAA violations committed against residents of their states. While HIPAA does not create a private right of action that would allow
individuals to sue in civil court for a HIPAA violation, its standards have been used as the basis for the duty of care in state civil
suits, such as those for negligence or recklessness in misusing personal information. In addition, HIPAA mandates that HHS conduct periodic
compliance audits of HIPAA covered entities and their business associates for compliance. It also tasks HHS with establishing a methodology
whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine
paid by the violator. In light of the HIPAA Omnibus Final Rule, recent enforcement activity, and statements from HHS, we expect increased
federal and state HIPAA privacy and security enforcement efforts. HIPAA also required HHS to adopt national standards establishing electronic
transaction standards that all healthcare providers must use when submitting or receiving certain healthcare transactions electronically.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many states in which we or our research and development
partners may operate also have laws that protect the privacy and security of sensitive and personal information, including health information.
These laws may be similar to or even more protective than HIPAA and other federal privacy laws. For example, the laws of the State of
California are more restrictive than HIPAA. Where state laws are more protective than HIPAA, we must comply with the state laws to which
we are subject, in addition to HIPAA. In certain cases, it may be necessary to modify our planned operations and procedures to comply
with these more stringent state laws. Not only may some of these state laws impose fines and penalties upon violators, but also some,
unlike HIPAA, may afford private rights of action to individuals who believe their personal information has been misused.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to HIPAA and state health information
privacy laws, we may be subject to other state and federal privacy laws, including laws that prohibit unfair privacy and security practices
and deceptive statements about privacy and security and laws that place specific requirements on certain types of activities, such as
data security and texting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In recent years, there have been a number of well-publicized
data breaches involving the improper use and disclosure of PII and PHI. Many states have responded to these incidents by enacting laws
requiring holders of personal information to maintain safeguards and to take certain actions in response to a data breach, such as providing
prompt notification of the breach to affected individuals and state officials. In addition, under HIPAA and pursuant to the related contracts
that we enter into with our business associates, we must report breaches of unsecured PHI to our contractual partners following discovery
of the breach. Notification must also be made in certain circumstances to affected individuals, federal authorities and others.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Employees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2024, we had a staff of 141
full-time employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We were incorporated in Texas on December 14, 2001.
Our principal executive offices are located at 1200 Summit Ave, Suite 414, Fort Worth, Texas 76102, telephone number (817) 529-2300.
Our website address is www.sanaramedtech.com. Information accessed through our website is not incorporated into this annual report and
is not a part of this annual report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Available Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company electronically files reports with the
Securities and Exchange Commission (the &#8220;SEC&#8221;). The SEC maintains an Internet site (www.sec.gov) that contains reports, proxy
and information statements, and other information regarding issuers that file electronically with the SEC. Copies of the Company&#8217;s
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and amendments to those reports filed or furnished
to the SEC are also available free of charge through the Company&#8217;s investor relations website (https://www.sanaramedtech.com/investor-relations/)
as soon as reasonably practicable after electronically filing with or otherwise furnishing such information to the SEC and are available
in print to any shareholder who requests them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="Section6"></span>Item 1A. RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The risks below are those that we believe are the
material risks that we currently face but are not the only risks facing us and our business. If any of these risks actually occur, our
business, financial condition and results of operations could be materially adversely affected. Below is a summary of our risk factors
with a more detailed discussion following.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We have had a history of losses,
                                            which may continue as we expand our investment in THP.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our revenue growth for a particular
                                            period is difficult to predict, and a shortfall in forecasted revenues may harm our operating
                                            results.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our current comprehensive, value-based
                                            wound and skincare strategy involves growth through technology development acquisitions and investments, which requires
                                            us to incur substantial costs and potential liabilities for which we may never realize the
                                            anticipated benefits.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Failure to manage our growth strategy
                                            could harm our business.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If we are unable to compete within
                                            our markets or our products, services and technologies do not gain market acceptance, our
                                            financial condition and operating results could suffer.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Security breaches and other disruptions
                                            could compromise our information and expose us to liability, which would cause our business
                                            and reputation to suffer.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If we fail to maintain an effective
                                            system of internal controls over financial reporting, we may not be able to accurately report
                                            our financial results or prevent fraud and our business may be harmed and our stock price
                                            may be adversely impacted.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our indebtedness could adversely
                                            affect our financial condition and prevent us from fulfilling our obligations.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our outstanding indebtedness is
                                            subject to certain operating and financial covenants that restrict our business and financing
                                            activities and may adversely affect our cash flow and our ability to operate our business.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We rely on our research and development
                                            partners to design, manufacture and supply certain products we have licensed for marketing.
                                            If we or one of our partners fails to perform adequately, fulfill our needs, or comply with
                                            regulations, we may be required to incur significant costs or even be subject to enforcement
                                            actions. We also may face significant delays in our product introductions and commercialization.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Revenue generated from the sale
                                            of certain products is dependent on license agreements with certain manufacturers, and the
                                            termination of any of these license agreements could harm our business.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Certain of our product candidates
                                            are still under development, and we may not be able to successfully commercialize any of
                                            these product candidates.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our future success will largely
                                            depend on our ability to maintain and further grow clinical acceptance and adoption of our
                                            products, and we may be unable to adequately educate healthcare practitioners on the use
                                            and benefits of our products.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Disruption of, or changes in, our
                                            distribution model or customer base could harm our sales and margins.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Interruptions in the supply of our
                                            products or inventory loss may adversely affect our business, financial condition and results
                                            of operations.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Failure of any third-party assessments
                                            to demonstrate desired outcomes in proposed endpoints could have a negative impact on our
                                            business performance.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Increased prices for, or unavailability
                                            of, raw materials used in our products could adversely affect our business, financial condition
                                            and results of operations.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our planned expansion into value-based
                                            wound, skincare and other services could have a material adverse effect on our business,
                                            financial condition and results of operations.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our planned expansion into value-based
                                            wound, skincare and other services will require entrance into certain markets, in which,
                                            in some cases, we have limited experience, which may not be successful and could be costly.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If we are unable to adequately protect
                                            our intellectual property rights, we may not be able to compete effectively.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">CellerateRX Surgical is not currently
                                            protected by any pending patent application or any unexpired patent. CellerateRX Surgical
                                            may be subject to competition from the sale of substantially equivalent products that could
                                            adversely affect our business and operations.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We may be found to infringe on or
                                            violate the intellectual property rights of others.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our business is affected by numerous
                                            regulations relating to the development, manufacture, distribution, labeling, marketing and
                                            sale of our products.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We are subject to various governmental
                                            regulations relating to the labeling, marketing and sale of our products.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If we fail to obtain or experience
                                            significant delays in obtaining regulatory clearances or approvals to market future medical
                                            device products, we will be unable to commercialize these products until such clearance or
                                            approval is obtained.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Delays in or changes to the FDA
                                            clearance and approval processes or ongoing regulatory requirements could make it more difficult
                                            for us to obtain FDA clearance or approval of new products or comply with ongoing requirements.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Disruptions in the FDA and other government agencies caused
                                            by leadership changes, funding shortages, or other legal or political pressures could hinder
                                            their ability to hire and retain key personnel, provide regulatory clarity, or otherwise
                                            prevent new products and services from being developed or commercialized in a timely manner
                                            or hinder our ability to continue marketing existing commercial products, which could negatively
                                            impact our business.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Failure to obtain or maintain adequate
                                            reimbursement or insurance coverage for our products could limit our ability to market those
                                            products and decrease our ability to generate revenue. Changes in reimbursement policies
                                            and regulations by governmental or other third-party payors may have an adverse impact on
                                            the use of our products.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We rely on our research and development
                                            partners to comply with applicable laws and regulations relating to product classification
                                            and when and what types of FDA marketing authorizations are needed to lawfully commercialize
                                            a new or updated medical product in the United States.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We and our employees and contractors
                                            are subject, directly or indirectly, to federal, state and foreign healthcare fraud and abuse
                                            laws, including false claims laws. If we are unable to comply, or have not fully complied,
                                            with such laws, we could face substantial penalties.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We and our research and development
                                            partners&#8217; use of PII, including health information, is subject to federal
                                            and state privacy and security regulations, and our failure to comply with those regulations
                                            or to adequately secure the information we hold could have a material adverse effect on our
                                            client base, business, financial condition and results of operations.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our officers, employees, independent
                                            contractors, principal investigators, consultants and commercial partners may engage in misconduct
                                            or activities that are improper under other laws and regulations, which would create liability
                                            for us.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We could be adversely affected if
                                            healthcare reform measures substantially change the market for medical care or healthcare
                                            coverage in the United States.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Defects, failures or quality issues
                                            associated with our products could lead to product recalls or safety alerts, adverse regulatory
                                            actions, product liability lawsuits and other litigation and negative publicity that could
                                            materially adversely affect our reputation, business, results of operations and financial
                                            condition.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to How We Operate Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have had a history of losses, which may
continue as we expand our investment in THP.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have incurred net losses in most years since we
began our current operations in 2004. We plan to continue making significant investments in our THP operating segment, which will substantially
increase our operating expenses. Consequently, we will need to continue our revenue growth to become profitable in future periods. If
we fail to achieve profitability, our stock price may decline, and you may lose part or all of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our revenue growth for a particular period
is difficult to predict, and a shortfall in forecasted revenues may harm our operating results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenue growth and results of operations are
potentially difficult to predict. We plan our operating expense levels based primarily on forecasted revenue levels. A shortfall in
revenue could lead to operating results being below expectations, as we may not be able to quickly reduce our fixed expenses in
response to short-term revenue shortfalls. We have experienced fluctuations in revenue and operating results from quarter to quarter
and anticipate that these fluctuations will continue until we achieve a critical mass with our product and service sales. These
fluctuations can result from a variety of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">economic conditions worldwide, including
                                            increases in inflation, as well as economic conditions specific to the healthcare industry,
                                            which could affect the ability of surgical and post-acute facilities to purchase our products
                                            and could result in a reduction in elective operative procedures;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">governmental regulations, including
                                            those adopted in response to pandemics or other potential outbreaks;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the uncertainty surrounding our
                                            ability to attract new customers and retain existing customers;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">changes in reimbursement rates for
                                            our products by government and private insurers;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the length and variability of our
                                            sales cycle, especially gaining approvals for the use of our products in additional hospitals
                                            and surgery centers, which makes it difficult to forecast the quarter in which our sales
                                            will occur;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">issues including delays in the sourcing
                                            of our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the timing of regulatory approvals;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the timing of operating expense
                                            relating to the expansion of our business and operations;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">changes in the pricing of our products
                                            and those of our competitors;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the development of new surgical
                                            wound care products or product enhancements by our competitors; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">actual events, circumstances, outcomes
                                            and amounts differing from assumptions and estimates used in preparing our operating plan
                                            and how well we execute our strategy and operating plans.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a consequence, operating results for a particular
future period are difficult to predict and prior results are not necessarily indicative of future results. Any of the foregoing factors,
or any other factors discussed elsewhere herein, could have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our current comprehensive, value-based
wound and skincare strategy involves growth through technology development, acquisitions and investments, which requires us to incur
substantial costs and potential liabilities for which we may never realize the anticipated benefits.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may be unable to continue implementing our growth
strategy, and our strategy ultimately may be unsuccessful. We engage in evaluations of potential acquisitions and investments and are
in various stages of discussion regarding possible acquisitions, certain of which, if consummated, could be significant to us. Any new
acquisition or investment could result in material transaction expenses, increased interest and amortization expense, increased depreciation
expense and increased operating expense, any of which could have a material adverse effect on our operating results. In addition, if
we are unable to integrate businesses and operations that we have acquired or will acquire in the future, our profitability could suffer.
These acquisitions and investments also involve other risks, including diversion of management resources otherwise available for the
running of our business and the development of our business, as well as risks associated with entering markets in which our marketing
teams and sales force has limited experience or where experienced distribution alliances are not available. We may not be able to identify
suitable acquisition or investment candidates in the future, obtain acceptable financing or consummate any future acquisitions or investments.
In addition, certain potential acquisitions may be subject to antitrust and competition laws, which could impact our ability to pursue
strategic acquisitions and could result in mandated divestitures. If we are unsuccessful in our value-based wound and skincare strategy,
we may be unable to meet our financial targets, and our financial performance could be materially and adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Failure to manage our growth strategy could
harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ability to successfully implement our business
plan and develop, market and sell our surgical, wound and skincare products, services and technologies requires an effective plan for
managing our future growth. Future expansion efforts will be expensive
and may strain our internal operating resources. To manage future growth effectively, we must maintain and enhance our financial and
accounting systems and controls, integrate new personnel and manage expanded operations. If we do not manage growth properly, it could
harm our operating results and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to compete within our markets
or our products, services and technologies do not gain market acceptance, our financial condition and operating results could suffer.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Competition from other medical device companies is
significant and we could be significantly affected by new product introductions and other activities of market participants. We compete
with other companies in acquiring rights to products or technologies from third-party developers. In addition, many specialized products
companies have formed collaborations with large, established companies to support research, development and commercialization of surgical
wound care products which may be competitive with ours. Academic institutions, government agencies and other public and private research
organizations are also conducting research activities and may commercialize surgical wound care products on their own or through joint
ventures. Although our products have performed well in customer evaluations, we are a relatively unknown brand in a market dominated
by companies with extensive product lines and large customer bases. We may not, even with more efficacious products, be able to secure
contracts and achieve significant growth with large national accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, if the anticipated full launch of our
THP platform is successful, we will face competition from other value-based care providers. The public health emergency caused by the
COVID-19 pandemic has led to the widespread adoption of telemedicine for most health care clinical specialties, including wound care
and dermatology. As such, any clinical wound care or dermatology physician and/or provider group that has incorporated telemedicine into
their practice could be considered competitive. If we are unable to compete with other value-based care providers, our operating results
and financial condition may suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Several factors may limit the market acceptance of
our products, services and technologies, including the timing of regulatory approvals and market entry relative to competitive products,
services and technologies, the availability of alternative products, services and technologies, the price of our products, services and
technologies relative to alternative products, services and technologies, the availability of third-party reimbursement and the extent
of marketing efforts by third-party distributors or agents that we retain. Our products, services or technologies may not receive market
acceptance in a commercially viable period of time, if at all. Furthermore, our competitors may develop products, services or technologies
that are more effective or achieve greater market acceptance than those being developed by us, which would render our products, services
and technologies less competitive or obsolete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competitors enjoy several competitive advantages
over us, including but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">large and established distribution
                                            networks in the United States and/or in international markets;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">greater financial, managerial and
                                            other resources for products research and development, sales and marketing efforts and protecting
                                            and enforcing intellectual property rights;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">greater name recognition;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">larger consumer bases;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">more expansive portfolios of products
                                            and intellectual property rights; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">greater experience in obtaining
                                            and maintaining regulatory approvals and/or clearances from the FDA and other regulatory
                                            agencies.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The presence of competition in our market may lead
to pricing pressure which would make it more difficult to sell our products, services and technologies at a profitable price or may prevent
us from selling our products at all. Our failure to compete effectively would have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Security breaches and other disruptions could
compromise our information and expose us to liability, which would cause our business and reputation to suffer.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the ordinary course of our business, we use networks
to collect and store sensitive data, including intellectual property, proprietary business information and important information of our
customers, suppliers and business partners, as well as personally identifiable information of our customers and employees. The secure
processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information
technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions.
Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen.
Any such access, disclosure or other loss of information could result in the loss of existing customers, difficulty in attracting new
customers, backlash from negative public relations, legal claims or proceedings, liability under laws that protect the privacy of personal
information, and regulatory penalties. Further, such access, disclosure or loss may cause disruption of our operations and the services
we provide to customers, damage to our reputation, and cause a loss of confidence in our products and services, which could adversely
affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have programs, processes and technologies in place
to prevent, detect, contain, respond to and mitigate security related threats and potential incidents. We undertake considerable ongoing
improvements to our systems, connected devices and information-sharing products in order to minimize vulnerabilities, in accordance with
industry and regulatory standards. Because the techniques used to obtain unauthorized access change frequently and can be difficult to
detect, anticipating, identifying or preventing these intrusions or mitigating them if and when they occur, may be challenging.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to maintain an effective system
of internal controls over financial reporting, we may not be able to accurately report our financial results or prevent fraud and our
business may be harmed and our stock price may be adversely impacted.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective internal controls over financial reporting
are necessary for us to provide reliable financial reports and to effectively prevent fraud. Any inability to provide reliable financial
reports or to prevent fraud could harm our business. The Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;) requires management
to evaluate and assess the effectiveness of our internal control over financial reporting. In order to comply with the requirements of
the Sarbanes-Oxley Act, we are required to continuously evaluate and, where appropriate, enhance our policies, procedures and internal
controls. If we fail to maintain the adequacy of our internal controls over financial reporting, we could be subject to litigation or
regulatory scrutiny and investors could lose confidence in the accuracy and completeness of our financial reports. If we fail to fully
comply with the requirements of the Sarbanes-Oxley Act or our management concludes that our internal controls over financial reporting
are not effective, our business may be harmed and our stock price may decline. In addition, because of its inherent limitations, internal
controls over financial reporting may not prevent or detect misstatements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Indebtedness</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our indebtedness could adversely affect our
financial condition and prevent us from fulfilling our obligations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A significant portion of our future cash flow is
required to pay interest and principal on our outstanding indebtedness, and we may be unable to generate sufficient cash flow from operations,
or have future borrowings available, to enable us to repay our indebtedness or to fund other liquidity needs. Among other consequences,
this indebtedness could:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">require us to use a significant
                                            percentage of our cash flow from operations for debt service and the satisfaction of repayment
                                            obligations, and not for other purposes, such as funding working capital and capital expenditures
                                            or making future acquisitions;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">cause our interest expense to increase
                                            if there is a general increase in interest rates, because our indebtedness bears interest
                                            at floating rates;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">limit our flexibility in planning
                                            for or reacting to changes in our business and limit our ability to exploit future business
                                            opportunities; and</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">cause us to be more highly leveraged
                                            than some of our competitors, which may place us at a competitive disadvantage.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our outstanding indebtedness is subject to
certain operating and financial covenants that restrict our business and financing activities and may adversely affect our cash flow
and our ability to operate our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 17, 2024 (the &#8220;Closing
Date&#8221;), we, as borrower, entered into a term loan agreement with the subsidiary guarantors party thereto from time to time
(collectively, the &#8220;Guarantors&#8221;), CRG Servicing LLC as administrative agent and collateral agent (the
&#8220;Agent&#8221;), and the lenders party thereto from time to time (as amended from time to time, the &#8220;CRG Term Loan
Agreement&#8221;), providing for a senior secured term loan of up to $55.0 million (the &#8220;CRG Term Loan&#8221;). The CRG Term
Loan Agreement requires us and the Guarantors to maintain compliance with certain operating and financial covenants, which, among
other things, limit our and the Guarantors&#8217; ability to incur additional debt, grant or permit additional liens, make
investments and acquisitions above certain thresholds, merge or consolidate with others, dispose of assets, pay dividends and
distributions and enter into affiliate transactions, in each case, subject to certain exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, the CRG Term Loan Agreement requires us to maintain:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">liquidity in an amount which shall
                                            exceed the greater of (i) $3.0 million and (ii) to the extent we have incurred certain permitted
                                            debt, the minimum cash balance, if any, required of us by the creditors of such permitted
                                            debt; and</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">annual minimum revenue of at least:
                                            (i) $60.0 million for the twelve-month period beginning on January 1, 2024 and ending on
                                            December 31, 2024, (ii) $75.0 million for the twelve-month period beginning on January 1,
                                            2025 and ending on December 31, 2025, (iii) $85.0 million for the twelve-month period beginning
                                            on January 1, 2026 and ending on December 31, 2026, (iv) $95.0 million for the twelve-month
                                            period beginning on January 1, 2027 and ending on December 31, 2027 and (v) $105.0 million
                                            during each twelve-month period beginning on January 1 of a given year thereafter.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A breach of any of the covenants under the CRG Term
Loan Agreement, subject to certain cure periods, will result in an event of default. Any event of default under the CRG Term Loan Agreement
could cause all of our outstanding indebtedness to become immediately due and payable, and a default interest rate of up to an additional
4.0% per annum may be applied to the outstanding loan balance. If our indebtedness is accelerated, we cannot be certain that we will
have sufficient funds available to pay the accelerated indebtedness or that we will have the ability to refinance the accelerated indebtedness
on terms favorable to us or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Products and Our Product
Pipeline</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We rely on our research and development partners
to design, manufacture and supply certain products we have licensed for marketing. If we or one of our partners fails to perform adequately,
fulfill our needs, or comply with regulations, we may be required to incur significant costs or even be subject to enforcement actions.
We also may face significant delays in our product introductions and commercialization.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we expect to have the capability to develop
certain of our pipeline in-house, we do not currently own any facility that may be used as a manufacturing and processing facility, and
therefore rely on our research and development partners from whom we license most of the products we currently commercialize to design,
manufacture and supply certain of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We and our research and development partners responsible
for manufacturing certain of our products and their contract manufacturers are obliged to operate in accordance with FDA&#8217;s current
good manufacturing practices (&#8220;cGMP&#8221;), current good tissue practices (&#8220;cGTP&#8221;), and the QSR, as applicable, as
well as other regulations applicable to medical product manufacturers. The manufacture of regulated medical products in compliance with
cGMP, cGTP, and the QSR, as applicable, requires significant expertise and capital investment, including the development of advanced
manufacturing techniques and process controls. Manufacturers of medical products often encounter difficulties in production, including
difficulties with production costs and yields, quality control, including product stability and quality assurance testing, shortages
of qualified personnel, as well as compliance with strictly enforced regulatory requirements, other federal and state regulatory requirements
and foreign regulations. If we or our research and development partners or their contract manufacturers were to encounter any of these
difficulties or otherwise fail to comply with their obligations to us or under applicable regulations, our ability to commercialize our
products would be jeopardized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We and the manufacturers of certain of our products
may be unable to comply with applicable FDA, state and foreign regulatory requirements. The FDA or similar foreign regulatory agencies
may also implement new standards at any time or change their interpretation and enforcement of existing standards for manufacture, packaging
or testing of regulated products. We have little control over the manufacturers&#8217; compliance with these regulations and standards.
Our failure or a failure of any of our current or future research and development partners or their contract manufacturers to establish
and follow cGMP, cGTP, and the QSR, as applicable, and to document their adherence to such practices may lead to significant delays in
obtaining marketing authorization of future products or the ultimate launch of products. Failure by us or our current or future partners
or manufacturers to comply with applicable regulations could also result in sanctions being imposed on us or our partners, including
fines, injunctions, civil penalties, failure of the government to grant marketing authorization, delays, suspension or withdrawal of
authorization, seizures or recalls of products, operating restrictions, and criminal prosecutions. If the safety of any product supplied
is compromised due to the manufacturers&#8217; failure to adhere to applicable laws or for other reasons, we may not be able to successfully
commercialize our products. Any of these factors could cause a delay of commercialization of our products, entail higher costs or impair
our reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Revenue generated from the sale of certain
products is dependent on license agreements with certain manufacturers, and the termination of any of these license agreements could
harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We rely on license agreements with certain manufacturers
in order to sell certain of our products. Many of these license agreements are nonexclusive, and our license agreements generally have
a term between one and five years. The license agreements are subject to renewal; however, the manufacturers may determine not to renew
the agreements or to terminate the contracts pursuant to their terms. We cannot be certain that these license agreements will continue
to be available to us or will be available to us on reasonable terms. If any of these agreements are terminated, we may be unable to
reacquire the necessary license on satisfactory terms or at all. The loss of, or inability to maintain, any of these license agreements
could negatively impact our ability to sell our products, which could have a material adverse effect on our business, financial condition
and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Certain of our product candidates are still
under development, and we may not be able to successfully commercialize any of these product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our pipeline contains products and product candidates
for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement, and cell
compatible substrates. We may also decide to develop other product candidates. Certain of our research and development programs are in
developmental stages. One or more of our product candidates may fail to meet safety and efficacy standards in human testing, even if
those product candidates are found to be effective in animal studies. To develop and commercialize product candidates, we must provide
the FDA and foreign regulatory authorities with human clinical and nonclinical animal data that demonstrate adequate safety and effectiveness.
To generate this data, we will have to subject our product candidates to significant additional research and development efforts, including
extensive nonclinical studies and clinical testing. Our approach to product discovery may not be effective or may not result in the development
of any product. It can take several years for a product to be approved and we may not be successful in bringing any therapeutic candidates
to the market. A new product candidate may appear promising at an early stage of development or after clinical trials and never reach
the market, or it may reach the market and not sell, for a variety of reasons. For example, the product may:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">be shown to be ineffective or to
                                            cause harmful side effects during preclinical testing or clinical trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">fail to receive regulatory approval
                                            on a timely basis or at all;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">be difficult to manufacture on a
                                            large scale;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">not be economically viable;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">not be prescribed by doctors or
                                            accepted by patients;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">fail to receive a sufficient level
                                            of reimbursement from government, insurers or other third-party payors; or</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">infringe on intellectual property
                                            rights of any other party.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If our delivery platform technologies or product
development efforts fail to generate product candidates that lead to the successful development and commercialization of products, or
if the product candidates we have (or may in the future) acquired are not approved or cleared for commercialization in the United States
or, otherwise experience adverse regulatory action, our business and financial condition will be materially adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our future success will largely depend on our
ability to maintain and further grow clinical acceptance and adoption of our products, and we may be unable to adequately educate healthcare
practitioners on the use and benefits of our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Healthcare practitioners play a significant role
in determining the course of a patient&#8217;s treatment and, ultimately, the type of products, if any, that will be used to treat the
patient. As a result, our commercial success is dependent on our ability to educate practitioners on the use of our products in both
surgical and post-acute care settings. Acceptance and adoption of our products in our markets depends on educating healthcare practitioners
as to the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products, including potential
comparisons to our competitors&#8217; products, and on training healthcare practitioners in the proper application of our products. If
we are not successful in convincing healthcare practitioners of the merits and advantages of our products compared to our competitors&#8217;
products, they may not use our products, and we will be unable to increase our sales and sustain growth or profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Convincing healthcare practitioners to dedicate the
time and energy necessary to properly train to use new products and techniques is challenging as healthcare practitioners may be hesitant
to change their medical practices, and we may not be successful in these efforts. If healthcare practitioners are not properly trained,
they may use our products ineffectively, resulting in unsatisfactory patient outcomes, negative publicity or lawsuits against us. Accordingly,
even if our products show superior benefits, safety or efficacy, based on head-to-head clinical trials, in comparison to alternative
treatments, our success will depend on our ability to gain and maintain market acceptance for our products. If we fail to do so, our
sales will not grow and our business, financial condition and results of operations will be adversely affected. We may not have adequate
resources to effectively educate the medical community, and our efforts may not be successful due to physician resistance or negative
perceptions regarding our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Disruption of, or changes in, our distribution
model or customer base could harm our sales and margins.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we fail to manage the distribution of our products
properly, there may be a material adverse effect on our business. Furthermore, a change in the mix of our customers between service provider
and enterprise, or a change in the mix of direct and indirect sales, could adversely affect our business. Several factors could result
in disruption of or changes in our distribution model or customer base, which could harm our sales and margins. For instance, we compete
with some of our resellers through our direct sales, which may lead these channel partners to use other suppliers that do not compete
with them. In addition, some of our resellers may have insufficient financial resources and may not be able to withstand changes in business
conditions. If either of these situations were to occur, our reseller channels would weaken, which would result in a material adverse
effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Interruptions in the supply of our products
or inventory loss may adversely affect our business, financial condition and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our products are manufactured using technically complex
processes requiring specialized facilities, highly specific raw materials and other production constraints. The complexity of these processes,
as well as strict company and government standards for the manufacture and storage of our products, subjects us to production risks.
In addition to ongoing production risks, process deviations or unanticipated effects of approved process changes may result in noncompliance
with regulatory requirements including stability requirements or specifications. Most of our products must be stored and transported
within a specified temperature range. For example, if environmental conditions deviate from that range, our products&#8217; remaining
shelf-lives could be impaired or their safety and efficacy could be adversely affected, making them unsuitable for use. These deviations
may go undetected. Severe weather conditions and natural disasters may make compliance with these processes and maintenance of these
standards more difficult, and climate change threatens more extreme weather events, which could increase our production risks. The occurrence
of actual or suspected production and distribution problems can lead to lost inventories, and in some cases recalls, with consequential
reputational damage and the risk of product liability. The investigation and remediation of any identified problems can cause production
delays and result in substantial additional expenses. Any unforeseen failure in the storage of our products or loss in supply could result
in a loss of our market share and negatively affect our revenues and operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Failure of any third-party assessments to demonstrate
desired outcomes in proposed endpoints could have a negative impact on our business performance.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our collaborators regularly conduct clinical studies
designed to test a variety of endpoints associated with product performance and use across a number of applications. If a clinical study
conducted by us or our collaborators fails to demonstrate statistically significant results supporting performance, use benefits or compelling
health economic outcomes from using our products, physicians may elect not to use our products as a treatment for conditions that may
benefit from them. Furthermore, in the event of an adverse clinical study outcome, our products may not achieve &#8220;standard-of-care&#8221;
designations, where they exist, for the conditions in question, which could deter the adoption of our products. Also, if serious adverse
events are reported during the conduct of a study, it could affect continuation of the study, product marketing authorization by regulatory
authorities and product adoption by healthcare professionals or could cause regulatory authorities to impose other restrictions on the
product or require additional warning or precaution statements to appear on the product labeling. If we or our collaborators are unable
to develop a body of statistically significant evidence from our clinical studies, whether due to adverse results or the inability to
complete properly designed studies, public and private payors could refuse to cover our products, limit the manner in which they cover
our products, or reduce the price they are willing to pay or reimburse for our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Increased prices for, or unavailability of,
raw materials used in our products could adversely affect our business, financial condition and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our profitability is affected by the prices of the
raw materials used in the manufacture of our products. These prices may fluctuate based on a number of factors beyond our control, including
changes in supply and demand, general economic conditions, labor costs, fuel related delivery costs, competition, import duties, excises
and other indirect taxes, currency exchange rates, and government regulation. Due to the highly competitive nature of the healthcare
industry and the cost containment efforts of our customers and third-party payors, we may be unable to pass along cost increases for
key components or raw materials through higher prices to our customers. If the cost of key components or raw materials increases, and
we are unable fully to recover these increased costs through price increases or offset these increases through other cost reductions,
we could experience lower margins and profitability. Significant increases in the prices of raw materials that cannot be recovered through
productivity gains, price increases or other methods could adversely affect our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our THP Platform and Planned
Expansion into Value-Based Wound, Skincare and Other Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our planned expansion into value-based wound,
skincare and other services could have a material adverse effect on our business, financial condition and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our planned expansion into value-based wound, skincare
and other services subjects us to risks associated with the use of new and novel technologies, operational, financial, regulatory, legal
and reputational risks, as well as the risk that we may be unable to timely or successfully launch our service offerings. The success
of these operations depends upon our ability to commercialize our service offerings, and our failure to do so could negatively affect
our ability to generate revenue from these activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our planned expansion into value-based wound,
skincare and other services will require entrance into certain markets in which, in some cases, we have limited experience, which may
not be successful and could be costly.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our planned expansion into value-based wound, skincare
and other services will require entrance into certain markets in which we have limited experience. While we intend to expand our staff
with individuals with more experience in these markets and will closely scrutinize individuals we engage, we may not be able to retain
or continue to hire well-qualified and experienced individuals or our assessment of individuals we retain may not be accurate. As we
enter new markets, we will face new technological and operational risks and challenges with which we are unfamiliar and may incur significant
costs. Entering new markets requires substantial management efforts and skills to mitigate these risks and challenges. Our lack of experience
with certain of these new markets may result in unsuccessful new market entries. If we do not manage our entry into new markets properly,
these costs and risks could harm our business, financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to adequately protect our
intellectual property rights, we may not be able to compete effectively.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Part of our success depends on our and our research
development partners&#8217; ability to protect proprietary rights to technologies used in certain of our products. We and our research
development partners rely on patents, copyrights, trademarks and trade secret laws to establish and maintain proprietary rights in our
technology and products. However, these legal means afford only limited protection and may not adequately protect our or our research
development partners&#8217; rights or permit us to gain or keep a competitive advantage. Patents and patent applications for the products
we have may not be sufficient or broad enough to prevent competitors from introducing similar products into the market. Our or our research
development partners&#8217; patents or attempts to enforce them may not be upheld by the courts and the damages or other remedies awarded
if we were to prevail in upholding such patents may not be commercially meaningful. Efforts to enforce any of our or our research development
partners&#8217; proprietary rights could be time-consuming and expensive, which could adversely affect our business and prospects and
divert management&#8217;s attention. There can be no assurance that our or our research and development partners&#8217; proprietary rights
will not be challenged, invalidated or circumvented or that such rights will in fact provide competitive advantages to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Furthermore, the issuance of a patent, while presumed
valid and enforceable, is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary
protection or competitive advantages against competitors with similar products. Competitors may also be able to design around our patents.
Other parties may develop and obtain patent protection for more effective technologies, designs or methods. In addition, we may not be
able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants, vendors, former employees
and current employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patent rights are territorial, and patent protection
extends only to those countries where we have issued patents. Filing, prosecuting and defending patents on our products and product candidates
in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some
countries outside the United States could be less or more extensive than those in the United States, and their litigation processes differ.
Competitors may successfully challenge or avoid our patents or manufacture products in countries where we have not applied for patent
protection. Changes in the patent laws in the United States or other countries may diminish the value of our patent rights. As a result
of these and other factors, the scope, validity, enforceability, and commercial value of our and our research development partners&#8217;
patent rights are uncertain and unpredictable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The patent positions of life sciences companies,
including our and our research development partners&#8217; patent positions, involve complex legal and factual questions, and, therefore,
the issuance, scope, validity and enforceability of any patent claims that we and our research development partners may obtain cannot
be predicted with certainty. Patents, if issued, may be challenged, deemed unenforceable, invalidated, or circumvented. A third-party
may submit prior patents, or we may become involved in opposition, derivation, reexamination, inter partes review, post-grant review,
supplemental examination, or interference proceedings challenging our patent rights or the patent rights of our licensors or development
partners. The costs of defending or enforcing our proprietary rights in these proceedings can be substantial, and the outcome can be
uncertain. An adverse determination in any such submission or proceeding could reduce the scope of, or invalidate, our patent rights,
allow third parties to commercialize our technology or products and compete directly with us, or reduce our ability to manufacture or
commercialize products. Furthermore, if the scope or strength of protection provided by our patents and patent applications is threatened,
it could discourage companies from collaborating with us to license, develop or commercialize current or future products. The ownership
of our proprietary rights could also be challenged.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our and our research development partners&#8217;
ability to enforce our respective patent rights depends on the ability to detect infringement. It is difficult to detect infringers who
do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement
in a competitor&#8217;s or potential competitor&#8217;s product, particularly in litigation in countries other than the United States
that do not provide an extensive discovery procedure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>CellerateRX Surgical is not currently protected
by any pending patent application or any unexpired patent. CellerateRX Surgical may be subject to competition from the sale of substantially
equivalent products that could adversely affect our business and operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our CellerateRX Surgical products, from which we
derive a substantial majority of our net revenue, have no patent protection, and therefore, in order to continue to obtain commercial
benefits from CellerateRX Surgical, we will rely on product manufacturing trade secrets, know-how and related nonpatent intellectual
property, such as potential regulatory rights that would require various resources to separately obtain. The effect of CellerateRX Surgical&#8217;s
lack of patent protection depends, among other things, upon the nature of the market and the position of our products in the market from
time to time, the size of the market, the complexities and economics of manufacturing a competitive product and applicable regulatory
approval requirements. In the event that competition develops substantially equivalent products, this competition could have a material
adverse effect on our business, financial condition and operating results. Trade secret protection is effective only against wrongful
acquisition, use or disclosure of confidential information. A competitor can avoid a claim of trade secret misappropriation by showing
independent development without use of a trade secret owner&#8217;s information, however, this typically requires some time, effort and
financial resources to develop independently. The entrance into the market of a product substantially equivalent to CellerateRX Surgical
may erode our product&#8217;s market share, which may have a material adverse effect on our business, financial condition and results
of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be found to infringe on or violate the
intellectual property rights of others.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may not have identified all patents, published
applications or published literature that affect our business either by blocking our ability to commercialize our products or R&amp;D
candidates, by preventing the patentability of one or more aspects of our products or R&amp;D candidates to us or our licensors, or by
covering the same or similar technologies that may affect our ability to market our products and R&amp;D candidates. For example, we
(or the licensor of a product or R&amp;D candidate to us) may not have conducted a patent clearance search sufficient to identify potentially
obstructing third party patent rights. Moreover, patent applications in the United States are maintained in confidence for up to 18 months
after their filing. In some cases, however, patent applications remain confidential in the USPTO, for the entire time prior to issuance
as a U.S. patent. Patent applications filed in countries outside of the United States are not typically published until at least 18 months
from their first filing date. Similarly, publication of discoveries in the scientific or patent literature often lags behind actual discoveries.
We cannot be certain that we or our licensors were the first to invent, or the first to file, patent applications covering our products
and candidates. We also may not know if our competitors filed patent applications for technology covered by our pending applications
or if we were the first to invent the technology that is the subject of our patent applications. Competitors may have filed patent applications
or received patents and may obtain additional patents and proprietary rights that block or compete with our patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Such third parties, including customers, may in the
future assert claims or initiate litigation related to exclusive patent, copyright, trademark and other intellectual property rights
to technologies and related standards that are relevant to us, our operations and our products. These assertions may emerge over time
as a result of our growth and the general increase in the pace of patent claim assertions, particularly in the United States. Because
of the existence of a large number of patents in the healthcare field, the secrecy of some pending patent applications and the rapid
rate of issuance of new patents, we believe that it is not economically practical or even possible to determine in advance whether a
product or any of its components is completely free of infringement of the patent rights of others even when we take reasonably objective
steps to determine that relevant patent rights might exist and, if so, to evaluate such patent rights relative to our proposed and actual
products and methods with patent counsel. The asserted claims or initiated litigation can include claims against us or our manufacturers,
suppliers or customers alleging infringement of their proprietary rights with respect to our existing or future products or components
of those products. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, intellectual
property litigation or claims could force us to cease developing, selling or otherwise commercializing one or more of our products; to
pay substantial damages for past use of the asserted intellectual property; to obtain a license from the holder of the asserted intellectual
property, which may not be available on reasonable terms, if at all; and redesign, or rename in the case of trademark claims, our product(s)
to avoid such third party rights, which may not be possible or which could be costly and time-consuming. Any of these risks coming to
fruition could have a material adverse effect on our business, results of operations, financial condition and prospects. Regardless of
the merit of these claims, they can be time-consuming, result in costly litigation and diversion of technical and management personnel,
or require us to develop a noninfringing technology or enter into license agreements. Where claims are made by customers, resistance
even to unmeritorious claims could damage customer relationships. There can be no assurance that licenses will be available on acceptable
terms and conditions, if at all, or that our indemnification by our suppliers will be adequate to cover our costs if a claim were brought
directly against us or our customers. Furthermore, because of the potential for high court awards that are not necessarily predictable
and the resources required to engage in a full defense of such allegations, it is not unusual to find even arguably unmeritorious claims
settled for significant amounts. If any infringement or other intellectual property claim made against us by any third party is successful,
or if we fail to develop noninfringing technology or license the proprietary rights on commercially reasonable terms and conditions,
our business could be materially and adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Regulations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our business is affected by numerous regulations
relating to the development, manufacture, distribution, labeling, marketing and sale of our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Government regulation by the FDA and similar agencies
in other countries is a significant factor in the development, manufacturing and marketing of our products and in the acquisition or
licensing of new products. Complying with government regulations is often time consuming and expensive and may involve delays or actions
adversely impacting the marketing and sale of our current or future products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following initial regulatory approval or clearance
of any products that we or our research and development partners may develop, we and/or our research and development partners will be
subject to continuing regulatory review, including, but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">appropriate establishment registration
                                            and product listing requirements;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">FDA&#8217;s cGMP, cGTP and QSR regulations,
                                            which govern the methods used in, and the facilities and controls used for, the design, manufacture,
                                            packaging, labeling, storage, installation, and servicing of finished devices, drugs and/or
                                            biologics, as applicable;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">FDA labeling requirements, which
                                            mandate the inclusion of certain content in medical product labels and labeling, and which
                                            also prohibit the promotion of products for uncleared or unapproved, i.e., &#8220;off-label,&#8221;
                                            indications;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">adverse event reporting regulations,
                                            which, generally, require applicable establishments (such as manufacturers and importers,
                                            among others) report to the FDA any adverse reactions, events, or experiences that meet the
                                            FDA&#8217;s reporting thresholds for the given product type (e.g., under FDA&#8217;s adverse-event
                                            reporting regulations under its device framework, adverse events must be reported if they
                                            may have caused or contributed to a death or serious injury or malfunctioned in a way that
                                            would likely cause or contribute to a death or serious injury if it were to recur); and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the Reports of Corrections and Removals
                                            regulation, which requires that manufacturers and importers report to the FDA corrective
                                            actions and product removals (both of which are defined under applicable regulations) that
                                            meet the definition of a &#8220;recall&#8221; if undertaken to reduce a risk to health posed
                                            by the product or to remedy a violation of the FDCA that may present a risk to health and
                                            that manufacturers and importers keep records of recalls that they determine to be not reportable.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Failure to comply with applicable regulatory requirements
can result in, among other things, the FDA or other governmental authorities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">imposing fines and penalties on
                                            us;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">preventing us from manufacturing
                                            or selling our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">delaying or denying pending applications
                                            for approval or clearance of our products or of new uses or modifications to our existing
                                            products, or withdrawing or suspending current approvals or clearances;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">ordering or requesting a recall
                                            of our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">issuing warning letters, untitled
                                            letters, or &#8220;It has Come to Our Attention&#8221; letters;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">imposing operating restrictions,
                                            including a partial or total shutdown of production or investigation of any or all of our
                                            products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">refusing to permit to import or
                                            export of our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">detaining or seizing our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">obtaining injunctions preventing
                                            us from manufacturing or distributing any or all of our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">commencing criminal prosecutions
                                            or seeking civil penalties; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">requiring changes in our advertising
                                            and promotion practices.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, private consumer and competitor litigation
tends to follow FDA enforcement actions and publications, such that a company that is targeted by FDA or another regulatory body is also
at an increased risk of facing civil litigation (often in the form of class actions).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The manufacturing facilities we or our research and
development partners use (and may use) to make any of our FDA-regulated products are or may become subject to periodic review and inspection
by the FDA. If a previously unknown problem with a product or a manufacturing or laboratory facility used or contracted by us or one
of our research and development partners is discovered, the FDA may impose restrictions on that product or on the manufacturing facility,
including requiring us and/or our research and development partner to withdraw the product from the market. Any changes to an approved
or cleared product, including the way it is manufactured or promoted, often requires FDA review and separate approval or clearance before
the product, as modified, may be marketed. In addition, for products we develop in the future, we and our contract manufacturers may
be subject to ongoing FDA requirements for submission of safety and other post-market approval information. If we violate regulatory
requirements at any stage, whether before or after marketing approval or clearance is obtained, we may be fined, be forced to remove
a product from the market or experience other adverse consequences, which would materially harm our financial results. Additionally,
due to limitations imposed on us by the scope of the cleared or approved indications or intended use of our products and by FDA and Federal
Trade Commission (&#8220;FTC&#8221;) regulations relating to promotional claims, we may not be able to obtain the labeling claims necessary
or desirable for product promotion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Distribution of our products outside the United States
is subject to extensive government regulation. These regulations, including the requirements for marketing authorizations or product
licenses necessary to bring a medical product to market, the time required for regulatory review and the sanctions imposed for violations,
vary from country to country. We do not know whether we will obtain the marketing authorizations or product licenses necessary to market
our products in such countries or that we will not be required to incur significant costs in obtaining or maintaining these regulatory
approvals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are subject to various governmental regulations
relating to the labeling, marketing and sale of our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Both before and after a product is commercially released,
we have ongoing responsibilities under regulations promulgated by the FDA, the FTC, and similar U.S. and foreign regulations governing
product labeling and advertising, distribution, sale and marketing of our products. Medical devices and biological products may only
be marketed or promoted for the uses and indications set forth in the approved or cleared product labeling. A number of enforcement actions
have been taken against companies that promoted products for &#8220;off-label&#8221; uses (i.e., uses that are not described in the approved
or cleared labeling), including actions alleging that claims submitted to government healthcare programs for reimbursement of products
that were promoted for &#8220;off-label&#8221; uses are fraudulent in violation of the Federal False Claims Act or other federal and
state statutes and that the submission of those claims was caused by off-label promotion. The failure to comply with prohibitions on
off-label promotion can result in significant monetary penalties, revocation or suspension of a company&#8217;s business license, suspension
of sales of certain products, product recalls, civil or criminal sanctions, exclusion from participating in federal healthcare programs,
or other enforcement actions. In the United States, allegations of such wrongful conduct could also result in a corporate integrity agreement
with the U.S. government that imposes significant administrative obligations and costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to obtain or experience significant
delays in obtaining regulatory clearances or approvals to market future medical device products, we will be unable to commercialize these
products until such clearance or approval is obtained.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The developing, testing, manufacturing, marketing
and selling of medical devices is subject to extensive regulation by governmental authorities in the United States and other countries.
The process of obtaining regulatory clearance and approval of certain medical technology products is costly and time consuming. Inherent
in the development of new medical products is the potential for delay because product testing, including clinical evaluation, is typically
required, especially for drugs, biologics and high-risk devices, before such products can be approved for human use. With respect to
medical devices, such as those that we currently market, before a new medical device, or a new indicated use of, or claim for, an existing
product can be marketed (unless it is a Class I device), it must first receive either premarket clearance under Section 510(k) of the
FDCA or approval of a PMA from the FDA, or be reclassified and receive marketing authorization through the de novo classification process,
unless an exemption applies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the 510(k)-clearance process, the FDA must determine
that the proposed device is &#8220;substantially equivalent&#8221; to a Class I or II device legally on the market, known as a &#8220;predicate&#8221;
device, with respect to intended use, technology, safety and effectiveness to clear the proposed device for marketing. Clinical data
is sometimes required to support substantial equivalence for certain device types. The PMA pathway requires an applicant to demonstrate
the safety and effectiveness of the device for its intended use based, in part, on extensive data including, but not limited to, technical,
preclinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose
the greatest risk, such as life-sustaining, life-supporting or implantable devices. If a device is novel and there is no appropriate
predicate to which the applicant can demonstrate substantial equivalence, the device will be automatically classified as a Class III
device and require approval through the PMA process prior to commercialization, unless the applicant submits a <i>de novo</i> classification
request demonstrating that the novel device should be reclassified into Class I or II. Demonstrating that a novel device should be reclassified
to Class I or II from Class III typically requires extensive information and data on the benefits and risks of the device, including
performance data and frequently data from one or more clinical studies. The 510(k), PMA and <i>de novo</i> classification approval processes
can be expensive and lengthy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Failure to comply with applicable regulatory requirements
can result in, among other things, suspension or withdrawal of clearances or approvals, seizure or recall of products, injunctions against
the manufacture, holding, distribution, marketing and sale of a product and civil and criminal sanctions. Furthermore, changes in existing
regulations or the adoption of new regulations could prevent us from obtaining, or affect the timing of, future regulatory clearances
or approvals. Meeting regulatory requirements and evolving government standards may delay marketing of any new products developed by
us for a considerable period of time, impose costly procedures upon our activities and result in a competitive advantage to larger companies
that compete against us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA or other regulatory agencies may not clear
or approve any products developed by us on a timely basis, or at all, or, if granted, clearance or approval may entail limiting the indicated
uses for which we may market the product, which could limit the potential market for any of these products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Delays in or changes to the FDA clearance and
approval processes or ongoing regulatory requirements could make it more difficult for us to obtain FDA clearance or approval of new
products or comply with ongoing requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">New government regulations may be enacted and changes
in FDA policies and regulations and, their interpretation and enforcement, could prevent or delay regulatory clearance or approval of
new products. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation
or administrative action, either in the United States or abroad. Therefore, we do not know whether we or our research and development
partners will be able to continue to comply with such regulations or whether the costs of such compliance will have a material adverse
effect on our business. Changes could, among other things, require different labeling, monitoring of patients, interaction with physicians,
education programs for patients or physicians, curtailment of necessary supplies, or limitations on product distribution. These changes,
or others required by the FDA could have an adverse effect on our business, and specifically, on the sales of affected products. The
evolving and complex nature of regulatory science and regulatory requirements, the broad authority and discretion of the FDA and the
generally high level of regulatory oversight results in a continuing possibility that from time to time, we will be adversely affected
by regulatory actions despite ongoing efforts and commitment to achieve and maintain full compliance with all regulatory requirements.
If we or our research and development partners are not able to maintain regulatory compliance, we may not be permitted to market our
products and our business would suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Disruptions in the FDA and other government
agencies caused by leadership changes, funding shortages, or other legal or political pressures could hinder their ability to hire and
retain key personnel, provide regulatory clarity, or otherwise prevent new products and services from being developed or commercialized
in a timely manner or hinder our ability to continue marketing existing commercial products, which could negatively impact our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ability of the FDA to review and approve new
products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel
and accept the payment of user fees, and statutory, regulatory, and policy changes and other events that may otherwise affect the FDA&#8217;s
ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government
funding of other government agencies that fund research and development activities is subject to the political process, which is inherently
fluid and unpredictable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, the recent presidential election and congressional
seat turnover may result in increased regulatory and economic uncertainty, including the spending priorities of the new U.S. presidential
administration and Congress and what challenges budget reductions will present for us and our industry generally. For example, on January
20, 2025, President Trump announced an executive order establishing the &#8220;Department of Government Efficiency&#8221; to reform federal
government processes and reduce expenditures. Changes in federal policy by the executive branch and regulatory agencies may occur over
time through the new presidential administration&#8217;s and/or Congress&#8217;s policy and personnel changes, which could lead to changes
involving our industry. However, the nature and timing of such potential changes remain highly uncertain. At this time, it is unclear
whether and how any future changes or uncertainty surrounding future changes will adversely affect our business, but material adverse
effects are possible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Failure to obtain or maintain adequate reimbursement or insurance
coverage for our products could limit our ability to market those products and decrease our ability to generate revenue. Changes in reimbursement
policies and regulations by governmental or other third-party payors may have an adverse impact on the use of our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The pricing, coverage, and reimbursement of our products,
if any, must be sufficient to support our commercial efforts and other development programs, and the availability and adequacy of coverage
and reimbursement by third-party payors, including governmental and private insurers, are essential for most patients to be able to afford
medical treatments. Sales of our products depend substantially, both domestically and abroad, on the extent to which the costs of our
products, if any, will be paid for or reimbursed by health maintenance, managed care, and similar healthcare management organizations,
or government payers and private payors. If coverage and reimbursement are not available, or are available only in limited amounts, we
may have to subsidize or provide medical products for free or we may not be able to successfully commercialize our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A significant portion of our wound care products
are purchased principally for the Medicare and Medicaid eligible population by hospital outpatient clinics, wound care clinics, durable
medical equipment (&#8220;DME&#8221;) suppliers and SNFs, which typically bill various third-party payors, primarily state and federal
healthcare programs (e.g., Medicare and Medicaid), and managed care plans, for the products and services provided to their patients.
Although the majority of our wound care products are currently eligible for reimbursement under Medicare Part B, adjustments to our reimbursement
amounts or a change in CMS&#8217;s reimbursement policies could have an adverse effect on our market opportunities in this area. The
ability of our customers to obtain appropriate reimbursement for products and services from third-party payors is critical to the success
of our business because reimbursement status affects which products our customers purchase. In addition, our ability to obtain reimbursement
approval in foreign jurisdictions may affect our ability to expand our product offerings internationally.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Third-party payors have adopted, and are continuing
to adopt, a number of policies intended to curb rising healthcare costs. These policies include the imposition of conditions of payment
by foreign, state and federal healthcare programs as well as private insurance plans, and the reduction in reimbursement amounts applicable
to specific products and services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Changes in healthcare systems in the United States
or internationally in a manner that significantly reduces reimbursement for procedures using our products or denies coverage for these
procedures would also have an adverse impact on the acceptance of our products and the prices which our customers are willing to pay
for them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, increasing efforts by governmental and
private payors in the United States and abroad to limit or reduce healthcare costs may result in restrictions on coverage and the level
of reimbursement for new medical products and, as a result, they may not cover or provide adequate payment for our products. We expect
to experience pricing pressures in connection with our products due to the increasing trend toward managed healthcare, including the
increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs
in general, and prescription drugs or biologics in particular, has and is expected to continue to increase in the future. As a result,
profitability of our current or future products may be more difficult to achieve.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We rely on our research and development partners
to comply with applicable laws and regulations relating to product classification and when and what types of FDA marketing authorizations
are needed to lawfully commercialize a new or updated medical product in the United States.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We rely on our research and development partners,
from whom we license most of the products we currently commercialize, to determine the appropriate classification for each such product
and to comply with applicable regulations related to obtaining the proper marketing authorization. With respect to each medical device
product we license, our respective research and development partner designs the product and determines whether the device should be classified
as a Class I, II, or III device and the appropriate FDA marketing authorization pathway to pursue (i.e., 510(k), PMA or de novo classification).
In addition, we rely on our research and development partners to determine whether specific legal or regulatory definitions or exemptions
apply to particular medical products, which individually may be subject to FDA oversight as a device, drug, biologic or human cellular
or tissue-based product. The FDA has broad regulatory authority to interpret and enforce the laws and regulations that govern medical
products in commercial distribution, and any adverse determination by the FDA relating to one of our licensed products could require
significant cost and effort to comply.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain devices that we market under a license (or
that we have acquired or have, otherwise, obtained commercialization rights in the United States) have been updated or modified since
their initial 510(k) clearance. Depending on the nature of the updates or modifications made to a 510(k)-cleared device, the FDA may
require the submission (and clearance) of a new 510(k). More specifically, any modification that could significantly affect the cleared
device&#8217;s safety or effectiveness, or that would constitute a significant change in its intended use, will require a new 510(k)
clearance. The FDA requires device manufacturers to make the initial determination as to whether a proposed modification to a cleared
device requires a new 510(k) submission, but the FDA can review any such decision not to submit a new 510(k) (if it becomes aware of
the modifications during an inspection or otherwise) and may disagree with the manufacturer&#8217;s determination that the given modification(s)
did not require new clearance. If the FDA finds that a manufacturer has improperly marketed a modified device (for which the FDA has
determined that a new 510(k) is required) under the original device&#8217;s 510(k), the FDA may mandate that the manufacturer cease marketing
and/or recall the modified device until the requisite clearance is obtained, in addition to one or more other enforcement actions. FDA
may disagree with our partners&#8217; decisions not to submit new 510(k) notifications for those of our 510(k)-cleared devices that have
been updated or modified since their initial clearance, in which case, we may be subject to a wide range of FDA enforcement actions,
including, but not limited to, warning letters, fines, and other penalties, and our business will be adversely affected, as we would
likely be required to cease commercialization (and, possibly, conduct a recall) of the modified product(s) at-issue and may incur additional
expenses in connection with the preparation and submission of a new 510(k).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We and our employees and contractors are subject,
directly or indirectly, to federal, state and foreign healthcare fraud and abuse laws, including false claims laws. If we are unable
to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operations are subject to various federal, state
and foreign fraud and abuse laws. These laws may affect our operations, including the financial arrangements and relationships through
which we market, sell and distribute our products. U.S. federal and state laws that affect our ability to operate include, but are not
limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the federal Anti-Kickback Statute,
                                            which prohibits, among other things, persons or entities from knowingly and willfully soliciting,
                                            receiving, offering or paying any remuneration (including any kickback, bribe, or rebate),
                                            directly or indirectly, overtly or covertly, in cash or in kind in return for, the purchase,
                                            recommendation, leasing or furnishing of an item or service reimbursable under a federal
                                            healthcare program, such as the Medicare and Medicaid programs;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">federal civil and criminal false
                                            claims laws and civil monetary penalty laws, which prohibit, among other things, individuals
                                            or entities from knowingly presenting, or causing to be presented, claims for payment or
                                            approval from Medicare, Medicaid, or other government payors that are false or fraudulent;</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Section 242 of HIPAA codified at
                                            18 U.S.C. &#167; 1347, which created new federal criminal statutes that prohibit a person
                                            from knowingly and willfully executing a scheme or from making false or fraudulent statements
                                            to defraud any healthcare benefit program (i.e., public or private);</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">federal transparency laws, including
                                            the so-called federal &#8220;sunshine&#8221; law, which requires the tracking and disclosure
                                            to the federal government by pharmaceutical and medical device manufacturers of payments
                                            and other transfers of value to physicians and teaching hospitals as well as ownership and
                                            investment interests that are held by physicians and their immediate family members; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">state law equivalents of each of
                                            these federal laws, such as anti-kickback and false claims laws that may apply to items or
                                            services reimbursed by any third-party payer, including commercial insurers, state laws that
                                            require pharmaceutical and medical device companies to comply with their industry&#8217;s
                                            voluntary compliance guidelines and the applicable compliance guidance promulgated by the
                                            federal government or otherwise restrict certain payments that may be made to healthcare
                                            providers and other potential referral sources, state laws that require drug and medical
                                            device manufacturers to report information related to payments and other transfers of value
                                            to physicians and other healthcare providers or marketing expenditures, state laws that prohibit
                                            giving gifts to licensed healthcare professionals and state laws governing the privacy and
                                            security of health information in certain circumstances, many of which differ from each other
                                            in significant ways and may not have the same effect, thus complicating compliance efforts
                                            in certain circumstances, such as specific disease states.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In particular, activities and arrangements in the
healthcare industry are subject to extensive laws and regulations intended to prevent fraud, waste and other abusive practices. These
laws and regulations may restrict or prohibit a wide range of activities or other arrangements related to the development, marketing
or promotion of products, including pricing and discounting of products, provision of customer incentives, provision of reimbursement
support, other customer support services, provision of sales commissions or other incentives to employees and independent contractors
and other interactions with healthcare practitioners, other healthcare providers and patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because of the breadth of these laws and the narrow
scope of the statutory or regulatory exceptions and safe harbors available, our business activities could be challenged under one or
more of these laws. Relationships between medical product manufacturers and health care providers are an area of heightened scrutiny
by the government. We engage in various activities, including the conduct of speaker programs to educate physicians, the provision of
reimbursement advice and support to customers, and the provision of customer and patient support services, that have been the subject
of government scrutiny and enforcement action within the medical device industry.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Government expectations and industry best practices
for compliance continue to evolve and past activities may not always be consistent with current industry best practices. Further, there
is a lack of government guidance as to whether various industry practices comply with these laws, and government interpretations of these
laws continue to evolve, all of which create compliance uncertainties. Any noncompliance could result in regulatory sanctions, criminal
or civil liability and serious harm to our reputation. Although we have a comprehensive compliance program designed to ensure that our
employees&#8217; and commercial partners&#8217; activities and interactions with healthcare professionals and patients are appropriate,
ethical, and consistent with all applicable laws, regulations, guidelines, policies and standards, it is not always possible to identify
and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in preventing such conduct,
mitigating risks, or reducing the chance of governmental investigations or other actions or lawsuits stemming from a failure to comply
with these laws or regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a government entity opens an investigation into
possible violations of any of these laws (which may include the issuance of subpoenas), we would have to expend significant resources
to defend ourselves against the allegations. Allegations that we, our officers, or our employees violated any one of these laws can be
made by individuals called &#8220;whistleblowers&#8221; who may be our employees, customers, competitors or other parties. Government
policy is to encourage individuals to become whistleblowers and file a complaint in federal court alleging wrongful conduct. The government
is required to investigate all of these complaints and decide whether to intervene. If the government intervenes and we are required
to pay damages, which in such cases are typically set at three times the actual monetary damages, to the government, the whistleblower,
as a reward, is awarded a percentage of such damages or any settlement amount. If the government declines to intervene, the whistleblower
may proceed on their own and, if they are successful, they will receive a percentage of any judgment or settlement amount the company
is required to pay. The government may also initiate an investigation on its own. If any such actions are instituted against us, those
actions could have a significant impact on our business, including the imposition of significant fines, and other sanctions that may
materially impair our ability to run a profitable business. In particular, if our operations are found to be in violation of any of the
laws described above or if we agree to settle with the government without admitting to any wrongful conduct or if we are found to be
in violation of any other governmental regulations that apply to us, we, our officers and employees may be subject to sanctions, including
civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid,
imprisonment, the curtailment or restructuring of our operations and the imposition of a corporate integrity agreement, any of which
could adversely affect our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We and our research and development partners&#8217;
use of PII, including health information, is subject to federal and state privacy and security regulations, and our failure
to comply with those regulations or to adequately secure the information we hold could have a material adverse effect on our client base,
business, financial condition and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Numerous state and federal laws and regulations,
including HIPAA, govern the collection, dissemination, use, privacy, confidentiality, security, availability and integrity of PII, including
protected health information. HIPAA establishes a set of basic national privacy and security standards for the protection of PHI by health
plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with
whom such covered entities contract for services, which likely includes us. HIPAA requires healthcare providers and business associates
to develop and maintain policies and procedures with respect to PHI that is used or disclosed, including the adoption of administrative,
physical, and technical safeguards to protect such information. HIPAA also implemented the use of standard transaction code sets and
standard identifiers that covered entities must use when submitting or receiving certain electronic healthcare transactions, including
activities associated with the billing and collection of healthcare claims. HIPAA imposes mandatory penalties for certain violations.
HIPAA also authorizes each state&#8217;s Attorney General to file suit on behalf of their residents. Courts will be able to award damages,
costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing
individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil
suits such as those for negligence or recklessness in the misuse or breach of PHI.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, HIPAA mandates that the Secretary of
HHS conduct periodic compliance audits of HIPAA covered entities or business associates for compliance with the HIPAA Privacy and Security
Standards. HIPAA further requires that patients be notified of any unauthorized acquisition, access, use or disclosure of their unsecured
PHI that compromises the privacy or security of such information, with certain exceptions related to unintentional or inadvertent use
or disclosure by employees or authorized individuals. HIPAA specifies that such notifications must be made without unreasonable delay
and in no case later than 60 calendar days after discovery of the breach. If a breach affects 500 patients or more, it must be reported
to HHS without unreasonable delay, and HHS will post the name of the breaching entity on its public web site. Breaches affecting 500
patients or more in the same state or jurisdiction must also be reported to the local media. If a breach involves fewer than 500 people,
the covered entity must record it in a log and notify HHS at least annually.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Numerous other federal and state laws protect the
confidentiality, privacy, availability, integrity and security of PII, including PHI. These laws in many cases are more restrictive than,
and may not be preempted by, the HIPAA rules and may be subject to varying interpretations by courts and government agencies, creating
complex compliance issues for us and our clients and potentially exposing us to additional expense, adverse publicity and liability.
In addition, new health information standards, whether implemented pursuant to HIPAA, congressional action or otherwise, could have a
significant effect on the manner in which we must handle healthcare related data, and the cost of complying with standards could be significant.
If we do not comply with existing or new laws and regulations related to PHI, we could be subject to criminal or civil sanctions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because of the extreme sensitivity of the PII we
or our partners may store and transmit, the security features of our technology platforms are very important. If our security measures,
some of which may be managed by third parties, are breached or fail, unauthorized persons may be able to obtain access to sensitive client
and patient data, including HIPAA-regulated PHI. As a result, our reputation could be severely damaged, adversely affecting client or
investor confidence. Clients may curtail their use of or stop using our products and services, which would cause our business to suffer.
In addition, we could face litigation, damages for contract breach, penalties and regulatory actions for violation of HIPAA and other
applicable laws or regulations and significant costs for remediation, notification to individuals and for measures to prevent future
occurrences. Any potential security breach could also result in increased costs associated with liability for stolen assets or information,
repairing system damage that may have been caused by such breaches, incentives offered to client or other business partners in an effort
to maintain our business relationships after a breach and implementing measures to prevent future occurrences, including organizational
changes, deploying additional personnel and protection technologies, training employees and engaging third-party experts and consultants.
While we maintain insurance covering certain security and privacy damages and claim expenses, our coverage may not be sufficient to compensate
for all liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our officers, employees, independent contractors,
principal investigators, consultants and commercial partners may engage in misconduct or activities that are improper under other laws
and regulations, which would create liability for us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are exposed to the risk that our officers, employees,
independent contractors (including contract research organizations (&#8220;CROs&#8221;)), principal investigators, consultants and commercial
partners may engage in fraudulent conduct or other illegal activity and/or may fail to disclose unauthorized activities to us. Misconduct
by these parties could include, but is not limited to, intentional, reckless and/or negligent failures to comply with:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the laws and regulations of the
                                            FDA and its foreign counterparts requiring, among other things, compliance with good manufacturing
                                            practice and/or quality system requirements, post-market vigilance reporting, product marketing
                                            authorization requirements, facility registration requirements, the reporting of true, complete
                                            and accurate information to such regulatory bodies, including but not limited to safety problems
                                            associated with the use of our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">laws and regulations of the FDA
                                            and its foreign counterparts concerning the conduct of clinical trials and the protection
                                            of human research subjects, including but not limited to good clinical practices;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">other laws and regulations of the
                                            FDA and its foreign counterparts relating to the manufacture, processing, packing, holding,
                                            investigating or distributing in commerce of medical devices, biological products and/or
                                            HCT/Ps;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">manufacturing standards we have
                                            established; or</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">healthcare fraud and abuse laws,
                                            including but not limited to, the Anti-Kickback Statute, the Stark Law, the FCA, and state
                                            law equivalents.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In particular, companies involved in the manufacture
of medical products are subject to laws and regulations intended to ensure that medical products that will be used in patients are safe
and effective, and, specifically, that they are not adulterated or misbranded, that they are properly labeled, and have the identity,
strength, quality and purity that which they are represented to possess. Further, companies involved in the research and development
of medical products are subject to extensive laws and regulations intended to protect research subjects and ensure the integrity of data
generated from clinical trials and of the regulatory review process. Any misconduct in any of these areas, whether by our own employees
or by contractors, vendors, business associates, consultants, or other entities acting as our agents, could result in regulatory sanctions,
criminal or civil liability and serious harm to our reputation. Although we have a comprehensive compliance program designed to ensure
that our employees&#8217;, CRO partners&#8217;, principal investigators&#8217;, consultants&#8217;, and commercial partners&#8217; activities
and interactions with healthcare professionals and patients are appropriate, ethical, and consistent with all applicable laws, regulations,
guidelines, policies and standards, it is not always possible to identify and deter misconduct, and the precautions we take to detect
and prevent this activity may not be effective in preventing such conduct, mitigating risks, or reducing the chance of governmental investigations
or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against
us, or our CRO partners, principal investigators, consultants, or commercial partners, those actions could have a significant impact
on our business, including the imposition of significant fines, and other sanctions that may materially impair our ability to run a profitable
business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We could be adversely affected if healthcare
reform measures substantially change the market for medical care or healthcare coverage in the United States.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Third party payors, governmental authorities, and
other applicable stakeholders have developed, and are continuing to develop, increasingly sophisticated methods of controlling healthcare
costs. In both the United States and certain foreign jurisdictions, there have been numerous legislative and regulatory changes to the
healthcare system that could impact our ability to sell our products profitably. In particular, the Affordable Care Act was enacted in
the United States in 2010, and various analogous or similarly intended state laws, as well as a number of executive, legislative, and
judicial challenges have followed in the years since. There remains substantial uncertainty and continued evolution with regard to healthcare
reform measures, and we cannot predict the effect that any current or future such measure will have on our business. Complying with any
new or amended legislation, policies, rulings, or other relevant healthcare cost-containment and/or transparency requirements may be
time-intensive and expensive, which could have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been, and likely will continue to be,
legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare.
We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed
care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may
adversely affect the demand for some or all of the products we currently market or may commercialize in the future, if any, including:
our ability to receive or set a price that we believe is fair for our products; our ability to generate revenue and achieve or maintain
profitability; the level of taxes that we are required to pay; and the availability of capital. We expect that existing healthcare reform
legislation, and any similar measures implemented in the future, will result in additional reductions in Medicare and other healthcare
funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the prices that we are
able to charge or receive for our products and/or may create additional challenges in relation to reimbursement/coverage. Any denial
in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction
in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize
our product candidates, if approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Defects, failures or quality issues associated
with our products could lead to product recalls or safety alerts, adverse regulatory actions, product liability lawsuits and other litigation
and negative publicity that could materially adversely affect our reputation, business, results of operations and financial condition.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Quality is extremely important to us and our customers
due to the serious and costly consequences of product failure. Quality and safety issues may occur with respect to any of our products,
and our future operating results will depend on our ability to maintain an effective quality control system and effectively train and
manage our workforce with respect to our quality system. The development, manufacture and control of medical products are subject to
extensive and rigorous regulation by numerous government agencies, including the FDA and similar foreign agencies. Compliance with these
regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the FDA and foreign
regulatory authorities. The FDA and foreign regulatory authorities may also require post-market testing and surveillance to monitor the
performance of products cleared or approved for use in their jurisdictions. Our manufacturing facilities and those of our suppliers and
independent sales agencies are also subject to periodic regulatory inspections. If the FDA or other regulatory authority were to conclude
that we or our suppliers have failed to comply with any of these requirements, it could institute a wide variety of enforcement actions,
ranging from a public warning letter to more severe sanctions, such as product recalls or seizures, withdrawals, monetary penalties,
consent decrees, injunctive actions to halt the manufacture or distribution of products, import detentions of products made outside the
United States, export restrictions, restrictions on operations or other civil or criminal sanctions. Civil or criminal sanctions could
be assessed against our officers, employees, or us. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively
manufacturing, marketing, and selling our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Relatedly, although we have contractual indemnity
from the manufacturers of our current products for certain liability claims related to their production, we could face product liability
lawsuits or other similar proceedings relating to actual or alleged injuries, defects, deficiencies, failures, and/or representations
relating to our products that could fall outside of the scope of the contractual indemnities. We do not have, and do not anticipate obtaining,
contractual indemnification from parties supplying raw materials or parties marketing the products we sell. In any event, indemnification
from the manufacturers of our products or from any other party is limited by the terms of the indemnity and by the creditworthiness of
the indemnifying party. A successful product liability or other applicable claim or series of claims brought against us could result
in judgments, fines, damages and liabilities that could have a material adverse effect on our business. We may incur significant expense
investigating and defending these claims, even if they do not result in liability. Moreover, even if no judgments, fines, damages or
liabilities are imposed on us, our reputation could suffer as result of any such claim, which could have a material adverse effect on
our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Product liability insurance for the healthcare industry
may become prohibitively expensive, to the extent it is available at all. We may not be able to maintain such insurance on acceptable
terms or be able to secure increased coverage as commercialization of our products progresses, nor can we be sure that existing or future
claims against us will be covered by our product liability insurance. In the event that we do not have adequate insurance or contractual
indemnification, product liability claims relating to defective products could have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, we cannot predict the results of future
legislative activity or future court decisions, any of which could increase regulatory requirements, subject us to government investigations
or expose us to unexpected litigation. Any regulatory action or litigation, regardless of the merits, may result in substantial costs,
divert management&#8217;s attention from other business concerns and place additional restrictions on our sales or the use of our products.
In addition, negative publicity, including regarding a quality or safety issue, could damage our reputation, reduce market acceptance
of our products, cause us to lose customers and decrease demand for our products. Any actual or perceived quality issues may also result
in issuances of physician&#8217;s advisories against our products or cause us to conduct voluntary recalls. Any product defects or problems,
regulatory action, litigation, negative publicity or recalls could disrupt our business and have a material adverse effect on our business,
results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Ownership of Our Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>It is possible that we will require additional
capital to meet our financial obligations and support business growth, and this capital might not be available on acceptable terms or
at all.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to continue to make significant investments
to support our business growth and expect to require additional funds to respond to business challenges. Accordingly, we may need to
engage in equity or debt financings to secure additional funds. If we raise additional funds through future issuances of equity or convertible
debt securities, our existing shareholders could suffer significant dilution, and any new equity securities we issue could have rights,
preferences and privileges superior to those of holders of our common stock. Any debt financing that we secure in the future could involve
restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more
difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. We may not be able
to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms
satisfactory to us when and if we require it, our ability to continue to support our business growth and to respond to business challenges
could be significantly impaired, and our business may be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The trading price of the shares of our common
stock is highly volatile, and purchasers of our common stock could incur substantial losses.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The market price of our common stock has been and
is likely to continue to be highly volatile and could fluctuate widely in response to various factors, many of which are beyond our control,
including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">technological innovations or new
                                            products and services by us or by our competitors, including announcements by us or our competitors
                                            of significant contracts, acquisitions, strategic partnerships or capital commitments;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">additions or departures of key personnel;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">changes in expectations as to our
                                            future financial performance;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">sales of our common stock;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to execute our business
                                            plan;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">loss of any strategic relationship;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">industry developments;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">changes in financial estimates by
                                            any securities analysts who follow our common stock, our failure to meet these estimates
                                            or failure of those analysts to initiate or maintain coverage of our common stock;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">general market conditions, including
                                            market volatility and inflation;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">fluctuations in stock market prices
                                            and trading volumes of similar companies;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">economic, political and other external
                                            factors;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">period-to-period fluctuations in
                                            our financial results;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">applicable regulatory developments
                                            in the United States and foreign countries, both generally or specific to us and our products;
                                            and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">intellectual property, product liability
                                            or other litigation against us.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although publicly traded securities are subject to
price and volume fluctuations, it is likely that our common stock will experience these fluctuations to a greater degree than the securities
of more established and better capitalized organizations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our common stock does not have a vigorous trading
market, and you may not be able to sell your securities at or near ask prices, or at all.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although there is a public market for our common
stock, trading volume has been historically low, which could impact our stock price and your ability to sell shares of our common stock
at or near ask prices, or at all. We can give no assurance that a more active and liquid public market for the shares of our common stock
will develop in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The potential sale of large amounts of common
stock may have a negative effect upon the market value of our shares.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales of a significant number of shares of our common
stock in the public market or the perception that these sales might occur could harm the market price of our common stock and make it
more difficult for us to raise funds through future offerings of common stock. As additional shares of our common stock become available
for resale in the public market, the supply of our common stock will increase, which could decrease the price of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have not paid, and we are unlikely to pay
in the near future, cash dividends on our securities. Because we have no plans to pay cash dividends on our common stock for the foreseeable
future, you may not receive any return on investment unless you sell your common stock for a price greater than that which you paid for
it.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not paid and do not currently intend to pay
dividends on our common stock, which may limit the current return available on an investment in our stock. Future dividends on our stock,
if any, will depend on our future earnings, capital requirements, financial condition and such other factors as our management may consider
relevant. Currently, we intend to retain earnings, if any, to increase our net worth and reserves. Consequently, shareholders will only
realize an economic gain on their investment in our common stock if the price appreciates. Shareholders should not purchase our common
stock expecting to receive cash dividends. Because we currently do not pay dividends, and there may be limited trading in our common
stock, shareholders may not have any manner to liquidate or receive any payment on their common stock. Therefore, our failure to pay
dividends may cause shareholders to not see any return on their common stock even if we are successful in our business operations. In
addition, because we do not pay dividends, we may have trouble raising additional funds, which could affect our ability to expand our
business operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>A few of our existing shareholders own a large
percentage of our voting stock and have control over matters requiring shareholder approval and may delay or prevent a change in control
or otherwise lead to actual or potential conflicts of interest.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March&#160;18, 2025, our directors beneficially
owned, including through their affiliates, approximately 41% of our outstanding common stock. As a result, our directors and their
affiliates could have the ability to exert substantial influence over all matters requiring approval by our shareholders, including (i)
the election and removal of directors, (ii) any proposed merger, consolidation or sale of all or substantially all of our assets as well
as other corporate transactions and (iii) any amendment to our Amended and Restated Certificate of Formation (the &#8220;Certificate
of Formation&#8221;). This concentration of control could be disadvantageous to other shareholders having different interests. This significant
concentration of share ownership may adversely affect the trading price for our common stock because investors sometimes perceive disadvantages
in owning stock in companies with controlling shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, our Certificate of Formation contains
a provision which under the Texas Business Organizations Code (the &#8220;TBOC&#8221;) could allow the shareholders who own a majority
of our common stock to approve certain major transactions without the approval of other shareholders that otherwise would be required
under Texas corporation law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Certificate of Formation includes provisions
limiting the personal liability of our directors for breaches of fiduciary duties under Texas law.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Certificate of Formation contains a provision
eliminating a director&#8217;s personal liability for acts or omissions in the director&#8217;s capacity as a director to the fullest
extent permitted under Texas law. Pursuant to the TBOC, a corporation has the power to indemnify its directors and officers against judgments
and certain expenses other than judgments that are actually and reasonably incurred in connection with a proceeding, provided that there
is a determination that the individual acted in good faith and in a manner reasonably believed to be in or not opposed to the best interests
of the corporation and, with respect to any criminal proceeding, had no reasonable cause to believe the individual&#8217;s conduct was
unlawful. However, no indemnification may be made in respect of any proceeding in which such individual is liable to the corporation
or improperly received a personal benefit and is found liable for willful misconduct, breach of the duty of loyalty owed to the corporation,
or an act or omission deemed not to be committed in good faith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The principal effect of the limitation on liability
provision is that a shareholder will be unable to prosecute an action for monetary damages against a director unless the shareholder
can demonstrate a basis for liability for which indemnification is not available under the TBOC. The inclusion of this provision in our
Certificate of Formation may discourage or deter shareholders or management from bringing a lawsuit against directors for a breach of
their fiduciary duties, even though such an action, if successful, might otherwise have benefited us and our shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Texas law, our Certificate of Formation and
our Amended and Restated Bylaws contain anti-takeover provisions that could delay or discourage takeover attempts that shareholders may
consider favorable.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under our Certificate of Formation, our board of
directors can authorize the issuance of preferred stock, which could diminish the rights of holders of our common stock and make a change
of control of the Company more difficult even if it might benefit our shareholders. The board of directors is authorized to issue shares
of preferred stock in one or more series and to fix the voting powers, preferences and other rights and limitations of the preferred
stock. Accordingly, we may issue shares of preferred stock with a preference over our common stock with respect to dividends or distributions
on liquidation or dissolution, or that may otherwise adversely affect the voting or other rights of the holders of common stock. Issuances
of preferred stock, depending upon the rights, preferences and designations of the preferred stock, may have the effect of delaying,
deterring or preventing a change of control, even if that change of control might benefit our shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, provisions of our Certificate of Formation
and our Amended and Restated Bylaws (&#8220;Bylaws&#8221;) may delay or discourage transactions involving an actual or potential change
in our control or change in our management, including transactions in which shareholders might otherwise receive a premium for their
shares, or transactions that our shareholders might otherwise deem to be in their best interests. For example, our Certificate of Formation
and Bylaws (i) do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock
entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose), (ii) require
that special meetings of the shareholders be called by the Chairman of the board of directors, the President or the board of directors,
or by the holders of not less than twenty-five percent (25%) of all the shares issued, outstanding and entitled to vote, (iii) permit
our board of directors to alter, amend or repeal our Bylaws or to adopt new bylaws, and (iv) enable our board of directors to increase
the number of persons serving as directors and to fill vacancies created as a result of the increase by a majority vote of the directors
present at a meeting of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we are subject to the provisions of Title 2,
Chapter 21, Subchapter M of the TBOC, which provides that a Texas corporation that qualifies as an &#8220;issuing public corporation&#8221;
(as defined in the TBOC) may not engage in specified types of business combinations, including mergers, consolidations and asset sales,
with a person, or an affiliate or associate of that person, who is an &#8220;affiliated shareholder,&#8221; the restrictions in Title
2, Chapter 21, Subchapter M of the TBOC do not apply to us because we have elected, in the manner provided under the TBOC, not to be
subject to such provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our failure to meet the continued listing requirements
of The Nasdaq Capital Market could result in a delisting of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our shares of common stock are currently listed for
trading on The Nasdaq Capital Market under the symbol &#8220;SMTI.&#8221; If we fail to satisfy the continued listing requirements of
The Nasdaq Stock Market, LLC (&#8220;Nasdaq&#8221;), such as the corporate governance requirements, the shareholder&#8217;s equity requirement
or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting or even notification
of failure to comply with such requirements would likely have a negative effect on the price of our common stock and would impair our
shareholders&#8217; ability to sell or purchase our common stock when our shareholders wish to do so. In the event of a delisting, we
expect that we would take actions to restore our compliance with Nasdaq&#8217;s listing requirements, but we can provide no assurance
that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity
of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future noncompliance
with Nasdaq&#8217;s listing requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="Section7"></span>ITEM 1B. UNRESOLVED STAFF
COMMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="Section8"></span>ITEM 1C. CYBERSECURITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_980_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPFAIAMT-DQ_z3GGzWuc5R42" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000050-01" escape="true" id="Fact000050" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">We recognize the critical importance of cybersecurity
in safeguarding sensitive information and maintaining operational resilience. <span id="xdx_90D_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zgAXqd46XXQb" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000051" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">We have processes for assessing, identifying and managing
cybersecurity risks, which are built into our information technology function and are designed to help protect our information assets
and operations from internal and external cyber threats, protect employee and customer information from unauthorized access or attack,
as well as secure our networks and systems</ix:nonNumeric></span>.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_C06_gBFCRMPFAIAMT-DQ_zj35vtBiIUmk"><ix:continuation continuedAt="ConU000050-02" id="ConU000050-01"><span id="xdx_907_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zKuu0cmyEY71" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000052" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">The audit committee of the board of directors (the
&#8220;Audit Committee&#8221;) is responsible for overseeing cybersecurity risk and periodically updates our board of directors on such
matters. The Audit Committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates
regarding any significant new cybersecurity threats or incidents.</ix:nonNumeric></span></ix:continuation></span></p>

<div id="xdx_C0F_gBFCRMPFAIAMT-DQ_z6dN7kgPhjqa"><ix:continuation continuedAt="ConU000050-03" id="ConU000050-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a company, we leverage the National Institute
of Standards and Technology (NIST) Cybersecurity Framework to align with industry best practices and to develop policies and procedures,
which include a Cybersecurity Response Plan focusing on detection, validation, mitigation, recovery, and refinement. In addition to the
Cybersecurity Response Plan, we provide cybersecurity awareness training to our employees, including training on social engineering,
phishing, password protection, confidential data protection, mobile security, and incident reporting, to help prevent and reduce the
impact of potential cybersecurity events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have strategically invested resources and tools
to combat the ever-changing cyber threat landscape. These investments include growing our internal technology team headcount and bolstering
our partnerships with entities with external expertise, resulting in increased protection, monitoring, and response capabilities. We
have also made investments to carry cybersecurity insurance that provides additional protection and resources to reduce a cybersecurity
event&#8217;s impact and potential losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our technology and management teams meet regularly
with key internal and external stakeholders to review cybersecurity concerns and areas for continued focus and improvement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_C07_gBFCRMPFAIAMT-DQ_zA5L1PsWRnW"><ix:continuation id="ConU000050-03">We face risks from cybersecurity threats that could
have a material adverse effect on our business, financial condition, results of operations, cash flows or reputation. To date, we have
not experienced any risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially
affected or are reasonably likely to materially affect our business strategy, financial condition, results of operations, or cash flows.
See &#8220;Risk Factors &#8211; Risks Related to Our Business &#8211; Security breaches and other disruptions could compromise our information
and expose us to liability, which would cause our business and reputation to suffer.&#8221;</ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="Section9"></span>ITEM 2. PROPERTIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not own any buildings or other real property.
As of December 31, 2024, our leased office space in Fort Worth, Texas consisted of approximately 11,414 square feet of rentable space located in Summit Office
Park, a twin-building, mid-rise, 242,000 square foot office park located on the perimeter of the Fort Worth central business district.
In March and September of 2023, we amended our primary office lease to obtain additional space, as well as to extend the lease term.
The lease had a remaining lease term of 72 months as of December&#160;31, 2024. In March 2025, we increased our lease office space in
Fort Worth, Texas by approximately 3,900 square feet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our leased office space in San Antonio, Texas
consists of approximately 7,289 square feet of rentable space located in a 14,500 square foot office park in an industrial district
in San Antonio, Texas. This lease had a remaining lease term of eight months as of December 31, 2024. We are currently evaluating
our renewal options for this lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our leased office space in Orlando, Florida
represents a lease we assumed in connection with our acquisition of Scendia Biologics, LLC. The lease consists of approximately 7,684 square feet
in a 22,947 square foot office building. However, we are co-tenants in the lease with an unaffiliated company with our share of the
lease being agreed to as 40% or approximately 3,074 square feet. The lease had a remaining term of two months as of
December&#160;31, 2024 and was not renewed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We periodically enter into operating lease contracts
for office space and equipment. Arrangements are evaluated at inception to determine whether such arrangements constitute a lease. In
accordance with the transition guidance of Accounting Standards Codification Topic No. 842, such arrangements are included in our balance
sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 7 to the consolidated financial statements
for additional information on our operating leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="section10"></span><b>ITEM 3. LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, we may be involved in claims and
legal actions that arise in the ordinary course of business. To our knowledge, there are no material pending legal proceedings to which
we are a party or of which any of our property is the subject.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="Section11"></span>ITEM 4. MINE SAFETY DISCLOSURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">This item is not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="Section12"></span>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="Section13"></span>ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY,
RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is traded on The Nasdaq Capital
Market under the trading symbol &#8220;SMTI.&#8221; The closing price of our common stock as reported by Nasdaq on March&#160;18, 2025,
was $33.64.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Record Holders</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March&#160;18, 2025, there were 310 shareholders
of record and there were 8,901,903 shares of common stock issued and outstanding. The number of shareholders of record does not reflect
the number of persons or entities who held stock in nominee or street name through various brokerage firms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Dividends</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have never declared or paid any cash dividends
on our common stock, and we do not intend to pay cash dividends in the foreseeable future. We currently expect to retain any future earnings
to fund our operations and the expansion of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recent Sales of Unregistered Securities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no sales of unregistered securities during
the year ended December&#160;31, 2024 that were not previously reported on a Quarterly Report on Form 10-Q or a Current Report on Form
8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Issuer Purchases of Equity Securities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We did not repurchase any of our equity securities
during the fourth quarter of the fiscal year ended December&#160;31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="Section14"></span>ITEM 6. RESERVED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="Section15"></span>ITEM 7. MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following discussion and analysis contains forward-looking
statements about future revenues, operating results, plans and expectations. Forward-looking statements are based on a number of assumptions
and estimates that are inherently subject to significant risks and uncertainties and our results could differ materially from the results
anticipated by our forward-looking statements as a result of many known or unknown factors, including, but not limited to, those factors
discussed in Part I, Item 1A. Risk Factors. Also, please read the &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221;
set forth at the beginning of this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, the following discussion should be read in conjunction with
Part I of this Annual Report on Form 10-K as well as our Consolidated Financial Statements and the related Notes to Consolidated Financial
Statements contained elsewhere in this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OVERVIEW</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a medical technology company focused on developing
and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic
wound and skincare markets. Our products, services and technologies are designed to achieve our goal of providing better clinical outcomes
at a lower overall cost for patients regardless of where they receive care. Through our two operating segments, Sanara Surgical and Tissue
Health Plus (&#8220;THP&#8221;), we strive to be one of the most innovative and comprehensive providers of effective surgical, wound
and skincare solutions and are continually seeking to expand our offerings for patients requiring treatments across the entire continuum
of care in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Change in Reportable Segments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Historically, we managed our business on the basis
of one operating and reportable segment. During the second quarter of 2024, we changed our reportable segments to reflect a change in
the manner in which the business is managed. Based on the growing importance of the value-based wound care program to our future outlook
and how our chief operating decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, reviews operating results and makes decisions
about resource allocation, we now have two reportable segments: Sanara Surgical and THP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sanara Surgical</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Sanara Surgical segment primarily markets and
sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Sanara Surgical&#8217;s
soft tissue repair products include, among other products, our lead product, CellerateRX Surgical Activated Collagen (&#8220;CellerateRX
Surgical&#8221;), a hydrolyzed collagen that supports a local environment for surgical sites to aid in the natural wound healing process,
and BIASURGE Advanced Surgical Solution (&#8220;BIASURGE&#8221;), a sterile no-rinse, advanced surgical solution used for wound irrigation.
Sanara Surgical&#8217;s bone fusion products include, among other products, BiFORM Bioactive Moldable Matrix (&#8220;BiFORM&#8221;),
an osteoconductive, bioactive, porous implant that allows for bony ingrowth across the graft site, and ALLOCYTE Plus Advanced Viable
Bone Matrix (&#8220;ALLOCYTE Plus&#8221;), a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable
bone fibers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Sanara Surgical segment also includes an in-house
research and development team, Rochal Technologies, with an extensive pipeline of innovative products under development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Tissue Health Plus</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our value-based care segment, THP, is focused on
value-based wound care services. Through THP, we plan to offer a first of its kind value-based wound care program to payers and risk-bearing
entities such as accountable care organizations and value-based primary care companies, with Medicare Advantage payers as the initial
target market for this program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">THP&#8217;s programs are expected to enable payers
to divest wound care spend risk, reduce wound related hospitalizations and improve patient quality of life. THP plans to coordinate delivery
of community and home-based wound care for its managed patients. Community based care spans a variety of settings, including physician
offices, skilled nursing facilities, assisted living facilities and senior living facilities. THP programs are intended to integrate
science and evidence-based medicine protocols to standardize wound prevention and treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Summary of Our Product, Service and Technology
Offerings and Development Programs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sanara Surgical Products</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Sanara Surgical segment markets and distributes
surgical, wound and skincare products to physicians, hospitals, clinics, and post-acute care settings. Our products are primarily sold
in the U.S. surgical tissue repair and advanced wound care markets. We believe we have the ability to drive our product pipeline from
concept to preclinical and clinical development while meeting quality and regulatory requirements. We are constantly seeking long-term
strategic partnerships with a focus on products that improve outcomes at a lower overall cost.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>CellerateRX Surgical</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CellerateRX Surgical is a medical hydrolysate of
Type I bovine collagen indicated for the management of surgical, traumatic, and partial and full-thickness wounds as well as first- and
second-degree burns. It is manufactured with a proprietary process. CellerateRX Surgical powder is sterilized, packaged and designed
specifically for use in the operating room or other sterile environment. CellerateRX Surgical products are primarily purchased by hospitals
and ambulatory surgical centers for use by surgeons on surgical wounds. The majority of CellerateRX Surgical products are used for a
variety of surgical wounds, including those associated with orthopedic, spine, trauma and oncologic procedures. Additional surgical wounds
that may benefit from the use of CellerateRX Surgical include cardiovascular, gynecologic, urologic, vascular and plastic/reconstructive related
procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CellerateRX Surgical is used in operative cases where
patients might have trouble healing normally due to underlying health complications. There is always a risk of complication with surgical
wounds. This is especially true in patients with certain comorbidities, including obesity, diabetes and hypertension. These complications
can include surgical wound infections, dehiscence (where an incision opens after primary closure) and necrosis. Surgeons use CellerateRX
Surgical to complement the body&#8217;s normal healing process. By supporting the body to heal normally without complications, improved
patient outcomes are achieved, thereby reducing downstream costs related to complications (such as re-operation, longer hospitalization,
re-admittance, extended rehabilitative care and other additional treatments). Surgical wound complications have become increasingly problematic
due to the high rates of surgical patient comorbidities and the financial strain on insurance payors as well as hospitals who suffer
exorbitant costs for readmission of these patients within 90 days of surgery.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>BIASURGE</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BIASURGE is a 510(k) cleared sterile no-rinse,
advanced surgical solution used for wound irrigation. It contains an antimicrobial preservative effective against a broad spectrum
of pathogenic microorganisms in the solution. BIASURGE is indicated for use in the mechanical cleansing and removal of debris, including
microorganisms, from surgical wounds. First sales of BIASURGE occurred in November 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>FORTIFY TRG</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FORTIFY TRG Tissue Repair Graft (&#8220;FORTIFY TRG&#8221;)
is a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet. The graft is 510(k) cleared for implantation to
reinforce soft tissue, is terminally sterilized, has a thin profile, is available in multiple sizes, and can be cut to size to accommodate
the patient&#8217;s anatomy. FORTIFY TRG is provided sterile and can be hydrated with autologous blood fluid. First sales of this product
occurred in the fourth quarter of 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>FORTIFY FLOWABLE</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FORTIFY FLOWABLE Extracellular Matrix (&#8220;FORTIFY
FLOWABLE&#8221;) is an advanced wound care device that presents small intestine submucosa extracellular matrix technology in a way that
can fill irregular wound shapes and depths. FORTIFY FLOWABLE is indicated for the management of wounds, including partial and full-thickness
wounds, pressure ulcers, venous leg ulcers, diabetic foot ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds
(donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence sites), traumatic wounds (abrasions, lacerations,
second-degree burns, and skin tears) and draining wounds. FORTIFY FLOWABLE is provided sterile and is intended for one-time use. It is
a 510(k) cleared product. First sales of this product occurred in the first quarter of 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Other Surgical Products</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TEXAGEN Amniotic Membrane Allograft is a multi-layer
amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement if needed. BiFORM is
an osteoconductive, bioactive, porous implant that allows for bony ingrowth across the graft site. It can be hydrated and used as a strip
or molded into a putty to fill a bone defect. ACTIGEN Verified Inductive Bone Matrix is a naturally derived, differentiated allograft
matrix with robust handling properties. ALLOCYTE Plus is a human allograft cellular bone matrices containing bone-derived progenitor
cells and conformable bone fibers. These viable cellular allografts are ready to use upon thawing and have fibrous handling properties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Tissue Health Plus Services and Technology</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2020, we formed a subsidiary, United Wound
and Skin Solutions, LLC (formerly known as &#8220;WounDerm&#8221;), to hold certain investments and operations in wound and skincare
virtual consult services. In 2024, United Wound and Skin Solutions, LLC was renamed to Tissue Health Plus, LLC. THP is continuing its
current mission to simplify skin health, starting with value-based wound care through a refined business plan. Through THP, we plan to
offer a first of its kind value-based wound care program to payers and risk-bearing entities such as accountable care organizations and
value-based primary care companies, with Medicare Advantage payers as the initial target segment for this program. THP services are
not expected to directly involve telemedicine or virtual consult services, and such services are no longer a primary focus of THP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We anticipate that THP&#8217;s customer contracts
will have three-to-five-year terms. These contracts are expected to incorporate a mix of value-based pricing methodologies including
episodic, &#8220;per member per month,&#8221; and &#8220;fee for value&#8221; pricing. We believe this approach is aligned with the financial
goals of the payers and will help deliver outstanding clinical outcomes for the patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our vision for our comprehensive approach consists
of three key sets of planned capabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(a)</td><td style="text-align: justify"><i>Care Hub</i> &#8211; This virtual
                                            patient monitoring, care coordination and navigation center is expected to help doctors and
                                            nurses support their patients throughout their wound care journey, from prevention to treatment.
                                            We expect to have Care Hub staffed by wound care certified nurse practitioners (&#8220;NPs&#8221;)
                                            and registered nurses (&#8220;RNs&#8221;), incorporating care delivery best practices from
                                            partnerships with Direct Dermatology Inc. and certain physician-led multispecialty wound
                                            care groups. With NPs leading Care Hub, RNs are expected to be the wound specialists, providing
                                            patients with expert review and support of the overarching plan of care on each patient&#8217;s
                                            journey through the process. In addition, care navigators are expected to serve as a primary
                                            point of contact for patients and their providers, coordinating care, managing appointments
                                            and ensuring seamless communication among all team members.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(b)</td><td style="text-align: justify"><i>Managed Services Organization (&#8220;MSO&#8221;)
                                            Network</i> &#8211; With respect to patient-side wound care, our plan is that THP&#8217;s
                                            programs would be performed by a network of third-party providers who will be contracted
                                            through managed services agreements. These providers would include podiatrists, wound care
                                            provider groups, primary care physicians, and home health agencies. The providers in the
                                            THP network are expected to leverage THP&#8217;s standard of care, patient education and
                                            tools to deliver optimal patient outcomes with high predictability and efficiency.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(c)</td><td style="text-align: justify"><i>Technology Platform</i> &#8211; THP&#8217;s
                                            technology platform will focus on scaling workflows of THP&#8217;s Care Hub and MSO Network
                                            through automation and integration. We expect the THP technology platform to enable enhanced
                                            patient empowerment and self-healthcare. We anticipate that our platform will leverage our
                                            technology investments and partnerships with Precision Healing Inc. (&#8220;Precision Healing&#8221;),
                                            Pixalere Healthcare, Inc. (&#8220;Pixalere&#8221;) and others, by leveraging modern technology
                                            including artificial intelligence and machine learning. Our platform technology is expected
                                            to manage program economics, standards of care, patient monitoring, wound assessments, network
                                            performance monitoring, and revenue cycle management. We expect that each of these components
                                            will work in concert with each other, constantly improving economics and care delivery.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are seeking partners to facilitate commercialization
of THP and share in the cost of development of the program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>SI Healthcare Technologies Joint Venture</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2022, we established a 50/50 joint venture,
SI Healthcare Technologies, LLC (&#8220;SI Technologies&#8221;) (formerly known as SI Wound Care, LLC), with InfuSystem Holdings, Inc.
(&#8220;InfuSystem&#8221;) focused on delivering a complete wound care solution targeted at improving patient outcomes, lowering the
cost of care, and increasing patient and provider satisfaction. The partnership is expected to enable InfuSystem to offer innovative
products, including our advanced wound care product line and Chemo Mouthpiece, a 510(k) cleared oral cryotherapy device that SI Technologies
currently has the right to distribute and sell in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Tufts University License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, we signed an exclusive license
agreement with Tufts University (&#8220;Tufts&#8221;) to develop and commercialize patented technology covering 18 unique collagen peptides.
As part of this agreement, we formed a new subsidiary, Sanara Collagen Peptides, LLC (&#8220;SCP&#8221;) and issued 10% of SCP&#8217;s
outstanding units to Tufts. SCP has exclusive rights to develop and commercialize new products based on the licensed patents and patents
pending. SCP will pay royalties to Tufts based on net sales of licensed products and technologies. Pursuant to the exclusive license
agreement, royalties will be calculated at a rate of 1.5% or 3%, depending on the type of product or technology developed. SCP will pay
Tufts a minimum annual royalty of $50,000 on January 1 of the year following the first anniversary of the first commercial sale of the
licensed products or technologies. SCP will pay Tufts a $100,000 minimum annual royalty on January 1 of each subsequent year during the
royalty term specified in the exclusive license agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RECENT DEVELOPMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>CRG Term Loan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 17, 2024 (the &#8220;Closing Date&#8221;),
we, as borrower, entered into a Term Loan Agreement (the &#8220;CRG Term Loan Agreement&#8221;) with the subsidiary guarantors party
thereto from time to time (collectively, the &#8220;Guarantors&#8221;), CRG Servicing LLC as administrative agent and collateral agent
(the &#8220;Agent&#8221;), and the lenders party thereto from time to time, providing for a senior secured term loan of up to $55.0 million
(the &#8220;CRG Term Loan&#8221;). In April 2024, our first borrowing (the &#8220;First Borrowing&#8221;) under the CRG Term Loan of
$15.0 million was used to repay the Cadence Term Loan and to pay fees and expenses related to the CRG Term Loan Agreement. In September
2024, we borrowed an additional $15.5 million under the CRG Term Loan (the &#8220;Second Borrowing&#8221;), a portion of the proceeds
of which were used for the investment in ChemoMouthpiece, LLC (&#8220;CMp&#8221;) described below. On March 19, 2025, we and the Guarantors entered into the First Amendment to the Term Loan Agreement with the Agent
and the lenders party thereto from time to time (the &#8220;CRG Amendment&#8221;) to provide for up to two additional borrowings following
the Second Borrowing under the CRG Term Loan, which must occur on or prior to December 31, 2025, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>ChemoMouthpiece Investment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 10, 2024, Sanara CMP LLC, a wholly owned
subsidiary of the Company (&#8220;Sanara CMP&#8221;), entered into a Unit Purchase Agreement (the &#8220;Unit Purchase Agreement&#8221;)
with CMp, pursuant to which Sanara CMP purchased 100,674.72 common units in CMp for an aggregate purchase price of $5.0 million, which
represented approximately 6.64% of the issued and outstanding membership interests of CMp immediately following such purchase. Subsequent
to our initial investment in CMp, units of CMp were sold to other investors, thereby decreasing our ownership of CMp to 6.59% as of December&#160;31,
2024. CMp is a privately held medical device company that develops and commercializes propriety oral cryotherapy products for cancer
patients, including, among other things, CMp&#8217;s Chemo Mouthpiece oral cryotherapy device, which is a 510(k) cleared cryotherapy
device designed to reduce the incidence and severity of chemotherapy induced oral mucositis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Unit Purchase Agreement, we,
CMp, certain subsidiaries of CMp, InfuSystem and SI Technologies, entered into an Exclusive Distribution Agreement (the &#8220;Distribution
Agreement&#8221;) pursuant to which SI Technologies was appointed as the sole and exclusive U.S. distributor of CMp&#8217;s Standard
Chemo Regiment Kits, each kit consisting of the Chemo Mouthpiece oral cryotherapy device and associated materials used in the treatment
of oral mucositis (the &#8220;CMp Product&#8221;), for a term of five years, subject to meeting certain minimum order requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The parties to the Distribution Agreement also entered
into an Intellectual Property Rights Agreement, pursuant to which SI Technologies was granted the exclusive right to use CMp&#8217;s
intellectual property rights to permit resale and use of the CMp Product in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>BMI Investment </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 16, 2025 (the &#8220;Execution Date&#8221;),
we entered into a Licensing and Distribution Agreement (the &#8220;BMI License Agreement&#8221;) with Biomimetic Innovation Limited,
a privately-held medical device company headquartered in Shannon, Co. Clare Ireland (&#8220;BMI&#8221;), pursuant to which we acquired
the exclusive U.S. marketing, sales and distribution rights to OsStic Synthetic Injectable Structural Bio-Adhesive Bone Void Filler (&#8220;OsStic&#8221;),
as well as an adjunctive internal fixation technology featuring novel delivery to promote targeted application of OsStic (&#8220;ARC&#8221;
and together with OsStic, the &#8220;BMI Products&#8221;), for use in the treatment of a wound or injury caused by a traumatic incident.
Pursuant to the BMI License Agreement, we were appointed by BMI as the exclusive distributor to promote, market, offer to sell, transfer,
distribute and sell the BMI Products for trauma indications inside the United States and its territories for an initial five-year term,
which term may be automatically renewed for successive two-year periods at our discretion, provided that we are in compliance with our
obligations thereunder (the &#8220;BMI Term&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the BMI License Agreement, on
the Execution Date, we entered into a Share Subscription and Shareholders&#8217; Agreement (the &#8220;BMI Subscription Agreement&#8221;)
with The Russell Revocable Living Trust, BMI and the existing shareholders of BMI, pursuant to which we agreed to contribute up to approximately
&#8364;8.0 million to BMI through a series of capital contributions in exchange for an aggregate of 16,460 ordinary shares of BMI, constituting
approximately 12.5% of the outstanding equity of BMI as of the Execution Date. We made an initial cash investment totaling approximately
&#8364;3.0 million on the Execution Date, and our previously announced convertible loan to BMI was converted into &#8364;1.0 million of
equity in BMI. Pursuant to the BMI Subscription Agreement, the remaining &#8364;4.0 million contribution is due upon the achievement of
certain development, clinical and regulatory milestones (the &#8220;Milestones&#8221;), which are expected to occur at various points during 2025. For more information regarding the BMI License
Agreement and BMI Subscription Agreement, see the <i>&#8220;Liquidity and Capital Resources</i>&#8221; section below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>COMPONENTS OF RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Sources of Revenue</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenue is derived primarily from sales of our
soft tissue repair and bone fusion products to hospitals and other acute care facilities. In particular, the substantial majority of
our product sales revenue is derived from sales of CellerateRX Surgical. Our revenue is driven by direct orders shipped by us to our
customers, and to a lesser extent, direct sales to customers through delivery at the time of procedure by one of our sales representatives.
We generally recognize revenue when a purchase order is received from the customer and our product is received by the customer. Prior
to 2024, we recognized royalty revenue from a development and licensing agreement with BioStructures, LLC. Under the terms of the development
and license agreement, royalties of 2% were recognized on sales of products containing our patented resorbable bone hemostasis. The minimum
annual royalty due to us was $201,000 per year throughout the life of the patent, which expired in 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue streams from product sales and royalties
are summarized below for the years ended December&#160;31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 0pt">Soft tissue repair products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">76,125,012</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">54,836,410</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Bone fusion products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,547,413</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,952,432</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">201,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total Net Revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">86,672,425</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">64,989,842</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Cost of Goods Sold</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of goods sold consists primarily of the acquisition
costs from the manufacturers of our licensed products, raw material costs for certain components sourced directly by us, and all related
royalties due as a result of the sale of our products. Our gross profit represents total net revenue less the cost of goods sold, and
gross margin represents gross profit expressed as a percentage of total revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Selling, general and administrative (&#8220;SG&amp;A&#8221;)
consists primarily of salaries, sales commissions, benefits, bonuses and share-based compensation. SG&amp;A also includes outside legal
counsel fees, audit fees, insurance premiums, rent and other corporate expenses. We expense all SG&amp;A as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development (&#8220;R&amp;D&#8221;)
includes costs related to enhancements to our currently available products and additional investments in our product, services and technologies
development pipeline. This includes personnel-related expenses, including salaries, share-based compensation and benefits for all personnel
directly engaged in R&amp;D activities, contracted services, materials, prototype expenses and allocated overhead, which is comprised
of compensation and benefits, lease expense and other facilities related costs. We expense R&amp;D costs as incurred. We generally expect
that R&amp;D will increase as we continue to support product enhancements and to bring new products to market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation and amortization includes depreciation
of fixed assets and amortization of intangible assets that have a finite life, such as product licenses, patents and intellectual property,
customer relationships and assembled workforces.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Change in fair value of earnout liabilities represents
our measurement of the change in fair value at the balance sheet date of our earnout liabilities that were established at the time of
our Precision Healing merger and acquisition of Scendia Biologics, LLC (&#8220;Scendia&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other Income (Expense)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other income (expense) is primarily comprised of
interest expense and other nonoperating activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents certain information
about the results and Segment Adjusted EBITDA (as described below) of our reportable business segments. See Note 14, Segment Reporting,
in Part II, Item 8 of this report for more information on our reportable business segments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year
                                            Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December
                                            31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left; padding-left: 0pt">Net revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">86,672,425</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">86,672,425</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">64,987,112</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,730</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">64,989,842</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Cost of goods sold</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,139,901</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,139,901</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,843,721</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,965</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,852,686</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,673,642</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,886,221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,559,863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,826,852</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,167,901</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,994,753</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,828,663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,874,699</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,703,362</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">902,782</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,229,643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,132,425</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,785,829</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,137,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,923,224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,046,859</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,628,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,675,026</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Change in fair value of earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,451</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,924,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,938,451</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,298,336</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,151,559</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,449,895</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Other expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,196,424</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,196,424</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">224,749</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">224,749</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,937,583</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,974,315</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,911,898</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">440,485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,880,387</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,439,902</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Segment Adjusted EBITDA</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,148,722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,457,415</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,691,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,289,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,162,387</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">127,247</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net Revenue.</i></b> For the year ended
December&#160;31, 2024, we generated net revenue of $86.7 million compared to net revenue of $65.0 million for the year ended
December&#160;31, 2023, a 33% increase over the prior year. The higher net revenue in 2024 was primarily due to increased sales of
soft tissue repair products, including CellerateRX Surgical and BIASURGE, and certain bone fusion products as a result of our
increased market penetration, geographic expansion and our continuing strategy to expand our independent distribution network in
both new and existing U.S. markets. In addition, during the fourth quarter of 2024, we experienced a growth in sales of BIASURGE as
a result of supply chain issues and shortages of intravenous (&#8220;IV&#8221;) fluids and saline solutions due to Hurricane Helene.
BIASURGE revenues returned to normal levels in the first quarter of 2025 as access to IV fluids and saline solutions used for the
treatment of wound irrigation was restored. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cost of Goods Sold. </i></b>Cost of goods sold
for the year ended December&#160;31, 2024 was $8.1 million compared to cost of goods sold of $7.9 million for the year ended December&#160;31,
2023. The higher gross margins realized in 2024 were due to increased sales of soft tissue repair products, particularly CellerateRX
Surgical, and the elimination of royalties paid on the sales of CellerateRX Surgical as a result of the Applied Asset Purchase (as described
in further detail in the &#8220;Liquidity and Capital Resources&#8221; section below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Gross Profit.</i></b> On a consolidated
basis, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we generated gross profit of $78.5 million for the
year ended December 31, 2024</span> compared to gross profit of $57.1 million for the year ended December&#160;31, 2023, a 37.4%
increase over the prior year period. The higher gross profit in 2024 was primarily due to increased sales of soft tissue repair
products, particularly CellerateRX Surgical and BIASURGE, as a result of our increased market penetration and geographic expansion,
and our continuing strategy to expand our independent distribution network in both new and existing U.S. markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Selling, general and administrative</i></b>.
SG&amp;A for the year ended December&#160;31, 2024 was $76.6 million compared to SG&amp;A of $57.0 million for the year ended December&#160;31,
2023. The higher SG&amp;A expenses in 2024 were primarily due to increased direct sales and marketing expenses, which accounted for approximately
$13.0 million of the increase compared to the prior year period. Our 2024 SG&amp;A also included $4.9 million of costs related to the
buildout of our THP platform and infrastructure, $1.0 million of executive separation costs and $1.4 million of acquisition costs related
to prospective investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Research and development.</i></b> R&amp;D for
the year ended December&#160;31, 2024 was $5.7 million compared to R&amp;D of $4.1 million for the year ended December&#160;31, 2023.
The higher R&amp;D in 2024 was primarily due to development projects associated with surgical product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Depreciation and amortization</i></b>. Depreciation
and amortization for the year ended December&#160;31, 2024 was $4.9 million compared to depreciation and amortization of $3.7 million
for the year ended December&#160;31, 2023. The increase in depreciation and amortization in 2024 was primarily due to amortization of
intangible assets acquired as part of the Applied Asset Purchase, which closed in August 2023, and a $0.5 million non-cash charge during
the fourth quarter of 2024 to write-off the remaining net book value of certain THP internal use software assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Change in fair value of earnout liabilities.
</i></b>Change in fair value of earnout liabilities was a benefit of $1.9 million for the year ended December&#160;31, 2024 compared
to a benefit of $3.4 million for the year ended December&#160;31, 2023. The benefit recognized in 2024 was due to a decrease in the estimated
fair value of earnout liabilities associated with the Precision Healing merger, as well as adjustments to the projected timing of payments
related to the Applied Asset Purchase earnout.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other expense.</i></b> Other expense for the
year ended December&#160;31, 2024 was $3.2 million compared to $0.2 million for the year ended December&#160;31, 2023. Other expense
for the year ended December&#160;31, 2024 primarily included higher interest expense and fees related to the CRG Term Loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net loss.</i></b> For the year ended December&#160;31,
2024, we had a net loss of $9.9 million, compared to a net loss of $4.4 million for the year ended December&#160;31, 2023. Our net loss
included $8.0 million and $4.9 million related to our THP segment for the year ended December&#160;31, 2024 and 2023, respectively. The
higher net loss in 2024 was primarily due to higher costs related to the buildout of our THP platform and infrastructure, increased interest
expense related to the CRG Term Loan, lower benefits realized in connection with changes in fair value of earnout liabilities, and higher
amortization of our acquired intangible assets, partially offset by higher gross profit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Segment Adjusted EBITDA.</i></b> Segment Adjusted
EBITDA is the primary profitability measure used by the CODM for purposes of assessing financial performance and resource allocation.
We define Segment Adjusted EBITDA for the reportable segments as net income (loss) excluding interest expense/income, provision/benefit
for income taxes, depreciation and amortization, non-cash share-based compensation expense, change in fair value of earnout liabilities,
share of losses from equity method investments, executive separation costs, legal and diligence expenses related to acquisitions, and
gains/losses on the disposal of property and equipment, as each are applicable to the periods presented. We have historically presented this profitability measure as Segment EBITDA and, starting with the fourth quarter
ended December 31, 2024, are presenting it as Segment Adjusted EBITDA. The definition and methodology for calculating this measure has
remained unchanged. Segment Adjusted EBITDA is a
non-GAAP measure and should be considered in addition to, not as a substitute for, net income (loss), cash flow and other measures of
financial performance reported in accordance with GAAP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe Segment Adjusted EBITDA is useful to investors
because it facilitates comparisons of our core business operations across periods on a consistent basis. Accordingly, we adjust for certain
items, such as change in fair value of earnout liabilities, when calculating Segment Adjusted EBITDA because we believe that such items
are not related to our core business operations. We do not, nor do we suggest that investors should, consider these non-GAAP financial
measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Material limitations associated
with the use of such measures include that they do not reflect all costs included in operating expenses and may not be comparable with
similarly named financial measures of other companies. Furthermore, these non-GAAP financial measures are based on subjective determinations
of management regarding the nature and classification of events and circumstances. We present these non-GAAP financial measures to provide
investors with information to evaluate our operating results in a manner similar to how management evaluates business performance. To
compensate for any limitations in such non-GAAP financial measures, management believes that it is useful in understanding and analyzing
the results of the business to review both GAAP information and the related non-GAAP financial measures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides a reconciliation of
net income (loss) to Segment Adjusted EBITDA for our business segments for the periods indicated below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year
                                            Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December
                                            31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left; padding-left: 0pt">Net Income (Loss)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(1,937,583</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(7,974,315</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(9,911,898</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">440,485</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(4,880,387</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(4,439,902</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Adjustments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,128,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,128,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475,783</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475,783</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 6pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,978</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,978</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6pt"><span style="font-size: 10pt">Depreciation and amortization <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,785,829</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,137,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,923,224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,046,859</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,628,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,675,026</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 6pt">Noncash share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,969,008</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,107,253</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,201,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,392</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,442,722</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6pt">Change in fair value of earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,451</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,924,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,938,451</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,298,336</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,151,559</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,449,895</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 6pt">Share of losses from equity method investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 6pt"><span style="font-size: 10pt">Executive separation costs <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">964,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">964,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 6pt"><span style="font-size: 10pt">Acquisition costs <sup>(3)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">185,029</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,165,260</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,350,289</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">423,513</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">423,513</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Segment Adjusted EBITDA</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,148,722</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,457,415</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,691,307</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,289,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,162,387</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">127,247</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 22.5pt">(1) Includes a $506,836 non-cash charge during the fourth quarter
of 2024 to write-off the remaining net book value of certain THP internal use software assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 22.5pt">(2) Includes $328,795 of share-based compensation related to
executive separation costs for the year ended December&#160;31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 22.5pt">(3) Acquisition costs include legal, tax and accounting services
related to prospective acquisitions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December&#160;31, 2024, our Segment
Adjusted EBITDA was $2.7 million compared to $0.1 million for the year ended December&#160;31, 2023. Our Segment Adjusted EBITDA included
$(6.5) million and $(5.2) million related to our THP segment for the year ended December&#160;31, 2024 and 2023, respectively. The higher
Segment Adjusted EBITDA in 2024 was primarily due to higher net revenue and gross profit as discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>LIQUIDITY AND CAPITAL RESOURCES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash on hand at December&#160;31, 2024 was $15.9
million, compared to $5.1 million at December&#160;31, 2023. Historically, we have financed our operations primarily from borrowings
under our credit facilities and the sale of equity securities. We expect to continue to investment in the THP strategy in
preparation for launch of our first pilot program with a wound care provider group during the second quarter of 2025. We expect our continued investment over the first half of 2025 is currently estimated at $7.5
million to $10.0 million. We are pursuing financial partners to invest in the execution of this strategy. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect our future needs for cash to include the
funding of our additional investment in THP, potential acquisitions, further development of our products, services and technologies pipeline,
clinical studies, repayment of debt as it becomes due and for general corporate purposes. If we seek to consummate acquisitions in the
future, we expect to finance such acquisitions with the proceeds from equity or debt issuances. Based on our current plan of operations,
we believe our cash on hand, when combined with expected cash flows from operations and available proceeds from the CRG Term Loan discussed
herein, will be sufficient to fund our growth strategy and to meet our anticipated operating expenses and capital expenditures for at
least the next 12 months. As of December 31, 2024, there was $24.5 million available for future borrowing under the CRG Term Loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>At-the-Market Offering</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2023, we entered into a Controlled Equity
Offering<sup>SM</sup> Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co., as sales agent (&#8220;Cantor&#8221;),
pursuant to which we could offer and sell from time to time, to or through Cantor, shares of our common stock having an aggregate offering
price of up to $75.0 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales of the shares, pursuant to the Sales Agreement,
were made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities
Act of 1933, as amended. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Cantor agreed
to use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules
and regulations and the rules of The Nasdaq Capital Market to sell the shares from time to time based upon our instructions, including
any price, time period or size limits specified by us. We had no obligation to sell any of the shares under the Sales Agreement and could
suspend or terminate the offering of our common stock pursuant to the Sales Agreement upon notice to Cantor and subject to other conditions.
Pursuant to the Sales Agreement, we paid Cantor a commission of 3.0% of the aggregate gross proceeds from each sale of the shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2023, we sold an aggregate of 26,143 shares of
common stock for gross proceeds of approximately $1.1 million and net proceeds of approximately $0.9 million pursuant to the Sales Agreement.
We paused the offering at the end of the first quarter of 2023 and did not reactivate it during the remainder of 2023. The Registration
Statement on Form S-3 relating to this offering expired in January 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Applied Asset Purchase</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 1, 2023, we entered into an asset purchase
agreement (the &#8220;Applied Purchase Agreement&#8221;) by and among the Company, Sanara MedTech Applied Technologies, LLC (&#8220;SMAT&#8221;),
The Hymed Group Corporation, Applied and Dr. George D. Petito (the &#8220;Owner&#8221;), pursuant to which SMAT acquired certain assets
of the Sellers and the Owner, including, among others, the Sellers&#8217; and Owner&#8217;s inventory, intellectual property, manufacturing
and related equipment, goodwill, rights and claims, other than certain excluded assets (the &#8220;Applied Purchased Assets&#8221;) and
assumed certain Assumed Liabilities (as defined in the Applied Purchase Agreement) upon the terms and subject to the conditions set forth
in the Applied Purchase Agreement. The transaction closed on August 1, 2023. The Applied Purchased Assets were purchased for an initial
aggregate purchase price of $15.25 million, consisting of (i) $9.75 million in cash (the &#8220;Cash Closing Consideration&#8221;), (ii)
73,809 shares of our common stock, with an agreed upon value of $3.0 million (the &#8220;Stock Closing Consideration&#8221;) and (iii)
$2.5 million in cash, to be paid in four equal installments on each of the next four anniversaries of the Closing (the &#8220;Installment
Payments&#8221;). The first Installment Payment of $625,000 was made in August 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the Cash Closing Consideration, Stock
Closing Consideration and Installment Payments, the Applied Purchase Agreement provides that the Sellers are entitled to receive up to
an additional $10.0 million (the &#8220;Applied Earnout&#8221;), which is payable to the Sellers in cash, upon the achievement of certain
performance thresholds relating to SMAT&#8217;s collections from net sales of a collagen-based product currently under development. Upon
expiration of the seventh anniversary of the Closing, to the extent the Sellers have not earned the entirety of the Applied Earnout,
SMAT shall pay the Sellers a pro-rata amount of the Applied Earnout based on collections from net sales of the product, with such amount
to be due credited against any Applied Earnout payments already made by SMAT (the &#8220;True-Up Payment&#8221;). The Applied Earnout,
minus the True-Up Payment and any Applied Earnout payments already made by SMAT, may be earned at any point in the future, including
after the True-Up Payment is made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Cadence Loan Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 1, 2023, we, as guarantor, and our wholly
owned subsidiary SMAT, as borrower, entered into a loan agreement (the &#8220;Cadence Loan Agreement&#8221;) with Cadence Bank (&#8220;Cadence&#8221;)
that provided for, among other things, a term loan in the aggregate principal amount of up to $12.0 million, which was evidenced by an
advancing promissory note. Pursuant to the Cadence Loan Agreement, Cadence agreed to make, at any time and from time to time prior to
February 1, 2024, one or more advances to SMAT. On August 1, 2023, Cadence made an advance under the Cadence Term Loan for $9.75 million,
the proceeds of which were used to fund the Cash Closing Consideration for the Applied Asset Purchase. The Cadence Term Loan Agreement was terminated and all outstanding amounts under the Cadence Term Loan were repaid
in full and all security interest and other liens granted to or held by Cadence were terminated and released in April 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>CRG Term Loan Agreement </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 17, 2024, we entered into the CRG Term Loan
Agreement by and among us, as borrower, the Guarantors, the Agent and the lenders party thereto from time to time, providing for a senior
secured term loan of up to $55.0 million. On the Closing Date, the First Borrowing of $15.0 million was made to repay the Cadence Term
Loan and to pay certain fees and expenses related to the CRG Loan Agreement. The remaining proceeds of $4.5 million were distributed
to us. As a result, the Cadence Term Loan Agreement was terminated and all outstanding amounts under the Cadence Term Loan were repaid
in full and all security interest and other liens granted to or held by Cadence were terminated and released.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 4, 2024, pursuant to our option
under the CRG Term Loan Agreement, we borrowed an additional $15.5 million under the CRG Term Loan Agreement (the &#8220;Second
Borrowing&#8221;). We used $5.0 million of the proceeds of the Second Borrowing for the investment in CMp (discussed in more detail
below). Prior to the CRG Amendment, pursuant to the CRG Term Loan Agreement, we were entitled to one additional borrowing, which was
required to occur on or prior to June 30, 2025 and be at least $5.0 million or a multiple of $5.0 million. On March 19, 2025, we entered into the CRG Amendment, which amended the CRG Term Loan Agreement to, among other
things, (i) entitle us to two additional borrowings following the Second Borrowing, which borrowings must occur on or prior to December
31, 2025, if at all, and (ii) remove the requirement that any borrowing be in whole multiples of $5.0 million. Any additional borrowings
under the CRG Term Loan will be subject to the satisfaction of certain conditions, including the Agent having received certain fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The First Borrowing, Second Borrowing and any additional
borrowings under the CRG Term Loan are due and payable on March 30, 2029 (the &#8220;Maturity Date&#8221;), absent any acceleration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The CRG Term Loan bears interest at a per annum rate
equal to 13.25% (subject to a 4.0% increase during an event of default), of which 8.00% must be paid in cash and 5.25% may, at our election,
be deferred through the 19<sup>th</sup> quarterly Payment Date (defined below) by adding such amount to the aggregate principal loan
amount, so long as no default or event of default under the CRG Term Loan Agreement has occurred and is continuing. We are required to
make quarterly interest payments on the final business day of each calendar quarter following the Closing Date, commencing on the first
such date to occur at least 30 days after the Closing Date (each, a &#8220;Payment Date&#8221;). Interest is payable on each Payment
Date in arrears with respect to the time between each Payment Date and upon the payment or prepayment of the CRG Term Loan, ending on
the Maturity Date. In addition, we are required to pay an upfront fee of 1.50% of the principal amount of the CRG Term Loan, which is
payable as amounts are advanced under the CRG Term Loan on a pro rata basis. We are also required to pay a back-end fee equal to 7.00%
of the aggregate principal amount advanced under the CRG Term Loan Agreement. We paid upfront fees of $225,000 on the Closing Date related
to the First Borrowing and $232,500 of upfront fees on September 4, 2024 related to the Second Borrowing. As of December 31, 2024, there
was $30.5 million of principal outstanding and $24.5 million available for future borrowing under the CRG Term Loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to certain exceptions, we are required to
make mandatory prepayments of the CRG Term Loan with the proceeds of certain assets sales and in the event of a change of control of
the Company. In addition, we may make a voluntary prepayment of the CRG Term Loan, in whole or in part, at any time. All mandatory and
voluntary prepayments of the CRG Term Loan are subject to the payment of prepayment premiums as follows: (i) if prepayment occurs on
or prior to the date that is one year following the applicable borrowing (the &#8220;Borrowing Date&#8221;), an amount equal to 10.0%
of the aggregate outstanding principal amount of the Loan being prepaid and (ii) if prepayment occurs one year after the applicable Borrowing
Date and on or prior to two years following the applicable Borrowing Date, an amount equal to 5.0% of the aggregate outstanding principal
amount of the CRG Term Loan being prepaid. No prepayment premium is due on any principal prepaid if prepayment occurs two years or more
after the applicable Borrowing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain of our current and future subsidiaries, including
the Guarantors, are guaranteeing our obligations under the CRG Term Loan Agreement. As security for our obligations under the CRG Term
Loan Agreement, on the Closing Date, we and the Guarantors entered into a security agreement with the Agent pursuant to which we and
the Guarantors granted to the Agent, as collateral agent for the lenders, a lien on substantially all of our and the Guarantors&#8217;
assets, including intellectual property (subject to certain exceptions).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The CRG Term Loan Agreement contains affirmative
and negative covenants customary for financings of this type, including limitations on our and the Guarantors&#8217; abilities, among
other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions above certain thresholds,
merge or consolidate with others, dispose of assets, pay dividends and distributions and enter into affiliate transactions, in each case,
subject to certain exceptions. In addition, the CRG Term Loan Agreement contains the following financial covenants requiring us and the
Guarantors in the aggregate to maintain:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">liquidity in an amount which shall
                                            exceed the greater of (i) $3.0 million and (ii) to the extent we have incurred certain permitted
                                            debt, the minimum cash balance, if any, required of us by the creditors of such permitted
                                            debt; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">annual minimum revenue of at least
                                            (i) $60.0 million for the twelve-month period beginning on January 1, 2024 and ending on
                                            December 31, 2024, (ii) $75.0 million for the twelve-month period beginning on January 1,
                                            2025 and ending on December 31, 2025, (iii) $85.0 million for the twelve-month period beginning
                                            on January 1, 2026 and ending on December 31, 2026, (iv) $95.0 million for the twelve-month
                                            period beginning on January 1, 2027 and ending on December 31, 2027 and (v) $105.0 million
                                            during each twelve-month period beginning on January 1 of a given year thereafter.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2024, we were in compliance
with all debt covenants.</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>ChemoMouthpiece Investment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 10, 2024, Sanara CMP entered into the
Unit Purchase Agreement with CMp, pursuant to which Sanara CMP purchased 100,674.72 common units in CMp for an aggregate purchase price
of $5.0 million, or $49.6649 per unit, which represented approximately 6.64% of the issued and outstanding membership interests of CMp
immediately following such purchase. Subsequent to our initial investment in CMp, additional units of CMp were sold to other investors,
thereby decreasing our ownership of CMp to 6.59% as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Unit Purchase Agreement, we,
CMp, certain subsidiaries of CMp, InfuSystem and SI Technologies, entered into the Distribution Agreement pursuant to which SI Technologies
was appointed as the sole and exclusive U.S. distributor of the CMp Product for a term of five years, subject to meeting certain minimum
order requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The parties to the Distribution Agreement also entered
into an Intellectual Property Rights Agreement, pursuant to which SI Technologies was granted the exclusive right to use CMp&#8217;s
intellectual property rights to permit resale and use of the CMp Product in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>BMI Investment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 16, 2025, we entered into the BMI License
Agreement with BMI, pursuant to which we acquired the exclusive U.S. marketing, sales and distribution rights to OsStic, as well as ARC,
for use in the treatment of a wound or injury caused by a traumatic incident.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the License Agreement, we were appointed
by BMI as the exclusive distributor to promote, market, offer to sell, transfer, distribute and sell the BMI Products for trauma indications
inside the United States and its territories for the BMI Term, provided that we are in compliance with its obligations thereunder. From
the Execution Date until October 13, 2025, we have an exclusive option to negotiate exclusive distribution rights for the BMI Products
in additional fields and/or additional territories on substantially the same terms as those set forth in the BMI License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The BMI License Agreement requires that we pay BMI
Quarterly Royalties based on a percentage of the Net Sales Value (as defined in the License Agreement) of the Products during the BMI
Term, with the applicable percentage of the Net Sales Value for OsStic being in the mid-single digit range. Pursuant to the BMI License
Agreement, we and BMI agreed to negotiate the applicable percentage of the Net Sales Value for ARC at a future date. The BMI License
Agreement also requires that we pay BMI minimum royalty payments being in the low to mid six figure range for the first, second and third
years, respectively, following the receipt of first regulatory approval for the marketing and sale of a Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the BMI License Agreement, on
the Execution Date, we entered into the Subscription Agreement, pursuant to which we agreed to contribute up to approximately &#8364;8.0
million to BMI through a series of capital contributions in exchange for an aggregate of 16,460 ordinary shares of BMI, constituting
approximately 12.5% of the outstanding equity of BMI as of the Execution Date. We made an initial cash investment totaling approximately
&#8364;3.0 million on the Execution Date, and the Company&#8217;s previously announced convertible loan to BMI was converted into &#8364;1.0
million of equity in BMI. Pursuant to the Subscription Agreement, the remaining &#8364;4.0 million contribution is due upon the achievement
of the Milestones, which are expected to occur at various points during 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Cash Flow Analysis</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December&#160;31, 2024, net cash
used in operating activities was $23,784 compared to $3.2 million used in operating activities for the year ended December&#160;31, 2023.
The lower use of cash in operating activities in 2024 was largely due to our net revenue growth outpacing the growth of our cash operating
expenses and partly due to the timing of cash expenditures for certain accrued payables.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December&#160;31, 2024, net cash
used in investing activities was $6.6 million compared to $10.2 million used in investing activities during the year ended December&#160;31,
2023. Cash used in investing activities during 2024 primarily included $5.3 million for our investment in CMp and $1.1 million for the
funding of a convertible loan related to our minority investment in BMI. Cash used in investing activities during 2023 primarily included
$9.9 million used for the Applied Asset Purchase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December&#160;31, 2024, net cash
provided by financing activities was $17.4 million compared to $9.6 million provided by financing activities for the year ended December&#160;31,
2023. The increase in cash provided by financing activities during the year ended December&#160;31, 2024 was due to the receipt of proceeds
from the CRG Term Loan, which were partially offset by the payoff of the Cadence Term Loan and the final earnout payment of approximately
$1.1 million related to the Scendia earnout.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>MATERIAL TRANSACTIONS WITH RELATED PARTIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>CellerateRX Surgical Sublicense Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 1, 2023, we acquired, among other things,
the underlying intellectual property of, as well as the rights to manufacture and sell, CellerateRX Surgical from Applied for human wound
care use. Prior to such time, we had licensed the rights to these products through a sublicense agreement (the &#8220;Sublicense Agreement&#8221;)
with CGI Cellerate RX, LLC (&#8220;CGI Cellerate RX&#8221;), an affiliate of The Catalyst Group, Inc. (&#8220;Catalyst&#8221;), both
of which are related parties. Prior to the Applied Asset Purchase, we paid royalties based on the annual Net Sales of licensed products
(as defined in the Sublicense Agreement) consisting of 3% of all collected Net Sales each year up to $12.0 million, 4% of all collected
Net Sales each year that exceed $12.0 million up to $20.0 million, and 5% of all collected Net Sales each year that exceed $20.0 million.
Ronald T. Nixon, our Chief Executive Officer and Executive Chairman, is the founder and managing partner of Catalyst.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Applied Asset Purchase, Applied
assigned its license agreement with CGI Cellerate RX to SMAT (the &#8220;License Agreement&#8221;), and on October 10, 2024, the License
Agreement and the Sublicense Agreement were terminated for no additional consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Consulting Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2021, we entered into an asset purchase agreement
with Rochal, a related party. Concurrent with the Rochal asset purchase, we entered into a consulting agreement with Ann Beal Salamone
pursuant to which Ms. Salamone agreed to provide us with consulting services with respect to, among other things, writing new patents,
conducting patent intelligence and participating in certain grant and contract reporting. In consideration for the consulting services
to be provided to us, Ms. Salamone is entitled to receive an annual consulting fee of $177,697, with payments to be paid once per month.
The consulting agreement had an initial term of three years, unless earlier terminated by us, and is subject to renewal. Effective July
13, 2024, the consulting agreement with Ms. Salamone was amended to provide that the initial term shall be automatically renewed for
successive one-year terms for up to three successive years unless earlier terminated by either party without cause at any time, provided
that the terminating party provides 90 days advance written notice of termination. Ms. Salamone is a director of the Company, is a significant
shareholder and the current chair of the board of directors of Rochal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Catalyst Transaction Advisory Services Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2023, we entered into a Transaction Advisory
Services Agreement (the &#8220;Catalyst Services Agreement&#8221;) effective March 1, 2023 with Catalyst, a related party. Pursuant to
the Catalyst Services Agreement, Catalyst, by and through its directors, officers, employees and affiliates that are not simultaneously
serving as directors, officers or employees of the Company (collectively, the &#8220;Covered Persons&#8221;), agreed to perform certain
transaction advisory, business and organizational strategy, finance, marketing, operational and strategic planning, relationship access
and corporate development services for us in connection with any merger, acquisition, recapitalization, divestiture, financing, refinancing,
or other similar transaction in which we may be, or may consider becoming, involved, and any such additional services as mutually agreed
upon in writing by and between Catalyst and us (the &#8220;Catalyst Services&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Catalyst Services Agreement, we agreed
to reimburse Catalyst for (i) compensation actually paid by Catalyst to any of the Covered Persons at a rate no more than a rate consistent
with industry practice for the performance of services similar to the Catalyst Services, as documented in reasonably sufficient detail,
and (ii) all reasonable out-of-pocket costs and expenses payable to unaffiliated third parties, as documented in customary expense reports,
as each of (i) and (ii) is incurred in connection with the Catalyst Services rendered under the Catalyst Services Agreement, with all
reimbursements being contingent upon the prior approval of the Audit Committee of our Board of Directors. We incurred costs relating
to the Catalyst Services Agreement of $288,594 and $174,486 during year ended December&#160;31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Receivables and Payables</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We had outstanding related party receivables totaling
$40,566 at December&#160;31, 2024 and $8,400 at December&#160;31, 2023. We had outstanding related party payables totaling $30,913 at
December&#160;31, 2024 and $77,805 at December&#160;31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>IMPACT OF INFLATION AND CHANGING PRICES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inflation and changing prices have not had a material
impact on our historical results of operations. We do not currently anticipate that inflation and changing prices will have a material
impact on our future results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>CRITICAL ACCOUNTING ESTIMATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our discussion and analysis of our financial condition
and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting
principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates
and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date
of the consolidated financial statements, and the reported revenue and expenses during the reporting period. We base our estimates on
historical experience and on various other assumptions that we believe to be reasonable under the circumstances. The results of these
assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from
other sources. Under different assumptions or conditions, actual results may differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have identified certain significant accounting
estimates which involve a higher degree of judgment and complexity in making certain estimates and assumptions that affect amounts reported
in our consolidated financial statements, as summarized below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Inventories</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower of cost or net
realizable value, with cost computed on a first-in, first-out basis. Inventories consist primarily of finished goods, and also include
an immaterial amount of raw materials and related packaging components. We recorded inventory obsolescence expense of $521,757 for the
year ended December 31, 2024 and $406,812 for the year ended December 31, 2023. The allowance for obsolete and slow-moving inventory
had a balance of $534,549 at December&#160;31, 2024 and $446,917 at December&#160;31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Goodwill</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The excess of purchase price over the fair value
of identifiable net assets acquired in business combinations is recorded as goodwill. As of December&#160;31, 2024 and 2023, all of our
goodwill relates to the acquisition of Scendia. Goodwill has an indefinite useful life and is not amortized. Goodwill is tested annually
as of December 31 for impairment, or more frequently if circumstances indicate impairment may have occurred. We may first perform a qualitative
assessment to determine if it is more likely than not that the fair value of the reporting unit is less than the respective carrying
value. If it is determined that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying value,
then we will determine the fair value of the reporting unit and record an impairment charge for the difference between fair value and
carrying value (not to exceed the carrying amount of goodwill). No impairment was recorded during the years ended December&#160;31, 2024
or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Impairment of Long-Lived Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets, including certain identifiable
intangibles held and to be used by us, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount of such assets may not be recoverable. We continuously evaluate the recoverability of our long-lived assets based on estimated
future cash flows and the estimated liquidation value of such long-lived assets and provide for impairment if such undiscounted cash
flows are insufficient to recover the carrying amount of the long-lived assets. If impairment exists, an adjustment is made to write
the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Fair values are
determined based on quoted market values, undiscounted cash flows or internal and external appraisals, as applicable. Assets to be disposed
of are carried at the lower of carrying value or estimated fair value less cost to sell. A $0.5 million non-cash charge to write-off
the remaining net book value of certain THP internal use software assets was recorded during the year ended December&#160;31, 2024. No
impairment was recorded during the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Investments in Equity Securities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our equity investments consist of nonmarketable equity
securities in privately held companies without readily determinable fair values. Unless accounted for under the equity method of accounting,
the investments are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly
transactions for the identical or similar investment of the same issuer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We apply the equity method of accounting for investments
when we have significant influence, but not controlling interest, in the investee. Judgment regarding the level of influence over each
equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation
in policy-making decisions and material intercompany transactions. As discussed further in Note 6, as of December&#160;31, 2024, we
had two investments that are recorded applying the equity method of accounting. Our proportionate share of the net income (loss) resulting
from these investments is reported under the line item captioned &#8220;Share of losses from equity method investments&#8221; in our
Consolidated Statements of Operations. Our equity method investments are adjusted each period for our share of the investee&#8217;s income
or loss and dividend paid, if any. We classify distributions received from our equity method investments using the cumulative earnings
approach in our Consolidated Statements of Cash Flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We reviewed the carrying value of our investments
and determined there was no impairment or observable price changes as of and for the years ended December&#160;31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for income taxes in accordance with ASC
Topic No. 740, Income Taxes. This standard requires us to provide a net deferred tax asset or liability equal to the expected future
tax benefit or expense of temporary reporting differences between book and tax accounting and any available operating loss or tax credit
carry forwards. A valuation allowance is provided if it is more likely than not that some or all of a net deferred tax asset will not
be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Off-Balance Sheet Arrangements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="Section25"></span>ITEM 7A. QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a smaller reporting company, we are not required
to provide this information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="Section26"></span>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SANARA MEDTECH INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Index to Consolidated Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 93%; padding-right: 2.65pt; padding-left: 0pt"><a href="#Section28"><span style="font-size: 10pt">Report of Independent
    Registered Public Accounting Firm</span></a><a href="#Section28"> <span style="font-size: 10pt">(Weaver and Tidwell, L.L.P. PCAOB
    No. <span id="xdx_900_edei--AuditorFirmId_c20240101__20241231_zzZ3GXkd7uLj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000053" name="dei:AuditorFirmId">410</ix:nonNumeric></span>)</span></a></td>
    <td style="width: 7%; padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 2.65pt; padding-left: 0pt"><a href="#Section29"><span style="font-size: 10pt">Consolidated Balance Sheets</span></a></td>
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 2.65pt; padding-left: 0pt"><a href="#Section30"><span style="font-size: 10pt">Consolidated Statements of
    Operations</span></a></td>
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 2.65pt; padding-left: 0pt"><a href="#Section31"><span style="font-size: 10pt">Consolidated Statements of
    Changes in Shareholders&#8217; Equity</span></a></td>
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 2.65pt; padding-left: 0pt"><a href="#Section32"><span style="font-size: 10pt">Consolidated Statements of
    Cash Flows</span></a></td>
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">F-7</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 2.65pt; padding-left: 0pt"><a href="#Section33"><span style="font-size: 10pt">Notes to Consolidated Financial
    Statements</span></a></td>
    <td style="padding-right: 2.65pt; padding-left: 0pt; text-align: center"><span style="font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 56; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><i><span id="Section28"></span>Report of Independent
Registered Public Accounting Firm </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Board of Directors and Shareholders</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sanara MedTech Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Opinion on the Consolidated Financial Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Sanara MedTech Inc. and subsidiaries (collectively, the Company) as of December 31, 2024 and 2023, and the related
consolidated statements of operations, changes in shareholders&#8217; equity and cash flows for each of the two years in the period
ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our
opinion, the financial statements present fairly, in all material respects, the financial position of Company as of
December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended
December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis for Opinion</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements are the responsibility
of the entity&#8217;s management. Our responsibility is to express an opinion on these  financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well
as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Critical Audit Matters</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90F_edei--AuditorOpinionTextBlock_c20240101__20241231_znxBtdHc6syg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000054" name="dei:AuditorOpinionTextBlock">The critical audit matter communicated below
is a matter arising from the current period audit of the financial statements that were communicated or required to be communicated to
the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our
especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion
on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate
opinion on the critical audit matter or on the accounts or disclosures to which it relates.</ix:nonNumeric></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Evaluation of Impairment Triggering Events for
Tissue Health Plus Segment Intangible Assets (Note 5 and Note 14)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Critical Audit Matter Description </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As discussed in Note 14, as of December 31, 2024,
the Company determined that it has two reportable segments. As of December 31, 2024, the Tissue Health Plus segment was primarily comprised
of research and development activities related to the intangible assets acquired in the 2022 acquisition of Precision Healing, Inc. as
the Company pursues its value-based wound care strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company performs an evaluation of whether
triggering events have occurred which may indicate that the carrying amount of an asset may not be recoverable. During the year-ended
December 31, 2024, management concluded that there were no triggering events which indicated that the carrying amount of the intellectual
property intangible assets acquired from Precision Healing, Inc. is not recoverable. Management did, however, determine that the historic
WounDerm software assets were no longer expected to be used in the Company&#8217;s strategic plans and, accordingly, concluded that the
carrying amount was not recoverable and recorded an impairment charge to reduce the carrying amount of those assets to $0.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 57; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We identified the evaluation of triggering events
as a critical audit matter because such analysis required the application of greater auditor judgment. Potential triggering events, such
as the changes to the Company&#8217;s segments, required a higher degree of auditor judgment to evaluate. These possible triggering events
could have a significant effect on the Company&#8217;s assessment to determine whether further quantitative analysis of recoverability
was required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>How the Critical Audit Matter
Was Addressed in the Audit</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our primary audit procedures
related to the Company&#8217;s analysis included the following, among others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; color: #212529">We obtained an understanding of the design and implementation
of management&#8217;s controls over the triggering event analysis.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; color: #212529; background-color: white">We obtained and evaluated the related
triggering event analysis prepared by management, evaluated responses as to factors considered, and evaluated whether the Company omitted
any significant internal or external factors in their evaluation. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; color: #212529; background-color: white">Inquired of management and the
board of directors to gain an understating of the Company&#8217;s strategic plans and considered such responses in relation to the matters
evaluated and management&#8217;s assessment contained in the triggering event analysis. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; color: #212529">Evaluated the appropriateness of the evaluation framework
utilized by management and the matters considered. This testing included inquiries with management as well as consideration of positive
and negative evidence impacting management&#8217;s considerations. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have served as the Company&#8217;s auditor since
2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>/s/ <span id="xdx_906_edei--AuditorName_c20240101__20241231_zyETL9jv9Umf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000055" name="dei:AuditorName">Weaver and Tidwell, L.L.P</ix:nonNumeric></span>.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_900_edei--AuditorLocation_c20240101__20241231_zTf1vtFXQjSb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000056" name="dei:AuditorLocation">Austin, Texas</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">March 25, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="Section29"></span>SANARA MEDTECH INC. AND
SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_111_zU3WfSUCbOYj" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zz8zt242Hlt7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_zPw4IlON7G2l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center; padding-left: 0pt">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pp0p0_maACzEzQ_z1F1pRvEvtn5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; padding-left: 12pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000064" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,878,295</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000065" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,147,216</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsReceivableNetCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maACzEzQ_ztZAbrl66nd1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember" id="Fact000067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,408,819</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,474,965</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsReceivableNetCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maACzEzQ_zlxjgTPWGPP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Accounts receivable &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,566</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsReceivableNetCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maACzEzQ_zGVSGoycm1E8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,566</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,400</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_ecustom--RoyaltyReceivable_i02I_pp0p0_maACzEzQ_zexlcwZkxhN" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Royalty receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0076">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:RoyaltyReceivable" contextRef="AsOf2023-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,344</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InventoryNet_i02I_pp0p0_maACzEzQ_zWuS0imgOWg5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Inventory, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,753,032</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,717,533</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherReceivablesNetCurrent_i02I_pp0p0_maACzEzQ_zvKvVrwhTS9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Convertible loan receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,101,478</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0083">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pp0p0_maACzEzQ_zC4tKv9xVix3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Prepaid and other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,123,798</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">608,411</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACzEzQ_maAzXJa_zgAtAQRGbckk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total current assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,305,988</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,005,869</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsNoncurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Long-term assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_pp0p0_maANz6v7_zUrxWM0OV9f2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,006,776</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,926,061</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Goodwill_i02I_pp0p0_maANz6v7_zxlbkqShiT07" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 12pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2024-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,601,781</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2023-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,601,781</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LongTermInvestments_i02I_pp0p0_maANz6v7_zq1aZNeY2Ou8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Investment in equity securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="AsOf2024-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,297,223</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="AsOf2023-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,084,278</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_pp0p0_maANz6v7_z2SPhvxv7Mp7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Right of use assets &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,447,907</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,995,204</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_i02I_pp0p0_maANz6v7_zEzW2725kQk3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Property and equipment, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">432,317</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,257,956</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsNoncurrent_i02TI_pp0p0_mtANz6v7_maAzXJa_zq7tsanp361j" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total long-term assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,786,004</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000110" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,865,280</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Assets_i01TI_pp0p0_mtAzXJa_zJDXyIOC2Vp4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total assets</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">88,091,992</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,871,149</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center; padding-left: 0pt">Liabilities and shareholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maLCzxsx_zoyRonKQ9zP7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember" id="Fact000121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,499,764</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="Fact000122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,924,082</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzxsx_z8zhZTgDYhuj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Accounts payable &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,913</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,805</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccountsPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzxsx_zFXpZlZyV941" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,913</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,805</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--AccruedSalesCommissionCurrent_i02I_pp0p0_maLCzxsx_zuoJB9tlFGS5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Accrued bonuses and commissions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedSalesCommissionCurrent" contextRef="AsOf2024-12-31" id="Fact000130" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,778,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedSalesCommissionCurrent" contextRef="AsOf2023-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,676,770</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedRoyaltiesCurrent_i02I_pp0p0_maLCzxsx_zEHM7e4aYBGd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Accrued royalties and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="AsOf2024-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,621,867</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="AsOf2023-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,047,678</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherLiabilitiesCurrent_i02I_pp0p0_maLCzxsx_zkr39oLlgdWj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Earnout liabilities &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0136">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LongTermDebtCurrent_i02I_pp0p0_maLCzxsx_z04pp1q5bBBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Current portion of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0139">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2023-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">580,357</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0p0_maLCzxsx_zaWMurM7rncc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Operating lease liabilities &#8211; current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">358,687</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">361,185</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_mtLCzxsx_maLzlol_ztr6HuGRjc7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total current liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,290,071</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000146" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,767,877</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesNoncurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Long-term liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebtNoncurrent_i02I_maLNzulm_zeaU8TKMs0ei" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Long-term debt, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,689,290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2023-12-31" id="Fact000152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,113,123</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherLiabilitiesNoncurrent_i02I_pp0p0_maLNzulm_z2Nsf4lbtEn8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Earnout liabilities &#8211; long-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">748,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,723,001</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_pp0p0_maLNzulm_zqSO6a7Kkj5e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Operating lease liabilities &#8211; long-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,237,051</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,737,445</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherLongTermDebt_i02I_pp0p0_maLNzulm_zC1XxtPqu4d6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Other long-term liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLongTermDebt" contextRef="AsOf2024-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,215,617</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLongTermDebt" contextRef="AsOf2023-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,941,686</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesNoncurrent_i02TI_pp0p0_mtLNzulm_maLzlol_zQvCgYaqvQ15" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total long-term liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000163" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,889,959</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000164" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,515,255</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Liabilities_i01TI_pp0p0_mtLzlol_maLASEzCJq_zJsXFr9PXy35" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,180,030</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000167" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,283,132</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0_maLASEzCJq_zEpnGm43pI0c" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Commitments and contingencies (Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0169">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0170">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Shareholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CommonStockValue_i02I_pp0p0_maSEz7ec_zU5YUbIxqDxb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 12pt">Common Stock: $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241231_zfhb0hMlIxte" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zw1MNSqlpI55" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zmGeC7LDIAi1" title="Common stock, shares authorized"><span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zbNNnPzkIrbl" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000184" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20241231_zBtdhHx8NY7a" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zncboCmfJps8" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000186" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,753,773</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding as
    of December&#160;31, 2024 and <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20231231_zzTbziTGtAca" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_z6zbLgR4vLqb" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000190" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,535,239</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding as of December&#160;31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000175" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,754</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,535</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_pp0p0_maSEz7ec_zbXb1Y1NMc4j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2024-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,179,211</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">72,860,556</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEz7ec_zrMj44zdbIHl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">37,784,392</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">28,036,814</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEz7ec_maSEIPAz3nK_z4fTH5m0NDL7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Total Sanara MedTech shareholders&#8217; equity</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,403,573</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,832,277</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--MinorityInterest_i02I_pp0p0_maSEIPAz3nK_ztvxBRCis0Ad" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Equity attributable to noncontrolling interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2024-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">491,611</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2023-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">244,260</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pp0p0_mtSEIPAz3nK_maLASEzCJq_zTIX6wM75ERk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total shareholders&#8217; equity</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,911,962</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,588,017</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzCJq_zdJXLeb1Kfw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total liabilities and shareholders&#8217;
    equity</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">88,091,992</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,871,149</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>The accompanying notes are an integral part of
these consolidated financial statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&#160;</i></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="Section30"></span>SANARA MEDTECH INC. AND
SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_113_zFZtB7PjHRh6" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20241231_z8W0pW7kCq32" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_z42f5uUAKuob" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPz4QZ_zPgFynET5Rf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-weight: bold; text-align: left; padding-left: 0pt">Net Revenue</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,672,425</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,989,842</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CostOfRevenue_msGPz4QZ_zqioVrThe8Al" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Cost of goods sold</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-01to2024-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,139,901</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,852,686</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--GrossProfit_iT_pp0p0_mtGPz4QZ_maOILzqxn_zAvMsEoR1Taf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Gross profit</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-01to2024-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,532,524</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">57,137,156</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pp0p0_maOEzYnk_z3EnzRng41z1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,559,863</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000225" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,994,753</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_maOEzYnk_z75Z9h7MxHOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,703,362</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,132,425</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DepreciationAndAmortization_i01_pp0p0_maOEzYnk_zZPsqxT5kEqb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,923,224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact000231" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,675,026</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ChangeInFairValueOfDeferredAndEarnoutLiabilities_i01N_pp0p0_di_msOEzYnk_znnb2Puhq9Y" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Change in fair value of earnout liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SMTI:ChangeInFairValueOfDeferredAndEarnoutLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,938,451</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SMTI:ChangeInFairValueOfDeferredAndEarnoutLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,449,895</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingExpenses_i01T_pp0p0_mtOEzYnk_msOILzqxn_zY56KCqQ0Zvg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total operating expenses</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">85,247,998</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000237" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">61,352,309</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_iT_pp0p0_mtOILzqxn_maPLzsy2_zjI3TDpudvC5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Operating loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000239" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,715,474</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,215,153</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestExpense_i01N_pp0p0_di_msONIEz0Dv_zpdFWcg9ogWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000245" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,128,395</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31" id="Fact000246" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">475,783</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromEquityMethodInvestments_i01_pp0p0_maONIEz0Dv_zL0yOEqyg0D3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Share of losses from equity method investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000248" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">90,007</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0249">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InterestIncomeOther_i01_maONIEz0Dv_zsiDzZsPsrnk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2024-01-01to2024-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,978</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EquityMethodInvestmentRealizedGainLossOnDisposal_i01_maONIEz0Dv_z6VjUxVJ4AB6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Gain on disposal of investment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0254">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="From2023-01-012023-12-31" id="Fact000255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,034</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_i01T_pp0p0_mtONIEz0Dv_maPLzsy2_zlakBaQF0Utf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Total other income (expense)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000257" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,196,424</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">224,749</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProfitLoss_iT_pp0p0_maNILz6H6_mtPLzsy2_z4kt0QfWpdc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Net loss</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">9,911,898</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31" id="Fact000261" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,439,902</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_msNILz6H6_zHTKgMKY0Bz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Less: Net loss attributable to noncontrolling interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2024-01-01to2024-12-31" id="Fact000263" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">247,351</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">136,705</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILz6H6_znESBO6c6TCl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Net loss attributable to Sanara MedTech
    shareholders</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000266" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">9,664,547</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000267" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,303,197</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Net loss per share of common stock, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zP7kM5uP0I75" title="Net loss per share of common stock, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zxhZoQ5CqV71" title="Net loss per share of common stock, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000269" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000271" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.14</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zYr7WVkqKnKl" title="Net loss per share of common stock, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zVXGWcnprnF8" title="Net loss per share of common stock, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000273" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000275" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.52</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Weighted average number of common shares outstanding, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z4nQyKRppr4" title="Weighted average number of common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zlI73bhu7w5b" title="Weighted average number of common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000277" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000279" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,484,224</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_znKudoRaWtol" title="Weighted average number of common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zaWtTFuH6Txa" title="Weighted average number of common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000281" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000283" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,278,949</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>The accompanying notes are an integral part of
these consolidated financial statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&#160;</i></p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="Section31"></span>SANARA MEDTECH INC. AND
SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_303_114_zVM7rwyrhtEa" summary="xdx: Statement - Consolidated Statements of Changes in Shareholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zRTQrrJ3uFig" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z01bfjEyJZa6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zNViSxpE98D4" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_z4nA97nsftG" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B4_zXEhUwy5W3J" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Common
                                            Stock </b></p> <p style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>$0.001
                                            par value</b></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Additional</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Paid-In</b></p></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Noncontrolling</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Total</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Shareholders&#8217;</b></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Interest</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43A_c20230101__20231231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zDUf08YCOTFf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; padding-left: 0pt">Balance at December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd5HyQplWZvg" title="Balance, shares" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,299,957</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,300</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,213,987</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000287" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,394,757</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000288" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">107,555</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" id="Fact000289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,719,975</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zTnQzSiZ46d9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4Kl9GJ9EGa2" title="Share-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000299" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,829</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,442,622</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,442,722</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards_zWHHUFNvEi9k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Net settlement and retirement of equity-based awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuDNBUdKt9dd" title="Net settlement and retirement of equity-based awards, shares" style="text-align: right"><ix:nonFraction name="SMTI:StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000307" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,501</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">203,031</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000303" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">338,860</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" contextRef="From2023-01-012023-12-31" id="Fact000305" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">135,794</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zQu6MSVOTmCd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Issuance of common stock for acquisitions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z80QzwiysWd4" title="Issuance of common stock for acquisitions, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000315" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,809</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000309" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000310" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,089,571</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2023-01-012023-12-31" id="Fact000313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,089,645</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zyBLA36waxYk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Issuance of common stock in equity offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAvxFg7WO0ce" title="Issuance of common stock in equity offering, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000323" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,143</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000317" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">911,345</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">911,371</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProfitLoss_zl0crFG3RhTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000327" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,303,197</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000328" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">136,705</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31" id="Fact000329" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,439,902</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43F_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zUDTLVGooiPb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqhKsTmNzRTb" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000337" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,535,239</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000331" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,535</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,860,556</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000333" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">28,036,814</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000334" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">244,260</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,588,017</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_z2mWCVtqpzNc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqBrtvEly8Q4" title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000345" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,535,239</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,535</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,860,556</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000341" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">28,036,814</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000342" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">244,260</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,588,017</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_z0oNWEmg6kBh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zokWWeXDDqd4" title="Share-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000353" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164,451</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,435,883</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,436,048</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards_zUun7QhvTuIk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Net settlement and retirement of equity-based awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwyKpq8rF2t7" title="Net settlement and retirement of equity-based awards, shares" style="text-align: right"><ix:nonFraction name="SMTI:StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000361" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">54,083</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000356" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,228</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000357" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">83,031</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" contextRef="From2024-01-01to2024-12-31" id="Fact000359" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">125,205</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zDL09zX7TuS" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Issuance of common stock in equity offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlAjlch50ktd" title="Issuance of common stock in equity offering, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000364" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-12-31" id="Fact000367" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--ProfitLoss_zKMOpohvH3hl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000373" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,664,547</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000374" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">247,351</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000375" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,911,898</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43A_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zWniEqAb16u3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFti4AB3p38" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000383" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,753,773</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,754</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,179,211</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000379" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,784,392</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000380" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">491,611</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,911,962</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_430_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zNIAvFLCH5ra" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSL6jnP9J1T4" title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000391" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,753,773</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,754</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,179,211</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000387" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,784,392</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000388" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">491,611</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000389" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,911,962</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>The accompanying notes are an integral part of
these consolidated financial statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="Section32"></span>SANARA MEDTECH INC. AND
SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_112_z8EQEHQMrPNi" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zsTLOvEEnvqg" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20230101__20231231_zGtOzjDYfDn8" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProfitLoss_i01_pp0p0_maNCPBUz3xf_zxK8fTuK0gR" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: left; padding-left: 0pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000396" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">9,911,898</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31" id="Fact000397" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,439,902</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DepreciationAndAmortization_i02_pp0p0_maNCPBUz3xf_zYxYgvdPgqn" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000402" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,923,224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact000403" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,675,026</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProvisionForDoubtfulAccounts_i02_pp0p0_maNCPBUz3xf_zKDgBpJtpIB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Credit loss expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2024-01-01to2024-12-31" id="Fact000405" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">624,448</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2023-01-012023-12-31" id="Fact000406" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">202,941</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryWriteDown_i02_pp0p0_maNCPBUz3xf_zZ5LnhWJUFN6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Inventory obsolescence</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2024-01-01to2024-12-31" id="Fact000408" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">521,757</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2023-01-012023-12-31" id="Fact000409" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">406,812</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_i02_pp0p0_maNCPBUz3xf_zmquG6Pz1D2c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000411" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,436,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000412" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,442,722</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherNoncashExpense_i02_pp0p0_maNCPBUz3xf_zNbWKja7FZc9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Noncash lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000414" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">547,297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="From2023-01-012023-12-31" id="Fact000415" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">342,972</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromEquityMethodInvestments_i02N_pp0p0_di_msNCPBUz3xf_zi3xHMeInxk3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Share of losses from equity method investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000417" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">90,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EquityMethodInvestmentRealizedGainLossOnDisposal_i02N_pp0p0_di_msNCPBUz3xf_zDs7ieADACdi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Gain on disposal of investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="From2023-01-012023-12-31" id="Fact000421" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">251,034</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--BackendFee_i02_pp0p0_maNCPBUz3xf_zwZFAD4oZoF9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Back-end fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:BackendFee" contextRef="From2024-01-01to2024-12-31" id="Fact000423" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">358,086</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PaidInKindInterest_i02_pp0p0_maNCPBUz3xf_z9NQiUEaBTvi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Paid-in-kind interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2024-01-01to2024-12-31" id="Fact000426" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">838,965</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AccretionOfFinanceLiabilities_i02_pp0p0_maNCPBUz3xf_zQF0VaGylWz9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Accretion of finance liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:AccretionOfFinanceLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000429" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">210,931</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:AccretionOfFinanceLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000430" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">98,926</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AmortizationAndWriteoffOfDebtIssuanceCosts_i02_pp0p0_maNCPBUz3xf_zUIuJtiQFfm8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Amortization and write-off of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:AmortizationAndWriteoffOfDebtIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000432" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">209,499</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:AmortizationAndWriteoffOfDebtIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000433" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,138</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ChangeInFairValueOfDeferredAndEarnoutLiabilities_i02N_pp0p0_di_msNCPBUz3xf_z2fdoNnvEUbd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Change in fair value of earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:ChangeInFairValueOfDeferredAndEarnoutLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000435" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,938,451</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:ChangeInFairValueOfDeferredAndEarnoutLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000436" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,449,895</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--AccruedInterestIncomeExpense_i02_pp0p0_maNCPBUz3xf_zGuk4xjPF2ih" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Accrued interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:AccruedInterestIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000438" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">21,978</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_pp0p0_di_msNCPBUz3xf_za0QIpg2N9Mj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-01to2024-12-31" id="Fact000444" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,508,958</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-12-31" id="Fact000445" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,821,895</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccountsReceivableRelatedParties_i03N_pp0p0_di_msNCPBUz3xf_zOXeLxaxLjpd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Accounts receivable &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" contextRef="From2024-01-01to2024-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,166</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" contextRef="From2023-01-012023-12-31" id="Fact000448" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">90,148</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInInventories_i03N_pp0p0_di_msNCPBUz3xf_zE63tzLq9Kg3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Inventory, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2024-01-01to2024-12-31" id="Fact000450" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,442,744</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-012023-12-31" id="Fact000451" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,545,339</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_pp0p0_di_msNCPBUz3xf_zbC4lB3JzV5b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Prepaid and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000453" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">515,496</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000454" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">496,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_pp0p0_maNCPBUz3xf_zoIaWWPvoNag" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000456" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">424,318</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-12-31" id="Fact000457" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">531,380</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IncreaseDecreaseInAccountsPayableRelatedParty_i03_pp0p0_maNCPBUz3xf_zjXooeDF1ajj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Accounts payable &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:IncreaseDecreaseInAccountsPayableRelatedParty" contextRef="From2024-01-01to2024-12-31" id="Fact000459" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">46,891</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:IncreaseDecreaseInAccountsPayableRelatedParty" contextRef="From2023-01-012023-12-31" id="Fact000460" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,768</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--IncreaseDecreaseInAccruedRoyaltiesAndExpenses_i03_maNCPBUz3xf_zqBlmPlb0Tg5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Accrued royalties and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:IncreaseDecreaseInAccruedRoyaltiesAndExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">574,189</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:IncreaseDecreaseInAccruedRoyaltiesAndExpenses" contextRef="From2023-01-012023-12-31" id="Fact000463" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">739,645</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--IncreaseDecreaseInAccruedBonusesAndCommissions_i03_maNCPBUz3xf_z5Cj2oXSfwne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Accrued bonuses and commissions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:IncreaseDecreaseInAccruedBonusesAndCommissions" contextRef="From2024-01-01to2024-12-31" id="Fact000465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,102,069</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:IncreaseDecreaseInAccruedBonusesAndCommissions" contextRef="From2023-01-012023-12-31" id="Fact000466" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">81,513</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUz3xf_zMWUWG4a4rX4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Operating lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">502,892</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact000469" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">252,366</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_mtNCPBUz3xf_maCCERCzew2_zR59IaPgtdEd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000471" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">23,784</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000472" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,245,556</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pp0p0_di_msNCPBUzGuC_z57Fe5YKttZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000477" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">205,848</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000478" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">265,246</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_pp0p0_di_msNCPBUzGuC_zXR19Bgv3Ash" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Purchases of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000480" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,452</ix:nonFraction></p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0481">-</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_i01_pp0p0_maNCPBUzGuC_zeEuCbxku8jh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Proceeds from disposal of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000484" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">650</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PaymentsToAcquireEquityMethodInvestments_i01N_pp0p0_di_msNCPBUzGuC_zMI8kljt7ur7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Investment in equity securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000486" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,302,952</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsToAcquireLoansReceivable_i01N_pp0p0_di_msNCPBUzGuC_zQBlfQisJxBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Convertible loan receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireLoansReceivable" contextRef="From2024-01-01to2024-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,079,391</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_i01N_pp0p0_di_msNCPBUzGuC_zKC18Bwhhwl7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Acquisitions, net of cash acquired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="From2023-01-012023-12-31" id="Fact000493" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,942,750</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_mtNCPBUzGuC_maCCERCzew2_z8s0sUuIgFCg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000495" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,611,643</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000496" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,207,346</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromShortTermDebt_i01_maNCPBUzYrj_ze6D28qiwlE6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Loan proceeds, net of debt issuance costs of $<span id="xdx_907_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231_z2OZuKCPAuhi" title="Net of debt issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,160,740</ix:nonFraction></span> in 2024 and $<span id="xdx_909_eus-gaap--PaymentsOfDebtIssuanceCosts_c20230101__20231231_zLIdSJ9nQ5U" title="Net of debt issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000506" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,658</ix:nonFraction></span> in 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2024-01-01to2024-12-31" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,339,260</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2023-01-012023-12-31" id="Fact000502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,688,341</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RepaymentsOfLinesOfCredit_i01N_pp0p0_di_msNCPBUzYrj_zkQiV6JEYRM5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Pay off line of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2024-01-01to2024-12-31" id="Fact000508" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,750,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0509">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_i01_pp0p0_maNCPBUzYrj_zYa7VQNcYRck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Equity offering net proceeds (expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-01-01to2024-12-31" id="Fact000511" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">75,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-01-012023-12-31" id="Fact000512" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">911,371</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromPaymentsForOtherFinancingActivities_i01_pp0p0_maNCPBUzYrj_zSCnJAVbuXWe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Net settlement of equity-based awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000514" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">125,205</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000515" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">135,794</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--CashPaymentOfFinanceAndEarnoutLiabilities_i01N_pp0p0_di_msNCPBUzYrj_zGFMED2vfE1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Cash payment of finance and earnout liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SMTI:CashPaymentOfFinanceAndEarnoutLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000517" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,022,549</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SMTI:CashPaymentOfFinanceAndEarnoutLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000518" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">822,795</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_mtNCPBUzYrj_maCCERCzew2_znNKk8AlI2si" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000520" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,366,506</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000521" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,641,123</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCzew2_zPBr2ZDbavQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000523" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,731,079</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000524" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,811,779</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0pt">Cash, beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000526" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,147,216</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000527" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,958,995</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0_zmJzPzuJ1oV2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt">Cash, end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000529" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,878,295</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000530" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,147,216</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Cash paid during the period for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPaidNet_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 12pt">Interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-12-31" id="Fact000535" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,580,984</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="Fact000536" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">283,948</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Supplemental noncash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i01_pp0p0_zBpBlirKobrk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Right of use assets obtained in exchange for lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact000542" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,531,773</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssued1_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12pt">Equity issued for acquisitions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2023-01-012023-12-31" id="Fact000545" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,089,645</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12pt">Earnout and other liabilities generated by acquisitions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0547">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" contextRef="From2023-01-012023-12-31" id="Fact000548" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,759,642</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>The accompanying notes are an integral part of
these consolidated financial statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&#160;</i></p>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="Section33"></span>SANARA MEDTECH INC. AND
SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000550" name="us-gaap:NatureOfOperations"><p id="xdx_804_eus-gaap--NatureOfOperations_zwh5tnIBXdx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8211; <span id="xdx_824_zju88NUxA3Dg">NATURE OF BUSINESS AND BACKGROUND</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sanara MedTech Inc. (together with its wholly owned
and majority owned subsidiaries on a consolidated basis, the &#8220;Company&#8221;) is a medical technology company focused on developing
and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic
wound and skincare markets. Each of the Company&#8217;s products, services and technologies are designed to achieve the Company&#8217;s
goal of providing better clinical outcomes at a lower overall cost for patients, regardless of where they receive care. Through its two
operating segments, Sanara Surgical and Tissue Health Plus (&#8220;THP&#8221;), the Company strives to be one of the most innovative
and comprehensive providers of effective surgical, wound and skincare solutions and is continually seeking to expand its offerings for
patients requiring treatments across the entire continuum of care in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As further discussed in Note 14, the Company historically managed its business on the basis of one operating
and reportable segment. During the second quarter of 2024, the Company changed its
reportable segments to reflect a change in the manner in which the business is managed. Based on the growing importance of the value-based
wound care program to the Company&#8217;s future outlook and how the Company&#8217;s chief operating decision maker, the Chief Executive
Officer, reviews operating results and makes decisions about resource allocation, the Company now has <span id="xdx_906_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240401__20240630_zaB4xXkgHaC4" title="Number of reportable segment"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2024-04-012024-06-30" id="Fact000552" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer">two</ix:nonFraction></span> reportable segments: Sanara
Surgical and THP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Sanara Surgical </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Sanara Surgical segment primarily markets and
sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Sanara Surgical&#8217;s
soft tissue repair products include, among other products, the Company&#8217;s lead product, CellerateRX Surgical Activated Collagen
(&#8220;CellerateRX Surgical&#8221;), a hydrolyzed collagen that provides a moist environment for surgical sites to aid in the natural
wound healing process, and BIASURGE Advanced Surgical Solution, a sterile no-rinse, advanced surgical solution used for wound irrigation.
Sanara Surgical&#8217;s bone fusion products include, among other products, BiFORM, an osteoconductive, bioactive, porous implant that
allows for bony ingrowth across the graft site, and ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor
cells and conformable bone fibers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sanara Surgical also includes an in-house research
and development team, Rochal Technologies, with an extensive pipeline of innovative products under development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Tissue Health Plus </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through the Company&#8217;s subsidiary, Tissue Health
Plus (formerly known as &#8220;WounDerm&#8221; and &#8220;United Wound and Skin Solutions, LLC&#8221;), the Company is seeking to simplify
skin health, starting with wound care through a refined business plan. Through THP, the Company plans to offer a first of its kind value-based
wound care program to payers and risk-bearing entities such as accountable care organizations and value-based primary care companies,
with Medicare Advantage payers as the initial target market for this program. The THP segment is focused on value-based wound care services.
Through THP, the Company plans to offer a first of its kind value-based wound care program to payers and risk-bearing entities such as
accountable care organizations and value-based primary care companies, with Medicare Advantage payers as the initial target market for
this program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">THP&#8217;s programs are expected to enable payers
to divest wound care spend risk, reduce wound related hospitalizations and improve patient quality of life. THP plans to coordinate delivery
of community and home-based wound care for its managed patients. Community-based care spans a variety of settings including physician
offices, skilled nursing facilities, assisted living facilities and senior living facilities. THP&#8217;s programs are intended to integrate
science and evidence-based medicine protocols to standardize wound prevention and treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the change in reportable segments,
certain prior period amounts have been recast to conform to the current period presentation. Throughout this Annual Report on Form 10-K,
unless otherwise indicated, amounts and activity reflect reclassifications related to the Company&#8217;s change in reportable segments.
The change in reportable segments had no impact on the Company&#8217;s previously reported Consolidated Balance Sheets, Consolidated
Statements of Operations, Consolidated Statements of Cash Flows or Consolidated Statements of Shareholders&#8217; Equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000554" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zQ5sa65pzRFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8212; <span id="xdx_829_zELV8x07mAM8">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000556" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_zWgD8C7GaIkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_866_z5VScNKQbWcd">Principles of Consolidation and Basis of Presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of Sanara MedTech Inc. and its wholly owned and majority-owned subsidiaries, as well as other entities in which
the Company has a controlling financial interest. All significant intercompany profits, losses, transactions and balances have been eliminated
in consolidation. Certain prior year amounts have been reclassified to conform to the current year presentation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000558" name="us-gaap:UseOfEstimates"><p id="xdx_840_eus-gaap--UseOfEstimates_zX6nXHAESdFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zeobAQWcjXK5">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and
the reported revenue and expenses during the reporting period. However, actual results could differ from those estimates and there may
be changes to the Company&#8217;s estimates in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000560" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zVH5nCCKGtJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_865_zgPXxcOOsSHg">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid investments
purchased with an original maturity of three months or less to be cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000562" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zpLuYGKBoAuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_z2p7h9RuBYk4">Income/Loss Per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes income/loss per share in accordance
with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 260, Earnings per Share, which requires the Company to present basic
and diluted income per share when the effect is dilutive. Basic income/loss per share is computed by dividing income/loss attributable
to common shareholders by the weighted average number of shares of common stock outstanding. Diluted income/loss per share is computed
similarly to basic income/loss per share, except that the denominator is increased to include the number of additional shares of common
stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common
stock were dilutive. All common stock equivalents were excluded from the calculations for the periods presented as their inclusion would
have been anti-dilutive during the years ended December&#160;31, 2024 and 2023 due to the Company&#8217;s net loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000564" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWXU0FDCQDwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the shares of common
stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the years ended December&#160;31,
2024 and 2023 as such shares would have had an anti-dilutive effect:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zf7w48RRD9A9" style="display: none">SCHEDULE
OF COMPUTATION OF DILUTED NET LOSS PER SHARE</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20240101__20241231_z2Dd1IDQxPbb" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_zfZm4fFZ5OOc" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zDvw2srqeA2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 0pt"><span style="font-size: 10pt">Stock options<sup id="xdx_F4C_zmB7sEMtIBwj">(a)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000566" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">31,013</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000567" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">93,892</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKD4QRq4eUl3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt"><span style="font-size: 10pt">Warrants<sup id="xdx_F48_zFdIWwfer048">(b)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000570" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,725</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zsbhPOlzXXF3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Unvested restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_UnvestedRestrictedStockMember" id="Fact000572" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">202,787</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_UnvestedRestrictedStockMember" id="Fact000573" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">144,211</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z6ObFpoJjSwj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_UnvestedRestrictedStockMember" id="Fact000575" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">202,787</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_UnvestedRestrictedStockMember" id="Fact000576" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">144,211</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td id="xdx_F0E_zLw243GCkSl4" style="width: 0.25in">(a)</td><td id="xdx_F1D_zQ2VZuA9Ai1g"><ix:footnote id="Footnote000577" xml:lang="en-US">Shares underlying stock options assumed pursuant to the merger agreement
                                            with Precision Healing, Inc. (&#8220;Precision Healing&#8221;) in April 2022.</ix:footnote></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td id="xdx_F0F_zRE6wyIXY6d7" style="width: 0.25in">(b)</td><td id="xdx_F1E_zt5c7r2IXmL5"><ix:footnote id="Footnote000578" xml:lang="en-US">Shares underlying warrants assumed pursuant to the merger agreement
                                            with Precision Healing in April 2022.</ix:footnote></td></tr></table>

</ix:nonNumeric><p id="xdx_8AE_zKpKnX5IfzJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000580" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zvpssZlOVqdl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_860_zBN1XGdmgHGh">Revenue Recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue in accordance with
ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Revenues are recognized when a purchase order is received
from the customer and control of the promised goods or services is transferred to the customer in an amount that reflects the consideration
the Company expects to be entitled to receive in exchange for transferring those goods or services. Revenue is recognized based on the
following five-step model:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: -9pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Identification of the contract with a customer</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Identification of the performance obligations
                                            in the contract</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Determination of the transaction price</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Allocation of the transaction price to the performance
                                            obligations in the contract</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Recognition of revenue when, or as, the Company
                                            satisfies a performance obligation</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Details of this five-step process are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Identification of the contract with a customer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Customer purchase orders are generally considered
to be contracts under ASC 606. Purchase orders typically identify the specific terms of products to be delivered, create the enforceable
rights and obligations of both parties and result in commercial substance. No other forms of contract revenue recognition, such as the
completed contract or percentage of completion methods, were utilized by the Company in either 2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Performance obligations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s performance obligation is generally
limited to delivery of the requested items to its customers at the agreed upon quantities and prices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Determination and allocation of the transaction price</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has established prices for its products.
These prices are effectively agreed to when customers place purchase orders with the Company. Rebates and discounts, if any, are recognized
in full at the time of sale as a reduction of net revenue. Allocation of transaction prices is not necessary where only one performance
obligation exists. For certain sales transactions, we incur group purchasing organization fees that are based on a contractual percentage
of applicable sales and are recorded as a reduction of the revenue for those transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Recognition of revenue as performance obligations are satisfied</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Product revenues are recognized when a purchase order
is received from the customer, the products are delivered, and control of the goods and services passes to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Disaggregation of Revenue</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000582" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zydaPT1G4ZKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue streams from product sales and royalties
are summarized below for the years ended December&#160;31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z9Njba69Dhx4" style="display: none">SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20241231_z9BTxnEdZ442" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20230101__20231231_ztPw1I3NSwZa" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SoftTissueRepairProductsMember_zneCjYnaFoe7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 0pt">Soft tissue repair products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_SoftTissueRepairProductsMember" id="Fact000584" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,125,012</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_SoftTissueRepairProductsMember" id="Fact000585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,836,410</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--BoneFusionProductsMember_zl6rE4Y3bJA6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Bone fusion products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_BoneFusionProductsMember" id="Fact000587" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,547,413</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_BoneFusionProductsMember" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,952,432</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zaDbFNK5EtN" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0590">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_us-gaap_RoyaltyMember" id="Fact000591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zKdc18lqmb9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total Net Revenue</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="Fact000593" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,672,425</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact000594" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,989,842</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zaRG0x0BD4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2024 and
2023, all of the Company&#8217;s net revenue was generated from Sanara Surgical. The Company is preparing to launch the first THP
pilot program with a wound care provider group during the second quarter of 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000596" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock"><p id="xdx_84C_eus-gaap--CreditLossFinancialInstrumentPolicyTextBlock_zau6cFpP84v6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86E_zkO6xtwjAUph">Accounts Receivable Allowances</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable are typically due within 30
days of invoicing. The Company establishes an allowance for credit losses to provide for an estimate of accounts receivable which
are not expected to be collectible. The Company bases the allowance on an assessment of customer creditworthiness, historical
payment experience, the age of outstanding receivables and other information as applicable and will record its allowance based on
the estimated credit losses. The Company&#8217;s accounts receivable balance, net was $<span id="xdx_90D_eus-gaap--AccountsReceivableNetCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zzTaJygWj6v1" title="Accounts receivable"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember" id="Fact000598" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,408,819</ix:nonFraction></span>, $<span id="xdx_906_eus-gaap--AccountsReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zoxigWdgakN6" title="Accounts receivable"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="Fact000600" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,474,965</ix:nonFraction></span>, and $<span id="xdx_90B_eus-gaap--AccountsReceivableNetCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zBusyyYA3Bsj" title="Accounts receivable"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember" id="Fact000602" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,805,761</ix:nonFraction></span> as of December
31, 2024, December 31, 2023, and December 31, 2022, respectively. The Company recorded credit loss expense of $<span id="xdx_90B_eus-gaap--ProvisionForDoubtfulAccounts_c20240101__20241231_zl7NwK9XaDN7" title="Bad debt expense"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2024-01-01to2024-12-31" id="Fact000604" format="ixt:numdotdecimal" decimals="0" unitRef="USD">624,448</ix:nonFraction></span>
and $<span id="xdx_90B_eus-gaap--ProvisionForDoubtfulAccounts_c20230101__20231231_zLbUbIGGyrgl" title="Bad debt expense"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2023-01-012023-12-31" id="Fact000606" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,941</ix:nonFraction></span>
during the years ended December&#160;31, 2024 and 2023, respectively. The allowance for credit losses was $<span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20241231_zLMuSoGtDiEd" title="Allowance for credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-12-31" id="Fact000608" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,173,441</ix:nonFraction></span>
at December&#160;31, 2024 and $<span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zboG2jZNi8lk" title="Allowance for credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2023-12-31" id="Fact000610" format="ixt:numdotdecimal" decimals="0" unitRef="USD">528,030</ix:nonFraction></span>
at December&#160;31, 2023. Credit loss reserves are maintained based on a variety of factors, including the length of time
receivables are past due and a detailed review of certain individual customer accounts. The Company also establishes other
allowances to provide for estimated customer rebates and other expected customer deductions. These allowances totaled $<span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_c20241231_ztbX3Z9Q2YI1" title="Allowance for customer rebates and deductions"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="AsOf2024-12-31" id="Fact000612" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,897</ix:nonFraction></span>
at December&#160;31, 2024 and $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_c20231231_zYAfTFwYXIgb" title="Allowance for customer rebates and deductions"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="AsOf2023-12-31" id="Fact000614" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,820</ix:nonFraction></span>
at December&#160;31, 2023. If circumstances related to customers change, estimates of the recoverability of receivables would be
further adjusted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000616" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_zuU61DQo9Vdk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_862_zateYLuhUsxd">Inventories</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower of cost or net
realizable value, with cost computed on a first-in, first-out basis. Inventories consist primarily of finished goods, and also include
an immaterial amount of raw materials and related packaging components. The Company recorded inventory obsolescence expense of $<span id="xdx_901_eus-gaap--InventoryWriteDown_c20240101__20241231_zCTwYKZUNe6f" title="Inventory obsolescence expense"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2024-01-01to2024-12-31" id="Fact000618" format="ixt:numdotdecimal" decimals="0" unitRef="USD">521,757</ix:nonFraction></span>
and $<span id="xdx_902_eus-gaap--InventoryWriteDown_c20230101__20231231_zovbIFGgdTr1" title="Inventory obsolescence expense"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2023-01-012023-12-31" id="Fact000620" format="ixt:numdotdecimal" decimals="0" unitRef="USD">406,812</ix:nonFraction></span> during the years ended December&#160;31, 2024 and 2023, respectively. The allowance for obsolete and slow-moving inventory
had a balance of $<span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_c20241231_zc074IrXpNph" title="Allowance for obsolete and slow-moving inventory"><ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2024-12-31" id="Fact000622" format="ixt:numdotdecimal" decimals="0" unitRef="USD">534,549</ix:nonFraction></span> at December&#160;31, 2024 and $<span id="xdx_902_eus-gaap--InventoryValuationReserves_iI_c20231231_zyOJP02HiKF4" title="Allowance for obsolete and slow-moving inventory"><ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2023-12-31" id="Fact000624" format="ixt:numdotdecimal" decimals="0" unitRef="USD">446,917</ix:nonFraction></span> at December&#160;31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000626" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zH8nmSqF4w6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_866_zb79f3OI2Ddf">Property and Equipment</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost, less accumulated
depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the related assets, ranging
from <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember_zP6XLLBlsNy2" title="Estimated useful lives::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl0628">two</span></span> to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_c20241231__srt--RangeAxis__srt--MaximumMember_zZiC3dzkTRu6" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MaximumMember" format="ixt-sec:durwordsen" id="Fact000630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">ten years</ix:nonNumeric></span>. Below is a summary of property and equipment for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000632" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zqRliQNnUB1d" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zQKNzkO8FU9g" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Useful</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Life</b></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zjuto5QPegHf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zwcZH3iFbWbi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVlyBmKFNc29" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; padding-left: 0pt">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: center; padding-left: 0pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zpfitIsrj9Ak" title="Useful Life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000637" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zuDth0z9viv1" title="Useful Life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000639" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember" id="Fact000634" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,963</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember" id="Fact000635" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,788</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zrthfTCFxxhk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Office equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zs8CneFLDiB6" title="Useful Life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000644" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span>-<span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_z2kIMVBvCVw2" title="Useful Life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000646" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember" id="Fact000641" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,491</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_OfficeEquipmentMember" id="Fact000642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,785</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zJ56vuocB1Ih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zeQhlRy083Za" title="Useful Life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000651" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zbWxC8rWUL7c" title="Useful Life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000653" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000648" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,508</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000649" format="ixt:numdotdecimal" decimals="0" unitRef="USD">304,338</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zLVSo8nF94k1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_z3ksmxolhQ3c" title="Useful Life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000658" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">2</ix:nonNumeric></span>-<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zfSPGPNrx4ye" title="Useful Life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000660" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000655" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,968</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000656" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134,170</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zkzxzTMzV3c3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Internal use software</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 0pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_ztngxXxxLfR" title="Useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_InternalUseSoftwareMember" format="ixt-sec:duryear" id="Fact000665" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0662">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_InternalUseSoftwareMember" id="Fact000663" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,618,999</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz6Up_znA7HeNhBpG8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000667" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,040,930</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000668" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,454,080</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz6Up_z5x7dqCdRrr7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000670" format="ixt:numdotdecimal" decimals="0" unitRef="USD">608,613</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,196,124</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz6Up_zph1Y9kIAJq5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000673" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,317</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000674" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,257,956</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zm4xRmkwAxS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense related to property and equipment
was $<span id="xdx_906_eus-gaap--Depreciation_c20240101__20241231_zjo3LfxdWLG2" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact000676" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,031,487</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--Depreciation_c20230101__20231231_z0BnoG2WACQ3" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000678" format="ixt:numdotdecimal" decimals="0" unitRef="USD">456,138</ix:nonFraction></span> during the year ended December&#160;31, 2024 and 2023, respectively. Depreciation expense for the year ended
December&#160;31, 2024 included a non-cash charge of $<span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_z8IlaiQpIepi" title="Depreciation"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2024-01-012024-12-31_custom_InternalUseSoftwareMember" id="Fact000680" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,836</ix:nonFraction></span> to write-off the remaining net book value of certain internal use software
assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000682" name="us-gaap:InternalUseSoftwarePolicy"><p id="xdx_849_eus-gaap--InternalUseSoftwarePolicy_zrF1Mx2vgan" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_zIKZP3FaoK1g">Internal Use Software</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounted for costs incurred to develop
or acquire computer software for internal use in accordance with ASC Topic 350-40, Intangibles &#8211; Goodwill and Other. The Company
capitalized the costs incurred during the application development stage, which generally included third-party developer fees to design
the software configuration and interfaces, coding, installation and testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company began capitalization of qualifying costs
when both the preliminary project stage was completed and management authorized further funding for the completion of the project. Costs
incurred during the preliminary project stage along with post implementation stages of internal-use computer software was expensed as
incurred. The Company also capitalized costs related to specific upgrades and enhancements when it was probable the expenditures would
result in additional functionality. Capitalized development costs were classified as &#8220;Property and equipment, net&#8221; in the
Consolidated Balance Sheets and were depreciated over the estimated useful life of the software, which was generally <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_c20241231_zEG0ftpJryRl" title="Software, estimated useful life"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:durwordsen" id="Fact000684" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">five years</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000686" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy"><p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z1WdfEV3R3Rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_864_zJk3m1hNnfCe">Goodwill</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The excess of purchase price over the fair value
of identifiable net assets acquired in business combinations is recorded as goodwill. As of December&#160;31, 2024 and December&#160;31,
2023, all of the Company&#8217;s goodwill relates to the acquisition of Scendia Biologics, LLC (&#8220;Scendia&#8221;), which is included
in the Sanara Surgical segment. Goodwill has an indefinite useful life and is not amortized. Goodwill is tested annually as of December&#160;31
for impairment, or more frequently if circumstances indicate impairment may have occurred. The Company may first perform a qualitative
assessment to determine if it is more likely than not that the fair value of the reporting unit is less than the respective carrying
value. If it is determined that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying value,
then the Company will determine the fair value of the reporting unit and record an impairment charge for the difference between fair
value and carrying value (not to exceed the carrying amount of goodwill). <span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_dxL_c20240101__20241231_zf8A9BY2laia" title="Impairment of goodwill::XDX::-"><span id="xdx_902_eus-gaap--GoodwillImpairmentLoss_dxL_c20230101__20231231_zSP9gN96Qp8" title="Impairment of goodwill::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0688"><span style="-sec-ix-hidden: xdx2ixbrl0690">No</span></span></span></span> impairment was recorded during the year ended December&#160;31,
2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000692" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"><p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_z0H17BQcYr0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_864_zesGLPv7Z3n7">Intangible Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets are stated at cost of acquisition
less accumulated amortization and impairment loss, if any. Cost of acquisition includes the purchase price and any cost directly attributable
to bringing the asset to its working condition for the intended use. The Company amortizes its finite-lived intangible assets on a straight-line
basis over the estimated useful life of the respective assets which is generally the life of the related patents or licenses, seven years
for customer relationships and five years for assembled workforces. See Note 5 for more information on intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000694" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQQvnP4shxjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_869_zbyigOjCH2M9">Impairment of Long-Lived Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets, including certain identifiable
intangibles held and to be used by the Company, are reviewed for impairment whenever events or changes in circumstances indicate that
the carrying amount of such assets may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets
based on estimated future cash flows and the estimated liquidation value of such long-lived assets and provides for impairment if such
undiscounted cash flows are insufficient to recover the carrying amount of the long-lived assets. If impairment exists, an adjustment
is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value.
Fair values are determined based on quoted market values, undiscounted cash flows or internal and external appraisals, as applicable.
Assets to be disposed of are carried at the lower of carrying value or estimated fair value less cost to sell. A $<span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn5n6_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zFeTMhSeGVo3" title="Depreciation"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2024-01-012024-12-31_custom_InternalUseSoftwareMember" id="Fact000696" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million non-cash
charge to write-off the remaining net book value of certain THP internal use software assets was recorded during the year ended December&#160;31,
2024. <span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20230101__20231231_z0RhOg8Dufg1" title="Impairment of long-lived assets"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2023-01-012023-12-31" id="Fact000698" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></span> impairment was recorded during the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000700" name="us-gaap:EquityMethodInvestmentsPolicy"><p id="xdx_84B_eus-gaap--EquityMethodInvestmentsPolicy_zCGU5SwufEW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_862_ztdSbWsdtScl">Investments in Equity Securities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s equity investments consist of
nonmarketable equity securities in privately held companies without readily determinable fair values. Unless accounted for under the
equity method of accounting, the investments are reported at cost minus impairment, if any, plus or minus changes resulting from observable
price changes in orderly transactions for the identical or similar investment in the same issuer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company applies the equity method of accounting
to investments when it has significant influence, but not controlling interest, in the investee. Judgment regarding the level of influence
over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors,
participation in policy-making decisions and material intercompany transactions. As discussed further in Note 6 as of December&#160;31,
2024, the Company had two investments that are recorded applying the equity method of accounting. The Company&#8217;s proportionate share
of the net income (loss) resulting from these investments is reported under the line item captioned &#8220;Share of losses from equity
method investments&#8221; in the Company&#8217;s Consolidated Statements of Operations. The Company&#8217;s equity method investments
are adjusted each period for the Company&#8217;s share of the investee&#8217;s income or loss and dividend paid, if any. The Company
classifies distributions received from its equity method investments using the cumulative earnings approach in the Company&#8217;s Consolidated
Statements of Cash Flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has reviewed the carrying value of its
investments and has determined there was no impairment or observable price changes as of or for the year ended December&#160;31, 2024
and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000702" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z8rBtA5vItM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_868_zccdqe3IkqB9">Fair Value Measurement</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As defined in ASC Topic 820, Fair Value Measurement
(&#8220;ASC 820&#8221;), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market
participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the
valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair
value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted
prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level
3 measurement). This fair value measurement framework applies at both the initial and subsequent measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The three levels of the fair value hierarchy defined
by ASC 820 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 &#8211; Quoted prices are available in active
markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or
liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of
financial instruments such as exchange-traded derivatives, marketable securities and listed equities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 &#8211; Pricing inputs are other than quoted
prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes
those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard
models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current
market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these
assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are
supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include
nonexchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 &#8211; Pricing inputs include significant
inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that
result in management&#8217;s best estimate of fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of cash, accounts receivable,
accounts payable and accrued expenses, other than acquisition-related expenses, approximate fair value because of the short-term nature
of these instruments. The fair value of acquisition-related accrued expenses is categorized as Level 2 of the fair value hierarchy. The
value of these instruments has been estimated using discounted cash flow analysis based on the Company&#8217;s incremental borrowing
rate. The carrying value of the Company&#8217;s CRG Term Loan (defined below), which has a fixed interest rate approximates fair value
based on instruments with similar terms (Level 2 inputs). The fair value of the contingent earnout consideration and the acquisition
date fair value of goodwill and intangibles related to the acquisitions discussed in Notes 3 and 5 are based on Level 3 inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Liabilities for contingent consideration for the
Precision Healing merger, acquisition of Scendia and Applied Asset Purchase (defined below) (see Note 3 for more information) are measured
at fair value each reporting period, with the acquisition-date fair value included as part of the consideration transferred. The contingent
consideration for the Scendia acquisition was settled as of September 30, 2024, and the final earnout payment of approximately $1.1 million
was paid in cash in October 2024. The Precision Healing contingent consideration is classified as a liability at its fair value at each
reporting period due to the fact that the monetary value of the shares to be issued is predominantly dependent on the exercise contingency
(i.e., revenue targets). Subsequent changes in fair value of contingent consideration related to the Precision Healing merger are reported
under the line item captioned &#8220;Change in fair value of earnout liabilities&#8221; in the Company&#8217;s Consolidated Statements
of Operations. The Company reviewed the thresholds necessary to trigger a payment on the Precision Healing earnout as of December 31,
2024 and deemed the thresholds to be unachievable by the sellers, therefore, the remaining fair value on the earnout was reduced to zero.
Due to the Applied Asset Purchase being accounted for as an asset acquisition and given that the transaction did not include contingent
shares, subsequent revaluations of contingent consideration for the Applied Asset Purchase results in an adjustment to the contingent
consideration liability and the intellectual property intangible asset with a cumulative catch-up amortization adjustment. The current
year change in fair value of earnout liability below is as a result of a net decrease in the estimated fair value of the earnout liability
established at the time of the Company&#8217;s Precision Healing merger. The current year revaluation of earnout liability below is a
result of a decrease in the estimated value of the earnout liability established at the time of the Applied Asset Purchase. The following
table sets forth a summary of the changes in fair value for the Level 3 contingent earnout considerations.</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000704" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zyMX4K6dm2g4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zlfDaPl3CVAl" style="display: none">SCHEDULE
OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_495_20240101__20241231_zGPyhUGHNZDf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_zZYTfAj7HLie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; padding-left: 0pt">Balance at December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-12-31" id="Fact000706" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,823,001</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_zooAX9QzVyf6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 9pt; padding-left: 0pt">Change in fair value of earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="From2024-01-01to2024-12-31" id="Fact000708" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,938,451</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability_zNjJ5pGNlySg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 9pt; padding-left: 0pt">Revaluation of earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000710" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">51,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements_zETuDA62VB44" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt">Settlements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SMTI:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements" contextRef="From2024-01-01to2024-12-31" id="Fact000712" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,085,549</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_zbXliTDqnde7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-12-31" id="Fact000714" format="ixt:numdotdecimal" decimals="0" unitRef="USD">748,001</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zR31WoaaVx26" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000716" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zXVrVoI0j0v" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_865_zQLkHdchx9E3">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Income taxes are accounted for under the asset and
liability method, whereby deferred income taxes are recorded for temporary differences between financial statement carrying amounts and
the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years
in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all the
deferred tax asset will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000718" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zW7kGy8BeOM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_861_z2uC0X764h8d">Share-based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for share-based compensation
to employees and nonemployees in accordance with ASC Topic 718, Compensation &#8211; Stock Compensation. Share-based compensation is
measured at the grant date, based on the fair value of the award, and is recognized as expense over the stipulated vesting period, if
any. The Company estimates the fair value of share-based payments using the Black-Scholes option-pricing model for common stock options
and warrants, and the closing price of the Company&#8217;s common stock for grants of common stock, including restricted stock awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000720" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zsaYDcSy2eR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86E_zmgxSQsBIQN5">Research and Development Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development (&#8220;R&amp;D&#8221;)
expenses consist of personnel-related expenses, including salaries, share-based compensation and benefits for all personnel directly
engaged in R&amp;D activities, contracted services, materials, prototype expenses and allocated overhead, which is comprised of compensation
and benefits, lease expense and other facilities-related costs. R&amp;D expenses include costs related to enhancements to the Company&#8217;s
currently available products and additional investments in the product and platform development pipeline. The Company expenses R&amp;D
costs as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000722" name="SMTI:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"><p id="xdx_84A_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_z7hRzsnmClZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_863_z1yk2PchwuZ1">Recently Adopted Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments - Credit Losses (Topic
326). This update amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate
credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The Company
adopted the new guidance effective January 1, 2023. The adoption did not have a material impact on the Company&#8217;s consolidated financial
position, results of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, FASB issued ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;), which requires disclosure of incremental
segment information on an annual and interim basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and
interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company adopted the new guidance
effective December 31, 2024. The adoption did not have a material impact on the Company&#8217;s consolidated financial position, results
of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000724" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3IibpPc84ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_z4TJcBV8RiWa">Recently Issued Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, FASB issued ASU 2023-09, Income
Taxes (Topic 740): Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;), which expands the disclosure required for income
taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the effect of this pronouncement on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2024, FASB issued ASU 2024-03, Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,
which requires new disclosures providing further detail of a company&#8217;s income statement expense line items. ASU 2024-03 is effective
for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is
permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</p>

</ix:nonNumeric><p id="xdx_853_zuGP1w71ll1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000726" name="us-gaap:AssetAcquisitionTextBlock"><p id="xdx_80F_eus-gaap--AssetAcquisitionTextBlock_zg4P3jX7T053" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 &#8211; <span id="xdx_82E_zib08xopEAP5">APPLIED ASSET PURCHASE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 1, 2023, the Company entered into
an Asset Purchase Agreement (the &#8220;Applied Purchase Agreement&#8221;) by and among the Company, as guarantor, Sanara MedTech Applied
Technologies, LLC, a Texas limited liability company and wholly owned subsidiary of the Company (&#8220;SMAT&#8221;), The Hymed Group
Corporation, a Delaware corporation (&#8220;Hymed&#8221;), Applied Nutritionals, LLC, a Delaware limited liability company (&#8220;Applied&#8221;,
and together with Hymed, the &#8220;Sellers&#8221;), and Dr. George D. Petito (the &#8220;Owner&#8221;), pursuant to which SMAT acquired
certain assets of the Sellers and the Owner, including, among others, the Sellers&#8217; and Owner&#8217;s inventory, intellectual property,
manufacturing and related equipment, goodwill, rights and claims, other than certain excluded assets, all as more specifically set forth
in the Applied Purchase Agreement (collectively, the &#8220;Applied Purchased Assets&#8221;), and assumed certain Assumed Liabilities
(as defined in the Applied Purchase Agreement), upon the terms and subject to the conditions set forth in the Applied Purchase Agreement
(such transaction, the &#8220;Applied Asset Purchase&#8221;). The Applied Purchased Assets include the underlying intellectual property
of, as well as the rights to manufacture and sell, certain hydrolyzed collagen products, including CellerateRX Surgical, for human wound
care use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Applied Purchased Assets were purchased for an
initial aggregate purchase price of $<span id="xdx_90E_eus-gaap--PaymentsToAcquireProductiveAssets_pn4n6_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zB9Il9w4xY8j" title="Assets purchase price"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember" id="Fact000728" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">15.25</ix:nonFraction></span> million, consisting of (i) $<span id="xdx_905_eus-gaap--AssetAcquisitionConsiderationTransferredOtherAssets_pn4n6_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--CashClosingConsiderationMember_zUdzufzCtdKj" title="Cash consideration paid"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember_custom_CashClosingConsiderationMember" id="Fact000730" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">9.75</ix:nonFraction></span> million in cash (the &#8220;Cash Closing Consideration&#8221;),
(ii) <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--StockClosingConsiderationMember_zDXhqTuf55Ll" title="Shares issued as consideration"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember_custom_StockClosingConsiderationMember" id="Fact000732" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,809</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;Stock Closing Consideration&#8221;) with an agreed upon value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_pn5n6_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--StockClosingConsiderationMember_zt97hdZrMyoi" title="Value of shares issued as consideration"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember_custom_StockClosingConsiderationMember" id="Fact000734" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction></span>
million and (iii) $<span id="xdx_909_eus-gaap--OtherLoansPayable_iI_pn5n6_c20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_z1OsLdc0mT1k" title="Installment payable"><ix:nonFraction name="us-gaap:OtherLoansPayable" contextRef="AsOf2023-08-01_custom_AppliedAssetPurchaseAgreementMember" id="Fact000736" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million in cash (the &#8220;Installment Payments&#8221;), to be paid in four equal installments on each of the
next four anniversaries of the closing of the Applied Asset Purchase (the &#8220;Closing&#8221;). The first Installment Payment of $<span id="xdx_900_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zyabbarSrsZg" title="Payment of installment"><ix:nonFraction name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="From2024-08-012024-08-31_custom_AppliedAssetPurchaseAgreementMember" id="Fact000738" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">625,000</ix:nonFraction></span>
was made in August 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the Closing, the Company licensed certain
of its products from Applied through a sublicense agreement (the &#8220;Sublicense Agreement&#8221;) with CGI Cellerate RX, LLC (&#8220;CGI
Cellerate RX&#8221;), a related party (see Note 13 for additional information regarding transactions with related parties). Pursuant
to the Sublicense Agreement, the Company had an exclusive, world-wide sublicense to distribute certain hydrolyzed collagen products,
including CellerateRX Surgical, into the surgical and wound care markets. In connection with the Applied Asset Purchase, Applied assigned
its license agreement with CGI Cellerate RX to SMAT (the &#8220;License Agreement&#8221;), and on October 10, 2024, the License Agreement
and the Sublicense Agreement were terminated for no additional consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the Cash Closing Consideration, Stock
Closing Consideration and Installment Payments, the Applied Purchase Agreement provides that the Sellers are entitled to receive up to
an additional $<span id="xdx_90B_ecustom--EarnoutPayable_iI_pn5n6_c20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zHnd4Q7GIKOi" title="Earnout payable"><ix:nonFraction name="SMTI:EarnoutPayable" contextRef="AsOf2023-08-01_custom_AppliedAssetPurchaseAgreementMember" id="Fact000740" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million (the &#8220;Applied Earnout&#8221;), which is payable to the Sellers in cash, upon the achievement of certain
performance thresholds relating to SMAT&#8217;s collections from net sales of a collagen-based product currently under development. Upon
expiration of the seventh anniversary of the Closing, to the extent the Sellers have not earned the entirety of the Applied Earnout,
SMAT shall pay the Sellers a pro-rata amount of the Applied Earnout based on collections from net sales of the product, with such amount
to be due credited against any Applied Earnout payments already made by SMAT (the &#8220;True-Up Payment&#8221;). The Applied Earnout,
minus the True-Up Payment and any Applied Earnout payments already made by SMAT, may be earned at any point in the future, including
after the True-Up Payment is made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Applied Asset Purchase and
pursuant to the Applied Purchase Agreement, effective August 1, 2023, the Company entered into a professional services agreement (the
&#8220;Petito Services Agreement&#8221;) with the Owner, pursuant to which the Owner, as an independent contractor, agreed to provide
certain services to the Company, including, among other things, assisting with the development of products already in development and
assisting with research, development, formulation, invention and manufacturing of any future products (the &#8220;Petito Services&#8221;).
<span id="xdx_90C_ecustom--PurchaseAgreementDescription_c20240101__20241231_zDR5wgh9ebt9" title="Purchase agreement description"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000742" name="SMTI:PurchaseAgreementDescription">As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of
the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain
products the Owner develops or co-develops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first
$50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%)
on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv)
$500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in
cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described
in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Petito Services Agreement has an initial term
of three years and is subject to automatic successive one-month renewals unless earlier terminated in accordance with its terms. The
Petito Services Agreement may be terminated upon the Owner&#8217;s death or disability or by the Company or the Owner &#8220;For Cause&#8221;
(as defined in the Petito Services Agreement); provided, however, that the base salary described in (i) of the foregoing paragraph shall
survive termination through the three-year initial term and the royalty payments and incentive payments described in (ii)-(v) of the
foregoing paragraph shall survive termination of the Petito Services Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As the contingent consideration was negotiated as
part of the transfer of assets, the contingent obligation was measured at fair value and included in the total purchase consideration
transferred. Accordingly, since the Applied Asset Purchase was accounted for as an asset acquisition and did not include contingent shares,
the contingent consideration is classified as a liability at its estimated fair value at each reporting period with subsequent revaluations
recognized as an adjustment to the intellectual property intangible asset and the earnout liability with a cumulative catch-up amortization
adjustment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_AppliedAssetPurchaseAgreementMember" escape="true" id="Fact000744" name="us-gaap:AssetAcquisitionTableTextBlock"><p id="xdx_898_eus-gaap--AssetAcquisitionTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zxJytX6QcDnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total purchase consideration for the Applied
Asset Purchase as determined by the Company was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_ztC3meezwqk9" style="display: none">SCHEDULE
OF ASSET PURCHASE CONSIDERATIONS</span></span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 92%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consideration</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_z2dmqgq7z4L2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Dollar Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetAcquisitionConsiderationTransferredOtherAssets_maAACTzk9b_zza98cZNX7N" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 0pt">Cash Closing Consideration</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember" id="Fact000746" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,750,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_maAACTzk9b_zwYdNodpNAke" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Fair value of Stock Closing Consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zXDdhJapU3eg" title="Equity Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember" id="Fact000750" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,809</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember" id="Fact000748" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,089,645</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments_maAACTzk9b_zw7h3kxU9WI3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Fair value of Installment Payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember" id="Fact000752" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,040,808</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AssetAcquisitionConsiderationTransferredCashPaidForInventory_maAACTzk9b_zkrHiYSUkVof" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Cash paid for inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:AssetAcquisitionConsiderationTransferredCashPaidForInventory" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember" id="Fact000754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,007</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments_maAACTzk9b_zPlGwUIoSCx1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Fair value of Petito Services Agreement defined payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember" id="Fact000756" format="ixt:numdotdecimal" decimals="0" unitRef="USD">825,834</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_maAACTzk9b_zN89THawGPna" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Fair value of Petito Services Agreement contingent consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember" id="Fact000758" format="ixt:numdotdecimal" decimals="0" unitRef="USD">893,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_maAACTzk9b_zktigTQotIah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Direct transaction costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember" id="Fact000760" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,743</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferred_iT_mtAACTzk9b_znTrnBD5j554" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 9pt; padding-left: 0pt">Total purchase consideration</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember" id="Fact000762" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,792,037</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zuJeAk47Ts45" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on guidance provided by ASC 805, Business Combinations
(&#8220;ASC 805&#8221;), the Company recorded the Applied Asset Purchase as an asset acquisition due to the determination that substantially
all the fair value of the assets acquired was concentrated in a group of similar identifiable assets. The Company believes the &#8220;substantially
all&#8221; criterion was met with respect to the acquired intellectual property being the only significant asset acquired. Accordingly,
the Company accounted for the transaction as an asset acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase consideration, plus transaction costs,
was allocated to the individual assets according to their fair values as a percentage of the total fair value of the assets purchased,
with no goodwill recognized. Based on the estimated fair value of the gross assets acquired, the total fair value of the net assets acquired
was primarily attributable to, and classified as, finite-lived intellectual property in the fourth quarter of 2023. The total purchase
consideration was allocated based on the relative estimated fair value of such assets as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_AppliedAssetPurchaseAgreementMember" escape="true" id="Fact000764" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zRoZpPa3rsZ2" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z7wHAGAOoyk" style="display: none">SCHEDULE
OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Description</b></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231__us-gaap--BusinessAcquisitionAxis__custom--AppliedAssetPurchaseAgreementMember_zc9DgPk03U69" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_maBCRIAz5eD_zp9BIsLjBOi7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; padding-left: 0pt">Inventory</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" contextRef="AsOf2024-12-31_custom_AppliedAssetPurchaseAgreementMember" id="Fact000766" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,007</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment_iI_maBCRIAz5eD_z3Yc4pd783Ae" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" contextRef="AsOf2024-12-31_custom_AppliedAssetPurchaseAgreementMember" id="Fact000768" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,062</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty_iI_maBCRIAz5eD_zN0Sy7fTNyt3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Intellectual property</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SMTI:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty" contextRef="AsOf2024-12-31_custom_AppliedAssetPurchaseAgreementMember" id="Fact000770" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,728,968</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iTI_mtBCRIAz5eD_zuI1kuvDP4p" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 9pt; padding-left: 0pt">Net assets acquired</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextRef="AsOf2024-12-31_custom_AppliedAssetPurchaseAgreementMember" id="Fact000772" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,792,037</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zovDFZZpCEz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000774" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"><p id="xdx_800_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zUMiHlNSvxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 &#8211; <span id="xdx_829_z6hnJIGhED54">CONVERTIBLE LOAN RECEIVABLE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with a potential equity investment
in an unaffiliated entity engaged in the development of certain surgical technologies, the Company entered into a convertible loan agreement
in July 2024 pursuant to which the Company loaned $<span id="xdx_908_eus-gaap--AccountsNotesAndLoansReceivableNetCurrent_iI_c20240731__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z6tWJaLouo96" title="Accounts and financing receivable, after allowance for credit loss, current"><ix:nonFraction name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" contextRef="AsOf2024-07-31_us-gaap_ConvertibleDebtMember" id="Fact000776" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,079,391</ix:nonFraction></span> to the unaffiliated entity. The loan was initially set to be repaid on <span id="xdx_907_eus-gaap--LoansHeldForSaleMaturityDate_iI_dd_c20240731__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zrz2NeNAiX9c" title="Maturity date"><ix:nonNumeric contextRef="AsOf2024-07-31_us-gaap_ConvertibleDebtMember" format="ixt:datemonthdayyearen" id="Fact000778" name="us-gaap:LoansHeldForSaleMaturityDate">October 1, 2024</ix:nonNumeric></span>. However, the Company extended the repayment date to <span id="xdx_906_eus-gaap--LoansHeldForSaleMaturityDate_iI_dd_c20240731__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--LoanRestructuringModificationAxis__us-gaap--ExtendedMaturityMember_zyHUucI2h076" title="Extended maturity date"><ix:nonNumeric contextRef="AsOf2024-07-31_us-gaap_ConvertibleDebtMember_us-gaap_ExtendedMaturityMember" format="ixt:datemonthdayyearen" id="Fact000780" name="us-gaap:LoansHeldForSaleMaturityDate">January 15, 2025</ix:nonNumeric></span>. On October&#160;1, 2024, the Company began accruing
interest at <span id="xdx_902_eus-gaap--LoansReceivableBasisSpreadOnVariableRate_iI_pid_dp_c20241001__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z8y8lKaCuoBh" title="Accruing interest"><ix:nonFraction name="us-gaap:LoansReceivableBasisSpreadOnVariableRate" contextRef="AsOf2024-10-01_us-gaap_ConvertibleDebtMember" id="Fact000782" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% per annum. Pursuant to the convertible loan agreement, the Company had the option to convert the outstanding balance of
the loan into noncontrolling equity interests of the unaffiliated entity upon satisfactory completion of certain due diligence activities.
As of December&#160;31, 2024, the loan balance was $<span id="xdx_90A_eus-gaap--OtherReceivablesNetCurrent_iI_c20241231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zHqtcgoRbx4j" title="Loan receivable"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-12-31_us-gaap_ConvertibleDebtMember" id="Fact000784" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,101,478</ix:nonFraction></span> including accrued interest and is recorded under the caption &#8220;Convertible
loan receivable&#8221; in the Company&#8217;s Consolidated Balance Sheets. As of January 16, 2025, the loan was converted into equity
of the unaffiliated entity (see Note 15 for additional information).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000786" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p id="xdx_805_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zhNJtyzKTZYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#8211; <span id="xdx_827_z6JXM58yrwO8">GOODWILL AND INTANGIBLES, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000788" name="us-gaap:ScheduleOfGoodwillTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfGoodwillTextBlock_zTGXs8g4Fheh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The changes in the carrying amount of the Company&#8217;s
goodwill were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zI1uAHA97Hv3" style="display: none">SCHEDULE
OF CHANGES IN  CARRYING AMOUNT OF  GOODWILL</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_zKF7tAVcgPsd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43B_c20230101__20231231_eus-gaap--Goodwill_iS_zvp0tyZIiUJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; padding-left: 0pt">Balance as of December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31" id="Fact000790" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,601,781</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GoodwillAcquiredDuringPeriod_zPUBBkKxaUY5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt">Acquisitions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20240101__20241231_eus-gaap--Goodwill_iS_zUmw9polaCCc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2023-12-31" id="Fact000794" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,601,781</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20240101__20241231_eus-gaap--Goodwill_iS_zpjNYIFHzTXg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2023-12-31" id="Fact000796" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,601,781</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--GoodwillAcquiredDuringPeriod_zUREqh5ZTQYg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 0pt">Acquisitions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0798">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20240101__20241231_eus-gaap--Goodwill_iE_zVslytut81yk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2024-12-31" id="Fact000800" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,601,781</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20240101__20241231_eus-gaap--Goodwill_iE_zC3jJ0CYOgQ3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2024-12-31" id="Fact000802" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,601,781</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A9_z8FhhmKtk4Xg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the change in reportable operating
segments, the Company reassessed goodwill with respect to the change in reportable operating segments as they are presented in this report.
Goodwill was recorded in connection with the acquisition of Scendia and is included entirely within the Sanara Surgical segment. The
Company&#8217;s assessment determined that these changes, or any other matters noted, did not alter the Company&#8217;s conclusion that
goodwill is not impaired as of December&#160;31, 2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000804" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zKnw0olVTIA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying values of the Company&#8217;s intangible
assets were as follows for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zSbQCCzgJQoe" style="display: none">SCHEDULE
OF CARRYING VALUE OF INTANGIBLE ASSETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated <br/>Amortization</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated <br/>Amortization</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Amortizable Intangible Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 22%; text-align: left; text-indent: 9pt; padding-left: 0pt">Patents and Other IP</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzacLpJoCB4f" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2024-12-31_us-gaap_PatentsMember" id="Fact000805" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,009,240</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z34r0mrsgYCd" style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_us-gaap_PatentsMember" id="Fact000806" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,008,856</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGD09bO2Heu8" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31_us-gaap_PatentsMember" id="Fact000807" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,000,384</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zU3Xvw5YNoJ4" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" id="Fact000808" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,570,549</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znSiCMFdFlF4" style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" id="Fact000809" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,181,186</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z9DMfstX9qC1" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" id="Fact000810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,389,363</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Customer relationships and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_z0Q7LkAuznS4" style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2024-12-31_custom_CustomerRelationshipsAndOtherMember" id="Fact000811" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,948,299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zboaEJaqV0w2" style="text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_custom_CustomerRelationshipsAndOtherMember" id="Fact000812" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,007,118</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zTRhoMuzUnFb" style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31_custom_CustomerRelationshipsAndOtherMember" id="Fact000813" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,941,181</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zUufLULozobf" style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2023-12-31_custom_CustomerRelationshipsAndOtherMember" id="Fact000814" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,947,332</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zxdi5Ww7uDTg" style="text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_custom_CustomerRelationshipsAndOtherMember" id="Fact000815" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,861,887</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zK66QEFscaT5" style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31_custom_CustomerRelationshipsAndOtherMember" id="Fact000816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,085,445</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt">Product Licenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zIplH3ty2SOe" title="Cost" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2024-12-31_us-gaap_LicensingAgreementsMember" id="Fact000818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,793,879</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zGkzAqnxsnfa" title="Accumulated amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_us-gaap_LicensingAgreementsMember" id="Fact000820" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,728,668</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zeLKiobF3Wui" title="Net" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31_us-gaap_LicensingAgreementsMember" id="Fact000822" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,065,211</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zZszQyhQUOU4" title="Cost" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2023-12-31_us-gaap_LicensingAgreementsMember" id="Fact000824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,793,879</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zE5FhTtwgnV" title="Accumulated amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_LicensingAgreementsMember" id="Fact000826" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,342,626</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zKQICmYYa6Ek" title="Net" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31_us-gaap_LicensingAgreementsMember" id="Fact000828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,451,253</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zTACvoj38QJd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2024-12-31_custom_AmortizableIntangibleAssetsMember" id="Fact000829" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,751,418</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z6bzJ0qtxY25" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_custom_AmortizableIntangibleAssetsMember" id="Fact000830" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,744,642</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zXE2wVpemuB2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31_custom_AmortizableIntangibleAssetsMember" id="Fact000831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,006,776</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z0U8AtRQIQoj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2023-12-31_custom_AmortizableIntangibleAssetsMember" id="Fact000832" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,311,760</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zKA4Nl2Kmlci" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_custom_AmortizableIntangibleAssetsMember" id="Fact000833" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,385,699</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z4lHAjeII1H" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31_custom_AmortizableIntangibleAssetsMember" id="Fact000834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,926,061</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z3qnmUBw0ZR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December&#160;31, 2024, the weighted-average
amortization period for finite-lived intangible assets was <span id="xdx_904_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20240101__20241231_zeH8Z3WgqU0c" title="Weighted-average amortization period"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact000836" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">14.6</ix:nonNumeric></span> years. Amortization expense related to intangible assets was $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_zPOYtVhC5IWc" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000838" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,891,737</ix:nonFraction></span>
and $<span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zOJ0pn353DX" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact000840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,218,888</ix:nonFraction></span> for the year ended December&#160;31, 2024 and 2023, respectively. The estimated remaining amortization expense as of December&#160;31,
2024 for finite-lived intangible assets is as follows:</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000842" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zr0bTaT8mq06" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zKy7TUmt7uU5" style="display: none">SCHEDULE
OF FUTURE AMORTIZATION EXPENSE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_498_20241231_zrea05s5Vkt1" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz6Rp_zPVZR6GPUrB6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; text-align: left; padding-left: 0pt">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact000844" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,894,221</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz6Rp_zqfIUhTZ1ei5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2024-12-31" id="Fact000846" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,876,965</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz6Rp_z1z70AMge649" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2024-12-31" id="Fact000848" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,763,113</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz6Rp_zsA2WMrUjKS1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2024-12-31" id="Fact000850" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,722,054</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz6Rp_zdTCe818pr8e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2024-12-31" id="Fact000852" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,722,054</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANz6Rp_zb2hTvQcaMx2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2024-12-31" id="Fact000854" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,028,369</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz6Rp_z3mOAudjHYph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact000856" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,006,776</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zbkNOpHLMLhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has reviewed the carrying value of intangible
assets and has determined there was no impairment during the year ended December&#160;31, 2024 or 2023.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000858" name="us-gaap:InvestmentHoldingsTextBlock"><p id="xdx_800_eus-gaap--InvestmentHoldingsTextBlock_zhHL8Ob4jeL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#8211; <span id="xdx_823_zmKO8uNoPkod">INVESTMENTS IN EQUITY SECURITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s equity investments consist of
nonmarketable equity securities in privately held companies without readily determinable fair values. Unless accounted for under the
equity method of accounting, the investments are reported at cost minus impairment, if any, plus or minus changes resulting from observable
price changes in orderly transactions for the identical or similar investment of the same issuer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>DirectDerm </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, the Company made a $<span id="xdx_905_eus-gaap--LongTermInvestments_iI_c20200731__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_zwgzQ4yKNTQg" title="Long term investments"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="AsOf2020-07-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember" id="Fact000860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> long-term
investment to purchase certain nonmarketable securities consisting of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20200731__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_z2rlGR01R9v5" title="Number of shares for purchase"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-07-012020-07-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember" id="Fact000862" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,142,857</ix:nonFraction></span> Series B-2 Preferred Shares of Direct Dermatology Inc.
(&#8220;DirectDerm&#8221;), representing approximately <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200731__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_zfbGfDRkcHK4" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-07-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember32609109" id="Fact000864" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.9</ix:nonFraction></span>% ownership of DirectDerm at that time. Through this investment, the Company
received exclusive rights to utilize DirectDerm&#8217;s technology in all acute and post-acute care settings such as skilled nursing
facilities, home health and wound clinics. In 2021, the Company purchased an additional <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_zhPkgESnUPe8" title="Purchase of additional shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,571,430</ix:nonFraction></span> shares of DirectDerm&#8217;s Series
B-2 Preferred for $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_z9H4fpGbWvyg" title="Value of shares purchased"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember" id="Fact000868" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. In March 2022, the Company purchased an additional <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220301__20220331__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_z7AUOXUn29Fg" title="Purchase of additional shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-03-012022-03-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,571,429</ix:nonFraction></span> shares of DirectDerm&#8217;s Series B-2 Preferred
for $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220301__20220331__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_zh3ALofMorD7" title="Value of shares purchased"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-03-012022-03-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember" id="Fact000872" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. The Company&#8217;s ownership of DirectDerm was approximately <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DirectDermatologyIncMember_zfVKIsJHOgV8" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_custom_DirectDermatologyIncMember" id="Fact000874" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.1</ix:nonFraction></span>% as of December&#160;31, 2024. The Company does not have
the ability to exercise significant influence over DirectDerm&#8217;s operating and financial activities. In accordance with ASC Topic
321, Investments - Equity Securities (&#8220;ASC 321&#8221;), this investment was reported at cost as of December&#160;31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Pixalere</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2021, the Company invested $<span id="xdx_90E_eus-gaap--Investments_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredSharesMember__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zSxCHf3lF808" title="Investments"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2021-06-30_custom_ClassAPreferredSharesMember_custom_PixalereHealthcareIncMember" id="Fact000876" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,084,278</ix:nonFraction></span> to
purchase <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210601__20210630__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredSharesMember__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zXATieq1zkif" title="Purchase of additional shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-06-012021-06-30_custom_ClassAPreferredSharesMember_custom_PixalereHealthcareIncMember" id="Fact000878" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">278,587</ix:nonFraction></span> Class A Preferred Shares (the &#8220;Pixalere Shares&#8221;) of Canada based Pixalere Healthcare Inc. (&#8220;Pixalere&#8221;).
The Pixalere Shares are convertible into approximately <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210601__20210630__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredSharesMember__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zSBlA6Gygs02" title="Conversion rate"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2021-06-012021-06-30_custom_ClassAPreferredSharesMember_custom_PixalereHealthcareIncMember" id="Fact000880" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">27.3</ix:nonFraction></span>% of the outstanding equity of Pixalere. Pixalere provides a cloud-based wound
care software tool that empowers nurses, specialists and administrators to deliver better care for patients. In connection with the Company&#8217;s
purchase of the Pixalere Shares, Pixalere granted Pixalere Healthcare USA, LLC (&#8220;Pixalere USA&#8221;), a subsidiary of the Company,
a royalty-free exclusive license to use the Pixalere software and platform in the United States. In conjunction with the grant of the
license, the Company issued Pixalere a <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PixalereHealthcareUSALLCMember_zaXt0zVypam9" title="Ownership interest"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-06-30_custom_PixalereHealthcareUSALLCMember" id="Fact000882" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">27.3</ix:nonFraction></span>% equity ownership interest in Pixalere USA valued at $<span id="xdx_905_eus-gaap--EquityMethodInvestmentAggregateCost_iI_c20210630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PixalereHealthcareUSALLCMember_zMHfkG0axJO5" title="Ownership value"><ix:nonFraction name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="AsOf2021-06-30_custom_PixalereHealthcareUSALLCMember" id="Fact000884" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,879</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviewed the characteristics of the Pixalere
Shares in accordance with ASC Topic 323, Investments &#8211; Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Due to the substantive
liquidation preferences of the Pixalere Shares over Pixalere&#8217;s common stock, the Pixalere Shares are not &#8220;in-substance&#8221;
common stock, and therefore, the Company does not utilize the equity method of accounting for this investment. In accordance with ASC
321, this investment was reported at cost as of December&#160;31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>ChemoMouthpiece </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2024, the Company, through its wholly
owned subsidiary, Sanara CMP LLC (&#8220;Sanara CMP&#8221;), entered into a Unit Purchase Agreement (the &#8220;Unit Purchase Agreement&#8221;)
with ChemoMouthpiece, LLC (&#8220;CMp&#8221;), pursuant to which Sanara CMP purchased <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240901__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonUnitsMember__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_z1eBwKcIz7c9" title="Number of shares purchased"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-09-012024-09-30_custom_CommonUnitsMember_custom_ChemoMouthPieceLLCMember" id="Fact000886" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,674.72</ix:nonFraction></span> common units in CMp for an aggregate
purchase price of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240901__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonUnitsMember__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zmaR5vSiQZqd" title="Purchase of shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-09-012024-09-30_custom_CommonUnitsMember_custom_ChemoMouthPieceLLCMember" id="Fact000888" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million, or $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonUnitsMember__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zwPOeEwhgTM3" title="Share price per unit"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-09-30_custom_CommonUnitsMember_custom_ChemoMouthPieceLLCMember" id="Fact000890" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">49.6649</ix:nonFraction></span> per unit, which represented approximately <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20240930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ChemoMouthPieceLLCMember_zMkguyl4WCBk" title="Ownership interest"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-09-30_custom_ChemoMouthPieceLLCMember" id="Fact000892" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.64</ix:nonFraction></span>% of the issued and outstanding membership
interest of CMp immediately following such purchase. Subsequent to the Company&#8217;s initial investment in CMp, units of CMp were sold
to other investors, thereby decreasing the Company&#8217;s ownership of CMp to <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ChemoMouthPieceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z8zEBmhITRD1" title="Ownership interest"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_custom_ChemoMouthPieceLLCMember_us-gaap_InvestorMember" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.59</ix:nonFraction></span>% as of December&#160;31, 2024. CMp is a privately
held medical device company that develops and commercializes propriety oral cryotherapy products for cancer patients, including, among
other things, CMp&#8217;s Chemo Mouthpiece oral cryotherapy device, which is a 510(k) cleared cryotherapy device designed to reduce the
incidence and severity of chemotherapy induced oral mucositis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has reviewed the characteristics of Sanara
CMP&#8217;s investment in CMp in accordance with ASC 323 and determined that Sanara CMP made a non-controlling investment in a limited
liability company. According to the guidance provided in ASC 323-30-S99-1, investments in limited liability companies whereby an investor
holds more than a 3% to 5% ownership interest would generally be accounted for under the equity method of accounting. Therefore, the
Company utilized the equity method of accounting for this investment and recorded its initial investment at cost plus transaction costs.
Sanara CMP&#8217;s share of the earnings or losses of CMp is recorded in the Company&#8217;s Consolidated Statements of Operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>SI Technologies </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2022, the Company established a 50/50
joint venture, SI Healthcare Technologies, LLC (&#8220;SI Technologies&#8221;) (formerly known as SI Wound Care, LLC), with InfuSystem
Holdings, Inc. (&#8220;InfuSystem&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Unit Purchase Agreement with
CMp, the Company, CMp, certain subsidiaries of CMp, InfuSystem and SI Technologies, entered into an Exclusive Distribution Agreement
(the &#8220;Distribution Agreement&#8221;) pursuant to which SI Technologies was appointed as the sole and exclusive U.S. distributor
of CMp&#8217;s Standard Chemo Regiment Kits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The parties to the Distribution Agreement also entered
into an Intellectual Property Rights Agreement, pursuant to which SI Technologies was granted the exclusive right to use CMp&#8217;s
intellectual property rights to permit resale and use of the CMp Product in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has reviewed the characteristics the
Company&#8217;s investment in SI Technologies in accordance with ASC 323 and determined that the Company made a non-controlling investment
in a limited liability company. According to the guidance provided in ASC 323-30-S99-1, investments in limited liability companies whereby
an investor holds more than a 3% to 5% ownership interest would generally be accounted for under the equity method of accounting. Therefore,
the Company utilized the equity method of accounting for this investment and recorded its initial investment at cost. The Company&#8217;s
share of the earnings or losses of SI Technologies is recorded in the Company&#8217;s Consolidated Statements of Operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000896" name="us-gaap:EquityMethodInvestmentsTextBlock"><p id="xdx_89C_eus-gaap--EquityMethodInvestmentsTextBlock_zMAOGUcywrpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company&#8217;s
investments for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B1_zCcxAJwBrCR7" style="display: none">SCHEDULE
OF INVESTMENTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Economic Interest</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Economic Interest</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; padding-left: 0pt">Equity Method Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-left: 0pt">ChemoMouthpiece, LLC</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--EquityMethodInvestments_iI_c20241231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zcpoyufaA91d" title="Equity method investment" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="AsOf2024-12-31_custom_ChemoMouthPieceLLCMember" id="Fact000898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,172,242</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20241231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zFILfgArJySa" title="Economic interest" style="width: 12%; text-align: right"><ix:nonFraction name="SMTI:EquityMethodInvestmentsEconomicInterest" contextRef="AsOf2024-12-31_custom_ChemoMouthPieceLLCMember" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.59</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--EquityMethodInvestments_iI_c20231231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zTWjiExoXqZ2" title="Equity method investment" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20231231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zvaLSPsMIXFd" title="Economic interest" style="width: 12%; text-align: right"><span style="font-size: 10pt">	<span style="-sec-ix-hidden: xdx2ixbrl0904">-</span></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">SI Healthcare Technologies, LLC</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EquityMethodInvestments_iI_c20241231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zsKNjv2gy1n" title="Equity method investment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="AsOf2024-12-31_custom_SIHealthcareTechnologiesLLCMember" id="Fact000906" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,703</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20241231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zsacXtxDj3Vk" title="Economic interest" style="text-align: right"><ix:nonFraction name="SMTI:EquityMethodInvestmentsEconomicInterest" contextRef="AsOf2024-12-31_custom_SIHealthcareTechnologiesLLCMember" id="Fact000908" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EquityMethodInvestments_iI_c20231231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zyubXmNPqhuf" title="Equity method investment" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0910">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20231231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zZSYDhwoUL77" title="Economic interest" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Total Equity Method Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--EquityMethodInvestments_iI_c20241231_z2mR1u00kUL9" title="Equity method investment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="AsOf2024-12-31" id="Fact000914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,212,945</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--EquityMethodInvestments_iI_c20231231_zeTm9EaiIrS2" title="Equity method investment" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; padding-left: 0pt">Cost Method Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Direct Dermatology, Inc.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember_zajuHWuZ0d86" style="text-align: right"><ix:nonFraction name="us-gaap:OtherInvestmentsAndSecuritiesAtCost" contextRef="AsOf2024-12-31_custom_DirectDermatologyIncMember32609359" id="Fact000917" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember_zYF0psdqkmd2" style="text-align: right"><ix:nonFraction name="us-gaap:OtherInvestmentsAndSecuritiesAtCost" contextRef="AsOf2023-12-31_custom_DirectDermatologyIncMember" id="Fact000918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Pixalere Healthcare Inc.</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zccDcGcAE01" title="Cost method investment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherInvestmentsAndSecuritiesAtCost" contextRef="AsOf2024-12-31_custom_PixalereHealthcareIncMember" id="Fact000920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,084,278</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zpkcWZajaP9" title="Cost method investment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherInvestmentsAndSecuritiesAtCost" contextRef="AsOf2023-12-31_custom_PixalereHealthcareIncMember" id="Fact000922" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,084,278</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Total Cost Method Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231_zx4UnM7vPRyg" title="Cost method investment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherInvestmentsAndSecuritiesAtCost" contextRef="AsOf2024-12-31" id="Fact000924" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,084,278</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231_zMWJbmdCEJ8b" title="Cost method investment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherInvestmentsAndSecuritiesAtCost" contextRef="AsOf2023-12-31" id="Fact000926" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,084,278</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 12pt">Total Investments</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iI_c20241231_zYIgxxc9imw9" title="Total Investments" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2024-12-31" id="Fact000928" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,297,223</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iI_c20231231_zJIX2dufIDGk" title="Total Investments" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2023-12-31" id="Fact000930" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,084,278</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_z3WmyT2ZRFLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000932" name="us-gaap:GainLossOnInvestmentsTextBlock"><p id="xdx_894_eus-gaap--GainLossOnInvestmentsTextBlock_zPv5lPsfHCz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company&#8217;s
share of losses from equity method investments reflected in the Company&#8217;s Consolidated Statements of Operations for the periods
presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zHAhEl1usZHf" style="display: none">SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zehAYE0OgDLd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zjVewtCWnOHg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year
                                            Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December
                                            31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; padding-left: 0pt">Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromEquityMethodInvestments_hdei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zpUm7WViBV5g" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: left; padding-left: 0pt">ChemoMouthpiece, LLC</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2024-01-012024-12-31_custom_ChemoMouthPieceLLCMember" id="Fact000934" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">105,710</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0935">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromEquityMethodInvestments_hdei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zLNnrROfrmJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">SI Healthcare Technologies, LLC</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2024-01-012024-12-31_custom_SIHealthcareTechnologiesLLCMember" id="Fact000937" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,703</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0938">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromEquityMethodInvestments_zULRmngvImI6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 12pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000940" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,007</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromEquityMethodInvestments_zkslVPI9vICb" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 12pt">Loss from equity method investment</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000943" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,007</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0944">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A4_znq0kSjxirih" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000946" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_z8YUS1o7i6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8211; <span id="xdx_82A_ziwQd4pvaMO8">OPERATING LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company periodically enters operating lease contracts
for office space and equipment. Arrangements are evaluated at inception to determine whether such arrangements constitute a lease. Right
of use assets (&#8220;ROU assets&#8221;) represent the right to use an underlying asset for the lease term, and lease liabilities represent
the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized on the transition
date based on the present value of lease payments over the respective lease term, with the office space ROU asset adjusted for deferred
rent liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2024, the Company had two material
operating leases for office space. In March and September of 2023, the Company amended its primary office lease to obtain additional
space, as well as extend the term. The leases had remaining lease terms of <span id="xdx_906_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceOneMember_zvaoNF3TiIL8" title="Remaining lease term"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_OfficeSpaceOneMember" format="ixt-sec:durmonth" id="Fact000948" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">72</ix:nonNumeric></span> and <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dt_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceTwoMember_zL9BumQvplok" title="Remaining lease term"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_OfficeSpaceTwoMember" format="ixt-sec:durwordsen" id="Fact000950" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">eight months</ix:nonNumeric></span> as of December 31, 2024. The Company is
evaluating its renewal options for the lease expiring in eight months. For practical expediency, the Company has elected to not recognize
ROU assets and lease liabilities related to short-term leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC Topic 842, Leases, the Company
has recorded ROU assets of $<span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20241231_zSGWkqdJYgjh" title="Operating lease right of use assets"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000952" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,447,907</ix:nonFraction></span> and a related lease liability of $<span id="xdx_904_eus-gaap--OperatingLeaseLiability_iI_c20241231_z0mFIu2M0Rs4" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000954" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,595,738</ix:nonFraction></span> as of December&#160;31, 2024. The Company recorded
lease expense of $<span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20240101__20241231_z9YOUM9yJMHi" title="Operating lease expenses"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000956" format="ixt:numdotdecimal" decimals="0" unitRef="USD">555,192</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--OperatingLeaseExpense_c20230101__20231231_zLoWAdiNqQB8" title="Operating lease expenses"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-012023-12-31" id="Fact000958" format="ixt:numdotdecimal" decimals="0" unitRef="USD">434,066</ix:nonFraction></span> for the year ended December&#160;31, 2024 and 2023, respectively. Cash paid for amounts included
in the measurement of operating lease liabilities was $<span id="xdx_902_eus-gaap--OperatingLeasePayments_c20240101__20241231_zUbsUiKKUoJ4" title="Operating lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-01to2024-12-31" id="Fact000960" format="ixt:numdotdecimal" decimals="0" unitRef="USD">505,017</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--OperatingLeasePayments_c20230101__20231231_zKIMHXQWlVb9" title="Operating lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-12-31" id="Fact000962" format="ixt:numdotdecimal" decimals="0" unitRef="USD">380,576</ix:nonFraction></span> for the year ended December&#160;31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The present value of the Company&#8217;s operating
lease liabilities as of December&#160;31, 2024 is shown below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000964" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z6SrZdDpjvZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Maturity of Operating Lease Liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B2_zVpEBCFbTnD9" style="display: none">SCHEDULE OF OPERATING LEASE LIABILITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zoNBxnuX22O6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,<br/>
    2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzW5D_zjc5xaOe24Ce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; text-align: left; padding-left: 0pt">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact000966" format="ixt:numdotdecimal" decimals="0" unitRef="USD">466,800</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzW5D_zpdsmcKdg2H2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact000968" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,369</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzW5D_zX1Mw46DoAX5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-12-31" id="Fact000970" format="ixt:numdotdecimal" decimals="0" unitRef="USD">291,220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzW5D_z6CxGiouOPN8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-12-31" id="Fact000972" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,689</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzW5D_zmtdZPUWLlMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2024-12-31" id="Fact000974" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,158</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzW5D_z6aPHovppDxa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2024-12-31" id="Fact000976" format="ixt:numdotdecimal" decimals="0" unitRef="USD">303,891</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzW5D_zujVdPcAhTD3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact000978" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,958,127</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zh2CjtCVwjI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="Fact000980" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362,389</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_z36I6Zs5X84b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Present Value of Lease Liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000982" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,595,738</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zO1XIQtOKK91" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Operating lease liabilities &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000984" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,687</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zWHH6k26Z8ol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Operating lease liabilities &#8211; long-term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000986" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,237,051</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zGC1yUjJxZz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December&#160;31, 2024, the Company&#8217;s
operating leases had a weighted average remaining lease term of <span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zbwSh6gGgX2d" title="Weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:duryear" id="Fact000988" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">5.5</ix:nonNumeric></span> years and a weighted average discount rate of <span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zRYLzp9Bg5Ih" title="Weighted average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact000990" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.8</ix:nonFraction></span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000992" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_zTK1cGuLprgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#8211; <span id="xdx_821_z1V9SP76OE92">DEBT AND CREDIT FACILITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>CRG Term Loan Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April&#160;17, 2024 (the &#8220;Closing Date&#8221;),
the Company entered into a term loan agreement, by and among the Company, as borrower, the subsidiary guarantors party thereto from time
to time (collectively, the &#8220;Guarantors&#8221;), CRG Servicing LLC as administrative agent and collateral agent (the &#8220;Agent&#8221;),
and the lenders party thereto from time to time (the &#8220;CRG Term Loan Agreement&#8221;), providing for a senior secured term loan
of up to $<span id="xdx_903_eus-gaap--SecuredDebt_iI_pn5n6_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zkyXn7Lb45Fd" title="Secured term loan"><ix:nonFraction name="us-gaap:SecuredDebt" contextRef="AsOf2024-04-17_custom_CRGTermLoanAgreementMember" id="Fact000994" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">55.0</ix:nonFraction></span> million (the &#8220;CRG Term Loan&#8221;). As of December 31, 2024, the CRG Term Loan Agreement provided for (i) $<span id="xdx_900_ecustom--GrossCashReceivedFromTermLoan_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_z2u5D3iR4xS5" title="Loans borrowed"><ix:nonFraction name="SMTI:GrossCashReceivedFromTermLoan" contextRef="AsOf2024-12-31_custom_CRGTermLoanAgreementMember" id="Fact000996" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15.0</ix:nonFraction></span> million of the CRG Term
Loan that was borrowed on the Closing Date (the &#8220;First Borrowing&#8221;) and (ii) up to an aggregate of $<span id="xdx_901_eus-gaap--DebtInstrumentUnusedBorrowingCapacityAmount_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_z87NT3YY1d25" title="Remaining amount available for borrowing"><ix:nonFraction name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" contextRef="AsOf2024-12-31_custom_CRGTermLoanAgreementMember" id="Fact000998" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">40.0</ix:nonFraction></span> million available
for borrowing in two subsequent borrowings, provided that <span id="xdx_907_eus-gaap--DebtInstrumentDescription_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zEF4Wk4NbXV7" title="Borrowing capacity description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CRGTermLoanAgreementMember" id="Fact001000" name="us-gaap:DebtInstrumentDescription">each such borrowing was required to be at least $5.0 million and occur between the Closing
Date and June 30, 2025,</ix:nonNumeric></span> subject to the satisfaction of certain conditions, including the Agent having received certain fees. The Company used a portion of the initial proceeds of the First Borrowing under the CRG Term
Loan to extinguish the Cadence Term Loan described further below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 4, 2024, the Company, pursuant
to its option under the CRG Term Loan Agreement, borrowed an additional $<span id="xdx_901_ecustom--GrossCashReceivedFromTermLoan_iI_pn5n6_c20240904__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zEwZVLQ5Nemb" title="Loans borrowed"><ix:nonFraction name="SMTI:GrossCashReceivedFromTermLoan" contextRef="AsOf2024-09-04_custom_CRGTermLoanAgreementMember" id="Fact001002" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15.5</ix:nonFraction></span> million under the CRG Term Loan Agreement (the &#8220;Second
Borrowing&#8221;). The Company used $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_pn5n6_c20240904__20240904__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_z25cvTlIG6Ef" title="Proceeds from loans used for investment"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" contextRef="From2024-09-042024-09-04_custom_CRGTermLoanAgreementMember" id="Fact001004" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million of the proceeds of the Second Borrowing for its investment in CMp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The First Borrowing, Second Borrowing and any additional
borrowings under the CRG Term Loan are due and payable on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20240904__20240904__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zLycjQHvx4Nc" title="Debt maturity date"><ix:nonNumeric contextRef="From2024-09-042024-09-04_custom_CRGTermLoanAgreementMember" format="ixt:datemonthdayyearen" id="Fact001006" name="us-gaap:DebtInstrumentMaturityDate">March 30, 2029</ix:nonNumeric></span> (the &#8220;Maturity Date&#8221;), absent any acceleration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The CRG Term Loan bears interest at a per annum rate
equal to <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20240417__20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zSKYLcZj6iCj" title="Interest rate per annum"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2024-04-172024-04-17_custom_CRGTermLoanAgreementMember" id="Fact001008" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13.25</ix:nonFraction></span>% (subject to a <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_uPure_c20240417__20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zwFCbP73kcle" title="Incremental increase during an event of default"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2024-04-172024-04-17_custom_CRGTermLoanAgreementMember" id="Fact001010" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.0</ix:nonFraction></span>% increase during an event of default), of which <span id="xdx_902_ecustom--CashPaidPercentage_iI_dp_uPure_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zbepd7w9vhDc" title="Cash paid percentage"><ix:nonFraction name="SMTI:CashPaidPercentage" contextRef="AsOf2024-04-17_custom_CRGTermLoanAgreementMember" id="Fact001012" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.00</ix:nonFraction></span>% must be paid in cash and <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zcvjZo14WRYb" title="Paid-in-kind and aggregate principal loan amount, percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2024-04-17_custom_CRGTermLoanAgreementMember" id="Fact001014" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.25</ix:nonFraction></span>% may, at the election
of the Company, be deferred through the 19<sup>th</sup> quarterly Payment Date (defined below) by adding such amount to the aggregate
principal loan amount, so long as no default or event of default under the CRG Term Loan Agreement has occurred and is continuing. The
Company is required to make quarterly interest payments on the final business day of each calendar quarter following the Closing Date,
commencing on the first such date to occur at least 30 days after the Closing Date (each, a &#8220;Payment Date&#8221;). Interest is
payable on each Payment Date in arrears with respect to the time between each Payment Date and upon the payment or prepayment of the
CRG Term Loan, ending on the Maturity Date. In addition, the Company is required to pay an upfront fee of <span id="xdx_901_ecustom--DebtInstrumentUpFrontFeePercentage_iI_dp_uPure_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zqb33vD88gO7" title="Debt upfront fee percentage"><ix:nonFraction name="SMTI:DebtInstrumentUpFrontFeePercentage" contextRef="AsOf2024-04-17_custom_CRGTermLoanAgreementMember" id="Fact001016" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.50</ix:nonFraction></span>% of the principal amount
of the CRG Term Loan, which is payable as amounts are advanced under the CRG Term Loan on a pro rata basis. The Company is also required
to pay a back-end fee equal to <span id="xdx_908_ecustom--DebtInstrumentBackEndFeePercentage_iI_dp_uPure_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_ziD61m5HNzIh" title="Debt instrument back-end fee percentage"><ix:nonFraction name="SMTI:DebtInstrumentBackEndFeePercentage" contextRef="AsOf2024-04-17_custom_CRGTermLoanAgreementMember" id="Fact001018" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.00</ix:nonFraction></span>% of the aggregate principal amount advanced under the CRG Term Loan Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December&#160;31, 2024, the Company
paid $<span id="xdx_903_eus-gaap--InterestPaid_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zhncjVlXJBR6" title="Interest paid"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2024-01-012024-12-31_custom_CRGTermLoanAgreementMember" id="Fact001020" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,278,424</ix:nonFraction></span> of interest in cash and recorded $<span id="xdx_900_eus-gaap--PaidInKindInterest_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zxdhlurrsHLh" title="Interest paid-in-kind"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2024-01-012024-12-31_custom_CRGTermLoanAgreementMember" id="Fact001022" format="ixt:numdotdecimal" decimals="0" unitRef="USD">838,965</ix:nonFraction></span> of interest paid-in-kind related to the CRG Term Loan. The paid-in-kind interest
was applied to the principal balance of the CRG Term Loan. The Company recorded $<span id="xdx_90C_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember__us-gaap--DebtInstrumentAxis__custom--BackendFeeMember_z36IRGzRIpk6" title="Interest expense related to back-end fee"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-12-31_custom_CRGTermLoanAgreementMember_custom_BackendFeeMember" id="Fact001024" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,086</ix:nonFraction></span> for the year ended December&#160;31, 2024 to
interest expense related to the back-end fee. The back-end fee is accreted and amortized to interest expense over the term of the CRG
Term Loan. Paid-in-kind interest and the accreted back-end fee are included in &#8220;Long-term debt, net of current portion&#8221; in
the Consolidated Balance Sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to certain exceptions, the Company is required
to make mandatory prepayments of the CRG Term Loan with the proceeds of certain assets sales and in the event of a change of control
of the Company. In addition, the Company may make a voluntary prepayment of the CRG Term Loan, in whole or in part, at any time. All
mandatory and voluntary prepayments of the CRG Term Loan are subject to the payment of prepayment premiums as follows: <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateTerms_dp_uPure_c20240417__20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zERu6NtwjzYk" title="Debt instrument rate description"><ix:nonNumeric contextRef="From2024-04-172024-04-17_custom_CRGTermLoanAgreementMember" id="Fact001026" name="us-gaap:DebtInstrumentInterestRateTerms">(i) if prepayment
occurs on or prior to the date that is one year following the applicable borrowing (the &#8220;Borrowing Date&#8221;), an amount equal
to 10.0% of the aggregate outstanding principal amount of the CRG Term Loan being prepaid and (ii) if prepayment occurs one year after
the applicable Borrowing Date and on or prior to two years following the applicable Borrowing Date, an amount equal to 5.0% of the aggregate
outstanding principal amount of the CRG Term Loan being prepaid.</ix:nonNumeric></span> No prepayment premium is due on any principal prepaid if prepayment
occurs two years or more after the applicable Borrowing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain of the Company&#8217;s current and future
subsidiaries, including the Guarantors, are guaranteeing the obligations of the Company under the CRG Term Loan Agreement. As security
for their obligations under the CRG Term Loan Agreement, on the Closing Date, the Company and the Guarantors entered into a security
agreement with the Agent pursuant to which the Company and the Guarantors granted to the Agent, as collateral agent for the lenders,
a lien on substantially all of the Company&#8217;s and the Guarantors&#8217; assets, including intellectual property (subject to certain
exceptions).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The CRG Term Loan Agreement contains affirmative
and negative covenants customary for financings of this type, including limitations on the Company&#8217;s and the Guarantors&#8217;
abilities, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions above certain
thresholds, merge or consolidate with others, dispose of assets, pay dividends and distributions and enter into affiliate transactions,
in each case, subject to certain exceptions. In addition, the CRG Term Loan Agreement contains the following financial covenants requiring
the Company and the Guarantors in the aggregate to maintain:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in">&#9679;</td><td style="text-align: justify">liquidity in an amount which shall
                                            exceed the greater of: (i) $<span id="xdx_907_ecustom--MinimumCashBalanceValue_iI_pn5n6_c20241231_zChe9SW0Jrqh" title="Minimum cash balance"><ix:nonFraction name="SMTI:MinimumCashBalanceValue" contextRef="AsOf2024-12-31" id="Fact001028" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction></span> million and (ii) to the extent the Company has incurred certain
                                            permitted debt, the minimum cash balance, if any, required of the Company by the creditors
                                            of such permitted debt; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in">&#9679;</td><td style="text-align: justify">annual minimum revenue of at least:
                                            (i) $<span id="xdx_90F_ecustom--AnnualMinimumRevenueYearOne_pn5n6_c20240101__20241231_zJhAc9AV4VWi" title="Annual minimum revenue, year one"><ix:nonFraction name="SMTI:AnnualMinimumRevenueYearOne" contextRef="From2024-01-01to2024-12-31" id="Fact001030" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">60.0</ix:nonFraction></span> million for the twelve-month period beginning on January 1, 2024 and ending on
                                            December&#160;31, 2024, (ii) $<span id="xdx_902_ecustom--AnnualMinimumRevenueYearTwo_pn5n6_c20240101__20241231_zOdXSo4iE0D1" title="Annual minimum revenue, year two"><ix:nonFraction name="SMTI:AnnualMinimumRevenueYearTwo" contextRef="From2024-01-01to2024-12-31" id="Fact001032" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">75.0</ix:nonFraction></span> million for the twelve-month period beginning on January
                                            1, 2025 and ending on December 31, 2025, (iii) $<span id="xdx_906_ecustom--AnnualMinimumRevenueYearThree_pn5n6_c20240101__20241231_zMSDUbJdoShb" title="Annual minimum revenue, year three"><ix:nonFraction name="SMTI:AnnualMinimumRevenueYearThree" contextRef="From2024-01-01to2024-12-31" id="Fact001034" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">85.0</ix:nonFraction></span> million for the twelve-month period
                                            beginning on January 1, 2026 and ending on December 31, 2026, (iv) $<span id="xdx_90B_ecustom--AnnualMinimumRevenueYearFour_pn5n6_c20240101__20241231_zhspa9GlKpB6" title="Annual minimum revenue, year four"><ix:nonFraction name="SMTI:AnnualMinimumRevenueYearFour" contextRef="From2024-01-01to2024-12-31" id="Fact001036" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">95.0</ix:nonFraction></span> million for the
                                            twelve-month period beginning on January 1, 2027 and ending on December 31, 2027, and (v)
                                            $<span id="xdx_90B_ecustom--AnnualMinimumRevenueYearFive_pn5n6_c20240101__20241231_z9TKPx1cYZmk" title="Annual minimum revenue, year five"><ix:nonFraction name="SMTI:AnnualMinimumRevenueYearFive" contextRef="From2024-01-01to2024-12-31" id="Fact001038" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">105.0</ix:nonFraction></span> million during each twelve-month period beginning on January 1 of a given year thereafter.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The CRG Term Loan Agreement contains representations
and warranties of the Company and the Guarantors customary for financings of this type, and also includes events of default customary
for financings of this type, including, among other things, non-payment, inaccuracy of representations and warranties, covenant breaches,
a material adverse change, bankruptcy and insolvency, material judgments and a change of control, in certain cases subject to customary
periods to cure. The occurrence and continuance of an event of default could result in the acceleration of the obligations under the
CRG Term Loan Agreement. As of December 31, 2024, the Company was in compliance with all debt covenants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cadence
Term Loan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the entry into the Applied Purchase Agreement, on August&#160;1, 2023, SMAT, as borrower, and the Company, as guarantor,
entered into a loan agreement (the &#8220;Cadence Loan Agreement&#8221;) with Cadence Bank (the &#8220;Bank&#8221;) providing for, among
other things, an advancing term loan in the aggregate principal amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230801__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zHZDNOKo9JLl" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-08-01_custom_CadenceTermLoanAgreementMember" id="Fact001040" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.0</ix:nonFraction></span> million (the &#8220;Cadence Term Loan&#8221;), which
was evidenced by an advancing promissory note. Pursuant to the Cadence Loan Agreement, the Bank agreed to make, at any time and from
time to time prior to February 1, 2024, one or more advances to SMAT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds of the advances under the Cadence Loan Agreement were used for working capital and for purposes of financing up to one hundred
percent (<span id="xdx_90D_ecustom--PercentageOfLoanProceedsUsedForAcquisition_iI_pid_dp_uPure_c20230801__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zj5ur4hsgQ87" title="Loan percentage used for acquisition"><ix:nonFraction name="SMTI:PercentageOfLoanProceedsUsedForAcquisition" contextRef="AsOf2023-08-01_custom_CadenceTermLoanAgreementMember" id="Fact001042" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction>%</span>) of the Cash Closing Consideration and Installment Payments for the Applied Asset Purchase and related fees and expenses,
including any subsequent payments that were due to the Sellers after the Closing. On August 1, 2023, the Bank, at the request of SMAT,
made an advance for $<span id="xdx_90A_eus-gaap--FederalHomeLoanBankAdvances_iI_pn4n6_c20230801__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zrYouzh5dNT" title="Loan bank advance"><ix:nonFraction name="us-gaap:FederalHomeLoanBankAdvances" contextRef="AsOf2023-08-01_custom_CadenceTermLoanAgreementMember" id="Fact001044" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">9.75</ix:nonFraction></span> million. The proceeds from the advance were used to fund the Cash Closing Consideration for the Applied Asset
Purchase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unpaid principal balance of outstanding advances bore interest, subject to certain conditions, at the lesser of the Maximum Rate (as
defined in the Cadence Loan Agreement) or the Base Rate, which was for any day, a rate per annum equal to the term secured overnight
financing rate (Term SOFR) (as administered by the Federal Reserve Bank of New York) for a one-month tenor in effect on such day plus
three percent (<span id="xdx_908_eus-gaap--FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate_iI_pid_dp_uPure_c20230801__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zza0MZCyOXT" title="Bank, interest rate"><ix:nonFraction name="us-gaap:FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate" contextRef="AsOf2023-08-01_custom_CadenceTermLoanAgreementMember" id="Fact001046" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>%). As of December&#160;31, 2023, the interest rate on the advance under the Cadence Term Loan was <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_z4Wz2wRpl15e" title="Interest rate on advances"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-12-31_custom_CadenceTermLoanAgreementMember" id="Fact001048" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.3</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date of the CRG Term Loan Agreement, the Cadence Loan Agreement was terminated and all outstanding amounts under the Cadence
Term Loan were repaid in full and all security interest and other liens granted to or held by Cadence were terminated and released. In
addition, unamortized debt issuance costs as of the termination date of $<span id="xdx_909_eus-gaap--InterestExpenseOther_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zsszZEWqhMe4" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2024-01-012024-12-31_custom_CadenceTermLoanAgreementMember" id="Fact001050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,438</ix:nonFraction></span> were included in &#8220;Interest expense&#8221; in the
Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001052" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfDebtTableTextBlock_zIsg681yAnZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the components of the Company&#8217;s outstanding debt for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B6_zmrsJBFytyAk" style="display: none">SCHEDULE
OF LONG-TERM DEBT</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_zNFyPgSXxZgf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_z9l8Zt0EA1H7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--CRGTermLoanMember_zeqhzEqyaw2e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">CRG Term Loan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-12-31_custom_CRGTermLoanMember" id="Fact001054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,500,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--PaidInKindInterestMember_zUfuoig8Q83b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Paid-in-kind interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-12-31_custom_PaidInKindInterestMember" id="Fact001057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">838,965</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--BackendFeeMember_z5aVyIYzPYHd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Back-end fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-12-31_custom_BackendFeeMember" id="Fact001060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,086</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1061">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--CadenceTermLoanMember_zaVWB1qZMKy8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cadence Term Loan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-12-31_custom_CadenceTermLoanMember" id="Fact001064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,750,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzYHB_zZEHdl4obr0k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-12-31" id="Fact001066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,697,051</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-12-31" id="Fact001067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,750,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredFinanceCostsNet_iNI_di_msLTDzYHB_zk74bRzhcld3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: unamortized debt issuance costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="AsOf2024-12-31" id="Fact001069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,007,761</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="AsOf2023-12-31" id="Fact001070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,520</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebt_iTI_mtLTDzYHB_zv5L08O0fdk5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt, net of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2024-12-31" id="Fact001072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,689,290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2023-12-31" id="Fact001073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,693,480</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LongTermDebtCurrent_iI_ztnJ6x50cnlj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Current portion of debt</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2023-12-31" id="Fact001076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">580,357</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LongTermDebtNoncurrent_iI_zklisHAOfnf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Long-term debt, net of current portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-12-31" id="Fact001078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,689,290</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2023-12-31" id="Fact001079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,113,123</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zMeBdRXHZnV2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001081" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zgsCXX4dXIna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the aggregate maturities of the Company&#8217;s outstanding debt as of December&#160;31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zEexwUetOxof" style="display: none">SCHEDULE
OF MATURITIES OUTSTANDING</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zxaa3sEEE7y8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maDICAzHTB_z4EjHutIBkMa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1083">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maDICAzHTB_zss0VSJhmmm9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1085">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maDICAzHTB_zosy1ThNwxbc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1087">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maDICAzHTB_zTKab2wyicN7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_maDICAzHTB_zJCOJs4T6aTk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2029</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextRef="AsOf2024-12-31" id="Fact001091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,697,051</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_iI_maDICAzHTB_z4VsxxZuRpOd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1093">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DebtInstrumentCarryingAmount_iTI_mtDICAzHTB_zJlKfsFP7l6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total debt</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-12-31" id="Fact001095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,697,051</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zVDT02dSa9Ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the CRG Term Loan, the Company incurred $<span id="xdx_90A_eus-gaap--DeferredFinanceCostsGross_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--CRGTermLoanMember_zyuyKfnj7jP1" title="Debt issuance costs"><ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="AsOf2024-12-31_custom_CRGTermLoanMember" id="Fact001097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,160,740</ix:nonFraction></span> in debt issuance costs during the year ended December&#160;31, 2024.
Debt issuance costs are amortized to &#8220;Interest expense&#8221; in the Consolidated Statements of Operations over the life of the
debt to which they pertain. The total unamortized debt issuance costs were $<span id="xdx_904_eus-gaap--DeferredFinanceCostsNet_iI_c20241231_zYQlxfSwzekk" title="Unamortized debt issuance costs"><ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="AsOf2024-12-31" id="Fact001099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,007,761</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--DeferredFinanceCostsNet_iI_c20231231_z7zEIB6Yu1lj" title="Unamortized debt issuance costs"><ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="AsOf2023-12-31" id="Fact001101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,520</ix:nonFraction></span> as of December&#160;31, 2024 and December&#160;31,
2023, respectively. Debt issuance costs are included in &#8220;Long-term debt, net of current portion&#8221; in the Consolidated Balance
Sheets. Amortization expense related to debt issuance costs was $<span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_c20240101__20241231_zq5OSL6zmSUb"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2024-01-01to2024-12-31" id="Fact001102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">209,499</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--AmortizationOfFinancingCosts_dc_c20230101__20231231_zQnBTZgFXudf" title="Amortization expense of debt issuance costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2023-01-012023-12-31" id="Fact001104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,138</ix:nonFraction></span> for the year ended December&#160;31, 2024 and 2023,
respectively. Amortization for the year ended December&#160;31, 2024 includes the write-off of debt issuance costs of $<span id="xdx_90B_eus-gaap--WriteOffOfDeferredDebtIssuanceCost_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--CadenceTermLoanMember_zLu9QJ4wHVtk" title="Write-off of debt issuance costs"><ix:nonFraction name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" contextRef="From2024-01-012024-12-31_custom_CadenceTermLoanMember" id="Fact001106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,520</ix:nonFraction></span> related
to the termination of Cadence Term Loan. The fair value of the Company&#8217;s long-term debt approximated its carrying value as December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001108" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zyn7a0RhC1ta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section42"></span>NOTE
9 - <span id="xdx_823_z1Qc7X96lzrf">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreements and Royalties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CellerateRX
Surgical</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--LicenseAgreementAndRoyaltiesDescription_c20180826__20180827__us-gaap--TypeOfArrangementAxis__custom--SubLicenseAgreementMember_z1wiiKLFpLik" title="License agreement and royalties description"><ix:nonNumeric contextRef="From2018-08-262018-08-27_custom_SubLicenseAgreementMember" id="Fact001110" name="SMTI:LicenseAgreementAndRoyaltiesDescription">In
August 2018, the Company entered an exclusive, world-wide sublicense agreement with CGI Cellerate RX to distribute certain hydrolyzed
collagen products, including CellerateRX Surgical, into the surgical and wound care markets. Pursuant to the Sublicense Agreement, the
Company paid royalties of 3-5% of annual collected net sales of these products.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed further in Note 3, on August 1, 2023, the Company purchased certain assets from Applied, including the rights to manufacture
and sell certain hydrolyzed collagen products, including CellerateRX Surgical, for use in the human wound care market. In connection
with the Applied Asset Purchase, Applied assigned the License Agreement with CGI Cellerate RX to SMAT, and on October 10, 2024, the License
Agreement and Sublicense Agreement were terminated for no additional consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Sublicense Agreement, royalty expense, which was recorded in &#8220;Cost of goods sold&#8221; in the accompanying Consolidated Statements
of Operations, totaled <span id="xdx_904_eus-gaap--RoyaltyExpense_dc_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zg9pirJt6j03" title="Payment for additional royalties"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-01-012024-12-31_us-gaap_CostOfSalesMember" id="Fact001112" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">zero</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zjYQogUF8Igd" title="Payment for additional royalties"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2023-01-012023-12-31_us-gaap_CostOfSalesMember" id="Fact001114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">991,099</ix:nonFraction></span>, respectively, for the year ended December&#160;31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>BIASURGE
Advanced Surgical Solution, BIAK&#332;S Antimicrobial Wound Gel and BIAK&#332;S Antimicrobial Skin and Wound Cleanser</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2019, the Company executed a license agreement with Rochal Industries, LLC (&#8220;Rochal&#8221;), a related party, pursuant to
which the Company acquired an exclusive world-wide license to market, sell and further develop antimicrobial products for the prevention
and treatment of microbes on the human body utilizing certain Rochal patents and pending patent applications (the &#8220;BIAK&#332;S
License Agreement&#8221;). Currently, the products covered by the BIAK&#332;S License Agreement are BIASURGE Advanced Surgical Solution,
BIAK&#332;S Antimicrobial Wound Gel, BIAK&#332;S Antimicrobial Skin and Wound Cleanser. All three products are 510(k) cleared.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
commitments under the terms of the BIAK&#332;S License Agreement include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company pays Rochal a royalty of <span id="xdx_901_ecustom--RoyaltyPercentage_pid_dp_uPure_c20190701__20190731__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember__dei--LegalEntityAxis__custom--RochalIndustriesLLCMember__srt--RangeAxis__srt--MinimumMember_z1GljJ0oTp5h"><ix:nonFraction name="SMTI:RoyaltyPercentage" contextRef="From2019-07-012019-07-31_custom_BIAKOSLicenseAgreementMember_custom_RochalIndustriesLLCMember_srt_MinimumMember" id="Fact001115" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2</ix:nonFraction></span>-<span id="xdx_900_ecustom--RoyaltyPercentage_pid_dp_uPure_c20190701__20190731__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember__dei--LegalEntityAxis__custom--RochalIndustriesLLCMember__srt--RangeAxis__srt--MaximumMember_zwPN1bjo2Vak"><ix:nonFraction name="SMTI:RoyaltyPercentage" contextRef="From2019-07-012019-07-31_custom_BIAKOSLicenseAgreementMember_custom_RochalIndustriesLLCMember_srt_MaximumMember" id="Fact001116" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>% of net sales. The minimum annual royalty due to Rochal
                                            will increase to a maximum amount of $<span id="xdx_909_eus-gaap--PaymentsForRoyalties_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember__dei--LegalEntityAxis__custom--RochalIndustriesLLCMember__srt--RangeAxis__srt--MaximumMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zAQaEqol1ZZe" title="Payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2025-01-012025-12-31_custom_BIAKOSLicenseAgreementMember_custom_RochalIndustriesLLCMember_srt_MaximumMember_srt_ScenarioForecastMember" id="Fact001118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> in 2025.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company may pay additional royalties annually based on specific net profit targets from sales
                                            of the licensed products, subject to a maximum of $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20190701__20190731__us-gaap--TypeOfArrangementAxis__custom--BIAKOSAgreementMember__srt--RangeAxis__srt--MaximumMember_zw7ai2w07Ee5" title="Payment for additional royalties"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2019-07-012019-07-31_custom_BIAKOSAgreementMember_srt_MaximumMember" id="Fact001120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> during any calendar year.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
previously terminated by the parties, the BIAK&#332;S License Agreement expires with the related patents in December 2031.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
this agreement, royalty expense, which is recorded in &#8220;Cost of goods sold&#8221; in the accompanying Consolidated Statements of
Operations, was $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember_ztxKteX7hEnh" title="Royalty expense"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-01-012024-12-31_custom_BIAKOSLicenseAgreementMember" id="Fact001122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">177,005</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember_zlO37oX9lW14" title="Royalty expense"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2023-01-012023-12-31_custom_BIAKOSLicenseAgreementMember" id="Fact001124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,000</ix:nonFraction></span> for the year ended December&#160;31, 2024 and 2023, respectively. The Company&#8217;s Executive
Chairman and Chief Executive Officer is a director of Rochal, and indirectly a significant shareholder of Rochal, and through the potential
exercise of warrants, a majority shareholder of Rochal. Another one of the Company&#8217;s directors is also a director and significant
shareholder of Rochal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CuraShield
Antimicrobial Barrier Film and No Sting Skin Protectant</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, the Company executed a license agreement with Rochal pursuant to which the Company acquired an exclusive world-wide license
to market, sell and further develop certain antimicrobial barrier film and skin protectant products for use in the human health care
market utilizing certain Rochal patents and pending patent applications (the &#8220;ABF License Agreement&#8221;). Currently, the products
covered by the ABF License Agreement are CuraShield Antimicrobial Barrier Film and a no sting skin protectant product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
commitments under the terms of the ABF License Agreement include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company will pay Rochal a royalty of <span id="xdx_90E_ecustom--RoyaltyPercentage_pid_dp_uPure_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zjsB3QQfie63" title="Royalty percentage"><ix:nonFraction name="SMTI:RoyaltyPercentage" contextRef="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MinimumMember" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2</ix:nonFraction></span>-<span id="xdx_904_ecustom--RoyaltyPercentage_pid_dp_uPure_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zIShVvIq8KB8" title="Royalty percentage"><ix:nonFraction name="SMTI:RoyaltyPercentage" contextRef="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MaximumMember" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>% of net sales. The minimum annual royalty due to
                                            Rochal will be $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zClDPwa1y06k" title="Payments for royalty"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MinimumMember" id="Fact001130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> beginning with the first full calendar year following the year in
                                            which first commercial sales of the products occur. The annual minimum royalty will increase
                                            by <span id="xdx_90D_ecustom--IncreaseInRoyaltyAnnualPercentage_pid_dp_uPure_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember_zTZDzuYBd0Ub" title="Increase in royalty annual percentage"><ix:nonFraction name="SMTI:IncreaseInRoyaltyAnnualPercentage" contextRef="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember" id="Fact001132" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% each subsequent calendar year up to a maximum amount of $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zWWWoVEq5YD1" title="Maximum amount of royalty"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MaximumMember" id="Fact001134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span>.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company will pay additional royalties annually based on specific net profit targets from
                                            sales of the licensed products, subject to a maximum of $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember_zJiaB7wATsw4" title="Payment for additional royalties"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MaximumMember_us-gaap_ProductAndServiceOtherMember" id="Fact001136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> during any calendar year.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
previously terminated or extended by the parties, the ABF License Agreement will terminate upon expiration of the last U.S. patent in
October 2033. No commercial sales or royalties have been recognized under this agreement as of December&#160;31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Debrider
License Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, the Company executed a product license agreement with Rochal, pursuant to which the Company acquired an exclusive world-wide
license to market, sell and further develop a debrider for human medical use to enhance skin condition or treat or relieve skin disorders,
excluding uses primarily for beauty, cosmetic, or toiletry purposes (the &#8220;Debrider License Agreement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
commitments under the terms of the Debrider License Agreement include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                            FDA clearance of the licensed products, the Company will pay Rochal $<span id="xdx_90F_eus-gaap--Cash_iI_c20200531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RochalMember__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember_zs3SfXcyEcD1" title="Payment in cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-05-31_custom_RochalMember_custom_DebriderLicenseAgreementMember" id="Fact001138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> in cash and
                                            an additional $<span id="xdx_90C_eus-gaap--PaymentsToAcquireBusinessesGross_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember_zTLIS1IQVXIa" title="Payment of cash"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember" id="Fact001140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span>, which at the Company&#8217;s option may be paid in any combination
                                            of cash and its common stock.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company will pay Rochal a royalty of <span id="xdx_90B_ecustom--RoyaltyPercentage_pid_dp_uPure_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zX5t1WBrt2c3" title="Royalty percentage"><ix:nonFraction name="SMTI:RoyaltyPercentage" contextRef="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember_srt_MinimumMember" id="Fact001142" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2</ix:nonFraction></span>-<span id="xdx_908_ecustom--RoyaltyPercentage_pid_dp_uPure_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zDvPKxsHK4qh" title="Royalty percentage"><ix:nonFraction name="SMTI:RoyaltyPercentage" contextRef="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember_srt_MaximumMember" id="Fact001144" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>% of net sales. The minimum annual royalty due to
                                            Rochal will be $<span id="xdx_908_eus-gaap--PaymentsForRoyalties_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zfcSCwc0e2y" title="Payments for royalty"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember_srt_MinimumMember" id="Fact001146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> beginning with the first full calendar year following the year in
                                            which first commercial sales of the licensed products occur and increase by <span id="xdx_90D_ecustom--IncreaseInRoyaltyAnnualPercentage_pid_dp_uPure_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember_zITPScHQdDGh" title="Increase in royalty annual percentage"><ix:nonFraction name="SMTI:IncreaseInRoyaltyAnnualPercentage" contextRef="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember" id="Fact001148" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% each subsequent
                                            calendar year up to a maximum amount of $<span id="xdx_90E_eus-gaap--PaymentsForRoyalties_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zhX2ywq8eWV2" title="Annual royalty"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember_srt_MaximumMember" id="Fact001150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company will pay additional royalty annually based on specific net profit targets from sales
                                            of the licensed products, subject to a maximum of $<span id="xdx_909_ecustom--PaymentsForAdditionalRoyalties_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zCOqqwqHkHbi" title="Payment for additional royalties"><ix:nonFraction name="SMTI:PaymentsForAdditionalRoyalties" contextRef="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember_srt_MaximumMember" id="Fact001152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> during any calendar year.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
previously terminated or extended by the parties, the Debrider License Agreement will expire in October 2034. No commercial sales or
royalties have been recognized under this agreement as of December&#160;31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisitions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rochal
Asset Acquisition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an asset purchase agreement with Rochal effective July 1, 2021, pursuant to which the Company purchased certain
assets of Rochal. Pursuant to the asset purchase agreement, for the three-year period after the effective date, Rochal was entitled to
receive consideration for any new product relating to the business that is directly and primarily based on an invention conceived and
reduced to practice by a member or members of Rochal&#8217;s science team. For the three-year period after the effective date, Rochal
was also entitled to receive an amount in cash equal to twenty-five percent of the proceeds received for any Grant (as defined in the
asset purchase agreement) by either the Company or Rochal. In addition, the Company agreed to use commercially reasonable efforts to
perform Minimum Development Efforts (as defined in the asset purchase agreement) with respect to certain products under development,
which if obtained, will entitle the Company to intellectual property rights from Rochal in respect of such products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Precision
Healing Merger Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, the Company closed a merger transaction with Precision Healing pursuant to which Precision Healing became a wholly owned
subsidiary of the Company. Pursuant to the terms of the merger agreement, holders of Precision Healing common stock and preferred stock,
other than the Company, were entitled to receive closing consideration, consisting of $<span id="xdx_906_eus-gaap--AssetAcquisitionConsiderationTransferred_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zUlp44IKFAe9" title="Cash consideration"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember" id="Fact001154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,966</ix:nonFraction></span> in cash consideration, which was paid
to stockholders who were not accredited investors, <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zIqg208eqk1" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember_custom_AccreditedInvestorsMember" id="Fact001156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">165,738</ix:nonFraction></span> shares of the Company&#8217;s common stock, which was paid only to accredited
investors, and the payment in cash of approximately $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zUeMrfm2EID4" title="Payment in cash"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember" id="Fact001158" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million of transaction expenses of Precision Healing. The Company recorded the
issuance of the <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zmpKxc1ygb6c" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember_custom_AccreditedInvestorsMember" id="Fact001160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">165,738</ix:nonFraction></span> shares to accredited investors and cash payments to nonaccredited investors based on the closing price per share
of the Company&#8217;s common stock on April&#160;4, 2022, which was $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20220404__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zfnHf1QNgh35" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-04-04_custom_PrecisionHealingMergerAgreementMember" id="Fact001162" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.75</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the merger, the Precision Healing outstanding options previously granted under the Precision Healing Plan converted, pursuant
to their terms, into options to acquire an aggregate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zXBcNOx8uZr7" title="Options to acquire shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember" id="Fact001164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">144,191</ix:nonFraction></span> shares of Company common stock with a weighted average exercise price
of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zFjXhuGyRW39" title="Weighted exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember" id="Fact001166" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.71</ix:nonFraction></span> per share. These options expire between August 2030 and April 2031. In addition, outstanding and unexercised Precision Healing
warrants converted into rights to receive warrants to purchase (i) <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCnnojVU6PD2" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_us-gaap_WarrantMember" id="Fact001168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,424</ix:nonFraction></span> shares of the Company&#8217;s common stock with an initial exercise
price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvBLCTopRBC2" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_us-gaap_WarrantMember" id="Fact001170" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.32</ix:nonFraction></span> per share and an expiration date of<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCKf6TKnFxRg" title="Expiration date"> <ix:nonNumeric contextRef="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_us-gaap_WarrantMember" format="ixt:datemonthdayyearen" id="Fact001172" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April 22, 2031</ix:nonNumeric></span>, and (ii) <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zSrwplEvgvfb" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_custom_WarrantOneMember" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,301</ix:nonFraction></span> shares of the Company&#8217;s common stock with
an initial exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zLlC6zn1gDJd" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_custom_WarrantOneMember" id="Fact001176" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.05</ix:nonFraction></span> per share and an expiration date of <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zbFxlszRdG9j" title="Expiration date"><ix:nonNumeric contextRef="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_custom_WarrantOneMember" format="ixt:datemonthdayyearen" id="Fact001178" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August 10, 2030</ix:nonNumeric></span>. Concurrent with the assumption of the Precision
Healing Plan, the Company terminated the ability to offer future awards under the Precision Healing Plan. As of December 31, 2024, all
warrants to purchase shares of the Company&#8217;s common stock pursuant to the transaction with Precision Healing were exercised and
there were <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_zLWpwM8Hpiv8" title="Options remaining to be exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact001180" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">31,013</ix:nonFraction></span> share options remaining to be exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the merger agreement, upon the achievement of certain performance thresholds, the securityholders of Precision Healing, including
the holders of options and warrants to purchase Precision Healing common stock and certain persons promised options to purchase Precision
Healing common stock, was also entitled to receive payments of up to $<span id="xdx_90D_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_pn5n6_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_z7sUU9ygK3Gg" title="Contingent consideration payments receivable"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember" id="Fact001182" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million, which was accounted for as contingent consideration
pursuant to ASC 805. The earnout consideration was payable in cash or, at the Company&#8217;s election, was payable to accredited investors
in shares of Company common stock at a price per share equal to the greater of (i) $<span id="xdx_908_eus-gaap--SharePrice_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zV1gW8aK2Zah" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember" id="Fact001184" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.13</ix:nonFraction></span> or (ii) the average closing price of Company
common stock for the 20 trading days prior to the date such earnout consideration was due and payable. Pursuant to the merger agreement,
a minimum percentage of the earnout consideration may be required to be issued to accredited investors in shares of Company common stock
for tax purposes. The amount and composition of the portion of earnout consideration payable was subject to adjustment and offsets as
set forth in the merger agreement. The Company reviewed the performance thresholds necessary to trigger an earnout payment as of December
31, 2024 and deemed the performance thresholds to be unachievable. Therefore, the remaining fair value of the earnout consideration was
reduced to zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Scendia
Purchase Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, the Company closed the Scendia acquisition pursuant to which Scendia became a wholly owned subsidiary of the Company. Pursuant
to the purchase agreement, the aggregate consideration for the acquisition at closing was approximately $<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zEcE7fYkqTYa" title="Acquisition consideration transferred"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2022-07-012022-07-31_custom_ScendiaPurchaseAgreementMember" id="Fact001186" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.6</ix:nonFraction></span> million, subject to customary
post-closing adjustments. The consideration consisted of (i) approximately $<span id="xdx_90C_eus-gaap--Cash_iI_pn5n6_c20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zXBSrZacQPIb" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-07-31_custom_ScendiaPurchaseAgreementMember" id="Fact001188" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million of cash, subject to certain adjustments, and
(ii) <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zTfNhl8NjtJh" title="Issuance of common stock for purchase of assets"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2022-07-012022-07-31_custom_ScendiaPurchaseAgreementMember" id="Fact001190" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">291,686</ix:nonFraction></span> shares of common stock of the Company. Pursuant to the purchase agreement, at closing, the Company withheld <span id="xdx_909_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zfdgusQS7Isc" title="Number of shares withheld"><ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="From2022-07-012022-07-31_custom_ScendiaPurchaseAgreementMember" id="Fact001192" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">94,798</ix:nonFraction></span> Indemnity
Holdback Shares, which such Indemnity Holdback Shares were withheld to the extent provided in the purchase agreement to satisfy Ryan
Phillips&#8217; (&#8220;Phillips&#8221;) indemnification obligations and subsequently issued and released to Phillips in July 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the cash consideration and the stock consideration, the purchase agreement provides that Phillips was entitled to receive
two potential earnout payments, payable on an annual basis, not to exceed $<span id="xdx_900_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_pn5n6_c20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_z3XdyLaK1EF7" title="Earnout consideration"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationAsset" contextRef="AsOf2022-07-31_custom_ScendiaPurchaseAgreementMember" id="Fact001194" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million in the aggregate, which was accounted for as
contingent consideration pursuant to ASC 805. The earnout consideration was payable to Phillips in cash or, at the Company&#8217;s election,
in up to <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zALt5ZMGHmMi" title="Number of shares issuable"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-07-012022-07-31_custom_ScendiaPurchaseAgreementMember" id="Fact001196" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">486,145</ix:nonFraction></span> shares of the Company&#8217;s common stock upon the achievement of certain performance thresholds relating to net revenue
attributable to sales of Scendia products during the two-year period following the closing. The Company made the first earnout payment
of approximately $<span id="xdx_904_ecustom--EarnoutPayment_c20230801__20230831__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zyBy2wRYzpEc" title="Earnout payment"><ix:nonFraction name="SMTI:EarnoutPayment" contextRef="From2023-08-012023-08-31_custom_ScendiaPurchaseAgreementMember" id="Fact001198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,000</ix:nonFraction></span> in cash in August 2023 and the second and final earnout payment of approximately $<span id="xdx_906_ecustom--EarnoutPayment_pn5n6_c20241001__20241031__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zsMlBoJNXpCe" title="Earnout payment"><ix:nonFraction name="SMTI:EarnoutPayment" contextRef="From2024-10-012024-10-31_custom_ScendiaPurchaseAgreementMember" id="Fact001200" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million in cash in October
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Applied
Asset Purchase</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&#160;1, 2023, the Company closed the Applied Asset Purchase. The Applied Purchased Assets were purchased for an initial aggregate
purchase price of $<span id="xdx_907_eus-gaap--PaymentsToAcquireProductiveAssets_pn4n6_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zNAQ2FIbS5o9" title="Assets purchase price"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember" id="Fact001202" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">15.25</ix:nonFraction></span> million, consisting of (i) the Cash Closing Consideration, (ii) the Stock Closing Consideration and (iii) the
Installment Payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Cash Closing Consideration, Stock Closing Consideration and Installment Payments, the Applied Purchase Agreement provides
that the Sellers are entitled to receive the Applied Earnout, which is payable to the Sellers in cash, upon the achievement of certain
performance thresholds relating to SMAT&#8217;s collections from net sales of a collagen-based product currently under development. Upon
expiration of the seventh anniversary of the Closing, to the extent the Sellers have not earned the entirety of the Applied Earnout,
SMAT shall pay the Sellers the True-Up Payment. The Applied Earnout, minus the True-Up Payment and any Applied Earnout payments already
made by SMAT, may be earned at any point in the future, including after the True-Up Payment is made. The first Installment Payment of
$<span id="xdx_90F_eus-gaap--PaymentsToAcquireOtherProductiveAssets_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zpLFHtKRplv" title="Assets purchase price"><ix:nonFraction name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="From2024-08-012024-08-31_custom_AppliedAssetPurchaseAgreementMember" id="Fact001204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">625,000</ix:nonFraction></span> was made in August 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Applied Asset Purchase and pursuant to the Applied Purchase Agreement, effective August 1, 2023, the Company entered
into the Petito Services Agreement with the Owner, pursuant to which the Owner, as an independent contractor, agreed to provide the Petito
Services. <span id="xdx_90F_ecustom--PurchaseAgreementDescription_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_ziOZVaacqzij" title="Purchase agreement description"><ix:nonNumeric contextRef="From2023-08-012023-08-01_custom_ServicesAgreementMember" id="Fact001206" name="SMTI:PurchaseAgreementDescription">As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the
term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of
certain products the Owner develops or codevelops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for
the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half
percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0
million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0
million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments
described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Petito Services Agreement has an initial term of three years and is subject to automatic successive one-month renewals unless earlier
terminated in accordance with its terms. The Petito Services Agreement may be terminated upon the Owner&#8217;s death or disability or
by the Company or the Owner &#8220;For Cause&#8221; (as defined in the Petito Services Agreement); provided, however, that the base salary
described in (i) of the foregoing paragraph shall survive termination through the three-year initial term and the royalty payments and
incentive payments described in (ii)-(v) of the foregoing paragraph shall survive termination of the Petito Services Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&#160;20, 2023, the Company signed an exclusive license agreement with Tufts University (&#8220;Tufts&#8221;) to develop and
commercialize patented technology covering 18 unique collagen peptides. As part of this agreement, the Company formed a new subsidiary,
Sanara Collagen Peptides, LLC (&#8220;SCP&#8221;) and issued <span id="xdx_903_ecustom--OutstandingUnitsPercentage_pid_dp_uPure_c20231220__20231220__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zSDmp5LMjP4a" title="Outstanding units percentage"><ix:nonFraction name="SMTI:OutstandingUnitsPercentage" contextRef="From2023-12-202023-12-20_custom_LicenseAgreementMember" id="Fact001208" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of SCP&#8217;s outstanding units to Tufts. SCP has exclusive rights
to develop and commercialize new products based on the licensed patents and patents pending. SCP will pay royalties to Tufts based on
net sales of licensed products and technologies. Under the exclusive license agreement, royalties will be calculated at a rate of <span id="xdx_909_ecustom--RoyaltyExpensePercentage_dp_uPure_c20231220__20231220__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zDpCnc6Xc9o7"><ix:nonFraction name="SMTI:RoyaltyExpensePercentage" contextRef="From2023-12-202023-12-20_custom_LicenseAgreementMember_srt_MinimumMember" id="Fact001209" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.5</ix:nonFraction></span>%
or <span id="xdx_90C_ecustom--RoyaltyExpensePercentage_dp_uPure_c20231220__20231220__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zNOUdJgpOwv" title="Royalty expense percentage"><ix:nonFraction name="SMTI:RoyaltyExpensePercentage" contextRef="From2023-12-202023-12-20_custom_LicenseAgreementMember_srt_MaximumMember" id="Fact001211" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>%, depending on the type of product or technology developed. SCP will pay Tufts a minimum annual royalty of $<span id="xdx_90D_eus-gaap--RoyaltyExpense_c20240101__20240101__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zdb49u65JHIj"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-01-012024-01-01_custom_LicenseAgreementMember" id="Fact001212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> on January 1
of the year following the first anniversary of the first commercial sale of the licensed products or technologies. SCP will pay Tufts
a $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20240101__20240101__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--RoyaltyAgreementTermsMember_zmM8L5EZFZTb"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-01-012024-01-01_custom_LicenseAgreementMember_us-gaap_RoyaltyAgreementTermsMember" id="Fact001213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> minimum annual royalty on January&#160;1 of each subsequent year during the royalty term specified in the exclusive license
agreement. There have been no material accounting impacts related to this arrangement as of December&#160;31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001215" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zzHl05Rhnwe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section43"></span>NOTE
10 &#8211; <span id="xdx_825_zHGBAGgWsh4">SHAREHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Company&#8217;s Annual Meeting of Shareholders held in July 2020, the Company approved the Restated 2014 Omnibus Long Term Incentive
Plan (the &#8220;2014 LTIP&#8221;) in which the Company&#8217;s directors, officers, employees and consultants are eligible to participate.
The 2014 LTIP terminated on September 3, 2024, and no future awards may be granted pursuant to the 2014 LTIP. Previously granted awards
under the 2014 LTIP will remain outstanding until they expire by their terms or under the terms of the 2014 LTIP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 12, 2024, the Company&#8217;s shareholders approved the 2024 Omnibus Long-Term Incentive Plan (the &#8220;2024 LTIP&#8221;),
which went into effect upon shareholder approval. The maximum number of shares of the Company&#8217;s common stock that may be delivered
pursuant to awards granted under the 2024 LTIP is <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240612__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_z5A725WRvSX6" title="Maximum number of shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-06-12_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember" id="Fact001217" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>, subject to increase by any awards under the 2014 LTIP (i) that were outstanding
on or after June 12, 2024, and that, on or after such date, are forfeited, expire or are canceled, and (ii) any shares subject to awards
relating to common stock under the 2014 LTIP that are settled in cash on or after June&#160;12, 2024 (the &#8220;Prior LTIP Awards&#8221;).
The 2024 LTIP also provides that, to the extent an award under the 2024 LTIP or a Prior LTIP Award is forfeited, expires or is canceled,
in whole or in part, the shares subject to such forfeited, expired or canceled award may again be awarded under the 2024 LTIP. As of
December&#160;31, 2024, a total of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20241231__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFourteenOmnibusLongTermIncentivePlanMember_zv1qPBD64qN1" title="Number of shares issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="From2024-12-312024-12-31_custom_TwoThousandFourteenOmnibusLongTermIncentivePlanMember" id="Fact001219" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">742,405</ix:nonFraction></span> shares had been issued under the 2014 LTIP, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20241231__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_zuEzD7RHw9kl" title="Number of shares issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="From2024-12-312024-12-31_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember" id="Fact001221" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,543</ix:nonFraction></span> shares had been issued under the 2024 LTIP
and <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_zvgy4Y23GsMe" title="Number of shares available for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember" id="Fact001223" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,137</ix:nonFraction></span> were available for issuance under the 2024 LTIP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2023, the Company closed the Applied Asset Purchase. Included in the purchase price was <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--StockClosingConsiderationMember_zJSCfIgzhMUc" title="Shares issued as consideration"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember_custom_StockClosingConsiderationMember" id="Fact001225" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,809</ix:nonFraction></span> shares of the Company&#8217;s
common stock. See Note 3 for more information regarding the acquisition of Applied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, the Company entered into a Controlled Equity Offering<sup>SM</sup> Sales Agreement (the &#8220;Sales Agreement&#8221;)
with Cantor Fitzgerald &amp; Co., as sales agent (&#8220;Cantor&#8221;), pursuant to which the Company could offer and sell from time
to time, to or through Cantor, shares of the Company&#8217;s common stock having an aggregate offering price of up to $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230201__20230228__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zzrhENfLwR51" title="Aggregate offering price"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-02-012023-02-28_custom_SalesAgreementMember" id="Fact001227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of the shares were made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under
the Securities Act of 1933, as amended. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement,
Cantor agreed to use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal
law, rules and regulations and the rules of The Nasdaq Capital Market to sell the shares from time to time based upon the Company&#8217;s
instructions, including any price, time period or size limits specified by the Company. The Company had no obligation to sell any of
the shares under the Sales Agreement and could suspend or terminate the offering of its common stock pursuant to the Sales Agreement
upon notice to Cantor and subject to other conditions. Cantor&#8217;s obligations to sell the shares under the Sales Agreement were subject
to satisfaction of certain conditions, including customary closing conditions. Pursuant to the Sales Agreement, the Company paid Cantor
a commission of 3.0% of the aggregate gross proceeds from each sale of the shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, the Company sold an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdzEWMdigE0j" title="Sale of stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_custom_SalesAgreementMember_us-gaap_CommonStockMember" id="Fact001229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,143</ix:nonFraction></span> shares of common stock for gross proceeds of approximately $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaHOdqJVwKN2" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_custom_SalesAgreementMember_us-gaap_CommonStockMember" id="Fact001231" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million and net proceeds
of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQuxBPvHxXk7" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31_custom_SalesAgreementMember_us-gaap_CommonStockMember" id="Fact001233" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span> million pursuant to the Sales Agreement. The Company paused the offering at the end of the first quarter of 2023
and did not reactivate it during the remainder of 2023. The Form S-3 registration statement for this offering expired at the beginning
of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, the Company closed a merger transaction with Precision Healing pursuant to which Precision Healing became a wholly owned
subsidiary of the Company. Pursuant to the terms of the merger agreement, holders of Precision Healing common stock and preferred stock,
other than the Company, were entitled to receive closing consideration, consisting of $<span id="xdx_90C_eus-gaap--AssetAcquisitionConsiderationTransferred_c20220401__20220430__us-gaap--AssetAcquisitionAxis__custom--PrecisionHealingIncMember_zwhML6wBZdj9" title="Cash consideration"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="From2022-04-012022-04-30_custom_PrecisionHealingIncMember" id="Fact001235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,966</ix:nonFraction></span> in cash consideration, which was paid
to stockholders who were not accredited investors, <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220401__20220430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zLsZtY9QlFIc" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-04-012022-04-30_custom_AccreditedInvestorsMember" id="Fact001237" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">165,738</ix:nonFraction></span> shares of the Company&#8217;s common stock, which was paid only to accredited
investors, and the payment in cash of approximately $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20220401__20220430__dei--LegalEntityAxis__custom--PrecisionHealingMember_zBMCHZboTBF2" title="Payment in cash"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMember" id="Fact001239" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction> </span>million of transaction expenses of Precision Healing. The Company recorded the
issuance of the <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220401__20220430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zaAH9tR5uvqg" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-04-012022-04-30_custom_AccreditedInvestorsMember" id="Fact001241" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">165,738</ix:nonFraction></span> shares to accredited investors and cash payments to nonaccredited investors based on the closing price per share
of the Company&#8217;s common stock on April&#160;4, 2022, which was $<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20220404__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonaccreditedInvestorsMember_zjH9EOTBmCMa" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-04-04_custom_NonaccreditedInvestorsMember" id="Fact001243" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.75</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the merger, the Precision Healing outstanding options previously granted under the Precision Healing Plan converted, pursuant
to their terms, into options to acquire an aggregate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220430_zPwPWdh8zcTc" title="Options to acquire shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-04-012022-04-30" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">144,191</ix:nonFraction></span> shares of Company common stock with a weighted average exercise price
of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_c20220401__20220430_ziKZdQAmjdad" title="Weighted exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="From2022-04-012022-04-30" id="Fact001247" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.71</ix:nonFraction></span> per share. These options expire between August 2030 and April 2031. In addition, outstanding and unexercised Precision Healing
warrants converted into rights to receive warrants to purchase (i) <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220430_zjPLfVYARmHl" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-30" id="Fact001249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,424</ix:nonFraction></span> shares of the Company&#8217;s common stock with an initial exercise
price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430_zBosu5CtKrV9" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-30" id="Fact001251" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.32</ix:nonFraction></span> per share and an expiration date of <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220430_zQ3CcwYs1cK8" title="Expiration date"><ix:nonNumeric contextRef="AsOf2022-04-30" format="ixt:datemonthdayyearen" id="Fact001253" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April 22, 2031</ix:nonNumeric></span>, and (ii) <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdDOrW58Omsj" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-30_us-gaap_CommonStockMember" id="Fact001255" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,301</ix:nonFraction></span> shares of the Company&#8217;s common stock with
an initial exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMe6HaJSlRP" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-30_us-gaap_CommonStockMember" id="Fact001257" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.05</ix:nonFraction></span> per share and an expiration date of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6e5k5ATMWL5" title="Expiration date"><ix:nonNumeric contextRef="AsOf2022-04-30_us-gaap_CommonStockMember" format="ixt:datemonthdayyearen" id="Fact001259" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August 10, 2030</ix:nonNumeric></span>. Concurrent with the assumption of the Precision
Healing Plan, the Company terminated the ability to offer future awards under the Precision Healing Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the merger agreement, upon the achievement of certain performance thresholds, the securityholders of Precision Healing, including
the holders of options and warrants to purchase Precision Healing common stock and certain persons promised options to purchase Precision
Healing common stock, were entitled to receive payments of up to $<span id="xdx_90C_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_pn5n6_c20220401__20220430__us-gaap--AssetAcquisitionAxis__custom--PrecisionHealingIncMember_zCACVhMdvcQa" title="Payment of contingent consideration"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" contextRef="From2022-04-012022-04-30_custom_PrecisionHealingIncMember" id="Fact001261" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million, which was accounted for as contingent consideration pursuant
to ASC 805. The earnout consideration was payable in cash or, at the Company&#8217;s election, payable to accredited investors in shares
of Company common stock at a price per share equal to the greater of (i) $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20220430__dei--LegalEntityAxis__custom--PrecisionHealingMember_zJ5q7Efnnppj" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-04-30_custom_PrecisionHealingMember" id="Fact001263" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.13</ix:nonFraction></span> or (ii) the average closing price of Company common stock
for the 20 trading days prior to the date such earnout consideration is due and payable. The Company reviewed the performance thresholds
necessary to trigger an earnout payment as of December 31, 2024 and deemed the performance thresholds to be unachievable. Therefore,
no earnout consideration is expected to be paid to the securityholders of Precision Healing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December&#160;31, 2024, the Company issued restricted stock awards under the 2014 LTIP which are subject to certain vesting
provisions and other terms and conditions set forth in each recipient&#8217;s respective restricted stock agreement. The Company issued
<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFourteenOmnibusLongTermIncentivePlanMember_zXiF5hjxZOqb" title="Stock granted and issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_custom_TwoThousandFourteenOmnibusLongTermIncentivePlanMember" id="Fact001265" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">161,908</ix:nonFraction></span> shares, net of forfeitures, under the 2014 LTIP and <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_zDsNimRzcPnk" title="Stock granted and issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember" id="Fact001267" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,543</ix:nonFraction></span> shares under the 2024 LTIP, of restricted common stock to employees,
directors, and certain advisors of the Company during the year ended December&#160;31, 2024. The fair value of these awards was $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20240101__20241231_zZ9s6JBATeyd" title="Restricted stock award, gross"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-01to2024-12-31" id="Fact001269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,747,656</ix:nonFraction></span>
based on the closing price of the Company&#8217;s common stock on the respective grant dates, which will be recognized as compensation
expense on a straight-line basis over the vesting period of the awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
compensation expense of $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20240101__20241231_zb95tl8U7sGk" title="Share-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact001271" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,436,048</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20230101__20231231_zrnrlLmS0BMk" title="Share-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact001273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,442,722</ix:nonFraction></span> was recognized in &#8220;Operating expenses&#8221; in the accompanying Consolidated
Statements of Operations during the year ended December&#160;31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December&#160;31, 2024, there was $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231_z9u25RmlQmIg" title="Unrecognized share-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-12-31" id="Fact001275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,189,272</ix:nonFraction></span> of total unrecognized share-based compensation expense related to unvested share-based equity
awards. Unrecognized share-based compensation expense is expected to be recognized over a weighted-average period of <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zbCvWw0vAFsa" title="Unrecognized share-based compensation expense period for recognition"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001277" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.5</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001279" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z6qxkf0tNoYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a summary of restricted stock activity for the year ended December&#160;31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z5VFOABi92Zf" style="display: none">SUMMARY
OF RESTRICTED STOCK ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2024</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant Date Fair Value</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Nonvested at beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231_z5JCnPbMX14f" title="Non-vested shares, beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31" id="Fact001281" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">144,211</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20241231_zc17mwwoYVK3" title="Weighted average grant date fair value, beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31" id="Fact001283" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">34.07</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231_zHscIUeYGuuk" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-01to2024-12-31" id="Fact001285" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">192,783</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zZJy94IlE743" title="Weighted average grant date fair value, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-01to2024-12-31" id="Fact001287" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">35.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231_zBmNK5U67uGd" title="Vested" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-01to2024-12-31" id="Fact001289" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">105,875</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zlU9B1uuFNVe" title="Weighted average grant date fair value, vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-01to2024-12-31" id="Fact001291" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">34.19</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231_zTROEIFXHzi7" title="Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-01to2024-12-31" id="Fact001293" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,332</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231_zyRmcP01KWC7" title="Weighted average grant date fair value, forfeited" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-01-01to2024-12-31" id="Fact001295" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">35.31</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231_zP8FFn04tnwd" title="Non-vested shares, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31" id="Fact001297" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">202,787</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20241231_z0QSPV0TdEpk" title="Weighted average grant date fair value, ending" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31" id="Fact001299" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">34.72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zFloXdegGY51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001301" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuHi6wwNrXq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the status of outstanding stock options at December&#160;31, 2024 and changes during the year then ended is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_zE4SbhyEYz85" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2024</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract Life</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding at beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zwAgg9EoMw7d" title="Options outstanding, beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact001303" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">93,892</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zVhLNEojQcmk" title="Weighted average exercise price outstanding, beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001305" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.22</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted or assumed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z8zVkBqcLNB3" title="Options, Granted or assumed" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zAqi3k5Q8F38" title="Weighted average exercise price, Granted or assumed" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231_zBCSDARL6fZ5" title="Options, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-01to2024-12-31" id="Fact001311" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,879</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zfLKWGHwa5fk" title="Weighted average exercise price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="Fact001313" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.05</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zexCYAjPo6xb" title="Options, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zpi1qmxtYm18" title="Weighted average exercise price, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1317">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20240101__20241231_zYGDoAXqFEoc" title="Options, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1319">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zCLZsMlDuWRd" title="Weighted average exercise price, Expired" style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1321">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_znAeFCWTCglb" title="Options outstanding, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact001323" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">31,013</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zzP5xdnTMCJg" title="Weighted average exercise price outstanding, ending" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001325" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.57</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_znfZyXZKxqqb" title="Weighted average remaining contract life outstanding"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001327" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.8</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp2d_c20241231_zkHVSzUHGD37" title="Aggregate intrinsic value, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31" id="Fact001329" format="ixt:numdotdecimal" decimals="2" unitRef="USD">701,975.3</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zz8wTmwNLtc" title="Options exercisable, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact001331" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">31,013</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zOCGiwedUe12" title="Weighted average exercise price exercisable, ending" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001333" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.57</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_znRXA31fwum8" title="Weighted average remaining contract life exercisable"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001335" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.8</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp2d_c20241231_z5IkBBHzKxu8" title="Aggregate intrinsic value, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-12-31" id="Fact001337" format="ixt:numdotdecimal" decimals="2" unitRef="USD">701,975.3</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zssu9gzM2B6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001339" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zM6bs8p5qup9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the status of outstanding warrants to purchase common stock at December&#160;31, 2024 and changes during the year then ended
is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z14rStEIKokj" style="display: none">SCHEDULE
OF WARRANTS TO PURCHASE COMMON STOCK</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2024</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract Life</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding at beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231_zqetGtIzzIk5" title="Number of warrants outstanding, beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact001341" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,725</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zfXL4f4sqUm4" title="Weighted average exercise price outstanding, beginning" style="width: 12%; text-align: right"><ix:nonFraction name="SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001343" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.80</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted or assumed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231_z69vSccbr4Yh" title="Number of warrants, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20240101__20241231_zwwFylDLrnl1" title="Weighted average exercise price, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1347">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231_zKtUIXzWQ24d" title="Number of warrants, exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-01-01to2024-12-31" id="Fact001349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,725</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_c20240101__20241231_z2tIDvFibrQl" title="Weighted average exercise price, exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1351">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20240101__20241231_zIGqfTSyRcwg" title="Number of warrants, forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice_c20240101__20241231_zOLXnJANg3M7" title="Weighted average exercise price, forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1355">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20240101__20241231_zYGAHTGZfZvi" title="Number of warrants, expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1357">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20240101__20241231_z5poFFZx1aHe" title="Weighted average exercise price, expired" style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1359">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231_zQx2MccL41C5" title="Number of warrants outstanding, ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1361">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zqUbQCKgYu72" title="Weighted average exercise price outstanding, ending" style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1363">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_c20240101__20241231_z75lDqKTVcl7" title="Weighted average remaining contract life outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20240101__20241231_zsFFs2LbWIvf" title="Number of warrants exercisable, ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1367">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zjxITHyaQFs6" title="Weighted average exercise price, exercisable, ending" style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1369">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_c20240101__20241231_zllBN8SiQ0I3" title="Weighted average remaining contract life exercisable, ending"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zgzGAXVlsqv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001373" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_80F_eus-gaap--ConcentrationRiskDisclosureTextBlock_zcoCAlUg23A5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section44"></span>NOTE
11 &#8211; <span id="xdx_82C_zmqHOHzS9loj">CUSTOMERS AND SUPPLIERS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had no customers in 2024 that accounted for at least <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomersMember_zgRDknZhGJT7" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember" id="Fact001375" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of the Company&#8217;s annual sales or whose accounts receivable balance
exceeded <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomersMember_zLmGSm7jZNla" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember" id="Fact001377" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of the year-end balance. The Company had no customers in 2023 that accounted for at least <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomersMember_z0dbiuCTnwq7" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember" id="Fact001379" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of Company&#8217;s annual
sales and whose accounts receivable exceeded <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomersMember_zikBQbSRy7Of" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember" id="Fact001381" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of the year-end balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s principal revenue producing products are purchased from one manufacturer. If this supplier became unable to provide finished
goods inventory in a timely manner, the Company&#8217;s business, operating results, and financial condition could be materially adversely
affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001383" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_zW8PLiy5wfUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section45"></span>NOTE
12 &#8211; <span id="xdx_823_zIUDeJqnjdEk">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC Topic No. 740, Income Taxes. This standard requires the Company to provide a
net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book
and tax accounting and any available operating loss or tax credit carry forwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
applying the provisions of Section 382 of the Internal Revenue Code, the unexpired net operating loss (&#8220;NOL&#8221;) carryforward
at December&#160;31, 2024 was approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231_zQBjEGhaq3vd" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001385" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">57.5</ix:nonFraction></span> million, of which, approximately $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20171231_z0uewXasegQl" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2017-12-31" id="Fact001387" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">26.5</ix:nonFraction></span> million, generated in 2017 and prior, will <span id="xdx_90D_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231_zt580QlQAC7c" title="Expiration description"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact001389" name="us-gaap:IncomeTaxExaminationDescription">expire
between 2024 and 2037</ix:nonNumeric></span>. Under the Tax Cuts and Jobs Act, the NOL generated from 2018 through 2024, of approximately $<span id="xdx_908_ecustom--EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount_pn5n6_c20240101__20241231_zhsv7fEpDm0j" title="NOL generated under tax cuts and job cuts"><ix:nonFraction name="SMTI:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount" contextRef="From2024-01-01to2024-12-31" id="Fact001391" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">30.9</ix:nonFraction></span> million, will
have an indefinite carryforward period but can generally only be used to offset 80% of taxable income in any particular year. The Company
may be subject to certain limitations in its annual utilization of NOL carry forwards to off-set future taxable income pursuant to Section
382 of the Internal Revenue Code, which could result in NOLs expiring unused.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001393" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zDexFok1wvv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the deferred income tax assets and liabilities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zO4X4e74S19e" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zXqFpu9ozH0h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_z0YMB7w7Jg67" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzdlW_zV5wMbphzigk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,907,965</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,467,570</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzdlW_zmCHALkULCMl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact001398" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,006,029</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact001399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,119,193</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzdlW_zm7Fd6nPHNvf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact001401" format="ixt:numdotdecimal" decimals="0" unitRef="USD">789,373</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact001402" format="ixt:numdotdecimal" decimals="0" unitRef="USD">711,598</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzdlW_zpqRpfmiqg91" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2024-12-31" id="Fact001404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2023-12-31" id="Fact001405" format="ixt:numdotdecimal" decimals="0" unitRef="USD">528,148</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxAssetsLeaseLiability_iI_maDTAGzdlW_zebjHgLkZGt" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001407" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389,882</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2023-12-31" id="Fact001408" format="ixt:numdotdecimal" decimals="0" unitRef="USD">512,668</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_iI_maDTAGzdlW_zfa1QhIUKbt9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Contingent liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" contextRef="AsOf2024-12-31" id="Fact001410" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,065</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" contextRef="AsOf2023-12-31" id="Fact001411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,028</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsAcquistionLiability_iI_maDTAGzdlW_zqJnSsTsgC0d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Acquisition liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:DeferredTaxAssetsAcquistionLiability" contextRef="AsOf2024-12-31" id="Fact001413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,722</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:DeferredTaxAssetsAcquistionLiability" contextRef="AsOf2023-12-31" id="Fact001414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,629</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTAGzdlW_zSbk2Pu5oAtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Bad debt and other reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" contextRef="AsOf2024-12-31" id="Fact001416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" contextRef="AsOf2023-12-31" id="Fact001417" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,924</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsInventory_iI_maDTAGzdlW_zXfhbudQYQph" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Inventory reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInventory" contextRef="AsOf2024-12-31" id="Fact001419" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,605</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInventory" contextRef="AsOf2023-12-31" id="Fact001420" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,176</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzdlW_z79OxiHDkbYa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other temporary differences</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact001422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,049,365</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact001423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">203,340</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzdlW_maDTANzNjR_zLoRnjRL8Er5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001425" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,902,236</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact001426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,179,274</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxLiabilitiesDepreciationAndAmortization_iNI_di_msDTANzNjR_z73LmKXbJo68" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:DeferredTaxLiabilitiesDepreciationAndAmortization" contextRef="AsOf2024-12-31" id="Fact001428" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,683,259</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:DeferredTaxLiabilitiesDepreciationAndAmortization" contextRef="AsOf2023-12-31" id="Fact001429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,180,688</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_msDTANzNjR_z0d3cnWqMnp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Right of Use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="AsOf2024-12-31" id="Fact001431" format="ixt:numdotdecimal" decimals="0" unitRef="USD">353,763</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="AsOf2023-12-31" id="Fact001432" format="ixt:numdotdecimal" decimals="0" unitRef="USD">487,402</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_msDTANzNjR_zYFFete0AkP1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1434">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="AsOf2023-12-31" id="Fact001435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">424,423</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxLiabilitiesContingentLiability_iNI_di_msDTANzNjR_zpkI1SPUqglg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Contingent liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:DeferredTaxLiabilitiesContingentLiability" contextRef="AsOf2024-12-31" id="Fact001437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,308</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:DeferredTaxLiabilitiesContingentLiability" contextRef="AsOf2023-12-31" id="Fact001438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,802</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxLiabilitiesOtherTemporaryDifferences_iNI_di_msDTANzNjR_zreAXdMSzRvb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:DeferredTaxLiabilitiesOtherTemporaryDifferences" contextRef="AsOf2024-12-31" id="Fact001440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,608</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:DeferredTaxLiabilitiesOtherTemporaryDifferences" contextRef="AsOf2023-12-31" id="Fact001441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,712</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzNjR_zMVXwnPkmLI2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,532,298</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,789,247</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzNjR_zRS3W84wCb1g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1446">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1447">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zvTC5MNUeP1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
<span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20240101__20241231_zGxppO0kIGJ6" title="Valuation allowance, percentage"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact001449" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% valuation allowance has been provided for all deferred tax assets, as the ability of the Company to generate sufficient taxable
income in the future is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliations
of the expected federal income tax expense (benefit) based on the statutory income tax rate of 21% to the actual benefit for the years ended December&#160;31,
2024 and 2023 are listed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001451" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zR9sd5vFkOF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_ziiFgjcbV2wl" style="display: none">SCHEDULE
OF INCOME TAX EXPENSE (BENEFIT)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zdUv5yhISozk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zeFeZkvncMS4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_maITEBzW13_zpcDyM73dcw7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Expected federal income tax benefit</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,019,060</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001454" format="ixt:numdotdecimal" decimals="0" unitRef="USD">903,220</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_maITEBzW13_zWii2kQ3ybA4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State and local taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact001456" format="ixt:numdotdecimal" decimals="0" unitRef="USD">338,138</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact001457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,714</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationFairValueAdjustments_iN_di_maITEBzW13_zgMNASbh1fuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:IncomeTaxReconciliationFairValueAdjustments" contextRef="From2024-01-01to2024-12-31" id="Fact001459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">497,373</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:IncomeTaxReconciliationFairValueAdjustments" contextRef="From2023-01-012023-12-31" id="Fact001460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">819,270</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_iN_di_maITEBzW13_zkh70zPU45Sj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2024-01-01to2024-12-31" id="Fact001462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,838</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2023-01-012023-12-31" id="Fact001463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">557,168</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_iN_di_maITEBzW13_zb6ZtLsiEPNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2024-01-01to2024-12-31" id="Fact001465" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">199,857</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-01-012023-12-31" id="Fact001466" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">118,765</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration_iN_di_maITEBzW13_zo5BoJh5RUWa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NOL carryover adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" contextRef="From2024-01-01to2024-12-31" id="Fact001468" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">97,806</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" contextRef="From2023-01-012023-12-31" id="Fact001469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,148,128</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxReconciliationIncomeTaxExpenseIntangibles_iN_di_maITEBzW13_zKyrGAhfc6s6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1471">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:IncomeTaxReconciliationIncomeTaxExpenseIntangibles" contextRef="From2023-01-012023-12-31" id="Fact001472" format="ixt:numdotdecimal" decimals="0" unitRef="USD">720,407</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps_iN_di_maITEBzW13_zJ9hso5GDaU9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other true ups</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" contextRef="From2024-01-01to2024-12-31" id="Fact001474" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,343</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SMTI:IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" contextRef="From2023-01-012023-12-31" id="Fact001475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,474</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_iN_di_maITEBzW13_zeNrwgUE2PZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in tax rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001477" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,732</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001478" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">673,449</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_maITEBzW13_zW1lPccamP2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact001480" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,743,051</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001481" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,813,167</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzW13_zCHKSOxvgkM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001483" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,380</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1484">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zgCOT5GQuJwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
tax years starting with 2021 are open for examination. The Company&#8217;s 2022 federal tax return was under audit as of March 24, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001486" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zt0nVz9F1OD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section46"></span>NOTE
13 &#8211; <span id="xdx_826_zbDYVFpMrdX8">RELATED PARTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CellerateRX
Sublicense Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had an exclusive, world-wide sublicense to distribute certain hydrolyzed collagen products, including CellerateRX Surgical into
the surgical and wound care markets from an affiliate of The Catalyst Group, Inc. (&#8220;Catalyst&#8221;), CGI Cellerate RX, which licensed
the rights to these products from Applied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed further in Note 3, on August 1, 2023, the Company purchased certain assets from Applied, including the underlying intellectual
property of, as well as the rights to manufacture and sell certain hydrolyzed collagen products, including CellerateRX Surgical. In connection
with the Applied Asset Purchase, Applied assigned the License Agreement with CGI Cellerate RX to SMAT, and on October 10, 2024, the License
Agreement and Sublicense Agreement were terminated for no additional consideration. Ronald T. Nixon, the Company&#8217;s Chief Executive
Officer and Executive Chairman, is the founder and managing partner of Catalyst.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2019, the Company executed a license agreement with Rochal, a related party, whereby the Company acquired an exclusive world-wide
license to market, sell and further develop antimicrobial products for the prevention and treatment of microbes on the human body utilizing
certain Rochal patents and pending patent applications. Currently, the products covered by the BIAK&#332;S License Agreement are BIASURGE
Advanced Surgical Solution, BIAK&#332;S Antimicrobial Wound Gel and BIAK&#332;S Antimicrobial Skin and Wound Cleanser. Each of these
products are 510(k) cleared. Mr. Nixon is a director of Rochal, and indirectly a significant shareholder of Rochal, and through the potential
exercise of warrants, a majority shareholder of Rochal. Another one of the Company&#8217;s directors is also a director and significant
shareholder of Rochal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, the Company executed the ABF License Agreement with Rochal whereby the Company acquired an exclusive world-wide license
to market, sell and further develop certain antimicrobial barrier film and skin protectant products for use in the human health care
market utilizing certain Rochal patents and pending patent applications. Currently, the products covered by the ABF License Agreement
are CuraShield Antimicrobial Barrier Film and a no sting skin protectant product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, the Company executed a product license agreement with Rochal, whereby the Company acquired an exclusive world-wide license
to market, sell and further develop a debrider for human medical use to enhance skin condition or treat or relieve skin disorders, excluding
uses primarily for beauty, cosmetic, or toiletry purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 9 for more information on these product license agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with the Rochal asset purchase, in July 2021, the Company entered into a consulting agreement with Ann Beal Salamone pursuant to which
Ms. Salamone agreed to provide the Company with consulting services with respect to, among other things, writing new patents, conducting
patent intelligence, and participating in certain grant and contract reporting. In consideration for the consulting services to be provided
to the Company, Ms. Salamone is entitled to receive an annual consulting fee of $<span id="xdx_903_eus-gaap--ProfessionalFees_c20210701__20210731__us-gaap--PlanNameAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSalamoneMember_zQU0p1QfVNAl" title="Consulting fee"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2021-07-012021-07-31_custom_ConsultingAgreementMember_custom_MsSalamoneMember" id="Fact001488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">177,697</ix:nonFraction></span>, with payments to be paid once per month. The
consulting agreement had an initial term of three years, unless earlier terminated by the Company, and was subject to renewal. Effective
July 13, 2024, the consulting agreement with Ms. Salamone was amended to provide that the initial term shall be automatically renewed
for successive one-year terms for up to three successive years unless earlier terminated by either party without cause at any time, provided
that the terminating party provides 90 days advance written notice of termination. Ms. Salamone is a director of the Company and is a
significant shareholder and the current Chair of the board of directors of Rochal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Catalyst
Transaction Advisory Services Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Company entered into a Transaction Advisory Services Agreement (the &#8220;Catalyst Services Agreement&#8221;) effective
March 1, 2023 with Catalyst, a related party. Pursuant to the Catalyst Services Agreement, Catalyst, by and through its directors, officers,
employees and affiliates that are not simultaneously serving as directors, officers or employees of the Company (collectively, the &#8220;Covered
Persons&#8221;), agreed to perform certain transaction advisory, business and organizational strategy, finance, marketing, operational
and strategic planning, relationship access and corporate development services for the Company in connection with any merger, acquisition,
recapitalization, divestiture, financing, refinancing, or other similar transaction in which the Company may be, or may consider becoming,
involved, and any such additional services as mutually agreed upon in writing by and between Catalyst and the Company (the &#8220;Catalyst
Services&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Catalyst Services Agreement, the Company agreed to reimburse Catalyst for (i) compensation actually paid by Catalyst to any of
the Covered Persons at a rate no more than a rate consistent with industry practice for the performance of services similar to the Catalyst
Services, as documented in reasonably sufficient detail, and (ii) all reasonable out-of-pocket costs and expenses payable to unaffiliated
third parties, as documented in customary expense reports, as each of (i) and (ii) is incurred in connection with the Catalyst Services
rendered under the Catalyst Services Agreement, with all reimbursements being contingent upon the prior approval of the Audit Committee
of the Company&#8217;s Board of Directors. The Company incurred costs pursuant to the Catalyst Services Agreement of $<span id="xdx_90A_eus-gaap--CostsAndExpensesRelatedParty_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_ziRcprlXAmHd" title="Cost and expenses related party"><ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="From2024-01-012024-12-31_custom_ServicesAgreementMember" id="Fact001490" format="ixt:numdotdecimal" decimals="0" unitRef="USD">288,594</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--CostsAndExpensesRelatedParty_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_zqcawDISSKx7" title="Cost and expenses related party"><ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="From2023-01-012023-12-31_custom_ServicesAgreementMember" id="Fact001492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,486</ix:nonFraction></span>
in the year ended December&#160;31, 2024 and 2023, respectively, and is recorded in &#8220;Selling, general and administrative&#8221;
in the accompanying Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001494" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_z9lcO0Mpn5v7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section47"></span>NOTE
14 &#8211; <span id="xdx_82B_z5uIoq8pO2La">SEGMENT REPORTING</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 1, the Company historically managed its business as <span id="xdx_908_eus-gaap--NumberOfOperatingSegments_dc_uInteger_c20240101__20241231_zxyyxpfKK3Y5" title="Number of operating segment"><span id="xdx_903_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240101__20241231_zfj3ZpGgI3Kk" title="Number of reportable segment"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2024-01-01to2024-12-31" id="Fact001496" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2024-01-01to2024-12-31" id="Fact001498" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer">one</ix:nonFraction></ix:nonFraction></span></span> operating and reportable segment. During the second quarter
of 2024, the Company changed its reportable segments to reflect a change in the manner in which the business is managed. Based on the
growing importance of the value-based wound care program to the Company&#8217;s future outlook and how the Company&#8217;s chief operating
decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, reviews operating results and makes decisions about resource allocation,
the Company has <span id="xdx_902_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240401__20240630_z67SpXJ8aYbh" title="Number of reportable segment"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2024-04-012024-06-30" id="Fact001500" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer">two</ix:nonFraction></span> reportable segments: Sanara Surgical and THP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment
Adjusted EBITDA is the primary profitability measure used by the CODM for purposes of assessing financial performance and resource
allocation. The Company defines Segment Adjusted EBITDA for the reportable segments as net income (loss) excluding interest
expense/income, provision/benefit for income taxes, depreciation and amortization, non-cash share-based compensation expense, change
in fair value of earnout liabilities, share of losses from equity method investments, executive separation costs, legal and
diligence expenses related to acquisitions, and gains/losses on disposal of property and equipment, as each are applicable to the
periods presented. The Company has historically presented this profitability measure as Segment EBITDA and, starting with the fourth
quarter ended December 31, 2024, is presenting it as Segment Adjusted EBITDA. The definition and methodology for calculating this
measure has remained unchanged. Segment Adjusted EBITDA, as it relates to the Company&#8217;s reportable segments, is presented in
conformity with ASC 280, Segment Reporting, and is excluded from the definition of non-GAAP financial measures under the Securities
and Exchange Commission&#8217;s Regulation G and Item 10(e) of Regulation S-K. Segment Adjusted EBITDA may not be comparable to
similarly titled measures reported by other companies. The CODM also reviews budget-to-actual variances for expenses on a monthly
basis when making decisions about allocating resources to the segments. The Company has not included any disclosure regarding total
segment assets, as no segment level asset information is regularly provided to the CODM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sanara
Surgical</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other
sterile environments. Sanara Surgical&#8217;s soft tissue repair products include, among other products, the Company&#8217;s lead product,
CellerateRX Surgical, and BIASURGE Advanced Surgical Solution, which is a sterile no-rinse, advanced surgical solution used for wound
irrigation. Sanara Surgical&#8217;s bone fusion products include, among other products, BiFORM, which is an osteoconductive, bioactive,
porous implant that allows for bony ingrowth across the graft site, and ALLOCYTE Plus, which is a human allograft cellular bone matrix
containing bone-derived progenitor cells and conformable bone fibers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara
Surgical also includes an in-house research and development team (Rochal Technologies) with an extensive pipeline of innovative products
under development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tissue
Health Plus</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
THP segment is focused on value-based wound care services. Through THP, the Company plans to offer a first of its kind value-based wound
care program to payers and risk-bearing entities such as accountable care organizations and value-based primary care companies, with
Medicare Advantage payers as the initial target market for this program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THP&#8217;s
programs are expected to enable payers to divest wound care spend risk, reduce wound related hospitalizations and improve patient quality
of life. THP plans to coordinate delivery of community and home-based wound care for its managed patients. Community based care spans
a variety of settings including physician offices, skilled nursing facilities, assisted living facilities and senior living facilities.
THP programs are intended to integrate science and evidence-based medicine protocols to standardize wound prevention and treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there are no allocated costs included in the THP segment. All corporate and overhead expenses are included in the Sanara Surgical segment,
as substantially all of those costs relate to supporting the operations and activities of the Sanara Surgical segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the change in reportable segments, certain prior period amounts have been recast to conform to the current period presentation.
Throughout this Annual Report on Form 10-K, unless otherwise indicated, amounts and activity reflect reclassifications related to the
Company&#8217;s change in reportable segments. The change in reportable segments had no impact on the Company&#8217;s previously reported
Consolidated Balance Sheets, Consolidated Statements of Operations, Consolidated Statements of Cash Flows or Consolidated Statements
of Shareholders&#8217; Equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001502" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z5lKpvEEPshb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table reflects results of operations including significant segment expenses that are regularly provided to the CODM for
the Company&#8217;s reportable segments and Segment Adjusted EBITDA for the periods indicated below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BF_zeVqkUwBWXb4" style="display: none">SCHEDULE
OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zLIukRbgfhrf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zkIysJvU6A6a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zRBwLO7WudVg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_z5jVy3pkifS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zXfWfYRJGQm7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zKvlVpSKttwl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zmmvrvDfHeIf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,672,425</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1505">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="Fact001506" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,672,425</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001507" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,987,112</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_THPMember" id="Fact001508" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,730</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact001509" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,989,842</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GrossProfit_pp0p0_zqxfeJsKF5k5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001511" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,532,524</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1512">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-01to2024-12-31" id="Fact001513" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,532,524</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001514" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">57,143,391</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-12-31_custom_THPMember" id="Fact001515" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,235</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-12-31" id="Fact001516" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">57,137,156</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pp0p0_z5CtTRvdihJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001518" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,673,642</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_THPMember" id="Fact001519" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,886,221</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001520" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,559,863</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001521" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,826,852</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_custom_THPMember" id="Fact001522" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,167,901</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact001523" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,994,753</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_zYg7XUlNl2A2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001525" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,828,663</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_THPMember" id="Fact001526" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,874,699</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001527" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,703,362</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001528" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">902,782</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_THPMember" id="Fact001529" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,229,643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact001530" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,132,425</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DepreciationAndAmortization_i01_pp0p0_zx27jzi1oRNf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001532" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,785,829</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-012024-12-31_custom_THPMember" id="Fact001533" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,137,395</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact001534" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,923,224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001535" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,046,859</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31_custom_THPMember" id="Fact001536" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,628,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact001537" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,675,026</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueAdjustment_zj2C1Ekwg4Fi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001539" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,451</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2024-01-012024-12-31_custom_THPMember" id="Fact001540" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,924,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2024-01-01to2024-12-31" id="Fact001541" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,938,451</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001542" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,298,336</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2023-01-012023-12-31_custom_THPMember" id="Fact001543" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,151,559</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2023-01-012023-12-31" id="Fact001544" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,449,895</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--InterestExpenseOther_i01_pp0p0_zYKipiwKsQsf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001546" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,196,424</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1547">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2024-01-01to2024-12-31" id="Fact001548" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,196,424</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001549" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">224,749</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1550">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2023-01-012023-12-31" id="Fact001551" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">224,749</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProfitLoss_pp0p0_zrla761eanxa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001553" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,937,583</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_custom_THPMember" id="Fact001554" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">7,974,315</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-12-31" id="Fact001555" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">9,911,898</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001556" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">440,485</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_custom_THPMember" id="Fact001557" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,880,387</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31" id="Fact001558" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,439,902</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--EarningsBeforeInterestTaxesDepreciationAndAmortization_pp0p0_z7OnNybafWI5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Segment Adjusted EBITDA</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001560" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,148,722</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="From2024-01-012024-12-31_custom_THPMember" id="Fact001561" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,457,415</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact001562" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,691,307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001563" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,289,634</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="From2023-01-012023-12-31_custom_THPMember" id="Fact001564" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,162,387</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact001565" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">127,247</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zbhZYin5XBLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001567" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"><p id="xdx_890_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zqzR2pBSdqxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a reconciliation of net income (loss) to Segment Adjusted EBITDA for the Company&#8217;s reportable segments
for the periods indicated below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zALkQpjlbLGj" style="display: none">SCHEDULE
OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zClfXTIsfWx9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_z2XqVdMcKLB6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zVNTBgAcyH0h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zSO6NUbYJ963" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zZGSpCyt7khd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_z4lguIpRj1df" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProfitLoss_pp0p0_zezQ8oQ9pkV2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net Income (Loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001569" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,937,583</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_custom_THPMember" id="Fact001570" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">7,974,315</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-12-31" id="Fact001571" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">9,911,898</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001572" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">440,485</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_custom_THPMember" id="Fact001573" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,880,387</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31" id="Fact001574" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,439,902</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Adjustments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InterestExpense_zAkGGoh0AeZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,128,395</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1577">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001578" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,128,395</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001579" format="ixt:numdotdecimal" decimals="0" unitRef="USD">475,783</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1580">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31" id="Fact001581" format="ixt:numdotdecimal" decimals="0" unitRef="USD">475,783</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestIncomeOther_iN_di_zzIY6DT7ud64" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,978</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1584">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2024-01-01to2024-12-31" id="Fact001585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,978</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1586">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1587">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1588">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DepreciationAndAmortization_i01_pp0p0_zHBp3n4G8a86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation and amortization <sup id="xdx_F4C_z1FJsCFRwQfh">(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001590" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,785,829</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-012024-12-31_custom_THPMember" id="Fact001591" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,137,395</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact001592" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,923,224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001593" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,046,859</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31_custom_THPMember" id="Fact001594" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,628,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact001595" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,675,026</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_zPTZHXKFCrW8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Noncash share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,969,008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" contextRef="From2024-01-012024-12-31_custom_THPMember" id="Fact001598" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" contextRef="From2024-01-01to2024-12-31" id="Fact001599" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,107,253</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001600" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,201,330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" contextRef="From2023-01-012023-12-31_custom_THPMember" id="Fact001601" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,392</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" contextRef="From2023-01-012023-12-31" id="Fact001602" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,442,722</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueAdjustment_zCl9HrZ6nePb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001604" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,451</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2024-01-012024-12-31_custom_THPMember" id="Fact001605" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,924,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2024-01-01to2024-12-31" id="Fact001606" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,938,451</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001607" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,298,336</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2023-01-012023-12-31_custom_THPMember" id="Fact001608" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,151,559</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2023-01-012023-12-31" id="Fact001609" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,449,895</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromEquityMethodInvestments_iN_di_z3253TAfteya" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share of losses from equity method investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001611" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1612">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact001613" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1614">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1615">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1616">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ExecutiveSeparationCosts_z5MSPLDWS9Tj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive separation costs <sup id="xdx_F4E_zRPyIqyrxbCd">(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:ExecutiveSeparationCosts" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001618" format="ixt:numdotdecimal" decimals="0" unitRef="USD">964,466</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1619">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SMTI:ExecutiveSeparationCosts" contextRef="From2024-01-01to2024-12-31" id="Fact001620" format="ixt:numdotdecimal" decimals="0" unitRef="USD">964,466</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1621">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1622">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1623">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_znqTCNw4Wcpk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition costs <sup id="xdx_F44_zbrOTqNsjIR3">(3)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001625" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,029</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2024-01-012024-12-31_custom_THPMember" id="Fact001626" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,165,260</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2024-01-01to2024-12-31" id="Fact001627" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,350,289</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001628" format="ixt:numdotdecimal" decimals="0" unitRef="USD">423,513</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1629">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2023-01-012023-12-31" id="Fact001630" format="ixt:numdotdecimal" decimals="0" unitRef="USD">423,513</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--EarningsBeforeInterestTaxesDepreciationAndAmortization_pp0p0_z6Q6PSNNOfwh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment Adjusted EBITDA</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember" id="Fact001632" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,148,722</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="From2024-01-012024-12-31_custom_THPMember" id="Fact001633" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,457,415</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact001634" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,691,307</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember" id="Fact001635" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,289,634</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="From2023-01-012023-12-31_custom_THPMember" id="Fact001636" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,162,387</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact001637" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">127,247</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F01_z0uipYDTBTz6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zWCjaXeLHmF2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001638" xml:lang="en-US">Includes
                                            a $<span id="xdx_90F_ecustom--PropertyAndEquipmentWriteOff_iI_c20241231_zJC0st7jzVq4" title="Property and equipment write off" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="SMTI:PropertyAndEquipmentWriteOff" contextRef="AsOf2024-12-31" id="Fact001640" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,836</ix:nonFraction></span> non-cash charge during the fourth quarter of 2024 to write-off the remaining net
                                            book value of certain THP internal use software assets.</ix:footnote></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0F_zwCBMaXL2AO" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_z6XS7fBBbkn5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001641" xml:lang="en-US">Includes
                                            $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231_zJKt3Xeqlclc" title="Share based compensation related to executive separation costs" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001643" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,795</ix:nonFraction></span> of share-based compensation related to executive separation costs for the twelve
                                            months ended December&#160;31, 2024.</ix:footnote></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0E_zMpKyZU4yTwh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F16_zC2lTmDvtW5h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001644" xml:lang="en-US">Acquisition
                                            costs include legal, tax and accounting services related to prospective acquisitions.</ix:footnote></span></td></tr></table>

</ix:nonNumeric><p id="xdx_8AB_zJY6ME8hV3Sf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001646" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_ztNHvCG7OWL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 &#8211; <span id="xdx_82C_z8ySwQNbRevf">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exclusive
License and Distribution Agreement With, and Minority Investment in, Biomimetic Innovations Ltd</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Licensing
and Distribution Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 16, 2025 (the &#8220;Execution Date&#8221;), the Company entered into a Licensing and Distribution Agreement (the &#8220;License
Agreement&#8221;), by and between the Company and Biomimetic Innovation Limited, a privately-held medical device company headquartered
in Shannon, Co. Clare Ireland (&#8220;BMI&#8221;), pursuant to which the Company acquired the exclusive U.S. marketing, sales and distribution
rights to OsStic&#174; Synthetic Injectable Structural Bio-Adhesive Bone Void Filler (&#8220;OsStic&#8221;), as well as an adjunctive
internal fixation technology featuring novel delivery to promote targeted application of OsStic (&#8220;ARC&#8221; and together with
OsStic, the &#8220;Products&#8221;), for use in the treatment of a wound or injury caused by a traumatic incident.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the License Agreement, the Company was appointed by BMI as the exclusive distributor to promote, market, offer to sell, transfer,
distribute and sell the Products for trauma indications inside the United States and its territories for an initial five-year term, which
term may be automatically renewed for successive two-year periods at the Company&#8217;s discretion, provided that the Company is in
compliance with its obligations thereunder (the &#8220;Term&#8221;). From the Execution Date until October 13, 2025, the Company has
an exclusive option to negotiate exclusive distribution rights for the Products in additional fields and/or additional territories on
substantially the same terms as those set forth in the License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#Section26" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement requires that the Company pay BMI quarterly royalties (the &#8220;Quarterly Royalties&#8221;) based on a percentage
of the Net Sales Value (as defined in the License Agreement) of the Products during the Term, with the applicable percentage of the Net
Sales Value for OsStic being in the mid-single digit range. Pursuant to the License Agreement, the Company and BMI agreed to negotiate
the applicable percentage of the Net Sales Value for ARC at a future date. The License Agreement also requires that the Company pay BMI
minimum royalty payments being in the low to mid six figure range for the first, second and third years, respectively, following the
receipt of first regulatory approval for the marketing and sale of a Product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subscription
and Shareholders&#8217; Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the License Agreement, on the Execution Date, the Company entered into a Share Subscription and Shareholders&#8217; Agreement
(the &#8220;Subscription Agreement&#8221;), by and among the Company,<span id="xdx_905_eus-gaap--SubsequentEventDescription_c20250116__20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAndShareholdersAgreementMember_zsBN6v56KJOj" title="Subsequent description"> <ix:nonNumeric contextRef="From2025-01-162025-01-16_us-gaap_SubsequentEventMember_custom_SubscriptionAndShareholdersAgreementMember" id="Fact001648" name="us-gaap:SubsequentEventDescription">The Russell Revocable Living Trust, BMI and the existing shareholders
of BMI, pursuant to which the Company agreed to contribute up to approximately &#8364;8.0 million to BMI through a series of capital contributions
in exchange for an aggregate of 16,460 ordinary shares of BMI, constituting approximately 12.5% of the outstanding equity of BMI as of
the Execution Date. The Company made an initial cash investment totaling approximately &#8364;3.0 million on the Execution Date, and the
Company&#8217;s previously announced convertible loan to BMI was converted into &#8364;1.0 million of equity in BMI. Pursuant to the Subscription
Agreement, the remaining &#8364;4.0 million contribution is due upon the achievement of certain development, clinical and regulatory milestones</ix:nonNumeric></span>
(the &#8220;Milestones&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Subscription Agreement, so long as the Company holds a five percent ownership interest or greater in BMI, the Company is entitled
to have one person appointed to BMI&#8217;s board of directors. <span id="xdx_908_eus-gaap--SubsequentEventDescription_c20250116__20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zIPXR1KYGaPf" title="Subsequent description"><ix:nonNumeric contextRef="From2025-01-162025-01-16_us-gaap_SubsequentEventMember_custom_SubscriptionAgreementMember" id="Fact001650" name="us-gaap:SubsequentEventDescription">The Company&#8217;s initial investment of approximately &#8364;4.0 million
caused the Company to exceed the five percent ownership interest threshold in BMI, and as a result the Company&#8217;s Chief Corporate
Development &amp; Strategy Officer, Tyler Palmer, has been nominated and appointed to BMI&#8217;s board of directors.</ix:nonNumeric></span> In addition, the
Company has the right to send one non-voting observer to attend meetings of the BMI board of directors, regardless of the Company&#8217;s
ownership interest level. The Company&#8217;s capital contributions must be used to fund the development and commercialization of the
Products, and the Company has certain veto and consent rights to further protect the Company&#8217;s investment in BMI and to support
its ability to successfully market and sell the Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>CRG Term Loan Amendment</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On [<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
19, 2025</span>], the Company and the Guarantors entered into the First Amendment to Term Loan Agreement with the Agent and the lenders
party thereto from time to time, which amended the CRG Term Loan Agreement to, among other things, <span id="xdx_90C_eus-gaap--DebtInstrumentDescription_c20250319__20250319__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zkx7qtxFiz0a" title="Debt description"><ix:nonNumeric contextRef="From2025-03-192025-03-19_us-gaap_SubsequentEventMember_custom_CRGTermLoanAgreementMember" id="Fact001652" name="us-gaap:DebtInstrumentDescription">(i) entitle the Company to two additional
borrowings following the Second Borrowing, which borrowings must occur on or prior to December 31, 2025, if at all, and (ii) remove the
requirement that any borrowing be in whole multiples of $5.0 million.</ix:nonNumeric></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_81A_zvb2Bwsp1Qld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section49"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section50"></span>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Evaluation
of Disclosure Controls and Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in the reports
that we file or submit to the SEC under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded,
processed, summarized and reported within the time periods specified by the SEC&#8217;s rules and forms, and that information is accumulated
and communicated to our management, including our principal executive and principal financial officers (whom we refer to in this periodic
report as our Certifying Officers), as appropriate to allow timely decisions regarding required disclosure. Our management evaluated,
with the participation of our Certifying Officers, the effectiveness of our disclosure controls and procedures as of December 31, 2024,
pursuant to Rule 13a-15(b) under the Exchange Act. Based upon that evaluation, our Certifying Officers concluded that, as of December
31, 2024, our disclosure controls and procedures were effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Management&#8217;s
Report on Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and
15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of the consolidated financial statements for external reporting purposes in
accordance with generally accepted accounting principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness of internal control over financial reporting to future periods are subject to the risk that controls
may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate
over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
believes that our policies and procedures provide reasonable assurance that our operations are conducted with a high standard of business
ethics. In management&#8217;s opinion, our financial statements present fairly, in all material respects, our financial position, results
of operations, and cash flows. Management recognizes that any controls and procedures, no matter how well designed and operated, can
provide only reasonable assurance of achieving their objectives. Management applies its judgment in evaluating the cost-benefit relationship
of possible controls and procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management, specifically its Certifying Officers, has assessed the effectiveness of the Company&#8217;s internal control
over financial reporting as of December&#160;31, 2024 using the criteria set forth by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO) in Internal Control &#8211; Integrated Framework (2013) and SEC guidance on conducting such assessments. Based
on this assessment, management has concluded that the Company&#8217;s internal control over financial reporting was effective as of December&#160;31,
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2024 that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>No
Attestation Report of Registered Public Accounting Firm</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm regarding internal control
over financial reporting. Management&#8217;s report was not subject to attestation by our registered public accounting firm pursuant
to the rules of the SEC that permit us to provide only management&#8217;s report in this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section51"></span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
9B. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_900_ecustom--NoInsiderTradingFlag_dbT_c20240101__20241231_zjGp4kMwIpvk" title="No Insider Trading Flag" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" style="display: none"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact001654" name="SMTI:NoInsiderTradingFlag">None</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>On
March 19, 2025, the Company and the Guarantors entered into the CRG Amendment, which amended the CRG Term Loan Agreement to, among other
things, (i) entitle the Company to two additional borrowings following the Second Borrowing, which borrowings must occur on or prior
to December 31, 2025, if at all, and (ii) remove the requirement that any borrowing be in whole multiples of $5.0 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Except as expressly amended pursuant to
the CRG Amendment, the terms and conditions of the CRG Term Loan Agreement remain in full force and effect.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The foregoing description of the CRG Amendment
is qualified in its entirety by reference to the full text of the CRG Amendment, which is filed as Exhibit 10.20 to this Annual Report
on Form 10-K and is incorporated by reference herein.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section52"></span>ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Options: NewSection; Value: 56 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section53"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section54"></span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required in response to this Item 10 is incorporated herein by reference to our Definitive Proxy Statement on Schedule 14A
to be filed with the SEC no later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section55"></span>ITEM
11. EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required in response to this Item 11 is incorporated herein by reference to our Definitive Proxy Statement on Schedule 14A
to be filed with the SEC no later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section56"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required in response to this Item 12 is incorporated herein by reference to our Definitive Proxy Statement on Schedule 14A
to be filed with the SEC no later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section57"></span>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required in response to this Item 13 is incorporated herein by reference to our Definitive Proxy Statement on Schedule 14A
to be filed with the SEC no later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section58"></span>ITEM
14. PRINCIPAL ACCOUNTING FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item 14 is incorporated herein by reference to our Definitive Proxy Statement on Schedule 14A to be filed
with the SEC no later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section59"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section60"></span>ITEM
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            Statements</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer
to Index to Financial Statements appearing on page F-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            Statement Schedules</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
financial statement schedules are provided because the information called for is not required or is shown in the financial statements
or the notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exhibits listed below are filed or incorporated by reference as a part of this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000165495421008050/smti_ex101000.htm">Asset
    Purchase Agreement, dated July 14, 2021, by and between Sanara MedTech Inc., as Purchaser, and Rochal Industries, LLC, as Seller
    (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on July 19, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315222008931/ex2-1.htm">Agreement
    and Plan of Merger, dated April 1, 2022, by and among Sanara MedTech Inc., United Wound and Skin Solutions, LLC, Precision Healing
    Inc., PH Merger Sub I, Inc., PH Merger Sub II, LLC and Furneaux Capital Holdco, LLC (d/b/a BlueIO) (incorporated by reference to
    Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed on April 4, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315222018458/ex2-1.htm">Membership
    Interest Purchase Agreement, dated July 1, 2022, by and among Sanara MedTech Inc., Scendia Biologics, LLC and Ryan Phillips (incorporated
    by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed on July 5, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315223026375/ex2-1.htm">Asset
    Purchase Agreement, dated August 1, 2023, by and among Sanara MedTech Inc., Sanara MedTech Applied Technologies, LLC, The Hymed Group
    Corporation, Applied Nutritionals, LLC and Dr. George D. Petito (incorporated by reference to Exhibit 2.1 to the Company&#8217;s
    Current Report on Form 8-K filed on August 2, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315224024163/ex3-1.htm">Amended
    and Restated Certificate of Formation of Sanara MedTech Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s current
    Report on Form 8-K filed on June 17, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315224010985/ex3-1.htm">Amended
    and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on March 22,
    2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000165495421003520/smti_ex41.htm" style="-sec-extract: exhibit">Description of Securities (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Annual Report on Form 10-K filed March 30, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.1&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315223008240/ex10-1_1.htm" style="-sec-extract: exhibit">Sanara MedTech Inc. Restated 2014 Omnibus Long Term Incentive Plan dated February 10, 2020 effective upon shareholder approval on July 9, 2020 (incorporated by reference to Exhibit 10.1.1 to the Company&#8217;s Annual Report on Form 10-K filed on March 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.2&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000165495421003520/smti_ex1012.htm" style="-sec-extract: exhibit">Form of Restricted Stock Award Agreement for Employees under the Sanara MedTech Inc. Restated 2014 Omnibus Long Term Incentive Plan (incorporated by reference to Exhibit 10.1.2 to the Company&#8217;s Annual Report on Form 10-K filed on March 30, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.3&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315223008240/ex10-1_3.htm" style="-sec-extract: exhibit">Form of Restricted Stock Award Agreement for Outside Directors under the Sanara MedTech Inc. Restated 2014 Omnibus Long Term Incentive Plan (2022) (incorporated by reference to Exhibit 10.1.3 to the Company&#8217;s Annual Report on Form 10-K filed on March 20, 2023).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.4&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315223008240/ex10-1_4.htm" style="-sec-extract: exhibit">Form of Restricted Stock Award Agreement for Employees under the Sanara MedTech Inc. Restated 2014 Omnibus Long Term Incentive Plan (2023) (incorporated by reference to Exhibit 10.1.4 to the Company&#8217;s Annual Report on Form 10-K filed on March 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.1&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315224024275/ex10-1.htm" style="-sec-extract: exhibit">Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on June 18, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.2&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315224031254/ex10-6.htm" style="-sec-extract: exhibit">Form of Restricted Stock Award Agreement under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 12, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315224037820/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement, effective September 1, 2024, by and between Sanara MedTech Inc. and Ronald T. Nixon (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on September 23, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315225003236/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement, effective January 15, 2025, by and between Sanara MedTech Inc. and Elizabeth B. Taylor (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on January 22, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315224013261/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement, effective April 15, 2024, by and between Sanara MedTech Inc. and Jacob A. Waldrop (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 5, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315225003236/ex10-2.htm" style="-sec-extract: exhibit">Amended and Restated Employment Agreement, effective January 15, 2025, by and between Sanara MedTech Inc. and Michael D. McNeil (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on January 22, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315222011475/ex10-1.htm" style="-sec-extract: exhibit">Amended and Restated Employment Agreement, dated April 28, 2022, by and between Sanara MedTech Inc. and Zachary B. Fleming (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 29, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315224031254/ex10-4.htm" style="-sec-extract: exhibit">Separation Agreement and General Release, dated as of May 29, 2024, by and between Sanara MedTech Inc. and Zachary B. Fleming (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 12, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000165495419009495/smti_ex101.htm" style="-sec-extract: exhibit">Exclusive License Agreement dated July 8, 2019 between Sanara MedTech Inc. and Rochal Industries, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 14, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000165495420012356/smti_ex101.htm" style="-sec-extract: exhibit">Amendment No. 1 to Exclusive License Agreement dated May 4, 2020 between Sanara MedTech Inc. and Rochal Industries, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 13, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/714256/000165495419012921/smti_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive License Agreement dated October 1, 2019 between Sanara MedTech Inc. and Rochal Industries, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 14, 2019).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000165495420005225/smti_ex101.htm" style="-sec-extract: exhibit">Exclusive License Agreement dated May 4, 2020 between Sanara MedTech Inc. and Rochal Industries, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 12, 2020).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000165495421008050/smti_ex102.htm" style="-sec-extract: exhibit">Consulting Agreement, dated July 14, 2021, by and between Sanara MedTech Inc. and Ann Beal Salamone (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K of the Company filed on July 19, 2021 by the Company with the SEC).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12.1&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315224031254/ex10-7.htm" style="-sec-extract: exhibit">First Amendment to Consulting Agreement, dated July 13, 2024, by and between Sanara MedTech Inc. and Ann Beal Salamone (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 12, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315222009477/ex10-3.htm" style="-sec-extract: exhibit">Precision Healing Inc. 2020 Stock Option and Grant Plan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on April 8, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315223006000/ex1-1.htm" style="-sec-extract: exhibit">Controlled Equity OfferingSM Sales Agreement, dated February 24, 2023, by and between Sanara MedTech Inc. and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed on February 24, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315223008240/ex10-15.htm" style="-sec-extract: exhibit">Transaction Advisory Services Agreement, dated March 1, 2023, by and between Sanara MedTech Inc. and The Catalyst Group, Inc. (incorporated by reference to Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K filed on March 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315223026375/ex10-1.htm" style="-sec-extract: exhibit">Professional Services Agreement, dated August 1, 2023, by and between Sanara MedTech Inc. and Dr. George D. Petito (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on August 2, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315224015133/ex10-1.htm" style="-sec-extract: exhibit">Term Loan Agreement, dated April 17, 2024, by and among Sanara MedTech Inc., as borrower, the Subsidiary Guarantors party thereto, the lenders party thereto and CRG Servicing LLC, as administrative agent and collateral agent (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 18, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315224015133/ex10-2.htm" style="-sec-extract: exhibit">Form of Security Agreement, by and among Sanara MedTech Inc., the Subsidiary Guarantors party thereto and CRG Servicing LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on April 18, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19*+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-19.htm">Share Subscription and Shareholders&#8217; Agreement, by and among the Company, The Russell Revocable Living Trust, Biomimetic Innovation Limited and the existing shareholders of Biomimetic Innovation Limited.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">10.20*</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex10-20.htm">First Amendment to Term Loan Agreement, dated <span>March 19, 2025</span>, by and among Sanara MedTech Inc., as borrower, the Subsidiary Guarantors party thereto, the lenders party thereto and CRG Servicing LLC, as administrative agent and collateral agent.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex19-1.htm">Insider Trading Policy.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21-1.htm">List of Subsidiaries.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of Weaver and Tidwell, L.L.P.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Principal Executive Officer in accordance with 18 U.S.C. Section 1350, as adopted by Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification of Principal Financial Officer in accordance with 18 U.S.C. Section 1350, as adopted by Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification of Principal Executive Officer in accordance with 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification of Principal Financial Officer in accordance with 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/714256/000149315224011128/ex97-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara MedTech Inc. Compensation Recovery Policy (incorporated by reference to Exhibit 97.1 to the Company&#8217;s Annual Report on Form 10-K filed on March 25, 2024).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
                                            herewith.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
                                            schedules and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of
                                            Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally
                                            to the Securities and Exchange Commission or its staff upon request. If indicated on the
                                            first page of such agreement, certain confidential information has been excluded pursuant
                                            to Item 601(b)(2)(ii) of Regulation S-K. Such excluded information is not material and is
                                            the type that the Company treats as private or confidential.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="vertical-align: top; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain schedules
and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule or exhibit
will be furnished supplementally to the Securities and Exchange Commission or its staff upon request. If indicated on the first page
of such agreement, certain confidential information has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K. Such excluded
information is not material and is the type that the Company treats as private or confidential.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            certifications attached as Exhibit 32.1 and Exhibit 32.2 are not deemed &#8220;filed&#8221;
                                            with the Securities and Exchange Commission and are not to be incorporated by reference into
                                            any filing of Sanara MedTech Inc. under the Securities Act of 1933, as amended, or the Securities
                                            Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report
                                            on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifies
                                            a management contract or compensatory plan.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="Section61"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
16. FORM 10-K SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#TOC01" title="Table of Contents">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section62"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SANARA
    MEDTECH INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Elizabeth B. Taylor</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elizabeth
    B. Taylor</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and duly authorized officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ronald T. Nixon</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer (Principal Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
    T. Nixon</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Elizabeth B. Taylor</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elizabeth
    B. Taylor</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Accounting Officer and Chief Administrative Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael D. McNeil</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    D. McNeil</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Robert DeSutter</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    DeSutter</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Roszell Mack III</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roszell
    Mack III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Eric D. Major</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    D. Major</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Sara Ortwein</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sara
    Ortwein</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ann Beal Salamone</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ann
    Beal Salamone</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Keith G. Myers</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keith
    G. Myers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Eric D. Tanzberger</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    25, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    D. Tanzberger</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>2
<FILENAME>ex10-19.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.19</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTAIN
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED AT THE APPROPRIATE PLACE WITH FIVE ASTERISKS [*****], HAS BEEN OMITTED IN RELIANCE ON
REGULATION S-K, ITEM 601(B)(10)(IV) BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS CONFIDENTIAL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
16, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(1)
The parties listed in Schedule 1</B></FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(2)
SANARA MEDTECH INC</B></FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(3)
THE RUSSELL REVOCABLE LIVING TRUST</B></FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(4)
Biomimetic Innovations Limited</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
subscription and Shareholders&rsquo; Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">relating
to Biomimetic Innovations Limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLause
and Schedule Index</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Clause</U></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpretation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
    for Shares</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Board</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
    of Shares</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drag
    Along</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tag
    Along</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidentiality</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matters
    Requiring Consent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrantors&rsquo;
    Covenants and Indemnities</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
    Funding for Licensing and Distribution Agreement Additional Fields</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Constitution</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
    to Procure Compliance by Company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Voting Agreements</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conflicts
    of Interest</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restrictive
    Covenants</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duration
    and Related Matters</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dispute
    Resolution</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Law
    and Jurisdiction</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Communications
    and Notices</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Schedule</U></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Existing Shareholders and Covenantors</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
    Contact Details</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Particulars
    of the Company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warranties</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tranche
    1 Subscription Provisions</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone
    Tranche Subscriptions</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deed
    of Adherence</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitations</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BMI
    Patents</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreed
    Form Constitution</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Certain
sections of this agreement that are immaterial and relate to the internal governance of Biomimetic Innovations Limited have been omitted.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
AGREEMENT </B>made on January 16, 2025</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BETWEEN</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
                                            PERSONS</B> whose names and registered offices are set out in Part 1 of Schedule 1(each an
                                            &ldquo;<B>Existing Shareholder</B>&rdquo; and together the &ldquo;<B>Existing Shareholders</B>&rdquo;);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            persons listed in Part 2 of Schedule 1 (each a &ldquo;<B>Covenantor</B>&rdquo; and together
                                            the &ldquo;<B>Covenantors</B>&rdquo;);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SANARA
                                            MEDTECH INC</B>, a company incorporated under the laws of the State of Texas with registered
                                            number 0800036706 having its registered office at 1200 Summit Avenue, Suite 414 Fort Worth,
                                            TX 76102 (&ldquo;<B>Sanara</B>&rdquo;);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
                                            RUSSELL REVOCABLE LIVING TRUST</B> C/O [*****] (&ldquo;<B>Russell</B>&rdquo;); and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIOMIMETIC
                                            INNOVATIONS LIMITED</B> a company incorporated under the laws of Ireland with registered
                                            number 669374, having its registered office at Unit 4 D, Western Business Park, Shannon,
                                            Co. Clare, Ireland (the &ldquo;<B>Company</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BACKGROUND</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company is a private limited company incorporated in Ireland under the Companies Act 2014
                                            more detailed particulars of which are set out in Schedule 3.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company wishes to raise additional capital for the business of the Company. Accordingly,
                                            each of Russell and Sanara have agreed to subscribe for Ordinary Shares upon the terms and
                                            subject to the conditions of this Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            parties have accordingly agreed to enter into this Agreement for the purposes of providing
                                            for the subscription by Russell and Sanara for Shares, regulating the future conduct of the
                                            business of the Company, regulating the relationship between the Shareholders as the holders
                                            of all of the issued voting share capital of the Company and regulating the internal administration
                                            of the Company.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(D)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has joined in this Agreement for the purpose of acknowledging its provisions and
                                            to assume the obligations on its part contained in this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW
IT IS AGREED</B> as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interpretation</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Defined
                                            Terms</B>: In this Agreement and the recitals above:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>2021
SSSA</B>&rdquo; means the share subscription and shareholders&rsquo; agreement between the Existing Shareholders, the Covenantors and
the Company relating to the Company dated 1 November 2021;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Affiliate</B>&rdquo;
means any entity that directly or indirectly Controls, is Controlled by, or is under common Control with that first entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Auditors</B>&rdquo;
means the auditors of the Company from time to time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Board</B>&rdquo;
means the board of Directors of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>BMI
Know-how</B>&rdquo; means all data, documents, ideas, concepts, discoveries, inventions, developments, trade secrets, techniques, methodologies,
modifications, innovations, improvements, designs, design concepts, tangible materials, processes, procedures and/or methodologies, including
but not limited to, technical information, expertise, processes, techniques, specifications, formulas, procedures, protocols, data, results,
Confidential Information, lists of customers or suppliers, and other information, developed, generated, obtained (including licenses
to the Company Disclosed in the Disclosure Letter) and/or owned by the Company, whether registered, unregistered, or unregistrable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>BMI
Patents</B>&rdquo; means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            patents and patent applications: listed in Schedule 9;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            and all national, regional or international counterparts and all divisional, continuation,
                                            and continuation&ndash;in-part applications of any of the foregoing as well as all re-issues,
                                            re-examinations, extensions and restorations of any of the foregoing;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>BMI
Technology</B>&rdquo; means (i) all the Company&rsquo;s adhesive substances consisting of any of the components [*****] thereof as well
as all (ii) BMI Patents, (iii) BMI Know-how and any and all Intellectual Property to the foregoing (i, ii and iii) worldwide;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Companies
Act</B>&rdquo; means the Companies Act 2014;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Completion</B>&rdquo;
means either Tranche 1 Completion or any Milestone Tranche Completion (as the context may require);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Completion
Date</B>&rdquo; means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            respect of the Tranche 1, the Tranche 1 Completion Date; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            respect of any Milestone Tranche, the applicable Milestone Tranche Completion Date;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Confidential
Information</B>&rdquo; means any information relating to the business, accounts, finances, contractual arrangements or Intellectual Property
(whether owned or licensed by the Company) or other dealings, transactions, affairs or property of the Company other than information
which:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            published or otherwise generally available to the public;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<BR></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">which
                                            has, after receipt by the recipient, been published or otherwise made generally available
                                            to the public, through no act or omission of the recipient;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
                                            the time of disclosure was already in the possession of the receiving party free from any
                                            obligation of confidentiality or restriction as to its use;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            received by the receiving party from an Affiliate or third party with the lawful right to
                                            disclose free from any obligation of confidentiality or restriction as to its use; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">has
                                            been or is independently developed by the receiving party (without use of Confidential Information
                                            of the other party), as can be shown by documentary proof;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            required by law, regulation or court order to be disclosed (but only to the extent of the
                                            relevant disclosure requirement) in which case the Party disclosing the information has to
                                            attempt to protect confidentiality to the extent reasonably and legally possible and the
                                            information shall still be considered confidential outside the recipients who receive access
                                            to the information due to disclosure under this sub-clause (f).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">but,
for the avoidance of doubt:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
                                            shall not be deemed to be published or otherwise generally available to the public, merely
                                            because its known to a limited number of third parties having experience in the relevant
                                            field; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            combination of elements of information shall not be deemed to be published or otherwise generally
                                            available to the public, merely because individual elements of that combination are published
                                            or otherwise generally available to the public;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Connected
Party</B>&rdquo; means a Shareholder, any company or individual legally or beneficially holding an interest in a Shareholder or a spouse
or civil partner, of any such person holding an interest in a Shareholder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Constitution</B>&rdquo;
means the constitution of the Company for the time being and from time to time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Control</B>&rdquo;
has the meaning given to it in section 432 of the TCA;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Deed
of Adherence</B>&rdquo; means a deed in the form set out in Schedule 7 or a deed in such other form as the Shareholders may agree from
time to time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Directors</B>&rdquo;
means the directors of the Company from time to time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Disclosed</B>&rdquo;
means clearly and accurately disclosed with sufficient details to enable the relevant Investor(s) participating in the relevant Investment
Tranche to identify the nature and scope of the matter disclosed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Disclosure
Letter</B>&rdquo; means, in respect of a particular Investment Tranche, the disclosure letter to be executed and delivered by the Warrantors
to the relevant Investor(s) immediately prior to completion of that Investment Tranche disclosing certain matters against the Warranties
being given in connection with that Investment Tranche;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Encumbrance</B>&rdquo;
means and includes any interest or equity of any person (including, without prejudice to the generality of the foregoing, any right to
acquire, option or right of pre-emption) or any mortgage, pledge, lien or assignment or any other encumbrance, priority or security interest
or arrangement of whatsoever nature over or in the relevant property;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>General
Warranties</B>&rdquo; means the statements in paragraphs 2 to 18 of Schedule 4;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>group</B>&rdquo;
means, in relation to any person, that person and its Affiliates;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Intellectual
Property</B>&rdquo; or &ldquo;<B>IP</B>&rdquo; includes any invention, discovery, improvement, patent, know-how, trade or other mark,
design, copyright, database right or any other right in the nature of any of the foregoing (or application, or right to apply for, any
of the foregoing), in each case subsisting anywhere in the world and whether registered, unregistered or un-registrable, and any licence
or right of user of any of the foregoing, and the full right to all legal protection relating to the same;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Interest
in Shares</B>&rdquo; includes an interest of any kind whatsoever (whether legal or beneficial) in or to any Share or any right to control
the voting or the rights attributable to any Share, disregarding any conditions or restrictions to which the exercise of any right attributed
to such interest may be subject and &ldquo;<B>Interest</B>&rdquo; shall be construed accordingly;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Investment
Tranche</B>&rdquo; means Tranche 1 or any Milestone Tranche;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Investor</B>&rdquo;
means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            respect of Tranche 1, any of Russell or Sanara;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            respect of any Milestone Tranche, Sanara</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Licensing
and Distribution Agreement</B>&rdquo; means the agreement in the agreed form between the Company and Sanara with regard to the sale marketing
and distribution by Sanara of OsStic and ARC products in the United States in the Trauma Field;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Loss</B>&rdquo;
includes any loss, damage, liability, fine, penalty, charge and any other cost and/or expense including any costs of recovery on a full
indemnity basis;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Milestone
Tranche</B>&rdquo; has the meaning given to that term in Schedule 6;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Milestone
Tranche Completion Date</B>&rdquo; has the meaning given to that term in Schedule 6;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Ordinary
Share</B>&rdquo; means an ordinary share of &euro;0.001 in the capital of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>PBC
Biomed</B>&rdquo; means Pharmaceutical Business Consultants Limited, a company incorporated under the laws of Ireland with registered
number 492832, having its registered office at Unit 4 D, Western Business Park, Shannon, Co. Clare, Ireland;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>PBC
Warranties</B>&rdquo; means the Warranties set out in paragraphs [*****] of Schedule 4;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Qualifying
Shareholders</B>&rdquo; means any of [*****] and Sanara and &ldquo;<B>Qualifying Shareholder</B>&rdquo; means any of them;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Qualifying
Shareholder Director</B>&rdquo; means any Director appointed by a Qualifying Shareholder pursuant to Clause 3.1 (<I>right to appoint
and remove</I>);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Qualifying
Takeover Offer</B>&rdquo; has the meaning given to that term in Clause 6 (<I>drag along</I>);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Relevant
Business</B>&rdquo; shall mean any activity related to BMI Technology;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Relevant
Territory</B>&rdquo; means [*****];</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Sanara
Director</B>&rdquo; means a Director nominated by Sanara pursuant to Clause 3.1(a) (<I>right to appoint and remove</I>);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Share</B>&rdquo;
means a share of whatever class in the share capital of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Shareholder
Approval</B>&rdquo; means the prior written approval of the Shareholder Majority;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Shareholder
Majority</B>&rdquo; means the holders of no less than [*****] per cent of the Ordinary Shares (to include at least one of [*****] or
Sanara);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Shareholders</B>&rdquo;
means the parties to this Agreement from time to time excluding the Company; and &ldquo;<B>Shareholder</B>&rdquo; means any of them;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Subscription
Price</B>&rdquo; means &euro;486.00 per Ordinary Share;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tax
Warranties</B>&rdquo; means the statements in paragraph 19 of Schedule 4;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>TCA</B>&rdquo;
means the Taxes Consolidation Act 1997;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tranche
1 Completion Date</B>&rdquo; has the meaning given to that term in Schedule 5;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tranche
1 Subscription Shares</B>&rdquo; has the meaning given to that term in Schedule 5;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Trauma
Competitor</B>&rdquo; means any company and/or group which generates more than [*****]% of its revenue in the Trauma Field;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Trauma
Field</B>&rdquo; means the development, manufacture, sale or marketing of products specifically for use in the treatment of wounds and
injuries caused by a traumatic incidence (including accidents and violence) but excludes any treatment in the [*****];</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Warranties</B>&rdquo;
means the warranties set out in Schedule 4; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Warrantors</B>&rdquo;
means the Company and PBC Biomed, and &ldquo;<B>Warrantor</B>&rdquo; means any of them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Companies
                                            Act Terms</B>: Save as otherwise expressly defined in this Agreement, or where a contrary
                                            intention is stated, each word and phrase defined in the Companies Act (excluding any modification
                                            or re-enactment thereof not in force on the date of this Agreement) shall, when used in this
                                            Agreement, have the meaning given to it in that legislation.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Construction</B>:
                                            In this Agreement, unless the contrary intention is stated, a reference to:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            singular shall include the plural and vice versa;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">either
                                            gender includes the other and the neuter, and vice versa;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            person shall be construed as a reference to any individual, firm or company, corporation,
                                            governmental entity or agency of a state or any association or partnership (whether or not
                                            having separate legal personality) or two or more of the foregoing;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            person includes that person&rsquo;s legal personal representatives, successors and permitted
                                            assigns;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">time
                                            shall be construed by reference to whatever time may from time to time be in force in Ireland;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            agreement document or instrument is to the same as amended, novated, modified, supplemented
                                            or replaced from time to time;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lsquo;this
                                            Agreement&rsquo; mean the Clauses of, and the Schedules to, this Agreement, all of which
                                            shall be read as one document;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            clause or other provision is a reference to a clause or provision of this Agreement, and
                                            any reference to a sub provision is, unless otherwise stated, a reference to a sub provision
                                            of the provision in which the reference appears;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lsquo;including&rsquo;
                                            means comprising, but not by way of limitation to any class, list or category;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            law includes any provision of any constitution, statute, statutory instrument, order, by-law,
                                            directive, regulation or decision of any governmental entity and any judicial or administrative
                                            interpretation of any of the foregoing, in each case, as amended, revised, modified or replaced
                                            from time to time;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            Irish legal or accounting term for any action, remedy, method of judicial proceeding, insolvency
                                            proceeding, event of incapacity, legal or accounting document, legal or accounting status,
                                            court, governmental or administrative authority or agency, accounting body, official or any
                                            legal or accounting concept practice or principle or thing shall in respect of any jurisdiction
                                            other than Ireland be deemed to include what most approximates in that jurisdiction to the
                                            Irish legal or accounting term concerned;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lsquo;writing&rsquo;
                                            shall include a reference to any electronic mode of representing or reproducing words in
                                            visible form;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lsquo;business
                                            day&rsquo; shall be construed as a reference to a day (other than a Saturday or Sunday) on
                                            which the banks are generally open for business in Ireland; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lsquo;agreed
                                            form&rsquo; means in the form previously agreed by or on behalf of the parties to this Agreement
                                            and signed for the purposes of identification by or on behalf of each of them.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
                                            Rules of Construction dis-applied</B>:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            Agreement shall be construed without regard to the rule of construction known as &ldquo;ejusdem
                                            generis&rdquo;.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            any ambiguity or question of intent or interpretation arises, this Agreement shall be construed
                                            as if drafted jointly by the parties and no presumption or burden of proof shall arise favouring
                                            or disfavouring any party by virtue of the authorship of any of the provisions of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Negative
                                            Undertakings Extended</B>: Any undertaking by a party not to do any act or thing shall be
                                            deemed to include an undertaking not to permit or suffer the doing of that act or thing.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Headings</B>:
                                            Headings and captions are to be ignored in the construction of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subscription
                                            for Shares</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tranche
                                            1</B>: The provisions of Schedule 5 shall apply to the subscription for Tranche 1 Subscription
                                            Shares.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Milestone
                                            Tranches</B>: The provisions of Schedule 6 shall apply to the subscription for Shares pursuant
                                            to each Milestone Tranche.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[*****]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
                                            Funding for Licensing and Distribution Agreement Additional Fields</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties acknowledge and agree that the Company shall be responsible for funding the regulatory and product development efforts related
to the launch of Products in any Additional Field (each as defined in the Licensing and Distribution Agreement) that is added to the
Licensing and Distribution Agreement following exercise by Sanara of its option with respect to that Additional Field, good faith negotiations
between the Company and Sanara with respect to the terms for that Additional Field and agreement of an addendum in respect of that Additional
Field, in each case, pursuant to the terms of the Licensing and Distribution Agreement. If the Company determines that is has insufficient
funds, it shall first offer the Shareholders the opportunity invest the required funds by way of subscription for Ordinary Shares in
accordance with the pre-emption provisions of the Constitution at a price per shares equal to the Subscription Price. [*****].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Duration
                                            and Related Matters</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Duration</B>:
                                            This Agreement shall remain in full force and effect for so long as any two or more Shareholders
                                            continue to hold Shares.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Departing
                                            Shareholder</B>: Subject to the succeeding provisions of this Clause 18, this Agreement shall
                                            cease to have any force or effect in relation to a person who has transferred all of its
                                            Shares in accordance with this Agreement and the Constitution.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Survival
                                            of Obligations</B>: The termination of this Agreement howsoever caused and/or the ceasing
                                            by any Shareholder to hold any Shares shall not affect any provision of this Agreement which
                                            is expressly or by implication to come into effect on or to continue in effect after such
                                            termination or cesser, including (without limitation) any of the provisions of Clauses 1
                                            (<I>interpretation)</I>, 9 (<I>confidentiality)</I>, 17 (<I>restrictive covenants</I>), 19
                                            (<I>dispute resolution),</I> 20 (<I>law and jurisdiction)</I>, 21 (<I>communications and
                                            notices</I>) and, to the extent applicable, Clause 22 (g<I>eneral provisions)</I>, each of
                                            which shall survive any such termination or cessation.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accrued
                                            Rights</B>: The termination of this Agreement however caused and the ceasing by any Shareholder
                                            to hold any Shares shall be without prejudice to any obligations or rights of any of the
                                            parties which have accrued prior to such termination or cessation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dispute
                                            Resolution</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Escalation</B>:
                                            In the event of a dispute between the parties under this Agreement, the matter shall be referred
                                            in writing in the first instance to the chief executive officer of the parties in dispute
                                            (the &ldquo;<B>Disputing Parties</B>&rdquo;) (or equivalent of the parties) with a view to
                                            it being resolved in good faith.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mediation</B>:
                                            If the dispute cannot be resolved with 15 business days of the referral, or such other longer
                                            period as may be agreed upon between the Disputing Parties, the Disputing Parties shall refer
                                            the dispute to a single mediator to be appointed in accordance with the mediation procedures
                                            of the Irish Commercial Mediation Association or such other organisation that provides mediation
                                            services. The cost of such mediator shall be borne equally by Disputing Parties.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Injunctive
                                            Relief</B>: No party shall be obliged to follow the procedures set out in Clauses 19.1 and
                                            19.2 above where that party intends to apply for injunctive relief against any of the others
                                            for the purpose of protecting its proprietary rights or confidential information, provided
                                            that there is no delay in the prosecution of that application.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Law
                                            and Jurisdiction</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Law</B>:
                                            This Agreement and any non-contractual obligations arising out of or in connection with this
                                            Agreement shall be governed by, and construed in all respects in accordance with, the laws
                                            of Ireland.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction</B>:
                                            Without prejudice to the provisions of Clause 19 (<I>dispute resolution</I>), each of the
                                            parties irrevocably agrees that the courts of Ireland shall have jurisdiction to hear and
                                            determine any suit, action or proceedings, and to settle any dispute, question or difference
                                            which may arise between the parties out of or in connection with this Agreement and, for
                                            those purposes, irrevocably submits to the jurisdiction of the Irish courts.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Service
                                            of Process</B>:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]
                                            irrevocably appoints [*****] as its as its agent for service of process in relation to any
                                            proceedings before the courts of Ireland in connection with this agreement. Any such notice
                                            such shall be addressed &ldquo;For the attention of [*****] &ndash; agent for service of
                                            process&rdquo;.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara
                                            irrevocably appoints [*****] as its agent for service of process in relation to proceedings
                                            before the courts of Ireland in connection with this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Communications
                                            and Notices</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Service</B>:
                                            Notices and other communications under or in connection with this Agreement may be given
                                            in writing by hand, by ordinary pre-paid post or by e-mail, save that service of any notice
                                            of any claim, dispute, termination, breach or legal proceedings in connection with this Agreement
                                            shall not be made by e-mail. Any such notice, if so given, shall be deemed to have been served:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            sent by hand, when delivered;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            sent by post, three business days after posting; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            sent by e-mail one hour after sending provided the sender has not received notice of failed
                                            or delayed delivery,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
that, if in accordance with the above provisions, any such notice or other communication would otherwise be deemed to be given or made
outside working hours (being 9 am to 5 pm Irish time on a business day) such notice or other communication shall be deemed to be given
or to be made at the start of working hours on the next succeeding business day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact
                                            Details</B>: The postal address and e-mail address of each party for the purpose of the giving
                                            of notices under this Agreement shall, in the case of any of the Shareholders, be that set
                                            forth opposite its name in Schedule 1 or Schedule 2 (as the case may be), and in the case
                                            of the Company that set forth below (or such other address or number or address (if any)
                                            as is from time to time notified to the party giving the notice in compliance with the provisions
                                            of this Clause):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unit
    4 D, Western Business Park, Shannon, Co. Clare, Ireland </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capacity
                                            &amp; Authority</B>: Each party hereto warrants and represents to each of the others that
                                            it has full authority, power and capacity to enter into this Agreement, and that all necessary
                                            actions have been taken to enable it lawfully to enter into this Agreement and perform its
                                            obligations hereunder.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Continuing
                                            Agreement:</B> All provisions of this Agreement shall so far as they are capable of being
                                            performed and observed continue in full force and effect notwithstanding Tranche 1 Completion
                                            except in respect of those matters then already performed.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Good
                                            Faith:</B> Each of the Shareholders shall exercise its rights, and perform its obligations,
                                            under this Agreement and the Constitution in good faith.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
                                            of Powers:</B> Where any of the parties is required under this Agreement to exercise its
                                            powers in relation to the Company to procure a particular matter or thing, such obligation
                                            shall be deemed to include an obligation to exercise its powers both as a Shareholder and
                                            as a Director (where applicable) of such company and to procure that any nominee of its or
                                            it or any Director appointed by it or it shall procure such matter or thing but, in each
                                            case, only insofar as the person in question can lawfully do so.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder
                                            Consent:</B> Where this Agreement provides that any particular transaction or matter requires
                                            the consent, approval or agreement of any Shareholder:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            consent, approval or agreement may be given subject to such reasonable and relevant terms
                                            and conditions as that Shareholder may impose and in the event that the party requiring consent
                                            proceeds with the relevant action which required that consent, any breach of such relevant
                                            and reasonable terms and conditions by any person subject thereto shall <I>ipso facto</I>
                                            be deemed to be a breach of the terms of this Agreement; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            giving, or refusing to give, any opinion, approval, consent or waiver under this Agreement,
                                            that Shareholder may act entirely at its discretion and shall have no liability or responsibility
                                            whatsoever to any person.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Further
                                            Assurance</B>: The parties shall, and shall use their respective reasonable endeavours to
                                            procure that any necessary third parties shall, do, execute and perform all such further
                                            deeds, documents, assurances, acts and things as any of the parties hereto may reasonably
                                            require by notice in writing to the others to carry the provisions of this Agreement and
                                            the Constitution into full force and effect</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Costs</B>:
                                            Each party shall pay its own costs in connection with or incidental to the preparation, negotiation
                                            and execution of this Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
                                            Partnership or Agency</B>: Nothing in this Agreement shall create, or be deemed to create,
                                            a partnership, joint venture, or the relationship of principal and agent, between the parties
                                            or any of them, and none of the parties shall have any right or authority to act on behalf
                                            of the other or to bind any of the others in any way.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assignment</B>:
                                            No party shall assign all or any part of the benefit of this Agreement, or purport to transfer
                                            all or any part of the burden of this Agreement, without the written consent of the other
                                            parties to this Agreement <B>provided</B> that this Clause shall not prevent the transfer
                                            of Shares in accordance with Clause 5 (<I>transfer of shares)</I>.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Successors
                                            Bound</B>: This Agreement shall be binding on and shall ensure for the benefit of the successors
                                            and assigns and personal representatives (as the case may be) of each of the parties hereto.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Language</B>:
                                            This Agreement is made only in the English language. If there is any conflict in meaning
                                            between the English language version of this Agreement and any version or translation of
                                            this Agreement in any other language, the English language version shall prevail. Each document
                                            and communication referred to in this agreement or to be delivered under it shall be in the
                                            English language or, if not, accompanied by an English translation of it, certified as accurate
                                            by an officer of the party issuing that document or communication; and in the case of conflict
                                            between English language version and any other version, English language version shall prevail.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
                                            days</B>: If any action or duty to be taken or performed under any of the provisions of this
                                            Agreement would fall to be taken or performed on a day which is not a business day such action
                                            or duty shall be taken or performed on the business day next following such day.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Severability</B>:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
                                            that the whole or any part of any provision of this Agreement may prove to be illegal or
                                            unenforceable, the other provisions of this Agreement and the remainder of the provision
                                            in question shall continue in full force and effect. In relation to any illegal or unenforceable
                                            part of this Agreement, the parties hereto agree to amend such part in such manner as may
                                            be requested from time to time by any of the parties hereto provided that such proposed amendment
                                            is legal and enforceable and to the maximum extent possible carries out the original intent
                                            of the parties in relation to that part</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            any part of this Agreement or the Constitution shall be held by any court of competent jurisdiction
                                            to be unenforceable against or by the Company, such part shall be treated as being severable
                                            from the remainder of this Agreement or, as the case may be, the Constitution and the Shareholders
                                            shall promptly exercise their powers in relation to the Company to procure (insofar as they
                                            have the power lawfully to do so) that the severable part is nevertheless put into or given
                                            effect in accordance with, or to the maximum extent possible in accordance with, the original
                                            intent of the parties hereto in relation to that part.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Counterparts</B>:
                                            This Agreement may be executed in two or more counterparts, each of which shall be deemed
                                            to be an original, but all of which together shall constitute one and the same instrument.
                                            This Agreement shall become effective and be dated (and each counterpart shall be dated)
                                            on the date first written above between the parties which have executed and delivered a counterpart.
                                            Immediate evidence that a counterpart engrossment has been executed may be provided by a
                                            scanned version thereof by email.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sole
                                            and Entire Agreement</B>: This Agreement contains the sole and entire agreement between the
                                            parties in relation to its subject matter, and supersedes all prior written and oral arrangements,
                                            understandings, representations, warranties and agreements between them in that regard (if
                                            any). Each party acknowledges that it is not relying, and will not seek to rely, on any arrangement,
                                            understanding, representation, warranty, agreement, term or condition which is not expressly
                                            set out in this Agreement, and for the avoidance of doubt, the Existing Shareholders, the
                                            Covenantors and the Company hereby agree and confirm to each other and each other Shareholder
                                            that the 2021 SSSA is hereby terminated and shall be of no further force and effect as between
                                            them. Nothing in this Clause excludes the liability of any party for fraud.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Waivers,
                                            Remedies Cumulative</B>: Each of the rights of each party under this Agreement may be exercised
                                            as often as is necessary, is cumulative and not exclusive of any other rights which that
                                            party may have under this Agreement, law or otherwise; and may be waived only in writing
                                            and specifically. Delay by a party in exercising, or the non-exercise by a party of, any
                                            such right shall not constitute a waiver of that right.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendments</B>:
                                            Any amendment to this Agreement must be in writing and duly signed for and on behalf of each
                                            of the parties to this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS OF WHICH</B>, this Agreement has been duly executed and delivered as a deed on the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]<BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warranties</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interpretation</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definitions</B>:
                                            In this Schedule 4:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Accounts</B>&rdquo;
means the unaudited balance sheet of the Company as at the relevant Accounts Date and the unaudited profit and loss account of the Company
for the period ended on the relevant Accounts Date, together with the directors&rsquo; reports thereon and includes all notes and other
documents annexed thereto in accordance with any legal requirement or otherwise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Accounts
Date</B>&rdquo; means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            respect to the Warranties to be given at Tranche 1 Completion, 31 December 2023; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            respect to the Warranties to be given at any Milestone Tranche Completion, the end of the
                                            last preceding financial year in which the Accounts were laid in accordance with section
                                            341 of the Companies Act;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company
Product</B>&rdquo; means any product developed, manufactured, marketed or supplied by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Founders</B>&rdquo;
means the Covenantors;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>GDPR</B>&rdquo;
means the General Data Protection Regulation (Regulation (EU) 2016/679);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Grant
Funding</B>&rdquo; means any funding or other aid or assistance from any central, state or local government body or authority, any statutory
undertaking, any other public body or authority, or any other body funded by public money;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Insolvent</B>&rdquo;
in respect of a company, means if that company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">becomes
                                            the subject of an examinership order or an examiner is appointed in respect of it;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            the subject of a proposal under Part 9, Chapter 1 of the Companies Act 2014 for a composition
                                            in satisfaction of its debts or a scheme of arrangement of its affairs or a compromise or
                                            arrangement between it and its creditors or any class of them, or it makes any arrangement
                                            or compromise with its creditors generally or ceases to carry on all or substantially all
                                            of its business;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            receiver, examiner or liquidator appointed over all or any substantial part of its assets;
                                            or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">becomes
                                            the subject of any occurrence analogous to those in paragraphs (a) to (c) (inclusive) in
                                            any jurisdiction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Privacy
Laws</B>&rdquo; means any applicable legislation relating to the processing of personal data or the protection of the privacy of individuals,
including the GDPR , together with any applicable implementing or supplementary national legislation; the Privacy and Electronic Communications
Directive 2002/58/EC (as amended), together with any applicable implementing or supplementary national legislation including the Privacy
and Electronic Communications (EC Directive) Regulations 2003 (as amended); the Investigatory Powers Act 2016 and the Investigatory Powers
(Interception by Businesses etc. for Monitoring and Record-keeping Purposes) Regulations 2018;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Taxation</B>&rdquo;
means all forms of taxation, duties, rates, levies, contributions, withholdings, deductions, liabilities to account, charges and imposts
whether imposed in Ireland or elsewhere in the world;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Imported
                                            definitions</B>: Save as otherwise expressly defined in this Schedule 4, or where a contrary
                                            intention is stated, each term and phrase defined in this Agreement shall, when used in this
                                            Schedule 4 have the meaning given to it in this Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Awareness
                                            Qualification</B>: Any Warranty which is qualified by the expression &ldquo;so far as the
                                            Warrantors are aware&rdquo; or any similar expression shall be limited to the actual awareness
                                            of Paul Burke 26 Heatherdale, Monaleen, Castletroy, Limerick and also such knowledge as the
                                            foregoing should reasonably have assuming the proper discharge of their duties in his role
                                            with the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
                                            Company</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has been duly incorporated and validly exists under the laws of Ireland.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Disclosure Letter sets out the entire issued share capital of the Company after all share
                                            interests and rights in the Company have been exercised and no person or persons has any
                                            further rights in respect of any shares (issued or unissued), or the right to call for the
                                            allotment of any shares, in the Company. The issued share capital of the Company is fully
                                            paid up. There are no contracts obligating the Company to (i) issue, sell, pledge, dispose
                                            of or encumber any Shares, (ii) redeem, purchase or acquire in any manner any Shares or (iii)
                                            make any dividend or distribution of any kind with respect to any Shares. There are no outstanding
                                            or authorized equity appreciation, phantom equity, profit participation, or similar rights
                                            affecting the Shares.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            only directors of the Company are the persons whose names are listed in the Disclosure Letter.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            person is a shadow director (within the meaning of section 221 of the Companies Act) of the
                                            Company but is not treated as one of its directors for all the purposes of the Companies
                                            Act.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            director of the Company has become a person to whom section 819 of the Companies Act applies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            most recent version of the constitution of the Company is attached to the Disclosure Letter
                                            and is true and complete in all respects and sets out in full the rights and restrictions
                                            attaching to each class of share capital in the Company. Except for this Agreement, there
                                            are no other agreements in place with regard to the management, ownership and control of
                                            the Company.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            register of members and other statutory books of the Company are in the possession of the
                                            Company, have been properly maintained and contain an accurate and up to date record of all
                                            matters with which they should deal and do not contain or reflect any material inaccuracies
                                            or discrepancies and the Company has not received any notice or allegation that any of the
                                            foregoing is incorrect, in particular the Company has received no notice of any intended
                                            application or proceedings to rectify the said registers.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            returns, particulars, resolutions and other documents required to be filed and/or delivered
                                            on behalf of the Company (pursuant to the Companies Act, any other statute or otherwise)
                                            to the Registrar of Companies, Revenue Commissioners or other governmental or statutory body
                                            have been made and the documentation filed was correct in all respects.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            of the Company and the Warrantors has all requisite power, authority and legal capacity to
                                            execute and deliver this Agreement and to perform its obligations hereunder. The execution
                                            and delivery of this Agreement by each of the Company and the Warrantors have been duly and
                                            validly approved by all action necessary on behalf of each of the Company and the Warrantors.
                                            This Agreement has been duly and validly executed and delivered by each of the Company and
                                            the Warrantors and constitutes the legal, valid and binding obligation of each of the Company
                                            and the Warrantors, enforceable against each of the Company and the Warrantors, in accordance
                                            with its terms.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            execution and delivery by the Company of this Agreement and the documents referred to in
                                            it, and compliance with their respective terms, shall not breach or constitute a default
                                            under the Constitution, or any other agreement or instrument to which the Company is a party
                                            or by which the Company is bound, and shall not constitute a breach under any order, judgment,
                                            decree or other restriction applicable to the Company.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            information contained in Schedule 3 is true, complete and accurate and not misleading.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Group
                                            Structure</B></FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not have any subsidiary companies nor has it at any time been the holding company of any company or a member of or the beneficial
owner of any shares, securities or other interest in any company or other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
                                            Plan</B></FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not have any business plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accounts</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Accounts have been prepared in accordance with accounting principles, standards and practices
                                            which are generally accepted in Ireland and on the same basis and in accordance with the
                                            same accounting policies as the corresponding accounts for the preceding three financial
                                            years, comply with the requirements of the Companies Act and give a true and fair view of
                                            the state of affairs of the Company at the Accounts Date and of the profits and losses for
                                            the period concerned.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Accounts make proper provision for or, in the case of actual liabilities, properly disclose,
                                            note or take into account as at the Accounts Date:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            liabilities whether actual contingent or disputed;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            capital commitments whether actual or contingent;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            bad and doubtful debts; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            Taxation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Accounts properly provide or reserve for all Taxation for which the Company was liable at
                                            the Accounts Date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            profits (or losses) shown in the Accounts have not to a material extent been affected (except
                                            as disclosed therein) by any extraordinary or exceptional event or circumstance or by any
                                            other factor rendering such profits unusually high or low.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Events
                                            since the Accounts Date</B></FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the Accounts Date as regards the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
                                            business has been carried on in the ordinary course and so as to maintain the same as a going
                                            concern;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                            has not acquired or disposed of or agreed to acquire or dispose of any business or any material
                                            asset (other than trading stock in the ordinary course of the business carried on by it)
                                            or assumed or acquired any material liability (including a contingent liability) except as
                                            disclosed in the Disclosure Letter;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            dividend or other distribution (as defined by section 123 of the Companies Act) has been
                                            declared, made or paid to its members nor has it repaid any loan capital or other debenture;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            change has been made (or agreed to be made) in the Emoluments or other terms of employment
                                            of any of its employees who are in receipt of remuneration in excess of &euro;50,000 per
                                            annum or of any of the Directors nor has it paid any bonus or special remuneration to any
                                            such employee or Director;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                            has not borrowed monies (except in the ordinary course of the business carried on by it or
                                            from its bankers under agreed loan facilities);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            employee has been dismissed or made redundant nor has the Company taken or omitted to take
                                            any action which would entitle any employee to claim that he has been constructively dismissed;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
                                            has not been any material deterioration in the financial position or prospects of the Business
                                            (whether in consequence of normal trading or otherwise); and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
                                            are no liabilities (including contingent liabilities) outstanding on the part of the Company
                                            other than those liabilities fully, clearly, and accurately disclosed in the Accounts or
                                            incurred in the ordinary and proper course of business since the Accounts Date which</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">do
                                            not result from, arise out of, relate to or are in the nature of, or were caused by breach
                                            of contract, breach of warranty, tort, infringement or violation of law); and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are
                                            similarly fully, clearly, and accurately disclosed in the books and records of the Company</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
                                            Funding</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not applied for or received any Grant Funding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Agreements
                                            and capital commitments</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Disclosure Letter contains copies of all contracts to which the Company is party that are
                                            material to the Business (excluding individual contracts of employment and those between
                                            the Company and [*****]).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">has
                                            no material capital commitments;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            not a party to any contract, arrangement or commitment (whether in respect of capital expenditure
                                            or otherwise) which is of an unusual, onerous or long-term nature (excluding any contracts
                                            included with the Disclosure Letter);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">has
                                            not become bound and no person has become entitled (or with the giving of notice and/or the
                                            issue of a certificate and/or the passage of time or otherwise may become entitled) to require
                                            it to repay any loan capital or other debenture, borrowed money or grant made to it by any
                                            governmental or other authority or person prior to the stipulated due date;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            not a party to any agreement which is or may become terminable as a result of the entry into
                                            this Agreement or Completion;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            not bound by any guarantee or contract of indemnity save as provided for in any contract
                                            included the Disclosure Letter and those between the Company and [*****];</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">has
                                            not entered into any agreement which requires or may require, or confers any right to require,
                                            the sale (whether for cash or otherwise) or the transfer by it of any asset (excluding those
                                            contained in the Disclosure Letter and with [*****]);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            not a party to any joint venture, consortium, partnership, unincorporated association or
                                            profit sharing arrangement or agreement (otherwise than Disclosed);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            not a party to or enjoys the benefit of any agreement requiring registration or notification
                                            under or by virtue of any statute; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            not a party to any distribution agreement which contains a &ldquo;most favoured nation&rdquo;
                                            clause or similar provision;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            not a party to any arrangement (including [*****]) that may restrict and/or otherwise negatively
                                            impact the enjoyment and/or exercise of the rights in favour of Sanara pursuant to the Licensing
                                            and Distribution Agreement; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            not in material default of any agreement or arrangement to which it is a party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has not been and is not a party to any contract or arrangements binding upon it for
                                            the purchase or sale of property or the supply of goods or services at a price different
                                            to that reasonably obtainable on an arm&rsquo;s length basis.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assets,
                                            debts and stock</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has not granted any security over any part of its undertaking or assets.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            assets used by and all debts due to the Company are as of each Completion Date its absolute
                                            property and none is the subject of any Encumbrance (save in respect of liens arising in
                                            the normal course of trading) or the subject of any factoring arrangement, hire-purchase,
                                            retention of title, conditional sale or credit sale agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            present stock and work-in-progress of the Company, having regard to its age and normal usage,
                                            is in good condition.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            asset, having regard to its age and normal usage, needed for the proper conduct of the Business
                                            is in good repair and working order (fair wear and tear excepted).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
                                            Property related to BMI Technology</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has taken reasonable steps as would be expected of a company of similar standing
                                            for the protection of all BMI Technology and other Intellectual Property owned by it and
                                            the Company has not itself granted any rights to third parties in relation to any of its
                                            Intellectual Property. A schedule of all BMI Technology and other Intellectual Property registered
                                            in the name of the Company, or in respect of which the Company has made application for registration,
                                            is Disclosed in the Disclosure Letter.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            operations of the Company and any products or services supplied by them do not use or infringe
                                            the rights of any person or infringe any right of privacy.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Warrantors are not aware of any claims or applications for registration which might infringe
                                            the BMI Technology or any Intellectual Property of the Company.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            BMI Technology and all other Intellectual Property related to BMI Technology which is used
                                            by the Company (including without limitation all Intellectual Property in any Company Product):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            (or in the case of pending applications Disclosed in the Disclosure Letter), will be) legally
                                            and beneficially vested exclusively in the Company; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            licensed to the Company by third parties by way of an agreement and/or licence which enable
                                            the Company to use the Intellectual Property as Disclosed in the Disclosure Letter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So
                                            far as the Warrantors are aware, no BMI Technology or any other Intellectual Property in
                                            which the Company uses or has any interest is:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
                                            (or has been) infringed, misappropriated or used without permission (as Disclosed in the
                                            Disclosure Letter) by any other person; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            to any licence, estoppel or authority or similar right in favour of any other person (excluding
                                            those licences Disclosed in the Disclosure Letter).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            BMI Technology, and all other Intellectual Property of the Company which is registered in
                                            the name of the Company or in respect of which the Company has made application for registration,
                                            is legally and beneficially vested in the Company and, so far as the Warrantors are aware,
                                            has been validly submitted and is not subject to any claims of opposition from any third
                                            party.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            renewal fees in respect of the BMI Technology, and all other Intellectual Property of the
                                            Company registered or applied for by the Company, have been duly paid, and all reasonable
                                            steps required for the maintenance and protection of such BMI Technology and other registered
                                            Intellectual Property have been taken, in any jurisdiction in which they are registered.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
                                            has been done or omitted to be done whereby any of the BMI Technology or other Intellectual
                                            Property owned or used by the Company have ceased or might cease to be valid and enforceable
                                            or whereby any person is or will be able to seek cancellation, rectification or any other
                                            modification of any registration of the BMI Technology or any such other Intellectual Property.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So
                                            far as the Warrantors are aware, no other person has registered or applied to register in
                                            any country anything that is, or that is claimed to be, BMI Technology or other Intellectual
                                            Property made, or claimed to be owned, by the Company.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            licences, agreements and arrangements entered into by the Company have been entered into
                                            in the ordinary course of business, are in full force and effect and no notice has been given
                                            on either side to terminate any of them and no amendment has been made or accepted to their
                                            terms since they were first entered into; and the obligations of all parties under each of
                                            the same have been materially complied with and so far as the Warrantors are aware, no disputes
                                            exist or are anticipated in respect of any of them.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has not disclosed or permitted to be disclosed to any person any of its BMI Know-how
                                            which was not subject to a non-disclosure covenant.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            of each Completion Date, the Company is the sole, unrestricted and exclusive legal and beneficial
                                            owner, free and clear of any Encumbrance, lien mortgage or pledge, of all right, title and
                                            interest in and to all BMI Patents and BMI Know-How.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            BMI Patents are in full force and effect as of each Completion Date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            filing and maintenance fees payable in respect of the BMI Patents have been paid and all
                                            steps have been undertaken to prosecute and maintain the BMI Patents as of each Completion
                                            Date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company is not actually aware that any third party owns or claims that it owns any rights
                                            to any of the BMI Technology.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statutory
                                            and legal requirements</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            statutory, municipal, governmental, court and other requirements applicable to the carrying
                                            on of the business of the Company as carried on the date of this Agreement, the formation,
                                            continuance in existence, creation and issue of securities, management, property or operation
                                            of the Company at the date of this Agreement have been complied with in all material respects,
                                            and all permits, authorities, licences and consents have been obtained and all conditions
                                            applicable thereto complied with in all material respects and so far as the Warrantors are
                                            aware there are no circumstances which might lead to the suspension, alteration or cancellation
                                            of any such permits, authorities, licences or consents, nor is there any agreement which
                                            restricts the fields within which the Company may carry on its business.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has obtained all export licences required for all products, technology or services
                                            exported by or on behalf of the Company to or from any part of the world as required at the
                                            date of this Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So
                                            far as the Warrantors are aware, the Company has not committed any criminal, illegal, unlawful,
                                            or unauthorised act or breach of statutory duty.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            Founder has:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            convicted of a criminal offence (except any road traffic offence not punished by a custodial
                                            sentence);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            disqualified or restricted from being a company director; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">given,
                                            or offered to give, a disqualification undertaking under Chapter 4 of Part 14 of the Companies
                                            Act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            person, not being a Director, has any actual or ostensible authority, whether under a power
                                            of attorney, agency agreement or otherwise, to commit the Company to any obligation other
                                            than an obligation of a nature which it is usual for it to incur in the ordinary course of
                                            its business.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
                                            complies with all applicable Privacy Laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Records
                                            and registers</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            records (including computer records), statutory books, registers, minute books and books
                                            of account of the Company are duly entered up and maintained in accordance with all legal
                                            requirements applicable thereto and contain true and accurate (in all material respects)
                                            records of all matters required to be dealt with therein and all such books and all records
                                            and documents (including documents of title) which are its property are in its possession
                                            or under its control.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Warrantors are not aware of any outstanding matter required to be entered in any of the records,
                                            statutory books, registers, minute books and books of account of the Company which has not
                                            been so entered at the date of this Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            accounts, documents and returns required to be delivered or made to the Registrar of Companies
                                            have been duly and correctly delivered or made. There has been no notice of any proceedings
                                            to rectify the register of members of the Company or the Company&rsquo;s beneficial ownership
                                            register.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
                                            and consultancy agreements</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            list of the jurisdictions in which the Company&rsquo;s employees, workers and consultants
                                            are (so far as the Company is aware) ordinarily resident is Disclosed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
                                            of the template contracts of service or for services (each a &ldquo;<B>Template</B>&rdquo;)
                                            of all officers, workers, employees and consultants are included with the Disclosure Letter
                                            on an anonymised basis and all such officers, workers, employees and consultants are engaged
                                            on such terms.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            are no agreements or other arrangements (binding or otherwise) or, so far as the Warrantors
                                            are aware, outstanding or anticipated claims or disputes between the Company and any trade
                                            union or other body representing all or any of the employees of the Company.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
                                            as provided for in the Disclosure Letter, the Company does not owe any amount to, nor does
                                            it have any outstanding obligations in respect of, any of its present or former directors,
                                            employees or shareholders other than remuneration and expenses accrued during the month in
                                            which this Agreement has been entered into.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            consultant engaged in the Republic of Ireland on a contract for services made or is making
                                            an individual claim to be deemed an employee of the Company in the Republic of Ireland whether
                                            to the Revenue Commissioners, the Department of Social Protection, the Workplace Relations
                                            Commission or any other body.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            is not in existence nor is it proposed as of the date of this Agreement to introduce any
                                            share incentive, share option, profit sharing, enhanced redundancy, bonus or other incentive
                                            arrangements for or affecting any employees or former employees.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            gratuitous payment has been made or promised in connection with the actual or proposed termination
                                            or suspension of employment or variation of any contract of employment or of any contract
                                            for services of any present or former director, employee, worker or consultant of the Company.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            person has been or is employed by the Company who did not or does not have leave to enter,
                                            remain or work in the Republic of Ireland or otherwise was or is in breach of the Employment
                                            Permits Acts 2003-2014 (as applicable).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
                                            as disclosed in the Disclosure Letter, there are no agreements or arrangements (whether legally
                                            enforceable or not) in relation to which the Company has incurred any liability or responsibility
                                            for or in relation to the provision of any pensions, allowances, lump sums gratuities or
                                            other like benefits on redundancy, retirement, withdrawal from service or on death or during
                                            periods of sickness or disablement or accident for or in respect of any director, or former
                                            director or employee or former employee of the Company or any person who has at any time
                                            agreed to provide services to the Company or any dependants of any such persons and no proposals
                                            or announcements have been made about the introduction, continuance, variation of, or payment
                                            of any contribution towards any such agreements or arrangements.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            is no outstanding dispute or complaint in relation to the types of benefits described in
                                            paragraph 13(i) above and there have been no communications with the Revenue Commissioners
                                            and/or the Pensions Regulator in relation to such benefits.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
                                            as disclosed in the Disclosure Letter, no current or former employee or director of the Company
                                            has at any time had his/her contract of employment transferred during the present period
                                            of continuous employment as a result of a relevant transfer for the purposes of either the
                                            European Communities (Safeguarding of Employees&rsquo; Rights on Transfer of Undertakings)
                                            Regulations, 1980 (before those Regulations were revoked) or the European Communities (Protection
                                            of Employees on Transfer of Undertakings) Regulations 2003, where he had previously been
                                            a member of an occupational pension scheme that provided benefits available other than on
                                            old age, invalidity or death.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
                                            as disclosed in the Disclosure Letter, there is not in operation any pension scheme or PHI
                                            scheme in the Company and no proposal has been announced to enter into or establish, any
                                            agreement, arrangement, custom or practice (whether legally enforceable or not or whether
                                            or not approved) for the payment of, or payment of any contributions towards, any pensions,
                                            allowances, lump sum or other like benefits on retirement, death, termination of employment
                                            (whether voluntary or not) or during periods of sickness or disablement, for the benefit
                                            of any employee or officer or any prospective or former employee or officer or for the benefit
                                            of the dependants of any of them; (ii) The Company has no obligations in the Republic of
                                            Ireland under or in connection with any pension scheme or PHI scheme in respect of any past
                                            or present employee or officer or any dependant or beneficiary or any of them; and (iii)
                                            There are no excluded employees (as such term is defined in pensions legislation in the Republic
                                            of Ireland) in respect of whom the Company is obliged to provide, and has not yet provided,
                                            access to a standard PRSA in the accordance with Irish pensions legislation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Litigation</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
                                            the Company nor, so far as the Warrantors are aware, any person for whose acts and defaults
                                            it may be vicariously liable, is at present engaged whether as claimant, defendant or otherwise
                                            in any legal action, proceeding or arbitration (other than as claimant in the collection
                                            of debts arising in the ordinary course of the business carried on by it none of which exceeds
                                            &euro;1,000 and which do not exceed &euro;5,000 in aggregate) or is being prosecuted for
                                            any criminal offence and so far as the Warrantors are aware no governmental, regulatory or
                                            official investigation or inquiry concerning the Company is threatened or in progress or
                                            so far as the Warrantors are aware pending.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            are no circumstances known to any of the Warrantors likely to lead to any such claim or legal
                                            action, proceeding or arbitration, prosecution, investigation or inquiry.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
                                            the Company nor any of the Founders nor, so far as the Warrantors are aware, any person acting
                                            for or on behalf of the Company is being prosecuted for an offence, nor are they or have
                                            they been the subject of any investigation, or inquiry by, or on behalf of, any governmental,
                                            administrative or regulatory authority, in respect of any offence or alleged offence, under
                                            any laws relating to bribery or corruption.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contracts
                                            with connected persons</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            are no loans made by the Company to any of its current or former directors or shareholders
                                            and/or any person connected with any of them and no debts or liabilities owing by the Company
                                            to any of its current or former directors or shareholders and/or any person connected with
                                            them as aforesaid save as Disclosed in the Disclosure Letter.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            are no existing contracts or arrangements to which the Company is a party and in which any
                                            of its directors or shareholders and/or any person connected with any of them is interested
                                            save as Disclosed in the Disclosure Letter.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            are no agreements between any of the Founders or between any of the Founders and the Company
                                            other than this Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            Founder nor any person connected with a Founder owns any property used by the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Borrowings
                                            and facilities</B></FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the Company&rsquo;s Indebtedness are contained in the Disclosure Letter and the Company is not in breach of any of their terms and
none of such facilities or terms of borrowing will be terminated as a result of the entry into of this Agreement or the subscription
for any Shares pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insolvency</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
member of the Group is Insolvent, nor, so far as the Warrantors are aware, have any steps been taken or threatened by any person which
may cause any member of the Group to be Insolvent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insurance</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Disclosure Letter contains accurate details of all insurance policies held by the Company. In respect of such insurances:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            premiums have been duly paid to date;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            the policies are in full force and effect and are not voidable on account of any act, omission
                                            or non-disclosure on the part of the insured party nor could they be declared null and void
                                            or as a consequence of which any claim might be rejected; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
                                            are no circumstances which would or might give rise to any claim and no insurance claim is
                                            outstanding.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Taxation:</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has duly made all returns and given or delivered all notices, accounts and information
                                            which ought to have been made to and is not and has not been involved in any dispute with
                                            any taxing authority concerning any matter likely to affect in any way the liability (whether
                                            accrued, contingent or future) of it to Taxation and the Company is not aware of any matter
                                            which may lead to such dispute.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has duly paid all Taxation for which it is liable and there are no circumstances
                                            in which interest or penalties in respect of Taxation not duly paid could be charged against
                                            it in respect of any period prior to Completion.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            Taxation due in respect of payments made by the Company to any person, which ought to have
                                            been made under deduction or reduction of Taxation, has been properly deducted and accounted
                                            for to the appropriate taxation authority from all such payments made.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            documents to which the Company is a party or which form part of the Company&rsquo;s title
                                            to any asset owned or possessed by it or which the Company may need to enforce or produce
                                            in evidence in the courts of Ireland have been duly stamped and (where appropriate) adjudicated.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            directors, officers or employees of the Company have received any securities, interests in
                                            securities or securities options as defined in the TCA.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            directors, employees or officers of the Company have received any securities or interests
                                            in securities in a form which is treated as convertible securities as defined in section
                                            128C of the TCA.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company is a close company as defined in Part 13 of the TCA.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            has not been in respect of the accounting period ending on the Accounts Date, any excess
                                            of distributable investment or estate income within the meaning of section 434 of the TCA
                                            and no distribution under the TCA, including section 436 of the TCA, has been made by the
                                            Company, no loan or advance within section 438 of the TCA has been made (and remains outstanding)
                                            or agreed to, by the Company, and the Company has not, since the Accounts Date, released
                                            or written off the whole or part of the debt in respect of any such loan or advance.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            acquisitions or disposals of assets by the Company and all supplies of services by and to
                                            the Company have occurred at arm&rsquo;s length between unconnected persons and for a consideration
                                            in cash at market value.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company is registered for the purposes of the VATCA (and has not at any time been treated
                                            as a member of a group of companies for such purpose). The Company has complied with all
                                            statutory provisions, regulations and notices relating to VAT and has duly accounted for
                                            and/or paid the appropriate taxation authority all amounts of VAT which it ought to have
                                            so accounted for and/or paid.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tranche
1 Subscription Provisions</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interpretation</B></FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definitions</B>:
                                            In this Schedule 5.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Convertible
Loan Agreements</B>&rdquo; means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Sanara Convertible Loan Agreement;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Russell Convertible Loan Agreement,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
&ldquo;<B>Convertible Loan Agreement</B>&rdquo; means any of them;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Russell
Convertible Loan Agreement</B>&rdquo; means the convertible loan agreement dated 14 December 2023 between Russell and the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Sanara
Convertible Loan Agreement</B>&rdquo; means the convertible loan agreement dated 1 July 2024 between Sanara and the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tranche
1</B>&rdquo; means the issue of Ordinary Shares to the Investors as more particularly detailed in section 2;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tranche
1 Completion</B>&rdquo; means completion of the subscription for the Tranche 1 Subscription Shares pursuant to section 4;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tranche
1 Subscription Monies</B>&rdquo; means the amounts payable pursuant to section 2 in respect of the Subscription Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tranche
1 Subscription Shares</B>&rdquo; the Ordinary Shares to be subscribed for at Tranche 1 Completion as detailed in section 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
                                            References</B>: Save where a contrary intention is stated, a reference in this Schedule 5
                                            to a section is a reference to a section of this Schedule 5.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subscription
                                            for Tranche 1 Shares</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tranche
                                            1 Subscription Shares</B>: Upon the terms and subject to the conditions of this Schedule
                                            5, each of the following Investors irrevocably subscribes for, and the Company shall allot,
                                            the number of Ordinary Shares set against its name and at the Subscription Price as set out
                                            in the table below and the Company accepts such subscription:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">No. of Ordinary Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Aggregate Subscription Price Payable</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Sanara</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">6,173</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 20%; text-align: right">2,999,780</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
                                            Loans</B>: In accordance with the provisions of each Convertible Loan Agreement, each of
                                            the following Investors shall be issued at Tranche 1 Completion with the following number
                                            of Ordinary Shares set against its name and at the Subscription Price as set out in the table
                                            below on conversion of the amount owing under the relevant Convertible Loan Agreement:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Name</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">No. of Ordinary Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Convertible Loan Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Sanara</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">2,057</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 20%; text-align: right">1,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Russell</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
such Investor confirms and agrees that it irrevocably waives, releases and relinquishes all rights such Investor may have under its Convertible
Loan Agreement other than to convert the amounts owing under such Convertible Loan Agreement into (and irrevocably applying the redemption
monies in subscribing for) Ordinary Shares pursuant to section 2.2 with effect from Tranche 1 Completion, and that following Tranche
1 Completion the Company&rsquo;s obligations under such Convertible Loan Agreement shall have been satisfied in full and the Convertible
Loan Agreement shall be of no further force or effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Simultaneous
                                            Completion</B>: None of the Company or any of the Investors shall be obliged to complete
                                            the subscription and allotment of the Tranche 1 Subscription Shares unless the subscription
                                            for all Tranche 1 Subscription Shares is completed simultaneously.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Waivers</B></FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the Existing Shareholders irrevocably waives any pre-emption rights which they may have in respect of the issue of the Tranche 1 Subscription
Shares to the Investors whether such rights exist under the Constitution or otherwise and each Existing Shareholder consents to the issue
of the Tranche 1 Subscription Shares. This waiver shall not be regarded as a waiver of pre-emption rights in any respect other than as
mentioned above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tranche
                                            1 Completion</B></FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Venue
                                            and Time for Completion</B>: Tranche 1 Completion shall take place by correspondence immediately
                                            after the execution of this Agreement (the &ldquo;<B>Tranche 1 Completion Date</B>&rdquo;).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acts
                                            at to be undertaken at Completion</B>: At Tranche 1 Completion:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Existing Shareholders shall procure that a meeting of the Board is held at which:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            entry into and execution of this Agreement and the Licensing and Distribution Agreement is
                                            approved and authorised by the Company;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            application for the Tranche 1 Subscription Shares is accepted and, subject to receipt of
                                            the relevant Tranche 1 Subscription Monies, the Tranche 1 Subscription Shares are allotted
                                            and issued to the Investors and registered in the name of each Investor credited as fully
                                            paid;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            issuing of and delivery to each Investor of a duly sealed share certificate in respect of
                                            the Tranche 1 Subscription Shares subscribed for by it is approved subject to receipt by
                                            the Company of the Tranche 1 Subscription Monies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            appointment of Tyler Palmer as a Director is approved; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Constitution shall be amended, and evidence of such amendment shall be provided to Sanara,
                                            in the form attached hereto at Schedule 10.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara
                                            shall:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">execute
                                            and deliver a counterpart of the Licensing and Distribution Agreement to the Company; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">procure
                                            the delivery of the balance of the Tranche 1 Subscription Monies payable by it to the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filings</B>:
                                            The Company shall procure that within the time limits prescribed by statute those documents
                                            and forms that require filing with the Registrar of Companies in connection with Tranche
                                            1 Completion shall be so filed.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
                                            of Funds: </B>For the avoidance of doubt, unless Sanara has otherwise agreed to a different
                                            use of proceeds as set forth in a written agreement between Sanara and the Company, the Company
                                            shall use the Tranche 1 Subscription Monies solely for the purposes of funding the development
                                            of products for the purposes of the Licensing and Distribution Agreement and related working
                                            capital requirements of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warranties</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warranties</B>:
                                            In consideration of, and as an inducement to Investors to subscribe for the Tranche 1 Subscription
                                            Shares, the Warrantors hereby jointly and severally warrant to the Investors that save as
                                            Disclosed, the statements in Schedule 4 are accurate in all respects as at the Tranche 1
                                            Completion Date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Separate
                                            Warranties</B>: Each of the Warranties shall be construed as separate and independent and,
                                            save as otherwise expressly provided, shall not be limited by reference to any other warranty,
                                            clause, sub-clause, paragraph, sub-paragraph or any provision in this Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations</B>:
                                            The liability of the Warrantors under the General Warranties and Tax Warranties shall be
                                            limited in accordance with the provisions of Schedule 8.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigation</B>:
                                            The rights and remedies of the Investors in respect of any breach of any of the Warranties
                                            shall not be affected by Tranche 1 Completion or any investigation made by or on behalf of
                                            the Investors into the affairs of the Company or any other event or matter whatsoever which
                                            otherwise might have affected such rights and remedies except a specific and duly authorised
                                            written waiver or release.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
                                            Warranties</B></FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Investor severally warrants in respect of itself only to the Company and the other Investors as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                            has the full legal right, power and authority to enter into and perform this Agreement and
                                            all transactions referred to herein, and without obtaining the consent or approval of any
                                            other person;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">this
                                            Agreement has been, and all other instruments and agreements to be executed by that Investor
                                            provided for herein will be on Tranche 1 Completion, duly executed and delivered by that
                                            Investor and this Agreement constitutes, and all such other instruments and agreements will
                                            constitute on Tranche 1 Completion, the valid and binding obligations of each that Investor,
                                            enforceable against it in accordance with its terms; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            execution and delivery by that Investor of this Agreement and the performance by that Investor&rsquo;s
                                            obligations hereunder will not, or with the giving of notice or the lapse of time or both,
                                            would not:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conflict
                                            with or result in a breach of or constitute a default under any provision of the constitution
                                            or other by bye-laws of that Investor or of any contract or arrangement to which that Investor
                                            is a party or by which that Investor is affected or bound; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">violate
                                            any order, writ, injunction, decree, law, statute, rule or regulation to which that Investor
                                            is subject.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone
Tranche Subscriptions</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interpretation</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definitions</B>:
                                            In this Schedule 6.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Expert</B>&rdquo;
means an independent Irish qualified lawyer with at least 20 years post-qualification experience including not less than 10 years&rsquo;
experience of international corporate/commercial law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Long
Stop Date</B>&rdquo; means the third anniversary of Tranche 1 Completion or such later date as may be agreed and determined by the Board
and Sanara;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Milestone</B>&rdquo;
means in respect of a Milestone Tranche, the milestone to be achieved by the Company in respect of that Milestone Tranche as set out
in the table at section 2 below;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Milestone
Subscription Shares</B>&rdquo; means, in respect of a given Milestone Tranche, the number of Ordinary Shares to be subscribed for by
Sanara in respect of that Milestone Tranche as set out in the table at section 2 below;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Milestone
Subscription Monies</B>&rdquo; means, in respect of a given Milestone Tranche, the amount payable by Sanara in respect of the Milestone
Subscription Shares as set out in the table at section 2 below;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Milestone
Tranche</B>&rdquo; means a subscription for Ordinary Shares by Sanara following the achievement of a Milestone as more particularly detailed
in section 2;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Milestone
Tranche Completion </B>means completion of Milestone Tranche pursuant to section 4;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Milestone
Tranche Completion Date</B>&rdquo; means the earlier of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the event that the requirement for the Company to have achieved the relevant Milestone has
                                            been waived by the Board and Sanara, the next business day immediately following waiver by
                                            the Board and Sanara of the requirement for the Company to have achieved the relevant Milestone;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            next business day following receipt of a Satisfaction Notice; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Satisfaction
Notice</B>&rdquo; has the meaning given to that term in section 3.2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
                                            References</B>: Save where a contrary intention is stated, a reference in this Schedule 6
                                            to a section is a reference to a section of this Schedule 6.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Milestone
                                            Tranche Subscription</B></FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the terms and subject to the conditions of this Schedule 6, Sanara shall at each Milestone Tranche Completion subscribe for, and the
Company shall allot to Sanara, the relevant Milestone Subscription Shares at the Subscription Price as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Milestone Tranche No.</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Milestone</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">No. of Milestone Subscription Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Milestone Subscription Monies</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left">2</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">2,058</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 20%; text-align: right">1,000,188</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,058</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">1,000,188</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,058</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">1,000,188</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,028</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">499,608</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">6</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,028</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">499,608</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Milestones</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Milestones</B>:
                                            The obligation on the Sanara to subscribe for Milestone Subscription Shares at each Milestone
                                            Tranche Completion shall be subject to:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company having achieved the applicable Milestone, as determined by the Board and Sanara pursuant
                                            to the provisions of section 3.2 on or before the Long Stop Date, or in default of such determination
                                            and at the instance of either the Company or Sanara, by the Expert in accordance with the
                                            provisions of section 6; and/or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            requirement for the Company to have achieved the applicable Milestone having been waived
                                            by the Board and Sanara; and/or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Licensing and Distribution Agreement not having been terminated for any reason or there being
                                            any uncured breach or default by the Company thereunder; and/or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
further that if anything is Disclosed in the Disclosure Letter (or any draft thereof) which (in Sanara&rsquo;s opinion) alone or together
with any other disclosure in the Disclosure Letter, has a material adverse effect on the Business or the Company (and for this purpose
material shall mean a reduction in the turnover or net assets of the Company of more than [*****]% to be calculated by Sanara acting
reasonably) then Sanara may elect, in addition and without prejudice to any other right or remedy available to Sanara arising out of
or in connection with this Agreement to either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                            complete its subscription for the relevant Milestone Subscription Shares by giving notice
                                            in writing to the Company to that effect; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
                                            its subscription for Milestone Subscription Shares in accordance with section 4.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Determination</B>:
                                            Achievement of a Milestone shall be determined as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>t</B>he
                                            Company shall notify Sanara in writing by mail and by email (the &ldquo;<B>Milestone Achievement
                                            Notice</B>&rdquo;) when it has achieved the relevant Milestone;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara
                                            shall respond in writing to the Company as soon as practicable but not later than 15 business
                                            days from the date of receipt of the Milestone Achievement Notice confirming whether it accepts
                                            that the Milestone has been achieved;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the absence of receipt of the response to the Milestone Achievement Notice from Sanara by
                                            the date falling 15 business days from the date of receipt of the Milestone Achievement Notice
                                            or Sanara notifies the Company that it disagrees with the Milestone Achievement Notice, either
                                            the Company or Sanara may refer the determination to the Expert in accordance with the provisions
                                            of section 6;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            applicable, upon receipt of Sanara&rsquo;s response to the Milestone Achievement Notice to
                                            the effect that the relevant Milestone has been achieved (or waived as the case may be) or
                                            upon receipt of a determination by the Expert in accordance with the provisions of section
                                            6 (in either case, a &ldquo;<B>Satisfaction Notice</B>&rdquo;), the Milestone shall be deemed
                                            to have been achieved.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Waivers</B>:
                                            Each of the Shareholders irrevocably waives any pre-emption rights which they may have in
                                            respect of the issue of the any Milestone Tranche Shares whether such rights exist under
                                            the Constitution or otherwise and each Shareholder consents to the issue of Milestone Tranche
                                            Shares. This waiver shall not be regarded as a waiver of pre-emption rights in any respect
                                            other than as mentioned above. The occurrence of a Milestone Tranche Completion in accordance
                                            with this Schedule 6 shall be conclusive evidence of the fulfilment to the satisfaction of
                                            (or waiver by) the Board and Sanara of the applicable Milestone.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Milestone
                                            Tranche Completion</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Venue
                                            and Time for Milestone Tranche Completion</B>: Completion of a Milestone Tranche shall take
                                            place virtually at the Milestone Tranche Completion Date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acts
                                            at to be undertaken at a Milestone Tranche Completion</B>: At a Milestone Tranche Completion:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Shareholders shall procure that a meeting of the Board is held at which:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            subscription for the relevant Milestone Subscription Shares is accepted and, subject to receipt
                                            of the relevant Milestone Subscription Monies, the relevant Milestone Subscription Shares
                                            are allotted and issued and registered in the names of Sanara credited as fully paid;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            issuing of and delivery to Sanara of duly sealed share certificates in respect of the relevant
                                            Milestone Subscription Shares is approved subject to receipt by the Company of the relevant
                                            Milestone Subscription Monies; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara
                                            shall procure delivery of the Milestone Subscription Monies to the Company to such account
                                            as the Company may specify in writing to Sanara at least three business days prior to a Milestone
                                            Tranche Completion Date by electronic transfer of immediately available funds.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filings</B>:
                                            The Company shall procure that within the time limits prescribed by statute those documents
                                            and forms that require filing with the Registrar of Companies in connection with a Milestone
                                            Tranche Completion shall be so filed.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
                                            of Funds: </B>For the avoidance of doubt, unless Sanara has otherwise agreed to a different
                                            use of proceeds as set forth in a written agreement between Sanara and the Company, the Company
                                            shall use the Milestone Tranche Monies solely for the purposes of funding the development
                                            of products for the purposes of the Licensing and Distribution Agreement and related working
                                            capital requirements of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warranties</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warranties</B>:
                                            In consideration of, and as an inducement to Sanara to subscribe for Milestone Subscription
                                            Shares, the Warrantors warrant to Sanara at each Milestone Completion Tranche Date that save
                                            as Disclosed, the statements in Schedule 4 are accurate in all respects as at that Milestone
                                            Completion Tranche Date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Separate
                                            Warranties</B>: Each of the Warranties shall be construed as separate and independent and,
                                            save as otherwise expressly provided, shall not be limited by reference to any other warranty,
                                            clause, sub-clause, paragraph, sub-paragraph or any provision in this Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations</B>:
                                            The liability of the Warrantors under the General Warranties and Tax Warranties given at
                                            each Milestone Tranche Completion shall be limited in accordance with the provisions of Schedule
                                            8.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expert
                                            Determination</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application:
                                            </B>Where the Company and Sanara are unable to determine that any given Milestone has been
                                            met in accordance with the provisions of section 3.1 either the Company or Sanara may request
                                            that the matter be sent for determination by the Expert in accordance with this section 6.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Appointment</B>:
                                            The Company and Sanara shall all use reasonable endeavours to reach agreement regarding the
                                            identity of the person to be appointed as the Expert. If the Company and Sanara fail to agree
                                            on an Expert within 10 business days of either serving details of a proposed Expert on the
                                            other, either shall be entitled to request the President for the time being of Bar Council
                                            of Ireland to appoint the Expert or if he is unable or willing to act, the next most senior
                                            officer. The provisions of this section 6.2 shall apply in relation to the appointment of
                                            any replacement to the Expert should the Expert become unable or unwilling to act.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Duty
                                            of Co-operation</B>: The Company and Sanara shall co-operate with the Expert and shall give
                                            the Expert reasonable access to any documents, books and records in that party&rsquo;s possession
                                            or control, which the Expert may reasonably require for the purpose of making his determination
                                            and the Expert shall be required to make his determination in writing (including reasons
                                            for his determination) and to provide a copy to each party as soon as reasonably practicable
                                            and in any event within 30 business days of his appointment.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status
                                            of the Expert</B>: The Expert shall act as an expert and not as an arbitrator. Save in the
                                            event of manifest error or fraud, the Expert&rsquo;s determination of any matters referred
                                            to him under this paragraph 6 shall be final and binding on the Company and Sanara.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Costs</B>:
                                            The Company and Sanara shall each bear and pay its own costs incurred in connection with
                                            the Expert&rsquo;s determination pursuant to this section 6. The Expert&rsquo;s fees and
                                            any costs or expenses incurred in making his determination shall be borne:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            the Company if it requests that the Expert determine whether the relevant Milestone has been
                                            met; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            the Company and Sanara equally (or, if applicable, in such other proportions as the Expert
                                            may direct) if Sanara requests that the Expert determine whether the relevant Milestone has
                                            been met.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
8</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitations</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the purposes of this Schedule 8</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Basket
Threshold</B>&rdquo; means in respect of an Investment Tranche an amount equal to [*****];</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Claim</B>&rdquo;
means a claim brought by an Investor for breach of any of the General Warranties or Tax Warranties in respect of a particular Investment
Tranche;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>De
Minimis Threshold</B>&rdquo; means in respect of an Investment Tranche an amount equal to [*****];</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Fundamental
Warranties</B>&rdquo; means the Warranties set out at paragraphs 2 and 3 of Schedule 4; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Investment
Monies</B>&rdquo; means the aggregate amount subscribed for by an Investor pursuant to an Investment Tranche which shall include all
amounts owing under any Convertible Loan Agreement that are converted pursuant to such Investment Tranche;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Investment
Tranche</B>&rdquo; means Tranche 1 or any Milestone Tranche.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            liability of PBC Biomed to each Investor in respect of any and all Claims (excluding those
                                            arising in respect of the PBC Warranties) shall not exceed [*****].</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            liability of PBC Biomed to each Investor in respect of any and all Claims arising in respect
                                            of the PBC Warranties shall not exceed the aggregate amount of [*****].</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            liability of the Company to each Investor in respect of all Claims shall not exceed the [*****].</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Warrantors will not be liable to an Investor for a Claim unless the amount awarded or agreed
                                            in respect of that Claim (when aggregated with other Claims based on reasonably related matters,
                                            facts, events or circumstances) exceeds the De Minimis Threshold and unless the amount awarded
                                            or agreed of all such Claims exceeds the Basket Threshold, in which event the relevant Investor
                                            shall be entitled to recover the full amount and not just the excess.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Warrantors will not be liable to any Investor for any Claim unless notice of it is given
                                            in writing by that Investor to the Warrantors:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the case of the Fundamental Warranties, indefinitely.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the case of the General Warranties no later than the date which is 24 months after the relevant
                                            Completion Date<I>;</I> and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the case of the Tax Warranties, no later than the fifth anniversary of the end of the accounting
                                            period of the Company which is current on the relevant Completion Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Warrantors will not be liable for a Claim to the extent that the Claim:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">relates
                                            to matters that have been Disclosed in the relevant Disclosure Letter;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">relates
                                            to any matter specifically and fully provided for in the Accounts;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">arises
                                            or is increased as a result of an increase in rates of Taxation after the date of this agreement
                                            with retrospective effect; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">arises
                                            or is increased as a result of any legislation, subordinate legislation or Revenue Commissioners
                                            enunciated practice enacted, made, in force or allowed (as appropriate), after the date of
                                            this agreement with retrospective effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
                                            in this Schedule 8 shall limit the liability of any Warrantor (including, without limitation,
                                            the Basket Threshold):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            respect of any Claim in respect of the Fundamental Warranties or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            respect of any other Claim that arises or is delayed, wholly or partly, as a result of fraud,
                                            intentional misrepresentation or wilful concealment of that Warrantor.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
                                            in this Schedule 8 shall or shall be deemed to in any way diminish an Investor&rsquo;s common
                                            law obligations to mitigate its loss or damage or both in relation to any Claim.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            Investor shall not be entitled to recover the same loss in respect of any Claim more than
                                            once.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            respect of any matter which gives rise to a Claim, the Company shall promptly notify the
                                            Investor(s) that have any right to bring such a Claim if the Company is entitled to claim
                                            under any policy of insurance and the Company shall make a claim against the relevant insurer(s)
                                            (unless it has secured the agreement of the Investor(s) not to make that claim) and use all
                                            reasonable endeavours to pursue that claim, and the amount of that Claim shall be reduced
                                            by the amount actually recovered from such insurers (less the reasonable costs incurred by
                                            the Company of such recovery).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execution
Page</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNED
    AND DELIVERED</B> for and on behalf of and as the act and <B>DEED</B> of <B>SANARA MEDTECH INC</B> acting by tis authorised signatory
    in the presence of:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    of <B>A</B>uthorised Signatory</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Witness
    Signature</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name:</FONT></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Address</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Witness
    occupation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNED
    AND DELIVERED</B> for and on behalf of and as the act and <B>DEED</B> of <B>THE RUSSELL REVOCABLE LIVING TRUST</B> acting by tis
    authorised signatory in the presence of:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    of <B>A</B>uthorised Signatory</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Witness
    Signature</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Address</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Witness
    occupation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GIVEN
                                            </B>under the <B>COMMON SEAL of BIOMIMETIC INNOVATIONS LIMITED</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director/Secretary/</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Person
    duly authorised by the board</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[*****]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>3
<FILENAME>ex10-20.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.20</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST
AMENDMENT TO TERM LOAN AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
FIRST AMENDMENT TO TERM LOAN AGREEMENT (this &ldquo;<B><I>Agreement</I></B>&rdquo;), dated as of March 19, 2025, is entered into among
SANARA MEDTECH INC., a Texas corporation (&ldquo;<B><I>Borrower</I></B>&rdquo;), the Subsidiary Guarantors party hereto, the Lenders
party hereto and CRG SERVICING LLC, as administrative agent and collateral agent (the &ldquo;<B><I>Agent</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RECITALS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Borrower, the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto and the Agent entered
into that certain Term Loan Agreement, dated as of April 17, 2024 (as amended, restated, amended and restated, supplemented or otherwise
modified from time to time, the &ldquo;<B><I>Term Loan Agreement</I></B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Borrower has requested that the Lenders amend the Term Loan Agreement to provide for certain modifications thereto; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Lenders are, subject to the terms and conditions hereof, willing to amend the Term Loan Agreement to provide for certain modifications
thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Definitions; Interpretation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Term Loan Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The rules of interpretation set forth in Section 1.03 of the Term Loan Agreement shall be applicable to this Agreement and are incorporated
herein by this reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Amendments to Term Loan Agreement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The defined term &ldquo;Commitment Period&rdquo; as it appears in Section 1.01 of the Term Loan Agreement shall be amended and restated
in its entirety as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Commitment
Period</I></B>&rdquo; means the period from and including the first date on which all of the conditions precedent set forth in <B>Section
6.01 </B>have been satisfied (or waived by the Lenders) and through and including December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Section 2.07(b) of the Term Loan Agreement is hereby amended and restated in its entirety as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Mandatory</B>. The Commitments shall be automatically and permanently reduced (i) on the Closing Date, by the amount of the Borrowing
made on such date, (ii) on each Borrowing Date for a Borrowing made in accordance with <B>Section 6.02(b)</B>, by the amount of each
such Borrowing and (iii) on the earlier of (A) the Borrowing Date on which the third subsequent Borrowing under the first additional
tranche has been made in accordance with <B>Section 6.02(b) </B>and (B) December 31, 2025, by the sum of (1) $40,000,000 <I>minus </I>(2)
the aggregate amount of the Borrowings made in accordance with <B>Section 6.02(b)</B>. Additionally, the Commitments shall be automatically
and permanently reduced to zero on the date that the Commitment Period shall end. Upon any reduction of the Commitments, the Commitments
of each Lender shall be reduced by such Lender&rsquo;s Proportionate Share of such reduction amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Section 6.02(b) of the Term Loan Agreement is hereby amended and restated in its entirety as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>First Additional Tranche</B>. Up to three (3) subsequent Borrowings shall be subject to the following conditions precedent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<B>First Borrowing</B>. The Borrowing on the Closing Date referred to in <B>Section 6.02(a) </B>shall have occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<B>Borrowing Date</B>. Each such Borrowing shall occur on or prior to December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
<B>Amount of Borrowings</B>. The aggregate amount of such Borrowings under this <B>Section 6.02(b) </B>shall not exceed $40,000,000,
and each such Borrowing shall be in a minimum amount of $5,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
<B>Financing Fee</B>. Administrative Agent shall have received, for the account of each Lender, the fees payable pursuant to the Fee
Letter with respect to each such Borrowing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Conditions Precedent</U>. The effectiveness of this Agreement shall be subject to the satisfaction of each of the following conditions
precedent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
receipt by the Agent of counterparts of this Agreement duly executed by Borrower, the Subsidiary Guarantors, the Lenders and the Agent;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
the representations and warranties in <B><I>Section 6(c)</I></B> shall be true and correct on the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Expenses</U>. The Obligors agree to reimburse the Agent for all fees, charges and disbursements of the Agent in connection with the
preparation, execution and delivery of this Agreement, including the fees, charges and disbursements of Moore &amp; Van Allen PLLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Reaffirmation</U>. Each of the Obligors acknowledges and reaffirms (a) that it is bound by all of the terms of the Loan Documents
to which it is a party and (b) that it is responsible for the observance and full performance of all Obligations, including, without
limitation, the repayment of the Loans. Furthermore, the Obligors acknowledge and confirm (i) that the Lenders have performed fully all
of their obligations under the Term Loan Agreement and the other Loan Documents arising on or before the date hereof other than their
respective obligations specifically set forth in this Agreement and (ii) that by entering into this Agreement, the Lenders do not, except
as expressly set forth herein, waive or release any term or condition of the Term Loan Agreement or any of the other Loan Documents or
any of their rights or remedies under such Loan Documents or any applicable law or any of the Obligations of the Obligors thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Term Loan Agreement and the Obligations of the Obligors thereunder and under the other Loan Documents are hereby ratified and confirmed
and shall remain in full force and effect according to their terms. This Agreement is a Loan Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Each Subsidiary Guarantor (i) acknowledges and consents to all of the terms and conditions of this Agreement, (ii) affirms all of its
Obligations under the Loan Documents and (iii) agrees that this Agreement and all documents executed in connection herewith do not operate
to reduce or discharge its Obligations under the Term Loan Agreement or the other Loan Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Obligors represent and warrant to the Agent and the Lenders that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
each Obligor has taken all necessary corporate, limited liability company or other organizational action to authorize the execution,
delivery and performance of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
this Agreement has been duly executed and delivered by each Obligor and constitutes a legal, valid and binding obligation of each Obligor,
enforceable against each such Obligor in accordance with its terms, subject to bankruptcy, insolvency and similar laws affecting enforceability
of creditors&rsquo; rights generally and to general principles of equity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
no approval, consent, exemption, authorization or other action by, or notice to, or filing with, any Governmental Authority or any other
Person is necessary or required in connection with the execution, delivery or performance by, or enforcement against, any Obligor of
this Agreement other than (A) those that have already been obtained and are in full force and effect and (B) those that may be required
under any applicable notices under securities laws;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
the representations and warranties of each Obligor contained in Section 7 of the Term Loan Agreement or in any other Loan Document, or
which are contained in any document furnished at any time under or in connection therewith, are true and correct in all material respects
(and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Change
or Material Adverse Effect) on and as of the date hereof, except to the extent that any such representation or warranty specifically
refers to an earlier date, in which case such representation or warranty is true and correct in all material respects (and in all respects
if such representation or warranty is already qualified by materiality or reference to Material Adverse Change or Material Adverse Effect)
as of such earlier date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
there has been no Material Adverse Effect since the date of the Term Loan Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
no Default or Event of Default under the Term Loan Agreement has occurred and is continuing, and no Default or Event of Default will
result after giving effect to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Each of the Obligors hereby affirms the Liens created and granted in the Loan Documents in favor of the Agent, for the benefit of the
Secured Parties, and agrees that this Agreement does not adversely affect or impair such Liens and security interests in any manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute
an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature
page of this Agreement by facsimile or other electronic imaging means (e.g. &ldquo;pdf&rdquo; or &ldquo;tif&rdquo;) shall be effective
as delivery of a manually executed counterpart of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
If any provision of this Agreement is held to be illegal, invalid or unenforceable, (i) the legality, validity and enforceability of
the remaining provisions of this Agreement shall not be affected or impaired thereby and (ii) the parties shall endeavor in good faith
negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as
close as possible to that of the illegal, invalid or unenforceable provisions. The invalidity of a provision in a particular jurisdiction
shall not invalidate or render unenforceable such provision in any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<B>THIS AGREEMENT AND ANY CLAIM, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING
OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH,
THE LAWS OF THE STATE OF NEW YORK.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES FOLLOW]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BORROWER:</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SANARA
  MEDTECH INC.</B>,</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
  Texas corporation</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  Ronald T. Nixon </I></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
  T. Nixon</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
  Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SANARA
MEDTECH INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST
AMENDMENT TO TERM LOAN AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUBSIDIARY
    GUARANTORS:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELLERATE,
    LLC,</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Texas limited liability company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ronald T. Nixon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
    T. Nixon</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and President</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WOUND
    CARE INNOVATIONS, LLC,</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Nevada limited liability company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ronald T. Nixon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
    T. Nixon</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President and Treasurer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TISSUE
    HEALTH PLUS, LLC (F/K/A UNITED WOUND AND SKIN SOLUTIONS, LLC),</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Delaware limited liability company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ronald T. Nixon</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
    T. Nixon</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and President</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SANARA
    CMP LLC (F/K/A SANARA BIOLOGICS, LLC),</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Texas limited liability company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ronald T. Nixon</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
    T. Nixon</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCENDIA
    BIOLOGICS, LLC,</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Delaware limited liability company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ronald T. Nixon</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
    T. Nixon</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SANARA
MEDTECH INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST
AMENDMENT TO TERM LOAN AGREEMENT</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ROCHAL
    TECHNOLOGIES, LLC,</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Texas limited liability company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ronald T. Nixon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
    T. Nixon</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SANARA
    MEDTECH APPLIED TECHNOLOGIES, LLC,</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Texas limited liability company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ronald T. Nixon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
    T. Nixon</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WOUNDERM,
    LLC,</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Delaware limited liability company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ronald T. Nixon</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
    T. Nixon</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President and Treasurer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRECISION
    HEALING, LLC,</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Delaware limited liability company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael D. McNeil</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0">Michael D. McNeil</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SANARA
    COLLAGEN PEPTIDES, LLC,</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Delaware limited liability company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ronald T. Nixon</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
    T. Nixon</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PIXALERE
    HEALTHCARE USA, LLC,</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Delaware limited liability company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ronald T. Nixon</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
    T. Nixon</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SANARA
MEDTECH INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST
AMENDMENT TO TERM LOAN AGREEMENT</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGENT:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CRG
  SERVICING LLC</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  Nathan Hukill</I></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nathan
  Hukill</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
  Signatory</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LENDERS:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CRG
PARTNERS V DELAWARE PARALLEL FUND LP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
CRG PARTNERS V DELAWARE GP LP, its general partner</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
CRG PARTNERS V GP LLC, its general partner</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  Nathan Hukill</I></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nathan
  Hukill</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
  Signatory</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CRG
PARTNERS V CAYMAN PARALLEL FUND &ldquo;C&rdquo; LP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
CR GROUP L.P., its investment advisor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.25in; width: 96%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  Nathan Hukill</I></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nathan
  Hukill</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
  Signatory</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SANARA
MEDTECH INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST
AMENDMENT TO TERM LOAN AGREEMENT</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>4
<FILENAME>ex19-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 19.1</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex19-1_001.jpg" ALT="" style="width:720px">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex19-1_002.jpg" ALT="" style="width:720px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex19-1_003.jpg" ALT="" style="width:720px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex19-1_004.jpg" ALT="" style="width:720px">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex19-1_005.jpg" ALT="" style="width:720px">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex19-1_006.jpg" ALT="" style="width:720px">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiaries
of Sanara MedTech Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a list of subsidiaries of Sanara MedTech Inc., a Texas corporation (the &ldquo;Company&rdquo;), as of December 31,
2024, the states in which they are organized and the Company&rsquo;s percentage ownership of the issued and outstanding stock or other
equity interests for each entity. The names of particular subsidiaries may be omitted if the unnamed subsidiaries, considered in the
aggregate as a single subsidiary, would not constitute a significant subsidiary as of the end of the year covered by the annual report
on Form 10-K of which this Exhibit 21.1 forms a part. (See the definition of &ldquo;significant subsidiary&rdquo; in Rule 1-02(w) (17
CFR 210.1-02(w)) of Regulation S-X.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Name of Subsidiary</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">State of Incorporation</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Direct or <BR>Indirect Ownership Percentage</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; font-weight: bold; text-align: left">Cellerate, LLC</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 22%">Texas</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">100</TD><TD STYLE="width: 3%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Wound Care Innovations, LLCTT</TD><TD>&nbsp;</TD>
    <TD>Nevada</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Sanara CMP, LLC</TD><TD>&nbsp;</TD>
    <TD>Texas</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%<SUP>(1)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Rochal Technologies, LLC</TD><TD>&nbsp;</TD>
    <TD>Texas</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Tissue Health Plus, LLC</TD><TD>&nbsp;</TD>
    <TD>Delaware</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%<SUP>(2)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Precision Healing, LLC</TD><TD>&nbsp;</TD>
    <TD>Delaware</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%<SUP>(3)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Pixalere Healthcare USA, LLC</TD><TD>&nbsp;</TD>
    <TD>Delaware</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73</TD><TD STYLE="text-align: left">%<SUP>(4)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Scendia Biologics, LLC</TD><TD>&nbsp;</TD>
    <TD>Delaware</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Sanara MedTech Applied Technologies, LLC</TD><TD>&nbsp;</TD>
    <TD>Texas</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Sanara Collagen Peptides, LLC</TD><TD>&nbsp;</TD>
    <TD>Delaware</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
In 2024, Sanara Biologics, LLC was renamed to Sanara CMP, LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
In 2024, United Wound and Skin Solutions, LLC was renamed to Tissue Health Plus, LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Ownership of Precision Healing, LLC is held indirectly through Tissue Health Plus, LLC, a wholly owned subsidiary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Ownership of Pixalere Healthcare USA, LLC is held indirectly through Tissue Health Plus, LLC, a wholly owned subsidiary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin: 0pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File Nos. 333-236558 and 333-267103) of
our report dated March 24, 2025 relating to the consolidated financial statements of Sanara MedTech Inc. and its subsidiaries, which
appear in this Annual Report on Form 10-K for the year ended December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Weaver and Tidwell, L.L.P.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Austin,
Texas</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
25, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
ACCORDANCE WITH 18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED BY SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Ronald T. Nixon, certify that:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Annual Report
    on Form 10-K of Sanara MedTech Inc. for the fiscal year ended December 31, 2024;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain
    any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
    under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Based on my knowledge, the financial statements,
    and other financial information included in this report, fairly present in all material respects the financial condition, results
    of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s)
    and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
    and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls
    and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
    relating to the registrant, including its consolidated subsidiaries is made known to us by others within those entities, particularly
    during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting,
    or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
    the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
    accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Evaluated the effectiveness of the registrant&rsquo;s
    disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
    and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Disclosed in this report any change in the registrant&rsquo;s
    internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
    fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
    the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;The registrant&rsquo;s other
    certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
    the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent
    functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and
    material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely
    affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management
    or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 25, 2025</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ronald T. Nixon</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald T. Nixon,
    Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
ACCORDANCE WITH 18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED BY SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Elizabeth B. Taylor, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of Sanara MedTech Inc. for the fiscal year ended December 31, 2024;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
    financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or
    persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 25, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Elizabeth B. Taylor</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elizabeth
    B. Taylor, Chief Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
ACCORDANCE WITH 18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report on Form 10-K of Sanara MedTech Inc. (the &ldquo;Company&rdquo;) for the fiscal year ended December 31, 2024
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Ronald T. Nixon, in my capacity
as Chief Executive Officer of the Company and not in my individual capacity, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant
to &sect; 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company as of, and for, the periods presented in the Report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
25, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ronald T. Nixon</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald
    T. Nixon, Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing certification is being furnished as an exhibit to the Report pursuant to Item 601(b)(32) of Regulation S-K and Section 906
of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and, accordingly,
is not being filed as part of the Report for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated
by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language
in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
ACCORDANCE WITH 18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report on Form 10-K of Sanara MedTech Inc. (the &ldquo;Company&rdquo;) for the fiscal year ended December 31, 2024
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Elizabeth Taylor, in my capacity
as Chief Financial Officer of the Company and not in my individual capacity, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant
to &sect; 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company as of, and for, the periods presented in the Report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
25, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Elizabeth B. Taylor</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elizabeth
    B. Taylor, Chief Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing certification is being furnished as an exhibit to the Report pursuant to Item 601(b)(32) of Regulation S-K and Section 906
of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and, accordingly,
is not being filed as part of the Report for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated
by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language
in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex19-1_001.jpg
<TEXT>
begin 644 ex19-1_001.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[@ .061O8F4 9       _]L 0P " @(#
M @,%! 0%!P8&!@<(!P@(!P@)"0H*"@D)"PH+"PL+"@L+# P,#0T+# P,# P.
M# P,# P,# \,# P,# P,_\  "P@&<@3[ 0 1 /_$ !\   $% 0$! 0$!
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MS"OD#]D#]KOQ5^UWX5U3Q'8^&+'3K:TEN+*%)M8FDDEO(H8)D1PNFA8K=UG
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M"J'_  65TFQT#X!>'[&QMXK:VMO$%C###"BQQQQQZ=?JB(B@*J*H"JJ@!0
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M-'#*TT:2&]U;>J2-'"TB*V0KM'&6 #&-"=H_8ZOR _X)Q?\ );_C[_V,B_\
MI?J]>P?M%_LH^$/VM?B!XJT36U\B[@\-^')-/U"- TUI,U]KX) )7?$^U1/
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M%K^K:I8ZA8W>HZU<O9@MJ,=P99T2VM+H!(I)@MO9JJ)';A8A./*4OY_^R?\
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M_8YT?X">+]9\3:3XDUNXN->N6O-4AO#I;0W<Q,[!W$6GQ21;7N9)%6W>%2Q
M8-&-E:'Q5_8V\!?$_P :V/CF&2^T/Q+9RPR)JVCS)#<2+#&\8CF2:.>WF1D?
MRY#)"SR0HENSFW!B/7VO[/>GZEJFGZCXIUC4O$LNE7*WNGKJOV)(;6X5'03K
M!I]I90RR@-F*2Z2=[=AOMS"[2,_L'BG1KSQ!I<UG::E<Z9+)MVW5FMLTT>UP
MQV"[@N83N *-OB?Y6)7:^UE^</V7_P!D;0?V3+&YTSPYK>KW.G7,LEP]G?M8
M21BXD6%#.'ALH9]^R%4"F4PX+'RRY##ZOHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MK/U;5K'0+&XOKZXBMK:VB>:::9UCCCCC4L[N[$*J*H+,S$!0"20!7G_@KXW_
M  Z^)5\]CX<\2Z1JMS'$9GAL-0M;F18U95+E(9'8(&=5+$8!91G)&?4*****
M*\/^+W[1OP^^!,+S>)[^6VCCBCFF>&RO;M8(Y9?)B>Y-I!,+=)I T<#3^6)W
M21(R[1R!?8-)U:QU^QM[ZQN(KFVN8DFAFA=9(Y(Y%#(Z.I*LC*0RLI(8$$$@
MUG^*?%FA^!M+FU36[^VT^R@V^;<WDT<$*;W"+ODD947<S*JY(RS!1R0*S_ ?
MC_P[\3]&CUGP_>Q7UC++<11W$))CD:VGDMY"C8 =!)$X61<I( '1F1E8]A11
M117/ZCXLT/2-4L=+N[^V@O=0\[[);2S1I-<>0@>7R8V8/+Y:D-)L#;%(9L#F
MN@HHKG].\6:'J^J7VEVE_;3WNG^3]KMHIHWFM_/0O%YT:L7B\Q06CWA=Z@LN
M1S7045GZMJUCH%C<7U]<16UM;1/---,ZQQQQQJ6=W=B%5%4%F9B H!)( KC_
M (>_%7PA\6;>\N?#.JVVJ6]G<_8YI[.02PB;R(IRB2KF.3"3QEFC9U5B8R1(
MCJOH%%%%%%%%%%%%%%9^K:M8Z!8W%]?7$5M;6T3S333.L<<<<:EG=W8A515!
M9F8@* 22 *\?^'/[1OP^^*OB+4?#FCW\O]K:;%'-=6%[97NGW4<<H!5_(OH+
M>5DPR%F56""2+<5\V/=[A7E][\:_ 5AXMMO"+ZY8G6[F4Q)IT<Z27086KWF9
M(4+/$GD1M())0B$%%#%I(U;U"BBN/\:^/-&^'UBEWJ<DH6640Q16]O/=7$TA
M5GV06UM'+/,X1'E98HW*0QR3,!%&[KS_ ,(?C1X*^/7AU/$'A'4XM1L6EDA,
MD:R(R21GYDDCE5)8W *L%D52R,D@!1T9O4*\O^*'QK\!?!6Q%YXLURQTJ-HI
MY8Q=3HDDRP*&D$$6?-G=0R_NX5=R610I9E!]0HHHKR_P#\:_ 7Q5OKVS\,:Y
M8ZM)8Q6\MP;"=+F.-;EIEB!EB+1;V-O)F,,70!69562,MZA1111117/Z_P"+
M-#\*?9/[4O[:S^V7,=E;?:9HXO.N)<^7!%O9=\K[3LC7+M@X!P:Z"N?_ .$L
MT/\ MS^POM]M_:7V;[;]C\Z/[1]G\SRO/\G=YGE;_D\S;LW_ "YW<5T%%%<?
MXU^(7A7X:V*7WB/5K'2K:240I-?W,-M&TC*S! \S(I<JC,%!R0K'& <:'A/Q
M3I?CG0[#6]+F\^RU"VAO+:7:Z;X9XUDC?:X5UW*P.UE5AG! .17044445S^H
M^+-#TC5+'2[N_MH+W4/.^R6TLT:37'D('E\F-F#R^6I#2; VQ2&; YKH***\
MOO?C7X"L/%MMX1?7+$ZW<RF)-.CG22Z#"U>\S)"A9XD\B-I!)*$0@HH8M)&K
M>H444444444445S_ (6\6:'XYTN'5-$O[;4+*?=Y5S9S1SPOL<HVR2-F1MK*
MRM@G#*5/((KH*****S]6U:QT"QN+Z^N(K:VMHGFFFF=8XXXXU+.[NQ"JBJ"S
M,Q 4 DD 5X_\.?VC?A]\5?$6H^'-'OY?[6TV*.:ZL+VRO=/NHXY0"K^1?06\
MK)AD+,JL$$D6XKYL>[U#7_%FA^%/LG]J7]M9_;+F.RMOM,T<7G7$N?+@BWLN
M^5]IV1KEVP< X-=!11111111111111111111111111111111111111111111
M11111111111117Y8?$37H?VG?VL(?A??R2_\(]X3T@ZMJ>GR>;]GU6ZE>SE@
MCN$2X$4UO;F:TGC$T3#SH[B)XWBE##Z _;P^&4/C'X3:QKUG=2Z;K?AJQO-6
MTS4[5I8[JV:"!GN(XI89(G5+J!'MY1N*8=96CD:*,#Q_2_V]/$4WPV^'GC2/
MPM%J-MXKOK'1)4@OQ:W2:E+-<6\XM[6:*2!K??:N;=IK^)F#QK+Y(#R#Z 3]
MH'Q5X5^)/AGP7XNT"QM)/$T6IFQN-+U6:_59--ACN)%N$N-/T\HC1NVQXS,=
MZA3&%8NOG_C_ /;4F\*^!KWXBZ=H$5_X2T^^-E->_P!IQ+=7"QZF-.EN=/MH
M(;F"XM]YW0M/=V;S!7S'''Y4LOV?X3\4Z7XYT.PUO2YO/LM0MH;RVEVNF^&>
M-9(WVN%==RL#M9589P0#D5Y_XZ^*G]BZY;^%]"AMM1\0W-L]\EC/=_94BLXI
M%CDNKF58KB2*(NRPQ;()I)IV"K&(8[J>WX#P+^T=]K^(=Q\._&%C;:)XA^S)
MJ%C#!?\ VVWU"S96#26TSP6LGFQ/%,LMO+#'($C,\?G0AWC^3_@KJWQ%\8_M
M"?%C3-:T;2+RV>+PQ8ZA:W&KW4]O;6<MC<,8K59-+VW22+-/++!*EG'YTCKN
M<2O*/U/KX0_8T^+/Q%^*VL^/YO$=I8QVUEXIU'34-OJ%U.;>2Q@LK86T$,UL
MBFW*HT[7 EA,EQ)(WV&(2$K\H?L;?&3XA_"']D;3/$&D^$;;5--T:VU6YF:?
M6%LKB9(]2NI9Y+>%;2YC:*)"<F::"=WBF5+=U\A[C[_C_:6M_%G_  C=CX2T
MW[?JGB+1!XAM[:\NX+-+6Q/V;$M^\?VJ:+S#<"*'[/;W8DG21"4BCDFC/V</
MVG-+^/\ <>)-(:U^PZUX8U*;3-3M4D>XA5DGFBCE@N6A@\Z*7R),;HXI49&5
MH@OER2>G_&+XG+\'/"MYXCFTJ^U*VL8I;BZ2P-IYD-O##)-+.1=W-LK(BQX*
MQL\Q++MC8;BOS!<_M@^+=,^'6F_$>[\ 7P\/2V-O>WOV>_M;C4((IK7S_M,%
MI&/*GLE+1JTLMS:W4:&2:2QBBA+-H:U^V1?S>.&\(>&?!6I:U>OHEQKMI)%?
MZ-';W=M]H2WL[B&8WSI]DN6+DR-BYB3RV%G*)&\K0N_BMH-S\5/ .G>,/!E]
M8>);^QU :7=22V%W:VTC6$%WJ<4<L5V90\81;4W#6L9D(=8F^SRR,QJW[27C
MVS^,-Q\-+7PE8W%VVD/K=K=#6W2W^RB]-JINPVG>; [!3E;=+XK,T,?,+2W,
M'0> _P!J&&_U'QYI?BRPBTBY\$16MUJ,EK<RZA:FUNK$WJ2Q2&UMIV=$CD$L
M7V?(*KL:4N0O/_\ #2WCW1X?#NKZ]X%ET_1]>U>UTM#]N>74K-;^5XK*XU"R
M%FL%LDC^0LR?;7>W:=(B))QY1T/@Y\4?"?B'QG\0H]+\(ZEIWB2P_LRYUF&Y
M_LXW%X\M@18Q1317\]N<00!41IH8(WE+$J\D[US_ (*_:N\9_%VW\3-X0\ W
M,TN@:E=Z9(NJZK862RSV4$336RO;F^(N_.D\N)2OV%XE\YM0C<^0.@M?VS?"
M&K^!-/\ $=I;7,5WJ>MKX9MM,OU$%S%J\EP]NEK?"'[3]CV[#/,7#R1VV'6&
M25XX)._\"_&NXU+QQ<>!/$EG;:?K\>FIK4<-C=3WUO+8O<-:EQ<2V=D5E29-
MLD+1 ;)(GCDES,L'@'[ O_-5?^RD^(__ &VK[?\ %.LWGA_2YKRTTVYU.6/;
MMM;-K99I-SA3L-W/;0C:"7;?*GRJ0NY]JM\8> _VP?%OQ7^'T?CSPSX OKO2
M1+<.Z/?VJWEQ:PWLEN9-/M81.;BX2.)Y)K6X>Q/F!8+:6\W"2N@TG]L.Q\4>
M+?AQ8:/IT5UI/CRQO[JVO?MJ^?:R6%J;B>":VCBEB+H2D+[;DE)A,C(/)!EZ
M#X4_M$^(O&_BWQSX6U7PY%;ZCX2BTV1H]-U$7JWC:A:RW4<<+W5MIRHX5%3,
MI1"[G+HB[SY_X3_;#\8?$N;4QX6^&NKWT>D^('T2^:74M%MFB%M%$;M@KWC"
M2XBDD*1PHQMYD"R?;HV9HDT/!7[5WC/XNV_B9O"'@&YFET#4KO3)%U75;"R6
M6>R@B::V5[<WQ%WYTGEQ*5^PO$OG-J$;GR!Z!X6_:V\#^*? D/BH+<VC3:DV
MB)I=X+>'4O[4%P;=-.> SE(KN1@K+'+(@CA<3S-#"LDB<_XP_:7USX):IH__
M  LK1]-T?2-6N3I\>J6.L27L-O>,ADACNTN+"P>**94EQ<)YL<+1_OO*C;S5
MS_%O[56K'2?&.N^$=%L=5TOP=+J%KJ4M[J5QI\[76FVXN;N*VA73;M9$166-
M99)81),L@"^2L<\OK_C[XPS:#XJLO!V@V,6IZ[>V-QJ2PS7D5K;V]K;S0PM-
M=R!9[B-)7F\NV\FUN#+,CJ1'&DLT?@'A?]OOP5+X2\;ZOXBMY=/N_ ]]+8:O
M:6QDO%,GVJ2UMC:3&*W$R7,D9C0R);F-PWG+%"%F?V_PO\2_''_"<6?AGQ-H
M>FV7VW3;_48)].U:XOO^/&XL87CD2;3;';N^W(RLK/\ <8%1D&O<-6U:QT"Q
MN+Z^N(K:VMHGFFFF=8XXXXU+.[NQ"JBJ"S,Q 4 DD 5\H>*?VC?%^D>$)O'N
MF^%[:_\ "T5LNIB8:L8=2ETT 227D=E)9?9_]1NNH8)+V*:2$(DBV]TS6T?S
M_P#\%!OB]<>-/V6M5\1^![NVN]%U.VMA-J$-[/!,L,U_;0F.*%;=O-\W=+;W
M<,TMJT*^9&Z2-OB'W_X%MM<N?M&H^(-(TW3]2EV6[-IUW)>^9;P[GA$D\ME8
MR?(\TY6+8R)O9U?=*ZK\P?MN?%3QQ\-+/P3;^&8;9O[:\7:-ID\DUW<6S_-<
MK<) K0Q2;8KCR&ANI6\S9 S1BUN/.)A\O_::U7Q%8?'SX'7,6F17.J&+Q2#:
M170$ GDTJ!6!N98HV^SQ,Q>280&8PHS1VLDQ2W;W#P?^T_JD7Q+UCP)XXT.V
MT&XT_1!XACOH-42\L9;%91#/*\LMO920>4YVGS8@"(YG)2-8GF\_\:_MS_\
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M7$MG9%94F3;)"T0&R2)XY)<S+!XA\)OVL?'OQ3\!>-?$*>!XH-1\+WUWIO\
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MK7?B6YTM6.GRV\\NGV:7<-Y/?7ML\T,L,4,4)0I($D-U)!:[5EF4#YP^(/\
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M/&/]J7]M9_;-$U6RMOM,T<7G7$MA<>7!%O9=\K[3LC7+M@X!P:^3]._:'OO
MW[,WPZU/PA<17MM#%H6D^(+RPA;49-'LTTH/J%R4MQ,L-Q9JJ.1<Q31QDJ);
M>0.%//\ PXU;P?X6_:TMM0TJXU>;2]3\&OIUE=ZB^M7HO;L:S!(ZV%QJ)F>Z
MMU@DCN6EM'DLX[<R7A=81-,.@^,'PG\1:;^T!J^E:9)++I?Q5\/M9:DNP/\
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MDP_9_M.]QY/G9'E>9M\S(VYS7/\ QJTWX">/?BUK]Y>^)+;P'X[\,7-DEKK
MOX;9[E)=+CF@EF@NA';746;A[>XA!:=X+>.*2>.WF2*OM_\ 98U_XA^*?A1X
M?U#X@6GV37YK8M=QF-86XD<1/)$I(BEDA$<DT8">7*[IY4.WRD\ _P""@G^A
M:7\.]4F_=V6F?$#P]>WMR_RPVMNCS(T\\A^2*(-(BF20J@9U4G+ 'Q_X[?M
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MUA\&?VU/ G[2/D0^ 5N=2NA]EDOXY[>XM$T^&;ES<W#Q-"TJA7CB@MWG:XG
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MBF+4M)U[5[236_#(NH;Z*VT][7$VHA9W%]8/"J#SO.??-=26MNX_=Q6DF_\
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M1OYA%,?M$I2222-2B%#"SR))[_\ M8_\D0\>?]BWK/\ Z034?LG?\D0\!_\
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M.H:1>:;I/_$OU'6+_4+ZPO$GU'[1]HBOKBY>V\U6@1-DACG-L\B;HPDLG/\
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M8((CJ,EN1<2QW5H]U+;W*7T*6US+%<2/NNE[#]FK3/C5X=^*_B:VU72M2L_
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M]<EMKB+6;^R6(Z;]KBMLQ6,UM%<.# LDD]VMQ<3.S"69XQ'&GT_%X@\9>/\
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M$?3?&ESK&K+/?6MW]HAN-5CEAFLBD4WE^5L\AH[_ ',\3I*&TZX61#$?$?\
M9C^*=[X0^&OA72)-$OXO!.I:+J9O+JYN].:Z_L@30QVXM8[741'OA,6^X^T/
MF42$6R(54>H?MC_"'XB_M%?".?P;I%MI%O<ZK%;&]ENM1NECM9+>YMKG;!Y>
MGR-=(S1/'OD%H5&Q_+)8HFA\??@[XX^./ACPK<>7IMEK7A_Q)IOB'[']LN)K
M.?[#+*/(^V_8XY8]\4F_S?L;[)!Y7ELI\X>?_$3X3?&_QG\3_!'C/[#X;?\
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M.?&EYIGA]H_%,6FD6\6M7K-;R:782V\2EVT=!(D\C)YCX0VZ%F6.X90C>?\
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M!V<QWD?L'PR\ _$75;[3]>^)-[I$^HV$5REM9Z);W26<,EPP1KAGO)I7FN!
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M4+)&J.B,OO\ I.DV.@6-O8V-O%;6UM$D,,,*+''''&H5$1% 5450%55 "@
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M)K&MZSXF\2Z;=03->?V<L*V=E]B62X=+:TLD78R65LHCWR,TX?R619YX>?\
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M2US0/%URGAX7DL&CQ7VDZI<%A:3PF"UMX;B*8,_F136THA-L)?,??]EFY_\
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MD.$E\F1I0DOEL0LFPML8A6P>*] _X2S0_P"P_P"W?M]M_9OV;[;]L\Z/[/\
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M3/B%X5UKPZWB.SU:QGTE8IIC?Q7,+VHC@+"5S.K&()&4<2-NPA5MQ&TX\O\
MV=_VC_"'[2F@3:MH%[;2^5<W43P13B2:.&.\N(+6::)ECE@^U10"XCCFC1@K
ME<OL+'Z HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKS_XL76EV7@?7IM4
MU"YTRRCTV]>YO;)G2XM85MW,D\#(DCK+$N9(RJ.P=00K' /Y@?%KQ'KFC>&_
M@C#X=M_LWAF'Q=X6L]*U%]1D_M*[LS:S6J-/:Q6D4445W;,['_2#(T,BI-:0
M/+-;P?0'P[\1Z7\1_P!JWQO::T+:2]\(Z;I%OH<;R.7BAO[9KC4;F*%Y&3S7
M::WMYKF*-66 00%@)&\WR_\ :UL/!7P!\.GP_8W<5M8^.?'>E3>)8Y[Z2)H;
M/5BWVUUD26*6WM[L:;,LC2,T91[V-"B!5A^W_%?PA\!)K/A'Q#=)%ITGA662
MVTKRI$MK=%U& ::+3RN(BDA>%($4*XF2&.-@K/')^:/P.^!'B_\ :V_9B%C_
M ,)/IMI9>++FYU/49V\-E;^2^&K-/<2/+!JR6\G[^#RHY/LZ$VB1)Y<14*GI
M^K^'_BSH^O>%O&WPUUFQ\;2:1X6M=$OM.U.XGM;B]@>_02:K9O-,8E?4#9NR
M7DS-#-#:K+$^H*8PI-+#^TK\*]/'PRU671-4TWQW<:@VG>*4EM6FU*WO[G6+
MC3+N.V.YD1IOMB1Q"=E2V17*31RS0>P?LV_&:;QG\1=3TGQEH=]X?\=?\(_I
MAO[)_*ET^:UL[J[*76GSQ-*'0R7Y699)"8W9;=#*]M<2G[OKX _YO>_[IM_[
MGZT/V+O'\WQ!\1?%*75+V*[U2Q\9:AIH!,7GPZ;:!8K"$JH#+;JPNC#D!7F:
MZERTTD[MG_LA^'-4^''Q/^*OA"S-R/#.F:EIMQI,,D:+;VTVIVC7]];6K)&B
M)%&T\)6V3Y8$=&V[YGDE^_Z_+#XCZO#%\,?C+%X$,NNVTLOB5]?OM:U"6W:T
MOAI_V>>RL(UL)'N$LX(8@B2F&W"-!%%>3#S1:_;_ .S)JU]K_P 'O!=]?7$M
MS<W/A_29IIIG:22222RA9W=V)9G9B69F)+$DDDFO<*_.#]A"'PQ^T1\%=5\1
M:Q!;76I>,;G58_$9AGE9VWSSP16;.9GG@BALGB2U@$B^3 ZR)AI3(^?X'\0:
M3X4_:1\*?#FVUB*[T30_ CQZ5#/+;R,=2M+]]-FD5D5=][':VEQ#($ :!!>H
MJ1+)<JW8?$3PYJG@K]JWP1JOATW,47B?3=7M_$,,$:&WFATFV5K.YN L>1*D
MUU' +EVW!/)MD9$D=)?G#]EW2;'3O^"?.KS6]O%%)=>'_%<T[QHJM+(&OX0\
MA !=Q'%'&&;)"1HF=JJ ?M!Z38Z+_P $[;.&SMXH(V\/^&)BD2*BF2>[T^:5
MR% !>21WDD;J[LSL2S$GT_\ :?\ A/X'\0_M._"3^T-!TVY_M?\ X2;^T//L
MK>3[9]ETF'[/]IWH?.\G \KS-WEX&W&*/VI?#FE^!OCMX<\169N='BUKPWXM
MM_$^JZ7&_P!H33;#3X)8;DND<IBEMYC#Y-RB><7%O;[I$$<->?\ Q:\1ZYHW
MAOX(P^';?[-X9A\7>%K/2M1?49/[2N[,VLUJC3VL5I%%%%=VS.Q_T@R-#(J3
M6D#RS6\'N%[I-CJ/[<EM-<6\4LEK\.S- \B*S12'6GA+QD@E',<LD99<$I(Z
M9VLP)\#M)L=?_:/^.UC?6\5S;7,7A2&:&9%DCDCDT>971T8%61E)5E8$,"00
M0:\ ^#5]XB^ NC>-O@"UW+#=P7T%MX6NEG"7CZ;XAG=&N[:.."VEN7TD-/?7
MDT)*K(D\7FVT,"RK^OVDZ38Z!8V]C8V\5M;6T20PPPHL<<<<:A41$4!515 5
M54 *    *^,/VN/!/Q+US7_"6O\ P[U'37UKP]_:]_%HFJRRI#J"RV8M&E58
MY8]TMOYXAB9RD2->_/<0J2LW0?LL_%G0_B1J_C2#^S-2T;Q#!J5I<:[I>I"-
MOLUQ)IEM:1FUFB'ESVDB6.89<[Y<-/L2&: 'Z_K\\/V?-)L9OVJ_C5?/;Q-<
MPQ>%88YBBF1(YM++2(KXW*CM#$SJ" QCC)!*+CY U'Q_XB^&'[/?Q_UGP_>R
MV-]%\1-8BCN(2!)&MS?:=;R%&P2CF.5PLBX>,D.C*ZJP^_\ ]K/P5X5\8_L[
MZO-I#Q06VCZ1_;FB76E&%!;2:9;F[LI;*6-66)-L:QJ\&T_9Y'2-T#AA\W_!
MU-4\5_M/>$=2\5VV_6D^$EA>7!NK9(IH;Z74!'<.(]B>1+^^FC=45"JO)%@*
M66O0/A!X3T/QS^T3\==+UNPMM0LI_P#A#O-MKR&.>%]FF.Z[XY%9&VLJLN0<
M,H8<@&N/_P""<WP4\!>._P!E33+/5M#L9X]>BOHM3)@1)+I8-4O%@,LJ!96>
M$8^SR;M\!"M$R,H(\ _9XU/Q%JVH_LNRZ\LJW*V/C&)!+"(6^RPV/E61"A4R
MAM4@,<F"94*REG+[V^S_ -GC_DYWXW_]RC_Z:9:\O_8Z^"G@+XEWWQ2O/$NA
MV.KR1_$3Q%%$-2@2[CB4- Q,,4XDBA=RP\V2)4>8)"LC.L$(3Y0T+PYJG@3P
M)X.\+RFY;3=!^.T.E:.]U&BL]C;W%P-P=(XUFS<&YWR@$>:)(QM6,1I]O_';
MPGH>D?M8_![5+2PMH+W4/^$H^UW,4,:37'D:/&D7G2*H>7RU)6/>6V*2JX'%
M=!\._$>E_$?]JWQO::T+:2]\(Z;I%OH<;R.7BAO[9KC4;F*%Y&3S7::WMYKF
M*-66 00%@)&\WZ?^&'PW\(?"O5/$=IH<NVXU?4G\0WMLTXD:.:_186E5#^\2
M*=[25UWEE\T3K&1&@CC]@K\X/V3_  GH?@;]HGXTZ7HEA;:?90?\(GY5M9PQ
MP0IOTR9VV1QJJ+N9F9L 99BQY)-:'[ .DV,-]\6KY+>);F;XB:_#),$42/'"
MT31HSXW,B--*R*20IDD( +MGX0_YQB_Y_P"AKK]#_P!OOQ_-X%\.^#8I;V*T
MTO5?&6BZ;K!G,2P2Z;(9I;J&X:4;5MW6$"XR55X?,BD)ADD1L_\ X*.>'-4C
M^&$/B_PV;F'Q-X;U*PN-&FL8T>X,U[=PV$EL%,<CR17"W&)+9?EN'2)9%D0&
M-O'_ ($_L]?"S5_VB?C#I=WX2T2>RT__ (1?[);2Z9:/#;^?IDCR^3&T12+S
M& :38%WL S9/->H?L^:38S?M5_&J^>WB:YAB\*PQS%%,B1S:66D17QN5':&)
MG4$!C'&2"47!^P#I-C#??%J^2WB6YF^(FOPR3!%$CQPM$T:,^-S(C32LBDD*
M9)" "[9^</V7KKPA:_LG?"QO$>H:E;;?$@DT^UTQ@K:EJ4&L7\]G82[T,1BF
MEC#?OWMX5ECB=KF':''O_@7Q'XXN?VPKBS\06]MI_F_#])6M=.U&XO;>3R=;
M989I#+:6/[U/.G11Y3;$=BLG[UU4_8N\)Z'XYTOXMZ7K=A;:A93_ !)\0^;;
M7D,<\+['M'7?'(K(VUE5ER#AE##D U\H> _'_B+X8?\ !-Z/6?#][+8WT45Q
M%'<0D"2-;GQ));R%&P2CF.5PLBX>,D.C*ZJP^_\ ]K/P5X5\8_L[ZO-I#Q06
MVCZ1_;FB76E&%!;2:9;F[LI;*6-66)-L:QJ\&T_9Y'2-T#AA\W_!U-4\5_M/
M>$=2\5VV_6D^$EA>7!NK9(IH;Z74!'<.(]B>1+^^FC=45"JO)%@*66O8/V>/
M^3G?C?\ ]RC_ .FF6OO^O@#_ )O>_P"Z;?\ N?KR_5O@A\.M?_;0N+&^\-:1
M<VUSX$?4YH9M/M9(Y+R372KW3HT95KAE)5IF!D8$@L0:]P\-G2_"7Q/\6V/P
MZA_M35X;;0[74M/U"]?3M+T>TMK20Z?;61BL+AU\]9Y9A!!'-;J5G:26UD,4
M-Q\(?#GQSJU_^R!\)M"O)I;FV\4^*;+POJ!DGN%E.FR:M>*]O'+%+&Z(T%LE
MH5R5%JSPJJ@J5^K_ -NCPGH>C?\ "GOL=A;0?8?B!X=LK7RH8T\BW;S,P0[5
M'EQ'R(<QIA#Y4?'R+CS_ .%7@+Q?\?[?XPQ6.OZ;:_VQXDUWP]J4MWX?,UVL
M-K MA;1075OJEJLD4-FT9B\ZWW)</<%A+N,DF?<?!3XB^"O"O@2P^''B^Q\1
M:WX EU]%L]8%U;V^ICR3;,(5%R5D?35NDTZ,B4V]M-*]O)<VK12VQ^L/V6?B
MSH?Q(U?QI!_9FI:-XA@U*TN-=TO4A&WV:XDTRVM(S:S1#RY[21+',,N=\N&G
MV)#- #]?U\ ?\WO?]TV_]S]9_P"SYI-C-^U7\:KY[>)KF&+PK#',44R)'-I9
M:1%?&Y4=H8F=00&,<9()1<?"&DV=OI7A#6_"=B;:QTW5/CM-H[VYTV"\M&A0
M1SVMM):-+;*;0W%M;+,D4L3"W5U7>N8G^_[_ . ?B31?CEX=^*/BCQK;&XCM
MO^$>33=*TBZM5OUG^TR)$P.I7LC^6\INY?D:***U^T.(HX))T^_Z^ /VO/$>
MEZK\3_A5X#\0BV?0-?U+4KB^AN9'C2YFTZT5K"VD'F)'-%)=SQ,;:59%GGCM
MTVGE'] _:6T#0_AQ;Z_\4K*[^P^)K;PCK.DV,C21E9?*@DU2)5@F#))+ UK+
M,H4?-$9S*LJ(GE9_P4\%>%?V@_V8]#T747BO+37/#\"7TT1AF=KR:(-=W!=U
ME4WJ7IEFDED5Y%O5:1\S!J^ /A#J?B+XGZS^S'?>.%EOKZ6+Q=.7U&$&21;:
M /87#>8H+N(XK>>*X.7D(2Y\QG;S#]?WNDV.H_MR6TUQ;Q2R6OP[,T#R(K-%
M(=:>$O&2"4<QRR1EEP2DCIG:S Y_P@\)Z'XY_:)^.NEZW86VH64__"'>;;7D
M,<\+[-,=UWQR*R-M959<@X90PY -<?\ \$YO@IX"\=_LJ:99ZMH=C/'KT5]%
MJ9,"))=+!JEXL!EE0+*SPC'V>3=O@(5HF1E!''_LT^(?M'PT^"-QXBNM2?Q5
M#;:P/#^CY^QVE^D<4EG%->'[,R+%::;(DT5Q_KVMWEDACOII1#+[A^RGK_BK
M4?CY\9+77DBMI(Y?#$QL[6]FN[6*272F1GB>6"U)>6.&#S6\B,DHL9+K&C'P
M#]EW2;'3O^"?.KS6]O%%)=>'_%<T[QHJM+(&OX0\A !=Q'%'&&;)"1HF=JJ!
MU_Q%^".J?%7]DWP!K?AM,>)O"FB:%KVC2I"DLIFM+&WDD@53!.\GFJF4MU4+
M-=16HD)12*^D/@I\4+']J'Q%H?BRS$1L=,\/P71CBG6\@CU760/-@,BA4CO=
M,M[9X9/E\_R=68,ENCE;C[/K\8=!\1^+_P!EOP39Z/\ $P?V_P"!!J6GZO8^
M+_#\ANIO.DU[^UHIM5CFDED:*=PDDL]LLJA72".6ZN+A'C_9ZOE#]KSX>>*O
MB3X=T*T\+:U8Z;JUIX@T[4[2#4I)DM=0DT\R70LYA PE= (C=[$60DVH.U-O
MGQ?+]C^T=K,-C\0)->TF^\,?$?3_  )]MFMW6"XT]X],74)8+S3Y5,Z2H)[W
M]\DSN%<K;CSFM[F0\?<_LI:Y\6_V?/!5G#XYTWP]H&CVVG>(K*\M]!DL+N#R
MK)Y5N;F8:V\,<N)WN+F6,+_I&Z42#DGW#X2^-=&^,/[3_C!M42)KGPSI&BIH
M$5R)X;B&WU.T:ZU"X%G<L&BN':>VM[B40Q31PB"VDV%W$GE_[>_PW\(?"O\
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M#- DRV<L:Q;[5GAA>/U_X._"JQ^#'A6S\/65]?7L-I%%#'+?S+)((X(8X(4
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ME]<:I<O(FB.POKF6%YKF/=I6U7=8?*,9#6ZH[E(5EV2)Q_A[]@KP/HGP\M?
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MJ_B:'198KFPAUL:;*L-U!$T,-V9+>QMYYKB-'D"O<2S#>_GE3<)%-'Y?H'[
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MS:IK=_;:?90;?-N;R:."%-[A%WR2,J+N9E5<D99@HY(%=!1111111117S_\
M$CX3_!"]U2+5/%^@^&Y+W4[F"RCN=5LK!IKJX=-D,"R7";Y92L>V*,%G*IM4
M87 ^@****Y_PMX3T/P-I<.EZ)86VGV4&[RK:SAC@A3>Y=MD<:JB[F9F; &68
ML>236?XU^(7A7X:V*7WB/5K'2K:240I-?W,-M&TC*S! \S(I<JC,%!R0K'&
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M/#M[XA\0WL5CIUC$99YY2=JKD    LSLQ"1QH&>1V6-%9V53\X?$C]HWQ?\
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MLB73KGQKXIDU^VT_4%BM[J%;W5K66&V=%EDW7'V6U^TRQ@AX098W0&!V/O\
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M$,<MA(F?"YB72Y)I5;[1=7*6T=NCVB+-<+&EW&;M[8V]M<>;)&]<?\-/VB-
M_8A^(?Q \+_$N&YTJRUKQ)J/B/2]86UO)[.[6]6V=[9/+MRYE@5HO,:,21"0
MRQLZ&.(W'J'[2&I>*K?Q;\/OC"=#E70O"U]JJWT<C3+?1:9JEK!:G4Y;1;=Y
M8T@"S7$EJ ]TEN(6F2WD:ZBLN@^/?BOP;^T;K/@FT\.:[8WECX=\00^*]7U.
MRNK.YL]/M=(@F=5O)5N5$+W4DBI#G)\N.ZN-I2UD!\__ &&/C?\ #K18?BG-
M>>)=(@C;QWKVIAY=0M44V<\MI#%= M( ;>21TCCF_P!6[LJ*Q9@#XA^SO\6/
M ^E_L#ZCI=SKVFPWL>B>(K)[:2]MTF6XO9-4>U@,;.'$LZJS01D;Y55F0, 3
M6?\ $#XW_#J]^#WP L8?$ND27.E>(/!4U_"FH6K26D=M9,L[W""3="D3?+*T
M@41GAB#7O_[1/QO^'2?M'_!R^/B72!;6,7B.:ZF.H6OEP1WVCP-:/*_F;8TN
M%96MV<@3!E*%@17F'[0OC#PWXY_:+\6Z)I>L:;/>ZA\+=3\-6T7V^U3?J\^I
MRQQZ?N>546[9F \AF609R5 R:/@7\2/V<?'OA"UT0?#[3=2\?66FF.^T9_":
M03-J5L!;RB>6'3WM+**6ZV@SRM'#;+*IF6$J\:>OIX^T/P_^VM;6VMZWIJWO
M_"O[;2Y6$L=LLFHS:PDJV\<,DTKI+,KK+#;&26;RG0@R AV\_P# 5[H?Q]^*
M7[16A>&=:TV[E\0Z)H]M82QW<<L,F=$FLY)0T/FEXH9IHTG>-7\MF52-[*I-
M#_:=^'FL_LBZIX6DU#[)K^E>$;WP_=:-=(R:DEY9:6UK-BS&Z9HE*F5YE4QP
M0B1YVA\BX6'S#P[J/[-?QS\.^"/#_C#58M!UG0_!OARZT[Q%#?G39UD0[;B"
MWNI8UM9'M)K=5^9K@Q337<<20W-K=,GZ/_L<^)/B3XG\%7LOC>[BU&2+5[^#
M3=4B@AMQJ>FQR 6U_P"5 [1*DQ\PP% JR6XAE7S5<7$WU?7YX?M6:M8^#/CY
M\&_$>L7$5CI-G+XGAN;^Z=8;6&2YTI1 DL\A6*-Y3&XB5F!D*-M!VG'G^D_&
MOP%K7[:%O>0ZY8K'/X$32T$TZ02"_?70PL7BF*2QWH!^:SD5;E#E6B5@0/F#
MXDZLOQG\1?M#0> 9['7[ZZB\$ZC806KVE^MW'I0@ENFBA8R17:1%0DL064.[
M+;E'>58V^G_A9\1_V:_C+#;3_";P9I%QXACEL)$SX7,2Z7)-*K?:+JY2VCMT
M>T19KA8TNXS=O;&WMKCS9(WK]3Z*_(#]@K]IWX>?"']F+P[;ZMJ&=2@^W+#I
M42,VHWKSZM<B!+"U;;)=^:\@A22'= )A+&\J-!/Y6!XW^#.N?LZ_L\_![3]4
M@N9_^$8\7:5KNM/;6LEQ]AMU>^O[UY1:_:,Q6GG&-YE)1]@<8WJE>OZ1\3M
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M_%.LWGA_2YKRTTVYU.6/;MM;-K99I-SA3L-W/;0C:"7;?*GRJ0NY]JM\@?\
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MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOF#_AF*+_A:?\
MPL;_ (2K6_[2^S?V?Y6W2?L_V#[7]L^Q;?[-\SRM_'F^9]KV<?:=WS5]/T45
MY?\ &CX0^'?CUX*U/PCX@25K'48ECD,,ACD1DD66.1&Y >.1$D4,&1BH5T="
MR,?"'X0^'?@EX=31=%25E:62YN;FYD,UU>74QW37=W,WS37$K<NYP,!414B1
M$7U"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOF ?L[2^(_&?B77?$&N
M:W);W]S:_P!G6=CK^K6-O:V\%A;Q/B&SGME666X$[R?-*A3RF79(TP;X?_9?
M^$7B']HG]EJQUI?%?B2#Q5J%MJ7V?43XEUI%%Q!?W,=OYD7VB6$1$11Q3;8&
M<Q%V3$VUQV'P5\?Z%\&_VA/BQHU]>ZO>1P1>&(K&W)U?7KQ8!8W%Q,54"^O/
MLZ371+R-^YBDN(T+(TT:M]W_  W^/WP\^+?A"7Q=H&M6UQI$'G^?=.6@6#[.
M-TOGB<1O!L7$A\Y4_=,LO^K=6.?X;_:-^'WBSQ%::#9W\HN[Z*>:Q\^RO;:"
M^CMPC2/87-Q!';WJ!'64-:23!X3YZEH<O7N%?/\ X[_:@^'/PYU34M-U*^N7
MN-)MH[S4!8Z;J.H+90RH\B/=R65M/';;DC>0+,R-Y0\W'EE6/H&O_%+PQX<T
M.TUJ6[^T6E[Y?V1K&*6^>Z\V,RI]EALTFEN<Q*TW[A),0)).<11NZ\?H7[17
M@;Q-8ZO<V,U]+)HTL$5]9C2M3&H0-<*CPEM.-J+XI(KATD6 HR+(P;;%(4X#
M3/VW/@_KOAUO$6G:E?7NEQQ32S7EEHNLW,$"P%O-%S)!9.MLZ*OF-'.8W$+1
MSE?)EB=_;]?^*7ACPYH=IK4MW]HM+WR_LC6,4M\]UYL9E3[+#9I-+<YB5IOW
M"28@22<XBC=UY_1OCWX$U?0]2UN34?[/LM+N5L[V75X+C2OL\SQP2(DJZC';
M.F];F HS*%?S4"DDXH\"_'?P9\1-<N-"T^XN8M2M[9+U[/4=/O\ 3;@V\DC1
M">.&_@MY)8@ZE&DC5T1RJL59T#9_B3]HWX?>$_$5WH-Y?RF[L8H)K[R+*]N8
M+&.X#M&]_<V\$EO9(41I2UW)"$A'GL5AP]9_B/\ :C^&'A;P(/'5SJ^_0#<R
M6GV^UM;N[AWQW$EJS$VT,I$1FB:-)R/(D8Q[)&\V+?T&H_'?P9I'CNQ\$7=Q
M<P:OJ'G?9(I=/OTAN/(MQ<R^3=M +67RXR#)LE;8Q$;8D^2M#QK\9/"7@"^3
M3KZZEEOGB$XL;"UNM0O/(+,@N#:6,5Q<+;[U,9N&C$(DVQF0.RJ> \2?M;?"
MOPKX*T_QK=:K*^A7\7FQ:A:V%_=VZKYB18G>VMY1;/YCB+R[CRG\X/%M\R-U
M6_:_M0?#FYU33[ WUS%_:=RMG8W5QINHP6-W-(CO$EMJ$ULEE/YRHS6S13.M
MR-ODF3>F[H/'7QW\&?#O7+?0M0N+F74KBV>]2ST[3[_4K@6\<BQ&>2&P@N)(
MHB[!%DD5$=PRJ69'"EK\?OAY>^$-/\6PZU;2:7J>U;*9"S-=2N'*V\$('G2W
M9,;H+..-KHRHT(A\U2@T/AS\9/"7Q6FU&WT6ZE:YTR6.*\M;JUNK*ZMVFB$L
M1EMKR*"=$D0[HI"@20!MC,4<+S^A_M%>!O$>LV&E6DU\TFHRO%93OI6IQV=T
MR02W.;>^DM5LYD:&&2:*2*9DFC7?&SJ03[A7Y :MK_@']LCXK^/_  =XTTG4
MKC3[>V\/Z;HLBZ'K"7-B]U'/<7%TS2VCG399)I(@TUPEM!<VUM )5GMXG+??
M_BGX[^ ?@S;S:??W&I/%I%LOVJ:'3]8U9;9(X!)_IEY!!=!)1#LGD^TR^>8G
M2XDRDJ2/T'CK]H'X:?#30[?6]=\2:;9V5W;/>6LLEU$?M4,<:R%[558O<_*Z
M%5MUD9]Z!0Q=03X:?'[X>?&35-6T[PKK5MJLND?9OM;69:6%/M2.\6R=1Y,N
M1&X;R7D\ME*/M<;:[#QKX\T;X?6*7>IR2A991#%%;V\]U<32%6?9!;6T<L\S
MA$>5EBC<I#'),P$4;NIX*\>:-\0;%[O3))2L4IAEBN+>>UN(9 JOLGMKF.*>
M%RCI*JRQH7ADCF4&*1';0\4^);/P?I<VHW<=S)%#MW+9VES>S'<X0;(+2*:9
M^6!;8C;5R[8168>7^"OVBO WQ'\%/XRT&:^O])64Q++;Z5J;R2LLBQL8+<6O
MVB=%=MK20QR(I60%AY4NSS#1OBC\//CCX[\(ZOH?CSR6M;;4)8]!2Y:SFU'[
M;;Q-#-=6-P8KAXH8$EN;</!\ZRQ7<<@A'[[W_P =?$[0/AU]G746N7EN=YBM
M[&RO-0N'6/;YD@M[*&>;RHR\:R3%/*C>6)&=7EC5N?T#Q9X,_:+\,7?]EW]S
M+:"YDLKG[--?Z7>6]Q:RCS()=C6M[:RJRC?&WE.T;#(:*4;OF#_@G)XL_P",
M8M UW7;_ /Z#-[>7E[-_U%KV6:>>:5O]YY)';U9CU-?5_@KXP^&O'U\]C9?;
MH+E8C,(=2TS4=,DDC5E5WA34+>W:9(V>-96A#B$RPB0H9H]WB'AC]KG0-<^*
M_B_PA<QW-G:>'+:S,MW<Z?>0PI,T=Y<W<D]TRFWM[18(H#;S7/V9;AO.:%[B
M)HG/?_L\#0[C2]:O=(\8_P#"5Q7VMZA>FX2^CO(;3SW62.P@,<DHBBMX3$!%
MO^\S2A8TE6-#Q3^U!\.?!5Q,FJ7US!;P7*V<U^=-U%M-BF:<6Y234EMFL4V3
M-Y$S/.%@F#Q2E)$=5/'7[4'PY^&GB>W\-:[?7-GJ%WO%K')INHE+IHXEE,=K
M.ML8;F7#HBPV[R2O.Z6RHUPZQ'H/ OQW\&?$37+C0M/N+F+4K>V2]>SU'3[_
M $VX-O)(T0GCAOX+>26(.I1I(U=$<JK%6= WL%?/_BG]J#X<^"KB9-4OKF"W
M@N5LYK\Z;J+:;%,TXMRDFI+;-8ILF;R)F><+!,'BE*2(ZKX!^W=\;D\ 6?A7
MPY]GN98M<\2:)9ZB%TW4+B*339+EY+BW22")H9I9Q;^1)8YFFN+665/LKI(&
M'N'[./P=^'WPQL=6U/P79WVGV>O7S7[V5U%>V<<$BJ('$%A=QPM:HS1L^/*4
MN&0*QM8[6.+YO_:N^-6D1_%KP#X"U;3;F^T6\N=5N=7MGT34[U+K[+I9>TBB
MCCMY(K^));@3S)"ES]GG@@E<P-"2?</AE9?"O]DOP5I^B:7<WT%I?RW-]I^G
MW O[O4'6>03R0VNGLCWVRW653+!'!O@0//<CSFN)W]O^&_Q2\,?%O2Y=1T"[
M^T107,]E.KQ2P307%N^R6">"=(YH)4."8YD1]K*^-CJQ_,#_ (*$_'[P#\1O
M@3KU[X<UK4A<1?Z%9W5L=8LM.O?,U"&UO8(YP(=.U/,27 $8>Z_<I<2Q#RTF
M<?I?XU^,GA+P!?)IU]=2RWSQ"<6-A:W6H7GD%F07!M+&*XN%M]ZF,W#1B$2;
M8S('95/'ZC^U5\(-(\(6/BV[\4Z;!I>H6TUW:32W"HUPD !E6&%L32RQDA)(
M$C:=)2(6C$OR5H>"OVE/A=\19M=30_$5C>1^'XH9M1N(I<VL$<T4DJ.;H@6[
MH$BD,C1R.(BC+(48$5T'@KXP^&O'U\]C9?;H+E8C,(=2TS4=,DDC5E5WA34+
M>W:9(V>-96A#B$RPB0H9H]WR!^RW8-H'[0GQ@TA+N^N;;3XO"D-L+^^N[^2.
M.2QNKED$UY+--L\V:60*7(4NV  <5^A]>/\ A;X[^#/&6J0Z?87%R6N-WV6:
M;3[^WM+O:AD_T.\G@CM;O=&KSQ_9I9?-MT>XCWPH\B\AJW[6?PST+Q5<>%;N
M\OH]8AB>9;$Z/JQN)XTF,+/:1BT+7B;E=@UH)@88YIP3!#+(G?\ PY^,GA+X
MK3:C;Z+=2M<Z9+'%>6MU:W5E=6[31"6(RVUY%!.B2(=T4A0)( VQF*.%_-#_
M (*$_'[P#\1O@3KU[X<UK4A<1?Z%9W5L=8LM.O?,U"&UO8(YP(=.U/,27 $8
M>Z_<I<2Q#RTF<?K_ %Y?XU^,/AKP#?)8WOVZ>Y:(3&'3=,U'4Y(XV9E1YDT^
MWN&A21DD6)I@@F,4PC+F&3;XA\<OVN= ^&'ACP?K>G1W-]%XKU+2+>QEAT^\
MG0VUY+#)+(RQJLBRM:-(;6 *US+/M"VTJ1SA/;_$GQA\->%+'3[J[^W%M0B\
MZWMK?3-1N;PQA49W>RM[>2[C2/S(UF:6)!!)+%%(4ED1&S_%GQQ\,>$_AY?^
M.B;F[TVQMIKF1;2VEDN/W#,DL30%5DBEB=6CG2<1?9723[28%BE9.0^#7[0^
MC>-OA-I7C?Q#<1:3')8V,M]-?0SZ;:QW%Q! S>2]^(P]NTDP2"='EAE)"I-(
MP-=?X%^._@SXB:Y<:%I]Q<Q:E;VR7KV>HZ??Z;<&WDD:(3QPW\%O)+$'4HTD
M:NB.55BK.@;T#Q3X:L_&&ES:==R7,<4VW<UG=W-E,-CAQLGM)89DY4!MCKN7
M*-E&93\0?\$Y/%G_ !C%H&NZ[?\ _09O;R\O9O\ J+7LLT\\TK?[SR2.WJS'
MJ:^K_!7QA\->/KY[&R^W07*Q&80ZEIFHZ9))&K*KO"FH6]NTR1L\:RM"'$)E
MA$A0S1[N/\)?M0?#GQYKGB+1-%OKF]O?#?GC4XK?3=1?R&MY'C>,,+;9+*6C
M<10PM)+/L<Q)(%8BAX;_ &L_AGXN\%:AXTTZ\OIM$T^+SIKT:/JRQF,2/&[Q
M;K0-.D31O]H: 2"W"LTQC49KK[[X[^#+/0](UA+BYNK?6;9+VQ2QT^_O;B:W
M>..3SQ:VL$MRL2B6(22/$J1/+%'(4DEC5NP\!^/-&^)6C1ZOI$DLEM)+<0@S
M6\]M(LEM/);3(\-S'%-&\<L3QLLB*05/&,$\?\2/V@?AI\'[B*V\4>)--TRX
ME\@I!=744<S+//Y"2"(MYGE;\AYMOE1JDDCND<<C+S^D?M3_  HUG5)]-'B"
MVM[B*V-\HOA)9+/:!)I#=VDEVD,=Y:!+>:0W5JTUN(D\WS/+*L<!/VT_@;<Z
MI;:7;>+]-NKNZU*VTF"&SE^U-)<W2(T000"3,1\Q4:Y'^C)+F%YEE5D7T_QK
M\8?#7@&^2QO?MT]RT0F,.FZ9J.IR1QLS*CS)I]O<-"DC)(L33!!,8IA&7,,F
MWX0_X*#>,- ^)O[+6J^./"^L7,MNUM;"UN-/O[RWAEAO;^VM;F.X@BECCFRA
MDADANXW:!C+'LCD\P5]81?M;?"M_$6E:#)JLL%SK,KQ::]S87]O:WS* 0;2]
MFMTM+E'W)Y,D,SI.98A$SF:+>>&]5\*^*OC#J%_IOCB*]N;32/[,E\.VNHPR
M1V\D%Z[7-Y/:I*["X#/#;;RD9A"O&[2&5%B^+_AU\6/!G[,WQB^,=QXKUZYM
M](TW_A$;*UDU.]O]2F7[18W5QY$33O=74N9)IIO+3?L4RR86-'*_0'Q ^/OP
M@^/_ ,, VE_$NV\/6FJ7*11:E%?KIEXOV&[MY;N&'[2]O+%*T6(R64[([F.8
MQRQ2(LGH'[3W[2%G^SO9^'M]K<W%QK>MZ=I<7DV-S=(J2W,?VDM]G&[S?L_F
M_984\R>:?;Y=O-''/L-0\4>$/'GQ/\+O;>-OL5[I]M>R-X<6[%K<7C7UI#)"
M;ZPE=+C_ $: 23I!+ LL;R+*6C$3I)H:M^UG\,]"\57'A6[O+Z/6(8GF6Q.C
MZL;B>-)C"SVD8M"UXFY78-:"8&&.:<$P0RR)W_PY^,GA+XK3:C;Z+=2M<Z9+
M'%>6MU:W5E=6[31"6(RVUY%!.B2(=T4A0)( VQF*.%X_Q'^U'\,/!^J"QU?5
M_L*M<R60O;JUNX=--Q$DC20#4Y(5L/-3R98WC^T;UFBD@($R-&/8/"WBS0_'
M.EPZIHE_;:A93[O*N;.:.>%]CE&V21LR-M965L$X92IY!%>(>&]5\*^*OC#J
M%_IOCB*]N;32/[,E\.VNHPR1V\D%Z[7-Y/:I*["X#/#;;RD9A"O&[2&5%BS]
M._;%^%NKZI?:1;76I2ZE8>2;G3UT+6S?1+,A=)&L_L/VGRL;=TPC,49E@5W5
MKB$2=_H'Q[\">)_#%WXDLM1WV5G<R6-P&@N([B*[CE$!M'M)(UNENVD9(X[4
MQ?:)GDB6.-S+'NS]*_:-^'VHPZG-<7\NEQZ7%:S7CZW97NCK%'>2RPV[DZG!
M:@I+)#)&K+D%UV9W$ G[-VD6.@_#;1K2S\4R^+(XXI =9ENENVNY/.D,K"97
ME!1)"\4:>9(8D186D=D+'\\/^"A/Q^\ _$;X$Z]>^'-:U(7$7^A6=U;'6++3
MKWS-0AM;V".<"'3M3S$EP!&'NOW*7$L0\M)G'Z?^.OBEX8^&_P!G35KO9<76
M_P"S6D$4MU>7/E;3+]FL[9);FX\H.'E\F-_*CS(^V,%AQ^F?M*?"[4?#K>('
M\16-G8I?3:9))J4O]GM%>0EO,M9H[T02PW"A&;R9520IB0*4(8Y_PT_:G^%'
MQDUR/1/"WB"VU.]DTU=6\JV$C[+9I$CS*VS9%*&D0/;2LES'N!>%1S5#]K/X
M^P_LT?"[5_%AMY;B>"+RK1$MY9X_M4V4MS<>6R".W$A7S9'DC&/W:,T\D,;W
M]?\ VI_A1X/L[2XUWQ!;:0UWY9BMM6$FGWA66Y-JLC65XD-TD7F*V9GB6)8U
M:=G$*M(#0/VH_AAXMT.[UK1]7_M&TMM2DT@M8VMW=/->11B5XK6&"%Y;O$1\
M[?:I-&8%DG#F*.1U]0\%>/-&^(-B]WIDDI6*4PRQ7%O/:W$,@57V3VUS'%/"
MY1TE598T+PR1S*#%(CM\8?M6_'[P#J_P_P#&=C8ZUJ4&H:%;:@JWNF'6+2VM
M]4@L7:&WEU.S$5F91)+'']CFN&#W+Q0-"UQLCK/^'&J^%=5^&/P:T.\\<1>'
MKZ"Q\-:F+&+48;6ZU.-=/\F*S,;2J\EO/<,@D39*)A$T*J'821_1_CK]J#X<
M_#3Q/;^&M=OKFSU"[WBUCDTW42ETT<2RF.UG6V,-S+AT18;=Y)7G=+94:X=8
MCT'@7X[^#/B)KEQH6GW%S%J5O;)>O9ZCI]_IMP;>21HA/'#?P6\DL0=2C21J
MZ(Y56*LZ!L_QY^T;\/OAG?26NMW\MNL,MO#<7(LKV6SM9+EHUB2[O8H'M+1V
M\V)BMS+$5CFAE8+%+&[>@>"OB%X5^)5B]]X<U:QU6VCE,+S6%S#<QK(JJQ0O
M"SJ'"NK%2<@,IQ@C.?\ $CXI>&/A)I<6HZ_=_9XI[F"R@5(I9YI[BX?9%!!!
M DDT\KG)$<*.^U6?&Q&8<_X/^/?@3QQ;ZQ-::CY']AX.I1ZC!<:=-9JT N%D
MN(;Z.WEBB:+,B3.@B=5<JYV/MT/!7QA\->/KY[&R^W07*Q&80ZEIFHZ9))&K
M*KO"FH6]NTR1L\:RM"'$)EA$A0S1[O,-._;%^%NKZI?:1;76I2ZE8>2;G3UT
M+6S?1+,A=)&L_L/VGRL;=TPC,49E@5W5KB$2>O\ PW^*7ACXMZ7+J.@7?VB*
M"YGLIU>*6":"XMWV2P3P3I'-!*AP3',B/M97QL=6/H%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%? '_!+C_DV+PC_ -Q/_P!.UY1^SQ_R
M<[\;_P#N4?\ TTRU\0>)-:_X1_\ 9V^/MRS7*Q?\+)U.*X6SN/LTTEO-J>F1
M7$*3;)0GG0O)$Q:.5-KD-'(A9&^S_BO^SQX1\3MX5^(OB3QCX@\1+H%]8WNB
MK"=#$=S<7MW:"UB1K33K5)$NYUM8UDDFCA4,',\,1>4?H?7YP?\ !.?Q+H?Q
M-^#NH:3K<=M/K[:EK'_"565Q:1PS->7U]<L_VVV,48;S8=L7*&/;$UL,?9WB
MCY_P9XIT#PW^T]X/TW2)KE/#=U\/[C2?#P9;Q[26:SU 22BVDE#*^;.SBD^T
M[BMQ;K:RB:5)K9I/0/BKX:^U?M:_#K4=$DQ>QZ)KO]MK%=[&.EQJB67G0&4;
MHC?7+&/"$O*I<[A;;HOG_P#9I_Y1YWW_ &+?BS_T=J5= /@WJGQ6^&_P:N_"
M7BC^P/&.B>$3?:0TMHEU;S0R:586EVLPDC=(_FGM4$I$C(DLC+;3, T7B'Q=
M^/<UY<IX>\66<OA76=/^(GA8^(KS2]4B^QW#7&ER?8]1CDO(IXH[>,Z=;7;6
M=U R)';P^8XN6E>'[?US]F_PSX0^+GA3XB:[XA\0:YXA24Z)IL<PTF.-UFMK
MV20.EK8V2;(+=[RZ9F=7(B*)YTIAMY,__@FKXE_X2GX.O/?Q[-?&MZS_ ,)
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MC-<R:OIFI:O9ZLMZLZW$=\VH3W<B3F<!VE*W,;R,2QWN58^8KJOP!XP\-?\
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M$J?*I'S?=;U_XG6WCB/]IWX,3>)KK39/-_X2MX+?3K:XC^S9TE"\4ES-</\
M:\915F6WLMVQG,">8(XO0/V>/^3G?C?_ -RC_P"FF6O'_@5_;G_"K/V@O["^
MT_VE_P )=XV^Q_8O,^T?:/LD?D^1Y7[SS=^WR]GS[\;?FQ7TA^S7JW@KXE?L
MM^'1J5Q%)HDGA:+3M1>9Y+:-8[:S-E?J\C&)HTC:*9&E#* %,B/MVN?@#]GC
M3/$6DZC^R[%KS2M<M8^,94,LPF;[+-8^;9 ,&?""U> 1QY!B0+$50IL7[/\
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MJ+X:M!8W.H2K<6%U:QK!;W45KO22YCB$Z2R2$0RV_G0N(I3YH^3S/<*\_P#
M'Q2\,?%#^U?["N_M/]D:E<Z1>?NI8_*O+7;YT7[U$W[=Z_.FZ-L_*YP<>@44
M5Y_XB^*7ACPIXGT/PSJ%WY6I:]]L_L^#RI6\[[%$)KCYT1HTV(P;]XR;LX7<
MW%>@444444445X?HG[0GA+Q#\19O -J+X:M!8W.H2K<6%U:QK!;W45KO22YC
MB$Z2R2$0RV_G0N(I3YH^3S/4/%/B6S\'Z7-J-W'<R10[=RV=I<WLQW.$&R"T
MBFF?E@6V(VU<NV$5F''_  ;^+WAWX[^$K7Q3X>>633KN6ZC@DEC,;2+;74MJ
M9 A^94=H2\8<*^QEWI&^Y%]0HHKY@^)W[5.A_"[5&MI]$UO4+6#4K+2+N^TR
MTCNH;2\ODADBBEB687C9CN;=]\%O-&S3Q6Z.]TWD#Z?HKP_X8?M">$OB_P"(
MM;T+11?"YT2*QDO!>V%U8-&U\)VBC\J\CAGW[(?,8F((4EB*.Y+A/<***\/^
M//[0GA+]G'P[+KOB07WV:.*20&TL+JY4LA15C>6*,P0/*\B1PFZE@21VP'PK
ME?<***************\/UW]H3PEX>^(.D>!;@7PU;5I9X[=3874=NRV]D]Y+
M(MU+'';S(B*L;BWDF=)I8T9%_>&/W"BBO/\ Q_\ %+PQ\+_[*_MV[^S?VOJ5
MMI%G^ZED\V\NMWDQ?ND?9NV-\[[8UQ\SC(SZ!7G_ /PM+PQ_PG'_  A7VO\
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M^+YK:'^S;;PS<WL]FL[0^3;:1<.TZ1$/*FZ)/-:W!G:%F,"S7.P32>?^-?\
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MS=XM\>R%V!D4D^?_ + 'A;Q?I_AB]N_%D-M%>Z;Y7@ZV:Q8FWGL?#$MS:1W
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M3LI"_P"\FEBNDMKF/[.$:Z0+Y,\GDH;>1)'BE'R_\(OC5X'T#7-.U3QSIOQ
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M965G5_*180C.BOMEF@5@!)N'SAHGQ5\>Q?M,S> =3O;&;21X6N==@6ULGMY
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M);6QNO"[^!-5\;Z3I\]HLBZ/J"B6T?[ TC2"%'D::Y"QK&D#R[8$A'FF;/\
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M&)9U1U6XF$GF'@'PW\2=:^&WCC1O -I%>VVC_%;4HI=":>&U@N=$@FBDGTJ
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M^A0_8M(M+GP[>6]C$SBW@FOM/EFN7AB)*1>8P7*H%4(D<:A8XHT7Z?\ VI]
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MM>)M)U/4M-U+2_LGV:?3M1O;/'VG4+2&7S$MIHXYLH2J^<LGE[F*;&8D\?\
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M)9I2[,Q/8?![POX5_:Q\:^.?$OC+2XM470?$%]X5TRPU)8;RSM+>QCMC//#
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MZ*]NO])L/M422)]I?RM0T^Z=IX1#Y DM[R%Y/-+;]C#Q/X<\-^-?#NC>-/\
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M$ D,L6R1Y'VE&0*8W^3_ (">"?B-X:^'.G>,M+^-=MI_A.6YGU.&+6M+TZ]
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M_8Z3IT/A_3O#_P#9E_I4VHQ^7ILUP]M*)UU"TG#QI<O$ 78,"S2>8^PQ^/\
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M;[P]J.H13RZ?!JDNFLUZMJ$-R+<V-[>*7A62-WCD,;LC&2-9$BG:+S#X./\
M!WXB^,_B%-HZW-WJFJ?V8GB&TU:POK;9"; VUI UK?VT \J2%)9""CM)YS%V
M,30HOE__  3OTFQT"Q^)MC8V\5M;6WQ$\00PPPHL<<<<:VJHB(H"JBJ JJH
M4    5]_ZM>S:=8W%Q#;2W4D43R)!"8A)*RJ2(T,SQ1!W(VJ9'C0$C<ZKEA\
M8?LH_M2WGQ5^#MS\0/%5C<Z;90_VKJ+74IMIH39PWUZPCA%HQN'^QP1)#(TU
MM!),R!T68LS5Z /VK?#>F>+]%\-Z]INI:$_B#SQH]SJJ6L,-\T)B_=JB7,ES
M;RR">,Q0WT%K*S'R"BW)$)X_5/VZ/ T5]K.G:5HOBG5[[2(K*2XL[#PYJ9N
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M?8Y1MDD;,C;65E;!.&4J>01705\ ?\%1_P#DV+Q=_P!PS_T[6='[?7_-*O\
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MEN9O"WC&:.$NHD>.&XOED=4SN9$::)78 A3)&"077-_]I;_E'G8_]BWX3_\
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M7PG\#_%#[/\ \)-H.FZO]FW^1_:-E;W7E>9MW^7YR/LW;$W;<;MJYS@8-?\
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MVCX@^,GQ>\1?'?\ X)Y77BGQ"\4FHW<5K'/)%&(UD:V\0Q6HD*#Y5=UA#R!
MJ;V;8D:;47T_]KGPI\0_V:M+C^,ECXVUO4KC3-2T^?5M)FO5MM(GLYG6TFM[
M.P6"9(-S2QK&9GGDBCWSM-/>*LK^P?\ -[W_ '3;_P!S]>/^(_%7Q&^/MO\
M$0Z;I?B2XN++4M7T70&T/Q!IUC:6,UE MHLET(=2TV[>66ZC-T\5]%=+#;O"
M(%,<CM/]W_LW7OQ)O_AMHS_$:VBMO$8BDCODB,)4M'-(D<A^SO)#OEB6.601
M$('=@J1@"-?8-6TR'6K&XLYFE6.>)XG,,TL$@5U*DI+"R2QN ?EDC970X965
M@"/R0_94T[2/A)X;^,7C=!J5U+X8\7>+IH;9]9U,0SI9VJ.%GC:>2&>5QD&Z
MN8KB?=MD+.\:$?2&C?#'7OCC\)M.\8V'B#5]/\5ZQI%GK%M/%J]_#807DT$=
MU#"=/5Y;$V2,5MY(WM9I);8,TKSW3O</\P>*_P!HGX@_&7X5_"?QM8:[?>'I
M/%/BG2-!O[/3?L30 +?W237$+W%I+<*\CVBGR7FEM_))MY8KA6E:7]/OA5\-
M)OAA8WUO-KVKZY)>7TU\\^L7$4TD;3*@,,(AA@BAMU*;HX(T5(R[[0%(4>@:
MMID.M6-Q9S-*L<\3Q.89I8) KJ5)26%DEC< _+)&RNAPRLK $?CC^R7I.J>"
M_P!B)O%GA[6]2TO4K;3=<U/?',EU"S:?/J311"UU".[MH(G.UI_LD5O+,RJS
M2ELD^_\ PM^&/Q7U?X0:1XO\-^-]2O?$VJ^$=,M[:/Q!<QOI=NURMM<2W/DV
MUF'ENXU,HAN;G[5*Y*K<-,F:S]$^,6E>#OCAX%\,>"[S5[O2?$L6MI?R:Q+K
MUY!,+*S2ZL[C3;O59'BD0D2 RV,DMO/#,KOO_P!$E3/^#/@&7Q5\=OBGX5O?
M$/B1]%T/_A'&LK/_ (2'5AL>\T^2:1_M7VK[;][?^[%P('\S,D4C0VS0<_X!
M^)?Q?MO@K\6E\(27.L:UX=\7:YI.BK=LU]<1V<$]NVU7N':6[E@BEGD@$[3R
M.ZQP[9E"0'U#]EGQ_P"!OB?XRCO_  EK.KVS6=CJ]CJ_A[Q'K.IW&I074=YI
MXAF:QOKN[5$B5+A'GB8!6N$A8F42QP^'_'OXJ^*?V>?ASJ/BK5M5N;WX@Z;<
MP37(TR3Q#<^'8A/J,82SEA^33(/^)=-''Y=P(;P^9%=*[74T-U)]8?%WQ1??
M$SXPZ/\ "FTU2^TJV32)/$^JRV#-!<75O%>Q6MM90WD4RS6R22^9)>/$JS-#
M''#',@FE*^?_ !H^"^O>!OAC\7HKG7KZ^\/7GA^6\TNUN;^_FNK*XMM/G^UQ
MM=SS27$MO,\5O+Y;SF%@]Q UN(F<W'A_C;4_$_[/_P"Q=H7C'P9XAU+3KVTT
M30KMHY)(M0AF>^73K=U*ZG%>/#%&K,8(+1[:"-F8^61P/M#X\_%"^T[X@^!?
MAW )8(?%TNK"ZO+>=H;B*WTRR%RT4#*-T;W#,D;7",LT,/F&%H[AXKFW\/\
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M-^,7C+QCK=CHD=EXK_LKS8[/5;N>:T_LRQDMUV+)I=NEQYS,I;+P>4N2/-(
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M93Y;QB..X9S,C0 ><IC'T!7RA\</VH].^#?Q!\'^$Y;2^FDUR6\EG>WTR^O
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M',LJF.ZG876L>2[1Q"YM_,2PM%N&&/M&GW0B2)&9[CC_ -@7_FJO_92?$?\
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M/-C64QQ.B%R[%29)"WO^DZ38Z!8V]C8V\5M;6T20PPPHL<<<<:A41$4!515
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M#PW%=-IT4D4,OVF\BG*RRF:0S3PSI-<N\K23/)</*[32S3%C+/,[^OZM\%/
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M%E]LMM&6]B:^FUJXL7GBEE2:WU*TM[2TEGC$%J[F9Y%5[EQ%&T:'Q_XP^/\
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MLKW3;[3YM/TC3K"2._MVMI&DMK*".8B&3$RHLHDA!F2(R&)I8U>W>&:7Y_\
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M &O=]DV?-Y^WFL_X#^,1I7Q\^*OB&[T?Q!!IVN1:%+83R^'=;C69=,TJ870
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MVD()7-+@US]F/X_:_JFI:9K>N:1XSTW27?5['3I+QK2\T:U>T:*[M]-A=_\
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MRTK^VOMMR=#U9(;?^UM,@2T\R1[147<S;9LG_16#K<>28W"\_P##/XC?$/\
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MT0N2&Q,+6TRN8%-=A1111111111111111111111117R!^V[\'?''[0GPPO\
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M[3?#NK^'+FW:06-C'##J%G>7$5K-8W<=NT"21,SQ3!W#R1-#F%H9'\U?/Y/
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M**)9;FYD0,)9_P!\4DN)5CBV>P5\ >'?V./%_@GX47OPST;QA;1Z++;:II\
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MAV+4FTF)#J=]J5[-IMG#<3QQ306D,B65Z]S<&"47$HCC$,$;0AYO-E$8^?\
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MB7#<Z59:UXDU'Q'I>L+:WD]G=K>K;.]LGEVY<RP*T7F-&)(A(98V=#'$;CZ
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MHWXH?"Z_^"]_KVM"QU_PK=2V5K=O#/Y]N;>XU*"REG22V$K,]JSM,OD_OA-
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MOX<N;A8S?7T<,.H6=Y<2W4-]:27"P))$S/+"40O)$T.)EAD?RE^8/B-I%O\
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MQ UV^\F]D$#1VERELT%W,'QY-I-E$ANIMEO+++!"DC2SPH_0?\$I_%FAZO\
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MSPE>Z0+F/4-/CU*">[U<3S^7I:7ME\ZN\$)N(K:U,5Y<S1Q0+)+'.;2X\_\
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M3X U^/Q)Y5[/K=Y?:W<W,,<[W5C'J&H^9:1(R%(O,800H8S"+:!3Y7$:0O\
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MW,Y/W_I.K6.OV-O?6-Q%<VUS$DT,T+K)')'(H9'1U)5D92&5E)# @@D&N/\
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M+;4;:)YIK2;4+6.XCCC@-R[O$T@=46 &9F90%A!D)"#=6AX%^+'@?XH?:/\
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M:*2+7?$&N+:11Q6$6NZB;N#3UCB>'-E L<4,+F)S#Y@0ND):&-HXI9DD\?\
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M-A#<V;QK$;TW\4"&XLYG1(;AI'64-]JF#B.YN+F*&V2'W_Q_\"-)^+7PVO?
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M+3=7M[;^SWNM,OI;9KBP)E9[*4 LGE.TS2>;$L5W%*D4L-S#)%&RGP>_9O\
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M?95OQYCPH"T+RW,&AX1_:2\>^-?%OB7P79^$K$:WX<ELC>O)K;C3?(OK5;B
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M\9)M'U:QOH[R+PQ-;/:W,,RS1VVG-#.\1C9A(D4DB1RLN1&[JC$,P!_2^OS
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M73KF]U?Q9+90:P;J"ZDBO=+B-@)C?A9_M%VA+VT=R1=7@CN)$64P7#1_1_\
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MKWT>FI9%RQTV.79:27.YY%^T2JK2L(R%"/&"D<HDC7U"OC#1/BKX]B_:9F\
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MJ:I.VBM,=/N[W48H+.RN(;26TBNIA"/W96-XVC2474,SK@7/[,GQ;^)_P_\
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ML+SQ3I%O)X?U>SUT-%H-T5FO+*6<Q JVL$I;F.5$DBW-(SHTBSHKB*/H+O\
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MQ)J;1ZW'H4\EOH5^L-O*R1F6:YEGCA2WBMVD$=RDQ2ZC96?[,T.V5L_]E/\
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M^=?DSQQ2"%'D:RB"NR+-<26RG[N],_\ 8%_YJK_V4GQ'_P"VU? '_.,7_/\
MT-=??_[?7_-*O^RD^'/_ &YK0_;#\#0_$OQK\*=*LH8FU:U\4PZV)7@E8Q:;
MI<?G7Y,\<4@A1Y&LH@KLBS7$ELI^[O3/_8%_YJK_ -E)\1_^VU?"'AN]A?\
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MW^1_:-E;W7E>9MW^7YR/LW;$W;<;MJYS@8/^%3^!_P#A&/\ A%O[!TW^Q?\
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M\"_"?P/\+_M'_",Z#IND?:=GG_V=96]KYOE[MGF>2B;]N]MN[.W<V,9.>?\
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MPGH?BO[)_:EA;7GV.YCO;;[3#'+Y-Q%GRYXMZMLE3<=DBX=<G!&37/ZQ\)_
M_B'^U/[0T'3;G^U_L_\ :'GV5O)]L^RX^S_:=Z'SO)P/*\S=Y>!MQBN/D_9D
M^#TUC%8OX+\/M;0RRS1PG2;(QI),L:R.J>3M5W6&)78 %A'&"2$7'8:_\)_
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MSQ78V-]8VVI1--##J,*PW'E^8RH[(KR+LE51+$RLP>%T<'#5G_$[XUZ'\-/
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M7<V]M9ZUJ]M82VVBK<1R0VAM+J*Z>%KWRT\^[FV,C2'R[-&$$* +'-?77/\
M[3EA\4OC%_PA3:?X"U)%T7Q=I/B&0-?Z)O\ LECYRRQ.#J"HMVS,6CCC>:W:
M Q.UU',TMM!]7_&CX4V/[27PNU/PMJ\,MBNL6*@I-M>2TN/EFA9Q;3[)'MYU
M1V2.9H93&4\QXF)/(? OP]XS^$GPHM;CQ%:W.N^)KK.HZJMJ+"*YGO+N0,\9
M>6YAM6^R1LEJC>>D?V:TC2%5188!\W_LT?!'X@Z=^ROJ/PKUS19='U;^R-8L
M(YKNXLI;6634Y+UHRCV5Q=2A(A-'YQDB0@M^[67!QY_\7OAW\8/'O[*]M\,+
M3P+?+J*:1H>FAWU#1MHGTR2T>X>3_3MJV[K#BU='EFD<2B:VM42&2X]P_:,\
M#?$_QIJG@/XG>$-"W:OX5N=0\SP_JL]I#-<6^I(EI-MNK>ZGM8Y5C3S(LR.F
MV3>V9(OLLW87<_QX^(?A6]UR?28O#.J6FD:L=,TFWU6*_DFU.6%HK.6ZE\FW
MM D.US%;N]W:S&[2:989K.+'E_B/X*:O\>/'?@WQ>?!ESX*U_2-2MM3U/56G
MTR4W-O';^7/IRRZ=?/-=><1# LMU#$B6:S_=WFTG^D/ 7Q7\:ZC\4?$/@_Q#
MH$5K;6\2W^E7]E=1W,<MF?+B O$RLUM<22^:T(>)(YA%=11-*+%[BX]/^+&@
M:YXK\#Z]I>A7?V/4KS3;VVL[GS)(O)N);=TAE\R(-(FQV5MZ NN-R@L *_.#
MQ1\'OC5XA\"> -,F\+6PE\&>)-)U:_:+5H)+O5I;"XD6YN[1)(XH7^VB=KYY
M;^ZM+HW!N(Y8&?9//[ GA?XC6W[3UMXUN?"ER^FOX1MO#T]Q9WNG2PQW<NH)
M>RRH)[FUN9+2$,R-(;9+AV0E+4J5)\/UW]FCQS\>M9^--OJ_A^^T*T\:V.A2
M:7/=W>F,$NM&@4)'<BSN;YT22X",3&D@:W67YXIC&K=!^T;:_'S]I3]GN_\
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M!%,TDEREFZ@V^V"1I9EM?;_VL?\ DB'CS_L6]9_]()J^0/ Q^)_Q2_9T\+>
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M_#OXRWOB+P;XI3RM;MM+OKN[U;P_;7BV\4BW M8[-+07$<4%X^FO&U\DU_)
M\ETC2P_8Q)#;VI\#OAW\4?!WQP\;^)->T6QBM/%46C3&>RU/[3!;#3;.XM6A
MS+;6UQ+<.Y@D5?L\5N(7E8W1FB2"?C_V7_#_ ,6OV=O@[8_#U?"%S/J^G_VE
M!;ZD;G2WT@RSWUS+;W$G_$QBOS:#S8WF"VJW0C#A(3)M4\?\5/V</$OP^\%?
M"SP-X+\-WVKVWA'Q!HVNWEY#/IT$<PM9+E[P(E[J*3"XFEE:=8L?9T$HC6<!
M-J^@?&;P7\7/#7Q9T/XN^"?#L6M23^'_ /A']1T*[O+:QNH(WG:^25+HS2VI
M=)BL4P4S !,1^<LQFM_I_P"%]KX]\0WQ\1>+K>+2I)+&"W@T>UOWO8[9F8S7
M$L\RPVT4MPY,,&SRYTMA;.UO<LM[<*?<****************************
M*********************Y_1O"VE^'[S4KNSA\N74[E;RZ;<[>9,MM!:!\,2
M%Q#;0IM0*OR;L;V9FZ"BBBBBBBBBBBBBBBBBBBO'_CQ\/-<^+/@?4_#.EZE;
M:;_:EM<6-S/<V4EYBWN;>2&01(EU:;)?G#)(S2(NT@Q/N!4^ _P\USX3>!],
M\,ZIJ5MJ7]EVUO8VT]M926>;>VMXX8Q*CW5WOE^0L\BM&C;@!$FTEO8*****
M******************^0/A'^SUXX^'?Q/\2>-=0\2:;>_P#"2_8/[0MH-%N+
M;']G6CVUO]FE?5+CRL[@\OF)/OP57RLY7Z_HHKR_XT?#R^^*W@K4_#]CK5]H
M=S=Q*(=0TZ1H[BWD219$92K(Q0L@65%9#)"SQB2,MO7/^"GPF_X5'H<UO<ZG
M<ZOJ5_<OJ&IZC=G#W=Y)''&\BQ F.WB5(HX8+>+$<$$4<8W,&=_8*^0/A'^S
MUXX^'?Q/\2>-=0\2:;>_\)+]@_M"V@T6XML?V=:/;6_V:5]4N/*SN#R^8D^_
M!5?*SE?K^BBBBBBBBBBBBBBBBBBBBBBBBBO'_C7\#O#'Q[T.'2]=%RGV6Y2^
ML[FRN9;6XM+R*.1(;J"2)AB6'S&:/>'C#X9HVP!7/_\ #/\ ;ZW\OBCQ#K?B
M"(<+;WMS!:6Y5O\ 61SV^DV^GPWD4H"K)#?I=1% 45%2699?H"BBBBBBBBBB
MBBBBBBOD#_AGKQQ_PN__ (67_P ))IO_ "#?[#^Q?V+<?\@[[?\ ;=OG?VI_
MQ]_\L_M'E^3_ !?9/X:^G_%-MKEWI<T>B75M:7IV^5->6TEW"N'!;?#'<6KO
ME=RKB9-K$,=P4HW@'[)?P#US]F;P);>#KO6K;5K*Q\S[))%I\EG,OG7$]Q+Y
MS->722Y:8"/8D.Q5(;S"V5^GZ***********************************
M**********S]6U:QT"QN+Z^N(K:VMHGFFFF=8XXXXU+.[NQ"JBJ"S,Q 4 DD
M 5X?^SO^T?X0_:4T";5M O;:7RKFZB>"*<231PQWEQ!:S31,L<L'VJ* 7$<<
MT:,%<KE]A8]AIGQO^'6M>(F\.6?B72)]666:$V$6H6KW0D@#&5# LAE#QA',
MB[<H%;<!M./4*^(/&_QI\7_$OXOW/PJ\$R_V:NE6UEJ&N:[Y)F>U65O,73[:
M&>V>U^UW,9A>.>9Y8D@:Y*P236^T<?\ M5Z!\<_A#\-M;\3^"_'E]?3Z=8R7
M$UOJFG:)(WEQ302RSV\L%K8I$\-O'<%UFCNQ,C%(XTG$4@^S_'7Q8\#_  O^
MS_\ "3:]IND?:=_D?VC>V]KYOE[=_E^<Z;]N]-VW.W<N<9&37_BQX'\*:'::
M[JFO:;9Z;>>7]FO+F]MXK>;S8S+'Y4SNL;[T4NFUCN0%AE037/I^T+\+)=4M
MM+7Q;HAO;O[-]GMAJ=H9I?M:(]OY<?F[W\Y9(VAV@^:KHR;@RDZ&F?&_X=:U
MXB;PY9^)=(GU999H381:A:O="2 ,94,"R&4/&$<R+MR@5MP&TXZ#Q)\0O"O@
MR&[FUC5K&QCLXH)KE[JYAA6&.YE>&!Y3(RB-)9(WCB9L"1T9%)92!T&DZM8Z
M_8V]]8W$5S;7,230S0NLD<D<BAD='4E61E(964D,"""0:X_P+\6/ _Q0^T?\
M(SKVFZO]FV>?_9U[;W7E>9NV>9Y+OLW;&V[L;MK8S@XX^/\ :;^#TUC+?)XT
M\/M;0RQ0R3#5K(QI),LC1HS^=M5W6&5D4D%A'(0"$;'07OQO^'6G>';;Q'<>
M)=(BTFZE,,%_)J%JMK+("X*1SF01.X,4@*JQ(,;\?*V"]^-_PZT[P[;>([CQ
M+I$6DW4IA@OY-0M5M99 7!2.<R")W!BD!56)!C?CY6QZ!I.K6.OV-O?6-Q%<
MVUS$DT,T+K)')'(H9'1U)5D92&5E)# @@D&N/\4_%CP/X&MYKC6]>TW3XH+E
M;*62\O;>!4N'@%PL#M(ZA96A99EC.',3"0#80:[#5M6L= L;B^OKB*VMK:)Y
MIIIG6....-2SN[L0JHJ@LS,0% )) %<_X*^(7A7XE6+WWAS5K'5;:.4PO-87
M,-S&LBJK%"\+.H<*ZL5)R RG&",B_$+PJ]]9V(U:Q-S?2W<-K"+F'S)Y+%F6
M[2)-VZ1[=E9;A4!,)5@X4@US^I_&_P"'6B^(E\.7GB72(-6:6&$6$NH6J71D
MG"F)! T@E+R!T,:[<N&7:#N&=#QU\6/ _P +_L__  DVO:;I'VG?Y']HWMO:
M^;Y>W?Y?G.F_;O3=MSMW+G&1DU_XL>!_"FAVFNZIKVFV>FWGE_9KRYO;>*WF
M\V,RQ^5,[K&^]%+IM8[D!894$USZ?M"_"R75+;2U\6Z(;V[^S?9[8:G:&:7[
M6B/;^7'YN]_.62-H=H/FJZ,FX,I)=?M"_"RRN-0MYO%NB1RZ9N^VQOJ=HK6N
MR=+=O/4RYBQ-(D)\S;B5UC/SL >P\%?$+PK\2K%[[PYJUCJMM'*87FL+F&YC
M6155BA>%G4.%=6*DY 93C!&<_P#X6QX'_P"$G_X1;^WM-_MK_H'?;;?[9_JO
M/_X]]_F_ZK][]W_5_/\ =YKY0T3Q-XMTS]K2;PM=:_?7VDMX-N=9BM+@6J1P
M3W&LQ0;4%M! 9$BCA"0M<&>:,-+^^/FON^W]6U:QT"QN+Z^N(K:VMHGFFFF=
M8XXXXU+.[NQ"JBJ"S,Q 4 DD 5X?^SO^T?X0_:4T";5M O;:7RKFZB>"*<23
M1PQWEQ!:S31,L<L'VJ* 7$<<T:,%<KE]A8]AIGQO^'6M>(F\.6?B72)]666:
M$V$6H6KW0D@#&5# LAE#QA',B[<H%;<!M./4*_.#X1?&A_AW\8OB?I'CSQKO
MTW1O^$9L["XURXT^R4->6-W>R(!#%9VQE<L^66,2O%$BL76%2OW_ .%O%FA^
M.=+AU31+^VU"RGW>5<V<T<\+['*-LDC9D;:RLK8)PRE3R"*Y_0/BQX'\5ZY=
MZ%I>O:;>:E9^9]IL[:]MY;B'RI!%)YL*.TB;'8(^Y1M<A3AB!7RA^S9XF\6S
M?'#XI>&M9U^^UBVT.+PU%9M>BU1D6ZL[FZE/EV<%K!O9Y,-((E=D2)'9A&F/
MJ_Q3\6/ _@:WFN-;U[3=/B@N5LI9+R]MX%2X> 7"P.TCJ%E:%EF6,X<Q,) -
MA!KT"N?UKQ9H?AK=_:-_;6NRVN+UOM$T<6+>UV>?.=[#$4/F1^;(?DCWIN(W
M+D\+>+-#\<Z7#JFB7]MJ%E/N\JYLYHYX7V.4;9)&S(VUE96P3AE*GD$5GK\0
MO"KWUG8C5K$W-]+=PVL(N8?,GDL69;M(DW;I'MV5EN%0$PE6#A2#6?\ \+8\
M#_\ "3_\(M_;VF_VU_T#OMMO]L_U7G_\>^_S?]5^]^[_ *OY_N\UGZ9\;_AU
MK7B)O#EGXETB?5EEFA-A%J%J]T)( QE0P+(90\81S(NW*!6W ;3C0T#XL>!_
M%>N7>A:7KVFWFI6?F?:;.VO;>6XA\J012>;"CM(FQV"/N4;7(4X8@4?\+8\#
M_P#"3_\ "+?V]IO]M?\ 0.^VV_VS_5>?_P >^_S?]5^]^[_J_G^[S7/W7[0O
MPLLKC4+>;Q;HD<NF;OML;ZG:*UKLG2W;SU,N8L32)"?,VXE=8S\[ $NOV@?A
MI;>$-0\7KXDTV?1=-W"ZO;6ZBN88V4(?++0-)F4^9&$A7,KM)&J(S.@)\!_C
M-H?Q[\#Z9XFTN>V?[5;6\ES!;74=U]DN);>.:2UE=,8EA\P*ZLJ.."47(%:'
MB;0O&NH^-?#U[IFKQ6FB6D6H'5+,P1R27LDD<26:J[)NA2)O.F=T=2Q6.(QR
M+(S19]U^T+\++*XU"WF\6Z)'+IF[[;&^IVBM:[)TMV\]3+F+$TB0GS-N)76,
M_.P![#P5\0O"OQ*L7OO#FK6.JVT<IA>:PN8;F-9%56*%X6=0X5U8J3D!E.,$
M9Y_3/C?\.M:\1-X<L_$ND3ZLLLT)L(M0M7NA) &,J&!9#*'C".9%VY0*VX#:
M<'A'0O&MAXM\2WVL:O%<Z3=2V0TBQC@C5K..*U47+23!$>1Y[AG8(QD$21H5
MD_>-'%G_ !(\?^$[2XB\+W/C"VT#5]0\C[(J76G)?-YD^Q/(@OHYTD\UD:$9
M@DW$LJ8D 9? /V#?BKJGC3]G;1O%_B_5?-N)?[7O+V]O)$C55CU.\+.[';'%
M%$BX51LBAB0*H2- !]7^"OB%X5^)5B]]X<U:QU6VCE,+S6%S#<QK(JJQ0O"S
MJ'"NK%2<@,IQ@C(OQ"\*O?6=B-6L3<WTMW#:PBYA\R>2Q9ENTB3=ND>W966X
M5 3"58.%(-'C_P ?^'?A9X=O?$/B&]BL=.L8C+//*3M5<@   %F=F(2.- SR
M.RQHK.RJ?/\ X._'SPK\7?AU9^-(;ZQAMFL8KJ_"7L,T=A(;6.YG@N)AM5'M
MU?\ >^8(RH&YD0'%>@2_$+PK!-JL+ZM8K)HT23:BAN80UE&\1F1[H%LP(T:M
M(K2[044N#M!-'@KXA>%?B58O?>'-6L=5MHY3"\UA<PW,:R*JL4+PLZAPKJQ4
MG(#*<8(SQ_Q(\?\ A.TN(O"]SXPMM U?4/(^R*EUIR7S>9/L3R(+Z.=)/-9&
MA&8)-Q+*F) &7Y _9<\1?%?X\_LK:1J6G>)/LGB;4[FZD;5KN&.Y\I1K\WGE
M8'1HFVVRR1P0!4B7]W$K0(JO']OZ_P#%CP/X4URTT+5->TVSU*\\O[-9W-[;
MQ7$WFR&*/RH7=9'WNI1-JG<X*C+ BL_P5\;_ (=?$J^>Q\.>)=(U6YCB,SPV
M&H6MS(L:LJERD,CL$#.JEB, LHSDC.AK_P 6/ _A37+30M4U[3;/4KSR_LUG
M<WMO%<3>;(8H_*A=UD?>ZE$VJ=S@J,L"*] HHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHK\,? ?C_ ,1?##_@F]'K/A^]EL;Z**XBCN(2!)&MSXDDMY"C8)1S
M'*X61</&2'1E=58??_[6?@KPKXQ_9WU>;2'B@MM'TC^W-$NM*,*"VDTRW-W9
M2V4L:LL2;8UC5X-I^SR.D;H'##W_ ."&I^(M:^'7AJ\\1K*NK3Z1I\M^)H1!
M(+I[6-IP\05!&XD+;HPJA#E=JXP/S0_80_XH3]I;XW^&=5_<:E?:E'J]O!]_
M?9M=7<PEWQ[HU^34+1MC,)/WN-FY) GZ_P!?"'[%WC^;X@^(OBE+JE[%=ZI8
M^,M0TT F+SX=-M L5A"54!EMU871AR KS-=2Y::2=V^;[3PYJGPX\/?M(^$+
M,W(\,Z9IL]QI,,D:+;VTVIZ+<W]];6K)&B)%&T\)6V3Y8$=&V[YGDEH?M!Z3
M8Z+_ ,$[;.&SMXH(V\/^&)BD2*BF2>[T^:5R% !>21WDD;J[LSL2S$GW_P#;
MDTFQT"Q^$=C8V\5M;6WQ$\,0PPPHL<<<<:W"HB(H"JBJ JJH 4    5Q_P"S
M!\)_ _A[]IWXM_V?H.FVW]D?\(S_ &?Y%E;Q_8_M6DS?:/LVQ!Y/G9/F^7M\
MS)W9S7F$GA#P5\/%^/7A36[J^\+?#^.^T"03:3%(@AN-3M+9K^*!X[>X8I,S
M6L4ULJO##;S!%BABEY]?^(/C#Q[=?M+_  A&JZ?%H]M>1>*HTA@U)[B>: Z=
M#/Y5_$EO%!&\;Q0.8X9[Z'SDRLS"*.63H/V?-)L9OVJ_C5?/;Q-<PQ>%88YB
MBF1(YM++2(KXW*CM#$SJ" QCC)!*+CC_ -EKX::'\9/"'QJ\+:W'YEEJ?Q \
M3VTN%C9DW"VVRQ^8DB++$VV6%RK>7*B.!E17'_LZ^+?$7B;P%IOP3\3&+^V]
M$\0)H&HI&P9GT32D74$N9+0Q0.VF7L$4.C"291%<)=I+(\S3&VD_5_5M)L=?
ML;BQOK>*YMKF)X9H9D62.2.12KHZ,"K(RDJRL"&!(((-?FA^P+\)_ __ !=7
M_B0Z;_R._B/1O^/*W_Y!W^C?Z#]S_CT_Z=_]3_L5\H?"S3O$5GXU\)?#RTFB
MT_2=.\=^/&\.P:CI U&TVZ/'&;5F+7-G<2);O=:DT5RMQ*ZWBHK!O)5H/M_P
MS^RY#HGQEUOQ#XY\0V.O-XTL4MIM CT:6.QE;3%M6CNY()KR_79;+ J":<;(
M[B[2-94EN(8I>/\ ^"7'PG\#_P#"B?"/BG^P=-_MK_B9_P#$Q^Q6_P!L_P"0
MA>0?\?&SS?\ 5?NOO?ZOY/N\5Y!H/B/Q?^RWX)L]'^)@_M_P(-2T_5['Q?X?
MD-U-YTFO?VM%-JL<TDLC13N$DEGMEE4*Z01RW5Q<(\?U?^Q=X_F^(/B+XI2Z
MI>Q7>J6/C+4-- )B\^'3;0+%80E5 9;=6%T8<@*\S74N6FDG=OF^T\.:I\./
M#W[2/A"S-R/#.F:;/<:3#)&BV]M-J>BW-_?6UJR1HB11M/"5MD^6!'1MN^9Y
M):'[0>DV.B_\$[;.&SMXH(V\/^&)BD2*BF2>[T^:5R% !>21WDD;J[LSL2S$
MGW^]TFQU']N2VFN+>*62U^'9F@>1%9HI#K3PEXR02CF.62,LN"4D=,[68'R]
M/%.J>!OB5^TYK>ES>1>Z?HFB7EM+M1]DT'AZZDC?:X9&VLH.UE93C!!&17/W
M/[*6N?%O]GSP59P^.=-\/:!H]MIWB*RO+?09+"[@\JR>5;FYF&MO#'+B=[BY
MEC"_Z1NE$@Y)]PTG4X=:_;0M[R%95CG^&22H)H98) KZZ& >*94EC< _-'(J
MNARK*K @?H?7X8^ _'_B+X8?\$WH]9\/WLMC?117$4=Q"0)(UN?$DEO(4;!*
M.8Y7"R+AXR0Z,KJK#[__ &L_!7A7QC^SOJ\VD/%!;:/I']N:)=:484%M)IEN
M;NRELI8U98DVQK&KP;3]GD=(W0.&'O\ \$-3\1:U\.O#5YXC65=6GTC3Y;\3
M0B"073VL;3AX@J"-Q(6W1A5"'*[5Q@?('[/FDV,W[5?QJOGMXFN88O"L,<Q1
M3(D<VEEI$5\;E1VAB9U! 8QQD@E%Q\817UO\-OV;?CO#IS_V79)\0-5TQOL5
MK!)Y%C<WFFV,\<%N[11'%M+)''&'A X"R1$*Z_7_ ,5?V:?$DNN>"?&&N^,M
M-TJR\#7*O:VVA:!=6?FPS26T)L$1=5NG/VA84LX;>WB9I?.\A89C(L9T/@=I
M-CK_ .T?\=K&^MXKFVN8O"D,T,R+)')')H\RNCHP*LC*2K*P(8$@@@UQ_P"P
M+\)_ _\ Q=7_ (D.F_\ ([^(]&_X\K?_ )!W^C?Z#]S_ (]/^G?_ %/^Q7J'
M_!/[2;[PKX2\5^'Q;RV^DZ-XR\0:=HL<B,%73X;KY5CD<;YT6X:X4RNTC[U>
M,O\ N]J^7_\ "I_ _P#PV]_R =-_Y$C^V?\ CRM_^0C_ &__ ,?WW/\ C[_Z
M>/\ 7?[==!I_PGT.#]J?Q1H<>@VTOA[Q!X1LM7UJWELHY[.XU2/5YH[:682H
M\:2LB3R!%V":1)+AD>9&D'@'['O@_P -^!OV-A\1-+T?38/$VGZ)XFO+;5OL
M%J]XDT$NHK&_G/$SMM50FUBRF,>604RM;]S^REKGQ;_9\\%6</CG3?#V@:/;
M:=XBLKRWT&2PNX/*LGE6YN9AK;PQRXG>XN98PO\ I&Z42#DGW#]I+4X?A9X]
M\!?&:P66*VN)8/#.MFYAEME72=4?S8+B[:Y7_04LKK;(X>*&61Y5MY9H@ A[
M"Y\4ZI8_"3X@_%+39O*N]5TW4-6TF9E25H;&RTUDTPJ90<Q3>6VJ+;21H+>7
M49X9(3+YSR_+]S^REKGQ;_9\\%6</CG3?#V@:/;:=XBLKRWT&2PNX/*LGE6Y
MN9AK;PQRXG>XN98PO^D;I1(.2?8+5-+\5_MK:?J36V_9\-EO+4W5L\4T+2ZP
M\>\1SHDL$OE321NK*DJJ\D3 9=:\?\4_\C=^U7_V+>E?^HU=U]__ +)W_)$/
M ?\ V+>C?^D$-?,'QV\)Z'I'[6/P>U2TL+:"]U#_ (2C[7<Q0QI-<>1H\:1>
M=(JAY?+4E8]Y;8I*K@<5H7NDV.H_MR6TUQ;Q2R6OP[,T#R(K-%(=:>$O&2"4
M<QRR1EEP2DCIG:S \?X0L?[3^,W[1MM_:_\ 8GFZ;X=C_M/?Y?V'=H5P/M6_
MS(MOD9\W=YD>W9G>F-PY_P"&WC#Q?\"[_P"'_@3XP:/]F33-2L].\-ZWH),^
MFW4W]C3:;';WXE)N896%RZH_E0K/-EPD=M:RRR>@?LG^$]#\#?M$_&G2]$L+
M;3[*#_A$_*MK.&."%-^F3.VR.-51=S,S-@#+,6/))KH/V!K72_BY\'9?&FMZ
M?;3ZEXTN=3N-9:17F6X5;ZZM(K8BX>9OLD%NBV\%L6,4<6X!=SR,_P  ?LS3
M:IKO@3]GGPW:WMM;_:+GQ?J=NE[I::E;-?:;<7!MY)D^U6<J>3%<74D,D4I*
MW(@8QMM62+[O\,_LN0Z)\9=;\0^.?$-CKS>-+%+:;0(]&ECL96TQ;5H[N2":
M\OUV6RP*@FG&R.XNTC65);B&*7C_ /@EQ\)_ _\ PHGPCXI_L'3?[:_XF?\
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MO&ESJ=QK+2*\RW"K?75I%;$7#S-]D@MT6W@MBQBCBW +N>1G_.#4?">AZO\
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MX O+&6^TN^E%SJ#W-Q-]JO[KSDN'N[NZB:.:2XDEC1W?<HPJQJJPJL:\?/\
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M\.OAK?/?>'/#6D:5<R1&%YK#3[6VD:-F5BA>&-&*%D5BI."54XR!CU"O'_\
MAGKX6?VY_;O_  B6B?VE]I^V_;/[,M/M'VCS/-\_SO*\SS=_S^9NW[_FSNYK
MV"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOS@
M_P""K'A/0]7_ &=O$&J7=A;3WNG_ &+[)<RPQO-;^?J=FDODR,I>+S% 6385
MWJ K9'%?('[0WPJ^&G@3]B[PUXPL-*TW2?$D6F^%[RPU*SCBLKY[YUM6D=)X
M?+EFE,1N)F5BYRAN,;X5D3]+_P!F[QKXJ\*_L_Z-KWQ/26POM.TB2XU%IQ-)
M.MO:"0I/<*6FF:X>VC2:X4YF\YI%,:/F)?SP_89_:<\7W'[27C7PO\0+6YTW
M4/%7V?5;.QN)"WV1H;-9H;4Q10JBRMIK0^;-*()?]!2.93<,$3]GO%/A/0_'
M.ES:7K=A;:A93[?-MKR&.>%]CAUWQR*R-M959<@X90PY -?B#_P2@^$_PL\5
M_!#7==\8Z#HEY]CUN\\R\U:RM)?)MXK"RE;=-<(VR)-SN<L$7+,<9)KT#_@F
MKXF\<7WQ3^(>EZ?<7.H> =/N;BQTFYFO;B\M[;['=LEE:V$DT\BF(V<A:3RQ
M)\D=HS2('C$N?^VK^R9X*^%O[/'COQ;=:18R>*-5OH=2N[X>9.T,E[KR3&&U
MDG ,:11W)M6EACMC=H@DEA4MY:>__LZ?LF>"D\,_"GXC>'M(L;+7;'2-)ENI
M8_,MUN[>ZTF2"Y\P1!HC<9NS="=X7FG>!+9YHHY#-%^C^K:38Z_8W%C?6\5S
M;7,3PS0S(LD<D<BE71T8%61E)5E8$,"000:_&'_@F[\/?"L'QU^-$R:38K)H
MWB PZ<XMH0UE&]WJT+I:D+F!&C58V6+:"BA"-H K]KJ*****************
M************************************************************
M************************************************************
M***********^ /\ @J/_ ,FQ>+O^X9_Z=K.N@_9._9Z^%G_"K/ >N_\ "):)
M_:7]B:->_;/[,M/M'VC[)#+Y_G>5YGF[_G\S=OW_ #9W<UZ!^TG;:YXZ_L3P
M-H=U;6]QK%RUW>M=VTEU%_9>F[);E9(5N+59HI[B2QL+F RDS6M[./+:-97C
M_(#_ (*5_"+QQ\%/%_A?XWW.H:)?7MMJ5A;/%::5<:>LEQ9F2\M99U:]NWN-
MRP-#*YFA=(HK>- PRT?[O?"KXEZ'\9/"&E>*=$D\RRU.VCN8LM&S)N'S12>6
M\B++$VZ*9 S>7*CH3E37\X/[)W[%&A_M6?LPZ_>VEOY?B;3-;OVTVXB\M6GV
M:?8R"QF,C1HT4K9$;NZ_9I7,JML:>.;[ _X)/?M7:I=_:?@[XQ:YCU32O/.G
M&^=$=8;?9'+IICD"3>;;$/)&A\UE@$L9$,5HBM]?_P#!4?\ Y-B\7?\ <,_]
M.UG7O_[)W_)$/ ?_ &+>C?\ I!#7T!7Y ?\ !.+_ )+?\??^QD7_ -+]7K]?
MZ***********************************************************
M************************************************************
M*****************************\_\=?"?P/\ %#[/_P )-H.FZO\ 9M_D
M?VC96]UY7F;=_E^<C[-VQ-VW&[:N<X&#P+\)_ _PO^T?\(SH.FZ1]IV>?_9U
ME;VOF^7NV>9Y*)OV[VV[L[=S8QDYS]3^"'PZUKQ$OB.\\-:1/JRRPS"_ET^U
M>Z$D 41.)VC,H>,(@C;=E J[2-HP>-?@A\.OB5?)?>(_#6D:K<QQ"%)K_3[6
MYD6-69@@>:-V"!G9@H. 68XR3DLO@A\.M.\.W/ARW\-:1%I-U*)I["/3[5;6
M60%"'D@$8B=P8HR&9208TY^5<9_A;]GKX6>!M4AU31/"6B:?>P;O*N;/3+2"
M9-Z%&V21Q*Z[E9E;!&58J>"16AJ?P0^'6M>(E\1WGAK2)]666&87\NGVKW0D
M@"B)Q.T9E#QA$$;;LH%7:1M&-#QU\)_ _P 4/L__  DV@Z;J_P!FW^1_:-E;
MW7E>9MW^7YR/LW;$W;<;MJYS@8T/!7P]\*_#6Q>Q\.:38Z5;22F9X;"VAMHV
MD954N4A5%+E452Q&2%49P!CH-6TFQU^QN+&^MXKFVN8GAFAF19(Y(Y%*NCHP
M*LC*2K*P(8$@@@UY?X6_9Z^%G@;5(=4T3PEHFGWL&[RKFSTRT@F3>A1MDD<2
MNNY696P1E6*G@D5[!1111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111117G^L_%7PAX
M?\3Z;X7O-5MH]7U/<;6Q\P-<2*L4\QD\I<NL06VF_?.%BWIY>_S&5&] HHHK
MCX_'_AV7Q5+X6%[%_:T5C%J36A)$AM99I(%F4$ .@DB9'V%C&3'O"^;%O["B
MBBO#[W]HWX?:=\2;;X=7%_+%XANHC-!:265ZJRQB%YR\=P8!;N@2*3++*0'C
M>+/FJR#H-"^-'@KQ+XUU?P79:G$^MZ/%!->6161)$CGC21'7>JK*FV2/>T)<
M1&2-9"C.H/J%%%9\>K6,U]+8I<1-<PQ1320AU,B1S-(L;LF=RH[0RJC$ ,8Y
M "2C8\_^'GQH\%?%:^UJQ\/ZG%=W.AWTFG:A"%D22WN(V92K)(J,4+(ZI*H:
M&0I($=C&^WU"BBBBN/\ '_C_ ,._"SP[>^(?$-[%8Z=8Q&6>>4G:JY    +,
M[,0D<:!GD=EC16=E4^?_  Y_:-^'WQ5\1:CX<T>_E_M;38HYKJPO;*]T^ZCC
ME *OY%]!;RLF&0LRJP021;BOFQ[L_P"-?[4'PY_9V\EO&-]<Z?%/L$=Q_9NH
MSVY9_,VQ_:+>VEA$I$3MY)<2A%WE-A#' U']LGX2^']4L=.UO4[G19;_ ,[[
M,VN:5JFD0R>0@>3$^HVMM"-H*@Y<?,Z(,NZ*WT_7'^/_ !YHWPP\.WOB#69)
M8K&QB,UQ)%;SW+1Q@C<YCMXY92B [I&"D1H&D<JBLP\O_P"&H_AA_P *P_X6
M7_:__%-_\_OV6[_Y^_L7^I\G[1_K_P!W_J_]K[GS5[AI.K6.OV-O?6-Q%<VU
MS$DT,T+K)')'(H9'1U)5D92&5E)# @@D&M"BBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOQ1\7^ /#OPZ_;^^
M'=GHME%:QR^'[J>8H"9)YVM]95[BXE8M+<7$@1?-N)FDFE(W/(S<U^UU%%9^
MK:M8Z!8W%]?7$5M;6T3S333.L<<<<:EG=W8A515!9F8@* 22 *_G!UKXI^/?
MV4OVG/#_ ,4?'"2V]MXXL5GU&%K9T6QL;F7R4L&D-J'EN-,@AL)[D1PQ7#N@
M@;(E,TO[W?M ^,=<^'7PT\2>(M$:V%[I6FW6HQ"\ADFA?[)$T[1ND<T#_O%1
MD5A(/+9A(5D"F-OA#P/^TO\ 'WXC?LYR_%JS/A:UDMK'4;TV,MEJ,JSQZ?<3
MB5Q,M]&;=S'"ZQP;+H.\:R-<QK<&.US_ -I']O[Q)X.^ GA#XK^"(--DBUJY
M2SN;34;>ZG\N9X9VD2.5)K,_Z/-:30,QB99\K*A1%'F^H?M"_M'_ !._95F\
M,^(O%DOA^?PYJ>KQZ;J,5K:Z@EUIZW$4DB/%<&:9;U(%CD:5_LEJ\XC54MHC
M.?L_A_QD_P"4AGPX_P"Q;N?_ $3K=>@?!WXCW%]^VCX\\,W>C:(MQ;:)#+_:
MMI9SP7TT*M8RP0SN]U-&VQ+P1RR(D;7!M[<L%CAAABT-5_:_^(OCG1O%OC'X
M<:78ZQHGAK5X-'BL8K>ZOM0UB2.> 7LUM-9S^3;VXBN$>UD$-\9$1YY$C4B,
M>P>*_P!HKQ5K7C7PCX.\.:-?:7<^(=(DUM[[5]'FNK>TCCC!-I<PPWMFT5PC
M,J7#&9A;326L'E2F\$EOS_P _:@\5>)?C+XM^$OC*VL7U;0XEO[>^TF.:&UG
MLY%MBHDAN)II8K@"ZB8A7EC):2,,/)62X^8/V M<\>^+_P!H#XR7FJZK8SM;
M:O:V5_C3WC:X6S.HV=K]E*W>VU2-85W+*MZ\B *91+NG?K_V,_C?9V_B_P"-
MUQK^F:)IB^'-2\_4M1TBPN;=KO[,;^.>YGB:XO'^[9F98H?^6LMQ)B6:>1W]
M T/]ISXI_$'X4:I\7] CT2+0+;[;?6NDWMM=F^N-.TV1DN3-?177DVUW*+>Y
M:&-+2ZAB)@1Y9<R.O'_M3_M]:MX(^"7ACXJ?#I;&ZL=9OOL3P:O9W!D#-'<$
M\PW4 1X)+26&1<3)*6#QR[$#2]!\0OVL?BS\'OC+X*T;Q5I&D6WASQA?/96<
M-LT]SJUNVV"&/[7)YL=DK_:+J$S+;_:4CB$J1RSE$FE_2^O@#X8?M%_$#]J^
MW\1ZY\,+K1+31=,N7TRP;6K&^GFU"[A@6:25_)NK7[':-YT"0YCNK@KYDLD4
M;;;>OS@_X*#?M*:7^UA^S#X:\6:)_HMNOB2.SU"QGB=IH;Y-/N'")<!DC>)4
M=F#")C,LT+$VTD4T#?M=\.?@[#X:\1:CXLUF'2+GQ'J$4=K-J.FZ;+8,]K"
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M>K>+?"=[8V\EC$D<BW5D]S(S7=S!:QR02?:(XHGA,K2XF@NDE(12BJ&W^_\
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ML?#\GBJZM1*OV?4+A=1BM+2"[B\O=);V[+)<&$R>3<3-#YL;+ %?T#0OV._
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MOZBU_I=Q/I]U+<:?-J8M6N)[.2&6X2$'"13M)"!C*':,>O\ @#]G_P ):/\
ML_Z-XNL?$DOA+6]0\&Z-ILGB.^U"ZN5L[6Y%I-)#"E[>K!;)(^8X/(,!MWE#
M0%&P"6NOVGP__:$^&^E>#O"4OA#2=?B\0QWJBQTVQCU6*VL8[FUD:WMY&N(W
M@==Z"]AM;J 3R0[$\VZB'H'P>\+^%?VL?&OCGQ+XRTN+5%T'Q!?>%=,L-26&
M\L[2WL8[8SSPP/"J?:+N<F66:023)&L-LD@BC/F?.'PI\.II?P0^.[6=[J5K
M+HOB[QE>6=Q;:IJ$%PLUG8)Y+RW$5PLUQ@@,ZW#RK*X#R!W :M#]KW2;'QM^
MPII?B/6;>*_U:#P_X<FBO[M%GNHY+N;31<.D\@:57F'$S!@91]\M7I_[67PJ
M\(?"#5/A?J_AC2K;3=2G^(&A6=QJ%O&%OKB&Y2Y2X2YO.;FX^T G[2T\DC7!
M+-*79F)[#]H#4])L/CKHT7Q+6Q/@.Y\/W$5H=8AMY--&O"[$K&9IE:.*X^PQ
ML+:2Y**5-Q%;L9))T8_X)\?"C5O OAW6;F_U#5[VSCU>_L?#TM]JMQ<P2Z#
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M[;:?;M;:SXG\+Z7X>UB^MVTPPQ7<LZ1&&+3I'M(GN;0>0%:S\TB1H(Y)1O\
MJ#]B_P"!'@SPUX'\'>-;>WN7UJZ\(Z5927-SJ%_=8MY;>WN6@BBN)Y(H8A*
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MOI^OQ1^.%G-X7UGQU9_&WPO%<:3K<NJC1O' L(M631[6:"&#3[5H(K?[1:)
M\GR,&C,U_)(R"3S)KVOH_P"+/B/4/C'\;],\,:;;Z)XAT6/PB-<CTW4-1O;>
MSO\ [=?B);N3[/::A97L5LMO$;>.XB&V2[^TQ,[1AH?$+N;XH_L$_"OXFZGJ
M5_I"1W<LFH^&-'TVZ\U=+%[?_9[AH4N+& -;VLE_9OY21&W9P04@:Y9G^O\
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M6;:;Q-K/V-)KV>SNI+"*&RRL,%OIQU#?%$%DGD(6[W/=W,UPS%"ENF!^R7\
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MY8_3_"W[0FGZMXOA\):WH^I>'M4N[9KNQAU7[$5ODB)$ZVLUE=W<,DL "O-
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MEPF?'^UA:#Q5+X0N/"GB"#Q#]ABU*WTPQZ;+)<6KS20O,MQ;W\MC D31D/\
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M44444444444444444444444444445^0'[-/_ "CSOO\ L6_%G_H[4J/VEO\
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M%BD61$=)8UG5)D*_)*KJ"P 8_7__ #>]_P!TV_\ <_1^SQ_R<[\;_P#N4?\
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M;2,JJ7*0JBERJ*I8C)"J,X QG_\ "I_ _P#PD_\ PE/]@Z;_ &U_T$?L5O\
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M>D7[''=2>3%+*]L'$LQW9D+M;1/##%$]?3_[17PQU[X3> M2\<>$?$&KG7=
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M+&]^W3W+1"8PZ;IFHZG)'&S,J/,FGV]PT*2,DBQ-,$$QBF$9<PR;>@\ >/\
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MWX$^*&J7FD:1J/\ Q,K+FXT^\@N+&^B79$XD>SO8X+D1$3Q;9O+\IBX4.6R
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M-Q7/_#GXR>$OBM-J-OHMU*USIDL<5Y:W5K=65U;M-$)8C+;7D4$Z)(AW12%
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M7#MY,R:O=203;4DB+^3,D<OEEU639L8[&8'H/V1/B7KGQW_X130O$,GF:UX
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M@=(TQ+>X>\M[4PR?9#<7TEVZ2.;< RPK;YBD?RQ=7(A,]Q]'_P#-[W_=-O\
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M4FW71G)1]S+>))\Z3'/TG4X=:_;0M[R%95CG^&22H)H98) KZZ& >*94EC<
M_-'(JNARK*K @:'[ O\ S57_ +*3XC_]MJ/^"7'_ ";%X1_[B?\ Z=KROG_]
MFG_E'G??]BWXL_\ 1VI4?M+?\H\['_L6_"?_ *.TVO</VLM85/CA\(M*GUR^
MT:.^E\0B"XM+FTB5+P6=O%;L\5];7=O.[I//:0HT:R![O,<@;,<G/^-?V;_A
MC\,?%OB?Q%XF\0^(+_4?%7A;6;35;J4:?M@TFTM;9+N\$=K8VZAX56T@C6*.
M>5WF5OLTJ">6+C_#_P#PL/\ 9 U?P+X7\?\ V;Q9X>;6[#2/#NKVFVPO-,N)
M=,ET^&*YLEQ'<1,DLT:/YTSI&LT\KO,UM OZOU\ ?L"_\U5_[*3XC_\ ;:O@
M#]ESQ3<>#_#'[--W>37,.D2:EXMLYF19WMS?7LMU::>DHC#)YKM-,D+.,JC3
MME8Q,P^__P!L_P -?VWX[^$$^D2;=?@\71>2([OR)CI8MY)]7PAE021>3!$)
M^&)5E@'_ !\>7*?L\?\ )SOQO_[E'_TTRU]_U^./[-WPY\._%_\ 8.T;PMKV
MHRZ;;:K+)9)=11F5H[J;Q+(EEF, [D:Z,"2+E 49LRPC]ZGM_P .?'7Q#^%_
MQ?\ #'@SXIV]MK>I:G;:]!H?B;3W6#S;=6@O)[:]T\+%'#+LM8',L7F(O[B%
M#(QNYS\X6EEXB_8N^&=EK"W,7C?X4>;I.J6<9 TW5=,6;5EU"UN5PD8O4$CP
M,\<SPO-.\:>3:6J3AOJ__F][_NFW_N?KX@\2:U_PC_[.WQ]N6:Y6+_A9.IQ7
M"V=Q]FFDMYM3TR*XA2;9*$\Z%Y(F+1RIM<AHY$+(WV?\5_V>/"/B=O"OQ%\2
M>,?$'B)= OK&]T583H8CN;B]N[06L2-::=:I(EW.MK&LDDT<*A@YGAB+RCH/
MV--3FU;Q;\6I=86)=;7QE<Q2AX8H;K^S8;6WBTDR*JHYMS CFUD8%909959V
M>1VS_P!@7_FJO_92?$?_ +;4?\%1_P#DV+Q=_P!PS_T[6=9__!13P'8W7P/M
M-)T&.*SU:UU?0X?#,5M<+8-'J!O(K:W2TVR0HKI;R3[%SLA16F 3R0Z9_P"V
MCI%Q\&_''@_XWZ?/]GBT>Y@T7Q"6,[(^BW]P(S(\<<RF3[+-*7CBCBE>2>6*
M5E9+55KZ?_9U_P")[H>H^+3_ ,S1J4^KQ%>$:S\N*RTV5%/SIY^G6EG<2)*?
M,6>64,D/$$7T!1111111111111111111111111111111111117/^*?#5GXPT
MN;3KN2YCBFV[FL[NYLIAL<.-D]I+#,G*@-L==RY1LHS*?/\ X.? CP9\ M+;
M2_"MO<VED<;;:74+^[ACP\CGR8[N>9(-S2NTGDA/,8AGW%5(\P\%?L,_ ?X>
M>*G\3Z1X2L8=1:4S([^;-'#(9EF#V]O-(\%LZ.JF)H(XS"!LC*(2IZ__ (9B
M\ _\)Q_PFOEZE_;7W?M/]MZQ_JOM'VG[/Y7VSROLGF_/]CV?9?X?)V\4:E^R
MK\(-9UR\UB\\+:;/<7VUKI);=7MYY5DED%Q-:MFVDNP9Y@+QXC=!)9(_.\MV
M4B?LN?#"+PA;>%%TC&GVES;7MOBZNQ<Q7%H$6WGCO?.^V)+#'''!#(LP>*V1
M+5"MNJQ# U']CKX6ZIJECJDEKJ2W>G^<;6:'7=;A:!KA MS)$8KY-DMSR]W,
MN);N5I)IWEEDD=NOU/\ 9U\#:MX]7QU+#?+K:Q0P"YBU74X5\B%UD6W,$5TD
M!MRZ"22W,9AE<L\D;L[EL#1?@-X:^",WB#Q9X1TN^OM=O+%A)'=:WJ,S:A);
M1?Z-%+)?W-Q$KY588KB128$=@&$;.K?GA\+?V9/@B]G::CJGPT\21^-%N9;J
MYMK"WU?38H;Y+EY9!87J7-IHT-I P+:>ZWJEK5(%$DMVP5_T^^ F@>)_"W@3
M3M/\27=S=WL/GJ)+Z2*:[^SFXD-HEW+ !%+=QVQACNI(RZ27"2.LLP;S7/'7
MP$\"?$G7+?6]8T[S;V"V>Q,L<]Q!Y]I)(LCVETL$D:7=HS+EK6Z6:W.YP8\2
M2!CQU\"/!GQ$URWUW4+>YBU*WMGLDO-.U"_TVX-O)(LI@DFL)[>26(.H=8Y&
M=$<LRA6=RWH'A;PMI?@O2X=-TV'RK>+<0"SR,S2.9)))))"TDLLKLTDTTC/+
M-*[RR.\CLQY_XE_"KPA\9-#DT3Q3I5MJ=E)N/E7,8?8S1O'YD3??BE"R.$FB
M9)8]Q*.IYKS_ $W]ECX4:1KEGKEKX?MH]0M-Q^TJ9!+<,9(IO,OGWYOY1-#%
M<)-??:)4ND6Z5UN!YE4/"?[*'P[\"PZG%HZ:O:+JLKSWAB\0:ZK2SR2Q2R7!
M;[=N6X=H4$EPI69TW1-(8I'1N/U_6?AA_P $^/AY:?9]-U*W\/?VE'!)]F:[
MU%+#[8QW7$OVB>22&T#@;Q#NS/,-D+S3G=V'[./A^:ZL=6\:ZGH\NE:MXJOF
MOKB"ZBBCN8[6!1::;#,$:1D=;*&&:6!Y',-W<76!%N,2?1]>/^.O@1X,^(FN
M6^NZA;W,6I6]L]DEYIVH7^FW!MY)%E,$DUA/;R2Q!U#K'(SHCEF4*SN6/$?P
M(\&>*?" \)7=O<KI?[SS(;?4+^V:?SA()OM,UO/'-<^>9I'N?M$DOVF5VFF\
MR4[ZZ#X:?#'0/A%H<>B:$MS'90[1%%<WMY>^4JQI&L<37DT[QQ*J*$A1EB3D
MJ@+,2?$CX6^&/BWI<6G:_:?:(H+F"]@9)98)H+BW??%/!/ \<T$J'($D+H^U
MF3.QV4^0:C^QU\+=4U2QU22UU);O3_.-K-#KNMPM UP@6YDB,5\FR6YY>[F7
M$MW*TDT[RRR2.W7Z9^SKX&TGQZWCJ*&^;6VBF@-S+JNIS+Y$SM(UN();IX!;
MAW,D=N(Q#$X5XXT9$*\!JW[#/P'U_P :W'C&^\)6-SJES*\TS3>;);R221E'
M=[-I#:,[9+LS0DM,3.29CYE?5]>?_$OX5>$/C)H<FB>*=*MM3LI-Q\JYC#[&
M:-X_,B;[\4H61PDT3)+'N)1U/->?_P##,7@&Y^34(]2U2W/W[35];UC5+.3N
M/-L[^\N+:7:<.GF1OLD5)%VR(C+Z!\2/A;X8^+>EQ:=K]I]HB@N8+V!DEE@F
M@N+=]\4\$\#QS02H<@20NC[69,['93G^&_@]X:\*6.H6MI]N+:A%Y-Q<W&IZ
MC<WAC"NJ(E[<7$EW&D?F2-"L4J""2666,)+([MP'A/\ 90^'?@6'4XM'35[1
M=5E>>\,7B#75:6>26*62X+?;MRW#M"@DN%*S.FZ)I#%(Z-GZ1^QU\+= \(3^
M$+*UU*#19\A[*/7=;6':PF#QA1??+%+]HE,\*XBG8JTJ.R1E?@#X^Z!\%?AI
M\;OA+X2EU:VM]+TC_A(OMD-_KD\K:;YFD6HL?WUU=O-I^#'$]CLD@\N54FM]
MLN'K]3OAS\&_"7PIFU&XT6UE6YU.6.6\NKJZNKVZN&AB$40EN;R6>=TC0;8H
MRY2,%MBJ7<MYA=?L6? V\M]0MI/"&FFWO]Q>#RL0PL\"0/)9Q B.QED2.,2S
M62V\LK112.[211LNAKO[)GPS\17VD7T]G?1W.CQ3QV4UMK&K6LD)N6=KF4/;
MW<3-<7+2.UU<N6N+HMF:60XHUGX*>!OA]XBU'XGQ:=J]]K=I8WC'R-1U.[GF
M@Q).UG;VDMV8&1G)-O:!%A28QF-(V5&7R_X%^/\ 0_VMO%]K\1K'2KE-(T;3
M3::-=7]M'$TEYJ)#:JT89I'/V5;>VLUGB\N,ROJ,*R74>&3[?KQ_XE_ CP9\
M6]4TG5-;M[DWNC_:?L-S9ZA?V$T'VM$2?9)93P/^\5%5LD_+E1@,P/8>"O >
MC?#ZQ>TTR.4++*9I9;BXGNKB:0JJ;Y[FYDEGF<(B1*TLCE(8XX5(BC1%Y_XJ
M_!OPE\:K&QL_$=K+/'87T.I6IANKJTDANH%=8IDEM)895=!(VW#8!(;&Y5(T
M/ OPQT#X=?:&TY;EY;G8);B^O;S4+AUCW>7&;B]FGF\J,O(T<(?RHWEE=45Y
M9&;Q#P5^PS\!_AYXJ?Q/I'A*QAU%I3,COYLT<,AF68/;V\TCP6SHZJ8F@CC,
M(&R,HA*GK_C7^RQ\*/VB?);QCX?MM0E@V".XS)!<!4\S;']HMWBF,0,KMY)<
MQ%VWE-X##L-)^"G@+1?!5OX*AT.Q;0H(DB33YH$GMRJ2"4%TF#B1S(/-:23<
M[S9E9FD)8\!X7_9"^#7@^^TN_L_"]BUWI42Q6ES<JUW<1JC0M$3-<M+*[P""
M)+621F>TA3R8&BA+(;_@7]F+P#\-_$]QXFTF/4DU*ZV?:9Y];UBZ^T^5$T,7
MVE+F\ECN/*1RL7G*_E<%-K $'@7]F+P#\-_$]QXFTF/4DU*ZV?:9Y];UBZ^T
M^5$T,7VE+F\ECN/*1RL7G*_E<%-K $%U^R_\.9]4U#4HK&YM;C4+EKZ8V6I:
MC9J+MT2.2[ACMKF*.WNY43RYKJW6*XFBDGBDD>.XG630^&7[.7P^^$/AVZ\.
M:'82KI-U$T,EA=WM[?VOEN9#(B07L\\4:2F:0S+&JB8M^\#X&.0^#G[%_P %
M?@%JC:IX5\,VUI>G&VYE>>[FCPDB'R9+N29X-RRNLGDE/,4A7W!5 T+;]DSX
M9V5]J5U#9WT:ZK?7&HW]LFL:LMG=W%RVZ=KBR%W]DF27[LL4D30R1_NF0Q?)
M7?\ C7X+^"OB+XBT+Q!KFF17E]X?EFFTZ25I"L$DPCWN(PPB=P8HVC:17,3H
MLD91P&KU"BOG_P "_LQ> ?AOXGN/$VDQZDFI76S[3//K>L77VGRHFAB^TI<W
MDL=QY2.5B\Y7\K@IM8 CH- ^ G@3PMXGN_$FGZ=Y-[=W,E](%GN#;_:YHA!+
M=I:&0VL5W)&#')=1Q)<2(\JM(PFEW^H:MI-CK]C<6-];Q7-M<Q/#-#,BR1R1
MR*5='1@59&4E65@0P)!!!KYP_P"&+_@JMG]FC\,VT6RY^UV\T3SQ7%F_VG[6
M%L+F.1;BPB6<M*D%E)! CO*5C'FR;]#2?V3/AGH'BJW\3V-G?6VHVT26\+PZ
MQJT<<=M',)DLTMUNQ MDK@%;%8Q:* $$(0;:+;]DSX9V5]J5U#9WT:ZK?7&H
MW]LFL:LMG=W%RVZ=KBR%W]DF27[LL4D30R1_NF0Q?)7I_P 2/A;X8^+>EQ:=
MK]I]HB@N8+V!DEE@F@N+=]\4\$\#QS02H<@20NC[69,['92>!?ACH'PZ^T-I
MRW+RW.P2W%]>WFH7#K'N\N,W%[-/-Y49>1HX0_E1O+*ZHKRR,W0>*?">A^.=
M+FTO6["VU"RGV^;;7D,<\+['#KOCD5D;:RJRY!PRAAR :\ M?V+_ (*VEOI\
M2>&;8MI^U89W>=[EHE@>V%O/=-(;BYM/(<VQL[F26U:V"VYA,*(B_#_P9NOA
M1\9OVG?BFS:Y;32WW_".#2KC2M:DL[BY6'29/MD=K<:?<PS3Q*8D:YAC=X@\
M,3RIOAC9/K#]I'3/ 7P!_9N\2>'K-K'1=.7P_JFFZ?!),D*R3RV%P4AC,K;I
MKB5M[GEYIG+R,7<LQ\__ &._@]\(_'OPQ\"Z[9^5J,^DV.ES&"+4[FXL;358
M]/C\USIZW#6,-ZK3/+(WD+.MQ*UPQ$[F0_1__#,7@'_A./\ A-?+U+^VON_:
M?[;UC_5?:/M/V?ROMGE?9/-^?['L^R_P^3MXH\"_LQ> ?AOXGN/$VDQZDFI7
M6S[3//K>L77VGRHFAB^TI<WDL=QY2.5B\Y7\K@IM8 CD-6_89^ ^O^-;CQC?
M>$K&YU2YE>:9IO-DMY))(RCN]FTAM&=LEV9H26F)G),Q\RN_\:_LZ^!O'_BI
M/%-]#?1:LEB--%W8:KJ>GR?91,TXA)L;JW#)YC%SN!).W).U<>H>%O"VE^"]
M+ATW38?*MXMQ +/(S-(YDDDDDD+22RRNS2332,\LTKO+([R.S'G_ (D?"WPQ
M\6]+BT[7[3[1%!<P7L#)++!-!<6[[XIX)X'CF@E0Y DA='VLR9V.RGG]?^ G
M@3Q/X8M/#=[IV^RL[F.^MRL]Q'<17<<IG%VEW'(MTMVTC/))="7[1,\DK22.
M99-W0>!?ACH'PZ^T-IRW+RW.P2W%]>WFH7#K'N\N,W%[-/-Y49>1HX0_E1O+
M*ZHKRR,WH%?*%M^Q!\%[*QU+38-$EBT[4Y;B:ZTZ+4=233Y)+A=K/]@6Z%HK
MKA# R1*;9XX7A,3PQ,G0:G^R+\(]:\!+X%O-!BGT9989A#+-<O*)($6*)Q=-
M*;H/'"B6T;>;E+55M%(ME$0O^!?V7/AA\+_#%QX<\,Z1_9%I<[//DTZZN[6\
ME\N5ID\R_AF2]?:SL%W3G;&S0C$1*$\"_LQ> ?AEX8N/#.@1ZE8Z;/L_<0:W
MK"^5LE:;_1G^V>9:[W=FE^S-%Y^2)=Z\5T'P<^!'@SX!:6VE^%;>YM+(XVVT
MNH7]W#'AY'/DQW<\R0;FE=I/)">8Q#/N*J1Z!;>%M+M-<NM;CAQ>W=M;6<TN
MYSNAM)+B2%-I.P;&NISN50S;\,6"H%\O\6_LU_"[QWXB/B#5_#MC=7SQ-#/(
M\7RW4;"+"7L8(BO4C,$+0K=K,('BCDB$;HK#/L?V6/A1IWAC5_#$7A^V&EZQ
MO%U:DR,FUI9)Q'#N<FVBBFEEGMX;8Q16T\DDT"12NSG U_\ 8Z^%OBG[(=0M
M=2F:TN8[Z-VUW6P_VN'(BNW<7P>6[C4B*.ZD+W$<"16ZR+##%&GT?I.F0Z+8
MV]G"TK1P1)$AFFEGD*HH4%Y9F>61R!\TDC,[G+,S,23G^$_"VE^!M#L-$TN'
MR++3[:&SMHMSOLA@C6.--SEG;:J@;F9F.,DDY-?.&K?L,_ ?7_&MQXQOO"5C
M<ZI<RO-,TWFR6\DDD91W>S:0VC.V2[,T)+3$SDF8^97U?7S_ *Q^S%X!UGQ/
MJGB;R]2M=2U;[/\ ;9].UO6-/\_[+$(8?,2RO((SY:#:OR\98_>9B>@^)'P!
M^'GQ;\(1>$=?T6VN-(@\CR+5 T"P?9QMB\@P&-X-BYC'DLG[IFB_U;LI/@Y\
M ?AY^S_I;:=X.T6VTR*3'FM$&::;:\CKYT\A>:;897$?FN_EJQ1-J84>8:3^
MPS\!] \:V_C&Q\)6-MJEM*DT+0^;';QR1QA$=+-9!:*ZX#JRP@K,!.")AYE>
MG_$+X _#SXJZI9ZIK^BVUW>V?RQ7)#1S&(I*C6\DD91YK219YEFLY2]K,LCK
M)"X8BL_PW^S=\-O!.C:AI/A_1HM&@U&7S;E](DFTZXD83O<*/M5G)#<*B/(Z
MQQK(J10L;=%6#]W6?X%_9B\ _#+PQ<>&= CU*QTV?9^X@UO6%\K9*TW^C/\
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MOC6Q^)7A72?$=BDL=MJMC;7\*3!5D6.YA69 X5G4.%<!@K, <X8CD]A117S
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MIL^JS:AK\SI;VT,=Q'#"J0E[5+N6Y;SU6);RV:!())V\P!(I>?\ V-OVMO\
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M3ODOIK'XFO?110W+?$3Q 9HX96FC20K:[U21HX6D16R%=HXRP 8QH3M'T_\
M%?XO0^"]9T#PI8O%_;OB66ZATT7$<K6\:V<!N+JYG\O:62&/!6!7C>YF>.$2
M01M+=6_B'C#X\_$#X#>+]'T3QBFFZI:>)<V.DZAI]E?:?##J^2(;+4 TVJ>7
M%=[T$%S$SR1M'.7M6B1IDY_X5_'3XW_'VW\8+HFG^&]'ET#6[_1HFO)[_45D
MN+""%6A=(X[$B*6:1I%O@V^.+$)TV1P9SX?^T]^TQXB^)_[)GC+7-.BBT+5-
M/OI_#NN:?)B_:!C>I8W-K'<[882[Q7$4AN(TF14=XDQ-B>'Z@^,/Q=\5?!2^
M\#1^(]'TC75U3Q!8Z.FHV\DUC):WFH-<PB:"QFBO]J1VI9&D%\))3))'LCB<
MUZ?XZ^+5Q)XXM_AYX;N+:+7Y]-?6I);ZWGGM[:QCN%MPYBBDMS<2S3-Y4<*S
MPB-%EN))/W<-O=^8:9\=?&7A7XDM\,_%S6*ZIK%C->^'=7LM.O$L+AH86,]M
M<VTEU*RW%LT;3LL=X4FMGC!DM9GC67C_ (!?%GXW_'3_ (2J'[=X;T__ (1W
MQ)J6@?:/[*O[C[7]C\H;_LW]J0_9L;MV[[1<^;YFSRX/L_F7/G_A;_@H%_PD
MGP\^'6H:B^F^']2\9_VHC7VH'?I=E_8[2)/+(KW-I(WVETCCMX3.GEF?+3RM
M"J7/V_\ "35O'%Z^O67BL6TDNGZDMM:W-G8W%C#=6[:?9W/FI%/<W9.V:>:!
MG25D+0D85U<#/^*_Q>A\%ZSH'A2Q>+^W?$LMU#IHN(Y6MXULX#<75S/Y>TLD
M,>"L"O&]S,\<(D@C:6ZM_(-:^.OC+X&>/?#^@^/VL;[2_$TJV&GZII&G7EHM
MMJ6_"6EY%+=7R[+I77[-,DRL'CF$D'DJUQ'Q_P ._BS\;_'?Q/\ &_@3[=X;
MB_X1?^R'_M+^RK\^;_:%HUQY7V+^U/\ R-]K7R_*V^1-]HWVOL'[+/QKUSXS
M:7XECUN&V2]\/>)-4\/2S6:210W/V%T*SI#)),\&Y955HC--AE+"3#!$^/\
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M&]=T+6[C3=:UNZ\56&LZ=I-[J%O)_:2Q"6SDCL(KJ2&6!XV56?'G(K2LD"M
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M8MV[RGW(/WD7R^8B;TW9_P"U_P#L\>-=7\>^$?BU\/+>*[\0^&Y1;W%C)-'
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M"3X1_,^KZ*************************************************^
M/^"7'_)L7A'_ +B?_IVO*\_^&/PZL_B%^T[\9X[V^U*"WA_X11C#IU_<Z?YC
MMI+A7DFLG@N3Y8#JL8F$#>:S2122) \/'_"CQ?\ $'3O@5\53%XOU=KOP/X@
M\46^G7UR;*\NI;?2[3SH8+N2\M9Q,C2.7=@J3 !8XY(H56,>P?$'XJ_%&?\
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M7T.M^#/$&H^&9[ZTAL+==34ZC:VXN'C%JSV;QP712$6<T;HZ^<TTC%0GT?\
MM8V?B?\ 9A\&?\+0TGQ7K=[=Z-<V9U.UOKB*2WU6SGO[6%[<VPA6RL)54JL=
MW8VL4@3S?,6:69IET/@=93:C^T?\=K>&YEM9)8O"D:3PB(R1,VCS 2()DEB+
MH3N42)(A(&Y&7*D^ WQ_\6Z=\.OBMKWB.\EUV3P;X@\26MJ9DM;626UTFUCE
MBB=K2WBB#N0VZ40D@N3M*A4'@&OI^T?J_@WPEXF\%:5X@O?%:RV-[J-Y?:]H
M[Z)J%NUG()HH;*SU@6)MY&>+R)(;2"8Q*)_/%T6F?T_XT?&A/"/QJN]&^*4>
MMZ5X5N?[,M?#VK:9>ZAING+--!-)=G4;RPO8#YLDR+%$DP98(8?/\NWADFN9
MON_X(6U]9?#KPU#?:E%JMS'I&GI-?PW#7,=W(MK&'N$G;YIDE;,BRMS(&#GD
MU\8?\%%?#5GK_P#PJWSY+E=WQ T.T/V>[N;?Y+CSM[#R)8\2CRU\J<8G@R_E
M21^9)N]0\2>*F\0_&'3_ (.![ZVTNV\+?V]-=6^I7<=Y<&.]2Q@MWNU<7:HN
M&GFF2<7%S((D>40BYCNN/@U[Q)^SO\?O#W@R"\N=3\-^-;:^DMX]3U"ZO;O3
MK[2[7S9S%/=>;*UI/$(1Y$LTA6X:66-H$!BG^W_%G]N?V'?_ -A?9O[2^S3?
M8_MOF?9_M'EMY/G^5^\\K?M\S9\^S.WYL5^8'BCXJWOP3U3P!'9:KJ6I^(=3
M\2:3H'B*>:37;O19VNTDAU(6;W&W2XI8KM=T<=D(9;9X7MC#'#'=6U>P?\WO
M?]TV_P#<_1^SQ_R<[\;_ /N4?_33+7V?\0O&MC\-?"NK>([Y)9+;2K&YOYDA
M"M(T=M"TSA S(I<JA"AF4$XRP'(_.#Q'\/\ 5O'?[,WB'X@Z]XCU>?6=;\+7
MVMLMO>W$&GVT5UI1D73X--,LMF;=(3Y#231RW3NTET)XKDQ/#GW?CGQG\+_A
M9\ ]0T+7;FVM]7N?!>@7ECY%A);RV]U:;YGW2VKW*2L$6/<DZHJ#*QB0ESZA
M^T5>^.;7X^?#?P]IGC'5].T[Q%+KDLT%K'IFV%M-TH&,1&:QE:1)&E=Y8[LW
M2;RLD:Q/%"T?/Z[+XE\$^.M(^%%G-XI\1:7IWA^?5[V6'7=.BUB^DO=3=+;S
MKFXN--NQ;VGD2AI+&XC)\VUMYP824GX_P[\7OC5^RW\,/B9X@\<Z7<KINEW+
M3^%EU*[@U&\V7]W+%!;WDT5_/))%;O):[S),TXC>94FF5(DC^D/^&9O&7A^'
MP[J&E>-M7N=;LM7M;W5KG4+Z\>UU&UDE<7]LNG"9["T1HY6-HL5N3 888Q(C
M$W2^/_L[>!].7]JOXQW@EOO,LY?#DL8.HWQC9KS2YVD$L7G^5.BEC]GCG61+
M4;5MUA55 [#X$6Z?MJ_#"W\>:Q?ZWI-UK/\ :$=O%I&N:A9)80PW<]K (DMI
M(89Y5$7G//=0S-+.[@JMJL%K#\@:E\?/C%XR\,>&X=1\2W.F:I:?$FP^'^K-
MI"V(M[LVTIFDOXO/L3-%+(1'&\1?['*B.&LUBG>W7W_]HA_%_P"R_I^E2RW/
MB[Q3X5O-2U74_$UW!<F35+919*]K%;2V3Z>;+3UFC:XE\CR8HA&8C*D,QMY_
MJ#]EG4- UO1]9U+PWXC_ +>T6]U*.XT]WU.\U*:VA;2[ /;3O>R27$,HG$TQ
MMI&+1+.NY49FC7Z?KY0^//Q0OM.^(/@7X=P"6"'Q=+JPNKRWG:&XBM],LA<M
M% RC=&]PS)&UPC+-##YAA:.X>*YM_'_BS=Z]^R;X]\%:EH-[?7^A>)M7M/#&
MI:?J^K7]^T=Q=NS6E[9R7K7,L3H!.+E/-$,R+"@A$G^D1>?_ +.7PAT*']I?
MXLQ"YU?;I4OA.6 G7-79G9].>4BZ8W9:\3<H"QWAG14S$JB)F0FK?"'0M:_;
M0N+.:YU=8Y_ CZ@YAUS5X)!*^NE2J2PW:2QVX!^6TC9;5#AEA5@"/</V<?'/
MC.[^,7Q-\':WKMSK%EX>_P"$?^PR7D%A%,OV^QEN)][65K:H^6VA<I\JJ .2
MQ;S_ .$?A[4/VSO FJ^/Y?$^MZ>VO_VA;:%#97E[IT.DV]K<75I:RO;6-[&E
MW=LR_:;I[B21';9;QB.&,;SQ;XW^(UQXX\._#W5X=2U9K/PC!J>N?\(WJ>G:
M?<7]]-<);+(C3SZ7=16D,EK<2/)830EGN;>&:-86\J7S_P -/^T3X$^&GQ/N
M=?N=2T&TT3^T=:\,3W%SIFIWSVRQ7TXLKV6=]4\R*+;;'+L+G+-&EVT2JJ:&
MF>'?BYX<_9_M?B/X5\2>(/$7BBY\&Z:EMI]]+;7%JAN!:W$]Q#:QP0FXO88S
M,8);AKFXF.(I/M181MZ!^RSX_P# WQ/\91W_ (2UG5[9K.QU>QU?P]XCUG4[
MC4H+J.\T\0S-8WUW=JB1*EPCSQ, K7"0L3*)8X?T/K\@/CW\5?%/[//PYU'Q
M5JVJW-[\0=-N8)KD:9)XAN?#L0GU&,)9RP_)ID'_ !+IHX_+N!#>'S(KI7:Z
MFANI/8/VCM&U!/VB?AEIEAKNMZ?:^)/^$@74X;/5KU(9DL=,B:-$@:5H;?(+
MAI+:.&=6<SQRQW2QSIGW/CQOV<?C[K^F"_U>Y\.67P[F\3W-G=:A=ZG(;BRU
M&1&D@?4;B9XW:#<GEI+%#(=A<9567G_$?P_U;QW^S-XA^(.O>(]7GUG6_"U]
MK;+;WMQ!I]M%=:49%T^#33++9FW2$^0TDT<MT[M)=">*Y,3P_9_[)W_)$/ ?
M_8MZ-_Z00UYA^U%\2O$NC>+?!7@_1K>^ECUR74[B^72[W3K2^FM+"U4-:VS7
M\EN \LEU%))+:W$%Y!;V\TD+JP,L7E_P3\#_ !?OOB'XKT7Q!INMZ?X!U"VM
M[G3O[1U]IM4MKR%;-7BCO;/5KJ]CBF99Y63SVCPJJIB$LT4O@'P/TK6/&O[&
MUWX_UCQ-XDNM<@T3Q#=6]S_;VJ0>2UG+?>0-EM<0I/M:+?ONA<2G=Y1D^S1P
M0Q;_ ,<-0\2>%OV4K3XMP>(];/BI]-\/:J;O^T[J.W\Z[N;$NO\ 9D$D6F&(
M)*T7E&T*R)\TOFS-)*_L&M0^,]?_ &IV\%3^,M;716\(W&MFVMVL+?FXU=+9
M[82P6<<HB$4:I%.'&HP9=HKZ-I)"W8?"+Q!XB^%WQ]UCX776L7VLZ3<>'X_$
MNF-J,HFN+!3J,MM/:-<.K7%XCO('BEN)6>"&-(,2<RGY@_9R^-]]^SC^P-8>
M,K&TBO+G3XKT0Q3,RQF2XU^>V1GV_,R(TPD9%*&0*4$D9;>OT_\ M%?#'7OA
M-X"U+QQX1\0:N==T")]8<ZIJ]_<6-]';(TE[#<V!=K-4FA\TQQV<%F(;@0^0
M]K&GR_-^D>.-8\$_&KX=^/M0OM;_ .$5^(NFQ".QFUC5+JSTO6M0@2:*/R@G
MDO%,)!#;0R81)'N+E4MX;2)$]0^)?B[5OA=X2^)GQ&T"\OI)C?'0M&6]UJX^
MP12O=6]A<7OD:E--:V[P:I-<Q-YB0VHMK")8EAMYI;BXS[W1OCMI'Q+\':IX
M/T/Q)%IYN9(/$Y\2ZWI]W#<6]S+; W$-I!J]Q#;RPA9YE%C!:HC%8HX6MRUO
M7/\ B/Q5\1OC[;_$0Z;I?B2XN++4M7T70&T/Q!IUC:6,UE MHLET(=2TV[>6
M6ZC-T\5]%=+#;O"(%,<CM.?$SXM_'+X>_#3P)J'Q%T'4I;1?[4/C$^&VVWT:
MVL4IL)%FL+R+[/%+L6ZO9H)8HE,?DEX8I3:S?8'[+.H:!K>CZSJ7AOQ'_;VB
MWNI1W&GN^IWFI36T+:78![:=[V22XAE$XFF-M(Q:)9UW*C,T:Z'[7/QOOOV<
M?A'KWC*QM(KRYT^*$0Q3,RQF2XN8K9&?;\S(C3"1D4H9 I021EMZ^/\ [17P
MQU[X3> M2\<>$?$&KG7= B?6'.J:O?W%C?1VR-)>PW-@7:S5)H?-,<=G!9B&
MX$/D/:QI\OS?\1].TCXV?&;X#>)IAJ5G_P )5INM:C/!!K.IIY&[0K:9([9X
M9X?LV-VV5K1;;[3@F97W$5^M^DZ9#HMC;V<+2M'!$D2&::6>0JBA07EF9Y9'
M('S22,SN<LS,Q)/YP:GX'T[5OVY%EEEOE9? D.H 1:C?0KYL.M+$JE8IT4VY
M5 9+0@VLKEI9(7E=W;/^&/PZL_B%^T[\9X[V^U*"WA_X11C#IU_<Z?YCMI+A
M7DFLG@N3Y8#JL8F$#>:S2122) \/G_P^^.'COX5_ 'XHRIJ]SJ]_X:\7:GX:
MTB]UB\M_.C62ZM+2VFN;NY3RG\B6[-P[7.(MJ^46BMPOE^@7NC?';2/B7X.U
M3P?H?B2+3S<R0>)SXEUO3[N&XM[F6V!N(;2#5[B&WEA"SS*+&"U1&*Q1PM;E
MK>OT_K\D/^"/FIS>,_AUXM\4ZDL4NK:MXIO);V[$,4<DS&UM9\,8U4;%DN)G
M2, )&99-BKN.?U/\2^%M+\86<=IJ,/G11W-I>*NYTQ-97,5W ^4*GY)H8WVD
M[6V[6#(64_('PKUA/VKM4\87.LRZE96_ASQ)?^'+.VTS5]0L%*V*0^9<RO83
M6LDTL[R$[96>*")(HXD60W,US\ ?'KXE?$#PU\,/BCX9U#6]2&K_  XN=&CT
MO6K+5[ZWN+FQUJ[@, OUMS;17-W%;*(Y9Y$<,[L542"2XN/J_P#:I\-:M\&9
MO -[X=\3>(+?4=8\9:5HU[=RZK<72RP:A%<QW#"PNFFTN-V.)(UCLDA@=5\F
M&-%5!T'C"SN_@K^T)\+]%T'5-7^P^(8O$D6HV]_J^I:G',MG8PW$!"ZC<7(B
M=)!D20^6Y!9"Q1F4\_\ ";1O%OQ#^.'Q*\*>(/&GB"]TOP_%X=BAACGM;!IE
MN[.>[8R2Z;:V<T3I*V1)9O:O,BI#<-<0HL8Y_P '>*?BC%J/C;X:/XHBN+3P
MAJ^A2WVNZS/]DNAX;O;'[3<VZSVL:%;V*.!D;499%DD$TTXDM)DBD3L/A-\2
MX-7^-^I_#729-;_X1Z[\(G5G&LMX@@U&*\^WFSD:WN=5>.^CB>&2/!B;RXYH
M@\#13?:3)S_[(?@&7XI?\+ CU_Q#XDN[?1_&^MZ3I\/_  D.K0_9[>W\@*OG
M074=S-D%5Q<S3(FS=$L4DMR\_D&@Z;\4_P!I']BK1/$VE^)-;3Q9IUM?SP3V
M%_=V\MZEG?3PM;SI:@M=RO;P!8"RF=[I4)F FN#+]'Z-XNT+]J3PK\+WT.\U
M>TCU.*:[N5L]:U>WN(;'385CO4DN5FMS>.NH"RL))KA9KB2&XN+BWV,SW<7Z
M'U\8?LJ>)X?B5XM^)_B22&6.YB\4R^' )+F695M=$M8(HEC5L)$CSSW=T4C1
M2'NG#/(5#GG_ (?,W[5?C7Q=J=]K&KVVC^&]7NO#%EIFGWMWI0:XM([=[R]N
M9["Z2:Y=Y6,5JC.D,-NFXPF>=RG/CQ!X]^%TWPS^$/B76)=4O/$,NNP7NN02
MO!=/8Z5%)<0*I"[X[BX@:WAN+@2-<1!9S%.UT\5]$?%F[U[]DWQ[X*U+0;V^
MO]"\3:O:>&-2T_5]6O[]H[B[=FM+VSDO6N98G0"<7*>:(9D6%!")/](BT/V>
M/^3G?C?_ -RC_P"FF6O/_P!EWQU_PJ_P/\<_$WV?[3_9'C?QAJ/D;_+\W[+;
MPS>7OVOLW;-N[:VW.=IQ@^8:^G[1^K^#?"7B;P5I7B"]\5K+8WNHWE]KVCOH
MFH6[6<@FBALK/6!8FWD9XO(DAM()C$HG\\71:9_J^_U6X_:&^-6O>$&U;4M.
MTCP7;:;)=VVG3SV$M_?:K!/+&9+VTN$N/LEM $*P1^09;IV:5GC@B5_E_P#;
M?^%/B3P!^RUX]LM=URYU:W@UNWOM'>6ZNFFAL;B_LA':7;R2-)=^0\MPJ&YD
MN0RBWF^22.*.W^@/VD]3\3_L_P!Q\.AX7\0ZE#9:CXNT?0+JSO)(M16:WO9[
MB:=WNK^*YOS*V!$K?:MD<0"I&A 89_[8MG=_!WQ%X8^*:ZIJ\>B:=J]O'XBL
MHM7U**U-K<B.U@O#;QW#)LM)Q$\EI;6S&^,K"4%?,8]AXWUA/"WC/QUX]AEU
M*YM?!^B&5K)-7U"*SN-2%A)=SPRVCS26R^59?8&ADBMQ#YE]/*XN+J)?LORA
MKZ?M'ZOX-\)>)O!6E>(+WQ6LMC>ZC>7VO:.^B:A;M9R":*&RL]8%B;>1GB\B
M2&T@F,2B?SQ=%IG^C_\ F][_ +IM_P"Y^O/_ (@C6/V>?VHO#.L:AJVMW7A7
MQ=Y^G1V\VJZI-9V&M3']T/LX#P^5<@B.VMY&9(I'N)U$,-G$J?4'P0\.IJ7B
M_P 7>*(KW4I;234I],L8I]4U"XM-MJ46^E2TN;B1(91J(N[0;$BB2WM(1;1)
M%+)+=?3]%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%<_XIN=
M<M-+FDT2UMKN]&WRH;RYDM(6RX#;YH[>Z=,+N9<0ON8!3M#%U^8/V(O@[XX_
M9[^&%AX*\31Z:W]F>=Y%SIUY<3^?]IN[BY?S(IK.V\GR_-1%VO-YGS,?+P W
M'_"GX5?&'P/\5/'/C2\TSP^T?BF+32+>+6KUFMY-+L);>)2[:.@D2>1D\Q\(
M;="S+'<,H1O/_"W[.'QA\/\ PZ^)OAQ[3P^]SXVU?6K^-QJ]Z([6/6;5X9 Q
M_LG=(]NRQ% %07 >3+6YB42^H>'_ (<?&_PA\-_ NCZ6-$AU+PO<V%O<Q-JE
M^;/4-.MM*ELI \B6$<D<KO()8XFAGAADBBF+S,@CKL/AS\![Z/XLZC\4=>M+
M'3=6N](CT0VFEW+7<$D:3B=KNXN);*REDN&"06Z+Y>(H;<9EE\Q$M_H_Q3<Z
MY::7-)HEK;7=Z-OE0WES):0MEP&WS1V]TZ87<RXA?<P"G:&+K\P?L1?!WQQ^
MSW\,+#P5XFCTUO[,\[R+G3KRXG\_[3=W%R_F136=MY/E^:B+M>;S/F8^7@!N
M@_:3_9]N/B__ &)K^A7O]G^)O#%RU]H]S(\XMV9]GGVEXD+*[6EVL:PSE")5
M3[N]#+#,3_#3Q?\ %GQ/H.J>-K33;*R\/7,FHVMA879U-+J^:)H8+B>2ZTVS
M>'[&KS/ D.XR3S),SQFU19?+_A3\*OC#X'^*GCGQI>:9X?:/Q3%II%O%K5ZS
M6\FEV$MO$I=M'02)/(R>8^$-NA9ECN&4(Q^SS^SSXR\*V/CS0?&]AI$VD^+]
M7UG5YA8:G>2R*NJK%$]F5:QM#L$:R9N4F1\E0L*YWKQ_P+^ G[2WP2M[7P4G
MB[1+_P *VV8H=2N+2Z.M6]N8!B&VA9I+-?*DREL;E[M(4*L8Y88TLE]@_;#^
M&^E^(/@K>:2DMS'>VGV$:'<+.[WD>KI/%!I92[G\V5)9KEXK>2Z>19/+GE:2
MXC#/*OO_ ,*O O\ PK3PAI6A-<?:Y;.VCCN+HIY;75P1NN+J0;G/FW,QDN)F
M9W=Y9'=G=V9CY!^U3\"]<^..AZ)_86H6UEJ7A_6[3Q#9_;8))K>>XL8YO)@G
M\J2.2.)WD7S)4WNB [8V8C'G^F_ OXIK\;[/XDWFH:(WGZ(VAW5K%!=K]CMQ
M?Q7X6%VD;[?*V)K8W#C3D3,=W]D?:UFWS_\ LH7/Q3M/^%L_\(=:Z)=>;\0/
M$J1_VM<W=K]GN!Y.V5OL]O=?:HFW)F$?8WC\IL3R^>/LQ^VM\([?X+_L=^+=
M+^T_;KVXN;74=1OVMX+=[V^O-;M9KBX>.!51=S-LC3YC% D4.]Q&&/U!XV^%
M?Q+^-UQIV@^+QHD'ANVN8KO4%LFENIM7:SGBFMH'MKRU$5C:22Q^==1":_E9
M52T6X*-+._'_  I^%7QA\#_%3QSXTO-,\/M'XIBTTBWBUJ]9K>32["6WB4NV
MCH)$GD9/,?"&W0LRQW#*$;/^!_[-GCC1M#^(GAGQC#IL>F^--2US4Y)])U*X
MFN(/[7CCA:W5+C38(SY:!V%P6.7V@VVTDC/^$/P1_:1\*>'4\ ZUXF\/KX<L
M[&33+;4M/MK]-;-JI\F'85F@MK2X2V.(K@?:C!+'$72[.^5O4!X%^*?A;5_$
MNEZ?H_AO5O">H?98]/T^^U&[L_LENFF6]E<69MTTR^MOLCF$M'!&$1?,E9MY
MFVQ^G_LW?!"Q_9P^&VC>"[.[EO(]-BD!N)55&DDFFDN)6"+D(ADE?RTRY1-J
MM)(P+MR'[4WP4USXS:7X:DT2:V2]\/>)-+\0Q0WCR10W/V%W#0/-'',\&Y96
M991#-AE"F/#%TX_Q[\ O&6M>*O#WQ,TFXL8/&&F1-975J;B\CTR^TV>:1VL)
M9%5Y=]N)3);WGD;9;J-9I;%4:**U] \-_##Q%XJ\>VGC?QE#8P7.EV,]AI=A
M93"^@MVNW1KN]^U3V-G.+B9(XK98U4)##'*0\ANW6+T_XL>!?^%H>!]>\,_:
M/LW]KZ;>Z=Y^SS/*^U6[P^9LW)OV[]VW<N[&-PSD?"&M_LK?&'6?!7@G0IM3
M\/R+X%U?2+VPA2*]A.HQZ1(8H'N+HM-]A>2U?;+!':WP6XC\Q;GRIO*A] TG
MX0_&&'X^V_Q#OK;P_-;+X?3PU,(=1O89'C&HB[>^2!M/F6-V7.VQ:XD"DA#?
MN!YAT/@E\)OBGX-^,7C+QCK=CHD=EXK_ +*\V.SU6[GFM/[,L9+==BR:7;I<
M><S*6R\'E+DCS2 &^O\ Q9X6TOQSH=_HFJ0^?9:A;36=S%N=-\,\;1R)N0JZ
M[E8C<K*PSD$'!KX T/X&?M!Z9\&-4^%=W=>&[VW.FWNBV&L/->Q3"Q-LT%LD
M]A':>7YNS$1F2Z(@5EE:.]DA<7?/^)?V;/C?K7@?X;^'/)\-O_PAFI:#J>_^
MTK^+S?[&MS;?9_\ D&R[O/QY_P!HQ%Y/F_9OLTWD?:[CU#XK?"KXP^./BIX&
M\:6>F>'UC\+1:D3;RZU>JUQ)JEA%;RJ'71W$:02*_EOAS<(%9H[=F*+H?'SX
M!_$N[^)>E_$SX9ZIIL&M0::^AWEGKB2M8W%BTKW*D-;(UPDJ3LK$*0) $^=%
M22.YT/%W[+VK?'7P5K=C\1;^QN=6UC2(M-1M-MKB*STYHY/M0>VCFNGGD<W8
MBDN'\VW2]CL[&.2VC\D[N?\ A#\*_P!I'2X4\+>-?%&D7OA^VBD@&I6*W\>O
M7D22_NEFF9EAMGDB^2>XB,UTJ@^7.+IQJ$?8>&_@IXX\!_&KQ;XMTN;39M-\
M5_V&]RUR]PMQ9_V7!)!)%%;I&8[C[0A 29KFW^SNY<P7*PB.?G_A-\#_ (@?
MLN?VGH'@>#3=6\,SW)OM/MM7U:^M+C36FS]HM(W2QU%)K3<%F@.(94>2;S?/
M=O.;R_X@_LB^/8M&\(Z3X<.D7\FD>*;7QGJFIZC<OI]QJ6I+/<370:WLM-GB
MC24S*L4IDD:&%$M_+D6)9&^H/'NF_&%_$7AC6_#L>D-';V-_;ZQIE[J5[# \
MET+-X7MIX;*4.\$D$BK-/;*3#)(JQ1M.QC\?T_X$>(OA9I/Q+\;:5?Z1X;\1
M^*(H[QRQ%QI.G-8V[KYS2O!:,[RL\]U<W4T(2.64,UM<B"0W?T_\%_$GBKQ=
MX*TS4?%&GQ:?JDT3&XAA\X1DK(RI*B7"1SQ).@6=;>X1;BW$@@F431O7F'[2
M?[/MQ\7_ .Q-?T*]_L_Q-X8N6OM'N9'G%NS/L\^TO$A97:TNUC6&<H1*J?=W
MH989B?X:>+_BSXGT'5/&UIIME9>'KF34;6PL+LZFEU?-$T,%Q/)=:;9O#]C5
MYG@2'<9)YDF9XS:HLOG_ ,$OA-\4_!OQB\9>,=;L=$CLO%?]E>;'9ZK=SS6G
M]F6,ENNQ9-+MTN/.9E+9>#RER1YI #'_  J;XI_\-%_\+&^PZ)_9O]B?\(WY
M7]JW?VC[/_:?VS[9M_LOR_-V<?9/,V;^/M>WYJ/@E\)OBGX-^,7C+QCK=CHD
M=EXK_LKS8[/5;N>:T_LRQDMUV+)I=NEQYS,I;+P>4N2/-( ;R_X9?LT?'W]F
MG5KK1/A[X@\/W'@^[OFNH;778-1EGTF.:XD:2"R6&?,Z+&R-^^N8Q-,&;9 \
MDTLO8?%/]F3XEZ'XXT7Q_P##37[:77+739M%OX_%!EFM[VTFN);PR-):Q^;%
M*+F3>(H!#;J@BBA6VMH/LTW0>/O@I\4_&W@?6_[1FT34?$FN:)+H#;'N]/T[
M3K>YMYO/>UWQZE<2RO/)'Y['[*EY#;6>Z.![5?,T-(^&?QAT+X#Z9X4TR32+
M#Q'HL6B6UG,E_>RV<\>ERV3.;ATM+:=$N4@FBEMT60&-]AG(D;9H0? O7/B)
M\5_#WQ#\5Z?INE7OANVOK>U72KZ2^:[^VQ^5BZFGTZQ=(K96F:&)/,WRW+/O
MA$;I<?7]?E!=?L,?%/\ X4#J'P8A\0:)_9<.Y[*]>QN_M-UNNDU%8IT%QY=E
MY=V'C,T?V_SK:12(()83Y_N'Q0^$/QA\8?$GX?\ C2WMO#\TGAB+6))[>34;
MVU623583;B"-QI]T2EM&L>;E@ANWWM]DLU*H#6?V>?&7C[XZZCXJ\0V&D-X<
MU#PM>>$9[>+4[QKJ2UFNY+@3E18P*CR*1%)"DX,(9I$N9"BJW'Z'\#/V@],^
M#&J?"N[NO#=[;G3;W1;#6'FO8IA8FV:"V2>PCM/+\W9B(S)=$0*RRM'>R0N+
MOZO_ &<?!7BKX;_#K1/#_B-[%KG3+&TL$%@9GC$=I:Q6X)EF6-I'D:-IB1%"
M(A(MOME,)N9_,/VI/@'XO^)>J>%O%_@?5+:P\2>%;FXELEU%"]C<0WR1PW<-
MQL1Y4W1)A)(OF +J CNEQ!H>&_!7QANH;3Q'XN?P_J6NZ=%.ECIM@;VQTV.2
MYE2.2XDNKA=0F>X6V1DMY8[6 PK<7EL?-CN3*GS_ /##]G#XP_#S]FN\^$[V
MGA^>YDL=1TV.\&KWJQF/4S>O),R?V265X&GB5(@6$X\QC- 459#XG_LX?&'X
MA_LUV?PG2T\/P7,=CIVFR7AU>]:,1Z8;)XYE3^R0S/.T$JO$2H@'EL)IR[+'
MS][>_$5_VO;:YM[#2$U9?AV3/927UT]J\?\ ;[J%COA9I+&X!CF+M92@E7MO
M+'F+=1_4'@KX8>/=$U;7?'NL0Z1J'BK4(H;"SM$F>WL;'3;>XDDCM([_ .PR
MW<CR>:]S=3- %GN!%$L$,4*./'_@5^Q_JUK^SW)\'/B+#8R6*Q2QI=:1J%P\
MDC2WTU\)-LUG;B![>1HC&-URDQ4^8@3,;]A_PJ?XS^+/AY_PKCQ)>Z:;*6V_
MLJ[\06E]<R:C<V*MY;LUC>6,T2W=W;+Y$\K7LHAFFDNH_,*)"W0?MA_#30];
M^"MYH]G']AN++["OA\V*QP/;:HD\4&DI:N$VVN^X>&U\Q/*$4$L@\V&/=(NA
MX\_96L?B'\!Y/A=?:G*K36-O%-J4<2B2:\AECNGO98V9M[W%TAN+D-(9)C)+
MF<2OYPX_P%\-/V@_&^EC1/BKJWAN335^QB<:+;7K7.H+ XDECN9)W@MHXK@Q
MI'=PI:2Q75M-<VX2V5E8<?HO[/\ \=?@KX]\03_#W6?#\OASQ+J[:W=Q:_;W
M<EU9W5T_^FFV6S,"SHRA&C6::,81(OW9$ES/ZA=_"_XI^ -<T34_"ESINJ;O
M[9EU^/5+J[L!>W&H26LL$T)@@OMOV3[/]EM1<BX>VTY4LUD?_7+T'P$^ ?\
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M@HHHHHHHHK/U/5K'185FO+B*"-I880\KJBF2>588D!8@%Y)'2.->KNRHH+,
M="BBOF"^_9#^'FJ?%=_B/<Q7,VH2?997M9)V:Q:\LHVAM;\VS @W<$+-% Y;
MRX@S2I$MP3-7T_11111111111111111111111111111111111117/^*?$MGX
M/TN;4;N.YDBAV[EL[2YO9CN<(-D%I%-,_+ ML1MJY=L(K,/G#X6?MA>$OC5?
M:/%X:TGQ!=VFJ2ZA&FI'1[J+3X5LFE422W<RI%LN#$PMQ$97#E8ITMYLQC/U
M;]M7P/X?M]$U?4K/4K+P[KES#:6.OWD5O;V,CW$$DT3/'-<)?PQ/Y3JL\UG'
M!@";S/LK).WC_P"TM\6_%>@_M _"[1+30=2NK);G7;P10-I0_M":+16C1[9I
M[R)X_LJW<XE6Y:T5]Q,8N"L9'T!X?O/ _P"SMI>G^'_#/A2YM+W6OMFK1:)I
MEO;^<7#P->-+-YRV$/D?:(H\RW:0!1%:VK2!;>$Y_A_]L_X;:SX=UG6+B2^L
MVT&^N-/U>S-E->76G2VYFWM=1Z:+U4M]L$C+=J[VI"E/.$JNB\_I/[='@;4;
M&WU6;1?%-KI,ND)J[ZG-X<U,V<2,H<Q/+##*2Z1GS6FC62R,8++=MP#T'@K]
ML+PEXVL7U5=)\066DQ>'SXBFU._T>ZM[..!55W@$K+F>X6-O- M5GAEC#-%/
M+C%: _:M\-Z9XOT7PWKVFZEH3^(//&CW.JI:PPWS0F+]VJ)<R7-O+()XS%#?
M06LK,?(*+<D0G0\?_&[0;GQ%>^!+/0+[Q5=K8F35+.PCL'@MK>Y 2.*]?4+J
MUMP]RC.8[;>\TD*O(T0A*LWS?_P3932XM#^(RZ7;?9+(?$#71;6_V9[3RH1'
M:>7']G=(W@V+A?)9$:+&PHI4J/T?KXP_93_:(\2_'76?&L>I:%?6-MIGB"\T
MZW>:33GCMQ906<+VCFWG,S7#2F:Z9A'-;H)#$E[*$0'L/%/[4>G^%M+F\0'P
M[K=WX=AVR/K=G%936GV<N%>\2$7@OY;2/+2-/%:.DENANH?.M6CF?Z/TG5K'
M7[&WOK&XBN;:YB2:&:%UDCDCD4,CHZDJR,I#*RDA@002#7SA^VAX3T/Q7\$/
M&/\ :EA;7GV/1-5O;;[3#'+Y-Q%87'ESQ;U;9*FX[)%PZY.",FOF_P"%G[6V
MD_ _X%>!M2U_PWX@CT2/2-"L9=8CM;=K6)FM(86FDA^U"_6W60%!.;39,=A@
M,ZSVS3?9_C'XPV_AO7&T#3M(U+6M4CMH;V6UTZ*!?*MIY)HHYI+F]FM+,;I(
M)$6$3FY?:SK T222)XA)^WQ\(T^%T7Q%CN;Z;2WBE+K;V%S/)!<1>6#:730H
M\%I<,\L<<0NIH89C(CQS/"PEKT"P_:@\-3PZU>7FE>(-.L=*ETZ$7=_H>HP+
M>R:C*((DLK=H?MD[K,R0R+]G4AW0J'1@]9^D?M6^&V\7S^$->TW4M!UI=-.K
M065\EK<37ELIF$AM%TNYO_.E3R')MEQ<NHW1PR*KE.?^ 6O_  \TKPQXJU3X
M<VFI:T\OB34KG4[;RVM;QM4N98GN8O+U4Z?'%Y"21+L)C CBVDRW.\OS_AK]
MN71_&OP\D\?Z/X1\276AP6UW=7%SY6EP>2MFTOGC9<ZC"\^U8M^^U%Q$=WE"
M3[3'/#%]?^$_%.E^.=#L-;TN;S[+4+:&\MI=KIOAGC62-]KA77<K [656&<$
M Y%9_C_Q_P"'?A9X=O?$/B&]BL=.L8C+//*3M5<@   %F=F(2.- SR.RQHK.
MRJ?/_#?QQM-1\16GA[7-)OO#VHZA%/+I\&J2Z:S7JVH0W(MS8WMXI>%9(W>.
M0QNR,9(UD2*=HN0\;?M3:/X6M]?O=-T;4M=L/#GVA-5O=*DTLPVDUI +BX@8
M75_:RR2PQ,C2B&.559O)W&XCEBC^GZ^8/VL]'^(>L>$+1?!NEVVM-'J5M)J6
MD75PMLNI:=B19[43,51=S-%(ZR,(98HY(9DN89)+.X/%6C_$-OCEX?OETNVU
M+PJ--N(S,UPL<VE:B/.)NEA8@3?:87CLU95EF@4S['MH9;E+WY/_ &=OAGX-
M\&?M'_&.XTGPQ8F30XO#DFF065I9PR0M<:/.9X[,OY,4#W))5SOA20M^]<+E
MA](> /VO(OBE_:L>@>"_$EW<:/J5SI.H0[-)A^SW%OM#+YT^IQVTV267%M-,
MZ;-TJQ1RVSS]AX?_ &JO 7B?X;:/X[LYY6L]:EBM-/MY%2*ZN;Z:9K=+&-)7
M1#<&='B)\P6ZA'G:<6J-.+^B_M 6]S<:Q;:OX>UO2;C2;:PO)8);:#4)I(=0
MGN8(7ABT:XU*23#VLHD7:&10)"/+RRX'[+EU\*/!_P %=(F\$:AN\*V-M=/%
M>WK2196&>8W<\[7*0E/WRS22$I%$O)14A" ? '_!0;XJ>&_CA^SMJNOIX/U)
M;?\ T8Z+KFH6%KM99-3ME:2WQ-+?6<5W#$7CFN8+2*>+RD+^9/;Q2_I]XQ^,
M-OX;UQM T[2-2UK5([:&]EM=.B@7RK:>2:*.:2YO9K2S&Z2"1%A$YN7VLZP-
M$DDB>(2?M\?"-/A=%\18[F^FTMXI2ZV]A<SR07$7E@VETT*/!:7#/+''$+J:
M&&8R(\<SPL):] L_VH_"0L?$>JZM::OHFDZ!%;RRZCK>F76G6]PLZL<6B7*1
MW$SHZB%H_)5VF>)(EE\U"W/^+/'Y^*]CJ_@'6_"?B#3)-9\/ZO(BO+HADN((
MU@M;B.WDAU&ZB2XS?1"(W/EPY;+/M5J\/\7_ +%NJ:[\#?"7P\?5M2-_HVI1
MWEGJ5O?)NTYH_M;6[R3R1)+<16,4P@@6VBM9;F6*V &FV[R26OZ/UY_\2/B7
MH?PLTN*]U23YKFY@L;.W1HQ-=WER_EV]K )'C1I96X&]TC10TLLD4,<DB<?X
M;^.-IKU]J&C3Z3?6&NV=C_:2Z-=2Z:;RXM69XXYH#!>S6K(\T;P?/<1F*389
MA#'+#))YAX _:\B^*7]JQZ!X+\27=QH^I7.DZA#LTF'[/<6^T,OG3ZG';39)
M9<6TTSILW2K%'+;//T%K^UY\/+WX4:?\1X9;F33]3VQ65JD#-?75X\CPK806
MP.9;LS1O$$C9HR4:42_9U,P^/_'MYI^L?M8_";4&\*7/A_5+G_A)6O'O+>R$
MUVB:.L=N[W5A-=0S^6%DC6-IVGMU +11130-+^K]>7^/OBK8^!;ZRTN.QOM3
MU34(KB:TL;"%6DECM6A%PYFG>"T@2/SXR6NIX Y98HS),R1MYAX2_; ^&GB3
MPQXBUZ\O_P"R5\,7,]GK5MJ!B%Q8S0RO#LD2WDG23S60K;M;O,MP_P"ZC+S*
M\:]?X;^.-IJ/B*T\/:YI-]X>U'4(IY=/@U2736:]6U"&Y%N;&]O%+PK)&[QR
M&-V1C)&LB13M%G^*?VA-/TGQ?-X2T31]2\0ZI:6RW=]#I7V(+8I*0(%NIKV[
MM(8Y9P6>& 2-.T2-,8UBVNWP!^U1\1?AY\8/#'P?^*^BV/F?:O&^@1K=?8&?
M45MX);QIK/$227$FR>-QY$)E229=T7F[D9ON#1_VH]/D^(>E^!==\.ZWH.I:
MO;7%S8-J,5E);W/V92\L4<]A>7D8E1%:1D<IM0+N(:6!9?I^O'_'7QET_P (
M:Y;^'K*RN=9UJ>V>^&FZ=)9+<)9QR+$UU)]MNK2)(O-=(ES)YDKEO+C=89VB
MY#6?VFM!T_P%J/C"QT^^U*#2);R'5K6R>P-UITE@DC7B7*S7<,1>W,95E@EF
M,H>.6 3P2)*?/[_]MC0=(\%6GCJ]\,^(+;PS<16,S:K-#8)'%'>R11*[VQOO
MM[(DDP5FBM91( 9K<W%NT4LGV?7S!\=]'^(=]XO\#W&AZ7;:QH<&I-_;-G/<
M+ T>XQ&TU% Q5)OL#)+,('\S=*T,D<'VF*"ZM#PKH_Q#M?CEX@N]8TNVN= F
MTVW_ +'U1;A?.L\>2MUIS6[$$>?,K7;3QH-ZQP1S3S^5;0V7R?\ L[?#/P;X
M,_:/^,=QI/ABQ,FAQ>')-,@LK2SADA:XT><SQV9?R8H'N22KG?"DA;]ZX7+#
MZ0\ ?M>1?%+^U8] \%^)+NXT?4KG2=0AV:3#]GN+?:&7SI]3CMILDLN+::9T
MV;I5BCEMGGZ#P[^UMX'\:>$/#?B#0UN;^7Q-YRZ7ID8MX;ZX>U#F[0)=3P0K
M]E$4OGR/,L&458Y97FMUFY_Q_P#&?PAXW^&_C"T\76&MZ'90_:M!U1?L@O;B
MW6XTJ.[>?.E'4XDB6VNE?[1(3%&_RR '"MZ?HWC_ .&WPL^$VG>(;>]BL?"M
MCI%G+:SRF;:MCY$8M@!*#.SLAC2.-@UQ([+'M:5@I_/#]J_Q7I_Q"USX3:[=
M^"=2T/4I_&_AI8+S5K*R6XDLS)-*UNTUK/=26^QY$<V=VUO(SEF2%V@N##^C
M_C'XPV_AO7&T#3M(U+6M4CMH;V6UTZ*!?*MIY)HHYI+F]FM+,;I()$6$3FY?
M:SK T222)XA)^WQ\(T^%T7Q%CN;Z;2WBE+K;V%S/)!<1>6#:730H\%I<,\L<
M<0NIH89C(CQS/"PEKV_X:?&2S^*.J:M9VFC:W91:=]FVW6JZ7<Z=#=_:$=C]
ME%VL4S^24*3;XH]K%2N]&5CYAXF^ 4VO?M :)\1+6XOK1M,TA["Z(N(A:WD$
MANO+M!;HOG,Z2S"ZFFF=84,5JD4$\LDLUES_ ,'OV6;'PGJWC^>^:^;3/%.K
MG4%L+N[5VAN4N)I9+^W>U\L6CRR-"]KY;-=P):6EP]TER?L]GZ?^SKXQ\3^(
M=#U'2?%3>;K7A_4I]'O+E88H$O/+CBN;6\2*&:98_M-G<VTTD>4\N=Y8Q&BH
MHKZ KYP\0?M-:#I$VL2V>GWVIZ9H,LL.L:I8O8/:Z?);Q+/=),LMW%=2O;0N
MLDZVEO<$$F%0]RDD"9_Q>_:M\-_!O_A'[J\TW4M0TO7[FRL[/4])2UO;=YK[
M>T*+'%<_;)<QQF4-;VTRR(RK&9)6$=:&E_M(6@\:Z-X1U[P]J^@WVN17LFG&
M_.FS1W#6,:2SQAM.OKTQNL;^8#,(T8*RAR^U&Y_Q=\:O!OQ%OM;\*CPM?>*]
M,TN6*#6)K>SL[S3X)T;SGMWCN)UEO+BV")+-;V,%Y-$YBC$9N2L->7_\$N/^
M38O"/_<3_P#3M>5]WZM>S:=8W%Q#;2W4D43R)!"8A)*RJ2(T,SQ1!W(VJ9'C
M0$C<ZKEA^6%K\3W_ &N?V2O%GB7Q5X<SMTWQ'J-A-?)I]Q"K1MJ:VQM#&QE6
M6QB5+<W$UO:RNP\Q#)O=Z[#X6?M;:3\#_@5X&U+7_#?B"/1(](T*QEUB.UMV
MM8F:TAA::2'[4+];=9 4$YM-DQV& SK/;--]G^,?C#;^&]<;0-.TC4M:U2.V
MAO9;73HH%\JVGDFBCFDN;V:TLQND@D181.;E]K.L#1))(GRA\4_VC?V>_P!H
M;X'IJ?B._OO^$7U.6V-XT%E?2-;26=Y:SFTOY+*"X%F[2&*(AWC,R2;K:9@T
M<P^C_C/^TMX,^ UQ86VO)J1EU"YM+2V6STN_NEEENYS$D:30PM"TJA7E:V60
MW311DQP2.T:2=A\*OBC#\5[&^O(=(U?3([6^FLD&L6,MA)<+&J,+F&*;$IMY
M _[MI%C?*NK1HRD5V'BGQ+9^#]+FU&[CN9(H=NY;.TN;V8[G"#9!:133/RP+
M;$;:N7;"*S#YP^%G[87A+XU7VCQ>&M)\07=IJDNH1IJ1T>ZBT^%;)I5$DMW,
MJ1;+@Q,+<1&5PY6*=+>;,8S]6_;5\#^'[?1-7U*SU*R\.ZY<PVECK]Y%;V]C
M(]Q!)-$SQS7"7\,3^4ZK/-9QP8 F\S[*R3MZ?XD^.-IIWB*[\/:'I-]XAU'3
MXH)=0@TN735:R6Z#FV%P;Z]LU#S+'(Z1QF1U11)(L:2P-+P'B7]LSX?>$/#O
MAG6K^'5UC\2Q:5)81Q:3>W#.=4*^3$9+>.6W-PB%I9+9)GN"D;&**9FB63H-
M#_:=\.ZAXUL/".I:9J^CWVK1//I)U*R,<>HQ11RRRM"T3RF!XHXQ)+;WPM+J
M(2PJ\"N^P<_X_P#VO_"OP]TZ]UNYTO5Y]"TV^.G7^L16\*6MM<)?"PF4QW$\
M-Y<)#,0LDME;74).Y8WDDCE1/3_B1\=/"'PQ\(1>*+NZ^U6EUY"6"6 %U-J,
MUT,VT%BD9/VB6XR/)"':5S(S+$KR+R'AO]I"TUSQ5J'A*Z\/:OI^NVND?VW%
MIUT=-:2[M?.>#,$UM?7%JK^<HBVW$]N<R(W^K#NGR_\ #/\ :5L?CU^SGJNN
M_$&PU?3-)UF+6K:2]M;9;Y4L[BXU"/$7]GQ7$T:6-M&(9;J]M+>-G17/F[R6
M]P\9_M">!_V:?A!HGB;3-'U*^\)P:;8_9Y].^SM]GLW6WALO,34+NVN6\P2Q
MJN%ED7#&;8>6]/\ B'\9[GX>6.BSR>&=7O9M6ECMTM;-]+-Q#<2*K""19M0A
M61U7S'D:U:XAAAM[BXDD2WB,IP/B3^TOI/P^77GM]%U?5X_#L3RZO)80V\<=
MFJVB7N#)?W%FEPYMY!*8[,W+Q@J)5C:2$2>O^ /'_AWXI^';+Q#X>O8K[3KZ
M(2P3Q$[67)!!! 975@4DC<*\;JT;JKJRCH-6TFQU^QN+&^MXKFVN8GAFAF19
M(Y(Y%*NCHP*LC*2K*P(8$@@@U^6'[$G[/7PL\5_\+*_M3PEHEY]C^(&OV5M]
MITRTE\FWB^S^7!%OB;9$FX[(UPBY. ,FO</A]JOPZ^"NK7]]X3LI81XFOI],
MLO#%@MK;M-J'A^XO[34;RTAENX;.))(8(VF?-LA2U@+L]W<QPGW_ $+XXVGB
M:QU=;'2;Z76=&E@BOM"$NFC4(&N%22$L3>BS*20N)TD6Z*,BR1AOM,4D">(>
M&OVY='\:_#R3Q_H_A'Q)=:'!;7=U<7/E:7!Y*V;2^>-ESJ,+S[5BW[[47$1W
M>4)/M,<\,70>)?VS/#?A;PQ'XRGT+6SX5?[(XUSR+6.W\F[EBA2?[+/=1:F8
M@\J\BR+2)^]B66%HY'T/&^L_"O5_CAX0MM:EOH_$VG1:M'HL4EG?Q6LK7-G#
M)=R1W'V<6T[Q6T>P@3LD9E=70W'E>7X?H'A/0_"G[;UW_9=A;6?VSX?R7MS]
MFACB\ZXEU\>9/+L5=\K[1OD;+M@9)P*^@/@K^U'I_P :_%_B'PM#X=UO2KWP
M]Y2ZA_:L5E$L;S%O)1?)O)WD\U4>6*2-6@>)=XEQ)%YG?_";XMO\5O[3/]@Z
MEI2Z?<FS9[]M/=)IDR)D@>QO+M)/(8>5.V0J3A[?)FAN(XO4-6TFQU^QN+&^
MMXKFVN8GAFAF19(Y(Y%*NCHP*LC*2K*P(8$@@@U^&/[*M];_ ++W[3>IZ7*_
MV/0/'MSKT-E&EK!;6<-]I?B#4+2VM5E9E'R0PLB108/F7]K"8#^ZEK[/_P""
MCFO>(M1^'5[X/T*26VDU#2-:U:_NTQB+3=%M5GGC!%Q ^^[N)K.R(59E-O<7
M+/&57GU#]EM/"'P;_9T\.ZW]FMM,LH_#=CK&HRVUL$WLNF0R7%S*L";Y92L>
M7?:\LFT#YC@5T _:M\-Z9XOT7PWKVFZEH3^(//&CW.JI:PPWS0F+]VJ)<R7-
MO+()XS%#?06LK,?(*+<D0GG_  [^UY%XJ\3ZYX5LO!?B1]:T/[&U[9[-)&Q+
MR(S1O]J_M/[%]W9^[-P)W\S,<4BPW+0:'@W]K"T^)$-X/#GA3Q!J-SIM]=:;
MJ=M''IL#6-U;2F-H9)[J_@M)W;&\?89[L1H4,IB,L0?XO_:H^)'PT^+?ACX/
M_%G3HK:"*X\;Z C:E>P16]Q!:02WC3P3SORD4,T<AD D:WWH959TVR'[ \$?
MMG^&/&/Q#MO!-QH'B31KN_\ MO\ 9UQK.D2V-O?_ &)?,E^SF1O-_P!5F8>=
M%%M3"OLE=(V[#XD_M+Z3\/EUY[?1=7U>/P[$\NKR6$-O''9JMHE[@R7]Q9I<
M.;>02F.S-R\8*B58VDA$G/\ BC]M7X5^&=&T+6$N[Z_M->ELXM/FT[2[^ZCG
M>[G, C66. Q"XC*2M+9EQ>J(G06S3;(GT+']JG0]1MT5-$UN'4+O4KK3=,TN
M^M(]/OM3^R0+<375I#?S6P%HL),AFN6M\%?)*BX>*&3T_P"&/Q.7XE+JJ/I5
M]I5SI5\+"YMK\VC2+(UI;7BD-9W-U"R-%=1$$29!W*5!'/J%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%?DA^RGI-]K_ .P#/8V-O+<W-SX?\4PPPPHT
MDDDDEQJ*HB(H+,[,0JJH)8D  DUR'@E?V3OC!\&- ?7K[^T[B+3;>9?#<7B?
M6))EOH+8Q&ST_2[O5?,\W?OMK*-1F1718W>.17;Z/^.,E]-^T?\  E[Z**&Y
M:+Q69HX96FC20Z/#O5)&CA:1%;(5VCC+ !C&A.T>?_'?4_ WAO\ :LL'\<W4
MNCZ=J7@T6UGJPU+4](4W5KJ4\TMH+RSNK6'8T4BRS).6&];4*R/(B3&M>&/A
M'X;^'7Q<F^&5M%=VU_X6U*ZU;68M6N=3CN+QK6],4"S2S7:R7"*T\]YF6*2(
M7%FQ2<7.Z#U#_FR'_NFW_N KQ_XVVMQ<_L#Z6T.G_P!I>1X;\*W4EJ5G99(;
M:33IYA)]G>.41"*-VF>-XV2(.XD3;O7H+JU_9B\?W'A_7M!U'_A+M?M;FSN=
M"LI_%>K7ES'<33P,DC6US>W$UO%"52XORUL[V]M;RR26\GDF(^@?L<^+/[.\
M=_%7PCKE_G7T\77VKK:SS>9-_9=W;V:V$J'<P:)85BC"(Q-LODQ2)%NC4\__
M ,$\_%FAZS_PLC['?VT_V[X@>);VU\J:-_/MU^PYGAVL?,B'GPYD3*#S8^?G
M7/Z/U^2'P6TR;Q/\,?CSX>LVB;4=:\9>-]-T^"2:*)KFZFT\%(8S*R*7*H[G
MD!41Y&(1&8?2'[,7Q(\(:O\ LTZ?-KL7E66@:(^D:]:7T D>W;2;7[-?0W5J
MOFN,K$TGD.GFO!)&6B!DV5T'[ _PTUSX1? 'PGH6MQ^3>QVTUS+$5D5HOMMU
M->+%(LB(Z2QK.J3(5^2574%@ Q[_ /:Q_P"2(>//^Q;UG_T@FKX _:6_Y1YV
M/_8M^$__ $=IM:!U?X9Z!^TO\3+'Q]J<OAV2]BT*_P!.NSK>K:&M];QZ=';3
M RP7MK:SI!,A6$$&;>]T TBQNL/ ?M+>%/AMX)_9,^(NF_#;38K?PXM]I4D5
MY#?37D5]=/>Z=]HEMY)'G5[>-1#;^8DQ!NHKN%H8C;[Y_I__ (*.WNG:'X5\
M%ZQJ]M++I.F^,M)N=2FB-\AM+4PW4#7?FV#QW$3PO*C0/&X/VCR4VR;O*<\,
M^'OV>[[XDZ!KW@VZB\4^*(I3:Q7*^*+[5GL;-H9S<3S^9>7ICMUC>6*+=&8W
MO;FW@+P&X\^/0_8%_P":J_\ 92?$?_MM7S_^S3_RCSOO^Q;\6?\ H[4J^_\
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M>*2[TN6UNUL+>0)(_P!HN(Y"(4N)(842 ,9KAT$BPO#:W$UO^</[-NK6,/[
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MQL;&37;[Q%_9FL7$=GYFC-<S"[GAT^-X!$KW)NS96B9"1G[.)8;Y5-O+Y_\
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M/[1\1:%=>5YFW?Y?G6[[-VQ-VW&[:N<X&#QUXO\ C-\4/L__  DW[.6FZO\
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MC?8_M'?#ZP\96-I+9VVH2WHABF96D$=O>SVR,^WY5=UA$C(I<1EB@DD"[V]
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MJ^)= _:P\/>!V\67T6EZWI#7\6F6MKIS&.YM7D<B>>>P9Q97,%K.,0SR7:W
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MOM2M+.[N1-;QMI]C*Y^U7T:7(,<TL*#$,160&5TD:&>.-X9/G#X(?M&6FO\
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MX1]==35Q<:;+)#.M[]DELF_LRWM[=DV-#,F46:,M)O:5)8A!G_L"_P#-5?\
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MF3>%K82^#/$FDZM?M%JT$EWJTMA<2+<W=HDD<4+_ &T3M?/+?W5I=&X-Q'+
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M%X\\CI)9011":3Z/_:ITSXB?%^'P"^C^!]7+:/XITKQ%>)+=:$C1P6,MRDD
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MFA^.=+AU31+^VU"RGW>5<V<T<\+['*-LDC9D;:RLK8)PRE3R"*Y__A;'@?\
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MO?B4FYAE87+JC^5"L\V7"1VUK++)[!^SQ_R<[\;_ /N4?_33+7P!_P XQ?\
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MZ^+[;5M;\-:TUL;.YO?#E\+":[AS&42Y;RI/,V>6H5AM8JJ*Y=8H1%]'^"O
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M65^),7B'5[;418PZ6;>(::;4V,<ZW#6Q66QDFV2RJ7DD$HN 798YHT"*N?\
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MW;Z7J'VX7^F6ES EO=*FK7*O&TCV\EY!%/'&L4\-G<VT4B&1M@EGN))?T/\
MBK^SQX*^+OA6Q\.7UO+9VVF2PW&FOIDTEE)87%O"\-M/:F JJ/;JY,*LKPJ0
MN8V"@5@>$OV7/"7A3QZ/'37>KWVM_85L3<WNIW4BE-\LDO[A72 ),\OF-;+&
MME \43VUK;,I+9^D_LQ1>#]4UN\\+^*M;T.+6M2FU>ZM;-=)GA-Y<)&L\J&_
MTV\F7S#&'9/-,:L2$1$PHS_B;^QYX-^(?PVM?AS:7=]H?AR")8FL=)^QJLRI
M-'<1F22ZM;J;>LL?FF1'1YG>1IFF+9!\2_V5C\6H=!36?&7B"1M#OK?5+9XT
MT1&-];2S/#<R;=*VLZ+-Y0C 6W9$0O"TN^1]#XX?LF>$/VA-+T:+Q%=ZE_:6
MB;7L-8L[D6M]!-O@>2=/)C6V$LAMT+'[/MC.3"L+;2O?_!SX,:7\&M+:VAO]
M2U:[EP)]2UJ[>]OIE1Y&BC>=P,10^8XAAC5(D+R2!/-FFDD]@HHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHKG_"WBS0_'.EPZIHE_;:A93[O*N;.:.>%]
MCE&V21LR-M965L$X92IY!%=!7'^-?'FC?#ZQ2[U.24++*(8HK>WGNKB:0JS[
M(+:VCEGF<(CRLL4;E(8Y)F BC=UY_P"$/QH\%?'KPZGB#PCJ<6HV+2R0F2-9
M$9)(S\R21RJDL;@%6"R*I9&20 HZ,WJ%%%%%%<_XI\6:'X&TN;5-;O[;3[*#
M;YMS>31P0IO<(N^21E1=S,JKDC+,%') KH*******^?_  M^U'\,/&7B^'PE
M8:OG5+BV:]M89K6[MUN[=21Y]G-/#'#=Q,%=XY+:25)8D>:,O$CNOT!6?JVK
M6.@6-Q?7UQ%;6UM$\TTTSK''''&I9W=V(545069F("@$D@"N/^'OQ5\(?%FW
MO+GPSJMMJEO9W/V.:>SD$L(F\B*<HDJYCDPD\99HV=58F,D2(ZKZ!1117A^D
M_M-_![7[ZWL;'QIX?N;FYE2&&&'5K*22221@J(B+,69V8A5502Q( !)KU#PM
MXLT/QSI<.J:)?VVH64^[RKFSFCGA?8Y1MDD;,C;65E;!.&4J>01704444444
M44444445Y?\ %#XU^ O@K8B\\6:Y8Z5&T4\L8NIT2298%#2""+/FSNH9?W<*
MNY+(H4LR@^H444444444444444444444444445Q_C7X>^%?B58I8^(])L=5M
MHY1,D-_;0W,:R*K*'"3*ZAPKLH8#(#,,X)R>"OA[X5^&MB]CX<TFQTJVDE,S
MPV%M#;1M(RJI<I"J*7*HJEB,D*HS@#'845Y?X!^-?@+XJWU[9^&-<L=6DL8K
M>6X-A.ES'&MRTRQ RQ%HM[&WDS&&+H K,JK)&6[#4?">AZOJECJEW86T][I_
MG?9+F6&-YK?ST"2^3(REXO,4!9-A7>H"MD<5T%%%%%%%<_J/BS0](U2QTN[O
M[:"]U#SOLEM+-&DUQY"!Y?)C9@\OEJ0TFP-L4AFP.:Z"BBBBBBBBBBBO'_"_
M[0/PT\;_ -JMH_B33;Z+2+:*\OKBVNHI;>WAE\_:\MPC&%<"VE9U+[HT4.X5
M'1FZ#X>_%7PA\6;>\N?#.JVVJ6]G<_8YI[.02PB;R(IRB2KF.3"3QEFC9U5B
M8R1(CJOH%%>7^ ?C7X"^*M]>V?AC7+'5I+&*WEN#83I<QQK<M,L0,L1:+>QM
MY,QABZ *S*JR1EO4*\OT3XU^ O$WBJ;PMIFN6-[JT$5S+/:6LZ3R0+:S103"
M<1%A"ZR3(GERE'8[]JMY<FSU"BBBBBBBBN?\4^$]#\<Z7-I>MV%MJ%E/M\VV
MO(8YX7V.'7?'(K(VUE5ER#AE##D US_@7X3^!_A?]H_X1G0=-TC[3L\_^SK*
MWM?-\O=L\SR43?MWMMW9V[FQC)ST'BGQ3I?@O2YM2U*;RK>+:"0KR,S2.(XX
MXXXPTDLLKLL<,,:O+-*Z11H\CJI\_P#A-\>_ GQP_M-?#.H_:9=*N39WUO+!
M<6MQ;3#/R36]U'#,G*LH9D"EXY$!+Q2*OL%<?XU^(7A7X:V*7WB/5K'2K:24
M0I-?W,-M&TC*S! \S(I<JC,%!R0K'& <:'A/Q3I?CG0[#6]+F\^RU"VAO+:7
M:Z;X9XUDC?:X5UW*P.UE5AG! .1704444444444444444444444444444444
M44444445S_BG6;SP_I<UY::;<ZG+'MVVMFULLTFYPIV&[GMH1M!+MOE3Y5(7
M<^U6^,/A[\;O#OAS]FNT\;?"_P ,Q)H6FV-_<IIU_<G3Y$M=/-R+A@\,.HB2
MX>2!F'F-F8R-++<+(6#9_B+]L?Q?X0^%%E\4]4\'VT'AZ:VTN\F0:R7U)(;^
M2WB+QVRV!MI,&?S(5>\A:6'8THM9F>"+C_VF_%'Q%LOVC_A38Z996,ML9?$,
MUG#-JUU!'=R1Z.JN]VB6$RV[P+-,MLR"\,@D<$VXD:OJ_4?B'_PB-Q8^$]$T
MW39/$U[;3:M)I<5[]GMH4:<->7<UPMJTOE/<S,D<HM&GN[F0N8%1;N:VX#3O
MVI[S2O%]]X'\2Z!]G\3);0ZAI^GZ9J-M=+JEG(2CR6=Q>C3$$L#1S^?;W @D
M\J%IH?/3=MX_X6?M9_$'X_:-H^M^"_AY+)I>HRZ@#?ZOK-E96\<=M/+%"VRV
M2_NV>7RF61/LRB&8A5DGAS<#G_ _[9?CWXB_!J7XI:=X*L8=+MK'4;V:*]UY
MXYW73VG\W[,L&F7"R(5AVJT[6KF82(8A"L5S/T'CC]L/Q%X*^&T7Q1E\*1#P
MK)%IUT#+JH75OLM]-!$LHLHK2:TW_OA+'$=0!:+;YC02EXH_;_'7QKN--\<6
M_@3PW9VVH:_)IKZU)#?74]C;Q6*7"VH<W$5G>EI7F?;'"L1&R.5Y)(L0K/P&
MM?M.7&K?"#QGXJ\-VML^K^%/[5L[VTNY)Q;Q7VE*6N46585>XB"CSH&583<(
MT<<ALY&E\CY_O?C);^'_ -EWPYK?Q9\+W.NZ1)INB7-W+97<%_YBH-/DM9[]
M;Z33Y7EN+EE,MO$M[%\K"::2-R&^[_B-\4+'P)-IVF1"*YUG6)9+?2[!IUA:
MYDBB,LKLY#&.W@C4RW,P20H@"QQ3W,EO;S>(:C^TOKG@/Q?8^$O&>CZ;I.H:
MY;3-H,T6L27%C>WD)"O8S3O86\UI*3) 8W-M-'*)2D;/<*L$G/\ PA_:6^)?
MQK_X2"+2?!NFPR^'];O=#NWN]?E2WDFM-@8VSQ:5-,_+$N)K>W54:$H\SO-'
M;>W_ +-WQOL?VC_AMHWC2SM);./4HI";>5E=HY(9I+>50ZX#H)(G\M\(73:S
M1QL2B^X5\_W7Q=USQ=JFH67@/3]-UA=)N6L=1N+S59+*&*\5$D:UB-O97[RR
MPJZ&YW)%'$TD<2R2S+<QVWSAXX_:DOOBK\"O&]]X6ABL?$.A6.JV>MV,^I-!
M=:1<6]I<B62":U@G%PZ21%K.1#!#<!6/VB"6*2-/4/V+[;7-0^%G@Z\UK2--
MM_LWAO2K?3KJVNY+JX>WFM+=I1*)+*V^S;_)MW>**6X1W4 N?)1G^OZ^$/A!
M\6?B+XQ_:,^(?A^\M+$:3H<6B6H":A=;H8YK>]NXIXX&MC%+<7)E1;KYK40)
M%%&KWGDB1_#_ -E#Q7\0]!_X6S_PBGAFVU?R?B!XEG;[7JJZ?YK_ +G9;VVV
MVN]\OR?.;G[) OFP[9I,S_9_J#P3^V/X;\6_!W0/B*VGW,?]N7-OIUKIJ2VI
MN9KZ>^-C]G@:>:WBEQ*LD@=GB)MHVG9(]KHIX>_:EN-/^+]K\+O&.E6VF:OJ
M.FC4].?3KZ?4;>=5:Y$L4CR6-D\,JK;/*N4>)T# RI)LCD^OZ_,#]L7QI<?%
M'XU> ?@?#=W-C9:OY^KZT\+SQ?:[&*"[']G[[>YA<Q7*V]U'<JRX7=;RHS%'
MC/Z'ZG\/?"NM>'5\.7FDV,^DK%#"+"6VA>U$<!4Q((&4Q!(RB&-=N$*KM VC
M'S!\)=$L?V._A]H'PZ@FBU#5+B^U>WT2S>Y5)+J-KVZOD>:4Q+L2WM722_F2
M%A&0R0Q7$TEM!/T$7[25]X*\>Z5X/^(6F6.ASZ]$YT>ZM-3:^M;JXA<+-:.T
MUI8RP7 $D+0AHFAN#)Y23>>%B?C_  9^TM\2_&WCOQ5X(MO!NFKJ7AK^SFN9
MVU^7["RW]NTZ*LO]E?:?-QMVJ+5HF"SEYXF2%;G0^%W[27CWXSPZO'H/A*Q2
MYT'5[[1-2-_K;PVINK27:192PZ=<SW";"DDC7%M9!#(B1^>1*8_/[7_@H)::
MA\/O!GBVU\':O<1^*[ZSTNW6*?31&M]->S6LMMYDMU'*746TTL$C01V\P\E9
M)K5I)/)]@?\ :1UGPCXUT;P_XS\,2Z/;>(91!I6H)?075N+@QS2"RU XA6UO
M66.-888&OH;B:1HX+B41.]9^K_M2W$]OXJUK0-*MK_0O"%S>V>L7,U]/:W8F
MTV!;B^2SM#8RQW'E(X2-IKFU6:X5TRD 2YDS_C/^UE??#6Q\&Z[HNA1:]HGB
MN^TJPM)H;]K6\:34UDEB*6MS:I"4,2*RF:ZMR9'$;K"JM*-#5/VA?''@_P =
MZ!X.U_PWIL5[XDMM6?2Y+'6KBYA-QIMNEP8KMI=+M7@BD5B!-"ETZL,>0P.1
MG_LQ_M1^(OVBK'Q:DWAZQTC5O#M]+ICZ=)K(N9#=1*X/VAX;/$%NTB^5'<1B
MY$ACN"J'R0)/;_@7\0]<^*WA"U\0ZIIMMIZWV9[-;6]DO%FLW :WN2\EK:/'
MYZGS4B>,2)$T?FB.8R01>P5S_BSQ3I?@;0[_ %O5)O(LM/MIKRYEVN^R&"-I
M)'VH&=MJJ3M568XP 3@5\P:1^U+<06_A76M?TJVL-"\7W-E9Z/<PWT]U=F;4
MH&N+%+RT%C%';^:B%)&AN;I8;AD3+P%[F//U;]I+Q[9_&&X^&EKX2L;B[;2'
MUNUNAK;I;_91>FU4W8;3O-@=@IRMNE\5F:&/F%I;F#H/ ?[4,-_J/CS2_%EA
M%I%SX(BM;K49+6YEU"U-K=6)O4EBD-K;3LZ)'()8OL^0578TI<A?B_\ ;U^)
M7Q#\<_LQ>(K_ %;P?_9&FWWV%H?-U%7U&!/[6MF@>_LFMXH[?S40;XX;F[G@
MFEBB>+:)Y8/U_KQ_]H'QUKGPP^&GB3Q)HEO;7%[I6FW5]%'>/(D)^SQ-*Q<Q
MJSMM5698QL\U@(C+"',R>(? WXU7WA3X%>$-<\;-%]KO['1[2Q6*^:[NM4N+
MRT@%LI:ZCM0+VYD9C)&SR0Q --)>>2LLL>AXP_:7USX):IH__"RM'TW1](U:
MY.GQZI8ZQ)>PV]XR&2&.[2XL+!XHIE27%PGFQPM'^^\J-O-7Z_KR_P"-'Q>\
M._ 7P5J?B[Q \JV.G1+)((8S)([/(L4<:+P"\DCI&I8JBE@SNB!G7@-+^.&K
M:!XUT;PCXTTZQTV^U^*]DTHZ;?W&HQS-I\:2W,<S2Z?8F!Q'(LD1Q(D@296>
M)UB2?R_P9^TM\2_&WCOQ5X(MO!NFKJ7AK^SFN9VU^7["RW]NTZ*LO]E?:?-Q
MMVJ+5HF"SEYXF2%;G/D_;#\17GPN\6>+=,\*175]X0U?4M+U>P.JB*/;IGS7
M%Q:73VF9T6-DE"2P6SL!,JAG2)9^PLOVE]<U_P""NB_$/1]'TV\N-4^R;;!=
M8DV;[V?[+!;)=I82*;LW$D%M)'+%!!!.\HEN4C@:1OJ_29+Z:QMWOHHH;EHD
M,T<,K31I(5&]4D:.%I$5LA7:.,L &,:$[1Q_Q2^)&E_"3PQ=Z_J,5S/%;^4B
MP64#W%Q/-/*D$$$$2<O+--)'#&"57>XW,B;F'B&A?'?Q[IOBWPMH/C'P?%I:
M^)8KL03V&IOJ*VMU:VHNS:WI-C:0QN\2S^6T$UR'>!PH:(-*N@_QN\7^.-+N
M=;^'6A:;XATJ+[3'!<3:T;)KZ:U=XY19JEC=Q/%YJ-!'//-;++*CN%^R>3=3
M^/\ Q _;QTNR^"H^+/@S3[;7=(@V)?07&H/8WEK-)/;P+ 8DM+M#*K3YE#R1
M*(PDL37$<J,>P^)?[37C7X-S:#<^(?!T7V'7=7M]&M8K'5XY]26XO(IGMDFM
MI;:VL5<M&(Y]FHR0Q,Q*33HH=M#5/VC?%_@3QWH'A/Q1X7MA<>(;;5I=/_L7
M5C?,\VEVZ7+PR+>V6EQQ^:C%8I/-9?-"JXCC9I4Y_P %?M7>,_B[;^)F\(>
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MC-?*'Q-MK']I#6?VD-(\&ZE8ZI<ZA8^$K^R2TN%N3=QZ5 DUR+86_FM,X9!
M!&& N)8HG9"X(]@_;?\ VL_A=\??V5-;F\-:O%<7.H1:=+]@'S7EL$U2U,GV
MN",NULB,OEF>7%N\C0I'-(;BW\W];O"WBG2_&NEPZII<WGVD^XPS!75955RH
MDC+!=\3[=\,R9BGB*31.\3H[>7_M-Z3?:_\ ![QI8V-O+<W-SX?U:&&&%&DD
MDDDLIE1$1069V8A5502Q( !)K\X==DOOBS^S=\,K[P#%%XAOO <OA/7KVQM9
M6W2G3[!A-8Q3)'+$;U"0TMJ";B)"I,)>:VCG]O\ VEO'W@?]LSX8)X$\"ZW;
M:M=^);G2U8Z?+;SRZ?9I=PWD]]>VSS0RPQ0Q0E"D@20W4D%KM6690/T?KY__
M &H_'_CCX7_##5]=\%:5_:^M6WV7[-9_9KBZ\WS+N&*7]S;,DK[8GD?Y&&W;
MN.5!!_.'Q%XR\ I\;OA)XTT75M;U;2_^)[]JU:^_MBYMIKB]T@FVBM!+&+,7
M<\BS1'3]*BC=;E/L?V2.6*.W3U_X&?%CP/H?[3OQJ^VZ]IMOYO\ PC_E^=>V
M\>_^S=)G^W;=SC/V78_VK&?L^QO,V;3CH/\ @G5XLT/Q+_PM+^SK^VNM_P 0
M-<O5^SS1RYM[KR?(G&QCF*;RY/*D'R2;'VD[6QY_^S[\+=<^&'Q7O?A ;2Y/
MAG1=2?QKI]S)+)/;&SNXVM[/23"[R^5]GOC/>P2S2F26YTYKI;9787"?J_7P
MA_P4$\+^*M2\%>'?$'AS2Y=7N?"WBG1_$#Z?;K,UQ=1VLDD9B@$,,S;]TRLQ
M*X2%9)/F*!&[#X,_MJ>!/VD?(A\ K<ZE=#[+)?QSV]Q:)I\,W+FYN'B:%I5"
MO'%!;O.UQ. %9;5;B\M_G_\ 8K^(^A_LN>!&^%OQ*U'3?#NK^'+FX6,WU]'#
M#J%G>7$MU#?6DEPL"21,SRPE$+R1-#B989'\I?F#]HG2+?X:_LG>/Y=<G_LS
M4O'?B2Y\2V6DZB8+>^2&?6+%EA,(FD:25+>.*XN%3YK<RF*15:,LWT?^W/\
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MO$>FZ%\9+[Q%JUK;QV6H[M#FMY(9+D6TY:.6*5&D\J4#:NU[A9(UMWFB^_\
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MG2U8Z?+;SRZ?9I=PWD]]>VSS0RPQ0Q0E"D@20W4D%KM6690./_9V^-_PZ?\
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MF_#I;JVMKV;36U=EN@^^ZA+3PI!9;2J>:C0O/<-(Q9((PL5O.)9[BPH?"_\
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M[2=6L=?L;>^L;B*YMKF))H9H762.2.10R.CJ2K(RD,K*2&!!!(-?&'['.O\
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M?)8ZKX5?P;_PDZ1$+/;WEQ+J*6T$DOS-#<V\<69+>-E:'SI%N2'EAM7@\/\
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M)!J6I:Y_R!;B'R-1OO*^;_D*2>9:)Y?_ ![_ "3/G_C[7'/G_@+]D#QQ\/\
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M?!C]E75O %CXRT?Q'K5CK6D^+K[5=2O[:'3;BPD\_55CCG1)QJ5P5M_+5E5
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M_P#@FL/_ (S1_P ,G?!#_H0_#?\ X)K#_P",T?\ #)WP0_Z$/PW_ .":P_\
MC-?0%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
,%%%%%%%%%%%%?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex19-1_002.jpg
<TEXT>
begin 644 ex19-1_002.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[@ .061O8F4 9       _]L 0P " @(#
M @,%! 0%!P8&!@<(!P@(!P@)"0H*"@D)"PH+"PL+"@L+# P,#0T+# P,# P.
M# P,# P,# \,# P,# P,_\  "P@&<@3[ 0 1 /_$ !\   $% 0$! 0$!
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MQZIJ%QJ*P74>I"S!MY;QYIXT9-[.OF,'>0ELK' D6A\"+=/VU?AA;^/-8O\
M6])NM9_M".WBTC7-0LDL(8;N>U@$26TD,,\JB+SGGNH9FEG=P56U6"UA] _8
MM^,?B_XM^$-6MO%ZVS:UX:UN^\.7MS9D^3=S6 BW7*(8X_+W^9AE"JI93(J1
M*XAB[_\ :DU#7_#_ ,+/$6MZ%J]SI5[I&FWVIQ2VT5G+YC6MI-(L4JWEO<H8
MF8*7V+'+\H"RJ"P;YP^#MOK/PU^#UG\7=7\3>(/$%S!X$BO'TV_O8%LV*64=
M^2%AM48W!9&B%Y.;BX,;L)'F.,> :^G[1^K^#?"7B;P5I7B"]\5K+8WNHWE]
MKVCOHFH6[6<@FBALK/6!8FWD9XO(DAM()C$HG\\71:9_3_C1\:$\(_&J[T;X
MI1ZWI7A6Y_LRU\/:MIE[J&FZ<LTT$TEV=1O+"]@/FR3(L423!E@AA\_R[>&2
M:YFT-%\7_$'X=?$3X*>'W\7RZQ8^(](O4U%0;*[M9Y-,T*!TN+6\-JEY(D\S
M-<M++.YE+ C8A,=>H7^JW'[0WQJU[P@VK:EIVD>"[;39+NVTZ>>PEO[[58)Y
M8S)>VEPEQ]DMH A6"/R#+=.S2L\<$2O\_P#PGUK_ (4-\4OVA]6#7.J+H6FZ
M!?HMY<9FE2VT2ZG2![@HSMM55A6>433LJB29YYC)))R&OI^T?J_@WPEXF\%:
M5X@O?%:RV-[J-Y?:]H[Z)J%NUG()HH;*SU@6)MY&>+R)(;2"8Q*)_/%T6F?]
MCJ_/#_@HM#JWA;PEH?CFWUO5[#3O#NKV<FLVFE:A<637NFW=U!!/&!;O"TEP
MK>6("TT"QI)<'>'*8\_^(/C_ $ZQ_:P\(JFLZO<:%K^D6LN8=9OK?1XKZ9[B
M73)T:&[^SW#WR6$MLMB8X[>XR)Q]JDDE1>PUZS\3Z-X'^*_Q!T'Q7K=ELN=7
MN=.MY+B*]B@_L"WN;:>(0:C#>)!%<ZC%=2LENRYM4LE0VVV2 >7_ +9^K7WQ
M'_84M_$&L7$LM]/I'AK49I(W:!9;BXFLO-:2. QQ.C&9V$3*85?9(J*\43)Z
M!^W/X-AT#P[\+-%TZ\OH5'Q$T&..YENI;ZZC:4W;>8)M0-VTCHS9C$_G(H"H
M4,2A*T/%FC:A\$?VDOAIIVA:[K;:;XDMM?MK^PU'5KW4K=OL%FMU%+&+^6XD
MBE+LH9T=?DC5%"J\_F_H_7P!^T/_ ,G._!#_ +F[_P!-,5<?JWA2[U7]K2X\
M*#7_ !!!HUUX-?6[FRAUO4ECDNGUDQ91C.9;5 -A5;%[4*(Q"/\ 1I)X9M#X
M3>)O''AKQ]\;?"OAVXN=4_L"VT>YT&SU:]N+W%Y>:/),8FNKR<W!BFGCCRCW
M"QQY8H8M[L?+_P!G;XC:=\8M5T+3W\0>(/#OC>QEV^(-.US4KZWN+EKG0;LR
M3Z=I-W+<V#(+N2*\AB%K&EO# '-O%"88YO</V</CWK]IX'^)^M^,=1N=7B\'
M^)/$-G'+Y%G'<-8Z3;Q2*FVWCM87E(WG<50,[8)5  OE_B/X?ZMX[_9F\0_$
M'7O$>KSZSK?A:^UMEM[VX@T^VBNM*,BZ?!IIEELS;I"?(:2:.6Z=VDNA/%<F
M)X2P^)7B71OA[\#O!^C6]]+'KGA^&XOETN]TZTOIK2PT:W#6MLU_);@/+)=1
M222VMQ!>06]O-)"ZL#+%V'P3\)_'9?B'XKTNZCUO0/!E];6]SI5SJ.I:?JNJ
M6=Y$MFDL4<ES=:Q^ZN,7+,DXGC0!6B-O([!_/_V2K/XG_%7X*Z/\46\5ZWJ_
MB&*V\1W-GI,]Q:0Z7<WDD][!#%<QQ0V\DL0=8S$DMR([4@" V\(" _9@^*6D
M?%#Q'X;M[G5];T?QGIERC>(]'\1:GJ=L]]Y^AW3RO9:5-<R6AB-U)'=1QQ00
M?9H(=XB@C,"2_J_7QAXF\3P^*OVI/#WA:YAE\O0_"VH>(X6%S*L;75Y>1:8C
M- NU&>&W^UHCR&08O)-J1LNYL_XJ^.?&?@;]HGX=:+::[<OI'B?^W?M>G2P6
M!A3^SM,22+R95M5NEW2,99-\\F6PJ[(_DKR_5O"EWJO[6EQX4&O^((-&NO!K
MZW<V4.MZDL<ET^LF+*,9S+:H!L*K8O:A1&(1_HTD\,VA\)OB?<?"+Q]\;;#4
M+[4K[0/"%MH^JVUO<W4^H7$2RZ/)=7:Q3WTSS/YA@#)%)-Y2/G;Y>]R3PS\'
M/B!\:/A!;^,K/QGJ5KXQUZVLM>L[A;V^@TNR:58+F&P33(KAK5K18U%M(]Q%
M=RRF26YD$S,(1T'_ #>]_P!TV_\ <_6?\'[.[\8_'#XT>%-1U35Y=+MI?#4M
MM"-7U*-K9KJSENYQ:RQW"S6R22\M' \:; (0HA C'A_P1_:&\7Z-^R=X#N6U
M>YE\0^*];'ARUU2]4ZBT$U[K%W%]IF$\R-+Y%O%(859G4RI!&R&'?CH/VK_@
MW9_"W_A4WV36=;O?^+@>&H)_[6U2YU'[0Z^=MN&^U-)Y,HP^1:?9H'\YM\+^
M7;^1] :!XY\9Z-^U/=^"KC7;F^T6?PC)K\=M<P6"^1</JXME2*6WM8)3%'$"
MB+,\KG)9Y';!'C_P9\ R^*OCM\4_"M[XA\2/HNA_\(XUE9_\)#JPV/>:?)-(
M_P!J^U?;?O;_ -V+@0/YF9(I&AMF@\_TKXZ?$OP%\ ?C!J6B75SJ-_X6\7:U
MI6EO>"74)K:QBNK4%G>4R2S_ &6*>>99;II@BQCS=]O'Y=>@>*?#GB_PW\:O
M NF^ O&6MKX9\6:;?W%X8KDZWY2Z; 9X;V&[UC^U$BBN6O;:$^6J1/MC^9WE
MCV?I_7YP?M>?&74/A9\0-*_X2^RUM/A^VF[IM1T&2]@:WU22^B@5[^XL+J"X
MCM(H'^2,<3RSG;%=311BW\__ &DO$'B?X;_LK:MXE\)>.KF;['<Z@MK>:=?Q
M:DES9ZAKY@@22_NHKB[,MI:S"%9+>XBDBG1@99?+1AZ!^UC9^)_V8?!G_"T-
M)\5ZW>W>C7-F=3M;ZXBDM]5LY[^UA>W-L(5LK"55*K'=V-K%($\WS%FEF:9?
M4+'Q4WQ^^+GC3P1J#WUEIWA"+1R@TW4KNQDN[C4[:2Y:6::S>WG"0HJQ16ZR
M^2Q:::99G^S"U^7_ (D>-/&7PMOOB=\+I]3OKFQM_!NH>,] U(ZI>?VG9+$Q
M4VDMVICGF1+M7>W+RR.MJJP32W*2&.$^(&NZ]9?#KX >)X=:U>/4=5U?P5IU
M^Z:I?K'=V]S:M-.MQ;B?R)GE?F662-II!\C.4^6O4/VO/C+J'PL^(&E?\)?9
M:VGP_;3=TVHZ#)>P-;ZI)?10*]_<6%U!<1VD4#_)&.)Y9SMBNIHHQ;\_K'Q$
MU_0+/P)X/\/:I<^(K+7M2\4WDEYHVNV<]Y<Z59W-PT%C;WNJ3QO+*JWELEQ+
M;W:7MM'9W'D3$IY\?H'[-6F?&KP[\5_$UMJNE:E9^!KJVBN=,77-4@U.^M[R
M..UBDB$RZC?S"*8_:)2DDDD:E$*&%GD23[_HHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHKG_%-SKEII<TFB6MM=WHV^5#>7,EI"V7 ;?-';
MW3IA=S+B%]S *=H8NOS!^Q%\'?''[/?PPL/!7B:/36_LSSO(N=.O+B?S_M-W
M<7+^9%-9VWD^7YJ(NUYO,^9CY> &X_X4_"KXP^!_BIXY\:7FF>'VC\4Q::1;
MQ:U>LUO)I=A+;Q*7;1T$B3R,GF/A#;H698[AE"-Y_P"%OV</C#X?^'7Q-\./
M:>'WN?&VKZU?QN-7O1':QZS:O#(&/]D[I'MV6(H J"X#R9:W,2B7U#P_\./C
M?X0^&_@71]+&B0ZEX7N;"WN8FU2_-GJ&G6VE2V4@>1+".2.5WD$L<30SPPR1
M13%YF01UV'PY^ ]]'\6=1^*.O6ECINK7>D1Z(;32[EKN"2-)Q.UW<7$ME92R
M7#!(+=%\O$4-N,RR^8B6_P!7U\0?!+X3?%/P;\8O&7C'6['1([+Q7_97FQV>
MJW<\UI_9EC);KL632[=+CSF92V7@\I<D>:0 WT?\:/A#X=^/7@K4_"/B!)6L
M=1B6.0PR&.1&2198Y$;D!XY$210P9&*A71T+(WSA_P *G^,_BSX>?\*X\27N
MFFREMO[*N_$%I?7,FHW-BK>6[-8WEC-$MW=VR^1/*U[*(9II+J/S"B0MG_%;
MX(?$74_BIX&\1^%M*\/Q:3X+BU*&TM9=2NK1IX[^PBM @B@TJ>*U2W*$1JC3
MB1 O$.=JZ'_"IOBG_P -%_\ "QOL.B?V;_8G_"-^5_:MW]H^S_VG]L^V;?[+
M\OS=G'V3S-F_C[7M^:O/]3_9L^-_P;^(?B'Q)\)-;T0Z;XEN9+Z]T;Q"M_\
M9X+QUB,EU!);O+(TL[B9I<?9XU1HXO+E6*$P?;^@>!?*T.[T_7[C^V'U'S#?
M_:4S;R^=&(WABM7:2.&T" 1I;Y?* O-)<7,MQ<3?,'[!/PF_X5K\/'N_[3N=
M4M]3N9)M*N;X[[A-#C8II$!D)W>5]G_TN.'9 MN]Y+']FBD\P-]OU\81? ?X
MB^"?BYXJ\8>%M5TC[-XMBL!=KJ5I=226$FF6T<%NT,<%Q$MXDRF=94>6R,)>
M&59)A$\,WQ!^T!\$/%7[.7[$/B?P9J]W8W5MIDMK'92VJS"2:.7Q$ESY\_F8
M6)W6=(_LT8E$)B=_M<XG"6_W?XV^%?Q+^-UQIV@^+QHD'ANVN8KO4%LFENIM
M7:SGBFMH'MKRU$5C:22Q^==1":_E952T6X*-+._S_P##&Y\<6/[3OQGF\,VN
MFWO_ "*B3V^HW-Q99SI+E)8[F&WO,;-K*T+6Y\WS%<3P^28[CU#4OV=O'J?#
M'Q?:;](U+Q;XWBN(]8O)7?3[6!9]/:RABM3#9W4\UO8H(T@CN,/,6GN'FBDE
M:.O/_B?^SA\8?B'^S79_"=+3P_!<QV.G:;)>'5[UHQ'IALGCF5/[)#,\[02J
M\1*B >6PFG+LL?J'Q[^!GQ+^*W_"(^,]"NM-T;QCX6N;N6WMY9I;[2YH;W;!
M<PS3&T@N/WD"*1(D*,A:2)0&:.ZBT+OX1?&'X@^%;VZ\6:QI$7B--(U:STI-
M$CO;:SLKR^A:&.]:XGEGG>XC0*L-Q#%;26L=Q?1 7 F##/\ $?P+\<?'O5/!
MMU\0-/T2PE\+ZE;:RM[HM]<74T]Q;IS;I'=Z= ;6TFF$<\P$]PY6WCAPSLMS
M#]OU\@>.O@IXXC^-]O\ $;PS-ILGF^&W\-SQ:B]Q']FS?K>)>1K#&_VO&6#6
MC266[8H%VGF%HL_1?@5XR^!GCWQ!KW@!;&^TOQ-*U_J&EZOJ-Y:+;:EOR]W9
MRQ6M\NRZ5V^TPO"K!XX3'/Y*K;Q^O_!GX3S> 9M<UO59(KC6_$5]]OOYHTBV
MQJD2P6ME%*L,#RV]G BQ1R2J'F<S7)2)KAHE]0\6>%M+\<Z'?Z)JD/GV6H6T
MUG<Q;G3?#/&T<B;D*NNY6(W*RL,Y!!P:^8/V4=:US1/AHO@F_;39O%7@^V32
M+NR@N)(X1Y,1_LR1Y"DTBQ7=HMO,9UB?#-,ODK-#+;19_P"R;\(?B+\'+[Q<
MGB.VT@6VO^(-3\1))8:C=7$D,E\T.+4QS:?;*R(L;$W D!)VK]G )9=#X.V.
ME_%GXIZ[\4K)+:?3_P"S;?PUH]_;W3R_:H;2[N9M1F$:JL:Q-=LEO$Q,C2?8
MGGC86\\;2_7]?$'_  J;XI_\-%_\+&^PZ)_9O]B?\(WY7]JW?VC[/_:?VS[9
MM_LOR_-V<?9/,V;^/M>WYJX^U_9-^(NBV/Q#\+:;KND)HGC6^U75);NXL+J6
M\MI-662"YM$MTNH89$6+R7AO#,I21)4>RE65'AX_Q+^S9\;]:\#_  W\.>3X
M;?\ X0S4M!U/?_:5_%YO]C6YMOL__(-EW>?CS_M&(O)\W[-]FF\C[7<>H?%;
MX5?&'QQ\5/ WC2STSP^L?A:+4B;>76KU6N)-4L(K>50ZZ.XC2"17\M\.;A K
M-';LQ135OA5\88?C[<?$FQTSP_-;+X??P[#;3:U>PR/&-1-XET[+H\RQNRX1
MK=?,"DDBX<#D_9U^%7QA^",/C,W&F>'[J37O$&H^(H%CUJ]14DOY;<&UD8Z.
M2$CC21Q<*K%W"1_9T5VEC[#]B+X.^./V>_AA8>"O$T>FM_9GG>1<Z=>7$_G_
M &F[N+E_,BFL[;R?+\U$7:\WF?,Q\O #<?\ #'X(6-C^T9XO\3Z7=R_V3!%;
MF;3F5?LL7B&\MT>ZNX(AL$=P-/-J9;@1R/<'4KA/M/RS0+]WU\8?M9?"'XB_
M&.^\(IX<MM(-MH'B#3/$3R7^HW5O)-)8M-FU$<.GW*JCK(I%P9"0=R_9R &;
MG_BM\*OC#XX^*G@;QI9Z9X?6/PM%J1-O+K5ZK7$FJ6$5O*H=='<1I!(K^6^'
M-P@5FCMV8HO/_$+]G#XB_$KXPZMXCOK32(]$U7PM<^#)DAU>Z6\6SN;UIGO4
M#:2\(N!$Y"VK,T8DQFY*\D^$/P1_:1\*>'4\ ZUXF\/KX<L[&33+;4M/MK]-
M;-JI\F'85F@MK2X2V.(K@?:C!+'$72[.^5N@TGX(?$70/C[;^-['2O#]MHEM
MX?3PK#:0ZE=1R1V<>HBY2Y2)=*$*NL0"+9*XC4@*+H*-U'PI^%7QA\#_ !4\
M<^-+S3/#[1^*8M-(MXM:O6:WDTNPEMXE+MHZ"1)Y&3S'PAMT+,L=PRA&Y_X2
M_LT?$73?"OQ+\+>(QI%K;>-K[Q!J27=A>W5Y):R:Q"D A-O-8V:RI$H9S*)H
MRY"IY*ABZ]!HWP9^+.L_";3OA=K$6D:;IRZ19Z)>ZIINJ3W=T]K!!'!<"&TN
MM(BA5[J)'@W-,3:B8SKYSQ*C\_XK_9M^+/PJ^).I>+O@Y>^'X+;7+&QM-0TK
M789X[6%M,A2VLWLC81AU18 T?DDJB$LW[T/$ML?M+_LO_$7XM?#;Q!X<L;G2
M+[5O$TMH]_J5W)=:?%;1Z?-;26MO9VJPZE*;?$4SM%)= 1W5S<W*9^TM%']'
M_$[2?BGXP^'+1Z(=-TKQ,MS97,2F^NYK$?9=1AG:*2XCMK:XDBG@B:.9!#'N
M$KPDE"9#P$'P+USXB?%?P]\0_%>GZ;I5[X;MKZWM5TJ^DOFN_ML?E8NII].L
M72*V5IFAB3S-\MRS[X1&Z7'U_7RA^TS^S/#^T%J/A2Z$L5NVE7UTEY))YK-+
MI.H6,UKJ-E&B,J[[M3#"9B4EMDWS0R"50DA>_LSPS_M 6WQ+66);9=(,$MI'
MYL+-J4)>"WOY!&PCN7%C=W=H#."T"% F\/\ N./^-OPF^*?C+XQ>#?&.B6.B
M267A3^U?*CO-5NX)KO\ M.QCMVWK'I=PEOY+*Q7#S^:N"?*)(70TSX0_$67]
MI%OB+>6VD1:3_P (_-X="1:C=2W1C%^U[%=&-M/BB#N0D<EOYQ$89G6XEVA'
MS_A-\#_B!^RY_:>@>!X--U;PS/<F^T^VU?5KZTN--:;/VBTC=+'44FM-P6:
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MSV^BZOJ\?AV)Y=7DL(;>..S5;1+W!DO[BS2X<V\@E,=F;EXP5$JQM)")./\
M&O[:O@?P?I?AG78;/4M5T/Q)<VEE9:II45O<PFXNGE58&MQ<+?\ FIY+F6..
MTD=6'D@-<@PCL-+_ &D+0>-=&\(Z]X>U?0;[7(KV33C?G39H[AK&-)9XPVG7
MUZ8W6-_,!F$:,%90Y?:C?1]<?X_\?^'?A9X=O?$/B&]BL=.L8C+//*3M5<@
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M7]+],U:QUJ%IK.XBGC66:$O$ZNHD@E:&5"5) >.1'CD7JCJR, RD#\@?B?\
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M#IKRXB@C:7Q3"'E=44R3Z=!#$@+$ O)(Z1QKU=V5%!9@#T'Q(LH?B;^T_P"
MX](N8II/!ECKE]K"@2D6ZZK:0VME"TB(T2W$QWS)!(Z.;>*2;&TQ^9^<'Q_^
M,'AGXN?L@7FMZ9J]CX9MKV5+:R\'Z:VDI &M=6MVG5P;5;N6X_>"_?[,;1$A
MFMM]NX\VXNOO_P".NK6.M?M+_!*:SN(IXUE\:0EXG5U$D&G)#*A*D@/'(CQR
M+U1U9& 92!Y_\=]3\#>&_P!JRP?QS=2Z/IVI>#1;6>K#4M3TA3=6NI3S2V@O
M+.ZM8=C12++,DY8;UM0K(\B),:UX8^$?AOX=?%R;X96T5W;7_A;4KK5M9BU:
MYU..XO&M;TQ0+-+-=K)<(K3SWF98I(A<6;%)Q<[H./\ VEO^4>=C_P!BWX3_
M /1VFU] ?M#_ /)SOP0_[F[_ --,5<?K7POL?BQ\3/$'CGX0^,9=*\36$NF?
MVC;23K=Z/J\;:2EQ8R7%O#*7^SSP7*01W:G">1<26]N;@?:#[!^RG^TQX=\?
M^"O!.G:M%8^']=UC2)+JUT2+,(^RV<A@66VA95,=O+'&)[6+DFW#F)IX[:64
M?9]?D!XX^''_  C&E^/_ (H_"K7_ /1[>Y\3?\)'X6UX?;](O+BV<Q7^Z".;
M?;2RK;O=1[R[SQRV\1^RV<CQ'T#PGXZ_M/\ :GL/$VNV_P#8GF_"2'4;R"]?
MR_L.[5UFFCG>58MOD999&=8]NPEE3! \@^$,GP1N-<^*'AGXCZK_ &!>GQ=K
M;S6=SXAU?18K^QU&0R0SR6YO[>UN/.C9HR8DPUJEN9%(D2270^.R^"OA_P##
M;X5KH-G%HOA?3OB;I36,D]W)(C6<<U[))?--<,P6WFD\^XMY/.FCDLF@N1(@
ME,,/T_\ M=64/Q+\:_#/P;IES$VK6OBFP\43P$2L8M-TN.X,UQ*8DD$*/(R6
MUNTNQ9KB18U;Y9&3G_V?-6L8?VJ_C58O<1+<S1>%9HX2ZB1XX=+*R.J9W,B-
M-$KL 0IDC!(+KGP#Q'X[\.^$K'XX?&.;2;'Q7X7U*^\.6-I:W (M[]M,6"QN
M)D:>VFAEMX[F?$,\:S))-:R[2 J2-?\ 'OB[1[3]I7X37U[X^MM=^SVWB6_O
M,2Z7%::?#-H:W*RQK;()8;2:(^;"U[<73&WC1Q<28DED^@/V>/\ DYWXW_\
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MZ!\)_ _A37+O7=+T'3;/4KSS/M-Y;65O%<3>;()9/-F1%D?>ZAWW,=S@,<L
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MT,E\KO*EE!,+*"=UC=X8PWEPAS$OI_BSPG_Q0]_H6A6&F_\ (-FLK.SO8?\
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MN5\4^(++PUJ$4FGSK.6DO[RV>[CFBO(X4=HK9"8OLQ03,\BE8BL"^X?M#_\
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MK[Q9X7GL=3AN9+V'2X&M]0AN+'[,GEVVGZ?=([0O=LRRJR%/*DPHDA:3Y/\
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M#ZO-8^&HM7DO +K0ED9M5TV*)(XE?5%#/#)NCN"Q1,HS0O.A5V]0_;E\"_\
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M$K;P@O\ H:WNH6^N)<33H'#W:65O:1R/!YZQM;^8][%/9K<K<02SS0<_;]?
M'P"\/^/M&^.WQ \3:MX0U+3]-\5?V)]FGGN='D\C^S-/EAE^TI;:C/(/,<A8
MO)6?.X%_+4$C/_96TSXB?""'Q\^L>!]7#:QXIU7Q%9I%=:$[207TMLD<!_XF
M@5;A5#RR!B(0D;!9WE*1OZ!_P3]^'7BWX0? _1?"WBG2Y=-U'39;V.2.2:UF
M619KR6Z22-[6:9=FV8(0Y1PZ/\FS8[Z'[8OPM\3_ !)TOPA>:!:?;I?#WB[1
MM?GM4EBBFGM[-Y%E2 SO%"90)0X6:6%"JL/,W[5;Q_XJV'Q2\7_&+X=>+X_
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MQ/$T%M;F,!HIY)PT('T_J?QO^'6B^(E\.7GB72(-6:6&$6$NH6J71DG"F)!
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MDD947<S*JY(RS!1R0*Y__A;'@?\ X1C_ (2G^WM-_L7_ *"/VVW^Q_ZWR/\
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MOBU\(]>\,6.M1:+<ZI%#:0W4TC11F26YB5+9V5E;9=L19L%WEA.5$4Q/E/\
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M=ZCIKZUX>_X2J_BT35994AU!9;J[M&E58Y8]TMOYXAB9RD2->_/<0J2LWO\
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M(=3TZZM8)]-&KG4!;1RB-H?+26=+22=]Q,ES,DDSES#'Y//_ /!+CX3^!_\
MA1/A'Q3_ &#IO]M?\3/_ (F/V*W^V?\ (0O(/^/C9YO^J_=?>_U?R?=XKH/^
M"K'A/0]7_9V\0:I=V%M/>Z?]B^R7,L,;S6_GZG9I+Y,C*7B\Q0%DV%=Z@*V1
MQ1^WS\)]#\)_!&+4?"&@VUOJ_AC4M,N_#JZ=91AK:\N-7M4*V\$2;'\YI,O
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MQT[_ ()\ZO-;V\44EUX?\5S3O&BJTL@:_A#R$ %W$<4<89LD)&B9VJH&_P#
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MM=6U"6RT_3((;:1[**VD2PNI2]R+B:X,<230[Q</+-;2M'%<?G!J>K7VM?\
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M'P*_9ET'X$>"I/!=OJ%]J^B-%+"EEJZ6$T<<<\DTEPG[FT@:5)FG;S%N#,,
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M^ K#Q;;>$7URQ.MW,IB33HYTDN@PM7O,R0H6>)/(C:022A$(**&+21JW8?\
M"6:'_;G]A?;[;^TOLWVW['YT?VC[/YGE>?Y.[S/*W_)YFW9O^7.[BN@HHHKG
M_"WBS0_'.EPZIHE_;:A93[O*N;.:.>%]CE&V21LR-M965L$X92IY!%=!1111
M6?JVK6.@6-Q?7UQ%;6UM$\TTTSK''''&I9W=V(545069F("@$D@"O/\ P5\;
M_AU\2KY['PYXETC5;F.(S/#8:A:W,BQJRJ7*0R.P0,ZJ6(P"RC.2,^H45S_B
MGQ9H?@;2YM4UN_MM/LH-OFW-Y-'!"F]PB[Y)&5%W,RJN2,LP4<D"N@KR^]^-
M?@*P\6VWA%]<L3K=S*8DTZ.=)+H,+5[S,D*%GB3R(VD$DH1""BABTD:MZA17
M/Z_XLT/PI]D_M2_MK/[9<QV5M]IFCB\ZXESY<$6]EWROM.R-<NV#@'!KH**\
MO\9?&OP%\/M6L]'UG7+&TU&^EM8K:RDG3[5,UW<"UA,=NI,S(TIVF0(40*[N
MRI&[+ZA111117'^-?B%X5^&MBE]XCU:QTJVDE$*37]S#;1M(RLP0/,R*7*HS
M!0<D*QQ@'&AX3\4Z7XYT.PUO2YO/LM0MH;RVEVNF^&>-9(WVN%==RL#M9589
MP0#D5T%<_P"*?%FA^!M+FU36[^VT^R@V^;<WDT<$*;W"+ODD947<S*JY(RS!
M1R0*S_ ?C_P[\3]&CUGP_>Q7UC++<11W$))CD:VGDMY"C8 =!)$X61<I( '1
MF1E8\_\ %#XU^ O@K8B\\6:Y8Z5&T4\L8NIT2298%#2""+/FSNH9?W<*NY+(
MH4LR@^H5GZGJUCHL*S7EQ%!&TL,(>5U13)/*L,2 L0"\DCI'&O5W944%F .A
M117C_A?]H'X:>-_[5;1_$FFWT6D6T5Y?7%M=12V]O#+Y^UY;A&,*X%M*SJ7W
M1HH=PJ.C-T'P]^*OA#XLV]Y<^&=5MM4M[.Y^QS3V<@EA$WD13E$E7,<F$GC+
M-&SJK$QDB1'53QU\)_ _Q0^S_P#"3:#INK_9M_D?VC96]UY7F;=_E^<C[-VQ
M-VW&[:N<X&.@\+>$]#\#:7#I>B6%MI]E!N\JVLX8X(4WN7;9'&JHNYF9FP!E
MF+'DDUT%<_K_ (LT/PI]D_M2_MK/[9<QV5M]IFCB\ZXESY<$6]EWROM.R-<N
MV#@'!KH***\OT3XU^ O$WBJ;PMIFN6-[JT$5S+/:6LZ3R0+:S103"<1%A"ZR
M3(GERE'8[]JMY<FSU"BBL^]U:QTZ:VAN+B**2ZE,,"2.JM+((GF*1@D%W$<4
MDA5<D)&[XVJQ'/\ B3XA>%?!D-W-K&K6-C'9Q037+W5S#"L,=S*\,#RF1E$:
M2R1O'$S8$CHR*2RD#R__ (:Q^"'_ $/GAO\ \'-A_P#'J]@\+>+-#\<Z7#JF
MB7]MJ%E/N\JYLYHYX7V.4;9)&S(VUE96P3AE*GD$5T%%%<__ ,)9H?\ ;G]A
M?;[;^TOLWVW['YT?VC[/YGE>?Y.[S/*W_)YFW9O^7.[BN/\  /QK\!?%6^O;
M/PQKECJTEC%;RW!L)TN8XUN6F6(&6(M%O8V\F8PQ= %9E59(RWJ%%>7^-?C?
M\.OAK?)8^(_$ND:5<R1"9(;_ %"UMI&C9F4.$FD1BA9&4,!@E6&<@X]0KS_7
M_BQX'\*:Y::%JFO:;9ZE>>7]FL[F]MXKB;S9#%'Y4+NLC[W4HFU3N<%1E@17
MH%%%<_XI\6:'X&TN;5-;O[;3[*#;YMS>31P0IO<(N^21E1=S,JKDC+,%') K
M/\!^/_#OQ/T:/6?#][%?6,LMQ%'<0DF.1K:>2WD*-@!T$D3A9%RD@ =&9&5C
MV%%%%<?;?$+PK>V.I7T.K6,EMI4MQ#?S)<PM':26R[ITN'#;87B7YI5D*F,<
ML *T--\6:'K/V/['?VT_VZV:]M?*FC?S[=?*S/#M8^9$//AS(F4'FQ\_.N>@
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK/U;5K'0+&XOKZXBMK:V
MB>:::9UCCCCC4L[N[$*J*H+,S$!0"20!7S!\!M=UF\^&T7Q!O-(EU+6?$44>
MIM;V$\$D_P!CN9GETZSCEO7L8 EG:3H'3,$;3"ZN%62YN99)_+_"?Q1^%EY^
MR['K/A[PCJ4G@R33=2MIM-MOLD%Q#80"ZBO)9?,OXMV[RI6=XIY;N5Y1+AI&
MD9=#XW_&3X8Z'\!](\0ZSX/OM0\&75CI-\;6UAT]8[2#S;.6PAGMI+RW#)YC
M0IY$ N(<1O'*/(.'^C_CI\/=4^)'A"ZM-$O/[/UJWQ>:3>C8#;7T()A<LT4^
M(I,M;W2B-C+9S7$!!65@=#X*?%"Q^-7@+0_%EF(ECU6Q@NC'%.LZPR.@\V R
M*%#/#)OAD^52'1@R(P*CQ#XN?M&^+_AE\3_#?@RW\+VVHKXF^WKIUQ'JQA=6
ML;1)Y6NH9++9%$&D 9H9KF7R$>5()9MEK)H>&_VDKZP^(NH>"/&FF6.CW-IX
M?_X247=KJ;7=F+-+I[:8SRW-II[0O&RJ_P!R2,QEV:2,H%;/\4_M&^+](\(3
M>/=-\+VU_P"%HK9=3$PU8PZE+IH DDO([*2R^S_ZC==0P27L4TD(1)%M[IFM
MH^?^*G[9'_"'Z7X/\1^&-)MO$N@>*=2L-)M;BSU+R+LW%X\PVI;3VRP_((2C
M">[MG6X)@E6#8\@[!/V@?%7A7XD^&?!?B[0+&TD\31:F;&XTO59K]5DTV&.X
MD6X2XT_3RB-&[;'C,QWJ%,85BZ_5]?EA\%=6^(OC']H3XL:9K6C:1>6SQ>&+
M'4+6XU>ZGM[:SEL;AC%:K)I>VZ219IY98)4LX_.D==SB5Y1](:O^U+<3V_BK
M6M TJVO]"\(7-[9ZQ<S7T]K=B;38%N+Y+.T-C+'<>4CA(VFN;59KA73*0!+F
M3/\ C/\ M97WPUL?!NNZ+H46O:)XKOM*L+2:&_:UO&DU-9)8BEK<VJ0E#$BL
MIFNK<F1Q&ZPJK2@\3?M)>/? 'C7P]X1UKPE8O?>)8M0&F'3-;>XC\^QCBE<7
MC76G6)@MQ'(TCS0B[F C94M9G94.AIW[2OB?3_B!?>!=;\)^9J\.B0Z_;1:'
MJ45ZL]N]\;*1#)J,6D)%+&Q60*2R/%OQ()%2.3R^V\6> O&W[&FO:CX$TR72
MM";PMK\5G:3(B21K!#=P.7"2S!G>2-Y&D,CO*6,DC&1FKG]0_:)\1?LN?LM^
M _%UCX<BURQM_#^AQWP.HBRDMUFL[6*&15-M.)D:1Q&X4JZ%HV".AD>+Z@\<
M_&'Q5HND^%+K0-*TC5Y_$$L-NB#69HH#)+;FZWVMRFG3I<6Z6\5S<--(+8O#
M /*BFGFC@/O^K27T-C</8Q137*Q.88YI6AC>0*=BO(L<S1HS8#.L<A4$L(W(
MVGXP^$/[2WQ+^-?_  D$6D^#=-AE\/ZW>Z'=O=Z_*EO)-:; QMGBTJ:9^6)<
M36]NJHT)1YG>:.VY_P -?MC^+_B!\()/BCH7@^V&D6^FW=].FI:R;:X9K!93
M=+:I;6%ZDD0:)XH9;A[265T8M;0Q[))/8(_VEK?Q9_PC=CX2TW[?JGB+1!XA
MM[:\NX+-+6Q/V;$M^\?VJ:+S#<"*'[/;W8DG21"4BCDFC\?T?]M^X\3>$/&]
M_INA6SZUX$N;Z+7-.FU&>*$0V8NCYUG>+I\GVCS?LK+'')#;,&#^88U6)YCQ
M%^V/XO\ "'PHLOBGJG@^V@\/36VEWDR#62^I)#?R6\1>.V6P-M)@S^9"KWD+
M2P[&E%K,SP1>@>-?VC?%_P +=4\,GQ/X7MK73?$6MVFAV[V^K&YOH)KY)6MS
M<VOV*.V&#&%N1!>W"Q$L8GNE52_S_P#$OQAJG@K]L*2YTG1[G6M0?X;-':6-
ML4C\Z;^VW=1+<2D0VT6$)>>9@HXC19;B2&"7T#P/^WGIZ6_C>W^(&B?\(MJ_
M@ZVBOKO3FU.RO6FMYX$DB-M*K0))*S/'#Y8PBRW%K'YIDGV)V'B/]K*^^&'C
MWPKX;\;Z%%I4'BV6XM],F@OVO9X[B-[=8H+^!+5(H'D-RD9:VN+V&.;Y?,:#
M-R.??]L/QAXA\1>)O#7ACX:ZO?ZMX?BTPSV]UJ6BV:K)?B24++*+RX14^SJL
ML3P?:2[EHI([;:LDGL&J?'#5M?\ &NL^$?!>G6.I7V@164FJG4K^XTZ.%M0C
M>6VCA:+3[XSN8XVDE.(TC#PJKRNTJ0>G_"?QU_PM#P/H/B;[/]F_M?3;+4?(
MW^9Y7VJW2;R]^U-^W?MW;5W8SM&<#Q"R_:)\177[0%S\+G\.10VT.D#6TU23
M406FM24@S':);/AQ=.T!66:,[(WG&08TDS_@A^T+XX^+NJ>+M+N?#>FZ9>^&
M[F>P>VDUJX>:6X5$>UE,;:7$\6GW:LS07A#NZHS);2#)'R?^TE\5]9^*?PN^
M"_C.[T"6RN=0\=^';^+3(;J"YD:-_M;VP2=S;PE[B+RY%$IA$9E"2,A1R/K"
M#]HWQ?X9^*_A[P'XO\+VUE_PD=M?2Z??Z9JQOX3-8Q^=-#+'-96$L>V(;O,"
MNI9XD4-F5H>@?XW>+_'&EW.M_#K0M-\0Z5%]IC@N)M:-DU]-:N\<HLU2QNXG
MB\U&@CGGFMEEE1W"_9/)NI^_^!?QT\(?M%^$+7Q1X7NO/M)\HZ. LUO,H!>"
M= 6V2IN&1DJRE9$9XGCD;Y@_:'_Y.=^"'_<W?^FF*O4/#?Q%\&ZG\?=0T*?P
MU?6/BA?#_FKJ%T+-XY])M]1>*,0/!=SO&DMQ,\GEO%!+(%0S*#%"JGPH_:!\
M5>,/BCK_ ("\1Z!8Z1<Z18VM\DD.JS71O8[K&);2.;3[-I;>)@T-S.#B*XV0
M[7+ED-(_:2OM%\%>*?&/C+3+'3-+T&6ZA26QU-KPW<EE(\%RD0NK33MCBZ0V
M4"R8-S<*VP"%H)KCG_$?[65]\,/'OA7PWXWT*+2H/%LMQ;Z9-!?M>SQW$;VZ
MQ07\"6J10/(;E(RUM<7L,<WR^8T&;D?5_BG6;SP_I<UY::;<ZG+'MVVMFULL
MTFYPIV&[GMH1M!+MOE3Y5(7<^U6^,/A[\;O#OAS]FNT\;?"_PS$FA:;8W]RF
MG7]R=/D2UT\W(N&#PPZB)+AY(&8>8V9C(TLMPLA8-G^(OVQ_%_A#X467Q3U3
MP?;0>'IK;2[R9!K)?4DAOY+>(O';+8&VDP9_,A5[R%I8=C2BUF9X(OO^OD#5
M_P!J6XGM_%6M:!I5M?Z%X0N;VSUBYFOI[6[$VFP+<7R6=H;&6.X\I'"1M-<V
MJS7"NF4@"7,F?\9_VLK[X:V/@W7=%T*+7M$\5WVE6%I-#?M:WC2:FLDL12UN
M;5(2AB164S75N3(XC=855I1T"?M ^*O"OQ)\,^"_%V@6-I)XFBU,V-QI>JS7
MZK)IL,=Q(MPEQI^GE$:-VV/&9CO4*8PK%U^KZ_.#]BZYURTTOXMR:):VUW>C
MXD^(?*AO+F2TA;+V@;?-';W3IA=S+B%]S *=H8NNAX'_ &R_'OQ%^#4OQ2T[
MP58PZ7;6.HWLT5[KSQSNNGM/YOV98-,N%D0K#M5IVM7,PD0Q"%8KF?V"V_:A
MA\<7V@:/X-L(KS5M9\/P^*5MM4N9=/C@TV9HXXVDG@M;\&X:24*L,:.H$<SO
M,F(1/Y?\9OV@_#;_  9GU_XB>#;F_P!(AU*ZM=4M].GM;VWAFTC7?L4)D-W+
MITMQ%-<P(ZHL#JR;DGC$9(?Z?^-?Q9_X5'H<-Q;:9<ZOJ5_<II^F:=:##W=Y
M)')(D;2D&.WB5(I)I[B7$<$$4DAW,%1_B#XG:UXOU+]IWX,1>)-'MM/EC_X2
MMHWL;\WUO*KZ2@*AY;:RF65"F9%:W$6R2(QSRN9HX/4/'_[:DWA7P->_$73M
M BO_  EI]\;*:]_M.);JX6/4QITMSI]M!#<P7%OO.Z%I[NS>8*^8XX_*EEZ#
MQ7^V5::3XE\(Z/H_A;5]8C\61276F75O)IL,=U:Q:<+YY8%NKR&57020JT5X
MEF2&D=&D:-8Y<_XR_![7/VP_A!9:3XN\+6VE:E<7,DCVUSJTDO\ 9;A;JVBO
M8I;&,QWTL:2+,EG(8()?,,<D\;)D^W_%?XSP_#_6= \-6,$5WKOB*6ZCTVVN
M)I;:W9;* W-U)/<QV]R8D2, *%BE>2:2- @C\V:'0^$GQ#USQR^O6>MZ;;:?
M>Z-J2Z=*EG>R7L+[]/L[Y9$EDM;-_NWBHRF(89"0S BOE#_@HA>S:=8_#*XA
MMI;J2+XB>'Y$@A,0DE95NB(T,SQ1!W(VJ9'C0$C<ZKEAZA!^T;XO\,_%?P]X
M#\7^%[:R_P"$CMKZ73[_ $S5C?PF:QC\Z:&6.:RL)8]L0W>8%=2SQ(H;,K0]
M_=?%W7/%VJ:A9> ]/TW6%TFY:QU&XO-5DLH8KQ421K6(V]E?O++"KH;G<D4<
M321Q+)+,MS';?.'B[]OVQT3X1ZWXTL=&BGU3PS?1:=X@T.XU%8;BQN&N?L;*
MDT5O<I<)YY'DRJ$AGA$K!TFA>W'N'C/X^:YX&^,7A7P-=Z+;/9>)_P"T?LE_
M%J$AF3^SK%;J7SK1K-47<S"./9<R97,C;#^[K0U3XX:MK_C76?"/@O3K'4K[
M0(K*353J5_<:='"VH1O+;1PM%I]\9W,<;22G$:1AX55Y7:5(.?T7]IN;QE8^
M%+30=(BNM=\1^'X_$:V4VH10V]E:LML6:[G$<EP$9[GR;9X;.8SS1N"D,:2R
MQ>'^(?VG-+^/_P &/C!I#6OV'6O#&FZ_IFIVJ2/<0JR6U[%'+!<M#!YT4OD2
M8W1Q2HR,K1!?+DDX_P *_M->-?V=OV=_!?BK4/!T5SX<M-(T"WN9HM7C74([
M>2W@M_M7V,VQ@9&<J8(EO3,Z2PF9+8F=;?[O\=?%3^Q=<M_"^A0VVH^(;FV>
M^2QGN_LJ16<4BQR75S*L5Q)%$7988MD$TDT[!5C$,=U/;\!X%_:.^U_$.X^'
M?C"QMM$\0_9DU"QA@O\ [;;ZA9LK!I+:9X+63S8GBF66WEACD"1F>/SH0[Q_
M/_\ P3D\4Z7X&_9&T#6]4F\BRT^VUF\N9=KOLA@U*]DD?:@9VVJI.U59CC !
M.!7C_P"WK\2OB'XY_9B\17^K>#_[(TV^^PM#YNHJ^HP)_:ULT#W]DUO%';^:
MB#?'#<W<\$TL43Q;1/+!^O\ 7S!\/M:_X6U\3_$VHR-;7.F^%KF#1M.$=QYV
MS4?LGGZG<%%18TE"7D%@I9YIH/(O8U,"W5Q'+H:Y\9O%6J^-;_POX-\.Q:DV
MDQ(=3OM2O9M-LX;B>.*:"TAD2RO7N;@P2BXE$<8A@C:$/-YLHC'/^"_VJ;'Q
MKX*\.ZFFF2V>O>(9;RRL]"OI5@N/MEA)-%>I*Y4M';VK02O/.8O,6%5 MFNY
M8;.0B_:2OO!7CW2O!_Q"TRQT.?7HG.CW5IJ;7UK=7$+A9K1VFM+&6"X DA:$
M-$T-P9/*2;SPL3^7_L\?\G._&_\ [E'_ --,M9_[#>K6.@6/Q<OKZXBMK:V^
M(GB>:::9UCCCCC6W9W=V(545069F("@$D@"M#QK^W/\ \*V\-^&?'.O^'_L/
MA'Q#<VD$%V]]YNI0)>6LMQ%<3Z?!;RPB(B(L1#?33B%E;R?/W6R^_P#Q"^,6
MN:3XOL_!_A70O[8U22V_M"[>YN)+&QL;-C+'%)/=+;71,MQ-"\5O;PQ22,(Y
MI7\J*+<WR!^TC^U;XX@_9Y\=ZUI^C_V-K6AZE-X=OEENK@>1YKP1+>Z?,D-O
M+-OBO+>:UDD2SV^89QYBQ(ES[A\8?B=I/AR^\#0?$?PA++/=>(+&+3[BPN+>
M_P!/M=6N&N;>U):X>QNG>.$O.9#8F*%V5HV>>*-AT'Q4_:!\5?"WXD^%_#=Q
MH%BVD^([YK&#5I=5FA6&1(5E,4\1T]HEN)CYD=C MPQNWCV[H<MLZ_4OB[KF
MD?$.\T*YT_38M%T_35U:^U2759(GM;>195B::WDLEB'F2V]T 4NW2."VDFF:
M%G@AF\ \:_MS_P#"MO#?AGQSK_A_[#X1\0W-I!!=O?>;J4"7EK+<17$^GP6\
ML(B(B+$0WTTXA96\GS]ULI_S>]_W3;_W/UV&F?M1^(E_: ;X4ZQX>L=/62QF
MU.SOVUD.UY:J66/R+7[&C&X+(_FV[2*8DAN)5>:*-&F]?\!?$?Q5XL\:^(=&
MNM(L8=.T:5;?[;;ZC-/))<2QQW$<#VTEC;^6XM9H9YF66:%#/%#').ZW!@]P
MKYPUWX<^/?\ A=ND>+M-U&Q?0O[(GTO4+&[C<W$+>8]Q'<6$BA@KS2>3'=H3
M$CPV\3.+B2.W-L? SX<^/?AUXB\9_P!O:C8ZAI>IZN^J:7+'&Z7R+<@^;;WC
M$;9$MU6"WM'WRN+>,(3%"EO;0?%__!.']H7X6>!OV=O"^EZWXMT33[V#^T?-
MMKS4[2"9-^IW3KOCDE5UW*RLN0,JP8<$&O8/A1\6M+AO+6S\#Z-;'7_&NFP?
M$"]T^\O'L[.TAN[:RLY&6YM]/G,DLLR*VWR2TL@N[B66'=#%+Z!J'[4MQ>?#
M3Q'XLT'2K:\N_"MSJ=GK5C<7T]JL,VDQ2/=I;7 L9OM.=J-;,T4"RQ2JTAMY
M5>!?/_$7[8_B_P (?"BR^*>J>#[:#P]-;:7>3(-9+ZDD-_);Q%X[9; VTF#/
MYD*O>0M+#L:46LS/!%Z!XU_:-\7_  MU3PR?$_A>VM=-\1:W::';O;ZL;F^@
MFODE:W-S:_8H[88,86Y$%[<+$2QB>Z55+Z'AOXB^#=3^/NH:%/X:OK'Q0OA_
MS5U"Z%F\<^DV^HO%&('@NYWC26XF>3RWB@ED"H9E!BA5?'_@=)?0_M'_ !V>
MQBBFN5B\*&&.:5H8WD&CS;%>18YFC1FP&=8Y"H)81N1M/H'[,?[4?B+]HJQ\
M6I-X>L=(U;P[?2Z8^G2:R+F0W42N#]H>&SQ!;M(OE1W$8N1(8[@JA\D"3V_X
M%_$/7/BMX0M?$.J:;;:>M]F>S6UO9+Q9K-P&M[DO):VCQ^>I\U(GC$B1-'YH
MCF,D$7RA_P %(?A#-\=_!&@>%K=)9+F[U>[DM8XI(HVDNK;PYK-U;1EY?D5'
MGAC20L5&QF^>,X=>P_86_:/TOXR? 32_$.HWOERZ/;'3]6N+V=VV36$*>9<3
MW$ZQAO-A\N[DD)98_-*-*SQNU?*'[+^@^(H/VM+GQ%XDCE@U;Q1X$DUVZM)<
M9LEGUF&"TLL?9[5@]M96]K!/YD>\W"3,6;<*^S_'_P"T_JFF:?XPU+PIH=MJ
MUEX.^U)JEQ=:HEHCS6ME'>S060M[>_>66%7\NX%RMFL<^(E:4B8P^?\ BO\
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M/X5\3:C;6U[8^-]'U&[6XE@B\E3/=7=X21*Z-%9M=I#+<*QB^Y(2@E5:]_\
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M^T75REM';H]HBS7"QI=QF[>V-O;7'FR1O6A^S!\6/ _B']IWXM_V?KVFW/\
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MNV@X KC_ (F_#F;XG0VNG7&HRVVEB59;VU@CB+7RQRQNMK/)*)%^Q2JLD=Y
ML8>Z1UC\^.$317'J%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%?('Q<_:%\<?#OXG^&_!6G^&]-O?\ A)?M_P#9]S/K5Q;8_LZT2YN/
MM,2:7<>5G<4B\MY]^ S>5G"_7]%%>7_"[QKXB\;PZO+K&A2Z.MIJ]]868EF$
MC7EK:R^5'>A?+C:))V#F.-@Q**LJO)%(CG/^/'Q#USX3>!]3\3:7IMMJ7]EV
MUQ?7,%S>R6>;>VMY)I#$Z6MWOE^0*D;+&C;B3*FT!M#X(>-;[XE?#KPUXCOD
MBCN=5TC3[^9(0RQK)<VL<SA S.P0,Y"AF8@8RQ/)]0HHHHHHHHHHHHHHHHHK
MR_XE^-?$7@^;08M%T*76&U+5[>PN3',(5LK5XII9KV1FC=2D*Q8$9,9E=TB1
M_-=$?R#Q_P#'CQ5X*^-'@WP.^E6(T[Q++J1CO1=S27'EZ=IK7$BM;?9XDA<S
MO$$<3W(:%),QQO(IC^C_ !3<ZY::7-)HEK;7=Z-OE0WES):0MEP&WS1V]TZ8
M7<RXA?<P"G:&+KXA^R3\;[[]H_X5Z5XTO+2*SDU*6_(MXF9UCCAO[BWB4NV"
M[B.)/,?"!WW,L<:D(OT?17S_ /&3XM7'A+7_  OX1TBXMH-:\3W-W%:R7EO/
M<PPPV%G)=W,SQ126_FXVQ0+']H@8-<"8&189(FZ#X':C\2]2\,!OB'8Z;9ZN
MES<Q,-)FEDMY88Y66&91*"\7F* PC9Y&V;7<Q2.]M![!117S_P#%+XUW'A;X
M>:OXQ\,V=MJ\6C_VFUW%<W4]A\NDM<QWBQ,+.Y+RI-;-$BLB12<N)P@4OV'P
M0\:WWQ*^'7AKQ'?)%'<ZKI&GW\R0AEC62YM8YG"!F=@@9R%#,Q QEB>3ZA11
M7/\ A/Q3I?CG0[#6]+F\^RU"VAO+:7:Z;X9XUDC?:X5UW*P.UE5AG! .1704
M444445S_ (E\4Z7X/LX[O49O)BDN;2S5MKOF:]N8K2!,(&/SS31IN(VKNW,5
M0,PX_P 3>-?$6D>-?#VAV.A2WMCJ,6H2WVHB81QZ>MK'$80R&,B5[F241I&K
MHX"R2A72.0IZA11117RA^V5\>/%7[-GPVU'Q=HNE6.H1V<0$OVN[FA:*2>:&
MVMV2&.WD%P@DFW3(9[0A$PDA9\I]7T445\8?M/?M0ZM\)?@TWQ)\(V%CJ^G2
M6,%TDMW<W%LP6^:".RE2W%JS3H6N%>:*26S=47:&WM\GV?17E_QD\:^(OA]X
M2NM5\/:%+K^HI+:Q0:=%,(&F:XNHH"3,8Y%C2-9#+)(Z[$1&9V1 SKZA17S!
M^UI\?-<_9F\"7/C&TT6VU:RL?+^UQRZA)9S+YUQ!;Q>2JV=TDN6F)DWO#L50
M5\PMA=#5O&'QUTZQN+B'P=X?NI(HGD2"'Q/=B25E4D1H9M"BB#N1M4R/&@)&
MYU7+#U_X>^-;'XE>%=)\1V*2QVVJV-M?PI,%618[F%9D#A6=0X5P&"LP!SAB
M.3V%%%>/Z/XY\7ZWK_BS35\._9[?2/LL>F7MU=F.'4YIK,7$@ 6W>2"*%WCA
M>=5N%9C)L4R0R1#@/V7_ (Z:Y\=+?Q9)J^GVVGRZ'XDO= $-K/)<+_H,%L)'
M,TD<!DW3/*R-Y,.(C&ICWJSO]/T5\0?MJ_M;:Y^Q]H=GX@_X1VVU?3;FYBL=
MW]J26MPMQ)'<2X\G[#/&8@D'^L\X.7;;Y04;S]?^$_%.E^.=#L-;TN;S[+4+
M:&\MI=KIOAGC62-]KA77<K [656&<$ Y%?(&C?MD?\)W\>]2^%?A;2;:]_L>
MV6YU'49]2\E$VS01W$5O%!;77G2P_:$4I+);?OTFA<Q>6'?[?HHK/U:2^AL;
MA[&**:Y6)S#'-*T,;R!3L5Y%CF:-&; 9UCD*@EA&Y&T_.'[+_P =-<^.EOXL
MDU?3[;3Y=#\27N@"&UGDN%_T&"V$CF:2. R;IGE9&\F'$1C4Q[U9W^GZ****
M**^4/VD/CQXJ^">K>$X+/2K&XL?$'B#2-"-U+=S">&2]N&\TBT6W".@MXG\N
M7[4I69U+0.B$2?5]%%%%%%%<?\0O$E]X.\*ZMJ]CI\NI7-C8W-U#90[O,N9(
M86D2!-J2-OE91&NU'.6&$8\'0\)ZCJFKZ'87>J6/]GWL]M#+<VGG)/\ 9YGC
M5I(?-0!)?+8E/,4!7V[@,$5T%%%<_P"+/%.E^!M#O];U2;R++3[::\N9=KOL
MA@C:21]J!G;:JD[55F., $X%?,'P8^(7QG^(.J>'M<N[/1)/">O:(NJ[H/M-
MO?:?-<)%-!:OOEGCO?DE"&9([19"DTK+;E(;>Z^OZ*******************
M********************************^ /VA_\ DYWX(?\ <W?^FF*N/U;P
MI=ZK^UI<>%!K_B"#1KKP:^MW-E#K>I+')=/K)BRC&<RVJ ;"JV+VH41B$?Z-
M)/#-Y_>>.?BSX#U'X[>'? $U]JMSX>B\.SZ+:WT\^J3P-?V(>^:&2]EEGF<(
MC3P6[R2IYR!8X',C12^H?LW^,_!GQ@\223^#/$.MZ9+!INMZ;JFC:YK%_=:O
M9WBW5@EO="PU2XU"%/LX6<&8!XQ).D$BN_G11=!^SA\>]?M/ _Q/UOQCJ-SJ
M\7@_Q)XALXY?(LX[AK'2;>*14VV\=K"\I&\[BJ!G;!*H %\O\1_#_5O'?[,W
MB'X@Z]XCU>?6=;\+7VMLMO>W$&GVT5UI1D73X--,LMF;=(3Y#231RW3NTET)
MXKDQ/"6'Q*\2Z-\/?@=X/T:WOI8]<\/PW%\NEWNG6E]-:6&C6X:UMFOY+<!Y
M9+J*226UN(+R"WMYI(75@98NP^"?A/X[+\0_%>EW4>MZ!X,OK:WN=*N=1U+3
M]5U2SO(ELTEBCDN;K6/W5QBY9DG$\: *T1MY'8/Y_P#LE6?Q/^*OP5T?XHMX
MKUO5_$,5MXCN;/29[BTATNYO))[V"&*YCBAMY)8@ZQF));D1VI $!MX0$!^S
M!\4M(^*'B/PW;W.KZWH_C/3+E&\1Z/XBU/4[9[[S]#NGE>RTJ:YDM#$;J2.Z
MCCB@@^S00[Q%!&8$E_5^OS0^/'B#6_A[I/C;7/$^L7Q\06D6I:AX=A\.2Z_)
M:V5A!;DZ:^J6MHOV)7>XAGDFEU))+:X*S1>;):V[0P<_\=OB?\0?$/@+X0>)
MK#Q+?:-)XOU?PE97]MIL=DL"C4$-Y-+"UQ;7%PK[U6/RWFDMWA4Q2P2J\OF=
MA\31XK^#&O\ ACP/IFK>)/$/_"4:EK.KZC-)JNE1:D]M:V<2R:?8&Y%A%#$\
ML\4VVQDMKFTABN9+9D^_#T'[-6F?&KP[\5_$UMJNE:E9^!KJVBN=,77-4@U.
M^M[R..UBDB$RZC?S"*8_:)2DDDD:E$*&%GD23[OU:RFU&QN+>&YEM9)8GC2>
M$1&2)F4@2()DEB+H3N42)(A(&Y&7*G\T/V7_  UXS^-NJ>++W7_'OB1U\-_$
M"]M(+>WFL+:&XBTI+:.*.Y$%E&[12KD7-M"\-K,Q:7R%F9I&\@_X2KXW?M"_
M"7_A,/"VE^)#XFU"Y^W:3=6GB#2$T>UMEU3S8[1K:#4K:*Y\JV5K><ZA82W+
MW!DBFPB)'#Z?\>?CCXR^'NK>$[CXI:3J]EX5G\/VTNJW7AJ6\A6RUZ>X@BF%
MW<Z?>K.EE;H[+%&KR+</,=JWDL49@S_VDO$'B?X;_LK:MXE\)>.KF;['<Z@M
MK>:=?Q:DES9ZAKY@@22_NHKB[,MI:S"%9+>XBDBG1@99?+1AZ!^UC9^)_P!F
M'P9_PM#2?%>MWMWHUS9G4[6^N(I+?5;.>_M87MS;"%;*PE52JQW=C:Q2!/-\
MQ9I9FF7T#X5ZPG[5VJ>,+G69=2LK?PYXDO\ PY9VVF:OJ%@I6Q2'S+F5[":U
MDFEG>0G;*SQ01)%'$BR&YFN?F^7QIXRF\"_&#P#X@U.^EOOAS8R7NEZS9ZI>
M6UY/!<:9=W6G_;9+4VIGN((T07#-F&XDP7BD>+SYL#XM+KWP\_9$TWXG67B7
MQ _B:/2/#=^MY-K-^T9DGGL0P>R$RV$J>7(8F$MO(9QF2X:>X>6:3T_XT?&A
M/"/QJN]&^*4>MZ5X5N?[,M?#VK:9>ZAING+--!-)=G4;RPO8#YLDR+%$DP98
M(8?/\NWADFN9M#XF^+_B#\(O"OP:NK'Q?+>-J>K^%?#VI>2;*]L[^.XA=KF[
M2YGM6NW>XV#;.LZ!HR)!&LK%ZT/VL-.U35_VB?@M;:;??8+B7_A+%%R(4F:)
M3ID/F-&DA\OS=FX0M(LL4<I222"XC5H9.?\ !^B^+_V5?VAO#'A5O%&M^)-
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MZ6&W>$0*8Y':?G_C!/\ %^T\"?"35/%FIZEH'B[4/%VCZ!JATK462%K>2XO
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M_()I;BZ:[E>7RD$,=Q';Q/:PW5]%Y=TLU<?^R;\(?B+\'+[Q<GB.VT@6VO\
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M!INK>&9[DWVGVVKZM?6EQIK39^T6D;I8ZBDUIN"S0'$,J/)-YOGNWG-[_P#
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M1=WT4\UCY]E>VT%]';A&D>PN;B".WO4".LH:TDF#PGSU+0Y>N \2?MT_L_\
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MAP@"W/D"[;>C>5$\[K9)]0?M._L]?\-*?"#4/".J26TFI26R2VUTL7D11ZC
MNZ.9 XNY((G?,<@5I9A:RRQ"1F8L<_\ 8SO?$7B_X=0^-?$EM%:ZMXLE76[J
M"W(^SHK6L%I:& ;Y65)+*TM9F6221Q-))G9Q%']7U\__ +4?_"S_ /A6&K_\
M*T_Y&3_1?L7_ !Z?\_</G?\ '[_H_P#J/-_UG_ ?GVU\ :CX5M[?XM?#+Q]X
M4^&FMZ?I]G_;":A<2:=!'J-W<ZAI;1VZWBO.U\TJW"RPSW^J>5;>=)]I:]>W
MG^U/[!\'=?E\(?M$_%S5-1TG6XK+5?[%^Q7(T/5GAN/[)TR=+ORY$M&1MK+M
MAP?]*8HMOYQD0-\H:?\ #GQEX@\%>,-<TSP_J\E]H/Q6D\?6.G76FWEC)JEB
MLBA$@>[BB(=XQ-)M1)[A3&D1MM\\0;W_ /:E^)=W\8['X<7FC>%O%)CTSQEH
M.LZD)O#^I1R64$*S,ZO$8?-G=0S;FLENH4,95YE::U%Q^G^DWLVHV-O<36TM
MK)+$DCP3&(R1,R@F-S"\L1="=K&-Y$)!VNRX8Z%?DA\0O!GCGXH6/Q'\/>-/
M ]]XAUV>75X_"MU);:8]G:Z7<K/%8R07,T\5K;7$4P5[D97598WM)&2YCM@;
M7D/BMJVJ:?\ !#X$13Z)J4-UI7B[P;9FTN84M;B>:TL'21(HKJ2$I^^5[=&N
MOLZN\9E4FU>*XD^K_B"K?M5^-?".F6.CZO;:/X;U>U\3WNIZA97>E!KBTCN$
ML[*V@O[5)KEWE82W3JB0PVZ;1,9YT">7_#'XBV?P]_:=^,\E[8ZE/;S?\(HI
MFTZPN=0\MUTERJ20V23W(\P%V600F!?*99)8Y'@2;P#]I'X?>)/%?PH^)7B4
M^&M;AUWXC7.BR6&CPV5U?30V.BR620F\^R6KQV5W*GGW$D$TQ"J4@5FGAG%?
M1_[9'C$?$&'X;RZ+H_B"[6Q\9:-KMR(_#NM[H;&TENHII)%:R#*ZL,B @7#H
MR2I$T4B.Q\??^$]^&OQA\._&?PKX=OO$6DW/A\:'JUC;VKQZA;6LE['=13P6
MTKQW#W#/,-UNUN#$EO(LS0^9YL'H'Q%^)?QP^+GPKU36OAOH-]H&HF*&/3[;
M6[>S@U*6<7\*SR&&YF>VMK=+99PHN-TURTF]$MTAA>]^;]1\*V]O\6OAEX^\
M*?#36]/T^S_MA-0N)-.@CU&[N=0TMH[=;Q7G:^:5;A989[_5/*MO.D^TM>O;
MS_:G]P\'WEW\%?VA/BAK.O:7J_V'Q#%X;ETZXL-(U+4XYEL[&:WG!;3K>Y$3
MI(,&.;RW(*N%*,K'C_&?@?4-.\%_&'QI=Z7J0U#Q_;3:=IVGVEI>WTWV>TTB
M:RTZ2>W@L_.M);H^9-*MP ELLMO!,T5PLBGG_$NE?$#5?V=/AOJ7A'2=2?5_
M ESH-]?:9/!?:7>7*Z=IAM[VTMQ<6Z/-YBSM&3&LD4\?G11^?)B!_K#P!\:O
M%OQWFLCI7A;Q!X9LH;X-?W/B"SM;.62"&(R>1:P-/<3%YI6@1Y7@$/V7[8([
MB*\2$K]7UY_\6-?USPIX'U[5-"M/MFI6>FWMS9VWER2^=<16[O#%Y<161][J
MJ[$(=L[5(8@U^<&D?"W2-2\=^%?$?P;TC6_!][/J5E<^)+&YTS4]'TV72X[=
MEFBGM[BV%A+=QY$%NEF6/G7,UR"P5KR#H/AG\1OB'^S)XX\6>$M=\&>)-?M-
M9\27FLZ+?Z)$M[9I;ZM<%_L\KW$EM%8^3+N>4/($\R6:9@D6RXN#]H_P;\:K
M:\\&?%?2=)_MC5_#>I:S<R: OD*8]+U&V\D1))%)N:[BM[>,2)$;\OJ-U*T!
MEM(H8#]8?"'XU>(OC=,EW:^%M7\.Z=;2R)='Q+9BTNKAO*_=QVEND[L$#.'E
MNIL( @MXHIWEEFLORPF^'/Q/A_8[G^# \$:VWB&VN8+:8K':?8U^TZW#J$,J
M71N1'<1,DICD>V\[[))#*;L6L(29_K_]MO6=0\1_\*UCM]"UN2XL/%V@>(+Z
M&VTF]OOLMG!]H$_FS6$5S;-+$2%>&&:60\,BO&R.Q^VWK\OBO_A6O]EZ3K=Y
M]C\7:!XBN?LVAZM+Y-A%]H\R279:-LE3<-]HV+M<C, R*Z#]H6#4)_BU\(?'
MT&F:E<:+IG]O?;)+;3KV>XM_[2TM%M?-L887O4W,C(^8!Y+X27RV90>/TGQ7
M=ZC^UI;^)9M \06MC+X-307EFT34C'%J+:R)C;O/#!+;E$0Y:[CEDL2 76Z9
M,.<_X9_$;XA_LR>./%GA+7?!GB37[36?$EYK.BW^B1+>V:6^K7!?[/*]Q);1
M6/DR[GE#R!/,EFF8)%LN+CT#XKW]QK7]D:)\4/"5SKFB:_\ VW<3Q6FCSZH=
M&:/[/'ID;-IRS202M:2W GGA:YE&HR2&UN4LD4Q]!^QS\/?$GP_O/%445YJ3
M^#I+FS'AFTUG[4+RUACM@EU&(KV*.Z@M$DVV]I#/\WEVYE"%91<7/V_7P!_P
M4O@U#Q+\"=:\,Z3IFI:EJ6J?9/LT&G:=>WF?LVH6DTOF/;0R1PX0%E\YH_,V
ML$WLI T/C_XO\5>)K[P9J>G:3J^H>![B6_B\364>F3)=O&S0P67FV%Q'#J4E
MNL^][F"")A<68E$T-Q;2>7)Y_P#LJ>#-1^&/QP\?E/ ]]X=TOQ!%H4^GPQVU
MBEK!%96=U#<M))8SS64;M<;0+>*62Z<W"3F#R1/-$:5^R[?0_&WQ;HDMI+<>
M!_$$NF^*[Z&Y5I+-]022Z62Q"32-O>XNDM]4N)8L(L=K!830M;7$>>P_8M^#
MGB_X?7&K6GBAKE[?PO<WWASPW]L!:8Z1+/%?"Y>X60QW'VA#96ZJL:1V:Z<(
M$2*0W*5X?\8/#.A?&N'Q%>OX5\0:'\1-/OM:L=%U?1])U>P:Z9)6M].F.I6\
M;6SV]Q;);VTT][,B1(URT9M8&26OL"7XV>(O@_?>"?#7C+2[Z]DU.QMK6_\
M$-E )-/CU9FM[9(I5B17A2ZN)"(Y9(H(@\D"(K*;@VGU?17YP?LXZ_++^T3\
M3=4ETG6[:R\1_P#"/_V;<WFAZM:PR_V?IDJ7.^2XM(T@V-\J_:#%YK$+'O+
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MCX;UN3Q-IG]JPK8?V1JBV\URVH74D$7]II:2V"13;XQ]K,S6T:/YK2;%8CZ
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MX6_9Y_X6AX%NK:SBGTVSO%BU&Q,]QMU1[6.!XV2Z6&&6 7!D99(KR*1U5,;
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M#'+FWNO.\^ [U.8IO+C\V,_))L3<#M7&?^TUX \.ZM\?/@=X=ELHETM8O%,
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MMK6OZ5OL]0N;:8S?-N\ZW25WCBD,HM);9G:9!+)N$K&3S/,?Z KX _X*C_\
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M)WB6X,<4K)OD>4JD\L^[P_\ 9I_Y1YWW_8M^+/\ T=J5=AX\_9=L?VH_V/\
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MC0^ ?#?]C'QG\&=4ET_PA\2-2TKPB;F>YAT5-/L+N:V\Y,M%!?WZ712(3?O
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MC?1O">F:%KL6GKX>\0+XG>6^L&OI+S4%GEN3)+Y-U8I&DL]Q<2SQQ(J$R*L
MMHHPAT/%_P"SUXX\<?$_P9XUO?$FFK_PBWVGR[:'1;A?/^WVD5M?;I6U1]F[
M8[VN$;[/N59/M>PF3CY?V/O%OA+Q[JNO> ?']]X;TO7;Y-2U72Q86NH+)=,Y
M-S-:RWID6U>=2-V(90' )#PQPV\6A\6/V2=<\;6?AC3]%\16UC::!K<'B53>
MZ7)>W%UJB7-S=333R17UE$(KB6Z>22"&"((Y(B>*+9%'Z!\6/V>]4^)NJ>$O
M$\.O?V?XD\+^<UM<Q622V,K7B0Q7JS64LIE,4T4;QQK'=QRP"4L)W=%:N/\
M#/[+OBWX=^-?$/BO0?&LLMWKT6GF\.LZ9:W1DGL(Y;>(O]A;34%O]GEQY,*0
M3?:(H9C=-")[6XX_P%^R!XX^'_P-NOA1;>+--DLIK:\L4NI-"N/.6WO_ +6U
MT"%U8(TI:Y4P2 *D2QLKQ3F0-'[_ /"?2?\ AGOP/H/AGQ3XATV7[/\ 8M$T
MZ?R/[-\_R[=(;>WV3WESYUW)Y3M^Z9/,SA(%V$MY!^Q_\-_"%IKGCWXA^&)=
M]EXNUN5X=DXFB9=.DFMIIU8;_P#CYOC?SH4EDB:U>U*+"=\2_;]?.'BWX3^/
M7^(L_B[PQXEL;".ZTBTTNXL;_2'OXW:TNKJXBN!)%?V4J.HNY(P@)0AF9@[>
M68_#_B;^Q!<>-/AAK/@?2]=MM.7Q)J4^M:[=R:=/<O<7T]W!=E[5/[0B2TB5
MH!$L+?:3Y 0&1IA)/-V'QJ_9U^(OQLA\+"\\4Z1;R>']7L]=#1:#=%9KRREG
M,0*MK!*6YCE1)(MS2,Z-(LZ*XBCZ"7]FV^\%>/=5\8?#W4['0Y]>B0:Q:W>F
M-?6MU<0N6ANT6&[L98+@"299BLK0W!D\UX?/#2OU^F_L^Z6/ _B3PYJ-[<W,
MOBG[?)JUXKN'DFU"W%M(;=9VN!;Q0PK'!9P$RK!!#"C-,ZO))X!>?L0:OKFA
M^%-"U'QYJ36'A/4K>\TQ+:PTR)TBL(YET_S9)()_,N[?S(T><JMK<00A6T];
MAWNCZ!_PSUXX_P"%W_\ "R_^$DTW_D&_V']B_L6X_P"0=]O^V[?._M3_ (^_
M^6?VCR_)_B^R?PT0?LY>+_ OQ#U[Q1X'\46VF66O^7<7NCW^DF]LQ?*JI)>P
M?9[VP>*6947S^7,TC/)*TA\D0:'[-G[-VL_L_P!]XC>X\3RZO;:SJ]_K/ER6
M,%O)]HOFB\Q[B2,E9718%$?V>.SA!EN&:%PUNMK]7T444444444444444444
M44444444444444444444445S^H^+-#TC5+'2[N_MH+W4/.^R6TLT:37'D('E
M\F-F#R^6I#2; VQ2&; YKH*\O\ _&OP%\5;Z]L_#&N6.K26,5O+<&PG2YCC6
MY:98@98BT6]C;R9C#%T 5F55DC+>H45Y?>_&OP%8>+;;PB^N6)UNYE,2:='.
MDET&%J]YF2%"SQ)Y$;2"24(A!10Q:2-6[#0/%FA^*_M?]EW]M>?8[F2RN?LT
MT<ODW$6/,@EV,VR5-PWQMAUR,@9%=!17E_C+XU^ OA]JUGH^LZY8VFHWTMK%
M;64DZ?:IFN[@6L)CMU)F9&E.TR!"B!7=V5(W9?4***Y_3O%FAZOJE]I=I?VT
M][I_D_:[:*:-YK?ST+Q>=&K%XO,4%H]X7>H++D<UT%%%%%>7_%[X+^"OCUX=
M?P_XNTR+4;%I8YA'(TB,DD9^5XY(F26-P"REHV4LC/&24=U;T#2=)L= L;>Q
ML;>*VMK:)(88846....-0J(B* JHJ@*JJ %    %:%%%%%<_X6\6:'XYTN'5
M-$O[;4+*?=Y5S9S1SPOL<HVR2-F1MK*RM@G#*5/((KH*\O\  /QK\!?%6^O;
M/PQKECJTEC%;RW!L)TN8XUN6F6(&6(M%O8V\F8PQ= %9E59(RWJ%%%%%%%%%
M>7^,OC7X"^'VK6>CZSKEC::C?2VL5M923I]JF:[N!:PF.W4F9D:4[3($*(%=
MW94C=E] U;5K'0+&XOKZXBMK:VB>:::9UCCCCC4L[N[$*J*H+,S$!0"20!7'
M_#WXJ^$/BS;WESX9U6VU2WL[G['-/9R"6$3>1%.425<QR82>,LT;.JL3&2)$
M=5Z#PMXLT/QSI<.J:)?VVH64^[RKFSFCGA?8Y1MDD;,C;65E;!.&4J>01704
M45Y?XU^-_P .OAK?)8^(_$ND:5<R1"9(;_4+6VD:-F90X2:1&*%D90P&"589
MR#C0\+?%CP/XYN(;?1->TW4)9[9KV*.SO;>=GMTG-NTZ+&[%HEF5H6D&4$JF
M,G>"*] HHHHHHHHHHKG_ !3XLT/P-I<VJ:W?VVGV4&WS;F\FC@A3>X1=\DC*
MB[F957)&68*.2!7045X?\7OVC?A]\"87F\3W\MM''%'-,\-E>W:P1RR^3$]R
M;2"86Z32!HX&G\L3NDB1EVCD"^P:3JUCK]C;WUC<17-M<Q)-#-"ZR1R1R*&1
MT=259&4AE920P(()!K0HHHHHKG]1\6:'I&J6.EW=_;07NH>=]DMI9HTFN/(0
M/+Y,;,'E\M2&DV!MBD,V!S70444444445X?JW[3?P>T"^N+&^\:>'[:YMI7A
MFAFU:RCDCDC8JZ.C3!E=6!5E8 J000"*Z#P5\;_AU\2KY['PYXETC5;F.(S/
M#8:A:W,BQJRJ7*0R.P0,ZJ6(P"RC.2,^H445S_BGQ9H?@;2YM4UN_MM/LH-O
MFW-Y-'!"F]PB[Y)&5%W,RJN2,LP4<D"N/\9?&OP%\/M6L]'UG7+&TU&^EM8K
M:RDG3[5,UW<"UA,=NI,S(TIVF0(40*[NRI&[+ZA117G_ (Z^+'@?X7_9_P#A
M)M>TW2/M._R/[1O;>U\WR]N_R_.=-^W>F[;G;N7.,C/8:3JUCK]C;WUC<17-
MM<Q)-#-"ZR1R1R*&1T=259&4AE920P(()!KC_'7Q8\#_  O^S_\ "3:]IND?
M:=_D?VC>V]KYOE[=_E^<Z;]N]-VW.W<N<9&?0****\?\+_%7X:?'3^U=$T?5
M=-U^*&VB%]%;217MOY-[Y\:QRLF^%_,$$H>$LS!,%T"2(7Z#P+\)_ _PO^T?
M\(SH.FZ1]IV>?_9UE;VOF^7NV>9Y*)OV[VV[L[=S8QDY] HHHHHHKS_QU\6/
M _PO^S_\)-KVFZ1]IW^1_:-[;VOF^7MW^7YSIOV[TW;<[=RYQD9X_P :^ _A
M=^UGX*2TU..Q\0Z)<RB:*6WN/,C,D$C)O@N;:0,KJP>)FBD4X,D+$JSH?8-)
MTFQT"QM[&QMXK:VMHDAAAA18XXXXU"HB(H"JBJ JJH 4    5H5S^@>+-#\5
M_:_[+O[:\^QW,EE<_9IHY?)N(L>9!+L9MDJ;AOC;#KD9 R*Z"BBBO+_ /QK\
M!?%6^O;/PQKECJTEC%;RW!L)TN8XUN6F6(&6(M%O8V\F8PQ= %9E59(RWJ%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%<_XL\4Z7X&T._UO5)O(LM/
MMIKRYEVN^R&"-I)'VH&=MJJ3M568XP 3@5\P:1^U+<06_A76M?TJVL-"\7W-
ME9Z/<PWT]U=F;4H&N+%+RT%C%';^:B%)&AN;I8;AD3+P%[F/07]H'Q5IOQML
M_AWJ^@6-G;:A8W>HV6IC59F%S';R,GD102:?"LEZJ[)[BVCF<06[-+YT@4!]
M!OVAKCPSJGB^X\5VNFZ7X>\,;4GU5=2GF8S2)%/% UJ]A PE-O/;RL(I)U,M
MS!;0-<S><(>?^)'[1OB_X*:7%XG\8>%[:R\-BY@BN[FWU8W5]8PW+^5%-<V2
MV21/ME>*.YCL[N[:,NS0FZ1-S'B'XM_#_4/C%X)L;W0;FZO]1MM3/AS6T:QN
M+%X7L8+N\D@:.\>5-T211"9K=6<,R1.;>65G[_XA?&+7-)\7V?@_PKH7]L:I
M);?VA=O<W$EC8V-FQECBDGNEMKHF6XFA>*WMX8I)&$<TK^5%%N;Y@_9/U'5-
M5_:)^-,VJ6/V&[/_  B:S0"9)U5DTR9"T<JA=\3[?,A9TBE,3(98()=\*?H_
M7C_QK^+/_"H]#AN+;3+G5]2O[E-/TS3K08>[O)(Y)$C:4@QV\2I%)-/<2XC@
M@BDD.Y@J/\(?&3Q-XU/[1_P@?7O#T4-S;1>+IH(]+U".]CN@='7$,<EU%IS)
M<!DPRS1QVX$L+"Z8F=;?Z0^ OQA^&G_"(>-->TO2+GP_::)K>M/KJWD433?;
MH +O4)W-I->>?C?M4H[G;&(HE$21+6AX0_:!\5>);GPA>S:!8PZ)XME L+A-
M5FDO$CETNZU2!KBT.GQPH[16VR5([N812/A9)E7<>@USXS>*M5\:W_A?P;X=
MBU)M)B0ZG?:E>S:;9PW$\<4T%I#(EE>O<W!@E%Q*(XQ#!&T(>;S91&/B_P#:
M ^+/_"\/ GP9\3-IESI4MS\2=#BN+&\&)K:XM;B]M;B%^%/R30R*I98W*@%H
MXG+1K]_^.OBI_8NN6_A?0H;;4?$-S;/?)8SW?V5(K.*18Y+JYE6*XDBB+LL,
M6R":2:=@JQB&.ZGM_(+']K?2_"/B?5_"WQ$M[;P]JFGZ:^MPB"\?4+>]TV**
M22:>VD%M;S-+ 8)Q+:M;K,4B,T0GBWM'H>$/V@?%7B6Y\(7LV@6,.B>+90+"
MX359I+Q(Y=+NM4@:XM#I\<*.T5MLE2.[F$4CX6295W'/^#GQ)\-^+/&?Q"MM
M"\*W.E>*K/\ LR?54U:2UC^TS36!6P1KJRGU$+$L,"@A%98?,:187FDF#<_\
M(?VEOB7\:_\ A((M)\&Z;#+X?UN]T.[>[U^5+>2:TV!C;/%I4TS\L2XFM[=5
M1H2CS.\T=MT'A;]LWPAJOP!A^,6J6US8Z:;9I9K<*)YEF2Z-D88RNU7WW"^7
M#(_E*59))1 N\)S^L_M:^)_A_P#$/3? OB;P1<R:EK-LUSI;:!?17MO<>0L[
MW43SZG'HT<<L"1)(R*9<I+'DHS(K_;]>/_'CXAZY\)O ^I^)M+TVVU+^R[:X
MOKF"YO9+/-O;6\DTAB=+6[WR_(%2-EC1MQ)E3: WS!XB_;'\7^$/A19?%/5/
M!]M!X>FMM+O)D&LE]22&_DMXB\=LM@;:3!G\R%7O(6EAV-*+69G@B] \:_M&
M^+_A;JGAD^)_"]M:Z;XBUNTT.W>WU8W-]!-?)*UN;FU^Q1VPP8PMR(+VX6(E
MC$]TJJ7[#5/CAJVO^-=9\(^"].L=2OM BLI-5.I7]QIT<+:A&\MM'"T6GWQG
M<QQM)*<1I&'A57E=I4@^;_VG?VKKC6?V4M0^)7P\;]U?VR0+-<O/:W%HMS<_
M8)GB6($F[@F8HA65(E=3<)-,D:1S_3_BKXRZIX%M_#^F:EIEM)XDU^YN+2ST
MVRU%)(=T$$UPT[W-S#:R_9(HHE:ZECM9986E2..WN':,2>8>"?VNIM<\:^*/
M .H^'I3XH\/Q6UT;#2;N*[CN[6XCM6,L%U?)I<2O";I!-%/Y)Q@PM.=RIS_P
ML_;#\8?&G1M'\1^&OAKJ]YHE_+J >[&I:+%(L=O/+!;M%;S7D;2/(T>+A)6M
MQ;G=Y<EVH5WT/A;^T5\(/AW^S;:>/]#TZYTCPG86TJV]IY"FX'EWCV839'+*
MK2SW _UDDIWO+YT\JDR.OJ&E_'#5M \:Z-X1\::=8Z;?:_%>R:4=-O[C48YF
MT^-);F.9I=/L3 XCD62(XD20),K/$ZQ)/X?^SQ_R<[\;_P#N4?\ TTRU]_U\
MP?M:?'S7/V9O ESXQM-%MM6LK'R_M<<NH26<R^=<06\7DJMG=)+EIB9-[P[%
M4%?,+87G_&O[1OB_X6ZIX9/B?PO;6NF^(M;M-#MWM]6-S?037R2M;FYM?L4=
ML,&,+<B"]N%B)8Q/=*JE_3_$GQ9OKKQ%=^&?!]I8ZMJVG107&HQW6H-906<=
MR'^SI+)%;7LOVB<(TD4*PD"%&EEEA\RU6Z\ U+]LR^T_2?%]JVB6,?BCP;%<
M7NK:-/J[(K:?%;M<I>6%U'8RFY26,PX22"V>%Y?+G\@^5YV?XB_;'\7^$/A1
M9?%/5/!]M!X>FMM+O)D&LE]22&_DMXB\=LM@;:3!G\R%7O(6EAV-*+69G@B]
M0^*_[4-S\,/B#H'@R/PAJ^HW.N2W0M);>;2XXYX[.R-S<-!Y][&V^)FCC9+H
M6@8&1XY)3&B3&B?M$^(HO&LW@3Q'X<BTK7;BQN;[2'&HB;2M26".(M#%>M;0
MW"W"/(WVB 63O#!&USB2-H]WA^H_MX:Y%^SM8_&>T\*VTED_G?:[*75Y(YHL
M:F-.B\EUT^1)][9DDW_9_*7 7S2>-#_@HAJ<.BV/PRO)EE:.#XB>'Y7$,,L\
MA5%NF(2*%7ED<@?+'&K.YPJJS$ ]!I?[8OB70OBCHW@[QWX)E\,6WB&6]AT>
M^N-8TZZ,\EML*)/#;L5@>59$15$TQ-Q)'!&)0S2)Q_[%VLWGA_2_BW>6FFW.
MIRQ_$GQ#MM;-K99I-SVBG8;N>VA&T$NV^5/E4A=S[5;W#]G+XJ_"Y/@/8>*_
M#%C+HGA6QL;V9(9H?WD%O82SK<.Z0O<-(Y:&25F#2S3%B[%I7:N?_P"&EO'N
MCP^'=7U[P++I^CZ]J]KI:'[<\NI6:W\KQ65QJ%D+-8+9)'\A9D^VN]NTZ1$2
M3CRC]GU\_P#[4_QK_P"&=OA1X@\8K#Y\NGVP^SQE-ZFXGD2WM_,7S(B8A-+&
M9MKJXB#E,OM!\P_8/^&4/@[X3:-KUY=2ZEK?B6QL]6U/4[II9+JY:>!7MXY9
M9I)79+6!TMXAN"81I5CC:60'H/\ AG[PK\-?C#<?%2S%CI5M)X?U&SU<XAMH
MVD:]M[Y;V0K$BERJ7/VNXFER0MO@8$C#/\4_M&^+](\(3>/=-\+VU_X6BMEU
M,3#5C#J4NF@"22\CLI++[/\ ZC==0P27L4TD(1)%M[IFMH^?^*G[9'_"'Z7X
M/\1^&-)MO$N@>*=2L-)M;BSU+R+LW%X\PVI;3VRP_((2C">[MG6X)@E6#8\@
MT/$W[27CWP!XU\/>$=:\)6+WWB6+4!IATS6WN(_/L8XI7%XUUIUB8+<1R-(\
MT(NY@(V5+69V5#H:=^TKXGT_X@7W@76_"?F:O#HD.OVT6AZE%>K/;O?&RD0R
M:C%I"12QL5D"DLCQ;\2"14CDX_P'^V#XM^*_P^C\>>&? %]=Z2);AW1[^U6\
MN+6&]DMS)I]K")S<7"1Q/)-:W#V)\P+!;2WFX25Z W[67AWQ)I/@N3PLD5_J
M/C6*:72;:YN#;Q!;2W-S>"[N;>*]6![=087C1)W^U%8=H0330]!X1^.&K>-9
MO$OAZSTZQ'BKPY+91WMA)?W L=M]$MQ!)'?C3R[(T!?(^R!UN(GB9!$8KF3Y
M_P# _P"V7X]^(OP:E^*6G>"K&'2[:QU&]FBO=>>.=UT]I_-^S+!IEPLB%8=J
MM.UJYF$B&(0K%<SZ&I?MLZI:^._ &CKX;MHM%\=VUO=Z9JM[K"6[!9+>*>2"
M:U6UEVW:^;''#$LSQ7,LL$:7"L\@A^CX_B/XJN/BC+X4BTBQ?3H+&*_GOAJ,
MPN(8Y_,CMPUHUB$9YYX+E4$=U($AMY)96B=[>";W"OE#]L?XB^#?AQ\/I[SQ
MMX:OM=\/++;2WHM19O'$T-[;-;">*XN[9Y4>X,?[N-9D8*ZSJ(F(<_:3_:)\
M1?L^7WAQH?#D6KV.MZO8:(AAU$07BW5XTN EO-;"W= D7RM)>0!I&"-Y2 S4
M)^T#XJ\*_$GPSX+\7:!8VDGB:+4S8W&EZK-?JLFFPQW$BW"7&GZ>41HW;8\9
MF.]0IC"L77Y?^"NK?$7QC^T)\6-,UK1M(O+9XO#%CJ%K<:O=3V]M9RV-PQBM
M5DTO;=)(LT\LL$J6<?G2.NYQ*\H^L'^-WB_QQI=SK?PZT+3?$.E1?:8X+B;6
MC9-?36KO'*+-4L;N)XO-1H(YYYK9994=POV3R;J?R_Q;^W[X-T[X-'XH^'],
MOM;TM8F$P@DLX6LKK=%%':WZS7 FB=Y9XT+6\5V%0^> \+0O+G_&K]K?XG_!
MCPQK_BW4/AO]FT72/L6QM1UZTCO+G[5+' ?+M["#4HD\J60!O,N5W1E77+%X
MT[#XE_M->-?@W-H-SXA\'1?8==U>WT:UBL=7CGU);B\BF>V2:VEMK:Q5RT8C
MGV:C)#$S$I-.BAVZ!/V@?%7A7XD^&?!?B[0+&TD\31:F;&XTO59K]5DTV&.X
MD6X2XT_3RB-&[;'C,QWJ%,85BZY^K_M2W$]OXJUK0-*MK_0O"%S>V>L7,U]/
M:W8FTV!;B^2SM#8RQW'E(X2-IKFU6:X5TRD 2YD\_P#VL/C[XDTSPQ\.M2\"
M_9KBR\5>)/#\"W$US=6;O#<RQWL$:A(&>.*Z6(QW3R*[1P,T7V2<S,8?0/$/
MQ)\-VWQB\$Z-XJ\*W,7B&ZMM3CTC44DM;JQC;[#!<ZD()//CN1@1I;B>:R@E
M<;E15AEESZ?XD^+-]=>(KOPSX/M+'5M6TZ*"XU&.ZU!K*"SCN0_V=)9(K:]E
M^T3A&DBA6$@0HTLLL/F6JW7@&I?MF7VGZ3XOM6T2QC\4>#8KB]U;1I]79%;3
MXK=KE+RPNH[&4W*2QF'"206SPO+Y<_D'RO.S_$7[8_B_PA\*++XIZIX/MH/#
MTUMI=Y,@UDOJ20W\EO$7CMEL#;28,_F0J]Y"TL.QI1:S,\$7W_17P!^R5\;_
M !QXXO/B/JGC%--LM-TGQ)JEI).NIW#I9_V;;6<+1(EQ;1QBT"1O<R71E@WS
MO*YLH5<E?0/%/[1OB_2/"$WCW3?"]M?^%HK9=3$PU8PZE+IH DDO([*2R^S_
M .HW74,$E[%-)"$21;>Z9K:/Z/\  'C_ ,._%/P[9>(?#U[%?:=?1"6">(G:
MRY((((#*ZL"DD;A7C=6C=5=64=A7YH>-?B%X5^&O[:"7WB/5K'2K:3X=B%)K
M^YAMHVD;768('F9%+E49@H.2%8XP#CL/B7^T?\&-0U2[\:7%[;:C:?#VVM-7
MBU'1Y[:^9YM:34M+;3_W:OLW;(7*^=&KRO;22M'% 6?W#2_CAJV@>-=&\(^-
M-.L=-OM?BO9-*.FW]QJ,<S:?&DMS',TNGV)@<1R+)$<2)($F5GB=8DG\O\&?
MM+?$OQMX[\5>"+;P;IJZEX:_LYKF=M?E^PLM_;M.BK+_ &5]I\W&W:HM6B8+
M.7GB9(5N=#X7?M)>/?C/#J\>@^$K%+G0=7OM$U(W^MO#:FZM)=I%E+#IUS/<
M)L*22-<6UD$,B)'YY$IC\O\ &W[6GP_^)'[.VG?$#Q5X/U+4/#>H>5/?VT1L
M9EMIK/4XH8TF2:[M6N(GO(U$8CCD66)3]HAB1VC/0?M]?\TJ_P"RD^'/_;FN
MP^*G[4?B+X5_&7POX%O/#UBNG>)I6CLM7GUD0+NA53/$UL;-V%P&=([>/S"E
MR\T"+,CO*L/K\?Q'\57'Q1E\*1:18OIT%C%?SWPU&87$,<_F1VX:T:Q",\\\
M%RJ".ZD"0V\DLK1.]O!-[A7RA^VQX*L?B5\)[CPY?/+';:KJ_ARPF>$JLBQW
M.OZ?"Y0LKJ'"N2I96 .,J1P?G_\ X)>?%"^UKX;7O@#71*FN^"+Z;2+V.6=K
MAA'YTWD8D ,02,I+:1QQR2A$M58%8Y(E'B$UOJGC#]KGX<>/K^3]UK-SXJT_
M2HDD22(:1I.FO':W"L((B_VV:>[ODDWSQM:W-J(Y2BY/Z7>/OC#-H/BJR\':
M#8Q:GKM[8W&I+#->16MO;VMO-#"TUW(%GN(TE>;R[;R;6X,LR.I$<:2S1_.&
MC_MOW'B;PAXWO]-T*V?6O ES?1:YITVHSQ0B&S%T?.L[Q=/D^T>;]E98XY(;
M9@P?S#&JQ/,>(OVQ_%_A#X467Q3U3P?;0>'IK;2[R9!K)?4DAOY+>(O';+8&
MVDP9_,A5[R%I8=C2BUF9X(O0/&O[1OB_X6ZIX9/B?PO;6NF^(M;M-#MWM]6-
MS?037R2M;FYM?L4=L,&,+<B"]N%B)8Q/=*JE_E_PU\0?$_@7]HGXV?\ "+^&
M;GQ)JDW_  B316<4\5E"$33")7FO;C]S%@2#RX_GGF;.R(Q1W$T'T!\,_P!N
M+PWXG^'GBSQ/XDLO[#O?!]S>6>LZ8;VUN98IK=BL:0R!XDE^T,/(MV81+-=+
M)#&7""1M#Q'^UE??##Q[X5\-^-]"BTJ#Q;+<6^F307[7L\=Q&]NL4%_ EJD4
M#R&Y2,M;7%[#'-\OF-!FY'/O^V'XP\0^(O$WAKPQ\-=7O]6\/Q:89[>ZU+1;
M-5DOQ)*%EE%Y<(J?9U66)X/M)=RT4D=MM623H/%O[56K'2?&.N^$=%L=5TOP
M=+J%KJ4M[J5QI\[76FVXN;N*VA73;M9$166-99)81),L@"^2L<\OV?1117P!
M_P %1_\ DV+Q=_W#/_3M9UH?M)?%GXB^%?C1\,_"_ARTL9;;5I=8NG6XU"ZM
M#<26.FS P3M#;7"I;HMPMPN8[DS7$<8V6PA$LOW?6?JU[-IUC<7$-M+=211/
M(D$)B$DK*I(C0S/%$'<C:ID>- 2-SJN6'RA\!?C#\-/^$0\::]I>D7/A^TT3
M6]:?75O(HFF^W0 7>H3N;2:\\_&_:I1W.V,11*(DB6M#PA^T#XJ\2W/A"]FT
M"QAT3Q;*!87":K-)>)'+I=UJD#7%H=/CA1VBMMDJ1W<PBD?"R3*NX_5]>7_&
MCXO>'?@+X*U/Q=X@>5;'3HEDD$,9DD=GD6*.-%X!>21TC4L512P9W1 SKP&E
M_'#5M \:Z-X1\::=8Z;?:_%>R:4=-O[C48YFT^-);F.9I=/L3 XCD62(XD20
M),K/$ZQ)/X?^SQ_R<[\;_P#N4?\ TTRUV&C?M5:MXST+3O&/A[1;&\\*ZAJ]
MGI<%Y+J5Q;WSK<:O'I!N!8G370()W,D:/=([VX5G$,K-"GI]U\7=<\7:IJ%E
MX#T_3=872;EK'4;B\U62RABO%1)&M8C;V5^\LL*NAN=R11Q-)'$LDLRW,=L?
ML^_M"Z'\?-+O?)C^PZOI%R^GZQI<DL<LUA>1.T<D9>,[)8BT;^1<1_NYE5L;
M9$EBC^@*************************************\_\ BQK^N>%/ ^O:
MIH5I]LU*STV]N;.V\N27SKB*W=X8O+B*R/O=578A#MG:I#$&OQQ^+7C_ $+X
MA:-\-/&%W>ZO)JUIXR\/WOB5K@ZO%I6CO#.\%Y;3Q3!=,T][2=H[=5E"7I@,
M<\DD_P!J>ZN/M_\ ;6TF^U/P%HGQ+\/6\K7W@V^MO$J1LC6-U/IZ(?[0LVDG
M$<UHDMLQ>YB>-GD$ @>V=RJKS_QN_9X\:_%/]F#6O#D-O$/%6NQ6^K7\4TT8
M#:@;NWO9[99P74I"L7V"Q,DCI';PVL+7'E1^:#XA?M-^%?CK\$M6T;2)(I?%
M6NZ1<Z2/#<=Q"-3M]0NHVLIH);:Y-M,J6<K.]S-)'&B6L,MUCR@"?#_B/K_@
M?X'?&;X#>&=0\3:;_P 4EINM:=J$\]S;V_D?\2*VAMY+E'E;[-]HVAHED;Y]
MP"L_4^H6/C_P[^S/^T_XT?QI>Q:9:>.;'1[W2KZX)BL]VD6DEK<VT]S*$BCN
M 2LJKED\MXPTB3311/G_ +,'Q2\,>(/VG?BW]BN_._M7_A&6LMD4I\Z*VTF;
MS+A?D_X]/N;+PXM9?/M?+F?[7;>;^G]?GA^VEJ</PH^(/PR^*6K+*="\.7VJ
MV6IR6\,LTENNLV0M8+ET12!;QR(%F;=OS)$D4<TCA*\?_:-_:4^%R?'SX3>(
MT\16,^DZ3%XLDN[^VE^T6J%]*C"Q+/"'BDN"0H^S1,]P#+;YB'VF#S,_]EWX
MS>!],\#_ !SN?/TW6_*\2>,-=_LS[5;R?;M.6WA._9^]W6D^/*\[RY(6WX^?
M.TT/AGI'A7X7^+?#$G[.?BF+4M)U[5[236_#(NH;Z*VT][7$VHA9W%]8/"J#
MSO.??-=26MNX_=Q6DE_X:?M$:!^Q#\0_B!X7^)<-SI5EK7B34?$>EZPMK>3V
M=VMZML[VR>7;ES+ K1>8T8DB$AEC9T,<1N.@_;;^,VAWW_"M?[6GMM(>+X@:
M!J<=M?74<-X-+C^T*=0NK679):1%Q)Q+DQ1B/SS;W)FM;?T#XGZU_P *P_:#
M\.?%RX:VG\':QX;3PW/JT5QNALGGO6OK6ZF*(Z?9+EC#;QW&]8$:0O++$OE"
M;G_C[XC\-_%KQG8>/-'%MXAT#P!X;\4:E?20R6MUIU_-?V'V==)\Y))0)3#%
M+-<@PS+#"]N'0_:DQYA\,](\*_"_Q;X8D_9S\4Q:EI.O:O:2:WX9%U#?16VG
MO:XFU$+.XOK!X50>=YS[YKJ2UMW'[N*TD]/_ &8/BQX'\0_M._%O^S]>TVY_
MM?\ X1G^S_(O;>3[9]ETF;[1]FV.?.\G!\WR]WEX.[&*S_V&/C?\.M%A^*<U
MYXETB"-O'>O:F'EU"U139SRVD,5T"T@!MY)'2..;_5N[*BL68 ^(?!'4?"&K
M_P#!/"XAUBQN=;M+*VU);NSTJ8"YBF75I;F)F90_D>3O@O)6D218[8><\$T1
M\N3U_P"!7Q\^#OQK^(?AN[UWXC:;X@U_0;:XM](9-)OM \R;4%@M+B247<SP
MW5W, B0P6XA5?,G9;:3$;6WZOU\P?MH>+-#\*?!#QC_:E_;6?VS1-5LK;[3-
M'%YUQ+87'EP1;V7?*^T[(UR[8. <&OS@_:(^+'@?5/V!].TNVU[39KV31/#M
MDEM'>V[3-<64FEO=0"-7+F6!65IXP-\2LK.%!!KV_P#;G^-_PZUJ'X636?B7
M2)XU\=Z#J9>+4+5U%G!+=PRW1*R$"WCD1XY)O]6CJR,P92!V&O?'2P\:_$_6
M_#OBRZU*UT"*VL+WPP^@#687UQ9K2"6\FAN=))FO_LAF3;#9N(E@FFN)X)_L
MRSVOQ!8I<:E_P3LU?PQ!;7+ZIHN\:A:BVGWVK1^)I)Y8YODPDL,,;3W$)/FV
M\!CFE2.*6)W^G_VO?B+X'U?Q/\/OB!?6-MXC\":9<ZOI>M7BV%OJEG%]OBLQ
M;3(94D62)+B-5DNK/?Y<D<MEO-PS6LGL'PE^(/P-@N+?Q;X TC1-%\/+;7']
MI>(9='_L:$J9XX(+.&XN8+%9/.N,O)*C7$4+68MY(EFNK>2/S_\ X)H?%CP/
MX>_9BT7^T->TVV_LC[7_ &AY][;Q_8_M6K7?V?[3O<>3YV1Y7F;?,R-N<UY!
M^R7\:]<\#?L3VUQ\/X;;7?$VC>9NTJ))+V9/M>O3@>=:VDBW"[H&DFCSLRJ&
M3YD5J/$7C+P"GQN^$GC31=6UO5M+_P")[]JU:^_MBYMIKB]T@FVBM!+&+,7<
M\BS1'3]*BC=;E/L?V2.6*.W3U_\ 9@^+'@?Q#^T[\6_[/U[3;G^U_P#A&?[/
M\B]MY/MGV729OM'V;8Y\[R<'S?+W>7@[L8K]/Z_/#_@JGJUCIW[-'B6&XN(H
MI+J7388$D=5:60:C;S%(P2"[B.*20JN2$C=\;58CS_\ ;G^-_P .M:A^%DUG
MXETB>-?'>@ZF7BU"U=19P2W<,MT2LA MXY$>.2;_ %:.K(S!E('86NM?\,S_
M +27B_6_&#6UAX>\<VVEM8ZO/<>7;Q7FD6?DM8W+.@CAEF0S3Q/+(D<B1".-
MI9F>.'R_X\C2?'E]\4/BE:WT0T*U^'=UX4L[TR6[6FHW5TT]T[6EPD["1(I)
M+>R'R8EO))K=&\RW96\P_:(^+'@?5/V!].TNVU[39KV31/#MDEM'>V[3-<64
MFEO=0"-7+F6!65IXP-\2LK.%!!KZ/_::\?\ AW2?CY\#O$4M[$VEM%XIG%Y$
M3-!Y$VE0;;@R1!U%N%<227!(ABA#3R2)"CNO8-J6A_M-?'[PIK_A6\^VZ7X%
MMM7:[U&V6.:QGO-6M;>"*Q@N%E EECA+W-P\*RQPCR87999L1_G!-XB2W_83
MG^&+66I?\)5;7,%G<:4-+U W%O-<^(8;RV2X46Y$'VF&>-K1I2BW3EH8#+-'
M)&OZ'_MW:G#>^'?AGXAVRPZ=9^._#6I7<]S#+;K:6I,P,UV)UC:U16EC1_M
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MK:P\/>.;;2VL=7GN/+MXKS2+/R6L;EG01PRS(9IXGED2.1(A'&TLS/'#Y?\
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M_P#$]^U:M??VQ<VTUQ>Z03;16@EC%F+N>19HCI^E11NMRGV/[)'+%';IZ_\
MLP?%CP/XA_:=^+?]GZ]IMS_:_P#PC/\ 9_D7MO)]L^RZ3-]H^S;'/G>3@^;Y
M>[R\'=C%?,&@WO@>PT"S^(?[.FM6VE>+M<_L\W?@N"[M[J"\=[S-U;O97/DS
M6_V<R2,;N#[/!#803/"MO!,]P/J_X#^,;']E7Q[\0/#'Q"NK'1(-=\07_BK1
M]1N[M8;6^M[YT2:!)9ECB2XM"L(FA:3SF,V](V@19Y/8/V9_"4VI_$'XB_$A
M!+'8^*+[3H-/618L3VND60M1?Q21RR![>[D:5[8D(9+=(K@;DN$V_9]%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?/_[2GPT\
M7_%;PA_9?AG5K;3[A;F*YFAOK8W%IJ$,(9CIUV%=)$M+E_+2Z:/<S6XDA,<D
M<KHW(>/_ (<?$7X_>';WPSXIMO#^E:3>Q&WNXX'NM:GFC<C+V\D\&EQ65Q 5
M$EO,\.H 3&.7RD\C;-]7T44444444444444445\ ?'WP_P"/M9^.WP_\3:3X
M0U+4--\*_P!M_:9X+G1X_/\ [3T^*&+[,ESJ,$A\MP5E\Y8,;24\Q2"?O^BB
MBBBBBBBBBBBN?\4ZS>>']+FO+33;G4Y8]NVULVMEFDW.%.PW<]M"-H)=M\J?
M*I"[GVJWR!_P3Y\#>,_A)\'=*\'>*M"N=+O=*^T[I)9[":&?[3?7-P/):TNI
MW_=JZ"3SDA^9@$\P!B/M^BBOD#]H6'X]^(=<C\-^"X--@T+6=-EM+G67GFCO
M=)N&D(DN4C2:-ILVY*V20X=;W$LTT," 2?5^DZ38Z!8V]C8V\5M;6T20PPPH
ML<<<<:A41$4!515 554 *    *T*****************************^0/V
MA8?CWXAUR/PWX+@TV#0M9TV6TN=9>>:.]TFX:0B2Y2-)HVFS;DK9)#AUO<2S
M30P(!)]7Z3I-CH%C;V-C;Q6UM;1)###"BQQQQQJ%1$10%5%4!550 H    K0
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHKY0^!WQX\5?$?XD^-_".O:58Z=)X8BT8$65W->K+)J,-Q<LWG2V
M]H=@C6!53R%*N)29)%9 GU?7E_B;QKXBTCQKX>T.QT*6]L=1BU"6^U$3"./3
MUM8XC"&0QD2O<R2B-(U=' 624*Z1R%/4**Y_Q3<ZY::7-)HEK;7=Z-OE0WES
M):0MEP&WS1V]TZ87<RXA?<P"G:&+KXA^R3\;[[]H_P"%>E>-+RTBLY-2EOR+
M>)F=8XX;^XMXE+M@NXCB3S'P@=]S+'&I"+S_ (_^/'BKP5\:/!O@=]*L1IWB
M674C'>B[FDN/+T[36N)%:V^SQ)"YG>((XGN0T*29CC>13']7T5S^L^*=+\/W
MFFVEY-Y<NIW+6=JNUV\R9;:>[*94$+B&VF?<Y5?DVYWLJMT%%%%%%?*'[2'Q
MX\5?!/5O"<%GI5C<6/B#Q!I&A&ZENYA/#)>W#>:1:+;A'06\3^7+]J4K,ZEH
M'1")/J^BBN/O?%L,M]J6CZ88I]6L[&&]^S3-+#&5NFN8[;?.L4H5))+2969$
ME>,(7,1R@?Q#]E_XZ:Y\=+?Q9)J^GVVGRZ'XDO= $-K/)<+_ *#!;"1S-)'
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MFKPZBVIFWL]3U:]>*5+BY%Q]IN+6U1;=1,98X[A!O^T11-%+G_M5V^L?L?\
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MOLM;3X?MINZ;4=!DO8&M]4DOHH%>_N+"Z@N([2*!_DC'$\LYVQ74T48M_/\
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M\0RQWNM:1/JM[<LNH3J&O+RP9M.01N)"0$=METB_/]F#6\=CG_ []GO]H/\
M9RQX,\,Z]X;G\'6]S<RV-QJUE>W&J6\,^Z?R6AM9;*WEQ.S R-,K,':4!%\N
MUC^[_ '@JQ^'7AVRT6S>66.UB"&:<JT\\A):6XN'54$EQ/(SS7$NT&6:221O
MF8U\P6/P9^(OP]^+GC3QAX<.D7=MXJBT>1UOY[J"2VDTJVD@, CAMYEE2Y7:
MHN3+&;0R-+]DO! (;CG_ -G7X5?&'X(P^,S<:9X?NI->\0:CXB@6/6KU%22_
MEMP;61CHY(2.-)'%PJL7<)']G17:6/Q_PS^P[X]A_9ST#P'<:K8Z=XC\*:N=
M;T:^LI'NK5[J*XGN8#<I<6D;*FZZDC9524*4CG_? O:GZ@\ > ?C#XSFLKCX
MI7OA_P O3[X7L%CX?M[WRII(HB+=[J:^F82)%)(UPD"VZF.ZM[.Z6Y#1&,^'
MZY^S9\4_CI\*-+^&WQ,AT2:*#[$+C7++4KNZOO\ 0I%(FA@O=- %W/"K6TUP
MUUP9YY_+=";1^@^(/P#^,_@GXKZSX\^%6J:(W_"2VUI%JUAXC2Y\E9K"-8;:
M:VDLD\W_ %6]6C=E569W)EWQK;?5_P .? -]X5FU'4]8O8M0U;4Y8WN;B&W:
MWB6."(106]O%)-<RQ6Z /-Y33RC[5<7<Z[/M!C7XP_:P_MP?M$_!9M$^S&]7
M_A+'B6\\P0R;=,A9HG>/+Q>8H:-9@LOD,PF,%P$,$GT!X.^%?B_Q/\0U\<>.
MAIJ2Z;;36.B:=IS&[BLUNEA-Y=R7EQ:VTTEW.8A"HCCAB@M0T?[UYY7'S_\
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M3\GS[G4;RX@\C[-=V]RGEQ0V=SYWF>4R-N>'R_E8>9DA>?\ CW\#/B7\5O\
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M]PS_ -.UG1_S9#_W3;_W 5^8'_"JO"#_ /!.S_A*)=*MIM77B.^GC$UQ"O\
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M<>%;*+3+F]\0217EU; I=7:O=Z9%(;NYSY]T\B33+-)</(\PFE\QG,KEN_\
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MM]\-?%7[47B.Q2*2YTJ^OK^%)@S1M);3:W,@<*R,4+( P5E)&<,#R/0/V/\
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M#J\VG36(TM+B0::+J&Q$"6_V:-DL4A*&)&0R2Q27&)'83!Q&T?E__#"/A/\
MX4K_ ,*C_M[6_P"POM/GYWZ=]HV>?]J^S^9]@V^5]H_TC.SS]_R>=Y'[JO0-
M,_9<T_1-+\,6MCXBUNWN/#&FW.DZ?>Q2V0F%O</:Y6:,V9M;C9':1P1B:!T"
MYF97O$AN8M"__9ET'4O"OB;1YM0OC>>*8A#J^L!+!=0NHQ"+948K:"V5%MA]
MG18[= B-)*H6ZDDN&X_0/V*O ^C?!6[^$=Q>:E?:%/YGEFYEMUN(-\XNE\J2
MWMX%/EW -PGG)+ER4??!B(<?\5?V!]!^.'A6Q\.>+O&'BG5+;3Y89;5YKNP6
M1#%"\)WF*P1;EW5@6GNUGN%*GRYHQ-<B?T#XV?L;> OC]#I=SK\E\NMZ5%!'
M::]93)::E&T,J2B3?!&D!<NA=08"D+2RM D#/D%M^R!X5A\%:EX>FU35[R\U
M.QN-,NM=O[B&]UA[.XDW2VHN[N"98[=E^00QQI&N6F55NF:<]?\ LZ?L]Z?^
MS3X83PSI.L:E?:;!G[-!J/V)OL^^66:7RWMK2VD;S'E+-YS2[<*$V+D-] 5\
MH?M0?LC:#^UG8VVF>(];U>VTZVECN$L[!K".,W$:S()R\UE-/OV3,A42B' 4
M^6'!8_1_A;1KSP_I<-G=ZE<ZG+'NW75XMLLTFYRPWBT@MH1M!"+LB3Y5!;<^
MYF^8/@?^QSH_P$\7ZSXFTGQ)K=Q<:]<M>:I#>'2VANYB9V#N(M/BDBVO<R2*
MMN\*EB P:,;*/CY^Q;X0^/OB_2_%\^K:WHFM:9;/9PWNAWPM)C"Q<A"S12[=
MOFS -%Y;,LSK(9%"!#PM^Q/X$\#_ !7A^)&D7^MP:D+9K6XBEU2XNX;Q6C,8
M-VUZ;BYEVCRBB>>(D:WMV$89"6Y_0_V%/#?AGPAJG@K3O$_B2W\-ZC]M!TE+
MRU,,"W@;,<$[6C7J1(S;Q";EHIF#"X2X2>Y28_X81\)_\*5_X5'_ &]K?]A?
M:?/SOT[[1L\_[5]G\S[!M\K[1_I&=GG[_D\[R/W5'Q/_ &$?"?Q=^&GASX?:
MQKVMMI?A_9]G,3Z<DTODQ-!;^<_V @^1"S11^6L6]6+3>=*%D'0?&?\ 8YT?
MXZ:YX5UO6/$FMQWOA?RY;&6V.EI_I*212-=RJ^GNCRR-!$70*ML/+ 2WC#.'
M_/#]I?X<0^,?VC/$%[>?$+5_AK<QV-I!9:G>W,J6.IVHM[9Y[?3I2^G) EK.
MZ-<6_P!JNS/<3-.L<)CE%?1_[$-E\2_"/CC5M#E\8W/CSPBVFQWT>OW4<I1=
M2:X\DVEE=2W-P+N(0QL]P8))H8)U$1^SSF99ON_XQ?#%?C'X5O/#DVJWVFVU
M]%+;W3V M/,FMYH9(98";NVN55'63):-4F4JNV11N#<!^SQ^S?:?LV:-;Z#I
M'B'5[S2;6*:.WL;\::T<333FX>026]C;W#/O9\"29T D8;.$*=_\7OA#X=^-
MOAU]%UE)5598[FVN;:0PW5G=0G=#=VDR_-#<1-RCC(P61U>)W1N/\+?L]Z?I
M/B^'Q;K>L:EXAU2TMFM+&;5?L06Q24DSM:PV5I:0QRS@JDTYC:=HD6$2+%N1
MN0\)_LC:#X0^,NI_%2#6]7EU;5(GM[J&5K VKVY6)8X B622JD0@@\MEE$Q,
M*^9)+NE\P^ 7[(V@_L]>*O$7B/3-;U>^N?$<IN-12_:P,<MQYTDPG M[*W:-
MPTTP"HRPXE;,9*QE/+_ '_!.7X>?#;^U;'3-;\2+H6K?:5N]"_M5DTZ1+C;N
M3$4<=R,"../S!<">2%/(FEF@DFCE\/\ C+\6O#O[;'BKQ)\!+[P]?6-W8ZOI
MOE7<T1,@M;:;S]0U!2;>1+)#;H;:QF9I3=G4;4%(X9IO+_6^BBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBL_2=6L=?L;>^L;B*YMKF))H9H762.2.10R.CJ2K(RD
M,K*2&!!!(-:%%%%%%%%%%9]EJUCJ,US#;W$4LEK*(9TC=6:*0Q),$D )*.8Y
M8Y K8)21'QM92="BBBBBBBBL^RU:QU&:YAM[B*62UE$,Z1NK-%(8DF"2 $E'
M,<L<@5L$I(CXVLI.A1111111111111111111111111111111111111111111
M16?J>K6.BPK->7$4$;2PPAY75%,D\JPQ("Q +R2.D<:]7=E1068 Z%%%%%%%
M%%%%%9\FK6,-]%8O<1+<S12S1PEU$CQPM&LCJF=S(C31*[ $*9(P2"ZY(]6L
M9KZ6Q2XB:YABBFDA#J9$CF:18W9,[E1VAE5&( 8QR $E&QH4444445Y__P +
M8\#_ /"3_P#"+?V]IO\ ;7_0.^VV_P!L_P!5Y_\ Q[[_ #?]5^]^[_J_G^[S
M1K_Q8\#^%-<M-"U37M-L]2O/+^S6=S>V\5Q-YLABC\J%W61][J43:IW."HRP
M(KT"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOG#
MX77LWQ<\1:OXEU*VE6VTC5[[2M$CE,6P+9#[%>WPCC>3_2);I;VUCEE*NEE&
MJQ16XNKPW6?_ ,-8>$_L?]N?9KG_ (1C[3]D_P"$E\[3O[+W_:?L6[/VS[7Y
M7VK_ $;S_LOD9_TCS/L?^DT?M*7&J?#/2_\ A8VAQYN-$\J75H4C1FOM%B=F
MO(<23V\?FVR22WMG([,\<L<L$8$=[<I+]/U^:'_!0S]F>'XZ7/@J70Y8M*\4
M-J\EK8ZL/-22-8-+U'4XXFDA97"?:+2,I* [VI:26)26D27H/V1/VE?"O[8W
M@J?P?XTL(I/$>E11V^N:1J]M"QFDMI$1KK[.\2(4,Z*TD7E*;.XQ$R >1++Z
M!^R+I/@KX%?L[^%;V"WBT^VN=(T[4;IHDDDDN+R_MX"S;5#S3W$\KI%!$@>1
MR8;6%"!%$/0(OVD+32O$6E:+XG\/:OX<;6)7MK&YU,Z:]K-= !EM/.L+Z\6*
MXE4L;=)_*$YC=(V>4!#]'U^8'[3_ ,)_ _B']IWX2?VAH.FW/]K_ /"3?VAY
M]E;R?;/LNDP_9_M.]#YWDX'E>9N\O VXQ7TAJW[6%II/Q%N/ !\*>()M96Q?
M4K:*&/37CNK5+HVWG),+_P J!&*NZ_;FM"0HC(%S+!!+H:/^UMX'>W\6/KZW
M/AV7PC]E;5H-5%N6A2\@$ULZO93W<,WG@E(HX9'G:4>7Y0=XP^_I/QZ>77#I
M&L>%];T>4Z;?:K&;E=/N_-AL)+:.=8H]+O;^9Y0;N+9$(]TN2J;G&TX'[+,W
MPPN]+\2W/@2>YG6X\2:I<ZJUY!=V\RZI.Z2W$3PW4,#Q^4KQ1*BQJ%5 &+S>
M:[?-_P"TW\:O!OQS^#WC1K7PM?:WHUC8ZLEKKIL[.YT];Z"RFC6YM T[7DB1
M32& 7]O:M;Q.)I/M"VT4LZ>P? SXJV/@7X/?#;2X[&^U/5-0\+:=-:6-A"K2
M2QVME9"X<S3O!:0)'Y\9+74\ <LL49DF9(V] ^'G[4W@KXC:-K5]:K?1W.@W
MTFG:IIHM)+S4+2X2=H-K6VG?;&E1V4LDMN9H619#O!AF$?/_  L_;"\)?&J^
MT>+PUI/B"[M-4EU"--2.CW46GPK9-*HDENYE2+9<&)A;B(RN'*Q3I;S9C'U?
M7S!^VAX3T/Q7\$/&/]J6%M>?8]$U6]MOM,,<ODW$5A<>7/%O5MDJ;CLD7#KD
MX(R:^?\ X3_!KX(>%/V=-!\8Z[X'T2\^Q^$;+5KR3^R+"6XF\K3$N)FW2QKO
ME?:QR[C<YRS#)->X>%-8TG]FW3M-^'6E)?>(M1ABOKVTTZTFMS=6^D_;G$&]
M]2OHE%O:K-!80L\YEF$>8XBD4X@Z#6?VFM!T_P !:CXPL=/OM2@TB6\AU:UL
MGL#=:=)8)(UXERLUW#$7MS&598)9C*'CE@$\$B2GS^__ &V-!TCP5:>.KWPS
MX@MO#-Q%8S-JLT-@D<4=[)%$KO;&^^WLB23!6:*UE$@!FMS<6[12R=AJW[4>
MG^&-4T2WUSP[K>EV6NZE#I-AJ%Y%9"&6XN4D>V5[>.\DOX//\O"BXM(7A9@M
MPL!#[>?^#C_!WXB^,_B%-HZW-WJFJ?V8GB&TU:POK;9"; VUI UK?VT \J2%
M)9""CM)YS%V,30HOC_[ MK;^#]#^*L.EZ?NBL?B!XC2VLK)8(LK#';"."!7>
M&%.%$<89XHEX!9$!(^@/@/\ M1Z?^T-H>NZIHWAW6[;^Q;F6QDMM1BLK:XEO
M((]\MK'&;QMDJ;HU;[2;>,/(J^9\LIC]/^$/Q.7XO^'4UR+2K[38)99$@6^-
MH6GC0X%Q"UI<W43V\AR8)0^)T FCW0212R? '_!4KX!V/QC\(Z,+&QB.MO?7
M*PW,-DL]Y-'8Z'K&HI8HRXF9)Y8 BQJQ DD$@C=AM;ZP_8V^.EO^T3\(- \1
M_:OM%Z;9+742P@5Q?6ZB.X+QP$I%YC#SXTPA,$L3^6@<*/SP_9^L9OC1^UH/
M&'BRTBNH]8\&CQ'HUI>P12G3;5=9B@TQH@9[M([AK>);V1X6C,=Q=SJ$1MV?
MU.\8_&&W\-ZXV@:=I&I:UJD=M#>RVNG10+Y5M/)-%'-)<WLUI9C=)!(BPB<W
M+[6=8&B221/ -7_;X^']I\*(/B=IMCJ6JZ%PE[)8BQ\[3YC)#$(+N"XO()!*
M7G10(1.I7]]N\AXI9.P\6?M;:3\/IM,E\1>&_$&FZ=JM\FGV5_+:V\JS3S12
MRVZ"RM;J?5$><1%8XI+))D=ECFBA?<JZ#_'K1]=\3Z=X#\6^%]2TJ7Q);:@E
MI#JRZ7<V]ZMK$KW4#"QO;X#]S(6(N%CBD0,@9G(1OA#]EKXX^'?V>;'XCZ5I
M_AW5]7DC^(FO1QZ9X8TPW<EI:A84ADDBC,<5O;DPM% &9#(4=84=8)C%^AWA
M/]IKP)XP^&%A\1;>>Y72+[R4C_T.XEN!--=K8K!]GMTFE>7[2P@Q"LJL_P R
M,\9#G TC]JWPVWB^?PAKVFZEH.M+IIU:"RODM;B:\ME,PD-HNEW-_P"=*GD.
M3;+BY=1NCAD57*<_X<_;5\&>-]4.GZ!H_B34VCUN/0IY+?0K]8;>5DC,LUS+
M/'"EO%;M(([E)BEU&RL_V9H=LK?7]?,'BG]J/3_"VES>(#X=UN[\.P[9'UNS
MBLIK3[.7"O>)"+P7\MI'EI&GBM'22W0W4/G6K1S/H?%']JWX??"6'2)K^6^N
MH]9EL8K"73=.O;Z"Y-_+LA\FYMX7MY'*!I_(25KB2%"T4,K/$DG?_"KXHP_%
M>QOKR'2-7TR.UOIK)!K%C+827"QJC"YABFQ*;>0/^[:18WRKJT:,I%?,'[=W
MQ_\ $7PHT;P]X8\'WD5GXH\7:O:Z7ID\R!H[=3/")[AP]O<Q,@,D4#(R[\7!
MFC#F$K7H&F?L0?!*V\.MI%_X9L=5DEBF2YU'4H8[C4KF2<LTUQ-?LHN#<2.[
M2>:CH8V(\KRE5%7G_P!GSX90_LFZ3XZ.L74ITZ\\4W6K6<\K2W$\T6H6]B(X
MP/,N;FXN/M)>SC#%[J\F166-GG16] B_:0M-*\1:5HOB?P]J_AQM8E>VL;G4
MSIKVLUT &6T\ZPOKQ8KB52QMTG\H3F-TC9Y0$/'^'?VO(O%7B?7/"MEX+\2/
MK6A_8VO;/9I(V)>1&:-_M7]I_8ON[/W9N!._F9CBD6&Y:#0\&_M86GQ(AO!X
M<\*>(-1N=-OKK3=3MHX]-@:QNK:4QM#)/=7\%I.[8WC[#/=B-"AE,1EB#Y^H
M_MQ?##2_A18_$N5M2;2+ZVFGB,6FW<K*\,@@:WF>.-K>WE,Y^SQFXFB@EESY
M<SQ@R5T%]^U?X8T37-(L-6TO6],M-;N4L=,U&^TV6&WN;QY(XTM3$?\ 3;65
MV=O+^W6UK'*D,LL<CQ*KMH>(/VFM!TB;6);/3[[4],T&66'6-4L7L'M=/DMX
MEGNDF66[BNI7MH762=;2WN""3"H>Y22!,_XO?M6^&_@W_P (_=7FFZEJ&EZ_
M<V5G9ZGI*6M[;O-?;VA18XKG[9+F.,RAK>VF61&58S)*PCK0TO\ :0M!XUT;
MPCKWA[5]!OM<BO9-.-^=-FCN&L8TEGC#:=?7IC=8W\P&81HP5E#E]J-G_!7]
MJ/3_ (U^+_$/A:'P[K>E7OA[REU#^U8K*)8WF+>2B^3>3O)YJH\L4D:M \2[
MQ+B2+S._^$WQ;?XK?VF?[!U+2ET^Y-FSW[:>Z33)D3) ]C>7:2>0P\J=LA4G
M#V^3-#<1Q>P5^./[9WQW\>_#+XN:1X^TVPE;POX%OH=$U=H@[37#:Y;075V/
M+CG5&MX;?[ 8&NOLZ#4I81^_ 'E_K]JVK6.@6-Q?7UQ%;6UM$\TTTSK''''&
MI9W=V(545069F("@$D@"O /#/[2%IXGU'0(X_#VKPZ=XBE,>F:I*=-^RW*FQ
MGU"*01I?/>QI-;V[R1B:VC=2525(G)49_C;]J;1_"UOK][INC:EKMAX<^T)J
MM[I4FEF&TFM(!<7$#"ZO[6626&)D:40QRJK-Y.XW$<L4?I_C7XG+X6ODTS3]
M*OM;U$Q"X>STTV@DAMV9D6>9[RYM((T=U9(E:433E)C#'(EM<M#G_";XUZ'\
M7/[3MK>&YL-2TBY-IJ.F:@D<=Y:.<F)I$CDEC:*= );>>&26">,Y20LKJGB&
MN?MQ>#=%T:_\3+I6KW7A>PODL9O$-O'9MIY9IXK9YH%:[2\NK>.:7RFGM;:9
M'>.3RC*$R>@\-ZS\*_$/Q]U"X@EOAXP@\/\ V%H+JSO[6-=-M]1<R30&>WBA
MG26YD1?/1YE<1)Y)"><TG0>(/VFM!TB;6);/3[[4],T&66'6-4L7L'M=/DMX
MEGNDF66[BNI7MH762=;2WN""3"H>Y22!//\ ]J?]I+4?A7HW@RZ\,64NJQ^)
M?$&CV$5W8S6+1F">>.<QQ&>0)*][;I)# X*0H':9KJ!EA\WV_P 4?&&W\+?V
M59MI&I7&KZK;2W5OI-M% ]QMM_(^TB6<S+80^1]HC#O+=I%(Y$<$DTCQH^?\
M$_V@?"OQVAU1-*,MO?:-?3Z=J6GW1A%U9W$,KQE91#+-$R.8V,4L4DD,@5E#
M[XY43/\ VB_VA-/_ &:?##^)M6T?4K[38,?:9].^Q-]GWRQ0Q>8ES=VTC>8\
MH5?)67;AB^Q<%N0\6?M;:3\/IM,E\1>&_$&FZ=JM\FGV5_+:V\JS3S12RVZ"
MRM;J?5$><1%8XI+))D=ECFBA?<J]!I?[2%H/&NC>$=>\/:OH-]KD5[)IQOSI
MLT=PUC&DL\8;3KZ],;K&_F S"-&"LH<OM1CQ!^TUH.D3:Q+9Z??:GIF@RRPZ
MQJEB]@]KI\EO$L]TDRRW<5U*]M"ZR3K:6]P0285#W*20)S_QB_:YT'X/7WAJ
M$Z)J^L6WB:6VM],O](6PFLYKBZ8""#SYKV!4>12LD;/MADC)=)'$<WE^G^,/
MBV_A+Q?H_AM=!U*^?5<F.YM&T\PPK&3Y\DZ2WD5RL4 ,9EF6!X@T]O CO<SQ
M0MZAJVIPZ+8W%Y,LK1P1/*XAAEGD*HI8A(H5>61R!\L<:L[G"JK,0#\H:3^V
M?X8\86^MR^%] \2:XVBW,UM=1V>D2P,#;P1RS[#?M9HTL;2"!K+<-1:4$I9O
M#B8Z'C7]LGP%X5^$:?%2QCOM9\/-*(S-80HDBJ;EK0R&*^DM'V"X40D*&?+*
MX0Q;I%Z_Q%^T)I_A3XGZ'X"U#1]2BN->^V?V???Z$UG-]BM!=7'W+MKE-@81
M_O+=-TA^7='^\KS#5/VZ/ T5]K.G:5HOBG5[[2(K*2XL[#PYJ9N UXS[(S'<
M0P&%UC03DW/D))"ZF!YW#HGI_BG]H33])\7S>$M$T?4O$.J6ELMW?0Z5]B"V
M*2D"!;J:]N[2&.6<%GA@$C3M$C3&-8MKM\ ?M4?$7X>?&#PQ\'_BOHMCYGVK
MQOH$:W7V!GU%;>"6\::SQ$DEQ)LGC<>1"94DF7=%YNY&;[@T?]J/3Y/B'I?@
M77?#NMZ#J6KVUQ<V#:C%926]S]F4O+%'/87EY&)416D9'*;4"[B&E@670\0?
MM-:#I$VL2V>GWVIZ9H,LL.L:I8O8/:Z?);Q+/=),LMW%=2O;0NLDZVEO<$$F
M%0]RDD"=?XP^-WAOPO;Z.;1_[6N]>R=)L].FM6FOU2 W,DENT\\%N8HX 9GF
M>9(MI1%=I9H(Y,_P[\=])U'0?$FL:O87VAQ^&I98]2COQ;RR1+#80:@T@^P3
MWB2)]GN$8"-V<G<FS<,'D!^U;X;TSQ?HOAO7M-U+0G\0>>-'N=52UAAOFA,7
M[M42YDN;>603QF*&^@M968^046Y(A/T_7C_BGXMOI&J3:;HV@ZEK]Q:[1>#3
M&T]%M6D021QRR7]Y9QF5T82>3$TLL<312RI%'<6S3>0:U^W%\,/#WP\;QM=M
MJ2VD7VB*YMUTV[DN+.\MF2.2PO@D;165WYLB0HEW+#'([JR2O$1)7K_PT^,E
MG\4=4U:SM-&UNRBT[[-MNM5TNYTZ&[^T(['[*+M8IG\DH4FWQ1[6*E=Z,K'H
M/B1\2]#^%FEQ7NJ2?-<W,%C9VZ-&)KN\N7\NWM8!(\:-+*W WND:*&EEDBAC
MDD3G_AY\6W\<ZYJ6B7F@ZEHU[I]M97CQ:BVGOOAO9+J.)XVL;R\3[UG,&5V1
MAA3@ALUY!JW[:O@?P_;Z)J^I6>I67AW7+F&TL=?O(K>WL9'N())HF>.:X2_A
MB?RG59YK..# $WF?962=O'] \)Z'X4_;>N_[+L+:S^V?#^2]N?LT,<7G7$NO
MCS)Y=BKOE?:-\C9=L#).!1^R?X3T/P-^T3\:=+T2PMM/LH/^$3\JVLX8X(4W
MZ9,[;(XU5%W,S,V ,LQ8\DFOT?K/U;5K'0+&XOKZXBMK:VB>:::9UCCCCC4L
M[N[$*J*H+,S$!0"20!7SAK_[4>G^"OLE[XB\.ZWH^BW5S';+K-]%9)9Q>?D0
M2W4:7CWME%*VR/?>6L'D22QI<"W8L%S_ !C^V1X&\(>*KKPL+#Q!?:M;6-W?
M-:6.@ZG+(Z6TRP+Y0,""1)Y&9(+E";(F-M]U'NB\SZ/\)Z__ ,)7H=AJGV2Y
ML_MEM#<_9KV/RKB'S8U?RIX\MLE3=MD3)VN"N3C-<?XU^)R^%KY-,T_2K[6]
M1,0N'L]--H)(;=F9%GF>\N;2"-'=62)6E$TY28PQR);7+0\?X/\ VA-/\>:7
MK#Z7H^I2:OHMR+2_T*3[%!J4#LX\MB)KN.U:*6/_ $B"=+EH)X0WE2/(K1CX
M@_8>FB^./PE\,>(_%O@VYUC4M*N==U^RU21=)"3W\^J7<DB6J?;(Y(Y7>0E5
MN(+:T2>!)A(C0VTH/V:9HOVF+SQYI?CSP;<ZI:-\0-0G\^]726M[%],MK2&U
MMYTCO/-:6**WCMI#;Q7,$Z2%))IHI;@U]0:M^VKX'\/V^B:OJ5GJ5EX=URYA
MM+'7[R*WM[&1[B"2:)GCFN$OX8G\IU6>:SC@P!-YGV5DG;0\8_MD>!O"'BJZ
M\+"P\07VK6UC=WS6ECH.IRR.EM,L"^4# @D2>1F2"Y0FR)C;?=1[HO,^C_">
MO_\ "5Z'8:I]DN;/[9;0W/V:]C\JXA\V-7\J>/+;)4W;9$R=K@KDXS7RAKG[
M1'B6U_:1L_AW;:%?2V*>'Y-1FEBDT[;(;B_M8([LB:>.5+>T"W$<BHQN)GE8
MK92)%#,_M_BGXMOI&J3:;HV@ZEK]Q:[1>#3&T]%M6D021QRR7]Y9QF5T82>3
M$TLL<312RI%'<6S3:'PA^+WAWXV^'4UK17E55EDMKFVN8S#=6=U"=LUI=PM\
MT-Q$W#H<C!5T9XG1V]0HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHKX0_X)L:9-X8^ >D^'KQHEU'1;[6--U"".:*5K:ZAU6Z+PR&)G4.%=
M'')#(Z2*2CJQ_.#X_P#Q@\,_%S]D"\UO3-7L?#-M>RI;67@_36TE( UKJUNT
MZN#:K=RW'[P7[_9C:(D,UMOMW'FW%U^O_P"T]JUCK7P*\?36=Q%/&OA_7X2\
M3JZB2"TN894)4D!XY$>.1>J.K(P#*0.O_9Z\+:IX&^%GA+1-4A\B]T_1-,L[
MF+<C[)H+2*.1-R%D;:RD;E9E.,@D8-<_\9/^1N^''_8R7/\ ZC6MU\8?MQ_!
M#QK\/?$0^/7PSNXK;6=%L6&L64BQI!J&GVX,DC2X\LS.D:A9$D?>\,,)MY(;
MFU@$O'_&"UU33_V8?@QXHMM/N;^T\*W/@_Q#J26:H\R6-CIY,\J(SIOV[UW8
M.$4F1RD222)] ?\ !0'PYI?QT^"MMH&E&VOKWQ)J6D6^ASK&]S%YTLZ3M<I+
M!'/Y<2V*7<TERHVBU$OS,'VO]_U\ ?M#_P#)SOP0_P"YN_\ 33%1_P WO?\
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M#2C;7U[XDU+2+?0YUC>YB\Z6=)VN4E@CG\N);%+N:2Y4;1:B7YF#[7/V>/\
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M%^LQ7,=[H.FP>%[B.^@2UN(]739<:XYABP@BG9=.$8DVR1/;2JL%L&?SOO\
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M%K+1-1D$$L32ZE<W*WJ 2&(1SO%8QVOG,)&:-);6/D9$>?\ \$N/^38O"/\
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M+,6/))KG_P#A4_@?_A)_^$I_L'3?[:_Z"/V*W^V?ZKR/^/C9YO\ JOW7WO\
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MU>YUNRU>UO=6N=0OKQ[74;625Q?VRZ<)GL+1&CE8VBQ6Y,!AAC$B,3=+Y_\
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M<V^D1ZD\_AUM1O8+Z^%G<3W#FWN)XKN[>3R%$ 0S.\@,CH)I8T18OM^OR0\
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M;&\UN6Q@L@FFV\T-G:1AC-,EL+F:XF+S2LHN)]T(N8[6QW6T;6X+>X5\0?\
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MA(S<7"Q7A,H4?H?\*OAOI?P?\(:5X7TN6YEM-,MH[6%[R=YYF6,8!=V_\=1
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M3)8ZG;,;BYCO)+EOMD( MHO)2W^QSNUJ\TOFO;23H8)*^7_V3?CWX4^$=O\
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MV6<O*&<2.9 VZ0,P<Y;<V<GU#]GC_DYWXW_]RC_Z:9:/^"7'_)L7A'_N)_\
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M_P"Y^C]GC_DYWXW_ /<H_P#IIEKY@\(ZS\//#_P=^.-Y\0--N=3T"/XDZO\
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MXVCE:SF@>2)E=@\+LT3\%D)52/,-3_9,^&>M> E\"7EG?3Z$LL,@LY=8U9U
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M^,FAR:)XITJVU.RDW'RKF,/L9HWC\R)OOQ2A9'"31,DL>XE'4\UY_P#\,Q>
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M?"$WA36](_M#3Y[E;V7[9=7<]R]P@"K.][),UXTJQJL"R&8N+91:@_9P(J/
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MMX;F6UDEB>-)X1$9(F92!(@F26(NA.Y1(DB$@;D9<J?B#4_C)IWQ&^$RZ?\
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M-P]C%%-<K$YACFE:&-Y IV*\BQS-&C-@,ZQR%02PC<C:?C#X0_M'?%/XT_\
M"0?V7X1T2+^P=;O= N?M/B.[7?<66SS'BV:')F(^8-C-L<X.8UXS[?\ ##XG
M^(O$_B+6_#GB/1(M+U'2XK&Z!M;X7UK<VM\)UBEBE:"UF5UEM;F*6*6WC*F-
M75I$D!'N%%%>7^)O&OB+2/&OA[0['0I;VQU&+4);[41,(X]/6UCB,(9#&1*]
MS)*(TC5T<!9)0KI'(4\@T3X\>*KKX^S?#;4M*L;:VC\/W.NQ7-O=S7,DT?\
M:,5G;!U>WMEMWVB9YHA]I&6B"3X1_,^KZ**^ /VJOVW[C]DKQ?X=L-?T*VDT
M77+EHDU&+49S-;PP&V%U--9KI[9\O[06CCAFE:98SS&S!!]_U\0?L_?MD?\
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MM+C*V\MS')<F2&T;[?HHHHKG[GQ3I=IKEKHDDV+V[MKF\ABVN=T-I);QS/N
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MI)#J0LWN-NEQ2Q7:[HX[(0RVSPO;&&.&.ZMJ[#4_ ^G:M^W(LLLM\K+X$AU
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MUQ+M!EFDDD;YF-=A7RA9?LSPVOQXO_B()8EM+JQL7:U'FM))JUK%>6*WK,6
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M************S]6U:QT"QN+Z^N(K:VMHGFFFF=8XXXXU+.[NQ"JBJ"S,Q 4
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MBBBBBBBBBBBBL_5M6L= L;B^OKB*VMK:)YIIIG6....-2SN[L0JHJ@LS,0%
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MO(-:::6U(5B1<1QH\DD/^L1%9V4*I([#]GC_ ).=^-__ '*/_IIEKX ^)O\
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MH.FV>I7GF?:;RVLK>*XF\V02R>;,B+(^]U#ON8[G 8Y8 T>.OA/X'^*'V?\
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MOA/X'^*'V?\ X2;0=-U?[-O\C^T;*WNO*\S;O\OSD?9NV)NVXW;5SG P:_\
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MXA&P>+S89'T/V>?VC]6\5>%?'FL>-Y;&&/PAX@UG2YKFPM;B*-K72H8I'N#
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M,EN-2L[N8Q0QOI,S"=YG*!HH44S1W3>?</*HO3$0JVK;>0T+PY;W?[0/P?\
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M"S^)K[6].\4Q:]'=1ZI;Z8K0MI]G%=0R6[Z?963*Y8LCB4RHR,<(KA77YO\
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MPO+MGFM;28L-_E6LGE(US\H?\*&^-R_L=_\ "HF\$W)U1OE61-2T@HK+K?\
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MBU".Z\&_\(_+#:W\*QVE_P#VBEWNGEN5MY6LL,5\^WM[BYQ&[?8=Q2-\_P"
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MRI=,NK3/ @9UZ#]BWPGXY\ 7WCBW\1^&;[2X]<\4ZOXBM9YKC3)H_(O&MQ%
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M&H6QT_2[?3[FTE6(RWTNG-*\[)<W!N([3SB\JVLK&"UM9#T'[5.F?$3XOP^
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M?Q'X9OM+CUSQ3J_B*UGFN-,FC\B\:W$4#BTO;B5;C"LS (80%/[\L54_=]?
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MZ^+NTL;C3Y[..;3=%5HXQ+:1"9LFY\^2&YGF7S#%(J)LBV_;_CKXL>!_A?\
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M=6L=?L;>^L;B*YMKF))H9H762.2.10R.CJ2K(RD,K*2&!!!(->7Z!\8OA_\
M%O[7I'A;Q=IMW>FVD?.DW]C=W$"G$?GK'F=/W;.F#+&\6\JKJP;:?D#]EO\
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MD5RHC9Y(H%M6F3<?+MMTUP L@66,_9X_Y.=^-_\ W*/_ *:9:^ /^<8O^?\
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MBCPC;>=%'XN\*:/:WU[;1)J(M+)KF$VT\JHI^2:%O,2,_9VF4R1[D*N?I_\
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M+S7BE9I85U^%;61RP5GWVZPNLS9:=2)F=V<NW[?5Y_\ %BQ_M/P/KUM_:_\
M8GFZ;>Q_VGO\O[#NMW'VK?YD6WR,^;N\R/;LSO3&X?G!\-O&'B_X%W_P_P#
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M17/^*?%FA^!M+FU36[^VT^R@V^;<WDT<$*;W"+ODD947<S*JY(RS!1R0*S_
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M>9L@9HQ:W'G$P_9^DR7TUC;O?110W+1(9HX96FC20J-ZI(T<+2(K9"NT<98
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MG]HNXNO'<W@3P3I']MZU8;9-6-S-/I]CIL,MN)X#/=_9;GS);C>BV\%M%,S
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M[=VU=V,[1G ^0/\ F][_ +IM_P"Y^O/_ (,^ 9?%7QV^*?A6]\0^)'T70_\
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MNX;BWN9;8&XAM(-7N(;>6$+/,HL8+5$8K%'"UN6MZ] _9X_Y.=^-_P#W*/\
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MGB_Q/I=W+_9,$5N9M.95^RQ>(;RW1[J[@B&P1W T\VIEN!'(]P=2N$^T_+-
MOV_JTE]#8W#V,44URL3F&.:5H8WD"G8KR+',T:,V SK'(5!+"-R-I^</V=O
MWQ+\,ZIXKU3QXVFSW>K:E]ILYK&ZEN&@L53;;Z<QDLK/$5I\[Q,N1-+<W,S1
MQRO(\WA_QV_9Y^)WBSX\>%OB7X4L/#Z2>'HIK5WU'4]062^M9XF0Q-##8R16
MKPFXN_*E5YRYE22166,05Z@- ^-\>K^)4O=)\-ZSHNM_99([&^UF_7[-NTRW
MM;ZU.[2;F*:TDEB=XU$<&[S)9)$+3F.+C_ 7[//Q%_9MT;P-H?@*\L=5T[1+
M'5[74X-8O+JP%W)?SP723PBUMKM$>*=)A'YJ2F*WE>$.[R-.#3/V)/#OB^Q^
M(+^*[:*UD\>RV<E]9:3<$V]HU@N898)S;6SRW#W!>]FDEA5'F<1/#*J22W.A
M_P *G^,_BSX>?\*X\27NFFREMO[*N_$%I?7,FHW-BK>6[-8WEC-$MW=VR^1/
M*U[*(9II+J/S"B0MQ_Q$_96^(O@3XD_\)[\&=3TC2Y+JQL]-U#1-3BNETVYC
MM(9(8)O]&9C&\$:V\5O%!%"$6-SYVV6:*8_:-_9Y^,/QP^$=_P"&)KS2+G6-
M>BLAJ$[WE[9Z?8FRN8+F.+3[1;:\:5'991-<3R17$CLKLQ@6WL[3T#XK?!GX
MB_$+Q%X&\>69TBSUWPK+J1.F2SW5Q8W,>HB*VE47ZV\$T+K;([QO]BE N&56
MC:-"SGP?^ _Q%^'7Q<\4^+=3U72+^V\31:7)>/;VEU:2))IMM/:I!!;/<7*J
MCK)#,UR]S(08Y(!:8F6>#Q_P;^Q+XJF^ =Y\%?$.HV,.DQQ74=KJ-CYTUU/(
M^JG4;:>:"6.**V2(@+/;))=FX#D)=VOE!IO4/ 7PT_:#\;Z6-$^*NK>&Y--7
M[&)QHMM>M<Z@L#B26.YDG>"VCBN#&D=W"EI+%=6TUS;A+965A]GZM)?0V-P]
MC%%-<K$YACFE:&-Y IV*\BQS-&C-@,ZQR%02PC<C:?B#]G7X5?&'X(P^,S<:
M9X?NI->\0:CXB@6/6KU%22_EMP;61CHY(2.-)'%PJL7<)']G17:6/S_X8?LX
M?&'X>?LUWGPG>T\/SW,ECJ.FQW@U>]6,QZF;UY)F3^R2RO T\2I$"PG'F,9H
M"BK)H6'[,?Q3M=/^&.JQR:)#K7P\MI-.AM&N;N>SU*WGLK2QFD>Z%K!+92^5
M%.T:K;7J+(8MS.N\#U#X/_ ?XB_#KXN>*?%NIZKI%_;>)HM+DO'M[2ZM)$DT
MVVGM4@@MGN+E51UDAF:Y>YD(,<D M,3+/!S_ (L^"%CXF_:<TS7M-NY88[72
M$OO$-BJK]EO)(Y98="EGC_=B:X21;R:*=_M)MCIMNH6W9H9'^[Z_-#QK)XJM
M_P!M!)?#D5C/<I\.P7@OY9H(YHSKK*5%Q#'.T#JQ60.;>X#B-H?+0RBXA]@B
M_9M\1?$"Q\;:GXRO;&/7?%&D7/A^ V$(GM]*TUEN%A@AEECM[BY=GG-S>22&
M!9YA'&D44<$9/C^J_LF_&'Q/X5\!>&KK7?#]K;>"M7T^ZMIH["]N)+F/1X9T
MLKB56NH%1Y%,,5S9*2%(EN8]0(*6@]0^-OPF^*?C+XQ>#?&.B6.B267A3^U?
M*CO-5NX)KO\ M.QCMVWK'I=PEOY+*Q7#S^:N"?*)(4_:3_9L\<>+_'&B?$?X
M<:W;:3XDTFV:QDCOEN'L]1LWN$E%K=&)VV1)NG?Y(7DDD>,B2%X89HCQA\+_
M (W_ ! ^&FL66NW.B76OZQIM_HQM[.ZO[#2+.WO(I8S<(&@O)KR[)\DL9TB1
M(P8H#;YN9+[R_P")_P"SA\8?B'^S79_"=+3P_!<QV.G:;)>'5[UHQ'IALGCF
M5/[)#,\[02J\1*B >6PFG+LL?L'BSX(?$6?XLZ9\3="N](@OI/#Z>'=0L+U;
MJ>""-YY;M[JVN(O)>X>&X,06WDAM1<PI(IN+1Y%>+R_PM^S9\;_AEH'C2RT#
M6]$>]U?Q(OB>UN76_M%EN)KS3[FYMYXHGF>WM MK<P&));Q[R*Y4/+:B.03^
MP0? O7/B)\5_#WQ#\5Z?INE7OANVOK>U72KZ2^:[^VQ^5BZFGTZQ=(K96F:&
M)/,WRW+/OA$;I<>/_ []GO\ :#_9RQX,\,Z]X;G\'6]S<RV-QJUE>W&J6\,^
MZ?R6AM9;*WEQ.S R-,K,':4!%\NUC^[_  !X*L?AUX=LM%LWEECM8@AFG*M/
M/(26EN+AU5!)<3R,\UQ+M!EFDDD;YF-?,&B_ KQE\#/'OB#7O "V-]I?B:5K
M_4-+U?4;RT6VU+?E[NSEBM;Y=ETKM]IA>%6#QPF.?R56WCS_ !1^SUXOD^'_
M (VM[%=-O?$GCG[6FI7%W<&UAM89[%[.V@@FM]/DEN8K"(1Q1":.)KAC<7+-
M;O,81[?^SCX2\5?#[X=:)X<\1P6,5SI%C:::CV%W-=1S1VMK%")B9K6T:-W9
M6)B"R!!M_?.20N?\4])^*:>+_#^L>#CIMQ96MMJ=MJ5CJ=]=V:S?:3:/;2Q-
M;VUVGFPM XWRQ/MBEEC0 S%T^<-6_83L?B)X=^(\>L2Q:/?>/I;":YATIEN+
M6SDTTAX'1I+:T>Y>>X#W5XS1P&0S-$I5U-W+V'@+X:?M!^-]+&B?%75O#<FF
MK]C$XT6VO6N=06!Q)+'<R3O!;1Q7!C2.[A2TEBNK::YMPELK*PS_ (4_"KXP
M^!_BIXY\:7FF>'VC\4Q::1;Q:U>LUO)I=A+;Q*7;1T$B3R,GF/A#;H698[AE
M"-T'[)OPA^(OP<OO%R>([;2!;:_X@U/Q$DEAJ-U<20R7S0XM3'-I]LK(BQL3
M<"0$G:OV< EE]/\ VH_@7_PTI\,-7\%?VA_9W]H_9?\ 2?(^T>7]GNX;G_5>
M9%NW>5L^^N-V[G&#X!XI^!?QO\=^,_ OCC4=0\-Q:EX<^WQ-96\%^;=/[2L#
M:3W(N'D\RZV.D=Q%9F&R^1GM6ORR+=OT'P_^$WQ3\ _&+X@^,5L=$N++Q1]A
M^SQG5;N.:+^RK&:WM_,7^RW3_26,9FVN?LJLY3[6442=!^R1\'?''P>_X3/_
M (2:/35_M[Q)?>(8/[.O+BY\O[?MWP2>=9VO^J\I-LJ[O-WMF.+8-_'_  Q^
M"%C8_M&>+_$^EW<O]DP16YFTYE7[+%XAO+='NKN"(;!'<#3S:F6X$<CW!U*X
M3[3\LT"_=]?G!KG[-GQ3^.GPHTOX;?$R'1)HH/L0N-<LM2N[J^_T*12)H8+W
M30!=SPJUM-<-=<&>>?RW0FT?H/B#\ _C/X)^*^L^//A5JFB-_P )+;6D6K6'
MB-+GR5FL(UAMIK:2R3S?]5O5HW955F=R9=\:VW0?&#]CNX^-GA"_MM5U_P G
MQ)<ZE8:K;ZU9VT\(L9M/ BMUL[?[:TJ1)$UPRQ274JI>7EW>)L>143H/@SX/
M_:#U#R(/BAK&B-;V/V62,^'1>Q7%]-#R3>S2B%$BW*DLD%K%$MP_[MV2S$UK
M=>/WG[*7Q3\/Z'\2O#/A_6-$?3?&ESK&K+/?6MW]HAN-5CEAFLBD4WE^5L\A
MH[_<SQ.DH;3KA9$,6A\<OV7_ (B^+_V<[+X1Z+<Z1>2)8V5A+J5W)=:>J1Z=
M<6TEN4M8X=1,CO'!LF)GB ?]ZBE7\J/L/VM/A-\4_P!H_P"#MSX.M+'1+*]U
M7R_M<DNJW;PVWV:^@N(O)9=+#W/FK$1)O2U\EB OG#FN@^/OP=\<?''PQX5N
M/+TVRUKP_P")--\0_8_MEQ-9S_8991Y'VW[''+'OBDW^;]C?9(/*\ME/G#Z/
MTS2;[Q!X=:R\4V]C<27<4T=W;1(TMJ8YBP-N?/&9T6-A#)(Z1BX(:7[/ LGD
M1_*'[!/PF_X5K\/'N_[3N=4M]3N9)M*N;X[[A-#C8II$!D)W>5]G_P!+CAV0
M+;O>2Q_9HI/,#>W_ +1WA+Q5\0?AUK?ASPY!8RW.KV-WIKO?W<UK'#'=6LL)
MF!AM;MI'1F4B(K&'&[]\A #>(>'_ (<?&_PA\-_ NCZ6-$AU+PO<V%O<Q-JE
M^;/4-.MM*ELI \B6$<D<KO()8XFAGAADBBF+S,@CK/U+]FCQ5XH\1>+_ !Z1
M8Z#XHU?PM<>&[-=+O9I8%D<,\>H7%Y]AM+C[0'6WB0I$3;PVP(DF+I';Z'B/
MX%^./CWJG@VZ^(&GZ)82^%]2MM96]T6^N+J:>XMTYMTCN].@-K:33".>8">X
M<K;QPX9V6YAT(O@/\1?!/Q<\5>,/"VJZ1]F\6Q6 NUU*TNI)+"33+:."W:&.
M"XB6\293.LJ/+9&$O#*LDPB>&;P_3/V$/%^F_L\^'O D?B2VBU_PQJ4>OZ1>
MP6I%O%?1O+<+#<"8SF>)9KB=1.L4)V>2[6C^7)%/](> / /QA\9S65Q\4KWP
M_P"7I]\+V"Q\/V][Y4TD41%N]U-?3,)$BDD:X2!;=3'=6]G=+<AHC&?/_@G\
M&?C#^SK#JGA+P\?#]WX7^W3S:&]U/>Q76EV]W*\TD,MNMO*+]())28E>\MYI
M@K![J(2HMMV'[$7P4\<?L\?#"P\'^)IM-E_L[SD@.G/<2[_.N[BZ>622:.#&
M?/2)85B.SR6E,\GV@16^A\>?@SXJ\7_$'P+XX\.&QGN?"TNK![*_GFM([B/4
M[(6Y87,-O=LCQ,BD(8&$@9OWD90!^@\-_##Q%XJ\>VGC?QE#8P7.EV,]AI=A
M93"^@MVNW1KN]^U3V-G.+B9(XK98U4)##'*0\ANW6+Q_]I_X(6/Q5^*/@&2R
MNY;/41+=C4TB5?+OO#UOY4UY:7H^3[3;O=-96HMWD= +^>4VTR+*8_N^OD#X
MA? OQP?C/9_$KPIJ&FB5M$_X1NZM-3@N"L=NUS+=_;(I() 998YC#_HCK$D\
M2RI]KMW=)8_']!_9:^*?A+P/\3_#,=]HE_\ \)?<ZQ?0SL+NRS<:W;P0S%T"
MWGV:*TVSM'&K7KWF^(-+9>4YES_B?^SA\8?B'^S79_"=+3P_!<QV.G:;)>'5
M[UHQ'IALGCF5/[)#,\[02J\1*B >6PFG+LL?L&I_ KQEX5^)*_$SPBMBNJ:Q
M8PV7B+2+W4;Q+"X:&%1!<VUS':RLMQ;-&L"M)9E)K9Y"([69Y&E]/^&GPKU2
MT\7ZMXZ\3"V.M:C;6VG0P6S)<0Z?8VI=Q;P736MK<3>?/))=7#R(@+-# $*V
MJ2R?*'@K]FCXP_#?X#W_ ,)[$>'[NV-CK.EPWDU[>P231ZG+=.EVZ+8S+;O
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M+XAM8A-/:1V5ZRQ1F%)P\EP(#;HA26/#-* 7D2+/FLJ'/\ ?M.^ ?BA_:O\
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MU"X=8]OF2"WLH9YO*C+QK),4\J-Y8D9U>6-6S],^,GA+5O"3>*HKJ5=.66:
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M_P#'_AWX6>';WQ#XAO8K'3K&(RSSRD[57(   !9G9B$CC0,\CLL:*SLJGC_
MOQW\&?$37+C0M/N+F+4K>V2]>SU'3[_3;@V\DC1">.&_@MY)8@ZE&DC5T1RJ
ML59T#<_XI_:@^'/@JXF35+ZY@MX+E;.:_.FZBVFQ3-.+<I)J2VS6*;)F\B9G
MG"P3!XI2DB.JZ'Q5_:-^'WP0OK&U\5W\NFK?2PPPW,UE>_8_,F9U1'O5@:TB
M?]V[,LLJ%(U,KA8OGK D_:S^&=E?16-_>7VG7-Q%+);0ZGH^K:?)=F)HU:*S
M2\M(6N[@M+&J6UL);B0NH2)B:OZ=^U'\,+NXOK>[U?\ LJ6PMH;V>/7+6[T9
MEMYIS;QSA=4AM2\1FQ"9$W(LK)&Q#R(&P/\ AM#X*R6?VV'Q-;7%HMS]DGNK
M5)[BWM7-S]E1KV>&-XK**67BWGNWA@N$!EADDB!<>OZ_\4O#'AS0[36I;O[1
M:7OE_9&L8I;Y[KS8S*GV6&S2:6YS$K3?N$DQ DDYQ%&[KGV7QA\-:CX=N==M
M_MTL%K*(9X(],U%KZ*0E,))IXMS?(Y66.4*T )MY$N,>0RR'R#3/VW/@_KOA
MUO$6G:E?7NEQQ32S7EEHNLW,$"P%O-%S)!9.MLZ*OF-'.8W$+1SE?)EB=^@^
M(?[6WPK^%M]HMGJ^JR^9KT4<NEFTL+^^CO5E9506TMG;SQ3.Q=,1QLSXDB;;
MMEC+=_XL^,/AKP3XBTS0=1^W+=ZK*D-IY6F:C/!)(XE8(;F"WDMT=4AEED62
M13%"C3N%A&^O4*^8/!_[9/PE\?\ A#6/%VC:G<W>D:+C[;=1Z5JFV/(#-@&U
M#R^6I$D_E*_V>(K++Y<;!CH:G^UG\,]%\!+X[O+R^@T)I88Q>2Z/JR*1.BO%
M*$:T$IMY Z".YV?9W=EC64R,%/R?K7BS2/@_^V$R7U_J3VESX(N+N&T:;4]5
M=KR\UM#,MC9AKJ5<Q6JN\%G&(XX+=I/+2*%V7[/^'G[2/PV^*5CK5YI&LQ>7
MH,LD6J"[CFL9+)HE9G-S%>1P2PHH1\R2*J9CE7=NBD"GAO\ :-^'WBSQ%::#
M9W\HN[Z*>:Q\^RO;:"^CMPC2/87-Q!';WJ!'64-:23!X3YZEH<O7(:=^V+\+
M=7U2^TBVNM2EU*P\DW.GKH6MF^B69"Z2-9_8?M/E8V[IA&8HS+ KNK7$(D]?
M^&_Q2\,?%O2Y=1T"[^T107,]E.KQ2P307%N^R6">"=(YH)4."8YD1]K*^-CJ
MQ] HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKR_XWZGXBT7X=>);SPXLK
M:M!I&H2V AA$\ANDM9&@"1%7$CF0+MC*L'.%VMG!^4/V7O\ A4'Q;_95T;3+
MG^S;C0(-$AM-8C?;!#!<6\"2WS3D^68)4FW71G)1]S+>))\Z3'/^ ?CQK_\
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M5GK#>!#<:EXAT:X::WOM'MVNX7G2V,(:VN(6O9_E6W?SYA,XC2!;6)\_P_\
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M'$:AI_E\H2(?L\?\G._&_P#[E'_TTRU\_P#[-/\ RCSOO^Q;\6?^CM2K[_\
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M=%6$Z&([FXO;NT%K$C6FG6J2)=SK:QK))-'"H8.9X8B\HT/V>/\ DYWXW_\
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M_P"(WP;\)?%:;3KC6;65KG3)9);.ZM;JZLKJW::(Q2B*YLY8)T21#MEC#A)
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M_#7'PTC\236/V&]MKE].O8T.83<1112M) 2S/Y3K,C!9/GC8M$6E"":3Z?\
M%-SKEII<TFB6MM=WHV^5#>7,EI"V7 ;?-';W3IA=S+B%]S *=H8NOQ!X3_:*
MUSQI^R['\2O!VG:;H'V#3=2NX]-N8)+ZW6WTD742VT7V>73O*W_9DV.%*0IE
M!"_##C_&O[2_QA^'_P ![#XP7Q\/R6SV.C7\VD0V5[YCQWTMK&X34&O@L3NL
MYE4-93"W)$!:Z$?VB7/_ &G]-\<3_M._"3^S]4TV'S/^$F_L_P _3+B;[/MT
MF'[1]IV:A#]J\SGRO+^R>3D;OM&.?K#Q)\5=67Q5I_PYTF]L?^$HETC^V+JY
MN+*X-G#:Q3);-,ELMPKR//<,8X;;[6IAC$LTMPQBBAN_+_\ AH+X@> _B'_P
MKKQ%9:;?ZOJMM]N\/7L"7VF:=>K"N;RTN&9=4>VN[94DG!1KB*6%H5?[-)(@
MDX_X!_&_X^_M/^$M"\6:+:>%M#TG4)=2,LEVVHZE=".&ZFAMU2UC^P1!U,6R
M9S=,)@WGI'!C[,>/^&G[2?QO^)?[/,_Q9\[PW8?9M-U:^^Q?V;?W7VC^SGN>
M?,_M*V^S;_)\KR]MWC;]H\T^=]F@Z#XE_M.?%/P+\%8/C'Y>B+ILMMI.H_V'
M]FNYKC[/?SVT?E_VI]J@C$I2?S-W]G,D+GRMMPJ>=)]/^.O&WCB^\<6_A#PS
M:?8O^):^J3ZUJ.FW%[IPQ<+;I8Q^3=6>;M]S3MNF'E0QKB*;SB]OXAJ/[1_B
M+QI\$OB+K&BRQ:?KO@^77=+FN7M1+;R76CQF1[BW@:9BJ31[6B29Y1;3/L<7
MD<.;CQ^V^+OBK]GC]D_PKXKU;1](\2Z=8Z1H-R83)-ITD$933UL J21:DES<
M13L)7N-UD$,<;Q0!QQ]O_%?XO0^"]9T#PI8O%_;OB66ZATT7$<K6\:V<!N+J
MYG\O:62&/!6!7C>YF>.$201M+=6_B'C#XX?$#X)^+]'\/^,9]-N+3Q1G3M)U
MC3])OHH;/5R2L-OJ%JU]<^9%<;T,#Q74,A:*='1(@US%S_P"^+/QO^.G_"50
M_;O#>G_\([XDU+0/M']E7]Q]K^Q^4-_V;^U(?LV-V[=]HN?-\S9Y<'V?S+GW
M#]D7XWWW[1WPCT'QE?6D5G<ZA%,)HH69HQ);W,ML[)N^94=H3(J,7,88(9)"
MN]NO^/VO^./"GP\UK5/!5I;7FM6=L;FVMKN.XE2;RF#RQ+';%97E>)9%@1"-
MTYC4D*2:^(/B'^U_XX\)_ WP%\1X=5\-B+6;FQAUB9[.XEAMDO<F1K6&/4UF
MFEL"CQ7%K&T\\S)+*%M4AE1?K"\\6_$6U^*/ASPY;SZ1=Z<VD7%[KKK:745Q
M#)'MAMW@(NITB2\G=C!!<*Q\FRO=MS.\9$?A_BG]J#QQX&^',WQ9UO3O[/T"
M"Y5)= O-*N(-:2W?41IRRO<R7RPK*P9;U83:!"C"U$_(O:] ^+/[1W]@_%/3
M/AIIVIZ;HVI7NFC5%O=9A\^WE\R[%E!8V\*7UC))=S/YD@Q)\J0A5BF:9FM_
M;_@]K?BK7_#7G>)X8HM1BOM3M7,-M-:QR1VNHW%M;SI#-+.Z)/!%%.N99 PD
M#*Y0J:[#Q9XITOP-H=_K>J3>19:?;37ES+M=]D,$;22/M0,[;54G:JLQQ@ G
M KY0U/XF?&'7O 2_$/PM'I%U8SV,.L6FA2V%Z]_<6;(LXA%[!=LBWLUOEHXT
ML9HXKEUMM]RB?:I/E_XD?&^Q^,OQ4^ ?C3P9:2ZA'J,7BXVMO.RVC"3[!';R
M+<.^\1I!(K_:'B%P=D4C6\=TQB27W#X6_M!?%OPQ\7[3X=?%>RT2.76M-EOM
M(O= 34OL\LULSFXM':[5@TJPJ9V(:-84$:MYCW,87C_V0/'?CT+\6?$7B"ZB
MUB/3?%.MP26FF:4Z7EQ/IEI901BU'VQDV-;VZ00VC1O,TFUGO9&+;O4+G]H'
MQQ\/+?P5KGB^"V%EXPU+3M)CTRWT^XMK[3+C5('FA6YGN+UTN/L[)]FN0+6T
M=BS7"JAB^RR=AX;^,U\_Q]U#P%J7AVQM;E_#_P#;$6IVMZT\D]G!J+VMM#.C
MV5NT;AIII?+$L\<)D<([F1VKR_X=_%GXW^._B?XW\"?;O#<7_"+_ -D/_:7]
ME7Y\W^T+1KCROL7]J?\ D;[6OE^5M\B;[1OM>?TG]NBX\.>!-;U+Q-#IHU+2
M_&\W@F%S-/I]C=3)<1@74CLE\UC$EN\DTWF-<*!;OB3=*D:GPU_;:_M#XY6'
MPTN]7T3Q-%J^FF[M-4\.1^5#!<0_:I);:Y1M0U -F&W$BNDB.C,BM"R2^;'[
M!X)^*GQ+^-UQJ.O>$#HD'ANVN9;33VO5ENIM7:SGEAN9TN;.Z$5C:22Q^3:R
MF&_E95>[:W*-% _G_P#P2X_Y-B\(_P#<3_\ 3M>5]'_M'>++[P+\.M;U>'1;
M'6K:SL;NXO[*_NFMXY;.*UEDG08M+Q97=5\L0R(D;AVW2J!AOG#]H7]ISQQX
M+_9YL/BWX9CTV#?INF:C/I^HVUQ>;O[3>T1(X[B&ZL]GD_:&+,T4GG84!8><
M]!\5/C%\4_@?JG@^ZUN31+RR\1>)+#0);&SL[N*:U_M!)MKI?R7CI<?9V10S
M&QMOM*@D1VI8!/M^OSP_:CUSQZ/CY\)=#T/5;&TMKV77KI$NM/>Z5;JSTJ9/
M-EV7=L\B&"[DCBBC> 1N6ED:X!CCBY_QK'XJN/VT$B\.2V,%R_P[ >>_BFGC
MAC&NLQ86\,D#3NS!8PAN+<(':;S',0MYO4/@_P#M*>)(M?\ B7H?Q$_LV+_A
M!?LMY+J&E1720RV-U9R7BNUM(US*LL<41>54DE!9_*0-Y0EF^7_&O_!2[_A!
M/#?AGQK-J7AN_LM5N;1+WPYI4_VK5["WN+665I6NC=Q(\L+(GFPR6%NBR2?9
M3."HNG_7^OG#XN_%CQ%I_BK1_ W@V.QFUW4HI+^>6_</;Z=IMO-%'-=S6\4T
M5Q.\KR""SAC:-99O,=YXX[>3/G]Y^T-XJ^!MCXWO_BC9Q#2_#L6G75EJNEV<
MT,>HQWRF+R([:2YN]EQ%=)Y#;[D B:&61+>$B60^+WQ,^,/P)\.OXUU6/2-5
MTFRECFU/2]+L+T7T%G(=LKVUX]V\5T]H6621I;.RCGMXII";/A5/$G[1^K#X
MJ?##2]"EL;OPYXXL=2NA)):W"72K:6 O8I8Y&F10DRRQ Q26X>,(^6)D B/@
MQ\9OB+XG^(/Q'\&ZN-(OKGPK%I!LI;6"ZTV.YDU&REN=L_F7&I-$@94CWQB0
MJ-[^6Y(0<?\ ![X^?&_XZ:IJZZ;HOAO3[+0_%TNAZ@UQJ%_<3?9[%(5O%MD2
MS@225F=I+:XD:% I6&2TRIG?/^%G[5/BK]H'0K;Q?X-O=(EL6U>PM;C0C837
M6K6MG<:NM@T]U/;ZGL@=K=9;]=UH8XHE*%YTB:X?L/B3^UEI>F?$/5?!%GXF
M\-^'9='MK&>ZO?$,CMOFO%E<6D%HUQIPDV0B&>6Z2[=8_-C@^SL[L\/0?L0?
MM2_\-<?#2/Q)-8_8;VVN7TZ]C0YA-Q%%%*TD!+,_E.LR,%D^>-BT1:4()I/;
M_C1\7O#OP%\%:GXN\0/*MCIT2R2"&,R2.SR+%'&B\ O)(Z1J6*HI8,[H@9U\
M ^+WQ,^,/P)\.OXUU6/2-5TFRECFU/2]+L+T7T%G(=LKVUX]V\5T]H6621I;
M.RCGMXII";/A5^?_ -N37-6\?V/PCU[PYJMB=)U+QEX8N+ S:?</)Y]PMQ+!
M<NQN[<M;^6R[K0PPS$Y/VJ/[@_2_PM;:Y::7#'K=U;7=Z-WFS6=M):0MER5V
M0R7%TZ87:K9F?<P+#:&"+\0?M^>(/%^C6?P^M-"U"VM(M3\;Z#8W"W%F;G>P
MN1=VS$B>$B*.:U5Y8D*2S_(JW,"+(LW/_M]?VY9Z'\*O^/:\U)/B!X<_YZ6=
MO-<+'<_]?<D$3O\ ]?+Q(?\ ELR_-Z!=?&+XI_#3XU>$/!7B:31-4TWQ3;:I
MY%SIUG=Z?<6]QIT'VE_,BFO+^.2)D*(NUT<O(S'8L($_S?X__P""D,-IX&O?
M'?A[6O"TMM:7QA@T"6:635M0M8]3%H;D,;BU>Q>:#-Q' ]C>&&)5E>202-'#
M^G_P]\:V/Q*\*Z3XCL4ECMM5L;:_A28*LBQW,*S('"LZAPK@,%9@#G#$<GR_
M]K'_ )(AX\_[%O6?_2":OD#Q9\8O''[/?[(/A+QKX9DTUO[,\-Z!Y]MJ-G<3
M^?\ :8[&V3RY8;RV\GR_-9VW)-YGRJ/+P2WL'Q4^,7Q3^!^J>#[K6Y-$O++Q
M%XDL- EL;.SNXIK7^T$FVNE_)>.EQ]G9%#,;&V^TJ"1':E@$X^]_:I\5?$F;
MQY'X!O=(COO",NJ6JZ)?6$U_J6H2:9$IDGA2UU.V>*WFN'%I!B"<ED$A??+]
MFB]@\;_&:^\&?'#PAX4OO#MC)'XABU:&PU6.]9KJ&.TLX;RZ22W:R41I+)'"
MH6.Z<2"))7"LBQC0\8_%3Q?XG^(;>!_ ITU)=-MH;[6]1U%3=Q6:W2S"SM([
M.WNK::2[G,1F8R20Q06H63]Z\\2#Y?\ V>_%-QX%^-WQXUGQ?-;0_P!FVWAF
MYO9[-9VA\FVTBX=ITB(>5-T2>:UN#.T+,8%FN=@FD\_\:_\ !2[_ (03PWX9
M\:S:EX;O[+5;FT2]\.:5/]JU>PM[BUEE:5KHW<2/+"R)YL,EA;HLDGV4S@J+
MI_I#QC^T#\83\8;KX;>'] \/BY'A^[UNWN;[5;TQM&;U;.UDE6+3PRNK!WGM
M%WB0.H2_C,9\WV"#X*WWBKQ;X5\8^)5TA=6T:Q3S7T^Q83M>/:W-O/&E]-(T
MITS%W,\5H85D\Y8IVN.'A;S_ %3]HJ^\9?%S6?AMX<UC2-%U'18K(N-9M6O)
M-1DO+9[LK8P0ZE8OLM8$5YW/FEC*1Y<*0B2X^C_A/K^N>*_ ^@ZIKMI]CU*\
MTVRN;RV\N2+R;B6W1YHO+E+2)L=F78Y+KC:Q+ FL_P"-'Q>\._ 7P5J?B[Q
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MM2W0?5)K&:\T_3H[2 SEKM89K=B]PVVWMD,T(9W>3S&,(@FY#X6_'S^TM?\
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M#;_L^BBBBBBBL_5M6L= L;B^OKB*VMK:)YIIIG6....-2SN[L0JHJ@LS,0%
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M"]KYSYAB@M_J^OS@_P""BOA/0_$O_"K?[1L+:ZW_ ! T.R;[1#'+FWNO.\^
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M:2W1"AA#*CR7!4NVA_PSUXX_X7?_ ,++_P"$DTW_ )!O]A_8O[%N/^0=]O\
MMNWSO[4_X^_^6?VCR_)_B^R?PU\O_LH>%/B'KW_"V?\ A%/$UMI'G?$#Q+ W
MVO2EU#RG_<[+BVVW-ILE^?YQ<_:X&\J';#'B?[1](:[^QO8VT/@ZZ\,Z]?6&
MK>$);Z:RO+X+J:W,FJ2H^HOJ*2F.6X>Z'G;FAGM3&\[R1E=L:KH>!OV8M?\
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M*/.@95A-PC1QR&SD:7R/G^]^,EOX?_9=\.:W\6?"]SKND2:;HES=RV5W!?\
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M:Y.GQZI8ZQ)>PV]XR&2&.[2XL+!XHIE27%PGFQPM'^^\J-O-7C]<^+/Q%?\
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M9*D=W,(I'PLDRKN/U?7Q!_PV=9_\(9_PLK[!;?\ ""?:?(_M/[7<_;]GV_\
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MS?8[*[^'[V-K+(KG[5=QZVLAM+55!>YN]KH5M;=9+A]Z!8V+J#S_ .S!\6/
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M>,/A!=:WH]Y]CU3PC<P^*K&5MA03:6LDC;U>*8/^Y:4QH5"M.(@["+>#\O\
MQ'\)^./AEXGT#XW>&[#R_$/B[4CHM_8W\-PD$5GJ\4-KHHO\+))9_8GM;!M0
M2)3)/?3SVZ72PF".NP_X**VWA7X/?LF77@A-2B22*QTBPTZ&[N(1=74>GWM@
MKE$'EF9TC57F,284'<552*[#]K#7OV<?CA_PBVA^.KS39M+UNVUJ?2]?BU!(
MTMKFR^S0ND-U'NA^<32.1/)]F,]I'%)#-*8E7P#Q?IWQB^('P5^)F@:7??\
M";Z7IMSHDOA;5'AL;N748;2>VO+N%MI>'4OLHA$3R-$[7MT+J(B67-K#Z?\
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M********************************************************\O\
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M=?,8.\A+96.!(M#X$6Z?MJ_#"W\>:Q?ZWI-UK/\ :$=O%I&N:A9)80PW<]K
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MZ_8^=Y5_%K&HQ3-YWB,6K><8[A1<8A'EQ_:!+Y2Y\O9DU]?_ /!17PU9Z_\
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MM;2_DUB77KR"865FEU9W&FW>JR/%(A(D!EL9);>>&97??_HDJ9_P,^'5G?\
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M"^R216GAX3/_ &C8O<2^<S:0R-M90(]B1X7(;>>:^@/##>*_ 'B^^?4O%_\
M;7ANVTVX;4)]372H)M*OK8VTZ+)+9162B*XL[IYY%F@8PK;QR^>J7"JW7Q_M
M-_!Z:QEOD\:>'VMH98H9)AJUD8TDF61HT9_.VJ[K#*R*2"PCD(!"-CU#_A+-
M#_L/^W?M]M_9OV;[;]L\Z/[/]G\OS?/\[=Y?E;/G\S=LV?-G;S7/^!?BQX'^
M*'VC_A&=>TW5_LVSS_[.O;>Z\KS-VSS/)=]F[8VW=C=M;&<'!_PMCP/_ ,)/
M_P (M_;VF_VU_P! [[;;_;/]5Y__ ![[_-_U7[W[O^K^?[O-=!K7BS0_#6[^
MT;^VM=EM<7K?:)HXL6]KL\^<[V&(H?,C\V0_)'O3<1N7/'ZM\:_ 6B^"KCQK
M-KEBVA01/*^H0SI/;E4D,1"/"7$CF0>4L<>YWFQ$JM(0IS_@/\9M#^/?@?3/
M$VESVS_:K:WDN8+:ZCNOLEQ+;QS26LKIC$L/F!75E1QP2BY KV"BO/\ P+\6
M/ _Q0^T?\(SKVFZO]FV>?_9U[;W7E>9NV>9Y+OLW;&V[L;MK8S@XS_&OQO\
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M8[Q2_.'_  3OTFQT"Q^)MC8V\5M;6WQ$\00PPPHL<<<<:VJHB(H"JBJ JJH
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MO#>MZ"3/IMU-_8TVFQV]^)2;F&5A<NJ/Y4*SS9<)';6LLLGL'[/'_)SOQO\
M^Y1_]-,M?('Q[\6W&B_LAZC/\.KFYU#PW;W,%U!XCU/4YXM7GNV\11W4MS%
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M_&?_ (1G5--L-O\ PBGG_P!HZ9<7^_.DOL\OR=0L/+VX;=N\W?N7&S:=^?\
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MXGUSQ-I_COQ)%J6O?8_[0G\OP^WG?8HC#;_(^CM&FQ&*_NU3=G+;FYKH+?\
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M?LK8-C(T[+;_ *?Z3)?36-N]]%%#<M$AFCAE::-)"HWJDC1PM(BMD*[1QE@
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MQ0_:.\<>(/'WP<B\'6-LVF^*[:_UF..^O[BREF\O1Y)5M[HV\%W''%&EVD^
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MI$$;>.]>U,/+J%JBFSGEM(8KH%I #;R2.D<<W^K=V5%8LP!\ _9X\3_!J_\
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M?:Z1!,ZK>2K<J(7NI)%2'.3Y<=U<;2EK(#X!^SGK.D_%?X=?'KPMX<U&QO\
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MCCC4L[N[$*J*H+,S$!0"20!7YH?L"_%CP/\ \75_XGVF_P#([^(]9_X_;?\
MY!W^C?Z=]_\ X]/^GC_4_P"W7@'[._Q8\#Z7^P/J.EW.O:;#>QZ)XBLGMI+V
MW29;B]DU1[6 QLX<2SJK-!&1OE569 P!-:'PE\?^'?@QXJ^$GQ"UR]B7P]K7
MP[L/!RW\1,EO::E:S0W#)>S >5 C%9(02[,DT,_FI%%!+*OK^D_&CP5X@_;0
MM[[3M3BO+:Z\")IUK-:K)/'=7#ZZ&*VKQ*RW*1KO:>6 R0VX@NC,\8M+GRO
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M559D# $T?M$?%CP/JG[ ^G:7;:]ILU[)HGAVR2VCO;=IFN+*32WNH!&KES+
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M[Z:QN$L98H;EHG$,DT331I(5.QGC62%I$5L%D62,L 5$B$[A\H?L@?%KQ?\
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MSM-+1O"X@M2+2Q2[GNTD26P>%[AEL=UY%*QNI;:*>ZB>YY_X_P ^H?$'X:?
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M+TJV@\0P:)X5O(=8$8;4HIFGTXAX[YMURFP-Y<*I(%@A"01!(41%^W_'6O\
M_"R_VB[?X9:[:6U[X>B\(OX@>TGC\Q+B\.IK9Q_:48F.:*% SQ0NAC$[BX97
MFAM7@\O\0>#K'X#?M">%_"OAZUL8/"OQ"L=7M]5T(6B_8Q<:98^8;J*+=Y,;
MW$316UQ$D2PRQQ,TJ32NDD6A_P $I_">AZ1^SMX?U2TL+:"]U#[;]KN8H8TF
MN/(U.\2+SI%4/+Y:DK'O+;%)5<#BO4/VV_&.O>'O#OA?2M'NHK637_%.E:3)
M))=W]BS1L9;KR([O3UDN+9[I[9+0S+'($2=RP1<RQ^/^"/V?_'OPM^-NG>-;
M6#PMX-\+RV,>DZII.D7CF.]G>2X6SDVMI=A";@W-S;Q1GB; ,22,)FA;YP^*
MWP'^'GP$^-Z^&;73--A\-_$G^SK&^!MVN9=-N!?F=;6%$C_T2TU?R&@M]KJ\
M%U%)>V\D":4D8^W_ -J;5[?X*>!/#7A+PG!_85OXD\2:7X:271Q!9M8PZC</
M)=36RK"\:2LB3(C*JM'+-]H5O,C ;L-"_8[\!> /%OA;Q!X.M8O#[:'%=VL\
M-A"B+J5K<VHA$5[(,33O%+'!<1RSO,=Z.65I9%FB_/#PM\)OB1^V%\$8?$5A
M8^&WU_6KEM2M?$TVJZK]NT]X]7-S]ELTGTN::RBM3&]G'#;7GD*0\\;2>:[R
M^G_$;PI=Z_\ &#X*:=K6OWU]<ZE%KT>MR:7K>I0VLFI:1HRVLLELEK/ EHZ3
MFYCD%K':LQ>:.9,M(E>H:GX6TO\ 9N_:2\#:;X.A_L[2_&=MKL.HZ7 SQZ<D
MVG6=O<17EM9QE(8;MQ$D,L@4J\*G"+*[RMX_^R[9:'\%O _QS\8Z%HNFQ:EH
M/B3QA'9R?9(UV6]E;PW$-GNB\N06@>-3Y".B#&5VM@C N?V9/BW\3_A_X*US
MP6OANP\0VW]G:LOB]]6U*ZU+45-BZ$SO=Z,MR8K@3*QMKB66*.%5M#"855%^
MC]'D\*_M<_'#Q)IVN11:MH7@ZQT633K1Y8;K3;NXUJSGN7U&2(1[)W6W:."U
M\QYH8E,L\8$DX://_9/\+:7X*_:)^-.EZ7#Y%I!_PB8AA#.RQ*VF3,(XPQ;9
M$F[9#"F(H(@D,2)$B(OT!^VAX3T/Q7\$/&/]J6%M>?8]$U6]MOM,,<ODW$5A
M<>7/%O5MDJ;CLD7#KDX(R:_.#XX?"WPQX'_8:M/$V@6G]D:E/X;\/?:I]+EE
ML/MGVTV,,_VY+5XH[[>DTR_Z6L^SSI2FUI7+?5_[3&C:=^Q9\(_'7C[P)%+%
MKM[%IL<]YJ-Y?:G(["YCLH9&-_<3DO!'<N8@<IE4$B21KY=:'[4/[.'A#P7\
M--9\6^#[*VT/Q)X>MIM<M-:MX ]\TUE$\THN;AF$MY]KB$L%R;Q[A9C,TTR3
MN.?F#X3^"?"'QF_:+T'5-8T#30NO_"VR\0ZA9P6XCL[F^O=32266XM\E+GYG
MWC[5YY$D<,Q)FABD3T_X&_!3P%KOQ\^+GAJ\T.QFT32I?#<]EI,D"-IL$]YI
M69[B.P(^R+</Y* W'E><%WHL@664/ZA_P3[_ -"TOXB:7#^[LM,^('B&RLK9
M/EAM;='A=8((Q\D40:1V$<85 SLP&6)/W_11111111111111111111111111
M11111111116?JT=]-8W"6,L4-RT3B&2:)IHTD*G8SQK)"TB*V"R+)&6 *B1"
M=P^$/ 7[('CCX?\ P-NOA1;>+--DLIK:\L4NI-"N/.6WO_M;70(75@C2EKE3
M!( J1+&RO%.9 T>?J'[#OB*UL?!^H^'/&TNA^*/#6D1^'SJMKIXEM[S38598
MH)]/N+J6(NA*R>89&4S;Y/*R+;[+[!JG[)VD^/\ P5K.@^.=7OM?N]<L;*RO
M]1=;>RDVV,CSV_V>&TBCAB2&YEFN(ED6=R9/*GEN841!S_PL_9G^(.BPVUGX
M\^(M]XJL;*6PFMK0Z=962F2PE6>%[JX43WEPZ3103*WVB(N\1$YN4E=#H0?L
MY>+_  +\0]>\4>!_%%MIEEK_ )=Q>Z/?Z2;VS%\JJDE[!]GO;!XI9E1?/Y<S
M2,\DK2'R1!H?LV?LW:S^S_?>(WN/$\NKVVLZO?ZSY<EC!;R?:+YHO,>XDC)6
M5T6!1']GCLX09;AFA<-;K:]_^TC\$+']H_X;:SX+O+N6SCU**,"XB57:.2&:
M.XB8HV Z"2)/,3*%TW*LD;$.O ?$W]F2;XS^';4>)-7B?Q'IM\NIZ1J]GI\4
M"Z9=1&,Q?9[:62X:2W+0H]S;W4]P+ARY#Q!;5;7K]'^$OB36?$^EZ_XQUFVU
M"71OM#Z=!IEG=:;;I-=1&"6>XBDU"^%S*D)>&V),:P)/<Y61Y$:'V#Q3;:Y=
MZ7-'HEU;6EZ=OE37EM)=PKAP6WPQW%J[Y7<JXF3:Q#'<%*-X!^R7\ ]<_9F\
M"6W@Z[UJVU:RL?,^R21:?)9S+YUQ/<2^<S7ETDN6F CV)#L52&\PME?G^Z_X
M)[O+\*-0^%L7C;4D\-MN;3[?['I[31,\B716\G,.ZZB2\3[1$MN+"4+)+!)/
M,GDF'T#QG^S3\2_%_COPKXOD\9::;OPS_:+6JS:!*ZNVJ6ZPW*R^5JL&8H\$
M6BKMEBB$:SSWDJR7$OH ^$?Q+\.^,_$NM^'?%6FP66NW-K>&QU'0Y;O[/-!8
M6]D[QSP:G9.WFK;1EE=65=BA I\QI/#]4_X)^V/A"'PQ=?##Q-?>$]6\/V,N
MEK>F-=26[LYI9;B6.ZMIWCA=VN9GN%8!8T=SB']W:FV^K_A7\++SP)YVH:SK
M5SKNM7=M:6UWJ%S#;6^]+3S7CCBM[2****)9;FYD0,)9_P!\4DN)5CBV<!^U
MI\ ]<_:9\"7/@ZTUJVTFROO+^UR2Z?)>3-Y-Q!<1>2RWEJD6&A(DWI-O5@%\
MLKEN/^-7[.OQ%^-D/A87GBG2+>3P_J]GKH:+0;HK->64LYB!5M8)2W,<J))%
MN:1G1I%G17$49\1?V=?B+X^^(/A3QF/%.D6]SX8BO!:Q'0;J2.234+*.VNVE
M_P")PC%"R-);HA0PAE1Y+@J7;H)?V;;[P5X]U7QA\/=3L=#GUZ)!K%K=Z8U]
M:W5Q"Y:&[18;NQE@N ))EF*RM#<&3S7A\\-*_'_%O]CNX^)OPHUSP7%K_P!G
MN_$>I)JNL:C<6T]X99A)#+MMH7O4^S1)]FMK>VB,DRP6<*PGS92;BM#XU?LZ
M_$7XV0^%A>>*=(MY/#^KV>NAHM!NBLUY92SF(%6U@E+<QRHDD6YI&=&D6=%<
M11Y_Q2_9*\3ZI\0[OQU\//&]SX2U+5;:*VU9?L,6IV]Y]G5$MI?(N9%CBEB1
M3'O4-\A^01,]PT_O_AS2?#?P3MR-4UO?=ZWJ48DO-5FM89KZ^E@CMH(U6*.V
MMS*8+:*&*&WA0NL.\H\IED?P#]C_ .&_A"TUSQ[\0_#$N^R\7:W*\.R<31,N
MG236TTZL-_\ Q\WQOYT*2R1-:O:E%A.^)?M^OD#X1_L]>./AW\3_ !)XUU#Q
M)IM[_P )+]@_M"V@T6XML?V=:/;6_P!FE?5+CRL[@\OF)/OP57RLY70E_9MO
MO!7CW5?&'P]U.QT.?7HD&L6MWIC7UK=7$+EH;M%AN[&6"X DF68K*T-P9/->
M'SPTK^?_ !@_8VU;XG?#;5_!MOXDBMF\17S:GKE[<V-Q>RSW7G6LL?V16U&-
M;2WA6UCMH;=OM(2UCBCWF5'FE^S_  M;:Y::7#'K=U;7=Z-WFS6=M):0MER5
MV0R7%TZ87:K9F?<P+#:&"+X_^T5\ [?]H#0].M/[4N=*O=(U*#6M.N[9()?)
MOK6.5;=Y8IT=)HD:7>\.8S)M"^8H)SP&F_LQ:_:?%.S^(D_C"YGU Z:VE7T;
M6%FL36WVN*^6"Q"*#;1><CHYNCJ-RUK*T:W27"I=KG_!7]G7XB_!.'Q2+/Q3
MI%Q)X@U>\UTM+H-T%AO+V6 R@*NL O;B.)TCBW+(KNLC3NJ&*3T#]D_X#WW[
M,_PVL?!=QJL6JQV$MP8+B.T:T;RYYGN"LB&XN SB223#J4&PHOE[D9WX_P"/
MG[+>J?$OQ?I?CCPAXIN?"OB2PMGTYKV*W2^AN+%R[_9YK2:1(GVROYL;G(#9
M+([I;O >(_V:O$^N^!]9TF3Q9]LUK7]-32-4U?4M-BDW6:V]U'Y5K:6,NGQ0
M;9;R>:%Y#<R+YK1RO<*L1B\_\>_L@>./B!\#;7X47/BS38[*&VL[%[J/0KCS
MFM[#[(UJ &U8HLH:V8SR$,DJR*J10&,M)V'QJ_9U^(OQLA\+"\\4Z1;R>']7
ML]=#1:#=%9KRREG,0*MK!*6YCE1)(MS2,Z-(LZ*XBCY_QY^R-XUOO&LGC?P7
MX\E\,:WJ=C;VNN-#ID=[9W\EM'&D,Z6=Y<.MLZ*K(OSS%8R%5U9KB2XT/CE^
MR#JGQ9^'FJ^#;/Q-Y"Z[<QWFKZAJ.GI=WEU- UF+=XQ:3Z=:V_EQV4,#*ENR
MR1HK86;S)I<_]M/5X=%^ ][H/C+Q%%97WB"6/1(+^PCETVV-U=2LT(G\V:\-
MO9".,_VBTDSA[1+D)\\D<)\_\6WOQP_9GA.JZS\4=(\3W,L3?8_#^I:/9Z7/
MJ312Q-+#I\MG.9VO60^3;((;I&FFC1X271U]0^*7[)7B?5/B'=^.OAYXWN?"
M6I:K;16VK+]ABU.WO/LZHEM+Y%S(L<4L2*8]ZAOD/R")GN&GT/C=^R+-\5_A
M=K7@JV\0RQ3Z]?6][J>J7]I%=7%PUO\ 9PF(K5]/MXG"6=I"&CC">3$VZ)IY
M6N*/C5^SK\1?C9#X6%YXITBWD\/ZO9ZZ&BT&Z*S7EE+.8@5;6"4MS'*B21;F
MD9T:19T5Q%'Q_C+]BC7]/^(>K>./AIXXN?"%[KO.J6ZZ;9W]G.RK'LD2WD\E
M$EW+++)-)YTKR3RE7C$DJR?5^DVWA7X-V-O!>ZE%%-J=\D376HW$*7&H:A<*
M%7<Q\M9+B18PD4$2JD<,:6]O#%;PQ11_.'['_P -_"%IKGCWXA^&)=]EXNUN
M5X=DXFB9=.DFMIIU8;_^/F^-_.A262)K5[4HL)WQ+]OU\ ?#?]C'QG\&=4ET
M_P (?$C4M*\(FYGN8=%33["[FMO.3+107]^ET4B$W[P(8&RI8,6GDDN7]PL/
M@?JVE>)?#)M=1L8O#7AF(QZ=I(L+AKB-AIQL(I&OWU!C(\4<DR(&@*-#/()$
MDN%@NH?/_@[^R_XJ^#?Q1\2^)['Q5$VB>(KZYU"ZT(:?-Y:7$V2+B*XEOYFC
MN&;!N'6,0S@L@@B5+86WS?\ LH>%/B'KW_"V?^$4\36VD>=\0/$L#?:]*74/
M*?\ <[+BVVW-ILE^?YQ<_:X&\J';#'B?[1] ?$']B32];\,>&;3PSX@U+1M<
M\+7,]YINMR2/?7!FO9?-U![Q)71+K[:Q9YU8HI=MH MFEMI?4/AW\%_%OAB'
M^U/$'BV7Q#XCBL;RRM;^[T^UMK6V6ZECE;996/V=G1VM[0S+-<2.QM_W,ML)
M9%/A_@+]D#QQ\/\ X&W7PHMO%FFR64UM>6*74FA7'G+;W_VMKH$+JP1I2URI
M@D 5(EC97BG,@:/H/$?[(.J:Y\-/!N@6WB;^SO$/@[[,-+UZRT]%9%MXOLQC
M>WEGE9HI[<*EU")UBN)41W0PC[,<_P")/[+GQ1^)'BWP[XN?QW8V>K>'XM4A
MM#;>'\VJ#4;46S3+#-J,LIN$!9MTL\MNQ2W M4V3FZ] _9L_9^\5? B^\1O?
M:_8ZG;:]J]_KLT<.E36<D=Y>M%O"2-J%TOV=5C(6)HS)E@QG(7:W/_"?]D6;
MX=?#;4/AM=>(9;KPY+8ZKIMK%#:16]TD&J3322/<W#O<+/<0K*4@>&*TA :1
MI;:8F+R./O/V(-7US0_"FA:CX\U)K#PGJ5O>:8EM8:9$Z16$<RZ?YLDD$_F7
M=OYD:/.56UN((0K:>MP[W1] ^+G[/7CCXB?$_P -^-=/\2:;9?\ "-?;_P"S
M[:?1;BYS_:-HEM<?:94U2W\W&TO%Y:0;,A6\W&6/CY^RWJGQ+\7Z7XX\(>*;
MGPKXDL+9].:]BMTOH;BQ<N_V>:TFD2)]LK^;&YR V2R.Z6[P=_X4\*V_P0TN
M[\1>*_$%SK&I36UC:WFHW%O!$TH@>06]M;6=A"B_-<7<WV:!$GO)9;E;?S;A
MA B^(0>![X?#'X@^,M7U27PK?>*HIM8DO[2P:._TO3[;3XHK.&X1_-F>X@MH
M#)=1Q%'BN;B[2T>)Q'<'Z?\ @O'XUA\%:8GC.6*;6%B87$D<4<)<"1O*:6.*
M2:&.X:+RS<I!));K<&58)'@$;'@/C-^SK8_$GQ%H?C#2;F+2?%&A2YLM3-JM
MTK6\@9)[2Z@+Q&>WECDE50LL4T#N989HRTHDOZ!\)?$D.N7?BG6-9MKS7_[-
MDTJQDAL[JWTZTADD$[-]@?4)S)++,D1N91<1M+#;6\*>1L>27D/V;/V?O%7P
M(OO$;WVOV.IVVO:O?Z[-'#I4UG)'>7K1;PDC:A=+]G58R%B:,R98,9R%VM[?
M\6/ O_"T/ ^O>&?M'V;^U]-O=.\_9YGE?:K=X?,V;DW[=^[;N7=C&X9R/$/^
M&?O%7CJ;PZOQ"U^QUR#P]?6NK6WV+2IM,GEU"TB>.&>YD74+F)D!D>9H88;=
M&F$?(@5[>7G_ (=?LZ_$7P#\0?%?C,^*=(N+GQ/%9BZB&@W4<<<FGV4EM:-%
M_P 3AV"!G62X1RYF"LB26Y8.I\%?V=?B+\$X?%(L_%.D7$GB#5[S72TN@W06
M&\O98#* JZP"]N(XG2.+<LBNZR-.ZH8I/'_AS^P'XB^'.C>$(+7QG%]N\%2W
MLFB7*:.%C*ZG.9+^/4()+V4W*2QDPPFWDL7@#,^^5]A3V#PS^R[XM^'?C7Q#
MXKT'QK++=Z]%IYO#K.F6MT9)[".6WB+_ &%M-06_V>7'DPI!-]HBAF-TT(GM
M;CC_  %^R!XX^'_P-NOA1;>+--DLIK:\L4NI-"N/.6WO_M;70(75@C2EKE3!
M( J1+&RO%.9 T?T_\!_AYKGPF\#Z9X9U34K;4O[+MK>QMI[:RDL\V]M;QPQB
M5'NKO?+\A9Y%:-&W ")-I+<_^T/\"_\ A>FEZ+'#J']GWNAZWI^OV4SP?:(?
MM%B[%4GA$D#R1,KNI6.:%PQ5A)A2C^0>,_V:?B7XO\=^%?%\GC+33=^&?[1:
MU6;0)75VU2W6&Y67RM5@S%'@BT5=LL40C6>>\E62XE]0^-W[/\WQ3\1>&?%6
ME:S+I.M^&9;F2PE-O%=VK+>B&.ZCNK=C&\B201M$IBGMWC,AD#[E7''^!OV8
MM?\ AMX[\1>+--\87-U<:_;6GVK^T["SE:2[L;>XMK5Y&LUL8_LB),C26T,5
MO<22P1M]N2-IHI?/_ 7[('CCX?\ P-NOA1;>+--DLIK:\L4NI-"N/.6WO_M;
M70(75@C2EKE3!( J1+&RO%.9 T?0> /V:?B7\+;C2I]$\9::/L?AO3?#D\-U
MH$LL-PNESW+6MR FJQ2Q2K%<M$ZB5HG8R2%!NB2 \1_L0Z'K?A :=;:M<Z?J
MX\22>,_[2M8XV4ZXXD*SFUN?/3[)&SJ$M X8Q11H]P\AEFEZ#3?V8M?M/BG9
M_$2?QA<SZ@=-;2KZ-K"S6)K;[7%?+!8A%!MHO.1T<W1U&Y:UE:-;I+A4NU\O
M\-_L-^)?A+XJU"\^''Q!OO#>B:K??;[[2%TS3KN,2-,[2"Q:9!#9IY3)#&!;
MRE1%&9&G6..-/8/'_P"R]#J>L^#=<\*W\6DWWA*74FM1=VTNH6\ZZI T5VUR
MOVJVN);AW(G-RUR7DF:6283/*77G])_9M\>Z=\8;?XAS>+;&ZDBTA/#[PS:(
MXDEL%O1=EGEAU&*(7KD;6GCMX[8$EEL57$8Z"7]FV^\%>/=5\8?#W4['0Y]>
MB0:Q:W>F-?6MU<0N6ANT6&[L98+@"299BLK0W!D\UX?/#2OH:O\ LZ7%U\-/
M%7ABVU?;J7BK[;)J6I74,]TIFOXEMYS#;-=*T445NJVUE )V6VBB@#M<,DAF
M\?\ 'O[('CCX@? VU^%%SXLTV.RAMK.Q>ZCT*X\YK>P^R-:@!M6*+*&MF,\A
M#)*LBJD4!C+2>H:1\'OBSX7\2Z]K&F>+]($>N2V-U/:W7AZ>:.*ZM].M[&:6
M!HM7@E"3BV1O*E>81!416+>9)+Y?\0/@KJGP)\#^!?"_PN\0W.D7&FZDT%A9
MW,27=OJTTMO=7,\>HL6A=(MJW5W,\3JL2"4VUI+>+I\<7W_7Q /V,7M?^$QT
MJR\7:E::!XON;[4-1LHK;3VN!=ZAYB78ANYK>4):30ND9A,#7"/#')'>1YF2
M7C];_8T\>ZQX5\$^'CXUL3!X0OM(U*T,N@NQ:?2(3;VZ?N]3B(MWC"O.CF29
MKAII$N8H'AM;?V#X^_LT7WQPL?#NI0^()=%\5>'91<6.L6$#>6DDJQI=H;*2
M=E>WN%3!ADE<J J-++$9XY^O^$OP;U_PE<6^K^+O%%SXGUJ"VN+..ZEM+.PA
MAAN9XY94AMK2-<>9]GM?,:>2X8- &B,*R2QMV'QK\ WWQ5\!:YX8L[V*QDU:
MQGL#<2V[7*QQW*&*4B)9K<L_ELXC/F (Y5V615,;?*'CW]D#QQ\0/@;:_"BY
M\6:;'90VUG8O=1Z%<><UO8?9&M0 VK%%E#6S&>0ADE6152* QEI/8/B?^SC_
M ,+#U3PYXMM[ZVT_QCH&SR-7BL/,AE1T:.ZMIK1Y][VDRR3"./[2)[5I"\5R
M&,IEZ_P5\*M6L_%3^+/$^J1:EJRV)TRW^Q07%E9V]J\RSR[+26\O1]HGD2+S
M[@R9>.WMHU2/RY&FY#]F7]GO5/V<- @\,Q:]]NT73_MBZ?;_ &)(9@MU>/=%
MKR<RR_:)8M_EQ-;I91;6E,D$K-"8-_\ :4_9]TO]I#PA_8ES>W.G7=K<Q:CI
MNH6;NDUE?6X807"!63?MWL&0LI*L2CQ2B.:/D/ ?P&^(.FK'>^+O'4OB75+&
M6XN-+>;2;*RL[6XDM)+5)WMK/RI[AT2>X1E:[2%XYB!&DT<<Z\_XO_95U;XD
M?"[Q?X2\0ZU8W5]XGOC>S7\6FW$$:,OV58/]%74B6>VCM(8H&6>-&$4+7$5R
M_P!I:Z-3_9%F^*/P:7X<_$OQ#+XA:*6%H=6BM(K6^18&5HF+3O>JUP%#PR7.
M%>6WD9'!E:6:70^#/[.?COPIY$7C[QY<^,+6Q^RO86T^GV]FD<UM]R>Y='EF
MO94(1XC<2LJ3J+IEDNDMYH//_AO^QCXS^#.J2Z?X0^)&I:5X1-S/<PZ*FGV%
MW-;><F6B@O[]+HI$)OW@0P-E2P8M/))<OY_^T)X%_P"$;^-WP'\/>%[C^REL
M+;Q-;6+%/M2Q):Z1;K%'(DS;Y8BL8BF'F1SO$S[+B&8I.GU_\/?@[KFD^+[S
MQAXJUW^V-4DMO[/M$MK>2QL;&S8Q22QP6K7-T3+<30I+<7$TLDC".&)/*BBV
MMP'@W]E+_A%;SQ?I\NL?:?#?BK4M4U6]TUK79</+JMLMO<P/>K-_QZ?>DC2"
M"WND<1 WCHDJ3^?_  W_ &,?&?@_2Y?"6J_$C4M4\'"VGL8='?3[".8V<K[1
M:SZBR37#Q>0SVY\@6LBJ5,$ELL:1CU#QK^SMXB;XHI\0?!?B.+0[NXL18ZK9
MW&G"]L]16'=]FFGCBN;*7[1 '95G\UG\M8X5*0B5)L_X1_LU>)_AQ\3_ !)X
MUO?%GV__ (2+[!+>VR:;%;YEL;1[:-%E\V7;:+YKND03[4/+M5DOI]ER;SU_
MX\?#S7/BSX'U/PSI>I6VF_VI;7%C<SW-E)>8M[FWDAD$2)=6FR7YPR2,TB+M
M(,3[@5^8/'O[('CCX@? VU^%%SXLTV.RAMK.Q>ZCT*X\YK>P^R-:@!M6*+*&
MMF,\A#)*LBJD4!C+2?5^K?#>'XC^"KCPUX[2QUF.]B>*\$-K+:V\JF0LA2)[
MFYEB= $*R"=G69!-&T;;0G@&D_LO^*O^$*M_A[J_BJ*]\*PQ)9&*/3YK/4Y=
M/@D!ALY=0MK](2AB1+2Y>.SC>YM?-7]U+*9ET/\ AGKQQ_PN_P#X67_PDFF_
M\@W^P_L7]BW'_(.^W_;=OG?VI_Q]_P#+/[1Y?D_Q?9/X:S_AU^SK\1? /Q!\
M5^,SXITBXN?$\5F+J(:#=1QQR:?926UHT7_$X=@@9UDN$<N9@K(DEN6#KT'[
M-G[/WBKX$7WB-[[7['4[;7M7O]=FCATJ:SDCO+UHMX21M0NE^SJL9"Q-&9,L
M&,Y"[6^KZ**************************************S])U:QU^QM[ZQ
MN(KFVN8DFAFA=9(Y(Y%#(Z.I*LC*0RLI(8$$$@UH444445GZGJUCHL*S7EQ%
M!&TL,(>5U13)/*L,2 L0"\DCI'&O5W944%F .A11111111111117E_Q>^"_@
MKX]>'7\/^+M,BU&Q:6.81R-(C))&?E>.2)DEC< LI:-E+(SQDE'=6] TG2;'
M0+&WL;&WBMK:VB2&&&%%CCCCC4*B(B@*J*H"JJ@!0   !6A1111111111111
M16?JVDV.OV-Q8WUO%<VUS$\,T,R+)')'(I5T=&!5D92596!# D$$&N/\"_"?
MP/\ "_[1_P (SH.FZ1]IV>?_ &=96]KYOE[MGF>2B;]N]MN[.W<V,9.?0***
M*\O^+WP7\%?'KPZ_A_Q=ID6HV+2QS".1I$9)(S\KQR1,DL;@%E+1LI9&>,DH
M[JWH&DZ38Z!8V]C8V\5M;6T20PPPHL<<<<:A41$4!515 554 *    *T***S
M]6TR'6K&XLYFE6.>)XG,,TL$@5U*DI+"R2QN ?EDC970X965@"/'_A5^SKX&
M^"M]?7GAR&^@DOY9I[H3:KJ=W'-/.R-+</%=W4T37#F-=UP5\X@%?,VLP/N%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?/_CK
M]F+P#\2/$]OXFU:/4GU*UW_9IX-;UBU^S>;$L,OV9+:\BCM_-1 LODJGF\E]
MS$D_0%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%9^K7LV
MG6-Q<0VTMU)%$\B00F(22LJDB-#,\40=R-JF1XT!(W.JY8?EA:_$]_VN?V2O
M%GB7Q5X<SMTWQ'J-A-?)I]Q"K1MJ:VQM#&QE66QB5+<W$UO:RNP\Q#)O=Z[#
MX6?M;:3\#_@5X&U+7_#?B"/1(](T*QEUB.UMVM8F:TAA::2'[4+];=9 4$YM
M-DQV& SK/;--] >&]9^%?B'X^ZA<02WP\80>'_L+075G?VL:Z;;ZBYDF@,]O
M%#.DMS(B^>CS*XB3R2$\YI-#QM^U-H_A:WU^]TW1M2UVP\.?:$U6]TJ32S#:
M36D N+B!A=7]K+)+#$R-*(8Y55F\G<;B.6*/Z?K\L-6^"'PZU_\ ;0N+&^\-
M:1<VUSX$?4YH9M/M9(Y+R372KW3HT95KAE)5IF!D8$@L0:] ^".F0_"?]I'Q
M-X%\*-*WAEO#]MJ\]F)I9K72-2FOYL6MK&&\FQ2[BEDO&M2H9R!)%LMT5![A
MXI_:CT_PMI<WB ^'=;N_#L.V1];LXK*:T^SEPKWB0B\%_+:1Y:1IXK1TDMT-
MU#YUJT<S_-_[<FD^%=?OOA'XKL;>QN;FY\=^&(8=2A2&222SD:XG1$N5!9K=
MF(E558QL2' ).:^@/&^L_"O5_CAX0MM:EOH_$VG1:M'HL4EG?Q6LK7-G#)=R
M1W'V<6T[Q6T>P@3LD9E=70W'E>7W_P 1OCOI/@'Q%IWAFUL+[6M;U"*2YCT[
M2Q;M/':Q A[NX>ZGMH+>WW@0H\TJ&:9A%$LC!PO@'C'_ (* ^#?!7@JZ\67'
MA_Q!-::=J]WH6JI;VUG))IM]:R*ACNO],$120NOE3V\D]N2R1M*DSI&WO_Q#
M^,]S\/+'19Y/#.KWLVK2QVZ6MF^EFXAN)%5A!(LVH0K(ZKYCR-:M<0PPV]Q<
M22);Q&4^X444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444445^./[-NK6,/[ -S8O<1+<S>%O
M&,T<)=1(\<-Q?+(ZIG<R(TT2NP!"F2,$@NN;_P"TM_RCSL?^Q;\)_P#H[3:^
M@/\ F][_ +IM_P"Y^OG_ ,<?#C_A&-+\?_%'X5:__H]O<^)O^$C\+:\/M^D7
MEQ;.8K_=!'-OMI95MWNH]Y=YXY;>(_9;.1XC^I_P]\27WC'PKI.KWVGRZ;<W
MUC;74UE-N\RVDFA61X'W)&V^)F,;;D0Y4Y13P/@#QKX'T[Q_^V@EG?2WT4:?
M#L2@V&HWVGR;AKK* 9;&>WE9,,<QLQ0G:Q4LJD?0'CC]F[P[X6^$WC?0?!&C
M11ZCKFD:K$SF0O=7MU<P7)C-U>W4C33N9;A]LES,PC#D;E3IQ_[,7Q(\(:O^
MS3I\VNQ>59:!HCZ1KUI?0"1[=M)M?LU]#=6J^:XRL32>0Z>:\$D9:(&397Q
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M\?>$_$&AZ[:RR6MY!;:!K%_:R20G:9[2XLK6ZB>WD.2F9&*D,H>:,1W$V?\
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MTG$<K,(9BJ^6[^;%OP/VD?V9]6U[]KOPQ?Z3++:Z9XOTB^M=?%O]HE-Q:V$
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M-)%)(D#P^?\ P^_:/\7_   ^ /Q1UFYO;GQ'<>#O%VIZ'ILFL3F69H1=6EO
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M!'XP_LP_$IOV7?V&5^(FF6\M[?+%.!!=WMV]J)&UR>SB9(&D:*%%,PDF2V6
MW)7#R!R)5^O_ -HKX8Z]\)O 6I>./"/B#5SKN@1/K#G5-7O[BQOH[9&DO8;F
MP+M9JDT/FF..S@LQ#<"'R'M8T^7ZO^$_CK_A:'@?0?$WV?[-_:^FV6H^1O\
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MKDLT%K'IFV%M-TH&,1&:QE:1)&E=Y8[LW2;RLD:Q/%"T?A_[0'P_UC]CK7/
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MW,,OG&.Z9I99I?I#Q]XF\6_"SX^?#+PSIVOWTNB:_%K45S878M;A572]*C:
MI=20&_9VD/FS23W,SR/U8*2IZ"Q\5-\?OBYXT\$:@]]9:=X0BT<H--U*[L9+
MNXU.VDN6EFFLWMYPD**L45NLODL6FFF69_LPM?D_XJ>(?%GP[U3XB_#2[U74
MKBRT[PCJ/CCP[J*:SJ,>I6GEI) ;2ZN(GBENXDN6DDMUN))]D*1+,]P=@MZ'
MQ:77OAY^R)IOQ.LO$OB!_$T>D>&[];R;6;]HS)//8A@]D)EL)4\N0Q,);>0S
MC,EPT]P\LTG['5^8'Q+\'ZIX^_;"DTBRUBYT=;GX;-'<75B$%XL+:VX(M9I
MR6\I8I^_,<K+&)%C6*9H[B#S!?AG\1;#Q[XT^"47C3Q!<BZ\/P^*O#FK7.NW
M2WUG<1.+%X+N>&!'DMY[AB7A'F0Q6\:R1Q_:Y#+%U_P@^($OQO\ V>?#6A/=
M:W9>)!K</AN]W:KJT&HQ7\#M)J<KW320.98].%UJ,=O<-+:13+%:>3.\,=NW
MZGZ3ID.BV-O9PM*T<$21(9II9Y"J*%!>69GED<@?-)(S.YRS,S$D_G!^SMX'
MTY?VJ_C'>"6^\RSE\.2Q@ZC?&-FO-+G:02Q>?Y4Z*6/V>.=9$M1M6W6%54#C
M_P!E#X-V?Q2_X6S]KUG6[+_BX'B6"#^R=4N=.^SNWD[KA?LK1^=*<I@7?VF!
M/)79"GF7'G\_\,/VC_B-/^RU\.-02]N;S7?$6MPZ&UZ)].CNQ#%?WA<QMJ:_
M9)[N2UL3:PBY(::XE1R\DYQ)[!\-=&^-7AOXY6$NE:'K=CX&O--,&IQ^(];@
MU2:*\B^U2QW%L6U?49H]Y-O PC;RW4N7AW)',GU_^T+XIU3P-\+/%NMZ7-Y%
M[I^B:G>6TNU'V306DLD;[7#(VUE!VLK*<8((R*^4/^"5FDV.G?LT>&IK>WBB
MDNI=2FG>-%5I9!J-Q"'D( +N(XHXPS9(2-$SM50/J_XXZCI?@_PG>>,;RQ^V
MR^%;:_URUB\YX<S6^G749&Y0P^>&::++I(J^9OV%U4CYPT;X8Z]\<?A-IWC&
MP\0:OI_BO6-(L]8MIXM7OX;""\F@CNH83IZO+8FR1BMO)&]K-)+;!FE>>Z=[
MA_E#QO\ &GQ)\=/AA\'OB'9ZAJ7AW5/$/B[2M#O!I.I72V_DB[OH)BMI*[V;
M^9) )0+B"X8)MMY'GB0[_;_BSX4N_A]\</AKX6T+7_$%IIWB>+Q%!JD<FMZE
M>M-%9V<%U&L;ZA/=-:N65D-Q:&"Z1)'\J>)RKKH:=INN>&_VD[[X?:)XDUNQ
MTN\\$0ZN3+?R:I-%>1:T8/-A?6AJ(CWPEHI$"^6ZD,4\U(Y$X_\ 9)\'^-?V
ME?@'I7BK5?'?B"'7;V6_N;2ZBN(T@L[B/5;C!-I D$5Y;N8D62UOS<PI"&@M
M?L<;8'0?"_XL^,OV@O@UX \7ZQJ$6GZ)+%=KXE:"YO+?4KR>V:2PLUL'TV.*
M17NKY%E>VMO*FD9H;.$S*\D,_0?LZ^.1\7_%OQ(\ /-JXT'1)=#DT][J?6[#
M5HUOK4W$\<MU<RPZEL\^%GB,K!S%*T8=[0PQI\X? _2M8\:_L;7?C_6/$WB2
MZUR#1/$-U;W/]O:I!Y+6<M]Y V6UQ"D^UHM^^Z%Q*=WE&3[-'!#%O_M(CX@:
M_P# 3P+\7=/U;6Y;W3M-T34=>L=-U6^TZ+4K&:&*:\/E6 V12AI"[7$:PB&U
M,[L7$$"1_8$D^D?&_P")?AC5-%U/4CI]OHD6OS&TU'4[*&5+N4#2$GM!-%#+
M%< :A-*I@,^ZSMXKB1+=OL]S]?T444444444444444444444444444444444
M44444444444445\0?&WX3?%/QE\8O!OC'1+'1)++PI_:OE1WFJW<$UW_ &G8
MQV[;UCTNX2W\EE8KAY_-7!/E$D+V'C*V^/OC>&STR*Q\/Z-:2WUJ-2N;;7-1
MN+HZ>)0;N*TVZ59&&XECRB7 E5X@6,;13>7/%Y_\*?A5\8? _P 5/'/C2\TS
MP^T?BF+32+>+6KUFMY-+L);>)2[:.@D2>1D\Q\(;="S+'<,H1C]G7X5?&'X(
MP^,S<:9X?NI->\0:CXB@6/6KU%22_EMP;61CHY(2.-)'%PJL7<)']G17:6/X
MP^-7P=\<?L]_L)Z_X*\31Z:W]F?8O(N=.O+B?S_M/B&.Y?S(IK.V\GR_-1%V
MO-YGS,?+P WW_P"-OA7\2_C=<:=H/B\:)!X;MKF*[U!;)I;J;5VLYXIK:![:
M\M1%8VDDL?G740FOY654M%N"C2SOS_P2^$WQ3\&_&+QEXQUNQT2.R\5_V5YL
M=GJMW/-:?V98R6Z[%DTNW2X\YF4MEX/*7)'FD ,?";X'_$#]ES^T] \#P:;J
MWAF>Y-]I]MJ^K7UI<::TV?M%I&Z6.HI-:;@LT!Q#*CR3>;Y[MYS>_P#P.^$=
MO\%_# TO[3]NO;BYN=1U&_:W@MWO;Z\E::XN'C@547<S;(T^8Q0)%#O<1AC\
MX?LB?!"Q^'_BKQQK.F7<LVB2ZO=6.AVLJKY>GQQ3,VJQ62C:+:WDU+SH# D4
M(<:?!,6N%:&6N?T7]G_XZ_!7Q[X@G^'NL^'Y?#GB75VUN[BU^WNY+JSNKI_]
M--LMF8%G1E"-&LTT8PB1?NR)+F?0^+G[)7B^_P#^$;\5>#M<MD\8Z#J5_J?V
MC4H#]BOVU79'>Q3JHGN(XE@1+6RQ)-+;64,5H)2RQ74/87?PB^,/Q!\*WMUX
MLUC2(O$::1JUGI2:)'>VUG97E]"T,=ZUQ/+/.]Q&@58;B&*VDM8[B^B N!,&
M&?XC^!?CCX]ZIX-NOB!I^B6$OA?4K;65O=%OKBZFGN+=.;=([O3H#:VDTPCG
MF GN'*V\<.&=EN8?M^OE"R_9GAM?CQ?_ !$$L2VEU8V+M:CS6DDU:UBO+%;U
MF+ 1I%I]RUJD*;HIC-),\:3012.?LQ_LSP_L\WWBV598I8]6U>6>P6'S8X[3
M32SW,%@EN6,,"6]S=WQ40 +()1*VUF\J+S_X4_"KXP^!_BIXY\:7FF>'VC\4
MQ::1;Q:U>LUO)I=A+;Q*7;1T$B3R,GF/A#;H698[AE"-S_PP_8_U;6?!7Q%\
M(_$6&Q^P^+_$%[KJ'2-0N)9(6O)(I0FZ:SM0'MI+>*2.3$B3DE9(%12DO8?\
M*G^,_BSX>?\ "N/$E[IILI;;^RKOQ!:7US)J-S8JWENS6-Y8S1+=W=LOD3RM
M>RB&::2ZC\PHD+?9^DZ38Z!8V]C8V\5M;6T20PPPHL<<<<:A41$4!515 554
M *    *^8/VM_P!E^Q_:?\.Z?8FYEL;NSOHG6[MI%AG%G<G[-J=NLODS,$N+
M*29?* $<TR6XFS"K*>__ &CO"7BKX@_#K6_#GAR"QEN=7L;O37>_NYK6.&.Z
MM983,##:W;2.C,I$16,.-W[Y" &\ F_91U;XG_ K1/ /BR:+2=4\/1:>-+U+
M1+ZXG:"ZTVT2&WO@7M[)E<L9 UO\P5&RERLVR6'L-<^&GQ+^.>EZ7H/Q M-$
ML]-@N;*^U)=*NY;]=3:R=9EM&MK[38EM[26X2.:4B:>7RH?LGS+.\Z<_\$OA
M-\4_!OQB\9>,=;L=$CLO%?\ 97FQV>JW<\UI_9EC);KL632[=+CSF92V7@\I
M<D>:0 WS_=?L,?%/_A0.H?!B'Q!HG]EP[GLKU[&[^TW6ZZ345BG07'EV7EW8
M>,S1_;_.MI%(@@EA/G_2'Q0^#/Q%\8>+?A_XZMSI$VK>&)=8,^GR3W5K:R1Z
MK:F +'>"WNI2]L%C4NUJ@NSOF\NSRL \_P#%?[/_ ,=? 7Q)U+QS\.=9\/W%
MSXCL;&'7+37;>[BM3=:?"D$-S9"U,T\:,GF#R)9G$9=BTEP6C^S_ %_\.? -
M]X5FU'4]8O8M0U;4Y8WN;B&W:WB6."(106]O%)-<RQ6Z /-Y33RC[5<7<Z[/
MM!C7S#]J;X*:Y\9M+\-2:)-;)>^'O$FE^(8H;QY(H;G["[AH'FCCF>#<LK,L
MHAFPRA3'ABZ>/_$3X3?&_P 9_$_P1XS^P^&W_P"$6_M=_)_M6_@\_P#M6T6#
MRL_V7/L^RXV>=\WVS9YWD67F?9XN@?X3?%,?M!W/Q'6QT0V2^&[GP];P'5;L
M32;;U[VWGD_XE92+S&$<4T2M+Y"L\J27!18I./\ A+\ OC#X(\*_$O2)FTBR
MN?%E]X@UFPO;#5;UY+.\U.%(X(CG3K=@D++YANXW\P$+MML\CL/$?P+\<?'O
M5/!MU\0-/T2PE\+ZE;:RM[HM]<74T]Q;IS;I'=Z= ;6TFF$<\P$]PY6WCAPS
MLMS#]GZM)?0V-P]C%%-<K$YACFE:&-Y IV*\BQS-&C-@,ZQR%02PC<C:?D#]
MDWX0_$7X.7WBY/$=MI MM?\ $&I^(DDL-1NKB2&2^:'%J8YM/ME9$6-B;@2
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M/U&\N[&XM=4F5$NI8[B.SU#S8I_+\QD<*$=E2)(4B;[1X_X:_9C^-_A3P/\
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M=HLR*N]_$/V"?A-_PK7X>/=_VG<ZI;ZG<R3:5<WQWW":'&Q32(#(3N\K[/\
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M,I#*RDA@002#6A1116?'JUC-?2V*7$37,,44TD(=3(D<S2+&[)G<J.T,JHQ
M#&.0 DHV-"BL_4]6L=%A6:\N(H(VEAA#RNJ*9)Y5AB0%B 7DD=(XUZN[*B@L
MP!T***SY-6L8;Z*Q>XB6YFBEFCA+J)'CA:-9'5,[F1&FB5V (4R1@D%USH44
M444445\P?%G]D/X>?&OQQIGBW7XKF6XLK864UJL["SOK>.X%U#!?0$%9HH;@
M"X2/*))(%$PFC1$7Z/CU:QFOI;%+B)KF&**:2$.ID2.9I%C=DSN5':&548@!
MC'( 24;&A7G_ /PMCP/_ ,)/_P (M_;VF_VU_P! [[;;_;/]5Y__ ![[_-_U
M7[W[O^K^?[O->@444444444445\_ZK^S?X8UKQ?=>(KBZU(K=W.G:A/IZWTJ
M6,E_IAC^RWK1(5?S46&%&B\S[),(());:2:&*5/H"BBBBBBBBBBBBBOF#X:?
MLQ1?#3QWJWC&+Q5K=]>ZU]F_M*.\72?)NOLEN]O;;UM]-@>/RE?*_9WAWL 9
M/,&0?I^BBBBBOF#XL_LA_#SXU^.-,\6Z_%<RW%E;"RFM5G86=];QW NH8+Z
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MJWW_  F.D:Q;:]+9:O?0RMK.EPPM!/)#=769$GM';[)%YC>2TMS)&,11V]M
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M \%?#WPK\-;%['PYI-CI5M)*9GAL+:&VC:1E52Y2%44N515+$9(51G &./\
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M;O;;NSMW-C&3G/TSX(?#K1?$3>([/PUI$&K-+-,;^+3[5+HR3AA*YG6,2EY
M[B1MV7#-N)W'.?XI_9Z^%GCG5)M4UOPEHFH7L^WS;F\TRTGF?8@1=\DD3.VU
M555R3A5"C@ 5[!7G_CKX3^!_BA]G_P"$FT'3=7^S;_(_M&RM[KRO,V[_ "_.
M1]F[8F[;C=M7.<#'0>*?">A^.=+FTO6["VU"RGV^;;7D,<\+['#KOCD5D;:R
MJRY!PRAAR :/^$3T/^W/[=^P6W]I?9OL7VSR8_M'V?S/-\CSMOF>5O\ G\O=
MLW_-C=S6>WP]\*O?7E\=)L3<WTMI-=3&VA\R>2Q96M'E?;ND>W95:W9R3"54
MH5(%9_CKX3^!_BA]G_X2;0=-U?[-O\C^T;*WNO*\S;O\OSD?9NV)NVXW;5SG
M QT'A;PGH?@;2X=+T2PMM/LH-WE6UG#'!"F]R[;(XU5%W,S,V ,LQ8\DFN?\
M"_"?P/\ "_[1_P (SH.FZ1]IV>?_ &=96]KYOE[MGF>2B;]N]MN[.W<V,9.>
M@T[PGH>D:I?:I:6%M!>ZAY/VNYBAC2:X\A"D7G2*H>7RU)6/>6V*2JX'%=!1
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111117/\ BGQ9H?@;2YM4UN_MM/LH-OFW
M-Y-'!"F]PB[Y)&5%W,RJN2,LP4<D"N@HHKS_ ,=?%CP/\+_L_P#PDVO:;I'V
MG?Y']HWMO:^;Y>W?Y?G.F_;O3=MSMW+G&1GG_"W[0OPL\<ZI#I>B>+=$U"]G
MW>5;6>IVD\S[$+MLCCE9VVJK,V <*I8\ FO8**\_\=?%CP/\+_L__"3:]IND
M?:=_D?VC>V]KYOE[=_E^<Z;]N]-VW.W<N<9&=#2?B%X5U^^M[&QU:QN;FYL4
MU.&&&YADDDLY&"I=(BL6:W9B%6908V) #$FNPHKG_"WBS0_'.EPZIHE_;:A9
M3[O*N;.:.>%]CE&V21LR-M965L$X92IY!%:&K:M8Z!8W%]?7$5M;6T3S333.
ML<<<<:EG=W8A515!9F8@* 22 *-)U:QU^QM[ZQN(KFVN8DFAFA=9(Y(Y%#(Z
M.I*LC*0RLI(8$$$@UH444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444444444444444444444444444444445^$/\ P5L\=^+_ !;\
M/([W2]2^S^%8];719+9(RDNH7ULU[]IDE??D6EI-9B"&)D0S72SW!5H8;&:7
M]WJ**^ /^"H__)L7B[_N&?\ IVLZT/#/P&\._M)?LI^%?"FLQ1%;GPMI)MIY
M(S(UI=#38Q#=1A7C;?$S9*AT$J%X7)BD=3\H?\$ZOVXOMOP-\47GCN]N;J7P
M9FYFO+B;S)KJWO/-EMXO.NKC,MV9HY;>)&,2%3:1*6<L1]/Z'^W/Y&N>"(?$
M_A_^R--\>>?_ &%<+??:[@_O+<6GVZVBMUCMOM:7,3)Y-Q=^2[JDVQ1))'\8
M6P\9?$#]M?XF:%-IMCJL<WA9]*>RO=8O+6W739TTTD13PV,\L;RB;S)((XD6
M.:><K<.R"6;T#PUX+^&W[/\ ^U1\._A[9>%Y6N;#P_>1Z7JQUF:1O(FCO[B6
M2ZLS:HAN#.E^JB.40A+PR;,I;PVOO\_[<7B)?C+XJ^%UKX)EU#5-'L7N[,V.
MH!UO&9;:6!)FGM;>&R0Q7(>>::5DB=#!%]JFD@2;T#]F/]K*^_:.L?%MDVA1
M:3XC\,WTMA<:7-?M/&) KK$7O(K78J//#/"QA2X,8A,NUP\:M\@?L6_&#1O#
M7[+?CCQ9\./"T6E-I-]J]ZMEJ.J3WL;R16=O=,[3""-]D4#)#% %4RBW027*
MRS2W0O\ [*OC3Q)/^Q5J>K^(M*MM9LAINO74HGU>ZCN-1ADOM0DU(7,@LV>W
ME*F3RG22Y:=R&>2V)++ZA^S1^T5\+O@=^R9X?\7W%M+HNC017<,%G)=?;KJ>
MX2]N4*1N4MQ-<7,D<DY54AAB#N<0VT+,GL&M?M1^(OA'-X?N/BAX>L?#NEZW
M*MF+V#61?K97TD7FQ6]^K6=HL:.JS*;F![FWB>+]XZ0L)AS_ ,3OVT;[X7?'
MC2OAA/X7EOEU6Q-[:W5A=-+<./*N=L1M&MHT1VGMGB,CW*V\4++=33PQ+*(M
M#]G+]K[5/B[\0_$7P_\ %7AG_A&=?T6VMKPVG]H)J/FPS*C._FP0)"GEB>V.
MWS'9_/X \J3&?#^V9?>*O 6M_$3PCHECK?AK2HM0<O'J[0:BQL4<L9+*6Q\J
M!&*K.!)=?:/L+I<"V:X=+)ON^BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBO/\ XL:!KGBOP/KV
MEZ%=_8]2O--O;:SN?,DB\FXEMW2&7S(@TB;'96WH"ZXW*"P K^<']O7X5?M-
M?#;X6:1#\1O$NB:AH$&I6MK9V6DVT,'D3):7(A*K%IMD%B2%)8P@<J-R@1\
MK^I\'[5_C7]FO7OAW\./B;9RZWK?B.62&ZUNP$<5F)+B_>"T2%?L]NLSQJ\
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M[K5PTB3.DL#^1-]E6\]0K/U:2^AL;A[&**:Y6)S#'-*T,;R!3L5Y%CF:-&;
M9UCD*@EA&Y&T_$'[,?[;</Q\^(OBWP#J>CQ:3JWAR66/;#>2WL=RMM=/:W,B
M2-9VH1(Y/)"A\/()@0@\M\>W_M._M"Z'^R_\/-0\7:I']H^S[(K:U66.)[JX
ME;;'"A<_620JLCQP1RRB.3RRIZ#X#_$/7/BSX'TSQ-JFFVVF_P!J6UO?6T%M
M>R7F+>YMXYHS*[VMILE^<J\:K(B[01*^XA?8*Y_1O%.E^(+S4K2SF\R73+E;
M.Z7:Z^7,UM!=A,L &S#<PON0LOS[<[U95Z"BO+_$WC7Q%I'C7P]H=CH4M[8Z
MC%J$M]J(F$<>GK:QQ&$,AC(E>YDE$:1JZ. LDH5TCD*>H5\H?ME?'CQ5^S9\
M-M1\7:+I5CJ$=G$!+]KNYH6BDGFAMK=DACMY!<())MTR&>T(1,)(6?*?5]%?
M('PC_:%\<?$3XG^)/!6H>&]-LO\ A&OL']H7,&M7%SG^T;1[FW^S1/I=OYN-
MH27S'@V9++YN,-]?UX_\?OC'I?[/_P /-:\8ZBOF1:9;&58LNOG3.PC@AW)'
M*4\Z9XXO,*,L>_>PV*Q'/_#2X^,]MXOU:P\7QZ)=:*EM;2Z?J.F1W-G-),Y<
M30RV<T]YC9MW>8)E4*8MHF:65+3Z HHHHHKG]&\4Z7X@O-2M+.;S)=,N5L[I
M=KKY<S6T%V$RP ;,-S"^Y"R_/MSO5E7C_@OXU\1?$7P5IFN>(-"E\/WUY$TL
MFG33":2!3(PC#OY<1#O&$D:-D1XBYB=0Z,*]0HHHHHKR_P :_%"Q\)^(M"\.
M((I-3UN68VT,LZP*;>T$;WDH9@QD>*.13';Q*\TKLN5BMDNKNVSX/BI_PD7B
M?7O#N@0VUU=Z%;1F[%Q=_9]MY=1+/9VY1(IY1%)$2\MWY?EIE(X5NY5NX[3Y
MP_9C_;;A^/GQ%\6^ =3T>+2=6\.2RQ[8;R6]CN5MKI[6YD21K.U")')Y(4/A
MY!,"$'EOCV_]IW]H70_V7_AYJ'B[5(_M'V?9%;6JRQQ/=7$K;8X4+GZR2%5D
M>.".641R>65/0? ?XAZY\6? ^F>)M4TVVTW^U+:WOK:"VO9+S%O<V\<T9E=[
M6TV2_.5>-5D1=H(E?<0OL%<_HWBG2_$%YJ5I9S>9+IERMG=+M=?+F:V@NPF6
M #9AN87W(67Y]N=ZLJ]!17E_B;QKXBTCQKX>T.QT*6]L=1BU"6^U$3"./3UM
M8XC"&0QD2O<R2B-(U=' 624*Z1R%/4*^4/VROCQXJ_9L^&VH^+M%TJQU".SB
M E^UW<T+123S0VUNR0QV\@N$$DVZ9#/:$(F$D+/E.@^-?Q]OO@UXJ\(:8?#M
M]J.G:_?&PNM1M0QCTZ26:VM[0SCRRFR>>Y5,O+$0%<HLS@1D\,_'V^U?XRZW
M\.[[P[?64=G8I?V&JR!C:ZA&JVOVH1EHXP'@DO(8R(VG!.\NT+!4?Z/KR^/Q
MKXBE^(LOAT:%+_9,6D17[:P9@(S=2W4D*V2PF,%W$<33O(DC",&-71?-B9_4
M******Y_PUXITOQA9R7>G3>=%'<W=FS;73$UE<RVDZ8<*?DFAD3<!M;;N4LA
M5CT%%%%%%>7_ !D\:^(OA]X2NM5\/:%+K^HI+:Q0:=%,(&F:XNHH"3,8Y%C2
M-9#+)(Z[$1&9V1 SKZA117RA\#OCQXJ^(_Q)\;^$=>TJQTZ3PQ%HP(LKN:]6
M6348;BY9O.EM[0[!&L"JGD*5<2DR2*R!/J^BBN?\4W.N6FES2:):VUW>C;Y4
M-Y<R6D+9<!M\T=O=.F%W,N(7W, IVABZ^(?LD_&^^_:/^%>E>-+RTBLY-2EO
MR+>)F=8XX;^XMXE+M@NXCB3S'P@=]S+'&I"+]'U\0:A\:_BG\2=4U>?X8PZ)
M?V6@>)(O#U]::FEW!-/Y*6[W\\5X)%2'R&N##Y36EQE;>6YCDN3)#:-]'_!?
MQKXB^(O@K3-<\0:%+X?OKR)I9-.FF$TD"F1A&'?RXB'>,)(T;(CQ%S$ZAT85
MZA117RA^V5\>/%7[-GPVU'Q=HNE6.H1V<0$OVN[FA:*2>:&VMV2&.WD%P@DF
MW3(9[0A$PDA9\I]7UQ_Q"\27W@[PKJVKV.GRZE<V-C<W4-E#N\RYDAA:1($V
MI(V^5E$:[4<Y881CP=#PGJ.J:OH=A=ZI8_V?>SVT,MS:><D_V>9XU:2'S4 2
M7RV)3S% 5]NX#!%=!17/^+/%.E^!M#O];U2;R++3[::\N9=KOLA@C:21]J!G
M;:JD[55F., $X%?.'[2'QX\5?!/5O"<%GI5C<6/B#Q!I&A&ZENYA/#)>W#>:
M1:+;A'06\3^7+]J4K,ZEH'1")/J^BBBBBBBBBO+_ (E^-?$7@^;08M%T*76&
MU+5[>PN3',(5LK5XII9KV1FC=2D*Q8$9,9E=TB1_-=$?L-9\4Z7X?O--M+R;
MRY=3N6L[5=KMYDRVT]V4RH(7$-M,^YRJ_)MSO95;CX_&OB*7XBR^'1H4O]DQ
M:1%?MK!F C-U+=20K9+"8P7<1Q-.\B2,(P8U=%\V)G]0HHHKY0^!WQX\5?$?
MXD^-_".O:58Z=)X8BT8$65W->K+)J,-Q<LWG2V]H=@C6!53R%*N)29)%9 GU
M?111111111111111111111111111111111111111111111111111117QA^P5
MXGA^)7PK_P"$W,,L-SXGU?6-6N5EN9;EE8W\UK!&)),?)!:VUO;1A%C0)"I$
M:DG/R?\ 'OXJ^*?V>?ASJ/BK5M5N;WX@Z;<P37(TR3Q#<^'8A/J,82SEA^33
M(/\ B731Q^7<"&\/F172NUU-#=2?>'[8&F0ZC\$O&+NTJ26>D7>I6\D,TL,D
M5UI\9O;69)(F1U>*X@BE7!P2@!!4D'T_X3^.O^%H>!]!\3?9_LW]KZ;9:CY&
M_P SROM5NDWE[]J;]N_;NVKNQG:,X'H%?A#\7O[<_9VUWPY\=]+^TSV6G^)/
M%6@:];0^8X.G3^*M6='$:>4APTLN&N)UA%X-/Q&3N)^K_P!IO5M&^.>F>-+Z
MQN);G3O!_@W5IH9H7G-G<ZAK>CS,CHZE+>=[33B&5E-RACUD$&%X_P!YZ!X,
MMO%5U^S=\.QHNI6.F6BZ1X>EUN[O;B:U:/1X["*2_P#LUQ%S!<-&NQ9RT?DH
MTDB303+',G/_  0^+P3X^W?@'0WU=M"?PLNM[?$$>M_;$ODU'[*YBDUO%T;>
M2%XP5&ZW$D68O+D-SYGC_P"R.VG?!7PK\:_&4*7UW)H/BGQ;LMYM4OGCFBLH
M8+@!UFEFB:X<Q[6O9(Y;H@D-(ZY4X&OI^T?J_@WPEXF\%:5X@O?%:RV-[J-Y
M?:]H[Z)J%NUG()HH;*SU@6)MY&>+R)(;2"8Q*)_/%T6F?W_]HJ]\<VOQ\^&_
MA[3/&.KZ=IWB*77)9H+6/3-L+:;I0,8B,UC*TB2-*[RQW9NDWE9(UB>*%H\]
MX?&?[.WQB^%W@BT\9:WK.D:[_P )%]KBUQK"[F/V*Q^TQ8NULXKHXDE).^5\
M*B1KMC78?4/B;;3Q^-=0F\<:E??V/)%;)X?L/#%QXB74,1QDZE<7L&B[9I4\
MV2WC24^;;VZ>2G[B>Y;[1\0?&3XO>(OCO_P3RNO%/B%XI-1NXK6.>2*,1K(U
MMXABM1(4'RJ[K"'D"!4WLVQ(TVHO[745^>'P.TR'6OVC_CM9S-*L<\7A2)S#
M-+!(%?1YE)26%DEC< _+)&RNAPRLK $<?^R'X!E^*7_"P(]?\0^)+NWT?QOK
M>DZ?#_PD.K0_9[>W\@*OG074=S-D%5Q<S3(FS=$L4DMR\_RA\3=9U;XQ_P#!
M/*U\5^)-1OKW5+:)8A,;RXC694\0QVBFZBBD2&[=8HD"R723.K@S!A,[R-^A
M_P 1-83X7^,_!'POTF74EM?&-SJ\MW?3ZOJ%W>0PZ;8+.\-O/>37$T/V@^7&
M9(I4:WC\YX!%=2I=0\?\6;O7OV3?'O@K4M!O;Z_T+Q-J]IX8U+3]7U:_OVCN
M+MV:TO;.2]:YEB= )Q<IYHAF184$(D_TB+S_ ,'^#?'/QD^+GQ0\$ZK\1O%,
M-CH<7AN*WDL)=,L[AENK::]<F2WTY!&XD)4R6RP/+#MBG:9$0+H?!GP#+XJ^
M.WQ3\*WOB'Q(^BZ'_P (XUE9_P#"0ZL-CWFGR32/]J^U?;?O;_W8N! _F9DB
MD:&V:#0_90\*7?QAA\;VWB/7_$%U;>'O&6N:)ID4>MZE:M#:P2I(HDN+6>&[
MNW/F[ U]/<F-(T6+R@9?,S_V<?&WQ+^+/[+7@W6)M?MHG:Y<:_J>IW$MO,-%
MLK^ZBNC%=0@-'=FW@2/[5(R.JF6<W$=SMN%[#X(?%X)\?;OP#H;ZNVA/X676
M]OB"/6_MB7R:C]E<Q2:WBZ-O)"\8*C=;B2+,7ER&Y\SS_P#88^%T,T/Q3.G:
MOJ^G7,?CO7M/CN8KZ6Y9(HI;23<8-0^V6DMP^W9)=SP2W3(S S9((/ ?[8/C
M7PU^Q;'\6-7\K6-;2*X!,R1P1O(^LR:?"SI;)&NR)61F2,1F41E?,1G,@]@_
M:*^&.O?";P%J7CCPCX@U<Z[H$3ZPYU35[^XL;Z.V1I+V&YL"[6:I-#YICCLX
M+,0W A\A[6-/E^?_ (>W]W\9?C[I,0U?Q!I^C>(?AW;>*[G2X=?U)HQ=7NHJ
M=J2F59;=(PZ!?L)LQB(1!5MI9[>7Z _9DUG5M,^-'Q6\&G4;ZZTG1)?#TMA%
M?WEQ?20-?Z:TEP!<7<DUPR.\:L(WD9(SN**F]]WW?117E_Q#^"_@KXK7VBWW
MB#3(KNYT.^CU'3YBTB26]Q&RL&5XV1BA9$9XF+0R%(RZ,8TVEE\%_!6G>/;G
MQW;Z9%%KMU8C3I[R-I%:6W#HX61 PB=P8HP)60S!(TCW^6JJ/QQ^+W]N?L[:
M[X<^.^E_:9[+3_$GBK0->MH?,<'3I_%6K.CB-/*0X:67#7$ZPB\&GXC)W$_5
M_P"TWJVC?'/3/&E]8W$MSIW@_P &ZM-#-"\YL[G4-;T>9D='4I;SO::<0RLI
MN4,>L@@PO'^\] \&6WBJZ_9N^'8T74K'3+1=(\/2ZW=WMQ-:M'H\=A%)?_9K
MB+F"X:-=BSEH_)1I)$F@F6.9.?\ @A\7@GQ]N_ .AOJ[:$_A9=;V^((];^V)
M?)J/V5S%)K>+HV\D+Q@J-UN)(LQ>7(;GS/'_ -D=M.^"OA7XU^,H4OKN30?%
M/BW9;S:I?/'-%90P7 #K-+-$UPYCVM>R1RW1!(:1URIP-?3]H_5_!OA+Q-X*
MTKQ!>^*UEL;W4;R^U[1WT34+=K.0310V5GK L3;R,\7D20VD$QB43^>+HM,_
MK_C'3?'/C']IFZ\ GQWX@LM)G\&W>KJMB=,@DA>ZU5;5HHI!8$A(XT403/OO
M8#N*7:^9+O[#Q1K/C/X-_&[X5^$+3Q1J5_I&M6VKVUW;ZBEA.S_V1I$1BE-R
MMI'=-++)F>X=YG\R4G:$C/EUV'Q-MIX_&NH3>.-2OO['DBMD\/V'ABX\1+J&
M(XR=2N+V#1=LTJ>;);QI*?-M[=/)3]Q/<M]H^(/C)\7O$7QW_P"">5UXI\0O
M%)J-W%:QSR11B-9&MO$,5J)"@^57=80\@0*F]FV)&FU%_8[4?"VEZOJECJ5S
M#YMQ8><;8LSE8FF01O(L>?+\W9NC68J98XI9XD=8[B99#3O"VEZ5JE]JD,.+
MN^\D3S,SNS+ A6*-2Y;9$FYW6&/;$)99Y@GFSS._05\0:!XY\9Z-^U/=^"KC
M7;F^T6?PC)K\=M<P6"^1</JXME2*6WM8)3%'$"B+,\KG)9Y';!'RA\1_B_=W
M_BWQIX3^(U]J_A'6[J76(O".JMJFI:/H)M8+6+["6GM+Q8);C?(;FYDFBE(:
M06K,K"WLE_8ZOG#]KJP:;X/>*KZ&[OK.YTS2-1U&UFL+Z[LI$N+>RG:)B]I+
M"TB*WS&*0O"Q"ED8JN/@#XM+KWP\_9$TWXG67B7Q _B:/2/#=^MY-K-^T9DG
MGL0P>R$RV$J>7(8F$MO(9QF2X:>X>6:3[/\ '7CVX\=_&^W^%$IN;33QX;?Q
M'<W%C>3VEQ.POULX;836YCF@B0[IY&@E269Q%$76W6XANO+[^[U[X(_'#1?
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M#69;Y]4N8DO;]+[4;C46@NIT5YK:&:XGN&%O;M^Y@422#8@=Y)IGEGE]PKX
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MIW>;#9^(K2[A7#D+LFD6U=\KM9LPIM8E1N"AVW_^&L?@A_T/GAO_ ,'-A_\
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M_P#9I_Y1YWW_ &+?BS_T=J5??_[)W_)$/ ?_ &+>C?\ I!#6!^V9K/P\\/\
MP=UV\^(&FW.IZ!']C^UVMFS+-)NOH%BV%9[8C;,8W;$J?*I'S?=;Y?\ B=;>
M.(_VG?@Q-XFNM-D\W_A*W@M].MKB/[-G24+Q27,UP_VO&459EM[+=L9S GF"
M.+T#]GC_ ).=^-__ '*/_IIEH_8%_P":J_\ 92?$?_MM7W_7X0_'O4+/Q/\
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M>&Y[^/?H!\7:%_PD >T^UP_V7'<&>7ST\J4B(S16X.T9D8K!\WFF-_I_Q/\
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MW)-<P:7I_C?0+S5Y8%G=$L8)9)&>X6$,6B698"%96!G$(4&7RQ1_P4J\-?\
M"4_!U(+"39KXUO1O^$?*7?V2;^U)+Z."+R'\V(&40RW!&XXC4-/\OE"1#_F]
M[_NFW_N?H_YO>_[IM_[GZ\?^ /@B+]H;_A;>AS^,-;L_,\7:_IVJ6-O<:3<>
M;;R_Z+#(/M>FSW=M$UK&MG$HF*#[(YB9,&./D/B=X*\*_##X??"7PKX6>^FT
MO1?BMIMA#<WYA,D\D5[?FZ(\I8_DBNFGM@7BA+&!F59(6BGF^C_VA_\ DYWX
M(?\ <W?^FF*OO^OS@^(5V^N_M=6>@#Q)J6B7$G@CS;%[.XT\JS-JDK74*6NH
M65Y&\LR6\$S20B.58K([A)&,Q>@?!#]G+X?_  =\<>--(M[C4M<O?%%M%JNN
MG5EL9+?;<7%['&K1Q6]LA^V,]]F)(Y8E2W99/(#P+/\ -_[.VK7TNK/^S[J5
MQ*T_A+Q ^HJ]R[2W)\/:7<6>HZ.S7 +PM<2W,]G'Y2(B1Z=#<1%+6=;<O](:
M)J%GK?QB\>Z=\/[>VTK7[;^Q7\1:EJL%S?0W.^Q)T^*UM8K^V VPF033%[?R
MV14\BZ\XS6_YP?\ .,7_ #_T-=??_P"WU_S2K_LI/AS_ -N:/^;WO^Z;?^Y^
MO'_&FH6?B3X6?&;_ (5S;VVC:;9W/BN+7O[2@N;RXO\ 5%M&^W/:[;]([2(H
M(O)E/GAWD;-C;K!_I7/_ !)_Y(A^S=_V,G@/_P!('KV#XA7;Z[^UU9Z /$FI
M:)<2>"/-L7L[C3RK,VJ2M=0I:ZA97D;RS);P3-)"(Y5BLCN$D8S%X!^T3\&M
M/_9H^'/Q@3P7>ZWJNO\ B'3;35M:GNH[*98K>ZU&>&9@D%K;A?M$,NINYBCD
M2WBMI)&:TQ;F7W__ (*-_P!A_P##(VO_ -A?9O[-^S:-]C^Q>7]G^S_VE9>3
MY'E?N_*V;?+V?)LQM^7%?H_7P!_P5'_Y-B\7?]PS_P!.UG6?_P %%/ =C=?
M^TTG08XK/5K75]#A\,Q6UPM@T>H&\BMK=+3;)"BNEO)/L7.R%%:8!/)#IG_M
MHZ1<?!OQQX/^-^GS_9XM'N8-%\0EC.R/HM_<",R/'',ID^RS2EXXHXI7DGEB
ME962U5:^G_V=?^)[H>H^+3_S-&I3ZO$5X1K/RXK+3944_.GGZ=:6=Q(DI\Q9
MY90R0\01?0%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%<_P"*?#5GXPTN
M;3KN2YCBFV[FL[NYLIAL<.-D]I+#,G*@-L==RY1LHS*?+_AE^SE\/OA#X=NO
M#FAV$JZ3=1-#)87=[>W]KY;F0R(D%[//%&DIFD,RQJHF+?O ^!CD/^&+_@JM
MG]FC\,VT6RY^UV\T3SQ7%F_VG[6%L+F.1;BPB6<M*D%E)! CO*5C'FR;^O\
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M;2_!>EPZ;IL/E6\6X@%GD9FD<R22222%I)9979I)II&>6:5WED=Y'9CG^/\
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MJ&G7<")$Z):VZ1M&9;CST\R>5DAM_L_X3_\ "3_\(/H/_"4_\AK^S;+^T?\
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M3O$JRQW(\#27VBO$]G)J?V-1')%;/?R.;0-<&XCG:-;I7<P"W1[-?4/VA_\
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M!T'AWP=K\7CC7/BQJGAZY?4)--L]#TO28'LQ?Q6,=P9[@W$C:C_9SRS7,AE
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M3]IT?_6_VO\ :?M?E?VCYOV3ROG^Y]J_A^R[N*\?^.5I\2]=^.6MW>D>!?\
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8*****************************__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex19-1_003.jpg
<TEXT>
begin 644 ex19-1_003.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[@ .061O8F4 9       _]L 0P " @(#
M @,%! 0%!P8&!@<(!P@(!P@)"0H*"@D)"PH+"PL+"@L+# P,#0T+# P,# P.
M# P,# P,# \,# P,# P,_\  "P@&<@3[ 0 1 /_$ !\   $% 0$! 0$!
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M<W#*I1R\?V=U199-#_A4WQ3_ .&B_P#A8WV'1/[-_L3_ (1ORO[5N_M'V?\
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MBKP[\2O ^K6.A^+=+L1975O<-=7.GW]O)-'*UG/*HC;[/$S7#*XM1-,[QO\
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MX8\&:7X9FTW4+W2?%T7C+6+_ %*0Z<^H7R2R32GR[*QN$7SVG9%9LFU@A@A
MN -R>@?$#X3?%/Q]\8OA]XQ:QT2WLO"_V[[1&-5NY)I?[5L8;>X\M?[+1/\
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MO9V=YI\$Z-YSV[QW$ZRWEQ;!$EFM[&"\FB<Q1B,W)6&OF_\ X)]?$C2_AO\
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M;7;:DMI%]HBN;==-NY+BSO+9DCDL+X)&T5E=^;(D*)=RPQR.ZLDKQ$25Z_\
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MBBBBBBBBBOQQ_9MU:QA_8!N;%[B);F;PMXQFCA+J)'CAN+Y9'5,[F1&FB5V
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MO<UQ^I_LR?![6IEFO/!?A^>18H80\NDV3L(X(EAB0%H20D<:)'&O1$544!5
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M^%=:\.KX<O-)L9])6*&$6$MM"]J(X"IB00,IB"1E$,:[<(57:!M&,_P+\)_
M_P +_M'_  C.@Z;I'VG9Y_\ 9UE;VOF^7NV>9Y*)OV[VV[L[=S8QDYZ#0/">
MA^%/M?\ 9=A;6?VRYDO;G[-#'%YUQ+CS)Y=BKOE?:-\C9=L#).!7045Y?XU^
M"'PZ^)5\E]XC\-:1JMS'$(4FO]/M;F18U9F"!YHW8(&=F"@X!9CC).=#7_A/
MX'\5Z'::%JF@Z;>:;9^7]FL[FRMY;>'RHS%'Y4+HT:;$8HFU1M0E1A217'R?
MLR?!Z:QBL7\%^'VMH999HX3I-D8TDF6-9'5/)VJ[K#$KL "PCC!)"+CL-?\
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M!4_-][^T?XE^+?BWQYX/TKQ)?>&O&&C2ZI;Z#H$<&G!-1CL[59+6ZDFU33I
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MX=BUJ2?P_P#\(_J.A7=Y;6-U!&\[7R2I=&:6U+I,5BF"F8 )B/SEF,UO]/\
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M[#^S[NXTVVT/3;.4H;FVL897N9S=M;75S:22W%TY9!"6$5M#;_.)9;B-?/\
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MQ]J1UO)K)9[>X4HT,BS%H!;^4T!+FYES_$/P-\3O\/\ XJZV=*^T^)O'=M/
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M^B:I87-WIE[?1RI;RPZ1J%A<PW,L<JJ9C=P%O^);M+1PW5PTDD31&5TS[?\
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MO^&_$$>B1Z1H5C+K$=K;M:Q,UI#"TTD/VH7ZVZR H)S:;)CL,!G6>V:;[?\
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M/X@\/6PTA4OG-K#?2)9ZI#?P_:%.CR:JL21K97)>6X5(XB(]V0Z@^OZ-X_\
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M<74UNI-1A@M+BXFBDMXI;:WB Q'&&N"SSQ[[A?)VW.A_S>]_W3;_ -S]?/\
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M]HA?V8_!5WXIN-"OM4MK:)B[VLEI''%(TD<-NLYFG28)-+*J;[>&Z,8#NT8
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M#':B8L\0=K:;T#]BWPGXY\ 7WCBW\1^&;[2X]<\4ZOXBM9YKC3)H_(O&MQ%
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MYO"6B:/J7B'5+2V6[OH=*^Q!;%)2! MU->W=I#'+."SPP"1IVB1IC&L6UV^
M/VJ/B+\//C!X8^#_ ,5]%L?,^U>-] C6Z^P,^HK;P2WC36>(DDN)-D\;CR(3
M*DDR[HO-W(S?<&C_ +4>GR?$/2_ NN^'=;T'4M7MKBYL&U&*RDM[G[,I>6*.
M>PO+R,2HBM(R.4VH%W$-+ LNAX@_::T'2)M8EL]/OM3TS0998=8U2Q>P>UT^
M2WB6>Z299;N*ZE>VA=9)UM+>X(),*A[E)($S_B]^U;X;^#?_  C]U>:;J6H:
M7K]S96=GJ>DI:WMN\U]O:%%CBN?MDN8XS*&M[:99$95C,DK".M#2_P!I"T'C
M71O".O>'M7T&^UR*]DTXWYTV:.X:QC26>,-IU]>F-UC?S 9A&C!64.7VHW/_
M !%_;#\&_#B'5-0EM+Z]T?1;Z'3=6U:Q^QRVMA=22PQM#,C727<CP_:(3/\
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MKE?%%]JSV-FT,YN)Y_,O+TQVZQO+%%NC,;WMS;P%X#<>?']'_M8_\D0\>?\
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M[PU9^$]:_:.TO09+G1;+0--TG5]-MM%N[G2X;:\_X1VY=I4CL98$_>,B-,C
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M98TC'J'C7]G;Q$WQ13X@^"_$<6AW=Q8BQU6SN-.%[9ZBL.[[--/'%<V4OVB
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M22%00ID<C<="OG#Q;\)_'K_$6?Q=X8\2V-A'=:1::7<6-_I#W\;M:75U<17
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MQOHWA/3-"UV+3U\/>(%\3O+?6#7TEYJ"SRW)DE\FZL4C26>XN)9XXD5"9%6
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MHOQ)\::)J\JBQTLWLD*Z69)C=6\'^GI''>H@MYIY518_W=PA<%K2.(%E]O\
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M;V-C;RW-S<_#M(8884:222230@J(B*"S.S$*JJ"6)  )-?*'@E?V3OC!\&-
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M@[[?]MV^=_:G_'W_ ,L_M'E^3_%]D_AH^$?[/7CCX=_$_P 2>-=0\2:;>_\
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MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\\/\
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M\2:EH'VC^RK^X^U_8_*&_P"S?VI#]FQNW;OM%SYOF;/+@^S^9<_.'Q"_:/\
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MMX8Q J@[_P -_M&_#[Q9XBM-!L[^47=]%/-8^?97MM!?1VX1I'L+FX@CM[U
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MYC7=<%?.(!7S-K,#ZAXI\-6?C#2YM.NY+F.*;;N:SN[FRF&QPXV3VDL,R<J
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M+\WC/3;S0+'2]6\-7SZ<+)]5FE:>01&2*>3=I\,L%E<@H;6Y\J8SIYKK#^Z
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MLW*$VQ@3YI0Z6LA_P5"U;PKX)_9HUGPXEQ8V$D\6G0Z=8!X8&DCM-1LBZ6L
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MMSMW+G&1GG_&L'B?QY;^&;WP7KUM:61U*TO[VX2.*[6\TL02R-! 2KI_I+&
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MN]"TO7M-O-2L_,^TV=M>V\MQ#Y4@BD\V%':1-CL$?<HVN0IPQ KH/%/BS0_
MVES:IK=_;:?90;?-N;R:."%-[A%WR2,J+N9E5<D99@HY(%<?>_&_X=:=X=MO
M$=QXETB+2;J4PP7\FH6JVLL@+@I'.9!$[@Q2 JK$@QOQ\K8ST_:%^%DNJ6VE
MKXMT0WMW]F^SVPU.T,TOVM$>W\N/S=[^<LD;0[0?-5T9-P92=#3/C?\ #K6O
M$3>'+/Q+I$^K++-";"+4+5[H20!C*A@60RAXPCF1=N4"MN VG&AXZ^+'@?X7
M_9_^$FU[3=(^T[_(_M&]M[7S?+V[_+\YTW[=Z;MN=NY<XR,FO_%CP/X4URTT
M+5->TVSU*\\O[-9W-[;Q7$WFR&*/RH7=9'WNI1-JG<X*C+ BL_P5\;_AU\2K
MY['PYXETC5;F.(S/#8:A:W,BQJRJ7*0R.P0,ZJ6(P"RC.2,\!X3_ &I? 7C/
MXHZUX LM4L7OM+BM1@72"2:ZD^UM<VL43!3(]I';QO<-"THC,S1R")X7!]OT
M#Q9H?BO[7_9=_;7GV.YDLKG[--'+Y-Q%CS()=C-LE3<-\;8=<C(&17044444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444444444444444444444444444444444445^4'_!7+X,_$/XN
M_#32&\*P7.HQ:=J0GN]-L[59YI?,B:**Y3;F8^06>-HH5?>MR9G 2WW#Y@_X
M(U_ OXE^$=<UCQ?J=K<Z?H%_IJ6\,=R98?MLSR0W$%S%"P EBCA,@2Y.%/V@
MK"TF9_+_ '^HHK\X/'$/Q?\ @[\8O$?CSPO!;>+] O\ ^R[36-*MYV.KZ8FG
MV,TGEV43S"%LBY%Y]F_U]S)=K&D$?F&[;P#XH)\-/&'P\^ /BCPC;>=%'XN\
M*:/:WU[;1)J(M+)KF$VT\JHI^2:%O,2,_9VF4R1[D*N?K_\ :E_MSPQ\1OAC
MXN3[3<Z1I6I:G!?6-EYDUS++J&G26]O<0V2?/=_95^T23"!9;J&V:>6.&2-9
MRO'_ +,'[..C:1\7/'WQ)31(H;/6KZTN-%DO[2>+4(I#;2_VI.([Z)+FT2XN
M;B5 I\LR(C$1BU-NTG@'[+NDV.G?\$^=7FM[>**2Z\/^*YIWC15:60-?PAY"
M "[B.*.,,V2$C1,[54#/\"^$]#TCXA?LQ:I:6%M!>ZAX;O\ [7<Q0QI-<>1X
M7M$B\Z15#R^6I*Q[RVQ257 XKZ?_ &A_^3G?@A_W-W_IIBKG_CMX3T/2/VL?
M@]JEI86T%[J'_"4?:[F*&-)KCR-'C2+SI%4/+Y:DK'O+;%)5<#BN@^'?B/2_
MB/\ M6^-[36A;27OA'3=(M]#C>1R\4-_;-<:C<Q0O(R>:[36]O-<Q1JRP""
ML!(WFGQ6\ ?"#X0[;:?5=2M+C5?&^G>)DTS3KE7EO=8N,FUM)$D5E6TO+C3W
ME7[5)#;BZB8K=6\<*K%S_@7Q'XXN?VPKBS\06]MI_F_#])6M=.U&XO;>3R=;
M989I#+:6/[U/.G11Y3;$=BLG[UU70_8!TFQAOOBU?);Q+<S?$37X9)@BB1XX
M6B:-&?&YD1II6122%,DA !=L_"'PR_Y-B_9\_P"RDZ?_ .G;5:_?ZO@#X=^(
M]+^(_P"U;XWM-:%M)>^$=-TBWT.-Y'+Q0W]LUQJ-S%"\C)YKM-;V\US%&K+
M(("P$C>;X_\ M[_#?PA\*_V=OBC::'+MN-7U+3_$-[;-.)&CFO\ 4[*%I50_
MO$BG>TE==Y9?-$ZQD1H(X_0/VZ/">AZ-_P *>^QV%M!]A^('AVRM?*AC3R+=
MO,S!#M4>7$?(AS&F$/E1\?(N./\ B/J\,7PQ^,L7@0RZ[;2R^)7U^^UK4);=
MK2^&G_9Y[*PC6PD>X2S@AB")*8;<(T$45Y,/-%KQ_P =?^*]^"'[/O\ ;O\
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M@"^\SPAXIL/$%S<1ZGHC+-'%?ZC<311(VH*=ZQW%OY9<J)':96\I8D>?[O\
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MM$O-!U+1KW3[:RO'BU%M/??#>R74<3QM8WEXGWK.8,KLC#"G!#9KU#5M6L=
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M%N9;&2VU&*RMKB6\@CWRVL<9O&V2INC5OM)MXP\BKYGRRF/T_P"$/Q.7XO\
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M)NVXW;5SG QV&DZ38Z!8V]C8V\5M;6T20PPPHL<<<<:A41$4!515 554 *
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MWKR^0GM_[36J^(M/^/GP.O(],BN=12+Q3)+9070VLW]E0&>.WGFBA61U7?\
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MM$:6XF%[<S7$L68F1WC:950-))(9$:V6U]_\"_%CP/\ %#[1_P (SKVFZO\
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MDV.B_P#!.VSAL[>*"-O#_AB8I$BHIDGN]/FE<A0 7DD=Y)&ZN[,[$LQ)]_\
MVY-)L= L?A'8V-O%;6UM\1/#$,,,*+''''&MPJ(B* JHJ@*JJ %    %>?\
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MK4O&-SJL?B,PSRL[;YYX(K-G,SSP10V3Q):P"1?)@=9$PTID?G_&6@:'X/\
MC=^SWH6B7?VNRTBV\5:3%*9(Y6/]GZ1%9LLC1A4\U&A9)@%7;*KJ54@J/4/@
M]X_F\3?M/_$[1=4O8I9-&L=!BTBWD,0D@M;BT^T7Y@7 <I)</;&YD&2Q6T21
MML5NJ?,'QX^#/B+5_BM\1? WAC7)="TGQ;X6L=6N&EQ%IZ:W=:O%811[XE0P
MOJD=O+!. SRWCS3.T=UY<<*^_P#PL^,WB*7XLZ#X>^*^ARZ/XM:QUVTTNXTW
M$VB:G:O/:7$KPN6EGBN%2P1_)G*%(@9)-DEU;P)\X? [X$>+_P!K;]F(6/\
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MK^-(/[,U+1O$,&I6EQKNEZD(V^S7$FF6UI&;6:(>7/:2)8YAESOEPT^Q(9H
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M_P!F&P)O^*?V>]/U;Q?-XMT36-2\/:I=VRVE]-I7V(K?)$08&NH;VTNX9)8
M&2&<1K.L3M"9&BVHM#Q!^RKX"\3_  VUCP)>02M9ZU++=ZA<1LD5U<WTTRW#
MWTCQ(B&X,Z)*!Y8MU") L M46 >O^"O"<WA"Q>"XU.^U2>64RRW5^\1D=BJH
M (X(H+>%%1%41V\,*$AI65IY9I9.PKY@TG]F*+P?JFMWGA?Q5K>AQ:UJ4VKW
M5K9KI,\)O+A(UGE0W^FWDR^88P[)YIC5B0B(F%&?\0_V+/A=X^\%:+X5ALI=
M'AT"6.;2+O29/L]Y82)(LC/!<,LC;Y67=,T@D,LF)V)N$CF3K_AO^S?X8\ :
M7+9WMUJ7B.6>VGLI[KQ)?2ZI-);W#[I8,3DPQ12 1I-'!%$EPL,)F$KQ*P\@
M^&_[ _@3X97$L-KK/B2YT5O/$6@76LW#:1$L\_G-&+6/R_.B.7C>&Z>XBGCD
MD$Z3,Q:O4-3_ &;[2_\ BROQ)B\0ZO;:B+&'2S;Q#33:FQCG6X:V*RV,DVR6
M52\D@E%P"[+'-&@15/A1^S?:?"KQKK_BX>(=7U2^\016L=^+\::(Y&LXQ%;R
M!;2QM2CQQ[HP$(1P[,Z.X1U^CZ^</B-^S1I/CSQ[IWCJSUK5]#UNQL9--^TZ
M7-;[9[61S((;B"\M[N"1$=GD3]V#O8.Q9HH#%Q_AW]CW3_"/B?7/$VF>+?$D
M&I:W]CDNY_M-E+NGM(C"DVR:RDC.4DG7[,ZO8Q>=F"U@:VL3:9_AC]B?0?"?
MPKF^&UKXF\0#2?-MIK1Q-8175C);W_\ :(>UN(+&)P[W #LTWG% H$1BZUZ_
MX;^!UIIWB*T\0ZYJU]XAU'3XIXM/GU2+35:R6Z""Y-N+&RLU#S+'&CR2"1U1
M3'&T:2SK+XAJ7[ _@0^.+SQ7HNL^)-!EU*Y6\U.UT;6;BTM[^;[1+.[W&-TW
MSF9T*PRPK&A/E")RSGL/&O[)FF>+?%NA>([7Q%J^DR>'8IH='M=-BT>.UL([
MBUCM)DABFTV8LCQQ@;9FE$9)\H1J%5>_^(WP(TGQ]XBT[Q-:W]]HNMZ?%);1
MZCI9MUGDM902]I<)=07,%Q;[R)D2:)S#,HEB:-BY;D->_92\-^)/#&MZ5<ZE
MJ2ZAKES87E_KEN]K;ZI+-ILL$EFXE@MHX8_LXMXXXEB@14 >0#[1++,_7^&_
M@=::=XBM/$.N:M?>(=1T^*>+3Y]4BTU6LEN@@N3;BQLK-0\RQQH\D@D=44QQ
MM&DLZR^(:!^P/X$\'^)[O5="UGQ)I&GW=S)>2Z'I.LW&GZ69I8A&SK%9^3,G
M*K(%2=54JL:@6ZK"/4/BI^R_X5^)LWA>ZM[F^T&[\*RL^DW&B20VS6\;Q+$]
MN(I(9K=K=TCC5HFB(*)Y7$+RQR<_I/[).DV'Q%M_'USXD\07NK)8II\[375O
M''<P1W0NHT>.VM8!"BR)$6BL_LT,XB(GBF^T7OVGZOKP_P"*_P "-)^*NLZ!
MKQO[[2]6\/RW4EA?6!MS)&MY ;>XC,=W!=6[I(FW)>$NA12CIEPV?XP_9UT/
MQ)JFCZUI^HZEH^KZ1;&QAU.QGCENY;-D(:UNWOXKQ+R(MMF'VI)9$N%\])%D
M:1G[#X<_"?2?AS-J-\DDM[JFJRQRZAJ5TENMU=M!$(8!*;:&WA"0Q*L<4<44
M:*-TA4S2S2R>H5\_^.OV==#\;>.+?QC'J.I:9J2::^C7$FG3QQ?:K![A;@V\
MC21220X<,5N+)[6[3>Q6X#+&8^0\%?LK'P+XMUWQ3:>,O$$FHZ_%#'?R2IHA
M65K:UDM;60(NE*J/;J^^,(%1W5?.29-R-Q\?[ _P_OO"'B?POK=]J6L6GB/4
MI=:F>^-B)K;4I@1)>VCVUG;^5*WRY4AX=J^6(A%+/'+ZA\(?V9M&^%$R75QK
MGB#Q%=Q2R2P7'B+59[]K<R1>4?(B.RWC<(9%$ZQ"XV3SQ><89&CKZ/K\\/\
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MJU&IM/9ZG;M&^&BN_LD4T;QRQ2QW$3VGG)'&UQ$EQ$'*<?\ "']I;XE_&O\
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M>?:3Y1T<!9K>90"\$Z MLE3<,C)5E*R(SQ/'(WL%?E!X:^(/B?P+^T3\;/\
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MPP_IG_"P?LW_  CWV;5?MWVO=LV?VO=;=NS]YYN_9Y'D_O\ S_+\G]]LK0^
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M(7JZ;H<]K#<6L@G<3)?2&9[- %>:WCCN$#I.NWL/^%L>!_\ AB'_ )#VF_\
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M?\.M%A^*<UYXETB"-O'>O:F'EU"U139SRVD,5T"T@!MY)'2..;_5N[*BL68
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M'-M>26L\]\=0U'2K[28!/<&WEU6"^#VES"L2&"X,Y6:2:6)K;:%EX_\ 8Q\
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M37"S_4&@>.?&>C?M3W?@JXUVYOM%G\(R:_';7,%@OD7#ZN+94BEM[6"4Q1Q
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MIIWMY(9WA@O;N(6P2:-9(X#-/*D44D4,8S_B=\.K/X>_M._!B.ROM2GMYO\
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M;?PY)J&AZE?64-U-#?Z?#-<F&W>VC;S$E*!98V5&WRQ);B7RH_I_]I/1M0^
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MNUC^@/BK^S7I?C7X&ZK\-[;]_P"?ILD,$]]*ZM+?+^_BO+N6!59Y7O%6ZNI
MA,\ID=T?>RMY?\7/V+8?B3X*\)Z(U]$]WI.KK?:E>%);:34(-0DE_M^%9()/
M-M$U$7,\KP0MY)(CML1PA7B]_P#C=HGQ%U)= N_!$UB+G3]7CNKNWU&YNK:W
MNK,VEU;RP,]M%,V_=-'+%OC>-)HDF9',:HW ?#GX#WT?Q9U'XHZ]:6.FZM=Z
M1'HAM-+N6NX)(TG$[7=Q<2V5E+)<,$@MT7R\10VXS++YB);EE^S/#:_'B_\
MB()8EM+JQL7:U'FM))JUK%>6*WK,6 C2+3[EK5(4W13&:29XTF@BD<_9C_9G
MA_9YOO%LJRQ2QZMJ\L]@L/FQQVFFEGN8+!+<L88$M[F[OBH@ 602B5MK-Y47
MG_PI^%7QA\#_ !4\<^-+S3/#[1^*8M-(MXM:O6:WDTNPEMXE+MHZ"1)Y&3S'
MPAMT+,L=PRA&Z#]DWX0_$7X.7WBY/$=MI MM?\0:GXB22PU&ZN)(9+YH<6IC
MFT^V5D18V)N!("3M7[. 2R^?Z+^S_P#'7X*^/?$$_P /=9\/R^'/$NKMK=W%
MK]O=R75G=73_ .FFV6S,"SHRA&C6::,81(OW9$ES/]G_  W\"_\ "!Z7+%-<
M?:[V[N9[Z]NBFPSW%P^YB 6D=8HEV6UK')),\%G!;VYED$(8\?\ &[1/B+J2
MZ!=^")K$7.GZO'=7=OJ-S=6UO=69M+JWE@9[:*9M^Z:.6+?&\:31),R.8U1O
M$(_V4O\ A8WB_P 3^+_%EO;:5>^(/#<OA6>WT6Z^TJ]O,29;R2YGL+5WNROD
MP1*T+)#%;KN><2+';\?\(?@C^TCX4\.IX!UKQ-X?7PY9V,FF6VI:?;7Z:V;5
M3Y,.PK-!;6EPEL<17 ^U&"6.(NEV=\K=!I/P0^(N@?'VW\;V.E>'[;1+;P^G
MA6&TAU*ZCDCLX]1%RERD2Z4(5=8@$6R5Q&I 4704;J]O_:=^"G_"^_AYJ&A6
M\WV74DV7NE7BOY3VFHVK>;:SI,(Y)(<. DDD*^<('E5"&;-=AHWA*^^%7@+3
MM \+017TFDV-G86B:E=M;+)';)'"#-<06MP5?RU+92W(=P%VQJVY?C#X0?L=
M>)(_V;;SX,^-QIJQ?9KB*VOM.N[JYS-->3WL<TD#V]B4^S3-"RQB:5;C8RN8
MT)5NP^$/PK_:1TN%/"WC7Q1I%[X?MHI(!J5BM_'KUY$DO[I9IF98;9Y(ODGN
M(C-=*H/ESBZ<:A'S^B_L_P#QU^"OCWQ!/\/=9\/R^'/$NKMK=W%K]O=R75G=
M73_Z:;9;,P+.C*$:-9IHQA$B_=D27,_J%W\+_BGX US1-3\*7.FZIN_MF77X
M]4NKNP%[<:A):RP30F""^V_9/L_V6U%R+A[;3E2S61_]<OC^O_!KQQ\$M+\:
M_$'PU>Z)H7B+Q)J6DW=U:2QW%[IH2T<0_9H7@M8+J:[U"261Y'2U>>>:Y%I!
M"+IDOF^__">HZIJ^AV%WJEC_ &?>SVT,MS:><D_V>9XU:2'S4 27RV)3S% 5
M]NX#!%>(?M<_!"^_:.^$>O>#+&[BL[G4(H3#+,K-&)+>YBN45]OS*CM"(V=0
MYC#%Q'(5V-X?\??A-\;_ (U?\(JWV'PW!_8?B33?$FS^U;\?\>'FK]C\S^RV
M\WS=WF_:]D'E^9]G^R2>3]JN.@^('PF^*?C[XQ?#[QBUCHEO9>%_MWVB,:K=
MR32_VK8PV]QY:_V6B?Z,PD,.YQ]J54+?9"["/S_X'?L]_M!_LY8\&>&=>\-S
M^#K>YN9;&XU:RO;C5+>&?=/Y+0VLME;RXG9@9&F5F#M* B^7:Q_=_@#P58_#
MKP[9:+9O++':Q!#-.5:>>0DM+<7#JJ"2XGD9YKB7:#+-))(WS,:\_P#VCO"7
MBKX@_#K6_#GAR"QEN=7L;O37>_NYK6.&.ZM983,##:W;2.C,I$16,.-W[Y"
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M7I<VI:E-Y5O%M!(5Y&9I'$<<<<<8:2665V6.&&-7EFE=(HT>1U4^7^&_VBO
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M@/QCX=^ /P'CUV?Q)?>,K'1[&XN9]6AD.IW%ZR2R-,R-$\H*)(7C7?*4M84
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M  KFWMM&TVSN?%<6O?VE!<WEQ?ZHMHWVY[7;?I':1%!%Y,I\\.\C9L;=8/\
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M2ZL(V9D<VY@1!=1J2LH,43*[/&C9_P"SQ_R<[\;_ /N4?_33+7P!_P XQ?\
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M[^$$^D2;=?@\71>2([OR)CI8MY)]7PAE021>3!$)^&)5E@'_ !\>7*?L"_\
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ML&DWLVH_MH6]Q-;2VLDOPR21X)C$9(F;703&YA>6(NA.UC&\B$@[79<,>/\
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M^R_LWS_%EW_;:>'[V=I?L=EMM(O[0EN8XIXVFS;G,4.P^=(@B\^R#FY3Q_\
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M58K([A)&,Q?9_P"SU\"/!O[/WQ%\66^D7^KZGJVOQ6VMZO/?FS\N-I+J\$!
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M\-> ;Y[ZR^W3W+1&$3:EJ>HZG)'&S*SI"^H7%PT*2,D;2K"4$QBA,@<PQ[>
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ML<H>UNH&CN+=R\,99H)(RP0*Q*\5P$?[(WPCL+Z6]TS08M*FEBBC+:--<Z6
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MU'P_;7EW';"SEFNC).UY"J0JJ:@9';^T=GV>!XVO_M+1RQ),A650]> ?M#?
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MF6QN=.$UUKVM74D=O=-$TRP/<WLK6[NT$3>; 8YE,:%7! K/\ ?LQ> ?A?\
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MQ:6?V<26DDT_T?JVDV.OV-Q8WUO%<VUS$\,T,R+)')'(I5T=&!5D92596!#
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M7C7Q3X6?0K[2+GPW%I9N4OY+1I#)J,<\RJ!9SW4.Q8HXG#B9BQE9#'&8LO\
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MSPAXIL/$%S<1ZGHC+-'%?ZC<311(VH*=ZQW%OY9<J)':96\I8D>?[O\ B?\
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MTVNK%:3:9#=:=J4SC[4CK>362SV]PI1H9%F+0"W\IH"7-S+G^(?@;XG?X?\
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MLS (80%/[\L54_=]? 'Q]\/^/M9^.WP_\3:3X0U+4--\*_VW]IG@N='C\_\
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MMH9=5U*ST^WBN)Q#E9KF&.YN"Q5@L5I#(UQ+(^R(;4B:6-YHR>@U"#Q/XO\
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M<J0JWE,D\;U\W_"+XT/\._C%\3](\>>-=^FZ-_PC-G87&N7&GV2AKRQN[V1
M(8K.V,KEGRRQB5XHD5BZPJ5^[],^(7A76O#K>([/5K&?25BFF-_%<PO:B. L
M)7,ZL8@D91Q(V["%6W$;3@\%?$+PK\2K%[[PYJUCJMM'*87FL+F&YC6155BA
M>%G4.%=6*DY 93C!&?(/@C^U+X"^/FLZ_IGA_5+&YDTF^DMHQ#=)))<P106K
M27:185_LZW%P]LLRB2&0Q"1)6610/7_B%9>(M1\*ZM;^'+F*UU:6QN8[">8
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M36M_?:+K>GQ26T>HZ6;=9Y+64$O:7"74%S!<6^\B9$FB<PS*)8FC8N6P+_\
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M*Z3N3+*CS-)(Y\9OV0/"OQNFT/4[_5-7L-=T:+R8==TFXAL=2>-HFCD226&
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M)_$<WB;5[G3KF74-?U1+]+"2,7$BI-=7@%EI\,^_9#@0QL8<%ML!<J1Y_P"
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M-I!)*$0@HH8M)&K>H5Y?X!^-?@+XJWU[9^&-<L=6DL8K>6X-A.ES'&MRTRQ
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MS6T?/ZQ^W!H\FO\ A/3?#?A[4M?M_%7VJ33;VRGTM(;F&TLS<7)A%Q>Q2++
MY2&:"\6R96$^&>2$12_3_P +?$7B?Q7X8M-0\3:'_8.I2^;Y^G_;(KWR=LKH
MG^D0A8WWHJ2?*!MW[#\RFO$/#?Q%\&ZG\?=0T*?PU?6/BA?#_FKJ%T+-XY])
MM]1>*,0/!=SO&DMQ,\GEO%!+(%0S*#%"J\?X,_:6^)?C;QWXJ\$6W@W35U+P
MU_9S7,[:_+]A9;^W:=%67^ROM/FXV[5%JT3!9R\\3)"MR:!^VMI=_P"&+NZU
M#3/LFKP^+I/ \=DMP\UO/JXE"1!+L6ZNMHRL)9)Y+9)(T255MYI%B2?U_P '
M?$OQQK.N:_X?U30]-M=2TW3;'4;9;;5KBYMY_MTE_%''+,^FV\D&U[$[V6&X
MPD@8*S*4/QA\"OCUXB\?_LP:AXM^('A^76-)U*+7);P:5?![C[#+=ZDUX'BO
M9;,V]O;1J+>VCM[R[N##Y>U8]F!Z!^U;\;[[P3^R?+XP^']I%86UWI&G"U5V
M:TDL+/4DA@B:WCM,JMQ L\:Q(DL<<)'FB200K#-[!\6?V@?%7P8A\%'6- L9
M)/$7B"T\/W*VNJS2+:27LK""6)I-/B-RGEH[RAEMBCA8U\Q6,JZ&@?'S7+GX
MWW?PTU31;:WVZ))K]M>VVH27'F6XOQ91I+"]G;^5*W,CJLDR)@*)),EE\?\
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M_:(7]F/P5=^*;C0K[5+:VB8N]K):1QQ2-)'#;K.9ITF"32RJF^WANC& [M&
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M>/\ BWXITOQS^T#\ =;TN;S[+4+;Q1>6TNUTWPSZ+!)&^UPKKN5@=K*K#."
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MF*1F"W.T21C#A1^[U?F!_P +8\#_ /#;W_(>TW_D2/[&_P"/VW_Y"/\ ;_\
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M_C2]BTRT\<V.CWNE7UP3%9[M(M)+6YMI[F4)%'< E957+)Y;QAI$FFBB?/\
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MY?M_BG6;SP_I<UY::;<ZG+'MVVMFULLTFYPIV&[GMH1M!+MOE3Y5(7<^U6\
M^&G[4NA_$3X*S_%7[#<V^FQ6VK7WV?,<EP;?39[F/.-RQB61+??Y>\HCOY?F
MNJ^8WO\ X3U__A*]#L-4^R7-G]LMH;G[->Q^5<0^;&K^5/'EMDJ;MLB9.UP5
MR<9K0U:]FTZQN+B&VENI(HGD2"$Q"25E4D1H9GBB#N1M4R/&@)&YU7+#P_\
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MY6\BN;/[0T$1ECE#B599B)5,42)'NDN(O/\ ^R/BT_[1?_"QE\#7(TU_"/\
M8J12:GI8N%=-3^V2"95N7C25D206R127$$CO:B>ZM%ENFLL_X#>$_C!X \*_
M%:WA\,WVEZMKFK^)/$6B3S7&C31^;>0QBR@<1WMP%N/,7<PD0VH"G=.<A3H>
M(_@IJ_QX\=^#?%Y\&7/@K7](U*VU/4]5:?3)3<V\=OY<^G++IU\\UUYQ$,"R
MW4,2)9K/]W>;2?G[/P/\?OV5_B'XKN_!7ARV\8>&?$^I7&M+:-JEK87EE?7"
MPM<.\L\,:-%*WF)'"@N"(X8F,D+^9]HZ#]ISP-\6O&W_  A21:%<ZS<:7XNT
MGQ1=M8SZ7%9VUO:><CV%JUY=6ES/*@VOYT\:I<2222!K6-DLK;T#XG_"WQG;
M?$OPY\8?"]I<SWL6FIHNL:!++81S3:=/*T^(9W=K=;NTGD$TB?:%AN5A$:74
M8S]HS_B+X"^(/Q:UF7QS;:/+I&H^&_#^LV_AJSO6LFO#K&HP;#=.]O?75A]G
M6..&""*<MNDEN9)DC2*W9^/\1_!35_CQX[\&^+SX,N?!6OZ1J5MJ>IZJT^F2
MFYMX[?RY].673KYYKKSB(8%ENH8D2S6?[N\VD^?X&\*?'C]FGQ[XKTWP_P"$
M['Q1H7B?Q!-X@BU ZK%I;6,FHN%N(KJ.1;F65(0D94V\3%D!<;Y)?L]OT'QH
M^"7Q1M9O"7Q#T2&+7_%?A_5]0O9=-EOO)M9+/5XOLL]G:R3+&B/:6ZV\4$Q%
MK',8I[V:UDNKAX7S_BKI'Q:^(7QB^'7C'3? US#9>'O[=BECO]3TN*;S=1L4
MMXGE6WN;I$M VPM+"]U=;5N#]AS';B[^D/@%\5_&OCR^\1:-XOT"+2M1T6^,
M7F65U'>6<]O.TDEMLF4AUN%@$;SP3QPS>7+;71AA2[2&+Z/K\H/AO\+OBU\,
M?V9=0^%$O@ZYO+U=-U_2ENK:_P!+$,TNH37C6T\ FNXG-H%ES</<"VNHF:%8
M[.X#3M;'QB^&_P 4O'?[)5C\,[+P5J0UI=-TC3'$EYHBPHVEM82/*9!J1S%-
MY<JP;0TNZ-O-BA5HV?L-:\.?'#X,?%SQ!X^\(>#XO$ECXTL=,DO-.FU&STV\
MTRZTZV2!(WF>6>WF1D>0L8/-!DR Z)$KW7V_\.=$\503:CJOB6:(7=]+&([.
MUN9KBULK>"((D43R16PE=Y#-<RW!MX9B9UMF:6&TMVKC_P!J33]?\0?"SQ%H
MFA:1<ZK>ZOIM]ID45M+9Q>6UU:31K+*UY<6R")6*A]C22_,"L3 ,5\0TSX :
MC\;_ -F.U^&'BFSOO#US%I&FZ7(\CV-PWGZ=%:NEQ']EN+A)+<SP@%'>&9T5
MQB$LDE&K)\:/BG\+KCX?ZYX?ELM8U"Q?1M0UZ2;3;G3&C?-O=7T45O>6]Z7N
M+?S)K: V<(CNI8H90D"22CC_  G\-_%?@;]HNPUO2_!6I0>&=/\ ",/@ZVE^
MV:4^P0:FLD=QM?4FN&M%@4'<RM>'&#;E\BN@_P"$?\??\-3_ /":_P#"(:E_
M8O\ PC?_  C/VG[3H_\ K?[7^T_:_*_M'S?LGE?/]S[5_#]EW<5G_!C3/B)X
M5^-'Q'\7:AX'U>&Q\2Q:1)9@W6A-(K:5ILL3QRJFJ,%>:3;';E2Z9=6F>! S
MKX_X1^"GQPU'X??$_P -:9IU]X5U;Q+XIOO$6F:G-J-G%'%!<7MB_D/+IEW=
MW4=PT,4P8)$T)&4,_P V#Z!XD\!?%SQ-XY^&'C"S\#6.EVGA>+4K0:3'J]MY
ML!U#3!:+Y@B@%K%96TT2J'M);NX:U=)5L5F5[1/0- \%_$'X3?'#XA>)[3P[
M+K%CXHBT&:VEMKRRA6(:99RP7,,PN9HI1<.!FU5(WMY7>))KJT0S30<?^SA\
M'?%=WH?Q/\*>,?#FI:19>,-;\0ZG'=?:=*DVVFK1Q0+%_H]W=.EV%WOS$]NN
MWF5B0C=A\(4^-'P5\!)X!D\/RZO?:3%)INDZZLVFIILUNJ8L)KRW-Y;WT"6Z
MLD%W%##<S%8'DBFN7D!/E_Q8_9DU_P"'7P\^$_@[P5HESK,7A3Q)I>M7LMO-
M9P;ULFEDNG"W][&1+=37$DL4*.\4?SH9(D6(-Z!\4?#_ (^\=_';X8^)K7PA
MJ4>F^'O[4^W3S7.CC9_:^GPPKM1-1>1_LS[ENMJG_5L;?[2I0O\ =^K7LVG6
M-Q<0VTMU)%$\B00F(22LJDB-#,\40=R-JF1XT!(W.JY8? '[*VF?$3X00^/G
MUCP/JX;6/%.J^(K-(KK0G:2"^EMDC@/_ !- JW"J'ED#$0A(V"SO*4C?R_X.
M_#?XI>!/V2K[X9WO@K4CK3:;J^F(([S1&A=M4:_D242'4AB*'S(EGW!9=TB^
M5%,JR,G0>)?@K\3_ !C\$/AOI]GH'V76O FI:#J,NGZE>VD7V_\ L6P*-':W
M%G)>Q+]HE81PM<&';AGD6-0N[U#PE\._BCK7[2(^(NIZ+8Z=I)\++H@1M3\^
MZ DOY;U6:.*V,0N(RD<=S"LS6Z"8/!?7>QT'A_COX*>/OVI/ F@Z?XK\&7.@
M>.;3^S1_PE@GT=Q:/97 DEN(Y=/OH[QO-C\Z2&T2!8([R=!NC6,7B?0'CKX?
M>._#O[1=O\0-'T;^UK*X\(OX>"QW=O;_ &>[&IK=I+=&=E=;1E;#26L=Y<+L
M?%JY\M9/M^OSP^#&F?$3PK\:/B/XNU#P/J\-CXEBTB2S!NM":16TK398GCE5
M-48*\TFV.W*ETRZM,\"!G7P#2/@'\<+GPKXI2TT*6QDN?B)=>+WTZ^U*SBCU
MC2+F%Q)I,KV4U[%OG*)%/#=@6;"129)%5POT?IO@?XKW'[1=G\1+KPY;0Z?>
M>&VT#RUU2.26T5=3BOO.OAY*A96A:5$@L3J$7VJ-8VNTMY/M:=!^T3^S'JGQ
M-^)?A3Q1HUU]E0_\2?Q$AC29;S14E_M(6TBRS*HBDN+<6DR1(SS17SB7S+:)
MX7Z#]M+X.>+_ (M^$-)N?"#6S:UX:UNQ\1V5M> ^3=S6 EVVSN)(_+W^9E6+
M*I91&SQ*YFBT/ &L?&7XN364OBOPW%X.L[.^%Q-!%K2W]U>K#$3%$3:01)#;
MF=XYI'%PSRBU:TEMGM;J1C]7U\ ? SP_X^_9VU3QW9W/A#4M8BUKQ=JFOVEU
MI5SH_DFWOT@9$87VHV4RRH49)5,6P,,I)(A#'Q_Q)^R7\2_A?_PB7C[PM;:;
MK/BK2M;US7-9TZ.26UM[^;Q'Y<5X+.:ZG(A^S0HD,!EVK(D?VET,P:WG^T/A
ME/\ %'XAWVGZYXPTF+PS#:17)72;?5?M\DUQ*PBCENI8(;>$)#$LIBMU>[AF
M-VDTBPW%G#CY/_9E\,?M#?LPZ7!\,8?!VFZUI&G7-Y]B\0/K2:="]O.[W:^?
M:B&^NA+YDCQGRXRBL50;XT-U)T'Q+^%_Q&T#XG_"G6;72=2\41>%;;6Y-6U"
M*XTZ%[FYU6T\DF&&^U"$I^^5I3 I6VMH)(X+=BD8BC[#3/"?CF__ &K&\92^
M&;ZVT0>%IO#HO);C3"IGCU)KQ9Q%%>R3_9Y44+&3&)@[J)((U#NOW?7PAH/[
M*LVA?M :[XFM8(H?#FJQ:7K-U$&B7S];LS>PQJ($3:UNBS#49FF'FG5/LMU%
M,3%*B:'['_[->J? 6X\10ZES:6VI7EGX<A65)H;319Y_MZI"S+]H666>X>.]
M:9V>9K.V&7B@@D;G_@%X?\?:-\=OB!XFU;PAJ6GZ;XJ_L3[-//<Z/)Y']F:?
M+#+]I2VU&>0>8Y"Q>2L^=P+^6H)&?^S5X<^*G[,>C7_PZ7P?+JFDZ;?7(\/Z
MK#J-@D<MK=SRW*C4Q++%<1/"\NV>:UM)BPW^5:R>4C7/SAX+_9<^-2?LV^%?
M#B:1;:=XA\#ZW%XAL;>^NH)TU&XM[R^N?()M9C'#$R7,0CE>=7DG66&2.UA$
M=Y)]O^%O$GQJ^)=O#>^)?"7_  C%OIURUW)8V>N07U]J7V> O!;(T4=K;P12
M3M'(SO>+YAMC:3P_8[J5ZX_]BWPGXY\ 7WCBW\1^&;[2X]<\4ZOXBM9YKC3)
MH_(O&MQ% XM+VXE6XPK,P"&$!3^_+%5//^,O@A?7?[3EG?:/=Q?V3K%C:ZMX
MHL2K%FN-"E T2<S#S'A=[AD:&%3:PSIIET6-SB:.OT/KX@^-7P^\=^$/C/X>
M^)_@[1O[>W:;+X<UFQ^UV]O,EBURMY%<V?VAH(C+'*'$JRS$2J8HD2/=)<1>
M?_V1\6G_ &B_^%C+X&N1IK^$?[%2*34]+%PKIJ?VR03*MR\:2LB2"V2*2X@D
M=[43W5HLMTUEG_ ;PG\8/ 'A7XK6\/AF^TO5M<U?Q)XBT2>:XT::/S;R&,64
M#B.]N MQYB[F$B&U 4[ISD*=#Q'\%-7^/'COP;XO/@RY\%:_I&I6VIZGJK3Z
M9*;FWCM_+GTY9=.OGFNO.(A@66ZAB1+-9_N[S:3Y_P 8/AQXP_:&\)>(O"/C
M3X>2WU]]NUJWT'7&N-%,%M;W%TSZ==,R7<5];)$HMUN8H8)YIH;<&1+AY7@'
M/Z;\+/CQ^RK\0=1U[PQH\7Q!MO$.D:+:Z@\VH1:7>17FBV4=DL[R7<LRRI<K
MYDS8\R0R.59T$0>ZZ#]L#X6?%SXJ?"/Q-H<6CRZGK'B.6R$-O8:A;'3]+M]/
MN;258C+?2Z<TKSLES<&XCM/.+RK:RL8+6UD/0?M4Z9\1/B_#X!?1_ ^KEM'\
M4Z5XBO$ENM"1HX+&6Y22 ?\ $T*M<,I26,*3"4D4-.DH>-#XSZ9\1/%7QH^'
M'B[3_ ^KS6/AJ+5Y+P"ZT)9&;5=-BB2.)7U10SPR;H[@L43*,T+SH5=M#X!>
M'_'VC?';X@>)M6\(:EI^F^*O[$^S3SW.CR>1_9FGRPR_:4MM1GD'F.0L7DK/
MG<"_EJ"1G_LK:9\1/A!#X^?6/ ^KAM8\4ZKXBLTBNM"=I(+Z6V2. _\ $T"K
M<*H>60,1"$C8+.\I2-_ /@?\ _CA\-OA]\,(KC0I9(_"-]JYUC07U*S4ZBM[
M>I/975N$FEL9GL6D-U$MY+;.EQ;_ +HHS1S'Z?\ @=\._BCX.^.'C?Q)KVBV
M,5IXJBT:8SV6I_:8+8:;9W%JT.9;:VN);AW,$BK]GBMQ"\K&Z,T203_/_@W]
MD_XD^(/V7+SX(:G8Q:7<VT5T$U2:XAFM;J==:.H6HMH[=Y)_L\J*5GFN4M9K
M<M&4M;HF18OI#P%XD_:&^,&EC1_%OA*V\(+_ *&M[J%OKB7$TZ!P]VEE;VD<
MCP>>L;6_F/>Q3V:W*W$$L\T'//\ PY\+_$;]FOXA^,[33_"ESK_AGQ#J4OB.
MVN["]TY;R"^O5C6[MIXKZYL4,6Z,O T98QQ[%9YWD?[/H?L6^ _B3\-[[QQ;
M^*M!BT^/5O%.KZ['/'?PW,;K>M;B%+<1J)70"*9I)+E+-U!M]L$C2S+:_=]%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%?('PC_9Z\<?#OXG^)/&NH>)--O?^$E^P?VA;0:+<6V/[.M'MK?[-
M*^J7'E9W!Y?,2??@JOE9ROU_1111117/^+- _P"$KT._TO[7<V?VRVFMOM-E
M)Y5Q#YL;)YL$F&V2INW1O@[7 ;!QBO$/V=?@%??!:QN9]<\17WB76[V*UM[K
M4[TLA:WL5=+2"*#S)%C2-9)'D8L\UQ<33W$LCM( GT?1111111111117/^&O
M"VE^#[.2TTZ'R8I+F[O&7<[YFO;F6[G?+EC\\TTC[0=J[MJA4"J.@HHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKG_%F@?\)7H=_I?VNYL_ME
MM-;?:;*3RKB'S8V3S8),-LE3=NC?!VN V#C%>(?LZ_ *^^"UC<SZYXBOO$NM
MWL5K;W6IWI9"UO8JZ6D$4'F2+&D:R2/(Q9YKBXFGN)9':0!/H^BBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBL_5M3AT6QN+R996C
M@B>5Q##+/(512Q"10J\LCD#Y8XU9W.%568@'\D/A/!X!_;4\3^)Y/&&F:E_:
MNG^-YUTB_M-.UBSEL[/1XK8V]NVH>2/L/F>7-)/9RS6\BW5S)-'#;W<D#K]_
M^*?VH/ASX*N)DU2^N8+>"Y6SFOSINHMIL4S3BW*2:DMLUBFR9O(F9YPL$P>*
M4I(CJO0?$C]H'X:?!^XBMO%'B33=,N)?(*075U%',RSS^0D@B+>9Y6_(>;;Y
M4:I)([I''(RZ'PJ^-'@KXWV-]?>%-3BU*VL;Z;3IIH5D\O[1"J,ZH[*JRIMD
M1EEB+PN&!1V%=!XU\>:-\/K%+O4Y)0LLHABBM[>>ZN)I"K/L@MK:.6>9PB/*
MRQ1N4ACDF8"*-W4\%>/-&^(-B]WIDDI6*4PRQ7%O/:W$,@57V3VUS'%/"Y1T
ME598T+PR1S*#%(CMV%>'Z'^T5X&\1ZS8:5:37S2:C*\5E.^E:G'9W3)!+<YM
M[Z2U6SF1H89)HI(IF2:-=\;.I!)9_M%>!M1OO$=A:S7T]WX:EMXM3MH=*U.6
MXB:Z9E@*0I:M+<)(%+K);K*AAQ-N\DASP'CS]JWPU#\$K_XD^$Y9=3MFL=0E
MT^1-.U&:-[BUCN,?:(XX5F@MQ+;LDL\WD0J!DS(&1C\W_LM^%OA:-#\._%9=
M.UN'7[/PW8V^JSVVDZW'_:4VHQPO+<RQ1VH.KRF822/<Q"Z4^8+F=G\NTFA^
M</A3+\*_VCOAMI7COQEJLOA+QE/+K\Z>(U2_TJ 3WLU[;00+J<I@AO4M8FB^
MS6:WKS1PVAM@PMDNXF_8[PG>Z'X4\#V%Q_;7VS3;/389/[5O;N.7SK>*W4_;
M)[KY8WWHOG23\(V3)PIKS#PW^UM\*_$\UI&FJRV:WMC/J5K+JEA?Z9!<VMO$
MDTTUO/J%O;PS)'$ZS/Y3N5AS,1Y2LXO_ +/ T.XTO6KW2/&/_"5Q7VMZA>FX
M2^CO(;3SW62.P@,<DHBBMX3$!%O^\S2A8TE6-"U_:C^&%[JFGV,.K^8NIW*V
M5E>I:W;:;=7#([+!!J8A^P2RGRWC$<=PSF9&@ \Y3&*&K?M9_#/0O%5QX5N[
MR^CUB&)YEL3H^K&XGC28PL]I&+0M>)N5V#6@F!ACFG!,$,LB=?X/^._@SQY;
MZQ)I=Q<R2Z+C[?9R:??P7T&Z 3QYL)H([QO-C^:#9"WGD,L6]U91P'[)W[2%
MG^T[X,_X2""UN;?=<WFQ9K&YMT-N+^ZBM=LT@>WGE\B%/M7V6:9(IRRMY>52
MOH_5M6L= L;B^OKB*VMK:)YIIIG6....-2SN[L0JHJ@LS,0% )) %>?^"OC#
MX:\?7SV-E]N@N5B,PAU+3-1TR22-657>%-0M[=IDC9XUE:$.(3+")"AFCW>8
M:=^V+\+=7U2^TBVNM2EU*P\DW.GKH6MF^B69"Z2-9_8?M/E8V[IA&8HS+ KN
MK7$(DT-,_:S^&>O0L^F7E]J$D<LT-Q;V&CZM=W5I)#*T3)>VMO:27%DY='$:
MW<<)E".T8=48CO\ 2?C1X*U_P5;^,['4XKG1[F))(;B%9)#(9)!$D21*IF:X
M:4B!;94-PUP1;B(SGRZS_ OQW\&?$37+C0M/N+F+4K>V2]>SU'3[_3;@V\DC
M1">.&_@MY)8@ZE&DC5T1RJL59T#9]G^T5X&U&^\1V%K-?3W?AJ6WBU.VATK4
MY;B)KIF6 I"EJTMPD@4NLENLJ&'$V[R2'/(:C^V3\)=+\"6/CJ74[EM OO.\
MJ_BTK5)85\FX%JWG&.U8V^9CY<?V@1>:V?+WX-;]K^U!\.;G5-/L#?7,7]IW
M*V=C=7&FZC!8W<TB.\26VH36R64_G*C-;-%,ZW(V^29-Z;N0US]J/3M)^.MG
M\-!:7S,VD27UQ,FF7TR^;-=VL%IY<L*.HMPKW'VJY=!:Q.(HS=)*D\2_5]>7
M^-?C#X:\ WR6-[]NGN6B$QATW3-1U.2.-F94>9-/M[AH4D9)%B:8()C%,(RY
MADV^8?$_]IK0-#^#%]\1/#$_]J6[Z;=76G2V]G>7D+S1VTTD8N5MD,EO$KQ%
M+EYS MNP:.62&3@?/_[&7PP^'/B^W\+_ !%LK'4K7Q)#X;L[?4[E[74=/AU&
M:^@CFFN9WFAABU.4RI+(;E7N%D:59Y6D=;.2+[?^*OQ(TOX/^$-5\4:I%<RV
MFF6TEU,EG \\S+&,D(B_^/.Y2*-<R2R1Q(\B_(&H?'#PQ\=/@;HTNO\ C+_A
M!KW7;;39I;LR2Z)-OB^QWEZNFO?M \D3*Y@2ZA:X@"R@[K@!D?Z/^*O[1OP^
M^"%]8VOBN_ETU;Z6&&&YFLKW['YDS.J(]ZL#6D3_ +MV9994*1J97"Q?/6!)
M^UG\,[*^BL;^\OM.N;B*62VAU/1]6T^2[,31JT5FEY:0M=W!:6-4MK82W$A=
M0D3$UU_@7X[^#/B)KEQH6GW%S%J5O;)>O9ZCI]_IMP;>21HA/'#?P6\DL0=2
MC21JZ(Y56*LZ!N?M?VH_AA>ZII]C#J_F+J=RME97J6MVVFW5PR.RP0:F(?L$
MLI\MXQ''<,YF1H /.4QCZ KY0US]J/3M)^.MG\-!:7S,VD27UQ,FF7TR^;-=
MVL%IY<L*.HMPKW'VJY=!:Q.(HS=)*D\2^O\ C7XP^&O -\EC>_;I[EHA,8=-
MTS4=3DCC9F5'F33[>X:%)&218FF""8Q3",N89-O0> /'_AWXI^';+Q#X>O8K
M[3KZ(2P3Q$[67)!!! 975@4DC<*\;JT;JKJRCR#]KJP:;X/>*KZ&[OK.YTS2
M-1U&UFL+Z[LI$N+>RG:)B]I+"TB*WS&*0O"Q"ED8JN/F_P""W[:'P5^$7P_^
M'WA+Q'XFMK+5)/#?A_,+I.ZQ?:+& 1^?-'&T-OD$.?/DCV1,LS;8F5S]G^-?
MC)X2\ 7R:=?74LM\\0G%C86MUJ%YY!9D%P;2QBN+A;?>IC-PT8A$FV,R!V53
MT'@#Q_X=^*?AVR\0^'KV*^TZ^B$L$\1.UER0000&5U8%)(W"O&ZM&ZJZLHT/
M%/BG2_!>ES:EJ4WE6\6T$A7D9FD<1QQQQQAI)99798X88U>6:5TBC1Y'53S_
M (%^)V@?$7[0NG-<I+;;#+;WUE>:?<(LF[RY#;WL,$WE2%)%CF">5(\4J*[/
M%(J^8?$WXT?#.2^U#P?J^IWR36T5M-J#:8NK1BPCE8RQ/>:CIJJNGHRQ-([3
MW%N/LX:20BW8LWS_ /\ !/?XA6.B_LN>'O$?BG5HH(VEU2:[O]2N513)/K5V
M"\T\[ %Y)' W.V7=AR6;GZO\"_'?P9\1-<N-"T^XN8M2M[9+U[/4=/O]-N#;
MR2-$)XX;^"WDEB#J4:2-71'*JQ5G0-G^)/VC?A]X3\17>@WE_*;NQB@FOO(L
MKVY@L8[@.T;W]S;P26]DA1&E+7<D(2$>>Q6'#UG^(_VH_AAX6\"#QU<ZOOT
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MV#2=6L=?L;>^L;B*YMKF))H9H762.2.10R.CJ2K(RD,K*2&!!!(-<_X_\?\
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M*/X@:Q9K-_:FH)>"&RCL8H$^W)<+>?)'#''N,VYHU\MBR%@>P_X)G:M?:_\
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M>:8W_1_Q/_PKS7;SPMXGO?LUW<1W(_L.[@W3NSZC;/$WV9H-S2Q2V[/++C?
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MBK,MO9;MC.8$\P1Q>@?L\?\ )SOQO_[E'_TTRT?L"_\ -5?^RD^(_P#VVKX
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MQ/C%\99](DW:!/K>G^2([OSX1JAL?/U?"&5S'+YT\0GX4!E6 ?\ 'OY<7O\
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M[OTG4X=:L;>\A658YXDE030RP2!74, \4RI+&X!^:.15=#E656! T**^ /\
MF][_ +IM_P"Y^C]GC_DYWXW_ /<H_P#IIEH_8%_YJK_V4GQ'_P"VU>__ +6/
M_)$/'G_8MZS_ .D$U? '[2W_ "CSL?\ L6_"?_H[3:^@/V^O^:5?]E)\.?\
MMS7C_P  ?!$7[0W_  MO0Y_&&MV?F>+M?T[5+&WN-)N/-MY?]%AD'VO39[NV
MB:UC6SB43%!]D<Q,F#'']H?LI>"O"OPP^'T7A7PL]]-I>BWVHV$-S?F$R3R1
M7LQNB/*6/Y(KII[8%XH2Q@9E62%HIYOG_P#;(\>6/@7XJ?"&?Q+)%!X775]3
MFO9[JW5[6+4$L#%I;RS-&PA=9)IGB8LB*5:X8@6WF1?7^JZ3X*T_Q[IFK3V\
M0\0W5C=:=;2QI(T[6:O%<SK)Y8(%O'(D6)9@(X9IDA1TEO DWXX_'O4+/Q/^
MQ/J.H_#^WMM&\#?N$M--O(+FYU)\:]&)97NFOVCM\W9D*PE+W,*!_/C:?R;7
M[?\ CS\&_%_BGXMIXO\ AEXHMM-\6:5HEE9W>GZG:&:QN]-N=2FFB2298VD@
M\Q[6[$C0>9,PCC4&U#>;)\@:?\;]/^*7Q#^'&EE-2\#W$/B3QQIUW!;ZG93I
M;ZYMAF>0/>6UW;7GG'4+BVB4Q1LD]ZZ6[>6J"?[?\#?L]^$_A!\<F\5R:QK>
ML^)O$NFW4$S7G]G+"MG9?8EDN'2VM+)%V,EE;*(]\C-.'\ED6>>'W_\ :%_M
MS_A5GBW^POM/]I?V)J?V/[%YGVC[1]DE\GR/*_>>;OV^7L^??C;\V*\0_9KU
M;P5\2OV6_#HU*XBDT23PM%IVHO,\EM&L=M9FROU>1C$T:1M%,C2AE "F1'V[
M7/P!XXTSQ%I/_!-:*+7FE:Y:QTZ5#+,)F^RS:[!+9 ,&?""U> 1QY!B0+$50
MIL7]SJ^0/C[K/ABS^)_P_LO[-\_Q9=_VVGA^]G:7['9;;2+^T);F.*>-ILVY
MS%#L/G2((O/L@YN4\?\ V3[;7+3]HGXTQZW=6UW>C_A$_-FL[:2TA;.F3%=D
M,EQ=.F%VJV9GW,"PVA@B_H_7XHVEEXB_8N^&=EK"W,7C?X4>;I.J6<9 TW5=
M,6;5EU"UN5PD8O4$CP,\<SPO-.\:>3:6J3AOJ_\ 9X_Y.=^-_P#W*/\ Z:9:
M/V!?^:J_]E)\1_\ MM7RA^S7KO@K0/V5/A(_B/2)=4N9?%/DZ)&D\EO''K#:
MIJ7V*:XDC<,MNK!A*PCNMH;=]EF("U[_ ."K+Q58?MH.GB._L;ZY/P[)22PL
M9K&,1_VZN%,<UY>LSA@Q+B10057RP5+-V'[ O_-5?^RD^(__ &VH_P""7'_)
ML7A'_N)_^G:\K[_HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK/U;3(=:L
M;BSF:58YXGB<PS2P2!74J2DL+)+&X!^62-E=#AE96 (\?^%7[.O@;X*WU]>>
M'(;Z"2_EFGNA-JNIW<<T\[(TMP\5W=31-<.8UW7!7SB 5\S:S Y]U^R_\.;G
M5-0OQ8W,7]IW+7E]:V^I:C!8W<TB(DKW.GPW*64_G*BK<K+"ZW(W><)-[[M#
MXJ_LZ^!OC5?6-YXCAOIY+"6&>U$.JZG:1PSP,[17"16EU#$MPAD;;<!?. (7
MS-JJ![!I.F0Z+8V]G"TK1P1)$AFFEGD*HH4%Y9F>61R!\TDC,[G+,S,23Y_\
M3?@OX*^,,-JGB+3(KJ2SE6:TN TD-U:R++'*'M;J!H[BW<O#&6:"2,L$"L2O
M%<_X2_9K^%W@#Q$->T'P[8Z;=B)8Q]BB^SP902JLOV:(K;_:%2XGB6Y\O[0(
M9I8!+Y,CH?4/%GA;2_'.AW^B:I#Y]EJ%M-9W,6YTWPSQM'(FY"KKN5B-RLK#
M.00<&O+_  !^SKX&^&<UE)I4-\5T^(16<5[JNIW\%JHB,(-M!>W4\,#K$6A6
M2)$=87DA#"*21&/%O[-?PN\=^(CX@U?P[8W5\\30SR/%\MU&PBPE[&"(KU(S
M!"T*W:S"!XHY(A&Z*PS_ /AESX80>!_^$*L](^P:*W^MMM-NKNP^T9M_LS?:
MI;.:&6Z\R+"3?:'E\[:K2;V52.@\.? OPIX2\('PGIIU*WTW]V$1-8U7SH5B
M$:I'!=&[-S;Q*(D40PRQQ!=R[-LD@;@-(_8Z^%N@>$)_"%E:ZE!HL^0]E'KN
MMK#M83!XPHOOEBE^T2F>%<13L5:5'9(RO?\ ASX">!/#7A ^$%T[[9HI\L?8
MM5GN-4A"Q",11JNH27.V*/RHS%"N(HV7<B*Q)/ ?";]C/X._ O\ M-O"6A?V
M;+J=L;.XN(KR^:X\DYRD-Q).TUODD,6MWB8ND;D[XHV3K_A5^SKX&^"M]?7G
MAR&^@DOY9I[H3:KJ=W'-/.R-+</%=W4T37#F-=UP5\X@%?,VLP/ >"OV&?@/
M\//%3^)](\)6,.HM*9D=_-FCAD,RS![>WFD>"V='53$T$<9A V1E$)4]_J?[
M.O@;5O'J^.I8;Y=;6*& 7,6JZG"OD0NLBVY@BND@-N70226YC,,KEGDC=G<L
M?#G]G7P-\*?$6H^(=%AOEU'4XHXKR>ZU74[UKA80!$91>74ZN\:C9%(07C0M
M&C*CNK:'PW^ G@3X1W$LWA[3OLF_SQ''Y]Q+#;K<3_:)X[.&61XK**67;)+#
M:)#%(R1%D/DQ;/0/%/A/0_'.ES:7K=A;:A93[?-MKR&.>%]CAUWQR*R-M959
M<@X90PY -> 6O[%_P5M+?3XD\,VQ;3]JPSN\[W+1+ ]L+>>Z:0W%S:>0YMC9
MW,DMJUL%MS"841%T/#?[*'P[\(ZSJ&M:>FKQ7VI1>5>7!\0:Z\EPH@>W0RL]
M\QD>*.1A;R-E[<[7A:-U5E/"?[*'P[\"PZG%HZ:O:+JLKSWAB\0:ZK2SR2Q2
MR7!;[=N6X=H4$EPI69TW1-(8I'1CPW^R3\*_"O@K4/!5KI4KZ%?Q>5+I]U?W
M]W;JOF/+F!+FXE%L_F.9?,M_*?S@DN[S(T9>_P#!7P>\-> ;Y[ZR^W3W+1&$
M3:EJ>HZG)'&S*SI"^H7%PT*2,D;2K"4$QBA,@<PQ[>?\6_LU_"[QWXB/B#5_
M#MC=7SQ-#/(\7RW4;"+"7L8(BO4C,$+0K=K,('BCDB$;HK# U/\ 9%^$>I^
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MR%A&7D*!3(^[V_PMX3T/P-I<.EZ)86VGV4&[RK:SAC@A3>Y=MD<:JB[F9F;
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M-/\ !$>LZ)HU[=Z;/JLVH:_,Z6]M#'<1PPJD)>U2[EN6\]5B6\MF@2"2=O,
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MWWA^*RFU6YU*RN+N.-K^-Y+:VA@BN+(R.T:--+/YX2$>3$L<[S2FS^?]2_;
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M7H-M#IVI2W5XT\5S=SSW-@+$7-FGVEH[6![CRT(BDF?$5Q:L> ^.MSJ?BO\
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M:3X1L=3%O->V]WI\]SJ&J+';O%]COK2&8V]O;1F1K@%4DFN(DC9_L]RHX_\
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M6EZ=OE37EM)=PKAP6WPQW%J[Y7<JXF3:Q#'<%*-\X?L0?%[Q%\>O@OHGB[Q
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M9GQ3I%Q<^)XK,740T&ZCCCDT^RDMK1HO^)P[! SK)<(Y<S!61)+<L'7R^/\
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M/TS5K'6H6FL[B*>-99H2\3JZB2"5H94)4D!XY$>.1>J.K(P#*0-"BBBBO/\
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M?CM#JB:49;>^T:^GT[4M/NC"+JSN(97C*RB&6:)D<QL8I8I)(9 K*'WQRHG
M?MCZS\*XOA]/I7Q+EOH-"O);:2YEM;._FC"VM[;3+'//9V\PMTFD$<67:)Y
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M444444445GZMJ<.BV-Q>3+*T<$3RN(899Y"J*6(2*%7ED<@?+'&K.YPJJS$
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M\U>'3+[5;F.*46ME86EW<R7%PL,DD41^R07#0I(R>6;B1/)C++N;)4-\8?\
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MWL$MC?O,-K77FO)-/Y+0W,"/;Q01&.VFDDND^_Z*^4/'_P >+[7/@UK/Q \
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M)(9G+0?+'L]_\(WOCVZ\6^)4UJVL8=$AELH]%>$N;J93:J]W)<_.Z!!._E0
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M?_M"?#?2O!WA*7PAI.OQ>(8[U18Z;8QZK%;6,=S:R-;V\C7$;P.N]!>PVMU
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MAF(+-V'C7]G;Q$WQ13X@^"_$<6AW=Q8BQU6SN-.%[9ZBL.[[--/'%<V4OVB
M.RK/YK/Y:QPJ4A$J3<?X0_9!U2Q\9^,];\1>)O[5LO&5M;0:K8IIZ6GF"&PE
MLO)6=)W>.TVSR%$15O%\NU#W\ICN6N^?^&_[&/C/P?I<OA+5?B1J6J>#A;3V
M,.COI]A',;.5]HM9]19)KAXO(9[<^0+615*F"2V6-(QZ!_PSUXX_X7?_ ,++
M_P"$DTW_ )!O]A_8O[%N/^0=]O\ MNWSO[4_X^_^6?VCR_)_B^R?PU]?T5X_
M\>/AYKGQ9\#ZGX9TO4K;3?[4MKBQN9[FRDO,6]S;R0R")$NK39+\X9)&:1%V
MD&)]P*GP'^'FN?";P/IGAG5-2MM2_LNVM[&VGMK*2SS;VUO'#&)4>ZN]\OR%
MGD5HT;< (DVDMY!\(_V>O''P[^)_B3QKJ'B33;W_ (27[!_:%M!HMQ;8_LZT
M>VM_LTKZI<>5G<'E\Q)]^"J^5G*\^/V,7M?^$QTJR\7:E::!XON;[4-1LHK;
M3VN!=ZAYB78ANYK>4):30ND9A,#7"/#')'>1YF27/U?]C36=2^'7A;1(?%\M
MGX@\)RVKZ1K=MIT"&VCM[5+-K<6[.SO;W$";KJ*2Y<3W!W-_HJQV2'Q)_9<^
M*/Q(\6^'?%S^.[&SU;P_%JD-H;;P_FU0:C:BV:989M1EE-P@+-NEGEMV*6X%
MJFR<W78? +]GKQQ\#O\ A*O^*DTV]_X2#4M2US_D"W$/D:C?>5\W_(4D\RT3
MR_\ CW^29\_\?:XY\_\  7[('CCX?_ VZ^%%MXLTV2RFMKRQ2ZDT*X\Y;>_^
MUM= A=6"-*6N5,$@"I$L;*\4YD#1^?\ QY\(?\(3\//AC\))/&?]F^(6U+3(
M=(U"*V^SVLO]B-&ZM=V\TMQ'+M3R!#:M+_I>JFT*K'"9/)[#3M>^+GP(\5:5
MI.O?$/2/&=SJE]81/H\^FVVEZG'9W$TEO)>V*64TC2I Q^T7(F@:/[+:W#">
MW,;LWZ'T5\@?"/\ 9Z\<?#OXG^)/&NH>)--O?^$E^P?VA;0:+<6V/[.M'MK?
M[-*^J7'E9W!Y?,2??@JOE9ROT?X_\ >'?BGX=O?#WB&RBOM.OHC%/!*#M9<@
M@@@AE=6 >.1"KQNJR(RNJL/F#2?V7_%7_"%6_P /=7\517OA6&)+(Q1Z?-9Z
MG+I\$@,-G+J%M?I"4,2):7+QV<;W-KYJ_NI93,NA_P ,]>./^%W_ /"R_P#A
M)--_Y!O]A_8O[%N/^0=]O^V[?._M3_C[_P"6?VCR_)_B^R?PT?"/]GKQQ\._
MB?XD\:ZAXDTV]_X27[!_:%M!HMQ;8_LZT>VM_LTKZI<>5G<'E\Q)]^"J^5G*
M^7^&_P!AOQ+\)?%6H7GPX^(-]X;T35;[[??:0NF:==QB1IG:06+3((;-/*9(
M8P+>4J(HS(TZQQQI]?KK/@+X*V-GH\^HV.E1M%=SPQWEXB23+ K75Y<%[B3S
M9W4,]S>7#L[DL\\TA9F<^ ?L&_"'P[\*/A<MQH"2Q6/B*^N?$5M!+(9#;VM_
ML-E!ELL'CLDMEG#/.?M FVSR(4:N@_9=L_&M@WB:'5O$<OB+2$U>\CTV]O;>
M."\$D=W<1WUN_E-LDM[>=1!!)Y5L3(ERL5NE@MB6^KZX_P"(7@JQ^)7A75O#
ME\\L=MJMC<V$SPE5D6.YA:%RA974.%<E2RL <94C@_$'CC]C3Q[X]^#47PPN
M_&MBNG)8Z=II=-!?<(-,:![=X_\ B9[EN':'%T[O+#(@B$-M:NDTEQZ!\:OV
M=?B+\;(?"PO/%.D6\GA_5[/70T6@W16:\LI9S$"K:P2EN8Y422+<TC.C2+.B
MN(H^?E_8^\6^$O'NJZ]X!\?WWAO2]=ODU+5=+%A:Z@LETSDW,UK+>F1;5YU(
MW8AE < D/#'#;Q?7_@/P58_#[1H],M'EE42W%Q++,5,DUQ=3R7-S.^Q40/-/
M+)*RQ)'"A<K'''$$1>PKQ_XZ? OPA^T7X0NO"_BBU\^TGPZ.A"S6\R@A)X'(
M;9*FXX."K*6C=7B>2-N \+?#3XS^"]+ATJV\;:;?V]MNC@N-8T*YNKYH0Y\H
M7-Q!K%I'/*B;8WG$$33%?,=3(S,=#Q_^R_X5^+O@*]\(^,+F^UN.\E-PU[>R
M0BZBN @CBGMO(ABM[9XD 55MX(X9!YAFCF:XNC-GV7P4\<>*?[%M_'7B>VU>
MTTFYM-05=/TVXTJ6[O++YH)+UTU&XBEB67%T;>.""-KJ*!^(HF@DX_X=?LZ_
M$7P#\0?%?C,^*=(N+GQ/%9BZB&@W4<<<FGV4EM:-%_Q.'8(&=9+A'+F8*R))
M;E@ZGP5_9U^(OP3A\4BS\4Z1<2>(-7O-=+2Z#=!8;R]E@,H"KK +VXCB=(XM
MRR*[K(T[JABD^,/VDO@'KG[,W[$_B7P==ZU;:M96/V#[))%I\EG,OG:]%<2^
M<S7ETDN6F CV)#L52&\PME?O^^^!GB_QEKFD/XK\5_;](T>Y2]AL;2Q-A+=W
M-O)&]G-J=Q'=.EQ]G9//\FV@LK:6ZV2M (XHX%\_'[&+VO\ PF.E67B[4K30
M/%]S?:AJ-E%;:>UP+O4/,2[$-W-;RA+2:%TC,)@:X1X8Y([R/,R2\_X@_8X\
M7ZUX'\">&U\86V[P?J6FZG#+-HQ=)&TFW2WLXEBCOX72+:KR77F2SRS3RLT4
MMK"L=NGH'B_]GKQQXX^)_@SQK>^)--7_ (1;[3Y=M#HMPOG_ &^TBMK[=*VJ
M/LW;'>UPC?9]RK)]KV$R>?\ [8FA_#3]J30]&^'DFJ6UU>W_ (DCM8OL=[$9
M;2;3(WN=3+*C2;98K'SX-DD4JQW5W:"6.,.LJ??]%?*'[2?[/WBKX[WWAQ['
M7['3+;0=7L-=ACFTJ:\DDO+)I=@>1=0M5^SLL@#1+&),J6$X#;5S_%_[/7CC
MQQ\3_!GC6]\2::O_  BWVGR[:'1;A?/^WVD5M?;I6U1]F[8[VN$;[/N59/M>
MPF3GQ^QB]K_PF.E67B[4K30/%]S?:AJ-E%;:>UP+O4/,2[$-W-;RA+2:%TC,
M)@:X1X8Y([R/,R2GAO\ 9A^(?@BW\&/I'C:V6Z\,Z;=:0?M6AK-;7%G-!80Q
MQ"*.]AFBV'3XKAW^TRR27+R8>*U*VB^W_"CX,0_#_6=?\2WT\5WKOB*6UDU*
MYMX9;:W9;* 6UK'!;27%R8D2,$L6EE>2:21RXC\J&'W"BBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBL_2=6L=?L;>^L;B*YMKF))H9H762.2.10R
M.CJ2K(RD,K*2&!!!(-$FK6,-]%8O<1+<S12S1PEU$CQPM&LCJF=S(C31*[ $
M*9(P2"ZYT**SY-6L8;Z*Q>XB6YFBEFCA+J)'CA:-9'5,[F1&FB5V (4R1@D%
MUSH445GV6K6.HS7,-O<12R6LHAG2-U9HI#$DP20 DHYCECD"M@E)$?&UE)T*
M*SX]6L9KZ6Q2XB:YABBFDA#J9$CF:18W9,[E1VAE5&( 8QR $E&QH4445Y_H
M'Q8\#^*]<N]"TO7M-O-2L_,^TV=M>V\MQ#Y4@BD\V%':1-CL$?<HVN0IPQ K
MT"L^35K&&^BL7N(EN9HI9HX2ZB1XX6C61U3.YD1IHE=@"%,D8)!=<D>K6,U]
M+8I<1-<PQ1320AU,B1S-(L;LF=RH[0RJC$ ,8Y "2C8T**************^?
M_'7[,7@'XD>)[?Q-JT>I/J5KO^S3P:WK%K]F\V)89?LR6UY%';^:B!9?)5/-
MY+[F))^@**SX]6L9KZ6Q2XB:YABBFDA#J9$CF:18W9,[E1VAE5&( 8QR $E&
MQH44444444445Y_X%^+'@?XH?:/^$9U[3=7^S;//_LZ]M[KRO,W;/,\EWV;M
MC;=V-VUL9P<>@445GR:M8PWT5B]Q$MS-%+-'"742/'"T:R.J9W,B--$KL 0I
MDC!(+KG0HHHHHHHHHHHHHK/TS5K'6H6FL[B*>-99H2\3JZB2"5H94)4D!XY$
M>.1>J.K(P#*0-"BBBBBBBBN?\4^$]#\<Z7-I>MV%MJ%E/M\VVO(8YX7V.'7?
M'(K(VUE5ER#AE##D UG^"OA[X5^&MB]CX<TFQTJVDE,SPV%M#;1M(RJI<I"J
M*7*HJEB,D*HS@#'85GZ9JUCK4+36=Q%/&LLT)>)U=1)!*T,J$J2 \<B/'(O5
M'5D8!E(&A116?IFK6.M0M-9W$4\:RS0EXG5U$D$K0RH2I(#QR(\<B]4=61@&
M4@:%%>/_ !9^ /P\^.O]F?\ "7:+;:I_9=R+NU^T!OD?C*G:5WQ/M7S8)-\$
MVQ/,C?8N/8****S[W5K'3IK:&XN(HI+J4PP)(ZJTL@B>8I&"07<1Q22%5R0D
M;OC:K$:%%%%%%%%%9][JUCITUM#<7$44EU*88$D=5:601/,4C!(+N(XI)"JY
M(2-WQM5B/+_C'\"/!GQ]TM=+\56]S=V0SNMHM0O[2&3+QN/.CM)X4GVM$C1^
M<'\M@63:68GT#PMX:L_!^EPZ=:27,D4.[:UY=W-[,=SESOGNY9IGY8A=[MM7
M"+A%51H:GJUCHL*S7EQ%!&TL,(>5U13)/*L,2 L0"\DCI'&O5W944%F .A17
MC_@_X _#SP!XOUCQ=HVBVUIJ^M8^VW48;=)@AFP"2D7F,!)/Y2I]HE"RR^9(
MH8>P5GV6K6.HS7,-O<12R6LHAG2-U9HI#$DP20 DHYCECD"M@E)$?&UE)T**
M*****************************************^0-6_;5\#^'[?1-7U*S
MU*R\.ZY<PVECK]Y%;V]C(]Q!)-$SQS7"7\,3^4ZK/-9QP8 F\S[*R3MZ?XD^
M.-IIWB*[\/:'I-]XAU'3XH)=0@TN735:R6Z#FV%P;Z]LU#S+'(Z1QF1U11)(
ML:2P-+X!\>_VL=1\+^"OA[KWAC2+ZXC\9:OH,,3!K%)(H+V2&Z-NT<\NPW%U
M;B2W3#+#$3)*UW"R0^;[_P")/CC::#?:?HT&DWU_KMY8_P!I-HUK+IHO+>U5
MDCDFG,][#:JB32)!\EQ(99-YA$T<4TD?B'[1&O\ @?X_?L^>-KTVEM>MI6FZ
MVKV]Y';S3:=JEC97$;HX!E2*[MV+!9(G8%6$L,LD,L<C^'_"S]N7P5\&/A-X
M&@U'2/$%UID'A_0H;S7+'3))])M)&@AMI$FN]RAGAD^2=8%F*2YMP&N4>%>P
MT#PGH?A3]MZ[_LNPMK/[9\/Y+VY^S0QQ>=<2Z^/,GEV*N^5]HWR-EVP,DX%>
MX? ;6?A7XF^(/CK5?#$M\VNW<NDR:W%?V=_920*EEY-C&(+VWMBJ&..64$*S
ML969G\LP(F@G[4VCZ@EMJ.EZ-J6HZ%=:E;:5#K=G)I;V+S7&H)IH9 U^EV\2
MW3^4TJ6S*X4RQ>; 4E?Y/U;^R?A+^VA<3Z'X=EN)]1\"//):Z/:V\<ES=3:Z
M7FN)I)'MK=7*1EI+BZFC$A5(A(\\D,4GUAX!_:S\(>,[?Q@U]::EH=QX.W/K
M%KJML%F@A$#SK.OV62YCFBD2*1HC"\C2*F]5,<D+R _:M\-Z9XOT7PWKVFZE
MH3^(//&CW.JI:PPWS0F+]VJ)<R7-O+()XS%#?06LK,?(*+<D0G0\?_&[0;GQ
M%>^!+/0+[Q5=K8F35+.PCL'@MK>Y 2.*]?4+JUMP]RC.8[;>\TD*O(T0A*LW
MS?\ \$V4TN+0_B,NEVWV2R'Q UT6UO\ 9GM/*A$=IY<?V=TC>#8N%\ED1HL;
M"BE2H_1^OC#7/VB/$MK^TC9_#NVT*^EL4\/R:C-+%)IVV0W%_:P1W9$T\<J6
M]H%N(Y%1C<3/*Q6RD2*&9_F_X$WFG_!?]HGXPZ/X7\*7-S%_Q2[16.AV]E;0
MPH-,D>5RUQ-96<>9)01'YHGF9WD2*1(KAXOM#X7?M3>"OBEX"U?QDBWVFVFA
MRWT.J0:E:20W5E)IZ>;<)-"GFDND963;$9#A@A F5XUSQ^U;X;TSQ?HOAO7M
M-U+0G\0>>-'N=52UAAOFA,7[M42YDN;>603QF*&^@M968^046Y(A/T_7S_\
MM2?$+7_A=\+/$6MZ%9W-Q>VVFWTL4MM]C/V1H[2:1;N5;R6)'BA9%+HBSRMD
M!;>4;@/G#]F2#P:/AUX+\<^)?"LNG7V@>%M)T^RU:\2SGDN(KJUAC"6265S=
M7#O(^V.WBEACNF-V;>"(O=7$3?0$7[2%II7B+2M%\3^'M7\.-K$KVUC<ZF=-
M>UFN@ RVGG6%]>+%<2J6-ND_E"<QND;/* A^;] \)Z'X4_;>N_[+L+:S^V?#
M^2]N?LT,<7G7$NOCS)Y=BKOE?:-\C9=L#).!1^R?X3T/P-^T3\:=+T2PMM/L
MH/\ A$_*MK.&."%-^F3.VR.-51=S,S-@#+,6/))KZ?\ %GQZ?1/M\NC^%];\
M0VNG^<EQ<Z0NGN@FM]WGP1)<WMM-<RQ%=CBUBG43A[4,;J*>&+@/'W[:O@?P
M?I?@_5--L]2\067B^Y6RTVYTB*W:$W#NB1P3R7=Q:I!+(S,JQR%75H;A9!&8
M7 [#4_VD+2P^+*_#:+P]J]SJ)L8=4-Q$=-%J+&2=;=KDM+?1S;(I6*21B(W!
M*,T<,B%&;S_XF_'KP5XNT'X@^%_%&G>(-+T[3(I-'U*^CTZ2ZC,=]82S--;R
M6 O]J1VI6XDDN(XQ;B>W$R*\GEUH>,_VA/ _[-/P@T3Q-IFCZE?>$X--L?L\
M^G?9V^SV;K;PV7F)J%W;7+>8)8U7"RR+AC-L/+=!JW[4>G^&-4T2WUSP[K>E
MV6NZE#I-AJ%Y%9"&6XN4D>V5[>.\DOX//\O"BXM(7A9@MPL!#[>_\=?&73_"
M&N6_AZRLKG6=:GMGOAING262W"6<<BQ-=2?;;JTB2+S72)<R>9*Y;RXW6&=H
MN0_9^_:M^'W[35B+KPI+?3*L0>;SM.O88X) L3/;O<M#]D:X3SDW113R$@F1
M-\0WU]'U\P:U^UMX,TKQPW@J"RUN\UI;:XN1;6^C7Z[A%<);)B6>*&+RIY79
M(KTN-.'ENTMY"IC+Z'@K]J/PEXQAUV,VFKV>H^'I88M4TR73+J>^MFN)9$@(
MBL4NEN$F6,S1R6;W"?9V69F5#D<_\+/VPO"7QJOM'B\-:3X@N[35)=0C34CH
M]U%I\*V32J));N94BV7!B86XB,KARL4Z6\V8QH>*?VH]/\+:7-X@/AW6[OP[
M#MD?6[.*RFM/LY<*]XD(O!?RVD>6D:>*T=)+=#=0^=:M',_?_$CXZ>$/ACX0
MB\47=U]JM+KR$L$L +J;49KH9MH+%(R?M$MQD>2$.TKF1F6)7D7G_ O[0FG^
M+?'%QX*U#1]2T36HM-35TMM1^Q2>=9M<-;&6.6PN[R(;)5",DCQR'>K*CJ'*
M\!JW[:O@?P_;Z)J^I6>I67AW7+F&TL=?O(K>WL9'N())HF>.:X2_AB?RG59Y
MK..# $WF?962=O3_ (C?'?2? /B+3O#-K87VM:WJ$4ES'IVEBW:>.UB!#W=P
M]U/;06]OO A1YI4,TS"*)9&#A?SP_9[\:^&_@K\1OCQK^G^&;G3]-TBV\,W4
MNDV=I:VDUNL.G7#782%I8+8^61+*SPRM%<J#+;R7*RQ-+]H:W^USH.@6/@G4
MYM$U<Z=XRETBWL+Q%L#''<:LI>""X0WHG5U0;Y6CBEA4<+([_+70?$;]JGP-
M\+O%NG>%M3CU=]1U"62.&.UT74[E76*U-U))$\-LRW*1KL246AN'B>5?,1$6
M9XC2_P!I.QU;1M&N8_#GB"/5-9BO9K31+BP6WU#R[&=(;AY_/ECM+5%\V.16
MNKF$2I+&L9>:1(FS_"7[8'PT\2>&/$6O7E__ &2OABYGL]:MM0,0N+&:&5X=
MDB6\DZ2>:R%;=K=YEN'_ '49>97C7K_"7QGN=?\ %4'AS4_#.KZ+<W-C=W\#
MW[Z7)')'9S6L,P!L-0O&5PUY"0'5 P+88E<5[A7R!^U[\?-?^!MGX4BT?2[F
M\EUWQ)I6E&6W>S&Q9+E))( MTZAI;N&.6WB)\N*/<\KW4#I$)?;_ !)\3E\-
MV.GYTJ^N-4U"+S8=(MS:->$(J-/O9KE;1$M]ZK-.]R+?S&BA2:2:XMHYN?\
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M9[V"ZFCA$)2<I<++/++=7,,*#ZO_ .;WO^Z;?^Y^OB#]I>UN+G5/VEVAT_\
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M4NCZ=J7@T6UGJPU+4](4W5KJ4\TMH+RSNK6'8T4BRS).6&];4*R/(B39^O\
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M-<(N3@#)KU#2=)L= L;>QL;>*VMK:)(88846....-0J(B* JHJ@*JJ %
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MZ33[N[CLOLT;(EC'',\4 A>5PL+&V9Y)8N/_ &@O'/C[]C[2[+QU-KNI>*=
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M>60,1"$C8+.\I2-_F"3X _&!/V+8OA*/!U\VNO++&V+W1OLZ*FLQZDLC2G4
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M_DQ6M[/%%CSIXX^?_P"$?\??\-3_ /":_P#"(:E_8O\ PC?_  C/VG[3H_\
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M2FM/^$(NKN6TU*;4]]K>7.MP&9?L>I,);'S(H[9U@6.",P>1)''Y3QLW8?\
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M KX0^#/BFXM/VK?BGHFJ37(EN]-\.7FEQ3K.4:QM+:2.X>W9AY8B2[NB"JL
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M)%YU%H8$@N<2H/M_2=)L= L;>QL;>*VMK:)(88846....-0J(B* JHJ@*JJ
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MQX9NH;Y[&ZE>6ZQJNIK<7;20F!A=W:W0NKI##B$QW$LJ>3'#%MV0Q*G(:O\
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;BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex19-1_004.jpg
<TEXT>
begin 644 ex19-1_004.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[@ .061O8F4 9       _]L 0P " @(#
M @,%! 0%!P8&!@<(!P@(!P@)"0H*"@D)"PH+"PL+"@L+# P,#0T+# P,# P.
M# P,# P,# \,# P,# P,_\  "P@&<@3[ 0 1 /_$ !\   $% 0$! 0$!
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MF:-I$5\;E1VAB9U! 8QQD@E%Q^2'P;_Y2&?$?_L6[;_T3HE?0'_!1Y[CP)\
M?%&OZ!<W.DZE%<Z=>?:],N9[*9YGNK6Q9Y7MGC:;-N1#MF+KM2+C=#$4X_\
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M>*+S2!JFF7TU[HMW9/>/ C&1IU^TEUA8N[7%W;LRQ.D4,D<HBEFCYZ#]K_\
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MF-QV?-^A_P 0O!5C\2O"NK>'+YY8[;5;&YL)GA*K(L=S"T+E"RNH<*Y*EE8
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MJ%Q<RZE<6SWJ6>G:??ZE<"WCD6(SR0V$%Q)%$78(LDBHCN&52S(X7X@_:O\
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MT5P1N.9&+3_-YHD?[_\ VA_^3G?@A_W-W_IIBH_9X_Y.=^-__<H_^FF6OO\
MK\P/ACX-U?Q;^T[\9_[/\1ZEHGE?\(IO_LZ/3)/.W:2^/,^WV-YC9M.WR_+S
MO;=OPFT_:S^%/AC]F/\ 9:\76>B-J1BN[FQN=4G.HRF^OWN[^QMKZ22ZE$P6
M6[A5DF(B,!+N3;LC,C=A\5_V>/"/B=O"OQ%\2>,?$'B)= OK&]T583H8CN;B
M]N[06L2-::=:I(EW.MK&LDDT<*A@YGAB+RC0_9X_Y.=^-_\ W*/_ *:9:/\
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M1'Q!J_AVQNKYXFAGD>+Y;J-A%A+V,$17J1F"%H5NUF$#Q1R1"-T5A@#X40_
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ML;3SS,DLH6U2&5%^L+SQ;\1;7XH^'/#EO/I%WIS:1<7NNNMI=17$,D>V&W>
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M-LK30-2FT6\GU/3;J]:>^@2-[A(HH[W3_*B@\Q(_.9Y3<2F4+'%%#'-=\_\
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M'X?:OH?B6**2.\OKZTQH,4D,OE23PW'GB6Z0C][!;0;C,Q$0NUMP^H)Y_P#
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M )M \0>%KB]C&C7\LD=OI-DL=[.T,,,DT:1RR&%%G2*:Y,<DMO'-;[)G]O\
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MINFZ?XEUNS\':]I$5C&MCJ5GJ1DV/-;HR0^;; 3B.01&203F.21K=6@EY_\
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MW5OK5G::6C>%Q!:D6EBEW/=I(DM@\+W#+8[KR*5C=2VT4]U$]SS_ .T@EO\
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M_%/B_P /^)O#/B"VTFXTFVU.SFAO-,.H0W<.H&T8HX6[M)(_+>TCD5HW#,P
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MF.PP&=9[9IOM_P ??%6Q\"WUEI<=C?:GJFH17$UI8V$*M)+':M"+AS-.\%I
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M8XM8IU$X>U#&ZBGABY#Q1^VK\*_#.C:%K"7=]?VFO2V<6GS:=I=_=1SO=SF
M1K+' 8A<1E)6ELRXO5$3H+9IMD3\_P"-_P!M72? '@K4?&6H>$/%,6DZ=?26
M4\MQ86]E)M$EO'#<I;W]W:W#V]P]RJPLL9<%)1-'#MYZ#Q9^UMI/P^FTR7Q%
MX;\0:;IVJWR:?97\MK;RK-/-%++;H+*UNI]41YQ$5CBDLDF1V6.:*%]RKT&E
M_M(6@\:Z-X1U[P]J^@WVN17LFG&_.FS1W#6,:2SQAM.OKTQNL;^8#,(T8*RA
MR^U&^CZY_P 4^&K/QAI<VG7<ES'%-MW-9W=S93#8X<;)[26&9.5 ;8Z[ERC9
M1F4_$'_!+C_DV+PC_P!Q/_T[7E9_PM\'>%?VJOB3X\\3^*;6+6['0M7D\*Z5
MIVK6D,T%B;&&W?4)XXF:2%WN[E@1,\?VA888T\Q4?R(^P_9"U+_A"]?\=?"T
MWES>1>$=2M6T\SKE;?2]4LTNK.Q21Y99I?LA6>$/,2?*$(5@F(H?0/VT/">A
M^*_@AXQ_M2PMKS['HFJWMM]IACE\FXBL+CRYXMZMLE3<=DBX=<G!&37Q?X(\
M/Z3\2_@%H?PF\"Z/I#W>K^']#G\1W+16XM]+74-.CD%_<P(T<MUJ<PM]]FB_
M.LR075Q-!"(3-]__  &_9U\!?LV^'8M%\*:;%;*(HXY[DHANKMHR["2ZF"JT
MK[I)"H.$B#E(DCB"H/<*^?\ XN>(]4U#Q/X;\$Z>+F-=:^WW6H75M(D+P:;8
M1()1'-YBRQRSW-U96P>!&F2"6XDBDMIHXKB/H/&'Q"\-_!JWT?0[2S\V[O,V
M>DZ/IWV6*:9;6 R2);QSRVUO'%;P(7=GDBB10D2DRRP12:'PY^+&D_$:;4;%
M(Y;+5-*ECBU#3;I[=KJT:>(30&46TUQ"4FB99(I(I9$8;HRPFBFBC]0KY@\5
M:/\ $-OCEX?OETNVU+PJ--N(S,UPL<VE:B/.)NEA8@3?:87CLU95EF@4S['M
MH9;E+WQ^;XE^+_V:M+^*7C+X@:3;/;V5S]ITG4H+DLVI6DKR+I^G.BI+):_9
M7ECMBPB2W\VYFN?+DD-U>76?^RU^SWI/Q6\!:7XZ^*EI8^+/$?B&QM;V2YU*
MVM[J*WM70R6=M:0/;QPVJ+%*))UAC!DNI)G:24>65Y_X,>-[[]G/]H"?X*7^
MHRW.A:AI$.H^%8YY&GELXXC<>=8-)]G$KH!%.;=KB>006MI!")'DDVK[AIO[
M8VCZOX'\2>*[?PWK;Q>&-2O],U6UQI8N+=M.MQ/=2\Z@(98HP0G[F625W^Y$
MZ?/7I\W[0/A6V\!:)XPE,L<&O1:>=-M9#"EU<W&I(C6EI&K2B(W$A<*091#&
M \LDR01R2J>&_COI.JWVH:5J=A?:1JUC8_VH^F70M[F\DL2SH+F"+3)[X3H9
M(WB\N)GN%D"*T*^?;F;S#PY^VKX,\;ZH=/T#1_$FIM'K<>A3R6^A7ZPV\K)&
M99KF6>.%+>*W:01W*3%+J-E9_LS0[96S_P!E/]HCQ+\==9\:QZEH5]8VVF>(
M+S3K=YI-.>.W%E!9PO:.;><S-<-*9KIF$<UN@D,27LH1 =#5OVU? _A^WT35
M]2L]2LO#NN7,-I8Z_>16]O8R/<0231,\<UPE_#$_E.JSS6<<& )O,^RLD[:'
MC']LCP-X0\577A86'B"^U:VL;N^:TL=!U.61TMIE@7R@8$$B3R,R07*$V1,;
M;[J/=%YGS?\ #2RT/_AL*/5-+T7^QO[9^&RZM<VTEI':7'VB[UM'D:\C3_E[
MZ+.6+/O7:6;:#7U!H'[4>GZ[\7[OX8MX=UNUU*UMI+YKFYBLDLVLT8(EU%(M
MXTDL4KLD:>7&TBR,4ECB:*<1=_X/^+;^+_%^L>'!H.I6O]DX$M[.VGO:.SD&
M*-&M[R>42R1%;@0RQ12Q6[PR3)#]HMQ+[!11111111111111111111111111
M111111111117XXZ-\,O$4'BKQU^SN]U+::-K=]#XAT^;3V%M)9:#>S33:C#;
MQB22%+=;F&+2DM@L3$WT]\;>:V\R&O7_ -AZ]\1>/X=/T[7+:)%^&L5]X2>2
M$A[6[U*"5+7[1;H[F6-[6P@CC^T21QM.=5NXXU@B21)>P_9X_P"3G?C?_P!R
MC_Z:9:S_ -A'5K'3IOB9#<7$44EU\3?$L,"2.JM+((H9BD8)!=Q'%)(57)"1
MN^-JL1X?^S3_ ,H\[[_L6_%G_H[4J^__ -D[_DB'@/\ [%O1O_2"&OH"OQQ_
M9MU:QA_8!N;%[B);F;PMXQFCA+J)'CAN+Y9'5,[F1&FB5V (4R1@D%US?_:6
M_P"4>=C_ -BWX3_]':;78?'?4_ WAO\ :LL'\<W4NCZ=J7@T6UGJPU+4](4W
M5KJ4\TMH+RSNK6'8T4BRS).6&];4*R/(B3?0'[-'ACX1^&_%7B";X96T5W;7
M\4%UJVLQ:M<ZG'<7C33F*!9I9KM9+A%:>>\S+%)$+BS8I.+G=!]GU\P?$/4?
MAI\7_$]]\+/'-CIMQ+);6]_8VUW-$SW4-S%=PM+;(XCFCN[<V]V':VWM! T,
MZW"O,\<'S_\ LM^"=4^ OQG\4_#?PWJ/V_P99Z;;ZNEM/*DLVBWVH7,FS3T<
MRF4Q311S7061"54PNS"262:\^4/V3[#]G#Q?\#['PO\ $;5HM)OK*6XL-5T/
M4/$VL:9$EQ;7CN"^GW.HQ1!W(CN)3%&(1=-*%6-XVCC]/?XN:7^SS\;_ (>Z
MEXGMKGPWX5U7P0V@Z1!=W#NEA,M_!,JWJ3,)+:7[(EA'>2.KK%.4B>XFAMI+
ME/J#X[_$OP/\1OA9\1+CPO);:KGPCJT=UJNG-;SVZ^3:7!@LY+J-SYDH\^:9
M8(_,^SHS23>1]JMOM/Q!\3?BQX'B^#'[.]NVO::);36_!=[<1F]MPT5O:6TU
MO<3R+ORD4,T<D,TC82*5'C8JZL!]?_\ -[W_ '3;_P!S]'[0_P#R<[\$/^YN
M_P#33%6?JVK6.@?MH7%]?7$5M;6WPR>:::9UCCCCCUTL[N[$*J*H+,S$!0"2
M0!6A^SQ_R<[\;_\ N4?_ $TRU\8?LGV'[.'B_P"!]CX7^(VK1:3?64MQ8:KH
M>H>)M8TR)+BVO'<%]/N=1BB#N1'<2F*,0BZ:4*L;QM''[_??!/P[\7M>T"+P
MKJFK_#SQAHGA;2Y=/2.<S'^Q&OY1:VM]97#I+</;BU O8&(BAN+F.*:>_18\
M_4'['OQ#\5?$'PEJP\2Z+8Z5?:9X@UC3)6TN.:.QO)(+IC/>6RS*'*27#S)(
MY9S)<1S2,RNSQ1_5]?CC\3_C!X9\=_#KXPI:ZO8^#(])OO$6CRZ=9-I*2:S?
MFUG'VF\>YM6E9[\0F*&*W$5R3!='[7<ML%H>/=6L=1^"W[.\-O<12R6OBGP#
M#.D;JS12'2Q,$D )*.8Y8Y K8)21'QM92?H_]H?_ ).=^"'_ '-W_IIBK/\
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M&T(T1:Y,0:%YDVB&;>$NH=WZ'WOC_P .V'B*V\.O>Q'5+F(SI9QDR3B !_\
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M89;>YN97,4\?*BUQG=+)'%[A\1O!GCOP-^SI\0K3QCXJ_P"$GO7T37)8[O\
MLZWT[9"=,=5A\JW9D;:RN_F$[CYFTC""OSPU/]F?Q%\%?ACX-^//PCEBT_5]
M/\+:9=:YI[86UU"U73X9;F5DW(I<JGF7,65,Y47,31W\8:X_8[X%_'3PA^T7
MX0M?%'A>Z\^TGRCHX"S6\R@%X)T!;9*FX9&2K*5D1GB>.1O8*^$-5TR;0OVR
M-,U6\:*&VU7P)=:;9-)-$K3W5GJT5U/#'&6WLZ03)*?EP4WLI(BEV=!^TA\3
M=)\+?$GX?>&Y;6QMM1\02ZK;6.NW*V[SZ6T<, D6T6XC93<7JRBUARX03-$9
M+>\0&VD^?_V,O%.@S_'SXM/!XHBUZ.]E\+PVNH23V#->R)I5W(R1FQC@MY'B
M2&4%88P0D#LX+)(]?J?17SA^U[\(9OCO\&O%'A:W262YN[%I+6.*2*-I+JV9
M;JVC+R_(J//#&DA8J-C-\\9PZ\_^Q!XUL?&/P2\,PPI+!<Z/8PZ'?VMP%2XM
MKS3(UM)XIX@S-$^Z/S%23;)Y,D;LB%]H^?\ 0_!5C\=OVP[SQO9O*;'P'I$>
MAF9"OE3ZK<?:FEBC=5D21+:WO'2Z3?#/!=&)60IG=X!X1^(7A7PU\'OVB['4
MM6L;2YF\4^,X8H;BYABD>2[LG6V1$=@S/.T$RPJ 3*890@8QOCU^7XW^%?AU
M^S=\']2N+32-2CNY?#FDP7NH-#+:Z5>"P>,Z@^>"]C)!()466UD4B5/M,#!B
M,_X>Z[H^C?MEWBS>,?[>^S^"/L$UU>3:6&@NV\0Q0+8O]@M[2))?-=%6&1#<
M&68(2=T:#V#]@7_FJO\ V4GQ'_[;5\__  L_TWX2?M :7#^\O=3\7>.K*RMD
M^::ZN'TW>L$$8^>64K&[".,,Y5&8#"DC \$K^R=\8/@QH#Z]??VG<1:;;S+X
M;B\3ZQ),M]!;&(V>GZ7=ZKYGF[]]M91J,R*Z+&[QR*[?1^DR7TW[:%N]]%%#
M<M\,D,T<,K31I(==&]4D:.%I$5LA7:.,L &,:$[1H?\ -[W_ '3;_P!S]9_[
M<_@:;PC?>%OC1I$,IOO!=\DFHBT@BEN+C1+AO*OXU5HF,CQ1R.\9DEABMX9+
MR;>C[77Z/_9K_P")WX0_X2N3F7Q3<RZ^6/#&WNPJZ<DB#Y$EATV.RMIECRAE
MA=_,F=FGE^@**************************************SX])L8;Z6^2
MWB6YFBBADF"*)'CA:1HT9\;F1&FE9%)(4R2$ %VR66DV.G37,UO;Q1274HFG
M>-%5I9!$D(>0@ NXCBCC#-DA(T3.U5 \O\+?L]?"SP-JD.J:)X2T33[V#=Y5
MS9Z9:03)O0HVR2.)77<K,K8(RK%3P2*T-<^"'PZ\3WU_?:GX:TB[N=1B2&\F
MN-/M99+F.-HF1)W>,M*B-!"RJY8*8HR #&N.?C_9D^#T-C+8IX+\/K;32Q32
M0C2;(1O)"LBQNR>3M9T6:548@E1)( 0';/J'A;PGH?@;2X=+T2PMM/LH-WE6
MUG#'!"F]R[;(XU5%W,S,V ,LQ8\DFN@KQ_4OV>OA9K/VS[9X2T2?[=<K>W7F
MZ9:/Y]POFXGFW1'S)1Y\V)'RX\V3GYVSGR?LR?!Z:QBL7\%^'VMH999HX3I-
MD8TDF6-9'5/)VJ[K#$KL "PCC!)"+CL-?^$_@?Q7H=IH6J:#IMYIMGY?V:SN
M;*WEMX?*C,4?E0NC1IL1BB;5&U"5&%)%=AI.DV.@6-O8V-O%;6UM$D,,,*+'
M'''&H5$1% 5450%55 "@   "M"N/\2?#WPKXSANX=8TFQOH[R*"&Y2ZMH9EF
MCMI7F@242*PD2*21Y(E;(C=V=0&8DG@KX>^%?AK8O8^'-)L=*MI)3,\-A;0V
MT;2,JJ7*0JBERJ*I8C)"J,X QG_\*G\#_P#"3_\ "4_V#IO]M?\ 01^Q6_VS
M_5>1_P ?&SS?]5^Z^]_J_D^[Q70>*?">A^.=+FTO6["VU"RGV^;;7D,<\+['
M#KOCD5D;:RJRY!PRAAR :/"WA/0_ VEPZ7HEA;:?90;O*MK.&."%-[EVV1QJ
MJ+N9F9L 99BQY)-9^F?#WPKHLS36>DV,$C7TVIEXK:%&-Y/$T,MT2J@FXDC=
MXY)O]8Z,R,Q5B#Q__#/7PL_MS^W?^$2T3^TOM/VW[9_9EI]H^T>9YOG^=Y7F
M>;O^?S-V_?\ -G=S1XI_9Z^%GCG5)M4UOPEHFH7L^WS;F\TRTGF?8@1=\DD3
M.VU555R3A5"C@ 5V'B3X>^%?&-]I]]J^DV-]<Z;+YUE-=6T,TEM)N1M\#R*S
M1/NC1MT94Y1#G*C''^%OV>OA9X&U2'5-$\):)I][!N\JYL],M()DWH4;9)'$
MKKN5F5L$95BIX)%=!_PJ?P/_ ,)/_P )3_8.F_VU_P!!'[%;_;/]5Y'_ !\;
M/-_U7[K[W^K^3[O%9_C7X(?#KXE7R7WB/PUI&JW,<0A2:_T^UN9%C5F8('FC
M=@@9V8*#@%F.,DY] TG2;'0+&WL;&WBMK:VB2&&&%%CCCCC4*B(B@*J*H"JJ
M@!0   !6A7/_ /")Z'_;G]N_8+;^TOLWV+[9Y,?VC[/YGF^1YVWS/*W_ #^7
MNV;_ )L;N:\_U']GKX6:OI=CI=WX2T2>RT_SOLEM+IEH\-OY[AY?)C:(I%YC
M -)L"[V 9LGFA/V>OA9%JEMJB^$M$%[:?9OL]R-,M!-%]D1$M_+D\K>GDK'&
ML.TCRE1%3:%4#0U/X(?#K6O$2^([SPUI$^K++#,+^73[5[H20!1$XG:,RAXP
MB"-MV4"KM(VC'0>"OA[X5^&MB]CX<TFQTJVDE,SPV%M#;1M(RJI<I"J*7*HJ
MEB,D*HS@#'85X?JW[,GP>U^^N+Z^\%^'[FYN97FFFFTFRDDDDD8L[N[0EF=F
M)9F8DL2222:-,_9D^#VBS--9^"_#\$C130EXM)LD8QSQ-#*A*P@E)(W>.1>C
MHS(P*L0>@LO@A\.M.\.W/ARW\-:1%I-U*)I["/3[5;660%"'D@$8B=P8HR&9
M208TY^5<=!X*^'OA7X:V+V/AS2;'2K:24S/#86T-M&TC*JERD*HI<JBJ6(R0
MJC. ,<_X;^"'PZ\'6.H6.D>&M(L;;4HO)O8;73[6&.YCVNNR=(XU65-LCKMD
M###N,88YY^R_9D^#VG0W,-OX+\/Q1W40AG2/2;)5EC$J3!) (0'0211R!6R
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M[\JRVES<6=SAO+1F:*6SFF1XMS,B,XAE;86:",%<^@5Y_P".OA/X'^*'V?\
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M/U'X3_M3ZO;V-O=Z#\))XM/MIK*TCELM7=;>WG@%O+!"K(1%%)"!#)&FU'B
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M^+Q9J5OJ]M;36DLT0M"UTDFM#35:::2WDN%EB@_U<]O+!.929I))9,,/I_\
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M:1Z?\68/+U>RN7MH)'G@N)I[-(HC%+/+!-,CR[FDC+DK(ZQJ\@:1FED^;_\
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MK'6&M8OM*V&J:==02WUJ83.I^2:%HTS,0T3QSI)-$Z/)S_BGX%_&_P =^,_
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M;>ZCF6^OA:RHYMC<;88K*XMBZ0_:;HWBM&'DMEBDCN,_XR?!']I'X_? ^Z\
M>(9?"R:C/%:B?4XKN_9;MK:\BF -N+"%;5V6,/),C7",Z-&EK"EPLEKV'Q3^
M ?QGO/'&B_$[P=JFB6_B:+39M%U&PU%+E]+DL9+B6ZB2.6-#=&6"1D5I@(!=
MF-9A':)OM)?H_P"%_@'Q5:7Q\1^-+VQO-;EL8+()IMO-#9VD88S3);"YFN)B
M\TK*+B?="+F.UL=UM&UN"WN%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M>/\ QK^ G@3]HG0X=$\8Z=_:%E!<I>1Q>?<08F2.2-7W6\D3G"RN-I8J=V2,
M@$?,'_#KC]F+_H4?_*GJW_R91_PZX_9B_P"A1_\ *GJW_P F4?\ #KC]F+_H
M4?\ RIZM_P#)E'_#KC]F+_H4?_*GJW_R91_PZX_9B_Z%'_RIZM_\F4?\.N/V
M8O\ H4?_ "IZM_\ )E'_  ZX_9B_Z%'_ ,J>K?\ R91_PZX_9B_Z%'_RIZM_
M\F4?\.N/V8O^A1_\J>K?_)E'_#KC]F+_ *%'_P J>K?_ "91_P .N/V8O^A1
M_P#*GJW_ ,F4?\.N/V8O^A1_\J>K?_)E'_#KC]F+_H4?_*GJW_R91_PZX_9B
M_P"A1_\ *GJW_P F4?\ #KC]F+_H4?\ RIZM_P#)E'_#KC]F+_H4?_*GJW_R
M91_PZX_9B_Z%'_RIZM_\F4?\.N/V8O\ H4?_ "IZM_\ )E'_  ZX_9B_Z%'_
M ,J>K?\ R91_PZX_9B_Z%'_RIZM_\F5]?_"WX6^&/@MX8M/#/AFT^QZ;9^;Y
M$'FRR[/-E>9_GF>20Y>1F^9CC.!A0 .PU/2;'6H5AO+>*>-989@DJ*ZB2"59
MHG 8$!XY$22-NJ.JNI#*"-"BBBBBBBBBBBBBBOG_ /:+_9[T_P#:6\,/X9U;
M6-2L=-GQ]I@T[[$OVC9+%-%YCW-I<R+Y;Q!E\EHMV6#[UP%]@\+:->>']+AL
M[O4KG4Y8]VZZO%MEFDW.6&\6D%M"-H(1=D2?*H+;GW,W0444444444444444
M4445GQZ38PWTM\EO$MS-%%#),$42/'"TC1HSXW,B--*R*20IDD( +MG0HHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHK/DTFQFOHKY[>)KF&*6&.8HID2.9HVD17
MQN5':&)G4$!C'&2"47&A6?9:38Z=-<S6]O%%)=2B:=XT56ED$20AY" "[B.*
M.,,V2$C1,[54 CTFQAOI;Y+>);F:**&28(HD>.%I&C1GQN9$::5D4DA3)(0
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M\+164VMWVF3"&\N;]I'==-BNX+KS8+=@N+IX8X[E)+2YM#+$)58Y_P"TA?\
MB3]BJSM?B#X;O]2U'0$N;&S\0:9JE]=:KY=I)<A?MUC)J%\)HKL&3[-Y2R/;
MS>=%))"OV=I#H?ML?M":=X>T;P=I5B);ZQ\2^(-!BNY;>POKRVN=)N)VFEC@
MGMHWM[E[E(!$UFK3RW-I-(HMG257'C_Q[O\ P?\ L@? ?QIKWPUM-7TN;Q1*
MTT,4ECK5M;V,DLL%A.\4310+I3A9'FMFF\@RS>4L1FMX;:WC[#2?AA\ ;'XA
MZ?JWA7Q'<^!M0N]2TN6XT57NO#W]IK9K<)!"FE7BV9DBN9IHDDD6WFBF^SRP
M0B.XFNY6^_\ XD?%+PQ\)-+BU'7[O[/%/<P64"I%+/-/<7#[(H((($DFGE<Y
M(CA1WVJSXV(S#G_!_P >_ GCBWUB:TU'R/[#P=2CU&"XTZ:S5H!<+)<0WT=O
M+%$T69$F=!$ZJY5SL?;G^&_VC?A]XL\16F@V=_*+N^BGFL?/LKVV@OH[<(TC
MV%S<01V]Z@1UE#6DDP>$^>I:'+UP'B3]NG]G_P *0W<MUXWTAUM(H)9!:W N
MV*SRO$@B6U\UIG#(3+'"'>!"LLJQQ.CM]7UY?\1OC)X2^%,VG6^LW4JW.IRR
M16=K:VMU>W5PT,1EE,5M9Q3SND:#=+($*1@KO92Z!CP;\:/!7CWP[>>(-.U.
M+[#82W4-[)<K):-:269/VA+N.Z6*6V>(#<ZSK&50K(1L96//^&_VBO WB?Q%
M:>'DFOK/4;V*>6U@U32M3TQKE;<(9A;G4+6W69XU=7>.(NZIF0KL5F'(:=^V
M+\+=7U2^TBVNM2EU*P\DW.GKH6MF^B69"Z2-9_8?M/E8V[IA&8HS+ KNK7$(
MD]?^&_Q2\,?%O2Y=1T"[^T107,]E.KQ2P307%N^R6">"=(YH)4."8YD1]K*^
M-CJQ\PT/]K;X5^([ZPMK3596CU&^?3;*\>POX]/NKI&E3R;?49+=;&9V:&1(
MO*G83.NV,NQ /S_^RW8-H'[0GQ@TA+N^N;;3XO"D-L+^^N[^2..2QNKED$UY
M+--L\V:60*7(4NV  <5] 6W[6?PSO?"NI>)X;R^DT[2KZXTZ_=-'U9I+2XMH
M?.G6XMQ:>?"D2<RRR1K#&?D9P_RUW^I_&CP5HO@)?'=YJ<4&A-8PZB+R59$4
MV\Z*\3!&42EY Z".+9YSNRQJAD8*?@#QQX_T+Q7^U'\*SHU[JZ-=R^()[[3]
M2.KVBAH-%:&TN$TS41$L*%7N42X@@C2=Q<CS))4FV_;_ (__ &C?A]\-)KV'
M4[^5Y-.B,U^EA97NHM8Q^4)@]Z+""X-FC1DR1M<^4)45W0LL;E>PU_XI>&/#
MFAVFM2W?VBTO?+^R-8Q2WSW7FQF5/LL-FDTMSF)6F_<))B!))SB*-W4^'OQ.
MT#XH6]Y-I#7/^A7/V.XCO+*\L9HIO(BN CPWL,$HS%/%(K;-K*X()YQZ!111
M1111111111111111111111111111111117E_QOU/Q%HOPZ\2WGAQ96U:#2-0
MEL!#")Y#=):R- $B*N)',@7;&58.<+M;.#\8>&O[#_X85D_L?[-]G_X5_=[_
M +)Y>S[1_94OVK=Y?R^;]H\WS\_/Y_F;_P!YNKQ_PM_R-W[*G_8MZK_ZC5I7
MT!^SQ_R<[\;_ /N4?_33+1^P+_S57_LI/B/_ -MJ/V!?^:J_]E)\1_\ MM7S
M_P#LT_\ */.^_P"Q;\6?^CM2KH/'N@?VG^S3\&M1@N[9+_1[GP7J>GV-S)Y/
M]J7D5K''%IT4N'\J6?S6*2E'CCV%Y?*MQ+/%](?#GX/ZCK7QUU'XKW.D2Z L
M_A^/0FL;I;%KJYG%V+A[V62PNKJ'8L4=O;1;Y&F<(RLL,4,)F^SZ^ /V!?\
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M9FROU>1C$T:1M%,C2AE "F1'V[7/PA\$/^$GT3PW^S3IWB_YM+GN=8NY&O\
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M1^']O;:-X&_<)::;>07-SJ3XUZ,2RO=-?M';YNS(5A*7N84#^?&T_DVOV_\
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M!;Z=;7$?V;.DH7BDN9KA_M>,HJS+;V6[8SF!/,$<7H'[/'_)SOQO_P"Y1_\
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M^M>+M2T[2M+M5D@1I)EOH)RS>;)'B(>6L32C*I+/ 'VJ^]>?_:B\"_\ "K_
M_P #/#/VC[3_ &1XW\'Z=Y^SR_-^RV\T/F;-S[-VS=MW-MSC<<9/H'_!4?\
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M3/JD3PW$^FQ?8Y_+DBBB9(9K<QRVZ$0QOMMVB F!N !.S2'/\ ?LQ> ?A?\
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MU]>>'(;Z"2_EFGNA-JNIW<<T\[(TMP\5W=31-<.8UW7!7SB 5\S:S ^@>/\
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MO<()5=&$B122,;>-LI;C:D*QHJJO(6O[%_P5M+?3XD\,VQ;3]JPSN\[W+1+
M]L+>>Z:0W%S:>0YMC9W,DMJUL%MS"841%Z_Q)^SE\/O%?B*[\07=A*M]>Q01
MW,EM>WMJLYM0_P!FEFCMIXHI;BV+[K6Y=6N+5TBDAEC>"%D/A5^SKX&^"M]?
M7GAR&^@DOY9I[H3:KJ=W'-/.R-+</%=W4T37#F-=UP5\X@%?,VLP.?=?LO\
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M7/\ :XM-35]-OIWNVM998/.EDBO;0VD4LT;*D?D7,J0*EPY\V5K.W[_]FO\
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MQXEM<?\ ".7(CLY;.RNK"&_66QL9+<(LDVH,N^\NGLVG5Y(D9"S*OER ?/\
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MI-8S7FGZ=':0&<M=K#-;L7N&VV]LAFA#.[R>8QA$$V!\%_C-?>,?%OBWP1K
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MJ7>L6_V35/$FMZEXCOK1;A+E+2;4)=RVR2I'$'\F%(DD8!E:<2LCM$4QX?\
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M"-IX=UR/PVC7$PU2VEEN_MOV%8X$DB9GECADQ$(5FFSY):*&X] ^-7COQ?\
M$'X6>*KZ?0=;TZRU7PW=Z9I>DOIINM1N+Z^M+AC+=0Z<+][:)5$$,'FR6QBF
MDO%NX@?L;+\X?'6YU/Q7^Q1I_@O3]!\03:V=(T/3OL0T#6!(+C3GTV2Y5MUH
M%5%4-LE8B&<I(L+R-&X7];O"WB6S\8:7#J-I'<QQ3;MJWEI<V4PV.4.^"[BA
MF3E25WHNY<.N496/QA^WC^S/XB^._AW1]<\'2Q0>*O"M\-4TEY<;9&4H[VX\
MQO(5W>&"2-YT=-\*Q,8HII9%]0\+?M0V%YI<+:_X<\2:1J2[H[NR'A_6;]89
MHW*.([NQLIK:YB)4M#/"Y66)D?:C$HOE_P"T[\.OB3\?O 6F:IH>EQ:7K?AS
MQ!9>(M,T[5)H96NVT]'"P7+VLQ@@>5Y)#&([B9&1(?,GMVFE%KG_ !NU!/VS
M/ EOX%TW1M;LDUJYTV356U73=0TEM/L8+B*\N"LUU9O;3W>84M8H(7E!EF\_
M<UM#*XX_X#^,1I7Q\^*OB&[T?Q!!IVN1:%+83R^'=;C69=,TJ870 :R#*ZL-
MD<;A7G<K'"LKNJD_8W\8CX?0_$B76='\06BWWC+6==MA)X=UO=-8W<MK%#)&
MJV19G9CDP &X1%>5XEBC=U^,-8@U#PU_P3LU3PSJVF:EINI:7]G^TP:CIU[9
MX^T^)A-%Y;W,,<<V4(9O):3R]RA]C, ?O_\ :(NKC]J[0(?AC9>'];MDU:YM
M6UJ[O;.?3X=-M+&\M[FX5+J:"6VO+N0I]GM5LFNK=V+W!G^S1[Y/#_B%X,\<
M_%"Q^(_A[QIX'OO$.NSRZO'X5NI+;3'L[72[E9XK&2"YFGBM;:XBF"O<C*ZK
M+&]I(R7,=L#:X'CMM>O?@]\#;(>&O$ FT#Q!X6N+V,:-?RR1V^DV2QWL[0PP
MR31I'+(846=(IKDQR2V\<UOLF?V_XQ:_+XO_ &B?A'JFG:3K<MEI7]M?;;DZ
M'JR0V_\ :VF0):>9(]HJ+N9MLV3_ **P=;CR3&X70_;G\ >(M!OO"WQ6\$65
MC<^*/#U\FFPPWH"QW<&M-_9J0NRF)V>.XNXV@WW$,,0EN78L6VG[?^'O@JQ^
M&OA72?#EB\LEMI5C;6$+S%6D:.VA6%"Y544N50%BJJ"<X4#@>0?M+>)8= TG
M1;?4/#,OB/1]1U>&RU:UBTJ75FCM3;W$J7)MHU?*0W45JTC%)2J;O+C:<Q"O
MB_P+^SEK$W_"<Z!\/+C4K#P-JWA&ZTJSTW7UU2W2VUJZ\Y2UI!J5O]LBM!'(
M9KF50R33W1V>>T)CM?0/@7^T1\5]0\(6O@NZ\ >)(?%FFZ:;&74=7BC;2'N[
M8"U6[FOY+J&2ZBD?9<3BU6>X>-I3!]I""5^/\1?\+)_9%^.&N>+8O#NK^,?#
MGBNQTB*^N=,M89]2M[[3;.6VC/V:W>-9$D6,RW$@@M;=6N46-D,(AN/0/VI?
M#/Q)_:E_9[\1V>DZ!+:3ZM%I3Z9I5Z8;?4 L5];W$\EXSS_9X'9%.RUW%XDB
MW2RF><VEIS_BW6?%OQF^.'PF\5Z7X+\06^EZ3%K<MW-J$%K9M$NH6=M:$/%/
M=+,CV\KD2QR(CSI'+-9+>PKYAT/[?E_X;"_MW^R=;_LW_A$?^$=^V?V'JWV?
M[?\ VWYOE^=]D\ORMGS_ &O=]DV?-Y^WFC^WY?\ AL+^W?[)UO\ LW_A$?\
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M<-#L$DRV*2*X:.2^GCM4!(>\(BE=?T/K\P/AC\1;/X>_M._&>2]L=2GMYO\
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M;B*ZC!F4^_\ PJT[Q?I'A#2K;Q??6U_K45M&M[<V<)AAEF ^9D0G\&8+$LC
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M7V;/L^BN/^(5[XBT[PKJUQX<MHKK5HK&YDL()B!'+=+"Q@C<EX@$>0*K$O&
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M:AXRTO0K@1:OJ4,;V,6L:@T4?E17"1*\1@A\B=56XA$,*QRHL487[?\ V@/
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M@6VTA;33KEHYK&>\U:UN)Y;Z>W:("66.$I;6Z3-+'"/.F15EFS'X?\/;V'X
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MC)?ZO';:S+XAFNX;?6=4MX_,L='5;=X$@NHUM7599%9K40F42R"0N)'W<?\
MMA_ 'X>?#OPQ\(?#.EZ+;+IMM\0-(LHH+@-=8M[^6YFNX"]R99&BG<!I8V9D
M?:@(*H@7T#XLVVH>)OC?IGP[TW2-$U#1=*\(C4(]!U"[O;"SG\Z_%JLDD-O9
M7UE<16*VD2V]O<0KY,ESY\6YH@8?'[3X)_$#X&?#3XHVWB#7;;3[=K;6?$_A
M?2_#VL7UNVF&&*[EG2(PQ:=(]I$]S:#R K6?FD2-!')*-_0:!\"/!GAK]EB[
M\:V]O<OK5U\+9+*2YN=0O[K%O+I N6@BBN)Y(H8A* Z1PHB1\J@520=#QY^R
M[8_M1_L?^$M.AM(I-;L?"VE76D3%5\Q;A=/MV:!7:2)52Z5/(?S'\E2T<[(S
M01[=#P#J7@?]LOPA\)%OO#>FF*2VO=2N+6:PMQ!%;Z*(["XM;,9F>")M2ET^
M2.%61)["W>&X8H6M9OT_KX _X*C_ /)L7B[_ +AG_IVLZX_]M;PG\;9OA-JT
MMYK5CJ.DV\4EQJ]GH5K)H-]/I\<$IG2.]O+O6(@BG9)/#]G5[BW26%9?G\F;
MS_\ :S\:^"OB#^PC>:GX+26+1#8Z/;V44PD$D,=KJMI;>0_F,[%X6B:)FWR!
MRA99)%(=OL#]I'2M)UK6?#$&LZG%<6(EOI'\*FUM[J3Q#+Y CMXUCFE0%+.2
M07+F16M8CY=U<O;I;+<Q?+_P4^,VH_#/7?C=&FARZ9H_A&QTW5M/\/2?88%M
M6?2)KFYCC:Q:Z@A2Z>W68B)Y$5Y7F,8GEG#=!X#_ &1/"OQU^"5AK5_/*GBW
MQ+8Z?K\GB=XX9-3M]0ECM[N-[>;8C06\#)'#%;6S6Z):IY:-'(S3'S_]H?XJ
MWWP9_:IN->M;&6Y6+X=PI/,D+7$=A;R>(@LVH7$$3I//;VB$S2PV^9I NW=#
M$9+F'L/C%X3\#_L3? 'Q'X^^%=AIJ:I/;6TD6KB&WG:8:C=6D+31M&JPK$P9
M;B&VMTCTY951DM?*S&?0/VH?V</"'@OX::SXM\'V5MH?B3P];3:Y::U;P![Y
MIK*)YI1<W#,);S[7$)8+DWCW"S&9IIDG<<^/ZIK_ /PL3XS?LX>,;RTMHM2U
MO1-:N;J2WCVY\S0HK@1!F+2&*-[B8Q([OL\QSDL[%NP_9E^'OA71?CY\<?#E
MGI-C!I+1>%H3816T*6ICGTJ<RH8%41%)"[F1=N'+-N!W'.A_P2G\)Z'I'[.W
MA_5+2PMH+W4/MOVNYBAC2:X\C4[Q(O.D50\OEJ2L>\ML4E5P.*_1^OS0\:WO
MBJP_;01_#EA8WUR?AV \=_?36,8C_MULL)(;.]9G#!0$,:@@LWF J%;L-1\"
M^./A3_PGOQK\47&FW7B&#PW>0:996B7#6>GV=C]IO4MFF+6\E[Y[K!+/+)#;
MR+()$A*0LJK\P7/[,GQ;^)_P_P#!6N>"U\-V'B&V_L[5E\7OJVI76I:BIL70
MF=[O1EN3%<"96-M<2RQ1PJMH83"JHO?ZU\-_"GQ=_:G;1+G4-2U'0-3^']QJ
MRQ1:_JK6\IU'5TCF,+17@ M)X5C!MHF%FZ)&1#\B$>@?#3PZGPB_:GC\#Z%>
MZE'H$/P_6\BTZYU34+VWBF75TME>*.\N)Q'MA18D5-JHF0H&YL]!\#++0_VJ
MM4\=ZAX\T73=8;0_%VJ>'].CO+2.XAMK.P2 +Y45QYJ)+,SO)<S*!).QC1F\
MFWMHH?F"Z^.GB_\ 9/\ "'QJ\+V-U]MM/ _]D)X>>0'SK*'7P1;P%YS<^?%I
MWFQ^0)@S2+&T;,L31QP;_P"WK^S%\//A#^S%XBN-)T_.I0?86FU65V;4;UY]
M6MC.]_=+MDN_->0S/'-N@$PBD2)&@@\K]?Z_.#_@JQX3T/5_V=O$&J7=A;3W
MNG_8OLES+#&\UOY^IV:2^3(REXO,4!9-A7>H"MD<5Q_[9'P7\%?#J;X;W7A[
M3(M+OK[QWHVG76I6+26VI3V]Y%=17*S:E$R7TCSJQ\^5YS-*Q,CNSDM70?$'
MX>^%?@]^TO\ "&'PCI-CH<>J1>*H;Y-+MH;-;J.'3H9HTN!;K&)D215D19-P
M5P' # &CX'?#WPKK_P"T)\=M%OM)L;G3KF7PI--:36T,EO)))8S7+N\3*49V
MG)F9F4EIB9"2YW5X!^S]X;^)/B?]BWP)%X(M(M1DBU>2?4M+EGAMQJ>FQZS>
MFYL/-G1HE28^6)PY59+<31-YJN;>;Z/_ &2=9^$'Q USQ%9Z9H5MX<U*_P!$
MTNVUOP?<Z2MB]OY,E\9)9(VBBCNXKA+Z-"XBX@^SF8(UPD*'_!*?PGH>D?L[
M>']4M+"V@O=0^V_:[F*&-)KCR-3O$B\Z15#R^6I*Q[RVQ257 XK]'Z******
M******************************S]6COIK&X2QEBAN6B<0R31--&DA4[&
M>-9(6D16P619(RP!42(3N'PAX"_9 \<?#_X&W7PHMO%FFR64UM>6*74FA7'G
M+;W_ -K:Z!"ZL$:4M<J8) %2)8V5XIS(&CZ"']C?['H?@>YM=6MK?Q9X+MH+
M&QUN/3?DFLXHVMVM;JS>Y9I8I;=F1MMQ')%.[W%O);B1XF]O\%?"K5K/Q4_B
MSQ/JD6I:LMB=,M_L4%Q96=O:O,L\NRTEO+T?:)Y$B\^X,F7CM[:-4C\N1IO(
M/@K^SK\1?@G#XI%GXITBXD\0:O>:Z6ET&Z"PWE[+ 90%76 7MQ'$Z1Q;ED5W
M61IW5#%)\8?&#]GO5/V>?A1\)/ ;:]]J^R_$G1UM;^ULDM9HENI+R;<8YY;V
M)Y8Y99&1F7RBOEHT#;7:3]#]#^#/BK5?&MAXH\9>(HM2;28G&F6.FV4VFV<-
MQ/'+#/=S1O>WKW-P8)3;Q&200P1M,4A\V4R#G[O]F;4=/^).N>,O#OBN^TAO
M$D5M'JT*6MC<,S6,,<-G)927$+K;.BK(LPGCO$F2>0*D,JPS1>?V7["FDVO[
M.=S\&GU^^FMIH@4O)(K<-#.+A+S,<2(F;<W2-*899))MDCPBZ $;Q^P7/PA\
M9>.K[3?^$TUZQO;'3KZWU.*UTG3KS2S+=6K;[;[3(^J7HFMXI-MP+?8@:XAM
MW9RD;Q2\?_PSUXX_X7?_ ,++_P"$DTW_ )!O]A_8O[%N/^0=]O\ MNWSO[4_
MX^_^6?VCR_)_B^R?PT?"/]GKQQ\._B?XD\:ZAXDTV]_X27[!_:%M!HMQ;8_L
MZT>VM_LTKZI<>5G<'E\Q)]^"J^5G*^7^&_V&_$OPE\5:A>?#CX@WWAO1-5OO
MM]]I"Z9IUW&)&F=I!8M,@ALT\IDAC MY2HBC,C3K''&GW?X6\+:7X+TN'3=-
MA\JWBW$ L\C,TCF222220M)++*[-)--(SRS2N\LCO([,?/\ X\?#S7/BSX'U
M/PSI>I6VF_VI;7%C<SW-E)>8M[FWDAD$2)=6FR7YPR2,TB+M(,3[@5^</''[
M(GBKQ_\ L_Q?"6\\3V*1Q1:=9"^BT>8-]CT\0&)#"VI,/M#26Z-)/O\ +*%H
MUME8B0=!\:OV=?B+\;(?"PO/%.D6\GA_5[/70T6@W16:\LI9S$"K:P2EN8Y4
M22+<TC.C2+.BN(H]#_AGKQQ_PN__ (67_P ))IO_ "#?[#^Q?V+<?\@[[?\
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M[Z?81S&SE?:+6?462:X>+R&>W/D"UD52I@DMEC2,>@?\,]>./^%W_P#"R_\
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MX<O?#$K:WX4ETT3VFDWT%U'<QZG L\+07%^-+7>B^89DF6(*$'ER3,^P>?\
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MZM+/&#.)5A6 Q3,5Q] :':^+_A?\&-4UI=/^T>+)M-O=<NK4J;DRZO+;-/\
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M75WN$U.\9;..QDDCF:[E.U(8"JO)(Z*/O"N \;_!G7/V=?V>?@]I^J07,_\
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M99I[B";[,)[7\\-2\4Z7HO\ P3LO/#%[-]FU2QN5L;BUN%>)X[L^)I9S:'S
MH^UI#"\\MJ";B&#9-)&D4L;O]G_MS_&_X=:U#\+)K/Q+I$\:^.]!U,O%J%JZ
MBS@ENX9;HE9"!;QR(\<DW^K1U9&8,I ]@_;Q\!WP\.Z/\2]%CEDU;P#?#6UC
MBN&MVN-/4I_:=H9/,5(TEMX]\C&.=V2%H$B;SV5O?_V>-)OK7P5;ZIJ=O+;Z
MCK<LVMWD5PC+<0R:A(9TM)RX#N]C T.GJSA#Y-I&HBA15AC]PHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKG_%.LWGA_2YK
MRTTVYU.6/;MM;-K99I-SA3L-W/;0C:"7;?*GRJ0NY]JM\@?\$^? WC/X2?!W
M2O!WBK0KG2[W2OM.Z26>PFAG^TWUS<#R6M+J=_W:N@D\Y(?F8!/, 8C[?HHH
MHHHHHHHHHHHHHHHHHHHHHHKX0_;2\)^.?']]X'M_#GAF^U2/0_%.D>(KJ>&X
MTR&/R+-K@2P(+N]MY6N,,K*"@A(8?OPP91]OZ3>S:C8V]Q-;2VLDL22/!,8C
M)$S*"8W,+RQ%T)VL8WD0D':[+AC\(? +P_X^T;X[?$#Q-JWA#4M/TWQ5_8GV
M:>>YT>3R/[,T^6&7[2EMJ,\@\QR%B\E9\[@7\M02/O\ HHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHKXP^"6A_&WQOXJAUSXHV&D:>NA17UG96VFO)
M/'>7-Q,H_M5/,E?[,B6J_9;9'!NR+F_,A@BF$!^SZ*******************
M******^,/B5H?QM^(_CV?PI+8:1%X(GETV\?4M\CW,MM;NLE[I4UJ90)7O9$
M$3N5%HNG/,D@N9I?*3[/HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHKY0_;*^/'BK]FSX;:CXNT72K'4([.("7[7=S0M%)/-#;6[)#';R"
MX023;ID,]H0B820L^4^KZY^V\4Z7=ZY=:)'-F]M+:VO)HMKC;#=R7$<+[B-A
MWM:SC:K%EV98*&0MT%%%%%%%%>7Z[\381X*UKQ%X?M9=8DTV+5!':0K*DEQ=
M:9)/!):H/+9][7%N\"LL;ACAD$BE=W8>$]1U35]#L+O5+'^S[V>VAEN;3SDG
M^SS/&K20^:@"2^6Q*>8H"OMW 8(KH*******************************
M************************************************************
M*********************************************Y_Q3HUYX@TN:SM-
M2N=,EDV[;JS6V::/:X8[!=P7,)W %&WQ/\K$KM?:R_FA^R3X/\:_M*_ /2O%
M6J^._$$.NWLM_<VEU%<1I!9W$>JW&";2!((KRW<Q(LEK?FYA2$-!:_8XVP/(
M/AS\;_B9\<]1^"-TWB[5],C\61:^;^*U32=JW&AV+VWFQ;M-P4NI!+<2V]R+
MB&)Y%\I4:"%T^O\ Q/J-]\'M9^'/P>@U75]0A\2RZV+K6+^_:34_L]A U\T0
MN%C1@\S2I;BX0I-;VJ,L+1W!BN8./^-X\2?LO^+_  C<^&]6U*71?%>I0>%=
M0MM0U6ZU&:UN;TO]BU'3WU,7WERP_OC/'(SVTZI!&UL6S-'S_P"S9X4\3_M
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M1Q/(J+N9@[1QEEB\Q5SC;G0TSXW_  ZUKQ$WARS\2Z1/JRRS0FPBU"U>Z$D
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M_IGA_5+&YDTF^DMHQ#=)))<P106K27:185_LZW%P]LLRB2&0Q"1)6610/3]
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M/JRRS0FPBU"U>Z$D 8RH8%D,H>,(YD7;E K;@-IQZA7G_CKXL>!_A?\ 9_\
MA)M>TW2/M._R/[1O;>U\WR]N_P OSG3?MWINVYV[ESC(SG^-?C?\.OAK?)8^
M(_$ND:5<R1"9(;_4+6VD:-F90X2:1&*%D90P&"589R#C0U_XL>!_"FN6FA:I
MKVFV>I7GE_9K.YO;>*XF\V0Q1^5"[K(^]U*)M4[G!498$4>.OBQX'^%_V?\
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MOY-0M5M99 7!2.<R")W!BD!56)!C?CY6QH?\+8\#_P#"3_\ "+?V]IO]M?\
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MDOFB0L0J15\O_P#!+CX3^!_^%$^$?%/]@Z;_ &U_Q,_^)C]BM_MG_(0O(/\
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M/[+NDV.G?\$^=7FM[>**2Z\/^*YIWC15:60-?PAY" "[B.*.,,V2$C1,[54
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M6B-(98K>*:*VD@X_PKXHTSP9\+KGX;:?X7^-,>B3Q36_EGPWH[2);W/VG[3
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M)8 &2&<1K.L3M"9&BVHO0:'^T-X0T7PAJGA<_"#XDS6FL_;7U1W\.".:_FU
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MTW2?$FJ6DDZZG<.EG_9MM9PM$B7%M'&+0)&]S)=&6#?.\KFRA5R5/&O[<_\
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M_P#"-_\ ",_:?M.C_P"M_M?[3]K\K^T?-^R>5\_W/M7\/V7=Q7W_ $45Y?\
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M  3[^$_@>RU3XB:I#H.FQWNF?$#Q#965REE;K-:VZ)"BP02!-\4061U$<95
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M9(IK63T#0)]0\-?MA7>A6^IZD^FW7@B35Y+.YU&]NK<7DNMB)I8H;B:2.'"
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MC;3[C[-Y> )2D_J'[._P1\>_!'XN:[JM_+X?T+POXBBCCLO#NDW;R1IJ4%M
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MPZ.^GV$<QLY7VBUGU%DFN'B\AGMSY M9%4J8)+98TC'W_7S!^TQ\ ]<^//\
MPB_]G:U;:7_8&MVNOK]HT^2]\ZXL\^0AV7EILB^>3S5&YY,IMDBV-OY_Q?\
ML]>./''Q/\&>-;WQ)IJ_\(M]I\NVAT6X7S_M]I%;7VZ5M4?9NV.]KA&^S[E6
M3[7L)D/!_P"S1KGP2U36/^%:ZQINCZ1JUR-0DTN^T>2]AM[QD$<TEH]O?V#Q
M13*D6;=_-CA:/]SY4;>4NAX__9(\.^,_@?>_"N+4+Z&VN8B3?3RF[NGNC>"_
M:ZN&E_USRW69KA08PX>1(S "A3C_ (O?LT_$OXQ?\(^VH>,M-1M%UNR\0QA=
M EV?:['>L42 :JKK:,K!I(Y'FN&G,KK=1PM%;0=!\??V>O''QQ_X17_BI--L
MO^$?U+3=<_Y MQ-Y^HV/F_-_R%(_+M'\S_CW^>9,?\?;9XS_ (B_LZ_$7Q]\
M0?"GC,>*=(M[GPQ%>"UB.@W4D<DFH64=M=M+_P 3A&*%D:2W1"AA#*CR7!4N
MV?\ %+]DKQ/JGQ#N_'7P\\;W/A+4M5MHK;5E^PQ:G;WGV=42VE\BYD6.*6)%
M,>]0WR'Y!$SW#3]A\1?V3M)^(/@+5/#\NKWPU2^OH=7379%M_MT.I6J0QVMY
M&+>*VAB>**VAMR+5+9GMU<>8LTLD[>?_ !(_9<^*/Q:L?#":YX[L9+GPUJ^G
MZS;21>'_ "X[FXLE?Y[V,:B69V8@C[+)9PJ'G4PR%X&M?M_2;*;3K&WMYKF6
MZDBB2-YYA$))650#(XA2*(.Y&YA&D: D[45<*/ /C-^SK8_$GQ%H?C#2;F+2
M?%&A2YLM3-JMTK6\@9)[2Z@+Q&>WECDE50LL4T#N989HRTHDOZ!\)?$D.N7?
MBG6-9MKS7_[-DTJQDAL[JWTZTADD$[-]@?4)S)++,D1N91<1M+#;6\*>1L>2
M7D/V;/V?O%7P(OO$;WVOV.IVVO:O?Z[-'#I4UG)'>7K1;PDC:A=+]G58R%B:
M,R98,9R%VM]7U\H/^SMXB\/_ !)\3>,O#'B.*P;Q+%IAO8;G3A=LL^EPR0P&
M&07,"I;R*46ZA:.2:1/-$%U:2R130<_\%?V=?B+\$X?%(L_%.D7$GB#5[S72
MTN@W06&\O98#* JZP"]N(XG2.+<LBNZR-.ZH8I/']"_X)Z7WA[X;>%O#]GXP
MEM-=\(7UW=:)KEE8M$T,=[,)KF"YM'NY8KE)275OFB!01QLC1_:$N?J_X2_!
MO7_"5Q;ZOXN\47/B?6H+:XLX[J6TL["&&&YGCEE2&VM(UQYGV>U\QIY+A@T
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MYLDD$_F7=OYD:/.56UN((0K:>MP[W1] ^+G[/7CCXB?$_P -^-=/\2:;9?\
M"-?;_P"S[:?1;BYS_:-HEM<?:94U2W\W&TO%Y:0;,A6\W&6/^&>O''_"[_\
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MQKJ'B33;W_A)?L']H6T&BW%MC^SK1[:W^S2OJEQY6=P>7S$GWX*KY6<KY_\
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MW^FZ]ILOF65S]FFM[VW?=&/,@EV-)&<I(-\;9RCC(VL,G@7X3^!_A?\ :/\
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M>\,>#[R*S\4>+M7M=+TR>9 T=NIGA$]PX>WN8F0&2*!D9=^+@S1AS"5KL/\
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M*&$P.)3]EB2.WDDN+>V:5E$BB7<SUX__ ,%6/">AZO\ L[>(-4N["VGO=/\
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M#G_MS7W_ %^0'Q _XQ0_;)'Q#\0_)X;\:Z:FD-J<O[JWT^\2*W"13.OF_?\
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M>:SN?$.KZ+%?V.HR&2&>2W-_;VMQYT;-&3$F&M4MS(I$B22[_P 8-'\,>'?
MGPDT_P )Z7_9V@6_Q2T>/2U-Q+<&>W^T7C&Z#RESY5S,9I[5EEG2:S>WN%=/
M.\B']?Z_/#X7WLWPY_:S^(%AK5M+:KXQL='OM%N)#$(+M='LA;W<,;;]S7"-
M-O, 4NL,;S.$B,32=!X1\#0ZO^UQXE\6:7#%';:=X6LM$U&002Q-+J5S<K>H
M!(8A'.\5C':^<PD9HTEM8^1D1Y__  2X_P"38O"/_<3_ /3M>4?\%1_^38O%
MW_<,_P#3M9UG_MW:M8ZC-\,X;>XBEDM?B;X:AG2-U9HI#%-,$D )*.8Y8Y K
M8)21'QM92=#]H?\ Y.=^"'_<W?\ IIBKY@^$,GP1N-<^*'AGXCZK_8%Z?%VM
MO-9W/B'5]%BO['49#)#/);F_M[6X\Z-FC)B3#6J6YD4B1))?T>_9ET?PQX=\
M"0:?X3TO^SM M[F\CTM3<2W!GM_M#L;H/*7/E7,QFGM666=)K-[>X5T\[R(?
MC#X[ZGX&\-_M66#^.;J71].U+P:+:SU8:EJ>D*;JUU*>:6T%Y9W5K#L:*199
MDG+#>MJ%9'D1)O</V?M.^"OP\USQ/JG@$6S:;/;1ZCKFOG69[^WDN%DN'6,W
M,\]S&TL2&XN;YGEA>%)[1V69;G?!\O\ @[7[/]D[XOKXT\36G]D>&/B3YUS!
M]KCN6ET35+AH9GBO99B([/\ M%%2:\101'=6Z0$_8],%V_T!_P WO?\ =-O_
M '/U\_\ CCX<?\(QI?C_ .*/PJU__1[>Y\3?\)'X6UX?;](O+BV<Q7^Z".;?
M;2RK;O=1[R[SQRV\1^RV<CQ'U#XB^)+[QC\<_P!GK5[[3Y=-N;ZQ\2W4UE-N
M\RVDFT2"1X'W)&V^)F,;;D0Y4Y13P/+]*\6_"4?M$_$3_A+]:_L6+5K;P_JV
MD:C%KVJ:-#J5G_9D4#LEQ:WMM9W,44B_Z.1F0M)=;6D2-Q#R'[2WA3X;>"?V
M3/B+IOPVTV*W\.+?:5)%>0WTUY%?73WNG?:);>21YU>WC40V_F),0;J*[A:&
M(V^^?ZO_ &^O^:5?]E)\.?\ MS7G^F?'C0_@3^U;XYTOQ[J?]FV_B/3="N=$
MN;ZXC%FMO86UPDT1D:3;:[[A[EHTD$:22+*V1)-")^?_ &U_B%X$UWPWX<\2
MV-G]M\/67C?1;[5M9L/M MF4VMS9RW<5WIDL=S)+9 6R+=1,8EN1;V:R330S
MVD7J'AGP]^SW??$G0->\&W47BGQ1%*;6*Y7Q1?:L]C9M#.;B>?S+R],=NL;R
MQ1;HS&][<V\!> W'GQ^@?\%"_ 'B+XG_ +/?BK1?#]E+?7TL5I+';P@&21;:
M^M[B0(N07<1Q.5C7+R$!$5G95.?\?OB1X0^-O[+NM:_9Q?;K+7=$*6,'D"[E
M-]> 064'E6_G_P"EQWSPPX0L8+I/O*8RR^'_ +1G@J^^&OPZ^ OAR^>*2YTK
MQEX,L)GA+-&TEM:RPN4+*C%"R$J6521C*@\#]3Z_/#4OC!X9U+XN>/O#YU>Q
M\#2:#%I%SJ.L0MI*7FJK<VT0@::34;66)+>S,ZV[;TG=I+BU"7%JNZ"Y/^"6
MFK6,W[.'A:Q2XB:YABOII(0ZF1(YM8U!8W9,[E1VAE5&( 8QR $E&QH?\%1_
M^38O%W_<,_\ 3M9US_[8?P+^#'PP^%FL:_IUKIO@_5["VNKC2=2T@VVC7AOH
M[2=H[:*> 1/+]H420O; L98V?:HD5)$\0\>^-?&OQ'^#7P#U[QDD2ZM?^._#
M-Q*T0C598W:[-O.5C9D5YK?RII%7:%>1E$<6/*3Z?^+'Q6T&S^.L?@YYK'PW
M?/X6?5I/$S?8/MWV."[F,FGP->P21(BF%KV5Y?M$:V\5QBVC?%W!^>&F7MYK
MO[,OQTLO#FM?;[VX\7:_?1W$=W;1S7NG6LVER7]T#!Y$4D36SDS^0BPR+.L2
MQXFCC;]/_"?[8'P8^-OABPO-+O[;5;J\\FXMM#S;2:H;F&59(X_L3R926&:,
M2>>Q6V@$?VTW*6L9N5^$/&&D^-8/CY\7_$_A:WEU:?PY?>#-4ET#9&T6JQQZ
M5(K(3CS1<6H)O+(IYH%U#&WV2XG6V,7O_P"TOXUL?VVOV3/$%]\-TEU62\BM
M'%I&%%U'):7MM<W%O)%N)%Q'&C,(D+F8;#!YRRPM)ZA\?OB1X0^-O[+NM:_9
MQ?;K+7=$*6,'D"[E-]> 064'E6_G_P"EQWSPPX0L8+I/O*8RR_-_PSMK'X"_
MM(^&-%\2ZE8VLFF?!^TL)9I+A8X'DL+_ '3F-YO+)18[::8DJI6&-Y&551]O
MJ'_!.KQ9H?B7_A:7]G7]M=;_ (@:Y>K]GFCES;W7D^1.-C',4WER>5(/DDV/
MM)VMC0_X)>ZM8P_LX>#+%[B);F:+6)HX2ZB1XX=8N%D=4SN9$::)78 A3)&"
M077.A_P5'_Y-B\7?]PS_ -.UG7O^F_LO_#FRURSUNYL;G4[VPW&SEUG4M1U?
M[*S212&2W74KFY2"7=#&1-$J2C8 ' R#\('5_AGH'[2_Q,L?'VIR^'9+V+0K
M_3KLZWJVAK?6\>G1VTP,L%[:VLZ03(5A!!FWO= -(L;K#P'[2WA3X;>"?V3/
MB+IOPVTV*W\.+?:5)%>0WTUY%?73WNG?:);>21YU>WC40V_F),0;J*[A:&(V
M^^?]+OVL?^2(>//^Q;UG_P!()J^ /C!:ZII_[,/P8\46VGW-_:>%;GP?XAU)
M+-4>9+&QT\F>5$9TW[=Z[L'"*3(Y2)))$^@/^"@/AS2_CI\%;;0-*-M?7OB3
M4M(M]#G6-[F+SI9TG:Y26".?RXEL4NYI+E1M%J)?F8/M<_8Y\6?V=X[^*OA'
M7+_.OIXNOM76UGF\R;^R[NWLUL)4.Y@T2PK%&$1B;9?)BD2+=&IY_P#X)Y^+
M-#UG_A9'V._MI_MWQ \2WMKY4T;^?;K]AS/#M8^9$//AS(F4'FQ\_.N?T?HH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKR_QK\$/AU\2KY+[Q'X:TC5;F
M.(0I-?Z?:W,BQJS,$#S1NP0,[,%!P"S'&2<Z&O\ PG\#^*]#M-"U30=-O--L
M_+^S6=S96\MO#Y49BC\J%T:--B,43:HVH2HPI(KCY/V9/@]-8Q6+^"_#[6T,
MLLT<)TFR,:23+&LCJGD[5=UAB5V !81Q@DA%QV&O_"?P/XKT.TT+5-!TV\TV
MS\O[-9W-E;RV\/E1F*/RH71HTV(Q1-JC:A*C"DBNPTG2;'0+&WL;&WBMK:VB
M2&&&%%CCCCC4*B(B@*J*H"JJ@!0   !6A7A^K?LR?![7[ZXOK[P7X?N;FYE>
M:::;2;*22221BSN[M"69V8EF9B2Q))))KW"O+_!7P0^'7PUOGOO#GAK2-*N9
M(C"\UAI]K;2-&S*Q0O#&C%"R*Q4G!*J<9 QG_P##/7PL_MS^W?\ A$M$_M+[
M3]M^V?V9:?:/M'F>;Y_G>5YGF[_G\S=OW_-G=S6?IG[,GP>T69IK/P7X?@D:
M*:$O%I-DC&.>)H94)6$$I)&[QR+T=&9&!5B#\0?M\_ KP5X:^"^NZ1X&\#Q)
MK>L16L, \/\ AZ1Y'C@U*RN9DEFL+5EB3;&) L[H)3'\@=DP/N_X;^#/AY+<
M2^+M \/6VGWNI>?Y]T^CMIM]+OGW2^>)[>"Z_>2()#YRCS2%E^8%6)_PSU\+
M/[<_MW_A$M$_M+[3]M^V?V9:?:/M'F>;Y_G>5YGF[_G\S=OW_-G=S1X6_9Z^
M%G@;5(=4T3PEHFGWL&[RKFSTRT@F3>A1MDD<2NNY696P1E6*G@D5V$OP]\*S
MS:K,^DV+2:S$D.HN;:$M>QI$842Z)7,Z+&S1JLNX!&* ;217'Z_^SU\+/%?V
M3^U/"6B7GV.VCLK;[3IEI+Y-O%GRX(M\3;(DW'9&N$7)P!DUH:9\$/AUHOB)
MO$=GX:TB#5FEFF-_%I]JET9)PPE<SK&)2\@=Q(V[+AFW$[CG0_X5/X'_ .$G
M_P"$I_L'3?[:_P"@C]BM_MG^J\C_ (^-GF_ZK]U][_5_)]WBCQU\)_ _Q0^S
M_P#"3:#INK_9M_D?VC96]UY7F;=_E^<C[-VQ-VW&[:N<X&/0**\?_P"&>OA9
M_;G]N_\ "):)_:7VG[;]L_LRT^T?:/,\WS_.\KS/-W_/YF[?O^;.[FO0/%/A
M/0_'.ES:7K=A;:A93[?-MKR&.>%]CAUWQR*R-M959<@X90PY ->?Z=^SU\+-
M(TN^TNT\):)!9:AY/VNVBTRT2&X\AR\7G1K$$E\MB6CWAMC$LN#S6?'^S)\'
MH;&6Q3P7X?6VFEBFDA&DV0C>2%9%C=D\G:SHLTJHQ!*B20 @.V?0/!7P]\*_
M#6Q>Q\.:38Z5;22F9X;"VAMHVD954N4A5%+E452Q&2%49P!C/\"_"?P/\+_M
M'_",Z#IND?:=GG_V=96]KYOE[MGF>2B;]N]MN[.W<V,9.3_A4_@?_A)_^$I_
ML'3?[:_Z"/V*W^V?ZKR/^/C9YO\ JOW7WO\ 5_)]WBL_QK\$/AU\2KY+[Q'X
M:TC5;F.(0I-?Z?:W,BQJS,$#S1NP0,[,%!P"S'&2<^@:3I-CH%C;V-C;Q6UM
M;1)###"BQQQQQJ%1$10%5%4!550 H    HU;2;'7[&XL;ZWBN;:YB>&:&9%D
MCDCD4JZ.C JR,I*LK A@2""#1J>DV.M0K#>6\4\:RPS!)45U$D$JS1. P(#Q
MR(DD;=4=5=2&4$<?XZ^$_@?XH?9_^$FT'3=7^S;_ "/[1LK>Z\KS-N_R_.1]
MF[8F[;C=M7.<#''WO[,GP>U&&VAN/!?A^6.UB,,"2:39,L49E>8I&#"0B&26
M20JN 7D=\;F8DU/]F3X/:U,LUYX+\/SR+%#"'ETFR=A'!$L,2 M"2$CC1(XU
MZ(BJB@*H ]PKP^R_9D^#VG0W,-OX+\/Q1W40AG2/2;)5EC$J3!) (0'0211R
M!6R \:/C<JD>@>"OA[X5^&MB]CX<TFQTJVDE,SPV%M#;1M(RJI<I"J*7*HJE
MB,D*HS@#'/\ @KX(?#KX:WSWWASPUI&E7,D1A>:PT^UMI&C9E8H7AC1BA9%8
MJ3@E5.,@8T/$?PG\#^,-4&J:OH.FWUZMM)9"YNK*WFF%O*DB20"21&?RG6:5
M7CSL999%((=@>?T#]GKX6>%/M?\ 9?A+1+/[9;265S]FTRTB\ZWEQYD$NR)=
M\3[1OC;*-@9!P*T/!7P0^'7PUOGOO#GAK2-*N9(C"\UAI]K;2-&S*Q0O#&C%
M"R*Q4G!*J<9 Q\X?!_Q?\0_V@O%]AJGBGP9<^%[+PS]O!@OKE9&FUB0FUCFM
M&CBC\^T@L9+E3<$K;SRWVV*.8VBW"_;]<_J/A/0]7U2QU2[L+:>]T_SOLES+
M#&\UOYZ!)?)D92\7F* LFPKO4!6R.*\_UK]GKX6>)=W]H^$M$NM]S<7K?:-,
MM)<W%UL\^<[XCF6;RX_-D/SR;$W$[5QGWO[,GP>U&&VAN/!?A^6.UB,,"2:3
M9,L49E>8I&#"0B&2620JN 7D=\;F8GV#2=)L= L;>QL;>*VMK:)(88846...
M.-0J(B* JHJ@*JJ %    %&K:38Z_8W%C?6\5S;7,3PS0S(LD<D<BE71T8%6
M1E)5E8$,"000:\O\+?L]?"SP-JD.J:)X2T33[V#=Y5S9Z9:03)O0HVR2.)77
M<K,K8(RK%3P2*] \4^$]#\<Z7-I>MV%MJ%E/M\VVO(8YX7V.'7?'(K(VUE5E
MR#AE##D UQ]E\$/AUIWAVY\.6_AK2(M)NI1-/81Z?:K:RR H0\D C$3N#%&0
MS*2#&G/RKCGX_P!F3X/0V,MBG@OP^MM-+%-)"-)LA&\D*R+&[)Y.UG19I51B
M"5$D@! =LDG[,GP>FL8K%_!?A]K:&66:.$Z39&-))EC61U3R=JNZPQ*[  L(
MXP20BX^(/CYX;\-:!\:/AG8Z=X2OCX<\/1>)H=3AT[PSJ,^GQQZMIJ*B*EK9
M/!.D[NZRK )0KLXF"G=7Z/\ @KX>^%?AK8O8^'-)L=*MI)3,\-A;0VT;2,JJ
M7*0JBERJ*I8C)"J,X QGW7PG\#WNEZAI<V@Z;)9:G<M>WML]E;M#=7#NCM//
M&4V2REHT8R2!G+(K$Y4$9^I_!#X=:UXB7Q'>>&M(GU9989A?RZ?:O="2 *(G
M$[1F4/&$01MNR@5=I&T8Y^V^$/@WX/6.I:SX(\&:1%JR6-P(8K"UL]/DNF"^
M8EJ;A8E$:2R1Q@L^44[78';7F'[/6O>+_C7KDGC[Q+X:N?#L4>FQ:9I=CJ#D
M7D;2R";599(O+B*1330V<-OY^97CL?M*Q6R73))]?U^8'BFRTCQS^U?-<:WX
M:U+4- G\(KX=EDO/#FISV+WZ:\+A8W:2S:%HE"K,MV<V@"B03\ U^C_A;PGH
M?@;2X=+T2PMM/LH-WE6UG#'!"F]R[;(XU5%W,S,V ,LQ8\DFN?T#X3^!_"FN
M7>NZ7H.FV>I7GF?:;RVLK>*XF\V02R>;,B+(^]U#ON8[G 8Y8 US_P#PSU\+
M/[<_MW_A$M$_M+[3]M^V?V9:?:/M'F>;Y_G>5YGF[_G\S=OW_-G=S1XI_9Z^
M%GCG5)M4UOPEHFH7L^WS;F\TRTGF?8@1=\DD3.VU555R3A5"C@ 5ZAJVDV.O
MV-Q8WUO%<VUS$\,T,R+)')'(I5T=&!5D92596!# D$$&N/\  OPG\#_"_P"T
M?\(SH.FZ1]IV>?\ V=96]KYOE[MGF>2B;]N]MN[.W<V,9.>/LOV9/@]IT-S#
M;^"_#\4=U$(9TCTFR598Q*DP20"$!T$D4<@5L@/&CXW*I&A_PSU\+/[#_L+_
M (1+1/[-^T_;?L?]F6GV?[1Y?E>?Y/E>7YNSY/,V[]GRYV\5GWO[,GP>U&&V
MAN/!?A^6.UB,,"2:39,L49E>8I&#"0B&2620JN 7D=\;F8GL-?\ A/X'\5ZY
M::[JF@Z;>:E9^7]FO+FRMY;B'RI#+'Y4SHTB;'8NFUAM<EAAB36?XU^"'PZ^
M)5\E]XC\-:1JMS'$(4FO]/M;F18U9F"!YHW8(&=F"@X!9CC).?0-)TFQT"QM
M[&QMXK:VMHDAAAA18XXXXU"HB(H"JBJ JJH 4    5S_ (U^'OA7XE6*6/B/
M2;'5;:.43)#?VT-S&LBJRAPDRNH<*[*& R S#."<Y_\ PJ?P/_PC'_"+?V#I
MO]B_] [[%;_8_P#6^?\ \>^SRO\ 6_O?N_ZSY_O<T>!?A/X'^%_VC_A&=!TW
M2/M.SS_[.LK>U\WR]VSS/)1-^W>VW=G;N;&,G/8:MI-CK]C<6-];Q7-M<Q/#
M-#,BR1R1R*5='1@59&4E65@0P)!!!KQ^]_9D^#VHPVT-QX+\/RQVL1A@232;
M)EBC,KS%(P82$0R2R2%5P"\COC<S$Z"?L]?"R+5+;5%\):(+VT^S?9[D:9:"
M:+[(B);^7)Y6]/)6.-8=I'E*B*FT*H'0:_\ "?P/XKURTUW5-!TV\U*S\O[-
M>7-E;RW$/E2&6/RIG1I$V.Q=-K#:Y+##$FO0*X_QK\/?"OQ*L4L?$>DV.JVT
M<HF2&_MH;F-9%5E#A)E=0X5V4,!D!F&<$YS]?^$_@?Q7H=IH6J:#IMYIMGY?
MV:SN;*WEMX?*C,4?E0NC1IL1BB;5&U"5&%)%9_B3X(?#KQC8Z?8ZOX:TB^MM
M-B\FRANM/M9H[:/:B[($DC98DVQHNV,*,(@QA1CG])_9D^#V@7UO?6/@OP_;
M7-M*DT,T.DV4<D<D;!D='6$,KJP#*RD%2 0016A_PSU\+/[<_MW_ (1+1/[2
M^T_;?MG]F6GVC[1YGF^?YWE>9YN_Y_,W;]_S9W<UV'C7X>^%?B58I8^(])L=
M5MHY1,D-_;0W,:R*K*'"3*ZAPKLH8#(#,,X)SG^.OA/X'^*'V?\ X2;0=-U?
M[-O\C^T;*WNO*\S;O\OSD?9NV)NVXW;5SG QH>-?A[X5^)5BECXCTFQU6VCE
M$R0W]M#<QK(JLH<),KJ'"NRA@,@,PS@G/G][^S)\'M1AMH;CP7X?ECM8C# D
MFDV3+%&97F*1@PD(ADEDD*K@%Y'?&YF)] \:_#WPK\2K%+'Q'I-CJMM'*)DA
MO[:&YC61590X2974.%=E# 9 9AG!.=#_ (1/0_[#_L+[!;?V;]F^Q?8_)C^S
M_9_+\KR/)V^7Y6SY/+V[-GRXV\5G^"OA[X5^&MB]CX<TFQTJVDE,SPV%M#;1
MM(RJI<I"J*7*HJEB,D*HS@#'85Y?IGP0^'6B^(F\1V?AK2(-6:6:8W\6GVJ7
M1DG#"5S.L8E+R!W$C;LN&;<3N.3QK\$/AU\2KY+[Q'X:TC5;F.(0I-?Z?:W,
MBQJS,$#S1NP0,[,%!P"S'&2<^@:3I-CH%C;V-C;Q6UM;1)###"BQQQQQJ%1$
M10%5%4!550 H    K/U'PGH>KZI8ZI=V%M/>Z?YWV2YEAC>:W\] DODR,I>+
MS% 6385WJ K9'%&@>$]#\*?:_P"R["VL_MES)>W/V:&.+SKB7'F3R[%7?*^T
M;Y&R[8&2<"N?\=?"?P/\4/L__"3:#INK_9M_D?VC96]UY7F;=_E^<C[-VQ-V
MW&[:N<X&./TG]F3X/:!?6]]8^"_#]M<VTJ30S0Z391R1R1L&1T=80RNK ,K*
M05(!!!%=!XU^"'PZ^)5\E]XC\-:1JMS'$(4FO]/M;F18U9F"!YHW8(&=F"@X
M!9CC).>@N?A[X5O;'3;&;2;&2VTJ6WFL(7MH6CM)+9=L#VZ%=L+Q+\L31A3&
M.%(%:&G>$]#TC5+[5+2PMH+W4/)^UW,4,:37'D(4B\Z15#R^6I*Q[RVQ257
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MV_A/3;>YU_7Y=[R:7H[6LEQ;0QQ+*T]X;BXMX;2(B2)8S<2QM,\T:Q+)D[>
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MBK]AN;?38K;5K[[/F.2X-OIL]S'G&Y8Q+(EOO\O>41W\OS75?,;W_P )Z_\
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MJ7A_Q5,8[LP.L4GG:IYKI(L*W$CSNQEF:YFN"7Y0QJ2I/%'B/XJ? /\ 9/\
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M/P]X:OI=")TVWM9;R\U*&."6[>9M2LKB*&WMC)]FBCAC9IY/.G,_E"%&\_\
M^"=\=]#8_$U+Z6*:Y7XB>(!-)#$T,;R!;7>R1M),T:,V2J-)(5!"F1R-Q_0^
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBN?\ %.LWGA_2YKRTTVYU.6/;
MMM;-K99I-SA3L-W/;0C:"7;?*GRJ0NY]JM\0?L1>'_'WP$^!-AX9U_PAJ0U+
M1O._<07.CR?:_M>H7$W^C/\ VB(QY*2*TOVEK?/(B\YABN@_X)\^!O&?PD^#
MNE>#O%6A7.EWNE?:=TDL]A-#/]IOKFX'DM:74[_NU=!)YR0_,P">8 Q'V_7Y
M0?#?X7?%KX8_LRZA\*)?!US>7JZ;K^E+=6U_I8AFEU":\:VG@$UW$YM LN;A
M[@6UU$S0K'9W :=K8^,7PW^*7CO]DJQ^&=EX*U(:TNFZ1ICB2\T184;2VL)'
ME,@U(YBF\N58-H:7=&WFQ0JT;/V&M>'/CA\&/BYX@\?>$/!\7B2Q\:6.F27F
MG3:C9Z;>:9=:=;) D;S/+/;S(R/(6,'F@R9 =$B5[K[?^'.B>*H)M1U7Q+-$
M+N^EC$=G:W,UQ:V5O!$$2*)Y(K82N\AFN9;@V\,Q,ZVS-+#:6[5Q_P"U/\%/
M^&B?A1X@\'+-Y$NH6P^SR%]BBX@D2XM_,;RY2(C-%&)MJ,YB+A,/M(\0^$/B
M;]I_7H4\*^,O#UCIDD$4D,_BJVU"TG6X$<NP36FF")BMQ-'\R-<B.WB?=.]J
MRJNG2<_\&-,^(GA7XT?$?Q=J'@?5X;'Q+%I$EF#=:$TBMI6FRQ/'*J:HP5YI
M-L=N5+IEU:9X$#.O0?L6^$_'/@"^\<6_B/PS?:7'KGBG5_$5K/-<:9-'Y%XU
MN(H'%I>W$JW&%9F 0P@*?WY8JI\?^!7@O]HS]D1I/ .D>%['Q5X7%]+)I%^V
MLV]A)86MS=S,T=]NM?-G=0RW$A@MW*&218WG!CA@]@^,_P (?B2/&OPX\<6"
M1>(Y_"DNKG4+=9(=/N+A=7CBMR;%)/\ 1PEJAD>.&YN5=H88XGNIYW>=CX(?
M#OXH^"?BI\2_&_B#1;%8->BTLV]KINI_:IY)-+L%B583<6UE$R3F61-]P]J8
MIHBIC:!UN:Y_]E;3/B)\((?'SZQX'U<-K'BG5?$5FD5UH3M)!?2VR1P'_B:!
M5N%4/+(&(A"1L%G>4I&_E_P=^&_Q2\"?LE7WPSO?!6I'6FTW5],01WFB-"[:
MHU_(DHD.I#$4/F1+/N"R[I%\J*95D9.P^&,/Q0TGP[I/@WQ;\,+[5_#EKX6T
M339;:6?PS.O]I:<76=Q#-J&V:WE7[.T;RR*T3VRE;8&5W7C]=_8K\7VG[+7C
M'X?Z(W^D:KJ4VJZ3I=U<$C3[3[?;W<.F"=I9XS*$@8NPD^SF\GDS.\>Z[D]P
M^+NB_%SQSXB\&^+K'P_+_9FBWUW)?^')]3MDNKV.46J6MPT:O)IC7%E.DU[;
MQR7;!1#!(EQ#<RM%;Y_PD\#_ !7^'OQB\?>+-8\.6TUOXEMM)N5_LS5(YUC.
MEV-S;&UC:[AL9)+N9_(:,216]FL4DC/>K)"L4WC_ ,'?AO\ %+P)^R5??#.]
M\%:D=:;3=7TQ!'>:(T+MJC7\B2B0ZD,10^9$L^X++ND7RHIE61DT/%_[/'Q<
MO/AC\*M?\)V\6G^,_ -B+?\ L_4YK9X+B/\ L];2[@W0&>)GN3;QK;M]HMPD
M,SL\D$X4P_0$.E_%S]I7P;K>D>+M&B\#P7ECJ&FBWCO;;6)[DWEF]NLTCQ)'
M%%;PF5I!%&XN+B9$S-;01.E[Y?\  MOVFM \(6OPZO\ PIIND_V5IITJW\3)
MJ\,T.VW M;>Z@T[[/<2RRK%LG$-RUM%.T;+(UKYBQ+V'C3PUKOB&Y\1>#?%W
MP[OO%GA=);/^Q;@7FD3R+%_9<-O.&;4+^UO$N(YOM#)>M))=.9Y")(PB-)[?
M^RQ\)M<^!?PH\/\ A+6]3_M.]TVV,4MP#(5^:1Y%AC,A+F*!66WA)"9BB0B.
M(8C3@/VI/@IXG\9ZIX6\=>$)LZ_X/N;BZMK&1XHX=0M[M(X[VR,LL<@@EGAC
M\N"X(*1LS;@NY9X#Q/X.U_\ :+\3^%I=;\/7.BZ1X;U(:X\6IO9O<75]!$\=
M@+=M,U&Y2.*!I9;BX,^"[I;1(DD;W!3S_P" 7A_Q]HWQV^('B;5O"&I:?IOB
MK^Q/LT\]SH\GD?V9I\L,OVE+;49Y!YCD+%Y*SYW OY:@D??]? 'Q]\/^/M9^
M.WP_\3:3X0U+4--\*_VW]IG@N='C\_\ M/3XH8OLR7.HP2'RW!67SE@QM)3S
M%()Z#XA?#;XA^'?V@[/XCZ!I5MK%E/X;_P"$9E@-\MI-;RM>RWJW<GF1,C6B
MLL,4WE-)=*LCRQVLYB$4FA^QK\*O'OPLA\:/XKLK&T;7?%.J:[ EI>O=,JW<
MNPH^;>%=FV&.6&0$O(DV)8+66-HSX_\  +X$_$GPW^SGJ?P@U/28K.YCTCQ!
MIJ:C->0M:W$]_<71M7MDM_.G^S[)B\[W,=K-$?+5+:<O(8./U[X+?'+Q9X'^
M&'A=/#6FVS>"=;T>>>XN=:^2Y&AV\\:31+#9S.MI=JL6QW O(9Y3')8>3&;I
MO8/^$?\ 'W_#4_\ PFO_  B&I?V+_P (W_PC/VG[3H_^M_M?[3]K\K^T?-^R
M>5\_W/M7\/V7=Q1\?/A]\5_!/QGTOXJ^ ]&MO$N[1'\.7^DRW<=A,L/VE[V.
MYAN9F\K_ %NQ)%9&954!4?S6DMOH_P"%]KX]\0WQ\1>+K>+2I)+&"W@T>UOW
MO8[9F8S7$L\RPVT4MPY,,&SRYTMA;.UO<LM[<*<#]KGX(7W[1WPCU[P98W<5
MG<ZA%"899E9HQ);W,5RBOM^94=H1&SJ',88N(Y"NQO+_  %XD_:&^,&EC1_%
MOA*V\(+_ *&M[J%OKB7$TZ!P]VEE;VD<CP>>L;6_F/>Q3V:W*W$$L\T'.A^V
M1^SSXB^-5CH.I^$M2ETGQ#I%\8K>_A :2&QU118:D4#S0HKI;R?:5D!-P#;"
M.!HY90X[#]J/]GK_ (7?\%=7^'VA26VE^?;6L5F/*VV\7V.>&>&'9$!Y<1\A
M8LHK>4AW+&^P1MY_X"\2?M#?&#2QH_BWPE;>$%_T-;W4+?7$N)IT#A[M+*WM
M(Y'@\]8VM_,>]BGLUN5N()9YH.>?^%WA_P ?>!/CM\3O$UUX0U*33?$/]E_8
M9X;G1SO_ +(T^:%MR/J*2)]I?:MKN4?ZQ3<?9E#E/G"\_9H^*GCSX'_&'PL_
MA^73=1\1^*;KQ%ID=[=V!6>":\M;I8-]K<W*QW 6T9&$I2'?+%B<IYKQ?J]X
M*UW6?$EB]UJ>D2Z2S2D16UQ/!-<",*HW3_9GF@C=GW[4BGN!Y(CD:1)7>"'Y
M0_X*#>!O&?Q;^#NJ^#O"NA7.J7NJ_9MLD4]A##!]FOK:X/G-=W4#_O%1Q'Y*
M3?,I#^6"I/8?$'Q;\1-1OM!DB\#7VI:%J%CK%IKFDS3Z%]HB9VMUM'=9KQK>
MX21%N8VACN=AAN"\N9(TA//_ +)_P F^#NL^,M8M;.70])\0WUM=67A]WB8:
M>T,'EW,I%O<7-JCW4Q+"*W=DCMXK9-RX%O;?9]?"&@_LJS:%^T!KOB:U@BA\
M.:K%I>LW40:)?/UNS-[#&H@1-K6Z+,-1F:8>:=4^RW44Q,4J)H?L?_LUZI\!
M;CQ%#J7-I;:E>6?AR%94FAM-%GG^WJD+,OVA999[AX[UIG9YFL[89>*""1N?
M^ 7A_P ?:-\=OB!XFU;PAJ6GZ;XJ_L3[-//<Z/)Y']F:?+#+]I2VU&>0>8Y"
MQ>2L^=P+^6H)&?\ LU>'/BI^S'HU_P##I?!\NJ:3IM]<CP_JL.HV"1RVMW/+
M<J-3$LL5Q$\+R[9YK6TF+#?Y5K)Y2-<_*'PN_9M^/WPU\"?#35['PU;-K7P_
MN=75M)N[^U#:E#K=Q+]I:">&5[>#R8'C\III-SRM<,T 6V@2_P#T/\-^(/BY
MXCAM/$_B7PO+I@L(IS'X?TO5[:]NKJXFE2!);B:3^SK-4MX1,Z6YN+B&87(F
M98[NSMU/'_\ !/GP-XS^$GP=TKP=XJT*YTN]TK[3NDEGL)H9_M-]<W \EK2Z
MG?\ =JZ"3SDA^9@$\P!B./\ &7P0OKO]IRSOM'NXO[)UBQM=6\46)5BS7&A2
M@:).9AYCPN]PR-#"IM89TTRZ+&YQ-'7Z'U^>'[2G@GQAXW^-'@?5[?P3?:SH
MGAV+7H=0(FT7R[R/5]-CME2*&[U"%I$5MT=PMPD((#;1*I!)^R1X<^-'P/\
M$6H?#_6M)OM1\&6<LL>@ZU>76FFZ@MXQ\EO<117;RR6Y V6T@C6:,;%>WA@<
M0V)^RMIGQ$^$$/CY]8\#ZN&UCQ3JOB*S2*ZT)VD@OI;9(X#_ ,30*MPJAY9
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M<21@&W6-JS_$G@+XN>)O'/PP\86?@:QTNT\+Q:E:#28]7MO-@.H:8+1?,$4
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MYPIQS\G[3?P>AL8KY_&GA];::66&.8ZM9"-Y(5C:1%?SMK.BS1,Z@DJ)(R0
MZYT-?_:%^%GA3[)_:GBW1+/[9;1WMM]IU.TB\ZWESY<\6^5=\3[3LD7*-@X)
MP:^</C#XF\6^%?VC_ACI5OK]\VDZ]+KTMQIQ%JENK:?H^(@KQ01W#HSS-,\=
MQ-.GG"-U5/*C"_5_@7XL>!_BA]H_X1G7M-U?[-L\_P#LZ]M[KRO,W;/,\EWV
M;MC;=V-VUL9P<&O_ !8\#^%-<M-"U37M-L]2O/+^S6=S>V\5Q-YLABC\J%W6
M1][J43:IW."HRP(KL+W5K'3IK:&XN(HI+J4PP)(ZJTL@B>8I&"07<1Q22%5R
M0D;OC:K$9_A;Q9H?CG2X=4T2_MM0LI]WE7-G-'/"^QRC;)(V9&VLK*V"<,I4
M\@BL_P :_$+PK\-;%+[Q'JUCI5M)*(4FO[F&VC:1E9@@>9D4N51F"@Y(5CC
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MOBQX'^%_V?\ X2;7M-TC[3O\C^T;VWM?-\O;O\OSG3?MWINVYV[ESC(R:_\
M%CP/X4URTT+5->TVSU*\\O[-9W-[;Q7$WFR&*/RH7=9'WNI1-JG<X*C+ BL_
MP5\;_AU\2KY['PYXETC5;F.(S/#8:A:W,BQJRJ7*0R.P0,ZJ6(P"RC.2,\!X
M3_:E\!>,_BCK7@"RU2Q>^TN*U&!=())KJ3[6US:Q1,%,CVD=O&]PT+2B,S-'
M((GA<'Z/KCU^(7A5[ZSL1JUB;F^ENX;6$7,/F3R6+,MVD2;MTCV[*RW"H"82
MK!PI!K/_ .%L>!_^$G_X1;^WM-_MK_H'?;;?[9_JO/\ ^/??YO\ JOWOW?\
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MF9FP!EF+'DDU\8?![Q_-XF_:?^)VBZI>Q2R:-8Z#%I%O(8A)!:W%I]HOS N
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M!'#]D/ZO^$_%.E^.=#L-;TN;S[+4+:&\MI=KIOAGC62-]KA77<K [656&<$
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MJQS22R-%.X226>V650KI!'+=7%PCQ_3_ /S>]_W3;_W/U\@+\2]<^$7P!_:
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M2]M-7@$%Y:WUQ?RWUS!*B_(-C764"LY2-DCD;SDE \?_ &^O^:5?]E)\.?\
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MN+'Q#J]_'K-]=:I=P7XTTQO?7;1F6Y!MK&VE5R(PHC5Q;J&;$.[:RW_VL?\
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M^U"[WSO[?\6_@[X5^-^C0:1XCLXKNVAOK._1)8H91YEI.DP&)HY%V2JK03@
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MX@D;4XI+;4=4NKJWO=2O+5TG3[)+<7MK<*ENBW$GE);QPF)BTB,LLUP\W/\
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M\.0Q:+;:+%9%]0UG2+J\M]1DO(WD*V)AOK%=EJJ*L[EI2TTIC\N$0A[CXO\
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M+2Z2%K^YU?3[>Z0K]IO)($DLU\J3!D2 3H9'2TBFF9TNCT'_ #>]_P!TV_\
M<_7J'P&^,U]XW^(/CKPIJ?AVQTC4=!ETF:\FL+UKR.\DU&RW(Y=[*R<O'!!#
M$6=6)"J@(2)<\?:_%SXO_&/2_$'B/X=IHB:19?;+;1EO8FOIM:N+%YXI94FM
M]2M+>TM)9XQ!:NYF>15>Y<11M&A^K_A[XDOO&/A72=7OM/ETVYOK&VNIK*;=
MYEM)-"LCP/N2-M\3,8VW(ARIRBG@=A7A_P"TOXD\1>#/A-XKUKP]=Q6>HZ?I
M%[>P32P"X5&MX'F.(RZ*7*H1&S[T1RKO%,BM"_YH_'>VURV_X)YI_:EU;7&[
M1/"[VWV:VDM_+MS-IGEQ2[[BX\V5>=\R^2CY&((\'/U?\6?C-\8?@;XB\%3Z
MP/#]]I/B/Q!::%<VMK!>PW5G)?AO(,5W)<217:1%7\V5K6T,PC4+!#YY-OH?
M$G]K+2],^(>J^"+/Q-X;\.RZ/;6,]U>^(9';?->+*XM(+1KC3A)LA$,\MTEV
MZQ^;'!]G9W9X>@_8@_:E_P"&N/AI'XDFL?L-[;7+Z=>QH<PFXBBBE:2 EF?R
MG69&"R?/&Q:(M*$$TGU_7Q!K7Q\^*<_QO;X::=HNB09T2XUE;VXU"[GQ;M?I
M903&%+.#,L>)));$2!)MR*NI0;&:3C_$'[:6K? MO&6D?$BQL4U/P]I"ZW83
M:<]PMOK%K/=R6D!6(QW3V#BX:VM)5FEG(FE>9=UM'YAX^]_;T_X1'XE^#M!N
M=:\-^([+Q5<R6+Q^&I/.FTJXDEMH[437#7LJ7<3-.T;2&VL'=8VN$B!4VI]0
M\8_M _&$_&&Z^&WA_0/#XN1X?N];M[F^U6],;1F]6SM9)5BT\,KJP=Y[1=XD
M#J$OXS&?--&_:*\5>,OB#=?#:'6/#^B^(]%L=,-^+RUFO(]1O+RR:[G72H!J
M5C/]GM43>[R>;(PE :.$0^9<>@#X^ZM;:#X"TF^MXK/QAXRL5>*UN+>X2WM9
MX;!+O4))XRWFA+4$JMJTB33S&.W,L*&:ZM^/\8?'#X@?!/Q?H_A_QC/IMQ:>
M*,Z=I.L:?I-]%#9ZN25AM]0M6OKGS(KC>A@>*ZAD+13HZ)$&N8N?^ 7Q9^-_
MQT_X2J'[=X;T_P#X1WQ)J6@?:/[*O[C[7]C\H;_LW]J0_9L;MV[[1<^;YFSR
MX/L_F7//Z%^WA]H^ /@[Q_J]K;:?>^)]2AT,.[YL;2X>ZN+:2]G\R2%Q:1K:
MRW)A\P/C;;FX0%KM/I_X1>*/'&LZYJ%MK5YINJ::=-TK4=.U/2;"XM+>?[9)
M>B6-7DOK^.;8D%O*&BD7"7"DJ5=&/T!7R!\6?VCO[!^*>F?#33M3TW1M2O=-
M&J+>ZS#Y]O+YEV+*"QMX4OK&22[F?S)!B3Y4A"K%,TS-;Z$WQ]U;X<^!M/O/
M&%O%_;>H^(+CPW8016]Q907=T^IW-I8R$2-=O;6\T$*W<DK-.%A+/$)V:&*3
MC_BS\</B!^RY_9FO^.)]-U;PS/<BQU"YTC2;ZTN--:;'V>[D1[[44FM-P:&<
M9AE1Y(?*\]V\EOM^N?\ %-MKEWI<T>B75M:7IV^5->6TEW"N'!;?#'<6KOE=
MRKB9-K$,=P4HWYP?#3]I/XW_ !+_ &>9_BSYWANP^S:;JU]]B_LV_NOM']G/
M<\^9_:5M]FW^3Y7E[;O&W[1YI\[[-!] :!^TI<?%3_A&="\-_9K#7]=\-VWB
MJ07T4]W;V-C-Y2C(B:T-U*\TOD1HLMN%1);F1E\N&VNCPM\>?$G@_P"*\/PV
M\>);27>K6S7VAZGIEE=6UI=K!&6NK26.::Z\F[@\MYLK/+%);O$6\B5HXYO#
M_P!CWQ)\6=?F^*&I2W>D:M<P>,M3L!;RP3Z8LD]E%I]HL@NHGOO)MTM80D=N
M;2XF9U4R7CEG>OH#]F[XJWW[0/P/T;Q'X6L;'PU)=120VEK+"U_:VL=G>26@
M010/IQ9#' 1&J-"(BR\.J;7^$/V.M?\ ''@']CZUUYK31->T"UTW79KC2+R.
MXLYFMXKN^DN-]WF_AN=X21%MFLK=&64!K@>4PF^W_''[6^E^!OA!X7\>7EO;
M6\OB3^Q8[6VO;QX+=)M56.4B>]6VE$45O"9II)WA"E("-H=U6O'_ (:_MM?V
MA\<K#X:7>KZ)XFBU?33=VFJ>'(_*A@N(?M4DMM<HVH:@&S#;B1721'1F16A9
M)?-C]@\$_%3XE_&ZXU'7O"!T2#PW;7,MII[7JRW4VKM9SRPW,Z7-G="*QM))
M8_)M93#?RLJO=M;E&B@?S_\ X)<?\FQ>$?\ N)_^G:\K[_K\P/B7J/B^P_;"
MD7PE8VUWJDWPV:*W-],8;.!CK;L)KHQAIFB4J%\NW1Y9)'C0F&)I+F#/7]IW
M]H6TF\:>#+S3/#X\:^'K&'7;**VLM8GL=6TTQ#STM%+QS?:(I62))-[K/<,U
MJL"^7+<I[!X<_:&\9>/_ -GOP]X[T._TAM6U26QMV\W3+PV?VJ]OAIJVWE&^
MCGB2&[ECBGNQ)< QPS3Q6LOF11C[?TF.^AL;=+Z6*:Y6)!-)#$T,;R!1O9(V
MDF:-&;)5&DD*@A3(Y&XZ%?GA^PIKGCWQ5K/Q*OO$&JV-W'%XRU6PD6'3WMY&
MGLH+&UCD23[7(B6ZV\*1K;M%+-D"1[R5MV[Y@_9,\6_&'X>?L<6?BGPQ/X?2
MVT:QUB]2TU&TO;B2YCMM0NY[AVN(;JV6W?:)$B@$-P&,2.UR@N&2V^K];_;:
MTNY_X1'38]1T3PY>^(O#</B6:YU^Y<V]C#-Y'DPHA-DE]+,SSQJJW5HT26\E
MPRN D,G0?L;?M;?\-)W'BS1[E;:6]\,:D]H]]IPQ8W]O)/<):W-NK3W#IO6W
M8NAEF3&R1)G$A2+[?K\H/VN]7M_C%^TU\,/A%J\&[11YOB6Z0B"1;J:WAO3;
M0R)+"_[I?LDJ3+N*SQ73H51HXY*_5^OC#P_'HW[)VC>&/A5X<EB.HZW?:T-%
M2XBG:WM[<3W&IRM.?,=Y4LH)EB5#*DU[,(U\RV22:XML_P 8?'#X@?!/Q?H_
MA_QC/IMQ:>*,Z=I.L:?I-]%#9ZN25AM]0M6OKGS(KC>A@>*ZAD+13HZ)$&N8
MN?\ @%\6?C?\=/\ A*H?MWAO3_\ A'?$FI:!]H_LJ_N/M?V/RAO^S?VI#]FQ
MNW;OM%SYOF;/+@^S^9<\?X'_ &E_C#\4/V?Y?BU9GP_ID=KI&HWIL9;*]OVN
M9-,$XE<3+?60M4FD@=8X-EX84"R-<S,YCC[#XF_M;>./#OA#X>>(M$\.Z;+%
MXUN?#UI$+S5+A&M[C5AY[1.D=BP:)859%NA)O65Q(;*1(S')V'B+XW_$7X->
M-?#=EXVM-(ET3Q/?1:7!>::UU')IVH31SO#9S)+YS7Z3LL<,5[&EB@*S2SV]
MNIC4^7_L77.N6FE_%N31+6VN[T?$GQ#Y4-Y<R6D+9>T#;YH[>Z=,+N9<0ON8
M!3M#%U] ^%O[4']O_LVVGQ'T+P;<MMMI8K/P_I ^T/\ Z/>/I\,,7E01XB'E
MJ[E(3Y$ <K')Y85NP3XO>*OAK\2?#/@OQ=<V.IR>*HM3-C<:7ITU@MM)ID,=
MQ(MPEQJ%\94FCD;8\9C,3Q!3'*LQ>#R_X=_%GXW^._B?XW\"?;O#<7_"+_V0
M_P#:7]E7Y\W^T+1KCROL7]J?^1OM:^7Y6WR)OM&^UZ#X7?M;;OAYXY\2^-5M
MH?\ A"];UC1[F:R'DI>?V>R&)X(;F=_*EG\V.&.![B7?/@"7]X$30_X33]HC
MP_#X=UC5=(TBX@U+5[6UU'2-/@N'NM+L[V5XTG;4#>/%=/:%H#=^39+&P\YE
M>.!#<+X_\5?VZ(;)?&Y\/^(_"VF2>$Y;VUCM=8>6:\U6ZL[1)9(H;;[5IKVZ
M+<;[..53?"ZD5V18UC43_7_[-WQOL?VC_AMHWC2SM);./4HI";>5E=HY(9I+
M>50ZX#H)(G\M\(73:S1QL2B^X5^4'[+^KV_[0G[57Q,\6ZO!_I'@_P CPUI,
M3""18(?/O(YYE;R5D$LCV\KJV[='%=SVY:6/85] _P""HOARWMO@Z/'%L?(U
MKPCJ6G:KI=TL<#M',U]! 5;S8Y,Q'S%E:(85Y8("^Y4V'R_]KCQ;XJ^*WA7X
M*>*;&>QL+;6/%/A*]AM)K2:ZDM[R[AGG1WN%NK=9K>-7"- L,$DA4N+F,'8O
M8?\ !2_3?'$'[,6M?VAJFFS>5]D_M#R-,N(?M&[5K3[/]FWZA-]E\OCS?,^U
M^=@[?L^>/8/BI\6?''P0U3P>GBO3-$\01:OXDL-(M;^S%QILUE<:@DT'F)9S
MC4@VR'S@TZ7L+R+,;?R40/+)ZA\7?BQXBT_Q5H_@;P;'8S:[J44E_/+?N'M]
M.TVWFBCFNYK>*:*XG>5Y!!9PQM&LLWF.\\<=O)GR_P 1?M%>./@/H?C[4OB'
MIUM+:>'+:RN],U&Q@N+.WU3[;&T:6PB,NHM!+'>(+>1VE?:DT4[PQ1;7E\?O
M?V]/^$1^)?@[0;G6O#?B.R\57,EB\?AJ3SIM*N));:.U$UPU[*EW$S3M&TAM
MK!W6-KA(@5-J>PL?V@?C[\0_&OC3P9X<T#PM9ZCX;BT</+?ZKJ-Q;B2_CDN2
MP\G3X'G1H L80BU,$RL_F7*.$C_0^O#_ -H[Q;XJ^'WPZUOQ'X<GL8KG2+&[
MU)TO[2:ZCFCM;668P@0W5HT;NRJ!*6D"#=^Y<D%?D#QK^TO\8?A_\![#XP7Q
M\/R6SV.C7\VD0V5[YCQWTMK&X34&O@L3NLYE4-93"W)$!:Z$?VB7U#XJ?&+X
MI_ _5/!]UK<FB7EEXB\26&@2V-G9W<4UK_:"3;72_DO'2X^SLBAF-C;?:5!(
MCM2P">H:IXQ^(OC+QKK/A_PY#%HMMHL5D7U#6=(NKRWU&2\C>0K8F&^L5V6J
MHJSN6E+32F/RX1"'N/E_XC?M?_$7Q#^SGIWQB^'.EV/EB*2;4=-U2WNKJ58X
MK@VLSV\EG/""EO)')([2HH>US.QMVB:&3Z \8?$WQEJ>@^!+OP?J^D22>)9;
M>%;B\TF\:WG66P?46N8XQJ-O-:H+:UN7C@D^TO),]O;O) OFW"_5]<_XIMM<
MN]+FCT2ZMK2].WRIKRVDNX5PX+;X8[BU=\KN5<3)M8ACN"E&_.#X:?M)_&_X
ME_L\S_%GSO#=A]FTW5K[[%_9M_=?:/[.>YY\S^TK;[-O\GRO+VW>-OVCS3YW
MV:#Z T#]I2X^*G_",Z%X;^S6&OZ[X;MO%4@OHI[NWL;&;RE&1$UH;J5YI?(C
M19;<*B2W,C+Y<-M='A;X\^)/!_Q7A^&WCQ+:2[U:V:^T/4],LKJVM+M8(RUU
M:2QS377DW<'EO-E9Y8I+=XBWD2M''-Y?^PIKGCWQ5K/Q*OO$&JV-W'%XRU6P
MD6'3WMY&GLH+&UCD23[7(B6ZV\*1K;M%+-D"1[R5MV[]#Z^ /V_/$'B_1K/X
M?6FA:A;6D6I^-]!L;A;BS-SO87(N[9B1/"1%'-:J\L2%)9_D5;F!%D6;H/BE
M\?/BG\./B-X+\$6VBZ)J$OB+[;LO)-0N[-9?[.TX3W68%L[LV6Z9U,&)=1W1
M(T;['D$L70:/XV^-]]J&E^$-0M--LM:_LVXU34-:@TV_O=#&+TV]O8VV^ZLY
M3=O$PGE\R8>4L9VQ3+-OMSP;^UMH<GP\\7^)_$*_9_\ A#-2U31]2:,1Q)<W
M&FLJ[[-)9SC[5OB$$$LI=9Y?LWFS;5GE^/\ ]O6X^,^H_LQ>(M1\6QZ);17?
MV%IM+M([DW%@K:M;/"K7QGEAO94 CBG5+:TB+O)+'.R0I'<?8'QT_:ATOX<>
M.-/\$1ZSHFC7MWIL^JS:AK\SI;VT,=Q'#"J0E[5+N6Y;SU6);RV:!())V\P!
M(I>?_8V_:V_X:3N/%FCW*VTM[X8U)[1[[3ABQO[>2>X2UN;=6GN'3>MNQ=#+
M,F-DB3.)"D7V_1111111111111111111111111111111111117/^*?$MGX/T
MN;4;N.YDBAV[EL[2YO9CN<(-D%I%-,_+ ML1MJY=L(K,/R1^!5SJ?A3]BC4/
M!>H:#X@AUL:1KFG?8CH&L&0W&HOJ4ELJ[;0JR,I7?*I,,!>-9GC:1 Q\=;G4
M_%?[%&G^"]/T'Q!-K9TC0].^Q#0-8$@N-.?39+E6W6@5450VR5B(9RDBPO(T
M;A?7[O6]9^)'Q)UP^,?!.K^)_"]U%;2^%+2XTB!8$D@ACCU+[3;ZD;06MPTA
M+VD^K+$6ACNH[.;%R(;KYPL?A!\0[[]A/5_AP/#6I)KNE;UD@DA5/.>+Q#)>
MRI:Y;==;+=%E62!7@N/-2*VEN)Q+%%]/_M">+?'#>)_ _P 5/"GAW6]0TKP_
M<ZI8:EI\4%Q::C>6>IQ6L7GPV$J)<2Q03Q;C!<QP2/-!',J"T*WJ>X>&_CCX
MB\;PVGB:?P[X@\/Z#:13R7$%_I@DU*\G>5+:WCCL;(W]VMO'F>:X+16\Q9;.
M6-Y+3[6#X_\ \$YKR[\ ?L]Z9HVN:7J^GWVAQ7TMY;W6D:E#)MFOKRX00*]N
M#=.8\'R[7SG!9$*AW53Y_P#LS7GC+3O"OQAL]%TO5['7=4\0>*-=T(W^D7EG
M'*MS#"MC()=0MXK4.\P7$$S!P S/$(U<CR#QWX)UGQ9HWP^\13?#W5U\1Z'X
MIT2_\5:S)IL$EW(]G.T5\(O)DEO[ZW,C17%L+"&>P2S$4<+1"U-M![_I/BN[
MU']K2W\2S:!X@M;&7P:F@O+-HFI&.+46UD3&W>>&"6W*(ARUW'+)8D NMTR8
M<_I?7S_^U'_PL_\ X5AJ_P#PK3_D9/\ 1?L7_'I_S]P^=_Q^_P"C_P"H\W_6
M?\!^?;7P!J/A6WM_BU\,O'WA3X::WI^GV?\ ;":A<2:=!'J-W<ZAI;1VZWBO
M.U\TJW"RPSW^J>5;>=)]I:]>WG^U/[!\'=?E\(?M$_%S5-1TG6XK+5?[%^Q7
M(T/5GAN/[)TR=+ORY$M&1MK+MAP?]*8HMOYQD0-\H:?\.?&7B#P5XPUS3/#^
MKR7V@_%:3Q]8Z==:;>6,FJ6*R*$2![N*(AWC$TFU$GN%,:1&VWSQ!O?_ -J7
MXEW?QCL?AQ>:-X6\4F/3/&6@ZSJ0F\/ZE')900K,SJ\1A\V=U#-N:R6ZA0QE
M7F5IK47'Z?Z3>S:C8V]Q-;2VLDL22/!,8C)$S*"8W,+RQ%T)VL8WD0D':[+A
MB:MJ<.BV-Q>3+*T<$3RN(899Y"J*6(2*%7ED<@?+'&K.YPJJS$ _D#\"KG4_
M"G[%&H>"]0T'Q!#K8TC7-.^Q'0-8,AN-1?4I+95VVA5D92N^5288"\:S/&TB
M!M_X;^"_&7PMOOAC\48-,OKFQM_!NG^#-?TT:7>?VG9+$P87<5HPCGF1+M42
MX"12.MJK3PQ7*2"2'Z@3PZWQ\^,OAGQE%97UII/A&QU,6\U[;W>GSW.H:HL=
MN\7V.^M(9C;V]M&9&N 522:XB2-G^SW*CQ_]C?QB/A]#\2)=9T?Q!:+?>,M9
MUVV$GAW6]TUC=RVL4,D:K9%F=F.3  ;A$5Y7B6*-W7XPT6RUSP)^S;\$M.U'
M1=2@U+2_B3IRRV%S:26=P[M>:C=1I$+W[-&WF)+&$D+B#>Q1I49)-GZ'_$%6
M_:K\:^$=,L='U>VT?PWJ]KXGO=3U"RN]*#7%I'<)9V5M!?VJ37+O*PENG5$A
MAMTVB8SSH$Y_PQ!XM^#G[0GQ&UBX\*ZOJ-IXKBT232IM-2UECE;2K%8+F.:6
M6YABLWS.6B-X]NDX@F2)WF\J*7Y@LO@=\2;K_@G[<^"7\.7T.MPQ"=+*3R3/
M-$=835-T<:2NX<0.RFWE6.Z\Z-XA 6,?F?7_ .T));?M=>$A\/='T_5U@U6^
ML#J=U?:9JFD+::?:W4=W/+#+J&GK%-<,84MX+==SEYQ,R^1!,R\?_;\O_#87
M]N_V3K?]F_\ "(_\([]L_L/5OL_V_P#MOS?+\[[)Y?E;/G^U[OLFSYO/V\T?
MLXZ_++^T3\3=4ETG6[:R\1_\(_\ V;<WFAZM:PR_V?IDJ7.^2XM(T@V-\J_:
M#%YK$+'O+ 'R_P#9A\<?$G]CO3E^$_B+P!X@UBVLKZ>/1=6T*SAG@NK6ZOIV
M62]9[L06;[V,F))U,<,B^<D0C\Z?[0U[X\:Y\,?$GAK1/%6A7+1:UOCEU?3(
MI)]-LKR>ZCAL[*5OFF^<S)!]LFCMHYIC%(D")+<1V/T_7C_[0OA;5/'/PL\6
MZ)I</GWNH:)J=G;1;D3?-/:2QQIN<JB[F8#<S*HSDD#)K\P?CAJNL>+OV-K3
MP'8>&?$DFKKHGAZR$/\ 8.J#=<V,MBUW#@V^]/)6/=YTJQVT^[9;3W$D5PD/
MM_[9'C$?$&'X;RZ+H_B"[6Q\9:-KMR(_#NM[H;&TENHII)%:R#*ZL,B @7#H
MR2I$T4B.QXC\<^/?V7?CAXPUB\\*>(/$GASQ9%IUW9-X=A>_:SNK"SBLYTGM
M28UB>=0C&;> Z0P(OFE91;?;_P .;WQ;KLVHZIKMM+IT,\L<=CITQM6E@@BB
M >2X>V>X0W$T[2G$=Q+"+5+3"0W!N@_J%?FAXU\90^!?VT$OKBSOKJ#_ (5V
M(Y386LMY)$K:ZV)#;P![B1"X6,BWBF=3(LC(L"331>?_ !O^!_CW]J4>-/'?
MANPOM$U$:1I^A>'4OI7T^ZN5TS6UU:>]:&2))K)Y98(XM.\Z2)R$,\RP)+&T
M?TAX"_:.\=_'O2QIVE>!_$GA>_;[&MW>ZU9V]O;6BRN#=-;-<R>;=2I$DRVC
M"REB%R;9KJ".W=Q7G_\ ;\O_  V%_;O]DZW_ &;_ ,(C_P ([]L_L/5OL_V_
M^V_-\OSOLGE^5L^?[7N^R;/F\_;S1\:M+\ _%GQGK^E^/?">MP7>C7-DVA>(
M=$T/6)+@1-81S(]OJ&G07#&6TO)KEO+D M5?R&\J:5)2OG]]\'/CEX6\(?"C
MQYK;?VYXD\#?;VU:P0?:KNZL=1 AF6"19(EN-0M;-54*6875P&<3W#A5NOH#
MXC6"?M4>)_!EII]AJ4&E^'M;B\1WUW?V.H:4ZS6,4BV-M!%J%C&;GSYIB\[1
MD+!!;NK.DMQ;Y\O_ &-_&(^'T/Q(EUG1_$%HM]XRUG7;82>'=;W36-W+:Q0R
M1JMD69V8Y, !N$17E>)8HW=?+_V:[S4/AM^S+X&\.^*/!&I:E:G6[K3==TVZ
M\/WMW-!;S37]]#="TDB!EBCF-D[S+'.@4R1HK72JB^X?LK?">[^'?Q%U-_!<
MFKV?P].D110Z7K*:E"8-6-TSR&QM]4A2ZCMQ"6EGDSY4UQ=$*TQA*6GZ'U\(
M?M'P>!OB#XRE\(_$7P5?:QH@TBUO;'4K+1-3OFANGO)EN[;[7IR2SV[ND%G(
MJPB,.@E6:0J\,;?/][^SC\;?%7P:MA'JTNJ:MX=\9'Q3X:C\0-(]U=:?9L_V
M*UU"1Q;2Q7$P=Y]LQ#Q!X[64V>&6T]P^-VH)^V9X$M_ NFZ-K=DFM7.FR:JV
MJZ;J&DMI]C!<17EP5FNK-[:>[S"EK%!"\H,LWG[FMH97'W_6?JVIPZ+8W%Y,
MLK1P1/*XAAEGD*HI8A(H5>61R!\L<:L[G"JK,0#^0/P*N=3\*?L4:AX+U#0?
M$$.MC2-<T[[$= U@R&XU%]2DME7;:%61E*[Y5)A@+QK,\;2(&W_AOX+\9?"V
M^^&/Q1@TR^N;&W\&Z?X,U_31I=Y_:=DL3!A=Q6C".>9$NU1+@)%(ZVJM/#%<
MI()(?J!/#K?'SXR^&?&45E?6FD^$;'4Q;S7MO=Z?/<ZAJBQV[Q?8[ZTAF-O;
MVT9D:X!5))KB)(V?[/<J/+_V;-9U#X":I\1=/\0Z%K8:^\;ZQK,<EGI-[>0F
MPO4MS;W"2VT4B3[VVQM;VQGNXF8O+;QPPW,L!_P3YU^7X5?L[:5I?B'2=;L;
MW1?M/VNVET/5O.'VS4[EXO)C6T+W/RNK2?9A-Y*D-+Y8YKQ#X%7.I^%/V*-0
M\%ZAH/B"'6QI&N:=]B.@:P9#<:B^I26RKMM"K(RE=\JDPP%XUF>-I$#=?XET
MKX@:K^SI\-]2\(Z3J3ZOX$N=!OK[3)X+[2[RY73M,-O>VEN+BW1YO,6=HR8U
MDBGC\Z*/SY,0/]8> /C5XM^.\UD=*\+>(/#-E#?!K^Y\06=K9RR00Q&3R+6!
MI[B8O-*T"/*\ A^R_;!'<17B0E?G_P#9"\2ZM^S1X2N?A9KOAGQ!+<^'KZ[M
M].O;72KB>UUB"ZNIKJWEBN(E>TM';S525+NYCAMRRF6Y4BX6W[#_ ()H66N>
M&?@3HOAW6-%U+3+O3/M:S#4;22TR\^H7<X2-)]DK[8GB=I!'Y!\Y8TEDECN(
MX?O^O@#QU!J'P[_:GM_&NH:9J4NBW'@A](2YT[3KW4L7D>KK<F*2*PAN)8LQ
M,'5Y$2-\,JNS(X7T#X:>"[CQ[\9]6^*4UI<V5HNB6WAS2UN4GMIKF$7+WMW<
MSV=U;0W%MB=DM[=9"&=89IRABFMWKY_^!_P+U3X6_'[6?"EC:VT?A.QN6\=6
M3VY1)H+[5[6?2%LI$ CC%H$CU%X(H(B8EBMM]SDF)_T_HK\X/V;-9U#X":I\
M1=/\0Z%K8:^\;ZQK,<EGI-[>0FPO4MS;W"2VT4B3[VVQM;VQGNXF8O+;QPPW
M,L'B'P*N=3\*?L4:AX+U#0?$$.MC2-<T[[$= U@R&XU%]2DME7;:%61E*[Y5
M)A@+QK,\;2(&/!.K_$7X WWP]\<IX6\0:OHDW@33?"NJ:;IMK=#4+34-.:25
M9YM-G2%I$5O-@BF)5%22:02!98%NOT>^%_BSQ;\1[XZ[>Z9?:%I+6,"VNGZD
MEJEY+/,QEEGN4AEN3$B1B".WB,L,RR-?"YMSMM63W"OSP_:__9X\:ZOX]\(_
M%KX>6\5WXA\-RBWN+&2:.!M0T^5R'@CFN"UO"ZI-<J69 Y2X>19/-@@C?Z T
MG]IS0M:L;>2'0?%*W<\2,EE-X;U>"02NH(@>>:V2QC<,?+:62Y6U0Y=KA809
M1X?^T9X-^(>K:IX#^*NEZ3NO?"-SJ$UYH:;;J[FT[4D2"X\AHY(HGU"&V3>+
M9'>%KAFCBN+D11_:]#XN26W[1VL^$S:Z?J\6C^%]77Q3J-U<:9JEA<"33H)?
ML5K:VEWIXFO7N)92\JVZL8X;=X\B>YM@WG_[&_C$?#Z'XD2ZSH_B"T6^\9:S
MKML)/#NM[IK&[EM8H9(U6R+,[,<F  W"(KRO$L4;NOD'P*N=3\*?L4:AX+U#
M0?$$.MC2-<T[[$= U@R&XU%]2DME7;:%61E*[Y5)A@+QK,\;2(&S_BMKEQ:?
M!#X$0_V7J0O='\7>#;*>RN;*>PN&N;2P</#$NH+:H^6_=I-O%LSY'G@*Y7Z?
M^+&H)^TCXG\,06^C:W!H?A/4H/%E_J-UINH6+O-8Q7(M+&RL[JS^U7LLDC"6
MX$,05($$:2-<W$:+Q_[&_C$?#Z'XD2ZSH_B"T6^\9:SKML)/#NM[IK&[EM8H
M9(U6R+,[,<F  W"(KRO$L4;NOE_[.D'Q?\-?L=IX9\%:9J6F^-M+SY<&HZ<U
MGC[3K<LS>6^JPQVDV;4R,VQI/+W*#LE:,$U'PK;V_P 6OAEX^\*?#36]/T^S
M_MA-0N)-.@CU&[N=0TMH[=;Q7G:^:5;A989[_5/*MO.D^TM>O;S_ &I_8/@[
MK\OA#]HGXN:IJ.DZW%9:K_8OV*Y&AZL\-Q_9.F3I=^7(EHR-M9=L.#_I3%%M
M_.,B!O /#/P6\2?'#X*_&[PK!I^I:?>ZSXNU37--74=-NK+[5"\]M=V@C-\E
MJG^D-9M"Q+!K;>LDJ*"BO]7_  A_:;^*/Q+A3PUJ/P^U?0_$L44D=Y?7UIC0
M8I(9?*DGAN//$MTA'[V"V@W&9B(A=K;A]03R_P"&?Q&^(?[,GCCQ9X2UWP9X
MDU^TUGQ)>:SHM_HD2WMFEOJUP7^SRO<26T5CY,NYY0\@3S)9IF"1;+BX^_\
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MH?Q$O-<M]+D\W^Q-2;2;F16C9#<1VUO<2*C([9\O[0(9 VQTGCEC*C8"V?\
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M6U\/^&YGO=$N)],DN)+E[&.1[O[%)"MVY667:UT)C&9960HTCEO?_P#@HAX
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M,*JB_L=I.K6.OV-O?6-Q%<VUS$DT,T+K)')'(H9'1U)5D92&5E)# @@D&OS
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MMAK7BRV&G:G?26%U+;)8I:SVT=O86+:D/LFSSY)][3W >YFN9&1EECC@\_\
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M;8_LZT>VM_LTKZI<>5G<'E\Q)]^"J^5G*GPC_9Z\<?#OXG^)/&NH>)--O?\
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M9,[;(XU5%W,S,V ,LQ8\DFOH#_AK#PG]C_MS[-<_\(Q]I^R?\)+YVG?V7O\
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M8'PY_:7TGQYX]U'P+>:+J^AZW8V,>I?9M4AM]L]K(XC,UO/9W%W!(B.R1O\
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MDA5&< 8S[KX3^![W2]0TN;0=-DLM3N6O;VV>RMVANKAW1VGGC*;)92T:,9)
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MA1A$&,*,=!XU^'OA7XE6*6/B/2;'5;:.43)#?VT-S&LBJRAPDRNH<*[*& R
MS#."<^?WO[,GP>U&&VAN/!?A^6.UB,,"2:39,L49E>8I&#"0B&2620JN 7D=
M\;F8GT"]^'OA74?$5MXCN-)L9=6M8C#!?R6T+7449#@I'.5,J(1+("JL 1(_
M'S-GL*\O\:_!#X=?$J^2^\1^&M(U6YCB$*37^GVMS(L:LS! \T;L$#.S!0<
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MOP^UM#++-'"=)LC&DDRQK(ZIY.U7=88E=@ 6$<8)(1<?"'_""^#/^&F_L?\
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MTO0XK",WNB>&[C5)[F_N(6NI8A<+9ZI;1V\-M-:,T<EK%<O-+N6984*S<?\
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MA<3Z2;C2;C2X!.@*:9:6VWS<3Q2Q7*E]\:-&\?E31S'[/'_)SOQO_P"Y1_\
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MHV?]3])O9M1L;>XFMI;626))'@F,1DB9E!,;F%Y8BZ$[6,;R(2#M=EPQT*^
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MO@;X*WU]>>'(;Z"2_EFGNA-JNIW<<T\[(TMP\5W=31-<.8UW7!7SB 5\S:S
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MP $/GQR;XE6%MT2J@^C])TFQT"QM[&QMXK:VMHDAAAA18XXXXU"HB(H"JBJ
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M]G;SF\'>'[;3Y9]XDN,R3W!5_+W1_:+AY9A$3$C>2'$0==X3>2Q^@*X_Q_X
M\._%/P[>^'O$-E%?:=?1&*>"4':RY!!!!#*ZL \<B%7C=5D1E=58>?\ AO\
M9U\#>&/$5IXA2&^O-1LHIXK6?5-5U/4VMEN @F-N-0NKA87D5%1Y(@CLF8RV
MQF4Z'QC^!'@SX^Z6NE^*K>YN[(9W6T6H7]I#)EXW'G1VD\*3[6B1H_.#^6P+
M)M+,2>(_@7X4\6^$!X3U(ZE<:;^\#H^L:KYTRRB17CGNA=BYN(F$KJ89I9(B
MNU=FV.,+P&K_ +'7PMU_PA!X0O;74I]%@P$LI-=UMH=JB$)&5-]\T47V>(P0
MMF*!@S1(C/(6[_Q'\!/ GC3P@/">O:=_:^FKYA5-5GN+^96D$BF1;J[DEN5E
M42NL4RRB6%6VQNBA0,_X(?LW?#;]G"QN[/P7HT6FQWDJRW!$DTTDC(NU TMQ
M)+*40%MD>[8A>1E4-(Y;@/!7[#/P'^'GBI_$^D>$K&'46E,R._FS1PR&99@]
MO;S2/!;.CJIB:".,P@;(RB$J>O\ ^&8O /\ PG'_  FOEZE_;7W?M/\ ;>L?
MZK[1]I^S^5]L\K[)YOS_ &/9]E_A\G;Q7T!7C_QC^!'@SX^Z6NE^*K>YN[(9
MW6T6H7]I#)EXW'G1VD\*3[6B1H_.#^6P+)M+,3R'BS]E#X=^.H=,BUA-7NUT
MJ5)[,R^(-=9HIXY998[@-]NW-<(TSB.X8M,B;8ED$4:(IXD_90^'?B[6=/UK
M4$U>6^TV+RK.X'B#74DMU,"6[F)DOE,;RQQJ+B1</<'<\S2.S,V?=?L6? V\
MM]0MI/"&FFWO]Q>#RL0PL\"0/)9Q B.QED2.,2S62V\LK112.[211LN?\5_C
MIX*_8]L= TF?1]7FMM3ENK>U;3;62]+W@4SK!-(TAFDO=0E=_*9S))=7!FFF
MD4"68=_^SQX F\ >"K?[=916>K:I+-K.KQQ"(C^TM1D-U=KOC+"1(I)#;P,S
MRL+>&%#-+L#GW"O#]3_9U\#:MX]7QU+#?+K:Q0P"YBU74X5\B%UD6W,$5TD!
MMRZ"22W,9AE<L\D;L[ECX<_LZ^!OA3XBU'Q#HL-\NHZG%'%>3W6JZG>M<+"
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MGVO_  4#\,>.;/PI#I6KZ)H5QKVB2ZS<7>OSRK;V'DW*6AMTCD%BM]*]PEW
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M9HOT/KG_ !9XITOP-H=_K>J3>19:?;37ES+M=]D,$;22/M0,[;54G:JLQQ@
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M[\)/[/U338?,_P"$F_L_S],N)OL^W28?M'VG9J$/VKS.?*\O[)Y.1N^T8Y]
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MP7XNN;'4Y/%46IFQN-+TZ:P6VDTR&.XD6X2XU"^,J31R-L>,QF)X@ICE68O
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M]MM;BY6YN&O-0A<6E\NY;2Y<VL4:(URS3)NC30\.?M#?$[Q_\!_#WC+PW?\
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MX+A[K2[.]E>-)VU WCQ73VA: W?DV2QL/.97C@0W"\?^SQ_R<[\;_P#N4?\
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M'&G^"(]9T31KV[TV?59M0U^9TM[:&.XCAA5(2]JEW+<MYZK$MY;- D$D[>8
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MU+1M:E\[6]0L-?L&T_5+A[NYD2749DV)%/YTJ?-):EH( T-N%MU6*W3Z_KX
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M=$\22ZQ(\4=DZW2+INE&3RY+A[B5)$DGE64&*"W=!$D9>13)O^SZ***\_P#
M_P 2]#^(EYKEOI<GF_V)J3:3<R*T;(;B.VM[B149';/E_:!#(&V.D\<L94;
M6Z#Q3;:Y=Z7-'HEU;6EZ=OE37EM)=PKAP6WPQW%J[Y7<JXF3:Q#'<%*-\ ?
M3XU?M!_''X.Z=\1--_X1NYN+GSY1HHT^]M6G6UOI+>2&/4)-3FCBEE2%C#))
M;-$DK(L@$8:0?7_P!^,>E_M ?#S1?&.G+Y<6IVPE:++MY,R,8YX=SQQ%_)F2
M2+S BK)LWJ-C*3[!17E_P7O?'NH^"M,N/'=M8VNNRQ-)>0:<7-O$S2,4C4N\
MI+I&464AY$,P?RW:/:Q]0HKXPT3XJ^/8OVF9O .IWMC-I(\+7.NP+:V3V\@:
M358K6%)Y);BY,KPQHX\R+[,DAF<M!\L>S[/HHHHHHKS_ $7XEZ'X@\7ZQX6M
M)/,O='MK"YN]K1LL?V\W/E1-M<NLH6V,K(ZK^ZE@=2PD^7T"BBBO+X[WQZ_Q
M%EMS;6*^%TTB*19R7^V/J3W4@:-0'*"WCMT5G+HK&26/8\@$JQ^H44445Q_Q
M"\:V/PU\*ZMXCODEDMM*L;F_F2$*TC1VT+3.$#,BERJ$*&903C+ <CY@^ 4/
MQ<\:3>%O&]YXJBN="UOP_%?WVD3V%L&M[R\BAN(Q83V\<,JVZ"1D NWNI$2/
M:S7$DXGM?L^BN?\ %-MKEWI<T>B75M:7IV^5->6TEW"N'!;?#'<6KOE=RKB9
M-K$,=P4HWPA^SE\5?C[^T=\([#QQ8ZGX6L[G4(KTPV4VBZBT8DM[F>W17N5U
MC<J.T(+.L#F,,<1R%<-T"_M0>*O'7P2\2^,M%MK'1M;\+2ZS#JNF7\<VIQQ7
M&D1S/):">":P5GD402"YB,T*!V39*P)7Z/\ V>O%.J>.?A9X2UO5)O/O=0T3
M3+RYEVHF^:>TBDD?:@5%W,Q.U551G  &!7L%%?&'Q0^*OCWP9\?/A_X52]L3
MHGB276)'BCLG6Z1=-THR>7)</<2I(DD\JR@Q06[H(DC+R*9-_P!GT445Y_HO
MQ+T/Q!XOUCPM:2>9>Z/;6%S=[6C98_MYN?*B;:Y=90ML961U7]U+ ZEA)\O0
M>*;;7+O2YH]$NK:TO3M\J:\MI+N%<."V^&.XM7?*[E7$R;6(8[@I1O@#X"?&
MK]H/XX_!W3OB)IO_  C=S<7/GRC11I][:M.MK?26\D,>H2:G-'%+*D+&&22V
M:))619 (PT@^O_@#\8]+_: ^'FB^,=.7RXM3MA*T67;R9D8QSP[GCB+^3,DD
M7F!%639O4;&4GV"BO+_A=>^/;^'5W\76UC;,-7OH]-2R+ECIL<NRTDN=SR+]
MHE56E81D*$>,%(Y1)&OJ%%?&&B?%7Q[%^TS-X!U.]L9M)'A:YUV!;6R>WD#2
M:K%:PI/)+<7)E>&-''F1?9DD,SEH/ECV?9]9^K1WTUC<)8RQ0W+1.(9)HFFC
M20J=C/&LD+2(K8+(LD98 J)$)W#Y0_9 ^+7B_P"+-OXV/B:XMI[C1?%VI:'"
M;.W-M"(;""UC!2-I)Y!YCF29A)-,RM(4#^6J*OU_117A_P"T=XM\5?#[X=:W
MXC\.3V,5SI%C=ZDZ7]I-=1S1VMK+,80(;JT:-W95 E+2!!N_<N2"NA^SUXIU
M3QS\+/"6MZI-Y][J&B:9>7,NU$WS3VD4DC[4"HNYF)VJJJ,X  P*\0_:O^*O
MCWX2ZMX(;1;VQCT[7/%.AZ%<Q263O=!;FX>29X[AKCR51XH?(,9M6=0[R).K
M[-GV?1117G^B_$O0_$'B_6/"UI)YE[H]M87-WM:-EC^WFY\J)MKEUE"VQE9'
M5?W4L#J6$GR\?^T=XM\5?#[X=:WXC\.3V,5SI%C=ZDZ7]I-=1S1VMK+,80(;
MJT:-W95 E+2!!N_<N2"NA^SUXIU3QS\+/"6MZI-Y][J&B:9>7,NU$WS3VD4D
MC[4"HNYF)VJJJ,X  P*]@HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK
MG_%/A/0_'.ES:7K=A;:A93[?-MKR&.>%]CAUWQR*R-M959<@X90PY -?BC^S
MY\%/ 6N_L*7GB+4=#L;W5(_#_B>6&\O8$N9X&@FU#RA;23AVMD1E\Q8X#&@F
M:2<+YTLKO[_\'O&M]\:?%7@+P#XK2+5='?X9:9XGNHKT-.;S4)9K>V$EYYK,
MMRD:[Y$CE5D^T2?:7#SPVSP=A=:+_P ,S_M)>$-$\'K;6'A[QS;:HM]I$%OY
M=O%>:19^<M];*CB.&69##!*D4:1R)$9)%EF9)(>/_88^"_@K48?BFB:9%9R)
MX[U[3([C36DT^ZBLX9;26.UANK)H+B&W5T4^3%(D9&5*E20?4/V"O^+X_LQ>
M'?\ A-?^*@^V_;OM/]K_ .G>?Y.K7/E>;]I\SS-GEQ[-^=FQ,8VC'R!^S-\+
M?#%I^Q%+XQL;3^S]?MM$\27:ZKIDLNGWS/:SWYA66ZLWAFGB4Q1GR)GD@8Q1
M%HV\M-OT?XT^+/B+3/V=_A9:)J%]'?>,Y?">@7&IPW(%Y NI6\;W5RDLL<Q:
MX>..5%D.'CDE%P'WQ@-] :%^QWX"\ >+?"WB#P=:Q>'VT.*[M9X;"%$74K6Y
MM1"(KV08FG>*6."XCEG>8[T<LK2R+-%^>'Q[U:+X4?!'4?&'AX?\)-XFL;F"
MY/Q$L['28E:>75XR8DF:Y>XFB2"5=.9+1+JQ$6;!BB17-M;_ $?^U9\/?"OC
M/]I?X-PZQI-C?1WD7B>&Y2ZMH9EFCMM.6:!)1(K"1(I)'DB5LB-W9U 9B3V&
M@3ZAX:_;"N]"M]3U)]-NO!$FKR6=SJ-[=6XO)=;$32Q0W$TD<.$ 1$A5(XTR
MJ(JD@GP,LM#_ &JM4\=ZAX\T73=8;0_%VJ>'].CO+2.XAMK.P2 +Y45QYJ)+
M,SO)<S*!).QC1F\FWMHH?F"[T7[/X+^.WPMUM;;6-(\"Z:;_ ,/&]M_.FL$O
M](O+JW@22=YG/V%=L-K.3YZKO =8S'%%S_QM^%7A#P5^Q%I?C+2]*MH/$,&B
M>%;R'6!&&U**9I].(>.^;=<IL#>7"J2!8(0D$02%$1?V^KX ^!EEH?[56J>.
M]0\>:+INL-H?B[5/#^G1WEI'<0VUG8) %\J*X\U$EF9WDN9E DG8QHS>3;VT
M4/S!=Z+]G\%_';X6ZVMMK&D>!=--_P"'C>V_G36"7^D7EU;P)).\SG["NV&U
MG)\]5W@.L9CBB^[_ -BOX>^%?!WP>\)WVD:38V-SJ7A_1IKV:UMH89+F3[%&
MV^=XU5I7W2.VZ0L<NYSECD_:1TK2=:UGPQ!K.IQ7%B);Z1_"IM;>ZD\0R^0(
M[>-8YI4!2SDD%RYD5K6(^7=7+VZ6RW,7S_\ LR?9/'OQ!^*W@'5_#L5EX:TZ
M7P]+:>'+^UTV2WM&NK)II@(;5[FU"2S0)="..1T69FFVI<239^8/V?/@IX"U
MW]A2\\1:CH=C>ZI'X?\ $\L-Y>P)<SP-!-J'E"VDG#M;(C+YBQP&-!,TDX7S
MI97?]7OV9-6OM?\ @]X+OKZXEN;FY\/Z3---,[2222264+.[NQ+,[,2S,Q)8
MDDDDU\P?&^]U[XB_'VT\$QV&D:QIUEX6;5GT?5KZ_M+>[DNM1^SF>=(;._M+
MI+3[+&(8;J%3'-=&XC+O&&AX_P"#G[(.J1Z7XS\"?$F;1)=%UZYO=3\/Z/82
M)<MHZS/<)=R6/VNQ@\K[/]MMEADAB,4,KEQ'$UPPE\_^#EEH?Q9^"NC_  AU
M31=-GU+1?$DWAF]CBM(VM0FBSK+J>H0EM\\7GV4IMCJ"QPSKJNHQX-JUQ',O
MH$FB:A\3?C%XS\-0^'/#>NZ1X5MM!TVRT75;R]M+2R22Q:Z6Z6R&FZA822R^
M<]M%-&L4]O;VODA5CE+3?*'QT^!'B+X2?L<>(?#OQ#O](US7?#LMA)I4T)%S
M<:=IMYJ%C!'&DL\$-Q$DCP7,:G&UH8Q KF.$11?5_P"UE\*O"'P@U3X7ZOX8
MTJVTW4I_B!H5G<:A;QA;ZXAN4N4N$N;SFYN/M )^TM/)(UP2S2EV9B=#4_A[
MX5UK]N19KS2;&>1? D.IAY;:%V%Y!K2PQ70+*2+B.-$CCF_UB(JHK!5 'N'_
M  UY_P 5Q_PBW_"O_&__ "$O[-_M'^Q/^)=_Q\>1]J^T>?\ \>G_ "U\[;_J
M?GV]J^$/CA9S>%]9\=6?QM\+Q7&DZW+JHT;QP+"+5DT>UF@A@T^U:"*W^T6B
M0/)\C!HS-?R2,@D\R:]KV_\ :%T#2/&O[0/PA^R:MJ4NF^(O[>O9?L.N:G';
MR_9=%3[)/:_9KM(X/DF?]Y:>5YZ2R;S(LK[N/_:!O8?V)/B9I>H_#^VBLK37
MO#_BVYN](!E32A=:+I,=[;W<5E \,45Q(8(X+ATP)( P"I,[S-R%S^S)\6_B
M?\/_  5KG@M?#=AXAMO[.U9?%[ZMJ5UJ6HJ;%T)G>[T9;DQ7 F5C;7$LL4<*
MK:&$PJJ+]'Z/)X5_:Y^.'B33M<BBU;0O!UCHLFG6CRPW6FW=QK5G/<OJ,D0C
MV3NMNT<%KYCS0Q*99XP))PT?C_[7?P7;]F']GOQGJ?A;7M7LF@U<:GI4=C?W
M=A'IT>IWUA'<6<4-G-#!);J_GO CQ8@%PP5?-\R:7U#_ (*L>$]#U?\ 9V\0
M:I=V%M/>Z?\ 8OLES+#&\UOY^IV:2^3(REXO,4!9-A7>H"MD<5G_ +4O@/1O
M@5??#BZ\$1R^'EU#QWH.G7=MH]Q/86=Q;SM,TJS65M)':2/)Y<:R2O$TSQHD
M3.8E5!Z!\79+'XV?'W1_A=KD4LFB6/A^3Q5=6HE7[/J%PNHQ6EI!=Q>7NDM[
M=EDN#"9/)N)FA\V-E@"O[?\ "/\ 9ZT/X)^)_$FH^'Y/LNFZW]@E728(HX;.
MSN+6)X)IK:.()&GVE/(,HV;S)"7:1U9$B/VL?^2(>//^Q;UG_P!()J^0/!G@
M[X]Z[^S3X>A\,Z_IO[WPWHY@M;*QFT_46M_LMNSV\&J37]W;P7;P;HH[MK+8
MLS"0+;\21<_\'O'7P\\:_L.^(HO ]O<VEEIOAO7;&XMKQVEFAO!82W%P'FVH
MDWF-/YZR1*D964 16Y5K>+U#2[.QU']F[X80:CXCBT6Q:Q\,F\@DMUNFU>WC
ML(Y9-'CAW"65[T)L,,"S37"*]N()TE>-N?\ @AXBN?#7[3-WX0TGPW+X2T2;
MP:NJOHYBTN*-[R/5?LXO533)[F%7>*0P.V]))1#&)498;=AG_L]?"+P/^VQ\
M,+_X@>,].^V:EXO_ +3@26[^SW4NDV<5W=V=K;:8TEN([?[.@\WS4B$DUTSW
M$I=BJIQ_[35[XB^!OQ$^!SQ6U]XMU31-(\4QE(B%NM1GMM"@1I#YKR-OE93+
M( 9YB"PC2YFV1R>P:%X.^%W@7X=>(OCCX3M=(UK7KC2-1UU=9%ILCEN8K6Y=
MA% &#6:;F>"XB1DNW 9;R>XNQ+.VAX/_ &</"'[0GP8T?7-2LK:/Q3KFB6&I
MGQ"( =2@U*>VBN8[R.YC:*X7R)RK0P1RQ0QPQI:1K':JL2_(&N?$C5/C[\'?
M@#XX\216TNM2_$#2;5[J.!(V*QWUY Y&/N>?]DAEG2/9$TJ*5C14C1/I_0/"
M>A^%/VWKO^R["VL_MGP_DO;G[-#'%YUQ+KX\R>78J[Y7VC?(V7; R3@5G_\
M!._X>^%= OOB;?6.DV-M<VWCOQ!ID,T-M#')'9QM:LEJCJH9;=6 985(C4@$
M*"*_2^OR _8*/QGU?]F+P[IGA*'1-/BG^W10ZO=WMS/<6ZOJUSYTRZ:+ 0RR
MQ@R>1&]X(G=8WD.PO%78>-?AW=_!)?A%\&?#_P!AN[&6+6)[NUOKS4K"/5Y;
M*T#RP2R6T=^!;SR7MQ?3V=S'+:RB!;8L$VQ2]!\(/V:_&7@'XD^(WUJYTCP]
MX2\4101VGA_P[JUY;-'J5K#;L)+66"TTMXWD@L[F6X%J8VF3B9)HXMZ>?_L$
M?L\>#_C-\%_"'C3Q*^KWFMK+K4R7HU[6H9(I+C4KN.X>+R;V-8GG4#[0T00S
MDLTA=F8G \!_M%>/? '[ T?CZ'4I;S78XKB-+S47>[DW3:_)9"1C,S&1XHY,
MQ"3>@*(&1XP8S]'_ +4/[.'A#P7\--9\6^#[*VT/Q)X>MIM<M-:MX ]\TUE$
M\THN;AF$MY]KB$L%R;Q[A9C,TTR3N.?/].\=?\-;>./ 7A#Q5;YTV?P19^.M
M0LX'VV=_>3W%M%;V]Q"ZO(]I;/YLX@:9HYY##YR.L&)-#P5X \._#C]M![#0
M;**PM&^'9E6VMP4MXF;755A!"#Y4",5WM'"L:-,TDQ4S2RN_T!^W%\7O$7P(
M^!_B3Q3X>>*/4;2*VC@DEC$BQM<WD%J9 A^5G19B\8<,F]5WI(FY&\O_ &H?
MV</"'@OX::SXM\'V5MH?B3P];3:Y::U;P![YIK*)YI1<W#,);S[7$)8+DWCW
M"S&9IIDG<<_/_BSS?C!\2O@'JFI7>I6__"7:;J6K:C;6.L:M:VZW$7AZ%XFM
M8X[P?9-GGRKFW,;R))(LK2^8Y;]/_A;\+?#'P6\,6GAGPS:?8]-L_-\B#S99
M=GFRO,_SS/)(<O(S?,QQG PH 'PAK<6O?&SXX>.M(N-#\/\ B6Q\.Q:)9P:7
MK>H7]O!;&XLWO3>FU.G:C8S7$[7$D"W"B.XAAMO*PJ3,TQ\$/V0+[6?@E=_"
M'XP:I8ZY-:2K-9?8;AI+C3K-X_+LGBDF@BFC>.6*[6!G1XS"K6N9+=7MU\O_
M ."?O@_PA\1+B2W\1:/HDVM> +:QT2S^RV :$PF>:^M]:MKB2)?-_M'Y)H)/
MF9&AEOH6A759$;U#]G;X>^%4_:K^,=\-)L1<V,OAR:UF%M#YD$E]I<[7;Q/M
MW1O<,S-<,A!F+,7+$FOG#PM\)OB1^V%\$8?$5A8^&WU_6KEM2M?$TVJZK]NT
M]X]7-S]ELTGTN::RBM3&]G'#;7GD*0\\;2>:[R]_\2OAIH?B;XW? \:_'INI
M:IJ%MXBM/$-[IZQHNHWFFZ1#;W$=Q) D)GB6:*:"2VE41^49;22 1-)"?8/
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M*S]6COIK&X2QEBAN6B<0R31--&DA4[&>-9(6D16P619(RP!42(3N'PAX"_9
M\<?#_P"!MU\*+;Q9ILEE-;7EBEU)H5QYRV]_]K:Z!"ZL$:4M<J8) %2)8V5X
MIS(&CZ"']C?['H?@>YM=6MK?Q9X+MH+&QUN/3?DFLXHVMVM;JS>Y9I8I;=F1
MMMQ')%.[W%O);B1XF]O\%?"K5K/Q4_BSQ/JD6I:LMB=,M_L4%Q96=O:O,L\N
MRTEO+T?:)Y$B\^X,F7CM[:-4C\N1IO,/!7[.7B_X4:IXFF\*^*+:WM-;UN[\
M0^1>Z2;IEN[U(DGBFE2]M_-M!M>2&.%+6X27R"]U-%'-#<G[.G[/7CC]G+X8
M)X*T_P 2:;=_8L_V?<SZ+<#R_.NY;FX^TQ)J@^T;O-*1>6]KY6 S>=TKS_P%
M^R!XX^'_ ,#;KX46WBS39+*:VO+%+J30KCSEM[_[6UT"%U8(TI:Y4P2 *D2Q
MLKQ3F0-'V%_^QY8_$'X)6GPN\;ZC%J%M8Q6-O:7NG62V5Q#'81Q1Q.OVF74%
M%PRI(DLR; \,SQ+$@+%M#X,_LY^._"GD1>/O'ESXPM;'[*]A;3Z?;V:1S6WW
M)[ET>6:]E0A'B-Q*RI.HNF62Z2WF@\?NO^">[R_"C4/A;%XVU)/#;;FT^W^Q
MZ>TT3/(ET5O)S#NNHDO$^T1+;BPE"R2P23S)Y)A]P\?_ +.WB+QGK/@WQ1'X
MCB7Q#X7EU*1+BYTX36<RZI T-Q&;2&YM942,;%M3]J=XXTVSO=RLTYY_2?V;
M?'NG?&&W^(<WBVQNI(M(3P^\,VB.));!;T799Y8=1BB%ZY&UIX[>.V!)9;%5
MQ&.@E_9MOO!7CW5?&'P]U.QT.?7HD&L6MWIC7UK=7$+EH;M%AN[&6"X DF68
MK*T-P9/->'SPTKZ&K_LZ7%U\-/%7ABVU?;J7BK[;)J6I74,]TIFOXEMYS#;-
M=*T445NJVUE )V6VBB@#M<,DAF\?\>_L@>./B!\#;7X47/BS38[*&VL[%[J/
M0KCSFM[#[(UJ &U8HLH:V8SR$,DJR*J10&,M)]WZ3'?0V-NE]+%-<K$@FDAB
M:&-Y HWLD;23-&C-DJC22%00ID<C<?F"7]FV^\%>/=5\8?#W4['0Y]>B0:Q:
MW>F-?6MU<0N6ANT6&[L98+@"299BLK0W!D\UX?/#2N>(_P!G#5K[X=>(?#.F
MZY%%?>*);Z76=0O;2XO1*U_:FVF%K ;Z(VR11B&&SC,LZ6]O!'$ZSN6F;T_X
M#_#S7/A-X'TSPSJFI6VI?V7;6]C;3VUE)9YM[:WCAC$J/=7>^7Y"SR*T:-N
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MO")N9[F'14T^PNYK;SDRT4%_?I=%(A-^\"&!LJ6#%IY)+E^P\>?LJZM?^+?
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M\5:5K,NDZWX9EN9+"4V\5W:LMZ(8[J.ZMV,;R))!&T2F*>W>,R&0/N5<<_\
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M?>ZM8Z=-;0W%Q%%)=2F&!)'56ED$3S%(P2"[B.*20JN2$C=\;58C0HHKY_\
M'7[,7@'XD>)[?Q-JT>I/J5KO^S3P:WK%K]F\V)89?LR6UY%';^:B!9?)5/-Y
M+[F))^@*****************************************************
M*********************SX]6L9KZ6Q2XB:YABBFDA#J9$CF:18W9,[E1VAE
M5&( 8QR $E&QH4444444445GV6K6.HS7,-O<12R6LHAG2-U9HI#$DP20 DHY
MCECD"M@E)$?&UE)-6U:QT"QN+Z^N(K:VMHGFFFF=8XXXXU+.[NQ"JBJ"S,Q
M4 DD 5H44444444444444444444444444444444444444445\8:Y^W%X-T71
MK_Q,NE:O=>%["^2QF\0V\=FVGEFGBMGF@5KM+RZMXYI?*:>UMID=XY/*,H3)
M]_\ &OQ.7PM?)IFGZ5?:WJ)B%P]GIIM!)#;LS(L\SWES:01H[JR1*THFG*3&
M&.1+:Y:'R"Y_:YT&'PKK^M+HFKO<^&I9DUO2BMA'J&GQQ0R3_:)8YKV.&2WD
MBC\VWEM9K@7".IB\PK*(^?O_ -MC0=(\%6GCJ]\,^(+;PS<16,S:K-#8)'%'
M>R11*[VQOOM[(DDP5FBM91( 9K<W%NT4LG8:M^U'I_AC5-$M]<\.ZWI=EKNI
M0Z38:A>160AEN+E)'ME>WCO)+^#S_+PHN+2%X68+<+ 0^W/U;]K"TTGXBW'@
M ^%/$$VLK8OJ5M%#'IKQW5JET;;SDF%_Y4",5=U^W-:$A1&0+F6""4T+]K"T
M\3:SJ_AVQ\*>()==T:6!;[2Q'IHD@BN($GAG:[-^-.*2!PJ1+=FZ8K(PM_+B
MD=.?\0?MQ>#?#OPVUCQS+I6KO;:%J\NB:M:1QV9NK*ZBF6!A(&NU@E3?)" U
MK-< B9#T6;RO3_$7[0FG^%/B?H?@+4-'U**XU[[9_9]]_H36<WV*T%U<?<NV
MN4V!A'^\MTW2'Y=T?[RN0U;]K"TTGXBW'@ ^%/$$VLK8OJ5M%#'IKQW5JET;
M;SDF%_Y4",5=U^W-:$A1&0+F6""7C_&_[2'P\^(7A/QUX9\56NMZ)_9]L=-U
MJ#["UY<6EOJ>G23)=;]*&IVZQ& 2MYS,R0O'B94W1B3V_1O'_P -OA9\)M.\
M0V][%8^%;'2+.6UGE,VU;'R(Q; "4&=G9#&D<;!KB1V6/:TK!3R'A7]J/3]9
M\3^'_#NL>'=;\/W?B.VNKG2QJT5D//\ LD4<\T3):7EU+;RI%)O*74<&-K1D
MB4",G_#6'A/['_;GV:Y_X1C[3]D_X27SM._LO?\ :?L6[/VS[7Y7VK_1O/\
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MIM\=.O\ 6(K>%+6VN$OA83*8[B>&\N$AF(626RMKJ$G<L;R21RHFAXP_:_\
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M],U24Z;]EN5-C/J$4@C2^>]C2:WMWDC$UM&ZDJDJ1.2H^CZ**_,#_A4_@?\
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M11111111111111111117E_QOTSQ%K7PZ\2V?AQI5U:?2-0BL##,()!=/:R+
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MK'7_ -M"WOK&XBN;:Y^&230S0NLD<D<FNAD='4E61E(964D,"""0:T/V>/\
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MS]JD>Z::/RRR>4[3,T(#28B* R2D&1OH"OG_ /:Q_P"2(>//^Q;UG_T@FKX
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M+XGZS^TSHOA^REOKZ6+P-+';P@&21;:!+B0(N07<1Q.5C7+R$!$5G95/W?\
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M>UGPM<Z+97$DJFUAU ZE#<3O*ADS C1K:QR7!382T.]O*AE>'[/\"_$OP/\
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MM-"U30=-O--L_+^S6=S96\MO#Y49BC\J%T:--B,43:HVH2HPI(H\=?"?P/\
M%#[/_P )-H.FZO\ 9M_D?VC96]UY7F;=_E^<C[-VQ-VW&[:N<X&.PU;2;'7[
M&XL;ZWBN;:YB>&:&9%DCDCD4JZ.C JR,I*LK A@2""#7C\?[,GP>AL9;%/!?
MA];::6*:2$:39"-Y(5D6-V3R=K.BS2JC$$J)) " [9]PHKC_ !K\/?"OQ*L4
ML?$>DV.JVT<HF2&_MH;F-9%5E#A)E=0X5V4,!D!F&<$Y/&OP]\*_$JQ2Q\1Z
M38ZK;1RB9(;^VAN8UD564.$F5U#A790P&0&89P3G0\+>$]#\#:7#I>B6%MI]
ME!N\JVLX8X(4WN7;9'&JHNYF9FP!EF+'DDUT%%>7^-?@A\.OB5?)?>(_#6D:
MK<QQ"%)K_3[6YD6-69@@>:-V"!G9@H. 68XR3GL/%/A/0_'.ES:7K=A;:A93
M[?-MKR&.>%]CAUWQR*R-M959<@X90PY ->7ZG^S)\'M:F6:\\%^'YY%BAA#R
MZ39.PC@B6&) 6A)"1QHD<:]$1510%4 =!IGP0^'6B^(F\1V?AK2(-6:6:8W\
M6GVJ71DG#"5S.L8E+R!W$C;LN&;<3N.=#_A4_@?_ (2?_A*?[!TW^VO^@C]B
MM_MG^J\C_CXV>;_JOW7WO]7\GW>*Y_Q3^SU\+/'.J3:IK?A+1-0O9]OFW-YI
MEI/,^Q B[Y)(F=MJJJKDG"J%'  KV"BO@#_@I?!J'B7X$ZUX9TG3-2U+4M4^
MR?9H-.TZ]O,_9M0M)I?,>VADCAP@++YS1^9M8)O92!]/_#?P9\/);B7Q=H'A
MZVT^]U+S_/NGT=M-OI=\^Z7SQ/;P77[R1!(?.4>:0LOS JQZ#7_A/X'\5ZY:
M:[JF@Z;>:E9^7]FO+FRMY;B'RI#+'Y4SHTB;'8NFUAM<EAAB36?XU^"'PZ^)
M5\E]XC\-:1JMS'$(4FO]/M;F18U9F"!YHW8(&=F"@X!9CC).=#7_ (3^!_%>
MAVFA:IH.FWFFV?E_9K.YLK>6WA\J,Q1^5"Z-&FQ&*)M4;4)484D5H>"OA[X5
M^&MB]CX<TFQTJVDE,SPV%M#;1M(RJI<I"J*7*HJEB,D*HS@#'/Z9\$/AUHOB
M)O$=GX:TB#5FEFF-_%I]JET9)PPE<SK&)2\@=Q(V[+AFW$[CD\:_!#X=?$J^
M2^\1^&M(U6YCB$*37^GVMS(L:LS! \T;L$#.S!0< LQQDG.>_P"SU\+)=4N=
M4;PEHAO;O[3]HN3IEH9I?M:.EQYDGE;W\Y9)%FW$^:KNK;@S Z'@KX(?#KX:
MWSWWASPUI&E7,D1A>:PT^UMI&C9E8H7AC1BA9%8J3@E5.,@8[#3O">AZ1JE]
MJEI86T%[J'D_:[F*&-)KCR$*1>=(JAY?+4E8]Y;8I*K@<5T%%>/_ /#/7PL_
MMS^W?^$2T3^TOM/VW[9_9EI]H^T>9YOG^=Y7F>;O^?S-V_?\V=W-#_L]?"R7
M5+G5&\):(;V[^T_:+DZ9:&:7[6CI<>9)Y6]_.6219MQ/FJ[JVX,P/0>!?A/X
M'^%_VC_A&=!TW2/M.SS_ .SK*WM?-\O=L\SR43?MWMMW9V[FQC)SZ!17G]U\
M)_ ][I>H:7-H.FR66IW+7M[;/96[0W5P[H[3SQE-DLI:-&,D@9RR*Q.5!&?J
M?P0^'6M>(E\1WGAK2)]666&87\NGVKW0D@"B)Q.T9E#QA$$;;LH%7:1M&.?M
MOA#X-^#UCJ6L^"/!FD1:LEC<"&*PM;/3Y+I@OF):FX6)1&DLD<8+/E%.UV!V
MUYA^SUKWB_XUZY)X^\2^&KGP[%'IL6F:78Z@Y%Y&TL@FU662+RXBD4TT-G#;
M^?F5X['[2L5LETR2?7]%<_XI\)Z'XYTN;2];L+;4+*?;YMM>0QSPOL<.N^.1
M61MK*K+D'#*&'(!H\+>$]#\#:7#I>B6%MI]E!N\JVLX8X(4WN7;9'&JHNYF9
MFP!EF+'DDUH2:38S7T5\]O$US#%+#',44R)',T;2(KXW*CM#$SJ" QCC)!*+
MC/\ %/A/0_'.ES:7K=A;:A93[?-MKR&.>%]CAUWQR*R-M959<@X90PY -9^F
M?#WPKHOAUO#EGI-C!I+130FPBMH4M3'.6,J&!5$120NYD7;ARS;@=QSY_'^S
M)\'H;&6Q3P7X?6VFEBFDA&DV0C>2%9%C=D\G:SHLTJHQ!*B20 @.V>P_X5/X
M'_X1C_A%O[!TW^Q?^@=]BM_L?^M\_P#X]]GE?ZW][]W_ %GS_>YKS_QM\!]#
M\9ZYX3673--72O#NZYMU2WC2X@N+:2T:QBM7$9^SVB^4TDZ0-"\CV]G"2]H;
MF"3Z HKG]1\)Z'J^J6.J7=A;3WNG^=]DN988WFM_/0)+Y,C*7B\Q0%DV%=Z@
M*V1Q1H'A/0_"GVO^R["VL_MES)>W/V:&.+SKB7'F3R[%7?*^T;Y&R[8&2<"N
M@KYP_:ZOVA^#WBJQAM+Z\N=3TC4=.M8;"QN[V1[BXLIUB4I:13-&C-\IED"0
MJ2H9U++GS_\ 9%^&W@J;P+X5UJ;PM%9^(],TC3M.NKN_T22RU!+BWTR"VE42
MW=M#/(BI^Y$L;/"R!HU=@K*/I_QK\/?"OQ*L4L?$>DV.JVT<HF2&_MH;F-9%
M5E#A)E=0X5V4,!D!F&<$YS]?^$_@?Q7H=IH6J:#IMYIMGY?V:SN;*WEMX?*C
M,4?E0NC1IL1BB;5&U"5&%)%9]E\$/AUIWAVY\.6_AK2(M)NI1-/81Z?:K:RR
M H0\D C$3N#%&0S*2#&G/RKC0\"_"?P/\+_M'_",Z#IND?:=GG_V=96]KYOE
M[MGF>2B;]N]MN[.W<V,9.<_QK\$/AU\2KY+[Q'X:TC5;F.(0I-?Z?:W,BQJS
M,$#S1NP0,[,%!P"S'&2<Z'CKX3^!_BA]G_X2;0=-U?[-O\C^T;*WNO*\S;O\
MOSD?9NV)NVXW;5SG QSZ?L]?"R+5+;5%\):(+VT^S?9[D:9:":+[(B);^7)Y
M6]/)6.-8=I'E*B*FT*H'L%%?F!XILM(\<_M7S7&M^&M2U#0)_"*^'99+SPYJ
M<]B]^FO"X6-VDLVA:)0JS+=G-H HD$_ -?H_X6\)Z'X&TN'2]$L+;3[*#=Y5
MM9PQP0IO<NVR.-51=S,S-@#+,6/))KC]3^"'PZUKQ$OB.\\-:1/JRRPS"_ET
M^U>Z$D 41.)VC,H>,(@C;=E J[2-HP>-?@A\.OB5?)?>(_#6D:K<QQ"%)K_3
M[6YD6-69@@>:-V"!G9@H. 68XR3G0U_X3^!_%>AVFA:IH.FWFFV?E_9K.YLK
M>6WA\J,Q1^5"Z-&FQ&*)M4;4)484D5H>"OA[X5^&MB]CX<TFQTJVDE,SPV%M
M#;1M(RJI<I"J*7*HJEB,D*HS@#&?H'PG\#^%-<N]=TO0=-L]2O/,^TWEM96\
M5Q-YL@ED\V9$61][J'?<QW. QRP!KG_%/[/7PL\<ZI-JFM^$M$U"]GV^;<WF
MF6D\S[$"+ODDB9VVJJJN2<*H4< "N@\=?"?P/\4/L_\ PDV@Z;J_V;?Y']HV
M5O=>5YFW?Y?G(^S=L3=MQNVKG.!CG]1_9Z^%FKZ78Z7=^$M$GLM/\[[);2Z9
M:/#;^>X>7R8VB*1>8P#2; N]@&;)YHU']GKX6:OI=CI=WX2T2>RT_P [[);2
MZ9:/#;^>X>7R8VB*1>8P#2; N]@&;)YH3]GKX61:I;:HOA+1!>VGV;[/<C3+
M031?9$1+?RY/*WIY*QQK#M(\I414VA5 ^4-7^&FNZEX]\1:G\0OAG8^,UN)8
MTT>]L1I%PMMIL3S"&RF@UFXLVBN$9GN9YH3.L[W9C\Q8K:&)/</V>_@G<?"O
M5->U$:7IN@V^J_8L:/HMU/<6,<ULDJ27B>9;6,<4MRCP1310VR+BSCE:6625
MA']/UQ_C7X>^%?B58I8^(])L=5MHY1,D-_;0W,:R*K*'"3*ZAPKLH8#(#,,X
M)SY_)^S)\'IK&*Q?P7X?:VAEEFCA.DV1C2298UD=4\G:KNL,2NP +".,$D(N
M"]_9D^#VHPVT-QX+\/RQVL1A@232;)EBC,KS%(P82$0R2R2%5P"\COC<S$^@
M1?#WPK!-I4R:38K)HT3PZ<XMH0UE&\0A=+4A<P(T:K&RQ;044(1M %%M\/?"
MME8ZE8PZ38QVVJRW$U_"EM"L=W)<KMG>X0+MF>5?EE:0,9!PQ(K/_P"%3^!_
M^$8_X1;^P=-_L7_H'?8K?['_ *WS_P#CWV>5_K?WOW?]9\_WN:/^%3^!_P#A
M&/\ A%O[!TW^Q?\ H'?8K?['_K?/_P"/?9Y7^M_>_=_UGS_>YKG]._9Z^%FD
M:7?:7:>$M$@LM0\G[7;1:9:)#<>0Y>+SHUB"2^6Q+1[PVQB67!YKH/ OPG\#
M_"_[1_PC.@Z;I'VG9Y_]G65O:^;Y>[9YGDHF_;O;;NSMW-C&3DM?A/X'LM+T
M_2X=!TV.RTRY6]LK9+*W6&UN$=W6>",)LBE#2.PDC"N&=F!RQ)Y_PM^SU\+/
M VJ0ZIHGA+1-/O8-WE7-GIEI!,F]"C;)(XE==RLRM@C*L5/!(KV"BO+]3^"'
MPZUKQ$OB.\\-:1/JRRPS"_ET^U>Z$D 41.)VC,H>,(@C;=E J[2-HP>"O@A\
M.OAK?/?>'/#6D:5<R1&%YK#3[6VD:-F5BA>&-&*%D5BI."54XR!@TSX(?#K1
M?$3>([/PUI$&K-+-,;^+3[5+HR3AA*YG6,2EY [B1MV7#-N)W')XU^"'PZ^)
M5\E]XC\-:1JMS'$(4FO]/M;F18U9F"!YHW8(&=F"@X!9CC).>?U;X;?"[X:W
MUQXT'A:QCU&.5YGO=.T3[3J#27+&.1U^Q6TMW(\GFMYK(&)1G9SLWD?&'_!.
M_P"$'AB?X2^&K;Q7X/\ *\2>'_/S-K.@RP7%OYFJ7EW;?9[F\MDW[=_FC[-(
M_DNX+;'<9_2_5M)L=?L;BQOK>*YMKF)X9H9D62.2.12KHZ,"K(RDJRL"&!((
M(-9^B^$]#\-;?[.L+:UV6UO9+]GACBQ;VN_R(!L48BA\R3RHQ\D>]]H&YL^?
M^*?V>OA9XYU2;5-;\):)J%[/M\VYO-,M)YGV($7?))$SMM555<DX50HX %=!
MXZ^$_@?XH?9_^$FT'3=7^S;_ "/[1LK>Z\KS-N_R_.1]F[8F[;C=M7.<#''W
MO[,GP>U&&VAN/!?A^6.UB,,"2:39,L49E>8I&#"0B&2620JN 7D=\;F8GT#4
M_A[X5UKPZOAR\TFQGTE8H8182VT+VHC@*F)! RF()&40QKMPA5=H&T8T/"WA
M/0_ VEPZ7HEA;:?90;O*MK.&."%-[EVV1QJJ+N9F9L 99BQY)-=!11111111
M111111111111111111111111111117E_P7\:^(OB+X*TS7/$&A2^'[Z\B:63
M3IIA-) ID81AW\N(AWC"2-&R(\1<Q.H=&%>H5\__ !D^+5QX2U_POX1TBXMH
M-:\3W-W%:R7EO/<PPPV%G)=W,SQ126_FXVQ0+']H@8-<"8&189(FZ#X':C\2
M]2\,!OB'8Z;9ZNES<Q,-)FEDMY88Y66&91*"\7F* PC9Y&V;7<Q2.]M![!11
M1117A_CCXNWUM\-HO%_@K1Y?$TE[%ITVGV<4C6K7,=_- B.7EB8PHL<WGR-*
MBB-$8R&-0S+[A111111117/^+/%.E^!M#O\ 6]4F\BRT^VFO+F7:[[(8(VDD
M?:@9VVJI.U59CC !.!704445S_B7Q3I?@^SCN]1F\F*2YM+-6VN^9KVYBM($
MP@8_/--&FXC:N[<Q5 S#H*Y^Y\4Z7::Y:Z))-B]N[:YO(8MKG=#:26\<S[@-
M@V-=0#:S!FWY4,%<KT%%%?*'C_X\>*O!7QH\&^!WTJQ&G>)9=2,=Z+N:2X\O
M3M-:XD5K;[/$D+F=X@CB>Y#0I)F.-Y%,?U?17E_B;QKXBTCQKX>T.QT*6]L=
M1BU"6^U$3"./3UM8XC"&0QD2O<R2B-(U=' 624*Z1R%/4**Y_P 6>*=+\#:'
M?ZWJDWD66GVTUY<R[7?9#!&TDC[4#.VU5)VJK,<8 )P*^</!7QO^(OQ<L7US
MPGX3L3HDTI&GW6M:M=:=<7MN%7%VEI'I5XT5O*Q8VYF=)I80LQAC61 3]GS]
MI'6?C)XM\5>&-9\,2^'[[PW%HYN(I;Z"[9I-2M7G90;<&()&4Q&XD<RHRN\=
MN^Z%?J^BBBBBBBBBBBBBBBBO+X_&OB*7XBR^'1H4O]DQ:1%?MK!F C-U+=20
MK9+"8P7<1Q-.\B2,(P8U=%\V)G["V\4Z7=ZY=:)'-F]M+:VO)HMKC;#=R7$<
M+[B-AWM:SC:K%EV98*&0MQ_PN\:^(O&\.KRZQH4NCK::O?6%F)9A(UY:VLOE
M1WH7RXVB2=@YCC8,2BK*KR12(Y]0HHHHHHHHHKS_ %#QE<:K;ZO!X9CMK[4M
M+N8K.:WO)Y[.%9G@M[HH\ZVMRPQ;W,<JM'%*I9A&2C;RGF'[)/QOOOVC_A7I
M7C2\M(K.34I;\BWB9G6..&_N+>)2[8+N(XD\Q\('?<RQQJ0B_1]%%%%?*'P.
M^/'BKXC_ !)\;^$=>TJQTZ3PQ%HP(LKN:]66348;BY9O.EM[0[!&L"JGD*5<
M2DR2*R!/J^OE#]LKX\>*OV;/AMJ/B[1=*L=0CLX@)?M=W-"T4D\T-M;LD,=O
M(+A!)-NF0SVA")A)"SY3ZOHHHHHHHKY0^!WQX\5?$?XD^-_".O:58Z=)X8BT
M8$65W->K+)J,-Q<LWG2V]H=@C6!53R%*N)29)%9 GU?17/\ BFYURTTN:31+
M6VN[T;?*AO+F2TA;+@-OFCM[ITPNYEQ"^Y@%.T,77Q#]DGXWWW[1_P *]*\:
M7EI%9R:E+?D6\3,ZQQPW]Q;Q*7;!=Q'$GF/A [[F6.-2$7Z/HHHHHHKG]&\4
MZ7X@O-2M+.;S)=,N5L[I=KKY<S6T%V$RP ;,-S"^Y"R_/MSO5E7S_P"/'Q#U
MSX3>!]3\3:7IMMJ7]EVUQ?7,%S>R6>;>VMY)I#$Z6MWOE^0*D;+&C;B3*FT!
MM#X(>-;[XE?#KPUXCODBCN=5TC3[^9(0RQK)<VL<SA S.P0,Y"AF8@8RQ/)]
M0HHHHHHHKG_%GBG2_ VAW^MZI-Y%EI]M->7,NUWV0P1M)(^U SMM52=JJS'&
M "<"N/\ B7XU\1>#YM!BT70I=8;4M7M["Y,<PA6RM7BFEFO9&:-U*0K%@1DQ
MF5W2)'\UT1^?^/7Q>A^$.C:<R/$M]K6KZ=H6GB:.62/[5J$XB#NL>TLD,?FW
M+1F2 3"$P">)Y4<>8> /B#\>]-\=Q>&O%_AG3;S3[BYU!H]=TB>:WABL[:WM
MWA>>SN/M!66>:?R%C%UYFY+AUB>WMOM,_P!?T5\H?M(?'CQ5\$]6\)P6>E6-
MQ8^(/$&D:$;J6[F$\,E[<-YI%HMN$=!;Q/Y<OVI2LSJ6@=$(D^KZ*Y_Q9XIT
MOP-H=_K>J3>19:?;37ES+M=]D,$;22/M0,[;54G:JLQQ@ G KY@^#'Q"^,_Q
M!U3P]KEW9Z))X3U[1%U7=!]IM[[3YKA(IH+5]\L\=[\DH0S)':+(4FE9;<I#
M;W7U_1111111111111111111111111111111111117/^*=&O/$&ES6=IJ5SI
MDLFW;=6:VS31[7#'8+N"YA.X HV^)_E8E=K[67\T/ GQ"\5?&_\ 8HG\:>(-
M6OCK<&D>(-12]L+F;3)/M%B^H1V['^SFME9$6-,Q,#"Y56='8 UP'Q:77OAY
M^R)IOQ.LO$OB!_$T>D>&[];R;6;]HS)//8A@]D)EL)4\N0Q,);>0SC,EPT]P
M\LTGI_[3_P --(US]IWX2>=/J2_VG_PDWG^1JVIP;/LVDP[/LWDW*?9,X_>_
M9/)^T<^=YF3GW#Q)XJ;Q#\8=/^#@>^MM+MO"W]O375OJ5W'>7!CO4L8+=[M7
M%VJ+AIYIDG%Q<R")'E$(N8[KR_Q%+XO^"_QJT/P!INNZE_8'CFVO)+6>>^.H
M:CI5]I, GN#;RZK!?![2YA6)#!<&<K-)-+$UMM"R\?\ L8^ ?$7[2_PK\+>.
M/&'CCQ3<S32ZO+)96FI#3K5VDO[F+#MI\5M=LB>6KPQM<E("/*B6.W)A/F'P
M/TK6/&O[&UWX_P!8\3>)+K7(-$\0W5O<_P!O:I!Y+6<M]Y V6UQ"D^UHM^^Z
M%Q*=WE&3[-'!#%O_ !PU#Q)X6_92M/BW!XCUL^*GTWP]JIN_[3NH[?SKNYL2
MZ_V9!)%IAB"2M%Y1M"LB?-+YLS22O]H?&^VU,^*K2?Q!J4MOX26Q:**UT:XU
MB'6+K6'FW+L72<7,]O%9QS/Y$+'&9KB:%X[>.6W^3]'^)>H?'#]FGXQ6^IR7
M+6^@W/BG2;"21KVVO&L["U%Q:+>-*Z7+RJ'6&<7&V2>-/+NUED>X,O/^-M3\
M3_L__L7:%XQ\&>(=2TZ]M-$T*[:.22+4(9GOETZW=2NIQ7CPQ1JS&""T>V@C
M9F/ED<#[0^//Q0OM.^(/@7X=P"6"'Q=+JPNKRWG:&XBM],LA<M% RC=&]PS)
M&UPC+-##YAA:.X>*YM_#_C?;ZQ^S/XO\(RZ/?ZE>^'O%NI0>$]5L-0US5+B:
M*:^+_9;[3[F>2:YM98QYXG,=PBR*L 2-)@+F'G_V0_ ,OQ2_X6!'K_B'Q)=V
M^C^-];TG3X?^$AU:'[/;V_D!5\Z"ZCN9L@JN+F:9$V;HEBDEN7G]P_X)Z>/_
M !%\3_V>_"NL^(+V6^OI8KN*2XF(,DBVU]<6\9=L NXCB0-(V7D(+NS.S,?/
M_P!O&'5M%OOAYJ&BZWJ^DW>H^,M#T2:2PU"XCC-K<-<NX-FSO8R.6"DM-;RE
MPJQOOA'EGG_BSX4N_A]\</AKX6T+7_$%IIWB>+Q%!JD<FMZE>M-%9V<%U&L;
MZA/=-:N65D-Q:&"Z1)'\J>)RKKT'ANSN_"O[3.H?#VUU35WT*_\  G]I2V]U
MJ^I7<BW7]JO:>=!=7-Q+=6S^2Y7_ $>6(9"28\R-'7XPU'QGXLU3]@"Q\=2^
M(=;77['SO*OXM8U&*9O.\1BU;SC'<*+C$(\N/[0)?*7/E[,FON_]MSXG>*OA
M<OAR]&E:O>^$O-OY?$<F@&9-0BC@M#):;)K>YMIK>W\T--<SH\8"0+$\RQRM
M#<?('[5J^&O%7[)_C[5_#_B677-'DU?2;W3'&LZC?26\;II$+VMV;J9Y@XE>
MXG-G<EQ"9H93''.JB+]CO"WAJS\'Z7#IUI)<R10[MK7EW<WLQW.7.^>[EFF?
MEB%WNVU<(N$55'P!^T=HVH)^T3\,M,L-=UO3[7Q)_P ) NIPV>K7J0S)8Z9$
MT:) TK0V^07#26T<,ZLYGCECNECG3H/ L^H?#O\ :GN/!6GZGJ4NBW'@A-7>
MVU'4;W4L7D>KM;"6.6_FN)8LQ,49(W2-\*S(S(A4^!%NG[:OPPM_'FL7^MZ3
M=:S_ &A';Q:1KFH626$,-W/:P")+:2&&>51%YSSW4,S2SNX*K:K!:P_$'Q#\
M>^)/CUX0\!6WC8XUKP[\6['PC?7.F7EU;0W;0 ^;=QI";?RI6^41RJJRPL))
M(#:K.\*_N=I.F0Z+8V]G"TK1P1)$AFFEGD*HH4%Y9F>61R!\TDC,[G+,S,23
M^<&I^!].U;]N1999;Y67P)#J $6HWT*^;#K2Q*I6*=%-N50&2T(-K*Y:62%Y
M7=VY_P '^#?'/QD^+GQ0\$ZK\1O%,-CH<7AN*WDL)=,L[AENK::]<F2WTY!&
MXD)4R6RP/+#MBG:9$0+T'QX\0:W\/=)\;:YXGUB^/B"TBU+4/#L/AR77Y+6R
ML(+<G37U2UM%^Q*[W$,\DTNI));7!6:+S9+6W:&#H/%_QP\1?%'PS\*O#%O?
MRZ)JGQ&L1=W=]IT0W6MK;Z2M_?)9M)*6@N)6DC@MIF6<P(\LW^NCB+<?\3OA
MU9_#W]IWX,1V5]J4]O-_PE;"'4;^YU#RW724#/'->O/<CS 45HS,8%\I6CBC
MD>=YN?\ $?BKXC?'VW^(ATW2_$EQ<66I:OHN@-H?B#3K&TL9K*!;19+H0ZEI
MMV\LMU&;IXKZ*Z6&W>$0*8Y':?[O_9NO?B3?_#;1G^(UM%;>(Q%)'?)$82I:
M.:1(Y#]G>2'?+$L<L@B(0.[!4C $:^(?%7QSXS\#?M$_#K1;37;E](\3_P!N
M_:].E@L#"G]G:8DD7DRK:K=+ND8RR;YY,MA5V1_)7E^K>%+O5?VM+CPH-?\
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M);RTU*[GN=/A^QPV#::J2!YKZ52\%L8IIV$-M")%EDMI>/\ @=\:_%FNZO\
M%GPSX4AN;U/#-MI\_AZ#7$U%+QKB^TR68V]V^JR17;1-=1;HS<LCK',P686P
MMQ%Y_P#LP?%+2/BAXC\-V]SJ^MZ/XSTRY1O$>C^(M3U.V>^\_0[IY7LM*FN9
M+0Q&ZDCNHXXH(/LT$.\101F!)?T_\4^&K/QAI<VG7<ES'%-MW-9W=S93#8X<
M;)[26&9.5 ;8Z[ERC91F4_D#\#]*UCQK^QM=^/\ 6/$WB2ZUR#1/$-U;W/\
M;VJ0>2UG+?>0-EM<0I/M:+?ONA<2G=Y1D^S1P0Q?1]G\>?$7BC3/@QX6O99?
M/\?:0]WJ>HV\@MKA5L]'BO9T@\E%$+W4D@1IHC&]O#YGV?RIVAN+<^+-WKW[
M)OCWP5J6@WM]?Z%XFU>T\,:EI^KZM?W[1W%V[-:7MG)>M<RQ.@$XN4\T0S(L
M*"$2?Z1%S_\ P3O\#Z=HM]\3;R&6^:2#QWX@T]!-J-]/&8D:U8,\4T[Q27!(
M^:[D5KIQE6F920?J_P#:Q_Y(AX\_[%O6?_2":OSAUGX-?$.U_9IT+XC:%X^U
MNRU?1/".DZC:V-M=+:Z.+>QM8KDQRV:Q3-<RFW5P[7$CI<W& RPVA6VA]OU?
MX^^)?C5XJ\+:79Z1J[:7?^#;7Q/>V.A:OIUI>2R:G,@MHS-<7&FW8M[3R)3+
M/8SQ&62>"*=!"YCF\_T_XA_M"? 'X5_$N]\0V$MM!!?1IX2EU?5+&>ZACU:_
M>UC%Y>275[$R6)FMY@;UV!'F1/<M %,/87NC?';2/B7X.U3P?H?B2+3S<R0>
M)SXEUO3[N&XM[F6V!N(;2#5[B&WEA"SS*+&"U1&*Q1PM;EK>CX,^ 9?%7QV^
M*?A6]\0^)'T70_\ A'&LK/\ X2'5AL>\T^2:1_M7VK[;][?^[%P('\S,D4C0
MVS0>P?L-^+-<\0:7XZT[4K^YO8M#\;Z[I%BUY-)<31V=N\3Q1//,SS3;#*X5
MYGDDVD)OV*BKQ_[>,.K:+??#S4-%UO5])N]1\9:'HDTEAJ%Q'&;6X:Y=P;-G
M>QD<L%)::WE+A5C??"/+)XPL[OX*_M"?"_1=!U35_L/B&+Q)%J-O?ZOJ6IQS
M+9V,-Q 0NHW%R(G209$D/EN060L49E/8?"O6$_:NU3QA<ZS+J5E;^'/$E_X<
ML[;3-7U"P4K8I#YES*]A-:R32SO(3ME9XH(DBCB19#<S7/YX?M/^,?%5_P#
M_P"+GPX\4W4NH3^ [[P^;'4_M<WGWEGJ5Y&]HNH!%A2XN(;<@3.ZM'+,4E\L
MSP+=2_=_[2>I^)_V?[CX=#POXAU*&RU'Q=H^@75G>21:BLUO>SW$T[O=7\5S
M?F5L")6^U;(X@%2-" PX_P#X*(>!].UJ^^&5Y-+?+)/X[\/Z>XAU&^@C$3M=
M,62*&=(H[@$_+=QJMT@PJS*H '8>+-3\3_!;X[?#3PII/B'4I]"\0_V_]IL-
M1DBOMGV#3UGB\N\N8I-1.99#(WG74V,+$GEP*(AG^*_'OB7XD?%SQ9X=?2?$
M&H:/X>BTJWCMO#NM:=ITAN[FV:\DNKIO[0TO4$1HKB*WMXA-+9RF&XD*-.B^
M1Y?X/^*GQ^^#WP-T?1/B"?L'BS5_$EAX3TK4)5M=1:.&^\H)?78BNC'-+"@N
M@A9MTLL5N9XY \TSG[5_P;L_A;_PJ;[)K.MWO_%P/#4$_P#:VJ7.H_:'7SMM
MPWVII/)E&'R+3[- _G-OA?R[?R/U?KX@^%>L)^U=JGC"YUF74K*W\.>)+_PY
M9VVF:OJ%@I6Q2'S+F5[":UDFEG>0G;*SQ01)%'$BR&YFN?E_6]>\2>)?AO\
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M2QU'38[P:O>K&8]3-Z\DS)_9)97@:>)4B!83CS&,T!15D[#4OV3/$FM?#3P
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M@;]PEIIMY!<W.I/C7HQ+*]TU^T=OF[,A6$I>YA0/Y\;3^3:_9_Q%\>6/AO\
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M7@'X;^)[CQ-I,>I)J5UL^TSSZWK%U]I\J)H8OM*7-Y+'<>4CE8O.5_*X*;6
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MX>__  4<L;#PKHWQ U+PW+8^"M8U<:3;ZA->*^H ^3,7N7TZWAF06Z3V\T+
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M &CH>OVVN7#VWVFWTS2'6\U2XS'Y@BBT^,_:?-QRZ2)'Y #O.88XY'3\\/\
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MO(DCK&!)W\?Q5L9OB++X(2QOFN8=(BUB2[$*FS2.:ZDMHX6EW[EN':&5TC*
M-''(P<E&4>H445Y?\%_BK8_&_P %:9XKL;&^L;;4HFFAAU&%8;CR_,94=D5Y
M%V2JHEB968/"Z.#AJ]0KQ_XI_%3_ (02\T71M/AMKO6M=N9K;3[2YN_LB/\
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MVLH;>X_TK4;%+YY6N/*MWC$,<REC<L9&MI88S#*?";X_Q>,/BGJ?PTT?Q?\
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M  *\6>&?AW\0_&USI\5YIL]XWBV'3;.V^W7SZCY,-CY4MG>V-K%;V\@>YE8
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MD_L?6M/^UW>I7\4-G>+8PSZGJ'D036URDGG2W6TM'$C0-%%&;F2X13;VU_\
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MBV\7Z;XOMM/^TVW]H0:7<6-QI<"VT7[VY9HY8I4:1_D0N7.T^4L0-ST'Q_\
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M=9'5]+N=.L=>U&REMCJFDE1:G4$L&%S!*D-VZQ11M=10SW-NMQQ(BD1HO0?
M3]K;X5_#GX/> +;7-5ELXWTC1=-6\EL+_P#L\W1LHT:'^T1;FQ#QLDB3YGQ
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MS2K_ +*3X<_]N:^_Z^ /VA_^3G?@A_W-W_IIBH_YO>_[IM_[GZ/$7BFX\/\
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M*9T;P_=VB:1;ZM?:3;W%W'<2VKV7VF2Z@O9@L5N\997:P>VNB(8I E_-,\:
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M'5&\1^'+'2)-$OKC1+\PZB\\C:E9K!YX2W%L8DMR96VL+R=E*A/WJGSJX_\
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M\+/@]\8K^[T;5["V\;RZJ/#_ (=M].FN)+:.[LKIK9GM=.-TMF\RS1VTR2I
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M<L/R:9!_Q+IHX_+N!#>'S(KI7:ZFANI/8/VCM&U!/VB?AEIEAKNMZ?:^)/\
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M+FTV;3?%?]AO<M<O<+<6?]EP202116Z1F.X^T(0$F:YM_L[N7,%RL(CG\?\
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MB_&.^\(IX<MM(-MH'B#3/$3R7^HW5O)-)8M-FU$<.GW*JCK(I%P9"0=R_9R
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M)T&A_";XI_%OPWJFF?%G4]-A6ZMKVPCMO"ANX83%>VK6TD]Q+>%WFE199!!
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MC] ^,WP(^+.H^/=#^)_@&_TBR\1Q:1_8FI:?JQGN--EM7=KDB.>&".YWQ7+
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M*T&3598+G697BTU[FPO[>UOF4 @VE[-;I:7*/N3R9(9G2<RQ")G,T6_?\?\
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M%?Q%J6JP7-]#<[[$G3XK6UBO[8#;"9!-,7M_+9%3R+KSC-;_ )P?\XQ?\_\
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MP6^G6UQ']FSI*%XI+F:X?[7C**LRV]ENV,Y@3S!'%Z!^SQ_R<[\;_P#N4?\
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MD@_T7Q4?"/B"TL+NU\U;M;>&U-Y(Q>'E(H9HX62>7:D%Q+'%'(DUXJ3?)_\
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MH^S\?:G%]FDTC0X]3O=-M9;94M7T*Z$LD,#RW[J\<!/!:<LZE@F&$0T/#_\
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M3K%99)C'&TCL\DA^9Y))6>61R JAI&8JBI&"$1%7U"OG_P#X9B\ _P#"<?\
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M\#:3X];QU%#?-K;130&YEU74YE\B9VD:W$$MT\ MP[F2.W$8AB<*\<:,B%>
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M_ O[+GPP^'?ABX\+:?I'FZ+<;-^G:C=7>I68\N5IQY=O?S7$4696,K>6J;Y
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MG_%.LWGA_2YKRTTVYU.6/;MM;-K99I-SA3L-W/;0C:"7;?*GRJ0NY]JMY?\
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M38CQ^=%)+-\G_LT_\H\[[_L6_%G_ *.U*OO_ /9._P"2(> _^Q;T;_T@AKZ
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M=L;;NQNVMC.#C/U/XW_#K1?$2^'+SQ+I$&K-+#"+"74+5+HR3A3$@@:02EY
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MW2]!TVSU*\^&TGVF\MK*WBN)O-T02R>;,B+(^]U#ON8[G 8Y8 UY_P#M+?\
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MD4;@WF$W[*7AO5_A!/\ "[6M2U+5-(>V@LX7N7M8[BWAMEA%LD3VEM;HWD-
MDJ-,DS.^1*98SY=<_P"/_P!D.+XE_P!E-JWC3Q)*^EZE;:S"V_2?^/\ M=RP
M7&QM,:--B,(_L\*Q6C[/.>W>YEGGFZ#7OV8HO%/COPUXQU'Q5K<][X;W_8HR
MNDK#^_MX[>[\Q4TU7;[6L>9L.OEL[FW^S#8$^GZ^,+#]B?0="\%7?@O2O$WB
M"QT2>*^M8[*&:P:."TU"262ZM4\ZQE:1)&E&V>Y,]Y $"P74*RW(G/%7[%NF
M>,_A=;?#;4/%OB"31((H;?RQ_8ZR/;VWV;[- TBZ8&V0-;*Z,NV9R\@FDF78
MJ'Q-_8@\*_$GQ%:^)TU_Q!HNNI8K87>JZ%>PZ?=:A&@CVF],-N(G<&)3F*.$
M$;4*F.&!(OI_P5X#T;X?6+VFF1RA993-++<7$]U<32%53?/<W,DL\SA$2)6E
MD<I#''"I$4:(OPA^UAH'_"3_ +1/P6LA=W-FS_\ "6,EQ9R>7-$\>F0R(Z$A
MD;:RJ6CE22"9<Q312PO)&WT_X/\ V>]/\)ZIK&O2:QJ6H:_JML+(ZS??8GN[
M:W1 (X+2..TCLX(DDS<&-;8I-<'S)Q-A0M#X%_LWVGP%OM8N+'Q#J]_'K-]=
M:I=P7XTTQO?7;1F6Y!MK&VE5R(PHC5Q;J&;$.[:RDO[-]II7B+5=:\,>(=7\
M.-K$J7-];:8-->UFN@"K7?DW]C>+%<2J5%P\'E"<QH\BO*"YW]3_ &;OAMJW
MPV7X<RZ-$OAQ8H8A8Q230KMAF6X4F2*1)BYE02R2%R\KEFD9R[EN ^ W[(?A
MWX#3121:[X@UQ;2*.*PBUW43=P:>L<3PYLH%CBAA<Q.8?,"%TA+0QM'%+,DG
M'Z!^P/X$\'^)[O5="UGQ)I&GW=S)>2Z'I.LW&GZ69I8A&SK%9^3,G*K(%2=5
M4JL:@6ZK"/4/BI^R_P"%?B;-X7NK>YOM!N_"LK/I-QHDD-LUO&\2Q/;B*2&:
MW:W=(XU:)HB"B>5Q"\L<G/Z3^R3I-A\1;?Q]<^)/$%[JR6*:?.TUU;QQW,$=
MT+J-'CMK6 0HLB1%HK/[-#.(B)XIOM%[]IX^;_@G]\,)_#$_A(W.MCP\]S!<
MPZ0NKW8L[?9+#--$BA_,DBN7A#R)<R7'DR/+-:&TFE>0^@?%[]ES3_C!_P (
M_'<>(M;LK?P_<V5]8PVTME-MO+'>(+J6:_L[RYGE <J_G3/')@,\;2%G;0^-
MG[+_ (5^/_AW2]-\0W-]]NTF6"XLM9M9(;;4K>XB*%IXIHH5BC>4Q@RJD2P[
M@KI'&\4+19^A_LH>&-+\(:IX?O=4UO5I=3TV]TF?4]7U*6^OEM[T,)5@>?=#
M;Y!CW""&-)3!;M,LSQ*U:'A_]F^TM9M'/B#Q#J_B:'198KFPAUL:;*L-U!$T
M,-V9+>QMYYKB-'D"O<2S#>_GE3<)%-'Z_P#$+P58_$KPKJWAR^>6.VU6QN;"
M9X2JR+'<PM"Y0LKJ'"N2I96 .,J1P?(/#_[-]I:S:.?$'B'5_$T.BRQ7-A#K
M8TV58;J")H8;LR6]C;SS7$:/(%>XEF&]_/*FX2*:/S_Q)^PUX*U?Q[=^,-*U
M?Q!X?GU&6";4K70-3DTZUU"2%W8O<K"HE+R!V61HI8B2SR@K/)+*_I_C_P#9
MK\(>//#&E:#_ *38+H^I6VL6%S:2AKB"^MY6F%RSW2W"7$LC22M.]VEP9WED
MEDW3-Y@]@\+:!_PC&EPV1N[F\9-S/<7DGF32O(YD=W("HNYF8K'$D<$*XBAB
MBA2.-? /^&8HO^%I_P#"QO\ A*M;_M+[-_9_E;=)^S_8/M?VS[%M_LWS/*W\
M>;YGVO9Q]IW?-77_ !&^!&D^/O$6G>)K6_OM%UO3XI+:/4=+-NL\EK*"7M+A
M+J"Y@N+?>1,B31.89E$L31L7+<AK?[+.CZYX;UW2GUG4HKOQ'\FM:K%'I8OM
M0A^RM9K!,QL&MTB2!A'&+:"!D*F0,)9;B2;K_!7P(TGPK\.G\ WU_?:SI+6)
MTL+?FW21;$VJVHMA)8P6AV"-2!(VZXRS$S'Y=OB'B7]AK1_%WP\C\!W_ (N\
M22:0MM:61A\W2QNMK%HFM(<#3MB>2T>[SHECN9]VRYGN(XK=(>P^)?[*Q^+4
M.@IK/C+Q!(VAWUOJEL\::(C&^MI9GAN9-NE;6=%F\H1@+;LB(7A:7?(_U?7S
M!I/[,47@_5-;O/"_BK6]#BUK4IM7NK6S729X3>7"1K/*AO\ 3;R9?,,8=D\T
MQJQ(1$3"C0\:_LF?"[QS\+D^&T^D10:)!$$M8[?Y9+61=VVX@D8.PN SN[2O
MO,Q>03><LTJOG_#?]EG2_AS;RLWB7Q)K%_\ OS:ZAKFJ/J,UDTT'D^9:PSHU
MDDJ*TFR9K9Y=LTT+.]O*\1T/@7^S?:? 6^UBXL?$.KW\>LWUUJEW!?C33&]]
M=M&9;D&VL;:57(C"B-7%NH9L0[MK+S]M^R-H.DV.I:)I>MZO8>'-3EN'N- M
MVL#I_EW:[;JW@,ME)=VMO/F1FBM;F 1/+(UOY!(*^W^+/AIH?BOP/?\ @[R_
ML>FWFFS:3Y=DL<7DV\MNUOM@78T:;$;$8V%%P!M*C%<?XE_9X\%>)O#OAG07
MMY8;3PO?:5?Z6L4TFZ"32BHMP6<N9$,8:&02[RR.S!EF"2IV'Q2\ ?\ "T/#
M%WH7]JZEI'VGRO\ 3-(N?LMY%Y<J2_NIMK[-VS8_RG=&SKQG([#2=,AT6QM[
M.%I6C@B2)#--+/(510H+RS,\LCD#YI)&9W.69F8DG0HHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKQ_P 4_L]?"SQS
MJDVJ:WX2T34+V?;YMS>:9:3S/L0(N^22)G;:JJJY)PJA1P *]@HHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHK/DU:QAOHK%[B);F:*6:.$NHD>.%HUD=4SN9$::)78
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MI]]IFF:]+%#H^J7SV"6NH27$33VJ0K%=RW43W,*-) MW;VY) A8)<O' _?\
MQ&^+&D_#F;3K%XY;W5-5EDBT_3;5[=;J[:"(S3F(7,UO"$AB5I)9)98T4;8P
MQFEABD\P^$'[7/@3XT:Y>>'].CU*#5]/N;BSO[*?3[A_L4T$DZ%+F[M5N+!-
M_P!GD,3"Z99<!%)D^0<_JW[:O@?P_;Z)J^I6>I67AW7+F&TL=?O(K>WL9'N(
M))HF>.:X2_AB?RG59YK..# $WF?962=OK^BOD#X.>)?AAJOC/XA:[X2CU*\\
M0S_V9/K-G<VEW87"^58&*PMXH=2BLHT\Q(I'0NPR\Q:2983"$/ '[7D7Q2_M
M6/0/!?B2[N-'U*YTG4(=FDP_9[BWVAE\Z?4X[:;)++BVFF=-FZ58HY;9Y_;_
M (+_ !>\._'KP5IGB[P^\K6.HQ-)&)HS'(C)(T4D;KR \<B/&Q4LC%2R.Z%7
M;U"O'_'7QET_PAKEOX>LK*YUG6I[9[X:;ITEDMPEG'(L374GVVZM(DB\UTB7
M,GF2N6\N-UAG:+D-9_::T'3_  %J/C"QT^^U*#2);R'5K6R>P-UITE@DC7B7
M*S7<,1>W,95E@EF,H>.6 3P2)*?/[_\ ;8T'2/!5IXZO?#/B"V\,W$5C,VJS
M0V"1Q1WLD42N]L;[[>R)),%9HK642 &:W-Q;M%+)V'C#]J/3_!7Q7T?X<W/A
MW6WO=:RUC>1Q67V&9(XS+<.)GO$?_1E#&>,Q^> %*12"6 R]_P#\+;<_$/\
MX0U=!U)F%M]L;4$;3VLXX2N$>4+>&ZB\R0/!"LENK3R13M$'AMYYH_8*\O\
MC7\1IOA!X"USQ3%ITNI-I5C/>FUBDBB:184+MF24A515!>1@'<(K>7%-+LB?
MY@\*?MC6/@+X%:%XW^(-EJ]O)+I%K<23+8+<+=R&TMF\]7T\S6MHEU-.$MEO
M7L2SDJ8XE4X]03]J_P ,+_:+7&EZW9);W.GV-BVIZ;+IO]K7FH[E@M=.2_\
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M7&I6WA_4[&2?7-1T1KF$:9%;SQ2366H16-Q]EF4QIL>1O-:["2S1QMY1\7?
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M2(/D26'38[*VF6/*&6%W\R9V:>7Z KX _P""H_\ R;%XN_[AG_IVLZ/V^O\
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M=+\'6'A'4+*?S/[2MO%L-W/"^QX7MO*CMU9&VLKL_F@X98F3D$U\O^!?A/\
MM3_"_P"T?\(SH/PDTC[3L\_^SK+5[7S?+W;/,\E$W[=[;=V=NYL8R<Y_C7X(
M?M,_$J^2^\1^&O@_JMS'$(4FO]/U6YD6-69@@>:-V"!G9@H. 68XR3GH-3^'
MO[6FM>'5\.7FD_"F?25BAA%A+;:R]J(X"IB00,IB"1E$,:[<(57:!M&-#PMX
M3_;"\#:7#I>B6'PMT^R@W>5;6<.MP0IO<NVR.-51=S,S-@#+,6/))KH/^,WO
M^J;?^5^O/_\ A4_[4_\ PD__  E/]@_"3^VO^@C]BU?[9_JO(_X^-GF_ZK]U
M][_5_)]WBN?_ .&>OVB_[<_MW_A$O@W_ &E]I^V_;/[,U/[1]H\SS?/\[RO,
M\W?\_F;M^_YL[N:Z#7_A/^U/XKURTUW5-!^$EYJ5GY?V:\N;+5Y;B'RI#+'Y
M4SHTB;'8NFUAM<EAAB370>*?"?[87CG2YM+UNP^%NH64^WS;:\AUN>%]CAUW
MQR*R-M959<@X90PY -9^K?#W]K37[ZXOK[2?A3<W-S8OIDTTUMK,DDEG(Q9[
M5W92S6[,2S0L3&Q))4DUS_@KX(?M,_#6^>^\.>&O@_I5S)$87FL-/U6VD:-F
M5BA>&-&*%D5BI."54XR!CH)?A[^UI/-JLSZ3\*6DUF)(=1<VVLEKV-(C"B71
M*YG18V:-5EW (Q0#:2*X_7_V>OVB_%?V3^U/"7P;O/L=M'96WVG3-3E\FWBS
MY<$6^)MD2;CLC7"+DX R:T-,^"'[3.B^(F\1V?AKX/P:LTLTQOXM/U5+HR3A
MA*YG6,2EY [B1MV7#-N)W'.A_P *G_:G_P"$G_X2G^P?A)_;7_01^Q:O]L_U
M7D?\?&SS?]5^Z^]_J_D^[Q6AXU^'O[6GQ*L4L?$>D_"G5;:.43)#?VVLW,:R
M*K*'"3*ZAPKLH8#(#,,X)ST&DZ3^VAH%C;V-C;_#*VMK:)(8884UV....-0J
M(B* JHJ@*JJ %    %:'_&;W_5-O_*_7G_CKX3_M3_%#[/\ \)-H/PDU?[-O
M\C^T;+5[KRO,V[_+\Y'V;MB;MN-VU<YP,=!X6\)_MA>!M+ATO1+#X6Z?90;O
M*MK.'6X(4WN7;9'&JHNYF9FP!EF+'DDUY_\ \,]?M%_VY_;O_")?!O\ M+[3
M]M^V?V9J?VC[1YGF^?YWE>9YN_Y_,W;]_P V=W->@>*?"?[87CG2YM+UNP^%
MNH64^WS;:\AUN>%]CAUWQR*R-M959<@X90PY -9_@KX>_M:?#6Q>Q\.:3\*=
M*MI)3,\-A;:S;1M(RJI<I"J*7*HJEB,D*HS@#&?_ ,*G_:G_ .$G_P"$I_L'
MX2?VU_T$?L6K_;/]5Y'_ !\;/-_U7[K[W^K^3[O%'CKX3_M3_%#[/_PDV@_"
M35_LV_R/[1LM7NO*\S;O\OSD?9NV)NVXW;5SG QZ!_QF]_U3;_ROUX?9?LR?
M'W3H;F&W\%_!:*.ZB$,Z1Z3J*K+&)4F"2 0@.@DBCD"MD!XT?&Y5(] N?A[^
MUI>V.FV,VD_"F2VTJ6WFL(7MM9:.TDMEVP/;H5VPO$ORQ-&%,8X4@4:M\/?V
MM-?T:XT6^TGX4W.G7,KS36DUMK,EO))).;EW>)E*,[3DS,S*2TQ,A)<[JS_
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ME$R0W]M#<QK(JLH<),KJ'"NRA@,@,PS@G/G][^S)\'M1AMH;CP7X?ECM8C#
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ME\2:3-%=V^O_ &^VTVU:*06HDMKJRCL[6V=4-Q&T,D4LUT52=,(^U[B+XO\
M%/[5'Q3\:?#F;QOX37Q(FKR7*W&DZ##X1NVL;C3O[1'DF\NFLKOSI9[$F:26
MRU"VAPR)$BR(TDWZG_#WQ)?>,?"NDZO?:?+IMS?6-M=364V[S+:2:%9'@?<D
M;;XF8QMN1#E3E%/ \ ?XBZC\9?B3XF\#:+JE]H*^%(M,DO+NUAL9)[F?4X9)
MXHXC>0W<*6\429E)A\Z::10CP16[_;//_ 7Q%\<S?$7Q#\&_$>J7RWT%BNNZ
M1XBM8=,2XGTU[J.-DG@:&:U2XAF9K3S!;*MQ"CR^1;.(Y)O/_P#@E9X9U&U^
M ?AK5'UN^FMIHM2C33I$L1:PL-5N!YD;I:I=ESL8D2W$B9D?" ",1_5_[5MU
MJFG_  8\9W>EZA<Z==VNB:A=0W-FR),C6]L\P".R/LW;-C.@65%8M%)%*$D3
M\X?COHUYHW_!/-/M&I7-]Y^B>%YX_M*VR^0CS:9MMXOL\$&8H\'89O-G.3OF
M?C'T?\>/$?Q4^ ?B+X?ZI'XPEU*VUSQ38:%J6G7.G6$=J5U$."]H\,27<"0;
M',,<UQ=N28O-GE$<HN./^(?[1'CCQG;^.9="N?$FERZ-<ZGIV@P:5X6N+U=0
MN+& 0O)=7CV&J6KQ-J$<T$*P-9/'$C&=F=U\C[/_ &;OB'XJ^*OPVT;7O%.B
MRZ'JUS%(+NQECFB:.2&:2$L(YU66-)1&)HT?<4215\R3'F-\H?M3V&OZO^T3
M\(--LO$6I:9;WO\ PD3[+/[&5BFM-,8K.B7-M<1O*Z7$D+&=9ECB)\E89))9
M)-#QCX\^-NM_'VZ^&VD^)=(TVV?PM=ZW!<C0Y)Y(A-J*V<*LLNH[9+BW52Z3
M?);R&202V+CR_*]0\;:GX^\-7&G:;KWB'^Q= T_1(I]2\7+)H]JUSJGGQ6JV
M[6U]%<PVT4H9[ABL1#2R001S1^6Z7'A^C_M$^)?BS\"OB!X@T;79;2[\&7VO
MVMKJEC_9UPNJ1Z5:-/;3S++:36X2X22)I_LJQAW0R0O!#(($X_XD?%'XM?#C
M]F73_B^?&-S=:H--T#47L#8:7'ILOVR:S1XY$%HUY\\<S><T5W%NF+R0K;1&
M.WB]0\9_M'KJ?QXOOAGJ_B2^\&M'%IPT62V@M&.LR7D4DD[&;4-.NX$2)T2U
MMTC:,RW'GIYD\K)#;^H:KK7Q:LO"?@JSU1O[,\W33<>+=?6XTN-]+>TTY9I"
MD=PDMHWGW0*22K%-!! DI")YD4\/'_ G]JO2=:U'XB:=>ZW%K&C^"HK*]&OQ
MR6]PUS:W5C)=S^8NG01P.]J\,T8:VC4N@2,Q&>.22;G]/?\ :$^)7PN_X6'X
M?\011:QJ<5KK.E>'DAL3IBV<GDS1V-Q<SV?VV:XEM]_FSK<6<8NI=B&"",2G
M/U>PU_5?VUH+1?$6I06D'@@:C';1_8VA4-K$,,]L$EMI-L5QY$;SR*1>%@JI
M=)$D4:>P? +XQ>./%OQ/^('@KQ-)IMQ_PB_]B>1<Z=9W%GYW]I6DMR_F137E
MYC9M1%VN,X9C]X!>?^&/BCQ7^UWX$7QSX<\5ZEX8M]1^VQ:;:PV6E7"Q+;7$
MUK'->"[MKF2:61XC-)'!/;Q+$R6RDR1O>3_+_P 4_P!K3XC>)/V;?$'CO3[F
MY\+^)O".I'0]4LK>/3KJSEODO+*WG(-Q!=N8E6<M$(Y8RDC.C/<I''*_T!\<
M_%'Q&^ .J>!-1'BNYU3^W?%VEZ'?65Q9:=%8B'4$G$IMEAMEO8O*95:V$M[<
M,H55F>Y^<O\ ?]?E!\"?AYXK;]HGXPPV7C'4DN[/_A%V,]Q:Z5*MXSZ9(\:W
ML4=E!F*/'E[;)["5XBP,XEVS)Z!^S_XO^.7QZU3Q#-<^+=-T^T\.>-[G2IX+
M/0LM=VVF);I+ DL]]+]GBNMS2,2D]S#*Q*71B"PK[!X*\<ZO^TQJGB9M&UW4
MO#MEX;UN[\/;;.#3'FNKBS2)KB>5[ZUOD$6Z01VT42Q.%22:620SI!:?$'QB
M_:C^+7A?X8>/;:75[G3/%GPYN=.M9[JVM=+>SU>WU2[ACL[V6":&[:"5[?=*
M]O!)$D<D@))!^S6_T?\ M%>(_BI\")O!E]8>,);ZYU_Q3IVA7%M?:=8'38UU
M&*X5GAAMXK>_"0R*KP1OJ,C[5$<L\Q+.W0:_XL\<_!SXX?#WPL_B:^UO3O%,
M6O1W4>J6^F*T+:?9Q74,EN^GV5DRN6+(XE,J,C'"*X5U^[Z_.#]@*PU^YU3X
MF7VI>(M2U+R/&^MZ<8KS[&RR&V2SCCN7:.VCE$HBC6%8XY([-(@%CM4VJ5^8
M/V8M-^(V@_L51^*_#WC.YTB72M-UN^M+6#3].FMRMG?7D\BW'VN">:264I*@
MEBEMXHD:'_1I'BE>Y^GS^U+XD\:_\(=IA.I:8NJ>$;'Q'J^H:'H-UJKPS7_E
MBTMK01Q:@EOYC17K2->6MPI@B6.-Q,YFB] _8V^+GQ+^(-QXLTCQCI6I1V^D
M:DZZ3JVIZ?+ITVI6,\]QY+20-:VL?FQ)$GF-%'$"LL:O!'(K/+X__P %<_B7
MKGP[^ CV^ER>5_;>I6^DW,BM(KBWDAGN)%1D=<>9]G$,@;>CP22QE3O!7]'_
M  GX6TOP-H=AHFEP^19:?;0V=M%N=]D,$:QQIN<L[;54#<S,QQDDG)KYP^._
MB3PK^RAHWC'XNG3Y;BYFL=,M[JWM_)B%Q);3RV]H[OL#!RUZL4TSF4I;PQ!(
MF,023C_CH/BU\#_"%UX[TWQ+<Z[+H^-1U#1KBUTNVL;FS0$WD=M(ENEY:^3&
M6N+9I+J]D @6&1;QW);Q_P )_%'Q]\5?C?8:%HWC'4K3P]KW@B'Q?&D]AH[7
MEK]KOU6*"WD%HT:;$:-";E;_ #&9EW-,\5U!V'POUOXF>.OBI\0/ %QXTOH[
M'PO+H\T%]'8Z3_:4IU*P$QADD-D;$6\;)(P5;$7#,Z?Z4J1M'+S_ ((^/WQ1
MG^$WQ*U=-2L;F^\#>(/$EE'<:E8>:U[9Z3 ;B-)DLI]/B2X8NL?GQ(L81!FV
M=R7HN?%?QXLO@%IOQ2M?%EC<ZC:^'[?6Y].N-*BBT^[MO[.^T3+.8F>[%Z-Y
MD6:WGMK21XHX?L,"/))1\/?&MC\2OVM-)\1V*2QVVJ_"FVOX4F"K(L=SK*S(
M'"LZAPK@,%9@#G#$<GW#X!?&+QQXM^)_Q \%>)I--N/^$7_L3R+G3K.XL_._
MM*TEN7\R*:\O,;-J(NUQG#,?O +\W_%[]IWQA\!? S^-_%VL1:=XE66.Y'@:
M2^T5XGLY-3^QJ(Y(K9[^1S:!K@W$<[1K=*[F 6Z/9KZA\??%'Q&\._';X?\
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M:HUC:[2WD^UIG_LK:9\1/A!#X^?6/ ^KAM8\4ZKXBLTBNM"=I(+Z6V2. _\
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MN?LRW#><T+W$31.>@3]M/X&W.J6VEVWB_3;J[NM2MM)@ALY?M327-TB-$$$
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MHCE58JSH&\0^#?[9_A+XE3>,+C49)=(T[0M7FL8[K5+*ZT^!8H(K.)_M-S=
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ME62%HIYO+]$U"SUOXQ>/=.^']O;:5K]M_8K^(M2U6"YOH;G?8DZ?%:VL5_;
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MND:!'?SP@F2*U;0+D3R( DI+I&690$D)('R-]TY_A_\ X6'^R!J_@7POX_\
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MZ3G_ -D^VURT_:)^-,>MW5M=WH_X1/S9K.VDM(6SIDQ79#)<73IA=JMF9]S
ML-H8(OC_ .S3_P H\[[_ +%OQ9_Z.U*C]I;_ )1YV/\ V+?A/_T=IM?0'[0_
M_)SOP0_[F[_TTQ4?\WO?]TV_]S]>?_'S4K/]D+X_:7\5+N\^Q>&?%5L^C>(F
M9;F94O+2U>73[A88I7=Y9%@%LI2W:."*.<L0]T7'V_\  3PMJGA+P)IT.KP^
M1J5UY^IZA"&1UAOM3N)+^\BC9"RF*.XN)8X?GD(B5 996S(W/_M+?\BC8_\
M8R>$_P#U)=-K\P?BKK/B?]@[]H[5;SPOIO\ :%E\3[:3[#:EH@H\0*^V+S#-
M.)6B-S<AYOWMI$(M0<)N-FBU[_XR\"_\*T^-W[/>A-<?:Y;.V\51W%T4\MKJ
MX.D1-<74@W.?-N9C)<3,SN[RR.[.[LS'0\#BY\=?M+_%32(/%NKZ-?6D7A\Q
MQ6L^ES++9C3E?;%;:AI]X\26]Q<2R2O"ZQL]\N^-7P\OSA^T3\%/ _[.'[*7
MQ.\$^$IM2NK>RU+29[NXU%[=L7EU<Z7(UO&8HX&/EVXM9F)B\O\ TE56:219
MHX/K_P#;Z_YI5_V4GPY_[<T?M#_\G._!#_N;O_33%6?^P#I-C#??%J^2WB6Y
MF^(FOPR3!%$CQPM$T:,^-S(C32LBDD*9)" "[9^$-/%O\,OA1I$*:M<Z?X3N
M/C)+%I%U9ZK 88M(ADN!;3)-<B]@-I;WMJ;QH[E&CG:$S$@RK<5^A^N?LW^&
M?"'Q<\*?$37?$/B#7/$*2G1--CF&DQQNLUM>R2!TM;&R39!;O>73,SJY$11/
M.E,-O)G_ + O_-5?^RD^(_\ VVKY_P#''P]\7_!;2_'_ (O\(WEMXM\":Q<^
M)KSQ#X=OLZ;<I,7-IJ3VE^D7F-Y3V]P"K>6HMHML(N;B2.X'ZG_#WQK8_$KP
MKI/B.Q26.VU6QMK^%)@JR+'<PK,@<*SJ'"N P5F .<,1R?@#XL>)+[]EC]HR
M/Q8FGRW&A>-M(>SOTM=SSR:QH]O--9!!*FPW%U;A;&QLXIH?M4S2,4,D2F3Q
M#X)>'/%_PP_M?]G?Q&?ME[K-S9:NL]I&5L#HNH;7UZ".*",)IUHK6]Y86S(+
M9Y;N_@DBM[0,9D^G_P!H?_DYWX(?]S=_Z:8J\?\ VA?[<_X:+\6_V%]I_M+_
M (4WJ?V/[%YGVC[1_:<OD^1Y7[SS=^WR]GS[\;?FQ7TA^S7JW@KXE?LM^'1J
M5Q%)HDGA:+3M1>9Y+:-8[:S-E?J\C&)HTC:*9&E#* %,B/MVN?B#X0? GQK\
M0/@U\(IM/\4RZ%XZT;2-=U317NH8]0@FT^Z:.%4E+K,D2"WNM.CB)WO;PR,B
MVDCQX@/CI\<K[4/@U\8=%\1:'+HWB'2+[P\?$!TC4F,&HQZ@VGVAELYY$D:V
M2ZLK8Q&WDAD$4+QB99Y7N(Q]/_%?]GCPCXG;PK\1?$GC'Q!XB70+ZQO=%6$Z
M&([FXO;NT%K$C6FG6J2)=SK:QK))-'"H8.9X8B\H_0^OS@_X)R?V'_PR-H']
MN_9O[-^S:S]L^V^7]G^S_P!I7OG>?YO[ORMF[S-_R;,[OES7RAI>F>(M)_9S
M_9WBUYI6N6\=^'I4,LPF;[+-<7TMD P9\(+5X!''D&) L15"FQ?K_P#:RUA4
M^.'PBTJ?7+[1H[Z7Q"(+BTN;2)4O!9V\5NSQ7UM=V\[ND\]I"C1K('N\QR!L
MQR:%E^SWI_P@^*^H^*]&UC4M9\<^)=$U""%M8^Q+8JEE'9JMQ<I8VED5B29+
M"V<6^^=A/O6%E6:>'0DU/]JS1?"OBR\\1KX6:2#P_J4NECPU#J4]X=22'=:@
M17JO%(A(;]V%9GD\M=K*6!S_ -E[_A4'Q;_95T;3+G^S;C0(-$AM-8C?;!#!
M<6\"2WS3D^68)4FW71G)1]S+>))\Z3'/TG4X=:_;0M[R%95CG^&22H)H98)
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M7@'X;^)[CQ-I,>I)J5UL^TSSZWK%U]I\J)H8OM*7-Y+'<>4CE8O.5_*X*;6
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MV\#,\K"WAA0S2[ Y]0\4^&K/QAI<VG7<ES'%-MW-9W=S93#8X<;)[26&9.5
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M?9HXI) ;2PNKE2R%%6-Y8HS! \KR)'";J6!)'; ?"N5]PHHHHHHHKC]5\?\
MAW0O$6F>'KR]BAU'58KJ6R@D)5IULQ$9Q&2-K.BS(YCSO*;Y%4I%*R=A1111
M11111117C_Q4^,-O\,/)ACTC4M9O9;:[O5LM)B@DN#;67E"XF59YK='V-<01
MB&-WN97F4102!9"G0?"KXD:7\8/"&E>*-+BN8K34[:.ZA2\@>"95D&0'1O\
MQUT+Q2+B2*22)TD;T"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBN?\
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M7-CJ<GBJ+4S8W&EZ=-8+;2:9#'<2+<)<:A?&5)HY&V/&8S$\04QRK,7@\O\
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MTG6[:R\1_P#"/_V;<WFAZM:PR_V?IDJ7.^2XM(T@V-\J_:#%YK$+'O+ '/\
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M'*'?!=Q0S)RI*[T7<N'7*,K'Y@_;2^#GB_XM^$-)N?"#6S:UX:UNQ\1V5M>
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ML/\ F][_ +IM_P"Y^OG^3P+XL_:TM_B<LFC^&];E.MZYX?L;G5=1U%6T3[+
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M;V=KIDT:0O9^0J^9]HMA#<R73/<M+YGE^7T'_!+C_DV+PC_W$_\ T[7E??\
M7Y ?LX?LR^!/VBO^%GP^-(+G4K*W^)/B%X++[9<6UO',/*#3[;5X'DE97$>9
MGE6)$Q"L)EN#-YAX ^(7CKPC\&K+X>)JT4DFF_$T> X[Z6YU/3Y;BSM&-Y'"
M+JR:YN+1[AXUL(WB5X[>UD6,JJH9U^G_  1^S_X]^%OQMT[QK:P>%O!OA>6Q
MCTG5-)TB\<QWL[R7"V<FUM+L(3<&YN;>*,\38!B21A,T+?I?7PA^VYI'Q)E7
MPYJOA_P[%XLT+39;^?7/#KR0H;]?LA%HQ2:&83I;2!Y1;JLCR7'V9D@DD1)(
M/#X;OX0>-O@!\8XO",-M%;M;7]_=:%+IBV$NCWD.AV\0@FM& 598[BP:<3QJ
M(_M2R"-WDMVD/ ?$GPGH?_"K/V;M=^P6W]I?VWX#LOMGDQ_:/L_V1Y?(\[;Y
MGE;_ )_+W;-_S8W<UZ_\2_AOI?Q9_;"DT/5I;D:?<?#9DNX+:=[?[5"VMNC0
M2RQ;9EB8L'<0R1-)L$3L]N\T,O/_  ;^"?ACX,_M!^*/A':6-M>>#M=\-VGB
M9=)ODENX;:XMKV.Q*J+N:=)/-9#<2NZ;RR6R*56V4OXA^SY\%/ 6N_L*7GB+
M4=#L;W5(_#_B>6&\O8$N9X&@FU#RA;23AVMD1E\Q8X#&@F:2<+YTLKOT'[0?
M@#P[I/[&%G\08K*)O%3:1X8U(Z]*#-JWVJ:YT]VF&HRE[L.-Y6/$H$406&,)
M$B(OU?H$^H>&OVPKO0K?4]2?3;KP1)J\EG<ZC>W5N+R76Q$TL4-Q-)'#A $1
M(52.-,JB*I(/'_L[?#WPJG[5?QCOAI-B+FQE\.36LPMH?,@DOM+G:[>)]NZ-
M[AF9KAD(,Q9BY8DUY?\ LNV6A_!;P/\ '/QCH6BZ;%J6@^)/&$=G)]DC79;V
M5O#<0V>Z+RY!:!XU/D(Z(,97:V","Y_9D^+?Q/\ A_X*USP6OANP\0VW]G:L
MOB]]6U*ZU+45-BZ$SO=Z,MR8K@3*QMKB66*.%5M#"855%^C]'D\*_M<_'#Q)
MIVN11:MH7@ZQT633K1Y8;K3;NXUJSGN7U&2(1[)W6W:."U\QYH8E,L\8$DX:
M//\ V3_"VE^"OVB?C3I>EP^1:0?\(F(80SLL2MIDS".,,6V1)NV0PIB*"()#
M$B1(B+^C]?FA^U9\/?"OC/\ :7^#<.L:38WT=Y%XGAN4NK:&99H[;3EF@242
M*PD2*21Y(E;(C=V=0&8D^@:!<V/[0GQP^(7A3QAIMCJFD^$XM!33K2ZMUF@$
MFHV<MS<7$L4N^*2X)"Q12LN8(59(O+^T733\_P#!F.^^"/[2.N?#+298E\+W
M_A__ (2JRT\1,JZ;</?K:3P6K&1@MO-)YMRT*JL,3R!88X@)3-^A]?FAJ?P]
M\*ZU^W(LUYI-C/(O@2'4P\MM"["\@UI88KH%E)%Q'&B1QS?ZQ$545@J@#/\
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M\6G^)8['^S-1O;W3XKN/5;7RT ^V06\E@!<+)%#(EQ;/;D!/(9'MQ'%%Z?\
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M8KJ-K9ZH]@6N[<O*C-;O8W=Y$SQF%R\3.DVP&14:-)&3Z/KXP\#?ML:#X_\
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MX(?#KXE7R7WB/PUI&JW,<0A2:_T^UN9%C5F8('FC=@@9V8*#@%F.,DYS]?\
MV>OA9XK^R?VIX2T2\^QVT=E;?:=,M)?)MXL^7!%OB;9$FX[(UPBY. ,FL_4_
MV9/@]K4RS7G@OP_/(L4,(>72;)V$<$2PQ("T)(2.-$CC7HB*J* J@ U;]F3X
M/:_?7%]?>"_#]S<W,KS333:3922222,6=W=H2S.S$LS,26))))-=!X*^"'PZ
M^&M\]]X<\-:1I5S)$87FL-/M;:1HV96*%X8T8H616*DX)53C(&.@\-_#WPKX
M.OM0OM(TFQL;G4I?.O9K6VAADN9-SMOG>-5:5]TCMND+'+N<Y8Y["BBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBN?\4^+-#\#
M:7-JFMW]MI]E!M\VYO)HX(4WN$7?)(RHNYF55R1EF"CD@5T%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%?D!_P4XNM4^*/P=\5WUEJ%S::+X:N;:U>*
M!D\O5;Y[ZQC<NP0[K2P\V6$HLF9-36998XFTV,W'Z_T44444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M44444444444444444445S_BS3M4U?0[^TTN^_L^]GMIHK:[\E)_L\SQLL<WE
M.0DOEL0_EL0K[=I.":_$']LG]G'XQ?!O]FW4[34?B;_:^@:5;:59KI7_  C]
MC:[X8KRU@@3[4DLDR^4?+?<2S2>7M8G<QK]GOA;X=\3^%/#%II_B;7/[>U*+
MS?/U#['%9>=NE=T_T>$M&FQ&2/Y2=VS>?F8UZ!1111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
/11111111111111117__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex19-1_005.jpg
<TEXT>
begin 644 ex19-1_005.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[@ .061O8F4 9       _]L 0P " @(#
M @,%! 0%!P8&!@<(!P@(!P@)"0H*"@D)"PH+"PL+"@L+# P,#0T+# P,# P.
M# P,# P,# \,# P,# P,_\  "P@&<@3[ 0 1 /_$ !\   $% 0$! 0$!
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MBU&WO]7U+4XYEL[&&X@(74;BY$3I(,B2'RW(+(6*,RG]#Z*_$']D?]G'Q?\
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M"+0[?6KG59=>\;P6.CW)N[3[=9Z7=#[:]J)=;\V&YNU%O=V=K]KFD,IFMR)
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MYEN_MD4D$@,LL<QA_P!$=8DGB65/M=N[I+'X_H/[+7Q3\)>!_B?X9COM$O\
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M:>6*(.\4 =KBXMX9?/\ P?\ M":?XLU36-!DT?4M/U_2K87IT:^^Q)=W-NZ
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MA'-=3:4;!9EOBR+);1ZE+9S2I%*$@G'EAT>6-E1X2TJ^G^(OVA-/\*?$_0_
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MP\07VK6UC=WS6ECH.IRR.EM,L"^4# @D2>1F2"Y0FR)C;?=1[HO,^C_">O\
M_"5Z'8:I]DN;/[9;0W/V:]C\JXA\V-7\J>/+;)4W;9$R=K@KDXS7RA\,?VB/
M$OCKX\>-?!DNA7T6G:%%I5NLIDTYHXI)HKRY:ZEQ.L^R[0V\=O%$+HH(E>9+
M1Y)47T_Q9\>GT3[?+H_A?6_$-KI_G)<7.D+I[H)K?=Y\$27-[;37,L178XM8
MIU$X>U#&ZBGAB]0\ >/_  [\4_#MEXA\/7L5]IU]$)8)XB=K+D@@@@,KJP*2
M1N%>-U:-U5U91Y!\1OVJ? WPN\6Z=X6U./5WU'4)9(X8[71=3N5=8K4W4DD3
MPVS+<I&NQ)1:&X>)Y5\Q$19GB-+_ &D['5M&T:YC\.>((]4UF*]FM-$N+!;?
M4/+L9TAN'G\^6.TM47S8Y%:ZN81*DL:QEYI$B8^'G[36@_%;1M:N?#^GWUWJ
MFAWTFG:AH@>P34+>XCG:$JWF7:6A0['D25;EH9$214=IHWB7X?\ V,=?TGXI
M_!_PMXL\?>$K[4;G2;[5];M]:%C;WJM?7FLW/F&UM-.DFO\ ?YDQD939);QO
M;BX&TV]O*/K#P%^VQX$^)?\ 9]SI%AK;Z7>?VF\FL3Z7<6VEVL.G>:6GN;ZX
M$4*13"%S$4:1D.([A;:7*#L/#_[36@ZO-H\MYI]]IFF:]+%#H^J7SV"6NH27
M$33VJ0K%=RW43W,*-) MW;VY) A8)<O' _/^&]9^%?B'X^ZA<02WP\80>'_L
M+075G?VL:Z;;ZBYDF@,]O%#.DMS(B^>CS*XB3R2$\YI,_P ._M>1>*O$^N>%
M;+P7XD?6M#^QM>V>S21L2\B,T;_:O[3^Q?=V?NS<"=_,S'%(L-RT'?\ @#XA
M>$/VI/#&JP?8[F-;'4KG2;^TN\17%I?6$JL0LMK+(BRQ-Y4\%S:3L8W\N2.9
M)H_D/V=?&/B?Q#H>HZ3XJ;S=:\/ZE/H]Y<K#% EYY<<5S:WB10S3+']IL[FV
MFDCRGESO+&(T5%%?0%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?CC^S
M;JUC#^P#<V+W$2W,WA;QC-'"742/'#<7RR.J9W,B--$KL 0IDC!(+KGV_6_B
M/H?PD_8NT#Q#K>@6WB&RM/#?AKS=-O#&(9_-6QB7?YD,Z?NV=95S&WS(,;3A
MAX_X]\7:/:?M*_":^O?'UMKOV>V\2W]YB72XK33X9M#6Y66-;9!+#:31'S86
MO;BZ8V\:.+B3$DLGT!^SQ_R<[\;_ /N4?_33+7SA\.],\!:[\*_C5IWCII8]
M$O?B;JEE<S13) T#7-_IT$%R99&5$2WG>*>1I-R!(V+1RKF)]_Q1J?CW]D;6
M1X?\2+%\0_#UUX?\77\-UJL+MJMI:V<"7<]E>W;+<13V5P5M;=I)$4RSS("B
M16]M;2>8?%KQYH_CS2_@CJ=IXFMO^)EXN\+7UMX9LFTM;;3K3?-"BPQPP"]/
MV5D-E-*\WV<W*SA;:V_=VUO[?X6_:.\*_"?]I_QE#XNUN*VT[Q9I'A^_\/7]
MQ=POI[V=I:7 <)/YI2!)9Y+B2$-LCE<2N&WSP^>?\% /&OA7QS^S1X_O?#21
M7%I++H\LFIVHA-K>W']HV4+^5/&Q-R\$<,,4LX#0J0MJLS36UQ#;^@?MW:M8
MZC-\,X;>XBEDM?B;X:AG2-U9HI#%-,$D )*.8Y8Y K8)21'QM923Q[>S?#;]
ML#P]XAU:VEBTGQ!X6;PO:WQ,0MUU(:A)?K;RLSJ8WECC"6ZX+3S.L<2OME,?
M0?%#P-#XU_:H^'^HZ;#$+GPYI&L7VJSF"4-]EOHS8Z?";A8BC.TYO)(8'D!5
M(KJ0 $@29_[ O_-5?^RD^(__ &VH_P""7'_)L7A'_N)_^G:\H_:'_P"3G?@A
M_P!S=_Z:8JY_QA\&/^$Z^+7B?Q7\+_%5SH/B_1[G3X=7L+J3S]+U/;I:RVGV
MNTCE\U8I8KA;9;D8\HP7+P6YN%-P?I#]D+XAWWQ5^#7A?7KS18M#DN;%0+&"
M-HH(XX6:&)K>-E4QV\L<:36Z?,$ADC59)% D;P_QSXL_X0#]KKP[/K]_]DTO
M6O"-WI&DB>;]S)J@U2WGGB1-Q$4LD(M@'<(+AA# CR2JD8^</VH=6L=6^/OC
MRQM;B*:Y_P"%/W^F>3$ZO)]LO-1VVUKL4EOM$[7-NL$./,E,\(16,J;L_P $
MK^R=\8/@QH#Z]??VG<1:;;S+X;B\3ZQ),M]!;&(V>GZ7=ZKYGF[]]M91J,R*
MZ+&[QR*[?1^DR7TW[:%N]]%%#<M\,D,T<,K31I(==&]4D:.%I$5LA7:.,L &
M,:$[1H?L\?\ )SOQO_[E'_TTRU\0>%K6XN?^";$+0Z?_ &EY&ZZDM2L[+)#;
M>*3/,)/L[QRB(11NTSQO&R1!W$B;=Z_3]U:_LQ>/[CP_KV@ZC_PEVOVMS9W.
MA64_BO5KRYCN)IX&21K:YO;B:WBA*I<7Y:V=[>VMY9)+>3R3$?0/V.?%G]G>
M._BKX1UR_P Z^GBZ^U=;6>;S)O[+N[>S6PE0[F#1+"L481&)ME\F*1(MT:GQ
M_P#8[_:!^&GPWTOXAZIKGB33;.TU3XDZ\;*:6ZBVW*RO8HLD)#'S(AY\3R3)
MF**)Q-(Z1 N/U?K\\-6U:QT#]M"XOKZXBMK:V^&3S333.L<<<<>NEG=W8A51
M5!9F8@* 22 *T/V>/^3G?C?_ -RC_P"FF6OB#Q):W%S^SM\?6AT_^TO(^).I
MW4EJ5G99(;;4],GF$GV=XY1$(HW:9XWC9(@[B1-N]?I^ZM?V8O']QX?U[0=1
M_P"$NU^UN;.YT*RG\5ZM>7,=Q-/ R2-;7-[<36\4)5+B_+6SO;VUO+));R>2
M8CZ!^SQ_R<[\;_\ N4?_ $TRT?L"_P#-5?\ LI/B/_VVH_;Z_P":5?\ 92?#
MG_MS6?\ '75K'6OVE_@E-9W$4\:R^-(2\3JZB2#3DAE0E20'CD1XY%ZHZLC
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M2S@-"I"VJS--;7$-O^G]EJUCJ,US#;W$4LEK*(9TC=6:*0Q),$D )*.8Y8Y
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M *_/#X%:M8Z+^TO\;9KRXB@C:7P7"'E=44R3Z<\,2 L0"\DCI'&O5W944%F
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M- ^$_@?PIKEWKNEZ#IMGJ5YYGVF\MK*WBN)O-D$LGFS(BR/O=0[[F.YP&.6
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M"'PZ^&M\]]X<\-:1I5S)$87FL-/M;:1HV96*%X8T8H616*DX)53C(&.@\?\
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M_C/7-$N/#WA/^U_"VKZE?Z:NL6&I12/!]ADG@>ZGMFB6(6DDMO*8)HKN7S(
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M_# H(;>W97:8N\R/#';<?X#_ &P?&NN_L]_#;Q!?>4VL>,/$%IX8FO84CC,
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M).]MK-BLN$O(]/MHK>WEL9=/\J*#S'<&X2\GER%:88S7VA\:/B]-X9\6^$O
M=@\MMJ/BV74(XKY8XI%M(-.M?M-Q(J295KAE*QVP='A1W,\J3)#]EN/'_'/Q
M%\<_LP^/?"D&L:I?>)O#GBF^AT)I;N'3(;K3M2F<_971K.&R6>WN%+K-&T):
M 6_FK.2XMI>/^%5_\4O&WQB^(O@BY\>ZDNF^&O[":VG6PT3[<S7]B\[JTO\
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M:)G2Y$J0R)'+!'*9+=9BPDCO/)@GK]GM)LIM.L;>WFN9;J2*)(WGF$0DE95
M,CB%(H@[D;F$:1H"3M15PH^(/'GQVU;6OB3KWA>.[\0:-I>AQ6$9O=$\-W&J
M3W-_<0M=2Q"X6SU2VCMX;::T9HY+6*Y>:7<LRPH5FX_X*>+/VAOVBO@),UY)
M<^"_&=C<O;17-[IJ(E]Y,,;K+/:WEJ_E13^:8Y'MU^2>(S1CR]UG1^R/X_\
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MQXBE7POX@TBZN-(L8[.R"OJ%E'$+FUDF$,MT42$O?"5GMT+ND"NXC:.3R_\
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M?#-];:(/"TWAT7DMQIA4SQZDUXLXBBO9)_L\J*%C)C$P=U$D$:AW7/\ V??
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M-=N7#+M!W#/S!HGB;Q;IG[6DWA:ZU^^OM);P;<ZS%:7 M4C@GN-9B@VH+:"
MR)%'"$A:X,\T8:7]\?-?=]7^.OBQX'^%_P!G_P"$FU[3=(^T[_(_M&]M[7S?
M+V[_ "_.=-^W>F[;G;N7.,C/0>*?%FA^!M+FU36[^VT^R@V^;<WDT<$*;W"+
MODD947<S*JY(RS!1R0*/"WBS0_'.EPZIHE_;:A93[O*N;.:.>%]CE&V21LR-
MM965L$X92IY!%9Z_$+PJ]]9V(U:Q-S?2W<-K"+F'S)Y+%F6[2)-VZ1[=E9;A
M4!,)5@X4@UGZ!\6/ _BO7+O0M+U[3;S4K/S/M-G;7MO+<0^5((I/-A1VD38[
M!'W*-KD*<,0*Y^Z_:%^%EE<:A;S>+=$CETS=]MC?4[16M=DZ6[>>IES%B:1(
M3YFW$KK&?G8 ]AX*^(7A7XE6+WWAS5K'5;:.4PO-87,-S&LBJK%"\+.H<*ZL
M5)R RG&",\_J?QO^'6B^(E\.7GB72(-6:6&$6$NH6J71DG"F)! T@E+R!T,:
M[<N&7:#N&>@\:_$+PK\-;%+[Q'JUCI5M)*(4FO[F&VC:1E9@@>9D4N51F"@Y
M(5CC ..@TG5K'7[&WOK&XBN;:YB2:&:%UDCDCD4,CHZDJR,I#*RDA@002#7'
MZ_\ %CP/X4URTT+5->TVSU*\\O[-9W-[;Q7$WFR&*/RH7=9'WNI1-JG<X*C+
M BL_3/C?\.M:\1-X<L_$ND3ZLLLT)L(M0M7NA) &,J&!9#*'C".9%VY0*VX#
M:<<?XO\ $MY\</ E[_PJKQ;IL=ZUS;6Z:I:O;:E#;;+B"2Z!1?.B>7[,S[(G
MVY9X\O$&$J^(?MG>)O%O@75OA]=Z/K]]:6VJ^,O#^C7EC$+58)8)+B6XD8R>
M1]K5W\E(I%6X6%X=T;0D2.6/C#XF\6^%?VC_ (8Z5;Z_?-I.O2Z]+<:<1:I;
MJVGZ/B(*\4$=PZ,\S3/'<33IYPC=53RHPOW?7G^O_%CP/X4URTT+5->TVSU*
M\\O[-9W-[;Q7$WFR&*/RH7=9'WNI1-JG<X*C+ BNPU;5K'0+&XOKZXBMK:VB
M>:::9UCCCCC4L[N[$*J*H+,S$!0"20!7/^"OB%X5^)5B]]X<U:QU6VCE,+S6
M%S#<QK(JJQ0O"SJ'"NK%2<@,IQ@C.?\ \+8\#_\ "3_\(M_;VF_VU_T#OMMO
M]L_U7G_\>^_S?]5^]^[_ *OY_N\UG^)M"\:ZCXU\/7NF:O%::):1:@=4LS!'
M))>R21Q)9JKLFZ%(F\Z9W1U+%8XC'(LC-%GW7[0OPLLKC4+>;Q;HD<NF;OML
M;ZG:*UKLG2W;SU,N8L32)"?,VXE=8S\[ 'L/!7Q"\*_$JQ>^\.:M8ZK;1RF%
MYK"YAN8UD558H7A9U#A75BI.0&4XP1GY _X*.>)O%OP^^!^N>)?#>OWVDW-C
M%%$5M!:[9EO;RVM6+R2P23QO&DCF&2UEMW1VWEF*IM^K_P#A;'@?_A)_^$6_
MM[3?[:_Z!WVVW^V?ZKS_ /CWW^;_ *K][]W_ %?S_=YH\=?%CP/\+_L__"3:
M]IND?:=_D?VC>V]KYOE[=_E^<Z;]N]-VW.W<N<9&?0*X_P :_$+PK\-;%+[Q
M'JUCI5M)*(4FO[F&VC:1E9@@>9D4N51F"@Y(5CC ..?O?C?\.M.\.VWB.X\2
MZ1%I-U*88+^34+5;660%P4CG,@B=P8I 55B08WX^5L:'_"V/ _\ PD__  BW
M]O:;_;7_ $#OMMO]L_U7G_\ 'OO\W_5?O?N_ZOY_N\U\8?!7XI:CX,^+GQ8T
M[QIXNEN-)\.1>&(K>[UF6QM(X5O;:XG<N;>&SM5>2:98_,\M7D"PQLS[$Q]W
M^%O%FA^.=+AU31+^VU"RGW>5<V<T<\+['*-LDC9D;:RLK8)PRE3R"*X_X+Z%
MXU\->"M,LO&FKQ:QK:1,;V\A@C@C>1Y&?:B1I&NR)66%7V1F41B5HT9RHT/
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M111111111111111111111111111111111111111111111111111117E_QO\
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M/T!\0M<L?V=/V@/@CJE[?ZN_@^RTBXT6QGUI%LI89,W=A(\]M<16!MTACN;
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M6H^.KZ'5+;2-<O88K+3]&C@=M/DN_*^TK/8W#2.6AVLT#6J&$1H(A,LMS/\
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M#TC6_LMG%Y<21?NH?(?9NV;W^8[I&=N,X'G_ /PP+_U57XD_^%'_ /<U'_#
MO_55?B3_ .%'_P#<U'_# O\ U57XD_\ A1__ '-1_P ,"_\ 55?B3_X4?_W-
M1_PP+_U57XD_^%'_ /<U'_# O_55?B3_ .%'_P#<U'_# O\ U57XD_\ A1__
M '-1_P ,"_\ 55?B3_X4?_W-1_PP+_U57XD_^%'_ /<U'_# O_55?B3_ .%'
M_P#<U'_# O\ U57XD_\ A1__ '-1_P ,"_\ 55?B3_X4?_W-1_PP+_U57XD_
M^%'_ /<U'_# O_55?B3_ .%'_P#<U'_# O\ U57XD_\ A1__ '-1_P ,"_\
M55?B3_X4?_W-1_PP+_U57XD_^%'_ /<U'_# O_55?B3_ .%'_P#<U'_# O\
MU57XD_\ A1__ '-1_P ,"_\ 55?B3_X4?_W-1_PP+_U57XD_^%'_ /<U'_#
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M\_\ LZ]M[KRO,W;/,\EWV;MC;=V-VUL9P<'CKXL>!_A?]G_X2;7M-TC[3O\
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MH$53X4?LWVGPJ\:Z_P"+AXAU?5+[Q!%:QWXOQIHCD:SC$5O(%M+&U*/''NC
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MSXDN=%;SQ%H%UK-PVD1+//YS1BUC\OSHCEXWANGN(IXY)!.DS,6K[?HKY_\
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M](U2QTN[O[:"]U#SOLEM+-&DUQY"!Y?)C9@\OEJ0TFP-L4AFP.:Z"BBBN/\
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M>7%K#>R6YDT^UA$YN+A(XGDFM;A[$^8%@MI;S<)*\_\ 'O[4GBKQUXY^#Q\
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M3Z/HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\D+3]GZ^U'XL^/OA/J
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MD\0:;;WOAZV\4RZRL]Y:Q?V?-JM@+N.&Y(G=(_FG\F*1F"W.T21C#A1]/_\
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M(Z'\3=6BB7PO?^'_ /A%;W4#*RKIMP]^UW!/=*(V"V\TGE6RS,RPQ/(6FDB
MB$VAXDU7PW\;?C5X2\9Z/JUM-H'@73=<OK[5X9[6;3C-J,$=LMI]I2XPDL,,
M<MW<DJRP0_9]^W[4C+Q__!._XA>%=?OOB;8V.K6-S<W/COQ!J<,,-S#)))9R
M-:JETB*Q9K=F(59E!C8D ,2:_2^OQ1^(/_"IM4U;Q;XZ^'?B*+P?\2M-OM>T
MUM/M+J"5]6NK:X,,<+Z9=(%NGOE@CDA^RQD?;;G>YN[N"N_^+OQETG3_ (Y_
M VX\9:KI&EZMIMCKLFOP&^MTCTZZO-$MR(Y2T\@A1Y&*VYD<B4;=CR9#$^(W
MQBL=._:L\07WA:\L=4U:Q^&6I6MI:12K<M+JMGJ4MR+ Q02"5[@"(M);(1.$
M#'"XW#R#XM>/]"^(6C?#3QA=WNKR:M:>,O#][XE:X.KQ:5H[PSO!>6T\4P73
M-/>TG:.W590EZ8#'/))/]J>ZN/?])^-?@+6OVT+>\AURQ6.?P(FEH)IT@D%^
M^NAA8O%,4ECO0#\UG(JW*'*M$K @9_[5NL^!_A9^T'IOB;XHZ%;7G@[4_#::
M2E]>:3;ZE#;ZI;7MS=(KYBFN(-T$LBJ(EQ.S@E76VDDM^@\6>)O@KI'PYU[7
M+/P7IMO\/[VVT:'4)QHT^EM?_;]1BA$\:"V@N#%IT$PO(9HX9?M4MP@M;FWF
MM9B^?^SWI"_"OXHZ-X:^$7BF+Q'X#N8M6N=5L5NK348]#D.)+8P7<3^=&EQ*
MPB@M93*6"7MR?.D,L\'ZGU^:'P'\8V/[*OCWX@>&/B%=6.B0:[X@O_%6CZC=
MW:PVM];WSHDT"2S+'$EQ:%81-"TGG,9MZ1M BSR>?^.!I.C^$?CM\2-2OHM/
ML?&EB^EZ,M[);Q"]73=#GM8;BUD$[B9+Z0S/9H KS6\<=P@=)UV_:'[%_BS0
M_%?P0\'?V7?VUY]CT32K*Y^S31R^3<16%OYD$NQFV2IN&^-L.N1D#(KW_P 4
M^+-#\#:7-JFMW]MI]E!M\VYO)HX(4WN$7?)(RHNYF55R1EF"CD@5^4'[%CV_
MQ0_8BO?"&@7-M>ZU_8GB"S>RBN8/.BFOI]1%JDRLX\GSL@QM-L5ERV=H)&!\
M"_B1^SCX]\(6NB#X?:;J7CZRTTQWVC/X32"9M2M@+>43RPZ>]I912W6T&>5H
MX;995,RPE7C3K_BGI'P2\;_$S6+G7/%-CX)^(GA>73XTURWNH[ 7ADTF*:.=
M[2]=H)[<O<2036QEGN#;V\4$MV()40Y_Q=U_XAZW\%?@UXD^(]I]AU*R\;^'
M[[69)(U@2VMTGN8H[J\ /EVN]'@:??Y213R^48X6Q"O0?';]H'X::I^T3\'M
M4C\2::MII_\ PE!NIIKJ*%8%N-,C6VDE,K)LBN>'M)FQ%=Q-'- \L4D;MT'[
M3_Q8\#^'OVG?A)_:&O:;;?V1_P )-_:'GWMO']C^U:3#]G^T[W'D^=D>5YFW
MS,C;G-<_XG^+]G^QG^TEXQUWQM9W,/AOQI;:+);ZU!;W,UO:W&GV<UN+6X\N
M YEF\N9PL+2NB>2S)LDD>WZ#]N3QM<?'3]EKQAJF@:=<RZ5+;:7=6-RT4\<U
MW#'?V]Q<7*VCQ++%:11*'6>;8TJI/-Y26B07-SS_ .U[\1? ^K^)_A]\0+ZQ
MMO$?@33+G5]+UJ\6PM]4LXOM\5F+:9#*DBR1)<1JLEU9[_+DCELMYN&:UD[#
M2_#_ ,-OCWX5UBU^"_AS2+&TUKP_K5A/K8T*;2XW:>$VMO:12M:VSRH]P6FN
M)H1=);BQ:&2 37-O)'Y?H?[3OP\UG]D75/"TFH?9-?TKPC>^'[K1KI&34DO+
M+2VM9L68W3-$I4RO,JF."$2/.T/D7"P_<'[%_BG2_%/P0\''3YO.6TT32K.1
MU5PGG0V%N)41R DOEL3%(T9=8YTEMV*S0RQIS_[9FH_"A?#>A:3\3K&VN-"U
MC6X-/DGNII(%LYC:W4\%P)8@)(\O +=Y%DA5(IY&DE$ E5_C#PWHOBW3?"OQ
M \">"_$$OC;P+!X$O8M+NE:UOKBVU)X9XDTJ*YL\&Z<Q[I?*\MFMH7LH%6%#
M&;DUV2^^+/[-WPROO ,47B&^\!R^$]>O;&UE;=*=/L&$UC%,D<L1O4)#2VH)
MN(D*DPEYK:.?V_\ :6\?>!_VS/A@G@3P+K=MJUWXEN=+5CI\MO/+I]FEW#>3
MWU[;/-#+#%#%"4*2!)#=206NU99E \_\3_%^S_8S_:2\8Z[XVL[F'PWXTMM%
MDM]:@M[F:WM;C3[.:W%K<>7 <RS>7,X6%I71/)9DV22/;Y__  4(^//AWXA?
MLT>(9;>6*VL]7BTN317O9#:W6J+'J-I-<2VUC.D<_P!GB1HRLC /*/,E\E+4
M6US='@/]JCPK^RM\18_!>IZ[8ZAX*\22W&I^']934X;Z2TDN;J0WD&H3!C(U
MNU\;CR;V8RE"66:YGV7+67ZWU^>'[5FK6/@SX^?!OQ'K%Q%8Z39R^)X;F_NG
M6&UADN=*40)+/(5BC>4QN(E9@9"C;0=IQS_A_P 6P_ ']H3Q1XG\5&+3O#7Q
M L=(GT[5KUI;2.&ZTNQ\LV%XEQ%&;2XEC::=!<M""(?)7?<&2*'U#X::1;_%
M;]H/5OB9I$_G:+9^&[;PU:W41@EMM0F>]>_N9K2>*9]\5M^ZMG;9M:Y-Q$&#
M6L@;[?HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKY@^
M*?P]^)=W\0]%\6>';S3;^RT^VFMCHFJ^;:Q+-.LH?48+V"*Z=+L+Y=LBO;2*
MMK)>(DD9N9-VA:?"_P 5>./%NA^*/%QTBWDT26YN+&TTV":>>"2XM9+.1'U.
MX,1GMY8Y&E>&.QM")EM@995MBT_T?117QA\*O /QU^%5C?:1-/X?UV2[OIKI
M]?NI;NSNY&N53,MUIL-M-%.]L1Y,$4=_:H]G!:VJM:K&&7V_X/?"O_A6%OJ\
MDTUM+>ZSJ4NK7K65I]BMC<200P,T-N9;ATWK;I),9)IGEN7GF+*)!&GL%%%%
M%%%%%%%%%%%%%%%%%%%%<_XIUF\\/Z7->6FFW.IRQ[=MK9M;+-)N<*=ANY[:
M$;02[;Y4^52%W/M5OD#_ ()\^!O&?PD^#NE>#O%6A7.EWNE?:=TDL]A-#/\
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MTM[9(_H"2?2/C?\ $OPQJFBZGJ1T^WT2+7YC::CJ=E#*EW*!I"3V@FBAEBN
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M#O,_F2D[0D9\NN/U/P/IVK?MR++++?*R^!(=0 BU&^A7S8=:6)5*Q3HIMRJ
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M5TBOK^34FL[Q=0%DLMI)J0NG3"[I"DAECDE?]XCQI#''T'[.'Q2^)_BWP/\
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MH\9'F*\"C+-'AU&YOE#]@GX3?\*U^'CW?]IW.J6^IW,DVE7-\=]PFAQL4TB
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M%>';?1]8N+ZS:SOK?4K.\TVX-O=6MU;EO+FADVNH<*[K\R.%#EU"RJCIZ!X
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M0'P[K=WX=AVR/K=G%936GV<N%>\2$7@OY;2/+2-/%:.DENANH?.M6CF?Y_\
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M:PM-)^(MQX /A3Q!-K*V+ZE;10QZ:\=U:I=&V\Y)A?\ E0(Q5W7[<UH2%$9
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MOK.'2-#\00VUWI$6K)?W^E3VEGB5HP+83S;5EN-LBR P>=;O&&>.XD"FO?\
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MNM?;M(U?X@:FAO8[NTBFEBEOM(MX]4$D?DV_E0SW-K<SS(GV5%9<PM&ZPO\
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MD@F2...&\\Y[F>6\@"'+Q3322L)W5/M3;KJ/S;>:&XF] ^//P8T/XS?%M/\
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M515+$9(51G &.?TSX(?#K1?$3>([/PUI$&K-+-,;^+3[5+HR3AA*YG6,2EY
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M.OB5?)?>(_#6D:K<QQ"%)K_3[6YD6-69@@>:-V"!G9@H. 68XR3GT#2=)L=
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M'B/X*:O\>/'?@WQ>?!ESX*U_2-2MM3U/56GTR4W-O';^7/IRRZ=?/-=><1#
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M^$?\??\ #4__  FO_"(:E_8O_"-_\(S]I^TZ/_K?[7^T_:_*_M'S?LGE?/\
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MM)?*BT_3Y82C) TDANR\D2O$%%JFVZ*7TZQ6YO/O^ORP^$G[)_BWQ#^SA/\
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MDE%S<Z[<:T7;56CN(+R!HO,MC/+<(D"Z:_\ :#6:1)#;-'<3096W^_\ XU^
M['X\?!K7-&\91Q:'!?V,\DK3W"R+8B%C/;W%Q)')#$7MS'%/<1K*UN'22$7$
M\ \Z3/\ V/\ PYXOTKX:6&J>-3O\2:WC5=6D,9A9II8HXH%D@\N%898;.&UM
MYHDC11+"Y.]R\K_3]? 'P,\+_$;]GW5/'=M+X4N=5M]6\7:IXAAN;*]TY%DM
M+](/+BA2YN8)#=QN,31W"VUN(DGDCNII%@AN?'_@[\-_BEX$_9*OOAG>^"M2
M.M-INKZ8@CO-$:%VU1K^1)1(=2&(H?,B6?<%EW2+Y44RK(R:&N_!'XN:3X-^
M#OBOP]HL4OB'P#8FPNM!OKBVC:ZCN+.#3KDPW<5Q);HZI"98"[$%) [KYL1M
M)?L#X93_ !1^(=]I^N>,-)B\,PVD5R5TFWU7[?)-<2L(HY;J6"&WA"0Q+*8K
M=7NX9C=I-(L-Q9PX^CZ_,#]F7PQ^T-^S#I<'PQA\':;K6D:=<WGV+Q ^M)IT
M+V\[O=KY]J(;ZZ$OF2/&?+C**Q5!OC0W4GT!/X8\9ZG>:#X&U33M2U'1XO,F
MUW6KB6P^SZHYMFE,!MOM[W<5I/=2EY85C$$:0)IHMI=+N)&B\O\ V2_"?Q4^
M WBK6? ,_AF7_A!8KZ]FT#43<6 DM(I9I)S;2PK>SW$UNSNXMYWW70)4S1JD
MI2SX_P#9E\,?M#?LPZ7!\,8?!VFZUI&G7-Y]B\0/K2:="]O.[W:^?:B&^NA+
MYDCQGRXRBL50;XT-U)H>/OAY\3-*^*GPRU:#0-7\10>$(M:.IZF+G28FO[C5
MK"-&EM8+K4T>-!<&3=;N((;9 (;=6@2(5V'[2?PE^*^A_%/1/BQ\-+>VU.]M
M--;1=4TF[N([?[;8M=I.B6TDD>R*4-)+*\TDR!?)A"QS#S8)M#XC2_&CXH_"
M;Q -3\*RV5]K&D:EHUOH-A?Z;=M%)=02QK?7M]<26D6P%42."T9S$DKR2"Z>
M18[ \$WWQ@^'7PI^'MCIOA&^>[T673=+UG3GN]&22>Q@TB2":XMYC=RPE$N3
M#)$AE@N)3#Y;B&&1GKS_ ,+_ +'JZYXB\;ZGH^ER^!M)\2^%I?#LFD%+1E>\
ME$B?VF;?3[V:S1(862*&-7221WNF98-YENM#X%M^TUH'A"U^'5_X4TW2?[*T
MTZ5;^)DU>&:';;@6MO=0:=]GN)995BV3B&Y:VBG:-ED:U\Q8E_0_2=,AT6QM
M[.%I6C@B2)#--+/(510H+RS,\LCD#YI)&9W.69F8DGY ^,WPA\6Z+\6=#^+/
MA%)=1N;6Q_L+5='$EK$UWILL[3![6:YVHEQ;SNMPT<DL2W*1"(3P$,MP:KX;
M\2^.O'NF?$75?"M]''X7L;JWTK23)IW]I2WFI/%%=W1ECU4Z>+>.U18X8I9A
M(S/=.45H[7S<_P#X)\^!O&?PD^#NE>#O%6A7.EWNE?:=TDL]A-#/]IOKFX'D
MM:74[_NU=!)YR0_,P">8 Q'V_7Y@?#'Q5K_A3]IWXSRZ=X?N=:B?_A%%E2QN
M+..XC;^R7,;!+V:UA>(CS!(PN!*C^4%@E2222 ^('[(?CCXT?"CQ_)?1:;IG
MB[QY<Z5=3PF>X:VLK?39+46ME),@F$TL4,,C37$,*)+<S.J@P)$X[#7/!?QE
M^+?Q<^&GC6\\+V.C6GAZ+5I+N"YUE9KA6U"VM[26,BVM98BZ$RS6ICDD2YAB
M_?OI\SK$-#_A'_'W_#4__":_\(AJ7]B_\(W_ ,(S]I^TZ/\ ZW^U_M/VORO[
M1\W[)Y7S_<^U?P_9=W%<_P#$GX;?&KX*_&K5?B-\.=*MO$FF^)+:Q@UC1Y[Z
M"SN/M%G!+#!<6\\T2QQ11(L0(,DSR/-,##M\J6WS_P!K;P7\:/CC\#]5T/\
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M2[ZS\'>,+:26'R?-NM#NM.O9K;<Y9<B2.\A7S!&Z#S8FRN\IAU#+\P?L6_M
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M9'5=FZ60!S-*8=\H1)'Z"R^-_P .M1\.W/B.W\2Z1+I-K*(9[^/4+5K6*0E
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MW5[?Q##!&AMYH=)ME:SN;@+'D2I-=1P"Y=MP3R;9&1)'27Y ^&/Q+USX1?\
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M*1%AFNON_P#;@^%]C\0_!5K<V1BA\5:;?077ABX$"S7 U.*1;B.")&(5DG6
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M'5[;418PZ6;>(::;4V,<ZW#6Q66QDFV2RJ7DD$HN 798YHT"*OA_CWX$Z?\
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M>>)K"]M[G0[WPOY#ZK;ZLUJGV>&XMOM44[3VUQ<VIB:,.Q(F+1^6WF+&-I;
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M(OP/^(<WP]?Q!JDKK<ZOI&MZ&D,-YMFNKF*9-,-SY4):!)6DDE@6X-N)GMI
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MH7PI)7$UM,FUPK?)NQL96;[?K\@/@S_QAE^T=\1(_&7^@Z!XTN4U33]>O/\
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MM/VW[9_9FI_:/M'F>;Y_G>5YGF[_ )_,W;]_S9W<U]__  ^\)ZYJ^EZ-JGQ
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M,!D!F&<$YZ#2=)L= L;>QL;>*VMK:)(88846....-0J(B* JHJ@*JJ %
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MA$,DLDA5< O([XW,Q/L&DZ38Z!8V]C8V\5M;6T20PPPHL<<<<:A41$4!515
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M-*9+N>*WMX"QN \ZW,LMQ"$$T<KK-,9D63YY.O(?LQ?"[Q?\,/A!I^F:Q?\
MG^)KBV>ZOKV^0W3F^G7*BZ9+C?=_95\JTWBX4RP6T:I)$FP)H?LJ^+?'OC'P
M%!/XS-C<7L,K01ZCIK.;74X$1"E_"DD4#(DC%TR$$,YC-W;9L[BW-7_VH_@7
M_P -*?##5_!7]H?V=_:/V7_2?(^T>7]GNX;G_5>9%NW>5L^^N-V[G&#XA=_
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M\ ?"'PDAU?1(_$DVMLEM9>;+<VFM6*W4NH7L%T)8;:6&TCBE=[X1B036\ M
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MP6/A^WO?*FDBB(MWNIKZ9A(D4DC7"0+;J8[JWL[I;D-$8S\GW7[#'Q3_ .%
MZA\&(?$&B?V7#N>RO7L;O[3=;KI-16*=!<>79>7=AXS-']O\ZVD4B""6$^?]
M82:;\?=)\9'6;>/P_J%C=Z1;V\]A-J6HV:VUY#>7<H>V<65XDB?9[B.">9HH
M9+MX(YO*M41;>O'[;_@GYX=NOA=J7A@WDNDWU[X@N/%=I/I3E(](U*3BW6R$
M:VQ>WM8PL"[UB:4!YD6S=H5M_4-<^&GQ+^.>EZ7H/Q M-$L]-@N;*^U)=*NY
M;]=3:R=9EM&MK[38EM[26X2.:4B:>7RH?LGS+.\Z<_\ #_X3?%/P#\8OB#XQ
M6QT2XLO%'V'[/&=5NXYHO[*L9K>W\Q?[+=/])8QF;:Y^RJSE/M911)T'[)'P
M=\<?![_A,_\ A)H]-7^WO$E]XA@_LZ\N+GR_M^W?!)YUG:_ZKRDVRKN\W>V8
MXM@W^_\ Q8\"_P#"T/ ^O>&?M'V;^U]-O=.\_9YGE?:K=X?,V;DW[=^[;N7=
MC&X9R/D _LF>)/B=\&-)\">+[NVTJ[\/VVE+H]]H=S=336U]IEL88]1,LD=G
MG?NVBT$0,*AW6\:66)[3T#7/AI\2_CGI>EZ#\0+31+/38+FROM272KN6_74V
MLG69;1K:^TV);>TEN$CFE(FGE\J'[)\RSO.GU_7R!XZ^#OCC3_C?;_$OPS'I
MM_N\-OX>GLM1O+BPV8OUO4GCFAL[_P S=EHVB:.+9M5A(^XJG'_$;]CR;]H3
M1O%\WC*[BL]6\1V-EIL!L/*NX]+M=/G%W###<2VMI/<I/=@W5YYBPF0-';(4
M^S1W#:'@+X:?M!^-]+&B?%75O#<FFK]C$XT6VO6N=06!Q)+'<R3O!;1Q7!C2
M.[A2TEBNK::YMPELK*PS_A3\*OC#X'^*GCGQI>:9X?:/Q3%II%O%K5ZS6\FE
MV$MO$I=M'02)/(R>8^$-NA9ECN&4(V?\#_V;/'&C:'\1/#/C&'38]-\::EKF
MIR3Z3J5Q-<0?VO''"UNJ7&FP1GRT#L+@L<OM!MMI)&?\(?@C^TCX4\.IX!UK
MQ-X?7PY9V,FF6VI:?;7Z:V;53Y,.PK-!;6EPEL<17 ^U&"6.(NEV=\K?0'[0
M_P"S]8_%WX77'A32!%IES9Q0S:)-;A;<6%Y98:R>!XXG:V1&58F:!1(MN\B1
ME2PKK_\ A2FA_P#"K/\ A7/G7/\ 9O\ 8G]@>;OC^T?9_LGV/?N\OR_-V<[O
M+V;^?+V_+7RA\(?@C^TCX4\.IX!UKQ-X?7PY9V,FF6VI:?;7Z:V;53Y,.PK-
M!;6EPEL<17 ^U&"6.(NEV=\K??\ I.DV.@6-O8V-O%;6UM$D,,,*+''''&H5
M$1% 5450%55 "@   "OE#QU\%/'$?QOM_B-X9FTV3S?#;^&YXM1>XC^S9OUO
M$O(UAC?[7C+!K1I++=L4"[3S"T7'_"GX5?&'P/\ %3QSXTO-,\/M'XIBTTBW
MBUJ]9K>32["6WB4NVCH)$GD9/,?"&W0LRQW#*$;R_3/V*O''C/X8?$GP5XFO
M--TS_A+_ !)+XA@N=.EN-1\CS[NWN7@DBFM]/W;/LJ(LJO\ O/-9C''Y8$GH
M'BGX%_&_QWXS\"^.-1U#PW%J7AS[?$UE;P7YMT_M*P-I/<BX>3S+K8Z1W$5F
M8;+Y&>U:_+(MV_H'AOX*>./ ?QJ\6^+=+FTV;3?%?]AO<M<O<+<6?]EP2021
M16Z1F.X^T(0$F:YM_L[N7,%RL(CG^OZ^(/A7\'?BG\"=4\8+HD>B:C9:WXDO
M_$D37EY=VLS?;TA5K-TCL[A+?R65I%NPUUYRQ"$VD)N#/:^7_##]G#XP_#S]
MFN\^$[VGA^>YDL=1TV.\&KWJQF/4S>O),R?V265X&GB5(@6$X\QC- 459-#Q
M%^RE\2YO _PSO="U+3=/\8^ +9;.W$KRW6EW<+V\5E<I,YMHKA/.@A5@R1AH
MB\D*DL8[N+Z0^&7@'XBZK?:?KWQ)O=(GU&PBN4MK/1+>Z2SADN&"-<,]Y-*\
MUP($\J&5([4P1W-] ?/2?</;_%-SKEII<TFB6MM=WHV^5#>7,EI"V7 ;?-';
MW3IA=S+B%]S *=H8NOQA^S)^S1XJ\"_ >X^$_C06(MFL=0L!>:1>S322QZE+
M=/,=ES8P+ \:SJL9S<!R"S*@ 5N?^$/P1_:1\*>'4\ ZUXF\/KX<L[&33+;4
MM/MK]-;-JI\F'85F@MK2X2V.(K@?:C!+'$72[.^5CXB?LK?$7P)\2?\ A/?@
MSJ>D:7)=6-GINH:)J<5TNFW,=I#)#!-_HS,8W@C6WBMXH(H0BQN?.VRS13'[
M1O[//QA^.'PCO_#$UYI%SK&O160U"=[R]L]/L397,%S'%I]HMM>-*CLLHFN)
MY(KB1V5V8P+;V=IS_P"W/)XJU'P[\+#>16.GZL_Q$T$!8I9M0M8I,W8B8LT>
MGRS)C8\B;;<D[HUD&!*?H!_AAX]^*_C71M6\<PZ19Z3X?E%_8Z9I\SZD;C4C
M'-"EW<W%W8VAC2UCE+6L,$>[[0_VAY_W,4=<?\$OA-\4_!OQB\9>,=;L=$CL
MO%?]E>;'9ZK=SS6G]F6,ENNQ9-+MTN/.9E+9>#RER1YI #>?_ []GO\ :#_9
MRQX,\,Z]X;G\'6]S<RV-QJUE>W&J6\,^Z?R6AM9;*WEQ.S R-,K,':4!%\NU
MCZ#QU^S9XXTCQW\-]8\(0Z;>67@RVU42'5]2N+:[O[C5+?R)IIGM]-N4,K,/
MM4]P<O=7$TI:.,_O'[#3/A#\19?VD6^(MY;:1%I/_"/S>'0D6HW4MT8Q?M>Q
M71C;3XH@[D)');^<1&&9UN)=H1]#]CSX*>./V=O!EGX*U2;39]-TG[<EM<VS
MW#W%Y]IOY;F.66)XXH[/RT<H\*O?>:[AA/"L)%Q]/^*;G7+32YI-$M;:[O1M
M\J&\N9+2%LN V^:.WNG3"[F7$+[F 4[0Q=?@#X1_LV?%/P!^S+JOPHNX=$DO
M6TW4-.M+J+4KLPR?VG-=-+),&TU7A\A;@&-4$_VAE*LUN#N&?\3_ -G#XP_$
M/]FNS^$Z6GA^"YCL=.TV2\.KWK1B/3#9/',J?V2&9YV@E5XB5$ \MA-.798_
M8/$GP9^(K?&'3_B3I!TA;F?PM_PCM[;74]TT=G(;U+S[5 T=NK7Z(Q=/L\G]
MFF4(A^T0F4^3Y_HO[/\ \=?@KX]\03_#W6?#\OASQ+J[:W=Q:_;W<EU9W5T_
M^FFV6S,"SHRA&C6::,81(OW9$ES/H?&_]F/QQXETOPC%H$FFWM[IGBZ#Q?JE
MUJ-S<61NKBW=V$$0BM;YQ%MD%M;F:21[.SMK6WW7(7<O0?$#X3?%/Q]\8OA]
MXQ:QT2WLO"_V[[1&-5NY)I?[5L8;>X\M?[+1/]&82&'<X^U*J%OLA=A&>&/@
M[\4_@?\ $/Q3J'@R/1-0\-^(KDZN^GZC>7=C<6NJ3*B74L=Q'9ZAYL4_E^8R
M.%".RI$D*1-]H\?^'7[.O[1?PEO+ZXTO4?#<_P!I\;W_ (GN8VGU.U2_M]0M
MGMY+=U2*;[+Y?$T<3?V@AG:*0RC["!>_2'PY^ ]]'\6=1^*.O6ECINK7>D1Z
M(;32[EKN"2-)Q.UW<7$ME92R7#!(+=%\O$4-N,RR^8B6_P!7U^>'PD_8VU:P
M^"\_P<\:26-SX>BBO(8KJPFN!>7+3:D]];7)5XXXK)[<[28-VH)/(5W2+%$\
M=SV'_"I_C/XL^'G_  KCQ)>Z:;*6V_LJ[\06E]<R:C<V*MY;LUC>6,T2W=W;
M+Y$\K7LHAFFDNH_,*)"WV?I.DV.@6-O8V-O%;6UM$D,,,*+''''&H5$1% 54
M50%55 "@   "O /%NF_&'2/B+/J_AR/2-0T2YTBTM7LM2U*]LI(KRWNKJ0SP
M^397L(22*=8Y<H))#%#\ZK"!)\OZM^P%-!\+KC2?#FIQ:-KJ^*7\;V'DQQ/I
M]EJ0R(+-$-NI:RACVPJYB5BZBX^SB/\ T&O</"W@7XW^++>&[^(EQX;FETVY
M:^LM-T5+^&VN;B& BT-[=7;3GRHYG,PC2S=X;F"TO$E9X?);C_V=?A5\8?@C
M#XS-QIGA^ZDU[Q!J/B*!8]:O45)+^6W!M9&.CDA(XTD<7"JQ=PD?V=%=I8^P
M_8B^#OCC]GOX86'@KQ-'IK?V9YWD7.G7EQ/Y_P!IN[BY?S(IK.V\GR_-1%VO
M-YGS,?+P WU_11111111111111111111111111111111111111111117S!\6
M?V0_AY\:_'&F>+=?BN9;BRMA936JSL+.^MX[@74,%] 05FBAN +A(\HDD@43
M":-$1?I^L_2=)L= L;>QL;>*VMK:)(88846....-0J(B* JHJ@*JJ %    %
M:%%%%%%%%%%%%%%?,'Q+_9BB^)?CO2?&,OBK6[&]T7[3_9L=FND^3:_:[=+>
MYV+<:;.\GFJF6^T/-L8DQ^6, ?3]%%%%%%%%%%%%%%%>7_$WX+^"OC##:IXB
MTR*ZDLY5FM+@-)#=6LBRQRA[6Z@:.XMW+PQEF@DC+! K$KQ6?X6^ G@3PEJD
M.KPZ=]JU*#<(=0U.>XU.^A5T*-'%>7\EQ<Q1$,_[F.18@9)6";I9"WL%%%%%
M%?.%E^R3\*]*FN38:5+8VUW*);C3[&_O[339F\I(6$VF6]Q'82))'&J3QO R
M3J")5D#-GV_PMX3T/P-I<.EZ)86VGV4&[RK:SAC@A3>Y=MD<:JB[F9F; &68
ML>23704444444444444444444444444444444444444444444445\X?'3]F^
MT^/5]H]Q?>(=7L(]&OK75+2"P&FB-+ZT:0Q7)-S8W,K.!(5,;.;=@JYAW;F;
MW_2;*;3K&WMYKF6ZDBB2-YYA$))650#(XA2*(.Y&YA&D: D[45<*-"BBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBL_5M3A
MT6QN+R996C@B>5Q##+/(512Q"10J\LCD#Y8XU9W.%568@'\X+G]H&V_:C_9K
M\5>+K(ZOI=SIUCKVHV4ML=4TDJ+4Z@E@PN8)4ANW6**-KJ*&>YMUN.)$4B-%
MZ#X"?M;?"OX<_![P!;:YJLMG&^D:+IJWDMA?_P!GFZ-E&C0_VB+<V(>-DD2?
M,^('BF64QM#*$^O_ !K\9/"7@"^33KZZEEOGB$XL;"UNM0O/(+,@N#:6,5Q<
M+;[U,9N&C$(DVQF0.RJ>@\ >/_#OQ3\.V7B'P]>Q7VG7T0E@GB)VLN2""" R
MNK I)&X5XW5HW575E&?\5?B7H?P;\(:KXIUN3R[+3+:2YEPT:L^P?+%'YCQH
MTLK;8H4++YDKH@.6%?('[.'@;Q9^T/X0LO'_ ,1]4U*&]URV@N+73-%U74=*
ML;*SPQ@*)87P>:6Y5Q<S2W,DDBB2.W"0B JW0> /A#XX^%WQWB=/$&MZKX5N
MO#>H+#!J5[<7BVEZFK6\P1G9 &S#<E+22YDN+UHHIXS*884 ]?M?VH/AS<ZI
MI]@;ZYB_M.Y6SL;JXTW48+&[FD1WB2VU":V2RG\Y49K9HIG6Y&WR3)O3<>.O
MVH/AS\-/$]OX:UV^N;/4+O>+6.33=1*731Q+*8[6=;8PW,N'1%AMWDE>=TME
M1KAUB-"/]K/X9O?2Z;)>7T.HI%%,FG7&CZM!J$\<K2*'M;":T2[NT7RI#*UK
M%,(4C=Y"B*6J_IW[4_PHO+>^FN?$%MIGV"YAL[J/6A)I$T,T\!N(4>'4DMI5
M\V(-)"Q3;*J2%"WER;<"U_;0^"MW;Z?>)XFMA9:AM6&^=)TL5E:![@6\]ZT8
MM;:[\M"YL[F6*Z4%08070-Z_XZ^)V@?#K[.NHM<O+<[S%;V-E>:A<.L>WS)!
M;V4,\WE1EXUDF*>5&\L2,ZO+&K<_XC^._@SPMX0'BV[N+EM+_>>9-;Z??W+0
M>2)#-]IAMX))K;R##(ES]HCB^S2HT,WERC97 )^V3\)9-+MM8&IW/]EW/V;9
MJ9TK5!IH^TND:>9J!M?L<6))%BF\V9/L\P>&;RI8Y$7?U_\ :@^'/ACXAVGP
M_O;ZY37[SRS;VBZ;J,GFK(I82)+';-"T2A7,DPD\J'RY?,=/*DV]A)\8?#4/
MC6+P<_VY=4FBEFC4Z9J(MWCACC>1UO/L_P!D9$\Z)'83$+-)' 2)G6,^H5X?
MH?[17@;Q'K-AI5I-?-)J,KQ64[Z5J<=G=,D$MSFWOI+5;.9&AADFBDBF9)HU
MWQLZD$GC_P#:-^'WPTFO8=3OY7DTZ(S7Z6%E>ZBUC'Y0F#WHL(+@V:-&3)&U
MSY0E17="RQN5[#Q3\5?"'@OPA-XOU+5;:+18K9;PWHD$D+0R &-XVCW>;YNY
M1"L>]IF=%C#LZ@\?X;_:*\#>*K[4-.M9KY+ZPL?[2EL;K2M3M+QK7<Z>=!:7
M-K%<7*;T,?\ H\<I\PI'C?(BMR&H_MD_"72_ ECXZEU.Y;0+[SO*OXM*U26%
M?)N!:MYQCM6-OF8^7']H$7FMGR]^#77^-?VE_A-\.-931=>\5Z187S2B)K>X
MO8$DB9H&N%,ZE\P(T:Y62;RT8M&@8O+$K^0:S\9_A=\?H?!=UHWQ$BTJ.75X
M-3MX(KS[!=:K'!+=6:V9@N&AG>WFNUVR(8G$X@:)%#,LL?0?'#]J/3O@W\0?
M!_A.6TOII-<EO)9WM],OKP+:VME<.1!]E1WDN#<"WW1Q1SF*W\R2985>"1N@
M\-ZKX5\5?&'4+_3?'$5[<VFD?V9+X=M=1ADCMY(+UVN;R>U25V%P&>&VWE(S
M"%>-VD,J+%O^/_VC?A]\-)KV'4[^5Y-.B,U^EA97NHM8Q^4)@]Z+""X-FC1D
MR1M<^4)45W0LL;E>PU_XI>&/#FAVFM2W?VBTO?+^R-8Q2WSW7FQF5/LL-FDT
MMSF)6F_<))B!))SB*-W4^'OQ.T#XH6]Y-I#7/^A7/V.XCO+*\L9HIO(BN CP
MWL,$HS%/%(K;-K*X()YP?%+XI>&/@MX8N_$WB:[^QZ;9^5Y\_E2R[/-E2%/D
MA220Y>1%^53C.3A02/,-:_:S^&?A[P[X?\07=Y?+8^(I5ATR1='U:1KF1S^Z
M18TM&E5YA\ULKJIN4!DA$B L-_7?C)X&OM9TCP;?75]:WWB>QGEL8C:ZG922
MQ+ \DP6X$41MKB*,%GC:2&ZMR8R5C=X]WPA^R;\>_"GPCM_BA#XAU'4KC^S_
M !OKIDD\C5=9FM[&S@MK>"2\FBCNY8HEBMVCBFNW42+;RA7?R)=GU!XK^*GP
MT^-'_"$RZ7\1;;3%GU*RUBV@M-1BM;C585\^".R:)Y(Y6BEN<)/"T3LSP26I
MC2;+1>7_ !RL&T7]J/X1O!=WWEZG+XDFN;>2^NY+4R6>B^5 \=K)*UO"ZI-*
M"T,<9<R.SEF8D_7_ (U^,GA+P!?)IU]=2RWSQ"<6-A:W6H7GD%F07!M+&*XN
M%M]ZF,W#1B$2;8S('95/0> /'_AWXI^';+Q#X>O8K[3KZ(2P3Q$[67)!!! 9
M75@4DC<*\;JT;JKJRC/^*OQ(TOX/^$-5\4:I%<RVFF6TEU,EG \\S+&,D(B_
M^/.Y2*-<R2R1Q(\B_F!^UO\ $N7XT_L;3^.EDU*PU(:;IBS+;MJVEV[OJ4M@
MEX@@D>*.^M'29XXI)!=0%&?RI68R,?O"+]K;X5OXBTK09-5E@N=9E>+37N;"
M_M[6^90"#:7LUNEI<H^Y/)DAF=)S+$(F<S1;]_Q_^T;\/OAI->PZG?RO)IT1
MFOTL+*]U%K&/RA,'O1807!LT:,F2-KGRA*BNZ%EC<K[!I.K6.OV-O?6-Q%<V
MUS$DT,T+K)')'(H9'1U)5D92&5E)# @@D&N?\?\ C_P[\+/#M[XA\0WL5CIU
MC$99YY2=JKD    LSLQ"1QH&>1V6-%9V53^<'CCQ_H7BO]J/X5G1KW5T:[E\
M03WVGZD=7M%#0:*T-I<)IFHB)84*O<HEQ!!&D[BY'F22I-M^_P#QK\8?#7@&
M^2QO?MT]RT0F,.FZ9J.IR1QLS*CS)I]O<-"DC)(L33!!,8IA&7,,FW@/$G[6
MWPK\*^"M/\:W6JROH5_%YL6H6MA?W=NJ^8D6)WMK>46S^8XB\NX\I_.#Q;?,
MC=5OVO[4'PYN=4T^P-]<Q?VG<K9V-U<:;J,%C=S2([Q);:A-;)93^<J,ULT4
MSK<C;Y)DWIN] \=?$[0/AU]G746N7EN=YBM[&RO-0N'6/;YD@M[*&>;RHR\:
MR3%/*C>6)&=7EC5N/TS]I3X7:CX=;Q _B*QL[%+Z;3))-2E_L]HKR$MYEK-'
M>B"6&X4(S>3*J2%,2!2A#'/^&G[4_P */C)KD>B>%O$%MJ=[)IJZMY5L)'V6
MS2)'F5MFR*4-(@>VE9+F/<"\*CFO8/%/BS0_ VES:IK=_;:?90;?-N;R:."%
M-[A%WR2,J+N9E5<D99@HY(%>/_ 0:'X#^%&G.WC'_A)+*RMIY;C7[R^CN%GV
M22/<3/<^9(BQ1-YB*&D?R(HQ&TC&-G/0>#OCIX4\<ZXNB68U*"]>VFO$BU'1
M]5T[?#!)#'*\;7UI;H^QKB$,J,S#S%.,<U[!7C__  O?P9_;G]D?:+G?]I^Q
M?:?[/O\ [!]H\SR?(_M'R/L/F^=_HWE^?O\ M?\ HF/M/[JL_P 6?M&_#[P3
MX]TSP)J-_*NNZK$DUI9Q65[.TD;O*@<O!!)$B*893(TCJ(D1I'*QC=1X;_:*
M\#>+O&NH>#=/FOI=6TV7RKR(Z5J:1V[&-Y$,MP]JMO&DJ1LUO(T@2X&TPM)N
M7<>$_P!HWX?>-O#NIZ]IU_*UII5\^F7?FV5[!/'>(8E-J+:>".X>X9YHHHX8
MXVDEF=8$5ICLKH/#?QD\)>)K'4+Q+J6SCTZ+S[L:I:W6ER00%787$D6H16TJ
MVY$<NVX*^2QAF42%H90GF"?MI_ VYU2VTNV\7Z;=7=UJ5MI,$-G+]J:2YND1
MH@@@$F8CYBHUR/\ 1DES"\RRJR+O^*?VH_AAX-N)H[_5\16]RME=7D-K=W%C
M:7#3B#R+R_@ADL[259&19([F:)X@Z-($1T9OH"N?\4^*=+\%Z7-J6I3>5;Q;
M02%>1F:1Q'''''&&DEEE=ECAAC5Y9I72*-'D=5/G_@7X[^#/B)KEQH6GW%S%
MJ5O;)>O9ZCI]_IMP;>21HA/'#?P6\DL0=2C21JZ(Y56*LZ!OS@U;7_ /[9'Q
M7\?^#O&FDZE<:?;VWA_3=%D70]82YL7NHY[BXNF:6T<Z;+)-)$&FN$MH+FVM
MH!*L]O$Y;];])TR'1;&WLX6E:.")(D,TTL\A5%"@O+,SRR.0/FDD9G<Y9F9B
M2?G#3OVQ?A;J^J7VD6UUJ4NI6'DFYT]="ULWT2S(721K/[#]I\K&W=,(S%&9
M8%=U:XA$FAIG[6?PSUZ%GTR\OM0DCEFAN+>PT?5KNZM)(96B9+VUM[22XLG+
MHXC6[CA,H1VC#JC$=?:_'OP)J/A#3_%EEJ/VW3=3VBR>R@N+N:X8AV,<-K;Q
MR7,DJ".5IH5B,L"PSM*D:PRE.@T#XG:!XGT.[UBR:Y>*S\P7$+65Y'>1-'&)
M3&]C)"MXLK1LDD<)A\V:.2*2-'26,MXA^S)^U-HWQ^^'UQXNN%ETZVAEU"9Y
M;RTGL[>.SBO;I+=S<S9MI72V@5KQK>>6.&;>&,0*H._\-_M&_#[Q9XBM-!L[
M^47=]%/-8^?97MM!?1VX1I'L+FX@CM[U CK*&M))@\)\]2T.7K@/$G[=/[/_
M (4ANY;KQOI#K:102R"UN!=L5GE>)!$MKYK3.&0F6.$.\"%995CB=';H/#>J
M^%?%7QAU"_TWQQ%>W-II']F2^';7489([>2"]=KF\GM4E=A<!GAMMY2,PA7C
M=I#*BQ=?XI^._@SP;JDVGW]Q<AK?;]JFAT^_N+2TW()/],O(()+6TVQLD\GV
MF6+RK=TN)-D+I(WRA^W=8-IVK?#/4[>[OHI+KQWX:TZ>*.^NUM9;<7$UT%DL
MQ*+5W$T4;B5HC,#&@W[54#]#Z^?_ !U^U!\.?AIXGM_#6NWUS9ZA=[Q:QR:;
MJ)2Z:.)93':SK;&&YEPZ(L-N\DKSNELJ-<.L1Z#P+\=_!GQ$URXT+3[BYBU*
MWMDO7L]1T^_TVX-O)(T0GCAOX+>26(.I1I(U=$<JK%6= W/^*?VH/ASX*N)D
MU2^N8+>"Y6SFOSINHMIL4S3BW*2:DMLUBFR9O(F9YPL$P>*4I(CJNA\5?VC?
MA]\$+ZQM?%=_+IJWTL,,-S-97OV/S)F=41[U8&M(G_=NS++*A2-3*X6+YZS[
M']J#X<W.J)IMW?7.EW$EM=7D8UK3=1TA9(;-%DN7CDU*VM8Y/)1A)*J,S)$&
ME8"-&9<"Z_;0^"L5OJ$]MXFMM073=S78TI)]2:*)($G>X9+&.=_LD:NHEO #
M:Q2GR'F68&,=?XU_:1^&W@#P4GC6^UF*70GE$0U"PCFU"WW&1H@2]C'<!4\Q
M3$9&P@FVQ%A(RJ=#4?COX,TCQW8^"+NXN8-7U#SOLD4NGWZ0W'D6XN9?)NV@
M%K+Y<9!DV2ML8B-L2?)7P!\.OBQX,_9F^,7QCN/%>O7-OI&F_P#"(V5K)J=[
M?ZE,OVBQNKCR(FG>ZNI<R333>6F_8IEDPL:.5^@/BY\6/!G[0'[/GB?Q=X+U
MZYFBT[3=5N[:ZTR]O].FAO+*RF9%E$+VTPVDK)Y%POER*8I3&Z&-CQ^F:KX5
ME_9C\"Z#K/CB+P;)J7A_P^8KX:C#871CM8K&:X6UDDEB(=XQY+.-XC$P9XY%
M/EO]O^/_ !_X=^%GAV]\0^(;V*QTZQB,L\\I.U5R    69V8A(XT#/([+&BL
M[*IX_P "_'?P9\1-<N-"T^XN8M2M[9+U[/4=/O\ 3;@V\DC1">.&_@MY)8@Z
ME&DC5T1RJL59T#>@>*?%FA^!M+FU36[^VT^R@V^;<WDT<$*;W"+ODD947<S*
MJY(RS!1R0*^</AUXX\)? 3X-:7?ZCXKOO%.G6L4WGZ]&EUK#3,K32W$TCV*7
M;);Q,DJ!Y&9+=(TA>9G4%M!/VR?A+)I=MK U.Y_LNY^S;-3.E:H--'VETC3S
M-0-K]CBQ)(L4WFS)]GF#PS>5+'(B^/\ [=WQN3P!9^%?#GV>YEBUSQ)HEGJ(
M73=0N(I--DN7DN+=)((FAFEG%OY$ECF::XM994^RND@8>@?";PS\)?V<-#U/
M7O#UOJ6G6/B/4C<KIS66J!Q<",QO%8Z.T N8\B"6X=(K8OY"M)D6-O (/7_!
M_P >_ GCBWUB:TU'R/[#P=2CU&"XTZ:S5H!<+)<0WT=O+%$T69$F=!$ZJY5S
ML?;YAJ?[<WP'TZ98$\6V-Y.]]#IT<&F^;J$\MQ-$LL:PPV4<\LR,'5/-B5X1
M-FW+B<&,:&@?MB_"WQ9]K72;K4KZ6RN9+.[M[30M;N+BUFBQN2YMXK%IK?))
M5&F1%D>.9$+/!,L9_P -D_"6?0_[=L]3N;_35MOM<MYINE:I?V]N@C\UENIK
M.UFCM98TP\T%PT4\*,K21HK*3Z?XD^,GA+PS8Z?>/=2WD>HQ>?:#2[6ZU22>
M *C&XCBT^*YE:W DBW7 7R5,T*F0--$'S_%GQQ\,>$_AY?\ CHFYN]-L;::Y
MD6TMI9+C]PS)+$T!59(I8G5HYTG$7V5TD^TF!8I63Y@U#XX>&/CI\#=&EU_Q
ME_P@U[KMMILTMV9)=$FWQ?8[R]737OV@>2)E<P)=0M<0!90=UP R/]O^*?%.
ME^"]+FU+4IO*MXMH)"O(S-(XCCCCCC#22RRNRQPPQJ\LTKI%&CR.JGS_ ,"_
M'?P9\1-<N-"T^XN8M2M[9+U[/4=/O]-N#;R2-$)XX;^"WDEB#J4:2-71'*JQ
M5G0-P&G?MB_"W5]4OM(MKK4I=2L/)-SIZZ%K9OHEF0NDC6?V'[3Y6-NZ81F*
M,RP*[JUQ")/7_AO\4O#'Q;TN74= N_M$4%S/93J\4L$T%Q;OLE@G@G2.:"5#
M@F.9$?:ROC8ZL?0**^ /^"E\^H>&O@3K7B;2=3U+3=2TO[)]FGT[4;VSQ]IU
M"TAE\Q+::..;*$JOG+)Y>YBFQF)/U_\ \*TTC_A&/^$<\_4OLG_/3^UM3^V?
MZWSO^/\ ^T_;?O<?Z_\ U?[G_5?)7R!_P30GU#Q+\"=%\3:MJ>I:EJ6J?:_M
M,^HZC>WF?LVH7<,7EI<S21PX0!6\E8_,VJ7WLH(]_M?VH/AS<ZII]@;ZYB_M
M.Y6SL;JXTW48+&[FD1WB2VU":V2RG\Y49K9HIG6Y&WR3)O3=H>+/VC?A]X)\
M>Z9X$U&_E77=5B2:TLXK*]G:2-WE0.7@@DB1%,,ID:1U$2(TCE8QNH\-_M%>
M!O%WC74/!NGS7TNK:;+Y5Y$=*U-([=C&\B&6X>U6WC25(V:WD:0)<#:86DW+
MN/"?[2/PV\8^'=3\0V^LQ6VG:3?/IM]/J4<VFK;749B#0S"_CMVC<--&GS #
M>PCSO!4'AO\ :*\#>*K[4-.M9KY+ZPL?[2EL;K2M3M+QK7<Z>=!:7-K%<7*;
MT,?^CQRGS"D>-\B*Q\//VBO WQ5L=:O-!FOKF/0Y9(+X'2M3ADCGB5FDMUBF
MM8Y9KA OSV\*R3(6C4QAI(PQIG[1OP^U/PZVO?;Y;>T^W3:9']MLKVSGGO(2
MRO:VUM=017%S<;TDB6&WCDDDFCD@16FC=%-"_:1^&VO6.KWAUF*QCT66"+41
MJT<VE26C7*HT!GBU&.VEB28.ODR.H24Y5&9E8# \*?M>_!KQWXBTWP]HGBBQ
MU#4=2EOHK:"T9IV9K .9RYC5EB3;&[PR2E$N4'F0-*A#'Z/HHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHK\@/V:?^4>=]_V+?BS_ -':E1^TM_RCSL?^
MQ;\)_P#H[3:]0\#BY\=?M+_%32(/%NKZ-?6D7A\QQ6L^ES++9C3E?;%;:AI]
MX\26]Q<2R2O"ZQL]\N^-7P\ON'[(/P4\#_LX:?X@\$^$IM2NK>RU))[NXU%[
M=L7EU96TC6\9BC@8^7;BUF8F+R_])55FDD6:. _;X^&FN?%WX ^+-"T2/SKV
M2VAN8H@LC-+]BNH;QHHUC1W>618&2% OSRLBDJ"6!^P3\2]#^*'P$\(W&ER;
MOL&FVNDW,;-&7BN+"%+>175'?9NV":,-M=H)8I"J[P!Q_P#P4FU:^A_9[\66
M.DW$JZC-8I,(;9V%P]G#?6BW[A(SO:W2"8K=-@QK#)B4A'YZ#]KW5O!7Q/\
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M\U5_[*3XC_\ ;:OD#]C;6?#%G\,/@E9?V;Y_BR[_ .$N3P_>SM+]CLMMW/\
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M2W_*/.Q_[%OPG_Z.TVO</VR/'ECX%^*GPAG\2R10>%UU?4YKV>ZMU>UBU!+
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MX3C_ (0K[7_Q.O[-_M?[-Y4O_'G]H^S>;YNSRO\ 6_)LW^9_%LV\UZ!17/\
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MQUB]2TU&TO;B2YCMM0NY[AVN(;JV6W?:)$B@$-P&,2.UR@N&2V_6[X3^.O\
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M3?%=]#<JTEF^H))=+)8A)I&WO<726^J7$L6$6.U@L)H6MKB//8?L6_!SQ?\
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M6/1]6TBQDE^V++J'V^1[>2PGM'_>WG[YY;JY$5M"_G2_Z(_[/5\X?M+>)8=
MTG1;?4/#,OB/1]1U>&RU:UBTJ75FCM3;W$J7)MHU?*0W45JTC%)2J;O+C:<Q
M"OC_ .%_[-MW>7WC'P[X+O=7TKX>ZOX6GTF&QUF'4E-IJUVTJ226-IJD<-TM
MND,C3SGS$BN+BY*K)(8BMIZA\"_BEXL^$'PTM?!7B#PUJ4_B;P];'2+6*RTW
M46TW4?LL033Y(=32"XM88KB/R4FGNG@^SS>>TT,")M'A_P /OV9/%7[%FO>
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M11111117A]G\6)OB9\-M4\2^ 8XM0N1%J\6F+*\1@NKJPFN+6(B1)@C6\\\
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M/[/^+'_"3_\ "#Z]_P (M_R&O[-O?[._U7_'Y]G?[/\ Z_\ =?ZW9_K?W?\
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M<VFPKH=M>6NBZ3ICW%PMN][' EQ>RWTL=F\TLBK+#]G:V\B.(Q.I\X.[>/\
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M)?!,44.DZ[8VK(JQHD<#I-927,B2I-;Q1I.K2X=U)P+>26UD]O\ A+\&]?\
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M+.ZTVW2:ZB,$L]Q%)J%\+F5(2\-L28U@2>YRLCR(T/@'PW_8Q\9_!G5)=/\
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MUDF1/+E*.QW[5;RY-GJ%>7WOQO\ AUIWAVV\1W'B72(M)NI3#!?R:A:K:RR
MN"D<YD$3N#%("JL2#&_'RMCL/"?BG2_'.AV&MZ7-Y]EJ%M#>6TNUTWPSQK)&
M^UPKKN5@=K*K#." <BN@HHKR_P"*'QK\!?!6Q%YXLURQTJ-HIY8Q=3HDDRP*
M&D$$6?-G=0R_NX5=R610I9E!]0HHHHKR^]^-?@*P\6VWA%]<L3K=S*8DTZ.=
M)+H,+5[S,D*%GB3R(VD$DH1""BABTD:MZA1111111111111111117C_@_P"
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MTL6TFW\+2:D5?4+J%GCNM2M8);F2-;:6)[B P/':V^%!225VOH_/,,?8:O\
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MUB+@WJK8I$+A+ZUDCB1[FW>!HW8"%+B%W$,L",T1EY__ (:6\>Z/#X=U?7O
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M2ZTCPUIMI:6[VZW%U=7MO;010P"YFMXF?+&1MTBA88Y)"=J-6AX>_:EN-/\
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M?%,FOVVGZ@L5O=0K>ZM:RPVSHLLFZX^RVOVF6,$/"#+&Z P.Q]__ &Y_C?\
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MWNK7\]_IMYIUF7N&MKR1FNEMYH?)VH;EI(KEI)X9+<+Y<W'_ +(?@&7XI?\
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M"-R-I_.#X8?LX?&'X>?LUWGPG>T\/SW,ECJ.FQW@U>]6,QZF;UY)F3^R2RO
MT\2I$"PG'F,9H"BK)T&A_LH^,O"ECX \4:3-8V_C#PII%KX?NH3?7ATS5--A
M4PM!+(MNDL;@$W=O)]FD6*ZVI+%=)'%-'] >&_AAXB\5>/;3QOXRAL8+G2[&
M>PTNPLIA?06[7;HUW>_:I[&SG%Q,D<5LL:J$AACE(>0W;K%X_P#LZ_"KXP_!
M&'QF;C3/#]U)KWB#4?$4"QZU>HJ27\MN#:R,=')"1QI(XN%5B[A(_LZ*[2Q_
M&'C?X*>./@!\%?@]X*U2;35U+3_B3I26US;/<7ENWVB>^N8Y98GCL9/D>8H\
M*N-Z1AA.C2$1?H>_PP\>_%?QKHVK>.8=(L])\/RB_L=,T^9]2-QJ1CFA2[N;
MB[L;0QI:QREK6&"/=]H?[0\_[F*.N?B^ _Q%\$_%SQ5XP\+:KI'V;Q;%8"[7
M4K2ZDDL)-,MHX+=H8X+B);Q)E,ZRH\MD82\,JR3")X9O'[+]ASQ4G[)ES\&[
MC6[%[YHA)!<QVTR0))]M343!(QD=Y$-P)(A<K'$1"R/]D+QLLGT!XR^'/CWX
M\PV>B>,M/TC3M$BOK6_O(;'4'U1M06SE$\5E-%>:3:)';O.L4L\BL[ND)M@@
M6X>6/C_^%3?%/_AHO_A8WV'1/[-_L3_A&_*_M6[^T?9_[3^V?;-O]E^7YNSC
M[)YFS?Q]KV_-1\$OA-\4_!OQB\9>,=;L=$CLO%?]E>;'9ZK=SS6G]F6,ENNQ
M9-+MTN/.9E+9>#RER1YI #>7_#+]FCX^_LTZM=:)\/?$'A^X\'W=\UU#:Z[!
MJ,L^DQS7$C2062PSYG18V1OWUS&)I@S;('DFEE_0_P +:!_PC&EPV1N[F\9-
MS/<7DGF32O(YD=W("HNYF8K'$D<$*XBABBA2.-?D#X)?";XI^#?C%XR\8ZW8
MZ)'9>*_[*\V.SU6[GFM/[,L9+==BR:7;I<><S*6R\'E+DCS2 &S_ -G7X5?&
M'X(P^,S<:9X?NI->\0:CXB@6/6KU%22_EMP;61CHY(2.-)'%PJL7<)']G17:
M6/C_ (:?LV?%/X=_LNS_  J\G1+C4I;;5M,^T?VE=QVXM]2%S)]HS_9K2&6-
M[C9]GV!'1/,^THS>6O83?LHZM\3_ (%:)X!\631:3JGAZ+3QI>I:)?7$[076
MFVB0V]\"]O9,KEC(&M_F"HV4N5FV2P]AKGPT^)?QSTO2]!^(%IHEGIL%S97V
MI+I5W+?KJ;63K,MHUM?:;$MO:2W"1S2D33R^5#]D^99WG3G_ ()?";XI^#?C
M%XR\8ZW8Z)'9>*_[*\V.SU6[GFM/[,L9+==BR:7;I<><S*6R\'E+DCS2 &/^
M%3?%/_AHO_A8WV'1/[-_L3_A&_*_M6[^T?9_[3^V?;-O]E^7YNSC[)YFS?Q]
MKV_-6?\ "GX5?&'P/\5/'/C2\TSP^T?BF+32+>+6KUFMY-+L);>)2[:.@D2>
M1D\Q\(;="S+'<,H1OG^V_8N^,-_8ZDDT_A^QN1X[N/B'82)=7M]&;S;^XTZX
MC-G9,MN6.9;R.1I !M6T);<OTAIOP+^*:_&^S^)-YJ&B-Y^B-H=U:Q07:_8[
M<7\5^%A=I&^WRMB:V-PXTY$S'=_9'VM9L?"OX._%/X$ZIXP71(]$U&RUOQ)?
M^)(FO+R[M9F^WI"K6;I'9W"6_DLK2+=AKKSEB$)M(3<&>UX_X%?L?ZM:_L]R
M?!SXBPV,EBL4L:76D:A</)(TM]-?"3;-9VX@>WD:(QC=<I,5/F($S&_8?\*G
M^,_BSX>?\*X\27NFFREMO[*N_$%I?7,FHW-BK>6[-8WEC-$MW=VR^1/*U[*(
M9II+J/S"B0L?&/X%^.-0^)_P]\2>#M/T1=-\&VVIQ1VES?7%AO\ M]H+-88D
MM].NHX8H$C1D(W;\F(1Q*@=]#3/A#\19?VD6^(MY;:1%I/\ PC\WAT)%J-U+
M=&,7[7L5T8VT^*(.Y"1R6_G$1AF=;B7:$?W_ .$,?Q%3PZA\?2Z0^K-+(671
M(KI+5(\XC4-=2/+(Y +LY6( MY8C/E^;)ZA1111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111111111111111111111111111111111117SA\=/V;[3X
M]7VCW%]XAU>PCT:^M=4M(+ ::(TOK1I#%<DW-C<RLX$A4QLYMV"KF'=N9O?]
M)LIM.L;>WFN9;J2*)(WGF$0DE95 ,CB%(H@[D;F$:1H"3M15PHT*********
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M**********************************\/\?>/YKKQ59> ]%O8K;5K^QN-
M2FGS%))9V%O-# \T<+!PUQ+).L=IYR?9@4N)W$_V7[%=?.$7CS7_  ;^U/>Z
M)K'B:YET"#P1>:^8KYK."WM&DU>.-R6@@MPT4$,&(Y+III8D:4F;]Y(6^O\
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MX<L_$ND3ZLLLT)L(M0M7NA) &,J&!9#*'C".9%VY0*VX#:<:'CKXL>!_A?\
M9_\ A)M>TW2/M._R/[1O;>U\WR]N_P OSG3?MWINVYV[ESC(SV&DZM8Z_8V]
M]8W$5S;7,230S0NLD<D<BAD='4E61E(964D,"""0:\O\4_M _#3P7I<VI:EX
MDTV*WBTU=8)%U%(S6,CB..YCCC9I)8I798X7C5Q-*Z11[Y'52? ?XS:'\>_
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MXL>!_A?]G_X2;7M-TC[3O\C^T;VWM?-\O;O\OSG3?MWINVYV[ESC(R:_\6/
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MW=KJ"S']V6EC>5+>VM9+6%?0/^%L>!_^$G_X1;^WM-_MK_H'?;;?[9_JO/\
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M/,\EWV;MC;=V-VUL9P<'_"V/ _\ PD__  BW]O:;_;7_ $#OMMO]L_U7G_\
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M@R6_$T(@D%T]K*TX>(*@C<2%MT850ARNU<8'ZGU\ ?M#_P#)SOP0_P"YN_\
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MU6&2[N4"6+-'V'[&'C6Q^(OPVCUK9+%JUU?7KZY#<A5N8-5$Q6YMYDW/+&D
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MF6DV@175G;MJ&JO!?S0BVO-/E@N'$=NB[3(CQO=9$;.WG>H?LO\ P,N/V?\
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M_C'Q!I,FN2VTUU:VITN:U$EM:QVBO%%?:==F-VCB02LK R%5W$K'&J>O^ /
M'AWX6>';+P]X>LHK'3K&(1001 [57)))))9G9B7DD<L\CLTCLSLS'R_]HO\
M9[T_]I;PP_AG5M8U*QTV?'VF#3OL2_:-DL4T7F/<VES(OEO$&7R6BW98/O7
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MMZ!( RS>:LLZR_3^DZ38Z!8V]C8V\5M;6T20PPPHL<<<<:A41$4!515 554
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M]CX4N]7\C4-0N9K*T\VUNTMKBX@(66"&]:$6<LL<A$$D:3,Z7)%JP%Q^ZKZ
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MA515!9F8@* 22 *\?^'/[1OP^^*OB+4?#FCW\O\ :VFQ1S75A>V5[I]U''*
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M5[/2X+R74KBWOG6XU>/2#<"Q.FN@03N9(T>Z1WMPK.(96:%/L^OF!_C=XO\
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MHT.GO')IL*^;JQWI;R>;>!UN%@#R#Y/LK/LB:[C#-)'T#_M(ZSX1\:Z-X?\
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M!T5SX<M-(T"WN9HM7C74([>2W@M_M7V,VQ@9&<J8(EO3,Z2PF9+8F=;?[?\
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M.O%.E_#3]L*WUO79OL=E=_#][&UED5S]JNX];60VEJJ@O<W>UT*VMNLEP^]
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M.#YOE[O+P=V,5G_L,?&_X=:+#\4YKSQ+I$$;>.]>U,/+J%JBFSGEM(8KH%I
M#;R2.D<<W^K=V5%8LP!\0^".H^$-7_X)X7$.L6-SK=I96VI+=V>E3 7,4RZM
M+<Q,S*'\CR=\%Y*TB2+';#SG@FB/ER>O_ KX^?!WXU_$/PW=Z[\1M-\0:_H-
MM<6^D,FDWV@>9-J"P6EQ)*+N9X;J[F 1(8+<0JOF3LMM)B-K;]/_ !3XLT/P
M-I<VJ:W?VVGV4&WS;F\FC@A3>X1=\DC*B[F957)&68*.2!7XX_LU_$+PJG[
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MLVG6-Q<0VTMU)%$\B00F(22LJDB-#,\40=R-JF1XT!(W.JY8?$'[%OA/QSX
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MMK629 X5D8H60!@K*2,X8'D?*'@_]G#PA^T)\&-'US4K*VC\4ZYHEAJ9\0B
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M#'+FWNO.\^ [U.8IO+C\V,_))L3<#M7&?^TUX \.ZM\?/@=X=ELHETM8O%,
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MVHV/PRMX;F6UDE^(GA^-)X1$9(F9;H"1!,DL1="=RB1)$) W(RY4^/\ QJ^
M?AK]DGXH_#SQ[X$26SN=:\4Q>']8CN+O4;PZA'K6=\L\EQ>.Q>%HGF4$,)+A
MXYI-Q@56\PT&ZM_AW>V>D_'KP_;:/XA36]/U"V\>26<%[!J4T.N_:TMS>PP1
MM8;[>W^SP1S2(L%@C-)%;0Q1V\GT?K<6O?&SXX>.M(N-#\/^);'P[%HEG!I>
MMZA?V\%L;BS>]-Z;4Z=J-C-<3M<20+<*([B&&V\K"I,S3>0:5;_%']EKX-:#
M\,/$WB:*YU;6?%.C^';>ZT>]S=:7H^J-M5HVN+590^+2^@M79/W(93#+_HBQ
M)W_[47P7\%? F'X7P^#-,BT6.?QWX9TZZ2P:2!;RWCE>:-;T(P%Z\<EO')'+
M=^=-&^]U=6EE+]!\#OA[X5U_]H3X[:+?:38W.G7,OA2::TFMH9+>222QFN7=
MXF4HSM.3,S,I+3$R$ESNKP#X-^/]6^&?_!/*UU72KV+3[DQ75DMY*;@+:K?^
M(9;*2Y!M09U>!)VEC:)7=716$<A'EMZ_XC_9P^(OAOQ[X5\<Z+:>%O!=IH4M
MQ+X@NX-7NKJ?4]/E>WDN_M]Q<:3;&X<1P2R&>\ED<S/]I,T<R>=6?\"?V?OA
MIJ_[1/QATBY\-Z;+IMA_PBYMM/:UB-C$TVF2.\BV>W[-YN=VV8QF6,2SJCJM
MQ,)/E#XH:38R?LJ?&FQ:WB-MH7Q$OX=*A**8[",:I8*$M$QMMT"W$ZA80@Q-
M,,8D?=]W_MH^$]#\#:7\)-+T2PMM/LH/B3X>\JVLX8X(4WO=NVR.-51=S,S-
M@#+,6/))K/\ ^"EG[/MCXW\%0_$+3]*L;S6_!\L6I[+N%9([S3[60S7-G<AI
M85DMU7=<%&WN1'+#"JM=.3ZAI%EX'_:6^)?A7Q5_8MM*NG>&[+Q!')?6EO\
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MU35[NVL?'>LZ;;/)J^I?:H;6T-J888[U;@7:HN.<3 N&<.6$C[O/_P#@F_\
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M$*M)+':M"+AS-.\%I D?GQDM=3P!RRQ1F29DC;S#PE^V!\-/$GACQ%KUY?\
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MW;:%?2V*>'Y-1FEBDT[;(;B_M8([LB:>.5+>T"W$<BHQN)GE8K92)%#,_0?
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MJ,02HDD (#MGU#PMX3T/P-I<.EZ)86VGV4&[RK:SAC@A3>Y=MD<:JB[F9F;
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M'0211R!6R \:/C<JD=!9?!#X=:=X=N?#EOX:TB+2;J433V$>GVJVLL@*$/)
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MT:--B,43:HVH2HPI(KL-)TFQT"QM[&QMXK:VMHDAAAA18XXXXU"HB(H"JBJ
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M60QQF++_ $?16?'JUC-?2V*7$37,,44TD(=3(D<S2+&[)G<J.T,JHQ #&.0
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MUNQOH-'BFAM[IUCBO;26TM; F6&;9&;>03)<+/R;?RS.GW_7YP?M3V&OZO\
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M&X\4>([Z7Q!?F!YH;6?4)M1AOIHK<W#R%$6.%;2W+F-)#''++Y)DE9>@^/\
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MZXEQ-.@</=I96]I'(\'GK&UOYCWL4]FMRMQ!+/-!S]OU\ ?\(_X^_P"&I_\
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MHFFO?R0RQ*[137C>3'ODE5DM5=;,^5+(D3P/;$QRPR0Q?1_[0_\ R<[\$/\
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M-3U:^UK_ ()EK->7$L\BQ0PAY79V$<'B=88D!8DA(XT2.->B(JHH"J /M_\
M;DTFQT"Q^$=C8V\5M;6WQ$\,0PPPHL<<<<:W"HB(H"JBJ JJH 4    5S_[3
MF@S?L^?&WPE\9=,CBCL=0EB\+^)RWE0QK:W<B+;7T\IMV$:02*GGSRRH6$-E
M:JR([FOJ_P" _P#Q4W]N^,'^;^W-2E^R,?GQIUA_H-GY,Q_UEI<^3+JEOL"P
MC^TI&C\S>UQ-] 4444444444444444444444444444444444445Q_P 0O!5C
M\2O"NK>'+YY8[;5;&YL)GA*K(L=S"T+E"RNH<*Y*EE8 XRI'!\@\/_LWVEK-
MHY\0>(=7\30Z++%<V$.MC395ANH(FAANS);V-O/-<1H\@5[B68;W\\J;A(IH
M_/\ Q)^PUX*U?Q[=^,-*U?Q!X?GU&6";4K70-3DTZUU"2%W8O<K"HE+R!V61
MHI8B2SR@K/)+*_0?$O\ 9&T'XC0Z#:QZWJ^E6F@WUOJMG;V+6#J-0@EFE%[-
M+>V5W<3W#O.[3M-*Z3N3+*CS-)(YXU_96/CKQ;H7BF[\9>((]1T"*:.PDB31
M L37-K':W4A1M*97>X5-\@<,B.S>2D*;47/^,?[%OA#XM^+U\7VVK:WX:UIK
M8V=S>^'+X6$UW#F,HERWE2>9L\M0K#:Q545RZQ0B+0^*W[('A7XJ^"IO!SZI
MJ^GZ7>2^=?K;W$-Q<7TBR0/$]U>:E!?7<CQ?9XDB83*1"B0$M#'%'']'^%M&
MO/#^EPV=WJ5SJ<L>[==7BVRS2;G+#>+2"VA&T$(NR)/E4%MS[F;H*^8/^&8H
MO^%I_P#"QO\ A*M;_M+[-_9_E;=)^S_8/M?VS[%M_LWS/*W\>;YGVO9Q]IW?
M-6?<_L9_#ZXOM?83:O%IWB&6:ZU/2K?5KV"SN;NX:3S[IQ#(DX>9)6AF@29;
M.6-8M]JSPPO'GZ_^Q'\//&?PLM/AWK\NI:G867EM:SW-XPN('@M#96SQ>2L5
MNOD0$*D?D^1(X,\T4UQ)-+)T'P]_9?M_AOI=Y%;>+/$E[J5Q\D>L:K>P:E?6
ML)>)Y(+7[9;36T44IA4S 6Y:4A2[,T-L8?'[C_@G=X+OOA1'\,;G7];GT*"Y
MCNK:.4:0TULRR3RN(9_[,\Q?->X9I'),NT"%)$@>:*7U"Q_99N=)U:TU>S\>
M>*8KZ#2(-%EN#-I<[75O;W$]Q"]TESILT4MQ&9WC6XV"8IG<S/+.\OM_PW^&
MFA_"S2Y;+2X_FN;F>^O+AUC$UW>7+^9<74YC2-&EE;D[$2-%"Q11Q0QQQIZ!
M7RA\=_V.?!7QZ\16'B>XO=7T;7;"(6\&JZ)?R6ETEN!/F $B2((QN9"S+&LS
M [/,\O<C=_9?L\>"O^$"N?!>IV\NKV-]$$OY=4FDN;J^D"(GVBYN6(E>X BC
M\N52AMQ%"L'DI!"D>!X?_9OM+6;1SX@\0ZOXFAT66*YL(=;&FRK#=01-##=F
M2WL;>>:XC1Y KW$LPWOYY4W"131Y^@_LQ1>%O'?B7QCIWBK6X+WQ)L^VQA=)
M:']Q;R6]IY:OIK.OV19,PY=O,9$-Q]I&\.?##]F*+X1:7XCL]'\5:VLOB#4G
MU>XNI5TEYHKR9U:XEA']FB$>>%5)$DBEC15!A2%RS'C_  K^Q;IG@SX77/PV
MT_Q;X@CT2>*:W\L_V.TB6]S]I^TP+(VF%MD[7+.[-NF0I&(9(5WJ_83?LI>&
M]7^$$_PNUK4M2U32'MH+.%[E[6.XMX;981;)$]I;6Z-Y#0)*C3),SOD2F6,^
M77'^*/V,+3QQ8Z%;ZSXV\4WLGA^^L]0TV>:XTTR03V:D([@:>(KIR=K-+>I<
MS H=DJ+/=+.?$W]AKP5\0?$5KXCL-7\0>'=6BL5TZ:_T+4Y+>ZO+>,1B-;V>
M99Y;AT$2CS78S2 +YKR^7#Y?8?%+]DSPA\4?AY=^!I+O4K'3[^YBNKV6"Y%Q
M>7;1,C(+B[U&.]FDP8H '9O-6.WA@61;=/*.?\2_V5C\6H=!36?&7B"1M#OK
M?5+9XTT1&-];2S/#<R;=*VLZ+-Y0C 6W9$0O"TN^1^?^*W[#7@KXF>-9O&EE
MJ_B#PYK=W%Y-Y>^']3DM)+J,1P1HDN]9E"(MO'A81$&(W2"1@I7L/BS^R'\/
M/BYX8TS0[B*YL'TBY%[IVHZ?.T>HVEP91-+/'=R"61I9W!DN))O->>8_:')N
M529.O^$/P%T;X0PHZZCJ^M7RQ20G4-=U&?4+KRY)?,9$,I\J!&*Q"1;:.$3"
M"!I1*\2./<*^?_VB_P!GO3_VEO##^&=6UC4K'39\?:8-.^Q+]HV2Q31>8]S:
M7,B^6\09?):+=E@^]<!<#XG_ +,47Q=TOPY9ZQXJUMI?#^I)J]O=1+I*32WD
M+LUO+,/[-,)\@,R1I'%%&ZL3,DSA6!KW[,47BGQWX:\8ZCXJUN>]\-[_ +%&
M5TE8?W]O';W?F*FFJ[?:UCS-AU\MG<V_V8; GT_7E_QH^$/AWX]>"M3\(^($
ME:QU&)8Y##(8Y$9)%ECD1N0'CD1)%#!D8J%='0LC>(>/_P!D.+XE_P!E-JWC
M3Q)*^EZE;:S"V_2?^/\ M=RP7&QM,:--B,(_L\*Q6C[/.>W>YEGGFZ#7OV8H
MO%/COPUXQU'Q5K<][X;W_8HRNDK#^_MX[>[\Q4TU7;[6L>9L.OEL[FW^S#8$
M\_T#]@?P)X/\3W>JZ%K/B32-/N[F2\ET/2=9N-/TLS2Q"-G6*S\F9.560*DZ
MJI58U MU6$?9^DZ38Z!8V]C8V\5M;6T20PPPHL<<<<:A41$4!515 554 *
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M%X*L?B5X5U;PY?/+';:K8W-A,\)59%CN86A<H65U#A7)4LK '&5(X/D'A_\
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M_MF_%.7]DZQ^,]HNB1WJ>=]KLI;"[DAESK TZ+R774(W@V+F23?]H\UL!?*
MY^D/C1^T#\1?A_\ %3PEX+T?0-(NH_$<NH&VN+K5;J%FCT^P^T3K*D>GRBV?
MS'3RG4W@D2-E:.%I0\//Z)\9OB+X,^)/@7PI\0_#OA^35O$,6MPPZKHE[=,L
M,=I"EY*@M[NR66-)1';*RK=.)'B\U@NR.,<_KFN>/=0_;(L]%M]5L8].M/!L
ME_'#+I[R,L%SJUK#>1B1+N)OM$K6D9CN&W0PHJI]CD?S)I?8/@-\9K[QO\0?
M'7A34_#MCI&HZ#+I,UY-87K7D=Y)J-EN1R[V5DY>.""&(LZL2%5 0D2Y^/\
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M+/2?#\IL+[4]0A?4C<:D8X9GM+:WM+ZT,:6L<H6ZFGDW?:'^SI!^YEDKX_\
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M".XBO$A*^W_%C_A)_P#A!]>_X1;_ )#7]FWO]G?ZK_C\^SO]G_U_[K_6[/\
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MD^SO$MQ!XA\./"7B+X=_![XV>%I?!VKZ=)J=]XDO=/M+?3Q-&L&JV5O!IUM
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MT:2V_P!7_$*R\1:CX5U:W\.7,5KJTMC<QV$\P!CBNFA802."DH*)(59@4D!
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M)>V*64TC2I Q^T7(F@:/[+:W#">W,;LWJ'PC_9Z\<?#OXG^)/&NH>)--O?\
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M[2))?-=%6&1#<&68(2=T:#V#]@7_ )JK_P!E)\1_^VU'_!+C_DV+PC_W$_\
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MK;()8;2:(^;"U[<73&WC1Q<28DED/''PX_X1C2_'_P 4?A5K_P#H]O<^)O\
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M6FWO_(UO!<:=;7%EG.DH'BDMIKB\QLVHRS+<'S?,9#!#Y(DN/T_KX0_X*#^
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M&LVN85$+,\R+-:FX_0^OS@_M^7_AL+^W?[)UO^S?^$1_X1W[9_8>K?9_M_\
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MLY7F2XM]7:WC21EEB#P13+=O"_D2M"S"9BP>3E4D,8[#_A@7_JJOQ)_\*/\
M^YJ/^&!?^JJ_$G_PH_\ [FH_X8%_ZJK\2?\ PH__ +FH_P"&!?\ JJOQ)_\
M"C_^YJ/^&!?^JJ_$G_PH_P#[FH_X8%_ZJK\2?_"C_P#N:C_A@7_JJOQ)_P#"
MC_\ N:C_ (8%_P"JJ_$G_P */_[FH_X8%_ZJK\2?_"C_ /N:C_A@7_JJOQ)_
M\*/_ .YJ/^&!?^JJ_$G_ ,*/_P"YJ/\ A@7_ *JK\2?_  H__N:C_A@7_JJO
MQ)_\*/\ ^YJ/^&!?^JJ_$G_PH_\ [FH_X8%_ZJK\2?\ PH__ +FH_P"&!?\
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M_# O_55?B3_X4?\ ]S4?\,"_]55^)/\ X4?_ -S4?\,"_P#55?B3_P"%'_\
M<U'_  P+_P!55^)/_A1__<U'_# O_55?B3_X4?\ ]S4?\,"_]55^)/\ X4?_
M -S4?\,"_P#55?B3_P"%'_\ <U'_  P+_P!55^)/_A1__<U'_# O_55?B3_X
M4?\ ]S4?\,"_]55^)/\ X4?_ -S4?\,"_P#55?B3_P"%'_\ <U'_  P+_P!5
M5^)/_A1__<U>@?"W]D/_ (5?XGM-=_X6!XWU?[-YO^AZOK?VJSE\R)XOWL/D
M)OV[]Z?,-LBHW.,'Z_HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKY_
M^-7P5U3XFZIX>UO1_$-SH^I>'KF6ZM!Y275C*TZ+!*+RT9HVFS;F>")XYH)8
M!<RNDFXT)\(_$_BNXMIO&/B3[=%;7-M<K8:981:?8R/9SI=6TDHF>^OC+%<1
MI+F*]A@<111O;LGG^?\ 0%%%%%%%>7_&CX56/QO\%:GX4OKZ^L;;4HEAFFTZ
M98;CR_,5G179)%V2JIBE5E8/"[H1AJX#2?AO\7+JQM[+6O'D6V&) ;K1]#MK
M.\FD10I:9KZ;5+38_P SR)#:0'S-A22*)6BD]O\ "?A;2_ VAV&B:7#Y%EI]
MM#9VT6YWV0P1K'&FYRSMM50-S,S'&22<FN@HHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHKS_0/BQX'\5ZY=Z%I>O:;>:E9^9]IL[:]MY;B'RI!%)YL*
M.TB;'8(^Y1M<A3AB!6AXU^(7A7X:V*7WB/5K'2K:240I-?W,-M&TC*S! \S(
MI<JC,%!R0K'& <:'A;Q9H?CG2X=4T2_MM0LI]WE7-G-'/"^QRC;)(V9&VLK*
MV"<,I4\@BN/\%?&_X=?$J^>Q\.>)=(U6YCB,SPV&H6MS(L:LJERD,CL$#.JE
MB, LHSDC)XU^-_PZ^&M\ECXC\2Z1I5S)$)DAO]0M;:1HV9E#A)I$8H61E# 8
M)5AG(..@\2?$+PKX.OM/L=7U:QL;G4I?)LH;JYAADN9-R+L@21E:5]TB+MC#
M'+H,989S] ^+'@?Q7KEWH6EZ]IMYJ5GYGVFSMKVWEN(?*D$4GFPH[2)L=@C[
ME&UR%.&(%<?'^TW\'IK&6^3QIX?:VAEBADF&K61C2299&C1G\[:KNL,K(I(+
M".0@$(V,#XQ?M2^ OA-\+KSQ^-4L;^Q6*46)M[I'COKI?,6.U@EA$P9WDC9&
M9%D$(621P$BD*^W^%O%FA^.=+AU31+^VU"RGW>5<V<T<\+['*-LDC9D;:RLK
M8)PRE3R"*S_&OQ"\*_#6Q2^\1ZM8Z5;22B%)K^YAMHVD968('F9%+E49@H.2
M%8XP#CH-)U:QU^QM[ZQN(KFVN8DFAFA=9(Y(Y%#(Z.I*LC*0RLI(8$$$@UY_
MX*^-_P .OB5?/8^'/$ND:K<QQ&9X;#4+6YD6-652Y2&1V"!G52Q& 649R1GU
M"O+]3^-_PZT7Q$OAR\\2Z1!JS2PPBPEU"U2Z,DX4Q((&D$I>0.AC7;EPR[0=
MPST'C7XA>%?AK8I?>(]6L=*MI)1"DU_<PVT;2,K,$#S,BERJ,P4')"L<8!QX
MA\>_'CZS\&-=\7^!_$WE?V?INHZG:WNE-I]Y#.UE;3GRF:>"[B>+S4Q+Y6R4
M-'M$J?.#\?\ [0/CSQWX<_8NT?QII/B;4K+4HO#>B&>2)K>1KIM16QMY9)II
MX);E95$LCQS6\T$HE<R,[L%V_I_XI\6:'X&TN;5-;O[;3[*#;YMS>31P0IO<
M(N^21E1=S,JKDC+,%') K/TSXA>%=:\.MXCL]6L9])6*:8W\5S"]J(X"PE<S
MJQB"1E'$C;L(5;<1M./+_P!G?]H_PA^TIH$VK:!>VTOE7-U$\$4XDFCACO+B
M"UFFB98Y8/M44 N(XYHT8*Y7+["Q] T#XL>!_%>N7>A:7KVFWFI6?F?:;.VO
M;>6XA\J012>;"CM(FQV"/N4;7(4X8@5H>)/B%X5\&0W<VL:M8V,=G%!-<O=7
M,,*PQW,KPP/*9&41I+)&\<3-@2.C(I+*0,_QU\6/ _PO^S_\)-KVFZ1]IW^1
M_:-[;VOF^7MW^7YSIOV[TW;<[=RYQD9^4/\ @HYXF\6_#[X'ZYXE\-Z_?:3<
MV,4416T%KMF6]O+:U8O)+!)/&\:2.89+66W=';>68JFW[OKX _:=_:6\(>'O
MB-X/^'M_K]M86FHW-_+KD\6LC3YK.&UTYI[6&:6&2*XM?M,\MO)'(LUNTBPF
M'$L4\BU[A\(;+2?@-\-DN-<\=2ZUI8EDNX=:UN\MRHM;R;=:H;PE5E3;)&JS
M2.YE=_W?EPM#;Q>O^"OB%X5^)5B]]X<U:QU6VCE,+S6%S#<QK(JJQ0O"SJ'"
MNK%2<@,IQ@C(OQ"\*O?6=B-6L3<WTMW#:PBYA\R>2Q9ENTB3=ND>W966X5 3
M"58.%(-=A7G_ (%^+'@?XH?:/^$9U[3=7^S;//\ [.O;>Z\KS-VSS/)=]F[8
MVW=C=M;&<''8:MJUCH%C<7U]<16UM;1/---,ZQQQQQJ6=W=B%5%4%F9B H!)
M( KQ^3]IOX/0V,5\_C3P^MM-++#',=6LA&\D*QM(BOYVUG19HF=025$D9( =
M<Z&O_M"_"SPI]D_M3Q;HEG]LMH[VV^TZG:1>=;RY\N>+?*N^)]IV2+E&P<$X
M->@>*?%FA^!M+FU36[^VT^R@V^;<WDT<$*;W"+ODD947<S*JY(RS!1R0*/"W
MBS0_'.EPZIHE_;:A93[O*N;.:.>%]CE&V21LR-M965L$X92IY!%9Z_$+PJ]]
M9V(U:Q-S?2W<-K"+F'S)Y+%F6[2)-VZ1[=E9;A4!,)5@X4@UG_\ "V/ _P#P
MD_\ PBW]O:;_ &U_T#OMMO\ ;/\ 5>?_ ,>^_P W_5?O?N_ZOY_N\UG^)M"\
M:ZCXU\/7NF:O%::):1:@=4LS!'))>R21Q)9JKLFZ%(F\Z9W1U+%8XC'(LC-%
MGW7[0OPLLKC4+>;Q;HD<NF;OML;ZG:*UKLG2W;SU,N8L32)"?,VXE=8S\[ '
ML/!7Q"\*_$JQ>^\.:M8ZK;1RF%YK"YAN8UD558H7A9U#A75BI.0&4XP1GR_]
MJ34-?\/_  L\1:WH6KW.E7ND:;?:G%+;16<OF-:VDTBQ2K>6]RAB9@I?8L<O
MR@+*H+!M#]F35K[7_@]X+OKZXEN;FY\/Z3---,[2222264+.[NQ+,[,2S,Q)
M8DDDDUT'@KXW_#KXE7SV/ASQ+I&JW,<1F>&PU"UN9%C5E4N4AD=@@9U4L1@%
ME&<D9T-?^+'@?PIKEIH6J:]IMGJ5YY?V:SN;VWBN)O-D,4?E0NZR/O=2B;5.
MYP5&6!%&O_%CP/X4URTT+5->TVSU*\\O[-9W-[;Q7$WFR&*/RH7=9'WNI1-J
MG<X*C+ BL_P5\;_AU\2KY['PYXETC5;F.(S/#8:A:W,BQJRJ7*0R.P0,ZJ6(
MP"RC.2,]AXI\6:'X&TN;5-;O[;3[*#;YMS>31P0IO<(N^21E1=S,JKDC+,%'
M) KR^]_:;^#VG0VTUQXT\/Q1W41F@>35K)5EC$KPEXR9@'02121EER \;IG<
MK =!J?QO^'6B^(E\.7GB72(-6:6&$6$NH6J71DG"F)! T@E+R!T,:[<N&7:#
MN&>@\:_$+PK\-;%+[Q'JUCI5M)*(4FO[F&VC:1E9@@>9D4N51F"@Y(5CC .,
M_7_BQX'\*:'::[JFO:;9Z;>>7]FO+F]MXK>;S8S+'Y4SNL;[T4NFUCN0%AE0
M36?>_&_X=:=X=MO$=QXETB+2;J4PP7\FH6JVLL@+@I'.9!$[@Q2 JK$@QOQ\
MK8] TG5K'7[&WOK&XBN;:YB2:&:%UDCDCD4,CHZDJR,I#*RDA@002#7P!\%?
MBEJ/@SXN?%C3O&GBZ6XTGPY%X8BM[O69;&TCA6]MKB=RYMX;.U5Y)IEC\SRU
M>0+#&S/L3'W?X6\6:'XYTN'5-$O[;4+*?=Y5S9S1SPOL<HVR2-F1MK*RM@G#
M*5/((KG] ^+'@?Q7KEWH6EZ]IMYJ5GYGVFSMKVWEN(?*D$4GFPH[2)L=@C[E
M&UR%.&(%>@5Y?IGQO^'6M>(F\.6?B72)]666:$V$6H6KW0D@#&5# LAE#QA'
M,B[<H%;<!M.-#QU\6/ _PO\ L_\ PDVO:;I'VG?Y']HWMO:^;Y>W?Y?G.F_;
MO3=MSMW+G&1GS#]H[Q-J(^#VM^*?"FORV<ECI%WK-I=V L;F.X6&REGB4FY@
MNHGMY#L<M$$=@%V3*I;=O_LR:M?:_P#![P7?7UQ+<W-SX?TF:::9VDDDDDLH
M6=W=B69V8EF9B2Q))))KY _:5^/UIJVK>!KOP#X]BO+:\\9>'-&U*QTF[TVX
M@\BXN)[@M))#&]W&\WV<1%1<)#+"DD9A8-*6_1_5K*;4;&XMX;F6UDEB>-)X
M1$9(F92!(@F26(NA.Y1(DB$@;D9<J?@#]E;XZKHND^/KOXA>+8O+L/'>JZ';
M7NLW-I:*8[.WMHX8EVK;6ZN4C>5DACC#N9IMFYG)^O\ Q)\;_AUX.L=/OM7\
M2Z18VVI1>=9376H6L,=S'M1M\#R2*LJ;9$;=&6&'0YPPR>)/C?\ #KP=8Z??
M:OXETBQMM2B\ZRFNM0M88[F/:C;X'DD594VR(VZ,L,.ASAAGT#5M6L= L;B^
MOKB*VMK:)YIIIG6....-2SN[L0JHJ@LS,0% )) %?"&N?M/Z?\=/@;XH\8^
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M8SVS2^%9I=*,S:GIZR-II^=1<VUNKNZV]NSL;="'BC7+B%'.?_P2X^$_@?\
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MU_[$\W3;V/\ M/?Y?V'=;N/M6_S(MOD9\W=YD>W9G>F-P_.#X;>,/%_P+O\
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M-IX2MLGRP(Z-MWS/)*?$G_DB'[-W_8R> _\ T@>OH#_F][_NFW_N?K[_ *^
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MP1P_9#^K_A/Q3I?CG0[#6]+F\^RU"VAO+:7:Z;X9XUDC?:X5UW*P.UE5AG!
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MWMK2VD;S'E+-YS2[<*$V+D-Z!\4OA;X8^-/AB[\,^)K3[9IMYY7GP>;+%O\
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M>;3IA>22R:<-$DM+N]N/LC;H[EI+>1;E8IKR2-;>1@OU_P"#_P!G'Q7\7?\
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MMV6I>%[86.GZYIUU;V>J"S$;Q+:R3P6R1O$J/L7]T)  Q\S=-<F;Z/\ A?\
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M+FU36[^VT^R@V^;<WDT<$*;W"+ODD947<S*JY(RS!1R0*Z"BBBBO+_BA\:_
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M-7UCXH7P_P":NH70LWCGTFWU%XHQ \%W.\:2W$SR>6\4$L@5#,H,4*KG^/\
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M7ANUMGU?PI_:MG>VEW).+>*^TI2URBRK"KW$04>= RK";A&CCD-G(TOD<_\
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M/ ^E_L#ZCI=SKVFPWL>B>(K)[:2]MTF6XO9-4>U@,;.'$LZJS01D;Y55F0,
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M)+"YE;4==_X1Y].M]-LX;9Y;M_M<UK9QF5T:.V\M)Q)$EW]L>*:VMYHWS_\
M@G?\0O"NOWWQ-L;'5K&YN;GQWX@U.&&&YADDDLY&M52Z1%8LUNS$*LR@QL2
M&)-?&'[0GQ(O?V@?V;?$5[XFBUN/QS!Y0OM$M(-=@L]+AM[R"X4W-BF;:**2
MR!O4NM2\UI9&F$-QMM$@M?I_X[?M _#35/VB?@]JD?B335M-/_X2@W4TUU%"
ML"W&F1K;22F5DV17/#VDS8BNXFCF@>6*2-V_5^OS _X6QX'_ .&WO^0]IO\
MR)']C?\ '[;_ /(1_M__ (\?O_\ 'W_T[_Z[_8K0^ _C&Q_95\>_$#PQ\0KJ
MQT2#7?$%_P"*M'U&[NUAM;ZWOG1)H$EF6.)+BT*PB:%I/.8S;TC:!%GD\_\
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MLK?PYXDO_#EG;:9J^H6"E;%(?,N97L)K62:6=Y"=LK/%!$D4<2+(;F:Y\/\
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M?LX_L#6'C*QM(KRYT^*]$,4S,L9DN-?GMD9]OS,B-,)&12AD"E!)&6WK]/\
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M3;W3O/V>9Y7VJW>'S-FY-^W?NV[EW8QN&<CX0UO]E;XPZSX*\$Z%-J?A^1?
MNKZ1>V$*17L)U&/2)#% ]Q=%IOL+R6K[98([6^"W$?F+<^5-Y4/Z/Z3'?0V-
MNE]+%-<K$@FDAB:&-Y HWLD;23-&C-DJC22%00ID<C<?C#_A4WQ3_P"&B_\
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MUXF\/KX<L[&33+;4M/MK]-;-JI\F'85F@MK2X2V.(K@?:C!+'$72[.^5OO\
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M[))%JMVD-S]IOI[B7SF;2R]MY2R@1[$NO.8$-Y(YH_9._9T\2?#3X*_\*O\
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MMHG_  C=U::G!<%8[=KF6[^V1202 RRQS&'_ $1UB2>)94^UV[NDL9^R_P#
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MZ#X<_&3PE\5IM1M]%NI6N=,ECBO+6ZM;JRNK=IHA+$9;:\B@G1)$.Z*0H$D
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M$"*WF[YK>**;V#_F][_NFW_N?H_9X_Y.=^-__<H_^FF6C]@7_FJO_92?$?\
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M_P#:]U;P5\3_ -F/Q1JUS<12Z3?>'VU&SEE>2V620Q+<Z<PWF)P[W M_+B<
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M9UD\L$"WCD2+$LP$<,TR0HZ2W@2;\4?^<8O^?^AKK[__ &^O^:5?]E)\.?\
MMS7W_17X0_'O4+/Q/^Q/J.H_#^WMM&\#?N$M--O(+FYU)\:]&)97NFOVCM\W
M9D*PE+W,*!_/C:?R;7[?_:'_ .3G?@A_W-W_ *:8J^_Z\O\ C?>^'=.^'7B6
MX\1VTMUI,6D:A)?P0DB26U6UD,\:$/$0[QAE4AXR"1\Z_>'Y@_&R35M3\*_
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MN_$+PWUGJ-[%!%=3Z7JNIZ8URMN'$)N!I]U;K,\:NR))*'=4Q&&V*JC0\?\
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MW'GJ_A#36BFN8+S[.8O]'BFA\GY[>WSY-MYHMX5NUMTB6]2-4N1.@VUO^/\
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M+?B?\0/!7B:33;C_ (1?^Q/(N=.L[BS\[^TK26Y?S(IKR\QLVHB[7&<,Q^\
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MC'JWP<_9 ^'[Z-:RW.HZMJ\^EV_EZ?<:DL*R:M?SW5Q):6DL5S,D-G;W,H2
MERZH,;"[+Z_X,^,GQ9B^,MOX6TI?$&M>'-4TB0C6?$?AV>Q73-2B6[D4L(M.
MTA9[=UC@1X7*,[R)Y=U&0\;Z'[/_ (O^.7QZU3Q#-<^+=-T^T\.>-[G2IX+/
M0LM=VVF);I+ DL]]+]GBNMS2,2D]S#*Q*71B"PK^C]?G!J]AK^J_MK06B^(M
M2@M(/! U&.VC^QM"H;6(89[8)+;2;8KCR(WGD4B\+!52Z2)(HTY_X8^%=?\
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M111111111111116?JU[-IUC<7$-M+=211/(D$)B$DK*I(C0S/%$'<C:ID>-
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MD@'_ !-"K7#*4EC"DPE)%#3I*'C0^,^F?$3Q5\:/AQXNT_P/J\UCX:BU>2\
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M[I$TDL=M=:O?ZC8:?+*TITNSN9 T%AYAFG5WC4>9.T;M&;B6;;)./](F[_\
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M6HV'F0,-5%U*]U';RW!5_+60P1VOVM)2UJ))[;S;G['^A]?$'@KX?>._AO\
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M_P"%L>!_^$G_ .$6_M[3?[:_Z!WVVW^V?ZKS_P#CWW^;_JOWOW?]7\_W>:]
MHKX@_P""@WCGQG\)/@[JOC'PKKMSI=[I7V;;'%!830S_ &F^MK<^<MW:SO\
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M$WBJ76?"^L7VJV]R+JPTV&ZCD31GN;:"6:VCA$J&2UN)XF@MK<Q@-%/).&A
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M (WZGI/PJ^+GP:\%6*V.D^&KZ^UN673XH;>VM)+JVMDET\; JKO6]N!+!&N
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MQ-L;&WBMK:V^(GB"&&&%%CCCCC6U5$1% 5450%55 "@   "OD#P'XDF\*_\
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M44EUX?\ %<T[QHJM+(&OX0\A !=Q'%'&&;)"1HF=JJ!U_P 1?@CJGQ5_9-\
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M],C*RRW5O']H_P!?LF=QN?>HD 9U%?,$7PGL_P!J+P/\%]'30;DW_A*YTO\
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M];.NV=LVGRZI!=QVEQ>6#R3R-97"6<,%L(B9R1+;P6]W&\<,T=S'/$LM<?\
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MGQ9H?@;2YM4UN_MM/LH-OFW-Y-'!"F]PB[Y)&5%W,RJN2,LP4<D"L_P'X_\
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MU</-+<*B/:RF-M+B>+3[M69H+PAW=49DMI!DCR^\_:0T'QKX=^&.O^/O E]
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MBI9'="KMZA7YH?\ !/?Q_P"'?A9^R!X>\0^(;V*QTZQBU26>>4G:J_VM=@
M LSLQ"1QH&>1V6-%9V53[A\2/VC?%_P4TN+Q/XP\+VUEX;%S!%=W-OJQNKZQ
MAN7\J*:YLELDB?;*\4=S'9W=VT9=FA-TB;FZ!/VAKCQ]XGU'0/AY:Z;K<NDV
MVGW5_/=ZE/96ZKJ<33V8MI8+"_%SOA0S.ZA(E22'9)*[2K!Y?\3?VVX= ^!]
MK\7_  IH\6L:(\2R3QW=Y+I]U&SWD=D(TC%G=I(Z3M(DQ,D:*(]T3SJZFNP\
M:_M&^+_A;JGAD^)_"]M:Z;XBUNTT.W>WU8W-]!-?)*UN;FU^Q1VPP8PMR(+V
MX6(EC$]TJJ7^OZ*^8+KX^:XGQGU#X:PZ+;/+'X;;Q#97;ZA(JS?Z2EHL$\8L
MV-OF8OF6-KG;$JN(V=S$GE^B?M=^*M?^'7C;Q3#X8L1<^#=7U?3;^T?6)A')
M'I-J)YYK>X&FEF=F.R**2&(,/G:9#\E9_B+]L?Q?X0^%%E\4]4\'VT'AZ:VT
MN\F0:R7U)(;^2WB+QVRV!MI,&?S(5>\A:6'8THM9F>"(_:'_ .3G?@A_W-W_
M *:8J]_\0?&75+[Q?J'A'PAIEMJFI:7;6=WJ#WFHI9VELMX9Q# [PPWUS]K<
M0^<L1M5B^SL)&N$9XHY?$/A[^WWX*^)7PNTGQ?8V\L=YJNKVWAN'3IC(H76+
MG;LMWN5B=1;A7$[72HV+?)$)NO\ 1#V'B']J6X^$EGXJN_B'I5MIL7A[3=,U
M-FTF^GU/SUU*YO+2&)1+8V!24S6@0;@8OWRL\L:*[#O_  O\2_''_"<6?AGQ
M-H>FV7VW3;_48)].U:XOO^/&XL87CD2;3;';N^W(RLK/]Q@5&0:^@*^<-4^.
M&K:_XUUGPCX+TZQU*^T"*RDU4ZE?W&G1PMJ$;RVT<+1:??&=S'&TDIQ&D8>%
M5>5VE2#O_@O\7O#OQZ\%:9XN\/O*UCJ,321B:,QR(R2-%)&Z\@/'(CQL5+(Q
M4LCNA5V[#Q9J.J:1H=_=Z78_VA>P6TTMM:><D'VB9(V:.'S7!2+S& 3S&!5-
MVXC -?"&F?MM>*M:_9S;XQ6?@V*>-99I#IL6J3/*+."X:UEN#(NG$!XY$>22
M/9Y:6JM.UP&4PCW#7?C=XOT:W\#2V^A:;J7_  D^I)8RMIVM&6&"&2":\6[M
MYI+&%;R(6=O-<./]'8LJ11>?Y@<<_J_[4MQ/;^*M:T#2K:_T+PA<WMGK%S-?
M3VMV)M-@6XODL[0V,L=QY2.$C::YM5FN%=,I $N9,_XN_&[X=74WP]O]8T"^
MU?3-9U?2)M"U...U-K'J&H13)9O)!/=0W2ND,CS!FMG2$LCJ?M,:A.@^*G[0
M/BKX6_$GPOX;N- L6TGQ'?-8P:M+JLT*PR)"LIBGB.GM$MQ,?,CL8%N&-V\>
MW=#EMG7ZE\7=<TCXAWFA7.GZ;%HNGZ:NK7VJ2ZK)$]K;R+*L336\EDL0\R6W
MN@"EVZ1P6TDTS0L\$,W@'C7]N?\ X5MX;\,^.=?\/_8?"/B&YM((+M[[S=2@
M2\M9;B*XGT^"WEA$1$18B&^FG$+*WD^?NME[#QC^UEKNC?$6Z\ Z1X#U?4=6
MBTB[U:)3>:1;QS11W2VMM*LCWK!;>:3>':3;=0 1G[%+O?ROJ_PGJ.J:OH=A
M=ZI8_P!GWL]M#+<VGG)/]GF>-6DA\U $E\MB4\Q0%?;N P17PA_P5%U_Q5H'
M[/?B)M(2)+:6*WAO;@7LUO<1QRWUK%LBBC@=9TG5WAN%DFMPL+-Q,&,=?1]]
M\0_^%:Z6^O\ C33=-T_5+ZYM=)M8=,O?MDU^[NPLK2.:ZM=.+2M-//Y<3@00
M*TEP\\<1G>/@/&'[2^N?!+5-'_X65H^FZ/I&K7)T^/5+'6)+V&WO&0R0QW:7
M%A8/%%,J2XN$\V.%H_WWE1MYJ\>_[8?C#Q#XB\3>&O#'PUU>_P!6\/Q:89[>
MZU+1;-5DOQ)*%EE%Y<(J?9U66)X/M)=RT4D=MM623[OKY_\ '7QKN--\<6_@
M3PW9VVH:_)IKZU)#?74]C;Q6*7"VH<W$5G>EI7F?;'"L1&R.5Y)(L0K/T'P8
M^,>E_&72[^:V7RKO2=2N]%U* %W6&^LG"3I'*T<?G1'*R0S!$+Q.A>.&7S(8
M_8*^,-&_:JU;QGH6G>,?#VBV-YX5U#5[/2X+R74KBWOG6XU>/2#<"Q.FN@03
MN9(T>Z1WMPK.(96:%-#6OVIM7@^*;?#G3O!>I3ZD--N-366XN],@MS MVEG!
M<EDN9Y!:2.9#*PC-]"BH5T^=G98\^W_;,TGPM#XLMO'6E2^']4\+6/\ :5S;
M-=6\T5[:O++'!-I<\C6S7:2LD47[R*W,=U<16C 39 /$?[65]\,/'OA7PWXW
MT*+2H/%LMQ;Z9-!?M>SQW$;VZQ07\"6J10/(;E(RUM<7L,<WR^8T&;D>@:Y\
M9O%6J^-;_P +^#?#L6I-I,2'4[[4KV;3;.&XGCBF@M(9$LKU[FX,$HN)1'&(
M8(VA#S>;*(Q\_P!_^T]X-^(6C?#O6O%W@?5XAJ7B"VM;+[0MF\>GZ\)[S3?*
MGBDNH;@O;O'<.LK6I5!Y<H6.[41Q9_\ P4$\1^.-(N/AW;:1;VQLKCQOX>0L
M^HW%NUQ<+/-+':SPQVDJ"T+112F?S)725%(LW**]>@?%3QQX;\%:IX/'C_P1
MF[U3Q)8&WN],EM;RQBUJ=)K&TDE>=["[FECM4#><]DR0!8A&[RP1%?;_ (N_
M%V^\ WVCZ'H>CRZSK>LRR"UM1(UO;QV]NT7VN[N[ORIEM[>!9HP2$EFFFEAA
MBA=G)7/^$?QBUSQMXG\2>%_$&A?V3J6A?8)6:"XDN[.ZM]0B=X9K:>6VLY'V
MO#/#*/("))$5621MZQ_0%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>7_
M !O\%7WQ*^'7B7PY8O%'<ZKI&H6$+S%EC62YM9(4+E5=@@9P6*JQ SA2>#\@
M?LZ_M-^%?AU\)M-\->*I(M-\4>&;%-&N?#S7$+:E/<:? L<"6<$AA-V]]&L,
MMI]G\R&5ITBCFD*EJ^8/#?PRF_90U']G6#Q9=165MI$7BL:C>W3106MI=:G8
MM=):RW!D> .'>2&)O,Q<&%G08RJ^OZ3\:_ 6M?MH6]Y#KEBL<_@1-+033I!(
M+]]=#"Q>*8I+'>@'YK.15N4.5:)6! X#PQK.D_&OXB?M(Z5X3U&QU6YUSP_I
M<6G+:WENZW3+H4]JYBD$FQD2>:.*63=LB=U5V4D5G_ OXD?LX^/?"%KH@^'V
MFZEX^LM-,=]HS^$T@F;4K8"WE$\L.GO:644MUM!GE:.&V653,L)5XT]/TGXJ
M>%8?VT+=+[Q'I$URO@1-$FDAN(88WU4:Z-]HD;3S-'<,V2MHTDDZ@A27(W'U
M#]NCPYJGARX\$?%'2#<R7?A#6X$EM;6-)YKJQUB>"PNX+:!HV\V[EW110#?$
M KRD-YOE%?G#Q#^S]XJ^%'CVRT.S$3Q_%NQU#3_%;QB;[+;ZAOFU&\N;6X>*
M1@[65QJ-KI=JZQ)F&*XN?M+1S&O7_P#@HA\0O"N@7WPRL;[5K&VN;;QWX?U.
M:&:YACDCLXVNE>Z=&8,MNK JTS 1J006!%9_[3 _9Q^-/Q L=-\8ZM;:)J5M
MHFG:YH?B6UU5+&9X9KZ<XMKEA]F;RC;QR0&1IF*W4LMLD;)+,?$/B=J_Q4\0
M?!+2O$GC>PB\56/AKQV;Z:ZBTVPE&J>&;>.Y@?4?L+,]NR2I/)Y#(JA;?R;U
M7V+]N;Z?^"_BCX#_ !(UG3-1^#?A?2))H;YHKO5X?#<ME'8VZP,]QLN)+6T5
M[B57BM%@BF\Z,7@NVAFMX)HG_0^OS0\:^/\ P[\./VT$O]>O8K"T;X=B)KFX
M)2WB9M=9E,\Q'E0(Q78LDS1HTS1PAC-+$C^0?'/Q1X5^(-]\2?BC!JD5OHB^
M!-1\$:9=730PV^KZ@[7MW/\ V?*\P:=(FC2WC9(REU,9_)=UMRSY_P 1-?T_
MQ)^RQ\+-?TNTMO$NF^$[GPY<^(;6VCLM2\JSMM(:'4(I;:8M&98TN!O1@)+?
M<+@F%8C-']'_  7\4? ?XD:SIFH_!OPOI$DT-\T5WJ\/AN6RCL;=8&>XV7$E
MK:*]Q*KQ6BP13>=&+P7;0S6\$T3^?_L,_&CP5\!?A\_PK\6:G%I_B/PG?7UE
M/:3+(DEZ;B]N+FWETR)E$]ZEPDJ^1'#$;B0E,08FMVE\ ^!OB3P5KG_!/V]T
MW5M/OM:@TVQO7O;33/,26.1]8N9X#]H"-%&\!6*\N PF-O:[+B:VD@FB2?V_
MX%?'SX._&OXA^&[O7?B-IOB#7]!MKBWTADTF^T#S)M06"TN))1=S/#=7<P")
M#!;B%5\R=EMI,1M;=!^S!\6/ _B']IWXM_V?KVFW/]K_ /",_P!G^1>V\GVS
M[+I,WVC[-L<^=Y.#YOE[O+P=V,5G_L,?&_X=:+#\4YKSQ+I$$;>.]>U,/+J%
MJBFSGEM(8KH%I #;R2.D<<W^K=V5%8LP!\0^".H^$-7_ .">%Q#K%C<ZW:65
MMJ2W=GI4P%S%,NK2W,3,RA_(\G?!>2M(DBQVP\YX)HCY<GK_ ,"OCY\'?C7\
M0_#=WKOQ&TWQ!K^@VUQ;Z0R:3?:!YDVH+!:7$DHNYGANKN8!$A@MQ"J^9.RV
MTF(VMOU?K\P/VR_A5XO\'_%_P1\;O"NE7.M-H?\ Q+-5L+6,W%P;&=I8_-M+
M9/+>655O+D-^](5S;.8O)2Y<?6&D_M@?!+7[&WNK'QCI%RUS$DD-M#=QR7DA
MD4,D262DW;7#9"K;+$;AI"(A$93LKYO_ &G;[7+3Q/\ #7XQ0:1<G1?#%SJW
M]JPW"217EO8:I$EI_:)MDCFE\J")&NI8"JW<<;(LL$#+<_9M#X]^*_!O[1NL
M^";3PYKMC>6/AWQ!#XKU?4[*ZL[FST^UTB"9U6\E6Y40O=22*D.<GRX[JXVE
M+60'S_\ 88^-_P .M%A^*<UYXETB"-O'>O:F'EU"U139SRVD,5T"T@!MY)'2
M..;_ %;NRHK%F /B'[._Q8\#Z7^P/J.EW.O:;#>QZ)XBLGMI+VW29;B]DU1[
M6 QLX<2SJK-!&1OE569 P!-:'Q \?^'=1^ 7P O+&]BOH]+\4^"H+L6!-Y)%
M/;:<S2VYBMA+*;A 1FW53,2541EF4'Z?^,/BCPK^UCXU\#>&O!NJ1:HN@^(+
M'Q5J=_IK0WEG:6]C'<B"":=)E3[1=SD110QF29(UFN7C$48\SX0_:$^)%[^T
M#^S;XBO?$T6MQ^.8/*%]HEI!KL%GI<-O>07"FYL4S;11260-ZEUJ7FM+(TPA
MN-MHD%K]7_M!_&OP$W[0GP5UF37+&"QBB\53O<7,Z6\:P3V(M[>X+3%!]GN)
M(G%K<?ZFZ WP22HRL>@TSXA>%=:_;D:&SU:QGD7P)-IA2*YA=A>0:TTTMJ0K
M$BXCC1Y)(?\ 6(BL[*%4D<_^TQX#\5?"[XRQ>(/"4=]Y?Q)L?^$0OY+*XF1K
M#4"J_9=9\M9&:9[6RCN&5(EMT@2VED:ZB:X9C^G^DZ38Z!8V]C8V\5M;6T20
MPPPHL<<<<:A41$4!515 554 *    *\ _:V\2>"O"OPKU6Z\:Z?%?Z$\MA:Z
MA%+YFU;>[O[>V><>4CR[[<2_:(_* FWQ+Y;QR;77\X/^%?ZCHBZI\/\ X'>(
MXO%7@_6?#_BE;S3%O;&^CT:ZN;1_L2P7PE5X4NKB1(8+:=W!"7MRQE<S3V^A
M\"_B1^SCX]\(6NB#X?:;J7CZRTTQWVC/X32"9M2M@+>43RPZ>]I912W6T&>5
MHX;995,RPE7C3T_X^^,M6_9=^/OAWXG>)[.6_P!"O/"P\-:KJ.FVMP(]/G74
M8YS=S0XG$=O+)-$D41GDF(\X*9I(D2?W#Q[\7[/]ICX,>,I_ UG<ZGI=UX;U
MJ""\^SW,+75XUM+"EM9VLT"S7&"'$LH"1B4Q00FYE^TK:?$'C'XEZ1XC^%GP
M+T/3H-2N[_P_XD\,+J=O;:3J<SVLNC6EQ'J%O*([9L7=OY,DCV8S=& "X6%K
M=DD;W_\ X6QX'_X;>_Y#VF_\B1_8W_'[;_\ (1_M_P#X\?O_ /'W_P!._P#K
MO]BC_A;'@?\ X;>_Y#VF_P#(D?V-_P ?MO\ \A'^W_\ CQ^__P ??_3O_KO]
MBM#X?>/_  [\(?VE_B]+XGO8M-74XO"L]D+DE&N8(-.FBGN(5(W26]NRN;JX
M4&&U2.66>2***5T\@_9SUG2?BO\ #KX]>%O#FHV-_JVL^(/&<]A:0WEN9+B"
M[M8H(+A 9 #;R2.J+<$B'+#]Y6?\"_B1^SCX]\(6NB#X?:;J7CZRTTQWVC/X
M32"9M2M@+>43RPZ>]I912W6T&>5HX;995,RPE7C3K_BGI'P2\;_$S6+G7/%-
MCX)^(GA>73XTURWNH[ 7ADTF*:.=[2]=H)[<O<2036QEGN#;V\4$MV()40_=
M_P"RQK_Q#\4_"CP_J'Q M/LFOS6Q:[C,:PMQ(XB>2)21%+)"(Y)HP$\N5W3R
MH=OE(?M1^/\ QQ\+_AAJ^N^"M*_M?6K;[+]FL_LUQ=>;YEW#%+^YMF25]L3R
M/\C#;MW'*@@_G#XB\9> 4^-WPD\::+JVMZMI?_$]^U:M??VQ<VTUQ>Z03;16
M@EC%F+N>19HCI^E11NMRGV/[)'+%';IG_$'_ (5-JFK>+?'7P[\11>#_ (E:
M;?:]IK:?:74$KZM=6UP88X7TRZ0+=/?+!')#]EC(^VW.]S=W<%?K]\/;WQ%J
M/A72;CQ';16NK2V-M)?P0D&.*Z:%3/&A#R@HDA95(>0$ ?.WWC\(?MT7VN?"
MOQG\.?BK;:1<ZOIOA6YUB/4[>Q21[B.WU&P$;W0 C:,16Z0R/(TKQ)O,49=%
MD:2/T#4/C3H'[:/P_P#$>@_#67^T;>_TW4],N-2NH;RQM+::XL9(X8P9[827
M$K/+&SQPHRPV_F2RR)(;6"[X_P#9U_:;\*_#KX3:;X:\521:;XH\,V*:-<^'
MFN(6U*>XT^!8X$LX)#";M[Z-89;3[/YD,K3I%'-(5+5\@?$'P_I/[,GPC^!G
M@;Q'K-C!JVF>,M"UB_MYKBWCDMH)[F^N)Y'43./L]O)*T#70;R7,9?<N[:/?
M_P!HGXW_  Z3]H_X.7Q\2Z0+:QB\1S74QU"U\N".^T>!K1Y7\S;&EPK*UNSD
M"8,I0L"*] \:?%X:O\7/$7@_QV^KZ9I-C%9S^'DT:/6[:XUAFMH7OV2;3/\
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M&5C?:M8VUS;>._#^IS0S7,,<D=G&UTKW3HS!EMU8%6F8"-2""P(K0^)^M?\
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M;7$*3[6BW[[H7$IW>49/LT<$,6_\<-0\2>%OV4K3XMP>(];/BI]-\/:J;O\
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MCT#X1>(/$7PN^/NL?"ZZUB^UG2;CP_'XETQM1E$UQ8*=1EMI[1KAU:XO$=Y
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M2&5Y7:1O,:O /^"9?BFX\0? FRM-1FN9-7TS4M7L]66]6=;B.^;4)[N1)S.
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M]F/Q1JUS<12Z3?>'VU&SEE>2V620Q+<Z<PWF)P[W M_+B< R.5A9&W%#[_\
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MJWPF^+;ZE:[_ +-/!;:Q:_9O-B6&7[,EMJL4=OYJ(%E\E4\WDON8DGU#Q_\
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MJ:ZS13QRRRQW ;^U]S7"-,XCN&+3(FV)9!%&B+]'_P##?7_5*OB3_P"$Y_\
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M9!+<,9(IO,OG^V9OY1-#%<)-??:)4ND6Z5UN!YE<AXUU3X#_ !#\5)XGU?\
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M%:AX+TZSOH=$U"+R9K(:QJS1B,R/(Z1;KLM DK2/]H6 QBX#,LPD4XK/U?\
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MHHHHHHHHHHHHHHHHHHHHHHHHHKS_ .+'CK_A5_@?7O$WV?[3_9&FWNH^1O\
M+\W[+;O-Y>_:^S=LV[MK;<YVG&#\0?\ !+KPY;W/P=/CBY/GZUXNU+4=5U2Z
M:.!&DF6^G@"KY4<>(AY;2K$<JDL\Y3:K[%^O_'?P<TOQSXS\)>*I&\N]\-7-
M]+"V';?#?6$UI-#@2*B[F:";S&61AY'EJ%$KM7D'AKXH_$#]H/PQ)XN^&NI:
M);Z7/]KBTU-7TV^G>[:UEE@\Z62*]M#:12S1LJ1^1<RI J7#GS96L[?YOU_]
MNCQEXB\.^$O$?A.QL86U+Q38^#M4T/6[2\ANK/4I3(UPAODE"JBJ(U4_89F0
M/YCIYJO9I[!XW^+WQA^&GQ)\(>"[BY\/ZI)XMBU:."XCTZ]T];&33X8;@SR(
M=0OS=IY;R8ME-H975%^UPJS.O0>&_C-\1=)^,.H?#;5QI&JW/_"+?\)%97-K
M!=:5'YBWKV?V6=9+C5&V.VQ_M$?,0#C[/,2-O'_"OXZ?&_X^V_C!=$T_PWH\
MN@:W?Z-$UY/?ZBLEQ800JT+I''8D12S2-(M\&WQQ8A.FR.#.=#P-^U=XJ^,5
MCI6F:+X?ETW6[C5]8T;59)H)M5T_0[C2%,DB7<T#62SO<*8$MO*ECA+S.?.D
M:W,,WH'@#XO>*O'FL^,O B7-C#XC\+2Z:)-1.G3-I\\>HP+=QLME_: G5U02
MP.ANR-ZQW D82-;1?-_PT_:3^-_Q+_9YG^+/G>&[#[-INK7WV+^S;^Z^T?V<
M]SSYG]I6WV;?Y/E>7MN\;?M'FGSOLT&A\?OVKOB=X$\!>!OB-HL.D6GAS78M
M).KF]L=0U"?2EU%$E^U;K2XMUFMXU?RF4I"YF$2H7-R$A^K_ !SXH\<6OQ+\
M.Z#HMYIL=E?6UW?7D=W87$LPM["6WCN#!<1WT2++(U[:QQ1O;,B+]HN&E<QQ
MVLOJ'Q"\:V/PU\*ZMXCODEDMM*L;F_F2$*TC1VT+3.$#,BERJ$*&903C+ <C
MY0^#7QT\<?%J+PGXCT_4-$U+1=;N3%?6FFV-Q+<:1YFDW%^L-U?)J,T7FP2I
M;VLQDM+?S'F4B.!I$CKR_P"*O[=$-DOC<^'_ !'X6TR3PG+>VL=KK#RS7FJW
M5G:)+)%#;?:M->W1;C?9QRJ;X74BNR+&L:B?T#2OVS)OB7\+O"6N>$-*B/B'
MQE+/9:7IVH7421Q3VOGB\N;AU999+*T%O)([0)YTP,$0CAEN%">H:!K_ ,9[
M#QQ=^&M8CTVZLKC1)+ZQURTTZYM[>"^BN!"UI<VKZC=/+E9HKA"+BT,B)-&F
M\J\D'Q_J/[9OQ3E_9.L?C/:+HD=ZGG?:[*6PNY(9<ZP-.B\EUU"-X-BYDDW_
M &CS6P%\H#GZ@_:F^/GCCX&W'AJ/1-%TV^BU[6]+T.*:\U"X@9+B\G<LKPQV
M<H$1AB95N!,SQRR!C:3)&4E\_P#&OQK^*?PEU3PR_C_PQX;O(M8\76FD:;/I
M6I7;36']H)+#'(R7>G 2RQPFX26>*2V\Y9/+$,2,Y.?^U'KGCT?'SX2Z'H>J
MV-I;7LNO72)=:>]TJW5GI4R>;+LN[9Y$,%W)'%%&\ C<M+(UP#''%[!X;^,U
M\_Q]U#P%J7AVQM;E_#_]L1:G:WK3R3V<&HO:VT,Z/96[1N&FFE\L2SQPF1PC
MN9':OG_XJ_MT0V2^-SX?\1^%M,D\)RWMK':ZP\LUYJMU9VB2R10VWVK37MT6
MXWV<<JF^%U(KLBQK&HGT/^'@6A^)?"'P_P!2MGMO#TOC7^TMEYK9CDL=._LH
M,+KSRMS9F;S)E6WM<2V^\2B=]CH+67Z_^$FK>.+U]>LO%8MI)=/U);:UN;.Q
MN+&&ZMVT^SN?-2*>YNR=LT\T#.DK(6A(PKJX!\9_'^N> ]+L%T32KG4+W4]2
MM-+B:&VDN8;/[4Y5KZ\2-D?[);*&DDPT?F-LA,L D,\? >!?C%KEC\4[CX:>
M)I+:]U+^Q$\0P7NG6<EE;FW-VUD\$D,UY>2"5'5)%E60I*DC*8X6A#7'R?\
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M)8I9[62(*\*S3'$Q]P^-OQ"_:>^&WA#Q1XNAL_"*6^DVT=Y;:=%_:&H320Q
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M/<7]B^DM%J0@M8[&9+I)/[5N,M)=F\>*1"1)A%M8B R#S#Y;&3[/^,_C_7/
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MI'<FXL%;5K9X5:^,\L-[*@$<4ZI;6D1=Y)8YV2%([C[0^*'QF\5>!?CA\/\
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MO]DZW_9O_"(_\([]L_L/5OL_V_\ MOS?+\[[)Y?E;/G^U[OLFSYO/V\UY_\
MLH?&2S^%O_"V?M>C:W>_\7 \2SP?V3I=SJ/VAU\G=;K]E63R91A,&[^S0/YR
M[)G\NX\C/@^%WQ)^$D.C7FIZ+?7&@^)_$&OZ_P"-])TTPZFT#:K+;KI]L%AC
MCN[JW@PGV^.T69+A$NUD2XM)%A;L/V:O#]Y\%_C%\1KU_ NI>'](UFVT6\LK
M>UL+:2&&#3[&[CNF(TN6YMS*TX 2SMGFOIFN8Y1;&,S21>8? JYU/PI^Q1J'
M@O4-!\00ZV-(US3OL1T#6#(;C47U*2V5=MH59&4KOE4F& O&LSQM(@;[/^$_
MPPTOXM_LTZ#X-\26-S!%<>&[+2KN"[M7M[B":"U2!V6*\ARDL,T?F02M&R[T
MCGCWIL8^?_L >%O%^G^&+V[\60VT5[IOE>#K9K%B;>>Q\,2W-I'< .6E\U[F
M:]21G$(=(HF6WB!+2?7_ ,6-?USPIX'U[5-"M/MFI6>FWMS9VWER2^=<16[O
M#%Y<161][JJ[$(=L[5(8@U^<&D?"W2-2\=^%?$?P;TC6_!][/J5E<^)+&YTS
M4]'TV72X[=EFBGM[BV%A+=QY$%NEF6/G7,UR"P5KR#H/AG\1OB'^S)XX\6>$
MM=\&>)-?M-9\27FLZ+?Z)$M[9I;ZM<%_L\KW$EM%8^3+N>4/($\R6:9@D6RX
MN#]H_P &_&JVO/!GQ7TG2?[8U?PWJ6LW,F@+Y"F/2]1MO)$2212;FNXK>WC$
MB1&_+ZC=2M 9;2*& _6'PA^-7B+XW3)=VOA;5_#NG6TLB71\2V8M+JX;ROW<
M=I;I.[! SAY;J;" (+>**=Y99K+\L)OAS\3X?V.Y_@P/!&MMXAMKF"VF*QVG
MV-?M.MPZA#*ET;D1W$3)*8Y'MO.^R20RF[%K"$F?Z_\ VV]9U#Q'_P *UCM]
M"UN2XL/%V@>(+Z&VTF]OOLMG!]H$_FS6$5S;-+$2%>&&:60\,BO&R.Q^VWK\
MOBO_ (5K_9>DZW>?8_%V@>(KG[-H>K2^381?:/,DEV6C;)4W#?:-B[7(S ,B
MN@_:%@U"?XM?"'Q]!IFI7&BZ9_;WVR2VTZ]GN+?^TM+1;7S;&&%[U-S(R/F
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MOGS_ /M^7_AL+^W?[)UO^S?^$1_X1W[9_8>K?9_M_P#;?F^7YWV3R_*V?/\
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M@ZOX;T:**YDFBUNWM;>\NYRPA@C6!9KF6*W0"XEF,JVLSR"Q:%Y;9KE&]O\
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M J)X>#+'&K*3Q_Q&\(W?QF_:1\06,5GJ]IIVJ_#O4O"1U.71=26UBOI+^5V
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M/<S2:3J>D:'JE_;WUC>2R7 ,AL8[PPW<<S3+/!*(@B&'RVN$)G?S_3OAI9^
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M33+0^(+_ ,+ZO8RZ;X/TZYL=6O-0@:32)HI83;O:&\M;(3;+:U^UA$1(/,)
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M6E^DMO!HU]XSTJPLI1 &L+.&P\R&R'V=GBV6YE:*-4DDCC15AB?R(X@OW?\
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MNUW[!;?VE_;?@.R^V>3']H^S_9'E\CSMOF>5O^?R]VS?\V-W->__ +6&@?\
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MZ!X*LM#^,WQB\=^!?$6BZ;=Z!X*MO#UMI&G26D;VD/VVQDGEE-N^Z%I5"I!
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M-DLIK:\L4NI-"N/.6WO_ +6UT"%U8(TI:Y4P2 *D2QLKQ3F0-&>/?V0/''Q
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MZ??33V'VVWU"S95*QW,*3VLGFQ/%"T5Q%-'($C$$GG0A$CW_  [\)?$GAO\
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2*********************__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex19-1_006.jpg
<TEXT>
begin 644 ex19-1_006.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[@ .061O8F4 9       _]L 0P " @(#
M @,%! 0%!P8&!@<(!P@(!P@)"0H*"@D)"PH+"PL+"@L+# P,#0T+# P,# P.
M# P,# P,# \,# P,# P,_\  "P@&<@3[ 0 1 /_$ !\   $% 0$! 0$!
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M-]7;0G\++K>WQ!'K?VQ+Y-1^RN8I-;Q=&WDA>,%1NMQ)%F+RY#<^9H?L"_\
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MW>D^)8M;2_DUB77KR"865FEU9W&FW>JR/%(A(D!EL9);>>&97??_ *)*G/\
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MOV6_BO=2N-,G>Z E_=6RMIMQ!(A>&2!99;B$&:.0LJ6_DW,^?X _;6TOXM?
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M;_CJWB35;;2HKCQ(1'<7T@M[<LE_JN8S<2[85E8-NCA9Q+*B2O&CI#,R<?\
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MXS_#[PA\2?$OC3Q!>7?FZU*]@9[6+3Y&FO;NW(EAAM8Y9D0*KV\<LKI:NJK
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MS6E[9R7K7,L3H!.+E/-$,R+"@A$G^D1<?\&? ,OBKX[?%/PK>^(?$CZ+H?\
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MFFWGB;4+:STZULGNREG8V-M(6-O%J*Z;]J?SI))KR9WML-(8+;8$MEN&Y_\
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M+P]<R:C:V%A=G4TNKYHFA@N)Y+K3;-X?L:O,\"0[C)/,DS/&;5%E\_\ A_\
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MD_:C^&":7X8U1-7\VR\57,5EI5S!:W<T,UQ,X1('DBA9+>4L2ICN3"ZM',I
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M%O>0K*L<_P ,DE030RP2!7UT, \4RI+&X!^:.15=#E656! T/V>/^3G?C?\
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MYLT<,AF68/;V\TCP6SHZJ8F@CC,(&R,HA*GZOKQ_XA? 3P)\4-4L]7U?3O\
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M_@[7]53=<>%M2?4;?F4;]T1Q'^[EC48N([2YW,LF?LWD[?+FDS@?M)_LV?\
M"]_[$U32];N?#_B'P_<M<Z7JELOG>3YVQ;B*6W9TCGBF1 KHQ&<!26A::&;0
M^'?P%U&PA^T>/?$$OB_46L;S36DN[&QM+46M[+&]Q"EG;1!62=8+99OM+W))
MA_=F%)98V\/T/]D+XAZ!\--4^&L?Q!\_0+JVO;&U>ZTA9M2M;.>)HX;471O!
M#+%&"$?=:K(86DB@DL_]':V^G_@/\--4^$'@?3/#>H:M_:C:?;6]G'*MLEJB
MPVUO';Q(D0>5QE8A)(TDLS-/)*RF.$Q6\/L%?,'CKX!ZYJ'Q3M_B-X9UJVL-
M271'T">+4=/DO[=[<W:WB/&L-Y821RJX8,S22HZ,H$:,I9^O\%>!(?AC-KOB
M[Q+JT5QJ-_%#)J-ZQEM+&"UT^*00QP03W-RMI;Q*\T\I,SE[B>XG9PC)%%X
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MY#Y31PRVA9=\$L>]FE)79G_"']C[Q;\/(4\.ZSX_OM=\'VT4D%MH=S86L;&
M2[H;>[OE+3W-O&G[M[<"&&= L#QBRWV<GT_H7A'Q;8>-=7UB^\2RW6DW,4$=
MCI LK6*.S98T$TC7(5KBX>1T+(&>-(A)(A23]VT7J%>/_'3X%^$/VB_"%UX7
M\46OGVD^'1T(6:WF4$)/ Y#;)4W'!P592T;J\3R1MP%E\%/''BG^Q;?QUXGM
MM7M-)N;34%73]-N-*EN[RR^:"2]=-1N(I8EEQ=&WC@@C:ZB@?B*)H).?\(?L
M]>./ _Q/\9^-;+Q)IK?\)3]F\RVFT6X;R/L%I+;6.V5=43?MWH]UE%^T;&6/
M[)O!CZ#]F?X!ZY\!O^$H_M'6K;5/[?UNZU]OL^GR67DW%YCST&^\N]\7R1^4
MIVO'A]TDN]=GT_1111111111111111111111111111111111111111111116
M?JVK6.@6-Q?7UQ%;6UM$\TTTSK''''&I9W=V(545069F("@$D@"M"BBBBBBB
MBBBBBBO'_A-\ ?AY\"O[3_X1'1;;2_[4N3=W7V<-\[\X4;BVR)-S>5!'L@AW
MOY<:;VS[!1111111117S_P#\,Q> ?^$X_P"$U\O4O[:^[]I_MO6/]5]H^T_9
M_*^V>5]D\WY_L>S[+_#Y.WBO0/B7\,= ^+NAR:)KJW,EE-N$L5M>WEEYJM&\
M;1RM9S0/)$RNP>%V:)^"R$JI!\-/ACH'PBT./1-"6YCLH=HBBN;V\O?*58TC
M6.)KR:=XXE5%"0HRQ)R50%F)] HHHHHHHHHK/U;2;'7[&XL;ZWBN;:YB>&:&
M9%DCDCD4JZ.C JR,I*LK A@2""#7G_PA^"_@KX"^'4\/^$=,BTZQ6628QQM(
M[/)(?F>225GED<@*H:1F*HJ1@A$15]0HHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHK/U;2;'7[&XL;ZWBN;:YB>&:&9%DCDCD4JZ.C JR
M,I*LK A@2""#7Y8?L2?L]?"SQ7_PLK^U/"6B7GV/X@:_96WVG3+27R;>+[/Y
M<$6^)MD2;CLC7"+DX R:Z#Q'I>N?L2_%?P;_ &)J&I7?@;Q/<VWAF72[RZDO
METN\,?EZ>UB]W<F:**0AO-0;XXXHILAV:RB@^L/B3^TOI/P^77GM]%U?5X_#
ML3RZO)80V\<=FJVB7N#)?W%FEPYMY!*8[,W+Q@J)5C:2$27]?_:=^'FB_#RT
M\=0:A_:&FZAY<>GK8HTUQ?W$S%(K.U@^61[MW5H_((5XG63S?*6*5D/ O[0F
MG^+?'%QX*U#1]2T36HM-35TMM1^Q2>=9M<-;&6.6PN[R(;)5",DCQR'>K*CJ
M'*\!JW[:O@?P_;Z)J^I6>I67AW7+F&TL=?O(K>WL9'N())HF>.:X2_AB?RG5
M9YK..# $WF?962=M#5OVL+32?B+<> #X4\03:RMB^I6T4,>FO'=6J71MO.28
M7_E0(Q5W7[<UH2%$9 N98()30OVL+3Q-K.K^';'PIX@EUW1I8%OM+$>FB2"*
MX@2>&=KLWXTXI('"I$MV;IBLC"W\N*1T^+_V\/'_ ('_ &B/V8O&'B"#2MFI
M>'-272'74;:W-YIUY%JUE%=11S1M/&/,0IN>UF>.2-E5G+!D7ZPN?VY?!5EX
MUTWP]-I'B".SU6^M].L-=?3)%T>[N+F/= MO=EMTR2M\D4L<;0R?ZY7-K^_K
MV_QC\8;?PWKC:!IVD:EK6J1VT-[+:Z=% OE6T\DT4<TES>S6EF-TD$B+")S<
MOM9U@:)))$\0D_;X^$:?"Z+XBQW-]-I;Q2EUM["YGD@N(O+!M+IH4>"TN&>6
M..(74T,,QD1XYGA82U[?\-/C)9_%'5-6L[31M;LHM.^S;;K5=+N=.AN_M".Q
M^RB[6*9_)*%)M\4>UBI7>C*Q] \4^&K/QAI<VG7<ES'%-MW-9W=S93#8X<;)
M[26&9.5 ;8Z[ERC91F4_$'_!+C_DV+PC_P!Q/_T[7E<_\=O#5GI?[6/P>U&*
M2Y:6^_X2CS5EN[F6%?)T>-%\F"25H;?(.9/LZ1>:V'DWN U?H_17QAX__8P\
M)?M!^(KW6OB;'+K"K*8M*L$O;J&UTZU0!28_LQM6DN+ME^T74DH<H3%:(SQ6
MJS3?-_A'XE^)_P!F']EKQQ<W,ERT7A?4M<T+PY>.T5U<O;PWYTVPFG$CF,^1
M=LT10QQ(MM;J$MF0().P^,7[)OAWX/?!*\UWP^\5IXP\,V,NNKXF2W+:A=7U
MI')<WDEQ*\KRS)? W$<L%S+<6ZI/@Q2)%&E<_P#\%%=0T;XO?LF77C2U^W11
MSV.D7]I$;J>!?+O[VP<"ZMH)OL\[JC#:)A.(7RT3*QWG[_\ C?XUOOAK\.O$
MOB.Q2*2YTK2-0OX4F#-&TEM:R3('"LC%"R ,%921G# \CX0U_P"&FAZ[^SI:
M?%98_LOC.U\-Q^*UUZV6-+]K]-,-TXEF9&\VTEW/;O8R!K1;1A;10Q1Q0"+[
M_P#A/XZ_X6AX'T'Q-]G^S?VOIMEJ/D;_ #/*^U6Z3>7OVIOV[]N[:N[&=HS@
M>@4444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M44444444444444445\ ?L"_\U5_[*3XC_P#;:L_X]ZM8_M(_%'P3X(\,7$5Z
MOAGQ!#XEUV]M76>/3CIGG1V]G/@JGVB[G,D7E"7[1;B%YFMGBR5^</A#)\$;
MC7/BAX9^(^J_V!>GQ=K;S6=SXAU?18K^QU&0R0SR6YO[>UN/.C9HR8DPUJEN
M9%(D224^(OC3PQ^S7>?"+Q+IMA<Z5\.M'UOQ%9)Y-U+=B3[=;2PVM^T4DC22
MQ2NVH7-K+$UWG3F6:-E>[6T'U_\ ';XE^!_C-\/_ !5I_@N2V\3ZI)X;UVT6
M316M[]K5+BQ<^7)+"[&/[5-%!'%;(6GNI55T@DBM;B6W^0/!*_LG?&#X,: ^
MO7W]IW$6FV\R^&XO$^L23+?06QB-GI^EW>J^9YN_?;64:C,BNBQN\<BNWT?I
M,E]-^VA;O?110W+?#)#-'#*TT:2'71O5)&CA:1%;(5VCC+ !C&A.T:'[/'_)
MSOQO_P"Y1_\ 33+7P!\3?^38OV@_^RDZA_Z=M*K]#_\ @HOX&A^*OPC'A&"&
M*75M<U?2['23+!+,([HW*RRS;HHI6@2*RCO))Y\ );K,I)W;&^?SJ_PST#]I
M?XF6/C[4Y?#LE[%H5_IUV=;U;0UOK>/3H[:8&6"]M;6=()D*P@@S;WN@&D6-
MUAX#]I;PI\-O!/[)GQ%TWX;:;%;^'%OM*DBO(;Z:\BOKI[W3OM$MO)(\ZO;Q
MJ(;?S$F(-U%=PM#$;??/^UU%? '_  2X_P"38O"/_<3_ /3M>4?M#_\ )SOP
M0_[F[_TTQ5]?_$CXJ^$/@_I<6J>*-5MM,M);F"S2:ZD$:M-.^Q$!/XN[?=CB
M229RD4<CKZ!7RA\7OVE_!OAOQ$_@Q?%>D:+J*Q1RWUW?7MG"UC!*,H(8KE]L
MU[*O,$;*\-LA%W<JZ&UM-0^?_C3X2\!?&/\ 9S\6_#KX6B*73M)TBVGM)-'5
M+^UFGM[A[T6$,D$KM->NUHIN0Q:8&^M[AO.>;#>@?M%?M ^%?&?[,>I>(]*,
MMW'XKTA],TRU@,,MU->:K$UI%:K$DK"2XBDD87$,3221B"?"NT94^7_MW>!?
M^%7_ +%6H>&?M'VG^R--\/Z=Y^SR_-^RWUA#YFS<^S=LW;=S;<XW'&3^G]?D
M!\9OV?[?X6>&)_@Y\-?$.MW%[XE^U2VWA^>Y@DL-/L;F7;=7=S<);I?VNGPY
M81)]J<7EV1"]O?B:\BE_2^VUGP%\%;'0/"SZC8Z5&T4.FZ5:75XB23+ L<$<
M, GD\V=U#1)P7<EDR2S#/J%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%9^K:38Z_8W%C?6\5S;7,3PS0
MS(LD<D<BE71T8%61E)5E8$,"000:\/\ ^&3O@A_T(?AO_P $UA_\9KV#PMX3
MT/P-I<.EZ)86VGV4&[RK:SAC@A3>Y=MD<:JB[F9F; &68L>237/Z_P#"?P/X
MKURTUW5-!TV\U*S\O[->7-E;RW$/E2&6/RIG1I$V.Q=-K#:Y+##$FNPU;2;'
M7[&XL;ZWBN;:YB>&:&9%DCDCD4JZ.C JR,I*LK A@2""#7/^"OA[X5^&MB]C
MX<TFQTJVDE,SPV%M#;1M(RJI<I"J*7*HJEB,D*HS@#&?H'PG\#^%-<N]=TO0
M=-L]2O/,^TWEM96\5Q-YL@ED\V9$61][J'?<QW. QRP!KG_^&>OA9_;G]N_\
M(EHG]I?:?MOVS^S+3[1]H\SS?/\ .\KS/-W_ #^9NW[_ )L[N:S],_9D^#VB
MS--9^"_#\$C130EXM)LD8QSQ-#*A*P@E)(W>.1>CHS(P*L0=#0/V>OA9X4^U
M_P!E^$M$L_MEM)97/V;3+2+SK>7'F02[(EWQ/M&^-LHV!D' K0\%?!#X=?#6
M^>^\.>&M(TJYDB,+S6&GVMM(T;,K%"\,:,4+(K%2<$JIQD#&AXZ^$_@?XH?9
M_P#A)M!TW5_LV_R/[1LK>Z\KS-N_R_.1]F[8F[;C=M7.<#!XZ^$_@?XH?9_^
M$FT'3=7^S;_(_M&RM[KRO,V[_+\Y'V;MB;MN-VU<YP,=!X6\)Z'X&TN'2]$L
M+;3[*#=Y5M9PQP0IO<NVR.-51=S,S-@#+,6/))H\4^$]#\<Z7-I>MV%MJ%E/
MM\VVO(8YX7V.'7?'(K(VUE5ER#AE##D US_@7X3^!_A?]H_X1G0=-TC[3L\_
M^SK*WM?-\O=L\SR43?MWMMW9V[FQC)SS_BG]GKX6>.=4FU36_"6B:A>S[?-N
M;S3+2>9]B!%WR21,[;5557).%4*. !6A\9/ TWQ*\)76A1PV,RWDMK'*-0@B
MN(E@%U$T\BQ313PO<1Q!Y+03120BZ2$RHT0<'L/"?A;2_ VAV&B:7#Y%EI]M
M#9VT6YWV0P1K'&FYRSMM50-S,S'&22<FO+]6_9D^#VOWUQ?7W@OP_<W-S*\T
MTTVDV4DDDDC%G=W:$LSLQ+,S$EB22237H'@KX>^%?AK8O8^'-)L=*MI)3,\-
MA;0VT;2,JJ7*0JBERJ*I8C)"J,X QS^F?!#X=:+XB;Q'9^&M(@U9I9IC?Q:?
M:I=&2<,)7,ZQB4O('<2-NRX9MQ.XYT/'7PG\#_%#[/\ \)-H.FZO]FW^1_:-
ME;W7E>9MW^7YR/LW;$W;<;MJYS@8Z#PMX3T/P-I<.EZ)86VGV4&[RK:SAC@A
M3>Y=MD<:JB[F9F; &68L>236?X*^'OA7X:V+V/AS2;'2K:24S/#86T-M&TC*
MJERD*HI<JBJ6(R0JC. ,:&H^$]#U?5+'5+NPMI[W3_.^R7,L,;S6_GH$E\F1
ME+Q>8H"R;"N]0%;(XKH*****************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M**********************************S]6U:QT"QN+Z^N(K:VMHGFFFF=
M8XXXXU+.[NQ"JBJ"S,Q 4 DD 5S_ (*\?^'?B/8O?Z#>Q7]HLIB6YMR7MY65
M59C!,!Y4Z*6V-)"TB+,LD)8312HG84444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444445^./P=^)6H_&_Q5XE^+6O>#=7\7:3I]]<VWA1K*RL?L]I8V$QD-W9V
MVH:A;W$U[<O'$7FBM7N%FM_L\4HYM(/U.^%OQ2\,?&GPQ:>)O#-W]LTV\\WR
M)_*EBW^5*\+_ "3)'(,/&R_,HSC(RI!/H%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%?FA^R%\0O"O[*WA*Y^%7CO5K'0[[PU?7:6LNJ7,-FNIZ?=W4U
MS;:A;^:PB*2%Y8GABFN'MWA*RLCL$'N'['7PTUSX?Z7XOU#5(_)7Q)XNUGQ!
M9QNLB3+9WKQBW\^*1$>&5UB\PPN/,B5U258YA)%']?T44444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
2444444444444444444445__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>smti-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa+FmbP9z5Z8uekhvWBxbYnKfysqJmLA0SYnBdk2gVIL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:SMTI="http://sanaramedtech.com/20241231" elementFormDefault="qualified" targetNamespace="http://sanaramedtech.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://sanaramedtech.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity" id="StatementsOfChangesInShareholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Shareholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
          <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/NatureOfBusinessAndBackground" id="NatureOfBusinessAndBackground">
          <link:definition>999015 - Disclosure - NATURE OF BUSINESS AND BACKGROUND</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/AppliedAssetPurchase" id="AppliedAssetPurchase">
          <link:definition>999017 - Disclosure - APPLIED ASSET PURCHASE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ConvertibleLoanReceivable" id="ConvertibleLoanReceivable">
          <link:definition>999018 - Disclosure - CONVERTIBLE LOAN RECEIVABLE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/GoodwillAndIntangiblesNet" id="GoodwillAndIntangiblesNet">
          <link:definition>999019 - Disclosure - GOODWILL AND INTANGIBLES, NET</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/InvestmentsInEquitySecurities" id="InvestmentsInEquitySecurities">
          <link:definition>999020 - Disclosure - INVESTMENTS IN EQUITY SECURITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/OperatingLeases" id="OperatingLeases">
          <link:definition>999021 - Disclosure - OPERATING LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/DebtAndCreditFacilities" id="DebtAndCreditFacilities">
          <link:definition>999022 - Disclosure - DEBT AND CREDIT FACILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999023 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ShareholdersEquity" id="ShareholdersEquity">
          <link:definition>999024 - Disclosure - SHAREHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/CustomersAndSuppliers" id="CustomersAndSuppliers">
          <link:definition>999025 - Disclosure - CUSTOMERS AND SUPPLIERS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999026 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/RelatedParties" id="RelatedParties">
          <link:definition>999027 - Disclosure - RELATED PARTIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/SegmentReporting" id="SegmentReporting">
          <link:definition>999028 - Disclosure - SEGMENT REPORTING</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999029 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/AppliedAssetPurchaseTables" id="AppliedAssetPurchaseTables">
          <link:definition>999032 - Disclosure - APPLIED ASSET PURCHASE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/GoodwillAndIntangiblesNetTables" id="GoodwillAndIntangiblesNetTables">
          <link:definition>999033 - Disclosure - GOODWILL AND INTANGIBLES, NET (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesTables" id="InvestmentsInEquitySecuritiesTables">
          <link:definition>999034 - Disclosure - INVESTMENTS IN EQUITY SECURITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/OperatingLeasesTables" id="OperatingLeasesTables">
          <link:definition>999035 - Disclosure - OPERATING LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/DebtAndCreditFacilitiesTables" id="DebtAndCreditFacilitiesTables">
          <link:definition>999036 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ShareholdersEquityTables" id="ShareholdersEquityTables">
          <link:definition>999037 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999038 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/SegmentReportingTables" id="SegmentReportingTables">
          <link:definition>999039 - Disclosure - SEGMENT REPORTING (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/NatureOfBusinessAndBackgroundDetailsNarrative" id="NatureOfBusinessAndBackgroundDetailsNarrative">
          <link:definition>999040 - Disclosure - NATURE OF BUSINESS AND BACKGROUND (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails" id="ScheduleOfComputationOfDilutedNetLossPerShareDetails">
          <link:definition>999041 - Disclosure - SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails" id="ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails">
          <link:definition>999042 - Disclosure - SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>999043 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails" id="ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails">
          <link:definition>999044 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999045 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails" id="ScheduleOfAssetPurchaseConsiderationsDetails">
          <link:definition>999046 - Disclosure - SCHEDULE OF ASSET PURCHASE CONSIDERATIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails" id="ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails">
          <link:definition>999047 - Disclosure - SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative" id="AppliedAssetPurchaseDetailsNarrative">
          <link:definition>999048 - Disclosure - APPLIED ASSET PURCHASE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative" id="ConvertibleLoanReceivableDetailsNarrative">
          <link:definition>999049 - Disclosure - CONVERTIBLE LOAN RECEIVABLE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfChangesInCarryingAmountOfGoodwillDetails" id="ScheduleOfChangesInCarryingAmountOfGoodwillDetails">
          <link:definition>999050 - Disclosure - SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" id="ScheduleOfCarryingValueOfIntangibleAssetsDetails">
          <link:definition>999051 - Disclosure - SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails" id="ScheduleOfFutureAmortizationExpenseDetails">
          <link:definition>999052 - Disclosure - SCHEDULE OF FUTURE AMORTIZATION EXPENSE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/GoodwillAndIntangiblesNetDetailsNarrative" id="GoodwillAndIntangiblesNetDetailsNarrative">
          <link:definition>999053 - Disclosure - GOODWILL AND INTANGIBLES, NET (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails" id="ScheduleOfInvestmentsDetails">
          <link:definition>999054 - Disclosure - SCHEDULE OF INVESTMENTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails" id="ScheduleOfLossFromEquityMethodInvestmentDetails">
          <link:definition>999055 - Disclosure - SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative" id="InvestmentsInEquitySecuritiesDetailsNarrative">
          <link:definition>999056 - Disclosure - INVESTMENTS IN EQUITY SECURITIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails" id="ScheduleOfOperatingLeaseLiabilityDetails">
          <link:definition>999057 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative" id="OperatingLeasesDetailsNarrative">
          <link:definition>999058 - Disclosure - OPERATING LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails" id="ScheduleOfLong-termDebtDetails">
          <link:definition>999059 - Disclosure - SCHEDULE OF LONG-TERM DEBT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails" id="ScheduleOfMaturitiesOutstandingDetails">
          <link:definition>999060 - Disclosure - SCHEDULE OF MATURITIES OUTSTANDING (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative" id="DebtAndCreditFacilitiesDetailsNarrative">
          <link:definition>999061 - Disclosure - DEBT AND CREDIT FACILITIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails" id="SummaryOfRestrictedStockActivityDetails">
          <link:definition>999063 - Disclosure - SUMMARY OF RESTRICTED STOCK ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>999064 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails" id="ScheduleOfWarrantsToPurchaseCommonStockDetails">
          <link:definition>999065 - Disclosure - SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative" id="ShareholdersEquityDetailsNarrative">
          <link:definition>999066 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative" id="CustomersAndSuppliersDetailsNarrative">
          <link:definition>999067 - Disclosure - CUSTOMERS AND SUPPLIERS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails" id="ScheduleOfDeferredTaxAssetsDetails">
          <link:definition>999068 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails" id="ScheduleOfIncomeTaxExpenseBenefitDetails">
          <link:definition>999069 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE (BENEFIT) (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999070 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
          <link:definition>999071 - Disclosure - RELATED PARTIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails" id="ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails">
          <link:definition>999072 - Disclosure - SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails" id="ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails">
          <link:definition>999073 - Disclosure - SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical" id="ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical">
          <link:definition>999074 - Disclosure - SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/SegmentReportingDetailsNarrative" id="SegmentReportingDetailsNarrative">
          <link:definition>999075 - Disclosure - SEGMENT REPORTING (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999076 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="smti-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="smti-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="smti-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="smti-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="SMTI_UnvestedRestrictedStockMember" name="UnvestedRestrictedStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_SoftTissueRepairProductsMember" name="SoftTissueRepairProductsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_BoneFusionProductsMember" name="BoneFusionProductsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_InternalUseSoftwareMember" name="InternalUseSoftwareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_AppliedAssetPurchaseAgreementMember" name="AppliedAssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_CashClosingConsiderationMember" name="CashClosingConsiderationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_StockClosingConsiderationMember" name="StockClosingConsiderationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_CustomerRelationshipsAndOtherMember" name="CustomerRelationshipsAndOtherMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_AmortizableIntangibleAssetsMember" name="AmortizableIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_DirectDermatologyIncMember" name="DirectDermatologyIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_SeriesBTwoPreferredSharesMember" name="SeriesBTwoPreferredSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ClassAPreferredSharesMember" name="ClassAPreferredSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_PixalereHealthcareIncMember" name="PixalereHealthcareIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_PixalereHealthcareUSALLCMember" name="PixalereHealthcareUSALLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_CommonUnitsMember" name="CommonUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ChemoMouthPieceLLCMember" name="ChemoMouthPieceLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_SIHealthcareTechnologiesLLCMember" name="SIHealthcareTechnologiesLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_OfficeSpaceOneMember" name="OfficeSpaceOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_OfficeSpaceTwoMember" name="OfficeSpaceTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_CRGTermLoanAgreementMember" name="CRGTermLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_BackendFeeMember" name="BackendFeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_CadenceTermLoanAgreementMember" name="CadenceTermLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_CRGTermLoanMember" name="CRGTermLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_CadenceTermLoanMember" name="CadenceTermLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_PaidInKindInterestMember" name="PaidInKindInterestMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_SubLicenseAgreementMember" name="SubLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_BIAKOSLicenseAgreementMember" name="BIAKOSLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_RochalIndustriesLLCMember" name="RochalIndustriesLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_BIAKOSAgreementMember" name="BIAKOSAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ABFLicenseAgreementMember" name="ABFLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_RochalMember" name="RochalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_DebriderLicenseAgreementMember" name="DebriderLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_PrecisionHealingMergerAgreementMember" name="PrecisionHealingMergerAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_AccreditedInvestorsMember" name="AccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_WarrantOneMember" name="WarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ScendiaPurchaseAgreementMember" name="ScendiaPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ServicesAgreementMember" name="ServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember" name="TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember" name="TwoThousandFourteenOmnibusLongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_SalesAgreementMember" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_PrecisionHealingIncMember" name="PrecisionHealingIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_PrecisionHealingMember" name="PrecisionHealingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_NonaccreditedInvestorsMember" name="NonaccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_NoCustomersMember" name="NoCustomersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_MsSalamoneMember" name="MsSalamoneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_SanaraSurgicalMember" name="SanaraSurgicalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_THPMember" name="THPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_SubscriptionAndShareholdersAgreementMember" name="SubscriptionAndShareholdersAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_SubscriptionAgreementMember" name="SubscriptionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_RoyaltyReceivable" name="RoyaltyReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities" name="ChangeInFairValueOfDeferredAndEarnoutLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" name="StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards" name="StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_BackendFee" name="BackendFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_AccretionOfFinanceLiabilities" name="AccretionOfFinanceLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts" name="AmortizationAndWriteoffOfDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_AccruedInterestIncomeExpense" name="AccruedInterestIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_IncreaseDecreaseInAccountsPayableRelatedParty" name="IncreaseDecreaseInAccountsPayableRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses" name="IncreaseDecreaseInAccruedRoyaltiesAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions" name="IncreaseDecreaseInAccruedBonusesAndCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_CashPaymentOfFinanceAndEarnoutLiabilities" name="CashPaymentOfFinanceAndEarnoutLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_NoInsiderTradingFlag" name="NoInsiderTradingFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_DisclosureOperatingLeasesAbstract" name="DisclosureOperatingLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" name="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments" name="AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory" name="AssetAcquisitionConsiderationTransferredCashPaidForInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments" name="AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_EarnoutPayable" name="EarnoutPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_PurchaseAgreementDescription" name="PurchaseAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_EquityMethodInvestmentsEconomicInterest" name="EquityMethodInvestmentsEconomicInterest" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_GrossCashReceivedFromTermLoan" name="GrossCashReceivedFromTermLoan" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_CashPaidPercentage" name="CashPaidPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_DebtInstrumentUpFrontFeePercentage" name="DebtInstrumentUpFrontFeePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_DebtInstrumentBackEndFeePercentage" name="DebtInstrumentBackEndFeePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_MinimumCashBalanceValue" name="MinimumCashBalanceValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_AnnualMinimumRevenueYearOne" name="AnnualMinimumRevenueYearOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_AnnualMinimumRevenueYearTwo" name="AnnualMinimumRevenueYearTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_AnnualMinimumRevenueYearThree" name="AnnualMinimumRevenueYearThree" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_AnnualMinimumRevenueYearFour" name="AnnualMinimumRevenueYearFour" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_AnnualMinimumRevenueYearFive" name="AnnualMinimumRevenueYearFive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_PercentageOfLoanProceedsUsedForAcquisition" name="PercentageOfLoanProceedsUsedForAcquisition" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_LicenseAgreementAndRoyaltiesDescription" name="LicenseAgreementAndRoyaltiesDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_RoyaltyPercentage" name="RoyaltyPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_IncreaseInRoyaltyAnnualPercentage" name="IncreaseInRoyaltyAnnualPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_PaymentsForAdditionalRoyalties" name="PaymentsForAdditionalRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_EarnoutPayment" name="EarnoutPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_OutstandingUnitsPercentage" name="OutstandingUnitsPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_RoyaltyExpensePercentage" name="RoyaltyExpensePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_DeferredTaxAssetsAcquistionLiability" name="DeferredTaxAssetsAcquistionLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization" name="DeferredTaxLiabilitiesDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_DeferredTaxLiabilitiesContingentLiability" name="DeferredTaxLiabilitiesContingentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences" name="DeferredTaxLiabilitiesOtherTemporaryDifferences" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_IncomeTaxReconciliationFairValueAdjustments" name="IncomeTaxReconciliationFairValueAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" name="IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles" name="IncomeTaxReconciliationIncomeTaxExpenseIntangibles" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" name="IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount" name="EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization" name="EarningsBeforeInterestTaxesDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_ExecutiveSeparationCosts" name="ExecutiveSeparationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SMTI_PropertyAndEquipmentWriteOff" name="PropertyAndEquipmentWriteOff" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>smti-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sanaramedtech.com/role/Cover" xlink:href="smti-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/BalanceSheets" xlink:href="smti-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/BalanceSheetsParenthetical" xlink:href="smti-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/StatementsOfOperations" xlink:href="smti-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity" xlink:href="smti-20241231.xsd#StatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/StatementsOfCashFlows" xlink:href="smti-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/StatementsOfCashFlowsParenthetical" xlink:href="smti-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/NatureOfBusinessAndBackground" xlink:href="smti-20241231.xsd#NatureOfBusinessAndBackground" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="smti-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/AppliedAssetPurchase" xlink:href="smti-20241231.xsd#AppliedAssetPurchase" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ConvertibleLoanReceivable" xlink:href="smti-20241231.xsd#ConvertibleLoanReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/GoodwillAndIntangiblesNet" xlink:href="smti-20241231.xsd#GoodwillAndIntangiblesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/InvestmentsInEquitySecurities" xlink:href="smti-20241231.xsd#InvestmentsInEquitySecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/OperatingLeases" xlink:href="smti-20241231.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/DebtAndCreditFacilities" xlink:href="smti-20241231.xsd#DebtAndCreditFacilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/CommitmentsAndContingencies" xlink:href="smti-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ShareholdersEquity" xlink:href="smti-20241231.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/CustomersAndSuppliers" xlink:href="smti-20241231.xsd#CustomersAndSuppliers" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/IncomeTaxes" xlink:href="smti-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/RelatedParties" xlink:href="smti-20241231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SegmentReporting" xlink:href="smti-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SubsequentEvents" xlink:href="smti-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="smti-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="smti-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/AppliedAssetPurchaseTables" xlink:href="smti-20241231.xsd#AppliedAssetPurchaseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/GoodwillAndIntangiblesNetTables" xlink:href="smti-20241231.xsd#GoodwillAndIntangiblesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesTables" xlink:href="smti-20241231.xsd#InvestmentsInEquitySecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/OperatingLeasesTables" xlink:href="smti-20241231.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/DebtAndCreditFacilitiesTables" xlink:href="smti-20241231.xsd#DebtAndCreditFacilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ShareholdersEquityTables" xlink:href="smti-20241231.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/IncomeTaxesTables" xlink:href="smti-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SegmentReportingTables" xlink:href="smti-20241231.xsd#SegmentReportingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/NatureOfBusinessAndBackgroundDetailsNarrative" xlink:href="smti-20241231.xsd#NatureOfBusinessAndBackgroundDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails" xlink:href="smti-20241231.xsd#ScheduleOfComputationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails" xlink:href="smti-20241231.xsd#ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="smti-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails" xlink:href="smti-20241231.xsd#ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="smti-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails" xlink:href="smti-20241231.xsd#ScheduleOfAssetPurchaseConsiderationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails" xlink:href="smti-20241231.xsd#ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative" xlink:href="smti-20241231.xsd#AppliedAssetPurchaseDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative" xlink:href="smti-20241231.xsd#ConvertibleLoanReceivableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfChangesInCarryingAmountOfGoodwillDetails" xlink:href="smti-20241231.xsd#ScheduleOfChangesInCarryingAmountOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" xlink:href="smti-20241231.xsd#ScheduleOfCarryingValueOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails" xlink:href="smti-20241231.xsd#ScheduleOfFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/GoodwillAndIntangiblesNetDetailsNarrative" xlink:href="smti-20241231.xsd#GoodwillAndIntangiblesNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails" xlink:href="smti-20241231.xsd#ScheduleOfInvestmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails" xlink:href="smti-20241231.xsd#ScheduleOfLossFromEquityMethodInvestmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative" xlink:href="smti-20241231.xsd#InvestmentsInEquitySecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails" xlink:href="smti-20241231.xsd#ScheduleOfOperatingLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative" xlink:href="smti-20241231.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails" xlink:href="smti-20241231.xsd#ScheduleOfLong-termDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails" xlink:href="smti-20241231.xsd#ScheduleOfMaturitiesOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative" xlink:href="smti-20241231.xsd#DebtAndCreditFacilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="smti-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails" xlink:href="smti-20241231.xsd#SummaryOfRestrictedStockActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="smti-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails" xlink:href="smti-20241231.xsd#ScheduleOfWarrantsToPurchaseCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative" xlink:href="smti-20241231.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative" xlink:href="smti-20241231.xsd#CustomersAndSuppliersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="smti-20241231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails" xlink:href="smti-20241231.xsd#ScheduleOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/IncomeTaxesDetailsNarrative" xlink:href="smti-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative" xlink:href="smti-20241231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails" xlink:href="smti-20241231.xsd#ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails" xlink:href="smti-20241231.xsd#ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical" xlink:href="smti-20241231.xsd#ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SegmentReportingDetailsNarrative" xlink:href="smti-20241231.xsd#SegmentReportingDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative" xlink:href="smti-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RoyaltyReceivable" xlink:label="loc_SMTIRoyaltyReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_SMTIRoyaltyReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaapLongTermInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapLongTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalesCommissionCurrent" xlink:label="loc_us-gaapAccruedSalesCommissionCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalesCommissionCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOtherLongTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities" xlink:label="loc_SMTIChangeInFairValueOfDeferredAndEarnoutLiabilities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_SMTIChangeInFairValueOfDeferredAndEarnoutLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromEquityMethodInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapIncomeLossFromEquityMethodInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromEquityMethodInvestments" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncomeLossFromEquityMethodInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BackendFee" xlink:label="loc_SMTIBackendFee" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SMTIBackendFee" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AccretionOfFinanceLiabilities" xlink:label="loc_SMTIAccretionOfFinanceLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SMTIAccretionOfFinanceLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts" xlink:label="loc_SMTIAmortizationAndWriteoffOfDebtIssuanceCosts" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SMTIAmortizationAndWriteoffOfDebtIssuanceCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities" xlink:label="loc_SMTIChangeInFairValueOfDeferredAndEarnoutLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SMTIChangeInFairValueOfDeferredAndEarnoutLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AccruedInterestIncomeExpense" xlink:label="loc_SMTIAccruedInterestIncomeExpense" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SMTIAccruedInterestIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivableRelatedParties" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncreaseDecreaseInAccountsPayableRelatedParty" xlink:label="loc_SMTIIncreaseDecreaseInAccountsPayableRelatedParty" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SMTIIncreaseDecreaseInAccountsPayableRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses" xlink:label="loc_SMTIIncreaseDecreaseInAccruedRoyaltiesAndExpenses" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SMTIIncreaseDecreaseInAccruedRoyaltiesAndExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions" xlink:label="loc_SMTIIncreaseDecreaseInAccruedBonusesAndCommissions" />
      <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SMTIIncreaseDecreaseInAccruedBonusesAndCommissions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaapPaymentsToAcquireEquityMethodInvestments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireEquityMethodInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireLoansReceivable" xlink:label="loc_us-gaapPaymentsToAcquireLoansReceivable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireLoansReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaapProceedsFromPaymentsForOtherFinancingActivities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CashPaymentOfFinanceAndEarnoutLiabilities" xlink:label="loc_SMTICashPaymentOfFinanceAndEarnoutLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SMTICashPaymentOfFinanceAndEarnoutLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/NatureOfBusinessAndBackground" xlink:title="999015 - Disclosure - NATURE OF BUSINESS AND BACKGROUND" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/AppliedAssetPurchase" xlink:title="999017 - Disclosure - APPLIED ASSET PURCHASE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ConvertibleLoanReceivable" xlink:title="999018 - Disclosure - CONVERTIBLE LOAN RECEIVABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/GoodwillAndIntangiblesNet" xlink:title="999019 - Disclosure - GOODWILL AND INTANGIBLES, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/InvestmentsInEquitySecurities" xlink:title="999020 - Disclosure - INVESTMENTS IN EQUITY SECURITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/OperatingLeases" xlink:title="999021 - Disclosure - OPERATING LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/DebtAndCreditFacilities" xlink:title="999022 - Disclosure - DEBT AND CREDIT FACILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/CommitmentsAndContingencies" xlink:title="999023 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ShareholdersEquity" xlink:title="999024 - Disclosure - SHAREHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/CustomersAndSuppliers" xlink:title="999025 - Disclosure - CUSTOMERS AND SUPPLIERS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/IncomeTaxes" xlink:title="999026 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/RelatedParties" xlink:title="999027 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SegmentReporting" xlink:title="999028 - Disclosure - SEGMENT REPORTING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SubsequentEvents" xlink:title="999029 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/AppliedAssetPurchaseTables" xlink:title="999032 - Disclosure - APPLIED ASSET PURCHASE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/GoodwillAndIntangiblesNetTables" xlink:title="999033 - Disclosure - GOODWILL AND INTANGIBLES, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesTables" xlink:title="999034 - Disclosure - INVESTMENTS IN EQUITY SECURITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/OperatingLeasesTables" xlink:title="999035 - Disclosure - OPERATING LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/DebtAndCreditFacilitiesTables" xlink:title="999036 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ShareholdersEquityTables" xlink:title="999037 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/IncomeTaxesTables" xlink:title="999038 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SegmentReportingTables" xlink:title="999039 - Disclosure - SEGMENT REPORTING (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/NatureOfBusinessAndBackgroundDetailsNarrative" xlink:title="999040 - Disclosure - NATURE OF BUSINESS AND BACKGROUND (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails" xlink:title="999041 - Disclosure - SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails" xlink:title="999042 - Disclosure - SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999043 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails" xlink:title="999044 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999045 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF ASSET PURCHASE CONSIDERATIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferred" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredOtherAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetAcquisitionConsiderationTransferred" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetAcquisitionConsiderationTransferred" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments" xlink:label="loc_SMTIAssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetAcquisitionConsiderationTransferred" xlink:to="loc_SMTIAssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory" xlink:label="loc_SMTIAssetAcquisitionConsiderationTransferredCashPaidForInventory" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetAcquisitionConsiderationTransferred" xlink:to="loc_SMTIAssetAcquisitionConsiderationTransferredCashPaidForInventory" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments" xlink:label="loc_SMTIAssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetAcquisitionConsiderationTransferred" xlink:to="loc_SMTIAssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetAcquisitionConsiderationTransferred" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredTransactionCost" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetAcquisitionConsiderationTransferred" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredTransactionCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails" xlink:title="999047 - Disclosure - SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty" xlink:label="loc_SMTIBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_SMTIBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative" xlink:title="999048 - Disclosure - APPLIED ASSET PURCHASE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative" xlink:title="999049 - Disclosure - CONVERTIBLE LOAN RECEIVABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfChangesInCarryingAmountOfGoodwillDetails" xlink:title="999050 - Disclosure - SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" xlink:title="999051 - Disclosure - SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails" xlink:title="999052 - Disclosure - SCHEDULE OF FUTURE AMORTIZATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/GoodwillAndIntangiblesNetDetailsNarrative" xlink:title="999053 - Disclosure - GOODWILL AND INTANGIBLES, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails" xlink:title="999054 - Disclosure - SCHEDULE OF INVESTMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails" xlink:title="999055 - Disclosure - SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative" xlink:title="999056 - Disclosure - INVESTMENTS IN EQUITY SECURITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails" xlink:title="999057 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative" xlink:title="999058 - Disclosure - OPERATING LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails" xlink:title="999059 - Disclosure - SCHEDULE OF LONG-TERM DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails" xlink:title="999060 - Disclosure - SCHEDULE OF MATURITIES OUTSTANDING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative" xlink:title="999061 - Disclosure - DEBT AND CREDIT FACILITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails" xlink:title="999063 - Disclosure - SUMMARY OF RESTRICTED STOCK ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999064 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails" xlink:title="999065 - Disclosure - SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative" xlink:title="999066 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative" xlink:title="999067 - Disclosure - CUSTOMERS AND SUPPLIERS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999068 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxAssetsLeaseLiability" xlink:label="loc_SMTIDeferredTaxAssetsLeaseLiability" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_SMTIDeferredTaxAssetsLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxAssetsAcquistionLiability" xlink:label="loc_SMTIDeferredTaxAssetsAcquistionLiability" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_SMTIDeferredTaxAssetsAcquistionLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaapDeferredTaxAssetsInventory" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInventory" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="loc_SMTIDeferredTaxLiabilitiesDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_SMTIDeferredTaxLiabilitiesDepreciationAndAmortization" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxLiabilitiesContingentLiability" xlink:label="loc_SMTIDeferredTaxLiabilitiesContingentLiability" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_SMTIDeferredTaxLiabilitiesContingentLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences" xlink:label="loc_SMTIDeferredTaxLiabilitiesOtherTemporaryDifferences" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_SMTIDeferredTaxLiabilitiesOtherTemporaryDifferences" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails" xlink:title="999069 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE (BENEFIT) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncomeTaxReconciliationFairValueAdjustments" xlink:label="loc_SMTIIncomeTaxReconciliationFairValueAdjustments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SMTIIncomeTaxReconciliationFairValueAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" xlink:label="loc_SMTIIncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SMTIIncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles" xlink:label="loc_SMTIIncomeTaxReconciliationIncomeTaxExpenseIntangibles" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SMTIIncomeTaxReconciliationIncomeTaxExpenseIntangibles" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" xlink:label="loc_SMTIIncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SMTIIncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/IncomeTaxesDetailsNarrative" xlink:title="999070 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative" xlink:title="999071 - Disclosure - RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails" xlink:title="999072 - Disclosure - SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails" xlink:title="999073 - Disclosure - SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical" xlink:title="999074 - Disclosure - SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SegmentReportingDetailsNarrative" xlink:title="999075 - Disclosure - SEGMENT REPORTING (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative" xlink:title="999076 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>smti-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sanaramedtech.com/role/Cover" xlink:href="smti-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/BalanceSheets" xlink:href="smti-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/BalanceSheetsParenthetical" xlink:href="smti-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/StatementsOfOperations" xlink:href="smti-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity" xlink:href="smti-20241231.xsd#StatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/StatementsOfCashFlows" xlink:href="smti-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/StatementsOfCashFlowsParenthetical" xlink:href="smti-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/NatureOfBusinessAndBackground" xlink:href="smti-20241231.xsd#NatureOfBusinessAndBackground" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="smti-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/AppliedAssetPurchase" xlink:href="smti-20241231.xsd#AppliedAssetPurchase" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ConvertibleLoanReceivable" xlink:href="smti-20241231.xsd#ConvertibleLoanReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/GoodwillAndIntangiblesNet" xlink:href="smti-20241231.xsd#GoodwillAndIntangiblesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/InvestmentsInEquitySecurities" xlink:href="smti-20241231.xsd#InvestmentsInEquitySecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/OperatingLeases" xlink:href="smti-20241231.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/DebtAndCreditFacilities" xlink:href="smti-20241231.xsd#DebtAndCreditFacilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/CommitmentsAndContingencies" xlink:href="smti-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ShareholdersEquity" xlink:href="smti-20241231.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/CustomersAndSuppliers" xlink:href="smti-20241231.xsd#CustomersAndSuppliers" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/IncomeTaxes" xlink:href="smti-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/RelatedParties" xlink:href="smti-20241231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SegmentReporting" xlink:href="smti-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SubsequentEvents" xlink:href="smti-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="smti-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="smti-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/AppliedAssetPurchaseTables" xlink:href="smti-20241231.xsd#AppliedAssetPurchaseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/GoodwillAndIntangiblesNetTables" xlink:href="smti-20241231.xsd#GoodwillAndIntangiblesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesTables" xlink:href="smti-20241231.xsd#InvestmentsInEquitySecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/OperatingLeasesTables" xlink:href="smti-20241231.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/DebtAndCreditFacilitiesTables" xlink:href="smti-20241231.xsd#DebtAndCreditFacilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ShareholdersEquityTables" xlink:href="smti-20241231.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/IncomeTaxesTables" xlink:href="smti-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SegmentReportingTables" xlink:href="smti-20241231.xsd#SegmentReportingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/NatureOfBusinessAndBackgroundDetailsNarrative" xlink:href="smti-20241231.xsd#NatureOfBusinessAndBackgroundDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails" xlink:href="smti-20241231.xsd#ScheduleOfComputationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails" xlink:href="smti-20241231.xsd#ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="smti-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails" xlink:href="smti-20241231.xsd#ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="smti-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails" xlink:href="smti-20241231.xsd#ScheduleOfAssetPurchaseConsiderationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails" xlink:href="smti-20241231.xsd#ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative" xlink:href="smti-20241231.xsd#AppliedAssetPurchaseDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative" xlink:href="smti-20241231.xsd#ConvertibleLoanReceivableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfChangesInCarryingAmountOfGoodwillDetails" xlink:href="smti-20241231.xsd#ScheduleOfChangesInCarryingAmountOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" xlink:href="smti-20241231.xsd#ScheduleOfCarryingValueOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails" xlink:href="smti-20241231.xsd#ScheduleOfFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/GoodwillAndIntangiblesNetDetailsNarrative" xlink:href="smti-20241231.xsd#GoodwillAndIntangiblesNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails" xlink:href="smti-20241231.xsd#ScheduleOfInvestmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails" xlink:href="smti-20241231.xsd#ScheduleOfLossFromEquityMethodInvestmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative" xlink:href="smti-20241231.xsd#InvestmentsInEquitySecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails" xlink:href="smti-20241231.xsd#ScheduleOfOperatingLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative" xlink:href="smti-20241231.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails" xlink:href="smti-20241231.xsd#ScheduleOfLong-termDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails" xlink:href="smti-20241231.xsd#ScheduleOfMaturitiesOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative" xlink:href="smti-20241231.xsd#DebtAndCreditFacilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="smti-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails" xlink:href="smti-20241231.xsd#SummaryOfRestrictedStockActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="smti-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails" xlink:href="smti-20241231.xsd#ScheduleOfWarrantsToPurchaseCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative" xlink:href="smti-20241231.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative" xlink:href="smti-20241231.xsd#CustomersAndSuppliersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="smti-20241231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails" xlink:href="smti-20241231.xsd#ScheduleOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/IncomeTaxesDetailsNarrative" xlink:href="smti-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative" xlink:href="smti-20241231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails" xlink:href="smti-20241231.xsd#ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails" xlink:href="smti-20241231.xsd#ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical" xlink:href="smti-20241231.xsd#ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SegmentReportingDetailsNarrative" xlink:href="smti-20241231.xsd#SegmentReportingDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative" xlink:href="smti-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RoyaltyReceivable" xlink:label="loc_SMTIRoyaltyReceivable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_SMTIRoyaltyReceivable_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapInventoryNet_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_us-gaapGoodwill_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaapLongTermInvestments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_us-gaapLongTermInvestments_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_us-gaapAssetsNoncurrent_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableCurrent_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalesCommissionCurrent" xlink:label="loc_us-gaapAccruedSalesCommissionCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccruedSalesCommissionCurrent_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLongTermDebtCurrent_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapLongTermDebtNoncurrent_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapOtherLongTermDebt_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesNoncurrent_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommitmentsAndContingencies_70" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock_70" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" xlink:to="loc_us-gaapMinorityInterest_70" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="41" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" xlink:label="loc_SMTIStockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SMTIStockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards" xlink:label="loc_SMTIStockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SMTIStockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_60" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/NatureOfBusinessAndBackground" xlink:title="999015 - Disclosure - NATURE OF BUSINESS AND BACKGROUND" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/AppliedAssetPurchase" xlink:title="999017 - Disclosure - APPLIED ASSET PURCHASE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ConvertibleLoanReceivable" xlink:title="999018 - Disclosure - CONVERTIBLE LOAN RECEIVABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/GoodwillAndIntangiblesNet" xlink:title="999019 - Disclosure - GOODWILL AND INTANGIBLES, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/InvestmentsInEquitySecurities" xlink:title="999020 - Disclosure - INVESTMENTS IN EQUITY SECURITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/OperatingLeases" xlink:title="999021 - Disclosure - OPERATING LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/DebtAndCreditFacilities" xlink:title="999022 - Disclosure - DEBT AND CREDIT FACILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/CommitmentsAndContingencies" xlink:title="999023 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ShareholdersEquity" xlink:title="999024 - Disclosure - SHAREHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/CustomersAndSuppliers" xlink:title="999025 - Disclosure - CUSTOMERS AND SUPPLIERS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/IncomeTaxes" xlink:title="999026 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/RelatedParties" xlink:title="999027 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SegmentReporting" xlink:title="999028 - Disclosure - SEGMENT REPORTING" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SubsequentEvents" xlink:title="999029 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/AppliedAssetPurchaseTables" xlink:title="999032 - Disclosure - APPLIED ASSET PURCHASE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AppliedAssetPurchaseAgreementMember" xlink:label="loc_SMTIAppliedAssetPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIAppliedAssetPurchaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="loc_us-gaapAssetAcquisitionTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetAcquisitionTableTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/GoodwillAndIntangiblesNetTables" xlink:title="999033 - Disclosure - GOODWILL AND INTANGIBLES, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesTables" xlink:title="999034 - Disclosure - INVESTMENTS IN EQUITY SECURITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/OperatingLeasesTables" xlink:title="999035 - Disclosure - OPERATING LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/DebtAndCreditFacilitiesTables" xlink:title="999036 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ShareholdersEquityTables" xlink:title="999037 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/IncomeTaxesTables" xlink:title="999038 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SegmentReportingTables" xlink:title="999039 - Disclosure - SEGMENT REPORTING (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/NatureOfBusinessAndBackgroundDetailsNarrative" xlink:title="999040 - Disclosure - NATURE OF BUSINESS AND BACKGROUND (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails" xlink:title="999041 - Disclosure - SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_UnvestedRestrictedStockMember" xlink:label="loc_SMTIUnvestedRestrictedStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_SMTIUnvestedRestrictedStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails" xlink:title="999042 - Disclosure - SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SoftTissueRepairProductsMember" xlink:label="loc_SMTISoftTissueRepairProductsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_SMTISoftTissueRepairProductsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BoneFusionProductsMember" xlink:label="loc_SMTIBoneFusionProductsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_SMTIBoneFusionProductsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaapRoyaltyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapRoyaltyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999043 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_InternalUseSoftwareMember" xlink:label="loc_SMTIInternalUseSoftwareMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SMTIInternalUseSoftwareMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_210" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails" xlink:title="999044 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999045 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_InternalUseSoftwareMember" xlink:label="loc_SMTIInternalUseSoftwareMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SMTIInternalUseSoftwareMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInventoryWriteDown_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInventoryValuationReserves_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciation_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss_110" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF ASSET PURCHASE CONSIDERATIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AppliedAssetPurchaseAgreementMember" xlink:label="loc_SMTIAppliedAssetPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIAppliedAssetPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredOtherAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredOtherAssets_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments" xlink:label="loc_SMTIAssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SMTIAssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory" xlink:label="loc_SMTIAssetAcquisitionConsiderationTransferredCashPaidForInventory_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SMTIAssetAcquisitionConsiderationTransferredCashPaidForInventory_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments" xlink:label="loc_SMTIAssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SMTIAssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments_20" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredTransactionCost_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredTransactionCost_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferred_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferred_20" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails" xlink:title="999047 - Disclosure - SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AppliedAssetPurchaseAgreementMember" xlink:label="loc_SMTIAppliedAssetPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_SMTIAppliedAssetPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty" xlink:label="loc_SMTIBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SMTIBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_20" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative" xlink:title="999048 - Disclosure - APPLIED ASSET PURCHASE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AppliedAssetPurchaseAgreementMember" xlink:label="loc_SMTIAppliedAssetPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIAppliedAssetPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CashClosingConsiderationMember" xlink:label="loc_SMTICashClosingConsiderationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_SMTICashClosingConsiderationMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_StockClosingConsiderationMember" xlink:label="loc_SMTIStockClosingConsiderationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_SMTIStockClosingConsiderationMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredOtherAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredOtherAssets_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLoansPayable" xlink:label="loc_us-gaapOtherLoansPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapOtherLoansPayable_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireOtherProductiveAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapPaymentsToAcquireOtherProductiveAssets_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EarnoutPayable" xlink:label="loc_SMTIEarnoutPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_SMTIEarnoutPayable_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PurchaseAgreementDescription" xlink:label="loc_SMTIPurchaseAgreementDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_SMTIPurchaseAgreementDescription_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative" xlink:title="999049 - Disclosure - CONVERTIBLE LOAN RECEIVABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableModificationsLineItems" xlink:label="loc_us-gaapFinancingReceivableModificationsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:label="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanRestructuringModificationAxis" xlink:label="loc_us-gaapLoanRestructuringModificationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:to="loc_us-gaapLoanRestructuringModificationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanRestructuringModificationDomain" xlink:label="loc_us-gaapLoanRestructuringModificationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLoanRestructuringModificationAxis" xlink:to="loc_us-gaapLoanRestructuringModificationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanRestructuringModificationDomain" xlink:label="loc_us-gaapLoanRestructuringModificationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLoanRestructuringModificationAxis" xlink:to="loc_us-gaapLoanRestructuringModificationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtendedMaturityMember" xlink:label="loc_us-gaapExtendedMaturityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLoanRestructuringModificationDomain" xlink:to="loc_us-gaapExtendedMaturityMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaapAccountsNotesAndLoansReceivableNetCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapAccountsNotesAndLoansReceivableNetCurrent_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansHeldForSaleMaturityDate" xlink:label="loc_us-gaapLoansHeldForSaleMaturityDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapLoansHeldForSaleMaturityDate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:label="loc_us-gaapLoansReceivableBasisSpreadOnVariableRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapLoansReceivableBasisSpreadOnVariableRate_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfChangesInCarryingAmountOfGoodwillDetails" xlink:title="999050 - Disclosure - SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" xlink:title="999051 - Disclosure - SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CustomerRelationshipsAndOtherMember" xlink:label="loc_SMTICustomerRelationshipsAndOtherMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_SMTICustomerRelationshipsAndOtherMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicensingAgreementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AmortizableIntangibleAssetsMember" xlink:label="loc_SMTIAmortizableIntangibleAssetsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_SMTIAmortizableIntangibleAssetsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails" xlink:title="999052 - Disclosure - SCHEDULE OF FUTURE AMORTIZATION EXPENSE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/GoodwillAndIntangiblesNetDetailsNarrative" xlink:title="999053 - Disclosure - GOODWILL AND INTANGIBLES, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails" xlink:title="999054 - Disclosure - SCHEDULE OF INVESTMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ChemoMouthPieceLLCMember" xlink:label="loc_SMTIChemoMouthPieceLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIChemoMouthPieceLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SIHealthcareTechnologiesLLCMember" xlink:label="loc_SMTISIHealthcareTechnologiesLLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTISIHealthcareTechnologiesLLCMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DirectDermatologyIncMember" xlink:label="loc_SMTIDirectDermatologyIncMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIDirectDermatologyIncMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PixalereHealthcareIncMember" xlink:label="loc_SMTIPixalereHealthcareIncMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIPixalereHealthcareIncMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaapEquityMethodInvestments_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestments_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EquityMethodInvestmentsEconomicInterest" xlink:label="loc_SMTIEquityMethodInvestmentsEconomicInterest_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SMTIEquityMethodInvestmentsEconomicInterest_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:label="loc_us-gaapOtherInvestmentsAndSecuritiesAtCost_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherInvestmentsAndSecuritiesAtCost_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestments_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails" xlink:title="999055 - Disclosure - SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ChemoMouthPieceLLCMember" xlink:label="loc_SMTIChemoMouthPieceLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIChemoMouthPieceLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SIHealthcareTechnologiesLLCMember" xlink:label="loc_SMTISIHealthcareTechnologiesLLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTISIHealthcareTechnologiesLLCMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromEquityMethodInvestments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromEquityMethodInvestments_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative" xlink:title="999056 - Disclosure - INVESTMENTS IN EQUITY SECURITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DirectDermatologyIncMember" xlink:label="loc_SMTIDirectDermatologyIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIDirectDermatologyIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PixalereHealthcareIncMember" xlink:label="loc_SMTIPixalereHealthcareIncMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIPixalereHealthcareIncMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ChemoMouthPieceLLCMember" xlink:label="loc_SMTIChemoMouthPieceLLCMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIChemoMouthPieceLLCMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SeriesBTwoPreferredSharesMember" xlink:label="loc_SMTISeriesBTwoPreferredSharesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SMTISeriesBTwoPreferredSharesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ClassAPreferredSharesMember" xlink:label="loc_SMTIClassAPreferredSharesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SMTIClassAPreferredSharesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DirectDermatologyIncMember" xlink:label="loc_SMTIDirectDermatologyIncMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_SMTIDirectDermatologyIncMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PixalereHealthcareUSALLCMember" xlink:label="loc_SMTIPixalereHealthcareUSALLCMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_SMTIPixalereHealthcareUSALLCMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ChemoMouthPieceLLCMember" xlink:label="loc_SMTIChemoMouthPieceLLCMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_SMTIChemoMouthPieceLLCMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CommonUnitsMember" xlink:label="loc_SMTICommonUnitsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SMTICommonUnitsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaapLongTermInvestments_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermInvestments_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestments_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentRate_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentRate_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaapEquityMethodInvestmentAggregateCost_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentAggregateCost_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_140" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails" xlink:title="999057 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative" xlink:title="999058 - Disclosure - OPERATING LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_OfficeSpaceOneMember" xlink:label="loc_SMTIOfficeSpaceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SMTIOfficeSpaceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_OfficeSpaceTwoMember" xlink:label="loc_SMTIOfficeSpaceTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SMTIOfficeSpaceTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_60" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails" xlink:title="999059 - Disclosure - SCHEDULE OF LONG-TERM DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CRGTermLoanMember" xlink:label="loc_SMTICRGTermLoanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SMTICRGTermLoanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PaidInKindInterestMember" xlink:label="loc_SMTIPaidInKindInterestMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SMTIPaidInKindInterestMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BackendFeeMember" xlink:label="loc_SMTIBackendFeeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SMTIBackendFeeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CadenceTermLoanMember" xlink:label="loc_SMTICadenceTermLoanMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SMTICadenceTermLoanMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebt_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebtCurrent_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent_110" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails" xlink:title="999060 - Disclosure - SCHEDULE OF MATURITIES OUTSTANDING (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative" xlink:title="999061 - Disclosure - DEBT AND CREDIT FACILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CRGTermLoanAgreementMember" xlink:label="loc_SMTICRGTermLoanAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTICRGTermLoanAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CadenceTermLoanAgreementMember" xlink:label="loc_SMTICadenceTermLoanAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTICadenceTermLoanAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BackendFeeMember" xlink:label="loc_SMTIBackendFeeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SMTIBackendFeeMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CRGTermLoanMember" xlink:label="loc_SMTICRGTermLoanMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SMTICRGTermLoanMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CadenceTermLoanMember" xlink:label="loc_SMTICadenceTermLoanMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SMTICadenceTermLoanMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSecuredDebt_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_GrossCashReceivedFromTermLoan" xlink:label="loc_SMTIGrossCashReceivedFromTermLoan_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIGrossCashReceivedFromTermLoan_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaapDebtInstrumentUnusedBorrowingCapacityAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnusedBorrowingCapacityAmount_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfSecuredDebt_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfSecuredDebt_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CashPaidPercentage" xlink:label="loc_SMTICashPaidPercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTICashPaidPercentage_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DebtInstrumentUpFrontFeePercentage" xlink:label="loc_SMTIDebtInstrumentUpFrontFeePercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIDebtInstrumentUpFrontFeePercentage_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DebtInstrumentBackEndFeePercentage" xlink:label="loc_SMTIDebtInstrumentBackEndFeePercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIDebtInstrumentBackEndFeePercentage_170" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPaid_170" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaidInKindInterest_170" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpense_170" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms_170" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_MinimumCashBalanceValue" xlink:label="loc_SMTIMinimumCashBalanceValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIMinimumCashBalanceValue_170" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearOne" xlink:label="loc_SMTIAnnualMinimumRevenueYearOne_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIAnnualMinimumRevenueYearOne_170" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearTwo" xlink:label="loc_SMTIAnnualMinimumRevenueYearTwo_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIAnnualMinimumRevenueYearTwo_170" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearThree" xlink:label="loc_SMTIAnnualMinimumRevenueYearThree_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIAnnualMinimumRevenueYearThree_170" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearFour" xlink:label="loc_SMTIAnnualMinimumRevenueYearFour_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIAnnualMinimumRevenueYearFour_170" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearFive" xlink:label="loc_SMTIAnnualMinimumRevenueYearFive_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIAnnualMinimumRevenueYearFive_170" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_170" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PercentageOfLoanProceedsUsedForAcquisition" xlink:label="loc_SMTIPercentageOfLoanProceedsUsedForAcquisition_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIPercentageOfLoanProceedsUsedForAcquisition_170" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalHomeLoanBankAdvances" xlink:label="loc_us-gaapFederalHomeLoanBankAdvances_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFederalHomeLoanBankAdvances_170" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate" xlink:label="loc_us-gaapFederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate_170" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_170" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseOther_170" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaapDeferredFinanceCostsGross_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsGross_170" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet_170" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_170" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost_170" xlink:type="arc" order="31" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SubLicenseAgreementMember" xlink:label="loc_SMTISubLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTISubLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BIAKOSLicenseAgreementMember" xlink:label="loc_SMTIBIAKOSLicenseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIBIAKOSLicenseAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BIAKOSAgreementMember" xlink:label="loc_SMTIBIAKOSAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIBIAKOSAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ABFLicenseAgreementMember" xlink:label="loc_SMTIABFLicenseAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIABFLicenseAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DebriderLicenseAgreementMember" xlink:label="loc_SMTIDebriderLicenseAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIDebriderLicenseAgreementMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PrecisionHealingMergerAgreementMember" xlink:label="loc_SMTIPrecisionHealingMergerAgreementMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIPrecisionHealingMergerAgreementMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ScendiaPurchaseAgreementMember" xlink:label="loc_SMTIScendiaPurchaseAgreementMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIScendiaPurchaseAgreementMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AppliedAssetPurchaseAgreementMember" xlink:label="loc_SMTIAppliedAssetPurchaseAgreementMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIAppliedAssetPurchaseAgreementMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ServicesAgreementMember" xlink:label="loc_SMTIServicesAgreementMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIServicesAgreementMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_LicenseAgreementMember" xlink:label="loc_SMTILicenseAgreementMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTILicenseAgreementMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RochalIndustriesLLCMember" xlink:label="loc_SMTIRochalIndustriesLLCMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIRochalIndustriesLLCMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember_50" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaapProductAndServiceOtherMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductAndServiceOtherMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RochalMember" xlink:label="loc_SMTIRochalMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SMTIRochalMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AccreditedInvestorsMember" xlink:label="loc_SMTIAccreditedInvestorsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SMTIAccreditedInvestorsMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_WarrantOneMember" xlink:label="loc_SMTIWarrantOneMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SMTIWarrantOneMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="loc_us-gaapRoyaltyAgreementTermsMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_us-gaapRoyaltyAgreementTermsMember_350" xlink:type="arc" order="352" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_LicenseAgreementAndRoyaltiesDescription" xlink:label="loc_SMTILicenseAgreementAndRoyaltiesDescription_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTILicenseAgreementAndRoyaltiesDescription_370" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense_370" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RoyaltyPercentage" xlink:label="loc_SMTIRoyaltyPercentage_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTIRoyaltyPercentage_370" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties_370" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncreaseInRoyaltyAnnualPercentage" xlink:label="loc_SMTIIncreaseInRoyaltyAnnualPercentage_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTIIncreaseInRoyaltyAnnualPercentage_370" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapCash_370" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross_370" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PaymentsForAdditionalRoyalties" xlink:label="loc_SMTIPaymentsForAdditionalRoyalties_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTIPaymentsForAdditionalRoyalties_370" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferred_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferred_370" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_370" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_370" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSharePrice_370" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_370" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_370" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_370" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_370" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_370" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_370" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration_370" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_370" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_370" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation_370" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationAsset_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationAsset_370" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_370" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EarnoutPayment" xlink:label="loc_SMTIEarnoutPayment_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTIEarnoutPayment_370" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets_370" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireOtherProductiveAssets_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsToAcquireOtherProductiveAssets_370" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PurchaseAgreementDescription" xlink:label="loc_SMTIPurchaseAgreementDescription_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTIPurchaseAgreementDescription_370" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_OutstandingUnitsPercentage" xlink:label="loc_SMTIOutstandingUnitsPercentage_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTIOutstandingUnitsPercentage_370" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RoyaltyExpensePercentage" xlink:label="loc_SMTIRoyaltyExpensePercentage_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTIRoyaltyExpensePercentage_370" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails" xlink:title="999063 - Disclosure - SUMMARY OF RESTRICTED STOCK ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999064 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails" xlink:title="999065 - Disclosure - SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative" xlink:title="999066 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember" xlink:label="loc_SMTITwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SMTITwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember" xlink:label="loc_SMTITwoThousandFourteenOmnibusLongTermIncentivePlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SMTITwoThousandFourteenOmnibusLongTermIncentivePlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AppliedAssetPurchaseAgreementMember" xlink:label="loc_SMTIAppliedAssetPurchaseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIAppliedAssetPurchaseAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SalesAgreementMember" xlink:label="loc_SMTISalesAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTISalesAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_StockClosingConsiderationMember" xlink:label="loc_SMTIStockClosingConsiderationMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_SMTIStockClosingConsiderationMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PrecisionHealingIncMember" xlink:label="loc_SMTIPrecisionHealingIncMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_SMTIPrecisionHealingIncMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AccreditedInvestorsMember" xlink:label="loc_SMTIAccreditedInvestorsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SMTIAccreditedInvestorsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_NonaccreditedInvestorsMember" xlink:label="loc_SMTINonaccreditedInvestorsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SMTINonaccreditedInvestorsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PrecisionHealingMember" xlink:label="loc_SMTIPrecisionHealingMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIPrecisionHealingMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferred_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferred_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_210" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_210" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_210" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_210" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_210" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_210" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration_210" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_210" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_210" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation_210" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_210" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_210" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative" xlink:title="999067 - Disclosure - CUSTOMERS AND SUPPLIERS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_NoCustomersMember" xlink:label="loc_SMTINoCustomersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SMTINoCustomersMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999068 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails" xlink:title="999069 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE (BENEFIT) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/IncomeTaxesDetailsNarrative" xlink:title="999070 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative" xlink:title="999071 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ConsultingAgreementMember" xlink:label="loc_SMTIConsultingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SMTIConsultingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_MsSalamoneMember" xlink:label="loc_SMTIMsSalamoneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SMTIMsSalamoneMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ServicesAgreementMember" xlink:label="loc_SMTIServicesAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIServicesAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProfessionalFees_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostsAndExpensesRelatedParty_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails" xlink:title="999072 - Disclosure - SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SanaraSurgicalMember" xlink:label="loc_SMTISanaraSurgicalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SMTISanaraSurgicalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_THPMember" xlink:label="loc_SMTITHPMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SMTITHPMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGrossProfit_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaapLiabilitiesFairValueAdjustment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueAdjustment_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInterestExpenseOther_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_SMTIEarningsBeforeInterestTaxesDepreciationAndAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_SMTIEarningsBeforeInterestTaxesDepreciationAndAmortization_70" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails" xlink:title="999073 - Disclosure - SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SanaraSurgicalMember" xlink:label="loc_SMTISanaraSurgicalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SMTISanaraSurgicalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_THPMember" xlink:label="loc_SMTITHPMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SMTITHPMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInterestExpense_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInterestIncomeOther_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationNoncash_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationNoncash_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaapLiabilitiesFairValueAdjustment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueAdjustment_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromEquityMethodInvestments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeLossFromEquityMethodInvestments_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ExecutiveSeparationCosts" xlink:label="loc_SMTIExecutiveSeparationCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_SMTIExecutiveSeparationCosts_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_SMTIEarningsBeforeInterestTaxesDepreciationAndAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_SMTIEarningsBeforeInterestTaxesDepreciationAndAmortization_70" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical" xlink:title="999074 - Disclosure - SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SegmentReportingDetailsNarrative" xlink:title="999075 - Disclosure - SEGMENT REPORTING (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative" xlink:title="999076 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SubscriptionAndShareholdersAgreementMember" xlink:label="loc_SMTISubscriptionAndShareholdersAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTISubscriptionAndShareholdersAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SubscriptionAgreementMember" xlink:label="loc_SMTISubscriptionAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTISubscriptionAgreementMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CRGTermLoanAgreementMember" xlink:label="loc_SMTICRGTermLoanAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTICRGTermLoanAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventDescription_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>smti-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_UnvestedRestrictedStockMember" xlink:label="SMTI_UnvestedRestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_UnvestedRestrictedStockMember" xlink:to="SMTI_UnvestedRestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_UnvestedRestrictedStockMember_lbl" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SoftTissueRepairProductsMember" xlink:label="SMTI_SoftTissueRepairProductsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SoftTissueRepairProductsMember" xlink:to="SMTI_SoftTissueRepairProductsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_SoftTissueRepairProductsMember_lbl" xml:lang="en-US">Soft Tissue Repair Products [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BoneFusionProductsMember" xlink:label="SMTI_BoneFusionProductsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BoneFusionProductsMember" xlink:to="SMTI_BoneFusionProductsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_BoneFusionProductsMember_lbl" xml:lang="en-US">Bone Fusion Products [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US">Royalty [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_InternalUseSoftwareMember" xlink:label="SMTI_InternalUseSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_InternalUseSoftwareMember" xlink:to="SMTI_InternalUseSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_InternalUseSoftwareMember_lbl" xml:lang="en-US">Internal Use Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AppliedAssetPurchaseAgreementMember" xlink:label="SMTI_AppliedAssetPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AppliedAssetPurchaseAgreementMember" xlink:to="SMTI_AppliedAssetPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_AppliedAssetPurchaseAgreementMember_lbl" xml:lang="en-US">Applied Asset Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CashClosingConsiderationMember" xlink:label="SMTI_CashClosingConsiderationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CashClosingConsiderationMember" xlink:to="SMTI_CashClosingConsiderationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_CashClosingConsiderationMember_lbl" xml:lang="en-US">Cash Closing Consideration [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_StockClosingConsiderationMember" xlink:label="SMTI_StockClosingConsiderationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_StockClosingConsiderationMember" xlink:to="SMTI_StockClosingConsiderationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_StockClosingConsiderationMember_lbl" xml:lang="en-US">Stock Closing Consideration [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US">Convertible Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanRestructuringModificationAxis" xlink:label="us-gaap_LoanRestructuringModificationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoanRestructuringModificationAxis" xlink:to="us-gaap_LoanRestructuringModificationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoanRestructuringModificationAxis_lbl" xml:lang="en-US">Loan Restructuring Modification [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtendedMaturityMember" xlink:label="us-gaap_ExtendedMaturityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtendedMaturityMember" xlink:to="us-gaap_ExtendedMaturityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtendedMaturityMember_lbl" xml:lang="en-US">Extended Maturity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CustomerRelationshipsAndOtherMember" xlink:label="SMTI_CustomerRelationshipsAndOtherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CustomerRelationshipsAndOtherMember" xlink:to="SMTI_CustomerRelationshipsAndOtherMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_CustomerRelationshipsAndOtherMember_lbl" xml:lang="en-US">Customer Relationships and Other [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xml:lang="en-US">Licensing Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AmortizableIntangibleAssetsMember" xlink:label="SMTI_AmortizableIntangibleAssetsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AmortizableIntangibleAssetsMember" xlink:to="SMTI_AmortizableIntangibleAssetsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_AmortizableIntangibleAssetsMember_lbl" xml:lang="en-US">Amortizable Intangible Assets [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DirectDermatologyIncMember" xlink:label="SMTI_DirectDermatologyIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DirectDermatologyIncMember" xlink:to="SMTI_DirectDermatologyIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_DirectDermatologyIncMember_lbl" xml:lang="en-US">Direct Dermatology Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SeriesBTwoPreferredSharesMember" xlink:label="SMTI_SeriesBTwoPreferredSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SeriesBTwoPreferredSharesMember" xlink:to="SMTI_SeriesBTwoPreferredSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_SeriesBTwoPreferredSharesMember_lbl" xml:lang="en-US">Series B-2 Preferred Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ClassAPreferredSharesMember" xlink:label="SMTI_ClassAPreferredSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ClassAPreferredSharesMember" xlink:to="SMTI_ClassAPreferredSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ClassAPreferredSharesMember_lbl" xml:lang="en-US">Class A Preferred Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PixalereHealthcareIncMember" xlink:label="SMTI_PixalereHealthcareIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PixalereHealthcareIncMember" xlink:to="SMTI_PixalereHealthcareIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_PixalereHealthcareIncMember_lbl" xml:lang="en-US">Pixalere Healthcare Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PixalereHealthcareUSALLCMember" xlink:label="SMTI_PixalereHealthcareUSALLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PixalereHealthcareUSALLCMember" xlink:to="SMTI_PixalereHealthcareUSALLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_PixalereHealthcareUSALLCMember_lbl" xml:lang="en-US">Pixalere Healthcare USA LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CommonUnitsMember" xlink:label="SMTI_CommonUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CommonUnitsMember" xlink:to="SMTI_CommonUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_CommonUnitsMember_lbl" xml:lang="en-US">Common Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ChemoMouthPieceLLCMember" xlink:label="SMTI_ChemoMouthPieceLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ChemoMouthPieceLLCMember" xlink:to="SMTI_ChemoMouthPieceLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ChemoMouthPieceLLCMember_lbl" xml:lang="en-US">ChemoMouthpiece, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SIHealthcareTechnologiesLLCMember" xlink:label="SMTI_SIHealthcareTechnologiesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SIHealthcareTechnologiesLLCMember" xlink:to="SMTI_SIHealthcareTechnologiesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_SIHealthcareTechnologiesLLCMember_lbl" xml:lang="en-US">SI Healthcare Technologies LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_OfficeSpaceOneMember" xlink:label="SMTI_OfficeSpaceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_OfficeSpaceOneMember" xlink:to="SMTI_OfficeSpaceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_OfficeSpaceOneMember_lbl" xml:lang="en-US">Office Space One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_OfficeSpaceTwoMember" xlink:label="SMTI_OfficeSpaceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_OfficeSpaceTwoMember" xlink:to="SMTI_OfficeSpaceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_OfficeSpaceTwoMember_lbl" xml:lang="en-US">Office Space Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CRGTermLoanAgreementMember" xlink:label="SMTI_CRGTermLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CRGTermLoanAgreementMember" xlink:to="SMTI_CRGTermLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_CRGTermLoanAgreementMember_lbl" xml:lang="en-US">CRG Term Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BackendFeeMember" xlink:label="SMTI_BackendFeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BackendFeeMember" xlink:to="SMTI_BackendFeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_BackendFeeMember_lbl" xml:lang="en-US">Backend Fee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CadenceTermLoanAgreementMember" xlink:label="SMTI_CadenceTermLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CadenceTermLoanAgreementMember" xlink:to="SMTI_CadenceTermLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_CadenceTermLoanAgreementMember_lbl" xml:lang="en-US">Cadence Term Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CRGTermLoanMember" xlink:label="SMTI_CRGTermLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CRGTermLoanMember" xlink:to="SMTI_CRGTermLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_CRGTermLoanMember_lbl" xml:lang="en-US">CRG Term Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CadenceTermLoanMember" xlink:label="SMTI_CadenceTermLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CadenceTermLoanMember" xlink:to="SMTI_CadenceTermLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_CadenceTermLoanMember_lbl" xml:lang="en-US">Cadence Term Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PaidInKindInterestMember" xlink:label="SMTI_PaidInKindInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PaidInKindInterestMember" xlink:to="SMTI_PaidInKindInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_PaidInKindInterestMember_lbl" xml:lang="en-US">Paid In Kind Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SubLicenseAgreementMember" xlink:label="SMTI_SubLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SubLicenseAgreementMember" xlink:to="SMTI_SubLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_SubLicenseAgreementMember_lbl" xml:lang="en-US">Sub License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BIAKOSLicenseAgreementMember" xlink:label="SMTI_BIAKOSLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BIAKOSLicenseAgreementMember" xlink:to="SMTI_BIAKOSLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_BIAKOSLicenseAgreementMember_lbl" xml:lang="en-US">BIAKOS License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RochalIndustriesLLCMember" xlink:label="SMTI_RochalIndustriesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_RochalIndustriesLLCMember" xlink:to="SMTI_RochalIndustriesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_RochalIndustriesLLCMember_lbl" xml:lang="en-US">Rochal Industries LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BIAKOSAgreementMember" xlink:label="SMTI_BIAKOSAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BIAKOSAgreementMember" xlink:to="SMTI_BIAKOSAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_BIAKOSAgreementMember_lbl" xml:lang="en-US">BIAKOS Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ABFLicenseAgreementMember" xlink:label="SMTI_ABFLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ABFLicenseAgreementMember" xlink:to="SMTI_ABFLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ABFLicenseAgreementMember_lbl" xml:lang="en-US">ABF License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductAndServiceOtherMember" xlink:to="us-gaap_ProductAndServiceOtherMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductAndServiceOtherMember_lbl" xml:lang="en-US">Product and Service, Other [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RochalMember" xlink:label="SMTI_RochalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_RochalMember" xlink:to="SMTI_RochalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_RochalMember_lbl" xml:lang="en-US">Rochal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DebriderLicenseAgreementMember" xlink:label="SMTI_DebriderLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DebriderLicenseAgreementMember" xlink:to="SMTI_DebriderLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_DebriderLicenseAgreementMember_lbl" xml:lang="en-US">Debrider License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PrecisionHealingMergerAgreementMember" xlink:label="SMTI_PrecisionHealingMergerAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PrecisionHealingMergerAgreementMember" xlink:to="SMTI_PrecisionHealingMergerAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_PrecisionHealingMergerAgreementMember_lbl" xml:lang="en-US">Precision Healing Merger Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AccreditedInvestorsMember" xlink:label="SMTI_AccreditedInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AccreditedInvestorsMember" xlink:to="SMTI_AccreditedInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_AccreditedInvestorsMember_lbl" xml:lang="en-US">Accredited Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_WarrantOneMember" xlink:label="SMTI_WarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_WarrantOneMember" xlink:to="SMTI_WarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_WarrantOneMember_lbl" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ScendiaPurchaseAgreementMember" xlink:label="SMTI_ScendiaPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ScendiaPurchaseAgreementMember" xlink:to="SMTI_ScendiaPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ScendiaPurchaseAgreementMember_lbl" xml:lang="en-US">Scendia Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ServicesAgreementMember" xlink:label="SMTI_ServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ServicesAgreementMember" xlink:to="SMTI_ServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ServicesAgreementMember_lbl" xml:lang="en-US">Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_LicenseAgreementMember" xlink:label="SMTI_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_LicenseAgreementMember" xlink:to="SMTI_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="us-gaap_RoyaltyAgreementTermsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementTermsMember" xlink:to="us-gaap_RoyaltyAgreementTermsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyAgreementTermsMember_lbl" xml:lang="en-US">Royalty Agreement Terms [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember" xlink:label="SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember" xlink:to="SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_lbl" xml:lang="en-US">2024 Omnibus Long-Term Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember" xlink:label="SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember" xlink:to="SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember_lbl" xml:lang="en-US">2024 Omnibus Long Term Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SalesAgreementMember" xlink:label="SMTI_SalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SalesAgreementMember" xlink:to="SMTI_SalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PrecisionHealingIncMember" xlink:label="SMTI_PrecisionHealingIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PrecisionHealingIncMember" xlink:to="SMTI_PrecisionHealingIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_PrecisionHealingIncMember_lbl" xml:lang="en-US">Precision Healing Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PrecisionHealingMember" xlink:label="SMTI_PrecisionHealingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PrecisionHealingMember" xlink:to="SMTI_PrecisionHealingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_PrecisionHealingMember_lbl" xml:lang="en-US">Precision Healing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_NonaccreditedInvestorsMember" xlink:label="SMTI_NonaccreditedInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_NonaccreditedInvestorsMember" xlink:to="SMTI_NonaccreditedInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_NonaccreditedInvestorsMember_lbl" xml:lang="en-US">Nonaccredited Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_NoCustomersMember" xlink:label="SMTI_NoCustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_NoCustomersMember" xlink:to="SMTI_NoCustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_NoCustomersMember_lbl" xml:lang="en-US">No Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ConsultingAgreementMember" xlink:label="SMTI_ConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ConsultingAgreementMember" xlink:to="SMTI_ConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_MsSalamoneMember" xlink:label="SMTI_MsSalamoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_MsSalamoneMember" xlink:to="SMTI_MsSalamoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_MsSalamoneMember_lbl" xml:lang="en-US">Ms Salamone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SanaraSurgicalMember" xlink:label="SMTI_SanaraSurgicalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SanaraSurgicalMember" xlink:to="SMTI_SanaraSurgicalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_SanaraSurgicalMember_lbl" xml:lang="en-US">Sanara Surgical [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_THPMember" xlink:label="SMTI_THPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_THPMember" xlink:to="SMTI_THPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_THPMember_lbl" xml:lang="en-US">THP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SubscriptionAndShareholdersAgreementMember" xlink:label="SMTI_SubscriptionAndShareholdersAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SubscriptionAndShareholdersAgreementMember" xlink:to="SMTI_SubscriptionAndShareholdersAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_SubscriptionAndShareholdersAgreementMember_lbl" xml:lang="en-US">Subscription and Shareholders Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SubscriptionAgreementMember" xlink:label="SMTI_SubscriptionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SubscriptionAgreementMember" xlink:to="SMTI_SubscriptionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_SubscriptionAgreementMember_lbl" xml:lang="en-US">Subscription Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated By Reference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingParValuePerShare" xlink:label="dei_EntityListingParValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingParValuePerShare" xlink:to="dei_EntityListingParValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingParValuePerShare_lbl" xml:lang="en-US">Entity Listing, Par Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RoyaltyReceivable" xlink:label="SMTI_RoyaltyReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_RoyaltyReceivable" xlink:to="SMTI_RoyaltyReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_RoyaltyReceivable_lbl" xml:lang="en-US">Royalty receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Convertible loan receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Long-term assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US">Investment in equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets &#8211; operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total long-term assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalesCommissionCurrent" xlink:label="us-gaap_AccruedSalesCommissionCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalesCommissionCurrent" xlink:to="us-gaap_AccruedSalesCommissionCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalesCommissionCurrent_lbl" xml:lang="en-US">Accrued bonuses and commissions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued royalties and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Earnout liabilities &#8211; current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Current portion of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities &#8211; current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Earnout liabilities &#8211; long-term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities &#8211; long-term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="us-gaap_OtherLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebt" xlink:to="us-gaap_OtherLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebt_lbl" xml:lang="en-US">Other long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock: $0.001 par value, 20,000,000 shares authorized; 8,753,773 issued and outstanding as of December&#160;31, 2024 and 8,535,239 issued and outstanding as of December&#160;31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Sanara MedTech shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Equity attributable to noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Net Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities" xlink:label="SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities" xlink:to="SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities_lbl" xml:lang="en-US">Change in fair value of earnout liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Share of losses from equity method investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl" xml:lang="en-US">Gain on disposal of investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Less: Net loss attributable to noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss attributable to Sanara MedTech shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share of common stock, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share of common stock, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" xlink:label="SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" xlink:to="SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards_lbl" xml:lang="en-US">Net settlement and retirement of equity-based awards</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards" xlink:label="SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards" xlink:to="SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards_lbl" xml:lang="en-US">Net settlement and retirement of equity-based awards, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Issuance of common stock for acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Issuance of common stock for acquisitions, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock in equity offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock in equity offering, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Credit loss expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory obsolescence</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Noncash lease expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_2_lbl" xml:lang="en-US">Share of losses from equity method investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_2_lbl" xml:lang="en-US">Gain on disposal of investment</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BackendFee" xlink:label="SMTI_BackendFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BackendFee" xlink:to="SMTI_BackendFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_BackendFee_lbl" xml:lang="en-US">Back-end fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Paid-in-kind interest</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AccretionOfFinanceLiabilities" xlink:label="SMTI_AccretionOfFinanceLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AccretionOfFinanceLiabilities" xlink:to="SMTI_AccretionOfFinanceLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_AccretionOfFinanceLiabilities_lbl" xml:lang="en-US">Accretion of finance liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts" xlink:label="SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts" xlink:to="SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts_lbl" xml:lang="en-US">Amortization and write-off of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AccruedInterestIncomeExpense" xlink:label="SMTI_AccruedInterestIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AccruedInterestIncomeExpense" xlink:to="SMTI_AccruedInterestIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_AccruedInterestIncomeExpense_lbl" xml:lang="en-US">Accrued interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xml:lang="en-US">Accounts receivable &#8211; related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncreaseDecreaseInAccountsPayableRelatedParty" xlink:label="SMTI_IncreaseDecreaseInAccountsPayableRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncreaseDecreaseInAccountsPayableRelatedParty" xlink:to="SMTI_IncreaseDecreaseInAccountsPayableRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_IncreaseDecreaseInAccountsPayableRelatedParty_lbl" xml:lang="en-US">Accounts payable &#8211; related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses" xlink:label="SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses" xlink:to="SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses_lbl" xml:lang="en-US">Accrued royalties and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions" xlink:label="SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions" xlink:to="SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions_lbl" xml:lang="en-US">Accrued bonuses and commissions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchases of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xml:lang="en-US">Investment in equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireLoansReceivable" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLoansReceivable" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable_lbl" xml:lang="en-US">Convertible loan receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Acquisitions, net of cash acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US">Loan proceeds, net of debt issuance costs of $1,160,740 in 2024 and $61,658 in 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Pay off line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Equity offering net proceeds (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US">Net settlement of equity-based awards</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CashPaymentOfFinanceAndEarnoutLiabilities" xlink:label="SMTI_CashPaymentOfFinanceAndEarnoutLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CashPaymentOfFinanceAndEarnoutLiabilities" xlink:to="SMTI_CashPaymentOfFinanceAndEarnoutLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SMTI_CashPaymentOfFinanceAndEarnoutLiabilities_lbl" xml:lang="en-US">Cash payment of finance and earnout liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Cash paid during the period for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental noncash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use assets obtained in exchange for lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Equity issued for acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl" xml:lang="en-US">Earnout and other liabilities generated by acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Net of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_NoInsiderTradingFlag" xlink:label="SMTI_NoInsiderTradingFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_NoInsiderTradingFlag" xlink:to="SMTI_NoInsiderTradingFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_NoInsiderTradingFlag_lbl" xml:lang="en-US">No Insider Trading Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NATURE OF BUSINESS AND BACKGROUND</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xml:lang="en-US">APPLIED ASSET PURCHASE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Receivables [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE LOAN RECEIVABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">GOODWILL AND INTANGIBLES, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfInvestmentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract_lbl" xml:lang="en-US">Schedule of Investments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentHoldingsTextBlock" xlink:label="us-gaap_InvestmentHoldingsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentHoldingsTextBlock" xlink:to="us-gaap_InvestmentHoldingsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentHoldingsTextBlock_lbl" xml:lang="en-US">INVESTMENTS IN EQUITY SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DisclosureOperatingLeasesAbstract" xlink:label="SMTI_DisclosureOperatingLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DisclosureOperatingLeasesAbstract" xlink:to="SMTI_DisclosureOperatingLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_DisclosureOperatingLeasesAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">OPERATING LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT AND CREDIT FACILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">CUSTOMERS AND SUPPLIERS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT REPORTING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Income/Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl" xml:lang="en-US">Accounts Receivable Allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalUseSoftwarePolicy" xlink:label="us-gaap_InternalUseSoftwarePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalUseSoftwarePolicy" xlink:to="us-gaap_InternalUseSoftwarePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternalUseSoftwarePolicy_lbl" xml:lang="en-US">Internal Use Software</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US">Investments in Equity Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="SMTI_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="SMTI_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTableTextBlock" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSET PURCHASE CONSIDERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FUTURE AMORTIZATION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INVESTMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="us-gaap_GainLossOnInvestmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="us-gaap_GainLossOnInvestmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestmentsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPERATING LEASE LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LONG-TERM DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF MATURITIES OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">SUMMARY OF RESTRICTED STOCK ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INCOME TAX EXPENSE (BENEFIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Total Net Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Balance at December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US">Change in fair value of earnout liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability" xlink:label="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability" xlink:to="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability_lbl" xml:lang="en-US">Revaluation of earnout liability</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements" xlink:label="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements" xlink:to="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements_lbl" xml:lang="en-US">Settlements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_2_lbl" xml:lang="en-US">Balance at December 31, 2024</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_2_lbl" xml:lang="en-US">Bad debt expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xml:lang="en-US">Allowance for customer rebates and deductions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryWriteDown_2_lbl" xml:lang="en-US">Inventory obsolescence expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Allowance for obsolete and slow-moving inventory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_2_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Software, estimated useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Impairment of goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets_lbl" xml:lang="en-US">Cash Closing Consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US">Fair value of Stock Closing Consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Equity Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments" xlink:label="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments" xlink:to="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments_lbl" xml:lang="en-US">Fair value of Installment Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory" xlink:label="SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory" xlink:to="SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory_lbl" xml:lang="en-US">Cash paid for inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments" xlink:label="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments" xlink:to="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments_lbl" xml:lang="en-US">Fair value of Petito Services Agreement defined payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl" xml:lang="en-US">Fair value of Petito Services Agreement contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xml:lang="en-US">Direct transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Total purchase consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment_lbl" xml:lang="en-US">Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty" xlink:label="SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty" xlink:to="SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty_lbl" xml:lang="en-US">Intellectual property</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Net assets acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_BusinessAcquisitionContingentConsiderationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems_lbl" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Assets purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets_2_lbl" xml:lang="en-US">Cash consideration paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2_lbl" xml:lang="en-US">Shares issued as consideration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_2_lbl" xml:lang="en-US">Value of shares issued as consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLoansPayable" xlink:label="us-gaap_OtherLoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLoansPayable" xlink:to="us-gaap_OtherLoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLoansPayable_lbl" xml:lang="en-US">Installment payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xml:lang="en-US">Payment of installment</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EarnoutPayable" xlink:label="SMTI_EarnoutPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_EarnoutPayable" xlink:to="SMTI_EarnoutPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_EarnoutPayable_lbl" xml:lang="en-US">Earnout payable</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PurchaseAgreementDescription" xlink:label="SMTI_PurchaseAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PurchaseAgreementDescription" xlink:to="SMTI_PurchaseAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_PurchaseAgreementDescription_lbl" xml:lang="en-US">Purchase agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:label="us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:to="us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable_lbl" xml:lang="en-US">Financing Receivable, Modified [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableModificationsLineItems" xlink:label="us-gaap_FinancingReceivableModificationsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableModificationsLineItems" xlink:to="us-gaap_FinancingReceivableModificationsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableModificationsLineItems_lbl" xml:lang="en-US">Financing Receivable, Modified [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_AccountsNotesAndLoansReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableNetCurrent_lbl" xml:lang="en-US">Accounts and financing receivable, after allowance for credit loss, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansHeldForSaleMaturityDate" xlink:label="us-gaap_LoansHeldForSaleMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansHeldForSaleMaturityDate" xlink:to="us-gaap_LoansHeldForSaleMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansHeldForSaleMaturityDate_lbl" xml:lang="en-US">Extended maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:to="us-gaap_LoansReceivableBasisSpreadOnVariableRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate_lbl" xml:lang="en-US">Accruing interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_2_lbl" xml:lang="en-US">Loan receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xml:lang="en-US">Acquisitions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US">Weighted-average amortization period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Equity method investment</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EquityMethodInvestmentsEconomicInterest" xlink:label="SMTI_EquityMethodInvestmentsEconomicInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_EquityMethodInvestmentsEconomicInterest" xlink:to="SMTI_EquityMethodInvestmentsEconomicInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_EquityMethodInvestmentsEconomicInterest_lbl" xml:lang="en-US">Economic interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:label="us-gaap_OtherInvestmentsAndSecuritiesAtCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:to="us-gaap_OtherInvestmentsAndSecuritiesAtCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInvestmentsAndSecuritiesAtCost_lbl" xml:lang="en-US">Cost method investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">Total Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_3_lbl" xml:lang="en-US">Loss from equity method investment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermInvestments_2_lbl" xml:lang="en-US">Long term investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares purchased</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Purchase of shares, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Investments_2_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xml:lang="en-US">Conversion rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xml:lang="en-US">Ownership value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Share price per unit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DisclosureOperatingLeasesAbstract" xlink:to="SMTI_DisclosureOperatingLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SMTI_DisclosureOperatingLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Operating Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present Value of Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Remaining lease term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease right of use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Less: unamortized debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Debt, net of debt issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtCurrent_2_lbl" xml:lang="en-US">Less: Current portion of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xml:lang="en-US">Total debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebt_lbl" xml:lang="en-US">Secured term loan</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_GrossCashReceivedFromTermLoan" xlink:label="SMTI_GrossCashReceivedFromTermLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_GrossCashReceivedFromTermLoan" xlink:to="SMTI_GrossCashReceivedFromTermLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_GrossCashReceivedFromTermLoan_lbl" xml:lang="en-US">Loans borrowed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xml:lang="en-US">Remaining amount available for borrowing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Borrowing capacity description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xml:lang="en-US">Proceeds from loans used for investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate per annum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US">Incremental increase during an event of default</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CashPaidPercentage" xlink:label="SMTI_CashPaidPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CashPaidPercentage" xlink:to="SMTI_CashPaidPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_CashPaidPercentage_lbl" xml:lang="en-US">Cash paid percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Paid-in-kind and aggregate principal loan amount, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DebtInstrumentUpFrontFeePercentage" xlink:label="SMTI_DebtInstrumentUpFrontFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DebtInstrumentUpFrontFeePercentage" xlink:to="SMTI_DebtInstrumentUpFrontFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_DebtInstrumentUpFrontFeePercentage_lbl" xml:lang="en-US">Debt upfront fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DebtInstrumentBackEndFeePercentage" xlink:label="SMTI_DebtInstrumentBackEndFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DebtInstrumentBackEndFeePercentage" xlink:to="SMTI_DebtInstrumentBackEndFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_DebtInstrumentBackEndFeePercentage_lbl" xml:lang="en-US">Debt instrument back-end fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaidInKindInterest_2_lbl" xml:lang="en-US">Interest paid-in-kind</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest expense related to back-end fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US">Debt instrument rate description</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_MinimumCashBalanceValue" xlink:label="SMTI_MinimumCashBalanceValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_MinimumCashBalanceValue" xlink:to="SMTI_MinimumCashBalanceValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_MinimumCashBalanceValue_lbl" xml:lang="en-US">Minimum cash balance</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearOne" xlink:label="SMTI_AnnualMinimumRevenueYearOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AnnualMinimumRevenueYearOne" xlink:to="SMTI_AnnualMinimumRevenueYearOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_AnnualMinimumRevenueYearOne_lbl" xml:lang="en-US">Annual minimum revenue, year one</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearTwo" xlink:label="SMTI_AnnualMinimumRevenueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AnnualMinimumRevenueYearTwo" xlink:to="SMTI_AnnualMinimumRevenueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_AnnualMinimumRevenueYearTwo_lbl" xml:lang="en-US">Annual minimum revenue, year two</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearThree" xlink:label="SMTI_AnnualMinimumRevenueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AnnualMinimumRevenueYearThree" xlink:to="SMTI_AnnualMinimumRevenueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_AnnualMinimumRevenueYearThree_lbl" xml:lang="en-US">Annual minimum revenue, year three</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearFour" xlink:label="SMTI_AnnualMinimumRevenueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AnnualMinimumRevenueYearFour" xlink:to="SMTI_AnnualMinimumRevenueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_AnnualMinimumRevenueYearFour_lbl" xml:lang="en-US">Annual minimum revenue, year four</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearFive" xlink:label="SMTI_AnnualMinimumRevenueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AnnualMinimumRevenueYearFive" xlink:to="SMTI_AnnualMinimumRevenueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_AnnualMinimumRevenueYearFive_lbl" xml:lang="en-US">Annual minimum revenue, year five</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PercentageOfLoanProceedsUsedForAcquisition" xlink:label="SMTI_PercentageOfLoanProceedsUsedForAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PercentageOfLoanProceedsUsedForAcquisition" xlink:to="SMTI_PercentageOfLoanProceedsUsedForAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_PercentageOfLoanProceedsUsedForAcquisition_lbl" xml:lang="en-US">Loan percentage used for acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalHomeLoanBankAdvances" xlink:label="us-gaap_FederalHomeLoanBankAdvances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalHomeLoanBankAdvances" xlink:to="us-gaap_FederalHomeLoanBankAdvances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalHomeLoanBankAdvances_lbl" xml:lang="en-US">Loan bank advance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate" xlink:label="us-gaap_FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate" xlink:to="us-gaap_FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate_lbl" xml:lang="en-US">Bank, interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate on advances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="us-gaap_InterestExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US">Debt issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_2_lbl" xml:lang="en-US">Unamortized debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization expense of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xml:lang="en-US">Write-off of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_LicenseAgreementAndRoyaltiesDescription" xlink:label="SMTI_LicenseAgreementAndRoyaltiesDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_LicenseAgreementAndRoyaltiesDescription" xlink:to="SMTI_LicenseAgreementAndRoyaltiesDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_LicenseAgreementAndRoyaltiesDescription_lbl" xml:lang="en-US">License agreement and royalties description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Payment for additional royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RoyaltyPercentage" xlink:label="SMTI_RoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_RoyaltyPercentage" xlink:to="SMTI_RoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Annual royalty</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncreaseInRoyaltyAnnualPercentage" xlink:label="SMTI_IncreaseInRoyaltyAnnualPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncreaseInRoyaltyAnnualPercentage" xlink:to="SMTI_IncreaseInRoyaltyAnnualPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_IncreaseInRoyaltyAnnualPercentage_lbl" xml:lang="en-US">Increase in royalty annual percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Payment of cash</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PaymentsForAdditionalRoyalties" xlink:label="SMTI_PaymentsForAdditionalRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PaymentsForAdditionalRoyalties" xlink:to="SMTI_PaymentsForAdditionalRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SMTI_PaymentsForAdditionalRoyalties_lbl" xml:lang="en-US">Payment for additional royalties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_2_lbl" xml:lang="en-US">Cash consideration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_2_lbl" xml:lang="en-US">Payment in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options to acquire shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options remaining to be exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_2_lbl" xml:lang="en-US">Contingent consideration payments receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Acquisition consideration transferred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_3_lbl" xml:lang="en-US">Issuance of common stock for purchase of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Number of shares withheld</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="us-gaap_BusinessCombinationContingentConsiderationAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:to="us-gaap_BusinessCombinationContingentConsiderationAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationAsset_lbl" xml:lang="en-US">Earnout consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EarnoutPayment" xlink:label="SMTI_EarnoutPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_EarnoutPayment" xlink:to="SMTI_EarnoutPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_EarnoutPayment_lbl" xml:lang="en-US">Earnout payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_2_lbl" xml:lang="en-US">Assets purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_OutstandingUnitsPercentage" xlink:label="SMTI_OutstandingUnitsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_OutstandingUnitsPercentage" xlink:to="SMTI_OutstandingUnitsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_OutstandingUnitsPercentage_lbl" xml:lang="en-US">Outstanding units percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RoyaltyExpensePercentage" xlink:label="SMTI_RoyaltyExpensePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_RoyaltyExpensePercentage" xlink:to="SMTI_RoyaltyExpensePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_RoyaltyExpensePercentage_lbl" xml:lang="en-US">Royalty expense percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Non-vested shares, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Non-vested shares, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average grant date fair value, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Options, Granted or assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted or assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Options, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contract life outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Options exercisable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price exercisable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contract life exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of warrants, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of warrants, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Number of warrants, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of warrants, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of warrants outstanding, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contract life outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of warrants exercisable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contract life exercisable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Maximum number of shares available for grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Number of shares available for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">Number of shares issued, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_3_lbl" xml:lang="en-US">Payment of contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Stock granted and issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Restricted stock award, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized share-based compensation expense period for recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxAssetsLeaseLiability" xlink:label="SMTI_DeferredTaxAssetsLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DeferredTaxAssetsLeaseLiability" xlink:to="SMTI_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_lbl" xml:lang="en-US">Contingent liability</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxAssetsAcquistionLiability" xlink:label="SMTI_DeferredTaxAssetsAcquistionLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DeferredTaxAssetsAcquistionLiability" xlink:to="SMTI_DeferredTaxAssetsAcquistionLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_DeferredTaxAssetsAcquistionLiability_lbl" xml:lang="en-US">Acquisition liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Bad debt and other reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US">Inventory reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other temporary differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Right of Use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxLiabilitiesContingentLiability" xlink:label="SMTI_DeferredTaxLiabilitiesContingentLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DeferredTaxLiabilitiesContingentLiability" xlink:to="SMTI_DeferredTaxLiabilitiesContingentLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SMTI_DeferredTaxLiabilitiesContingentLiability_lbl" xml:lang="en-US">Contingent liability</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences" xlink:label="SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences" xlink:to="SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences_lbl" xml:lang="en-US">Other temporary differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Expected federal income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State and local taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncomeTaxReconciliationFairValueAdjustments" xlink:label="SMTI_IncomeTaxReconciliationFairValueAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncomeTaxReconciliationFairValueAdjustments" xlink:to="SMTI_IncomeTaxReconciliationFairValueAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SMTI_IncomeTaxReconciliationFairValueAdjustments_lbl" xml:lang="en-US">Fair value adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Other permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" xlink:label="SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" xlink:to="SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration_lbl" xml:lang="en-US">NOL carryover adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles" xlink:label="SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles" xlink:to="SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles_lbl" xml:lang="en-US">Intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" xlink:label="SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" xlink:to="SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps_lbl" xml:lang="en-US">Other true ups</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Changes in tax rates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US">Expiration description</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount" xlink:label="SMTI_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount" xlink:to="SMTI_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount_lbl" xml:lang="en-US">NOL generated under tax cuts and job cuts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Consulting fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xml:lang="en-US">Cost and expenses related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xml:lang="en-US">Net revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross profit (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US">Change in fair value of earnout liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpenseOther_2_lbl" xml:lang="en-US">Other expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_3_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization_lbl" xml:lang="en-US">Segment Adjusted EBITDA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_4_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpense_3_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeOther_2_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xml:lang="en-US">Noncash share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ExecutiveSeparationCosts" xlink:label="SMTI_ExecutiveSeparationCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ExecutiveSeparationCosts" xlink:to="SMTI_ExecutiveSeparationCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ExecutiveSeparationCosts_lbl" xml:lang="en-US">Executive separation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US">Acquisition costs</link:label>
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PropertyAndEquipmentWriteOff" xlink:label="SMTI_PropertyAndEquipmentWriteOff" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PropertyAndEquipmentWriteOff" xlink:to="SMTI_PropertyAndEquipmentWriteOff_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_PropertyAndEquipmentWriteOff_lbl" xml:lang="en-US">Property and equipment write off</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share based compensation related to executive separation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventDescription" xlink:label="us-gaap_SubsequentEventDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Subsequent description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentDescription_2_lbl" xml:lang="en-US">Debt description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_NoInsiderTradingFlag" xlink:to="SMTI_NoInsiderTradingFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_NoInsiderTradingFlag_doc" xml:lang="en-US">No Insider Trading Flag.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_RoyaltyReceivable" xlink:to="SMTI_RoyaltyReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_RoyaltyReceivable_doc" xml:lang="en-US">Royalty receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DirectDermatologyIncMember" xlink:to="SMTI_DirectDermatologyIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_DirectDermatologyIncMember_doc" xml:lang="en-US">Direct Dermatology Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SeriesBTwoPreferredSharesMember" xlink:to="SMTI_SeriesBTwoPreferredSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_SeriesBTwoPreferredSharesMember_doc" xml:lang="en-US">Series B-2 Preferred Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ClassAPreferredSharesMember" xlink:to="SMTI_ClassAPreferredSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ClassAPreferredSharesMember_doc" xml:lang="en-US">Class A Preferred Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PixalereHealthcareIncMember" xlink:to="SMTI_PixalereHealthcareIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_PixalereHealthcareIncMember_doc" xml:lang="en-US">Pixalere Healthcare Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PixalereHealthcareUSALLCMember" xlink:to="SMTI_PixalereHealthcareUSALLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_PixalereHealthcareUSALLCMember_doc" xml:lang="en-US">Pixalere Healthcare USA LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities" xlink:to="SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities_doc" xml:lang="en-US">Change in fair value of deferred and earnout liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CommonUnitsMember" xlink:to="SMTI_CommonUnitsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_CommonUnitsMember_doc" xml:lang="en-US">Common Units [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ChemoMouthPieceLLCMember" xlink:to="SMTI_ChemoMouthPieceLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ChemoMouthPieceLLCMember_doc" xml:lang="en-US">ChemoMouthpiece, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" xlink:to="SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards_doc" xml:lang="en-US">Stock issued during period value for net settlement and retirement of equity based awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards" xlink:to="SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards_doc" xml:lang="en-US">Stock issued during period shares for net settlement and retirement of equity based awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SIHealthcareTechnologiesLLCMember" xlink:to="SMTI_SIHealthcareTechnologiesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_SIHealthcareTechnologiesLLCMember_doc" xml:lang="en-US">SI Healthcare Technologies LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_EquityMethodInvestmentsEconomicInterest" xlink:to="SMTI_EquityMethodInvestmentsEconomicInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_EquityMethodInvestmentsEconomicInterest_doc" xml:lang="en-US">Equity Method Investments Economic Interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_OfficeSpaceOneMember" xlink:to="SMTI_OfficeSpaceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_OfficeSpaceOneMember_doc" xml:lang="en-US">Office Space One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BackendFee" xlink:to="SMTI_BackendFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_BackendFee_doc" xml:lang="en-US">Backend fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AccretionOfFinanceLiabilities" xlink:to="SMTI_AccretionOfFinanceLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_AccretionOfFinanceLiabilities_doc" xml:lang="en-US">Accretion of finance liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts" xlink:to="SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts_doc" xml:lang="en-US">Amortization and write-off of debt issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncreaseDecreaseInAccountsPayableRelatedParty" xlink:to="SMTI_IncreaseDecreaseInAccountsPayableRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_IncreaseDecreaseInAccountsPayableRelatedParty_doc" xml:lang="en-US">Increase decrease in accounts payable related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses" xlink:to="SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses_doc" xml:lang="en-US">Increase decrease in accrued royalties and expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions" xlink:to="SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions_doc" xml:lang="en-US">Increase decrease in accrued bonuses and commissions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CashPaymentOfFinanceAndEarnoutLiabilities" xlink:to="SMTI_CashPaymentOfFinanceAndEarnoutLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_CashPaymentOfFinanceAndEarnoutLiabilities_doc" xml:lang="en-US">Cash payment of finance and earnout liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CRGTermLoanAgreementMember" xlink:to="SMTI_CRGTermLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_CRGTermLoanAgreementMember_doc" xml:lang="en-US">CRG Term Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_GrossCashReceivedFromTermLoan" xlink:to="SMTI_GrossCashReceivedFromTermLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_GrossCashReceivedFromTermLoan_doc" xml:lang="en-US">Gross cash received from the term loan amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CashPaidPercentage" xlink:to="SMTI_CashPaidPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_CashPaidPercentage_doc" xml:lang="en-US">Cash paid percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DebtInstrumentUpFrontFeePercentage" xlink:to="SMTI_DebtInstrumentUpFrontFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_DebtInstrumentUpFrontFeePercentage_doc" xml:lang="en-US">Debt instrument upfront fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DebtInstrumentBackEndFeePercentage" xlink:to="SMTI_DebtInstrumentBackEndFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_DebtInstrumentBackEndFeePercentage_doc" xml:lang="en-US">Debt instrument back end fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_InternalUseSoftwareMember" xlink:to="SMTI_InternalUseSoftwareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_InternalUseSoftwareMember_doc" xml:lang="en-US">Internal Use Software [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_MinimumCashBalanceValue" xlink:to="SMTI_MinimumCashBalanceValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_MinimumCashBalanceValue_doc" xml:lang="en-US">Minimum cash balance value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AnnualMinimumRevenueYearOne" xlink:to="SMTI_AnnualMinimumRevenueYearOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_AnnualMinimumRevenueYearOne_doc" xml:lang="en-US">Annual minimum revenue year one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AnnualMinimumRevenueYearTwo" xlink:to="SMTI_AnnualMinimumRevenueYearTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_AnnualMinimumRevenueYearTwo_doc" xml:lang="en-US">Annual minimum revenue year two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AccruedInterestIncomeExpense" xlink:to="SMTI_AccruedInterestIncomeExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_AccruedInterestIncomeExpense_doc" xml:lang="en-US">Accrued interest income expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability" xlink:to="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability_doc" xml:lang="en-US">Business combination contingent consideration arrangements change in amount of contingent consideration revaluation of earnout liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements" xlink:to="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements_doc" xml:lang="en-US">Business combination contingent consideration arrangements change in amount of contingent consideration settlements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="SMTI_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_doc" xml:lang="en-US">Recently Adopted Accounting Pronouncements [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AnnualMinimumRevenueYearThree" xlink:to="SMTI_AnnualMinimumRevenueYearThree_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_AnnualMinimumRevenueYearThree_doc" xml:lang="en-US">Annual minimum revenue year three.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AnnualMinimumRevenueYearFour" xlink:to="SMTI_AnnualMinimumRevenueYearFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_AnnualMinimumRevenueYearFour_doc" xml:lang="en-US">Annual minimum revenue year four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AnnualMinimumRevenueYearFive" xlink:to="SMTI_AnnualMinimumRevenueYearFive_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_AnnualMinimumRevenueYearFive_doc" xml:lang="en-US">Annual minimum revenue year five.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CadenceTermLoanAgreementMember" xlink:to="SMTI_CadenceTermLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_CadenceTermLoanAgreementMember_doc" xml:lang="en-US">Cadence Term Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PercentageOfLoanProceedsUsedForAcquisition" xlink:to="SMTI_PercentageOfLoanProceedsUsedForAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_PercentageOfLoanProceedsUsedForAcquisition_doc" xml:lang="en-US">Percentage of the loan proceeds that were used for the acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AppliedAssetPurchaseAgreementMember" xlink:to="SMTI_AppliedAssetPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_AppliedAssetPurchaseAgreementMember_doc" xml:lang="en-US">Applied Asset Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CashClosingConsiderationMember" xlink:to="SMTI_CashClosingConsiderationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_CashClosingConsiderationMember_doc" xml:lang="en-US">Cash Closing Consideration [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_StockClosingConsiderationMember" xlink:to="SMTI_StockClosingConsiderationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_StockClosingConsiderationMember_doc" xml:lang="en-US">Stock Closing Consideration [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_EarnoutPayable" xlink:to="SMTI_EarnoutPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_EarnoutPayable_doc" xml:lang="en-US">Earnout payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CRGTermLoanMember" xlink:to="SMTI_CRGTermLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_CRGTermLoanMember_doc" xml:lang="en-US">CRG Term Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CadenceTermLoanMember" xlink:to="SMTI_CadenceTermLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_CadenceTermLoanMember_doc" xml:lang="en-US">Cadence Term Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments" xlink:to="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments_doc" xml:lang="en-US">Asset acquisition consideration transferred fair value of installment payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory" xlink:to="SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory_doc" xml:lang="en-US">Asset acquisition consideration transferred cash paid for inventory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments" xlink:to="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments_doc" xml:lang="en-US">Asset acquisition consideration transferred fair value of petito services defined payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty" xlink:to="SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty_doc" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed intellectual property.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CustomerRelationshipsAndOtherMember" xlink:to="SMTI_CustomerRelationshipsAndOtherMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_CustomerRelationshipsAndOtherMember_doc" xml:lang="en-US">Customer Relationships and Other [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AmortizableIntangibleAssetsMember" xlink:to="SMTI_AmortizableIntangibleAssetsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_AmortizableIntangibleAssetsMember_doc" xml:lang="en-US">Amortizable Intangible Assets [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_LicenseAgreementAndRoyaltiesDescription" xlink:to="SMTI_LicenseAgreementAndRoyaltiesDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_LicenseAgreementAndRoyaltiesDescription_doc" xml:lang="en-US">License agreement and royalties description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SubLicenseAgreementMember" xlink:to="SMTI_SubLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_SubLicenseAgreementMember_doc" xml:lang="en-US">Sub License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_RoyaltyPercentage" xlink:to="SMTI_RoyaltyPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_RoyaltyPercentage_doc" xml:lang="en-US">Royalty percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BIAKOSLicenseAgreementMember" xlink:to="SMTI_BIAKOSLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_BIAKOSLicenseAgreementMember_doc" xml:lang="en-US">BIAKOS License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_RochalIndustriesLLCMember" xlink:to="SMTI_RochalIndustriesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_RochalIndustriesLLCMember_doc" xml:lang="en-US">Rochal Industries LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BIAKOSAgreementMember" xlink:to="SMTI_BIAKOSAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_BIAKOSAgreementMember_doc" xml:lang="en-US">BIAKOS Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ABFLicenseAgreementMember" xlink:to="SMTI_ABFLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ABFLicenseAgreementMember_doc" xml:lang="en-US">ABF License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncreaseInRoyaltyAnnualPercentage" xlink:to="SMTI_IncreaseInRoyaltyAnnualPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_IncreaseInRoyaltyAnnualPercentage_doc" xml:lang="en-US">Increase in royalty annual percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_RochalMember" xlink:to="SMTI_RochalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_RochalMember_doc" xml:lang="en-US">Rochal [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DebriderLicenseAgreementMember" xlink:to="SMTI_DebriderLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_DebriderLicenseAgreementMember_doc" xml:lang="en-US">Debrider License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PaymentsForAdditionalRoyalties" xlink:to="SMTI_PaymentsForAdditionalRoyalties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_PaymentsForAdditionalRoyalties_doc" xml:lang="en-US">Payments for additional royalties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PrecisionHealingMergerAgreementMember" xlink:to="SMTI_PrecisionHealingMergerAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_PrecisionHealingMergerAgreementMember_doc" xml:lang="en-US">Precision Healing Merger Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_AccreditedInvestorsMember" xlink:to="SMTI_AccreditedInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_AccreditedInvestorsMember_doc" xml:lang="en-US">Accredited Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_WarrantOneMember" xlink:to="SMTI_WarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_WarrantOneMember_doc" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ScendiaPurchaseAgreementMember" xlink:to="SMTI_ScendiaPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ScendiaPurchaseAgreementMember_doc" xml:lang="en-US">Scendia Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_EarnoutPayment" xlink:to="SMTI_EarnoutPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_EarnoutPayment_doc" xml:lang="en-US">Earnout payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PurchaseAgreementDescription" xlink:to="SMTI_PurchaseAgreementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_PurchaseAgreementDescription_doc" xml:lang="en-US">Purchase agreement description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ServicesAgreementMember" xlink:to="SMTI_ServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ServicesAgreementMember_doc" xml:lang="en-US">Services Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_OutstandingUnitsPercentage" xlink:to="SMTI_OutstandingUnitsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_OutstandingUnitsPercentage_doc" xml:lang="en-US">Outstanding units percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_LicenseAgreementMember" xlink:to="SMTI_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_RoyaltyExpensePercentage" xlink:to="SMTI_RoyaltyExpensePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_RoyaltyExpensePercentage_doc" xml:lang="en-US">Royalty expense percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember" xlink:to="SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_doc" xml:lang="en-US">2024 Omnibus Long-Term Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PrecisionHealingIncMember" xlink:to="SMTI_PrecisionHealingIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_PrecisionHealingIncMember_doc" xml:lang="en-US">Precision Healing Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PrecisionHealingMember" xlink:to="SMTI_PrecisionHealingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_PrecisionHealingMember_doc" xml:lang="en-US">Precision Healing [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">Number of equity instruments other than options exercisable, including both vested and non-vested instruments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant expirations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Weighted average remaining contractual term for warrants awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Weighted average remaining contractual term for warrants awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_NoCustomersMember" xlink:to="SMTI_NoCustomersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_NoCustomersMember_doc" xml:lang="en-US">No Customers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount" xlink:to="SMTI_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount_doc" xml:lang="en-US">Effective income tax rate reconciliation tax cuts and jobs amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DeferredTaxAssetsLeaseLiability" xlink:to="SMTI_DeferredTaxAssetsLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_DeferredTaxAssetsLeaseLiability_doc" xml:lang="en-US">Deferred tax assets lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DeferredTaxAssetsAcquistionLiability" xlink:to="SMTI_DeferredTaxAssetsAcquistionLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_DeferredTaxAssetsAcquistionLiability_doc" xml:lang="en-US">Deferred tax assets acquistion liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization_doc" xml:lang="en-US">Depreciation and Amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DeferredTaxLiabilitiesContingentLiability" xlink:to="SMTI_DeferredTaxLiabilitiesContingentLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_DeferredTaxLiabilitiesContingentLiability_doc" xml:lang="en-US">Deferred tax liabilities contingent liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences" xlink:to="SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences_doc" xml:lang="en-US">Deferred tax liabilities other temporary differences.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncomeTaxReconciliationFairValueAdjustments" xlink:to="SMTI_IncomeTaxReconciliationFairValueAdjustments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_IncomeTaxReconciliationFairValueAdjustments_doc" xml:lang="en-US">Income tax reconciliation fair value adjustments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" xlink:to="SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration_doc" xml:lang="en-US">NOL Carryover Adjusted for Expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles" xlink:to="SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles_doc" xml:lang="en-US">Income tax reconciliation income tax expense intangibles.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" xlink:to="SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps_doc" xml:lang="en-US">Income tax reconciliation income tax expense other trueups.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ConsultingAgreementMember" xlink:to="SMTI_ConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ConsultingAgreementMember_doc" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_MsSalamoneMember" xlink:to="SMTI_MsSalamoneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_MsSalamoneMember_doc" xml:lang="en-US">Ms Salamone [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SanaraSurgicalMember" xlink:to="SMTI_SanaraSurgicalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_SanaraSurgicalMember_doc" xml:lang="en-US">Sanara Surgical [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_THPMember" xlink:to="SMTI_THPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_THPMember_doc" xml:lang="en-US">THP [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization_doc" xml:lang="en-US">Earnings before interest taxes depreciation and amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ExecutiveSeparationCosts" xlink:to="SMTI_ExecutiveSeparationCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_ExecutiveSeparationCosts_doc" xml:lang="en-US">Executive separation costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_NonaccreditedInvestorsMember" xlink:to="SMTI_NonaccreditedInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_NonaccreditedInvestorsMember_doc" xml:lang="en-US">Nonaccredited Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_OfficeSpaceTwoMember" xlink:to="SMTI_OfficeSpaceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_OfficeSpaceTwoMember_doc" xml:lang="en-US">Office Space Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_BackendFeeMember" xlink:to="SMTI_BackendFeeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_BackendFeeMember_doc" xml:lang="en-US">Backend Fee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SubscriptionAndShareholdersAgreementMember" xlink:to="SMTI_SubscriptionAndShareholdersAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_SubscriptionAndShareholdersAgreementMember_doc" xml:lang="en-US">Subscription and Shareholders Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SubscriptionAgreementMember" xlink:to="SMTI_SubscriptionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_SubscriptionAgreementMember_doc" xml:lang="en-US">Subscription Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember" xlink:to="SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember_doc" xml:lang="en-US">2024 Omnibus Long Term Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PropertyAndEquipmentWriteOff" xlink:to="SMTI_PropertyAndEquipmentWriteOff_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SMTI_PropertyAndEquipmentWriteOff_doc" xml:lang="en-US">Write off of the net book value of property &amp; equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities" xlink:to="SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities_3_lbl" xml:lang="en-US">ChangeInFairValueOfDeferredAndEarnoutLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses" xlink:to="SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses_3_lbl" xml:lang="en-US">IncreaseDecreaseInAccruedRoyaltiesAndExpenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions" xlink:to="SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions_3_lbl" xml:lang="en-US">IncreaseDecreaseInAccruedBonusesAndCommissions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLoansReceivable" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable_2_lbl" xml:lang="en-US">Payments to Acquire Loans Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2_lbl" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xml:lang="en-US">Repayments of Lines of Credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_CashPaymentOfFinanceAndEarnoutLiabilities" xlink:to="SMTI_CashPaymentOfFinanceAndEarnoutLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_CashPaymentOfFinanceAndEarnoutLiabilities_3_lbl" xml:lang="en-US">CashPaymentOfFinanceAndEarnoutLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_3_lbl" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Long-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_PaymentsForAdditionalRoyalties" xlink:to="SMTI_PaymentsForAdditionalRoyalties_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_PaymentsForAdditionalRoyalties_3_lbl" xml:lang="en-US">PaymentsForAdditionalRoyalties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesDepreciationAndAmortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DeferredTaxLiabilitiesContingentLiability" xlink:to="SMTI_DeferredTaxLiabilitiesContingentLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_DeferredTaxLiabilitiesContingentLiability_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesContingentLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences" xlink:to="SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesOtherTemporaryDifferences</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncomeTaxReconciliationFairValueAdjustments" xlink:to="SMTI_IncomeTaxReconciliationFairValueAdjustments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_IncomeTaxReconciliationFairValueAdjustments_3_lbl" xml:lang="en-US">IncomeTaxReconciliationFairValueAdjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" xlink:to="SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration_3_lbl" xml:lang="en-US">IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles" xlink:to="SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles_3_lbl" xml:lang="en-US">IncomeTaxReconciliationIncomeTaxExpenseIntangibles</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" xlink:to="SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps_3_lbl" xml:lang="en-US">IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_2_lbl" xml:lang="en-US">Liabilities, Fair Value Adjustment</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>smti-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sanaramedtech.com/role/Cover" xlink:href="smti-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/BalanceSheets" xlink:href="smti-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/BalanceSheetsParenthetical" xlink:href="smti-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/StatementsOfOperations" xlink:href="smti-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity" xlink:href="smti-20241231.xsd#StatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/StatementsOfCashFlows" xlink:href="smti-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/StatementsOfCashFlowsParenthetical" xlink:href="smti-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/NatureOfBusinessAndBackground" xlink:href="smti-20241231.xsd#NatureOfBusinessAndBackground" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="smti-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/AppliedAssetPurchase" xlink:href="smti-20241231.xsd#AppliedAssetPurchase" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ConvertibleLoanReceivable" xlink:href="smti-20241231.xsd#ConvertibleLoanReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/GoodwillAndIntangiblesNet" xlink:href="smti-20241231.xsd#GoodwillAndIntangiblesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/InvestmentsInEquitySecurities" xlink:href="smti-20241231.xsd#InvestmentsInEquitySecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/OperatingLeases" xlink:href="smti-20241231.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/DebtAndCreditFacilities" xlink:href="smti-20241231.xsd#DebtAndCreditFacilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/CommitmentsAndContingencies" xlink:href="smti-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ShareholdersEquity" xlink:href="smti-20241231.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/CustomersAndSuppliers" xlink:href="smti-20241231.xsd#CustomersAndSuppliers" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/IncomeTaxes" xlink:href="smti-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/RelatedParties" xlink:href="smti-20241231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SegmentReporting" xlink:href="smti-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SubsequentEvents" xlink:href="smti-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="smti-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="smti-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/AppliedAssetPurchaseTables" xlink:href="smti-20241231.xsd#AppliedAssetPurchaseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/GoodwillAndIntangiblesNetTables" xlink:href="smti-20241231.xsd#GoodwillAndIntangiblesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesTables" xlink:href="smti-20241231.xsd#InvestmentsInEquitySecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/OperatingLeasesTables" xlink:href="smti-20241231.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/DebtAndCreditFacilitiesTables" xlink:href="smti-20241231.xsd#DebtAndCreditFacilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ShareholdersEquityTables" xlink:href="smti-20241231.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/IncomeTaxesTables" xlink:href="smti-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SegmentReportingTables" xlink:href="smti-20241231.xsd#SegmentReportingTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/NatureOfBusinessAndBackgroundDetailsNarrative" xlink:href="smti-20241231.xsd#NatureOfBusinessAndBackgroundDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails" xlink:href="smti-20241231.xsd#ScheduleOfComputationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails" xlink:href="smti-20241231.xsd#ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="smti-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails" xlink:href="smti-20241231.xsd#ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="smti-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails" xlink:href="smti-20241231.xsd#ScheduleOfAssetPurchaseConsiderationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails" xlink:href="smti-20241231.xsd#ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative" xlink:href="smti-20241231.xsd#AppliedAssetPurchaseDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative" xlink:href="smti-20241231.xsd#ConvertibleLoanReceivableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfChangesInCarryingAmountOfGoodwillDetails" xlink:href="smti-20241231.xsd#ScheduleOfChangesInCarryingAmountOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" xlink:href="smti-20241231.xsd#ScheduleOfCarryingValueOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails" xlink:href="smti-20241231.xsd#ScheduleOfFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/GoodwillAndIntangiblesNetDetailsNarrative" xlink:href="smti-20241231.xsd#GoodwillAndIntangiblesNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails" xlink:href="smti-20241231.xsd#ScheduleOfInvestmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails" xlink:href="smti-20241231.xsd#ScheduleOfLossFromEquityMethodInvestmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative" xlink:href="smti-20241231.xsd#InvestmentsInEquitySecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails" xlink:href="smti-20241231.xsd#ScheduleOfOperatingLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative" xlink:href="smti-20241231.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails" xlink:href="smti-20241231.xsd#ScheduleOfLong-termDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails" xlink:href="smti-20241231.xsd#ScheduleOfMaturitiesOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative" xlink:href="smti-20241231.xsd#DebtAndCreditFacilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="smti-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails" xlink:href="smti-20241231.xsd#SummaryOfRestrictedStockActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="smti-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails" xlink:href="smti-20241231.xsd#ScheduleOfWarrantsToPurchaseCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative" xlink:href="smti-20241231.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative" xlink:href="smti-20241231.xsd#CustomersAndSuppliersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="smti-20241231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails" xlink:href="smti-20241231.xsd#ScheduleOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/IncomeTaxesDetailsNarrative" xlink:href="smti-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative" xlink:href="smti-20241231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails" xlink:href="smti-20241231.xsd#ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails" xlink:href="smti-20241231.xsd#ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical" xlink:href="smti-20241231.xsd#ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SegmentReportingDetailsNarrative" xlink:href="smti-20241231.xsd#SegmentReportingDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative" xlink:href="smti-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_deiEntityListingParValuePerShare" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityListingParValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RoyaltyReceivable" xlink:label="loc_SMTIRoyaltyReceivable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_SMTIRoyaltyReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaapLongTermInvestments" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapLongTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalesCommissionCurrent" xlink:label="loc_us-gaapAccruedSalesCommissionCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedSalesCommissionCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOtherLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities" xlink:label="loc_SMTIChangeInFairValueOfDeferredAndEarnoutLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_SMTIChangeInFairValueOfDeferredAndEarnoutLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeLossFromEquityMethodInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" xlink:label="loc_SMTIStockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SMTIStockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards" xlink:label="loc_SMTIStockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SMTIStockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncomeLossFromEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BackendFee" xlink:label="loc_SMTIBackendFee" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SMTIBackendFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AccretionOfFinanceLiabilities" xlink:label="loc_SMTIAccretionOfFinanceLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SMTIAccretionOfFinanceLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts" xlink:label="loc_SMTIAmortizationAndWriteoffOfDebtIssuanceCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SMTIAmortizationAndWriteoffOfDebtIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities" xlink:label="loc_SMTIChangeInFairValueOfDeferredAndEarnoutLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SMTIChangeInFairValueOfDeferredAndEarnoutLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AccruedInterestIncomeExpense" xlink:label="loc_SMTIAccruedInterestIncomeExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SMTIAccruedInterestIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivableRelatedParties" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncreaseDecreaseInAccountsPayableRelatedParty" xlink:label="loc_SMTIIncreaseDecreaseInAccountsPayableRelatedParty" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_SMTIIncreaseDecreaseInAccountsPayableRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses" xlink:label="loc_SMTIIncreaseDecreaseInAccruedRoyaltiesAndExpenses" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_SMTIIncreaseDecreaseInAccruedRoyaltiesAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions" xlink:label="loc_SMTIIncreaseDecreaseInAccruedBonusesAndCommissions" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_SMTIIncreaseDecreaseInAccruedBonusesAndCommissions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaapPaymentsToAcquireEquityMethodInvestments" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireLoansReceivable" xlink:label="loc_us-gaapPaymentsToAcquireLoansReceivable" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireLoansReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaapProceedsFromPaymentsForOtherFinancingActivities" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CashPaymentOfFinanceAndEarnoutLiabilities" xlink:label="loc_SMTICashPaymentOfFinanceAndEarnoutLiabilities" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_SMTICashPaymentOfFinanceAndEarnoutLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_NoInsiderTradingFlag" xlink:label="loc_SMTINoInsiderTradingFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_SMTINoInsiderTradingFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/NatureOfBusinessAndBackground" xlink:title="999015 - Disclosure - NATURE OF BUSINESS AND BACKGROUND">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/AppliedAssetPurchase" xlink:title="999017 - Disclosure - APPLIED ASSET PURCHASE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="loc_us-gaapAssetAcquisitionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapAssetAcquisitionTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ConvertibleLoanReceivable" xlink:title="999018 - Disclosure - CONVERTIBLE LOAN RECEIVABLE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/GoodwillAndIntangiblesNet" xlink:title="999019 - Disclosure - GOODWILL AND INTANGIBLES, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/InvestmentsInEquitySecurities" xlink:title="999020 - Disclosure - INVESTMENTS IN EQUITY SECURITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="loc_us-gaapScheduleOfInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentHoldingsTextBlock" xlink:label="loc_us-gaapInvestmentHoldingsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsAbstract" xlink:to="loc_us-gaapInvestmentHoldingsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/OperatingLeases" xlink:title="999021 - Disclosure - OPERATING LEASES">
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DisclosureOperatingLeasesAbstract" xlink:label="loc_SMTIDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SMTIDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/DebtAndCreditFacilities" xlink:title="999022 - Disclosure - DEBT AND CREDIT FACILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/CommitmentsAndContingencies" xlink:title="999023 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ShareholdersEquity" xlink:title="999024 - Disclosure - SHAREHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/CustomersAndSuppliers" xlink:title="999025 - Disclosure - CUSTOMERS AND SUPPLIERS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/IncomeTaxes" xlink:title="999026 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/RelatedParties" xlink:title="999027 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SegmentReporting" xlink:title="999028 - Disclosure - SEGMENT REPORTING">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SubsequentEvents" xlink:title="999029 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:label="loc_us-gaapCreditLossFinancialInstrumentPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalUseSoftwarePolicy" xlink:label="loc_us-gaapInternalUseSoftwarePolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInternalUseSoftwarePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaapEquityMethodInvestmentsPolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_SMTIRecentlyAdoptedAccountingPronouncementsPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SMTIRecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/AppliedAssetPurchaseTables" xlink:title="999032 - Disclosure - APPLIED ASSET PURCHASE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AppliedAssetPurchaseAgreementMember" xlink:label="loc_SMTIAppliedAssetPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIAppliedAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="loc_us-gaapAssetAcquisitionTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetAcquisitionTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/GoodwillAndIntangiblesNetTables" xlink:title="999033 - Disclosure - GOODWILL AND INTANGIBLES, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaapScheduleOfGoodwillTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfGoodwillTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesTables" xlink:title="999034 - Disclosure - INVESTMENTS IN EQUITY SECURITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="loc_us-gaapScheduleOfInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="loc_us-gaapEquityMethodInvestmentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="loc_us-gaapGainLossOnInvestmentsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsAbstract" xlink:to="loc_us-gaapGainLossOnInvestmentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/OperatingLeasesTables" xlink:title="999035 - Disclosure - OPERATING LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DisclosureOperatingLeasesAbstract" xlink:label="loc_SMTIDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SMTIDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/DebtAndCreditFacilitiesTables" xlink:title="999036 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ShareholdersEquityTables" xlink:title="999037 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/IncomeTaxesTables" xlink:title="999038 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SegmentReportingTables" xlink:title="999039 - Disclosure - SEGMENT REPORTING (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaapReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/NatureOfBusinessAndBackgroundDetailsNarrative" xlink:title="999040 - Disclosure - NATURE OF BUSINESS AND BACKGROUND (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails" xlink:title="999041 - Disclosure - SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_UnvestedRestrictedStockMember" xlink:label="loc_SMTIUnvestedRestrictedStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_SMTIUnvestedRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails" xlink:title="999042 - Disclosure - SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SoftTissueRepairProductsMember" xlink:label="loc_SMTISoftTissueRepairProductsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_SMTISoftTissueRepairProductsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BoneFusionProductsMember" xlink:label="loc_SMTIBoneFusionProductsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_SMTIBoneFusionProductsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaapRoyaltyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapRoyaltyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999043 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_InternalUseSoftwareMember" xlink:label="loc_SMTIInternalUseSoftwareMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SMTIInternalUseSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails" xlink:title="999044 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability" xlink:label="loc_SMTIBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SMTIBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements" xlink:label="loc_SMTIBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SMTIBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999045 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_InternalUseSoftwareMember" xlink:label="loc_SMTIInternalUseSoftwareMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SMTIInternalUseSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF ASSET PURCHASE CONSIDERATIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AppliedAssetPurchaseAgreementMember" xlink:label="loc_SMTIAppliedAssetPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIAppliedAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredOtherAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments" xlink:label="loc_SMTIAssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SMTIAssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory" xlink:label="loc_SMTIAssetAcquisitionConsiderationTransferredCashPaidForInventory" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SMTIAssetAcquisitionConsiderationTransferredCashPaidForInventory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments" xlink:label="loc_SMTIAssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SMTIAssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredTransactionCost" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredTransactionCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferred" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferred" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails" xlink:title="999047 - Disclosure - SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AppliedAssetPurchaseAgreementMember" xlink:label="loc_SMTIAppliedAssetPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_SMTIAppliedAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty" xlink:label="loc_SMTIBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SMTIBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative" xlink:title="999048 - Disclosure - APPLIED ASSET PURCHASE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AppliedAssetPurchaseAgreementMember" xlink:label="loc_SMTIAppliedAssetPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIAppliedAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CashClosingConsiderationMember" xlink:label="loc_SMTICashClosingConsiderationMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_SMTICashClosingConsiderationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_StockClosingConsiderationMember" xlink:label="loc_SMTIStockClosingConsiderationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_SMTIStockClosingConsiderationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredOtherAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLoansPayable" xlink:label="loc_us-gaapOtherLoansPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapOtherLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EarnoutPayable" xlink:label="loc_SMTIEarnoutPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_SMTIEarnoutPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PurchaseAgreementDescription" xlink:label="loc_SMTIPurchaseAgreementDescription" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_SMTIPurchaseAgreementDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative" xlink:title="999049 - Disclosure - CONVERTIBLE LOAN RECEIVABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:label="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableModificationsLineItems" xlink:label="loc_us-gaapFinancingReceivableModificationsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:to="loc_us-gaapFinancingReceivableModificationsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanRestructuringModificationAxis" xlink:label="loc_us-gaapLoanRestructuringModificationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:to="loc_us-gaapLoanRestructuringModificationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanRestructuringModificationDomain" xlink:label="loc_us-gaapLoanRestructuringModificationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLoanRestructuringModificationAxis" xlink:to="loc_us-gaapLoanRestructuringModificationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtendedMaturityMember" xlink:label="loc_us-gaapExtendedMaturityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLoanRestructuringModificationDomain" xlink:to="loc_us-gaapExtendedMaturityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaapAccountsNotesAndLoansReceivableNetCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapAccountsNotesAndLoansReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansHeldForSaleMaturityDate" xlink:label="loc_us-gaapLoansHeldForSaleMaturityDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapLoansHeldForSaleMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:label="loc_us-gaapLoansReceivableBasisSpreadOnVariableRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapLoansReceivableBasisSpreadOnVariableRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfChangesInCarryingAmountOfGoodwillDetails" xlink:title="999050 - Disclosure - SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaapGoodwillAcquiredDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAcquiredDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" xlink:title="999051 - Disclosure - SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CustomerRelationshipsAndOtherMember" xlink:label="loc_SMTICustomerRelationshipsAndOtherMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_SMTICustomerRelationshipsAndOtherMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicensingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AmortizableIntangibleAssetsMember" xlink:label="loc_SMTIAmortizableIntangibleAssetsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_SMTIAmortizableIntangibleAssetsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails" xlink:title="999052 - Disclosure - SCHEDULE OF FUTURE AMORTIZATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/GoodwillAndIntangiblesNetDetailsNarrative" xlink:title="999053 - Disclosure - GOODWILL AND INTANGIBLES, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails" xlink:title="999054 - Disclosure - SCHEDULE OF INVESTMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="loc_us-gaapScheduleOfInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ChemoMouthPieceLLCMember" xlink:label="loc_SMTIChemoMouthPieceLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIChemoMouthPieceLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SIHealthcareTechnologiesLLCMember" xlink:label="loc_SMTISIHealthcareTechnologiesLLCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTISIHealthcareTechnologiesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DirectDermatologyIncMember" xlink:label="loc_SMTIDirectDermatologyIncMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIDirectDermatologyIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PixalereHealthcareIncMember" xlink:label="loc_SMTIPixalereHealthcareIncMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIPixalereHealthcareIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaapEquityMethodInvestments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EquityMethodInvestmentsEconomicInterest" xlink:label="loc_SMTIEquityMethodInvestmentsEconomicInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SMTIEquityMethodInvestmentsEconomicInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:label="loc_us-gaapOtherInvestmentsAndSecuritiesAtCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherInvestmentsAndSecuritiesAtCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails" xlink:title="999055 - Disclosure - SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="loc_us-gaapScheduleOfInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ChemoMouthPieceLLCMember" xlink:label="loc_SMTIChemoMouthPieceLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIChemoMouthPieceLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SIHealthcareTechnologiesLLCMember" xlink:label="loc_SMTISIHealthcareTechnologiesLLCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTISIHealthcareTechnologiesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative" xlink:title="999056 - Disclosure - INVESTMENTS IN EQUITY SECURITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="loc_us-gaapScheduleOfInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DirectDermatologyIncMember" xlink:label="loc_SMTIDirectDermatologyIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIDirectDermatologyIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PixalereHealthcareIncMember" xlink:label="loc_SMTIPixalereHealthcareIncMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIPixalereHealthcareIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ChemoMouthPieceLLCMember" xlink:label="loc_SMTIChemoMouthPieceLLCMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIChemoMouthPieceLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SeriesBTwoPreferredSharesMember" xlink:label="loc_SMTISeriesBTwoPreferredSharesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SMTISeriesBTwoPreferredSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ClassAPreferredSharesMember" xlink:label="loc_SMTIClassAPreferredSharesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SMTIClassAPreferredSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DirectDermatologyIncMember" xlink:label="loc_SMTIDirectDermatologyIncMember_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_SMTIDirectDermatologyIncMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PixalereHealthcareUSALLCMember" xlink:label="loc_SMTIPixalereHealthcareUSALLCMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_SMTIPixalereHealthcareUSALLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ChemoMouthPieceLLCMember" xlink:label="loc_SMTIChemoMouthPieceLLCMember_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_SMTIChemoMouthPieceLLCMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CommonUnitsMember" xlink:label="loc_SMTICommonUnitsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SMTICommonUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaapLongTermInvestments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaapEquityMethodInvestmentAggregateCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentAggregateCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails" xlink:title="999057 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DisclosureOperatingLeasesAbstract" xlink:label="loc_SMTIDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SMTIDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SMTIDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SMTIDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SMTIDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SMTIDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SMTIDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SMTIDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SMTIDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SMTIDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SMTIDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SMTIDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative" xlink:title="999058 - Disclosure - OPERATING LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DisclosureOperatingLeasesAbstract" xlink:label="loc_SMTIDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SMTIDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_OfficeSpaceOneMember" xlink:label="loc_SMTIOfficeSpaceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SMTIOfficeSpaceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_OfficeSpaceTwoMember" xlink:label="loc_SMTIOfficeSpaceTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SMTIOfficeSpaceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails" xlink:title="999059 - Disclosure - SCHEDULE OF LONG-TERM DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CRGTermLoanMember" xlink:label="loc_SMTICRGTermLoanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SMTICRGTermLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PaidInKindInterestMember" xlink:label="loc_SMTIPaidInKindInterestMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SMTIPaidInKindInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BackendFeeMember" xlink:label="loc_SMTIBackendFeeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SMTIBackendFeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CadenceTermLoanMember" xlink:label="loc_SMTICadenceTermLoanMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SMTICadenceTermLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails" xlink:title="999060 - Disclosure - SCHEDULE OF MATURITIES OUTSTANDING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative" xlink:title="999061 - Disclosure - DEBT AND CREDIT FACILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CRGTermLoanAgreementMember" xlink:label="loc_SMTICRGTermLoanAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTICRGTermLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CadenceTermLoanAgreementMember" xlink:label="loc_SMTICadenceTermLoanAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTICadenceTermLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BackendFeeMember" xlink:label="loc_SMTIBackendFeeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SMTIBackendFeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CRGTermLoanMember" xlink:label="loc_SMTICRGTermLoanMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SMTICRGTermLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CadenceTermLoanMember" xlink:label="loc_SMTICadenceTermLoanMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SMTICadenceTermLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSecuredDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_GrossCashReceivedFromTermLoan" xlink:label="loc_SMTIGrossCashReceivedFromTermLoan" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIGrossCashReceivedFromTermLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaapDebtInstrumentUnusedBorrowingCapacityAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnusedBorrowingCapacityAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfSecuredDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CashPaidPercentage" xlink:label="loc_SMTICashPaidPercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTICashPaidPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DebtInstrumentUpFrontFeePercentage" xlink:label="loc_SMTIDebtInstrumentUpFrontFeePercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIDebtInstrumentUpFrontFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DebtInstrumentBackEndFeePercentage" xlink:label="loc_SMTIDebtInstrumentBackEndFeePercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIDebtInstrumentBackEndFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_MinimumCashBalanceValue" xlink:label="loc_SMTIMinimumCashBalanceValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIMinimumCashBalanceValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearOne" xlink:label="loc_SMTIAnnualMinimumRevenueYearOne" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIAnnualMinimumRevenueYearOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearTwo" xlink:label="loc_SMTIAnnualMinimumRevenueYearTwo" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIAnnualMinimumRevenueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearThree" xlink:label="loc_SMTIAnnualMinimumRevenueYearThree" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIAnnualMinimumRevenueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearFour" xlink:label="loc_SMTIAnnualMinimumRevenueYearFour" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIAnnualMinimumRevenueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AnnualMinimumRevenueYearFive" xlink:label="loc_SMTIAnnualMinimumRevenueYearFive" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIAnnualMinimumRevenueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PercentageOfLoanProceedsUsedForAcquisition" xlink:label="loc_SMTIPercentageOfLoanProceedsUsedForAcquisition" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SMTIPercentageOfLoanProceedsUsedForAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalHomeLoanBankAdvances" xlink:label="loc_us-gaapFederalHomeLoanBankAdvances" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFederalHomeLoanBankAdvances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate" xlink:label="loc_us-gaapFederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaapDeferredFinanceCostsGross" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SubLicenseAgreementMember" xlink:label="loc_SMTISubLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTISubLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BIAKOSLicenseAgreementMember" xlink:label="loc_SMTIBIAKOSLicenseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIBIAKOSLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_BIAKOSAgreementMember" xlink:label="loc_SMTIBIAKOSAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIBIAKOSAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ABFLicenseAgreementMember" xlink:label="loc_SMTIABFLicenseAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIABFLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DebriderLicenseAgreementMember" xlink:label="loc_SMTIDebriderLicenseAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIDebriderLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PrecisionHealingMergerAgreementMember" xlink:label="loc_SMTIPrecisionHealingMergerAgreementMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIPrecisionHealingMergerAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ScendiaPurchaseAgreementMember" xlink:label="loc_SMTIScendiaPurchaseAgreementMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIScendiaPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AppliedAssetPurchaseAgreementMember" xlink:label="loc_SMTIAppliedAssetPurchaseAgreementMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIAppliedAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ServicesAgreementMember" xlink:label="loc_SMTIServicesAgreementMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_LicenseAgreementMember" xlink:label="loc_SMTILicenseAgreementMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTILicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RochalIndustriesLLCMember" xlink:label="loc_SMTIRochalIndustriesLLCMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIRochalIndustriesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtStatementScenarioAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtProductOrServiceAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaapProductAndServiceOtherMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductAndServiceOtherMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RochalMember" xlink:label="loc_SMTIRochalMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SMTIRochalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AccreditedInvestorsMember" xlink:label="loc_SMTIAccreditedInvestorsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SMTIAccreditedInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_WarrantOneMember" xlink:label="loc_SMTIWarrantOneMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SMTIWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="loc_us-gaapRoyaltyAgreementTermsMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_us-gaapRoyaltyAgreementTermsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_LicenseAgreementAndRoyaltiesDescription" xlink:label="loc_SMTILicenseAgreementAndRoyaltiesDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTILicenseAgreementAndRoyaltiesDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RoyaltyPercentage" xlink:label="loc_SMTIRoyaltyPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTIRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncreaseInRoyaltyAnnualPercentage" xlink:label="loc_SMTIIncreaseInRoyaltyAnnualPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTIIncreaseInRoyaltyAnnualPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PaymentsForAdditionalRoyalties" xlink:label="loc_SMTIPaymentsForAdditionalRoyalties" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTIPaymentsForAdditionalRoyalties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferred" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationAsset" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EarnoutPayment" xlink:label="loc_SMTIEarnoutPayment" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTIEarnoutPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PurchaseAgreementDescription" xlink:label="loc_SMTIPurchaseAgreementDescription" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTIPurchaseAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_OutstandingUnitsPercentage" xlink:label="loc_SMTIOutstandingUnitsPercentage" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTIOutstandingUnitsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_RoyaltyExpensePercentage" xlink:label="loc_SMTIRoyaltyExpensePercentage" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SMTIRoyaltyExpensePercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails" xlink:title="999063 - Disclosure - SUMMARY OF RESTRICTED STOCK ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999064 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails" xlink:title="999065 - Disclosure - SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:label="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:label="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice" xlink:label="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" xlink:label="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_SMTISharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_SMTISharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_SMTIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_SMTISharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_SMTISharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative" xlink:title="999066 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember" xlink:label="loc_SMTITwoThousandTwentyFourOmnibusLongTermIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SMTITwoThousandTwentyFourOmnibusLongTermIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember" xlink:label="loc_SMTITwoThousandFourteenOmnibusLongTermIncentivePlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SMTITwoThousandFourteenOmnibusLongTermIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AppliedAssetPurchaseAgreementMember" xlink:label="loc_SMTIAppliedAssetPurchaseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIAppliedAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SalesAgreementMember" xlink:label="loc_SMTISalesAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTISalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_StockClosingConsiderationMember" xlink:label="loc_SMTIStockClosingConsiderationMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_SMTIStockClosingConsiderationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PrecisionHealingIncMember" xlink:label="loc_SMTIPrecisionHealingIncMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_SMTIPrecisionHealingIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_AccreditedInvestorsMember" xlink:label="loc_SMTIAccreditedInvestorsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SMTIAccreditedInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_NonaccreditedInvestorsMember" xlink:label="loc_SMTINonaccreditedInvestorsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SMTINonaccreditedInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PrecisionHealingMember" xlink:label="loc_SMTIPrecisionHealingMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SMTIPrecisionHealingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferred" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative" xlink:title="999067 - Disclosure - CUSTOMERS AND SUPPLIERS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_NoCustomersMember" xlink:label="loc_SMTINoCustomersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SMTINoCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999068 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxAssetsLeaseLiability" xlink:label="loc_SMTIDeferredTaxAssetsLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SMTIDeferredTaxAssetsLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxAssetsAcquistionLiability" xlink:label="loc_SMTIDeferredTaxAssetsAcquistionLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SMTIDeferredTaxAssetsAcquistionLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaapDeferredTaxAssetsInventory" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInventory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="loc_SMTIDeferredTaxLiabilitiesDepreciationAndAmortization" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SMTIDeferredTaxLiabilitiesDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxLiabilitiesContingentLiability" xlink:label="loc_SMTIDeferredTaxLiabilitiesContingentLiability" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SMTIDeferredTaxLiabilitiesContingentLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences" xlink:label="loc_SMTIDeferredTaxLiabilitiesOtherTemporaryDifferences" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SMTIDeferredTaxLiabilitiesOtherTemporaryDifferences" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails" xlink:title="999069 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE (BENEFIT) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncomeTaxReconciliationFairValueAdjustments" xlink:label="loc_SMTIIncomeTaxReconciliationFairValueAdjustments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SMTIIncomeTaxReconciliationFairValueAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" xlink:label="loc_SMTIIncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SMTIIncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles" xlink:label="loc_SMTIIncomeTaxReconciliationIncomeTaxExpenseIntangibles" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SMTIIncomeTaxReconciliationIncomeTaxExpenseIntangibles" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" xlink:label="loc_SMTIIncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SMTIIncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/IncomeTaxesDetailsNarrative" xlink:title="999070 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExaminationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount" xlink:label="loc_SMTIEffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SMTIEffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative" xlink:title="999071 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ConsultingAgreementMember" xlink:label="loc_SMTIConsultingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SMTIConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_MsSalamoneMember" xlink:label="loc_SMTIMsSalamoneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SMTIMsSalamoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ServicesAgreementMember" xlink:label="loc_SMTIServicesAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTIServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostsAndExpensesRelatedParty" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails" xlink:title="999072 - Disclosure - SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SanaraSurgicalMember" xlink:label="loc_SMTISanaraSurgicalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SMTISanaraSurgicalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_THPMember" xlink:label="loc_SMTITHPMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SMTITHPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaapLiabilitiesFairValueAdjustment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueAdjustment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInterestExpenseOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_SMTIEarningsBeforeInterestTaxesDepreciationAndAmortization" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_SMTIEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails" xlink:title="999073 - Disclosure - SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SanaraSurgicalMember" xlink:label="loc_SMTISanaraSurgicalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SMTISanaraSurgicalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_THPMember" xlink:label="loc_SMTITHPMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SMTITHPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationNoncash" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationNoncash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaapLiabilitiesFairValueAdjustment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueAdjustment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeLossFromEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_ExecutiveSeparationCosts" xlink:label="loc_SMTIExecutiveSeparationCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_SMTIExecutiveSeparationCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_SMTIEarningsBeforeInterestTaxesDepreciationAndAmortization" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_SMTIEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical" xlink:title="999074 - Disclosure - SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_PropertyAndEquipmentWriteOff" xlink:label="loc_SMTIPropertyAndEquipmentWriteOff" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_SMTIPropertyAndEquipmentWriteOff" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SegmentReportingDetailsNarrative" xlink:title="999075 - Disclosure - SEGMENT REPORTING (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative" xlink:title="999076 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SubscriptionAndShareholdersAgreementMember" xlink:label="loc_SMTISubscriptionAndShareholdersAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTISubscriptionAndShareholdersAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_SubscriptionAgreementMember" xlink:label="loc_SMTISubscriptionAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTISubscriptionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="smti-20241231.xsd#SMTI_CRGTermLoanAgreementMember" xlink:label="loc_SMTICRGTermLoanAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SMTICRGTermLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 18, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANARA MEDTECH INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000714256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">59-2219994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1200
    Summit Ave<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fort Worth<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">76102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(817)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">529-2300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SMTI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,175,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,901,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated By Reference</a></td>
<td class="text">The
information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated by reference
to the registrant&#8217;s Definitive Proxy Statement on Schedule 14A relating to the 2025 Annual Meeting of Shareholders which will be
filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Annual Report on Form
10-K relates.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingParValuePerShare', window );">Entity Listing, Par Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text">The critical audit matter communicated below
is a matter arising from the current period audit of the financial statements that were communicated or required to be communicated to
the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our
especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion
on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate
opinion on the critical audit matter or on the accounts or disclosures to which it relates.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Weaver and Tidwell, L.L.P<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Austin, Texas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 15,878,295<span></span>
</td>
<td class="nump">$ 5,147,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_RoyaltyReceivable', window );">Royalty receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">49,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">2,753,032<span></span>
</td>
<td class="nump">4,717,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Convertible loan receivable</a></td>
<td class="nump">1,101,478<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other assets</a></td>
<td class="nump">1,123,798<span></span>
</td>
<td class="nump">608,411<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">33,305,988<span></span>
</td>
<td class="nump">19,005,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-term assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">41,006,776<span></span>
</td>
<td class="nump">44,926,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,601,781<span></span>
</td>
<td class="nump">3,601,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investment in equity securities</a></td>
<td class="nump">8,297,223<span></span>
</td>
<td class="nump">3,084,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets &#8211; operating leases</a></td>
<td class="nump">1,447,907<span></span>
</td>
<td class="nump">1,995,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">432,317<span></span>
</td>
<td class="nump">1,257,956<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total long-term assets</a></td>
<td class="nump">54,786,004<span></span>
</td>
<td class="nump">54,865,280<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">88,091,992<span></span>
</td>
<td class="nump">73,871,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrent', window );">Accrued bonuses and commissions</a></td>
<td class="nump">10,778,840<span></span>
</td>
<td class="nump">7,676,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties and expenses</a></td>
<td class="nump">2,621,867<span></span>
</td>
<td class="nump">2,047,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Earnout liabilities &#8211; current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">580,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8211; current</a></td>
<td class="nump">358,687<span></span>
</td>
<td class="nump">361,185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">15,290,071<span></span>
</td>
<td class="nump">13,767,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">30,689,290<span></span>
</td>
<td class="nump">9,113,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Earnout liabilities &#8211; long-term</a></td>
<td class="nump">748,001<span></span>
</td>
<td class="nump">2,723,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities &#8211; long-term</a></td>
<td class="nump">1,237,051<span></span>
</td>
<td class="nump">1,737,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other long-term liabilities</a></td>
<td class="nump">1,215,617<span></span>
</td>
<td class="nump">1,941,686<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">33,889,959<span></span>
</td>
<td class="nump">15,515,255<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">49,180,030<span></span>
</td>
<td class="nump">29,283,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock: $0.001 par value, 20,000,000 shares authorized; 8,753,773 issued and outstanding as of December&#160;31, 2024 and 8,535,239 issued and outstanding as of December&#160;31, 2023</a></td>
<td class="nump">8,754<span></span>
</td>
<td class="nump">8,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">77,179,211<span></span>
</td>
<td class="nump">72,860,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(37,784,392)<span></span>
</td>
<td class="num">(28,036,814)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Sanara MedTech shareholders&#8217; equity</a></td>
<td class="nump">39,403,573<span></span>
</td>
<td class="nump">44,832,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Equity attributable to noncontrolling interest</a></td>
<td class="num">(491,611)<span></span>
</td>
<td class="num">(244,260)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">38,911,962<span></span>
</td>
<td class="nump">44,588,017<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">88,091,992<span></span>
</td>
<td class="nump">73,871,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">12,408,819<span></span>
</td>
<td class="nump">8,474,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,499,764<span></span>
</td>
<td class="nump">1,924,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">40,566<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 30,913<span></span>
</td>
<td class="nump">$ 77,805<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_RoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_RoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,753,773<span></span>
</td>
<td class="nump">8,535,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">8,753,773<span></span>
</td>
<td class="nump">8,535,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 86,672,425<span></span>
</td>
<td class="nump">$ 64,989,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,139,901<span></span>
</td>
<td class="nump">7,852,686<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78,532,524<span></span>
</td>
<td class="nump">57,137,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,559,863<span></span>
</td>
<td class="nump">56,994,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,703,362<span></span>
</td>
<td class="nump">4,132,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,923,224<span></span>
</td>
<td class="nump">3,675,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities', window );">Change in fair value of earnout liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,938,451)<span></span>
</td>
<td class="num">(3,449,895)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85,247,998<span></span>
</td>
<td class="nump">61,352,309<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,715,474)<span></span>
</td>
<td class="num">(4,215,153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,128,395)<span></span>
</td>
<td class="num">(475,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of losses from equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(90,007)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,978<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on disposal of investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">251,034<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,196,424)<span></span>
</td>
<td class="num">(224,749)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,911,898)<span></span>
</td>
<td class="num">(4,439,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(247,351)<span></span>
</td>
<td class="num">(136,705)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Sanara MedTech shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (9,664,547)<span></span>
</td>
<td class="num">$ (4,303,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,484,224<span></span>
</td>
<td class="nump">8,278,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,484,224<span></span>
</td>
<td class="nump">8,278,949<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes
                                            a $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--PropertyAndEquipmentWriteOff_iI_c20241231_zJC0st7jzVq4" title="Property and equipment write off">506,836</span> non-cash charge during the fourth quarter of 2024 to write-off the remaining net
                                            book value of certain THP internal use software assets.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of deferred and earnout liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="nump">$ 65,213,987<span></span>
</td>
<td class="num">$ (23,394,757)<span></span>
</td>
<td class="num">$ (107,555)<span></span>
</td>
<td class="nump">$ 41,719,975<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">8,299,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">3,442,622<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,442,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares</a></td>
<td class="nump">100,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards', window );">Net settlement and retirement of equity-based awards</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">203,031<span></span>
</td>
<td class="num">(338,860)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(135,794)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards', window );">Net settlement and retirement of equity-based awards, shares</a></td>
<td class="nump">34,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for acquisitions</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">3,089,571<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,089,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for acquisitions, shares</a></td>
<td class="nump">73,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in equity offering</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">911,345<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">911,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in equity offering, shares</a></td>
<td class="nump">26,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,303,197)<span></span>
</td>
<td class="num">(136,705)<span></span>
</td>
<td class="num">(4,439,902)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 8,535<span></span>
</td>
<td class="nump">72,860,556<span></span>
</td>
<td class="num">(28,036,814)<span></span>
</td>
<td class="num">(244,260)<span></span>
</td>
<td class="nump">44,588,017<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">8,535,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 165<span></span>
</td>
<td class="nump">4,435,883<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,436,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares</a></td>
<td class="nump">164,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards', window );">Net settlement and retirement of equity-based awards</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="num">(42,228)<span></span>
</td>
<td class="num">(83,031)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(125,205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards', window );">Net settlement and retirement of equity-based awards, shares</a></td>
<td class="nump">54,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in equity offering</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in equity offering, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,664,547)<span></span>
</td>
<td class="num">(247,351)<span></span>
</td>
<td class="num">(9,911,898)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 8,754<span></span>
</td>
<td class="nump">$ 77,179,211<span></span>
</td>
<td class="num">$ (37,784,392)<span></span>
</td>
<td class="num">$ (491,611)<span></span>
</td>
<td class="nump">$ 38,911,962<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">8,753,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares for net settlement and retirement of equity based awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value for net settlement and retirement of equity based awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (9,911,898)<span></span>
</td>
<td class="num">$ (4,439,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,923,224<span></span>
</td>
<td class="nump">3,675,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit loss expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">624,448<span></span>
</td>
<td class="nump">202,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory obsolescence</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">521,757<span></span>
</td>
<td class="nump">406,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,436,048<span></span>
</td>
<td class="nump">3,442,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Noncash lease expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">547,297<span></span>
</td>
<td class="nump">342,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of losses from equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90,007<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on disposal of investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(251,034)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_BackendFee', window );">Back-end fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">358,086<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-kind interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">838,965<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_AccretionOfFinanceLiabilities', window );">Accretion of finance liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">210,931<span></span>
</td>
<td class="nump">98,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts', window );">Amortization and write-off of debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">209,499<span></span>
</td>
<td class="nump">5,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities', window );">Change in fair value of earnout liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,938,451)<span></span>
</td>
<td class="num">(3,449,895)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_AccruedInterestIncomeExpense', window );">Accrued interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,978)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,508,958)<span></span>
</td>
<td class="num">(1,821,895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts receivable &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32,166)<span></span>
</td>
<td class="nump">90,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,442,744<span></span>
</td>
<td class="num">(1,545,339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(515,496)<span></span>
</td>
<td class="nump">496,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(424,318)<span></span>
</td>
<td class="nump">531,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_IncreaseDecreaseInAccountsPayableRelatedParty', window );">Accounts payable &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(46,891)<span></span>
</td>
<td class="nump">43,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses', window );">Accrued royalties and expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">574,189<span></span>
</td>
<td class="num">(739,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions', window );">Accrued bonuses and commissions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,102,069<span></span>
</td>
<td class="num">(81,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(502,892)<span></span>
</td>
<td class="num">(252,366)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,784)<span></span>
</td>
<td class="num">(3,245,556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(205,848)<span></span>
</td>
<td class="num">(265,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,452)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Investment in equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,302,952)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLoansReceivable', window );">Convertible loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,079,391)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(9,942,750)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,611,643)<span></span>
</td>
<td class="num">(10,207,346)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Loan proceeds, net of debt issuance costs of $1,160,740 in 2024 and $61,658 in 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,339,260<span></span>
</td>
<td class="nump">9,688,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Pay off line of credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,750,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Equity offering net proceeds (expenses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(75,000)<span></span>
</td>
<td class="nump">911,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Net settlement of equity-based awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(125,205)<span></span>
</td>
<td class="num">(135,794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_CashPaymentOfFinanceAndEarnoutLiabilities', window );">Cash payment of finance and earnout liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,022,549)<span></span>
</td>
<td class="num">(822,795)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,366,506<span></span>
</td>
<td class="nump">9,641,123<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,731,079<span></span>
</td>
<td class="num">(3,811,779)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,147,216<span></span>
</td>
<td class="nump">8,958,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,878,295<span></span>
</td>
<td class="nump">5,147,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,580,984<span></span>
</td>
<td class="nump">283,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental noncash investing and financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for lease obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,531,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Equity issued for acquisitions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,089,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1', window );">Earnout and other liabilities generated by acquisitions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,759,642<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes
                                            a $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--PropertyAndEquipmentWriteOff_iI_c20241231_zJC0st7jzVq4" title="Property and equipment write off">506,836</span> non-cash charge during the fourth quarter of 2024 to write-off the remaining net
                                            book value of certain THP internal use software assets.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_AccretionOfFinanceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of finance liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_AccretionOfFinanceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_AccruedInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest income expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_AccruedInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and write-off of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_BackendFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Backend fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_BackendFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_CashPaymentOfFinanceAndEarnoutLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payment of finance and earnout liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_CashPaymentOfFinanceAndEarnoutLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of deferred and earnout liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_IncreaseDecreaseInAccountsPayableRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accounts payable related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_IncreaseDecreaseInAccountsPayableRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued bonuses and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued royalties and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of loan receivable arising from the financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Net of debt issuance costs</a></td>
<td class="nump">$ 1,160,740<span></span>
</td>
<td class="nump">$ 61,658<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (9,664,547)<span></span>
</td>
<td class="num">$ (4,303,197)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_NoInsiderTradingFlag', window );">No Insider Trading Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_NoInsiderTradingFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No Insider Trading Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_NoInsiderTradingFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">We recognize the critical importance of cybersecurity
in safeguarding sensitive information and maintaining operational resilience. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zgAXqd46XXQb">We have processes for assessing, identifying and managing
cybersecurity risks, which are built into our information technology function and are designed to help protect our information assets
and operations from internal and external cyber threats, protect employee and customer information from unauthorized access or attack,
as well as secure our networks and systems</span>.<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zKuu0cmyEY71">The audit committee of the board of directors (the
&#8220;Audit Committee&#8221;) is responsible for overseeing cybersecurity risk and periodically updates our board of directors on such
matters. The Audit Committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates
regarding any significant new cybersecurity threats or incidents.</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a company, we leverage the National Institute
of Standards and Technology (NIST) Cybersecurity Framework to align with industry best practices and to develop policies and procedures,
which include a Cybersecurity Response Plan focusing on detection, validation, mitigation, recovery, and refinement. In addition to the
Cybersecurity Response Plan, we provide cybersecurity awareness training to our employees, including training on social engineering,
phishing, password protection, confidential data protection, mobile security, and incident reporting, to help prevent and reduce the
impact of potential cybersecurity events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have strategically invested resources and tools
to combat the ever-changing cyber threat landscape. These investments include growing our internal technology team headcount and bolstering
our partnerships with entities with external expertise, resulting in increased protection, monitoring, and response capabilities. We
have also made investments to carry cybersecurity insurance that provides additional protection and resources to reduce a cybersecurity
event&#8217;s impact and potential losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our technology and management teams meet regularly
with key internal and external stakeholders to review cybersecurity concerns and areas for continued focus and improvement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

We face risks from cybersecurity threats that could
have a material adverse effect on our business, financial condition, results of operations, cash flows or reputation. To date, we have
not experienced any risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially
affected or are reasonably likely to materially affect our business strategy, financial condition, results of operations, or cash flows.
See &#8220;Risk Factors &#8211; Risks Related to Our Business &#8211; Security breaches and other disruptions could compromise our information
and expose us to liability, which would cause our business and reputation to suffer.&#8221;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The audit committee of the board of directors (the
&#8220;Audit Committee&#8221;) is responsible for overseeing cybersecurity risk and periodically updates our board of directors on such
matters. The Audit Committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates
regarding any significant new cybersecurity threats or incidents.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND BACKGROUND<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF BUSINESS AND BACKGROUND</a></td>
<td class="text"><p id="xdx_804_eus-gaap--NatureOfOperations_zwh5tnIBXdx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8211; <span id="xdx_824_zju88NUxA3Dg">NATURE OF BUSINESS AND BACKGROUND</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sanara MedTech Inc. (together with its wholly owned
and majority owned subsidiaries on a consolidated basis, the &#8220;Company&#8221;) is a medical technology company focused on developing
and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic
wound and skincare markets. Each of the Company&#8217;s products, services and technologies are designed to achieve the Company&#8217;s
goal of providing better clinical outcomes at a lower overall cost for patients, regardless of where they receive care. Through its two
operating segments, Sanara Surgical and Tissue Health Plus (&#8220;THP&#8221;), the Company strives to be one of the most innovative
and comprehensive providers of effective surgical, wound and skincare solutions and is continually seeking to expand its offerings for
patients requiring treatments across the entire continuum of care in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As further discussed in Note 14, the Company historically managed its business on the basis of one operating
and reportable segment. During the second quarter of 2024, the Company changed its
reportable segments to reflect a change in the manner in which the business is managed. Based on the growing importance of the value-based
wound care program to the Company&#8217;s future outlook and how the Company&#8217;s chief operating decision maker, the Chief Executive
Officer, reviews operating results and makes decisions about resource allocation, the Company now has <span id="xdx_906_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240401__20240630_zaB4xXkgHaC4" title="Number of reportable segment">two</span> reportable segments: Sanara
Surgical and THP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Sanara Surgical </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Sanara Surgical segment primarily markets and
sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Sanara Surgical&#8217;s
soft tissue repair products include, among other products, the Company&#8217;s lead product, CellerateRX Surgical Activated Collagen
(&#8220;CellerateRX Surgical&#8221;), a hydrolyzed collagen that provides a moist environment for surgical sites to aid in the natural
wound healing process, and BIASURGE Advanced Surgical Solution, a sterile no-rinse, advanced surgical solution used for wound irrigation.
Sanara Surgical&#8217;s bone fusion products include, among other products, BiFORM, an osteoconductive, bioactive, porous implant that
allows for bony ingrowth across the graft site, and ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor
cells and conformable bone fibers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sanara Surgical also includes an in-house research
and development team, Rochal Technologies, with an extensive pipeline of innovative products under development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Tissue Health Plus </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through the Company&#8217;s subsidiary, Tissue Health
Plus (formerly known as &#8220;WounDerm&#8221; and &#8220;United Wound and Skin Solutions, LLC&#8221;), the Company is seeking to simplify
skin health, starting with wound care through a refined business plan. Through THP, the Company plans to offer a first of its kind value-based
wound care program to payers and risk-bearing entities such as accountable care organizations and value-based primary care companies,
with Medicare Advantage payers as the initial target market for this program. The THP segment is focused on value-based wound care services.
Through THP, the Company plans to offer a first of its kind value-based wound care program to payers and risk-bearing entities such as
accountable care organizations and value-based primary care companies, with Medicare Advantage payers as the initial target market for
this program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">THP&#8217;s programs are expected to enable payers
to divest wound care spend risk, reduce wound related hospitalizations and improve patient quality of life. THP plans to coordinate delivery
of community and home-based wound care for its managed patients. Community-based care spans a variety of settings including physician
offices, skilled nursing facilities, assisted living facilities and senior living facilities. THP&#8217;s programs are intended to integrate
science and evidence-based medicine protocols to standardize wound prevention and treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the change in reportable segments,
certain prior period amounts have been recast to conform to the current period presentation. Throughout this Annual Report on Form 10-K,
unless otherwise indicated, amounts and activity reflect reclassifications related to the Company&#8217;s change in reportable segments.
The change in reportable segments had no impact on the Company&#8217;s previously reported Consolidated Balance Sheets, Consolidated
Statements of Operations, Consolidated Statements of Cash Flows or Consolidated Statements of Shareholders&#8217; Equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zQ5sa65pzRFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8212; <span id="xdx_829_zELV8x07mAM8">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_zWgD8C7GaIkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_866_z5VScNKQbWcd">Principles of Consolidation and Basis of Presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of Sanara MedTech Inc. and its wholly owned and majority-owned subsidiaries, as well as other entities in which
the Company has a controlling financial interest. All significant intercompany profits, losses, transactions and balances have been eliminated
in consolidation. Certain prior year amounts have been reclassified to conform to the current year presentation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p id="xdx_840_eus-gaap--UseOfEstimates_zX6nXHAESdFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zeobAQWcjXK5">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and
the reported revenue and expenses during the reporting period. However, actual results could differ from those estimates and there may
be changes to the Company&#8217;s estimates in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zVH5nCCKGtJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_865_zgPXxcOOsSHg">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid investments
purchased with an original maturity of three months or less to be cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zpLuYGKBoAuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_z2p7h9RuBYk4">Income/Loss Per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes income/loss per share in accordance
with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 260, Earnings per Share, which requires the Company to present basic
and diluted income per share when the effect is dilutive. Basic income/loss per share is computed by dividing income/loss attributable
to common shareholders by the weighted average number of shares of common stock outstanding. Diluted income/loss per share is computed
similarly to basic income/loss per share, except that the denominator is increased to include the number of additional shares of common
stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common
stock were dilutive. All common stock equivalents were excluded from the calculations for the periods presented as their inclusion would
have been anti-dilutive during the years ended December&#160;31, 2024 and 2023 due to the Company&#8217;s net loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWXU0FDCQDwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the shares of common
stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the years ended December&#160;31,
2024 and 2023 as such shares would have had an anti-dilutive effect:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zf7w48RRD9A9" style="display: none">SCHEDULE
OF COMPUTATION OF DILUTED NET LOSS PER SHARE</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20240101__20241231_z2Dd1IDQxPbb" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_zfZm4fFZ5OOc" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zDvw2srqeA2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 0pt"><span style="font-size: 10pt">Stock options<sup id="xdx_F4C_zmB7sEMtIBwj">(a)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">31,013</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">93,892</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKD4QRq4eUl3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt"><span style="font-size: 10pt">Warrants<sup id="xdx_F48_zFdIWwfer048">(b)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,725</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zsbhPOlzXXF3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Unvested restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202,787</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,211</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z6ObFpoJjSwj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202,787</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">144,211</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td id="xdx_F0E_zLw243GCkSl4" style="width: 0.25in">(a)</td><td id="xdx_F1D_zQ2VZuA9Ai1g">Shares underlying stock options assumed pursuant to the merger agreement
                                            with Precision Healing, Inc. (&#8220;Precision Healing&#8221;) in April 2022.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td id="xdx_F0F_zRE6wyIXY6d7" style="width: 0.25in">(b)</td><td id="xdx_F1E_zt5c7r2IXmL5">Shares underlying warrants assumed pursuant to the merger agreement
                                            with Precision Healing in April 2022.</td></tr></table>

<p id="xdx_8AE_zKpKnX5IfzJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zvpssZlOVqdl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_860_zBN1XGdmgHGh">Revenue Recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue in accordance with
ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Revenues are recognized when a purchase order is received
from the customer and control of the promised goods or services is transferred to the customer in an amount that reflects the consideration
the Company expects to be entitled to receive in exchange for transferring those goods or services. Revenue is recognized based on the
following five-step model:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: -9pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Identification of the contract with a customer</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Identification of the performance obligations
                                            in the contract</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Determination of the transaction price</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Allocation of the transaction price to the performance
                                            obligations in the contract</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Recognition of revenue when, or as, the Company
                                            satisfies a performance obligation</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Details of this five-step process are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Identification of the contract with a customer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Customer purchase orders are generally considered
to be contracts under ASC 606. Purchase orders typically identify the specific terms of products to be delivered, create the enforceable
rights and obligations of both parties and result in commercial substance. No other forms of contract revenue recognition, such as the
completed contract or percentage of completion methods, were utilized by the Company in either 2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Performance obligations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s performance obligation is generally
limited to delivery of the requested items to its customers at the agreed upon quantities and prices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Determination and allocation of the transaction price</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has established prices for its products.
These prices are effectively agreed to when customers place purchase orders with the Company. Rebates and discounts, if any, are recognized
in full at the time of sale as a reduction of net revenue. Allocation of transaction prices is not necessary where only one performance
obligation exists. For certain sales transactions, we incur group purchasing organization fees that are based on a contractual percentage
of applicable sales and are recorded as a reduction of the revenue for those transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Recognition of revenue as performance obligations are satisfied</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Product revenues are recognized when a purchase order
is received from the customer, the products are delivered, and control of the goods and services passes to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Disaggregation of Revenue</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zydaPT1G4ZKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue streams from product sales and royalties
are summarized below for the years ended December&#160;31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z9Njba69Dhx4" style="display: none">SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20241231_z9BTxnEdZ442" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20230101__20231231_ztPw1I3NSwZa" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SoftTissueRepairProductsMember_zneCjYnaFoe7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 0pt">Soft tissue repair products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">76,125,012</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">54,836,410</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--BoneFusionProductsMember_zl6rE4Y3bJA6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Bone fusion products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,547,413</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,952,432</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zaDbFNK5EtN" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0590">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">201,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zKdc18lqmb9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total Net Revenue</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">86,672,425</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">64,989,842</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zaRG0x0BD4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2024 and
2023, all of the Company&#8217;s net revenue was generated from Sanara Surgical. The Company is preparing to launch the first THP
pilot program with a wound care provider group during the second quarter of 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p id="xdx_84C_eus-gaap--CreditLossFinancialInstrumentPolicyTextBlock_zau6cFpP84v6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86E_zkO6xtwjAUph">Accounts Receivable Allowances</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable are typically due within 30
days of invoicing. The Company establishes an allowance for credit losses to provide for an estimate of accounts receivable which
are not expected to be collectible. The Company bases the allowance on an assessment of customer creditworthiness, historical
payment experience, the age of outstanding receivables and other information as applicable and will record its allowance based on
the estimated credit losses. The Company&#8217;s accounts receivable balance, net was $<span id="xdx_90D_eus-gaap--AccountsReceivableNetCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zzTaJygWj6v1" title="Accounts receivable">12,408,819</span>, $<span id="xdx_906_eus-gaap--AccountsReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zoxigWdgakN6" title="Accounts receivable">8,474,965</span>, and $<span id="xdx_90B_eus-gaap--AccountsReceivableNetCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zBusyyYA3Bsj" title="Accounts receivable">6,805,761</span> as of December
31, 2024, December 31, 2023, and December 31, 2022, respectively. The Company recorded credit loss expense of $<span id="xdx_90B_eus-gaap--ProvisionForDoubtfulAccounts_c20240101__20241231_zl7NwK9XaDN7" title="Bad debt expense">624,448</span>
and $<span id="xdx_90B_eus-gaap--ProvisionForDoubtfulAccounts_c20230101__20231231_zLbUbIGGyrgl" title="Bad debt expense">202,941</span>
during the years ended December&#160;31, 2024 and 2023, respectively. The allowance for credit losses was $<span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20241231_zLMuSoGtDiEd" title="Allowance for credit losses">1,173,441</span>
at December&#160;31, 2024 and $<span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zboG2jZNi8lk" title="Allowance for credit losses">528,030</span>
at December&#160;31, 2023. Credit loss reserves are maintained based on a variety of factors, including the length of time
receivables are past due and a detailed review of certain individual customer accounts. The Company also establishes other
allowances to provide for estimated customer rebates and other expected customer deductions. These allowances totaled $<span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_c20241231_ztbX3Z9Q2YI1" title="Allowance for customer rebates and deductions">4,897</span>
at December&#160;31, 2024 and $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_c20231231_zYAfTFwYXIgb" title="Allowance for customer rebates and deductions">3,820</span>
at December&#160;31, 2023. If circumstances related to customers change, estimates of the recoverability of receivables would be
further adjusted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_zuU61DQo9Vdk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_862_zateYLuhUsxd">Inventories</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower of cost or net
realizable value, with cost computed on a first-in, first-out basis. Inventories consist primarily of finished goods, and also include
an immaterial amount of raw materials and related packaging components. The Company recorded inventory obsolescence expense of $<span id="xdx_901_eus-gaap--InventoryWriteDown_c20240101__20241231_zCTwYKZUNe6f" title="Inventory obsolescence expense">521,757</span>
and $<span id="xdx_902_eus-gaap--InventoryWriteDown_c20230101__20231231_zovbIFGgdTr1" title="Inventory obsolescence expense">406,812</span> during the years ended December&#160;31, 2024 and 2023, respectively. The allowance for obsolete and slow-moving inventory
had a balance of $<span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_c20241231_zc074IrXpNph" title="Allowance for obsolete and slow-moving inventory">534,549</span> at December&#160;31, 2024 and $<span id="xdx_902_eus-gaap--InventoryValuationReserves_iI_c20231231_zyOJP02HiKF4" title="Allowance for obsolete and slow-moving inventory">446,917</span> at December&#160;31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zH8nmSqF4w6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_866_zb79f3OI2Ddf">Property and Equipment</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost, less accumulated
depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the related assets, ranging
from <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember_zP6XLLBlsNy2" title="Estimated useful lives::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl0628">two</span></span> to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_c20241231__srt--RangeAxis__srt--MaximumMember_zZiC3dzkTRu6" title="Estimated useful lives">ten years</span>. Below is a summary of property and equipment for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zqRliQNnUB1d" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zQKNzkO8FU9g" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Useful</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Life</b></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zjuto5QPegHf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zwcZH3iFbWbi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVlyBmKFNc29" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; padding-left: 0pt">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: center; padding-left: 0pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zpfitIsrj9Ak" title="Useful Life">3</span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zuDth0z9viv1" title="Useful Life">5</span> years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">295,963</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">194,788</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zrthfTCFxxhk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Office equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zs8CneFLDiB6" title="Useful Life">3</span>-<span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_z2kIMVBvCVw2" title="Useful Life">7</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">216,491</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">201,785</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zJ56vuocB1Ih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zeQhlRy083Za" title="Useful Life">5</span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zbWxC8rWUL7c" title="Useful Life">10</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">346,508</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304,338</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zLVSo8nF94k1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_z3ksmxolhQ3c" title="Useful Life">2</span>-<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zfSPGPNrx4ye" title="Useful Life">5</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">181,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134,170</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zkzxzTMzV3c3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Internal use software</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 0pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_ztngxXxxLfR" title="Useful life">5</span> years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0662">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,618,999</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz6Up_znA7HeNhBpG8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,040,930</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,454,080</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz6Up_z5x7dqCdRrr7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(608,613</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,196,124</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz6Up_zph1Y9kIAJq5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">432,317</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,257,956</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zm4xRmkwAxS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense related to property and equipment
was $<span id="xdx_906_eus-gaap--Depreciation_c20240101__20241231_zjo3LfxdWLG2" title="Depreciation">1,031,487</span> and $<span id="xdx_90B_eus-gaap--Depreciation_c20230101__20231231_z0BnoG2WACQ3" title="Depreciation">456,138</span> during the year ended December&#160;31, 2024 and 2023, respectively. Depreciation expense for the year ended
December&#160;31, 2024 included a non-cash charge of $<span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_z8IlaiQpIepi" title="Depreciation">506,836</span> to write-off the remaining net book value of certain internal use software
assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p id="xdx_849_eus-gaap--InternalUseSoftwarePolicy_zrF1Mx2vgan" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_zIKZP3FaoK1g">Internal Use Software</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounted for costs incurred to develop
or acquire computer software for internal use in accordance with ASC Topic 350-40, Intangibles &#8211; Goodwill and Other. The Company
capitalized the costs incurred during the application development stage, which generally included third-party developer fees to design
the software configuration and interfaces, coding, installation and testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company began capitalization of qualifying costs
when both the preliminary project stage was completed and management authorized further funding for the completion of the project. Costs
incurred during the preliminary project stage along with post implementation stages of internal-use computer software was expensed as
incurred. The Company also capitalized costs related to specific upgrades and enhancements when it was probable the expenditures would
result in additional functionality. Capitalized development costs were classified as &#8220;Property and equipment, net&#8221; in the
Consolidated Balance Sheets and were depreciated over the estimated useful life of the software, which was generally <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_c20241231_zEG0ftpJryRl" title="Software, estimated useful life">five years</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z1WdfEV3R3Rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_864_zJk3m1hNnfCe">Goodwill</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The excess of purchase price over the fair value
of identifiable net assets acquired in business combinations is recorded as goodwill. As of December&#160;31, 2024 and December&#160;31,
2023, all of the Company&#8217;s goodwill relates to the acquisition of Scendia Biologics, LLC (&#8220;Scendia&#8221;), which is included
in the Sanara Surgical segment. Goodwill has an indefinite useful life and is not amortized. Goodwill is tested annually as of December&#160;31
for impairment, or more frequently if circumstances indicate impairment may have occurred. The Company may first perform a qualitative
assessment to determine if it is more likely than not that the fair value of the reporting unit is less than the respective carrying
value. If it is determined that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying value,
then the Company will determine the fair value of the reporting unit and record an impairment charge for the difference between fair
value and carrying value (not to exceed the carrying amount of goodwill). <span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_dxL_c20240101__20241231_zf8A9BY2laia" title="Impairment of goodwill::XDX::-"><span id="xdx_902_eus-gaap--GoodwillImpairmentLoss_dxL_c20230101__20231231_zSP9gN96Qp8" title="Impairment of goodwill::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0688"><span style="-sec-ix-hidden: xdx2ixbrl0690">No</span></span></span></span> impairment was recorded during the year ended December&#160;31,
2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_z0H17BQcYr0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_864_zesGLPv7Z3n7">Intangible Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets are stated at cost of acquisition
less accumulated amortization and impairment loss, if any. Cost of acquisition includes the purchase price and any cost directly attributable
to bringing the asset to its working condition for the intended use. The Company amortizes its finite-lived intangible assets on a straight-line
basis over the estimated useful life of the respective assets which is generally the life of the related patents or licenses, seven years
for customer relationships and five years for assembled workforces. See Note 5 for more information on intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQQvnP4shxjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_869_zbyigOjCH2M9">Impairment of Long-Lived Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets, including certain identifiable
intangibles held and to be used by the Company, are reviewed for impairment whenever events or changes in circumstances indicate that
the carrying amount of such assets may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets
based on estimated future cash flows and the estimated liquidation value of such long-lived assets and provides for impairment if such
undiscounted cash flows are insufficient to recover the carrying amount of the long-lived assets. If impairment exists, an adjustment
is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value.
Fair values are determined based on quoted market values, undiscounted cash flows or internal and external appraisals, as applicable.
Assets to be disposed of are carried at the lower of carrying value or estimated fair value less cost to sell. A $<span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn5n6_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zFeTMhSeGVo3" title="Depreciation">0.5</span> million non-cash
charge to write-off the remaining net book value of certain THP internal use software assets was recorded during the year ended December&#160;31,
2024. <span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20230101__20231231_z0RhOg8Dufg1" title="Impairment of long-lived assets">No</span> impairment was recorded during the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p id="xdx_84B_eus-gaap--EquityMethodInvestmentsPolicy_zCGU5SwufEW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_862_ztdSbWsdtScl">Investments in Equity Securities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s equity investments consist of
nonmarketable equity securities in privately held companies without readily determinable fair values. Unless accounted for under the
equity method of accounting, the investments are reported at cost minus impairment, if any, plus or minus changes resulting from observable
price changes in orderly transactions for the identical or similar investment in the same issuer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company applies the equity method of accounting
to investments when it has significant influence, but not controlling interest, in the investee. Judgment regarding the level of influence
over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors,
participation in policy-making decisions and material intercompany transactions. As discussed further in Note 6 as of December&#160;31,
2024, the Company had two investments that are recorded applying the equity method of accounting. The Company&#8217;s proportionate share
of the net income (loss) resulting from these investments is reported under the line item captioned &#8220;Share of losses from equity
method investments&#8221; in the Company&#8217;s Consolidated Statements of Operations. The Company&#8217;s equity method investments
are adjusted each period for the Company&#8217;s share of the investee&#8217;s income or loss and dividend paid, if any. The Company
classifies distributions received from its equity method investments using the cumulative earnings approach in the Company&#8217;s Consolidated
Statements of Cash Flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has reviewed the carrying value of its
investments and has determined there was no impairment or observable price changes as of or for the year ended December&#160;31, 2024
and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z8rBtA5vItM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_868_zccdqe3IkqB9">Fair Value Measurement</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As defined in ASC Topic 820, Fair Value Measurement
(&#8220;ASC 820&#8221;), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market
participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the
valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair
value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted
prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level
3 measurement). This fair value measurement framework applies at both the initial and subsequent measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The three levels of the fair value hierarchy defined
by ASC 820 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 &#8211; Quoted prices are available in active
markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or
liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of
financial instruments such as exchange-traded derivatives, marketable securities and listed equities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 &#8211; Pricing inputs are other than quoted
prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes
those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard
models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current
market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these
assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are
supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include
nonexchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 &#8211; Pricing inputs include significant
inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that
result in management&#8217;s best estimate of fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of cash, accounts receivable,
accounts payable and accrued expenses, other than acquisition-related expenses, approximate fair value because of the short-term nature
of these instruments. The fair value of acquisition-related accrued expenses is categorized as Level 2 of the fair value hierarchy. The
value of these instruments has been estimated using discounted cash flow analysis based on the Company&#8217;s incremental borrowing
rate. The carrying value of the Company&#8217;s CRG Term Loan (defined below), which has a fixed interest rate approximates fair value
based on instruments with similar terms (Level 2 inputs). The fair value of the contingent earnout consideration and the acquisition
date fair value of goodwill and intangibles related to the acquisitions discussed in Notes 3 and 5 are based on Level 3 inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Liabilities for contingent consideration for the
Precision Healing merger, acquisition of Scendia and Applied Asset Purchase (defined below) (see Note 3 for more information) are measured
at fair value each reporting period, with the acquisition-date fair value included as part of the consideration transferred. The contingent
consideration for the Scendia acquisition was settled as of September 30, 2024, and the final earnout payment of approximately $1.1 million
was paid in cash in October 2024. The Precision Healing contingent consideration is classified as a liability at its fair value at each
reporting period due to the fact that the monetary value of the shares to be issued is predominantly dependent on the exercise contingency
(i.e., revenue targets). Subsequent changes in fair value of contingent consideration related to the Precision Healing merger are reported
under the line item captioned &#8220;Change in fair value of earnout liabilities&#8221; in the Company&#8217;s Consolidated Statements
of Operations. The Company reviewed the thresholds necessary to trigger a payment on the Precision Healing earnout as of December 31,
2024 and deemed the thresholds to be unachievable by the sellers, therefore, the remaining fair value on the earnout was reduced to zero.
Due to the Applied Asset Purchase being accounted for as an asset acquisition and given that the transaction did not include contingent
shares, subsequent revaluations of contingent consideration for the Applied Asset Purchase results in an adjustment to the contingent
consideration liability and the intellectual property intangible asset with a cumulative catch-up amortization adjustment. The current
year change in fair value of earnout liability below is as a result of a net decrease in the estimated fair value of the earnout liability
established at the time of the Company&#8217;s Precision Healing merger. The current year revaluation of earnout liability below is a
result of a decrease in the estimated value of the earnout liability established at the time of the Applied Asset Purchase. The following
table sets forth a summary of the changes in fair value for the Level 3 contingent earnout considerations.</p>

<p id="xdx_898_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zyMX4K6dm2g4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zlfDaPl3CVAl" style="display: none">SCHEDULE
OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_495_20240101__20241231_zGPyhUGHNZDf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_zZYTfAj7HLie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; padding-left: 0pt">Balance at December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,823,001</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_zooAX9QzVyf6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 9pt; padding-left: 0pt">Change in fair value of earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,938,451</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability_zNjJ5pGNlySg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 9pt; padding-left: 0pt">Revaluation of earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(51,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements_zETuDA62VB44" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt">Settlements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,085,549</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_zbXliTDqnde7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">748,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zR31WoaaVx26" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zXVrVoI0j0v" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_865_zQLkHdchx9E3">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Income taxes are accounted for under the asset and
liability method, whereby deferred income taxes are recorded for temporary differences between financial statement carrying amounts and
the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years
in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all the
deferred tax asset will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zW7kGy8BeOM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_861_z2uC0X764h8d">Share-based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for share-based compensation
to employees and nonemployees in accordance with ASC Topic 718, Compensation &#8211; Stock Compensation. Share-based compensation is
measured at the grant date, based on the fair value of the award, and is recognized as expense over the stipulated vesting period, if
any. The Company estimates the fair value of share-based payments using the Black-Scholes option-pricing model for common stock options
and warrants, and the closing price of the Company&#8217;s common stock for grants of common stock, including restricted stock awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zsaYDcSy2eR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86E_zmgxSQsBIQN5">Research and Development Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development (&#8220;R&amp;D&#8221;)
expenses consist of personnel-related expenses, including salaries, share-based compensation and benefits for all personnel directly
engaged in R&amp;D activities, contracted services, materials, prototype expenses and allocated overhead, which is comprised of compensation
and benefits, lease expense and other facilities-related costs. R&amp;D expenses include costs related to enhancements to the Company&#8217;s
currently available products and additional investments in the product and platform development pipeline. The Company expenses R&amp;D
costs as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p id="xdx_84A_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_z7hRzsnmClZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_863_z1yk2PchwuZ1">Recently Adopted Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments - Credit Losses (Topic
326). This update amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate
credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The Company
adopted the new guidance effective January 1, 2023. The adoption did not have a material impact on the Company&#8217;s consolidated financial
position, results of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, FASB issued ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;), which requires disclosure of incremental
segment information on an annual and interim basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and
interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company adopted the new guidance
effective December 31, 2024. The adoption did not have a material impact on the Company&#8217;s consolidated financial position, results
of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3IibpPc84ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_z4TJcBV8RiWa">Recently Issued Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, FASB issued ASU 2023-09, Income
Taxes (Topic 740): Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;), which expands the disclosure required for income
taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the effect of this pronouncement on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2024, FASB issued ASU 2024-03, Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,
which requires new disclosures providing further detail of a company&#8217;s income statement expense line items. ASU 2024-03 is effective
for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is
permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</p>

<p id="xdx_853_zuGP1w71ll1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>APPLIED ASSET PURCHASE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">APPLIED ASSET PURCHASE</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--AssetAcquisitionTextBlock_zg4P3jX7T053" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 &#8211; <span id="xdx_82E_zib08xopEAP5">APPLIED ASSET PURCHASE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 1, 2023, the Company entered into
an Asset Purchase Agreement (the &#8220;Applied Purchase Agreement&#8221;) by and among the Company, as guarantor, Sanara MedTech Applied
Technologies, LLC, a Texas limited liability company and wholly owned subsidiary of the Company (&#8220;SMAT&#8221;), The Hymed Group
Corporation, a Delaware corporation (&#8220;Hymed&#8221;), Applied Nutritionals, LLC, a Delaware limited liability company (&#8220;Applied&#8221;,
and together with Hymed, the &#8220;Sellers&#8221;), and Dr. George D. Petito (the &#8220;Owner&#8221;), pursuant to which SMAT acquired
certain assets of the Sellers and the Owner, including, among others, the Sellers&#8217; and Owner&#8217;s inventory, intellectual property,
manufacturing and related equipment, goodwill, rights and claims, other than certain excluded assets, all as more specifically set forth
in the Applied Purchase Agreement (collectively, the &#8220;Applied Purchased Assets&#8221;), and assumed certain Assumed Liabilities
(as defined in the Applied Purchase Agreement), upon the terms and subject to the conditions set forth in the Applied Purchase Agreement
(such transaction, the &#8220;Applied Asset Purchase&#8221;). The Applied Purchased Assets include the underlying intellectual property
of, as well as the rights to manufacture and sell, certain hydrolyzed collagen products, including CellerateRX Surgical, for human wound
care use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Applied Purchased Assets were purchased for an
initial aggregate purchase price of $<span id="xdx_90E_eus-gaap--PaymentsToAcquireProductiveAssets_pn4n6_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zB9Il9w4xY8j" title="Assets purchase price">15.25</span> million, consisting of (i) $<span id="xdx_905_eus-gaap--AssetAcquisitionConsiderationTransferredOtherAssets_pn4n6_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--CashClosingConsiderationMember_zUdzufzCtdKj" title="Cash consideration paid">9.75</span> million in cash (the &#8220;Cash Closing Consideration&#8221;),
(ii) <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--StockClosingConsiderationMember_zDXhqTuf55Ll" title="Shares issued as consideration">73,809</span> shares of the Company&#8217;s common stock (the &#8220;Stock Closing Consideration&#8221;) with an agreed upon value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_pn5n6_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--StockClosingConsiderationMember_zt97hdZrMyoi" title="Value of shares issued as consideration">3.0</span>
million and (iii) $<span id="xdx_909_eus-gaap--OtherLoansPayable_iI_pn5n6_c20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_z1OsLdc0mT1k" title="Installment payable">2.5</span> million in cash (the &#8220;Installment Payments&#8221;), to be paid in four equal installments on each of the
next four anniversaries of the closing of the Applied Asset Purchase (the &#8220;Closing&#8221;). The first Installment Payment of $<span id="xdx_900_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zyabbarSrsZg" title="Payment of installment">625,000</span>
was made in August 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the Closing, the Company licensed certain
of its products from Applied through a sublicense agreement (the &#8220;Sublicense Agreement&#8221;) with CGI Cellerate RX, LLC (&#8220;CGI
Cellerate RX&#8221;), a related party (see Note 13 for additional information regarding transactions with related parties). Pursuant
to the Sublicense Agreement, the Company had an exclusive, world-wide sublicense to distribute certain hydrolyzed collagen products,
including CellerateRX Surgical, into the surgical and wound care markets. In connection with the Applied Asset Purchase, Applied assigned
its license agreement with CGI Cellerate RX to SMAT (the &#8220;License Agreement&#8221;), and on October 10, 2024, the License Agreement
and the Sublicense Agreement were terminated for no additional consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the Cash Closing Consideration, Stock
Closing Consideration and Installment Payments, the Applied Purchase Agreement provides that the Sellers are entitled to receive up to
an additional $<span id="xdx_90B_ecustom--EarnoutPayable_iI_pn5n6_c20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zHnd4Q7GIKOi" title="Earnout payable">10.0</span> million (the &#8220;Applied Earnout&#8221;), which is payable to the Sellers in cash, upon the achievement of certain
performance thresholds relating to SMAT&#8217;s collections from net sales of a collagen-based product currently under development. Upon
expiration of the seventh anniversary of the Closing, to the extent the Sellers have not earned the entirety of the Applied Earnout,
SMAT shall pay the Sellers a pro-rata amount of the Applied Earnout based on collections from net sales of the product, with such amount
to be due credited against any Applied Earnout payments already made by SMAT (the &#8220;True-Up Payment&#8221;). The Applied Earnout,
minus the True-Up Payment and any Applied Earnout payments already made by SMAT, may be earned at any point in the future, including
after the True-Up Payment is made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Applied Asset Purchase and
pursuant to the Applied Purchase Agreement, effective August 1, 2023, the Company entered into a professional services agreement (the
&#8220;Petito Services Agreement&#8221;) with the Owner, pursuant to which the Owner, as an independent contractor, agreed to provide
certain services to the Company, including, among other things, assisting with the development of products already in development and
assisting with research, development, formulation, invention and manufacturing of any future products (the &#8220;Petito Services&#8221;).
<span id="xdx_90C_ecustom--PurchaseAgreementDescription_c20240101__20241231_zDR5wgh9ebt9" title="Purchase agreement description">As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of
the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain
products the Owner develops or co-develops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first
$50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%)
on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv)
$500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in
cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described
in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Petito Services Agreement has an initial term
of three years and is subject to automatic successive one-month renewals unless earlier terminated in accordance with its terms. The
Petito Services Agreement may be terminated upon the Owner&#8217;s death or disability or by the Company or the Owner &#8220;For Cause&#8221;
(as defined in the Petito Services Agreement); provided, however, that the base salary described in (i) of the foregoing paragraph shall
survive termination through the three-year initial term and the royalty payments and incentive payments described in (ii)-(v) of the
foregoing paragraph shall survive termination of the Petito Services Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As the contingent consideration was negotiated as
part of the transfer of assets, the contingent obligation was measured at fair value and included in the total purchase consideration
transferred. Accordingly, since the Applied Asset Purchase was accounted for as an asset acquisition and did not include contingent shares,
the contingent consideration is classified as a liability at its estimated fair value at each reporting period with subsequent revaluations
recognized as an adjustment to the intellectual property intangible asset and the earnout liability with a cumulative catch-up amortization
adjustment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p id="xdx_898_eus-gaap--AssetAcquisitionTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zxJytX6QcDnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total purchase consideration for the Applied
Asset Purchase as determined by the Company was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_ztC3meezwqk9" style="display: none">SCHEDULE
OF ASSET PURCHASE CONSIDERATIONS</span></span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 92%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consideration</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_z2dmqgq7z4L2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Dollar Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetAcquisitionConsiderationTransferredOtherAssets_maAACTzk9b_zza98cZNX7N" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 0pt">Cash Closing Consideration</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9,750,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_maAACTzk9b_zwYdNodpNAke" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Fair value of Stock Closing Consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zXDdhJapU3eg" title="Equity Shares">73,809</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,089,645</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments_maAACTzk9b_zw7h3kxU9WI3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Fair value of Installment Payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,040,808</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AssetAcquisitionConsiderationTransferredCashPaidForInventory_maAACTzk9b_zkrHiYSUkVof" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Cash paid for inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,007</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments_maAACTzk9b_zPlGwUIoSCx1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Fair value of Petito Services Agreement defined payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">825,834</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_maAACTzk9b_zN89THawGPna" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Fair value of Petito Services Agreement contingent consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">893,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_maAACTzk9b_zktigTQotIah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Direct transaction costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">162,743</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferred_iT_mtAACTzk9b_znTrnBD5j554" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 9pt; padding-left: 0pt">Total purchase consideration</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">16,792,037</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zuJeAk47Ts45" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on guidance provided by ASC 805, Business Combinations
(&#8220;ASC 805&#8221;), the Company recorded the Applied Asset Purchase as an asset acquisition due to the determination that substantially
all the fair value of the assets acquired was concentrated in a group of similar identifiable assets. The Company believes the &#8220;substantially
all&#8221; criterion was met with respect to the acquired intellectual property being the only significant asset acquired. Accordingly,
the Company accounted for the transaction as an asset acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase consideration, plus transaction costs,
was allocated to the individual assets according to their fair values as a percentage of the total fair value of the assets purchased,
with no goodwill recognized. Based on the estimated fair value of the gross assets acquired, the total fair value of the net assets acquired
was primarily attributable to, and classified as, finite-lived intellectual property in the fourth quarter of 2023. The total purchase
consideration was allocated based on the relative estimated fair value of such assets as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_892_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zRoZpPa3rsZ2" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z7wHAGAOoyk" style="display: none">SCHEDULE
OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Description</b></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231__us-gaap--BusinessAcquisitionAxis__custom--AppliedAssetPurchaseAgreementMember_zc9DgPk03U69" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_maBCRIAz5eD_zp9BIsLjBOi7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; padding-left: 0pt">Inventory</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">30,007</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment_iI_maBCRIAz5eD_z3Yc4pd783Ae" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,062</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty_iI_maBCRIAz5eD_zN0Sy7fTNyt3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Intellectual property</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">16,728,968</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iTI_mtBCRIAz5eD_zuI1kuvDP4p" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 9pt; padding-left: 0pt">Net assets acquired</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">16,792,037</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zovDFZZpCEz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE LOAN RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">CONVERTIBLE LOAN RECEIVABLE</a></td>
<td class="text"><p id="xdx_800_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zUMiHlNSvxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 &#8211; <span id="xdx_829_z6hnJIGhED54">CONVERTIBLE LOAN RECEIVABLE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with a potential equity investment
in an unaffiliated entity engaged in the development of certain surgical technologies, the Company entered into a convertible loan agreement
in July 2024 pursuant to which the Company loaned $<span id="xdx_908_eus-gaap--AccountsNotesAndLoansReceivableNetCurrent_iI_c20240731__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z6tWJaLouo96" title="Accounts and financing receivable, after allowance for credit loss, current">1,079,391</span> to the unaffiliated entity. The loan was initially set to be repaid on <span id="xdx_907_eus-gaap--LoansHeldForSaleMaturityDate_iI_dd_c20240731__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zrz2NeNAiX9c" title="Maturity date">October 1, 2024</span>. However, the Company extended the repayment date to <span id="xdx_906_eus-gaap--LoansHeldForSaleMaturityDate_iI_dd_c20240731__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--LoanRestructuringModificationAxis__us-gaap--ExtendedMaturityMember_zyHUucI2h076" title="Extended maturity date">January 15, 2025</span>. On October&#160;1, 2024, the Company began accruing
interest at <span id="xdx_902_eus-gaap--LoansReceivableBasisSpreadOnVariableRate_iI_pid_dp_c20241001__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z8y8lKaCuoBh" title="Accruing interest">8</span>% per annum. Pursuant to the convertible loan agreement, the Company had the option to convert the outstanding balance of
the loan into noncontrolling equity interests of the unaffiliated entity upon satisfactory completion of certain due diligence activities.
As of December&#160;31, 2024, the loan balance was $<span id="xdx_90A_eus-gaap--OtherReceivablesNetCurrent_iI_c20241231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zHqtcgoRbx4j" title="Loan receivable">1,101,478</span> including accrued interest and is recorded under the caption &#8220;Convertible
loan receivable&#8221; in the Company&#8217;s Consolidated Balance Sheets. As of January 16, 2025, the loan was converted into equity
of the unaffiliated entity (see Note 15 for additional information).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLES, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLES, NET</a></td>
<td class="text"><p id="xdx_805_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zhNJtyzKTZYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#8211; <span id="xdx_827_z6JXM58yrwO8">GOODWILL AND INTANGIBLES, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89F_eus-gaap--ScheduleOfGoodwillTextBlock_zTGXs8g4Fheh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The changes in the carrying amount of the Company&#8217;s
goodwill were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zI1uAHA97Hv3" style="display: none">SCHEDULE
OF CHANGES IN  CARRYING AMOUNT OF  GOODWILL</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_zKF7tAVcgPsd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43B_c20230101__20231231_eus-gaap--Goodwill_iS_zvp0tyZIiUJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; padding-left: 0pt">Balance as of December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,601,781</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GoodwillAcquiredDuringPeriod_zPUBBkKxaUY5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt">Acquisitions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20240101__20241231_eus-gaap--Goodwill_iS_zUmw9polaCCc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,601,781</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20240101__20241231_eus-gaap--Goodwill_iS_zpjNYIFHzTXg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,601,781</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--GoodwillAcquiredDuringPeriod_zUREqh5ZTQYg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 0pt">Acquisitions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0798">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20240101__20241231_eus-gaap--Goodwill_iE_zVslytut81yk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,601,781</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20240101__20241231_eus-gaap--Goodwill_iE_zC3jJ0CYOgQ3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,601,781</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p id="xdx_8A9_z8FhhmKtk4Xg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the change in reportable operating
segments, the Company reassessed goodwill with respect to the change in reportable operating segments as they are presented in this report.
Goodwill was recorded in connection with the acquisition of Scendia and is included entirely within the Sanara Surgical segment. The
Company&#8217;s assessment determined that these changes, or any other matters noted, did not alter the Company&#8217;s conclusion that
goodwill is not impaired as of December&#160;31, 2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zKnw0olVTIA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying values of the Company&#8217;s intangible
assets were as follows for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zSbQCCzgJQoe" style="display: none">SCHEDULE
OF CARRYING VALUE OF INTANGIBLE ASSETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated <br/>Amortization</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated <br/>Amortization</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Amortizable Intangible Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 22%; text-align: left; text-indent: 9pt; padding-left: 0pt">Patents and Other IP</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzacLpJoCB4f" style="width: 10%; text-align: right">38,009,240</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z34r0mrsgYCd" style="width: 10%; text-align: right">(5,008,856</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGD09bO2Heu8" style="width: 10%; text-align: right">33,000,384</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zU3Xvw5YNoJ4" style="width: 10%; text-align: right">38,570,549</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znSiCMFdFlF4" style="width: 10%; text-align: right">(3,181,186</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z9DMfstX9qC1" style="width: 10%; text-align: right">35,389,363</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Customer relationships and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_z0Q7LkAuznS4" style="text-align: right">7,948,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zboaEJaqV0w2" style="text-align: right">(3,007,118</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zTRhoMuzUnFb" style="text-align: right">4,941,181</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zUufLULozobf" style="text-align: right">7,947,332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zxdi5Ww7uDTg" style="text-align: right">(1,861,887</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zK66QEFscaT5" style="text-align: right">6,085,445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt">Product Licenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zIplH3ty2SOe" style="border-bottom: Black 1pt solid; text-align: right" title="Cost">4,793,879</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zGkzAqnxsnfa" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(1,728,668</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zeLKiobF3Wui" style="border-bottom: Black 1pt solid; text-align: right" title="Net">3,065,211</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zZszQyhQUOU4" style="border-bottom: Black 1pt solid; text-align: right" title="Cost">4,793,879</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zE5FhTtwgnV" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(1,342,626</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zKQICmYYa6Ek" style="border-bottom: Black 1pt solid; text-align: right" title="Net">3,451,253</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zTACvoj38QJd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">50,751,418</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z6bzJ0qtxY25" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(9,744,642</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zXE2wVpemuB2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">41,006,776</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z0U8AtRQIQoj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">51,311,760</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zKA4Nl2Kmlci" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(6,385,699</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z4lHAjeII1H" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">44,926,061</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_z3qnmUBw0ZR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December&#160;31, 2024, the weighted-average
amortization period for finite-lived intangible assets was <span id="xdx_904_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20240101__20241231_zeH8Z3WgqU0c" title="Weighted-average amortization period">14.6</span> years. Amortization expense related to intangible assets was $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_zPOYtVhC5IWc" title="Amortization of intangible assets">3,891,737</span>
and $<span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zOJ0pn353DX" title="Amortization of intangible assets">3,218,888</span> for the year ended December&#160;31, 2024 and 2023, respectively. The estimated remaining amortization expense as of December&#160;31,
2024 for finite-lived intangible assets is as follows:</p>

<p id="xdx_89C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zr0bTaT8mq06" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zKy7TUmt7uU5" style="display: none">SCHEDULE
OF FUTURE AMORTIZATION EXPENSE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_498_20241231_zrea05s5Vkt1" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz6Rp_zPVZR6GPUrB6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; text-align: left; padding-left: 0pt">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,894,221</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz6Rp_zqfIUhTZ1ei5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,876,965</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz6Rp_z1z70AMge649" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,763,113</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz6Rp_zsA2WMrUjKS1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,722,054</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz6Rp_zdTCe818pr8e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,722,054</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANz6Rp_zb2hTvQcaMx2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22,028,369</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz6Rp_z3mOAudjHYph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">41,006,776</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zbkNOpHLMLhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has reviewed the carrying value of intangible
assets and has determined there was no impairment during the year ended December&#160;31, 2024 or 2023.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS IN EQUITY SECURITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsAbstract', window );"><strong>Schedule of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsTextBlock', window );">INVESTMENTS IN EQUITY SECURITIES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--InvestmentHoldingsTextBlock_zhHL8Ob4jeL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#8211; <span id="xdx_823_zmKO8uNoPkod">INVESTMENTS IN EQUITY SECURITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s equity investments consist of
nonmarketable equity securities in privately held companies without readily determinable fair values. Unless accounted for under the
equity method of accounting, the investments are reported at cost minus impairment, if any, plus or minus changes resulting from observable
price changes in orderly transactions for the identical or similar investment of the same issuer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>DirectDerm </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, the Company made a $<span id="xdx_905_eus-gaap--LongTermInvestments_iI_c20200731__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_zwgzQ4yKNTQg" title="Long term investments">500,000</span> long-term
investment to purchase certain nonmarketable securities consisting of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20200731__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_z2rlGR01R9v5" title="Number of shares for purchase">7,142,857</span> Series B-2 Preferred Shares of Direct Dermatology Inc.
(&#8220;DirectDerm&#8221;), representing approximately <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200731__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_zfbGfDRkcHK4" title="Ownership percentage">2.9</span>% ownership of DirectDerm at that time. Through this investment, the Company
received exclusive rights to utilize DirectDerm&#8217;s technology in all acute and post-acute care settings such as skilled nursing
facilities, home health and wound clinics. In 2021, the Company purchased an additional <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_zhPkgESnUPe8" title="Purchase of additional shares">3,571,430</span> shares of DirectDerm&#8217;s Series
B-2 Preferred for $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_z9H4fpGbWvyg" title="Value of shares purchased">250,000</span>. In March 2022, the Company purchased an additional <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220301__20220331__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_z7AUOXUn29Fg" title="Purchase of additional shares">3,571,429</span> shares of DirectDerm&#8217;s Series B-2 Preferred
for $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220301__20220331__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_zh3ALofMorD7" title="Value of shares purchased">250,000</span>. The Company&#8217;s ownership of DirectDerm was approximately <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DirectDermatologyIncMember_zfVKIsJHOgV8" title="Ownership percentage">8.1</span>% as of December&#160;31, 2024. The Company does not have
the ability to exercise significant influence over DirectDerm&#8217;s operating and financial activities. In accordance with ASC Topic
321, Investments - Equity Securities (&#8220;ASC 321&#8221;), this investment was reported at cost as of December&#160;31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Pixalere</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2021, the Company invested $<span id="xdx_90E_eus-gaap--Investments_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredSharesMember__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zSxCHf3lF808" title="Investments">2,084,278</span> to
purchase <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210601__20210630__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredSharesMember__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zXATieq1zkif" title="Purchase of additional shares">278,587</span> Class A Preferred Shares (the &#8220;Pixalere Shares&#8221;) of Canada based Pixalere Healthcare Inc. (&#8220;Pixalere&#8221;).
The Pixalere Shares are convertible into approximately <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210601__20210630__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredSharesMember__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zSBlA6Gygs02" title="Conversion rate">27.3</span>% of the outstanding equity of Pixalere. Pixalere provides a cloud-based wound
care software tool that empowers nurses, specialists and administrators to deliver better care for patients. In connection with the Company&#8217;s
purchase of the Pixalere Shares, Pixalere granted Pixalere Healthcare USA, LLC (&#8220;Pixalere USA&#8221;), a subsidiary of the Company,
a royalty-free exclusive license to use the Pixalere software and platform in the United States. In conjunction with the grant of the
license, the Company issued Pixalere a <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PixalereHealthcareUSALLCMember_zaXt0zVypam9" title="Ownership interest">27.3</span>% equity ownership interest in Pixalere USA valued at $<span id="xdx_905_eus-gaap--EquityMethodInvestmentAggregateCost_iI_c20210630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PixalereHealthcareUSALLCMember_zMHfkG0axJO5" title="Ownership value">93,879</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviewed the characteristics of the Pixalere
Shares in accordance with ASC Topic 323, Investments &#8211; Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Due to the substantive
liquidation preferences of the Pixalere Shares over Pixalere&#8217;s common stock, the Pixalere Shares are not &#8220;in-substance&#8221;
common stock, and therefore, the Company does not utilize the equity method of accounting for this investment. In accordance with ASC
321, this investment was reported at cost as of December&#160;31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>ChemoMouthpiece </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2024, the Company, through its wholly
owned subsidiary, Sanara CMP LLC (&#8220;Sanara CMP&#8221;), entered into a Unit Purchase Agreement (the &#8220;Unit Purchase Agreement&#8221;)
with ChemoMouthpiece, LLC (&#8220;CMp&#8221;), pursuant to which Sanara CMP purchased <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240901__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonUnitsMember__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_z1eBwKcIz7c9" title="Number of shares purchased">100,674.72</span> common units in CMp for an aggregate
purchase price of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240901__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonUnitsMember__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zmaR5vSiQZqd" title="Purchase of shares, value">5.0</span> million, or $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonUnitsMember__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zwPOeEwhgTM3" title="Share price per unit">49.6649</span> per unit, which represented approximately <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20240930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ChemoMouthPieceLLCMember_zMkguyl4WCBk" title="Ownership interest">6.64</span>% of the issued and outstanding membership
interest of CMp immediately following such purchase. Subsequent to the Company&#8217;s initial investment in CMp, units of CMp were sold
to other investors, thereby decreasing the Company&#8217;s ownership of CMp to <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ChemoMouthPieceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z8zEBmhITRD1" title="Ownership interest">6.59</span>% as of December&#160;31, 2024. CMp is a privately
held medical device company that develops and commercializes propriety oral cryotherapy products for cancer patients, including, among
other things, CMp&#8217;s Chemo Mouthpiece oral cryotherapy device, which is a 510(k) cleared cryotherapy device designed to reduce the
incidence and severity of chemotherapy induced oral mucositis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has reviewed the characteristics of Sanara
CMP&#8217;s investment in CMp in accordance with ASC 323 and determined that Sanara CMP made a non-controlling investment in a limited
liability company. According to the guidance provided in ASC 323-30-S99-1, investments in limited liability companies whereby an investor
holds more than a 3% to 5% ownership interest would generally be accounted for under the equity method of accounting. Therefore, the
Company utilized the equity method of accounting for this investment and recorded its initial investment at cost plus transaction costs.
Sanara CMP&#8217;s share of the earnings or losses of CMp is recorded in the Company&#8217;s Consolidated Statements of Operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>SI Technologies </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2022, the Company established a 50/50
joint venture, SI Healthcare Technologies, LLC (&#8220;SI Technologies&#8221;) (formerly known as SI Wound Care, LLC), with InfuSystem
Holdings, Inc. (&#8220;InfuSystem&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Unit Purchase Agreement with
CMp, the Company, CMp, certain subsidiaries of CMp, InfuSystem and SI Technologies, entered into an Exclusive Distribution Agreement
(the &#8220;Distribution Agreement&#8221;) pursuant to which SI Technologies was appointed as the sole and exclusive U.S. distributor
of CMp&#8217;s Standard Chemo Regiment Kits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The parties to the Distribution Agreement also entered
into an Intellectual Property Rights Agreement, pursuant to which SI Technologies was granted the exclusive right to use CMp&#8217;s
intellectual property rights to permit resale and use of the CMp Product in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has reviewed the characteristics the
Company&#8217;s investment in SI Technologies in accordance with ASC 323 and determined that the Company made a non-controlling investment
in a limited liability company. According to the guidance provided in ASC 323-30-S99-1, investments in limited liability companies whereby
an investor holds more than a 3% to 5% ownership interest would generally be accounted for under the equity method of accounting. Therefore,
the Company utilized the equity method of accounting for this investment and recorded its initial investment at cost. The Company&#8217;s
share of the earnings or losses of SI Technologies is recorded in the Company&#8217;s Consolidated Statements of Operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89C_eus-gaap--EquityMethodInvestmentsTextBlock_zMAOGUcywrpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company&#8217;s
investments for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B1_zCcxAJwBrCR7" style="display: none">SCHEDULE
OF INVESTMENTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Economic Interest</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Economic Interest</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; padding-left: 0pt">Equity Method Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-left: 0pt">ChemoMouthpiece, LLC</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--EquityMethodInvestments_iI_c20241231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zcpoyufaA91d" style="width: 12%; text-align: right" title="Equity method investment">5,172,242</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20241231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zFILfgArJySa" style="width: 12%; text-align: right" title="Economic interest">6.59</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--EquityMethodInvestments_iI_c20231231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zTWjiExoXqZ2" style="width: 12%; text-align: right" title="Equity method investment"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20231231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zvaLSPsMIXFd" style="width: 12%; text-align: right" title="Economic interest"><span style="font-size: 10pt">	<span style="-sec-ix-hidden: xdx2ixbrl0904">-</span></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">SI Healthcare Technologies, LLC</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EquityMethodInvestments_iI_c20241231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zsKNjv2gy1n" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment">40,703</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20241231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zsacXtxDj3Vk" style="text-align: right" title="Economic interest">50.00</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EquityMethodInvestments_iI_c20231231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zyubXmNPqhuf" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment"><span style="-sec-ix-hidden: xdx2ixbrl0910">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20231231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zZSYDhwoUL77" style="text-align: right" title="Economic interest"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Total Equity Method Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--EquityMethodInvestments_iI_c20241231_z2mR1u00kUL9" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment">5,212,945</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--EquityMethodInvestments_iI_c20231231_zeTm9EaiIrS2" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; padding-left: 0pt">Cost Method Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Direct Dermatology, Inc.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember_zajuHWuZ0d86" style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember_zYF0psdqkmd2" style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Pixalere Healthcare Inc.</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zccDcGcAE01" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment">2,084,278</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zpkcWZajaP9" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment">2,084,278</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Total Cost Method Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231_zx4UnM7vPRyg" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment">3,084,278</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231_zMWJbmdCEJ8b" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment">3,084,278</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 12pt">Total Investments</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iI_c20241231_zYIgxxc9imw9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Investments">8,297,223</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iI_c20231231_zJIX2dufIDGk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Investments">3,084,278</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_z3WmyT2ZRFLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_894_eus-gaap--GainLossOnInvestmentsTextBlock_zPv5lPsfHCz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company&#8217;s
share of losses from equity method investments reflected in the Company&#8217;s Consolidated Statements of Operations for the periods
presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zHAhEl1usZHf" style="display: none">SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zehAYE0OgDLd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zjVewtCWnOHg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year
                                            Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December
                                            31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; padding-left: 0pt">Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromEquityMethodInvestments_hdei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zpUm7WViBV5g" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: left; padding-left: 0pt">ChemoMouthpiece, LLC</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(105,710</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0935">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromEquityMethodInvestments_hdei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zLNnrROfrmJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">SI Healthcare Technologies, LLC</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,703</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0938">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromEquityMethodInvestments_zULRmngvImI6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 12pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(90,007</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromEquityMethodInvestments_zkslVPI9vICb" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 12pt">Loss from equity method investment</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(90,007</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0944">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_znq0kSjxirih" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentHoldingsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment holdings. This includes the long positions of investments for the entity. It contains investments in affiliated and unaffiliated issuers. The investments include securities and non securities (i.e. commodities and futures contracts).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentHoldingsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_z8YUS1o7i6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8211; <span id="xdx_82A_ziwQd4pvaMO8">OPERATING LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company periodically enters operating lease contracts
for office space and equipment. Arrangements are evaluated at inception to determine whether such arrangements constitute a lease. Right
of use assets (&#8220;ROU assets&#8221;) represent the right to use an underlying asset for the lease term, and lease liabilities represent
the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized on the transition
date based on the present value of lease payments over the respective lease term, with the office space ROU asset adjusted for deferred
rent liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2024, the Company had two material
operating leases for office space. In March and September of 2023, the Company amended its primary office lease to obtain additional
space, as well as extend the term. The leases had remaining lease terms of <span id="xdx_906_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceOneMember_zvaoNF3TiIL8" title="Remaining lease term">72</span> and <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dt_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceTwoMember_zL9BumQvplok" title="Remaining lease term">eight months</span> as of December 31, 2024. The Company is
evaluating its renewal options for the lease expiring in eight months. For practical expediency, the Company has elected to not recognize
ROU assets and lease liabilities related to short-term leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC Topic 842, Leases, the Company
has recorded ROU assets of $<span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20241231_zSGWkqdJYgjh" title="Operating lease right of use assets">1,447,907</span> and a related lease liability of $<span id="xdx_904_eus-gaap--OperatingLeaseLiability_iI_c20241231_z0mFIu2M0Rs4" title="Operating lease liability">1,595,738</span> as of December&#160;31, 2024. The Company recorded
lease expense of $<span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20240101__20241231_z9YOUM9yJMHi" title="Operating lease expenses">555,192</span> and $<span id="xdx_903_eus-gaap--OperatingLeaseExpense_c20230101__20231231_zLoWAdiNqQB8" title="Operating lease expenses">434,066</span> for the year ended December&#160;31, 2024 and 2023, respectively. Cash paid for amounts included
in the measurement of operating lease liabilities was $<span id="xdx_902_eus-gaap--OperatingLeasePayments_c20240101__20241231_zUbsUiKKUoJ4" title="Operating lease payments">505,017</span> and $<span id="xdx_90D_eus-gaap--OperatingLeasePayments_c20230101__20231231_zKIMHXQWlVb9" title="Operating lease payments">380,576</span> for the year ended December&#160;31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The present value of the Company&#8217;s operating
lease liabilities as of December&#160;31, 2024 is shown below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z6SrZdDpjvZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Maturity of Operating Lease Liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B2_zVpEBCFbTnD9" style="display: none">SCHEDULE OF OPERATING LEASE LIABILITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zoNBxnuX22O6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,<br/>
    2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzW5D_zjc5xaOe24Ce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; text-align: left; padding-left: 0pt">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">466,800</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzW5D_zpdsmcKdg2H2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,369</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzW5D_zX1Mw46DoAX5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">291,220</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzW5D_z6CxGiouOPN8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">295,689</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzW5D_zmtdZPUWLlMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,158</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzW5D_z6aPHovppDxa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">303,891</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzW5D_zujVdPcAhTD3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,958,127</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zh2CjtCVwjI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(362,389</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_z36I6Zs5X84b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Present Value of Lease Liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,595,738</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zO1XIQtOKK91" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Operating lease liabilities &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">358,687</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zWHH6k26Z8ol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Operating lease liabilities &#8211; long-term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,237,051</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zGC1yUjJxZz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December&#160;31, 2024, the Company&#8217;s
operating leases had a weighted average remaining lease term of <span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zbwSh6gGgX2d" title="Weighted average remaining lease term">5.5</span> years and a weighted average discount rate of <span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zRYLzp9Bg5Ih" title="Weighted average discount rate">7.8</span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT AND CREDIT FACILITIES</a></td>
<td class="text"><p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_zTK1cGuLprgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#8211; <span id="xdx_821_z1V9SP76OE92">DEBT AND CREDIT FACILITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>CRG Term Loan Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April&#160;17, 2024 (the &#8220;Closing Date&#8221;),
the Company entered into a term loan agreement, by and among the Company, as borrower, the subsidiary guarantors party thereto from time
to time (collectively, the &#8220;Guarantors&#8221;), CRG Servicing LLC as administrative agent and collateral agent (the &#8220;Agent&#8221;),
and the lenders party thereto from time to time (the &#8220;CRG Term Loan Agreement&#8221;), providing for a senior secured term loan
of up to $<span id="xdx_903_eus-gaap--SecuredDebt_iI_pn5n6_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zkyXn7Lb45Fd" title="Secured term loan">55.0</span> million (the &#8220;CRG Term Loan&#8221;). As of December 31, 2024, the CRG Term Loan Agreement provided for (i) $<span id="xdx_900_ecustom--GrossCashReceivedFromTermLoan_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_z2u5D3iR4xS5" title="Loans borrowed">15.0</span> million of the CRG Term
Loan that was borrowed on the Closing Date (the &#8220;First Borrowing&#8221;) and (ii) up to an aggregate of $<span id="xdx_901_eus-gaap--DebtInstrumentUnusedBorrowingCapacityAmount_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_z87NT3YY1d25" title="Remaining amount available for borrowing">40.0</span> million available
for borrowing in two subsequent borrowings, provided that <span id="xdx_907_eus-gaap--DebtInstrumentDescription_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zEF4Wk4NbXV7" title="Borrowing capacity description">each such borrowing was required to be at least $5.0 million and occur between the Closing
Date and June 30, 2025,</span> subject to the satisfaction of certain conditions, including the Agent having received certain fees. The Company used a portion of the initial proceeds of the First Borrowing under the CRG Term
Loan to extinguish the Cadence Term Loan described further below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 4, 2024, the Company, pursuant
to its option under the CRG Term Loan Agreement, borrowed an additional $<span id="xdx_901_ecustom--GrossCashReceivedFromTermLoan_iI_pn5n6_c20240904__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zEwZVLQ5Nemb" title="Loans borrowed">15.5</span> million under the CRG Term Loan Agreement (the &#8220;Second
Borrowing&#8221;). The Company used $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_pn5n6_c20240904__20240904__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_z25cvTlIG6Ef" title="Proceeds from loans used for investment">5.0</span> million of the proceeds of the Second Borrowing for its investment in CMp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The First Borrowing, Second Borrowing and any additional
borrowings under the CRG Term Loan are due and payable on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20240904__20240904__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zLycjQHvx4Nc" title="Debt maturity date">March 30, 2029</span> (the &#8220;Maturity Date&#8221;), absent any acceleration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The CRG Term Loan bears interest at a per annum rate
equal to <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20240417__20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zSKYLcZj6iCj" title="Interest rate per annum">13.25</span>% (subject to a <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_uPure_c20240417__20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zwFCbP73kcle" title="Incremental increase during an event of default">4.0</span>% increase during an event of default), of which <span id="xdx_902_ecustom--CashPaidPercentage_iI_dp_uPure_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zbepd7w9vhDc" title="Cash paid percentage">8.00</span>% must be paid in cash and <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zcvjZo14WRYb" title="Paid-in-kind and aggregate principal loan amount, percentage">5.25</span>% may, at the election
of the Company, be deferred through the 19<sup>th</sup> quarterly Payment Date (defined below) by adding such amount to the aggregate
principal loan amount, so long as no default or event of default under the CRG Term Loan Agreement has occurred and is continuing. The
Company is required to make quarterly interest payments on the final business day of each calendar quarter following the Closing Date,
commencing on the first such date to occur at least 30 days after the Closing Date (each, a &#8220;Payment Date&#8221;). Interest is
payable on each Payment Date in arrears with respect to the time between each Payment Date and upon the payment or prepayment of the
CRG Term Loan, ending on the Maturity Date. In addition, the Company is required to pay an upfront fee of <span id="xdx_901_ecustom--DebtInstrumentUpFrontFeePercentage_iI_dp_uPure_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zqb33vD88gO7" title="Debt upfront fee percentage">1.50</span>% of the principal amount
of the CRG Term Loan, which is payable as amounts are advanced under the CRG Term Loan on a pro rata basis. The Company is also required
to pay a back-end fee equal to <span id="xdx_908_ecustom--DebtInstrumentBackEndFeePercentage_iI_dp_uPure_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_ziD61m5HNzIh" title="Debt instrument back-end fee percentage">7.00</span>% of the aggregate principal amount advanced under the CRG Term Loan Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December&#160;31, 2024, the Company
paid $<span id="xdx_903_eus-gaap--InterestPaid_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zhncjVlXJBR6" title="Interest paid">1,278,424</span> of interest in cash and recorded $<span id="xdx_900_eus-gaap--PaidInKindInterest_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zxdhlurrsHLh" title="Interest paid-in-kind">838,965</span> of interest paid-in-kind related to the CRG Term Loan. The paid-in-kind interest
was applied to the principal balance of the CRG Term Loan. The Company recorded $<span id="xdx_90C_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember__us-gaap--DebtInstrumentAxis__custom--BackendFeeMember_z36IRGzRIpk6" title="Interest expense related to back-end fee">358,086</span> for the year ended December&#160;31, 2024 to
interest expense related to the back-end fee. The back-end fee is accreted and amortized to interest expense over the term of the CRG
Term Loan. Paid-in-kind interest and the accreted back-end fee are included in &#8220;Long-term debt, net of current portion&#8221; in
the Consolidated Balance Sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to certain exceptions, the Company is required
to make mandatory prepayments of the CRG Term Loan with the proceeds of certain assets sales and in the event of a change of control
of the Company. In addition, the Company may make a voluntary prepayment of the CRG Term Loan, in whole or in part, at any time. All
mandatory and voluntary prepayments of the CRG Term Loan are subject to the payment of prepayment premiums as follows: <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateTerms_dp_uPure_c20240417__20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zERu6NtwjzYk" title="Debt instrument rate description">(i) if prepayment
occurs on or prior to the date that is one year following the applicable borrowing (the &#8220;Borrowing Date&#8221;), an amount equal
to 10.0% of the aggregate outstanding principal amount of the CRG Term Loan being prepaid and (ii) if prepayment occurs one year after
the applicable Borrowing Date and on or prior to two years following the applicable Borrowing Date, an amount equal to 5.0% of the aggregate
outstanding principal amount of the CRG Term Loan being prepaid.</span> No prepayment premium is due on any principal prepaid if prepayment
occurs two years or more after the applicable Borrowing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain of the Company&#8217;s current and future
subsidiaries, including the Guarantors, are guaranteeing the obligations of the Company under the CRG Term Loan Agreement. As security
for their obligations under the CRG Term Loan Agreement, on the Closing Date, the Company and the Guarantors entered into a security
agreement with the Agent pursuant to which the Company and the Guarantors granted to the Agent, as collateral agent for the lenders,
a lien on substantially all of the Company&#8217;s and the Guarantors&#8217; assets, including intellectual property (subject to certain
exceptions).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The CRG Term Loan Agreement contains affirmative
and negative covenants customary for financings of this type, including limitations on the Company&#8217;s and the Guarantors&#8217;
abilities, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions above certain
thresholds, merge or consolidate with others, dispose of assets, pay dividends and distributions and enter into affiliate transactions,
in each case, subject to certain exceptions. In addition, the CRG Term Loan Agreement contains the following financial covenants requiring
the Company and the Guarantors in the aggregate to maintain:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">&#9679;</td><td style="text-align: justify">liquidity in an amount which shall
                                            exceed the greater of: (i) $<span id="xdx_907_ecustom--MinimumCashBalanceValue_iI_pn5n6_c20241231_zChe9SW0Jrqh" title="Minimum cash balance">3.0</span> million and (ii) to the extent the Company has incurred certain
                                            permitted debt, the minimum cash balance, if any, required of the Company by the creditors
                                            of such permitted debt; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-align: justify; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.5in">&#9679;</td><td style="text-align: justify">annual minimum revenue of at least:
                                            (i) $<span id="xdx_90F_ecustom--AnnualMinimumRevenueYearOne_pn5n6_c20240101__20241231_zJhAc9AV4VWi" title="Annual minimum revenue, year one">60.0</span> million for the twelve-month period beginning on January 1, 2024 and ending on
                                            December&#160;31, 2024, (ii) $<span id="xdx_902_ecustom--AnnualMinimumRevenueYearTwo_pn5n6_c20240101__20241231_zOdXSo4iE0D1" title="Annual minimum revenue, year two">75.0</span> million for the twelve-month period beginning on January
                                            1, 2025 and ending on December 31, 2025, (iii) $<span id="xdx_906_ecustom--AnnualMinimumRevenueYearThree_pn5n6_c20240101__20241231_zMSDUbJdoShb" title="Annual minimum revenue, year three">85.0</span> million for the twelve-month period
                                            beginning on January 1, 2026 and ending on December 31, 2026, (iv) $<span id="xdx_90B_ecustom--AnnualMinimumRevenueYearFour_pn5n6_c20240101__20241231_zhspa9GlKpB6" title="Annual minimum revenue, year four">95.0</span> million for the
                                            twelve-month period beginning on January 1, 2027 and ending on December 31, 2027, and (v)
                                            $<span id="xdx_90B_ecustom--AnnualMinimumRevenueYearFive_pn5n6_c20240101__20241231_z9TKPx1cYZmk" title="Annual minimum revenue, year five">105.0</span> million during each twelve-month period beginning on January 1 of a given year thereafter.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The CRG Term Loan Agreement contains representations
and warranties of the Company and the Guarantors customary for financings of this type, and also includes events of default customary
for financings of this type, including, among other things, non-payment, inaccuracy of representations and warranties, covenant breaches,
a material adverse change, bankruptcy and insolvency, material judgments and a change of control, in certain cases subject to customary
periods to cure. The occurrence and continuance of an event of default could result in the acceleration of the obligations under the
CRG Term Loan Agreement. As of December 31, 2024, the Company was in compliance with all debt covenants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cadence
Term Loan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the entry into the Applied Purchase Agreement, on August&#160;1, 2023, SMAT, as borrower, and the Company, as guarantor,
entered into a loan agreement (the &#8220;Cadence Loan Agreement&#8221;) with Cadence Bank (the &#8220;Bank&#8221;) providing for, among
other things, an advancing term loan in the aggregate principal amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230801__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zHZDNOKo9JLl" title="Principal amount">12.0</span> million (the &#8220;Cadence Term Loan&#8221;), which
was evidenced by an advancing promissory note. Pursuant to the Cadence Loan Agreement, the Bank agreed to make, at any time and from
time to time prior to February 1, 2024, one or more advances to SMAT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds of the advances under the Cadence Loan Agreement were used for working capital and for purposes of financing up to one hundred
percent (<span id="xdx_90D_ecustom--PercentageOfLoanProceedsUsedForAcquisition_iI_pid_dp_uPure_c20230801__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zj5ur4hsgQ87" title="Loan percentage used for acquisition">100%</span>) of the Cash Closing Consideration and Installment Payments for the Applied Asset Purchase and related fees and expenses,
including any subsequent payments that were due to the Sellers after the Closing. On August 1, 2023, the Bank, at the request of SMAT,
made an advance for $<span id="xdx_90A_eus-gaap--FederalHomeLoanBankAdvances_iI_pn4n6_c20230801__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zrYouzh5dNT" title="Loan bank advance">9.75</span> million. The proceeds from the advance were used to fund the Cash Closing Consideration for the Applied Asset
Purchase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unpaid principal balance of outstanding advances bore interest, subject to certain conditions, at the lesser of the Maximum Rate (as
defined in the Cadence Loan Agreement) or the Base Rate, which was for any day, a rate per annum equal to the term secured overnight
financing rate (Term SOFR) (as administered by the Federal Reserve Bank of New York) for a one-month tenor in effect on such day plus
three percent (<span id="xdx_908_eus-gaap--FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate_iI_pid_dp_uPure_c20230801__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zza0MZCyOXT" title="Bank, interest rate">3.0</span>%). As of December&#160;31, 2023, the interest rate on the advance under the Cadence Term Loan was <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_z4Wz2wRpl15e" title="Interest rate on advances">8.3</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date of the CRG Term Loan Agreement, the Cadence Loan Agreement was terminated and all outstanding amounts under the Cadence
Term Loan were repaid in full and all security interest and other liens granted to or held by Cadence were terminated and released. In
addition, unamortized debt issuance costs as of the termination date of $<span id="xdx_909_eus-gaap--InterestExpenseOther_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zsszZEWqhMe4" title="Interest expense">53,438</span> were included in &#8220;Interest expense&#8221; in the
Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfDebtTableTextBlock_zIsg681yAnZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the components of the Company&#8217;s outstanding debt for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B6_zmrsJBFytyAk" style="display: none">SCHEDULE
OF LONG-TERM DEBT</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_zNFyPgSXxZgf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_z9l8Zt0EA1H7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--CRGTermLoanMember_zeqhzEqyaw2e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">CRG Term Loan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">30,500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--PaidInKindInterestMember_zUfuoig8Q83b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Paid-in-kind interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">838,965</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--BackendFeeMember_z5aVyIYzPYHd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Back-end fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">358,086</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1061">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--CadenceTermLoanMember_zaVWB1qZMKy8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cadence Term Loan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,750,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzYHB_zZEHdl4obr0k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,697,051</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,750,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredFinanceCostsNet_iNI_di_msLTDzYHB_zk74bRzhcld3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: unamortized debt issuance costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,007,761</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(56,520</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebt_iTI_mtLTDzYHB_zv5L08O0fdk5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt, net of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,689,290</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,693,480</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LongTermDebtCurrent_iI_ztnJ6x50cnlj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Current portion of debt</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">580,357</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LongTermDebtNoncurrent_iI_zklisHAOfnf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Long-term debt, net of current portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30,689,290</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,113,123</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zMeBdRXHZnV2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zgsCXX4dXIna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the aggregate maturities of the Company&#8217;s outstanding debt as of December&#160;31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zEexwUetOxof" style="display: none">SCHEDULE
OF MATURITIES OUTSTANDING</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zxaa3sEEE7y8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maDICAzHTB_z4EjHutIBkMa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1083">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maDICAzHTB_zss0VSJhmmm9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1085">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maDICAzHTB_zosy1ThNwxbc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1087">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maDICAzHTB_zTKab2wyicN7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_maDICAzHTB_zJCOJs4T6aTk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2029</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">31,697,051</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_iI_maDICAzHTB_z4VsxxZuRpOd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1093">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DebtInstrumentCarryingAmount_iTI_mtDICAzHTB_zJlKfsFP7l6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total debt</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">31,697,051</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zVDT02dSa9Ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the CRG Term Loan, the Company incurred $<span id="xdx_90A_eus-gaap--DeferredFinanceCostsGross_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--CRGTermLoanMember_zyuyKfnj7jP1" title="Debt issuance costs">1,160,740</span> in debt issuance costs during the year ended December&#160;31, 2024.
Debt issuance costs are amortized to &#8220;Interest expense&#8221; in the Consolidated Statements of Operations over the life of the
debt to which they pertain. The total unamortized debt issuance costs were $<span id="xdx_904_eus-gaap--DeferredFinanceCostsNet_iI_c20241231_zYQlxfSwzekk" title="Unamortized debt issuance costs">1,007,761</span> and $<span id="xdx_901_eus-gaap--DeferredFinanceCostsNet_iI_c20231231_z7zEIB6Yu1lj" title="Unamortized debt issuance costs">56,520</span> as of December&#160;31, 2024 and December&#160;31,
2023, respectively. Debt issuance costs are included in &#8220;Long-term debt, net of current portion&#8221; in the Consolidated Balance
Sheets. Amortization expense related to debt issuance costs was $<span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_c20240101__20241231_zq5OSL6zmSUb">209,499</span> and $<span id="xdx_900_eus-gaap--AmortizationOfFinancingCosts_dc_c20230101__20231231_zQnBTZgFXudf" title="Amortization expense of debt issuance costs">5,138</span> for the year ended December&#160;31, 2024 and 2023,
respectively. Amortization for the year ended December&#160;31, 2024 includes the write-off of debt issuance costs of $<span id="xdx_90B_eus-gaap--WriteOffOfDeferredDebtIssuanceCost_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--CadenceTermLoanMember_zLu9QJ4wHVtk" title="Write-off of debt issuance costs">56,520</span> related
to the termination of Cadence Term Loan. The fair value of the Company&#8217;s long-term debt approximated its carrying value as December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zyn7a0RhC1ta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section42"></span>NOTE
9 - <span id="xdx_823_z1Qc7X96lzrf">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreements and Royalties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CellerateRX
Surgical</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--LicenseAgreementAndRoyaltiesDescription_c20180826__20180827__us-gaap--TypeOfArrangementAxis__custom--SubLicenseAgreementMember_z1wiiKLFpLik" title="License agreement and royalties description">In
August 2018, the Company entered an exclusive, world-wide sublicense agreement with CGI Cellerate RX to distribute certain hydrolyzed
collagen products, including CellerateRX Surgical, into the surgical and wound care markets. Pursuant to the Sublicense Agreement, the
Company paid royalties of 3-5% of annual collected net sales of these products.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed further in Note 3, on August 1, 2023, the Company purchased certain assets from Applied, including the rights to manufacture
and sell certain hydrolyzed collagen products, including CellerateRX Surgical, for use in the human wound care market. In connection
with the Applied Asset Purchase, Applied assigned the License Agreement with CGI Cellerate RX to SMAT, and on October 10, 2024, the License
Agreement and Sublicense Agreement were terminated for no additional consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Sublicense Agreement, royalty expense, which was recorded in &#8220;Cost of goods sold&#8221; in the accompanying Consolidated Statements
of Operations, totaled <span id="xdx_904_eus-gaap--RoyaltyExpense_dc_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zg9pirJt6j03" title="Payment for additional royalties">zero</span> and $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zjYQogUF8Igd" title="Payment for additional royalties">991,099</span>, respectively, for the year ended December&#160;31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>BIASURGE
Advanced Surgical Solution, BIAK&#332;S Antimicrobial Wound Gel and BIAK&#332;S Antimicrobial Skin and Wound Cleanser</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2019, the Company executed a license agreement with Rochal Industries, LLC (&#8220;Rochal&#8221;), a related party, pursuant to
which the Company acquired an exclusive world-wide license to market, sell and further develop antimicrobial products for the prevention
and treatment of microbes on the human body utilizing certain Rochal patents and pending patent applications (the &#8220;BIAK&#332;S
License Agreement&#8221;). Currently, the products covered by the BIAK&#332;S License Agreement are BIASURGE Advanced Surgical Solution,
BIAK&#332;S Antimicrobial Wound Gel, BIAK&#332;S Antimicrobial Skin and Wound Cleanser. All three products are 510(k) cleared.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
commitments under the terms of the BIAK&#332;S License Agreement include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company pays Rochal a royalty of <span id="xdx_901_ecustom--RoyaltyPercentage_pid_dp_uPure_c20190701__20190731__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember__dei--LegalEntityAxis__custom--RochalIndustriesLLCMember__srt--RangeAxis__srt--MinimumMember_z1GljJ0oTp5h">2</span>-<span id="xdx_900_ecustom--RoyaltyPercentage_pid_dp_uPure_c20190701__20190731__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember__dei--LegalEntityAxis__custom--RochalIndustriesLLCMember__srt--RangeAxis__srt--MaximumMember_zwPN1bjo2Vak">4</span>% of net sales. The minimum annual royalty due to Rochal
                                            will increase to a maximum amount of $<span id="xdx_909_eus-gaap--PaymentsForRoyalties_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember__dei--LegalEntityAxis__custom--RochalIndustriesLLCMember__srt--RangeAxis__srt--MaximumMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zAQaEqol1ZZe" title="Payments for royalties">150,000</span> in 2025.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company may pay additional royalties annually based on specific net profit targets from sales
                                            of the licensed products, subject to a maximum of $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20190701__20190731__us-gaap--TypeOfArrangementAxis__custom--BIAKOSAgreementMember__srt--RangeAxis__srt--MaximumMember_zw7ai2w07Ee5" title="Payment for additional royalties">1,000,000</span> during any calendar year.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
previously terminated by the parties, the BIAK&#332;S License Agreement expires with the related patents in December 2031.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
this agreement, royalty expense, which is recorded in &#8220;Cost of goods sold&#8221; in the accompanying Consolidated Statements of
Operations, was $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember_ztxKteX7hEnh" title="Royalty expense">177,005</span> and $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember_zlO37oX9lW14" title="Royalty expense">130,000</span> for the year ended December&#160;31, 2024 and 2023, respectively. The Company&#8217;s Executive
Chairman and Chief Executive Officer is a director of Rochal, and indirectly a significant shareholder of Rochal, and through the potential
exercise of warrants, a majority shareholder of Rochal. Another one of the Company&#8217;s directors is also a director and significant
shareholder of Rochal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CuraShield
Antimicrobial Barrier Film and No Sting Skin Protectant</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, the Company executed a license agreement with Rochal pursuant to which the Company acquired an exclusive world-wide license
to market, sell and further develop certain antimicrobial barrier film and skin protectant products for use in the human health care
market utilizing certain Rochal patents and pending patent applications (the &#8220;ABF License Agreement&#8221;). Currently, the products
covered by the ABF License Agreement are CuraShield Antimicrobial Barrier Film and a no sting skin protectant product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
commitments under the terms of the ABF License Agreement include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company will pay Rochal a royalty of <span id="xdx_90E_ecustom--RoyaltyPercentage_pid_dp_uPure_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zjsB3QQfie63" title="Royalty percentage">2</span>-<span id="xdx_904_ecustom--RoyaltyPercentage_pid_dp_uPure_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zIShVvIq8KB8" title="Royalty percentage">4</span>% of net sales. The minimum annual royalty due to
                                            Rochal will be $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zClDPwa1y06k" title="Payments for royalty">50,000</span> beginning with the first full calendar year following the year in
                                            which first commercial sales of the products occur. The annual minimum royalty will increase
                                            by <span id="xdx_90D_ecustom--IncreaseInRoyaltyAnnualPercentage_pid_dp_uPure_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember_zTZDzuYBd0Ub" title="Increase in royalty annual percentage">10</span>% each subsequent calendar year up to a maximum amount of $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zWWWoVEq5YD1" title="Maximum amount of royalty">75,000</span>.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company will pay additional royalties annually based on specific net profit targets from
                                            sales of the licensed products, subject to a maximum of $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember_zJiaB7wATsw4" title="Payment for additional royalties">500,000</span> during any calendar year.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
previously terminated or extended by the parties, the ABF License Agreement will terminate upon expiration of the last U.S. patent in
October 2033. No commercial sales or royalties have been recognized under this agreement as of December&#160;31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Debrider
License Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, the Company executed a product license agreement with Rochal, pursuant to which the Company acquired an exclusive world-wide
license to market, sell and further develop a debrider for human medical use to enhance skin condition or treat or relieve skin disorders,
excluding uses primarily for beauty, cosmetic, or toiletry purposes (the &#8220;Debrider License Agreement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
commitments under the terms of the Debrider License Agreement include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                            FDA clearance of the licensed products, the Company will pay Rochal $<span id="xdx_90F_eus-gaap--Cash_iI_c20200531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RochalMember__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember_zs3SfXcyEcD1" title="Payment in cash">500,000</span> in cash and
                                            an additional $<span id="xdx_90C_eus-gaap--PaymentsToAcquireBusinessesGross_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember_zTLIS1IQVXIa" title="Payment of cash">1,000,000</span>, which at the Company&#8217;s option may be paid in any combination
                                            of cash and its common stock.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company will pay Rochal a royalty of <span id="xdx_90B_ecustom--RoyaltyPercentage_pid_dp_uPure_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zX5t1WBrt2c3" title="Royalty percentage">2</span>-<span id="xdx_908_ecustom--RoyaltyPercentage_pid_dp_uPure_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zDvPKxsHK4qh" title="Royalty percentage">4</span>% of net sales. The minimum annual royalty due to
                                            Rochal will be $<span id="xdx_908_eus-gaap--PaymentsForRoyalties_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zfcSCwc0e2y" title="Payments for royalty">100,000</span> beginning with the first full calendar year following the year in
                                            which first commercial sales of the licensed products occur and increase by <span id="xdx_90D_ecustom--IncreaseInRoyaltyAnnualPercentage_pid_dp_uPure_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember_zITPScHQdDGh" title="Increase in royalty annual percentage">10</span>% each subsequent
                                            calendar year up to a maximum amount of $<span id="xdx_90E_eus-gaap--PaymentsForRoyalties_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zhX2ywq8eWV2" title="Annual royalty">150,000</span>.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company will pay additional royalty annually based on specific net profit targets from sales
                                            of the licensed products, subject to a maximum of $<span id="xdx_909_ecustom--PaymentsForAdditionalRoyalties_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zCOqqwqHkHbi" title="Payment for additional royalties">1,000,000</span> during any calendar year.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
previously terminated or extended by the parties, the Debrider License Agreement will expire in October 2034. No commercial sales or
royalties have been recognized under this agreement as of December&#160;31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisitions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rochal
Asset Acquisition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an asset purchase agreement with Rochal effective July 1, 2021, pursuant to which the Company purchased certain
assets of Rochal. Pursuant to the asset purchase agreement, for the three-year period after the effective date, Rochal was entitled to
receive consideration for any new product relating to the business that is directly and primarily based on an invention conceived and
reduced to practice by a member or members of Rochal&#8217;s science team. For the three-year period after the effective date, Rochal
was also entitled to receive an amount in cash equal to twenty-five percent of the proceeds received for any Grant (as defined in the
asset purchase agreement) by either the Company or Rochal. In addition, the Company agreed to use commercially reasonable efforts to
perform Minimum Development Efforts (as defined in the asset purchase agreement) with respect to certain products under development,
which if obtained, will entitle the Company to intellectual property rights from Rochal in respect of such products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Precision
Healing Merger Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, the Company closed a merger transaction with Precision Healing pursuant to which Precision Healing became a wholly owned
subsidiary of the Company. Pursuant to the terms of the merger agreement, holders of Precision Healing common stock and preferred stock,
other than the Company, were entitled to receive closing consideration, consisting of $<span id="xdx_906_eus-gaap--AssetAcquisitionConsiderationTransferred_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zUlp44IKFAe9" title="Cash consideration">125,966</span> in cash consideration, which was paid
to stockholders who were not accredited investors, <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zIqg208eqk1" title="Issuance of shares">165,738</span> shares of the Company&#8217;s common stock, which was paid only to accredited
investors, and the payment in cash of approximately $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zUeMrfm2EID4" title="Payment in cash">0.6</span> million of transaction expenses of Precision Healing. The Company recorded the
issuance of the <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zmpKxc1ygb6c" title="Issuance of shares">165,738</span> shares to accredited investors and cash payments to nonaccredited investors based on the closing price per share
of the Company&#8217;s common stock on April&#160;4, 2022, which was $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20220404__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zfnHf1QNgh35" title="Share price">30.75</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the merger, the Precision Healing outstanding options previously granted under the Precision Healing Plan converted, pursuant
to their terms, into options to acquire an aggregate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zXBcNOx8uZr7" title="Options to acquire shares">144,191</span> shares of Company common stock with a weighted average exercise price
of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zFjXhuGyRW39" title="Weighted exercise price">10.71</span> per share. These options expire between August 2030 and April 2031. In addition, outstanding and unexercised Precision Healing
warrants converted into rights to receive warrants to purchase (i) <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCnnojVU6PD2" title="Warrants to purchase shares">4,424</span> shares of the Company&#8217;s common stock with an initial exercise
price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvBLCTopRBC2" title="Exercise price">7.32</span> per share and an expiration date of<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCKf6TKnFxRg" title="Expiration date"> April 22, 2031</span>, and (ii) <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zSrwplEvgvfb" title="Warrants to purchase shares">12,301</span> shares of the Company&#8217;s common stock with
an initial exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zLlC6zn1gDJd" title="Exercise price">12.05</span> per share and an expiration date of <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zbFxlszRdG9j" title="Expiration date">August 10, 2030</span>. Concurrent with the assumption of the Precision
Healing Plan, the Company terminated the ability to offer future awards under the Precision Healing Plan. As of December 31, 2024, all
warrants to purchase shares of the Company&#8217;s common stock pursuant to the transaction with Precision Healing were exercised and
there were <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_zLWpwM8Hpiv8" title="Options remaining to be exercised">31,013</span> share options remaining to be exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the merger agreement, upon the achievement of certain performance thresholds, the securityholders of Precision Healing, including
the holders of options and warrants to purchase Precision Healing common stock and certain persons promised options to purchase Precision
Healing common stock, was also entitled to receive payments of up to $<span id="xdx_90D_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_pn5n6_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_z7sUU9ygK3Gg" title="Contingent consideration payments receivable">10.0</span> million, which was accounted for as contingent consideration
pursuant to ASC 805. The earnout consideration was payable in cash or, at the Company&#8217;s election, was payable to accredited investors
in shares of Company common stock at a price per share equal to the greater of (i) $<span id="xdx_908_eus-gaap--SharePrice_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zV1gW8aK2Zah" title="Share price">27.13</span> or (ii) the average closing price of Company
common stock for the 20 trading days prior to the date such earnout consideration was due and payable. Pursuant to the merger agreement,
a minimum percentage of the earnout consideration may be required to be issued to accredited investors in shares of Company common stock
for tax purposes. The amount and composition of the portion of earnout consideration payable was subject to adjustment and offsets as
set forth in the merger agreement. The Company reviewed the performance thresholds necessary to trigger an earnout payment as of December
31, 2024 and deemed the performance thresholds to be unachievable. Therefore, the remaining fair value of the earnout consideration was
reduced to zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Scendia
Purchase Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, the Company closed the Scendia acquisition pursuant to which Scendia became a wholly owned subsidiary of the Company. Pursuant
to the purchase agreement, the aggregate consideration for the acquisition at closing was approximately $<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zEcE7fYkqTYa" title="Acquisition consideration transferred">7.6</span> million, subject to customary
post-closing adjustments. The consideration consisted of (i) approximately $<span id="xdx_90C_eus-gaap--Cash_iI_pn5n6_c20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zXBSrZacQPIb" title="Cash">1.6</span> million of cash, subject to certain adjustments, and
(ii) <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zTfNhl8NjtJh" title="Issuance of common stock for purchase of assets">291,686</span> shares of common stock of the Company. Pursuant to the purchase agreement, at closing, the Company withheld <span id="xdx_909_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zfdgusQS7Isc" title="Number of shares withheld">94,798</span> Indemnity
Holdback Shares, which such Indemnity Holdback Shares were withheld to the extent provided in the purchase agreement to satisfy Ryan
Phillips&#8217; (&#8220;Phillips&#8221;) indemnification obligations and subsequently issued and released to Phillips in July 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the cash consideration and the stock consideration, the purchase agreement provides that Phillips was entitled to receive
two potential earnout payments, payable on an annual basis, not to exceed $<span id="xdx_900_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_pn5n6_c20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_z3XdyLaK1EF7" title="Earnout consideration">10.0</span> million in the aggregate, which was accounted for as
contingent consideration pursuant to ASC 805. The earnout consideration was payable to Phillips in cash or, at the Company&#8217;s election,
in up to <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zALt5ZMGHmMi" title="Number of shares issuable">486,145</span> shares of the Company&#8217;s common stock upon the achievement of certain performance thresholds relating to net revenue
attributable to sales of Scendia products during the two-year period following the closing. The Company made the first earnout payment
of approximately $<span id="xdx_904_ecustom--EarnoutPayment_c20230801__20230831__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zyBy2wRYzpEc" title="Earnout payment">693,000</span> in cash in August 2023 and the second and final earnout payment of approximately $<span id="xdx_906_ecustom--EarnoutPayment_pn5n6_c20241001__20241031__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zsMlBoJNXpCe" title="Earnout payment">1.1</span> million in cash in October
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Applied
Asset Purchase</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&#160;1, 2023, the Company closed the Applied Asset Purchase. The Applied Purchased Assets were purchased for an initial aggregate
purchase price of $<span id="xdx_907_eus-gaap--PaymentsToAcquireProductiveAssets_pn4n6_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zNAQ2FIbS5o9" title="Assets purchase price">15.25</span> million, consisting of (i) the Cash Closing Consideration, (ii) the Stock Closing Consideration and (iii) the
Installment Payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Cash Closing Consideration, Stock Closing Consideration and Installment Payments, the Applied Purchase Agreement provides
that the Sellers are entitled to receive the Applied Earnout, which is payable to the Sellers in cash, upon the achievement of certain
performance thresholds relating to SMAT&#8217;s collections from net sales of a collagen-based product currently under development. Upon
expiration of the seventh anniversary of the Closing, to the extent the Sellers have not earned the entirety of the Applied Earnout,
SMAT shall pay the Sellers the True-Up Payment. The Applied Earnout, minus the True-Up Payment and any Applied Earnout payments already
made by SMAT, may be earned at any point in the future, including after the True-Up Payment is made. The first Installment Payment of
$<span id="xdx_90F_eus-gaap--PaymentsToAcquireOtherProductiveAssets_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zpLFHtKRplv" title="Assets purchase price">625,000</span> was made in August 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Applied Asset Purchase and pursuant to the Applied Purchase Agreement, effective August 1, 2023, the Company entered
into the Petito Services Agreement with the Owner, pursuant to which the Owner, as an independent contractor, agreed to provide the Petito
Services. <span id="xdx_90F_ecustom--PurchaseAgreementDescription_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_ziOZVaacqzij" title="Purchase agreement description">As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the
term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of
certain products the Owner develops or codevelops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for
the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half
percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0
million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0
million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments
described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Petito Services Agreement has an initial term of three years and is subject to automatic successive one-month renewals unless earlier
terminated in accordance with its terms. The Petito Services Agreement may be terminated upon the Owner&#8217;s death or disability or
by the Company or the Owner &#8220;For Cause&#8221; (as defined in the Petito Services Agreement); provided, however, that the base salary
described in (i) of the foregoing paragraph shall survive termination through the three-year initial term and the royalty payments and
incentive payments described in (ii)-(v) of the foregoing paragraph shall survive termination of the Petito Services Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&#160;20, 2023, the Company signed an exclusive license agreement with Tufts University (&#8220;Tufts&#8221;) to develop and
commercialize patented technology covering 18 unique collagen peptides. As part of this agreement, the Company formed a new subsidiary,
Sanara Collagen Peptides, LLC (&#8220;SCP&#8221;) and issued <span id="xdx_903_ecustom--OutstandingUnitsPercentage_pid_dp_uPure_c20231220__20231220__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zSDmp5LMjP4a" title="Outstanding units percentage">10</span>% of SCP&#8217;s outstanding units to Tufts. SCP has exclusive rights
to develop and commercialize new products based on the licensed patents and patents pending. SCP will pay royalties to Tufts based on
net sales of licensed products and technologies. Under the exclusive license agreement, royalties will be calculated at a rate of <span id="xdx_909_ecustom--RoyaltyExpensePercentage_dp_uPure_c20231220__20231220__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zDpCnc6Xc9o7">1.5</span>%
or <span id="xdx_90C_ecustom--RoyaltyExpensePercentage_dp_uPure_c20231220__20231220__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zNOUdJgpOwv" title="Royalty expense percentage">3</span>%, depending on the type of product or technology developed. SCP will pay Tufts a minimum annual royalty of $<span id="xdx_90D_eus-gaap--RoyaltyExpense_c20240101__20240101__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zdb49u65JHIj">50,000</span> on January 1
of the year following the first anniversary of the first commercial sale of the licensed products or technologies. SCP will pay Tufts
a $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20240101__20240101__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--RoyaltyAgreementTermsMember_zmM8L5EZFZTb">100,000</span> minimum annual royalty on January&#160;1 of each subsequent year during the royalty term specified in the exclusive license
agreement. There have been no material accounting impacts related to this arrangement as of December&#160;31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zzHl05Rhnwe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section43"></span>NOTE
10 &#8211; <span id="xdx_825_zHGBAGgWsh4">SHAREHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Company&#8217;s Annual Meeting of Shareholders held in July 2020, the Company approved the Restated 2014 Omnibus Long Term Incentive
Plan (the &#8220;2014 LTIP&#8221;) in which the Company&#8217;s directors, officers, employees and consultants are eligible to participate.
The 2014 LTIP terminated on September 3, 2024, and no future awards may be granted pursuant to the 2014 LTIP. Previously granted awards
under the 2014 LTIP will remain outstanding until they expire by their terms or under the terms of the 2014 LTIP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 12, 2024, the Company&#8217;s shareholders approved the 2024 Omnibus Long-Term Incentive Plan (the &#8220;2024 LTIP&#8221;),
which went into effect upon shareholder approval. The maximum number of shares of the Company&#8217;s common stock that may be delivered
pursuant to awards granted under the 2024 LTIP is <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240612__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_z5A725WRvSX6" title="Maximum number of shares available for grant">1,000,000</span>, subject to increase by any awards under the 2014 LTIP (i) that were outstanding
on or after June 12, 2024, and that, on or after such date, are forfeited, expire or are canceled, and (ii) any shares subject to awards
relating to common stock under the 2014 LTIP that are settled in cash on or after June&#160;12, 2024 (the &#8220;Prior LTIP Awards&#8221;).
The 2024 LTIP also provides that, to the extent an award under the 2024 LTIP or a Prior LTIP Award is forfeited, expires or is canceled,
in whole or in part, the shares subject to such forfeited, expired or canceled award may again be awarded under the 2024 LTIP. As of
December&#160;31, 2024, a total of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20241231__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFourteenOmnibusLongTermIncentivePlanMember_zv1qPBD64qN1" title="Number of shares issued">742,405</span> shares had been issued under the 2014 LTIP, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20241231__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_zuEzD7RHw9kl" title="Number of shares issued">2,543</span> shares had been issued under the 2024 LTIP
and <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_zvgy4Y23GsMe" title="Number of shares available for issuance">1,000,137</span> were available for issuance under the 2024 LTIP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2023, the Company closed the Applied Asset Purchase. Included in the purchase price was <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--StockClosingConsiderationMember_zJSCfIgzhMUc" title="Shares issued as consideration">73,809</span> shares of the Company&#8217;s
common stock. See Note 3 for more information regarding the acquisition of Applied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, the Company entered into a Controlled Equity Offering<sup>SM</sup> Sales Agreement (the &#8220;Sales Agreement&#8221;)
with Cantor Fitzgerald &amp; Co., as sales agent (&#8220;Cantor&#8221;), pursuant to which the Company could offer and sell from time
to time, to or through Cantor, shares of the Company&#8217;s common stock having an aggregate offering price of up to $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230201__20230228__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zzrhENfLwR51" title="Aggregate offering price">75,000,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of the shares were made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under
the Securities Act of 1933, as amended. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement,
Cantor agreed to use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal
law, rules and regulations and the rules of The Nasdaq Capital Market to sell the shares from time to time based upon the Company&#8217;s
instructions, including any price, time period or size limits specified by the Company. The Company had no obligation to sell any of
the shares under the Sales Agreement and could suspend or terminate the offering of its common stock pursuant to the Sales Agreement
upon notice to Cantor and subject to other conditions. Cantor&#8217;s obligations to sell the shares under the Sales Agreement were subject
to satisfaction of certain conditions, including customary closing conditions. Pursuant to the Sales Agreement, the Company paid Cantor
a commission of 3.0% of the aggregate gross proceeds from each sale of the shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, the Company sold an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdzEWMdigE0j" title="Sale of stock">26,143</span> shares of common stock for gross proceeds of approximately $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaHOdqJVwKN2" title="Number of shares issued, value">1.1</span> million and net proceeds
of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQuxBPvHxXk7" title="Net proceeds">0.9</span> million pursuant to the Sales Agreement. The Company paused the offering at the end of the first quarter of 2023
and did not reactivate it during the remainder of 2023. The Form S-3 registration statement for this offering expired at the beginning
of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, the Company closed a merger transaction with Precision Healing pursuant to which Precision Healing became a wholly owned
subsidiary of the Company. Pursuant to the terms of the merger agreement, holders of Precision Healing common stock and preferred stock,
other than the Company, were entitled to receive closing consideration, consisting of $<span id="xdx_90C_eus-gaap--AssetAcquisitionConsiderationTransferred_c20220401__20220430__us-gaap--AssetAcquisitionAxis__custom--PrecisionHealingIncMember_zwhML6wBZdj9" title="Cash consideration">125,966</span> in cash consideration, which was paid
to stockholders who were not accredited investors, <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220401__20220430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zLsZtY9QlFIc" title="Issuance of shares">165,738</span> shares of the Company&#8217;s common stock, which was paid only to accredited
investors, and the payment in cash of approximately $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20220401__20220430__dei--LegalEntityAxis__custom--PrecisionHealingMember_zBMCHZboTBF2" title="Payment in cash">0.6 </span>million of transaction expenses of Precision Healing. The Company recorded the
issuance of the <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220401__20220430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zaAH9tR5uvqg" title="Issuance of shares">165,738</span> shares to accredited investors and cash payments to nonaccredited investors based on the closing price per share
of the Company&#8217;s common stock on April&#160;4, 2022, which was $<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20220404__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonaccreditedInvestorsMember_zjH9EOTBmCMa" title="Share price">30.75</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of the merger, the Precision Healing outstanding options previously granted under the Precision Healing Plan converted, pursuant
to their terms, into options to acquire an aggregate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220430_zPwPWdh8zcTc" title="Options to acquire shares">144,191</span> shares of Company common stock with a weighted average exercise price
of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_c20220401__20220430_ziKZdQAmjdad" title="Weighted exercise price">10.71</span> per share. These options expire between August 2030 and April 2031. In addition, outstanding and unexercised Precision Healing
warrants converted into rights to receive warrants to purchase (i) <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220430_zjPLfVYARmHl" title="Warrants to purchase shares">4,424</span> shares of the Company&#8217;s common stock with an initial exercise
price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430_zBosu5CtKrV9" title="Exercise price">7.32</span> per share and an expiration date of <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220430_zQ3CcwYs1cK8" title="Expiration date">April 22, 2031</span>, and (ii) <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdDOrW58Omsj" title="Warrants to purchase shares">12,301</span> shares of the Company&#8217;s common stock with
an initial exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMe6HaJSlRP" title="Exercise price">12.05</span> per share and an expiration date of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6e5k5ATMWL5" title="Expiration date">August 10, 2030</span>. Concurrent with the assumption of the Precision
Healing Plan, the Company terminated the ability to offer future awards under the Precision Healing Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the merger agreement, upon the achievement of certain performance thresholds, the securityholders of Precision Healing, including
the holders of options and warrants to purchase Precision Healing common stock and certain persons promised options to purchase Precision
Healing common stock, were entitled to receive payments of up to $<span id="xdx_90C_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_pn5n6_c20220401__20220430__us-gaap--AssetAcquisitionAxis__custom--PrecisionHealingIncMember_zCACVhMdvcQa" title="Payment of contingent consideration">10.0</span> million, which was accounted for as contingent consideration pursuant
to ASC 805. The earnout consideration was payable in cash or, at the Company&#8217;s election, payable to accredited investors in shares
of Company common stock at a price per share equal to the greater of (i) $<span id="xdx_90B_eus-gaap--SharePrice_iI_c20220430__dei--LegalEntityAxis__custom--PrecisionHealingMember_zJ5q7Efnnppj" title="Share price">27.13</span> or (ii) the average closing price of Company common stock
for the 20 trading days prior to the date such earnout consideration is due and payable. The Company reviewed the performance thresholds
necessary to trigger an earnout payment as of December 31, 2024 and deemed the performance thresholds to be unachievable. Therefore,
no earnout consideration is expected to be paid to the securityholders of Precision Healing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December&#160;31, 2024, the Company issued restricted stock awards under the 2014 LTIP which are subject to certain vesting
provisions and other terms and conditions set forth in each recipient&#8217;s respective restricted stock agreement. The Company issued
<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFourteenOmnibusLongTermIncentivePlanMember_zXiF5hjxZOqb" title="Stock granted and issued">161,908</span> shares, net of forfeitures, under the 2014 LTIP and <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_zDsNimRzcPnk" title="Stock granted and issued">2,543</span> shares under the 2024 LTIP, of restricted common stock to employees,
directors, and certain advisors of the Company during the year ended December&#160;31, 2024. The fair value of these awards was $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20240101__20241231_zZ9s6JBATeyd" title="Restricted stock award, gross">5,747,656</span>
based on the closing price of the Company&#8217;s common stock on the respective grant dates, which will be recognized as compensation
expense on a straight-line basis over the vesting period of the awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
compensation expense of $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20240101__20241231_zb95tl8U7sGk" title="Share-based compensation">4,436,048</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20230101__20231231_zrnrlLmS0BMk" title="Share-based compensation">3,442,722</span> was recognized in &#8220;Operating expenses&#8221; in the accompanying Consolidated
Statements of Operations during the year ended December&#160;31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December&#160;31, 2024, there was $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231_z9u25RmlQmIg" title="Unrecognized share-based compensation expense">4,189,272</span> of total unrecognized share-based compensation expense related to unvested share-based equity
awards. Unrecognized share-based compensation expense is expected to be recognized over a weighted-average period of <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zbCvWw0vAFsa" title="Unrecognized share-based compensation expense period for recognition">1.5</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z6qxkf0tNoYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a summary of restricted stock activity for the year ended December&#160;31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z5VFOABi92Zf" style="display: none">SUMMARY
OF RESTRICTED STOCK ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2024</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant Date Fair Value</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Nonvested at beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231_z5JCnPbMX14f" style="width: 16%; text-align: right" title="Non-vested shares, beginning">144,211</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20241231_zc17mwwoYVK3" style="width: 16%; text-align: right" title="Weighted average grant date fair value, beginning">34.07</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231_zHscIUeYGuuk" style="text-align: right" title="Granted">192,783</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zZJy94IlE743" style="text-align: right" title="Weighted average grant date fair value, granted">35.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231_zBmNK5U67uGd" style="text-align: right" title="Vested">(105,875</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zlU9B1uuFNVe" style="text-align: right" title="Weighted average grant date fair value, vested">34.19</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231_zTROEIFXHzi7" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited">(28,332</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231_zyRmcP01KWC7" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, forfeited">35.31</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231_zP8FFn04tnwd" style="border-bottom: Black 2.5pt double; text-align: right" title="Non-vested shares, ending">202,787</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20241231_z0QSPV0TdEpk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending">34.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zFloXdegGY51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuHi6wwNrXq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the status of outstanding stock options at December&#160;31, 2024 and changes during the year then ended is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_zE4SbhyEYz85" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2024</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract Life</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding at beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zwAgg9EoMw7d" style="width: 12%; text-align: right" title="Options outstanding, beginning">93,892</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zVhLNEojQcmk" style="width: 12%; text-align: right" title="Weighted average exercise price outstanding, beginning">10.22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted or assumed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z8zVkBqcLNB3" style="text-align: right" title="Options, Granted or assumed"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zAqi3k5Q8F38" style="text-align: right" title="Weighted average exercise price, Granted or assumed"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231_zBCSDARL6fZ5" style="text-align: right" title="Options, Exercised">(62,879</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zfLKWGHwa5fk" style="text-align: right" title="Weighted average exercise price, Exercised">10.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zexCYAjPo6xb" style="text-align: right" title="Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zpi1qmxtYm18" style="text-align: right" title="Weighted average exercise price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1317">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20240101__20241231_zYGDoAXqFEoc" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1319">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zCLZsMlDuWRd" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1321">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_znAeFCWTCglb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending">31,013</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zzP5xdnTMCJg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price outstanding, ending">10.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_znfZyXZKxqqb" title="Weighted average remaining contract life outstanding">5.8</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp2d_c20241231_zkHVSzUHGD37" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, ending">701,975.3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zz8wTmwNLtc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, ending">31,013</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zOCGiwedUe12" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price exercisable, ending">10.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_znRXA31fwum8" title="Weighted average remaining contract life exercisable">5.8</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp2d_c20241231_z5IkBBHzKxu8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, exercisable">701,975.3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zssu9gzM2B6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zM6bs8p5qup9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the status of outstanding warrants to purchase common stock at December&#160;31, 2024 and changes during the year then ended
is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z14rStEIKokj" style="display: none">SCHEDULE
OF WARRANTS TO PURCHASE COMMON STOCK</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2024</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract Life</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding at beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231_zqetGtIzzIk5" style="width: 12%; text-align: right" title="Number of warrants outstanding, beginning">16,725</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zfXL4f4sqUm4" style="width: 12%; text-align: right" title="Weighted average exercise price outstanding, beginning">10.80</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted or assumed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231_z69vSccbr4Yh" style="text-align: right" title="Number of warrants, granted"><span style="-sec-ix-hidden: xdx2ixbrl1345">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20240101__20241231_zwwFylDLrnl1" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1347">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231_zKtUIXzWQ24d" style="text-align: right" title="Number of warrants, exercised">(16,725</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_c20240101__20241231_z2tIDvFibrQl" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1351">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20240101__20241231_zIGqfTSyRcwg" style="text-align: right" title="Number of warrants, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice_c20240101__20241231_zOLXnJANg3M7" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1355">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20240101__20241231_zYGAHTGZfZvi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, expired"><span style="-sec-ix-hidden: xdx2ixbrl1357">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20240101__20241231_z5poFFZx1aHe" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl1359">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231_zQx2MccL41C5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding, ending"><span style="-sec-ix-hidden: xdx2ixbrl1361">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zqUbQCKgYu72" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price outstanding, ending"><span style="-sec-ix-hidden: xdx2ixbrl1363">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_c20240101__20241231_z75lDqKTVcl7" title="Weighted average remaining contract life outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20240101__20241231_zsFFs2LbWIvf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants exercisable, ending"><span style="-sec-ix-hidden: xdx2ixbrl1367">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zjxITHyaQFs6" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, exercisable, ending"><span style="-sec-ix-hidden: xdx2ixbrl1369">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_c20240101__20241231_zllBN8SiQ0I3" title="Weighted average remaining contract life exercisable, ending"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zgzGAXVlsqv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CUSTOMERS AND SUPPLIERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CUSTOMERS AND SUPPLIERS</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--ConcentrationRiskDisclosureTextBlock_zcoCAlUg23A5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section44"></span>NOTE
11 &#8211; <span id="xdx_82C_zmqHOHzS9loj">CUSTOMERS AND SUPPLIERS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had no customers in 2024 that accounted for at least <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomersMember_zgRDknZhGJT7" title="Concentration risk percentage">10</span>% of the Company&#8217;s annual sales or whose accounts receivable balance
exceeded <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomersMember_zLmGSm7jZNla" title="Concentration risk percentage">10</span>% of the year-end balance. The Company had no customers in 2023 that accounted for at least <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomersMember_z0dbiuCTnwq7" title="Concentration risk percentage">10</span>% of Company&#8217;s annual
sales and whose accounts receivable exceeded <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomersMember_zikBQbSRy7Of" title="Concentration risk percentage">10</span>% of the year-end balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s principal revenue producing products are purchased from one manufacturer. If this supplier became unable to provide finished
goods inventory in a timely manner, the Company&#8217;s business, operating results, and financial condition could be materially adversely
affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_zW8PLiy5wfUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section45"></span>NOTE
12 &#8211; <span id="xdx_823_zIUDeJqnjdEk">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC Topic No. 740, Income Taxes. This standard requires the Company to provide a
net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book
and tax accounting and any available operating loss or tax credit carry forwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
applying the provisions of Section 382 of the Internal Revenue Code, the unexpired net operating loss (&#8220;NOL&#8221;) carryforward
at December&#160;31, 2024 was approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231_zQBjEGhaq3vd" title="Operating loss carryforwards">57.5</span> million, of which, approximately $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20171231_z0uewXasegQl" title="Operating loss carryforwards">26.5</span> million, generated in 2017 and prior, will <span id="xdx_90D_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231_zt580QlQAC7c" title="Expiration description">expire
between 2024 and 2037</span>. Under the Tax Cuts and Jobs Act, the NOL generated from 2018 through 2024, of approximately $<span id="xdx_908_ecustom--EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount_pn5n6_c20240101__20241231_zhsv7fEpDm0j" title="NOL generated under tax cuts and job cuts">30.9</span> million, will
have an indefinite carryforward period but can generally only be used to offset 80% of taxable income in any particular year. The Company
may be subject to certain limitations in its annual utilization of NOL carry forwards to off-set future taxable income pursuant to Section
382 of the Internal Revenue Code, which could result in NOLs expiring unused.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zDexFok1wvv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the deferred income tax assets and liabilities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zO4X4e74S19e" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zXqFpu9ozH0h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_z0YMB7w7Jg67" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzdlW_zV5wMbphzigk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">12,907,965</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">12,467,570</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzdlW_zmCHALkULCMl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,006,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,119,193</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzdlW_zm7Fd6nPHNvf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">789,373</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">711,598</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzdlW_zpqRpfmiqg91" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">528,148</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxAssetsLeaseLiability_iI_maDTAGzdlW_zebjHgLkZGt" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">389,882</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">512,668</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_iI_maDTAGzdlW_zfa1QhIUKbt9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Contingent liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">221,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">221,028</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsAcquistionLiability_iI_maDTAGzdlW_zqJnSsTsgC0d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Acquisition liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176,629</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTAGzdlW_zSbk2Pu5oAtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Bad debt and other reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">287,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129,924</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsInventory_iI_maDTAGzdlW_zXfhbudQYQph" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Inventory reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,176</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzdlW_z79OxiHDkbYa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other temporary differences</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,049,365</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">203,340</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzdlW_maDTANzNjR_zLoRnjRL8Er5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,902,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,179,274</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxLiabilitiesDepreciationAndAmortization_iNI_di_msDTANzNjR_z73LmKXbJo68" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,683,259</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,180,688</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_msDTANzNjR_z0d3cnWqMnp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Right of Use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(353,763</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(487,402</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_msDTANzNjR_zYFFete0AkP1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1434">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(424,423</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxLiabilitiesContingentLiability_iNI_di_msDTANzNjR_zpkI1SPUqglg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Contingent liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(38,308</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(130,802</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxLiabilitiesOtherTemporaryDifferences_iNI_di_msDTANzNjR_zreAXdMSzRvb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(294,608</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(166,712</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzNjR_zMVXwnPkmLI2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,532,298</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,789,247</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzNjR_zRS3W84wCb1g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1446">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1447">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zvTC5MNUeP1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
<span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20240101__20241231_zGxppO0kIGJ6" title="Valuation allowance, percentage">100</span>% valuation allowance has been provided for all deferred tax assets, as the ability of the Company to generate sufficient taxable
income in the future is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliations
of the expected federal income tax expense (benefit) based on the statutory income tax rate of 21% to the actual benefit for the years ended December&#160;31,
2024 and 2023 are listed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zR9sd5vFkOF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_ziiFgjcbV2wl" style="display: none">SCHEDULE
OF INCOME TAX EXPENSE (BENEFIT)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zdUv5yhISozk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zeFeZkvncMS4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_maITEBzW13_zpcDyM73dcw7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Expected federal income tax benefit</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(2,019,060</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(903,220</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_maITEBzW13_zWii2kQ3ybA4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State and local taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(338,138</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(226,714</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationFairValueAdjustments_iN_di_maITEBzW13_zgMNASbh1fuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(497,373</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(819,270</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_iN_di_maITEBzW13_zkh70zPU45Sj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(237,838</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(557,168</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_iN_di_maITEBzW13_zb6ZtLsiEPNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199,857</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,765</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration_iN_di_maITEBzW13_zo5BoJh5RUWa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NOL carryover adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,806</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,148,128</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxReconciliationIncomeTaxExpenseIntangibles_iN_di_maITEBzW13_zKyrGAhfc6s6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1471">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(720,407</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps_iN_di_maITEBzW13_zJ9hso5GDaU9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other true ups</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,343</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(230,474</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_iN_di_maITEBzW13_zeNrwgUE2PZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in tax rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,732</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">673,449</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_maITEBzW13_zW1lPccamP2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,743,051</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,813,167</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzW13_zCHKSOxvgkM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">48,380</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1484">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zgCOT5GQuJwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
tax years starting with 2021 are open for examination. The Company&#8217;s 2022 federal tax return was under audit as of March 24, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zt0nVz9F1OD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section46"></span>NOTE
13 &#8211; <span id="xdx_826_zbDYVFpMrdX8">RELATED PARTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CellerateRX
Sublicense Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had an exclusive, world-wide sublicense to distribute certain hydrolyzed collagen products, including CellerateRX Surgical into
the surgical and wound care markets from an affiliate of The Catalyst Group, Inc. (&#8220;Catalyst&#8221;), CGI Cellerate RX, which licensed
the rights to these products from Applied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed further in Note 3, on August 1, 2023, the Company purchased certain assets from Applied, including the underlying intellectual
property of, as well as the rights to manufacture and sell certain hydrolyzed collagen products, including CellerateRX Surgical. In connection
with the Applied Asset Purchase, Applied assigned the License Agreement with CGI Cellerate RX to SMAT, and on October 10, 2024, the License
Agreement and Sublicense Agreement were terminated for no additional consideration. Ronald T. Nixon, the Company&#8217;s Chief Executive
Officer and Executive Chairman, is the founder and managing partner of Catalyst.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
License Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2019, the Company executed a license agreement with Rochal, a related party, whereby the Company acquired an exclusive world-wide
license to market, sell and further develop antimicrobial products for the prevention and treatment of microbes on the human body utilizing
certain Rochal patents and pending patent applications. Currently, the products covered by the BIAK&#332;S License Agreement are BIASURGE
Advanced Surgical Solution, BIAK&#332;S Antimicrobial Wound Gel and BIAK&#332;S Antimicrobial Skin and Wound Cleanser. Each of these
products are 510(k) cleared. Mr. Nixon is a director of Rochal, and indirectly a significant shareholder of Rochal, and through the potential
exercise of warrants, a majority shareholder of Rochal. Another one of the Company&#8217;s directors is also a director and significant
shareholder of Rochal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, the Company executed the ABF License Agreement with Rochal whereby the Company acquired an exclusive world-wide license
to market, sell and further develop certain antimicrobial barrier film and skin protectant products for use in the human health care
market utilizing certain Rochal patents and pending patent applications. Currently, the products covered by the ABF License Agreement
are CuraShield Antimicrobial Barrier Film and a no sting skin protectant product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, the Company executed a product license agreement with Rochal, whereby the Company acquired an exclusive world-wide license
to market, sell and further develop a debrider for human medical use to enhance skin condition or treat or relieve skin disorders, excluding
uses primarily for beauty, cosmetic, or toiletry purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 9 for more information on these product license agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with the Rochal asset purchase, in July 2021, the Company entered into a consulting agreement with Ann Beal Salamone pursuant to which
Ms. Salamone agreed to provide the Company with consulting services with respect to, among other things, writing new patents, conducting
patent intelligence, and participating in certain grant and contract reporting. In consideration for the consulting services to be provided
to the Company, Ms. Salamone is entitled to receive an annual consulting fee of $<span id="xdx_903_eus-gaap--ProfessionalFees_c20210701__20210731__us-gaap--PlanNameAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSalamoneMember_zQU0p1QfVNAl" title="Consulting fee">177,697</span>, with payments to be paid once per month. The
consulting agreement had an initial term of three years, unless earlier terminated by the Company, and was subject to renewal. Effective
July 13, 2024, the consulting agreement with Ms. Salamone was amended to provide that the initial term shall be automatically renewed
for successive one-year terms for up to three successive years unless earlier terminated by either party without cause at any time, provided
that the terminating party provides 90 days advance written notice of termination. Ms. Salamone is a director of the Company and is a
significant shareholder and the current Chair of the board of directors of Rochal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Catalyst
Transaction Advisory Services Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Company entered into a Transaction Advisory Services Agreement (the &#8220;Catalyst Services Agreement&#8221;) effective
March 1, 2023 with Catalyst, a related party. Pursuant to the Catalyst Services Agreement, Catalyst, by and through its directors, officers,
employees and affiliates that are not simultaneously serving as directors, officers or employees of the Company (collectively, the &#8220;Covered
Persons&#8221;), agreed to perform certain transaction advisory, business and organizational strategy, finance, marketing, operational
and strategic planning, relationship access and corporate development services for the Company in connection with any merger, acquisition,
recapitalization, divestiture, financing, refinancing, or other similar transaction in which the Company may be, or may consider becoming,
involved, and any such additional services as mutually agreed upon in writing by and between Catalyst and the Company (the &#8220;Catalyst
Services&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Catalyst Services Agreement, the Company agreed to reimburse Catalyst for (i) compensation actually paid by Catalyst to any of
the Covered Persons at a rate no more than a rate consistent with industry practice for the performance of services similar to the Catalyst
Services, as documented in reasonably sufficient detail, and (ii) all reasonable out-of-pocket costs and expenses payable to unaffiliated
third parties, as documented in customary expense reports, as each of (i) and (ii) is incurred in connection with the Catalyst Services
rendered under the Catalyst Services Agreement, with all reimbursements being contingent upon the prior approval of the Audit Committee
of the Company&#8217;s Board of Directors. The Company incurred costs pursuant to the Catalyst Services Agreement of $<span id="xdx_90A_eus-gaap--CostsAndExpensesRelatedParty_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_ziRcprlXAmHd" title="Cost and expenses related party">288,594</span> and $<span id="xdx_908_eus-gaap--CostsAndExpensesRelatedParty_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_zqcawDISSKx7" title="Cost and expenses related party">174,486</span>
in the year ended December&#160;31, 2024 and 2023, respectively, and is recorded in &#8220;Selling, general and administrative&#8221;
in the accompanying Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_z9lcO0Mpn5v7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Section47"></span>NOTE
14 &#8211; <span id="xdx_82B_z5uIoq8pO2La">SEGMENT REPORTING</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 1, the Company historically managed its business as <span id="xdx_908_eus-gaap--NumberOfOperatingSegments_dc_uInteger_c20240101__20241231_zxyyxpfKK3Y5" title="Number of operating segment"><span id="xdx_903_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240101__20241231_zfj3ZpGgI3Kk" title="Number of reportable segment">one</span></span> operating and reportable segment. During the second quarter
of 2024, the Company changed its reportable segments to reflect a change in the manner in which the business is managed. Based on the
growing importance of the value-based wound care program to the Company&#8217;s future outlook and how the Company&#8217;s chief operating
decision maker (&#8220;CODM&#8221;), the Chief Executive Officer, reviews operating results and makes decisions about resource allocation,
the Company has <span id="xdx_902_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240401__20240630_z67SpXJ8aYbh" title="Number of reportable segment">two</span> reportable segments: Sanara Surgical and THP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment
Adjusted EBITDA is the primary profitability measure used by the CODM for purposes of assessing financial performance and resource
allocation. The Company defines Segment Adjusted EBITDA for the reportable segments as net income (loss) excluding interest
expense/income, provision/benefit for income taxes, depreciation and amortization, non-cash share-based compensation expense, change
in fair value of earnout liabilities, share of losses from equity method investments, executive separation costs, legal and
diligence expenses related to acquisitions, and gains/losses on disposal of property and equipment, as each are applicable to the
periods presented. The Company has historically presented this profitability measure as Segment EBITDA and, starting with the fourth
quarter ended December 31, 2024, is presenting it as Segment Adjusted EBITDA. The definition and methodology for calculating this
measure has remained unchanged. Segment Adjusted EBITDA, as it relates to the Company&#8217;s reportable segments, is presented in
conformity with ASC 280, Segment Reporting, and is excluded from the definition of non-GAAP financial measures under the Securities
and Exchange Commission&#8217;s Regulation G and Item 10(e) of Regulation S-K. Segment Adjusted EBITDA may not be comparable to
similarly titled measures reported by other companies. The CODM also reviews budget-to-actual variances for expenses on a monthly
basis when making decisions about allocating resources to the segments. The Company has not included any disclosure regarding total
segment assets, as no segment level asset information is regularly provided to the CODM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sanara
Surgical</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other
sterile environments. Sanara Surgical&#8217;s soft tissue repair products include, among other products, the Company&#8217;s lead product,
CellerateRX Surgical, and BIASURGE Advanced Surgical Solution, which is a sterile no-rinse, advanced surgical solution used for wound
irrigation. Sanara Surgical&#8217;s bone fusion products include, among other products, BiFORM, which is an osteoconductive, bioactive,
porous implant that allows for bony ingrowth across the graft site, and ALLOCYTE Plus, which is a human allograft cellular bone matrix
containing bone-derived progenitor cells and conformable bone fibers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara
Surgical also includes an in-house research and development team (Rochal Technologies) with an extensive pipeline of innovative products
under development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tissue
Health Plus</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
THP segment is focused on value-based wound care services. Through THP, the Company plans to offer a first of its kind value-based wound
care program to payers and risk-bearing entities such as accountable care organizations and value-based primary care companies, with
Medicare Advantage payers as the initial target market for this program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THP&#8217;s
programs are expected to enable payers to divest wound care spend risk, reduce wound related hospitalizations and improve patient quality
of life. THP plans to coordinate delivery of community and home-based wound care for its managed patients. Community based care spans
a variety of settings including physician offices, skilled nursing facilities, assisted living facilities and senior living facilities.
THP programs are intended to integrate science and evidence-based medicine protocols to standardize wound prevention and treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there are no allocated costs included in the THP segment. All corporate and overhead expenses are included in the Sanara Surgical segment,
as substantially all of those costs relate to supporting the operations and activities of the Sanara Surgical segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the change in reportable segments, certain prior period amounts have been recast to conform to the current period presentation.
Throughout this Annual Report on Form 10-K, unless otherwise indicated, amounts and activity reflect reclassifications related to the
Company&#8217;s change in reportable segments. The change in reportable segments had no impact on the Company&#8217;s previously reported
Consolidated Balance Sheets, Consolidated Statements of Operations, Consolidated Statements of Cash Flows or Consolidated Statements
of Shareholders&#8217; Equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z5lKpvEEPshb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table reflects results of operations including significant segment expenses that are regularly provided to the CODM for
the Company&#8217;s reportable segments and Segment Adjusted EBITDA for the periods indicated below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BF_zeVqkUwBWXb4" style="display: none">SCHEDULE
OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zLIukRbgfhrf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zkIysJvU6A6a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zRBwLO7WudVg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_z5jVy3pkifS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zXfWfYRJGQm7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zKvlVpSKttwl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zmmvrvDfHeIf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">86,672,425</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1505">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">86,672,425</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">64,987,112</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">2,730</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">64,989,842</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GrossProfit_pp0p0_zqxfeJsKF5k5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,532,524</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1512">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,532,524</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,143,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,235</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,137,156</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pp0p0_z5CtTRvdihJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,673,642</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,886,221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,559,863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,826,852</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,167,901</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,994,753</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_zYg7XUlNl2A2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,828,663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,874,699</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,703,362</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">902,782</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,229,643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,132,425</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DepreciationAndAmortization_i01_pp0p0_zx27jzi1oRNf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,785,829</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,137,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,923,224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,046,859</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,628,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,675,026</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueAdjustment_zj2C1Ekwg4Fi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,451</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,924,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,938,451</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,298,336</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,151,559</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,449,895</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--InterestExpenseOther_i01_pp0p0_zYKipiwKsQsf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,196,424</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1547">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,196,424</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">224,749</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1550">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">224,749</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProfitLoss_pp0p0_zrla761eanxa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,937,583</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,974,315</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,911,898</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">440,485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,880,387</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,439,902</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--EarningsBeforeInterestTaxesDepreciationAndAmortization_pp0p0_z7OnNybafWI5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Segment Adjusted EBITDA</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,148,722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,457,415</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,691,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,289,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,162,387</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">127,247</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zbhZYin5XBLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zqzR2pBSdqxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a reconciliation of net income (loss) to Segment Adjusted EBITDA for the Company&#8217;s reportable segments
for the periods indicated below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zALkQpjlbLGj" style="display: none">SCHEDULE
OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zClfXTIsfWx9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_z2XqVdMcKLB6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zVNTBgAcyH0h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zSO6NUbYJ963" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zZGSpCyt7khd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_z4lguIpRj1df" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProfitLoss_pp0p0_zezQ8oQ9pkV2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net Income (Loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(1,937,583</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(7,974,315</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(9,911,898</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">440,485</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(4,880,387</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(4,439,902</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Adjustments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InterestExpense_zAkGGoh0AeZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,128,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1577">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,128,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475,783</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1580">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475,783</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestIncomeOther_iN_di_zzIY6DT7ud64" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,978</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1584">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,978</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1586">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1587">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1588">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DepreciationAndAmortization_i01_pp0p0_zHBp3n4G8a86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation and amortization <sup id="xdx_F4C_z1FJsCFRwQfh">(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,785,829</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,137,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,923,224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,046,859</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,628,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,675,026</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_zPTZHXKFCrW8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Noncash share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,969,008</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,107,253</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,201,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,392</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,442,722</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueAdjustment_zCl9HrZ6nePb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,451</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,924,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,938,451</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,298,336</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,151,559</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,449,895</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromEquityMethodInvestments_iN_di_z3253TAfteya" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share of losses from equity method investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1612">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1614">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1615">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1616">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ExecutiveSeparationCosts_z5MSPLDWS9Tj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive separation costs <sup id="xdx_F4E_zRPyIqyrxbCd">(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">964,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1619">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">964,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1621">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1622">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1623">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_znqTCNw4Wcpk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition costs <sup id="xdx_F44_zbrOTqNsjIR3">(3)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">185,029</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,165,260</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,350,289</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">423,513</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1629">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">423,513</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--EarningsBeforeInterestTaxesDepreciationAndAmortization_pp0p0_z6Q6PSNNOfwh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment Adjusted EBITDA</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,148,722</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,457,415</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,691,307</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,289,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,162,387</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">127,247</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F01_z0uipYDTBTz6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zWCjaXeLHmF2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            a $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--PropertyAndEquipmentWriteOff_iI_c20241231_zJC0st7jzVq4" title="Property and equipment write off">506,836</span> non-cash charge during the fourth quarter of 2024 to write-off the remaining net
                                            book value of certain THP internal use software assets.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0F_zwCBMaXL2AO" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_z6XS7fBBbkn5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231_zJKt3Xeqlclc" title="Share based compensation related to executive separation costs">328,795</span> of share-based compensation related to executive separation costs for the twelve
                                            months ended December&#160;31, 2024.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0E_zMpKyZU4yTwh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F16_zC2lTmDvtW5h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition
                                            costs include legal, tax and accounting services related to prospective acquisitions.</span></td></tr></table>

<p id="xdx_8AB_zJY6ME8hV3Sf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_ztNHvCG7OWL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 &#8211; <span id="xdx_82C_z8ySwQNbRevf">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exclusive
License and Distribution Agreement With, and Minority Investment in, Biomimetic Innovations Ltd</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Licensing
and Distribution Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 16, 2025 (the &#8220;Execution Date&#8221;), the Company entered into a Licensing and Distribution Agreement (the &#8220;License
Agreement&#8221;), by and between the Company and Biomimetic Innovation Limited, a privately-held medical device company headquartered
in Shannon, Co. Clare Ireland (&#8220;BMI&#8221;), pursuant to which the Company acquired the exclusive U.S. marketing, sales and distribution
rights to OsStic&#174; Synthetic Injectable Structural Bio-Adhesive Bone Void Filler (&#8220;OsStic&#8221;), as well as an adjunctive
internal fixation technology featuring novel delivery to promote targeted application of OsStic (&#8220;ARC&#8221; and together with
OsStic, the &#8220;Products&#8221;), for use in the treatment of a wound or injury caused by a traumatic incident.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the License Agreement, the Company was appointed by BMI as the exclusive distributor to promote, market, offer to sell, transfer,
distribute and sell the Products for trauma indications inside the United States and its territories for an initial five-year term, which
term may be automatically renewed for successive two-year periods at the Company&#8217;s discretion, provided that the Company is in
compliance with its obligations thereunder (the &#8220;Term&#8221;). From the Execution Date until October 13, 2025, the Company has
an exclusive option to negotiate exclusive distribution rights for the Products in additional fields and/or additional territories on
substantially the same terms as those set forth in the License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
License Agreement requires that the Company pay BMI quarterly royalties (the &#8220;Quarterly Royalties&#8221;) based on a percentage
of the Net Sales Value (as defined in the License Agreement) of the Products during the Term, with the applicable percentage of the Net
Sales Value for OsStic being in the mid-single digit range. Pursuant to the License Agreement, the Company and BMI agreed to negotiate
the applicable percentage of the Net Sales Value for ARC at a future date. The License Agreement also requires that the Company pay BMI
minimum royalty payments being in the low to mid six figure range for the first, second and third years, respectively, following the
receipt of first regulatory approval for the marketing and sale of a Product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subscription
and Shareholders&#8217; Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the License Agreement, on the Execution Date, the Company entered into a Share Subscription and Shareholders&#8217; Agreement
(the &#8220;Subscription Agreement&#8221;), by and among the Company,<span id="xdx_905_eus-gaap--SubsequentEventDescription_c20250116__20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAndShareholdersAgreementMember_zsBN6v56KJOj" title="Subsequent description"> The Russell Revocable Living Trust, BMI and the existing shareholders
of BMI, pursuant to which the Company agreed to contribute up to approximately &#8364;8.0 million to BMI through a series of capital contributions
in exchange for an aggregate of 16,460 ordinary shares of BMI, constituting approximately 12.5% of the outstanding equity of BMI as of
the Execution Date. The Company made an initial cash investment totaling approximately &#8364;3.0 million on the Execution Date, and the
Company&#8217;s previously announced convertible loan to BMI was converted into &#8364;1.0 million of equity in BMI. Pursuant to the Subscription
Agreement, the remaining &#8364;4.0 million contribution is due upon the achievement of certain development, clinical and regulatory milestones</span>
(the &#8220;Milestones&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Subscription Agreement, so long as the Company holds a five percent ownership interest or greater in BMI, the Company is entitled
to have one person appointed to BMI&#8217;s board of directors. <span id="xdx_908_eus-gaap--SubsequentEventDescription_c20250116__20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zIPXR1KYGaPf" title="Subsequent description">The Company&#8217;s initial investment of approximately &#8364;4.0 million
caused the Company to exceed the five percent ownership interest threshold in BMI, and as a result the Company&#8217;s Chief Corporate
Development &amp; Strategy Officer, Tyler Palmer, has been nominated and appointed to BMI&#8217;s board of directors.</span> In addition, the
Company has the right to send one non-voting observer to attend meetings of the BMI board of directors, regardless of the Company&#8217;s
ownership interest level. The Company&#8217;s capital contributions must be used to fund the development and commercialization of the
Products, and the Company has certain veto and consent rights to further protect the Company&#8217;s investment in BMI and to support
its ability to successfully market and sell the Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>CRG Term Loan Amendment</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On [<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
19, 2025</span>], the Company and the Guarantors entered into the First Amendment to Term Loan Agreement with the Agent and the lenders
party thereto from time to time, which amended the CRG Term Loan Agreement to, among other things, <span id="xdx_90C_eus-gaap--DebtInstrumentDescription_c20250319__20250319__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zkx7qtxFiz0a" title="Debt description">(i) entitle the Company to two additional
borrowings following the Second Borrowing, which borrowings must occur on or prior to December 31, 2025, if at all, and (ii) remove the
requirement that any borrowing be in whole multiples of $5.0 million.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation and Basis of Presentation</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_zWgD8C7GaIkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_866_z5VScNKQbWcd">Principles of Consolidation and Basis of Presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of Sanara MedTech Inc. and its wholly owned and majority-owned subsidiaries, as well as other entities in which
the Company has a controlling financial interest. All significant intercompany profits, losses, transactions and balances have been eliminated
in consolidation. Certain prior year amounts have been reclassified to conform to the current year presentation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_840_eus-gaap--UseOfEstimates_zX6nXHAESdFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zeobAQWcjXK5">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and
the reported revenue and expenses during the reporting period. However, actual results could differ from those estimates and there may
be changes to the Company&#8217;s estimates in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zVH5nCCKGtJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_865_zgPXxcOOsSHg">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid investments
purchased with an original maturity of three months or less to be cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income/Loss Per Share</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zpLuYGKBoAuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_z2p7h9RuBYk4">Income/Loss Per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes income/loss per share in accordance
with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 260, Earnings per Share, which requires the Company to present basic
and diluted income per share when the effect is dilutive. Basic income/loss per share is computed by dividing income/loss attributable
to common shareholders by the weighted average number of shares of common stock outstanding. Diluted income/loss per share is computed
similarly to basic income/loss per share, except that the denominator is increased to include the number of additional shares of common
stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common
stock were dilutive. All common stock equivalents were excluded from the calculations for the periods presented as their inclusion would
have been anti-dilutive during the years ended December&#160;31, 2024 and 2023 due to the Company&#8217;s net loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWXU0FDCQDwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the shares of common
stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the years ended December&#160;31,
2024 and 2023 as such shares would have had an anti-dilutive effect:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zf7w48RRD9A9" style="display: none">SCHEDULE
OF COMPUTATION OF DILUTED NET LOSS PER SHARE</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20240101__20241231_z2Dd1IDQxPbb" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_zfZm4fFZ5OOc" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zDvw2srqeA2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 0pt"><span style="font-size: 10pt">Stock options<sup id="xdx_F4C_zmB7sEMtIBwj">(a)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">31,013</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">93,892</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKD4QRq4eUl3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt"><span style="font-size: 10pt">Warrants<sup id="xdx_F48_zFdIWwfer048">(b)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,725</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zsbhPOlzXXF3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Unvested restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202,787</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,211</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z6ObFpoJjSwj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202,787</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">144,211</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td id="xdx_F0E_zLw243GCkSl4" style="width: 0.25in">(a)</td><td id="xdx_F1D_zQ2VZuA9Ai1g">Shares underlying stock options assumed pursuant to the merger agreement
                                            with Precision Healing, Inc. (&#8220;Precision Healing&#8221;) in April 2022.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td id="xdx_F0F_zRE6wyIXY6d7" style="width: 0.25in">(b)</td><td id="xdx_F1E_zt5c7r2IXmL5">Shares underlying warrants assumed pursuant to the merger agreement
                                            with Precision Healing in April 2022.</td></tr></table>

<p id="xdx_8AE_zKpKnX5IfzJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zvpssZlOVqdl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_860_zBN1XGdmgHGh">Revenue Recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue in accordance with
ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Revenues are recognized when a purchase order is received
from the customer and control of the promised goods or services is transferred to the customer in an amount that reflects the consideration
the Company expects to be entitled to receive in exchange for transferring those goods or services. Revenue is recognized based on the
following five-step model:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: -9pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Identification of the contract with a customer</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Identification of the performance obligations
                                            in the contract</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Determination of the transaction price</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Allocation of the transaction price to the performance
                                            obligations in the contract</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in">-</td><td style="text-align: justify">Recognition of revenue when, or as, the Company
                                            satisfies a performance obligation</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Details of this five-step process are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Identification of the contract with a customer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Customer purchase orders are generally considered
to be contracts under ASC 606. Purchase orders typically identify the specific terms of products to be delivered, create the enforceable
rights and obligations of both parties and result in commercial substance. No other forms of contract revenue recognition, such as the
completed contract or percentage of completion methods, were utilized by the Company in either 2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Performance obligations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s performance obligation is generally
limited to delivery of the requested items to its customers at the agreed upon quantities and prices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Determination and allocation of the transaction price</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has established prices for its products.
These prices are effectively agreed to when customers place purchase orders with the Company. Rebates and discounts, if any, are recognized
in full at the time of sale as a reduction of net revenue. Allocation of transaction prices is not necessary where only one performance
obligation exists. For certain sales transactions, we incur group purchasing organization fees that are based on a contractual percentage
of applicable sales and are recorded as a reduction of the revenue for those transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Recognition of revenue as performance obligations are satisfied</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Product revenues are recognized when a purchase order
is received from the customer, the products are delivered, and control of the goods and services passes to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Disaggregation of Revenue</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zydaPT1G4ZKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue streams from product sales and royalties
are summarized below for the years ended December&#160;31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z9Njba69Dhx4" style="display: none">SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20241231_z9BTxnEdZ442" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20230101__20231231_ztPw1I3NSwZa" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SoftTissueRepairProductsMember_zneCjYnaFoe7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 0pt">Soft tissue repair products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">76,125,012</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">54,836,410</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--BoneFusionProductsMember_zl6rE4Y3bJA6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Bone fusion products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,547,413</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,952,432</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zaDbFNK5EtN" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0590">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">201,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zKdc18lqmb9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total Net Revenue</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">86,672,425</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">64,989,842</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zaRG0x0BD4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2024 and
2023, all of the Company&#8217;s net revenue was generated from Sanara Surgical. The Company is preparing to launch the first THP
pilot program with a wound care provider group during the second quarter of 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Accounts Receivable Allowances</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--CreditLossFinancialInstrumentPolicyTextBlock_zau6cFpP84v6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86E_zkO6xtwjAUph">Accounts Receivable Allowances</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable are typically due within 30
days of invoicing. The Company establishes an allowance for credit losses to provide for an estimate of accounts receivable which
are not expected to be collectible. The Company bases the allowance on an assessment of customer creditworthiness, historical
payment experience, the age of outstanding receivables and other information as applicable and will record its allowance based on
the estimated credit losses. The Company&#8217;s accounts receivable balance, net was $<span id="xdx_90D_eus-gaap--AccountsReceivableNetCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zzTaJygWj6v1" title="Accounts receivable">12,408,819</span>, $<span id="xdx_906_eus-gaap--AccountsReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zoxigWdgakN6" title="Accounts receivable">8,474,965</span>, and $<span id="xdx_90B_eus-gaap--AccountsReceivableNetCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zBusyyYA3Bsj" title="Accounts receivable">6,805,761</span> as of December
31, 2024, December 31, 2023, and December 31, 2022, respectively. The Company recorded credit loss expense of $<span id="xdx_90B_eus-gaap--ProvisionForDoubtfulAccounts_c20240101__20241231_zl7NwK9XaDN7" title="Bad debt expense">624,448</span>
and $<span id="xdx_90B_eus-gaap--ProvisionForDoubtfulAccounts_c20230101__20231231_zLbUbIGGyrgl" title="Bad debt expense">202,941</span>
during the years ended December&#160;31, 2024 and 2023, respectively. The allowance for credit losses was $<span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20241231_zLMuSoGtDiEd" title="Allowance for credit losses">1,173,441</span>
at December&#160;31, 2024 and $<span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zboG2jZNi8lk" title="Allowance for credit losses">528,030</span>
at December&#160;31, 2023. Credit loss reserves are maintained based on a variety of factors, including the length of time
receivables are past due and a detailed review of certain individual customer accounts. The Company also establishes other
allowances to provide for estimated customer rebates and other expected customer deductions. These allowances totaled $<span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_c20241231_ztbX3Z9Q2YI1" title="Allowance for customer rebates and deductions">4,897</span>
at December&#160;31, 2024 and $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_c20231231_zYAfTFwYXIgb" title="Allowance for customer rebates and deductions">3,820</span>
at December&#160;31, 2023. If circumstances related to customers change, estimates of the recoverability of receivables would be
further adjusted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_zuU61DQo9Vdk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_862_zateYLuhUsxd">Inventories</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower of cost or net
realizable value, with cost computed on a first-in, first-out basis. Inventories consist primarily of finished goods, and also include
an immaterial amount of raw materials and related packaging components. The Company recorded inventory obsolescence expense of $<span id="xdx_901_eus-gaap--InventoryWriteDown_c20240101__20241231_zCTwYKZUNe6f" title="Inventory obsolescence expense">521,757</span>
and $<span id="xdx_902_eus-gaap--InventoryWriteDown_c20230101__20231231_zovbIFGgdTr1" title="Inventory obsolescence expense">406,812</span> during the years ended December&#160;31, 2024 and 2023, respectively. The allowance for obsolete and slow-moving inventory
had a balance of $<span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_c20241231_zc074IrXpNph" title="Allowance for obsolete and slow-moving inventory">534,549</span> at December&#160;31, 2024 and $<span id="xdx_902_eus-gaap--InventoryValuationReserves_iI_c20231231_zyOJP02HiKF4" title="Allowance for obsolete and slow-moving inventory">446,917</span> at December&#160;31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zH8nmSqF4w6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_866_zb79f3OI2Ddf">Property and Equipment</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost, less accumulated
depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the related assets, ranging
from <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember_zP6XLLBlsNy2" title="Estimated useful lives::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl0628">two</span></span> to <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_c20241231__srt--RangeAxis__srt--MaximumMember_zZiC3dzkTRu6" title="Estimated useful lives">ten years</span>. Below is a summary of property and equipment for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zqRliQNnUB1d" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zQKNzkO8FU9g" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Useful</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Life</b></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zjuto5QPegHf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zwcZH3iFbWbi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVlyBmKFNc29" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; padding-left: 0pt">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: center; padding-left: 0pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zpfitIsrj9Ak" title="Useful Life">3</span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zuDth0z9viv1" title="Useful Life">5</span> years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">295,963</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">194,788</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zrthfTCFxxhk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Office equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zs8CneFLDiB6" title="Useful Life">3</span>-<span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_z2kIMVBvCVw2" title="Useful Life">7</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">216,491</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">201,785</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zJ56vuocB1Ih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zeQhlRy083Za" title="Useful Life">5</span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zbWxC8rWUL7c" title="Useful Life">10</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">346,508</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304,338</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zLVSo8nF94k1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_z3ksmxolhQ3c" title="Useful Life">2</span>-<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zfSPGPNrx4ye" title="Useful Life">5</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">181,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134,170</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zkzxzTMzV3c3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Internal use software</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 0pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_ztngxXxxLfR" title="Useful life">5</span> years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0662">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,618,999</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz6Up_znA7HeNhBpG8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,040,930</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,454,080</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz6Up_z5x7dqCdRrr7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(608,613</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,196,124</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz6Up_zph1Y9kIAJq5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">432,317</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,257,956</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zm4xRmkwAxS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense related to property and equipment
was $<span id="xdx_906_eus-gaap--Depreciation_c20240101__20241231_zjo3LfxdWLG2" title="Depreciation">1,031,487</span> and $<span id="xdx_90B_eus-gaap--Depreciation_c20230101__20231231_z0BnoG2WACQ3" title="Depreciation">456,138</span> during the year ended December&#160;31, 2024 and 2023, respectively. Depreciation expense for the year ended
December&#160;31, 2024 included a non-cash charge of $<span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_z8IlaiQpIepi" title="Depreciation">506,836</span> to write-off the remaining net book value of certain internal use software
assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Internal Use Software</a></td>
<td class="text"><p id="xdx_849_eus-gaap--InternalUseSoftwarePolicy_zrF1Mx2vgan" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_zIKZP3FaoK1g">Internal Use Software</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounted for costs incurred to develop
or acquire computer software for internal use in accordance with ASC Topic 350-40, Intangibles &#8211; Goodwill and Other. The Company
capitalized the costs incurred during the application development stage, which generally included third-party developer fees to design
the software configuration and interfaces, coding, installation and testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company began capitalization of qualifying costs
when both the preliminary project stage was completed and management authorized further funding for the completion of the project. Costs
incurred during the preliminary project stage along with post implementation stages of internal-use computer software was expensed as
incurred. The Company also capitalized costs related to specific upgrades and enhancements when it was probable the expenditures would
result in additional functionality. Capitalized development costs were classified as &#8220;Property and equipment, net&#8221; in the
Consolidated Balance Sheets and were depreciated over the estimated useful life of the software, which was generally <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_c20241231_zEG0ftpJryRl" title="Software, estimated useful life">five years</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z1WdfEV3R3Rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_864_zJk3m1hNnfCe">Goodwill</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The excess of purchase price over the fair value
of identifiable net assets acquired in business combinations is recorded as goodwill. As of December&#160;31, 2024 and December&#160;31,
2023, all of the Company&#8217;s goodwill relates to the acquisition of Scendia Biologics, LLC (&#8220;Scendia&#8221;), which is included
in the Sanara Surgical segment. Goodwill has an indefinite useful life and is not amortized. Goodwill is tested annually as of December&#160;31
for impairment, or more frequently if circumstances indicate impairment may have occurred. The Company may first perform a qualitative
assessment to determine if it is more likely than not that the fair value of the reporting unit is less than the respective carrying
value. If it is determined that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying value,
then the Company will determine the fair value of the reporting unit and record an impairment charge for the difference between fair
value and carrying value (not to exceed the carrying amount of goodwill). <span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_dxL_c20240101__20241231_zf8A9BY2laia" title="Impairment of goodwill::XDX::-"><span id="xdx_902_eus-gaap--GoodwillImpairmentLoss_dxL_c20230101__20231231_zSP9gN96Qp8" title="Impairment of goodwill::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0688"><span style="-sec-ix-hidden: xdx2ixbrl0690">No</span></span></span></span> impairment was recorded during the year ended December&#160;31,
2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_z0H17BQcYr0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_864_zesGLPv7Z3n7">Intangible Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets are stated at cost of acquisition
less accumulated amortization and impairment loss, if any. Cost of acquisition includes the purchase price and any cost directly attributable
to bringing the asset to its working condition for the intended use. The Company amortizes its finite-lived intangible assets on a straight-line
basis over the estimated useful life of the respective assets which is generally the life of the related patents or licenses, seven years
for customer relationships and five years for assembled workforces. See Note 5 for more information on intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQQvnP4shxjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_869_zbyigOjCH2M9">Impairment of Long-Lived Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets, including certain identifiable
intangibles held and to be used by the Company, are reviewed for impairment whenever events or changes in circumstances indicate that
the carrying amount of such assets may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets
based on estimated future cash flows and the estimated liquidation value of such long-lived assets and provides for impairment if such
undiscounted cash flows are insufficient to recover the carrying amount of the long-lived assets. If impairment exists, an adjustment
is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value.
Fair values are determined based on quoted market values, undiscounted cash flows or internal and external appraisals, as applicable.
Assets to be disposed of are carried at the lower of carrying value or estimated fair value less cost to sell. A $<span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn5n6_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zFeTMhSeGVo3" title="Depreciation">0.5</span> million non-cash
charge to write-off the remaining net book value of certain THP internal use software assets was recorded during the year ended December&#160;31,
2024. <span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20230101__20231231_z0RhOg8Dufg1" title="Impairment of long-lived assets">No</span> impairment was recorded during the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Investments in Equity Securities</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--EquityMethodInvestmentsPolicy_zCGU5SwufEW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_862_ztdSbWsdtScl">Investments in Equity Securities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s equity investments consist of
nonmarketable equity securities in privately held companies without readily determinable fair values. Unless accounted for under the
equity method of accounting, the investments are reported at cost minus impairment, if any, plus or minus changes resulting from observable
price changes in orderly transactions for the identical or similar investment in the same issuer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company applies the equity method of accounting
to investments when it has significant influence, but not controlling interest, in the investee. Judgment regarding the level of influence
over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors,
participation in policy-making decisions and material intercompany transactions. As discussed further in Note 6 as of December&#160;31,
2024, the Company had two investments that are recorded applying the equity method of accounting. The Company&#8217;s proportionate share
of the net income (loss) resulting from these investments is reported under the line item captioned &#8220;Share of losses from equity
method investments&#8221; in the Company&#8217;s Consolidated Statements of Operations. The Company&#8217;s equity method investments
are adjusted each period for the Company&#8217;s share of the investee&#8217;s income or loss and dividend paid, if any. The Company
classifies distributions received from its equity method investments using the cumulative earnings approach in the Company&#8217;s Consolidated
Statements of Cash Flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has reviewed the carrying value of its
investments and has determined there was no impairment or observable price changes as of or for the year ended December&#160;31, 2024
and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z8rBtA5vItM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_868_zccdqe3IkqB9">Fair Value Measurement</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As defined in ASC Topic 820, Fair Value Measurement
(&#8220;ASC 820&#8221;), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market
participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the
valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair
value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted
prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level
3 measurement). This fair value measurement framework applies at both the initial and subsequent measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The three levels of the fair value hierarchy defined
by ASC 820 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 &#8211; Quoted prices are available in active
markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or
liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of
financial instruments such as exchange-traded derivatives, marketable securities and listed equities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 &#8211; Pricing inputs are other than quoted
prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes
those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard
models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current
market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these
assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are
supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include
nonexchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 &#8211; Pricing inputs include significant
inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that
result in management&#8217;s best estimate of fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of cash, accounts receivable,
accounts payable and accrued expenses, other than acquisition-related expenses, approximate fair value because of the short-term nature
of these instruments. The fair value of acquisition-related accrued expenses is categorized as Level 2 of the fair value hierarchy. The
value of these instruments has been estimated using discounted cash flow analysis based on the Company&#8217;s incremental borrowing
rate. The carrying value of the Company&#8217;s CRG Term Loan (defined below), which has a fixed interest rate approximates fair value
based on instruments with similar terms (Level 2 inputs). The fair value of the contingent earnout consideration and the acquisition
date fair value of goodwill and intangibles related to the acquisitions discussed in Notes 3 and 5 are based on Level 3 inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Liabilities for contingent consideration for the
Precision Healing merger, acquisition of Scendia and Applied Asset Purchase (defined below) (see Note 3 for more information) are measured
at fair value each reporting period, with the acquisition-date fair value included as part of the consideration transferred. The contingent
consideration for the Scendia acquisition was settled as of September 30, 2024, and the final earnout payment of approximately $1.1 million
was paid in cash in October 2024. The Precision Healing contingent consideration is classified as a liability at its fair value at each
reporting period due to the fact that the monetary value of the shares to be issued is predominantly dependent on the exercise contingency
(i.e., revenue targets). Subsequent changes in fair value of contingent consideration related to the Precision Healing merger are reported
under the line item captioned &#8220;Change in fair value of earnout liabilities&#8221; in the Company&#8217;s Consolidated Statements
of Operations. The Company reviewed the thresholds necessary to trigger a payment on the Precision Healing earnout as of December 31,
2024 and deemed the thresholds to be unachievable by the sellers, therefore, the remaining fair value on the earnout was reduced to zero.
Due to the Applied Asset Purchase being accounted for as an asset acquisition and given that the transaction did not include contingent
shares, subsequent revaluations of contingent consideration for the Applied Asset Purchase results in an adjustment to the contingent
consideration liability and the intellectual property intangible asset with a cumulative catch-up amortization adjustment. The current
year change in fair value of earnout liability below is as a result of a net decrease in the estimated fair value of the earnout liability
established at the time of the Company&#8217;s Precision Healing merger. The current year revaluation of earnout liability below is a
result of a decrease in the estimated value of the earnout liability established at the time of the Applied Asset Purchase. The following
table sets forth a summary of the changes in fair value for the Level 3 contingent earnout considerations.</p>

<p id="xdx_898_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zyMX4K6dm2g4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zlfDaPl3CVAl" style="display: none">SCHEDULE
OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_495_20240101__20241231_zGPyhUGHNZDf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_zZYTfAj7HLie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; padding-left: 0pt">Balance at December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,823,001</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_zooAX9QzVyf6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 9pt; padding-left: 0pt">Change in fair value of earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,938,451</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability_zNjJ5pGNlySg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 9pt; padding-left: 0pt">Revaluation of earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(51,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements_zETuDA62VB44" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt">Settlements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,085,549</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_zbXliTDqnde7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">748,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zR31WoaaVx26" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zXVrVoI0j0v" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_865_zQLkHdchx9E3">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Income taxes are accounted for under the asset and
liability method, whereby deferred income taxes are recorded for temporary differences between financial statement carrying amounts and
the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years
in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all the
deferred tax asset will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zW7kGy8BeOM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_861_z2uC0X764h8d">Share-based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for share-based compensation
to employees and nonemployees in accordance with ASC Topic 718, Compensation &#8211; Stock Compensation. Share-based compensation is
measured at the grant date, based on the fair value of the award, and is recognized as expense over the stipulated vesting period, if
any. The Company estimates the fair value of share-based payments using the Black-Scholes option-pricing model for common stock options
and warrants, and the closing price of the Company&#8217;s common stock for grants of common stock, including restricted stock awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zsaYDcSy2eR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86E_zmgxSQsBIQN5">Research and Development Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development (&#8220;R&amp;D&#8221;)
expenses consist of personnel-related expenses, including salaries, share-based compensation and benefits for all personnel directly
engaged in R&amp;D activities, contracted services, materials, prototype expenses and allocated overhead, which is comprised of compensation
and benefits, lease expense and other facilities-related costs. R&amp;D expenses include costs related to enhancements to the Company&#8217;s
currently available products and additional investments in the product and platform development pipeline. The Company expenses R&amp;D
costs as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84A_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_z7hRzsnmClZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_863_z1yk2PchwuZ1">Recently Adopted Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments - Credit Losses (Topic
326). This update amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate
credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The Company
adopted the new guidance effective January 1, 2023. The adoption did not have a material impact on the Company&#8217;s consolidated financial
position, results of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, FASB issued ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;), which requires disclosure of incremental
segment information on an annual and interim basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and
interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company adopted the new guidance
effective December 31, 2024. The adoption did not have a material impact on the Company&#8217;s consolidated financial position, results
of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3IibpPc84ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_z4TJcBV8RiWa">Recently Issued Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, FASB issued ASU 2023-09, Income
Taxes (Topic 740): Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;), which expands the disclosure required for income
taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the effect of this pronouncement on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2024, FASB issued ASU 2024-03, Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,
which requires new disclosures providing further detail of a company&#8217;s income statement expense line items. ASU 2024-03 is effective
for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is
permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently Adopted Accounting Pronouncements [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.2.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483530/326-20-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479366/326-20-35-8A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3D<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479175/326-30-30-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3D<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 13A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-13A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-4A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-7A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWXU0FDCQDwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the shares of common
stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the years ended December&#160;31,
2024 and 2023 as such shares would have had an anti-dilutive effect:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zf7w48RRD9A9" style="display: none">SCHEDULE
OF COMPUTATION OF DILUTED NET LOSS PER SHARE</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20240101__20241231_z2Dd1IDQxPbb" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_zfZm4fFZ5OOc" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zDvw2srqeA2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 0pt"><span style="font-size: 10pt">Stock options<sup id="xdx_F4C_zmB7sEMtIBwj">(a)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">31,013</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">93,892</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKD4QRq4eUl3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt"><span style="font-size: 10pt">Warrants<sup id="xdx_F48_zFdIWwfer048">(b)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,725</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zsbhPOlzXXF3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Unvested restricted stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202,787</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,211</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z6ObFpoJjSwj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202,787</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">144,211</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td id="xdx_F0E_zLw243GCkSl4" style="width: 0.25in">(a)</td><td id="xdx_F1D_zQ2VZuA9Ai1g">Shares underlying stock options assumed pursuant to the merger agreement
                                            with Precision Healing, Inc. (&#8220;Precision Healing&#8221;) in April 2022.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td id="xdx_F0F_zRE6wyIXY6d7" style="width: 0.25in">(b)</td><td id="xdx_F1E_zt5c7r2IXmL5">Shares underlying warrants assumed pursuant to the merger agreement
                                            with Precision Healing in April 2022.</td></tr></table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zydaPT1G4ZKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue streams from product sales and royalties
are summarized below for the years ended December&#160;31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z9Njba69Dhx4" style="display: none">SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20241231_z9BTxnEdZ442" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20230101__20231231_ztPw1I3NSwZa" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SoftTissueRepairProductsMember_zneCjYnaFoe7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 0pt">Soft tissue repair products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">76,125,012</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">54,836,410</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--BoneFusionProductsMember_zl6rE4Y3bJA6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Bone fusion products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,547,413</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,952,432</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zaDbFNK5EtN" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0590">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">201,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zKdc18lqmb9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total Net Revenue</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">86,672,425</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">64,989,842</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zqRliQNnUB1d" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zQKNzkO8FU9g" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Useful</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Life</b></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zjuto5QPegHf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zwcZH3iFbWbi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVlyBmKFNc29" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; padding-left: 0pt">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: center; padding-left: 0pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zpfitIsrj9Ak" title="Useful Life">3</span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zuDth0z9viv1" title="Useful Life">5</span> years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">295,963</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">194,788</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zrthfTCFxxhk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Office equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zs8CneFLDiB6" title="Useful Life">3</span>-<span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_z2kIMVBvCVw2" title="Useful Life">7</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">216,491</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">201,785</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zJ56vuocB1Ih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zeQhlRy083Za" title="Useful Life">5</span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zbWxC8rWUL7c" title="Useful Life">10</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">346,508</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304,338</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zLVSo8nF94k1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_z3ksmxolhQ3c" title="Useful Life">2</span>-<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zfSPGPNrx4ye" title="Useful Life">5</span> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">181,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134,170</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zkzxzTMzV3c3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Internal use software</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 0pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_ztngxXxxLfR" title="Useful life">5</span> years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0662">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,618,999</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz6Up_znA7HeNhBpG8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,040,930</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,454,080</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz6Up_z5x7dqCdRrr7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(608,613</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,196,124</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz6Up_zph1Y9kIAJq5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">432,317</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,257,956</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zyMX4K6dm2g4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zlfDaPl3CVAl" style="display: none">SCHEDULE
OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_495_20240101__20241231_zGPyhUGHNZDf" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_zZYTfAj7HLie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; padding-left: 0pt">Balance at December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,823,001</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_zooAX9QzVyf6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 9pt; padding-left: 0pt">Change in fair value of earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,938,451</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability_zNjJ5pGNlySg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 9pt; padding-left: 0pt">Revaluation of earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(51,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements_zETuDA62VB44" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt">Settlements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,085,549</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_zbXliTDqnde7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">748,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>APPLIED ASSET PURCHASE (Tables) - Applied Asset Purchase Agreement [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">SCHEDULE OF ASSET PURCHASE CONSIDERATIONS</a></td>
<td class="text"><p id="xdx_898_eus-gaap--AssetAcquisitionTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zxJytX6QcDnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total purchase consideration for the Applied
Asset Purchase as determined by the Company was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_ztC3meezwqk9" style="display: none">SCHEDULE
OF ASSET PURCHASE CONSIDERATIONS</span></span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 92%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consideration</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_z2dmqgq7z4L2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Dollar Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetAcquisitionConsiderationTransferredOtherAssets_maAACTzk9b_zza98cZNX7N" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 0pt">Cash Closing Consideration</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9,750,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_maAACTzk9b_zwYdNodpNAke" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Fair value of Stock Closing Consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zXDdhJapU3eg" title="Equity Shares">73,809</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,089,645</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments_maAACTzk9b_zw7h3kxU9WI3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Fair value of Installment Payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,040,808</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AssetAcquisitionConsiderationTransferredCashPaidForInventory_maAACTzk9b_zkrHiYSUkVof" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Cash paid for inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,007</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments_maAACTzk9b_zPlGwUIoSCx1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Fair value of Petito Services Agreement defined payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">825,834</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_maAACTzk9b_zN89THawGPna" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Fair value of Petito Services Agreement contingent consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">893,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_maAACTzk9b_zktigTQotIah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Direct transaction costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">162,743</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferred_iT_mtAACTzk9b_znTrnBD5j554" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 9pt; padding-left: 0pt">Total purchase consideration</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">16,792,037</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zRoZpPa3rsZ2" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z7wHAGAOoyk" style="display: none">SCHEDULE
OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Description</b></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231__us-gaap--BusinessAcquisitionAxis__custom--AppliedAssetPurchaseAgreementMember_zc9DgPk03U69" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_maBCRIAz5eD_zp9BIsLjBOi7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; padding-left: 0pt">Inventory</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">30,007</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment_iI_maBCRIAz5eD_z3Yc4pd783Ae" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,062</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty_iI_maBCRIAz5eD_zN0Sy7fTNyt3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Intellectual property</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">16,728,968</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iTI_mtBCRIAz5eD_zuI1kuvDP4p" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 9pt; padding-left: 0pt">Net assets acquired</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">16,792,037</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLES, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfGoodwillTextBlock_zTGXs8g4Fheh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The changes in the carrying amount of the Company&#8217;s
goodwill were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zI1uAHA97Hv3" style="display: none">SCHEDULE
OF CHANGES IN  CARRYING AMOUNT OF  GOODWILL</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_zKF7tAVcgPsd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43B_c20230101__20231231_eus-gaap--Goodwill_iS_zvp0tyZIiUJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; padding-left: 0pt">Balance as of December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,601,781</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GoodwillAcquiredDuringPeriod_zPUBBkKxaUY5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt">Acquisitions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20240101__20241231_eus-gaap--Goodwill_iS_zUmw9polaCCc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,601,781</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20240101__20241231_eus-gaap--Goodwill_iS_zpjNYIFHzTXg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,601,781</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--GoodwillAcquiredDuringPeriod_zUREqh5ZTQYg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 0pt">Acquisitions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0798">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20240101__20241231_eus-gaap--Goodwill_iE_zVslytut81yk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,601,781</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20240101__20241231_eus-gaap--Goodwill_iE_zC3jJ0CYOgQ3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,601,781</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zKnw0olVTIA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying values of the Company&#8217;s intangible
assets were as follows for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zSbQCCzgJQoe" style="display: none">SCHEDULE
OF CARRYING VALUE OF INTANGIBLE ASSETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated <br/>Amortization</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated <br/>Amortization</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Amortizable Intangible Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 22%; text-align: left; text-indent: 9pt; padding-left: 0pt">Patents and Other IP</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzacLpJoCB4f" style="width: 10%; text-align: right">38,009,240</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z34r0mrsgYCd" style="width: 10%; text-align: right">(5,008,856</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGD09bO2Heu8" style="width: 10%; text-align: right">33,000,384</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zU3Xvw5YNoJ4" style="width: 10%; text-align: right">38,570,549</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znSiCMFdFlF4" style="width: 10%; text-align: right">(3,181,186</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z9DMfstX9qC1" style="width: 10%; text-align: right">35,389,363</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Customer relationships and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_z0Q7LkAuznS4" style="text-align: right">7,948,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zboaEJaqV0w2" style="text-align: right">(3,007,118</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zTRhoMuzUnFb" style="text-align: right">4,941,181</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zUufLULozobf" style="text-align: right">7,947,332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zxdi5Ww7uDTg" style="text-align: right">(1,861,887</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zK66QEFscaT5" style="text-align: right">6,085,445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt">Product Licenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zIplH3ty2SOe" style="border-bottom: Black 1pt solid; text-align: right" title="Cost">4,793,879</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zGkzAqnxsnfa" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(1,728,668</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zeLKiobF3Wui" style="border-bottom: Black 1pt solid; text-align: right" title="Net">3,065,211</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zZszQyhQUOU4" style="border-bottom: Black 1pt solid; text-align: right" title="Cost">4,793,879</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zE5FhTtwgnV" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(1,342,626</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zKQICmYYa6Ek" style="border-bottom: Black 1pt solid; text-align: right" title="Net">3,451,253</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zTACvoj38QJd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">50,751,418</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z6bzJ0qtxY25" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(9,744,642</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zXE2wVpemuB2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">41,006,776</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z0U8AtRQIQoj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">51,311,760</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zKA4Nl2Kmlci" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(6,385,699</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z4lHAjeII1H" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">44,926,061</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">SCHEDULE OF FUTURE AMORTIZATION EXPENSE</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zr0bTaT8mq06" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zKy7TUmt7uU5" style="display: none">SCHEDULE
OF FUTURE AMORTIZATION EXPENSE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_498_20241231_zrea05s5Vkt1" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz6Rp_zPVZR6GPUrB6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; text-align: left; padding-left: 0pt">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,894,221</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz6Rp_zqfIUhTZ1ei5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,876,965</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz6Rp_z1z70AMge649" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,763,113</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz6Rp_zsA2WMrUjKS1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,722,054</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz6Rp_zdTCe818pr8e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,722,054</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANz6Rp_zb2hTvQcaMx2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22,028,369</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz6Rp_z3mOAudjHYph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">41,006,776</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS IN EQUITY SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsAbstract', window );"><strong>Schedule of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">SCHEDULE OF INVESTMENTS</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--EquityMethodInvestmentsTextBlock_zMAOGUcywrpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company&#8217;s
investments for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B1_zCcxAJwBrCR7" style="display: none">SCHEDULE
OF INVESTMENTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Economic Interest</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Carrying Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Economic Interest</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; padding-left: 0pt">Equity Method Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-left: 0pt">ChemoMouthpiece, LLC</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--EquityMethodInvestments_iI_c20241231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zcpoyufaA91d" style="width: 12%; text-align: right" title="Equity method investment">5,172,242</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20241231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zFILfgArJySa" style="width: 12%; text-align: right" title="Economic interest">6.59</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--EquityMethodInvestments_iI_c20231231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zTWjiExoXqZ2" style="width: 12%; text-align: right" title="Equity method investment"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20231231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zvaLSPsMIXFd" style="width: 12%; text-align: right" title="Economic interest"><span style="font-size: 10pt">	<span style="-sec-ix-hidden: xdx2ixbrl0904">-</span></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">SI Healthcare Technologies, LLC</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EquityMethodInvestments_iI_c20241231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zsKNjv2gy1n" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment">40,703</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20241231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zsacXtxDj3Vk" style="text-align: right" title="Economic interest">50.00</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EquityMethodInvestments_iI_c20231231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zyubXmNPqhuf" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment"><span style="-sec-ix-hidden: xdx2ixbrl0910">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20231231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zZSYDhwoUL77" style="text-align: right" title="Economic interest"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Total Equity Method Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--EquityMethodInvestments_iI_c20241231_z2mR1u00kUL9" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment">5,212,945</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--EquityMethodInvestments_iI_c20231231_zeTm9EaiIrS2" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; padding-left: 0pt">Cost Method Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Direct Dermatology, Inc.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember_zajuHWuZ0d86" style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember_zYF0psdqkmd2" style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Pixalere Healthcare Inc.</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zccDcGcAE01" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment">2,084,278</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zpkcWZajaP9" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment">2,084,278</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Total Cost Method Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231_zx4UnM7vPRyg" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment">3,084,278</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231_zMWJbmdCEJ8b" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment">3,084,278</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 12pt">Total Investments</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iI_c20241231_zYIgxxc9imw9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Investments">8,297,223</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iI_c20231231_zJIX2dufIDGk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Investments">3,084,278</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT</a></td>
<td class="text"><p id="xdx_894_eus-gaap--GainLossOnInvestmentsTextBlock_zPv5lPsfHCz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company&#8217;s
share of losses from equity method investments reflected in the Company&#8217;s Consolidated Statements of Operations for the periods
presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zHAhEl1usZHf" style="display: none">SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zehAYE0OgDLd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zjVewtCWnOHg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year
                                            Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December
                                            31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; padding-left: 0pt">Investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromEquityMethodInvestments_hdei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zpUm7WViBV5g" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: left; padding-left: 0pt">ChemoMouthpiece, LLC</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(105,710</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0935">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromEquityMethodInvestments_hdei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zLNnrROfrmJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">SI Healthcare Technologies, LLC</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,703</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0938">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromEquityMethodInvestments_zULRmngvImI6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 12pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(90,007</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromEquityMethodInvestments_zkslVPI9vICb" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 12pt">Loss from equity method investment</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(90,007</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0944">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF OPERATING LEASE LIABILITY</a></td>
<td class="text"><p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z6SrZdDpjvZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Maturity of Operating Lease Liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B2_zVpEBCFbTnD9" style="display: none">SCHEDULE OF OPERATING LEASE LIABILITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zoNBxnuX22O6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,<br/>
    2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzW5D_zjc5xaOe24Ce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; text-align: left; padding-left: 0pt">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">466,800</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzW5D_zpdsmcKdg2H2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,369</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzW5D_zX1Mw46DoAX5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">291,220</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzW5D_z6CxGiouOPN8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">295,689</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzW5D_zmtdZPUWLlMd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,158</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzW5D_z6aPHovppDxa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">303,891</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzW5D_zujVdPcAhTD3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,958,127</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zh2CjtCVwjI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Less imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(362,389</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_z36I6Zs5X84b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Present Value of Lease Liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,595,738</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zO1XIQtOKK91" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Operating lease liabilities &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">358,687</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zWHH6k26Z8ol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Operating lease liabilities &#8211; long-term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,237,051</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">SCHEDULE OF LONG-TERM DEBT</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfDebtTableTextBlock_zIsg681yAnZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the components of the Company&#8217;s outstanding debt for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B6_zmrsJBFytyAk" style="display: none">SCHEDULE
OF LONG-TERM DEBT</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_zNFyPgSXxZgf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_z9l8Zt0EA1H7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--CRGTermLoanMember_zeqhzEqyaw2e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">CRG Term Loan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">30,500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--PaidInKindInterestMember_zUfuoig8Q83b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Paid-in-kind interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">838,965</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--BackendFeeMember_z5aVyIYzPYHd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Back-end fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">358,086</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1061">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--CadenceTermLoanMember_zaVWB1qZMKy8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cadence Term Loan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,750,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzYHB_zZEHdl4obr0k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,697,051</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,750,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredFinanceCostsNet_iNI_di_msLTDzYHB_zk74bRzhcld3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: unamortized debt issuance costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,007,761</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(56,520</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebt_iTI_mtLTDzYHB_zv5L08O0fdk5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt, net of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,689,290</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,693,480</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LongTermDebtCurrent_iI_ztnJ6x50cnlj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Current portion of debt</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">580,357</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LongTermDebtNoncurrent_iI_zklisHAOfnf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Long-term debt, net of current portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30,689,290</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,113,123</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">SCHEDULE OF MATURITIES OUTSTANDING</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zgsCXX4dXIna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the aggregate maturities of the Company&#8217;s outstanding debt as of December&#160;31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zEexwUetOxof" style="display: none">SCHEDULE
OF MATURITIES OUTSTANDING</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zxaa3sEEE7y8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maDICAzHTB_z4EjHutIBkMa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1083">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maDICAzHTB_zss0VSJhmmm9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1085">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maDICAzHTB_zosy1ThNwxbc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1087">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maDICAzHTB_zTKab2wyicN7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_maDICAzHTB_zJCOJs4T6aTk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2029</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">31,697,051</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_iI_maDICAzHTB_z4VsxxZuRpOd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1093">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DebtInstrumentCarryingAmount_iTI_mtDICAzHTB_zJlKfsFP7l6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total debt</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">31,697,051</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">SUMMARY OF RESTRICTED STOCK ACTIVITY</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z6qxkf0tNoYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a summary of restricted stock activity for the year ended December&#160;31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z5VFOABi92Zf" style="display: none">SUMMARY
OF RESTRICTED STOCK ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2024</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant Date Fair Value</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Nonvested at beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231_z5JCnPbMX14f" style="width: 16%; text-align: right" title="Non-vested shares, beginning">144,211</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20241231_zc17mwwoYVK3" style="width: 16%; text-align: right" title="Weighted average grant date fair value, beginning">34.07</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231_zHscIUeYGuuk" style="text-align: right" title="Granted">192,783</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zZJy94IlE743" style="text-align: right" title="Weighted average grant date fair value, granted">35.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231_zBmNK5U67uGd" style="text-align: right" title="Vested">(105,875</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zlU9B1uuFNVe" style="text-align: right" title="Weighted average grant date fair value, vested">34.19</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231_zTROEIFXHzi7" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited">(28,332</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231_zyRmcP01KWC7" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, forfeited">35.31</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231_zP8FFn04tnwd" style="border-bottom: Black 2.5pt double; text-align: right" title="Non-vested shares, ending">202,787</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20241231_z0QSPV0TdEpk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending">34.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION ACTIVITY</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuHi6wwNrXq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the status of outstanding stock options at December&#160;31, 2024 and changes during the year then ended is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_zE4SbhyEYz85" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2024</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract Life</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding at beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zwAgg9EoMw7d" style="width: 12%; text-align: right" title="Options outstanding, beginning">93,892</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zVhLNEojQcmk" style="width: 12%; text-align: right" title="Weighted average exercise price outstanding, beginning">10.22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted or assumed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z8zVkBqcLNB3" style="text-align: right" title="Options, Granted or assumed"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zAqi3k5Q8F38" style="text-align: right" title="Weighted average exercise price, Granted or assumed"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231_zBCSDARL6fZ5" style="text-align: right" title="Options, Exercised">(62,879</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zfLKWGHwa5fk" style="text-align: right" title="Weighted average exercise price, Exercised">10.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zexCYAjPo6xb" style="text-align: right" title="Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zpi1qmxtYm18" style="text-align: right" title="Weighted average exercise price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1317">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20240101__20241231_zYGDoAXqFEoc" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1319">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zCLZsMlDuWRd" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1321">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_znAeFCWTCglb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending">31,013</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zzP5xdnTMCJg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price outstanding, ending">10.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_znfZyXZKxqqb" title="Weighted average remaining contract life outstanding">5.8</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp2d_c20241231_zkHVSzUHGD37" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, ending">701,975.3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zz8wTmwNLtc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, ending">31,013</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zOCGiwedUe12" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price exercisable, ending">10.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_znRXA31fwum8" title="Weighted average remaining contract life exercisable">5.8</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp2d_c20241231_z5IkBBHzKxu8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, exercisable">701,975.3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zM6bs8p5qup9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the status of outstanding warrants to purchase common stock at December&#160;31, 2024 and changes during the year then ended
is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z14rStEIKokj" style="display: none">SCHEDULE
OF WARRANTS TO PURCHASE COMMON STOCK</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2024</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract Life</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding at beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231_zqetGtIzzIk5" style="width: 12%; text-align: right" title="Number of warrants outstanding, beginning">16,725</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zfXL4f4sqUm4" style="width: 12%; text-align: right" title="Weighted average exercise price outstanding, beginning">10.80</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted or assumed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231_z69vSccbr4Yh" style="text-align: right" title="Number of warrants, granted"><span style="-sec-ix-hidden: xdx2ixbrl1345">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20240101__20241231_zwwFylDLrnl1" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1347">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231_zKtUIXzWQ24d" style="text-align: right" title="Number of warrants, exercised">(16,725</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_c20240101__20241231_z2tIDvFibrQl" style="text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1351">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20240101__20241231_zIGqfTSyRcwg" style="text-align: right" title="Number of warrants, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice_c20240101__20241231_zOLXnJANg3M7" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1355">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20240101__20241231_zYGAHTGZfZvi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, expired"><span style="-sec-ix-hidden: xdx2ixbrl1357">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20240101__20241231_z5poFFZx1aHe" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, expired"><span style="-sec-ix-hidden: xdx2ixbrl1359">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231_zQx2MccL41C5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding, ending"><span style="-sec-ix-hidden: xdx2ixbrl1361">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zqUbQCKgYu72" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price outstanding, ending"><span style="-sec-ix-hidden: xdx2ixbrl1363">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_c20240101__20241231_z75lDqKTVcl7" title="Weighted average remaining contract life outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20240101__20241231_zsFFs2LbWIvf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants exercisable, ending"><span style="-sec-ix-hidden: xdx2ixbrl1367">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zjxITHyaQFs6" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, exercisable, ending"><span style="-sec-ix-hidden: xdx2ixbrl1369">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_c20240101__20241231_zllBN8SiQ0I3" title="Weighted average remaining contract life exercisable, ending"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zDexFok1wvv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the deferred income tax assets and liabilities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zO4X4e74S19e" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zXqFpu9ozH0h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_z0YMB7w7Jg67" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzdlW_zV5wMbphzigk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">12,907,965</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">12,467,570</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzdlW_zmCHALkULCMl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,006,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,119,193</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzdlW_zm7Fd6nPHNvf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">789,373</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">711,598</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzdlW_zpqRpfmiqg91" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">528,148</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxAssetsLeaseLiability_iI_maDTAGzdlW_zebjHgLkZGt" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">389,882</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">512,668</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_iI_maDTAGzdlW_zfa1QhIUKbt9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Contingent liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">221,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">221,028</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsAcquistionLiability_iI_maDTAGzdlW_zqJnSsTsgC0d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Acquisition liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176,629</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTAGzdlW_zSbk2Pu5oAtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Bad debt and other reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">287,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129,924</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsInventory_iI_maDTAGzdlW_zXfhbudQYQph" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Inventory reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,176</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzdlW_z79OxiHDkbYa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other temporary differences</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,049,365</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">203,340</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzdlW_maDTANzNjR_zLoRnjRL8Er5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,902,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,179,274</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxLiabilitiesDepreciationAndAmortization_iNI_di_msDTANzNjR_z73LmKXbJo68" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,683,259</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,180,688</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_msDTANzNjR_z0d3cnWqMnp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Right of Use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(353,763</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(487,402</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_msDTANzNjR_zYFFete0AkP1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1434">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(424,423</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxLiabilitiesContingentLiability_iNI_di_msDTANzNjR_zpkI1SPUqglg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Contingent liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(38,308</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(130,802</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxLiabilitiesOtherTemporaryDifferences_iNI_di_msDTANzNjR_zreAXdMSzRvb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(294,608</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(166,712</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzNjR_zMVXwnPkmLI2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,532,298</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,789,247</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzNjR_zRS3W84wCb1g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1446">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1447">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF INCOME TAX EXPENSE (BENEFIT)</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zR9sd5vFkOF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_ziiFgjcbV2wl" style="display: none">SCHEDULE
OF INCOME TAX EXPENSE (BENEFIT)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zdUv5yhISozk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zeFeZkvncMS4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_maITEBzW13_zpcDyM73dcw7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Expected federal income tax benefit</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(2,019,060</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(903,220</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_maITEBzW13_zWii2kQ3ybA4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State and local taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(338,138</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(226,714</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationFairValueAdjustments_iN_di_maITEBzW13_zgMNASbh1fuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(497,373</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(819,270</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_iN_di_maITEBzW13_zkh70zPU45Sj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(237,838</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(557,168</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_iN_di_maITEBzW13_zb6ZtLsiEPNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199,857</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,765</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration_iN_di_maITEBzW13_zo5BoJh5RUWa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NOL carryover adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,806</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,148,128</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxReconciliationIncomeTaxExpenseIntangibles_iN_di_maITEBzW13_zKyrGAhfc6s6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1471">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(720,407</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps_iN_di_maITEBzW13_zJ9hso5GDaU9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other true ups</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,343</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(230,474</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_iN_di_maITEBzW13_zeNrwgUE2PZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in tax rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,732</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">673,449</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_maITEBzW13_zW1lPccamP2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,743,051</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,813,167</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzW13_zCHKSOxvgkM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">48,380</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1484">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z5lKpvEEPshb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table reflects results of operations including significant segment expenses that are regularly provided to the CODM for
the Company&#8217;s reportable segments and Segment Adjusted EBITDA for the periods indicated below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BF_zeVqkUwBWXb4" style="display: none">SCHEDULE
OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zLIukRbgfhrf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zkIysJvU6A6a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zRBwLO7WudVg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_z5jVy3pkifS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zXfWfYRJGQm7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zKvlVpSKttwl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zmmvrvDfHeIf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">86,672,425</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1505">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">86,672,425</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">64,987,112</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">2,730</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">64,989,842</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GrossProfit_pp0p0_zqxfeJsKF5k5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,532,524</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1512">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,532,524</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,143,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,235</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,137,156</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pp0p0_z5CtTRvdihJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,673,642</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,886,221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,559,863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,826,852</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,167,901</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,994,753</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_zYg7XUlNl2A2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,828,663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,874,699</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,703,362</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">902,782</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,229,643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,132,425</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DepreciationAndAmortization_i01_pp0p0_zx27jzi1oRNf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,785,829</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,137,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,923,224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,046,859</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,628,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,675,026</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueAdjustment_zj2C1Ekwg4Fi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,451</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,924,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,938,451</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,298,336</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,151,559</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,449,895</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--InterestExpenseOther_i01_pp0p0_zYKipiwKsQsf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,196,424</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1547">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,196,424</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">224,749</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1550">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">224,749</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProfitLoss_pp0p0_zrla761eanxa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,937,583</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,974,315</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,911,898</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">440,485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,880,387</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,439,902</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--EarningsBeforeInterestTaxesDepreciationAndAmortization_pp0p0_z7OnNybafWI5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Segment Adjusted EBITDA</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,148,722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,457,415</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,691,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,289,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,162,387</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">127,247</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zqzR2pBSdqxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a reconciliation of net income (loss) to Segment Adjusted EBITDA for the Company&#8217;s reportable segments
for the periods indicated below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zALkQpjlbLGj" style="display: none">SCHEDULE
OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zClfXTIsfWx9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_z2XqVdMcKLB6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zVNTBgAcyH0h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zSO6NUbYJ963" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zZGSpCyt7khd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_z4lguIpRj1df" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Sanara Surgical</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">THP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProfitLoss_pp0p0_zezQ8oQ9pkV2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net Income (Loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(1,937,583</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(7,974,315</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(9,911,898</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">440,485</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(4,880,387</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(4,439,902</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Adjustments:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InterestExpense_zAkGGoh0AeZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,128,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1577">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,128,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475,783</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1580">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475,783</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestIncomeOther_iN_di_zzIY6DT7ud64" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,978</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1584">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,978</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1586">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1587">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1588">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DepreciationAndAmortization_i01_pp0p0_zHBp3n4G8a86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation and amortization <sup id="xdx_F4C_z1FJsCFRwQfh">(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,785,829</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,137,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,923,224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,046,859</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,628,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,675,026</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_zPTZHXKFCrW8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Noncash share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,969,008</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,107,253</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,201,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,392</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,442,722</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueAdjustment_zCl9HrZ6nePb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of earnout liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,451</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,924,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,938,451</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,298,336</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,151,559</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,449,895</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromEquityMethodInvestments_iN_di_z3253TAfteya" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share of losses from equity method investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1612">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1614">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1615">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1616">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ExecutiveSeparationCosts_z5MSPLDWS9Tj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive separation costs <sup id="xdx_F4E_zRPyIqyrxbCd">(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">964,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1619">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">964,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1621">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1622">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1623">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_znqTCNw4Wcpk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition costs <sup id="xdx_F44_zbrOTqNsjIR3">(3)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">185,029</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,165,260</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,350,289</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">423,513</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1629">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">423,513</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--EarningsBeforeInterestTaxesDepreciationAndAmortization_pp0p0_z6Q6PSNNOfwh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Segment Adjusted EBITDA</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,148,722</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,457,415</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,691,307</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,289,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,162,387</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">127,247</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F01_z0uipYDTBTz6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zWCjaXeLHmF2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            a $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--PropertyAndEquipmentWriteOff_iI_c20241231_zJC0st7jzVq4" title="Property and equipment write off">506,836</span> non-cash charge during the fourth quarter of 2024 to write-off the remaining net
                                            book value of certain THP internal use software assets.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0F_zwCBMaXL2AO" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_z6XS7fBBbkn5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231_zJKt3Xeqlclc" title="Share based compensation related to executive separation costs">328,795</span> of share-based compensation related to executive separation costs for the twelve
                                            months ended December&#160;31, 2024.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0E_zMpKyZU4yTwh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F16_zC2lTmDvtW5h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition
                                            costs include legal, tax and accounting services related to prospective acquisitions.</span></td></tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND BACKGROUND (Details Narrative) - Integer<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">31,013<span></span>
</td>
<td class="nump">93,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SMTI_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">202,787<span></span>
</td>
<td class="nump">144,211<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Shares underlying stock options assumed pursuant to the merger agreement
                                            with Precision Healing, Inc. (&#8220;Precision Healing&#8221;) in April 2022.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Shares underlying warrants assumed pursuant to the merger agreement
                                            with Precision Healing in April 2022.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SMTI_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SMTI_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Net Revenue</a></td>
<td class="nump">$ 86,672,425<span></span>
</td>
<td class="nump">$ 64,989,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=SMTI_SoftTissueRepairProductsMember', window );">Soft Tissue Repair Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Net Revenue</a></td>
<td class="nump">76,125,012<span></span>
</td>
<td class="nump">54,836,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=SMTI_BoneFusionProductsMember', window );">Bone Fusion Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Net Revenue</a></td>
<td class="nump">10,547,413<span></span>
</td>
<td class="nump">9,952,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Net Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 201,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=SMTI_SoftTissueRepairProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=SMTI_SoftTissueRepairProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=SMTI_BoneFusionProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=SMTI_BoneFusionProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,040,930<span></span>
</td>
<td class="nump">$ 2,454,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(608,613)<span></span>
</td>
<td class="num">(1,196,124)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 432,317<span></span>
</td>
<td class="nump">1,257,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 295,963<span></span>
</td>
<td class="nump">194,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 216,491<span></span>
</td>
<td class="nump">201,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 346,508<span></span>
</td>
<td class="nump">304,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 181,968<span></span>
</td>
<td class="nump">134,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SMTI_InternalUseSoftwareMember', window );">Internal Use Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,618,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SMTI_InternalUseSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=SMTI_InternalUseSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance at December 31, 2023</a></td>
<td class="nump">$ 3,823,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of earnout liabilities</a></td>
<td class="num">(1,938,451)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability', window );">Revaluation of earnout liability</a></td>
<td class="num">(51,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements', window );">Settlements</a></td>
<td class="num">(1,085,549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance at December 31, 2024</a></td>
<td class="nump">$ 748,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration arrangements change in amount of contingent consideration revaluation of earnout liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration arrangements change in amount of contingent consideration settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">$ 624,448<span></span>
</td>
<td class="nump">$ 202,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses</a></td>
<td class="nump">1,173,441<span></span>
</td>
<td class="nump">528,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Allowance for customer rebates and deductions</a></td>
<td class="nump">4,897<span></span>
</td>
<td class="nump">3,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory obsolescence expense</a></td>
<td class="nump">521,757<span></span>
</td>
<td class="nump">406,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Allowance for obsolete and slow-moving inventory</a></td>
<td class="nump">534,549<span></span>
</td>
<td class="nump">446,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 1,031,487<span></span>
</td>
<td class="nump">456,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Software, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SMTI_InternalUseSoftwareMember', window );">Internal Use Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 506,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 12,408,819<span></span>
</td>
<td class="nump">$ 8,474,965<span></span>
</td>
<td class="nump">$ 6,805,761<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SMTI_InternalUseSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=SMTI_InternalUseSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ASSET PURCHASE CONSIDERATIONS (Details) - Applied Asset Purchase Agreement [Member]<br></strong></div></th>
<th class="th">
<div>Aug. 01, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets', window );">Cash Closing Consideration</a></td>
<td class="nump">$ 9,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Fair value of Stock Closing Consideration</a></td>
<td class="nump">$ 3,089,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Equity Shares | shares</a></td>
<td class="nump">73,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments', window );">Fair value of Installment Payments</a></td>
<td class="nump">$ 2,040,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory', window );">Cash paid for inventory</a></td>
<td class="nump">30,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments', window );">Fair value of Petito Services Agreement defined payments</a></td>
<td class="nump">825,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Fair value of Petito Services Agreement contingent consideration</a></td>
<td class="nump">893,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Direct transaction costs</a></td>
<td class="nump">162,743<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total purchase consideration</a></td>
<td class="nump">$ 16,792,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred cash paid for inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred fair value of installment payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred fair value of petito services defined payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible and intangible assets included as part of consideration transferred in asset acquisition, classified as other. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED (Details) - Applied Asset Purchase Agreement [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">$ 30,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment', window );">Equipment</a></td>
<td class="nump">33,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty', window );">Intellectual property</a></td>
<td class="nump">16,728,968<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">$ 16,792,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=SMTI_AppliedAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=SMTI_AppliedAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>APPLIED ASSET PURCHASE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_PurchaseAgreementDescription', window );">Purchase agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of
the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain
products the Owner develops or co-develops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first
$50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%)
on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv)
$500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in
cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described
in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember', window );">Applied Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Assets purchase price</a></td>
<td class="nump">$ 15,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets', window );">Cash consideration paid</a></td>
<td class="nump">$ 9,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Shares issued as consideration</a></td>
<td class="nump">73,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Value of shares issued as consideration</a></td>
<td class="nump">$ 3,089,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLoansPayable', window );">Installment payable</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Payment of installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_EarnoutPayable', window );">Earnout payable</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember', window );">Applied Asset Purchase Agreement [Member] | Cash Closing Consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets', window );">Cash consideration paid</a></td>
<td class="nump">$ 9,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember', window );">Applied Asset Purchase Agreement [Member] | Stock Closing Consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Shares issued as consideration</a></td>
<td class="nump">73,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Value of shares issued as consideration</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_EarnoutPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_EarnoutPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_PurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_PurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible and intangible assets included as part of consideration transferred in asset acquisition, classified as other. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term loans payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=SMTI_CashClosingConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=SMTI_CashClosingConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=SMTI_StockClosingConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=SMTI_StockClosingConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE LOAN RECEIVABLE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 01, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableModificationsLineItems', window );"><strong>Financing Receivable, Modified [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Loan receivable</a></td>
<td class="nump">$ 1,101,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableModificationsLineItems', window );"><strong>Financing Receivable, Modified [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,079,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansHeldForSaleMaturityDate', window );">Extended maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansReceivableBasisSpreadOnVariableRate', window );">Accruing interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Loan receivable</a></td>
<td class="nump">$ 1,101,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member] | Extended Maturity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableModificationsLineItems', window );"><strong>Financing Receivable, Modified [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansHeldForSaleMaturityDate', window );">Extended maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 15,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableModificationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-34<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 33<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-33<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481933/310-10-55-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-42<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableModificationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansHeldForSaleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of loan held for sale, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansHeldForSaleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableBasisSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage added to reference rate used to compute variable rate on loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableBasisSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanRestructuringModificationAxis=us-gaap_ExtendedMaturityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanRestructuringModificationAxis=us-gaap_ExtendedMaturityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance</a></td>
<td class="nump">$ 3,601,781<span></span>
</td>
<td class="nump">$ 3,601,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance</a></td>
<td class="nump">$ 3,601,781<span></span>
</td>
<td class="nump">$ 3,601,781<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">$ 41,006,776<span></span>
</td>
<td class="nump">$ 44,926,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Cost</a></td>
<td class="nump">38,009,240<span></span>
</td>
<td class="nump">38,570,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(5,008,856)<span></span>
</td>
<td class="num">(3,181,186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">33,000,384<span></span>
</td>
<td class="nump">35,389,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=SMTI_CustomerRelationshipsAndOtherMember', window );">Customer Relationships and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Cost</a></td>
<td class="nump">7,948,299<span></span>
</td>
<td class="nump">7,947,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(3,007,118)<span></span>
</td>
<td class="num">(1,861,887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">4,941,181<span></span>
</td>
<td class="nump">6,085,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Cost</a></td>
<td class="nump">4,793,879<span></span>
</td>
<td class="nump">4,793,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,728,668)<span></span>
</td>
<td class="num">(1,342,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">3,065,211<span></span>
</td>
<td class="nump">3,451,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=SMTI_AmortizableIntangibleAssetsMember', window );">Amortizable Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Cost</a></td>
<td class="nump">50,751,418<span></span>
</td>
<td class="nump">51,311,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(9,744,642)<span></span>
</td>
<td class="num">(6,385,699)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">$ 41,006,776<span></span>
</td>
<td class="nump">$ 44,926,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=SMTI_CustomerRelationshipsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=SMTI_CustomerRelationshipsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=SMTI_AmortizableIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=SMTI_AmortizableIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FUTURE AMORTIZATION EXPENSE (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 3,894,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">3,876,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">3,763,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">3,722,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">3,722,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">22,028,369<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 41,006,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLES, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">14 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 3,891,737<span></span>
</td>
<td class="nump">$ 3,218,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF INVESTMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="nump">$ 5,212,945<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestmentsAndSecuritiesAtCost', window );">Cost method investment</a></td>
<td class="nump">3,084,278<span></span>
</td>
<td class="nump">3,084,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total Investments</a></td>
<td class="nump">8,297,223<span></span>
</td>
<td class="nump">3,084,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SMTI_ChemoMouthPieceLLCMember', window );">ChemoMouthpiece, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="nump">$ 5,172,242<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_EquityMethodInvestmentsEconomicInterest', window );">Economic interest</a></td>
<td class="nump">6.59%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SMTI_SIHealthcareTechnologiesLLCMember', window );">SI Healthcare Technologies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="nump">$ 40,703<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_EquityMethodInvestmentsEconomicInterest', window );">Economic interest</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SMTI_DirectDermatologyIncMember', window );">Direct Dermatology Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestmentsAndSecuritiesAtCost', window );">Cost method investment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SMTI_PixalereHealthcareIncMember', window );">Pixalere Healthcare Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestmentsAndSecuritiesAtCost', window );">Cost method investment</a></td>
<td class="nump">$ 2,084,278<span></span>
</td>
<td class="nump">$ 2,084,278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_EquityMethodInvestmentsEconomicInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments Economic Interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_EquityMethodInvestmentsEconomicInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentsAndSecuritiesAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Includes other investments and securities that are not at fair value as of the balance sheet date and those that are not accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentsAndSecuritiesAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SMTI_ChemoMouthPieceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SMTI_ChemoMouthPieceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SMTI_SIHealthcareTechnologiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SMTI_SIHealthcareTechnologiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SMTI_DirectDermatologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SMTI_DirectDermatologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SMTI_PixalereHealthcareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SMTI_PixalereHealthcareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="num">$ (90,007)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SMTI_ChemoMouthPieceLLCMember', window );">ChemoMouthpiece, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="num">(105,710)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SMTI_SIHealthcareTechnologiesLLCMember', window );">SI Healthcare Technologies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">$ 15,703<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SMTI_ChemoMouthPieceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SMTI_ChemoMouthPieceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SMTI_SIHealthcareTechnologiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SMTI_SIHealthcareTechnologiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS IN EQUITY SECURITIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,297,223<span></span>
</td>
<td class="nump">$ 3,084,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Purchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
<td class="nump">911,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,297,223<span></span>
</td>
<td class="nump">$ 3,084,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=SMTI_DirectDermatologyIncMember', window );">Direct Dermatology Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=SMTI_PixalereHealthcareUSALLCMember', window );">Pixalere Healthcare USA LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Ownership value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=SMTI_ChemoMouthPieceLLCMember', window );">ChemoMouthpiece, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">6.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=SMTI_ChemoMouthPieceLLCMember', window );">ChemoMouthpiece, LLC [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SMTI_SeriesBTwoPreferredSharesMember', window );">Series B-2 Preferred Shares [Member] | Direct Dermatology Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SMTI_DirectDermatologyIncMember', window );">Direct Dermatology Inc. [Member] | Series B-2 Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,571,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Purchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SMTI_PixalereHealthcareIncMember', window );">Pixalere Healthcare Inc. [Member] | Class A Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,084,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SMTI_ChemoMouthPieceLLCMember', window );">ChemoMouthpiece, LLC [Member] | Common Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased</a></td>
<td class="nump">100,674.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Purchase of shares, value</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per unit</a></td>
<td class="nump">$ 49.6649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=SMTI_DirectDermatologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=SMTI_DirectDermatologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=SMTI_PixalereHealthcareUSALLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=SMTI_PixalereHealthcareUSALLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=SMTI_ChemoMouthPieceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=SMTI_ChemoMouthPieceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SMTI_SeriesBTwoPreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SMTI_SeriesBTwoPreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SMTI_DirectDermatologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SMTI_DirectDermatologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SMTI_PixalereHealthcareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SMTI_PixalereHealthcareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SMTI_ClassAPreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SMTI_ClassAPreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SMTI_ChemoMouthPieceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SMTI_ChemoMouthPieceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SMTI_CommonUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SMTI_CommonUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OPERATING LEASE LIABILITY (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 466,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">300,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">291,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">295,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">300,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">303,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,958,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(362,389)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present Value of Lease Liabilities</a></td>
<td class="nump">1,595,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8211; current</a></td>
<td class="nump">358,687<span></span>
</td>
<td class="nump">$ 361,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities &#8211; long-term</a></td>
<td class="nump">$ 1,237,051<span></span>
</td>
<td class="nump">$ 1,737,445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">$ 1,447,907<span></span>
</td>
<td class="nump">$ 1,995,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">1,595,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expenses</a></td>
<td class="nump">555,192<span></span>
</td>
<td class="nump">434,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="nump">$ 505,017<span></span>
</td>
<td class="nump">$ 380,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SMTI_OfficeSpaceOneMember', window );">Office Space One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">72 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SMTI_OfficeSpaceTwoMember', window );">Office Space Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">8 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SMTI_OfficeSpaceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=SMTI_OfficeSpaceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SMTI_OfficeSpaceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=SMTI_OfficeSpaceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF LONG-TERM DEBT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt</a></td>
<td class="nump">$ 31,697,051<span></span>
</td>
<td class="nump">$ 9,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less: unamortized debt issuance costs</a></td>
<td class="num">(1,007,761)<span></span>
</td>
<td class="num">(56,520)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt, net of debt issuance costs</a></td>
<td class="nump">30,689,290<span></span>
</td>
<td class="nump">9,693,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">580,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">30,689,290<span></span>
</td>
<td class="nump">9,113,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SMTI_CRGTermLoanMember', window );">CRG Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt</a></td>
<td class="nump">30,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SMTI_PaidInKindInterestMember', window );">Paid In Kind Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt</a></td>
<td class="nump">838,965<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SMTI_BackendFeeMember', window );">Backend Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt</a></td>
<td class="nump">358,086<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SMTI_CadenceTermLoanMember', window );">Cadence Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,750,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SMTI_CRGTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SMTI_CRGTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SMTI_PaidInKindInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SMTI_PaidInKindInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SMTI_BackendFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SMTI_BackendFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SMTI_CadenceTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SMTI_CadenceTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MATURITIES OUTSTANDING (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2026</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2027</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2028</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2029</a></td>
<td class="nump">31,697,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 31,697,051<span></span>
</td>
<td class="nump">$ 9,750,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 04, 2024</div></th>
<th class="th"><div>Apr. 17, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid-in-kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 838,965<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense related to back-end fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,128,395<span></span>
</td>
<td class="nump">475,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_MinimumCashBalanceValue', window );">Minimum cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_AnnualMinimumRevenueYearOne', window );">Annual minimum revenue, year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_AnnualMinimumRevenueYearTwo', window );">Annual minimum revenue, year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_AnnualMinimumRevenueYearThree', window );">Annual minimum revenue, year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_AnnualMinimumRevenueYearFour', window );">Annual minimum revenue, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_AnnualMinimumRevenueYearFive', window );">Annual minimum revenue, year five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,196,424<span></span>
</td>
<td class="nump">224,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,007,761<span></span>
</td>
<td class="nump">56,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,499<span></span>
</td>
<td class="nump">$ 5,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SMTI_CRGTermLoanMember', window );">CRG Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,160,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SMTI_CadenceTermLoanMember', window );">Cadence Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write-off of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_CRGTermLoanAgreementMember', window );">CRG Term Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_GrossCashReceivedFromTermLoan', window );">Loans borrowed</a></td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Remaining amount available for borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Borrowing capacity description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">each such borrowing was required to be at least $5.0 million and occur between the Closing
Date and June 30, 2025,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from loans used for investment</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">Mar. 30,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Incremental increase during an event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_CashPaidPercentage', window );">Cash paid percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Paid-in-kind and aggregate principal loan amount, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_DebtInstrumentUpFrontFeePercentage', window );">Debt upfront fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_DebtInstrumentBackEndFeePercentage', window );">Debt instrument back-end fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,278,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid-in-kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Debt instrument rate description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) if prepayment
occurs on or prior to the date that is one year following the applicable borrowing (the &#8220;Borrowing Date&#8221;), an amount equal
to 10.0% of the aggregate outstanding principal amount of the CRG Term Loan being prepaid and (ii) if prepayment occurs one year after
the applicable Borrowing Date and on or prior to two years following the applicable Borrowing Date, an amount equal to 5.0% of the aggregate
outstanding principal amount of the CRG Term Loan being prepaid.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_CRGTermLoanAgreementMember', window );">CRG Term Loan Agreement [Member] | Backend Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense related to back-end fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_CadenceTermLoanAgreementMember', window );">Cadence Term Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_PercentageOfLoanProceedsUsedForAcquisition', window );">Loan percentage used for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvances', window );">Loan bank advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate', window );">Bank, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_AnnualMinimumRevenueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual minimum revenue year five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_AnnualMinimumRevenueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_AnnualMinimumRevenueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual minimum revenue year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_AnnualMinimumRevenueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_AnnualMinimumRevenueYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual minimum revenue year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_AnnualMinimumRevenueYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_AnnualMinimumRevenueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual minimum revenue year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_AnnualMinimumRevenueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_AnnualMinimumRevenueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual minimum revenue year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_AnnualMinimumRevenueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_CashPaidPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_CashPaidPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_DebtInstrumentBackEndFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument back end fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_DebtInstrumentBackEndFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_DebtInstrumentUpFrontFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument upfront fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_DebtInstrumentUpFrontFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_GrossCashReceivedFromTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross cash received from the term loan amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_GrossCashReceivedFromTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_MinimumCashBalanceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_MinimumCashBalanceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_PercentageOfLoanProceedsUsedForAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the loan proceeds that were used for the acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_PercentageOfLoanProceedsUsedForAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalHomeLoanBankAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Federal Home Loan Bank (FHLBank) advances to member financial institutions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalHomeLoanBankAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest applicable on advance from Federal Home Loan Bank (FHLBank).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478878/942-470-45-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SMTI_CRGTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SMTI_CRGTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SMTI_CadenceTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SMTI_CadenceTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_CRGTermLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_CRGTermLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SMTI_BackendFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SMTI_BackendFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_CadenceTermLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_CadenceTermLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Dec. 20, 2023</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Aug. 27, 2018</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,089,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 22,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options remaining to be exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_PurchaseAgreementDescription', window );">Purchase agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of
the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain
products the Owner develops or co-develops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first
$50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%)
on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv)
$500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in
cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described
in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SMTI_AccreditedInvestorsMember', window );">Accredited Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Payment for additional royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">991,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_SubLicenseAgreementMember', window );">Sub License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_LicenseAgreementAndRoyaltiesDescription', window );">License agreement and royalties description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In
August 2018, the Company entered an exclusive, world-wide sublicense agreement with CGI Cellerate RX to distribute certain hydrolyzed
collagen products, including CellerateRX Surgical, into the surgical and wound care markets. Pursuant to the Sublicense Agreement, the
Company paid royalties of 3-5% of annual collected net sales of these products.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_BIAKOSLicenseAgreementMember', window );">BIAKOS License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Payment for additional royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,005<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_BIAKOSLicenseAgreementMember', window );">BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_BIAKOSLicenseAgreementMember', window );">BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_BIAKOSLicenseAgreementMember', window );">BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Maximum [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Annual royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_BIAKOSAgreementMember', window );">BIAKOS Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Payment for additional royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_ABFLicenseAgreementMember', window );">ABF License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_IncreaseInRoyaltyAnnualPercentage', window );">Increase in royalty annual percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_ABFLicenseAgreementMember', window );">ABF License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Payment for additional royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_ABFLicenseAgreementMember', window );">ABF License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Payment for additional royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_ABFLicenseAgreementMember', window );">ABF License Agreement [Member] | Maximum [Member] | Product and Service, Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Payment for additional royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_DebriderLicenseAgreementMember', window );">Debrider License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_IncreaseInRoyaltyAnnualPercentage', window );">Increase in royalty annual percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment of cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_DebriderLicenseAgreementMember', window );">Debrider License Agreement [Member] | Rochal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_DebriderLicenseAgreementMember', window );">Debrider License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Annual royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_DebriderLicenseAgreementMember', window );">Debrider License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Annual royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_PaymentsForAdditionalRoyalties', window );">Payment for additional royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_PrecisionHealingMergerAgreementMember', window );">Precision Healing Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_PrecisionHealingMergerAgreementMember', window );">Precision Healing Merger Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 22,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_PrecisionHealingMergerAgreementMember', window );">Precision Healing Merger Agreement [Member] | Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 10,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_PrecisionHealingMergerAgreementMember', window );">Precision Healing Merger Agreement [Member] | Accredited Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_ScendiaPurchaseAgreementMember', window );">Scendia Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of common stock for purchase of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Number of shares withheld</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationAsset', window );">Earnout consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_EarnoutPayment', window );">Earnout payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember', window );">Applied Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,792,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of common stock for purchase of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Assets purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Assets purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_ServicesAgreementMember', window );">Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_PurchaseAgreementDescription', window );">Purchase agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the
term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of
certain products the Owner develops or codevelops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for
the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half
percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0
million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0
million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments
described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Payment for additional royalties</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_OutstandingUnitsPercentage', window );">Outstanding units percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_LicenseAgreementMember', window );">License Agreement [Member] | Royalty Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Payment for additional royalties</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_LicenseAgreementMember', window );">License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_RoyaltyExpensePercentage', window );">Royalty expense percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_LicenseAgreementMember', window );">License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_RoyaltyExpensePercentage', window );">Royalty expense percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_EarnoutPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_EarnoutPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_IncreaseInRoyaltyAnnualPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in royalty annual percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_IncreaseInRoyaltyAnnualPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_LicenseAgreementAndRoyaltiesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement and royalties description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_LicenseAgreementAndRoyaltiesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_OutstandingUnitsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding units percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_OutstandingUnitsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_PaymentsForAdditionalRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for additional royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_PaymentsForAdditionalRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_PurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_PurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_RoyaltyExpensePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_RoyaltyExpensePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SMTI_AccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SMTI_AccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_SubLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_SubLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_BIAKOSLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_BIAKOSLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SMTI_RochalIndustriesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SMTI_RochalIndustriesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_BIAKOSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_BIAKOSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_ABFLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_ABFLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_DebriderLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_DebriderLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SMTI_RochalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SMTI_RochalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_PrecisionHealingMergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_PrecisionHealingMergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=SMTI_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=SMTI_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_ScendiaPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_ScendiaPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_ServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_ServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF RESTRICTED STOCK ACTIVITY (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested shares, beginning | shares</a></td>
<td class="nump">144,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, beginning | $ / shares</a></td>
<td class="nump">$ 34.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">192,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted | $ / shares</a></td>
<td class="nump">$ 35.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(105,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, vested | $ / shares</a></td>
<td class="nump">$ 34.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(28,332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited | $ / shares</a></td>
<td class="nump">$ 35.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested shares, ending | shares</a></td>
<td class="nump">202,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, ending | $ / shares</a></td>
<td class="nump">$ 34.72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted or assumed</a></td>
<td class="nump">144,191<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted or assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,879)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contract life outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 701,975.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price exercisable, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contract life exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 701,975.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding, beginning | shares</a></td>
<td class="nump">16,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning | $ / shares</a></td>
<td class="nump">$ 10.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of warrants, granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants, exercised | shares</a></td>
<td class="num">(16,725)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of warrants, forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of warrants, expired | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice', window );">Weighted average exercise price, expired | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding, ending | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, ending | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contract life outstanding</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of warrants exercisable, ending | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable, ending | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contract life exercisable, ending</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options exercisable, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant expirations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for warrants awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for warrants awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 12, 2024</div></th>
<th class="th"><div>Apr. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (75,000)<span></span>
</td>
<td class="nump">$ 911,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,089,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,191<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 22,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock award, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,747,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,436,048<span></span>
</td>
<td class="nump">3,442,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense</a></td>
<td class="nump">$ 4,189,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,189,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SMTI_PrecisionHealingMember', window );">Precision Healing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SMTI_AccreditedInvestorsMember', window );">Accredited Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SMTI_NonaccreditedInvestorsMember', window );">Nonaccredited Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=SMTI_PrecisionHealingIncMember', window );">Precision Healing Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 10,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember', window );">Applied Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Shares issued as consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,792,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember', window );">Applied Asset Purchase Agreement [Member] | Stock Closing Consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Shares issued as consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_SalesAgreementMember', window );">Sales Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember', window );">2024 Omnibus Long-Term Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Maximum number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="nump">2,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares available for issuance</a></td>
<td class="nump">1,000,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock granted and issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember', window );">2024 Omnibus Long Term Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="nump">742,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock granted and issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SMTI_PrecisionHealingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SMTI_PrecisionHealingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SMTI_AccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SMTI_AccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SMTI_NonaccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SMTI_NonaccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=SMTI_PrecisionHealingIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=SMTI_PrecisionHealingIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_AppliedAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=SMTI_StockClosingConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=SMTI_StockClosingConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CUSTOMERS AND SUPPLIERS (Details Narrative) - Customer Concentration Risk [Member] - No Customers [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=SMTI_NoCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=SMTI_NoCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 12,907,965<span></span>
</td>
<td class="nump">$ 12,467,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development costs</a></td>
<td class="nump">3,006,029<span></span>
</td>
<td class="nump">2,119,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation expense</a></td>
<td class="nump">789,373<span></span>
</td>
<td class="nump">711,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">7,330<span></span>
</td>
<td class="nump">528,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">389,882<span></span>
</td>
<td class="nump">512,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies', window );">Contingent liability</a></td>
<td class="nump">221,065<span></span>
</td>
<td class="nump">221,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_DeferredTaxAssetsAcquistionLiability', window );">Acquisition liability</a></td>
<td class="nump">112,722<span></span>
</td>
<td class="nump">176,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Bad debt and other reserves</a></td>
<td class="nump">287,900<span></span>
</td>
<td class="nump">129,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory reserves</a></td>
<td class="nump">130,605<span></span>
</td>
<td class="nump">109,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other temporary differences</a></td>
<td class="nump">1,049,365<span></span>
</td>
<td class="nump">203,340<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">18,902,236<span></span>
</td>
<td class="nump">17,179,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(5,683,259)<span></span>
</td>
<td class="num">(6,180,688)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of Use assets</a></td>
<td class="num">(353,763)<span></span>
</td>
<td class="num">(487,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Accrued expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(424,423)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_DeferredTaxLiabilitiesContingentLiability', window );">Contingent liability</a></td>
<td class="num">(38,308)<span></span>
</td>
<td class="num">(130,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences', window );">Other temporary differences</a></td>
<td class="num">(294,608)<span></span>
</td>
<td class="num">(166,712)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(12,532,298)<span></span>
</td>
<td class="num">(9,789,247)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_DeferredTaxAssetsAcquistionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets acquistion liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_DeferredTaxAssetsAcquistionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_DeferredTaxLiabilitiesContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities contingent liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_DeferredTaxLiabilitiesContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation and Amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities other temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INCOME TAX EXPENSE (BENEFIT) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected federal income tax benefit</a></td>
<td class="num">$ (2,019,060)<span></span>
</td>
<td class="num">$ (903,220)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes, net of federal benefit</a></td>
<td class="num">(338,138)<span></span>
</td>
<td class="num">(226,714)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_IncomeTaxReconciliationFairValueAdjustments', window );">Fair value adjustments</a></td>
<td class="num">(497,373)<span></span>
</td>
<td class="num">(819,270)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Share-based compensation</a></td>
<td class="num">(237,838)<span></span>
</td>
<td class="num">(557,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Other permanent differences</a></td>
<td class="nump">199,857<span></span>
</td>
<td class="nump">118,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration', window );">NOL carryover adjustments</a></td>
<td class="nump">97,806<span></span>
</td>
<td class="num">(5,148,128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles', window );">Intangibles</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(720,407)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps', window );">Other true ups</a></td>
<td class="nump">90,343<span></span>
</td>
<td class="num">(230,474)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Changes in tax rates</a></td>
<td class="nump">9,732<span></span>
</td>
<td class="nump">673,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">2,743,051<span></span>
</td>
<td class="nump">7,813,167<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 48,380<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_IncomeTaxReconciliationFairValueAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation fair value adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_IncomeTaxReconciliationFairValueAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation income tax expense intangibles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NOL Carryover Adjusted for Expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation income tax expense other trueups.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 57.5<span></span>
</td>
<td class="nump">$ 26.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Expiration description</a></td>
<td class="text">expire
between 2024 and 2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount', window );">NOL generated under tax cuts and job cuts</a></td>
<td class="nump">$ 30.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation tax cuts and jobs amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_ServicesAgreementMember', window );">Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Cost and expenses related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,594<span></span>
</td>
<td class="nump">$ 174,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SMTI_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Ms Salamone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Consulting fee</a></td>
<td class="nump">$ 177,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_ServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_ServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SMTI_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SMTI_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SMTI_MsSalamoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SMTI_MsSalamoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 86,672,425<span></span>
</td>
<td class="nump">$ 64,989,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78,532,524<span></span>
</td>
<td class="nump">57,137,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,559,863<span></span>
</td>
<td class="nump">56,994,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,703,362<span></span>
</td>
<td class="nump">4,132,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,923,224<span></span>
</td>
<td class="nump">3,675,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of earnout liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,938,451)<span></span>
</td>
<td class="num">(3,449,895)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Other expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,196,424<span></span>
</td>
<td class="nump">224,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,911,898)<span></span>
</td>
<td class="num">(4,439,902)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Segment Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,691,307<span></span>
</td>
<td class="nump">127,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=SMTI_SanaraSurgicalMember', window );">Sanara Surgical [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,672,425<span></span>
</td>
<td class="nump">64,987,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78,532,524<span></span>
</td>
<td class="nump">57,143,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71,673,642<span></span>
</td>
<td class="nump">54,826,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,828,663<span></span>
</td>
<td class="nump">902,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,785,829<span></span>
</td>
<td class="nump">2,046,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of earnout liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,451)<span></span>
</td>
<td class="num">(1,298,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Other expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,196,424<span></span>
</td>
<td class="nump">224,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,937,583)<span></span>
</td>
<td class="nump">440,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Segment Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,148,722<span></span>
</td>
<td class="nump">5,289,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=SMTI_THPMember', window );">THP [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(6,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,886,221<span></span>
</td>
<td class="nump">2,167,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,874,699<span></span>
</td>
<td class="nump">3,229,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,137,395<span></span>
</td>
<td class="nump">1,628,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of earnout liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,924,000)<span></span>
</td>
<td class="num">(2,151,559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Other expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,974,315)<span></span>
</td>
<td class="num">(4,880,387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Segment Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (6,457,415)<span></span>
</td>
<td class="num">$ (5,162,387)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes
                                            a $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--PropertyAndEquipmentWriteOff_iI_c20241231_zJC0st7jzVq4" title="Property and equipment write off">506,836</span> non-cash charge during the fourth quarter of 2024 to write-off the remaining net
                                            book value of certain THP internal use software assets.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings before interest taxes depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=SMTI_SanaraSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=SMTI_SanaraSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=SMTI_THPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=SMTI_THPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (9,911,898)<span></span>
</td>
<td class="num">$ (4,439,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,128,395<span></span>
</td>
<td class="nump">475,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,978)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,923,224<span></span>
</td>
<td class="nump">3,675,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash', window );">Noncash share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,107,253<span></span>
</td>
<td class="nump">3,442,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of earnout liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,938,451)<span></span>
</td>
<td class="num">(3,449,895)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of losses from equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90,007<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_ExecutiveSeparationCosts', window );">Executive separation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">964,466<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,350,289<span></span>
</td>
<td class="nump">423,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Segment Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,691,307<span></span>
</td>
<td class="nump">127,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=SMTI_SanaraSurgicalMember', window );">Sanara Surgical [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,937,583)<span></span>
</td>
<td class="nump">440,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,128,395<span></span>
</td>
<td class="nump">475,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,978)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,785,829<span></span>
</td>
<td class="nump">2,046,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash', window );">Noncash share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,969,008<span></span>
</td>
<td class="nump">3,201,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of earnout liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,451)<span></span>
</td>
<td class="num">(1,298,336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of losses from equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90,007<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_ExecutiveSeparationCosts', window );">Executive separation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">964,466<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">185,029<span></span>
</td>
<td class="nump">423,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Segment Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,148,722<span></span>
</td>
<td class="nump">5,289,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=SMTI_THPMember', window );">THP [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,974,315)<span></span>
</td>
<td class="num">(4,880,387)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,137,395<span></span>
</td>
<td class="nump">1,628,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash', window );">Noncash share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">138,245<span></span>
</td>
<td class="nump">241,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of earnout liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,924,000)<span></span>
</td>
<td class="num">(2,151,559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of losses from equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_ExecutiveSeparationCosts', window );">Executive separation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,165,260<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Segment Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (6,457,415)<span></span>
</td>
<td class="num">$ (5,162,387)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes
                                            a $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--PropertyAndEquipmentWriteOff_iI_c20241231_zJC0st7jzVq4" title="Property and equipment write off">506,836</span> non-cash charge during the fourth quarter of 2024 to write-off the remaining net
                                            book value of certain THP internal use software assets.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes
                                            $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231_zJKt3Xeqlclc" title="Share based compensation related to executive separation costs">328,795</span> of share-based compensation related to executive separation costs for the twelve
                                            months ended December&#160;31, 2024.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Acquisition
                                            costs include legal, tax and accounting services related to prospective acquisitions.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings before interest taxes depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_ExecutiveSeparationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Executive separation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_ExecutiveSeparationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=SMTI_SanaraSurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=SMTI_SanaraSurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=SMTI_THPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=SMTI_THPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SMTI_PropertyAndEquipmentWriteOff', window );">Property and equipment write off</a></td>
<td class="nump">$ 506,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation related to executive separation costs</a></td>
<td class="nump">$ 328,795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SMTI_PropertyAndEquipmentWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off of the net book value of property &amp; equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SMTI_PropertyAndEquipmentWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SMTI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details Narrative) - Integer<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 19, 2025</div></th>
<th class="th"><div>Jan. 16, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SMTI_CRGTermLoanAgreementMember', window );">CRG Term Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">each such borrowing was required to be at least $5.0 million and occur between the Closing
Date and June 30, 2025,<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Subscription and Shareholders Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Russell Revocable Living Trust, BMI and the existing shareholders
of BMI, pursuant to which the Company agreed to contribute up to approximately &#8364;8.0 million to BMI through a series of capital contributions
in exchange for an aggregate of 16,460 ordinary shares of BMI, constituting approximately 12.5% of the outstanding equity of BMI as of
the Execution Date. The Company made an initial cash investment totaling approximately &#8364;3.0 million on the Execution Date, and the
Company&#8217;s previously announced convertible loan to BMI was converted into &#8364;1.0 million of equity in BMI. Pursuant to the Subscription
Agreement, the remaining &#8364;4.0 million contribution is due upon the achievement of certain development, clinical and regulatory milestones<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Subscription Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company&#8217;s initial investment of approximately &#8364;4.0 million
caused the Company to exceed the five percent ownership interest threshold in BMI, and as a result the Company&#8217;s Chief Corporate
Development & Strategy Officer, Tyler Palmer, has been nominated and appointed to BMI&#8217;s board of directors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | CRG Term Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt description</a></td>
<td class="text">(i) entitle the Company to two additional
borrowings following the Second Borrowing, which borrowings must occur on or prior to December 31, 2025, if at all, and (ii) remove the
requirement that any borrowing be in whole multiples of $5.0 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_CRGTermLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_CRGTermLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_SubscriptionAndShareholdersAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_SubscriptionAndShareholdersAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SMTI_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SMTI_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>95
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .6*>5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( .6*>5K'4Z M\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( .6*>5I>U%HM,0H  /LZ   8
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&ULM9M=<^(X%H;O\RM4S-14=Q4)_H!
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M3=3+)<%@=^0-<'U!J=B\D5^P?=[U^O]02P,$%     @ Y8IY6A IIF9)"
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M-9]=*?D$E+4VWNR+=F[:T09-6=MEO-/*?%N:<7IV(^M&5N6":[$ 'WC%ZT*
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MM7V*;OM&RW7[(-I<:BU7[<NEX$8160/S_;V4^N6-?;9M_RSC[/]02P,$%
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M>TICG([WU")'*(BY-#V 8W1Z6R7ZRACE Z3POW9E]QQL>+<6,CT]\B&C64U
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MJ)\J2 /*&LZPK/'>%[S_](-,0M(NJ]HF70"V0"1C&*MM(18D02B.'7TAJOD
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M O#[2HCNY8M<8/^F]?Q_4$L#!!0    ( .6*>5J<FEM=8@(  +L%   8
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M/12$2=#G&\[5/C 7]*Z<_ %02P,$%     @ Y8IY6H%]VRX) @  KP0  !@
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MRPW=)W56>'/[9-!;83T=]&="A1N_</8/4BDG90#:&ETH6U8^)*':SY5Y&-/
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MGW PE4=NS11X K[//3I-.V '_?\U3OX$4$L#!!0    ( .6*>5J?5A<FE@D
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M%Q0RD78AQ&<DJ?9# 9FLVO3PS;FM5M)L^&GRYA]">^RI5*93A#1 %6-+N]Q
M#*\3N47F01)D9^H1A6NES9(UP8I*.8*"_H)W @ P/I9&%)>M+-(L6*&KE;-X
MG\*??!C*(D3@(PES*JM3)0HERU"DTBFAGE!L,QUJ^%AHPS;XVBUI[U"DA;,0
MDZQMC=TDP3]HPQM14!\4JK.XE' L($L[>V9/?G[C!73!@0&^H0#JM%%C1VD2
MEBFOE^1H6 !Q6I%ES^4E2TL6Y23W$?& .Q8J!$1RC[D!'D<#P$?XP\FRA"M]
M@*>=6,%WE%%#.&0I758J[TGL&J#@@S?XD"KR+]DZ$G?P0[V,6 EKFZ!#.<C
M^5XMJRBJ@=J\<1X;>J>]KY5XQ_X6-V7MQ0\-0N[>W;3H&/9M%4AQ',S!7"@
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M1Q;@R*=,:UB]K#(#PV6DZJ0-1\B^8?^'B^DE_37XX:UX+#=Z+H:G_51<R:J
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M6[C!AD/(6,EQ29B"*(*,QPFH#)03"PD.IT6&A(4^C2/V2OEHQ;PJC\[L'%B
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M(K&D/H)IMU[@R"-'S\?09",,P9Z#.?O2'K?AUHQ>;9U:^L4?^JHH1K';7)2
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M30;X?J902C<+"K#[-Z3W-U!+ P04    " #EBGE:AL'D9+P(   .&   &0
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M79J]=N;KLQPT*HV$NN,W9^4US2?OIV?7'Z;>Q;OVX=M[M/U]M"$>>!@?9L.
M3E<<>IJ"W'J%4\ZL9L0W);SM<T_K9.3MW)7BM.CWQZ$?#L-R)_D2C_;P[Z7W
MK4$Y#/QQ,,"0[>+D^+):=*5S<.!)$,Y>V _]P^&(#:%EP*L=8,L3+_&15^1L
M=E/-S1?4YZ.J.ZZVKKWF'-7"[!:T3JCU587R"=M0.VC6M*ZK5=N2!WYX./9#
M]*SVJA^@5U,.%?W=1X;MHFPS$/7,C?^_+(2'1/9V$)E Y \7\SF]^W1Q7G]
M.I]>O;\X:Q'<<Y1V+/X#Q>RY[X8-Q3U0O"7Q':Q\U0]&_K@?T"^.)M_B8G_D
MN+A7Y0CK#YD6XVKY!\3T^8@^7$*[OOCU6M]HL05<N"_1?*A'*9:?:YNGS<?N
MT_(;[[UX^:7\7)B%0@(2>8NE07<\ZI2#N[[)=>:^^-[H/-<K=[F4&'N&!?#^
M5NN\OF$#S7\!G/P;4$L#!!0    ( .6*>5I=%^I[^00  #4+   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;(U6VV[;.!!]UU<,W*)H :VMBV7)N1AP
M4K<UX#9!G':QC[1$6]Q*HDI2<;)?OS.4Y3A.&O3%%B]SSISAS)!G6ZE^ZIQS
M _=E4>GS7FY,?3(8Z#3G)=-]6?,*5]92E<S@4&T&NE:<9=:H+ :!YXT&)1-5
M;W)FYZ[5Y$PVIA 5OU:@F[)DZN&"%W)[WO-[W<2-V.2&)@:3LYIM^)*;[_6U
MPM%@CY*)DE=:R H47Y_WIO[)Q9#VVPT_!-_J@V\@)2LI?])@GIWW/'*(%SPU
MA,#P[XY?\J(@('3CUPZSMZ<DP\/O#OV3U8Y:5DSS2UG\+3*3G_>2'F1\S9K"
MW,CM%[[3$Q%>*@MM?V';[O7C'J2--K+<&:,'I:C:?W:_B\.!0>+]QB#8&036
M[Y;(>OF1&38Y4W(+BG8C&GU8J=8:G1,5'<K2*%P5:&<F5]>SF^GM_-MG6,RF
MR]GR;& 0E=8&Z0[AHD4(?H/@!_!55B;7,*LRGCT%&* [>Y^"SJ>+X%7$CSSM
M0^B[$'C!\!6\<*\QM'CA[S367#$CJ@TL.!Z@?DECBS!\&8$JXT37+.7G/4Q]
MS=4=[TW>O?%'WNDK_@WW_@U?0_^C,W@5X67_OEW=SB"&=V^2P/=/X9@%;G,.
ME[*L6?4 &"$A,Y&RHG@ 7AFN-,A]V H*&Z1XR@JK2#O8"T"NUR+E8%F!51GP
M7XVHL5Q-'Z9*L6K#::"!*0[\CA4-,SP#9D!4*:]M21J)!81<F-<<MCDW.:=^
MD>9H=(" Q-H(TQ@D:GWI@^T>CEQ#@YXQK3GN>T]2 ^_TYNK[;LI.^*<?L'W8
MN%0&D ,4&1.[-:Z@P<15Q0-)M79  FEC*YP\=*W&=EP(MA*%,(+K1V"']LM5
M(3:LTU:RGQU$S1ZZ: A-/&LERT>*/EP=!?M10TM\0+GE&%'%4[FIQ'\84B)#
M(#P;;)7$[608:MNK]HN=>CH'='-][):\XZUBW%=SVRF?B-\*D]OU)\>^=Q)8
M]B_V*N2CR&%3Y$KQS%%$V;G^@'FAB1K+FY<KY.M*W+7(72KF+ .SI>@AM6"%
M<Y2'&H[3KP_S"KXR17F#L5IB=K4$2(;XX5-\AHJQ3X% V;42=!5U:#O%$L_1
MX'V&JC(;4'3"$F$24/B+@O[YO4&@-O08H[ZMIYV'I$%QNA,?3Y0V6?UQ /:N
M@+)MFW.ZFU*I,H:%T49ZNKR$6UF+%))AX.[:UA,93LZT30)%6@ZR!0G>@N\.
MA[$[]F+\BL:1&X<)1%'D^N, AN'0]48CB+S(]?P8PL1SHWADW7^6)@>,MH_$
MIP=]P7E>#NSE$P:A0>=R6\&*G@$G>%JF49@3M/NH/</B &]Y^67V\?MB!E>?
MCAL8+.;3B_EB?ON/<\CG(%^$(1B.1F[B>30<0>AY;C@:TR"&8.R[V"9HD. @
M<D>)71G;;7Z4.!@*?."L#2%ZH9N,?>=6&E8<5XWOCJ/$]8/867"M091U0S4@
MJ']R;>!]. K<,!G#!^=Z%]D?762?:WW[>%C.<3LXC''7T--&V0)["R%Z,4KB
M/[(J9+7YBW+1\@5A['J1_T>5V27 \X*D=&=8&)35U..QF>"#[L4*()JH'T'<
M3^"EJW-P\)0IN=K8!QM= 4UEVE?-?G;_)IRV3Z''[>V#$CO"1E0:R==HZO7C
MJ-=V_FY@9&T?1BMI\)EE/W-\UW)%&W!]+:7I!D2P?RE/_@=02P,$%     @
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M:G1VBUP3WWBR8ITP1N)QC?03C'JRL:,04:.1XN&PX,;0'=^Y#S<VQB61'Y=
M%D=X<Q:TBYVX[LNX17B\0$R@3K#: )9&I0^V)9]4^<6!?2KSJ)4KJ=-&8PEU
M*UJT,B[@ XCM7,UKW.32EB<YCKTAL"^'*^$+< @V2F'Z!"6&JUMJM*G=&QK6
MN>\CZ3P^F) T!1<X@AG"1IJ](\+A?W!B9V6PXSXU%$:@TSE_B@(XT8H@H51R
M"@3Z9=U$I!N9%::I(!$41/XQ19M&\(0RKI@(]97&;:2-.38L'H]H&<Y*?&?L
M"ZU$J;0(9-):M6\MF?H01Z9JI'-7X-.@;Y?9CT@C2G,&:;H6Z 4/NLIKH%G%
M02;"XE!:688BS(,L4@"7AAFKQ5B>ST40@^YPQ+7.&41>N93%T?#:+]OD?:?+
M'KD00JLT\_@42MZZ:G;!GB[/B?W00X^$&=):FB<ZE''F69$0)!'&BD>?E9MA
M0 ; K)\Y,G[Z&-!YS0G,5%0X9#D7O8&E--TB1;^A9"=_OU: 8+M:;?3AWQE%
M?G=5T70?P-7&U&TJ8>5"NCLE5D%-7@3RF\"QN6:H$CF%/K' D-','-J( />(
M62WM(KB;9V,32U92K^>M 2B@FOK@VCR<W(6R4VF2+SZVU4A90D[^+8Z,=TJ9
M-[F(W91R6S"1FASI!NK$[JMK'5S6ZI[&EV=GHG-V&I_W+D2[M?S<:[?.3UUE
M0&<&BBLB.MML2F2JLD!#PK61F;F,T4B(8PK-1O[91N(FDPQB:)]*<LQ@Q<@I
M7%NG<G\7$ ZA/.,J2,:3,2PPIKH;7'=.3N+.90<51>N\(T[BD^Z).&_UNL*[
M6C?F 0)T$O?:]*>%-CU,Z'F,W&M3-FQW>K7U/3-;#,Z%OAL53*AX#-.\.BQ=
M_'.I14A:D(?X(J! 26UUN=CG-(TQ/9NGL3;H@J]$T#S*W%T)U*CQ Q[88+-P
MQC-3S6EFJ>A->M$V>F[RL1/V4;R%<0F41D\>DHG:HGO>@J9O$^K/913N"591
MPH^.=X $#^/=?N<5OD39!(2P:BL,B!^ @> (VXH)]H+:$S?K .<E2_:0[$.P
ML>9F4#XJ36P&1P_ALXA1_.M>=N*SBS-Q>1*?7UZ0-D)J"IC$273U/)XNDXNQ
MI=?08;L 9/L[K/)UR,T$&4+/BO5")Q@T*N=P#4-=+)6B* ]RH$%MYI@^<3)T
M!8N_4T,-H_$L-VP4-%:43;TCG%R<Q9V34W%VV7,M0:L3+HNBU4LD\:&^T]QZ
MI];PB^VW4"TJ7^MG-W5-V7>U),/MLM)TE08"4;.HM8VC6HE %M=*09335O=T
MFY4&9*6!-_A@U2*W;*:M#]F45SE@-LO83#>UALLM,C3B)M@S8GMRD/!5FAN!
M;XO1)L'7SJ"- 6HP:+AA]<1\%7<O%$;;H7"E'*:[O;H<]?>O#$-<=:Q<P\KZ
M2O.Q*XQ#>9V$"=UF)=1R:6YS+E/PM<R$O!1ZL$43 IQ1XB VMW6KZN2>BUR:
M@L#[':G7JK(FLZ[6B$05!:HHU]<VZ='G3[92CS_/@K57';:V#=K-:NMZ-T!$
M**QM6<*PS.AMHD4TE2FW".Y:E:X:ABH((DNF,3/:5>MTT(@'$\W;XV4[L,X$
MG(;(.^9'VA;E-D^F ?I#<=;E$2)%SO(V6=QSF^RJJ+42;7=(Q(V&91]^^'XV
MJE\_N%$(%KBGLG<(]&+]FIJ6?$ *L;NZ5_^04)YP)%4TC:;M$)7?=C'TM.XM
M?.0VCH["T?2^P8[<LL9DO#R9#+$EWI^(0WV$0*+XH<#R7O\0E1%9 O$JIO1:
MD4A1IK@W#R(JQH)/[]1*#,),.8QHO-<U.CUW)^=[O,/>WXX"4>G:CKW!'VTT
M/4M1?;CSU#0Q]3?&0'A\,FET;?J[QU^PNY_?E9;T\!3L0NM<D#FW?GA*&6Q*
M*=.0A5<*@7TP%B1Q8=6XI>0+@'5^2$=SXU]^4(^!'J.HYJK;(K[,GS^;D\["
M=^F%S]+D *M2#@$GOI+KM/$@\@](G7='M-@-RD*;[P&$H=;9HWD-RVD!?JJ+
MHFIT]ZN\T86<FC6N&.N^'!HYI$,[2S[V'"Q7A_"KIZZWU$]#/*9N\WH'3K2!
MAA1@C3HW0N9-K!ZZGIXU$ICTGH[#U-BXW%*[K\L((9D@_NCU%.H''\*\0?4,
MJ-%N4)H$H'$%RS)F*>AHDN/\"W(W!YU5:5!\ZH0:>=#C@3QYF<, Y%0U1W6/
MK$IS3V(/*&NCQM"3W#ZA2U:V):M)4VQ2_^9RP&Z6?>)I4*O+"59,716D2H(N
M[)3J0@YUIBG'VFC-'SPD.IWZL3L-M :R*E2XY-TR=]G)X-'2"ZC+G\.9N"OV
ME54#0M<-OVEO&@4#[.5LXLU=5#CN;BD]5XT3:ZKQ9'T$MV+34.6OP01;-]IT
M2;'&F3YZO,T=?XB]^U) 2WR@64;4?/$357OC#G];XO5OA*W<">VX9OI4C4#R
MLZO7R G"ZT#\(%RD\%N)];LY:=3$?N7CG^):)9/<9&:\<.^WD!8Z%W!U_;52
MC7?G@#U447,2IGF^4\/J&PA->:C>Y2D6S7^7[26J/YE#R5CG*=]XRJMO-MT.
M;FI!7, R2M%="<"@M[Q_=7^WO>1ZW'A)F:<7]#H=51" =O>^<OUK_;9WW[WD
MO%SN7A6_EG:LD4@R-<)6FAH=N*%@^%*:&;_R/#0EH(0_3E!C*DL+\'QDT"[Z
M+W1 _0[\B_\"4$L#!!0    ( .6*>5J. 22A @H  %49   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;*U9;7/;. [^KE^!\>[M-#.J(\FO:=/,N(F[
MR5Y3Y^RDG<[-?:!EVN95%E62BNO[]0>0E"W'3J:[=Q]:4Q0) GB !Z!ROI;J
MFUYR;N#'*LOUN\;2F.+-Z:E.EWS%=%,6/,<W<ZE6S."C6ISJ0G$VLYM6V6D2
M1=W3%1-YX^+<SMVIBW-9FDSD_$Z!+E<KIC;O>2;7[QIQHYH8B\72T,3IQ7G!
M%GS"S4-QI_#I="ME)E8\UT+FH/C\76,0OWG?IO5VP6?!U[HV!K)D*N4W>KB9
MO6M$I!#/>&I( L.?1W[)LXP$H1K?O<S&]DC:6!]7TC]8V]&6*=/\4F9?Q,PL
MWS7Z#9CQ.2LS,Y;K:^[MZ9"\5&;:_@]KMS;!$]-2&[GRF_%Y)7+WRWYX/]0V
M]*-G-B1^0V+U=@=9+:^881?G2JY!T6J41@-KJMV-RHF<0)D8A6\%[C,7D^O!
M>'@]^G@U'$]^^Z6?Q+VW,/S'P\W]U_-3@_)IU6GJ9;UWLI)G9,4)W,K<+#4,
M\QF?[0LX1<6VVB65=N^3%R5>\;0)K3B$)$K:+\AK;:UM67FM9^0-OY?";."?
M@ZDV"@/B7\>,="+:QT50DKS1!4OYNP9F@>;JD3<N?OLE[D9O7U"PO56P_9+T
M/PG'B[*.:_K\ 7 I5RN9!Q,CTV\P,(%9<IHK6+[Q*S4,\KQD&=QBN(E\ 7(.
MDR53?"FS&5<:ECR;@<CACS+;$&91"#4IP(I"R4<^LY-CK@TS^)!$<1M&JUQ,
M2PT?)8J]YVH%-WG*<TK9X"YC.;RB/:1'$KVU.S[>W]S9Y_CM"9VY7HIT"<>4
MG@F%'""5#E'AN4@YC?BJR.2&<PTLGT$J<XUYS'*#SXH#S\1"3#,.1D+!E!&I
M*%#99G"/\K?'@T%%16ZM0(:9\,+PU90K:+F(#:WL7,*\-"5*96NF9AK3=P-3
M#@N%Q^'.HE2ZQ"&=9>KBFW"G^*.0I49O5JN=C*#$#%/[RY$YL@R)DJ@8D'_1
MO?F,4"K1C1FMW0#_4: S8+JA1Z&L 1JD@IT\/S5_JLLH#_XH<PYQ4AEWS->Z
M'@Y[>-.>/9A?[\,,1V!.]F$. P?R&G<@Y.@O/I\CM% 6Z/[:T?YDEC6! $.^
M%*MR!7EIT4';[-JME4^-2&TF@+:98);,5)#-,"X>N>*SH Z:A[5"J Z--P"$
MACB,HHC^0:^=A.VH TG8:;?\?-SJD8<'Y0(Y'QSCM?:S)\VD]KX<%$4F<#S0
M&NOV7:G2)5:F)CDS*Y%Z*1]H7>'?0*$P[&'--/1:83\ZPY7!!SY5)1;B(T>A
M?\E*YV.&T[E1,LMPQC/H"/VN*+8FM]#K;"V;L(SKP'O5^WB-DM!_,TY*:5J
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M30OP_5Q*4SW0 =N_I%S\%U!+ P04    " #EBGE:T-;,BNH"   _!@  &0
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M];<6;^.]E459J\:4NF&M6IX-)N''BXCDG< ?I=J:HV=&D<RU_D$O-XNS04"
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MYCX7"9#"<N[S-'I9Y*,&PP(&8%%V27=\KFD0_*?[,(S])!,^CW-VPH:)'V8
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M=V]R:W-H965T<R]S:&5E=#(S+GAM;+59;6_;.!+^KE]!N(<B"ZA^2]JF;1+
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M)E,A2T'W2=[4**68"RY/7P&PA*+N=ELM4H6PJD5C221D++A!9)O4Z'SS#8D
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MK !RY%'4&?1D.D_IT1Z;@:M7GB JS?&&T1& :1)5.V9?2X-VSKPC@9K_:*-
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MJ!UAQQ$B+"N%S 8_8D3]CM#-^#+7>A*,ZSWPP.:X ]E3N30[X<+Y_O;;-ZI
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M]-JM'@Y]M@@B0.@X4 -J"JM[5M>VD/['Y),FF[SZH[:=$E6'I.[#1&&5KG?
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M296ZYLG?#S?Y,1*[/M",>U_/$(Q%_$;(3((YN_Z0UKWM/D.>U5_?-MOK;YA
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M\2T#.A&@H]'/%^"E2Z*R\=1IP_##!-Z0A_1[#M$HGO* 1'H)OE:Q(^C(H#J
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MB<Q^#([%=8*X6*_(Q1AT8MH)M?L_^ *H44HJ(C\4BRQ=L5'""->'!^]_E!!
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MNX#:'^8;F)JO;:Z'D%,VH36/D5LC\2$ML@(B?M!--S>7MLJEOS95+G/(W-5
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MVJPH+>F"_SIWSP^$/OQF;X^?QEJG\%X9KU^85#1SG59V%DEC5.MI,WTZ?F!
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M8=8T5]F2C-?)TP+CIX%T^@?[*Q' 27/6R"@.W@LH$L^U8AMD-]%$7EN18'_
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MIXNH7BW51/'"O!067.&[PPS7^-"C0@O@>L+Q-K>=: /[IV/G'U!+ P04
M" #EBGE:KB02E,H#  #U"   &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6R=5FUOXC@0_LZO&.6JTZV4;4+":P^04J J4KME">U]6-T'DPS$:A)G;5.6
M?W_C!&BI*%N=A(@=S\LS,\]XTML(^:P21 V_LC17?2O1NKAR'!4EF#%U*0K,
MZ60I9,8T;>7*485$%I=*6>IXKMMR,L9S:] KWTWEH"?6.N4Y3B6H=98QN;W&
M5&SZ5MW:OYCQ5:+-"V?0*]@*0]2/Q532SCE8B7F&N>(B!XG+OA74KZZ;1KX4
M>.*X46_68")9"/%L-I.X;[D&$*88:6.!T>,%AYBFQA#!^+FS:1U<&L6WZ[WU
MFS)VBF7!% Y%^@^/==*W.A;$N&3K5,_$YA9W\90 (Y&J\A\V.UG7@FBMM,AV
MRH0@XWGU9+]V>?B,@K=3\$K<E:,2Y8AI-NA)L0%II,F:692AEMH$CN>F**&6
M=,I)3P^"Z?1N,AY!$(;C.4P?9\/;(!S#7W.V2%%]@:\0%$7*,89 *>+(="VC
MA+( P4HB4G4T_+C';('RWYZC"9 QZT0[Y]>5<^\#YW4/[D6N$P7C/,;XV(!#
MD1S"\?;A7'MG+8XPN@2_;H/G>HTS]OQ#>OS2GO^!/2IVRA9",L,="*1D^:J*
MFN7QT?Y!)RA!)RR'8Z4?=V03)AHS=3)%%8#&:0"F)Z]4P2+L6]1T"N4+6H,_
M_ZBWW+_/A-<XA-<X9WT0#F_'H\>[,3S<O&? \.%;.!F-9\%\0JM3P,^:/@U\
MGB!HH5D*Q9Y'D: &C]$DBYJ4;AG*(>Y)5WM'.J:HXS1*:@1BY&);R@Y%5K!\
M"QLZI=^2LB\VZ@KVP=5^%UQM>(1A_'/-]1;"A!%N&)EB2GABZ1IK0Z82&*9"
M\7P%QUH7T+7;3==V7;=VP[B$%Z,!8@FA%M'S!UIMW^ZX7?!MM].U6XWF.]5)
MKBA9:4FP*=N:IP+/=ALNJ74J. 7C<9DWGK_0N9!;\ V,]CM;4]1<"PBI$CRB
MP%X;F"ZQ,I_%WD/':]H=O_%I U1#3;'MEF_"ZW3],B$C+ND6!DWMHEAU'4="
MD:=ZR[/;#;\V/T>*"Q*SVUV*VV_#&=8W#ZQO?IKUIRD!]+L))C-X"NX>7[LC
MA&#X_7$R&X].]<-9IZ?[X8BC_Q-*;80JDKPH4Q5D8IWKVN1 A8L]&0RKB[):
M/M6DY9&,IEE(95F;S$L:\Y)8;S+M=>QNJU/[1IW'3/]16T6D+8DBORV%\V84
M92A7Y<!55%""54VEP]O#3 ^J4?8J7GT0W#.YXKF"%)>DZEZV*<&R&K+51HNB
M'&P+H6E,ELN$ODM0&@$Z7PJA]QOCX/"E,_@/4$L#!!0    ( .6*>5J/!7@:
MA 0  ,8*   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;)U6;7/:.!#^
MSJ_0T)M..Z,+MFS+=@K,&$(29A+"!-+>R]P'801X:EM4$J&Y7W\K&5/2$)JY
M#X!WO?OL/MI=L>VMD%_5BG.-OA=YJ3K-E=;K\U9+I2M>,'4FUKR$-PLA"Z9!
ME,N66DO.YM:IR%O$<6BK8%G9[+:M;BR[;;'1>5;RL41J4Q1,/O5X+K:=IMNL
M%??9<J6-HM5MK]F23[A^6(\E2*T]RCPK>*DR42+)%YUFXI[WJ+&W!I\SOE4'
MS\@PF0GQU0C#>:?IF(1XSE-M$!C\//(^SW,#!&E\VV$V]R&-X^%SC7YIN0.7
M&5.\+_(OV5RO.LVHB>9\P3:YOA?;:[[C$QB\5.3*?J-M91MX391NE!;%SADR
M*+*R^F7?=^=PX! YKSB0G0.Q>5>!;)873+-N6XHMDL8:T,R#I6J](;FL-$69
M: EO,_#3W:N[NXLOPYL;E(PNT' T3497P][-8(+1:#!%'Z9LEG/UL=W2$,MX
MM-(=;J_"):_@N@3=BE*O%!J4<SY_#M"")/>9DCK3'CF)>,'3,^2Y&!&'^"?P
MO#USS^)YKS$78K[-\ARQ<HZ&I6;E,@.R*%&*:X4N,I7F0FTD1W\G,Z4E],\_
MQ\ZABN(?CV)FZERM6<H[31@:Q>4C;W;?OW.I\^D$!W_/P3^%WIWTKP<7#S<#
M='>)^M=0N\$$BHCZR?W]G\/1%4IN[QY&4_.VKO,Q!B=C'&<P77&4KN#(N$)9
MB;01F91/6;E$K!";4B.QL.J^*-:L?'K_+B)N^$DUEO6Q;SD<+5-H(7*X&=0Y
MJLDTWDRF,16:Y8T>RUF96C ("GW"BQF7=:\0]!OR,'5<'$9N(TF_;3*5F1M!
MH=]_X>H=.-:6_Q/*?Y9%;7N@0R?:(=BW0_#V=JB/[7-R\V U/Z8;)9/)8#HY
MU@LG YSHA;KXCRS?</5*\:%5ZC%KL&K,?NH"^)76<\UE)N8*V3"EYO.?^N/7
M[!HO2_"BOHV^4!HE:;HI-CF#*&@$_X/'E(VD$%)G_YK[\.5M<=X8@V$)?,QE
M<@<$)!J.37DC[#@Q)KX#PH< A A' 44?S3L/1 =[D5\9!J&# S\VAAYV(Q<^
M.\, C&+L4<C7_B, NN20FNF\5;:NH@H;-<2Q'V$2QP;$<4+LNA& ^* V@*XU
M"+'G$?3!Q1&%3Q2" <5.%&#?#QIC*>:;5*.;+(7_7JBEC\/8PU$8&X^01)A2
M PGP-,#$=9\;>#[!E%!KX <N)H%7C2D0"1P<@LJ'E(!DC$/?Q]0GEB2D!WL$
M#D-J# ''A6#4'AL%^@&FP,D: A<"Z=*3(T/W(T/?/#*7#].'^X&Y9^ZGP[^2
MZ?!NA 9_C >CR>#8J)P$/CXJSWKX1+@&-&=@;X<H]C$AKE%0(X84QS0P8@AB
M2*%37,^(D1$)P4[@&S$^$&% 85];:&@/HX$*>C3>%^7@X(^=9^M@MX#&6]H-
M2J'4W/'5FK'7[I>TI-I-?IA7&]XMD\L,[LJ<+\#5.0OALI'5UE0)6JSMIC(3
M&KK</JY@T>32&,#[A1"Z%DR _>K:_0]02P,$%     @ Y8IY6O?N:<7@ P
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M,E&]!ZJ.XFMS!R^XHAO=-%-Z0J'0!C2_Y%SM.MI!\R@;_PM02P,$%     @
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M49@$O;[@7+T%9H/JM]']"U!+ P04    " #EBGE:5SUBH+$#  !D"   &0
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MWH#U15G6^P$;.+SQ+_X/4$L#!!0    ( .6*>5H7VM0YB0(   @&   9
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M]]X*$N^/R)=<C9HXJPMME[2M*LZO*V>&.=1VW%+%T^ZT]U[])>?\9C/P_?(
M]TV9MKOR5BGYU:42?:*LTQ1D5 O*Z(5\"<I&O;!%D@*FJ#4A[Z>95)GY>&@!
M>H40HUR2S]E2HBVK_H)/_-9<KV B,>2VC[E 1IHM#^ RH5+PV]<OG2#PSM[M
MVW7_[#OP! :IY)&I&(,C>MN\-V*]^=3]K_KOZ5468.Y6QV U,)V7@E!DB=X4
M=<5JT=V=VYYF;WUHNKZ2=?+XZ7#3#K[;"6C'8KEO5V_:S&LFEYR<'>&"U/".
MVE1^R$WGMIEHD=I>YD%HZHSL<$7=+DIS@/870NC7B;F@Z)_[OP%02P,$%
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MV7!CWB64UL#LKX30IXD-4+QTT1]02P,$%     @ Y8IY6C]@<2%P!0  8A\
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MMD+[VH2=U%:'E57W ZMC2$Y)M_.-N([;(XL8A3^?_$UC8_1-"MPF!:[A[7[
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MZAMRKB_KN#$J;,I-2V 5;JX+;JZ-W"P"#*"[/(\/BJ@ZBC*\T1Y%E_TKZ_J
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M1A6LGJ;=HSLG?:5XB_F*4(%26"J\UQFIK8 7MW1%0;)-?@VU8%*R+']< TZ
MZPKJ^Y(Q>2CHFZWJKC3X#U!+ P04    " #EBGE:BD(Q?ZH"   \!P  &0
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M^FD8OH13:7]17N1>Z(K)6BJ>;<$ZS@@KGOAYVX<]@!<> ?A;@/\24#\""+:
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M>=]<7SJ(.-SUD\U*SHGDWWA7Y./'N3*7*:E=O86$F4@80\(L),Q&PAP0K.;
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M5 ?Y?D:I>&FH,XKR3&KP"U!+ P04    " #EBGE:0)^NU:<"   '"@  &0
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M79ZFNPDT\[28Y=DN-ENS40IVSD92TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4
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M[7I='OY2#?!UG?^Q>SJ?_Q=02P,$%     @ Y8IY6O@WBH M P  ^PD  !D
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M!4\W!],3&4;)_MHRE#+TD\,-4!=X?(/Z?16&\G 2#Y!OT8[_ U!+ P04
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MW=WH'B:/H\&?\/$&%66Q_*WK*AW<N'##3:#K(I"_(Q#QX8ZG:B%AF$88_>C
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MNGW8X4HW>!#&0.\O.%>[B0E0_66(?@%02P,$%     @ Y8IY6OGC> 00 P
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M&2-=+PQWH/:%UF[SP -4?Z.<_0=02P,$%     @ Y8IY6JX6IQ%, P  \!0
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MQHH!*R<%XTL7[D!@(KE4@3;%;*RT(5(].;CM>E#GM4[!A%0VM\O@?H_KX3O
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MFF@ A]I!^!..SWR=-!C/&==,U+T9RS(J7IRYC+PF8_/GW):^&9_1G,RYOF_
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( .6*>5I^=O3T- 8  ,PO   /
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M$F1HP@X &@B@\6* Y%52 $@3@33/")DJ"/4/'6DV)+X;=;6%0%HO!NEMBQI
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MK_'Z/TGU>#XW7R]_67[OG-R7"\[U;45Y^@M02P,$%     @ Y8IY6D!K%[H
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M_@)02P$"% ,4    " #EBGE:1L=-2)4   #-    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .6*>5K'4Z M\@   "L"
M   1              "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( .6*>5J97)PC$ 8  )PG   3              "  >0!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ Y8IY6E[46BTQ"@  ^SH  !@
M         ("!)0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( .6*>5H0*:9F20@  -<H   8              " @8P2  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #EBGE:*4TT)HH"   G!P
M&               @($+&P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ Y8IY6K"JB#7\!0  -1<  !@              ("!RQT  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .6*>5KT!#WS2 8
M $PG   8              " @?TC  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " #EBGE:4",CM>T)  !U+0  &               @(%[
M*@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ Y8IY6IR:
M6UUB @  NP4  !@              ("!GC0  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( .6*>5IYZ5MA30(  *$%   8
M  " @38W  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #E
MBGE:@7W;+@D"  "O!   &               @(&Y.0  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ Y8IY6O@)C6-;!@  XQ   !D
M         ("!^#L  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " #EBGE:GU87)I8)  !=%P  &0              @(&*0@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .6*>5K-LID"V2$   EA
M   9              " @5=,  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ Y8IY6K9")7)P#   SB$  !D              ("!9VX
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #EBGE:8"I)
M6<P"   $!@  &0              @($.>P  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( .6*>5I"9)1-G@4  )(,   9
M  " @1%^  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
MY8IY6H;!Y&2\"   #A@  !D              ("!YH,  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " #EBGE:71?J>_D$   U"P  &0
M            @('9C   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( .6*>5KL#&O670L  '<=   9              " @0F2  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ Y8IY6L*Y0R:'#P
M#R\  !D              ("!G9T  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " #EBGE:C@$DH0(*  !5&0  &0              @(%;
MK0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .6*>5K0
MULR*Z@(  #\&   9              " @92W  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ Y8IY6K[\B3;6!@  40X  !D
M     ("!M;H  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .6*>5I!L7&P.08  $8.   9              "
M@<8% 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ Y8IY
M6JXD$I3* P  ]0@  !D              ("!-@P! 'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " #EBGE:CP5X&H0$  #&"@  &0
M        @($W$ $ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( .6*>5KW[FG%X ,  * )   9              " @?(4 0!X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ Y8IY6D(*0N'@ @  0@8
M !D              ("!"1D! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " #EBGE:5SUBH+$#  !D"   &0              @($@' $
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .6*>5I!;W&B
M1P0  -$+   9              " @0@@ 0!X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ Y8IY6BTF)R)1!0  ;PL  !D
M ("!AB0! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #E
MBGE:K_J*5FL&  #O#P  &0              @($.*@$ >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( .6*>5H7VM0YB0(   @&   9
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M970T,"YX;6Q02P$"% ,4    " #EBGE:/V!Q(7 %  !B'P  &0
M    @(&_1 $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M .6*>5J_3+Q%5@,   P)   9              " @69* 0!X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ Y8IY6L>-WA>= @  TP4  !D
M             ("!\TT! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " #EBGE:)'IKBD$&   6'P  &0              @(''4 $ >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( .6*>5KV2AF'Q0,
M #<5   9              " @3]7 0!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ Y8IY6HI",7^J @  / <  !D              ("!
M.UL! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #EBGE:
MC,S;9T@$  #)%   &0              @($<7@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( .6*>5H?N[^3E0(  ,P&   9
M      " @9MB 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ Y8IY6N8&)+NX @  T 8  !D              ("!9V4! 'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #EBGE:P-\HK5X#  #H#0
M&0              @(%6: $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( .6*>5K<?FI%U0(  (X(   9              " @>MK 0!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ Y8IY6O11V3(=
M!P  3T0  !D              ("!]VX! 'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    " #EBGE:=!DY[V@#  "[#   &0
M@(%+=@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( .6*
M>5K\]W*WM0,  'P/   9              " @>IY 0!X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L! A0#%     @ Y8IY6D#NF_W: P  GQ(  !D
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M=#4Y+GAM;%!+ 0(4 Q0    ( .6*>5JAFEV>-00  *X5   9
M  " @82V 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @
MY8IY6LP.6J2. P  S0\  !D              ("!\+H! 'AL+W=O<FMS:&5E
M=',O<VAE970V,2YX;6Q02P$"% ,4    " #EBGE:3L8V]38-  #6K0  &0
M            @(&UO@$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4
M Q0    ( .6*>5JF:R/%PP(  '0)   9              " @2+, 0!X;"]W
M;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ Y8IY6A8:;:>B!
MT1   !D              ("!',\! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX
M;6Q02P$"% ,4    " #EBGE:K&6S2 \$  "U#   &0              @('U
MTP$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( .6*>5J2
MN@;^]0(  #X(   9              " @3O8 0!X;"]W;W)K<VAE971S+W-H
M965T-C8N>&UL4$L! A0#%     @ Y8IY6OGC> 00 P   0P  !D
M     ("!9]L! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .6*>5I*=^U]/ 8  %(9   9              "
M@?+Q 0!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ Y8IY
M6JX6IQ%, P  \!0   T              ( !9?@! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " #EBGE:EXJ[',     3 @  "P              @ '<^P$
M7W)E;',O+G)E;'-02P$"% ,4    " #EBGE:?G;T]#0&  #,+P  #P
M        @ '%_ $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ Y8IY6JQM
M4%<\ @  KRH  !H              ( !)@," 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ Y8IY6D!K%[H  @  QBD  !,
M     ( !F@4" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %  4 #G%0
&RP<"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>195</ContextCount>
  <ElementCount>428</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - NATURE OF BUSINESS AND BACKGROUND</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/NatureOfBusinessAndBackground</Role>
      <ShortName>NATURE OF BUSINESS AND BACKGROUND</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - APPLIED ASSET PURCHASE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/AppliedAssetPurchase</Role>
      <ShortName>APPLIED ASSET PURCHASE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - CONVERTIBLE LOAN RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ConvertibleLoanReceivable</Role>
      <ShortName>CONVERTIBLE LOAN RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - GOODWILL AND INTANGIBLES, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/GoodwillAndIntangiblesNet</Role>
      <ShortName>GOODWILL AND INTANGIBLES, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - INVESTMENTS IN EQUITY SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/InvestmentsInEquitySecurities</Role>
      <ShortName>INVESTMENTS IN EQUITY SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - OPERATING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/OperatingLeases</Role>
      <ShortName>OPERATING LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - DEBT AND CREDIT FACILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/DebtAndCreditFacilities</Role>
      <ShortName>DEBT AND CREDIT FACILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - SHAREHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ShareholdersEquity</Role>
      <ShortName>SHAREHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - CUSTOMERS AND SUPPLIERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/CustomersAndSuppliers</Role>
      <ShortName>CUSTOMERS AND SUPPLIERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/SegmentReporting</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - APPLIED ASSET PURCHASE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/AppliedAssetPurchaseTables</Role>
      <ShortName>APPLIED ASSET PURCHASE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/AppliedAssetPurchase</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - GOODWILL AND INTANGIBLES, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/GoodwillAndIntangiblesNetTables</Role>
      <ShortName>GOODWILL AND INTANGIBLES, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/GoodwillAndIntangiblesNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - INVESTMENTS IN EQUITY SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesTables</Role>
      <ShortName>INVESTMENTS IN EQUITY SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/InvestmentsInEquitySecurities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - OPERATING LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/OperatingLeasesTables</Role>
      <ShortName>OPERATING LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/OperatingLeases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/DebtAndCreditFacilitiesTables</Role>
      <ShortName>DEBT AND CREDIT FACILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/DebtAndCreditFacilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - SHAREHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ShareholdersEquityTables</Role>
      <ShortName>SHAREHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/ShareholdersEquity</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - SEGMENT REPORTING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/SegmentReportingTables</Role>
      <ShortName>SEGMENT REPORTING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/SegmentReporting</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - NATURE OF BUSINESS AND BACKGROUND (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/NatureOfBusinessAndBackgroundDetailsNarrative</Role>
      <ShortName>NATURE OF BUSINESS AND BACKGROUND (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/NatureOfBusinessAndBackground</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails</Role>
      <ShortName>SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails</Role>
      <ShortName>SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - SCHEDULE OF ASSET PURCHASE CONSIDERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails</Role>
      <ShortName>SCHEDULE OF ASSET PURCHASE CONSIDERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails</Role>
      <ShortName>SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - APPLIED ASSET PURCHASE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative</Role>
      <ShortName>APPLIED ASSET PURCHASE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/AppliedAssetPurchaseTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - CONVERTIBLE LOAN RECEIVABLE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative</Role>
      <ShortName>CONVERTIBLE LOAN RECEIVABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/ConvertibleLoanReceivable</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfChangesInCarryingAmountOfGoodwillDetails</Role>
      <ShortName>SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999051 - Disclosure - SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999052 - Disclosure - SCHEDULE OF FUTURE AMORTIZATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails</Role>
      <ShortName>SCHEDULE OF FUTURE AMORTIZATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999053 - Disclosure - GOODWILL AND INTANGIBLES, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/GoodwillAndIntangiblesNetDetailsNarrative</Role>
      <ShortName>GOODWILL AND INTANGIBLES, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/GoodwillAndIntangiblesNetTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999054 - Disclosure - SCHEDULE OF INVESTMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails</Role>
      <ShortName>SCHEDULE OF INVESTMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999055 - Disclosure - SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails</Role>
      <ShortName>SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999056 - Disclosure - INVESTMENTS IN EQUITY SECURITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative</Role>
      <ShortName>INVESTMENTS IN EQUITY SECURITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999057 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails</Role>
      <ShortName>SCHEDULE OF OPERATING LEASE LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999058 - Disclosure - OPERATING LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative</Role>
      <ShortName>OPERATING LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/OperatingLeasesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999059 - Disclosure - SCHEDULE OF LONG-TERM DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails</Role>
      <ShortName>SCHEDULE OF LONG-TERM DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999060 - Disclosure - SCHEDULE OF MATURITIES OUTSTANDING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails</Role>
      <ShortName>SCHEDULE OF MATURITIES OUTSTANDING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999061 - Disclosure - DEBT AND CREDIT FACILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative</Role>
      <ShortName>DEBT AND CREDIT FACILITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/DebtAndCreditFacilitiesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999063 - Disclosure - SUMMARY OF RESTRICTED STOCK ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails</Role>
      <ShortName>SUMMARY OF RESTRICTED STOCK ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999064 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999065 - Disclosure - SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999066 - Disclosure - SHAREHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative</Role>
      <ShortName>SHAREHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/ShareholdersEquityTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999067 - Disclosure - CUSTOMERS AND SUPPLIERS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative</Role>
      <ShortName>CUSTOMERS AND SUPPLIERS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/CustomersAndSuppliers</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999068 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999069 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE (BENEFIT) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>SCHEDULE OF INCOME TAX EXPENSE (BENEFIT) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999070 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/IncomeTaxesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999071 - Disclosure - RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/RelatedParties</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999072 - Disclosure - SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails</Role>
      <ShortName>SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999073 - Disclosure - SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>999074 - Disclosure - SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>999075 - Disclosure - SEGMENT REPORTING (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/SegmentReportingDetailsNarrative</Role>
      <ShortName>SEGMENT REPORTING (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/SegmentReportingTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>999076 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sanaramedtech.com/role/SubsequentEvents</ParentRole>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>smti-20241231.xsd</File>
    <File>smti-20241231_cal.xml</File>
    <File>smti-20241231_def.xml</File>
    <File>smti-20241231_lab.xml</File>
    <File>smti-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="816">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>102
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "SMTI",
   "nsuri": "http://sanaramedtech.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "smti-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "smti-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "smti-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "smti-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "smti-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 365,
   "keyCustom": 63,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 51,
   "hidden": {
    "total": 114,
    "http://sanaramedtech.com/20241231": 21,
    "http://fasb.org/us-gaap/2024": 90,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 195,
   "entityCount": 1,
   "segmentCount": 83,
   "elementCount": 755,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 816,
    "http://xbrl.sec.gov/dei/2024": 41,
    "http://xbrl.sec.gov/cyd/2024": 3
   },
   "report": {
    "R1": {
     "role": "http://sanaramedtech.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://sanaramedtech.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://sanaramedtech.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://sanaramedtech.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Shareholders' Equity",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://sanaramedtech.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherNoncashExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://sanaramedtech.com/role/StatementsOfCashFlowsParenthetical",
     "longName": "00000007 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "SMTI:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "SMTI:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://sanaramedtech.com/role/NatureOfBusinessAndBackground",
     "longName": "999015 - Disclosure - NATURE OF BUSINESS AND BACKGROUND",
     "shortName": "NATURE OF BUSINESS AND BACKGROUND",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://sanaramedtech.com/role/AppliedAssetPurchase",
     "longName": "999017 - Disclosure - APPLIED ASSET PURCHASE",
     "shortName": "APPLIED ASSET PURCHASE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://sanaramedtech.com/role/ConvertibleLoanReceivable",
     "longName": "999018 - Disclosure - CONVERTIBLE LOAN RECEIVABLE",
     "shortName": "CONVERTIBLE LOAN RECEIVABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://sanaramedtech.com/role/GoodwillAndIntangiblesNet",
     "longName": "999019 - Disclosure - GOODWILL AND INTANGIBLES, NET",
     "shortName": "GOODWILL AND INTANGIBLES, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://sanaramedtech.com/role/InvestmentsInEquitySecurities",
     "longName": "999020 - Disclosure - INVESTMENTS IN EQUITY SECURITIES",
     "shortName": "INVESTMENTS IN EQUITY SECURITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InvestmentHoldingsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InvestmentHoldingsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://sanaramedtech.com/role/OperatingLeases",
     "longName": "999021 - Disclosure - OPERATING LEASES",
     "shortName": "OPERATING LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://sanaramedtech.com/role/DebtAndCreditFacilities",
     "longName": "999022 - Disclosure - DEBT AND CREDIT FACILITIES",
     "shortName": "DEBT AND CREDIT FACILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://sanaramedtech.com/role/CommitmentsAndContingencies",
     "longName": "999023 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://sanaramedtech.com/role/ShareholdersEquity",
     "longName": "999024 - Disclosure - SHAREHOLDERS\u2019 EQUITY",
     "shortName": "SHAREHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://sanaramedtech.com/role/CustomersAndSuppliers",
     "longName": "999025 - Disclosure - CUSTOMERS AND SUPPLIERS",
     "shortName": "CUSTOMERS AND SUPPLIERS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://sanaramedtech.com/role/IncomeTaxes",
     "longName": "999026 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://sanaramedtech.com/role/RelatedParties",
     "longName": "999027 - Disclosure - RELATED PARTIES",
     "shortName": "RELATED PARTIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://sanaramedtech.com/role/SegmentReporting",
     "longName": "999028 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://sanaramedtech.com/role/SubsequentEvents",
     "longName": "999029 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://sanaramedtech.com/role/AppliedAssetPurchaseTables",
     "longName": "999032 - Disclosure - APPLIED ASSET PURCHASE (Tables)",
     "shortName": "APPLIED ASSET PURCHASE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_AppliedAssetPurchaseAgreementMember",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_AppliedAssetPurchaseAgreementMember",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://sanaramedtech.com/role/GoodwillAndIntangiblesNetTables",
     "longName": "999033 - Disclosure - GOODWILL AND INTANGIBLES, NET (Tables)",
     "shortName": "GOODWILL AND INTANGIBLES, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesTables",
     "longName": "999034 - Disclosure - INVESTMENTS IN EQUITY SECURITIES (Tables)",
     "shortName": "INVESTMENTS IN EQUITY SECURITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentHoldingsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentHoldingsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://sanaramedtech.com/role/OperatingLeasesTables",
     "longName": "999035 - Disclosure - OPERATING LEASES (Tables)",
     "shortName": "OPERATING LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://sanaramedtech.com/role/DebtAndCreditFacilitiesTables",
     "longName": "999036 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)",
     "shortName": "DEBT AND CREDIT FACILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://sanaramedtech.com/role/ShareholdersEquityTables",
     "longName": "999037 - Disclosure - SHAREHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "SHAREHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://sanaramedtech.com/role/IncomeTaxesTables",
     "longName": "999038 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://sanaramedtech.com/role/SegmentReportingTables",
     "longName": "999039 - Disclosure - SEGMENT REPORTING (Tables)",
     "shortName": "SEGMENT REPORTING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://sanaramedtech.com/role/NatureOfBusinessAndBackgroundDetailsNarrative",
     "longName": "999040 - Disclosure - NATURE OF BUSINESS AND BACKGROUND (Details Narrative)",
     "shortName": "NATURE OF BUSINESS AND BACKGROUND (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails",
     "longName": "999041 - Disclosure - SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE (Details)",
     "shortName": "SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails",
     "longName": "999042 - Disclosure - SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES (Details)",
     "shortName": "SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_SoftTissueRepairProductsMember",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "999043 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://sanaramedtech.com/role/ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails",
     "longName": "999044 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION (Details)",
     "shortName": "SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999045 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CreditLossFinancialInstrumentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails",
     "longName": "999046 - Disclosure - SCHEDULE OF ASSET PURCHASE CONSIDERATIONS (Details)",
     "shortName": "SCHEDULE OF ASSET PURCHASE CONSIDERATIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember",
      "name": "SMTI:AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails",
     "longName": "999047 - Disclosure - SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED (Details)",
     "shortName": "SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_AppliedAssetPurchaseAgreementMember",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_AppliedAssetPurchaseAgreementMember",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative",
     "longName": "999048 - Disclosure - APPLIED ASSET PURCHASE (Details Narrative)",
     "shortName": "APPLIED ASSET PURCHASE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "SMTI:PurchaseAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-08-01_custom_AppliedAssetPurchaseAgreementMember",
      "name": "us-gaap:OtherLoansPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative",
     "longName": "999049 - Disclosure - CONVERTIBLE LOAN RECEIVABLE (Details Narrative)",
     "shortName": "CONVERTIBLE LOAN RECEIVABLE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-07-31_us-gaap_ConvertibleDebtMember",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://sanaramedtech.com/role/ScheduleOfChangesInCarryingAmountOfGoodwillDetails",
     "longName": "999050 - Disclosure - SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL (Details)",
     "shortName": "SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:Goodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:Goodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails",
     "longName": "999051 - Disclosure - SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details)",
     "shortName": "SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_PatentsMember",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails",
     "longName": "999052 - Disclosure - SCHEDULE OF FUTURE AMORTIZATION EXPENSE (Details)",
     "shortName": "SCHEDULE OF FUTURE AMORTIZATION EXPENSE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://sanaramedtech.com/role/GoodwillAndIntangiblesNetDetailsNarrative",
     "longName": "999053 - Disclosure - GOODWILL AND INTANGIBLES, NET (Details Narrative)",
     "shortName": "GOODWILL AND INTANGIBLES, NET (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails",
     "longName": "999054 - Disclosure - SCHEDULE OF INVESTMENTS (Details)",
     "shortName": "SCHEDULE OF INVESTMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "us-gaap:InvestmentHoldingsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "us-gaap:InvestmentHoldingsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails",
     "longName": "999055 - Disclosure - SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT (Details)",
     "shortName": "SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_ChemoMouthPieceLLCMember",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "us-gaap:InvestmentHoldingsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
     "longName": "999056 - Disclosure - INVESTMENTS IN EQUITY SECURITIES (Details Narrative)",
     "shortName": "INVESTMENTS IN EQUITY SECURITIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LongTermInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_DirectDermatologyIncMember",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentHoldingsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails",
     "longName": "999057 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITY (Details)",
     "shortName": "SCHEDULE OF OPERATING LEASE LIABILITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative",
     "longName": "999058 - Disclosure - OPERATING LEASES (Details Narrative)",
     "shortName": "OPERATING LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails",
     "longName": "999059 - Disclosure - SCHEDULE OF LONG-TERM DEBT (Details)",
     "shortName": "SCHEDULE OF LONG-TERM DEBT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails",
     "longName": "999060 - Disclosure - SCHEDULE OF MATURITIES OUTSTANDING (Details)",
     "shortName": "SCHEDULE OF MATURITIES OUTSTANDING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
     "longName": "999061 - Disclosure - DEBT AND CREDIT FACILITIES (Details Narrative)",
     "shortName": "DEBT AND CREDIT FACILITIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PaidInKindInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "SMTI:MinimumCashBalanceValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_CostOfSalesMember",
      "name": "us-gaap:RoyaltyExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails",
     "longName": "999063 - Disclosure - SUMMARY OF RESTRICTED STOCK ACTIVITY (Details)",
     "shortName": "SUMMARY OF RESTRICTED STOCK ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "999064 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails",
     "longName": "999065 - Disclosure - SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK (Details)",
     "shortName": "SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative",
     "longName": "999066 - Disclosure - SHAREHOLDERS\u2019 EQUITY (Details Narrative)",
     "shortName": "SHAREHOLDERS\u2019 EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative",
     "longName": "999067 - Disclosure - CUSTOMERS AND SUPPLIERS (Details Narrative)",
     "shortName": "CUSTOMERS AND SUPPLIERS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails",
     "longName": "999068 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails",
     "longName": "999069 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE (BENEFIT) (Details)",
     "shortName": "SCHEDULE OF INCOME TAX EXPENSE (BENEFIT) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://sanaramedtech.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999070 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative",
     "longName": "999071 - Disclosure - RELATED PARTIES (Details Narrative)",
     "shortName": "RELATED PARTIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_ServicesAgreementMember",
      "name": "us-gaap:CostsAndExpensesRelatedParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_ServicesAgreementMember",
      "name": "us-gaap:CostsAndExpensesRelatedParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
     "longName": "999072 - Disclosure - SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS (Details)",
     "shortName": "SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_SanaraSurgicalMember",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails",
     "longName": "999073 - Disclosure - SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical",
     "longName": "999074 - Disclosure - SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details) (Parenthetical)",
     "shortName": "SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "SMTI:PropertyAndEquipmentWriteOff",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "SMTI:PropertyAndEquipmentWriteOff",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://sanaramedtech.com/role/SegmentReportingDetailsNarrative",
     "longName": "999075 - Disclosure - SEGMENT REPORTING (Details Narrative)",
     "shortName": "SEGMENT REPORTING (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999076 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_CRGTermLoanAgreementMember",
      "name": "us-gaap:DebtInstrumentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-162025-01-16_us-gaap_SubsequentEventMember_custom_SubscriptionAndShareholdersAgreementMember",
      "name": "us-gaap:SubsequentEventDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "SMTI_ABFLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ABFLicenseAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ABF License Agreement [Member]",
        "documentation": "ABF License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and financing receivable, after allowance for credit loss, current",
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r780"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "SMTI_AccreditedInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "AccreditedInvestorsMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accredited Investors [Member]",
        "documentation": "Accredited Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_AccretionOfFinanceLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "AccretionOfFinanceLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion of finance liabilities",
        "documentation": "Accretion of finance liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_AccruedInterestIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "AccruedInterestIncomeExpense",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest income",
        "documentation": "Accrued interest income expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued royalties and expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r736"
     ]
    },
    "us-gaap_AccruedSalesCommissionCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalesCommissionCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued bonuses and commissions",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r736"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r170",
      "r588"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://sanaramedtech.com/role/GoodwillAndIntangiblesNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average amortization period",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r731"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r943",
      "r944",
      "r945",
      "r947",
      "r1043",
      "r1102"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r840",
      "r854",
      "r880"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r843",
      "r857",
      "r883"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r833",
      "r844",
      "r858",
      "r875",
      "r884",
      "r888",
      "r896"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation related to executive separation costs",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r458"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for customer rebates and deductions",
        "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for credit losses",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r271",
      "r286",
      "r289",
      "r291",
      "r1068"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_AmortizableIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "AmortizableIntangibleAssetsMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortizable Intangible Assets [Member]",
        "documentation": "Amortizable Intangible Assets [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_AmortizationAndWriteoffOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "AmortizationAndWriteoffOfDebtIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization and write-off of debt issuance costs",
        "documentation": "Amortization and write-off of debt issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense of debt issuance costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r393",
      "r935",
      "r1050"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/GoodwillAndIntangiblesNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r325",
      "r332",
      "r754"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "SMTI_AnnualMinimumRevenueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "AnnualMinimumRevenueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual minimum revenue, year five",
        "documentation": "Annual minimum revenue year five."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_AnnualMinimumRevenueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "AnnualMinimumRevenueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual minimum revenue, year four",
        "documentation": "Annual minimum revenue year four."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_AnnualMinimumRevenueYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "AnnualMinimumRevenueYearOne",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual minimum revenue, year one",
        "documentation": "Annual minimum revenue year one."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_AnnualMinimumRevenueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "AnnualMinimumRevenueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual minimum revenue, year three",
        "documentation": "Annual minimum revenue year three."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_AnnualMinimumRevenueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "AnnualMinimumRevenueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual minimum revenue, year two",
        "documentation": "Annual minimum revenue year two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "SMTI_AppliedAssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "AppliedAssetPurchaseAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative",
      "http://sanaramedtech.com/role/AppliedAssetPurchaseTables",
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails",
      "http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Applied Asset Purchase Agreement [Member]",
        "documentation": "Applied Asset Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative",
      "http://sanaramedtech.com/role/AppliedAssetPurchaseTables",
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative",
      "http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r1039"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total purchase consideration",
        "label": "Cash consideration",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "SMTI_AssetAcquisitionConsiderationTransferredCashPaidForInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "AssetAcquisitionConsiderationTransferredCashPaidForInventory",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for inventory",
        "documentation": "Asset acquisition consideration transferred cash paid for inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of Petito Services Agreement contingent consideration",
        "verboseLabel": "Contingent consideration payments receivable",
        "terseLabel": "Payment of contingent consideration",
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "SMTI_AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of Installment Payments",
        "documentation": "Asset acquisition consideration transferred fair value of installment payments"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of Petito Services Agreement defined payments",
        "documentation": "Asset acquisition consideration transferred fair value of petito services defined payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferredOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Closing Consideration",
        "verboseLabel": "Cash consideration paid",
        "documentation": "Amount of tangible and intangible assets included as part of consideration transferred in asset acquisition, classified as other. Excludes cash."
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Direct transaction costs",
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r1039"
     ]
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTableTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ASSET PURCHASE CONSIDERATIONS",
        "documentation": "Tabular disclosure of asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchase"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APPLIED ASSET PURCHASE",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r143",
      "r173",
      "r201",
      "r232",
      "r240",
      "r259",
      "r263",
      "r280",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r506",
      "r510",
      "r528",
      "r578",
      "r676",
      "r747",
      "r748",
      "r780",
      "r801",
      "r995",
      "r996",
      "r1058"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r183",
      "r201",
      "r280",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r506",
      "r510",
      "r528",
      "r780",
      "r995",
      "r996",
      "r1058"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r280",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r506",
      "r510",
      "r528",
      "r995",
      "r996",
      "r1058"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r815",
      "r836"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r815",
      "r836"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r815",
      "r836"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "SMTI_BIAKOSAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "BIAKOSAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BIAKOS Agreement [Member]",
        "documentation": "BIAKOS Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_BIAKOSLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "BIAKOSLicenseAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BIAKOS License Agreement [Member]",
        "documentation": "BIAKOS License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_BackendFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "BackendFee",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Back-end fee",
        "documentation": "Backend fee."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_BackendFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "BackendFeeMember",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Backend Fee [Member]",
        "documentation": "Backend Fee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_BoneFusionProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "BoneFusionProductsMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bone Fusion Products [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r498",
      "r764",
      "r765"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r498",
      "r764",
      "r765"
     ]
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition consideration transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r12"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of earnout liabilities",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r934"
     ]
    },
    "SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revaluation of earnout liability",
        "documentation": "Business combination contingent consideration arrangements change in amount of contingent consideration revaluation of earnout liability."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlements",
        "documentation": "Business combination contingent consideration arrangements change in amount of contingent consideration settlements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationAsset",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout consideration",
        "documentation": "Amount of asset recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r126",
      "r500"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfChangesInFairValueForContingentEarnoutConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at December 31, 2023",
        "periodEndLabel": "Balance at December 31, 2024",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r126",
      "r500",
      "r522",
      "r523",
      "r524"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment",
        "documentation": "Amount of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "SMTI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intellectual property",
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed intellectual property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "documentation": "The amount of inventory recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "SMTI_CRGTermLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "CRGTermLoanAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CRG Term Loan Agreement [Member]",
        "documentation": "CRG Term Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_CRGTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "CRGTermLoanMember",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CRG Term Loan [Member]",
        "documentation": "CRG Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_CadenceTermLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "CadenceTermLoanAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cadence Term Loan Agreement [Member]",
        "documentation": "Cadence Term Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_CadenceTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "CadenceTermLoanMember",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cadence Term Loan [Member]",
        "documentation": "Cadence Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Cash [Default Label]",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r581",
      "r650",
      "r671",
      "r780",
      "r801",
      "r925"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r167",
      "r734"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, beginning of period",
        "periodEndLabel": "Cash, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r102",
      "r197"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r102"
     ]
    },
    "SMTI_CashClosingConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "CashClosingConsiderationMember",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Closing Consideration [Member]",
        "documentation": "Cash Closing Consideration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_CashPaidPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "CashPaidPercentage",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid percentage",
        "documentation": "Cash paid percentage."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_CashPaymentOfFinanceAndEarnoutLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "CashPaymentOfFinanceAndEarnoutLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash payment of finance and earnout liabilities",
        "documentation": "Cash payment of finance and earnout liabilities.",
        "label": "CashPaymentOfFinanceAndEarnoutLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_ChangeInFairValueOfDeferredAndEarnoutLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ChangeInFairValueOfDeferredAndEarnoutLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 4.0
      },
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows",
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of earnout liabilities",
        "documentation": "Change in fair value of deferred and earnout liabilities",
        "label": "ChangeInFairValueOfDeferredAndEarnoutLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "SMTI_ChemoMouthPieceLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ChemoMouthPieceLLCMember",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ChemoMouthpiece, LLC [Member]",
        "documentation": "ChemoMouthpiece, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_ClassAPreferredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ClassAPreferredSharesMember",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A Preferred Shares [Member]",
        "documentation": "Class A Preferred Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r177",
      "r178",
      "r179",
      "r201",
      "r223",
      "r224",
      "r226",
      "r228",
      "r234",
      "r235",
      "r280",
      "r362",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r401",
      "r402",
      "r404",
      "r407",
      "r413",
      "r528",
      "r628",
      "r629",
      "r630",
      "r631",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r651",
      "r663",
      "r685",
      "r707",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r914",
      "r937",
      "r948"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseTables",
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r133",
      "r580",
      "r662"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r352",
      "r353",
      "r728",
      "r985",
      "r990"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares available for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative",
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r791",
      "r792",
      "r793",
      "r795",
      "r796",
      "r797",
      "r798",
      "r943",
      "r944",
      "r947",
      "r1043",
      "r1099",
      "r1102"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r663"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r85",
      "r663",
      "r682",
      "r1102",
      "r1103"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock: $0.001 par value, 20,000,000 shares authorized; 8,753,773 issued and outstanding as of December\u00a031, 2024 and 8,535,239 issued and outstanding as of December\u00a031, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r582",
      "r780"
     ]
    },
    "SMTI_CommonUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "CommonUnitsMember",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Units [Member]",
        "documentation": "Common Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r65",
      "r66",
      "r269",
      "r727"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r65",
      "r66",
      "r269",
      "r625",
      "r727"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r65",
      "r66",
      "r269",
      "r727",
      "r923"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/CustomersAndSuppliers"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CUSTOMERS AND SUPPLIERS",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration risk percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r65",
      "r66",
      "r269"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r65",
      "r129",
      "r727"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r65",
      "r66",
      "r269",
      "r727"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation and Basis of Presentation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r737"
     ]
    },
    "SMTI_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement [Member]",
        "documentation": "Consulting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r372",
      "r373",
      "r383",
      "r384",
      "r385",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r201",
      "r280",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r528",
      "r747",
      "r995"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost and expenses related party",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable Allowances",
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r269"
     ]
    },
    "SMTI_CustomerRelationshipsAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "CustomerRelationshipsAndOtherMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Relationships and Other [Member]",
        "documentation": "Customer Relationships and Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r906"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r906"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r908"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r908"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r901"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r902"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r902"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r900"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r903"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r905"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r905"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r906"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r824",
      "r907"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r904"
     ]
    },
    "SMTI_DebriderLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "DebriderLicenseAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debrider License Agreement [Member]",
        "documentation": "Debrider License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentRate",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion rate",
        "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r27"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT AND CREDIT FACILITIES",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r199",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r360",
      "r361",
      "r371",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r387",
      "r394",
      "r395",
      "r396",
      "r537"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r75",
      "r76",
      "r131",
      "r132",
      "r205",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r778",
      "r938",
      "r986",
      "r987",
      "r988",
      "r1049",
      "r1051"
     ]
    },
    "SMTI_DebtInstrumentBackEndFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "DebtInstrumentBackEndFeePercentage",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument back-end fee percentage",
        "documentation": "Debt instrument back end fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      },
      "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails",
      "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt",
        "totalLabel": "Total debt",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r132",
      "r397"
     ]
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowing capacity description",
        "verboseLabel": "Debt description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r44",
      "r71",
      "r75",
      "r131",
      "r132",
      "r537"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r537",
      "r538",
      "r757",
      "r758",
      "r778"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate per annum",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r390",
      "r1049"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid-in-kind and aggregate principal loan amount, percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r399",
      "r537",
      "r538",
      "r778"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental increase during an event of default",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate on advances",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r373"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateTerms",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument rate description",
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r756",
      "r1045",
      "r1046"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r205",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r778",
      "r938",
      "r986",
      "r987",
      "r988",
      "r1049",
      "r1051"
     ]
    },
    "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnusedBorrowingCapacityAmount",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining amount available for borrowing",
        "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r360"
     ]
    },
    "SMTI_DebtInstrumentUpFrontFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "DebtInstrumentUpFrontFeePercentage",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt upfront fee percentage",
        "documentation": "Debt instrument upfront fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt issuance costs",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1051"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: unamortized debt issuance costs",
        "label": "Unamortized debt issuance costs",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1048",
      "r1049",
      "r1051"
     ]
    },
    "SMTI_DeferredTaxAssetsAcquistionLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "DeferredTaxAssetsAcquistionLiability",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition liability",
        "documentation": "Deferred tax assets acquistion liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory reserves",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "SMTI_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Deferred tax assets lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carry forwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other temporary differences",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bad debt and other reserves",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent liability",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "SMTI_DeferredTaxLiabilitiesContingentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "DeferredTaxLiabilitiesContingentLiability",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Contingent liability",
        "documentation": "Deferred tax liabilities contingent liability.",
        "label": "DeferredTaxLiabilitiesContingentLiability"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_DeferredTaxLiabilitiesDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation and amortization",
        "documentation": "Depreciation and Amortization.",
        "label": "DeferredTaxLiabilitiesDepreciationAndAmortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right of Use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "SMTI_DeferredTaxLiabilitiesOtherTemporaryDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "DeferredTaxLiabilitiesOtherTemporaryDifferences",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other temporary differences",
        "documentation": "Deferred tax liabilities other temporary differences.",
        "label": "DeferredTaxLiabilitiesOtherTemporaryDifferences"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued expenses",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails",
      "http://sanaramedtech.com/role/StatementsOfCashFlows",
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42"
     ]
    },
    "SMTI_DirectDermatologyIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "DirectDermatologyIncMember",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Direct Dermatology Inc. [Member]",
        "documentation": "Direct Dermatology Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "SMTI_DisclosureOperatingLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "DisclosureOperatingLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases",
        "verboseLabel": "Schedule Of Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r815",
      "r836"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r815",
      "r836",
      "r876"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated By Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "SMTI_EarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "EarningsBeforeInterestTaxesDepreciationAndAmortization",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Adjusted EBITDA",
        "documentation": "Earnings before interest taxes depreciation and amortization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share of common stock, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r221",
      "r223",
      "r226",
      "r227",
      "r228",
      "r231",
      "r496",
      "r503",
      "r520",
      "r521",
      "r573",
      "r595",
      "r740"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share of common stock, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r223",
      "r226",
      "r227",
      "r228",
      "r231",
      "r496",
      "r503",
      "r520",
      "r521",
      "r573",
      "r595",
      "r740"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income/Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r230"
     ]
    },
    "SMTI_EarnoutPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "EarnoutPayable",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout payable",
        "documentation": "Earnout payable."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_EarnoutPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "EarnoutPayment",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout payment",
        "documentation": "Earnout payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://sanaramedtech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance, percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r767",
      "r940",
      "r1029"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r920",
      "r1029",
      "r1030"
     ]
    },
    "SMTI_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOL generated under tax cuts and job cuts",
        "documentation": "Effective income tax rate reconciliation tax cuts and jobs amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash share-based compensation",
        "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized share-based compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized share-based compensation expense period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative",
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r160",
      "r187",
      "r188",
      "r189",
      "r206",
      "r207",
      "r208",
      "r210",
      "r215",
      "r217",
      "r219",
      "r233",
      "r281",
      "r282",
      "r340",
      "r415",
      "r485",
      "r486",
      "r493",
      "r494",
      "r495",
      "r497",
      "r502",
      "r503",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r539",
      "r542",
      "r553",
      "r594",
      "r619",
      "r620",
      "r621",
      "r639",
      "r707"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative"
     ],
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r492",
      "r916",
      "r917",
      "r918",
      "r1035",
      "r1036",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership value",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership interest",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows",
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on disposal of investment",
        "negatedLabel": "Gain on disposal of investment",
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932",
      "r935"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity method investment",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r251",
      "r263",
      "r275",
      "r926",
      "r958"
     ]
    },
    "SMTI_EquityMethodInvestmentsEconomicInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "EquityMethodInvestmentsEconomicInterest",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Economic interest",
        "documentation": "Equity Method Investments Economic Interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Equity Securities",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r67",
      "r278"
     ]
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INVESTMENTS",
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r840",
      "r854",
      "r880"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r837",
      "r851",
      "r877"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "SMTI_ExecutiveSeparationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ExecutiveSeparationCosts",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive separation costs",
        "documentation": "Executive separation costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtendedMaturityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ExtendedMaturityMember",
     "presentation": [
      "http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extended Maturity [Member]",
        "documentation": "Loan modification for an extension of the term of a loan in which it must be paid."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r752"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalHomeLoanBankAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FederalHomeLoanBankAdvances",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan bank advance",
        "documentation": "Amount of Federal Home Loan Bank (FHLBank) advances to member financial institutions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank, interest rate",
        "documentation": "Rate of interest applicable on advance from Federal Home Loan Bank (FHLBank)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r139"
     ]
    },
    "us-gaap_FinancingReceivableModificationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivableModificationsLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable, Modified [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r272",
      "r273",
      "r752"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software, estimated useful life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r309",
      "r331",
      "r754"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r981",
      "r1104"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r731",
      "r754"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r731",
      "r754"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r731",
      "r754"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r731",
      "r754"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r731",
      "r754"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r334",
      "r335",
      "r570",
      "r571",
      "r731"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r331",
      "r334",
      "r335",
      "r337",
      "r570",
      "r731",
      "r754"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r334",
      "r335",
      "r731"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r980"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r844",
      "r858",
      "r884"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r844",
      "r858",
      "r884"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r844",
      "r858",
      "r884"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r844",
      "r858",
      "r884"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r844",
      "r858",
      "r884"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnInvestmentsTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT",
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/ScheduleOfChangesInCarryingAmountOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r311",
      "r572",
      "r748",
      "r753",
      "r771",
      "r780",
      "r962",
      "r969"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfChangesInCarryingAmountOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r753"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/GoodwillAndIntangiblesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GOODWILL AND INTANGIBLES, NET",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r960",
      "r972"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r322",
      "r753"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r336",
      "r338"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of goodwill",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r312",
      "r318",
      "r322",
      "r753",
      "r771"
     ]
    },
    "SMTI_GrossCashReceivedFromTermLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "GrossCashReceivedFromTermLoan",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans borrowed",
        "documentation": "Gross cash received from the term loan amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross profit (loss)",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r93",
      "r142",
      "r201",
      "r280",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r528",
      "r742",
      "r747",
      "r949",
      "r951",
      "r952",
      "r953",
      "r954",
      "r995"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r815",
      "r836"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r110",
      "r772"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r112"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails",
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails",
      "http://sanaramedtech.com/role/StatementsOfCashFlows",
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share of losses from equity method investments",
        "negatedLabel": "Share of losses from equity method investments",
        "verboseLabel": "Loss from equity method investment",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r92",
      "r137",
      "r232",
      "r247",
      "r263",
      "r275",
      "r590"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r348",
      "r349",
      "r525",
      "r526",
      "r527",
      "r616",
      "r618",
      "r692",
      "r731",
      "r773",
      "r1070"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r525",
      "r526",
      "r527",
      "r616",
      "r618",
      "r692",
      "r731",
      "r773",
      "r1070"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r463",
      "r468",
      "r474",
      "r475",
      "r476",
      "r477",
      "r482",
      "r487",
      "r489",
      "r490",
      "r491",
      "r633",
      "r767"
     ]
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationDescription",
     "presentation": [
      "http://sanaramedtech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration description",
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r157",
      "r218",
      "r219",
      "r232",
      "r248",
      "r263",
      "r467",
      "r468",
      "r488",
      "r596",
      "r767"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r465",
      "r466",
      "r477",
      "r478",
      "r481",
      "r484",
      "r627"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r767",
      "r1029"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Changes in tax rates",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r468",
      "r472",
      "r767"
     ]
    },
    "SMTI_IncomeTaxReconciliationFairValueAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "IncomeTaxReconciliationFairValueAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fair value adjustments",
        "documentation": "Income tax reconciliation fair value adjustments.",
        "label": "IncomeTaxReconciliationFairValueAdjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r471",
      "r767",
      "r1029"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expected federal income tax benefit",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r767"
     ]
    },
    "SMTI_IncomeTaxReconciliationIncomeTaxExpenseIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangibles",
        "documentation": "Income tax reconciliation income tax expense intangibles.",
        "label": "IncomeTaxReconciliationIncomeTaxExpenseIntangibles"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "NOL carryover adjustments",
        "documentation": "NOL Carryover Adjusted for Expiration.",
        "label": "IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other true ups",
        "documentation": "Income tax reconciliation income tax expense other trueups.",
        "label": "IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State and local taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r767",
      "r1029"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "SMTI_IncreaseDecreaseInAccountsPayableRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable \u2013 related parties",
        "documentation": "Increase decrease in accounts payable related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable \u2013 related parties",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "SMTI_IncreaseDecreaseInAccruedBonusesAndCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "IncreaseDecreaseInAccruedBonusesAndCommissions",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued bonuses and commissions",
        "documentation": "Increase decrease in accrued bonuses and commissions.",
        "label": "IncreaseDecreaseInAccruedBonusesAndCommissions"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_IncreaseDecreaseInAccruedRoyaltiesAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "IncreaseDecreaseInAccruedRoyaltiesAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued royalties and expenses",
        "documentation": "Increase decrease in accrued royalties and expenses.",
        "label": "IncreaseDecreaseInAccruedRoyaltiesAndExpenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory, net",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r934"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "SMTI_IncreaseInRoyaltyAnnualPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "IncreaseInRoyaltyAnnualPercentage",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in royalty annual percentage",
        "documentation": "Increase in royalty annual percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r844",
      "r858",
      "r875",
      "r884",
      "r888",
      "r896"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r899"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r899"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r899"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "verboseLabel": "Net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r980",
      "r982"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails",
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest expense related to back-end fee",
        "verboseLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r240",
      "r244",
      "r250",
      "r263",
      "r536",
      "r747",
      "r748"
     ]
    },
    "us-gaap_InterestExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseOther",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "verboseLabel": "Other expense",
        "documentation": "Amount of interest expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails",
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "negatedLabel": "Interest income",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest paid",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r195",
      "r196"
     ]
    },
    "SMTI_InternalUseSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "InternalUseSoftwareMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal Use Software [Member]",
        "documentation": "Internal Use Software [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InternalUseSoftwarePolicy",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal Use Software",
        "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r735",
      "r780"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r166",
      "r181",
      "r305",
      "r306",
      "r308",
      "r568",
      "r738"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for obsolete and slow-moving inventory",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r928"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory obsolescence",
        "verboseLabel": "Inventory obsolescence expense",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_InvestmentHoldingsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentHoldingsTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVESTMENTS IN EQUITY SECURITIES",
        "documentation": "The entire disclosure for investment holdings. This includes the long positions of investments for the entity. It contains investments in affiliated and unaffiliated issuers. The investments include securities and non securities (i.e. commodities and futures contracts)."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Investments",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Investments",
        "verboseLabel": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r788",
      "r790"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r551"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OPERATING LEASE LIABILITY",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r1053"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r75",
      "r76",
      "r77",
      "r80",
      "r81",
      "r82",
      "r83",
      "r201",
      "r280",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r507",
      "r510",
      "r511",
      "r528",
      "r661",
      "r741",
      "r801",
      "r995",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r135",
      "r585",
      "r780",
      "r939",
      "r959",
      "r1047"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and shareholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r165",
      "r201",
      "r280",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r507",
      "r510",
      "r511",
      "r528",
      "r780",
      "r995",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of earnout liabilities",
        "label": "Liabilities, Fair Value Adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r80",
      "r81",
      "r82",
      "r83",
      "r201",
      "r280",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r507",
      "r510",
      "r511",
      "r528",
      "r995",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_LicenseAgreementAndRoyaltiesDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "LicenseAgreementAndRoyaltiesDescription",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License agreement and royalties description",
        "documentation": "License agreement and royalties description."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r462",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r980",
      "r982",
      "r983",
      "r984",
      "r1028"
     ]
    },
    "us-gaap_LoanRestructuringModificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoanRestructuringModificationAxis",
     "presentation": [
      "http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Restructuring Modification [Axis]",
        "documentation": "Information by concessions made to the terms of loan contracts."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r752"
     ]
    },
    "us-gaap_LoanRestructuringModificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoanRestructuringModificationDomain",
     "presentation": [
      "http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concessions made to the terms of loan contracts, including but not limited to, interest rate reductions, maturity extensions, principal forgiveness, and payment deferral."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r752"
     ]
    },
    "us-gaap_LoansHeldForSaleMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansHeldForSaleMaturityDate",
     "presentation": [
      "http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extended maturity date",
        "documentation": "Maturity date of loan held for sale, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1045",
      "r1046"
     ]
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/ConvertibleLoanReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONVERTIBLE LOAN RECEIVABLE",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r955"
     ]
    },
    "us-gaap_LoansReceivableBasisSpreadOnVariableRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansReceivableBasisSpreadOnVariableRate",
     "presentation": [
      "http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accruing interest",
        "documentation": "Percentage added to reference rate used to compute variable rate on loan receivable."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt, net of debt issuance costs",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r132",
      "r384",
      "r398",
      "r757",
      "r758",
      "r778",
      "r1067"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of debt",
        "verboseLabel": "Less: Current portion of debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r205",
      "r999"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r205",
      "r389"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r205",
      "r389"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r205",
      "r389"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r205",
      "r389"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfMaturitiesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r205",
      "r389"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt, net of current portion",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in equity securities",
        "verboseLabel": "Long term investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r359",
      "r459",
      "r755",
      "r991",
      "r992"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r359",
      "r459",
      "r755",
      "r991",
      "r992"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r269",
      "r763",
      "r782",
      "r786",
      "r1000",
      "r1069",
      "r1071",
      "r1072",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r848"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r849"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r850"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r850"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r850"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r850"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r420",
      "r459",
      "r524",
      "r567",
      "r615",
      "r617",
      "r624",
      "r653",
      "r654",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r729",
      "r730",
      "r752",
      "r761",
      "r766",
      "r774",
      "r775",
      "r776",
      "r777",
      "r783",
      "r997",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "SMTI_MinimumCashBalanceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "MinimumCashBalanceValue",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum cash balance",
        "documentation": "Minimum cash balance value."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r420",
      "r459",
      "r524",
      "r567",
      "r615",
      "r617",
      "r624",
      "r653",
      "r654",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r729",
      "r730",
      "r752",
      "r761",
      "r766",
      "r774",
      "r775",
      "r776",
      "r783",
      "r997",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity attributable to noncontrolling interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r134",
      "r201",
      "r280",
      "r362",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r528",
      "r584",
      "r665"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "SMTI_MsSalamoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "MsSalamoneMember",
     "presentation": [
      "http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ms Salamone [Member]",
        "documentation": "Ms Salamone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative"
     ],
     "auth_ref": [
      "r269",
      "r763",
      "r782",
      "r786",
      "r1000",
      "r1069",
      "r1071",
      "r1072",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://sanaramedtech.com/role/NatureOfBusinessAndBackground"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF BUSINESS AND BACKGROUND",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r158"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to Sanara MedTech shareholders",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r104",
      "r138",
      "r163",
      "r184",
      "r185",
      "r189",
      "r201",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r225",
      "r280",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r496",
      "r503",
      "r521",
      "r528",
      "r593",
      "r684",
      "r705",
      "r706",
      "r799",
      "r995"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: Net loss attributable to noncontrolling interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r128",
      "r184",
      "r185",
      "r215",
      "r218",
      "r219",
      "r592",
      "r930"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_NoCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "NoCustomersMember",
     "presentation": [
      "http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Customers [Member]",
        "documentation": "No Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_NoInsiderTradingFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "NoInsiderTradingFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Insider Trading Flag",
        "documentation": "No Insider Trading Flag."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "SMTI_NonaccreditedInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "NonaccreditedInvestorsMember",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonaccredited Investors [Member]",
        "documentation": "Nonaccredited Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental noncash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout and other liabilities generated by acquisitions",
        "documentation": "Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r415",
      "r943",
      "r944",
      "r945",
      "r947",
      "r1102"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r941",
      "r942"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://sanaramedtech.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r950"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://sanaramedtech.com/role/NatureOfBusinessAndBackgroundDetailsNarrative",
      "http://sanaramedtech.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r751",
      "r950"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_OfficeSpaceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "OfficeSpaceOneMember",
     "presentation": [
      "http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Space One [Member]",
        "documentation": "Office Space One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_OfficeSpaceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "OfficeSpaceTwoMember",
     "presentation": [
      "http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Space Two [Member]",
        "documentation": "Office Space Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r742",
      "r949",
      "r951",
      "r952",
      "r953",
      "r954"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expenses",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present Value of Lease Liabilities",
        "verboseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities \u2013 current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/ScheduleOfOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities \u2013 long-term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use assets \u2013 operating leases",
        "verboseLabel": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r779"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r779"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInvestmentsAndSecuritiesAtCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherInvestmentsAndSecuritiesAtCost",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost method investment",
        "documentation": "Includes other investments and securities that are not at fair value as of the balance sheet date and those that are not accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r927"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout liabilities \u2013 current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r780"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout liabilities \u2013 long-term",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_OtherLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Installment payable",
        "documentation": "Amount of long-term loans payable classified as other."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r132",
      "r1067"
     ]
    },
    "us-gaap_OtherLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-term liabilities",
        "documentation": "Amount of long-term debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r132",
      "r1067"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash lease expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible loan receivable",
        "verboseLabel": "Loan receivable",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r842",
      "r856",
      "r882"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r845",
      "r859",
      "r885"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r845",
      "r859",
      "r885"
     ]
    },
    "SMTI_OutstandingUnitsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "OutstandingUnitsPercentage",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding units percentage",
        "documentation": "Outstanding units percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid-in-kind interest",
        "verboseLabel": "Interest paid-in-kind",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "SMTI_PaidInKindInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "PaidInKindInterestMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid In Kind Interest [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentsMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r973",
      "r974",
      "r975",
      "r976",
      "r978",
      "r980",
      "r983",
      "r984"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r863"
     ]
    },
    "SMTI_PaymentsForAdditionalRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "PaymentsForAdditionalRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Payment for additional royalties",
        "documentation": "Payments for additional royalties.",
        "label": "PaymentsForAdditionalRoyalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual royalty",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net of debt issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of cash",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r499"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in equity securities",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_PaymentsToAcquireLoansReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireLoansReceivable",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Convertible loan receivable",
        "label": "Payments to Acquire Loans Receivable",
        "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative",
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of installment",
        "verboseLabel": "Assets purchase price",
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative",
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets purchase price",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "SMTI_PercentageOfLoanProceedsUsedForAcquisition": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "PercentageOfLoanProceedsUsedForAcquisition",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan percentage used for acquisition",
        "documentation": "Percentage of the loan proceeds that were used for the acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_PixalereHealthcareIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "PixalereHealthcareIncMember",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pixalere Healthcare Inc. [Member]",
        "documentation": "Pixalere Healthcare Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_PixalereHealthcareUSALLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "PixalereHealthcareUSALLCMember",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pixalere Healthcare USA LLC [Member]",
        "documentation": "Pixalere Healthcare USA LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "SMTI_PrecisionHealingIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "PrecisionHealingIncMember",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Precision Healing Inc [Member]",
        "documentation": "Precision Healing Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_PrecisionHealingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "PrecisionHealingMember",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Precision Healing [Member]",
        "documentation": "Precision Healing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_PrecisionHealingMergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "PrecisionHealingMergerAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Precision Healing Merger Agreement [Member]",
        "documentation": "Precision Healing Merger Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity offering net proceeds (expenses)",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from loans used for investment",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net settlement of equity-based awards",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r921",
      "r933"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from disposal of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan proceeds, net of debt issuance costs of $1,160,740 in 2024 and $61,658 in 2023",
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r569",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r733",
      "r762",
      "r781",
      "r783",
      "r784",
      "r787",
      "r789",
      "r993",
      "r994",
      "r1000",
      "r1069",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails"
     ],
     "auth_ref": [
      "r266",
      "r569",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r733",
      "r762",
      "r781",
      "r783",
      "r784",
      "r787",
      "r789",
      "r993",
      "r994",
      "r1000",
      "r1069",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting fee",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r747",
      "r799",
      "r1100",
      "r1101"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails",
      "http://sanaramedtech.com/role/StatementsOfCashFlows",
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity",
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net income (loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r184",
      "r185",
      "r193",
      "r201",
      "r209",
      "r215",
      "r218",
      "r219",
      "r280",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r496",
      "r503",
      "r505",
      "r508",
      "r509",
      "r521",
      "r528",
      "r574",
      "r591",
      "r638",
      "r684",
      "r705",
      "r706",
      "r769",
      "r770",
      "r800",
      "r930",
      "r995"
     ]
    },
    "SMTI_PropertyAndEquipmentWriteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "PropertyAndEquipmentWriteOff",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment write off",
        "documentation": "Write off of the net book value of property &amp; equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r551"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r169",
      "r589"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r551",
      "r575",
      "r589",
      "r780"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r153",
      "r156",
      "r587"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r551"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful life",
        "verboseLabel": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit loss expense",
        "verboseLabel": "Bad debt expense",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r290"
     ]
    },
    "SMTI_PurchaseAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "PurchaseAgreementDescription",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative",
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase agreement description",
        "documentation": "Purchase agreement description."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r418",
      "r420",
      "r448",
      "r449",
      "r450",
      "r459",
      "r524",
      "r565",
      "r566",
      "r567",
      "r615",
      "r617",
      "r624",
      "r653",
      "r654",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r729",
      "r730",
      "r752",
      "r761",
      "r766",
      "r774",
      "r775",
      "r776",
      "r777",
      "r783",
      "r793",
      "r989",
      "r997",
      "r1045",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r418",
      "r420",
      "r448",
      "r449",
      "r450",
      "r459",
      "r524",
      "r565",
      "r566",
      "r567",
      "r615",
      "r617",
      "r624",
      "r653",
      "r654",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r729",
      "r730",
      "r752",
      "r761",
      "r766",
      "r774",
      "r775",
      "r776",
      "r777",
      "r783",
      "r793",
      "r989",
      "r997",
      "r1045",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Pronouncements",
        "documentation": "Recently Adopted Accounting Pronouncements [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r826",
      "r837",
      "r851",
      "r877"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
      "http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r419",
      "r557",
      "r558",
      "r579",
      "r586",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r681",
      "r683",
      "r714"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r557",
      "r558",
      "r559",
      "r560",
      "r579",
      "r586",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r681",
      "r683",
      "r714"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r688",
      "r689",
      "r692"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
      "http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r419",
      "r557",
      "r558",
      "r579",
      "r586",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r681",
      "r683",
      "r714",
      "r1057"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/RelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTIES",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r555",
      "r556",
      "r558",
      "r561",
      "r634",
      "r635",
      "r636",
      "r690",
      "r691",
      "r692",
      "r711",
      "r713"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Pay off line of credit",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r938"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r1028"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r1028"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r731",
      "r747",
      "r1066"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r838",
      "r852",
      "r878"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r839",
      "r853",
      "r879"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r846",
      "r860",
      "r886"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r117",
      "r583",
      "r622",
      "r623",
      "r632",
      "r664",
      "r780"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r206",
      "r207",
      "r208",
      "r210",
      "r215",
      "r217",
      "r219",
      "r281",
      "r282",
      "r340",
      "r485",
      "r486",
      "r493",
      "r494",
      "r495",
      "r497",
      "r502",
      "r503",
      "r512",
      "r514",
      "r515",
      "r517",
      "r519",
      "r539",
      "r542",
      "r619",
      "r621",
      "r639",
      "r1102"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails",
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Revenue",
        "verboseLabel": "Total Net Revenue",
        "terseLabel": "Net revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r232",
      "r241",
      "r242",
      "r257",
      "r263",
      "r266",
      "r268",
      "r269",
      "r416",
      "r417",
      "r569"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r732",
      "r739"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use assets obtained in exchange for lease obligations",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r779"
     ]
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_RochalIndustriesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "RochalIndustriesLLCMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rochal Industries LLC [Member]",
        "documentation": "Rochal Industries LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_RochalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "RochalMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rochal [Member]",
        "documentation": "Rochal [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyAgreementTermsMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Agreement Terms [Member]",
        "documentation": "Terms of the royalty agreement under research and development arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for additional royalties",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "SMTI_RoyaltyExpensePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "RoyaltyExpensePercentage",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense percentage",
        "documentation": "Royalty expense percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "SMTI_RoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "RoyaltyPercentage",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty percentage",
        "documentation": "Royalty percentage."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_RoyaltyReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "RoyaltyReceivable",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty receivable",
        "documentation": "Royalty receivable."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "SMTI_SIHealthcareTechnologiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "SIHealthcareTechnologiesLLCMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SI Healthcare Technologies LLC [Member]",
        "documentation": "SI Healthcare Technologies LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issuable",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://sanaramedtech.com/role/CustomersAndSuppliersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r922"
     ]
    },
    "SMTI_SanaraSurgicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "SanaraSurgicalMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sanara Surgical [Member]",
        "documentation": "Sanara Surgical [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r421",
      "r946"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": [
      "r220",
      "r421",
      "r915",
      "r946"
     ]
    },
    "SMTI_ScendiaPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ScendiaPurchaseAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scendia Purchase Agreement [Member]",
        "documentation": "Scendia Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "documentation": "Disclosure of information about contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION",
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfPurchaseConsiderationOnFairValueOfAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r498"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseTables",
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INCOME TAX EXPENSE (BENEFIT)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF LONG-TERM DEBT",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEFERRED TAX ASSETS",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r45",
      "r46",
      "r47",
      "r48"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r492",
      "r916",
      "r917",
      "r918",
      "r1035",
      "r1036",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable",
     "presentation": [
      "http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable, Modified [Table]",
        "documentation": "Disclosure of information about financing receivable modified for debtor experiencing financial difficulty."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r272",
      "r273",
      "r752"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r331",
      "r334",
      "r335",
      "r337",
      "r570",
      "r731",
      "r754"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/GoodwillAndIntangiblesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r979"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/GoodwillAndIntangiblesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF MATURITIES OUTSTANDING",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://sanaramedtech.com/role/OperatingLeasesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r551"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r688",
      "r689",
      "r692"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION ACTIVITY",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r118"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF RESTRICTED STOCK ACTIVITY",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANTS TO PURCHASE COMMON STOCK",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/GoodwillAndIntangiblesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FUTURE AMORTIZATION EXPENSE",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r981"
     ]
    },
    "us-gaap_SecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured term loan",
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r132",
      "r1067"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r232",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r269",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r337",
      "r350",
      "r351",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r744",
      "r747",
      "r748",
      "r753",
      "r785",
      "r1069",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT REPORTING",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r232",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r253",
      "r255",
      "r256",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r743",
      "r745",
      "r746",
      "r747",
      "r749",
      "r750",
      "r751"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "SMTI_SeriesBTwoPreferredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "SeriesBTwoPreferredSharesMember",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B-2 Preferred Shares [Member]",
        "documentation": "Series B-2 Preferred Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_ServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ServicesAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Services Agreement [Member]",
        "documentation": "Services Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://sanaramedtech.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative",
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Non-vested shares, beginning",
        "periodEndLabel": "Non-vested shares, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average grant date fair value, beginning",
        "periodEndLabel": "Weighted average grant date fair value, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of warrants exercisable, ending",
        "documentation": "Number of equity instruments other than options exercisable, including both vested and non-vested instruments.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, exercisable, ending",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant exercisable.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of warrants, exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants, expired",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, expired",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant expirations."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, forfeited",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants, forfeited",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants, granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of warrants outstanding, beginning",
        "periodEndLabel": "Number of warrants outstanding, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120"
     ]
    },
    "SMTI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price outstanding, beginning",
        "periodEndLabel": "Weighted average exercise price outstanding, ending",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant outstanding.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum number of shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options remaining to be exercised",
        "periodEndLabel": "Options exercisable, ending",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price exercisable, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options to acquire shares",
        "verboseLabel": "Options, Granted or assumed",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, ending",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, beginning",
        "periodEndLabel": "Options outstanding, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted exercise price",
        "documentation": "Change in the weighted average exercise price of options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price outstanding, beginning",
        "periodEndLabel": "Weighted average exercise price outstanding, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Granted or assumed",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r426",
      "r445",
      "r446",
      "r447",
      "r448",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contract life exercisable, ending",
        "documentation": "Weighted average remaining contractual term for warrants awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining contract life outstanding",
        "documentation": "Weighted average remaining contractual term for warrants awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contract life exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contract life outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price per unit",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares withheld",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r986",
      "r987",
      "r988"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://sanaramedtech.com/role/ConvertibleLoanReceivableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r986",
      "r987",
      "r988"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r198"
     ]
    },
    "SMTI_SoftTissueRepairProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "SoftTissueRepairProductsMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfRevenueFromProductSalesAndRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soft Tissue Repair Products [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r162",
      "r232",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r269",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r337",
      "r342",
      "r350",
      "r351",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r744",
      "r747",
      "r748",
      "r753",
      "r785",
      "r1069",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r177",
      "r178",
      "r179",
      "r201",
      "r223",
      "r224",
      "r226",
      "r228",
      "r234",
      "r235",
      "r280",
      "r362",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r401",
      "r402",
      "r404",
      "r407",
      "r413",
      "r528",
      "r628",
      "r629",
      "r630",
      "r631",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r651",
      "r663",
      "r685",
      "r707",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r914",
      "r937",
      "r948"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative",
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r85",
      "r88",
      "r89",
      "r160",
      "r187",
      "r188",
      "r189",
      "r206",
      "r207",
      "r208",
      "r210",
      "r215",
      "r217",
      "r219",
      "r233",
      "r281",
      "r282",
      "r340",
      "r415",
      "r485",
      "r486",
      "r493",
      "r494",
      "r495",
      "r497",
      "r502",
      "r503",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r539",
      "r542",
      "r553",
      "r594",
      "r619",
      "r620",
      "r621",
      "r639",
      "r707"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails",
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r233",
      "r542",
      "r569",
      "r626",
      "r651",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r663",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r683",
      "r686",
      "r687",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r707",
      "r794"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r421",
      "r915",
      "r919",
      "r946"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfInvestmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfLossFromEquityMethodInvestmentDetails",
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r233",
      "r270",
      "r542",
      "r569",
      "r626",
      "r651",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r663",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r683",
      "r686",
      "r687",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r707",
      "r794"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r841",
      "r855",
      "r881"
     ]
    },
    "SMTI_StockClosingConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "StockClosingConsiderationMember",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Closing Consideration [Member]",
        "documentation": "Stock Closing Consideration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity issued for acquisitions",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative",
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for acquisitions, shares",
        "verboseLabel": "Issuance of shares",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r117"
     ]
    },
    "SMTI_StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net settlement and retirement of equity-based awards, shares",
        "documentation": "Stock issued during period shares for net settlement and retirement of equity based awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative",
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in equity offering, shares",
        "verboseLabel": "Number of shares purchased",
        "terseLabel": "Sale of stock",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r84",
      "r85",
      "r117",
      "r628",
      "r707",
      "r721"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative",
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Shares",
        "verboseLabel": "Shares issued as consideration",
        "terseLabel": "Issuance of common stock for purchase of assets",
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock granted and issued",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r84",
      "r85",
      "r117"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation, shares",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r84",
      "r85",
      "r117"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r84",
      "r85",
      "r117",
      "r432"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative",
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for acquisitions",
        "verboseLabel": "Payment in cash",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r85",
      "r88",
      "r89",
      "r117"
     ]
    },
    "SMTI_StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net settlement and retirement of equity-based awards",
        "documentation": "Stock issued during period value for net settlement and retirement of equity based awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/InvestmentsInEquitySecuritiesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative",
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in equity offering",
        "verboseLabel": "Purchase of shares, value",
        "terseLabel": "Number of shares issued, value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r84",
      "r85",
      "r117",
      "r639",
      "r707",
      "r721",
      "r800"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of Stock Closing Consideration",
        "verboseLabel": "Value of shares issued as consideration",
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock award, gross",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r117"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r84",
      "r85",
      "r117"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Sanara MedTech shareholders\u2019 equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r88",
      "r89",
      "r108",
      "r665",
      "r682",
      "r708",
      "r709",
      "r780",
      "r801",
      "r939",
      "r959",
      "r1047",
      "r1102"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://sanaramedtech.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets",
      "http://sanaramedtech.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r63",
      "r160",
      "r161",
      "r188",
      "r206",
      "r207",
      "r208",
      "r210",
      "r215",
      "r217",
      "r281",
      "r282",
      "r340",
      "r415",
      "r485",
      "r486",
      "r493",
      "r494",
      "r495",
      "r497",
      "r502",
      "r503",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r529",
      "r530",
      "r534",
      "r540",
      "r553",
      "r620",
      "r621",
      "r637",
      "r665",
      "r682",
      "r708",
      "r709",
      "r725",
      "r800",
      "r939",
      "r959",
      "r1047",
      "r1102"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS\u2019 EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r200",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r415",
      "r518",
      "r710",
      "r712",
      "r726"
     ]
    },
    "SMTI_SubLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "SubLicenseAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sub License Agreement [Member]",
        "documentation": "Sub License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_SubscriptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "SubscriptionAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreement [Member]",
        "documentation": "Subscription Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_SubscriptionAndShareholdersAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "SubscriptionAndShareholdersAgreementMember",
     "presentation": [
      "http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription and Shareholders Agreement [Member]",
        "documentation": "Subscription and Shareholders Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventDescription",
     "presentation": [
      "http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent description",
        "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r563"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r563"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r563"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r563"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r563"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://sanaramedtech.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r564"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for:"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_THPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "THPMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfOperationsAssetsAndCapitalExpendituresForOurBusinessSegmentsDetails",
      "http://sanaramedtech.com/role/ScheduleOfReconciliationOfNetIncomeLossToSegmentEbitdaForReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "THP [Member]",
        "documentation": "THP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "SMTI_TwoThousandFourteenOmnibusLongTermIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "TwoThousandFourteenOmnibusLongTermIncentivePlanMember",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Omnibus Long Term Incentive Plan [Member]",
        "documentation": "2024 Omnibus Long Term Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SMTI_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember",
     "presentation": [
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Omnibus Long-Term Incentive Plan [Member]",
        "documentation": "2024 Omnibus Long-Term Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://sanaramedtech.com/role/AppliedAssetPurchaseDetailsNarrative",
      "http://sanaramedtech.com/role/AppliedAssetPurchaseTables",
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative",
      "http://sanaramedtech.com/role/RelatedPartiesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfAssetPurchaseConsiderationsDetails",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative",
      "http://sanaramedtech.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "SMTI_UnvestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "UnvestedRestrictedStockMember",
     "presentation": [
      "http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://sanaramedtech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r151",
      "r152",
      "r154",
      "r155"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ScheduleOfComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r791",
      "r792",
      "r795",
      "r796",
      "r797",
      "r798"
     ]
    },
    "SMTI_WarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sanaramedtech.com/20241231",
     "localname": "WarrantOneMember",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant One [Member]",
        "documentation": "Warrant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://sanaramedtech.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sanaramedtech.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1045",
      "r1046"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r228"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://sanaramedtech.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r228"
     ]
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://sanaramedtech.com/role/DebtAndCreditFacilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Write-off of debt issuance costs",
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://sanaramedtech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-7"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "855",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478878/942-470-45-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-33"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-34"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "44",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-44"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-5A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479366/326-20-35-8A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-17"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.M.2.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483530/326-20-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-13A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3D"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-40/tableOfContent"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>103
<FILENAME>0001641172-25-000632-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-000632-xbrl.zip
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M38^[-CTV(?OTI\S4VI8''Y3>W$A%@?'=H6P..SHZ#W]HR%PS<5W#P-C $/F
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M:E)A=$;([Z$2J%5PNH&K4IN'>R.NCT<TW;=5GC<AXK%X> 0*]M^K  ,WH;;
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MG>9$&'^E=<9T\-+,P/  !4/C-8B;S-1H)$TP.S[9,0*#.\)J1+7 DX;HLA'
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MZ%_J[RIJ-^H&9F^J:BR)$I(LM$#(W]C%SM"=P[)S_D!/67' ,$8P&OP0=.@
ME/(8(>(([,FJ N'BUP-0 $75<I3KFX5ZO"W_&G4Y*AEJ1<>]LZZ[YI\S)>O/
MH@:*&NCN--!5[S50J*5U!1Y2I4I=40NZK@?CC2>0?HY\*VP;4!1L3C0!]J;D
MO%97&*)6A5B#I=ZTR.^IQUP-T<'O9J" 1%WJC225WNQ;NG3A@D#ZS+8160,
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M'A*4"@@^E93FXF*KT@_<BXPRL/C&O!4JTI2QI>WEJ_L[MWD8!XUA&4K\R#?
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MB^JFO0<S<@_F^2!JI<_D7* \N.WUEA8+3JRF;O5GM5N/6JO(2BX#R/4MN<8
MC,.Y) N1:B@<'0=6%Y9K)+]BQ"2/%Q7\8-)D!**X"D=3FGU6$5Q(G#]:0RT<
MQQ+& CP8*@+YP?R-$[W(Q/R2WZY>&LJ^JC5#U46V\A^\_AB]_AA"//0]BA,9
M(^O&1&,ESE6LBD5+@:!-4-.*_2H3-"!L[4*L*^)KE\)Q&X51">HV_5,J>^*E
ME]#12^@08I1L86N6Z#5E5%/D<4@+:8GJ6)C5N;5!-HC'&]8LL6%@0?=K<5TG
M2*A/<4'\TGR,=U(7Z0-6V9,''SFBQ";6321P&;CB=*V:"'O2VI&!$0F5M0-T
M%3<O61;@!"$<&IG0"^1HN@:7)T_1-6+^",=(967TS/#Q,.-CM3 V1V/CN<FO
M6+**?>7A46&-"&-"L(2DKD]W&XD)%1M^Q<RPPX\F8;SKD5:',L^C?5_FZ<L\
MMR^2NY\&V+X%]&)5Q']+P7US+M\EFN$YKC? <5W5JRX%@MMVHRIRB599$B]:
MZ+,JX<S&E,5'D>O>*?GKGIW+_==RO5-P8Z\&Z3_-GG)$5"!VA>JXL+E0+"^$
M;@\U">;I-<+0:V:L@BO<$9-><W?-948E8,NT78ZX-[A] 2HG%R$W3*+X;\9
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M[=+UU!5-C"RB)]"HP,*E9OV"(<DI0#I%CB'\3,H6U'>>*6(ULJ.9=V8LQE0
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MMC[8CSH.]DNN0C('Q$.JY\YXV&AT]IUFOTE%/@2$WADB8MUIFFLE42ORAM(
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MPZ/H>+A)?Q =[P5OZHO YNC8^J2D.M[V07YSNN*5H]Z84I#NL6$8\Y?O-3>
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M924#!W> AQH.UL4][W.#!W>1A?G&@R8>FQ^8N*Y@[<8@HP&+^?.8#5@TXF3
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MKI=A)K))R4UE&>?2SM=NUL$^?O"V^Z_[WL^W,GXG;3^<QN^K_P)02P,$%
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M\M:'D=W0KRRS=YCZ5>>?4$L#!!0    ( .6*>5H?DQO3R@4  +D=   *
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MY3HBIW@AO^WNS@KB.PI&GCI\SA9R@^_N+CWF^F"0BJ-@ -)R4\)YP Z@Z3
MPH9K)'Q4'XN;3'.P'ZU0[2Z_,B0/Y6?FL_XC\U9KNX=+Q[_59>R)\-+5U\OB
MD-)>=>D1!?+Q\EJ<90&Y_!IN&=,4"#&[Y<8CH%U^XNJ#H9V9H3 ;VN75E\Z
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ML9+^%J"_6<=7DF!)@@\=M5O*OU+^O1SB6\M8\6SB*^5?*?]*$EPE"7(G9>V
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M5FMP#J%Y8WG)+%-KG5P3L^(H@H X[12?]5^_]R=_79Y&?Y]82SGKG8Q3-P,
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M25X2-$E8:YW=N=X$UB!3],P*[2$'M<91?F^ZH#B;A,IK'ZCT@8]CN4AB\G(
MQB)VC5V',&RONE,##/O7^?_]/'9& \NKWX]A\]8N1#D^*2>/<CL/1+GV^8F&
M='*XS&'EJ%J#_[\S"^M,/K=%,@&>]*H8@.! D:@-F64I\PV? ON O5U:X3?D
M;9<L)"B*Y=Z7\,+^/OG]\."/H_N/<L;*;QZ5=[&[^Z@3U4?V4(W,S!-5M3.H
M!/+S!3X'EJ$TL)#-!RDRK(SP?S'*LVJZ_V7PCB^:UV>M\ZNNT3YO7G0N+SH-
M[&3_^0^STSII=5KGS=;Z\JQUYZGWM3V.TF95S/D\ 1H!# =;ZPJ@^.P!ORBF
M^^A@TAR[-_$MZ[TQ8ZQ ^^<;M:2IKVE^GIAJU4?KQ@Q4E#&\8SJRM%O8;/?>
M;7%USO4Y"T%NI2Q04,Z 1<5FN]U6.7"\/;C94=[7$_B=B8WM*V@3*F=]3"[\
M"!3#/C;( &TO9"Y<BHON5>U0X!VAA,D0"Q1H;L<B40CLU4O0K2:F&G^+,'3!
M4G+(V-EMF'P$"AJR?#641!+L,\;H*]B-/CE4%&;>NF!+]9C!7<P42LAE%B.G
M4S:4UIH2GW71*<;S=4VK'PN7%T/>V)]JQ0VP\7?./E0##Y7OAD6S>Q*N*[T]
M;5[\<XR!T<:Z/' 0C!H<\\MC8-;L9C,7@&!_A(=QTJ2-YT%[H(CU]'GF)N6D
M!YJ[G'U*#EJHB_7,_+5<GMMT#M("W:M%U^FI9):=G6S)>L$36'-?H#\4];N&
MU;+/4J _^P*]N[&8U#1UYB&S?F[U&+!DV.R8[DFGBDT[9$&EECD,46[^U]5%
MLUI38OB*]@',MXFR%40AB+K\1[^]MS[-/SZ=*I=$D*OOH:,WX^6'(B5%8;O;
MU5;I*@WAJ69>X&@!LT7Y MKH!.XT*MNG+)"I6]T^H#;[N?2BZHSV* \O\"]>
M87Z_J<?W_:AN/WP7CVS[@9SA =T\>@#@( P2W\'+"D)@Y(/>VWIUMU+?.:S4
M]_;>3=]%(7=\X(VDK%'$;7<?LI=&YXJ :&]GMF05YY[]"GQS[K8857_I%O/2
M\KZ[^3YT8[;<"UE@PR_G'%>,XW/QN7W5.C-K\W(GETI?>_?!\_FZVSYO=;N+
M4M42KFT^8+L+LZZ2/%X*>32>C#[V[P.HT^[^;IXTFE<7G?6CD=IA222OED@^
M/QF1'-P'T/5YI]6]./W6.N;=]*X:)R<T<A:#!VM'-3M')=6\6JII/AG5'-X'
M4/./SZV.&!CVQ]I1R6ZUI)+72B7U)R.2H_O@N>Q<7+8Z.%"OI)"20M:&0G96
M3R$1IY!:83>.3,N UI?&J0F$TFRUCMOG7TI**2EE?2AE]\ED2:UV'T!G[?.6
MV6V<M*[^($B.V]WFZ47WNE-*EY)FGBT&4JL_, ABMLL(2(GA&X#A]TN%O:>3
M"COW2H5&Y_<6CS">7'3,3NM+NXO#PJ]$ME^77%D7YV;KW]=@J5?@B5-*A.U^
M;71:7R].CUL=\ZQQ=076O-DX/S;;W>XU?'1YW6E^;71;79S^S7^KS0=?/X%3
M*P7.:R7'_:<CQWLC_J",M3K?6L<E@90$LC8$<O!T!')OR/ZL<=[XTL+8BA10
MRIBY[G;;(*A0",%#IW]TVR1\3MKGC?-FNW$*DNS\&,2/> 9([?KTBAY!+UL#
MOUA#P50OZ>[5TMW3I0+4[R6\?U^#4MB^ C+YUB)0D(;@PU/QF>Y/,!N?+ZZO
M3*Y;FIA%L'9TM;=7TM5KI:O#IR.K>U-LE'22R0-7)-RX+=6]OKP\I7\W.G^8
MQXVKQMK1T<E6J1B^6D(Z>C)"VKTW5MK\VCC_TN+:8)MK>""1&E\Z+4%0W]M7
M7\U&LWEQ#>2$'Z >R/_9/O]"/TA5Q528K1W%[>V7!/=J">[I-,*]>T.O8$Y=
M=2Y.NTH;I"CL\5H&E$JB><5$\W3)HGOW1F$OKKZV.B"@3BXZ9^1R*$FE))7U
M(96GRQ#=NS?PF^I@!$BG]:71P10?#%2UVE_.S7]==]K=XW:3/'?FU=?&%8B@
MUC?0]H# NI>MYGJZ]$H">ZD$-H7C]X9?T^2&,KNA1/$-0/$'5!E4GTZ&W!M/
M/6YW6E2^5B% 6O]I-:_)6WUQ<M)NRIP%U=_+_'+QK=5!)\ :VOT'I=AXM33U
MA$73]T:"%!$1',V+L\O6>7=-;9F29EXOS3Q=(<_>O6$>6>E&8%Q\/P?)\[5]
MB;D'((2N&NUS\W/KO 4B"9W/_'N23&FZ@\A9$,EW5Q?-W[/)=R7ME;2W/K2W
MNA*A^>;4%&4>O/DD*8R(!ST"0'G=##EAPFNWP=T%%1$ZXGJCV3X_;H%\.^;]
M7JU/B^RK)+&2Q%9'8D]76[1W;S7W9:=]WFQ?BBP&+:IZTFJ)5(96YQL87*68
M*FGHV;QQ]^80*&_<-]T7=]]/2L==20WK3PT/D"A/5Y>T?V]R0>L_7]N?VU=I
M<D&:FZ.2Y,QN\VOK^/IT':5*V9SJ]=+1TQ44[=^;;X!Y!M3OE^>77I^=-3KK
MUV]GOSB)=*43H%V%6>ZG%;;$=S]U+=\*+?@%_:]YQIPK9@\K9I"$IA<, C&R
M)30#G"IGQ*'E,)SC%>%@V8B%-SC;BG]@C<?,HL& -(W3C>3D71Q?B-V6QV$P
MALNCN5O9]^'XBVWS"A>GR12P!>U-"$+F53CSB. 1\^QHX,(B;X=_NS@B+QKS
MF;YF<.NS,-HVNX&'D[CXJ&C_AL'2OLTJM$ *446"8Z0 QBGP9G8L:184'  1
M)'PV*=SQP>['"OSOX>YA_2,>*=\6;,8#',=^T-%DU L\>&4/?H3CP](I&'PP
MI!_@'%0Y]3I0TU5QSBJ-=KRU)A4^,?*6\<D5.' #)QR'L1K%T4\\CT6Q',G!
MQQ5K8'C6+4<*(B^Z?1K (?Y%1VKHS\/I^%$01N(%4>'YF87GM[URK'\BXKKV
M/1PU1W=ZZ\(1R+MQZ,[K]>K''-W1I[6/1N9;^:G &?I&C"Y47XF/X8;R'R61
M^@0N37QXR]2'A$XTL'>:) V\&9P;#<1 G;)I$DN4]"+7<8':GN.NYDZ0 "*Z
M&-/0U _X4B&)/IHT/0N^+@=,+#)@(C-I1![R1_-J,@8 &Z'5<^V/YCF0++^(
M\P"/MYX9A"!_12-69KR]'%E1=&T;.[)B"=Q@B7,OWF1G7 B.@+E/7*GC+VHV
MKM'!CI5,J0672>K[#G]NG5Y<_ [_-M)2J)5,B5#L;T73/]3Z5YIR@G/%+->/
M4/FYM4)GRPN"GZA/:7.G^?0J ^70B('>Q0=DD?[ @%)P<'HZ @M4!M"H3F:O
M-F ^_L:;B-E5*(3Z29R 4L-N^,3WD'0.\6$ZGAT_!V6.IG<9\ >-)"-%C:M>
M+@WU&KMVQ%4F'+Z:B-F$8AKV+9IE7+4$N&S4I(12PO61*QI9:'YEEA</S4LO
MB<PQ (EO@EVUP5P(1L!(8"TX[DF0&#9A&$[<[D_FG6&/V582D4XZD8<.T(1.
M"JL0TI8[BO+2W(+U;7>,D[[R7_68Y\*Y17DE@@;&C<9>T6_P.]=/V/3GB>?D
M/P3]D$;53JW"[E"/GOH8.3$<4)P':)" (H&WE7N>:[%3RXRL*34'-N-//3<.
MHL@%#C?].7)#0)L\'..0@3HV#3=\[KDC0+9P^L5A\&?15B/&?DY_."PZQ1AH
MDDV=">KE!6H:+J!]C)3FXS!E/HY=*-:$/!7 [M"U^,#X[%>I71'!MCP<*L<
MB_%CN#FP@G R7620B0 (8;/0)W+AU\J7!)4]QCE\ [ E^.GCS^G&Z'LPG1!Y
MY^ ]45C2P^-#0H>W$.:';H0&0>*+#Y!UD-H)!DHRXKI<9E)?W[)CLBLXN'!
M)B<H^!QGX\%^$B\FN\-Q^ZC;(L["T2"CZ8?!"'X9X..*DLA.(]I+P=4X2<60
M-AMB!3\/;A'V01T(;N&1#TM@T?S_\0$T!<Q:? @6!,.EM^C)G(182+F9TF 6
M@5?,QIN>C'>?[O/FDS&MZJB]'.T?'$TIJ862"V@KC/MPIVAMFY+3P%6&*#J
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MQ,PD<Z_Z?J]J_DG[ON'[KABS3XC2,Y1V!L_I7ZI$=Y488JK$$'B4IWPT2<V
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M4WI,PG_C8HP(37.R(K"9=\9;2*X6WH//$,X6;:X7,4&N&<E"BM3#@:Z+G"^
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MA#2]LCA&K>O-13[7364V'&Y/=EF%J'*):>&(D8X+CE]'M"26E#^S:"8J,9B
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MFCMMU7)]'C[)>1W>XW7XDR-JE]4@.GDK0#9/#!3%3)K'Y9QGEY991/$/E#C
MA"5\7RG/+.5DD!88)?^):>>4Z78K_])GUI-'-*O#5U-WG[(:5*+S17=*!5)W
MPZEUN%1_&VWR\X:XSQOBVYC%5M$?U?>$WWAZ"60!JKOF<B<]7%WP0'E%53 E
MA^[X^!;91(E4,3WGY7*?EPL["JSL86Q?&@/^ [9+*+Z04P.R"["NXWF+=P83
MGNH*9P3_YR5X7Y>@(0@T4O"B1I#['@9&":>Y<LAOK"')R:07<AV(Y[O=-GB)
MPIF!UF4*LH8C?],U/@XA%U-+R6KA*Z466WOR9HBY/\UDD''JO!+O[TI\'J6(
M66@:1">/&H@9+^MI=JB<]=5M1#P/0L>6)W$."ASO;!]_185X6@#EO"KOZZK\
MR1&X$-,\"-<O&?;_ 4!BF="("001P369,8QM![I M3AMH5)<H;\)O.:\0L\K
M]%U6*.-\XT6MP5'14J305>P40U9&DJS35B@H1$!MI#Q+J02R;K;RJ.$5U<26
MI2X$S5&EW)3FY+7S!>4#<@.>E_-]7<Y38$:7<E&FKY/!, #DK-"P2R(5TUH6
M'JMC$!S#4$8PT'GIW.NE\PQO&#''R_\S>[4+XZ.*J#(!6Y/>J1&UBABHZ"MR
ME.37K2A1G,FTB%3BK@V6B0&/? ?:J8?#^C4P*@^*X,J44SLK6)$:,#40($<9
M3'0X!S#:Z.\J6T$PBJ=YL'<YR!Z<^W:7X:VKZ=U[SO]X[CG_D#WG?SSWG)][
MSD<DJ^?SQU!#:JJC F_3+DG@R6#MM 26T'.J%,X=WDL4GCZ':?=Y<?SDSTHT
MUQO+7O L3,?JU^*GO%*?2 OX$K[#E)1930FZ;^ X  @]Z8>#*.N4<9C;<2Y2
M?B0K\>>,Z=AK12:IZA,]U+O6XI$U=EXW']NZR;MENDL3T4J9F-/LQC2XDI>5
M]CZN*90P*6LI_*2(LDRA5- A[#14%(IJ4YX(/$%&RP$_;FO);EV.^BD=P"E#
M*T%D;=NLA-PK#O74X]Z>"F>#3,*Y3>9>;X=OTYI-, ^U>=]_^_2T+L:X:KP$
MKU#$HPHK<.VK;K0O,I9M27*NP;$,3GK2\ACCQFFE =3<!K?'P]-DZSH-,)CO
M-KQ"#SSP7/MIR&F<'V!-GY>O+%\'1XKH$KS+E,Y/!SXU%^>4ZD4C[&DN8'!A
MP_( ,_AUL[&]@'X!29:1W*7BGXP8,7S_JB*<:=.!RT+4G\-:IQZ"EK_P'D\S
MHJ(UX,"#UXV6+R!Z'*;@3;U/8LVE:1#E9TW5LSG8<SB>F#24?K9L9PAUOA9/
MF+*[K$G@+9ZZ<&-FAPS+U-5L&Q86E1["B$^;C'!!F<(QHC)2-26'K/XEQ 54
M68I#\"<BZROR5@R:<6(FU8 <9XCYO3$/[X0+RCR]!,75@LR)04*SOMSU@ZB/
M$:,6MCO/%'+8(T&U'!%.Z*(3L>$#8#!=/W+V_3J<G,I>$'8ROKIUA!@%U<7L
M681RCAX%)@RF\U? 05+8%&RH#[^2I?20K$VU[WHCPZ+V3P0%1*34J0:3 A+G
M..SCV9KONSG1>W!.M-G$U(\&^[%Y8U4-0]+./7534 10_E%MDV ,'!>70! 5
MBK_K,,BW6=<J:!)&.M&5<MI >'K#$=XLV!:FD:5K_./>^<^68(17VW.OROW?
M-=:9'74N%!P2E<=/;YLRM;"H<LYCS?ZKQ&I4X91RYG2<0G 61N?[1A(?1W5Y
M:KO(6 9J6:W0&;"JH( JBF''**)6XNCR,$&9/.Z;L.WKQ8E<H# 83()$22LY
MO:67UM':)77O\X[Y*';,;WK&*&^_^1TOGC^_6ZJP1$K,9:MU0YU\L,C^F]0R
MRWK1[:&7R07.!01%UR#^XM2@+ <TB>:35OD2;17@;MUJ<0H2],2,4P/7%=C
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MMJ=J\X:UUT2C[H989-_B^DG?<T)C>R1.PHX)YYL*$W%@_F'M;0U1O0@_M!]
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M=,*/ OIZ(\6AZ8'AQDJ]Z?E\O#2<NCG&L#W"H^)VQ/SY.8\T\]']$I^N;O@
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M9"(M.I6.$A?*D^VSR)6(=-,9Y1QCQ4WF[*Z9JLBZI O!U*T7(FYZ47;S:A&
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M@Q)R=B)^3/SCJ$&Y$T>W:,@ &,BRF!2)A<.81Y3PN>S'GU&RN!E3MQ -(.'
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MU)-%D']+/TE!ZH+4M<J=D:1X\=-\9=*#Z49C-\A6N#V26EKAT3IANR:$R7'
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MQJ]KY1>:?SKZN<0JHC")FC ":(@86I0T0;643XY*I$5E-OVI,,A\.2 9$1F
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M*V'2-65Q:R+>9@+>>KZ3(>9IWVRDS1O1XP6T2'V)GQWJALK/BS;G?04LH)8
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M9QI%+93&UP:&,H0OD380.7](QA)!,>93,DQQ.XM4'B7NYH3#!OQ*YO&0Z[T
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MS^!58P)VZ7.X\,),PAYU-T\)C=CS!'@]$KH091T*F36-S?'?"?CQ*>*D7T5
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MQH"XV19$V,3_F-CW.KPP;Y%Y8H(I=7'IN-.-XS:0 J:9459,QO<7; ZF#:,
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MGB]0\J>JM(8\JH0WW7J4V'EFOM5Z*C8211E3NK?U5&*1MJ.5PB#:#,JCR]7
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ME1;G<=_@.$5?WY VHU#C=-GA4CDMKYHQ5N\9ZX6=M^XU,[[.:HT )'[LS%!
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M/H4G@KCU,+ &:C Q,Z.)03,1ZE2771 9UB*UG%X3:43*.2#<$9.2-6DXP\X
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M$.(+7 <GOMB "'8_AADS$3X])QLABB(3!>!@H-7Y%MMCX50X/!2TE=[0+[N
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M<H1 .EEQY Y\G!UQ$]A#BD=FL\&(78I>B3 V"'0[&<G61 BH-KWD:$9YP=)
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M0]-UH X!W6_%]N0<22P3E2K"CFG[=71!J+2'273VHSS/CK]>\*D01H0-(0/
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M.43+#12<PTE>?,EL=+&'!M0*4"(D<W>SJ(427PY+@84OD4W4+4K>BA(X+)T
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M*.C)+C]7B2'Q3!7YT1@DPP U8,ZC?TY.$#;S[Z1WPS V.Q"5QZ?;08 5)CC
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M\2E*((BUH ]%D97IL$"LK.:BC7J[ VB"[3\F)@BR]K4>DVXSESL)^=$2CQR
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MW%:OFJV_MOMX&]@\/;0!X$,22%W>7,W&"="",9I;5F*]Z]@GA6UC14%N/#L
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M%^Q"OE-L)#%C%VHD^%VGAW.HT1(#[ K:#^N&W\-,;N:4SX+)F\'IFGP/DTN
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MK>J>.@/X:0G?)M\]S <KEX[]D7 %]NX="G/1\0>]".2"2VM]% ??%%@99%W
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MFZ96,\I:.0?VP',J3]([3,Y<SP\P94C3@$DC1DB,\=W#P=6A&Y8:+XVM.:_
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MCR^E32^&(Q"O=,D;1RM[2_O64>UNUQ^.;.\1W&S/'X.L#,BO/?2Y;P),"08
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MKY(D5HA_7!8:1^/;4M-Y]*:5D.3JWIH?IXC$GU07&&2Z*[.M$CJ= -<S2*V
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MV^E"/ME,VZ[4\W(C 7)>MESW."3<$HS)8IQVL5Z2&_N93A<<2]FU3 R#^@U
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MAY.#(-T$Q?Z1KA8S6$'3!MD=_B-U0>H95;L6TJ\6_-)_Q+?P+[Z ".GX[W^
MSA$4MS7EYF"@@4S#HV=T8)S*L*T71.(0.?^K2!,;]<W_Z6FD63!!S3N\KV@O
MX+*T4/DAS."'M5_]]S_*%A(&"8\'0NR\#QD3 K8O$1Y\\%OJ.;%*I7>B6[S7
M[#8OF]*7]O%5N_51ZG1;AU*S>YSK71_U.L>=YF6GW?OO?P9[5#&##]WSJW9/
MNCJ76N?=WOE9Y[AYU3Z63CK=9K?5:9Y)O2OXQ9=V]RJKE=!;!=V])[*KJ@LW
MIZT/$P<#-;@$9Z@![+D6ODDK(#$KU[CBSFWM?!1(!B&TL+ )ZR%<W_4/]Y=W
MDXIK=HY^@"GS[J'[1ZJ#EA;35L.X"_5BN;_\/:_7N]?WS=+Q^-V';O/J^K(M
MG9](1]>]3K?=ZR&?2$?-UN?3R_/K[K%G3^V!67[/'5<?+?8F+-[S>XJIV(KT
M15.OM.%$ZIC#0^F]:XTULG'O='<BZ:XCW4U XRTDZPZ<\AS:P%/EMV53[RO^
M2G+F T=7=<5&:QBL.25\D0\41X<U81X#R5_,_]-B9@']5/CG+W FX3M@PJ&*
MA)4.)R88[>.%Q,T'4*U#0MN"9ZO:K698,]#1.3&T3[/12M"7E"RQ%=/A.9Y;
MS7\6KLRU)'V*]>^@^@W=I)>!50^/X!, ;4V=PWTST13#G0S15*$F7E5'UG0P
M_H-[<.9 5/BN+ TGM@6/R=VAHT%/<&YTD[X(E+_1P%Z1V@H0%E0Q?C.P[4+M
M'P=K\>&%+M#&T>Q;?<B7$5HT/DS5L!H/]@\[@,?I&NYL_7FYL>4!2-_J>*U)
M \T%M1.U77!F),.Z@S\"/< 2,P@5A/SY&= .;PT9"#)6;-70'$* N0.FH!<O
M.+PHT!&6=RA= 1WF8\8K[IV5\V<6.=IXRA[%6:W'B4<;O:(@@O21Z"U=&'-'
M>L\YY.KCA> ..;A7";/2M^PP!W#',1@"_, 4EZ^;IG5+1R^X8V9K$\UT<+&\
M]<&FS6A43XF_]L\SXAR!B^>DC>C7P*<\Q:V@0#B:=D-,9R&CT <(*X=U^SI(
MS)P@)I ,P0(9CVH*0P2&T[0M("ZN'W[6;4T\?SYEN)3P&\YVU^!S  OTT!9&
M._BEZIPFT&5NDX)1=0?DFL/H=<$_D KE\&E/=,<%33,D<L/+P#)A1!YP-$94
M"?@%TC%(,N((P7\Y)M4SRV86'V?'0^G83ZV"WVS!I_[,P1-!:1@1.D]X&2P*
M26_.K3^.F!',,P,8"G4?BQ#S8X-%F_!8^.ENHH,JH,6*Q<.2^:8.I2.%:SC\
MQ-BV[G"!H*_P96@%<S:_17^#]2-SO4-, KP-_M045Q*E:49S5&$H_H9EW1 O
M3ZR[R(^B?AD%QHZA"XP3,6&E-YK-Z4*?:=]KPSG)VOEH!-K+1H5QJVMW3N#K
MH#CGALO$!Y_@> ^$WPTPJ *?L.8VMED:AC6DNS],?1-6.E$<:14K*1@F!3MF
MH-GGHTOO='K\</KJL#_'S-U8LSD655E@4>6KI7Q_J1R5[W_<C#\JK;*/FT3/
M0Z*OG_?6\$7L6N*2KF46H8#_5 ^P#"9D5X6CU1CGP2C%'7@ECF8&0Q2=[DD@
M-,&W_.X#:.18\*0(9OZ;J^I<6%5_O,A"YS #/>QF9V?CPH-7KYD,7_%$^A(#
M*:N[XF<%4@]';^ND&\G>P+/*.>C'PLTU<H&;Z8:%8U9TFPYR@ IR-">)%O8'
MW?J8\>(Z*R"]E@47D<V#G@XH2-W J^I6!\N'1616%^=9(Q$+\%ZH4Q&9)DO*
MU,(Z=WJ\;PY%Z25#4U3Q$5EJP1XIZ'KYPR<+=7N1R=E"%WVLF3EA3T1]WC<P
MP+U>J+9E+)::RMQ[^"ZL0G&%T4 &J@6W47#S1#?'.Q3=978)UNYP2IKHU2@&
MU]1H6")5"23&@7WB@1QUFKWKR].VU%1O4=&K_GYZW/C !0K:F]8!7%T.DDY\
MWE\!_SR#IL7%L??JMLU3E(>YF-.*YHLMQW2DGYQ??L%M2&!\:19>I',RJF1I
MH%L*_R>H& M,.[C+<. &D36'NOZ.,1Z\>0%OPBO/G00M(KC0@(.0K(Q2S;.S
M\]9/<./04J1#FX,\T;7!/HH!G+FAV&PSH#%M_9XTKJ)3.P7^^@ ,0%@5L1(<
ML@[F18X"/WP&."L00X7(***#*G_)YM::W6TXECA7AX5B#R86"C_<PYIB#R=D
M-'$WB[C<U92I#&\'P\:0K@+.B<Q<1 7SXJXPLO69)M#!?&O<9RG@1[3\_,>_
MB&LEPE-Y#3<+<]NBM*WGTB_DL)N68VX:2HEFP\5S ]89R* C7/OOH'&.-7O*
ME2M)%?\3]V"^>UY6#[PG3\G!NL_.6M%.']C) 5_+04T".\BAE\:]=1F3!#;=
M6<23 =/8Y=M4T$:G0@[/_D:%Y+NO8..$7XM_)HU.+AT\8*3;#I6'H L"+U<3
MF.,S98$N)WDBNH.Q:85\#_3W*'WHS,$M4!S*ELQ-'IK&AUCV6#'UI>+[GX&W
M\;M_P3[* B4HDCG:_A>*I< ?Z%)Q,: KUL%TJ\[PJ20@VEASN?E ZM@%GTNL
M'VFC(5T\BT-W@L&8X'H"NQ?1C,-<1J25'D;:7#:DE1Y(VER(M"]8;[#8C AA
MX6Y8G JC9=@Q0 $1DZC-2).#7Z@8MG%#;(*Q-3HY683>V%]MS2 K;F(Y,]W%
MT%[@H$0(CP=6T'$W& R?!$H!HU' KAY[#2WPDW0PPS"*9L 2[$4. RO6=(J>
MTH*[PM,(1D-A0&8480<1R3E$)F;?YE_BN\%7*L!(MJZQ]2"4& 6"=-$S(<TF
M"T<?ZHH)JT"?&6-_-SK8IJIDSFT'/S)2ACRQ+6,)&MB<\$=8>OAO+$P%!@P6
MHJW^D8@0?4:8>355=D8\"^MJ.6>H:Q[2$=J[\ /?'(5E\4*'Q[A@XAE$5]"V
MIJH :9?BT&;@^Z/@8?P7@Y@BR/6"&;WIT*6! 0P1?O&#.Q&NLPR6I(W&)FH0
M#*2RJGTPGN<8)9HHP+8#3:/I3 K( O$G&9PB;C.<VS8Y=NR;,[3)0,>0Z2[N
M*8R9D"9IFAB'E%B8 =7Q"3ZID#_X+.?F)HO:HL5^IY-KAVH+6$GVUH/'Q,M?
M%U[\"I9F(->-]"$7.B&-,:&EC13!&V +T8 LP/L4FH?%B #8>J@<V!+,5&/!
MGT%.7B#)<*08%";K330-?9/@'W,]KX  S]%/,84_)H4_1HT8)^2FP%EN^&!O
M H(UL0P,+?,%2ZQ*[I%XGY)YVCW9]!\V%BR4W@H6LBQ8J+\5+#RG@@4*<PHY
MV$O2_#^AK/F'[)/HY=4D>@^H3<K8=)O,BH73O@!IA!O;N8*W'1G6\&8EL1YL
MXTCV@/[R:\51JI79\O)DDDVRO<B2[<7U9'NCOVR??:O?YVO3YI?ZNP^]ZR]?
MFI<_,=O>ZYQV.R>=5K-[)35;K?/K[E6G>RI=G)]U6E2;D676?6/8(/.CK:X>
MK7^E@(#0B2QB#K0<A-G=]+7^\OOXN-ZJG2J=F\&#CQ%(LW)TU6I_6?G6&W8_
M?QU\'ZHXQ1AL6WUFL*'@H:6QZ*;(RUT$3!GO%%]^!&6ER'%K 6..A][(R.%N
M*3,B(DHQ1$8Y6'\A!>LO#M;K+]!GD.[@8L#_LH"MYPZ+)&0NE&+%T /QMPUO
M(3_"6[?.&]X.I:9A$"00UR3L+Z(\ SR#D8Y&EV'A?#R956&P5!,S,P?,.@O:
MP."-3<DQ4W,(N!7D'/"P0G;T OSZ:"N:FZK,.HVQI>G;(4MZ?PRQ09_L_>JH
MK^J7:T<['[5A95,L&5C1*/F 1@E_L+_\435_?&RV>^K)@W3(1AJM*I9Z?ZE9
M@^;7[\/?/SY7WGVX=L@@\%;UJG3&#/-AS ?Q<8;#BD)B0H$,#8+.HGJLT0!5
M 6@.;88Z1O&N=)05H8I9K8DF8A<LBF]1_EW2!$69_X>U\S,FJ)3O4J@NA@3(
M<[2XZ&'@A/?$X5<#+1 RE7* ]%.1P8@7L8SQM=%?P/HC? 4J2L^UWJ8[*0N4
M"ZV,8@YS'K?@ Q>"??/L@T0=\J@/I8_6'7S'EM'S1>]9U"< &0T5MD'A2!J2
MYDXL9Y5<+I5 395%;B#<6B?.,?:_"4?)"S#8*C+))SVILJFN%7MRV)!5@+N-
M5DU]!:9HZ_?[RV\?*V:K]?G4_53?AWE3Z2_'%S_NA^?G3N_CF(,QX,'3/P(+
M>U7JR"MS @ED!7)8#SC1QQ-0-88.NU9Y_S2S869S&WB?PJ4\_P?6"+P%Q&F*
M"6\>CG7!!<2Z/-.=4 B%(E*L;H]:LC6?G"]?((JK H$]8QC\O=!L"A E-_"W
M?+._G)W-?YY^/K*:\]$^A*#97Q9GM4GC<G[T\Z:,R!58,_J?,\S+PYI8O.N5
M"L!T-F<:F[:,]BSJ;,F9\$I,O&]M%6U9=B7[+C4&!2DD[L#C5"]^ZE6T-GM>
M<E.ZLF; =<5J7I;$8=-KB+(RKQ3T+O&@M8Y9+V;*4LGCD"7K=6/N4A4EKCJP
MX+N)QL*IK-H5LW?T6?U6HX)#6$3,3AU!"VIJ5'5>3QS\M.*ZMCZ84V@F1^;W
M%&2=/8!'0_&[^'H&XH"6!-8:CS7)],KKZ...Q',R^'WLA,5*14HQP$L/I>/0
M_C:L->> 3V$HF)=&/1._01D[^<&"8C8/62*::9$_@ED?Q\,%YGD2WV?S5XZ!
M.#QAM%%6-I%CFZ"'WY%AX7LM@9U).K-\9A8&O?2(!W%J8(B<OLR[KLDQ9-_=
MOHH[-%G\8V]2J7?@X0$US#[+(VBJ,(-071O#N<'S 2Q)[-DR@A]Q6<2KNLT(
M1J5$M/N<OWOP'?4#L9B@I89>FB.QU-2Q-M20RDST2P79'YB)?9SP-2W.Z,(9
M7'C4CY5UROP>60\ #B>:.C? 0VL"[03I>MH0[UDPI=O\M/!]+9(#.B=PZ%:N
MD9BKIQ'T!+-_67_Y_<=U_N2X]?7X3M^#-XGJ>V1A-1EQ$DLMS:=8%KGDNG.C
M="+#>_)G,%P#5OXU=V/%P=\Y#5?EZDGP7D W"5G9R-VY,'<KO&Z!+SN@/U -
M**LRQ%3[W\_W @;7<&8HB[\1BD=+$!X(=K53BF*D@%*'[V]YSWHZ([,G<1*$
M[:2C?'\YJMV5ZY>7QXUFP^/MT'[??>BU/K:/K\_:N?,3J77^Y>+ZJGG5.>]B
ML/NX<W:-O7_=]I5T=M[K21?M2ZGWL7G9]JRKT'^RWH]X.IWL3BFF7;F+HRDH
M<]?Z1]J>GZJ7_^U]TV;X3_C5=RO@BRN<%0T&X6,^[(^ X2[_-=RJ/;!BX,T>
M+ /69L!O_]^[XCL?>*-QU(^<OWVL%CK'7^\O!N$0WP:\+:^%-;.]X'*>!PV?
M[>G5^E&#OD>_IN71R:_*^?GP24^O]#QHR) SMJ*R!C1!-%!),N3^:-!?[_BJ
MJWGXV&**A"?6)--%6 T2& R)8,,CSB -E.WC$*V8-=&8:GDXF5[ /DL9LT/T
M)*$'^@--2B'T)UD][V@1_8#FO>[T^WXH;3HSK(6F$;S6.>4YOI 8]9?'MW=%
MQ_ZC-8OJ7M#4N"E3PTJ;1+"5ZQHRJ/5Z+"S"4C7_=>:^!W=2;O67TZ.:T_[B
M=H[N?K_[\%[Y"]3C?/8A1CV+4IU_;\0O]SZ5'"1=?*6X\IU$J$^9<-@F6%O?
M Q<,TH_ECQ6O/"EJ:[@%D];EO/N  XX*VY$"'T#P_Y637$/SVODDD\[SB#[)
M1DFN-[;C?"4F>-S$W1>N=K\KMJV8KE"UGX_+7R__E+5KH[0OC.T$&I0O:E5Y
MUOO+$[7S_6ZDV?ER'93G(%IY/C&(7[6!#Z5ZNI<$Y?<4JB#$?6'QKR6=,1$M
M_H6J7"ON!1ZS\%)E7LP&OZ;\L!:8&T*:6*@ 9S"Y.#>6/WZ<I%$!#\>N)0T@
MUHA%'WR1+ ?R2D5DW>YAI]7?>%@K$I,4+#E:8N#=<JU>>Z[#'9^/\DIQ,DG'
M;\;HLC+(4Z&P#V5V],J56?5\<#*S/OWN@;.U4RQZC[HMN_A:,YA>HK4X'IE6
M;:)'B8S&,N(C182W66T/2U*]Y+LA*>CXKG=#0OMVS^?_QMTOEKLSN5\?%O2)
MOU^? W>SC$DV2./L?P]K%=WD\0[=!/<5'G.0/RS";U=J"';*-*]U+.Z4=J86
MROQ:WVI^6Z_C.TPGK89S\H>XE__0J7GQ@WR[OSR[*Y9+IZV;GE%>7;<@ (5D
M^8E[WRT<]Y=?B]]^S9N-IEX8,W$969:+6.F,%_D/Q(^U=]+]U/C;4)!"FGEP
MW7OW@7$;0]4QJ 7)"0:*67T_@A?,;6>NL#8 @B74[#'B;HQMC8KK21TE_1^J
M?+RP!3#@1P9K)7/\6%[ON/9W'^W5E)HS6S>PW*5X2 (B-AW1]/G&G ]@SI/^
M\K)=O5MT?ORLJK58YAQ$,2<PMEL9UNQBY\?TK+*-.>N)F/..Q^ >DR]WY[?5
M8O% M5P3J/)Y]MG\4>F,EI^RJ+Y^DG+U^EK_QB7KI+G4AM;8U+=WI+:"<[^V
M?;>_O)TYSB_C_-L?U=A'R3I.#>L6?IRJT_''T\F[#WQ%4F!)K[)@W6;[6U+/
M%]MRJ$B=1"+7[+5XR7DU7Y4E01RJ9\2.>S1-'"8]+3*3L'0[4+>.7Q/:^U!\
MG<')> M06;&Y(HGF$(D2W%A+S<&BU9Q?0,G?(C#WL/54M('-X$,Z%EZ/+:PN
M1H1% 8X-SV+XWIIM^X DWL-PYR9O5F/5G1S4Q/'ZR["[A:S)4 LLPRT2O2G4
M+FNPYPN<Z]71;]XR6/DR-HJM+=>C%*>!H-,@ /2;\TM71_"> S!-9]+44C4C
MBX).^M_&ZEACSDBKMV$C:"GNLR(P=&GNYRIDU]K!)AO;$Z<.[M]OU_";$4DL
M>(>3QV2;[9.MNTF'VE)^0VW)$K6E\8;:\GI16YB$O>DQ<9MJ-L4P"$'>GU2Z
MDUG-L8R%2DQ6<IG-IHXU$'IJRPKL*8 N@4WO0^TQ5]3T0.ICER,,DP#M=Z)W
MX)R>DO8!VYGAX#-C!LT\&>T<)0S4O=,6'=B>,R(@@!@6S3P0\$36.G"PHAL.
M8Q9$3_7,/(X"SD;B.;R)R7G&C3P[=>[0)U1@(69O_\VC #JVQ.QJ<@7;5%X@
M781/M>(:L9/W,3V$?P*.$F^2]UPS!IK-/;%#Z6+E.>YBQD>DZ(RRK.O6 :\&
MJ2RA#G7X8""&PLU>P!%1$1,2NUU=C0^B 7$<:M362PD!!GT1U$KP*+C:)C2]
M46"1<IQ,@BT1,YD(F8C&EQQ*8'LQ."(4=D>@A-"!"]5B^QI']F"1T4O"ACM#
M<S75_PZ#UT2K$,T(UMN'GZ%))1JX9"H"]F+_WMS5#>9X+<*@TN#3Z;0BZK^S
MZ+^E;) (,F.I':3J(OJJ?_'B<Q71YAM]9Z"C[<E3#O&E.&ZI@/X5J@9;ZUDE
M$'QBRB:#(0:,%_S@3>$4AE2E^0R>_0?#E#[T+MWT&>%6/ 6WA"TK@@+:;MF\
M)EXBX#-@ M!SNC/1Q(EZL,]"5Q*$K:.)/Q/.M9@=ADA,C$6 @RC^Y;/0#+QP
M;4WET]T6T$(8)!IX\$*(HD102S*V]\.?Y94@6XZ@A!#<C3&H"[LG% 7%("-"
M84#:XA"Q(YDK5VK\#Y[OZME2>,VT7/@2FB6(?\X&OEDF8L^987LV('3:O>X@
M*O8)$$[@'^-ZG! ,'"ICQ 68VSC<:CX3E,'05Q"-71IIFH"BLC4_6*9XJA]1
MFWS53Z!4LYD!%R"U?M.+B9TYX6R5(1.LD(:I 1X(I2YM#.(%5_QR93O&<E?B
M]";C:F&3JR]>RB^8Z(J-)XM4YP*1:FDM4BV+V#2SG]A41L]ZB@ACLW P VGG
MX>L98J$YJV'K%S'_Y%AWE/$8QT$*IN*Q[4=.IV2>!UN#;0KO%(>XT3XIUA6'
MH-$,Y,(2?;^_7*C*Q57AM/SKL[H'4 R1>' 0A1_L&V)GSKP!%6E;"\5 BR9'
M\B]0,Q!K!ES19. 586B69PSV_VIA**K]9:/[>Z!4&\>3^_(V& K$G;AL?VMW
MK]O2R>7Y%^GB\OSXNG4E]9IG;3;D^/+\9_/L*HBV_+^)0E'-OZ%09(5CT(Q$
MH6@<7=V;;?57N5Q\0Z%XQJ=W%(E"X5[<%3JE;N_NE_*&0O':42A.N#'P$]&T
MVV@+_'=@_^?#&R[%&R[%H^-2%-=KSUBQ. L0?-?=B8BYLV)R>&L3?2]'4Z^4
M^_[$L=V# ^XEGML]YJ"%6X!ZULAE@P\O:78M_[0C>H!,K?7[IZF<6%KM><!'
M].+'[>X!->!?F0(&I#C$W9I:-I_FBD]83ECWGP]4_5_WCM]]J%7E0K$BPP*>
M*=;#\SRUV&:-G4XM:2_2VJE5RG*]5)7+A?R><1U*CZ"VCL '.2'HU56%953M
M=OEG:?"I6<T.A"&19CJ*&"W]I'V]>U<W<:>PPK))L4C66+:0EROE&K#L=E"9
M9]E8O7?-D?  ZFD/H"$W*D6Y7-JNZ%/HB>H>]83_8(K]+81V4(X')]W/E;;;
M?61XAI Q&*$\^#I%+#^!3;GQ>MQFWB9E^5V>LR/22R._#>DEDG9)5_Z2*/9$
M2D0 R81D)*PZ&H6TJJ.8+\CPA*V*(\4A1VJ3R@.UR?*S.BS4C3_302,[NV&+
M%QFM(HJ'E1@E<66YBB%U-==/2^WL)-/3=Y<$^IJD6O.!H6WUCF.L\(<_^"G,
MGG".+20<29%)UH2C7I6K-;A8$X LQ7!'HA-('4EY8Y+46G6%15([V=6RW*@W
MY'IYN^V5%8L(O9JL0[0&UM3E:?X^?W1<'N\AN;OOZHF3#6E?*9CQQ;D%)9EF
M1?&BAZAI'%[=N"**\UQ18,%G7O;FL""X37#">: \T^%C\JC%SI(,96X.6>W4
M2+<=%T?<YV:Z8;EBP+TH'&;SZ(>8TX:_X#1[47,4F#<"]I<%G_HS5VR7S7.!
MW51>_!RJQOJ465M3=1>'-YV(F7H=TX%O8GMU\A[?71X# C"O#D]F%_7R;74?
M[;[M_O+FO'KOWOUN7L\F[SXTQ2#52RK@H1PREKO=T=#15]/YZVW3]K>)7.[7
M?^-D')0"W91*^9RJ+*C06C=O+7U(HY2"$N87/SK4."L(1H4?0SIO/M&5C9TB
M4:(_PJ?%=$.:A!2Q+C9H%E>'-86LPY;525)ENX%]N3I\,+PD+/=CW;K^:BS6
MUDOW#4VRQ&)O45+/EGEGV;AG^( L373XDXWTR,V4!7T!WV[KV.0G\[)>6G9P
M$I._<E[M3H7ANLGN*"J1=8)UAOB9.]TP>(DA58SZ2Q95B]1E+"BEAFD:VKBG
M,:-(R8?GRJ1.48W^*RP/C7QP>IQ@$E\4P"YNL5FX?;W3'WKI]T P0#-P@1>@
M"Q=7@1+(HT7P+RL1A*YEVH&_BDC"\DKYM!A__UV]+7C-@Q&,NQ4;:,,VP@9'
MTSD?14 [1RYO15FFCO\4P$;-U^5ZH1&'[R.OGU)UQU,J[?&4K'M]_%T=*S?=
MZJ.>TJJ+O?V4JOFDF*WKWH1<KH&U6(UR)O@AH1RO'=31C@=5W.-!'<V=Q>)G
MLW3D_'[4@RJF.*BD4*'K-KU<SU?D6C46+8N&F?M#,'+"#)77+-,2.]/57Q=E
M;%":B;+]\*WCE8D'%+08)XROW<@@%W@O8J09[.9C<,3<T=P0U&;*=K7JR:AU
M[SXW?BC'W9IWI$>*"@0:N.*UV\YSTUM3.>W5?'J/#,ZA7*['G5UNJXQM)>%:
MZ='9X'K0.3U=V&/C\4BXV:6MYI/BQ46$!(MRHQS+_+ET8Q*C.'Z3C1=I681P
MJ<67(PCFZY6PC;$\^S+O6:?NL=Y6??T5OXJM>BS1&C89""N'EMX$D NU$O!]
M_+$I[J8C6B-U,36IN5 ,K-/B[U]=O6[</#&I(^6CD/H>KQ3K<KX4%3+?3.C2
MH=0*:'2<4VK?\G:0J:*;V*H4!.11I%L%_ 0VO7H$+[%L[,0R><B+!-#0S+$[
MH8 '^&ZYD-^  0?%<<D+HQ8DV!1V?[-!]3JX?>BZ\!8IW:2INMC-Y,,A<?*&
MKR<@BA5RUL@YR7FRO.:>!3P.\60[T&7&?!O/)?,^HXK^*/9^)Z N\!6N@AM9
M8]M:0K:]L+6I/I\Z35,]QP7X+.2LJ QW\*/TJ_&U^+-3B./CJ&WYRW\(9V]8
M9G*M4DAM"97E>B,6$7=7C9+/[FBXBOG9'%V=W/W\T1D/GO_11&NAU&9.2:X7
M4^F@#@B];@]AY2Z3)6Y(H]CZ_:(,74SVA-?QNQ2'%H[-'NB&SE134.FP\; #
M+3>:VR37BHKQ(DU]I%:<Y"A6E3<4JRQ1K KY-QBKUPMC%4PA/$4BH5I82R1T
MS%N@CF4ODB<-XK[27\ZOJX7CKU;CFWJSCP1!L;\$%?KS;#ZY=N[5=Q_$0O17
ME T([(GU;[MTJ7!D +A&65IK:#F$EF)J+EBK\) E\?LMJF*9I<SH(VRHN3"$
M*<5VH,.BV+^LN8MVL@ZF8?"]A%GC8 9.Q]Y1@UG.NLD0%:@'6N;@$F##,DM:
MR^%13?&.LQ$CA@-VXKVFW$GBUP)4AMV4H&=NE#':X+A,R]36C&0OAJ,+GI.L
M =P<P.&D%C>%<PI1+/O=UEWMV+HSHX,XK:N[GY]_77>UZLA3+IV-K]YF^JR_
M.5T@IY#:I:T4"W*MLL'\W.:VQA!O+7QCW0XZ)Z=C]<HN/"[QMH1PBJE=U'*^
M*M<CZ_Y9_')?(1Q&*Y?YFP[\Y6 *?B"!7G."Y"8*>J(\B92<_]%6H\S7)7>;
M5[RT8;Y6[M@_9MW9),85V+ZVQ*>ZMICDOE@QM2]6*97E2CDVPR,](+ZSG<I<
M4A;GGR[RQ8_ZYY/R<Z%RM.2D=JO*Y:K<*,0JG5@J9X34]72U&M7BFHEU85LS
ML'T7%R"K+KBY[3]S?;:]3J,:CJ4G>D1_^;%N3GM_3LIW>(-E;X)5^\M!K3$J
MG7>*Q^J(0%EH8<2GWJI>C346VIXFMK=BF*&A)8/WXE"B?SZ=DW634[49#BT@
MT3L$;O=_$M#A9-G,':]XR;45+%\[0+P?#G<G89! "A<<S!UM-#<DQ*D)A!.8
M284%%0@T92LF&E8,G'U384$L9UW36\[T$06DU?NS8(T!]2)<8FB#Y3OIYR]@
M(4[G4Y'CO*C^.#L[,ISNHN@IN7;D)O[^^\?QC[__OBC^3%Q/7RW6WWUP[ZPP
MB@7&7E8WV]Q]LULWJMP'-_I+;Y74Y<W5Y;RZ9:/O-JF;E8H'>%,_]**0*D;*
M_ WFQQTPD:.981546IL#D6#C0$[-9&;,FHYDU#V4C@A!1D?8+88KL^#XDU%"
M(H!FL$H'49-F&*F'[:J/!8::M68OK<$*Q9(U#E.HE(09 ]K\SZ6A?^V:UT>%
M-(!"KQ8<I]1??OW<7=Z<UT^N&^-MX#BY\Q/$P[EH7U[])"B<]M?KSL67=O<J
M&@IGKY@UR2)IJV@T*=$2]MD5Y(%^9"?&WB,''YA>$L:#M)^7H-H3K]@7 (,/
MM]((Q!E^SUVK\O5"&W\<98W1$(+N(#"/YXM.X1,G'X@CW U_?2SI)X/O _U1
MB+,_2(M*$G5_:EL..8B3[9\]6F#Z8*7&C(U3U&SO4\(P^68LCJ:?3[K#8IHF
MK\1H%I7*OR/[M\2Z'HA44?YWU%EN&)?KVWZ)Z+]BZ+H_(XMILSF21(;S;*2[
M'<?^W6CZ%1]LD1(SU)(;D:+.+VX]9&0&WQYI9*)1N&(*U5)9F*48R_)@]> :
M+^3@PH[ _-B=Y)>-6SU0)+W/@]OJ'40<7"/5P55B#D[X"\\<TV2S[DU4>!YS
M$"O431TO*S8J<J.Z'?CA-2#,I#B-U0+S9*>1&CRFT"C+M7I4[6N6R#&)E-R#
MK8/ST4@?:FNV@>U.1E>MD_O[R<TC \>P!?F!@ETQ2W:X_Q.%4/=QC403/='M
M[]1;IG9R=JP?5;.Z1*)7D_;N+Y?W>_?G7\2AA6_^XDWGR[>CV]:WN^(C'%J*
M>[^</"L1/+1:HGO_2="&,KC3(TF\0K?TB""%JEQN1-61OP HIPRNZ"3$39W$
M1;B56GT[G$2*6[G^*+?RR=R&#<UM#3YY GN'?WF8;I\JU=NY-3PJ=":/#-L4
MN$J]!5)4?\27N,>[NOU4:G_#422ZL+6O$^-RD:^7$# Y&]V_84EI;^U*(5/'
M;^W6?C)3:_?C"U_=@^_WK;K]_?JL-GRLXTMQ?U=*J8[/1[]\E1=X/*%7+IK4
MQ7.E<E6NY+=[@J_U%D],X49J"L-=52H]E,*15WGA4:[R,TUQM(EEJ)TIMFMI
M^$'O+C_[UK/JYDFC?%-X9#?;6Y:D!]:UQPO\R6*VFPX@T0U>NG&F]Y8Q^5K*
M[ K8M*;45W@]U1U03'J%)[)\G\D!AN_P4>_B]*)KWY<7VJ,=8(I+O)JN+B=9
M\/VEW# [$'J%_=.'<^L%N5']W[W$DY,X-=A!H526"[7M^*<I;O':/F]Q@;#>
MP6O.5 R0.\2GOU-L32B7F^7]\NK+\EMI6'IF*,IBT5AC*#E\V0^M =IT^V];
MT%/GWQ.<IFN.[W_<WY^-+E=O"F/'FX*#DL>^*^FE4'F$C.Q+@H=.6 !<+;X!
M:N_Y_MC.X2%&3HT/7)"KA;K<:$0UY60)G_U0_RN!.? X%L/V#SZB^9)F,1FX
MZU/EXJ+9[BZKU[/^TFS6/FK=R='LM)[I'1W61BOUU \J;([N+)$1TM9Q5A3:
MTS':OJS_%<V1?F2*G"_GY48DBM"S$(Y]Z>85 J:.;Q;E<J4LY^M[L=Q7$!=%
M9U2P%0K^;6CX#]A]<VJ!Q+*!\;&4Z>M=,!+U_M0)B'_EOJ;^::F7MIUF;-O.
M4;9M9O#92BN8%&P%>ZBAL>WS+].&>;\5Z#(3[DFNDVJIF\:K^3K8,]M+^1+:
M,G^]G6JJ4XU4E+74Y1P%N=# 08#EC,_U(>;I!KOES5+=IZ6:*%+>U>"RN@)#
MU0W<5+-)X6?CIM/\]*?R;.?NQ)FFIN9NX_7MDU2V?^-M=DM"(Q$8;(?[++5W
M7BX5Y5(DE$,"7G@;W?/HQQ]]\:7N3"C U5*3&Y7J,QW,T^XOI^7[R^G-7?.^
M5W^!DWE"R! "T"H )AG=7I^+!'8.5F$%GQN-=O7;*IV-[M7O9Z=^U7+P6]M8
M,_395*A6M?0))SE?*LCE^@:(F6T Y6L$6D.TRA^9UFGQ>[/UM;0? FU!KJJE
M]NO+%3!6(ZMJ(I&KT@%717+N*#!HBCTV%_-8#AR'.%:PQ(.AXDP0+]4>1^-9
MG021EJ8X.1KEX'QT9IGC,UB1VB3LDROK2#O6G9GE:.KY*)+QL\\JU3N&HG^=
M=;29GHI1$N]GMXG%"2/W]?08W@B05HJZ&CP\ECN$;CNP1@*G!B&ZD?5P[,W
MLFX89F$80SLBK9ECR#8O'AZJO@8B$G%(#-5I!0^J$4(:B_E.?VF?%+[<%V_'
MBKD/_*=F?]GY_.NB=*)8GPOC0 H:5B+UO!3T*X%_"N&U,[QJG'*'@-B6XSJH
MP7#8"EW3J@9*T9KE<)#6$-2(K0GP3=MC8OIJB+V!W?'!MDK(;X3;V>RUI"MK
M!MQ6JN0/RGE9 B(CG!,A0U/*L_"/=&I9*HVJ0N5,P-DAY,P<\)_N(BXHKFZB
MK2XXH/_Y_"O22GP3A-_CN HB5]/(+S[C#X>1>5K;G>BV>C##N3'B>[#5D<:0
MZU7- 5K2J"QO]R ](WT\M_GH+5-EM!@I0SR3H876(R+SPYL-P_^0B]!7YOB1
MH*_WS4<##413\HZ';1.TWY\Y_#A:,#14.*O<W40S,1; IB/"76+H4]U$S"6P
M"'_#+<Q.B"9\(*<A7*!*!(,5PA\84MG<G5@V<8& $A_-V7 T<5'S[_)EL'?1
M\P]AS;B0**:)7XYBP/W%.'F&"+0Z/AW7PG9*'^+SZY@<'* <K(L*;HO;% AK
MYJTB8HI"D-<9GP?,9S18]!%(TWPVMA658]=KY@0ECBJA)**TSJ:PP68&A/Q#
MF&OX?I7JGSDF>P[^-3=<DEOP=G!+(,E TB'[I^Z"7=0*K"<H46QM=QJ*@@'W
M&2R+]D9"7<S_LR'P0I\ L8?WPL)R+<NDJ"MM\HB#@/8FFN:R[=$[O*R#MAE&
M;J2)@Q?$%U+O3_=$R=_4L7,"E[JKD=GB:RLR8.*@U9;MT_S(G7VR%Y?^M)^>
MMX#(=>Y0GI,<+:V^UL^:9#/O/HS@[YOQTEZ\K;+6-"IN'3"55RCCB#]%VB[!
MU'[B9_27A>_JJ/VM=%E"%LG>F"GWEY]N2M/"I&N.6G"BXO6ORG[1[H>8CD2<
MOKD-[I6#RAL;\#V5, +7@UGA.53+*N@<T$RD!-%(9X:W,&KPSI8&"%J)3P6U
M/8!+@(: A% M47%P:AY*S="8MPCG<NU/VX<0BZ=S54\V!UDSN$Q'%]=9;X@*
M7)&.=,NPQOH0:'=VUI+><XW+_\RUZU]"[^F.9^;DF,9=G6HL.=H8E?.A;XA-
M%!JXJH/+.R(%$M*P9.TX-#9583DMO,J\+\.?T,RA"]R<D[I5(JF6(Q/2<Q=E
M!(&'Y\$IVC0KPD43;74T"4XE&N)85_^+P#L+6#*H,&L8=;'BG]E$9KB24)6"
METXF"M[CM\P=XY-;R=J#NWN*L*7P;KA)83NT*$._T6!!+ERVM'7XA[O"<SZ"
MZ0S) K8#NICX!$)4I:^ROXO0 PZ!MM%0RM$#:!0+^X:W#)6]:=M*E)6W>MP5
M6%YH(3@05KR=@^VCB6L&691-D/4IDFB[#!:?ALX2CKYW3#P@(HPU51^-X&ZG
M<;2:>Z?!J_'9C!+TE/#RI/>T68O4@' %Q"=\C'XA37\=KMWRU0C5[8<K<'2T
M#PZ[&F <U9N-HY]%0]']UEC_N\$7<PC8@_4:XF+R]Z_%[WH7C7&W4?TZJ^_X
M^NWEI_5Z\L\VX ;J6C%@DRQ0$CAQ-+H\/9HP3I<C50H\DA6$=J8S@JIO,X(R
MG1%4>)L1]#8C:&]6?V,M0KG!8E_].=+ZC[I"$C^KO\Q_+-2.O@Y_VGEE3UZ
MYIR>7=S6?I7,&H4T^3(DMHY7XPX$=B:,^C4@>Q2'@ V=6X6U%]9K((;G7UTX
MD%-&$Q#,(!8]6GF<,*L=%D0*.R0T40CL)UJ&"K[&$(U9Q75M?3 G4<R!(3/
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MMFR077$E;7 %Z6VY8-]6>#44[QU@;"A8^$L>3T11%=!1,198+^S59$6%V4&
MF+\-^G^ $9,[3-S9=(U>14:B(X/UEZ?2%1+SS((#>B_B< ,0CCNOSY%:%G&X
MHZ:N:*[ F07C"7[Q7Y *)(,BVXHGZ,4XBEQD_XHZ-P8^0)DI*K!3;!/O$G$+
M!P @PGV=.76%DP*-7 )5PJO8#" !K#PFF*/CN3D'U!H^H$):RMNKT'AL+R]8
M&9P%_'1FKGC4#U.=&QRY"YOG/J6/FD*IWZEFCS5;CNNS1>HU*;K$*X>E"U'D
MO\*#TGM'5)N7(JO-_Z)#X':+FH.K(W#DE(;S PPL(2<S3EPYYX-5=O%QIQP*
MY@9X,4 "$23V.F-]8N4BB>73($ :S/T %5R#O0XII<U<7J>49_D;V6-R-(<-
M3Q! _8IJKX XPAWWK\)A053*$0X<!;:Q@!A5#?SW'"Q,? ,K5</%KQ]D[-FC
MI@RA4P2CY-14&XHP*BX=1F[U,"1UK@FI0Y/7[_V=@FWE(G!(2!-0TE04CU)M
M!C5,SX#^%A:Q4&>SJB$@!Q'%Y @=F@T;"YS.<)%[KQ]JAU@ <*N9N BL("0=
MU//CFH&*DK FB:7+BB:)$XU004PN40J\16M97XI@A$!X+5W^.Q>?_PYG.3%&
MZN"D*$<R-<0-P&.BC(D^IKWY3&G&4$$L.ESD('E-JI3OUF!=:V_D-?4F<).N
M,7.0U]9C)D=#EXD2JACRD%>*0(.$XYS!U\$J!]7YD!W=4K.MP]RQSYLQVFJ@
MD<$4JI!B#?XL'AD4<MP29A!,G\>#^2,5A!,K:(1E'% DC.GE8,#=UCS'UMG(
MCT+MQ&R V;H.SVOY)>MBW['J+"#L7"VA:0 '(%Q2#E*SV@G$E*\2+"T BVLX
M.9C/5IK&O+5PQ<I]8$IT#Q/*PH)=(Z@B2$5QTQYU)96MJ!I848KC.:Z11>5<
M]:P].^<GGKR"=?+F8XRM.%T0VA]+Y >.=]NV<L$]Q>]G\U:D+5N)YAYNKE&Z
M@\K&>-2:Y0#HF)WY=(K:05R>D?I4\*BPH+:9>YYQE7EEP5J35V\(%)D;VOGH
MB*.9- .VX=$B\%/+6W4KN-B8VH-&$!T\P[?TEXLO/\J?J^JT."[O ><VA&;P
MH-DVV3V)&\3A,HJC<G]IC(Z5"Z/4^M;TD8%"XWG>?>BU/K:/K\_:N?,3J?6Q
MV3UM]Z1.5SII=BZE;\VSZ[9T<GXIM<Z[5QWX6_=*:C<ON^?75_BK7N>X?=F\
MZIQW8U ;B$EWBJ[O>E <D5V9N]8_TO;0?+W\;^^;-L-:QJ^^6QDNL#+"*,LY
MAK'S #-DA)6Y2/M\_O:Y WO>G3]OH%'I1Z&KG%XL)M>G'[N_CD?OHE89-5!O
M#\M\&OIL'3@D]&W+AZB*T;#"*U[T]5Y_^>OGU:CYN_;Q3-?V,NY3R&OEWY'#
M%P28'US5:PTMJR07J;-_;P3 ]SZ5"-5>?+JX\O%$6/4I:)X8PKZ63XT57I+K
MQ9*<SQ>V0MAOI-76L2"E5.S7M&TTG<A18YY@QVQ2H/9\M(UZH 4LJ_FC\77Y
M;3&J[G/V%?U&)]_[;ZD1,SED!T=VSZ->MDP>>J33206*7\OO@/J.69;_]^Y@
M'1V_ 0JH7-G.\4D&$_D<7NUKHL=UKR2\]+VD\U&;<8^OII?=WY\JL].NL>B-
M'VDD<R+VO]SBVST-S_>^7'7VR_ ;3RN=#!1V@*2/D8%* 51^FKF&FP2@_4@"
MT*.8,7VCOVQ?S8^;U>*WHW(Y.Q4?/Z9L&YL'UO;Z9M/M7UH"Y$LI&\4,[H=\
MO2)7RIE-7-XD,XV'6N7M_G+PP]"OCO\ 9Z:9\)G<>=T^'6V#@5Y^^'BT!$.E
MLAE-]62V?31+IQY/52O7$UGV,0><\22JRU+ANZ4HW^Z+U2SZAYZD":NPAOK=
MH8[%*^5^<\]5.S2@)/HK_>6/;_8WJY/_G;_=1X=5I;_\>G;S41U.[AOM$D(-
M4+,E+.05P0KP3;FX*5:S']W(+U)5IAJHG6=E45@!HMG:@+H=*,DM^E+]IWK]
MQ13%UZ8SR\: OX]0Y/@8Q%X=IR.2CNM51[@.2C\H]Q+'S1L%$9\"WB'.EN++
MPD]'?P@6.,*LE"0>:E.U"I;\#'FB=D#.J 8+AH\%&RJQ=5/4$890ET0IH?\,
M3"/;F!)I!DI.%<R,T#U .6IJ,5"3@%\[O/<7ZRZQPD)=VR?#C_: O-@<B6?7
M$E!_:PG(M"6@]-82\'I; IX:T[=6J*^E/['RX @KW#"9K9D.<]^I,H6P>9&Y
M]5L-\<ZB\86"\_A2/*V__%Z[.5W4C[3S+XU]F *%_K(X;^5_U*KE25T%MQ77
M>,"*^H*K?#5F00@/1M3PXJ7G!'8^#.P<T6#@6C>LA<8;T3 KZ/UBXVPR8"DY
M1$:O'KSG@IT7^M.AU(M9 =R5.5'A)ZH3QK;"NZCE<*'L>N&&@OT7LIBM@?;*
MV!3EO6(>I0?\"%2:<0SC6S91S"L;U$>Y5< -K\#"B7AWD*"\("H(KD&7':;^
M+:Q 9=7_!Z+_D!I._&813) AO7B/ &$YP*Z0!HY?&#@T+'HZG]P27842>AZ^
M@"C)BXC\/P4[6;#@%QZ)-&%?(XJ^>$S?6G$-.>U2<S2LZ09M=.R/Y&HS)HG4
M;\'!$PF^W5\ZRL_C86]1U"X?5)X1I\]PT/'XOO?5.>I\[58PVLS6Q"?H^&/&
M:&K;J]%JH6T&IZD)I(C+_ZM,9_\<"Z2(G%?R[\.JH: [EFEJ1D1[@B\-CF(H
M-K5NQ6E,6L1 ,[61SG4KVO'>T[T.N9QFCL&2H*)<OC[6<L=;PT2/%\J=9M_J
M0]8?S)"EX)_@4;B6"Q:CW\! 31C@=0R]>6X335$#$XMPG;;.$5=#:CZX:!G,
M+2PC$^H1_\8Z.49@_3''RB,2#:P[]';@-U-XE8PKP_9"8_5XH>&*FLKQ<CCL
M/?-:S6&_ZGS(7;S 8#T]C!3(4#_HHPPC&%Y,LXF"?#'39QH6VZZH<[%VOID<
M6[OBS\1\^4K/0\^A(/:E-B0R-U6X6S2UZ<& 7=B6"?_DQ[0YIM/T\QWIGM=?
MUB:72\><MHQ?E7VHQ5)_65C<%"^&D[OYKP+J"[9,B:]3\A<JA5?Z:E1DQY0^
MS4U-*N8+5588?>+%8P*[[_&>5R=W1"!X0H&>-'M'0GN*RONHKTG7,X9MXT'T
M7'M?PU<?%$IRX,W!CLL#J042IKO2&0-Y>T]&9*Y4K K,DCE[-K"OJ7(0E\"L
M,K*9!EBLCD/HJ,P<%D=!(,1'03TFVG$/#,LBV#X/SLP'+!=1'0XUAPJ+6WFY
M(5N? *&C?A2X._S 5B &)?"%+8[K%]&YC.&;H&$;L!]YVVP 7"^,]*9POF4
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M5NH<&I;P JV"JTWZA W/P_-DM1VHA-C(0M0BK.:> Y,$BO9P)@.&9H9H9N*
M)3P=E!JFU, XU^[ ?P'SG"9C8NN(KME!ISX"E07#$U0BR.85QB^9FWV!IWE^
M2;BT4]44>*Z%(W\=;^BZO<K?7-DP'A'-Q/#+%LYUY+=A5-%C[ +_\KE:EB;6
M'2*OR;Y_';P3/$:6B)'7^1?#6G [*K,)8]^<,X?7W?J[I]@!C^W1+8('=T!#
M>H)GZM7,KJ@]?KH;1(RM3/_KP!>O7.SRI*CE\3W%TNL%6]Q-1Q2P1D^WPKBT
M":2"<R"OR\D%1_6)X7P^@J"\^CAK &_TGQ73C,W/T!M^30^W</2F5\T46E<N
M-!:P28((+\2284=GSGNLVX#+2#Y0+'YJ&,_"RKF-!$PRQB]R*!8?Z+?6 22\
MX\A)9;DP^%+DQ+&$8\2$O*V/LDHX8"P7&##VS.IY:_FW>MY,ZWDK;_6\_U/U
MO$G]6M^KW2G4'-]F5UYK;E]KF4,*)9D)M_F+_4FF,?W[3POW1_7K\-@<[J'O
M\6K+=;DZI#*W&DE#<XE9/.ON$]V7#I]"Z/S]?&V=E:%JKV?07K6_=%NEJ:8M
M[_[<-)(,V@MW:H9'Z?7"0_2DYSM,KU%,-$PO>@#!^G"!;9<ZG<:=QEXTL(R5
M@17LOGSW(92W7,6WCWA&XF$<L'\\B?_WKKAZ@SUTR6U0<F"XL<K/1*,EUAX<
M-_(CJPW[4_9J_7U7;"Z+ZO3/^$]M63[+G-3'R,0VLRZSH'3D*(_C!W8I3)5F
MLW6UO&D,^LNETJ@/?W5_U+K[G+-7RT?,<HL>7A9;0+"'N7O1/+UE^-[F+Z5X
MS[,9'/@<VC96[+W4TP8;<JV23S1ZZF'3!D_2EJ<'A?#NI]JUU%FW>9-FVF7B
MZ8$1XG820E3>4+V_YZEIJ[FZ!&1]JI:6Y8]C=?))F5V7-+^^-73%/N]FD["$
M59*6\J3I(MD^Y2W,(/MBKN?;#[&B[G8H-5X=KIJO-^1J.:IF?I<SB-1Q%3]Q
MGO2*0+U"%#P?!<KZ1%5?6/G5)J6;^^O&]TYIKT/%8K5>5-WAGCER^P>?7#RH
MWB";X]ZW"MMA$M]*CXF<+^=!@=7W(36-W:4&C=\+15=/++LC8%U"LG)C?]1_
M]JYOOEFC1S84R"ZGOAD&UL=7]R8G.\E)U 'O6SI2#_4KH?U<VX=H'#WH0F&)
M6)&'/699[<BKY<(XO;ON6+W6?>&1)A1OO6SBRP)$>G[V=@4]\ K:R"#[%K?4
M'FN]6)'KI?(^Y*V5(F 4T\T<DJ]NO7'U4;D[O3"5)_5;XX4J+C'_)ER[!GUB
M^&'?XI3:(ZHW2BDGC^]%G*[\QC^<#!2VZEQ]?/75<CO*Y)&OJ5 H.D+,CFF2
M3K!KD4V;>>C$\83SK*-9?.N7-PIAUJ]^KI/5LY'Z%;;=L[17DP:CUJ2]4"W*
MM7(IJT'J6U5 .X4*Z.M7_:GKBSW\S3PZKORN5,K9W9Y;\E31XA\<PZU3K\G?
M4B-&)5QM*#1X^.3U5 /"=_KZ3LIAQ]<GR(9F,GP^P2&GFT>_Y<&9JI9]ZY+4
M4:%"5:XUBG*^M-WWC>&71.>3?L1]M;^<?]*:-^7:E5-^T#BO)RH[/A)=H=Y4
M):^-8K"@\:;U?$66CG"8)Q;@MZSI@%=C.SE_W@1]+(#M$JA:\J:F;VH@C*G[
MQ4937BPKRJ)$G3J.#I\/'%<QL3+=6.3X /&HJ:A\4A6'A*8Z*F!X+!2PO18"
M"77ZC#"=]*F.E0,Z:E]]I"M>*>[*R)V!9F#KLA/$"EY;$R>*-+1U'"3@55]'
M=ZAX:XRN#1YHHL7+,A'/&<Z2P)VQX\\GWEHI=B[4A!.JN/:*Q[D"B3F)%UQ8
MCR<6?4?*TLS -N)5DUHF$!A_MJ17KJWJ(!GSP.PS06/^$=T.<)_#:LQYXQ?6
M@XI:?;JV8]G4 TN%92"'F):'"!Z8Z'LH>9)+M>%1A>O\N<#8CK,J!/+&I6 #
MVLH7B"8S&]YBZSC3PF78);S)7Q8@Y7Y]O8S#H(#G#PS]-I:A17.UA?,_I#]S
MQ799$X,_QBU<3IE;[XKP#RHT'9E!!=S&TX;UM?-=/GI9Y9,5[E;7"G=[PXFF
MS@WM?'3I\5>'*S_^'H>C/JE-4PT@N'-0]XV5OL&QP1F_*>/2X$OKU^Q"*=G.
MKV**F_S5%KT>]Y>UNX_-T^:YM;A)4O,:7>TJP?^=-#N7TK?FV75;$K6Q/:G9
M^GK=N6P?AZMAGV\Q;#7_J,6P4;6-&6HG[Y$#3S^Q,3+[>4>@2]Y[T=X+68]\
M] "__DB8M '_*(7.&#:.QQ<W^=)UM9%U 6N3.KOW5KH:'"8H:!&P[M<5-(I@
M A7MI\OU3G^J'+4N.\UE10,M,FL<=9RSWT?G>FV?%:[URK\CPR6=U4SYLZW^
MW,MQ1,)/I3$M0L9$ZAQ;PI3VPTI"2WOB\;:8UK/&XZ6?P_),K=5+S0SK1R.8
MV5O!DV:L]D+3_3!J^GJ^DIRO%O>1O#KV:R^RE7C?T[K@CM8:GW;SO45M=-5=
MN/LI]4N?Z.I$.8JO+OM#!17[/O6]2%+M 9DAN5:LRXWJ]B*_K))#)P^_ $YY
M\"62ZET-KH KD"TW(%OS3N%F?GM\49Z]H&12=SWD\Y93R>[*V\9%^Q'5UYMX
MJ?>7UNWQR:]?LU9[^: YK-'.5RA6M^^1M;6UD!P-!D X:^?*5E0-N(8ZO2X)
M$P[IX_ACFF,";R%<^E3/ZR^OO^@?C6[O]OY!$^/]2;?EV$FWC?ZR.C$_=4XG
M[>-*^=V'UGGW6_ORJG-TUI;.SIM=Z;+=:G>^->'G5S'N-@)@4Y%F%D)-(-"2
MQIJ8L+B; ;<@/!D0;&XJHQ$H#S8S%-$"$2=SK(Q]M)X5I$@/BU)@@KNAD;4;
M #=A?71M8>3-L,24&+&83W-C0<C<,="9'K8\?!.>N0;K' * 8"DIQJ"H(9%;
M?=X$]=AB.+UHQC),R%HHEM.;6+9[I=G38VW@^C->@O-@Q%;P$R)X4W6_?U+.
MK+G5\+% Q%HHH3$"#6]B>)&C,>)J9#[N&],.=Y0QQ3P:@\.%W3I 5(XJO#4]
MGW3;,9=#OH:7 W]:/W*/*WHFM;=>D/.UAEQJ%&)AHGF2+()!61J'. C3-1Q+
MC(^C98#"MD;]#$"A53:IK2JQCYJ!-?L]Q="^* A-ZBZ.X67(&:J:)7/8RV)7
MZS;U'XVAQQSBC9*JN#[T=]1%L-LA!0\%'TW@=ZJR0/ US5PYQ'KD91%#EW<?
M/"1]!J0? TIX*'WTX>4"*@$!K$7R'D^)(5SB&O'H5D^K^E2GU0^]]A*4ICWG
MP+5?+)5RY'Z U_MLF^].+,T;F_+Q>C[L%"?YFJ\7Q&=!L^^#![R_1J]I-Q:I
MYW=CD4^*.4<,P4*%>*02RR/GWF &=C\6@L,9_+*(L4*8C/8<8;)UNE40(-Q=
MXY?B*K_XVN](<72G-T-TXW/SFV*337W)>6>FJWUUQOBGD,]G(.WU1=WXK+3F
MUM$D>!70%B2QA6T*/>D6XHS]/%99[:#/ZSO-G>/H_P?%@'('-P+./\H?IQ/_
M-^$+*R8\V!^&$IBU'6,?K(]$H9*5F1A/P;_)?CMWL6"&JB@&BD$7*H<NIH>2
M,0)+(\1MRS#P<YYUQ([%PZV/LHX(T-,!Z7=&A-?-1M<;FL"3%/81EAJI\-TQ
MX:4A&6[)13O,->GYQW"L4X_Q2R'.IX6*Q>,=MW%TWJKE'6'>K*2J4O+TQS_N
M<&Q=#N[+_AA19-& ,9-H2EGD6C<ZK+OP<.JFN()<R!?D<BV6>P-3STD;\2H4
MIHP8$JU7G,;&/Q!;*XQ/Q0@B?PLY(TP\4=K%#>_5R8Q8;8E10>+&(\X=O8E&
M=62,J3S%6V6*-\!.O$@-WRU,<L;VN0W,'IB"5-DP!>FO9P<#67B#@<P4!K+Z
M!@/Y>F$@UTHU'B%$5:^NFI2!B&;'@ZQE0<_ML:G@=._='M1?3KJ?W,7R\]6O
MGP]"</2C4I78J%2MOZQ^^O&E4E_8=^?U=Q].S\^/OW?.SJ1F]UCJ=*^:W5.,
M4/5DJ=N^>ORX5.:'O.9:^@5[XI3BROQ.(LO\UK[57UZ=_G#JX_+)1)OL"8!S
M.,$B0$?<RT/%MA=D!(3F(ZU<USFOR):FQKWA;#YER6&AO^P4YLV/S4;MXVTI
M2<UAZR/(8KL'0BE)K>;EY<].]U1J?CF_[EYAJ:$D)/>E%!G6LBDR?"RL2"P2
M_7Q2<YO?AN,+1\VZ%(XZW?95"5<ZXDAE8LY0B=RO]0NJK_?ZR]M9WEW\ZNC7
MGXI/4<0F_ @EY)1*W!\M/OO2-D'+2/>Q&#5WJ9&ZWJ D5\%!K-6C@M995IG5
MHHP9GO<-XICUEQ?71T<WG^^5ZY^5[*O#UFLEMN7\ Z6O#^XC?\H*F^!M=.!H
MPP/]_F"BJ[#YOR4XHJ)^/[ -X*3BNP\',7AX&16<E$XB9Y;%Z)+KZ5UC9AE*
MJS5\++RUS?JC]*35A!MU0RE2-Z1'5$JL&U(P06D7)IC][O[LG'Q<7OT81QLZ
M_TA[YHGLK#G.72LREKVY&'C^=N[<Y]N30*EF8G!G+3CIZ[8W"$Y"I-&]'@@)
M9-K[^?JR_6=2^77U]>=XS_?SVVW<J/__[+UK4]O:TB[Z^>A7Z&2O>2JI,BS+
M=\^Y=JJ,,<$)8()-(/E"R9:,!;+D2#+&_/K3/2ZZ2Y9EFTLF:]>[)P%I:%QZ
M]/7I[MU+XTYF1MRY>?IAZTMG[C0D7Y;;+CAO""BWMI"N;%[;(P-6<CN(R^WJ
M '%]61O%9[ /<A4CV5 U (ILE^^^%ML_>[??$WP@[ZK!:U$-_O/&M(+XJY0;
M+_PVM()LT.+FS5/C:#*9?G/N*SZ=_/6X?7,V;Z=N<?2*TTZ&-+0U(Z44C%O!
M5F])5<YP]19,"K"QKH+G((\I7)(^N,@'1Y$&CR]%F;0+5FW5<#ATE83C\=U]
MX8O[*=D7H]?BU^4O&(.=$T:JH6@RC_"[S2PQ1&ZI.NV:R$(#?=F0+5GL<VPL
MFR9M&QN.Y].-8 5BW1Y=O!FK[<8="B+KBDR;NL-M@H=M[%V)93=X&TM9=QC@
M(/P=+$VCSVU>YL8+3&@V;8 )CY,:,7(*, 7G0&IHO,U05*.84J7BB-05.<&R
M(N& 86HEBG9LB"KS:#=/WXQ%T=1_#+JM+68<!$-7/%;%2LC$QZI\/4(%EK,3
M"EJYM7UHJU+;NVL[#&>]J?A2?_B]W7ZZ_?K=5#/%EWA,R:U>X85_62&+%P@M
M90-4O*:@D11!@VS<YVM=\^@%VJKM?M7E;:S:9[%L1BJ[[+07MQM8$'7=.;S@
M=%LCUK(9A/C_AM9_L=2'VZWY#:WC3'U+N_Y.)&^&2+(RHGQ^CK5RJ?T.6G8
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M'KTB:4!MV:+NLT\%RKZZQGC>7X)B-!5X"9)"$#OA/>&ZV=_TX<1%M9,\E?B
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M==F7/5KB*HD+_]J(B/JG@VX2!867N#6*:A:WE$J=  1;@[3^>B8&M#I=UV5
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MY!L!/@Q3=N8.=O$C<]FGS1ZQ+2TV5Y2!;. YWKCXHG?)?N6VQK54AI0@Z(E
M;T<X>-(83R=-4<A[+LR"+AQG6"!KI/_F[?NPR9P[,.F59PYACV6^MJE\SX>8
MR4N^&YJ-WR$BW?W$OM@+;;:W!OIAWR<7F%2+G>UN#=*/SZ2 $M*T7,-O"P@B
M 5W%]O[(5X_G0%$KP6F9#ZPS(#PWP^:E#\'%NPV3 \?N3E*4%20KUF=04<>J
MA?TZ+?RDV^SPU34&KKPW!MYJ8^#F>V/@B!/]O3'P6A>Y10!OD;9W@3;LXD16
M1&>!_!4;RLJZ$))4%";GYU3[8M<03V4+)0MV90?Y0S\ '\, >G!\H&N#]RF=
M6:#,6TL^&N.))G!ZT@,>R0\/%"9!/E3 INH+($3\+RP0!J+,&;@H;6S*9HAK
ML-0IC.'Q?'R(K#^HCC0#,94X'>F"#T3^-8!A$,RL.*?^<@7N"+QA\KDN&T[+
M4#I<<!\L\8('HR\]LNX^KJUGJ%Z]>_/LJ#S0NB<-EY O8E;S(4W=C"\H$/?!
M@+V%.OW?RMR:PE"3D"K:R***1G?KP^=Z*:(G4Q6/T$OX/%HYSV.KQS%8F&[\
MJWDPGWY_F.GF_0Z/P_U@['$L@,V"BA$\D&HQ[X$0*TLD9VPG'DT\LP@T$!8U
M6V#:)^Z%1J"XAKJ0==!O@YA:ND_JXPP,,-(>6O1/8E\\@N=FQ%0'28#/J8H&
M FX99DYP\1G4%_B$83J>KB:$M;H8=5*7V9OVQ+2</3PVQC/><&_P;GSS[H$Y
M R)L5$H%D=IZ@:T4:!=QUL'9MW5PZ/\)7\E U:0@=>$A]L:7MMK"UT.Y4_TO
M5_>_E:\_;^\F[M4)Z^+47 C8&BL3;M.FD#T?JIJ[W(-4J%3JA6:LD\EC;+)+
M<$%27,;N<25QCT_X>Z'=+4Z/NO/2:?'"KB3NKOO-]?;4_>0:NYD[.5\J5)O5
M0KT<EP@3QXOH?8IG2)RB!9??J(:MQFYX*W'#._0MNM=AD';S9^_RM+G\>GJL
M)>XZ^^R:A,P^F\]O6LV=-UZM5@M2,Z[[F$?*D<TK9]J\")C[Q+QJ*=K9[^\'
MC6?<O+*+>HA-X:KFSHNLE"N%8JV6N'5<^"U5V1*IVAM/Q&23J:[L^0CTY;[8
MENT)6&H:M?UETE361B</VAV*P-)=IK #<XLX=)#4P[ZE@'\#[E+D-$N)IWG.
M?!CQ=^%R:%]JW[Y=FE^3.1#W@JQWG/R[^2Y#+7=27K58+12E=+X>V;[#;-L7
MN0W?NJ?'U]^O]!_#YG-NWXKK4,LM%LN-8J%:W^%U>+LZVB#.31B7J>;>72%Z
M=]/$(*CBJ-0N#'&HZN9B&QEKQ)?/-\;UQ6\[PE&K9+%B7(7D5':PLLJ2N'&2
M<A_+*TS(%:/=/-7ZUB_E<';W\$O=.!K"O^%+-H3;3>8AGGBGNZ5P1_RA;3AB
M*(>P=//T8]8Y:!\-!\9A,TL.82C$(YYT6P?=D^[@Y[.D#C(?)XW\RW/'S))-
M2!#E[$V+1B7QU7"&X:JT'M=EB:BY/>+&P@U:6'*LDS,>0!;[\O83\)H^T6Z>
M'3P:\^M2J9<]R2SK-.,R;?R.AO\-K?_2N<;E&<5^9<.D' _RLBIBZK(.+F(/
MY^H9K&>P4/4']91X,]!.F\HGO9.3\Z>KZN'-T]VH^BCWU%*EK>X$FL<38*M9
MDR!@7ZNO 5"?JM+DW?[L-FLM?VO#6JW0R%#?>#.X_V$.8L3\R\'"C-#@3+&G
MHV_*;>FXM+WLFZS$5MLQ[G8[A,2V;@WZR6TYEHO%0KFVNB]S#J*IYR6:B:6J
M$;*YEDX7E=JAV;JN/G/V1Y""ZF^'@G ?L]-0/7_IYJ94*)4VK;&^-2F(:S\R
MYU:$A&KMQR^:.>^=GS6>G_,TW@S=X-ZM03;Y:Q4WJX5:8R>L9U4H-7'I8-Y'
MR&;J*+_.+Z].]%/E13E/\^U0$&SC&A24OYHN""^INKIN50X**N6@H-88+(A$
M,JK)Y\?FPVQV^)@G?7'KC1L&$]5299SQ6\Y:VPK)!LYM#;K-7R&W6"XTFM(N
MD@^?M\KY6\MF6P7IB*..&VT -]GQW>3YW0_E?-2:# [+SZQ'T-*$08?\FY *
M:]RJ#9K]-*N-@E1:G7&1@W+:62GGTE T>X3A,57I/([@T18)EMUH9]T;1;MY
MFI3:=T[[Q^*N6W]E:>RX+E&;SN:T@!WMQ?V&I<.*Y*%<QYB=D!OY"W+62H5R
M!L4XHWCXE$+6&<$>3^5:M_;+KEXW*L/G5%YB4^9HWRD6P_K!8U@Q<8P,Z3Z;
MID%M)^=I;;:[,4BFL0'D*!DDDRF_ZEU_R2^%FJNO:WMN84(&N;4]Z;K[W>E]
M^]:4GEE128)_8?28IV.-Z$SS[7WDFFWK#K']6^,JY3=?05VI-7:NKB0L],PT
M1CY:N3H^KMV7:K\:IOYR7HXL9*.;\ X"9E\9X7C[N0;MY#8A)=CJ>J%876U$
M9J.>;.FKS9NG+VUI>7GW]?'7D[0)(N&%X"^M%.1*(;8"="3K!',Z9)%&<S'5
M$2X)IN+$I7FLRO((4M(5&[)%1XSBY26:7_#3C[T=+OJ3VNV7V^N2XD*WKK+,
M;8TL@=A, ,1.A8@YDI>Q[OH^?*[N5Y/R /"#-L,S1W:?*^NBA4F1,=M>S+KM
MAVRD"QCH7+5&C#_.-.5&F=W,S^>6ZM__BY\G3[/FP6VU.TG>_\#LUF,OJV>7
MG=LTLUHDW;,CN-O ^&%:>R4?Z\'5?_A<WT]$2/_U7-"X7>>[-R-%[P_5H8/;
MKYL(<4U*=/?[C1/>N'D:?)-&7^8G,^M6V4Z.>R,QQQU(5/K1[)_7:[T.K.GS
M8>=@(+;.#L7V1>>P.Q"/6FW$/W6WG>U.YO8_S3TT;=L#MR^^B,@TQ!,3%MRZ
MM525UDG9VI=>2$3U8#4S2]/I=Z0Z@U5^1.'$4M_;0%'(S0^!"_#D]X+@ST\B
M8";JQ3&!7]+\(MPHF6]401PN*3>=FM@-P7N99#>"U6J9"]6B0M&>#VU-T3!%
M\G8N6S*,"KQX)EO.$O]NJ? 5FNL.2Q7@'_A?\2-BV3AFE@[$%O#%'<2=OH@'
M"EOTH(T(+/&DC=.0E2G("-M!COB@PNS1YL=9$Y@<+$O6V2_]^]/"WW@;([/T
M3!VAOLGS%MUY^[<ZGLR\:<\L\T%32+(_ N-%6S4T^,'&QGN8XL5WGE0QF.$W
M4G,8^O0]9!U$[!A5H\8P[Q6I[DLHQ*S!WMA7@R%4_?;B"TX;9^U.FB<2WB^O
MC?K)L%(]\G2&?GB^J\24;Z()$J@(;+;N%GE-G$^([V:UIO:JKHBJ13-)]N/0
M"%2/F&JZCLM)/&5^MOMB>IYR/&4P@F!%$CYJGZ+G#;H(/Z8OEFG;F%MQ 1\!
M"E=06O&-"A% **-T P(HS:N'9>VB\MBON@2 #[K77DDZ_?[IH/MWZJ2SM!//
M3 Q9S:,T8I"R$ ,'P;,S%<B9.A/9(7DJ?%=XG0T__PW0T9%FV8YX0!Z'!]S"
M),B!/FI "Y0#$#X,"[]ERFJ$0J20%M$U@ 7.<9LNC;FM*NX7VC+BD9TECS'L
MB& :];-!^>=/22E58U*/:380:+NRIA/@-%+^D$]Q%2-98WU;I:VL<:8TVJH4
M,]"6NR]"8%](BZ"%260K*:+A>'^S"QX;(508)I!Z(H$<@DYK:23I.397:BOT
MT#FJ7-U7SH;7/^HN/;AG)H[8H<$FNG-)-3=75@C/=*82'&N<TAZ[-Q\^J_)H
M0LL0>4>R(+G(O^>:1;.SARJ6,D*CV1'_ WS$.U.XT.8()" \XBQ4-< 7!,(7
M\)&O<T,5RT4B-JJ%),L6*. .U"2B?Z"R!;J./69W!;C#2+5(%0K8,5J& JB#
M)MYI3'$C^HXXD1_P%Q9CRNY[8U6U@\FI>,5 59F9EN-C?G"9'0WT*:"\D:HJ
M-O]]B*G1.DIQ[-+$6ACPQ%RS:1FAMJR0VC">F*04,43I.+=((2B2)?2&$ZI
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M_6ME<?S#\:3;U8J%K"*;U>O8J%1DC&8E%?-C2],Y.V. @J_*-B_OB;"1< 4
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M"2IB>:_Z%VW_3'K"XWQ!],+VH%EOR[H+\[15=PW[$:TI#O?W9J[HF^8O+5L
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MS['@.8/HMOBV8ZDR<?FB#D%?0PO-KR,/364IPL70M2?26)MIXVQ+9K+CNN6
M>Q,%G/X.0P$P<0:/\+>3]UT;(:(J\UW<Y^5;D+?2F;.EC!!JX37Y]%_"J.*-
MJCV_\V+*G1<RW/DTQI!PX??%%IP3:QK*%X!SJDK%C_>?Q!$\!VMY5\1?8/)'
M<V)GCKRPAZ^!'QI1;D9J.HFQT.F.,D_WJYJ1(#+)+S68,GY@K[A?@D=W?;H[
MRKX,9-7[D_>+D9()Q4"6??9/Q.3C?_@LA("\:\V6G,V'_X;!P#G&V.JA-6OU
MIG=J4;!R;B5MV]GAXAK_\SR.2YO+'MFUE>&>QN"\N,^:F1>^+KGA%KE2LUBG
MAA+^M$Z+2F0-O7Z"2_Q&4;6]O1/U5M8[("V<9?!=N@Q/J0"5@K]H6P[\'3])
M7R'_/M4,[,OM^MN_Z'=?B^9@5ITD&5C$RQU9?IR!)37WBG5B8-&??.TFTE;(
MGDE>"4S\)C#OD'66%?&]H@EO*<E*VXNQF/\XNJ#]VCE=+,[/I.&=6?HAW[]R
MNO#/.T076^KI74ELS8P\PXU)4+#+E-(ICUUPYJ+,B>9-U[(6TUIHH/R!>F!A
M)UX<0P9A]DB_05(C5O;499X5^\BTW,@4\>Q47<].=;V>NB]'F/1WKLNI#S.0
M+<WT/<]_!:M51[+7/ZOU7>[\-G7IUR\U['.BEDUF3U/<?L;ZFZJNOZD:ZKZS
M7;(GOXE?=^A&Y*[Q)B46^7?Q]KC,_8#*X"\:]*[-OFNS[]KL+K39J4PTVEBG
M.1-#^E(<DH J\#)T-VMC;40$U\PRQYHC.D!/;H"5"+.U9L(L7.9A4GP!57L^
MO%-'3E!LQ<FK5FH,8E,5*B*B,JE =5DK+8KUCEI]QB#%*ETIO)05.E I=Z\
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M\]@1]\6689*XOFDDIM[QR=MD+;IM^A=$X+/>Q(7XS_Q+$4C/E3PSM^3^!-5
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MZ*D^RB"B86>Z\=,/Z?:J(7\K_9(GNT(S;$:B^0QMOY53JN^GR'"@0>+)(8*
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M*F_9^& ^?^M!UG2\+4>F17IC^EL$5XHUJ>1S/N!V(U,+^D &"W,P 9D*PG&
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M@&A&]50&R&)TX 4SJA.I;^M@FI"F-ZB8,>'S__?=R5).9K7*5XKKL_OVLH5
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M<U26%7R,J$]G%U%:$:/U)+S+89"9.+S+54X7*+$/B*S 4V  32BF(6D"X5F
M?$@F"TS.-MUV=)1_C651A3.@596A._"X&;=C;A8*TPRR"EA [(ZQ?5> [YRQ
MTUXXIQ51/32).S/BX"]+6,D:[Y6.C?=2;;PG'!OO'1OO_5ER[%I$73R7C=3%
M&3M<IY/O7(R!8B3W#33AB42B8F@B2T1'M:D>+VMCTJR5L'2P^*GUSZ&6CBHY
M_@,L!P56I(](BDEH"T!$T0QU<5C+A%,KL", *OE87Q9MM#,&NCF1@8YXLJ2N
MJ+)E$#_05(>7CJK8*VR^*\L9XJ^KDIN:Z-@J5Z/1?W+WVJ+;=1F/=W5O1S\,
M"]R ;F>KJ&IECL&:/=@\W,> *MJ>EY=IZL1_[?JUT6?,,6=-3@@("%2Z9(F$
M7( U#]P[#LJ'FJ9Q9S*:_J(J3M 4AN5-&Q5M>).$2S+7H/N[/Y/W)?R1==I>
M^"Y9T_<U4S8>@:!-^H,AF]AG"U[F<;0M_$XM<&L,SP)(GL!<Q[<T !:S2G@B
M)X Q('XRJX0ZYI613#JD$[,%4Q\&"OQ.'?>NB3-";P!Y!(/YF"8$FYCJ)%'"
M\:E[?F?7811V CAQ7W;;BV=8VUIV<)Y; )*"+6N)_D4@9<@#&44KAK0TS6;N
M;O:!H4Q4L7\'&]3[,X%O#'THFR9QE5_(LDF:R@O9,NO="/_*P[^\QU510^6Y
M]JR8=W=.;8Y'Z"Z=7Y.>@KXWHQ(+SF;^7Q;7O3:=<[/EYE]OLU/AZ_!;JZ:Z
M:FA]X<3K\LV"!PY--!-.LF6:%DG^!2"@6[J+/BE[(+CE0-9&\HEJY3)?JH8E
M41)6Q%,RF(HS(M@<E!(5C+* 7C2544)JUI@DZ&1"J9;%;Q7X+EK.&%2AWBMX
M@&8"\; I%8#'P7^H"AEAY@9>%C5 2CR8WV/:_=^4,@%9@?S0/^9V8J >82'O
M#_Y$<Y0%0L"UX6))^^8%E@':'BZS< QSC/WZ 2+86Q;U U =X<-D0T!Q2)RF
M/< F#TA,L/P)GI>\R]P@4QK&15#XGJ3Y42N!(BNT-0%B-SF&;EO<0$2]543^
M 6 #KLW[R-\Y@;..$T2:.<^87#7+2>(, $!]MH2] 0/C-!V.1GV.SLL8\PIR
MD$7?Z8+BCOY3>" 3Y3>ESE*X)2I(: S,6:6OBX:$_^%Y-W?MKCSJ6DS78J'%
MC(^W<C7I$>V<&;Y+1<U1#]N#S1/CF^0X+F46!+2KF)?)O<<U LDJ(<\Y^2N<
M[#)@NA&6Y<""]FR!I7#;*68!N!J<Y<^:6?X6[UNG/UL(LBB6+_X!%C4-KIM\
M1IY,57T&0IEZ:IT<'9-R=?3S H/C3&4"\D'49-TV@8D3-0J%1>BB:*][RP:X
MW7OTIU% .*YG!XC4\9RY@25 'GF)/SXE5390E+L*H>6[*Y'=%1S=-A4-I0-)
M>#!&HJ;,19:98%J8%C&"IX; JHG*29TA<!P>TVL-]F2&N.GIT\J FX(2II%G
MR/6@%C56IIQ(Q!)320T<,PG&,7.B$"QQ%4Y'&77@H/@S0"@2X)\GLC&2#9YZ
M<TSB4>$S &%QJL#-LG/P /5'&6@$4U.<D[#-^?X#10T1A'![BHJRU0<N^#Y-
MG_)O:B+.0&*3-_&?CCH-?QOH$UPSHVB/NOJ(F38$7> =$,UC?^Z'>V) CHF-
MZ388%*17:$_9EYEIP)"T+UM/..W'16U'XKE($T)K&0?_'40Y>H1>8?,.=\K$
MX4X+6H]+U(:L3/JPC.]E));WRH>%#G)LI@@@$U&Q 77<QY%O:YC,E:%?H $L
MQD>(RD=GE&@Z=5D!:].<OQ$<-RU7X57 /C6)HY&H^P/9RSN@S(<H?\#47#QW
MJ6L1 BY^D@PS21_8" 0B9^#((FQ-[",K]29223(P-18<?Z_ \5&!=A^%C]K6
MB3X\F>H#C  .=).%^5C%DHFF"'D0=F)K+BM']58QF%D=NAUJ1^%49&?\"S6K
MZ;,RRQ; "W&WIF 5-U%(I3!6%HH*P,<P50OY $G96HLOE"L2(# 4H9967R:!
M3]T=IT[X"HUB*AC+GZ+6#KR(R9X:J70 S)N@RBYG(O(#SAQ5^MR1:0NE%=Z!
M*>BG\05SJ$N@YG,)U''%FB:Q@BS3;Y^'SISSC'R,LK6'-<R4&)&/+=KSSF:"
MMO-<Z0RFAOJC-ODD^<QZQGQ=E%I01M;9^:M.L:JXS"N_<$SZB%TO6O;5Y#.N
M*Q6^6 UKSD"8, '!TGU5-KFOX"B.[>_K82 ^G3>[W2_/Y5>[KZ72U<WN*W&G
M&Z%<X N5L.99Y+XR+%N".! BIDMQ"].E>,=[R=109H,#V6.(BK TIFYTT3F)
MVA2=(4C#9:($VI!"M$-8@"D@SBY )Z0,@Z3_@GC!\#^Y%-)!FK(P8 AM1]E\
M4[&L71=A50M+\Z_D$<*TXWB"UQ=?^3MPQGC[;EY5!^WL]50K/I8/INBJ'"BZ
M*D0679W=S8MV4W^H3-NY*_'=/]W&Y76CU>,ZC9MVI]=L73IL\>B\V(/2":=D
M(A C&@,[T@WF9"6)\/@L*DNN-6QRJT0:D"CPR_:0L25MQ"C#O),&=W83Z':$
M+O>PV5O/L]GS=/CE2_YGT15-=#GD<[JS(*C,9,7@ +;%Z(BS#TJ1J,_&W\CP
M=_[7]'+4S'^Y#]F(X:[HV\E* 1D)DV2E\M7%#J98U8U"\ EDCBEK2P-U71G(
MSAQWM\N02[C=RI;;U34Y1&2'RW"'QWC8@H)V^<I.N7/;<.I[3&S,(7$/-F@L
MLH%ZO1?3< AC0-IU4%I87LZD%N@075(86G5[VN 20$8:+5+R7"4N.8&ZP,CL
ME#OSS<C,C S]B00N)^1CS%S$=\GX M8<W5<H!\;*R! GW&(0TC5+V$ABL/Y4
M7;\G8!GK3Z&/#D@-C0O"#-X0AMU@I_=P$+>VKGU^[;G7R$*+Q3<<*[Y!->E1
MD9],W[6 XF2KS/+$94W.^0K\K8^1%GA"MPTX-G8#HOFF?&:!5X6PHEQ2%E!P
M6$"VE,_>S4OE[O3'YXKXLS].E07$)ZJ"8]%D2R?Y[ ))%;/9+4G*>M(CK980
M[/Z;ZP*.&J)78(#7UOMT\Y94SH/9/,.<C-,=EVN<-7OG-:>4C:;!D9#C4+&<
M:>83641M%+/NO(@O$##Q2SG9<(C;F$]BFB0D3WW F WN\UE1?DI),^.1YJ*/
M0T(',JS'MLH%M^HXP\(X*5 UCDEBT];>@Q9M?O!2_4BB!WS?RC!C]2_Z( O#
M(@/YRS\OV!O:AB"5Y"D89XKHEOV($]37'7\XD,/)0#3'-&X:,G_"L9!YQN+1
M6!MZ(V4 ?& [:LB]5(5"GKC*R'+X*QY&9L6F\H--+\8:ZZB/H2M^0M-;9)>#
MFC*8X/33Q%W$<ZH\HO0'RAS+=UFVV]&5Z;G^36J9CD1%,_]B6]!))B7<.O5O
MN:6LQ T ;TZI[\QQW.'^6>(_<PVBC()7%%W"S$O9)&[ 12Q !KV@4+K/87:/
M&8&AHH<V#%M@3WR@E0FKV32L<8:)[8#%SCG&.BGQ9!\F^&/YOQ! 3+I_@KV*
MBR/TAG15']',4CC+P%:I&,-S9)R=XWD->0)@)LY)IC*<1GV,0%>QV*6948([
MA$;\9R*Z/*:%((4J+%.!JW7K7*Z2Y=UONY:IZZ5@2=H2Q49K\=R $D@,E[7:
MC8\/L(.:/L\KV(FV0= \0TMLF>Y#W*0D6<<]2$<>V33HQ5V2330M>0(\[;W\
M@20;>#]W3[Y$0HV$E#"8V)<):0)Y4(S,, ^Z.N-8EI6[70I"ROAH+(OZ5F#7
M#&.1$Y):+D=3Z=O22+9.+/V$#2%_% T%&:#)&N<PBD,<H?DYZBP## , ^S26
MB:J$^!%4:AR&234@PD3=BW=N=YF(\+BT%ERFT3+)=2_ ,B/1H*7JNB6J&;8*
MJVLG.(9E,^RO*@856<Z@/^66>*T0_H;J)JM(+D8"= ZAM*9\+*U)M;0F=RRM
M.9;6_#F)6-3&R3@VSC'/ZG6;$P5-3D>$>64^3FL@IZN*"8Q\: $AFJ9-; O4
MS$EF"&9/#FWBPXBJD?6Y)G30AYRLEPRH'O QT+&U1\70-2:A YMS=9R0#;@?
M9!)\,<W=:_82IONILB@YC_"9L"8PO%.]3UH!<*M: 5#O$TDB=0ZEZ2>&0NP9
MT7G1[<-DLA>IR8C0(LZFC&(8RHC9?%%@" 7XFO.?*1?MSK5_FZ"&PD9U)]D?
M^U+U%5VD_\R 2J?;)OK'5!(^)XEFV#*77BUL 6/MZ$;#\/_  +N'P'ADB$-,
M1;-8G4#MZJI=_]EK<#>J;2Y B=:KX9KT'11(J"+1XX'F9"C/J'EC$AG)0\+T
M8Y!-L#UR:V"<*9BI2P294W! ="Z4!Q1&"M@J;RIR=S";#[![JOXS'#5I.OW)
M6+=)&HLIDV1+O$)_6IXEBQ/N/2O$Z<F#L896(E@5'YQ4/# 40.*3C/.I,I55
MA?:54#1-?R117Y< ,M2F\BU_S+O>Z:Y[A$MG/M&N"$C\1XG_NA*_]^G&E?(*
M<O&!S0(B$2$/)WD.+6::H Q+!!J^@7 @%K:.8P.!J0\5PR295!C) 1M=6EX\
M$XRG3,49)B03UZ=BHCTCDN 1J>=2,'F/9*^:)&G#UI@Y0WQ^OKQANH#_:XZK
MECSJNB1HQEKFFM1)PP]$IEMH!#C[,!?K9.#"P)QG+3VH:Y5ZUW#_1]GR&MC\
MZ<;1A3+L'FAC)/0;#9B'5J;YF.Q226]-] $O(#CV7B$XAS$TD!,R^]5Q](YU
MTY_235$,5")#1]$"?T-:>K!%]+!B8%-5AO(I4HE'& -=1_\133E780L&YL B
M.DXP<#1CH<))"/T1![OE1C"=#V);&/=MYD2GIX%/9D3B2I-)VT2@8 MU;D<Y
M) 53XYFI#!34_DCX$/WG]XJ*#CW--FAD0ARXOG5L9DC<@[#UQ=^87:!A+N?2
MCZ>$VRS<#486G*(T_/>(9/::F%7+XAXRNL7@/Q@D2"<#E.C8B0;45)7 T[3@
M473)S9W+BFHU=B3-URBE=AL683 9XPVD.,7QS+IYN:Z_E=F'/N%TRM6PA:=;
MJ4$*1(!NQFBMN9YABE*+BT38M'R&EELBZB!+QU('E>4=ZZ;,=D1IGJ"8/67>
M?+_IZI _,9 H!;",@8C/'O'O=;*P1);]X%R/ERX2&NMQRI1H5CJ-N:$-;6.T
M="P"H^]CV0N6]] J!F9E.NY[I^"3O<GB1M2"SS#%"6,31&NHT5IT&BY"U>L"
M5Q*R)U_<$F)BN#\IQ'6"*HI%ZGC8?GP(.',S8F!K*O+IH=,WS!^HM+Q&U+X,
ME!40H?&1E8^0BF@@:I"$6-[/TOJ#7T&^K-!2-"="E%G(M#T351+S[HYE$DN)
ME8:[\K$Z1I<OB),"[C+B01347:]RUV0;YAHD8GP(D9C*,1*3:B0F?XS$'",Q
MVPO)E+/HB]G<4A;]8 QFBBJWA\&,^*87;3Z;L1\C,NNK"YGUR5:\FQ?5+]/'
M1N/&'/?3RK9_$2_(4$<G-M'M"+8R(6JZ*9->,C1*4L]P6FC\P-PHKC;JUF&O
M#O.C29>)F85"6[NOR?!R4H1<50&4%3C>WP>JO;V:ZND2Q]G%W5S^]G!_^W3V
M_4>_X*(V9G.I(AP)*%Q^]T^W_JEQ?GO5R+0ON/9-HU/K-=NM+L_5NMU&K\O5
M6N=<O7;3[-6NN,:/FT;KO-F[[32ZW$6[P[5O.]S9;;?9:G2['"OCZ"Z>>2,Y
M$1\N\23*.V=R8-C1/W+AH_]\(^W#![N1NWZ2<6X#OJ-*$0-+PR:]H>T/T/F_
M[W+OO'&&U?+=RI)+5^$[8\G@3DIPH)2/&&^.[>;4\5TU[?M.?S0<&\.@/([4
MJD).N*RP.($1SHN#QQCVN+1TU/B\]*%<307*8-X[H+UOSLS/C[>E6DE,&[3P
ME7T'YUD8..>=LZ>K=OF[+7T;I0X33%O;=ZA4[E96XVY%RL7?WV;YZ;TR[ I_
M."G74X&RCY1_#+\/?W8^7WZ=E/]44@Z"<_[E4?TV[7ZQK"=U;TF93 ]=827&
M%.D)X)>+#9,P .Q(%W273S,$_A/+W!L8\ C$O+E#.H4_WS]PCDVQP3^3>CN\
M2X64A25'R[;DB>)\#WG63@Z:3XT-[0U"Q&=-;TD[^$.D]IX*XGT_Z!&%W^PQ
M4]4EMV'BZPZ^XO'CVXG>]EV9:\TLE/9W,*'&EC%J@9$<+&'_KECC.K$ 9:/A
M5 O72#&S+/7$Y[OY9/)H/)X//\E-SV46C@H?N3X@[<C [!UT1NK&WYPQZK_/
M90M\+E_A<\7B!P]= H&I H:\EB-8+1GCX&3;0:QF+^;^$TYC@;A7Z.K_CEBS
M%'B:C*5=UZP@ 70W[,L6X@<)1)8*29M\54I\J9SC"[EB2(>#4!B%0S2<5[["
M5?FM)>ST<*(\GXP529+A&:",G/+<-U2 6/'=/R>N]7.(!WU)G(QL5U/,EHZ8
M]Y(7$MT,<#V3*">]JE*!KU;*O"#DCE>5PE6Y'M? _22>F9'CR_GL\6JVN)K
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M%])%BVBYEDOL*7\CEY\3]N_RXVY]#_6SN%O/IRK/_%%_I]MA79_T%8TF/@Q
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M)"P=7AK#AI] "F3HLQ3YV/,WAB[!D4WO"&@:HP-6H>AB&; Y@G+P,9%[PJ1
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MDC@#(WEHL9Q6TNEG^/_:.[>N1))LC[_[*>+4K#[+ZE'("Z!TU=1:J%C2K>@
M-3TS+[."))0\G68R>5'I3W]B1V1"@J"))A@)NQ]Z65R2?]Q^L6/'CAUQ2J0
M4KF)[/\6N,N3<Q@?X5\N=-=;.^JJL\L?72^E@'%Z?773;'?7['(N= .IR 8=
MV:!*ZQ6:#;4Y-A@E:.T?G5;O7^3Z]S:W)"Y:-]RJ(-RHZ#5:;7+2;#>YB0$'
MV.7[PM*X:K0;W\4A>/'/3O.26QUGI,N7!;]=7%^>-3O\([T>_S@RIC",,9 Q
MJK1>H1ES-,<8LS2AB0 %.%,Y9;HSZ.AU&MPJD9[6@SC5AESOD%;[K,EMEK,F
M+F>*A!,3<:)*ZQ4:)\=S.*F4R$VGU3YMW7";))5MY[S9E$CI-CO_:)VN,Q5)
MH1OLXUB1###)A\IZ^$!2?-A#/JQG;\N<;&,9N(NU_EVL(]S%PETLW,5ZD_DP
M3>DG=['^49B=GX)M5#VK^MI<UCB]"H[HB]9)J]>=RXW8[?%%H' G=4\OFF<_
M+M=IO96JMAMW1=N%2[E_(8?BQ76/HY5 F;V0,]Q,XUE[-M%J,QS-_A,+B/OI
MVUX*L"NKS;W"]^GG26W/SHE9M>6I9G)(44P*6?^;&+7!3%'24TW.XZ H4T?>
M6CNPP !70HL3X G6#--CI=-6@#0!? 4@LK^YPOXAYX?ZFJQ\Q-)68JF_15B:
M++213VO6VO;V%J1T(4%2_^)0<WP,<##)5@2>B[3G!;)<,)$2$WPM<%AQXHN1
M+P5#[]%-4H4NRB&S%]]-S+_+@N0J$@0@ C [ "V5 !@?+$%^K5DK^(!97-?$
M@1/00"E(5PO@DILW@*"EYW7$97J0AU9Z9.WD4/,:V;,YS*2Q,H^=]V%FJ7OM
M$[BG<F&,9-:GV-TU'<YS/M_^O,_W#2@ZRKE5OO83  CQ;9C)4EX&SH+Y0KU!
MM+[6GK1 8WX5O_YD':E[K>:K7F!XW9WT(^:<UUL052U7]8YN\?;F7V)9Y5=.
MHZ3_)1_N+.OY*O:4A=6Z?NPD^SW#,!P%OY3+CX^/I8!9I3OOH=SPK2%DARRS
MP1WURP,:TO*17C&JM;(F$S?4JQ6#3Z['6E4K!_>A_1_VI&O\!:TT#'D]-X*
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MIA*E9PJ^Y0@)(B>$;?5GH5ABBT<N(PT]\X9]PW7)">/&3Y<Z<&LS>TN [?+
M*XZ]E%V43BX$8F5T@0X_DO[4HQT.96:-YBEN_J"J'5_-8CZX(O%]49364:;,
M0[8?A&2Z#<3A^CKNS17CL]Z!^R,,S_KPX;"+JK87[";RO# \-R PZ^A(\CS3
M=1<W/K/L ()N+SAP@>%)9C@M3BEW+2\6%9&X/N7(7RTIW-(;*;(?A#C&<Q"H
M"EG,65Q!%A>&Q::FU?@_@<79(A# \^I[#J"O^=_(#L?D^I8SE3.Y>P66,"_
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M,M7L,ZA*^1E1C:*B*E2%0V@+&T %55/#L&%97N2&$!:0#@:1;LC&X-YV141
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MGAY<7BY)>8DY$"TXC>H"SCO9^EC7M51Y^_DS<&!;\!757N?2P7MJ@(8.JY#
MM2/B&)%O?Y-MZ+N"*<M)S %K,41K'X*APW)%5_L8=&F86O\W2>Z;ZJ?.D&VO
M5ADZV@8;4 XH#R4'FK5.HP1#;<H\N1V4)T+Y&>49R%33WT='K-<^9<!5@,J5
MAP/>6N?19UG7913&IG880#$> ]H)]!W4IQWRJ@B+:Z;C@+08%%5S\*O3J>=?
MT%5A+'&1<N!9\ Q57.#5@7FR!!Z0!0E@M6):#[6;X95T'# 6[SXZD+0#9:CH
M&&]FRE^Z[>Y3M\W2@YCIKG6/4&A1E:NH@9H#T%JGT?X\YWZ'NZ=,E*%J_M@A
MV_:\;=7^2C5!,WYO2FY(/CR#VPG3,^[I*P>L@88#LX([*'>/7P?;N1M>/@W3
M"&SJ]*V-&UD>DY".B\%!X= /M#C(CNBFYZRKU.5C%,DQ*&ICCM(=&&UB_&D7
MW(VN)7FJFO(H$<X#%>.2#'8Z2)OI^]/!Z>'O3A>W/PYJ^Q3]ONFQW@F)$FF-
M40^FGX*LS-W(L0#_Y* ^Q@TWC*A'*Y=C6-4>-=25OC9!S_/N,#'&/*4:Y >,
MNO@15\W9[0%*3S4',AM@R44"+(:Y&U[//+S*'NIZXDHX!EZMR^V)!E[W1-@9
M5X]4>'.:J#B&0M$]5[R.I+-XSKI$M^J$:@,5!W@E#X3E+MG]?P\>_@??B-?)
M0F)OR[^+@.S#1>BN-_BT5/)M%9 %?%M'[F7V>/??@>T7#VLO(\$::MZ69\CG
M>RJM."O""NQ"*?>O6!G7@.<5HX)"V/T%L'ZYRAJ?%1"Y$6:?'E0C83U@Q5P]
M(N>>-6_+.60AWA.R/,+RGX)7&*!M><V-Z2?BN+^OY2GXAMG5EN_C"?E$; ]V
ME12Y?G]E;38N7?CI%_B;4C^9!]DG8!R4H41!+(<;RZYCRJ48 &1#"T(PR=;6
MR+=94359\*_++-\E?KJ\OKE\=?WB(73V+6W3B'TWM&M$EN^$1K#20F*_6/IW
M *I[A8.BO/ZPBAQ_L,'$6^G""N>,A3B\7%K6AJ?2TCQ7Q(O"[,O)3<!I$I[?
M!E9,JT8<P>E$P146@87>7 *.KZZKF].4D_T=GC0(B.VT&009.?YHQ?Q1*>PR
MCF#;IN+#+-D?IPV!,(A:H9_1)\C#7V?PO6W5V1DY_BBKE'C)2\W,IAR;ZM]G
M[%  <7)Q-F.RGI/@@K7NPT43D>MYN-#\<!$%,8IH:)'[#D2WZSLFTS!.G#C>
M+J1$X\" 3&;#.\=?6RY5([)&2N 2#%T0[C%2WP9^O/EPD13G DD=(X:_B$PW
M#&/0,QO+#=++N\)C3AJI1&"EYU,RC$/(5LY$3;H(S5=I1 )J>;.08'??PT+^
MN/UU!"(P4'8IA+P,"",[9H6/5 2F\/GU/BS]8.5_=-G),3^-5"*PPH1/,R_-
M9"(PD\5EL,THW)M8N1O<F="B%0ERX'"1BL!4=F@;VI$_H9^;/QR$(C T< -B
M1P,2K*W(]_SE5J7V,2>U%"*P8$!U).R9]_XT2.-&6(!77D,VDHG 3-^SPE"N
M9:2>1 0FINZ#Y9& ?"26%ZUL:%]A5-63B,G$S)!'HWX3'SDJ$5A)0E9GU,U+
MJ;($(1H,*P)_[,?1:NH2FQ1ZO29=A.8;ZGXXF,1>492;('P*?/ 0BL"0MEBX
M-C%P-:?1G-%;D298LT'L5S;[,$V$9O?U6Q/4+5[T56&=UU*(P )>*$^H,R2Y
MP5+R783F]BV'4!@(#;W>1"4$*_NA43EFQ&KP<:_6=KE0#9]:KJ/2WUQVYP^8
M &%NN-2DB]!\(YZ/0 +22A= '8$(#/14^3?-J.>A@48$-G3?7EF>2IT8?9 E
M1D(=@0@,)'U<"X"8/2_WAO6CIXY ! :2D5$V6H1JYH#, _11U7=V(Y4(K,"J
MVW;108UVNTN78Q(L25#!$2^Q"(S)MLUN$2#IW5A^D'=HU1"(P$!Z4+.P/"GY
M+D)S#1OCLJT&+WPCE1"LD. .YFQ8Q4-EL@B-KY=)0LLB6+::*S\.+>J8]Y"R
M'?IQH*VI.X]#O* 'C685C&>*X6Y3+V]:GYY=,.:QW1$A]"366V46@?'DT::*
MJ5:>)D*S\[JPZ!"N(1"1@295+U#3)SZUFM1[ XT8;.R.>N?;7DP0H<&X-QM[
M&))>Y5"J(1"!@7$($L5:^WF;JN2[",TU6""Z$0=+/%J1%XVE:2(TV_PXS:FG
M@P\B-!!C].W 36ZVH<[A[1G5KB/^',*QR,&3D$PD[SAN]X^#['T"Q83&!B?Q
MO5&6-(<93S&8SR%S-\JX2-)0$D16L'V4G3]\_$(]?*@HNPP"7S),'K++[GUU
M\1WB;$>P=;X6D.6Z(-&33]8'++Y'Q5@^9Q '^% ;:U3VKM^$1 :)HB07/M])
M(C=@?VB+Y#:;'JP5'?G>"IQ=_SQRF=];WR5!$H_<>2<7VEI8)!0AJ^]1=^>*
M^W)G@?NTLH&YH#"7MABZ%&LL$01-1,(R=_ <" RASP%D\!<+%&/S",<>-J+O
MA]&>TS8YA&4;X(K);H<L.?B;7A5S"&D-C:BL03L#PIY=2_ZOTO3IS7!J;;'%
M!]=T;/<AQ.TR?5?,(XJ[QZ91+2<8AK7,UV3Z[ICO^30.27*IZWKMAN@Q:.:^
M*I>H[&.L-8S61/^E0KC>>&N105C+8^*K22BV&5AXG?;0LY9[#T5IVHEVP-SW
M/6(]3O1O=FHZ=RF_# 4&EAWM@X ;":WT5\;-R59.A!;68RR'"/IPO:WL^!N0
MF ?O'@<^C"L8$^SV"/8*\M8D#U'/ S-OMV8Z-?<9*\$H*^8Q;+STGA\0&7.8
M49A__R#XT:D!&3?(E@D[V3(J>W*P(HM.[F#AD-[7D9NF.U7VK"T0538^::?L
M%R'A/P6$X_I$[7)VZH*]<QRZ*?][%D @TS#Q$QRX#E3T?7@>EI/JI;W5_5BE
M":O(>#E,M+;KP (8-PQHY ?;MKU44<9WWS<'Z$]A-1KYV2XX.]B/YOO9HZJI
M7&'[L$0DX1502^K^ 8L\!_==%ZZU.RZ5O5 .!N&!)0AI\3I9$WH>L:/8\J;)
MK0IU^N>QZQ'4B9KJPW3%F/5'X>O)K7_B 5((=QF0G>=]M^%:3_/<MF?Y8X.A
M8H/MN';MS)6Q@X:;G!^SO'$)1&C1/@)S0 RS"B1WLJ$ 4BGPUUF(=L92$Y&H
M@R_32-.DNZPE.5ZEYE)$P(/Y^Z":(,;OLPWT-(V&A!19X*(4CR7T3BO,.]W$
M4@6E""R-7>JNXS6.HEXREIDBW^VI5R8+JF1D2D$9ILV&Y1BA,?E*K$"C>\=M
M+8FP!DI5L\U[OXFSA.3[XVP5D$;4,J+OCCN,\6MB+J7Y_GAC-RDV\);0",O;
M7E3CRY(67OYB$^*$LY#@PO!@6;2S_MKD$$'XYP.)<9,XV],HL6[YR9_;T$U#
M2XIZN2SA#-?HXT&1;;.H-&UB,FV*'/ 0"L%1MNC'D>\X;-A;WFZ\[.9,$Y6P
M\F&_<,7OQ>5L^E54_^/!$ZOLIH7B2*NE$&*(I3,@W7NMG.UEZ4*TGX7JL""<
MOK_&-N9=WKWMGB0=4BQ<9^+3Y$F_9(F^7VD<OIS[F;C+%6X2W9$ F%8>H-TN
M=$/@VKL>>M86G*4"6;/$Q. 6CW81YYGZGZ_V\\:_P)V?,?I<W<];_[\L *#)
M%\1]OO'/6_^_+ "@[MSTX9UGFP.\+1 (A'ES%\PKNR!LH09U@I'UR2V)+#8%
MS'=T0=\<(2)$<TY<QV5?19T?; PB8Y/XZ"S%/Z>NMF9/NC9^K##KI^7R>;4N
M1PO$,3H?>897=T'5#+]^2H%S6G.>7^ 4'GEE$86%,+)F,D$W2 H-3]R26$XS
MD^6TXG-Z$#HQ(!L\%9V=3S@\KE#"-G=&43>.RWG91\[58=Z8X?MBFMW;;!)\
M!P"J&;@+(,)KW,)ZUNNRB=H!N[=QCU^QV\5IR<X_XC2:X\"OW"*+J%[-"B[R
MSSU/M%'?"H*M#QHI88SMT.S7+0V]<DIYWWF7[>\+;QHR]3F_\VY(I $T?;9I
MVP^YK*)VA ("SL9+9O9L61$Y9@T^]F/VHN]?_7F8Q&/O=D!.SR]LEU@!VJMA
MCRQ\O!(\B7M+GQYO-"=.SBWNUM<#L6.$V" ;*TC#]P_.@-:D"\M3%C^+)[S
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MV]K(HD<OG?;\^DO*;[*D(BE9$JD>'QSLI+M)JJJ>(EFL*A;_\3]/:[?SB/S
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M;JGC4#A.<]Y> < *AVER. #AD>91(,3Z$;+C,KUQ\9^ 9B*)H 1W:QE8'$;
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M7*0[03TC)L/M^]Q!%I0 "+LTS\R45F_VD$V?R20<!YIE1>LHOB!.,S0LA['
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M]<9=O7%7;]S5&W?UQEV]<5=OG"+>N I,>F)F(K9=R33V!;K+*L18X!0@RH6
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M57:6UZ@"LMSHVM)',4FB_O14!TF.];(3+-_?GL-30X[WE"]/$ UF)UG%_ZJ
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M([8@&GD=6X<&S 2(AC1OQF%&TV4:7MB2K12' Z08=E5+.\]FKJ4Q#K"9MNW
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MEH]KO0@/H#@L99@!49)VJAX@0H#I?L5K1!GHFMYWS7ZD5C;C,,?HI#AHH@R
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M(4!^N!^AI>GJ9'4/M\#F1%IE&BF^&>61#"I^,W+>D0(N5:3)>8N&-Q&&Q#!
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M;@$@7.K!O:%:I3^\ 3_T#KM5_& 1=Q)P^[4 @P)\0&A(>[2$/MH(3PKZUQ8
MD*$6$K.TYT$.\W..XQ>'?-2- L)-$"#>VP6\GNV!1XP3"+J*GPM-+)B:;<>2
M,EW6-A%7B6)V:@$2HDQ ($A+A8GK"24>ZR+L!K2R6GQM/4Y2V)6&A^>1Z @M
M0+$41\K%16<AMK[3,O[([D<^X9KLE0ZV9RO31T&"+68\6W"(]H!:D"7E/-,
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M=F2Z]7Y,^V'Z=FQFULX26=KC(C.)Y?_TT;T>T?]Y, -$?O/_ 5!+ P04
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MG\KGNCZKU#:)M%MN*"'W.2(4!<05%3X)9QH55.DT)77]D.?SKJ!X5651;JE
MU#%MI& 'G.'D(!%&!HYC2X)#NMYREY5HE:&' J/R&2.6SAJ1?^]4@J_:\773
M2!C2 Q%55)Y&02ZBD$K8^:TC4L#<W2.<) @B:>')[R%I-5"CXI@U<\+AO#N/
M8R!F)=Y(3SOH55PQR!1\PR.=/ @V&8(<<HJI]2?73!%139_5C+K%[>4A7D_(
M<60L #@(C#L2(#@BA24+B[MW!?BIG;=]3.+P.LD"^2I+3\9QQ3P>WJ!8WDX
M$ -X5+(2>4P0,4DOW_\B2#_FVY<R?+O/LQ!CFF55M-Y*M_YFJ.V6,U8F]=ED
MI J(9S9X)0S<-8$Z;9QU1BR?BWDT:9Q6<\O"C^S.\6*^+0LZ@A)@\E5PI9+C
M[04# P:;# H-0-0S@"G;<&":B*F>55?)%ZBC[6E^5NRJ .+HXFV!USBGYPY6
M^'-Y01[T43'#,-!U/7LS-F<XF=,J@B"A+5K95*] W0;0!<T1JYMPS,-9N,Y9
M[DB63\H2D][ \I;$!PQ4PJZ8I@?<4$LN"8)+6GA#\LPNKQ>HUD =%1]G$'97
M@1!GO"FG>9[EEQD9L4,%?4R4W%_'HC. OYE%I@&"5L8P%?>U<+ECB#6#=NV@
M7VA+_^TE.KN)"QHAW@?Y3T&RQ?<X9Z.Y-&:0RKN-R32P^^&81!@$PTP02H*P
M6ND,$37$].CJ>!6-^<A\S?+K.-_,1&OB@]^=YK0.8?426)L?07!!A$B8FDJ\
M!Q5"LRL_WWG^$J?$;ZG":JFDXV\O@SI@P5 ,$A\DV&3,J,71+U0!,0W70TL-
M17+(KO>K8SJ(CM1U?H+TV14'Z)I/[>'87/UH6D!*<E:*DW#\B8?0!I^Y^1G2
MIQY@DGWN1NR@GWP=%(\,[;8X?PJ"E^J[XZ0LFG_9$:#^AU^7X3..M@F>KZ_P
M.D[)K!VGY _E/8%=7,5%F&3%EKRG5?#(':P<V88+$NUE'J79J :\$W$?U-R\
MI])$M2JBNF0DHAJ''83&T)8W:V?5#?F%;N<.4PPM=5W2U,J<+CV-%,'0T@:M
M$1UWZN@7V@#;QB_\TW-2%+@L)H_TDKYPN&$G$W)).#' +K/Z$F H)(3%C;),
M" @+Z@T[(S)PLNXY(8'+4V,@"(PA8G2R&W8#&(2Y#(KG21K1_TS_L8U?@X3N
MB4S*RR#/W^+TB:T,2<PVU'5)*"MSN@0S4@1#.!NT' &)DG?:U?F5Q0*'F, G
M =X=+L7))F8J3KV6 ?B>\U+(@Z&4 4ANS*M54-[J[$NL8E-62P;OWG_WCC%F
M>;N:_;K(WH*$%OQHGC,P0B;D@A5J@)0'8@GO7UX):_BM:[D#?NJ]?<@L?27<
MS/(W0E0)J?LB+GV$"%S7)W1_]\X$!2ANY[L1.4,I/FQ*V!@.U#G9#2<+[2BB
M4G#)#SWP+EODTF"XHX7(WPY"J)27,1%&249FUH!<RWV.7X(XFGY^P6F!2:3%
MK.N%^9+78*3IDF@6IG099Z &AGKF6 7EA:DF"M((9>R<!I!IF0G5/))*2Q]_
M1"FS,DAN3"?KLBJ#M!$4PIJJ5\#OR->Q6-X1B;MGBAPT3QI>%HRCT0#D[\E)
MG\Y+G&^@,&B6E@0?'7%K2W Y_1PF6YIT_2'+HD]Q(@\-353=1MCFQO0C;[T>
M&,99@.4C]4:UIA^,B%W#,S]<4O$%'"<TW[WYV?N7INYO1;P?G3(6I:B&I5+2
MY?=70.U202 &AA5R;*(I?"6!XA3A?VQI.FA15<B-L?]1:OZ"\X#FIM[@H,"+
M^.FYG*\?BLH#RF:?:AVG,WL3^+W)O4H!#+],4'*+AE2*%NO>%LT@A/[U=W]Y
M_^[=7U'6M(<2VJ!_VMWG%%+Y1G?Y2S*)I!LK+[27R)<7U2IN9_EZ\/WIO5P>
M#.4,0/(3^DJ%S>AQ(P\C\AG.'@PG&7[G:R;S-(CS>PZ=>(J?0)NB5>B5IOD@
MA)P&$#^^\I,#^= W<? 8)RSB(JZ-G85^SI((Y\64162:U1US=:=QM*51O>#:
M4!?,\&0)F%L=VJFST:J@)Z_J!EB0].>_UL$Y)*Z:I9:I%#SQT2#)3"X-D7-V
MZ6;)3M$[G9J\D?O@C>[VF:7]#(5])/R( 8M2??J28.BCA"=-[WFII"'P)M_B
M:!DDA/W99A,7]+9R+7U4.HY9I(<_()-< 1*GM"@%U*(ZZ#%+MT4]_H6M+@@/
M1?%524\[7ZM^ [RT!W;)( MX-12%QB@)/AF7\D:\FOM7R0#^J<1R$?AA6Y5%
M(Y)VGILDA\PE)O&B8*BDQL>51@CR--OV@J5VO3(\0A&T?795KO"C)M5-*.EC
M5T4 5;2KTA$#PQ\Y-EF@S8KF92E=]8Z(DG>^]-?MFZ[PIG%#&B5_^RDR ^0;
M*D,-,-PR@LE5$^YOF\!V5::CGN\!SVRL\SS,:=<^C8>Y?G8;I)6!C@G&>6X:
M'4\\,LMX4RJ <50F*.6Y;Z#XU1G.M1MQ,F%?(91Z4TXL"8=#*GAR\M 0BNW>
MTG@J[(=8WMDTG%QH&:52\#G!4S-++@V&75J(-C.]=D_8/\'$$:*>9WH] !&\
MAG4Z)3CD,T0Z)I0'Q$76Q3I>7-D5>W+N79L )N_1.D)PN"1!)KY4)H$99%F,
MB  &0^-QT/\0:#,%M$Z  DHAO:7>Z*(A"5AJJ D!B 9L.['*9:?53C)V(1M.
M0SDME!I."]'HH??*S\C%P8Q->HS\$>]6H][B[>B@W]]E)4;?_\$[S?C4K5E:
MG[&ZKZ::D[+,X\=M2=,@5AEUK<02\L((BB=V]S4N=,M4AWZ(TY*61WE!O9J7
M!WT"F"YS%+.&O6P)-W&P<T>0LI 8)^;:58M #OUS5P8,PR3 1)ZXN7+I!_0O
MWW[][;?OT$N0HU>J=(;>?WOV[;?L_ZH\5.*OM^5SEL?_Q-%?T5_._OS'[\[^
M_.?O4%P4-->"U4O87=B$@H*NSUWA$-/;+/_U=^_^].U?OWM'FWW_;TSX+V=_
M_.Z/9^^_^WY$"]]YI_$DBMC]P4%R'\31++T,7F(2*W7>O2R3Q4#1:9*0L2&]
M?"&M%ICN8 R5RR)J%1&M"'(>IRBL=+VS;X'+@-:AI6N6]&J^21AN-]N$7E=%
M*]2&L2SD,%%TR3YS0[KLTVN!89\Q5$$.6R.(HDK2.^WXV,4XR/$=G9I%F+#F
MYU)\XFGZ,DB#/$"W.%KA\!GRX9';."5Q!(U\JVA68C\OYI)#,I!=!@UEP+@=
M"3!NSZLZZ1]T9ARHS%#:FW.@N&[$.V\.,W<ZZL3,MY_;YX4<?O8-W9_N89/8
M!P-VNKJSB?I%8HD:I-.DFO5WH0XLDAJBU:[40S] VMY>.5^W5UK>9P6;<6G7
M34U4W?IA<V/Z7E:O!R:FL #+K4>V5Y5FZ\X-IHTV^J71]W]I2F==X#[(YSF#
M'JGN,K72]+2*J3-%LK I4P/#27.LDN7/HKIQOEWWA,0_!K^8M*NN^G? :WCB
MFPRZA&=#<8C\DF!4\XI;.8?'KQE;?3>UOY'VRJL^9"6G*E&X?.KA,^)2M5L"
MCT?SW=:-J?$]%:^,$H!7TJHC#Y=;/$@C@G7VX+RSC$S0LPUNPT?-Q$ J[;8(
ML1)RO^ZP4!0,H]3X^"*B5!KM8GU 4?T"O^)TBZ_)EZ)92A34SW'Y?+DEU-_@
MO"V@3(N%D?^-5L%GZ8;.B);<;JF--K6_QV;=#!C>CL<^Y/0=+E'=FG<.7V8%
MF7K7:*1C0$_&[9@J@-<?1#L"8+@B0L4/DP5;N7C*LJA 19;X#[\^Y%E1W.?9
M6KK5WY-P6CF=A]8KGK[[&=;**P^,JZ-.)= +$_'.@/:L4'W)C>ZB7X6\EY-?
M,MC"$U]#83#N0X=0?L(+3#FB)6;[6Q]P2J EDS2:1)LXC:D99?R*:\-DB\*&
MRDY7XZT,ZJW'&VF"(9\57&Y-OE(^0T^5.MLP"GH->*?F A>8O%MZL>T5&:&3
MC-7N5C-2H^,V%#> WP^Z%0I@:&>"DJO[7^LPED4[+>\4N\(O.0[C@.UBD1ZT
MH9D _V1_E9BOU'!)+P/H77(IQ,%02X]Q2*RN1N7".CI'NGOX\ID@P+/T.HAS
MMM<T7U_A-<YS'-$[":I" O(#BR/;<'9S\5CSVHN-;1MP0[_O*_JE^(GN$8IF
M ON Y^:,K!EZG<Z:-%1M+M(Y).;+3'CW@5P0:QKL>IXZ&$T98$TR9?#$^3P9
MO-E":T"UW'M#9L0Z4[N27OC"0Q4R9B<&E#,<0$7]$"+DGRNT),5=EF9] YI;
M>37K%8;*SDN)&!O$U1?1:H*)PZS@BBN1Q-5VT.]KS^7_3'>3P*N>/G)2CB\P
M%4$<W%7:%8$2.JGA"2XB95+-L : &XUGI9M&5:;M+2Z?LTA_5:6AKOL]:$-S
M^!UIC2(8+V6#5GA$G@;D=*3$!:(OL+GY<L/:(!ZL;00 0:L>4YG,/*RF!_8D
M?3@Q 521(^N( 2*6#)O4DU7#G7>>B#O! @<)S3[\$,0I[2[S]"HN7K(BD+T
M^V9<,FRLD5WZV;8!AILC@7-[F40092F*:C'J"G<.SSN/U0'HJ*@5TE3!?HH
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M>J%_NHII?1U,OJZ::+8-.$LX&&58FXE@I0V"FZ,@2])#VU;0KAFT:\??&M+
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M*UP!T+HGG9;_U1BUHU*K@*":.<ZQ"S5^*A *[9)O:JG%O?),LK&EDH6TM66
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M=,)#ORAQ7SS44P!VR0.;QA?;[^BC3@-L^;3[=W8%+"J?@Q3UE7YA[?LO'7&
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MB$^.^!EOLO1IA?.-YJ,)Q.#E4JE \A\D?4)D!-]T/H&OKJ2LA7B'/[&?[(M
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M93J#Y(R3:0)EGP8N?X-")<Y.!K ZT$&:;OV?=9$;-4O#G)Z.N,+5?ZW?"M\
M#%K*##.CYE#[!.@I@<Q3E/Q,=8.$#+^5*(H8M0E9$7ZEB5\LX6L=;)-CW=-*
MY^_W01Q)+V"22CE;.)%#;%=+>!'O/%'CXN[<((+HA4A27U6+ G96T_4:AV7\
MBJ6T&=D&#)>E,,_,:PD:\$[(?5!S<PG"U/,X/?\8IQ%Q5N3_FOL]Z,T+U0X.
MFV+4ZRAG!Z2UQ)$-%G]>R/0H+:^QG*'&6LX<G;D)NSLCM"K>>6>'4SBEV+ZL
MJ3Q:8^R:2!=!^'&:1I9$$FMY(I+*! F11"H0B:3 *212W&JB1Z)ZCHGK.BRI
M]AYT&X=,7:S$@_=%W-X<S8/KW[RW^]T[7Q2@I--%&H)Y2B:@\&;IW\B(VJ 1
MKE-R4O#.N2@P*E]\$U%XNU6RPJ(HCC00<?SJ34@^1"9]X74U))3CA!XT1&76
M<XG>_: \3*5;S+)#1%HM&!.,G@EF4PJF H9N9CAU8S!;G#O@#I@DHKN-TWBS
MW= Y]D60T/T25B=4%%Y(19W%;AJP;< FD?/.$ -P0UK4TBBDBR"/E?R1J#!)
MTVV0U ]<T#6VZFJ#>2JD@U+<&24,0+>T4,C"H(8>X) >E0;:U"S)*YTS]$:T
M4):ZI@I_J$\O[ITJ@\-Y.EG85)&?KE-2I?R4N::*X-B<B8)_N@R/O^FE@5-&
M<7Y-31JJZ)@V@J-I!O+>23,\8J85ADT9Q1DQ)6/61,\U8?C#,@;R_@DS..ZB
M%09.&/E)%35AB!ZPZ?9U$&*+M.>NN+\)-@]:/K/>R7KGE"% /IVOV6>KMMB.
MY')VZ^KS-4W>;[(('PH<76?Y)/S'-BYB0>:QM;8S=V1O4NN<S%6]TVH<7M%Y
MC<[NR"YA--BI>O==USC">9#\F&TPQ7L1I!\GT2M=19 M$RHU7'HP ^A=)Z80
M]TXX<XQ"DCT2.114@I 9=9&3_SS/U]<_WES0?^^N?=J_$75K0)AH8K(A2U5-
MG0*##?!SASZ(V%E[K1F,4M7RY?ME27>#]DCKXAN L>4B,\QL]V6H#8:KUI#5
MF=)9VOA@_[5 !UN:\_(9RRKVB$5]9$:(P"IVD)D<&#(IP.GVD;VS150-EYU0
MEG8<J;SOLL0]V+K"Q$P8#(-T",4[PA *S1Z@/C2<;! =PN%G> !>%GI2H0OH
M=),$7\PJ>J:;@I.\ K6*RRYN KY++Y4\&(89@.0603LJ;?J1?;%I)X3[.8]+
M/%^OY^NF*[% JP9)K92\%Q-%E^0S-Z1+0;T6&"(:0^5N$Z**Y]EZ#96#-[2\
M2I;2>Y,PZ5RX4-TD)!-V6_),!;A?T$PD"8932GC\ZE51H)XTF$N#.#MN-!<'
MJ12\,HD#KF33#;A+A+0035AU<[B[A"2[/3=Q2$?ER5..V='421HMLK<@H67Z
MY$5F[%2=[?-8&M-N\ACJ>>?6"+ <RRIM%#3J[#!?WC0 JCI-9=:;^J;EH9!+
MIR4&V'54?0GO!%+"XH]\LAJ=U>9?%+&=OR#9<>5('JG&ICY\)Q!RYF6D %M_
MPDEX__!*6%Q-M$H.TAFYYN+FZRQOG9V$VV)1I^6H%&#[)[MX.>],,0 GR76J
M',/;D=Q"4V-CEM;TK)ZJ=A,&2L[<AK$!K1O1:G@GBQ5,83D46@(E3AONL)H]
MA$J / \]T2+I(M5/+CU+%TS7D]!_AW8FM(-)5/O$^X=M'-PJ8TE1.;[8%F2Z
M5118N8ND5_,QU.B,$ T[,AWO7L42J"QNS=;L?-FQTB1WX^.D#8YEL8F1AKMT
M2"/HNQ1(I3@4MV,.]9#SG&-N(A&>EYU\S<LL+6*:ID3_LLJ#M*@6OX4;2H:Z
M@#8PK2$+"VJ%72U/'VY99N%'NAV!HV[=PN5S0-Y9QT+QU>BFRO"*0-A#YR+"
M9CN&N.Z"J<'ZA.Q(\\@OR.F>S >4(Y=Y4A+0'V+DW?]&$,JA^SP.98N'70&G
M]X%PP'H,:G\%XYTY2-QE(%2 EH(#D,O-L%R0F65TF6WH"B<;#28Y&42>V)KW
MQ=M.I.;LY%.01W.V[DV"RX#$$+.THK]J,G"4)SDGXG%>%<?HPSX&5M<XBFW#
M/E8KT,(]034A,A@E3Z+'S;=E409IU(XYPXJZ/^/XZ;G$T80,8\$3GG[&>1@7
M>M_N#],I]>*#O/Y#]O>] 'TQGN$0;X'+@:I5$*Z%@8S9ETE0%//USP%].^4\
M7U"8=]O-(\[KJR[8S8&709+@Z.*MEBMJ0=GXO'>K3A=W#_,*>NO"^S4)IB<=
MQ@ZN+]1B=$!](7"?Z68$D!%5:'&O@[<_MF:^LWE[^K:\<]_47"WC=0W!YKDA
M^B&[I[ <? .;IBLQW)W1S>#*'W-UI[G6ED;U,JX-=<&0TQ(PS\>7N%J7A7%/
MT+[16=V_:-YO-1(=*0H4/.>4YA;2UW3(^0+W$#"=YEB6R=8&\O8^2UK>%[=A
MOJ\2RZ;;.FWB<]F3V&=S2](DO'7W0QG$[8BU\OU],=3<OD[80N_QI>3R[HZ;
MO7W231[C-%"]!UF<:]>$2R<ZQK@NY6WTP;B^$:"YS,)=IQA0N-PIP]HCK+8[
M[^OIY'S-.K?]5N^P@5^_<_I=2YSOL=DK!:_:\ VSS89\V((VS'(QVBDY^3%@
M[7AW4K5Y04QK::V"SS_'Y?-SEM (F/R#>*Q7!0;633F/_$8:RP5WENV <6)[
M@!^2O8K?=KD-Z!-M"R=*!^9Q[!7%&JP_6_E[12O^1V"MB?I!6-H$& J/P\U-
MWX,\S;:E>8:5&X<<)/0J;#IFM,O!K'-50].L"C*"4.6(K9IPZH!'&-=SO!;Z
M8-@Z K36T;)C_@>8Y$A2@>NN4<_>17FI0PEGJ;YB:&UJ;_]G[QR08Y)YHWHF
MZ^T"KT&".JN?=9]GT9;=JBF/_<TTX2U56.+FYG/LYUUD?Y"M"4FO[*Q./Z1Q
M6:A/BJFDG?56/>2VY\I%8?1B+3YN 7.G@+94X_CW?O9/01L=.!;(NCYW+(4[
M/'[,"<)@A@:=[#!R4SX*T-' T6O[4^(ZR[==$<^">='5<Y#6R_AW6?J*BQ)'
MQ]E9LG_^2>PXC7VM!]F)LGVXT\[X4BW.E4%>*A?U'!O/!>Y9>EZ)U9'[&7K$
M3W%*][-^"[U]D,_',H/ICOIU$.>B"PQA0?O"?(3QQW#L/K2X?J.>Q?2]2#-B
M@TH1/5%-EJ."UD07O5+EWX8GZI]%</XMAX__,CR*^*6Z\1K]9WN? '@R>-CE
MF9!ZX_B+ZLCPX@IK?%^B*P 685B"^\TYDV,'&$]?O%?ZB05JWL*+X>._#)\B
M?JEN7$;_V6X\PO>51TCQ$[WMQL^D0VCWL-]70K^9[@POR+#&]R4Z!&!!AB6X
MWT"0,>Z-C TR7K]TIW2=Y6L<^PPS! B^#,<B?;5N7 ?W^-].O"$S?>@%6KDO
MOX-OR4>$%W+8@?NBW(+5!W'J,8R0_08BC1&O8VR8L39Q1"?)=E Y!&[S ZN]
MOFGJ:1"4&6^018!97MF7RT5@?M=B3_:WR6#S]S+6 >L9#SL,Y$M@';7(@N Y
M)Q&<Z5[3D8JR?8$I;!HC9?46LIW\%Y$BPK\&OZ47O\@BBQ[+*8(IG.B^/^]3
M+;$9;?M5$T?T?L $]5C+%]PYIV,:*1E*SE"=EH3H/11%04+($UC&*ZQ>Q#'&
MDD,B #6>'/[56G7CPSW^=);6#FZSY8 "TP>H2KVP'_NURK!TRVU$0TY[Y&A#
MC<OZ"%L!MX\UU@+IR#8UJ4)W&@-:8XK7,<T2Q$D-:Z->\$%'-BL$7\[@-L9L
MZ_'MA#R!YG5U=M..E6JB>A*H/CW^51UR9BEX#+BA]6@F2L?>$\H)T7DH@?4^
M1E]K&*#ZZI%>\D%'8$L,7\X8/,YPZU'XA'R"-FAIJLH?>Q06/@E4SQ[_J@Y;
MBYU[S.GTS]&V*::^1.44.II^>L#9[F?J:PD#5!<]TDL^\/37"L/I=.[C&#YB
M"JSU"(!'$4^I)E]2GIC62*-DD]/,:3R=9(@OFW%&IN^5#@$I _%1_\X>K=_9
MHKEJAU;3SH.PW ;)"N>;]ZJOYQJ)\^C'SZOF'(1;&+!B("^V:WW%[F:JL&X!
M)?&ZYS1@.(O#.-@9L3%.BS@\RD$T_?- 37OV?6U'&O_[#X/5B8]H(5>5^^DI
M9UL7*&[$S8\1 *:5IZL'O\# 46ZD;*J"=QJP0L'#O 4/2?'&3S\ESV_Y2H_4
M<<$L;[GNS$=(B0?;\?>(BN5O3!85RZZH](+DE.: >[SJ0\X!1\" %3YZL7WT
M'+#C-+XD9]&/OAWX!.Z!)]KU)2_N2#U\\+0OL2.+3;29"$+KH6,"H+NL/HG/
MG]0_]CESJT>?1 0_XF4>)'RW>.X7=:#5WF[YO8BD/7:2Z4C'UR7W;1W7=(LI
MN7<TSNX,\__*VUO)_$&!Y 9@O(KCGW,_U4"@/G_ISGFW#SSQ07_PXHX\U-=/
M@Q6J']-$_5A^L L$W(W>M8D 1FXC)*<\:EN\ZF..V 8PO/=I_[9;IY2>_-4A
M\K>F+2IPU$>>^*"L+E1PQ.=],><NS6TU&:&;?GM"8W1K)H!1VA#+*8_35J_[
MF".U$9 O=JRVL=YZM#Z8%X X7G=.L+KSQ;V'GOB8+7B!1QZU.T_TWJ&=FFDR
M9!M5LH<U9+>GNP$,V8983GG(MGK=QQRRC8!X[^$0K+<>L@_F!2 .V9USKRZG
M3YV'GOB0+7B!1Y]HMT_TWJ&=FFDVRSY(R067<^S63 !#MC&:4QZT+5_Y<6?:
M1E"\]W,8]H^8;9]DN8532*_ZDDXZC;';-L'*RVFZ_S\/"&))!RBO D")!U6<
M-2;[N7TYA<7;,2WF  N:VP@,@L4B9^(?%Y3K2P"^$PAU(9SOEO)'SMWL5W6?
M>]JS,\7)?6</_?*C!9G)!H'M$<[Y>NFF(!9< )WL]VZDTXX.9L'%=_<_8IZ#
M*Q=QX)!G_T/_L*"=]%QAS[( D' !6L<%\S(.43@ 3+6121AN-]N$IJ2R"\#I
M"\[Q,WG'\2N>I6&VP3=94:PH:,DJIET3+G=/QQC779>VT??>4_8 S1VMWS6!
M6!NHUPBJ6D&_I^W\ ?W"FOKO4Z'R39SB68DWLO0!^V8 4IHS<@2MVS9.C=I#
MX'O2FS:'6'O^.3X^KF:3XOF:_5I,7H,XH;WV.LO929^#;U#I'G<:231F+^TP
M6YGJ9X'I@T<V<-A7;X//\6:[06F[J%/\?^U=2W/D-I+^*SBM[0CUQ(X]>]I3
MZ=6CV6J50E*OP^%#!XM$272SR%H^]/"O'R0 DB@"($'6 UGR'G:GK<I,?D F
M@$0BD>#\S-F2 B#=3=PI.]W1*?I$O&)ZJ)>!S-\XB7'8USU[&7RF#YS^B.MI
ME3UF*H=7S+F\CRC6XG66\F=\+X)-7 :):-0]+6C^0B,V>UQ7D"4/K0Q2:SW3
M"7*..3(F-U.U_M%"T%CX5.2#5KR]2,22VU=VE?FE:E[D[):^\E_,*;DNC-]^
M.:HZ2YJ;3W6G@7:<C\Y$A3=<"A2V.D6#'<X34:$-=5>'#P$;=Z!!$.-]);G+
MLY#2J+AF*JVGD<5*F7DLG># =\R5PKD9JOD-,J%9"5R1:O,%+<E&\GJ:'69%
M0<M9^']57,3@H%UD:1%'5"0+/S)GK5C1/ <G+BW96&).VA:%,5"SFTAL\\F^
MFM-5OO1Y8:X)&U;X9\OK??KIG4N9GU/F<5C2B).)[3(M%RN'^\F[RSWJ%G!?
MW>"\NKH(13/][:LEVE(,#'7A'1*D$9;]79^7N/]1,4(L@D$QNA-<]PP?84B,
M;4AW1+2LPC\E 3!#<:JLZ/4@CC(LKM:;)'NG](%M?^.0FB- MUGZPEI!(][N
MXC%C^V;U]XNL*&^S\C=:WM,P>TKC/ZUUJ0[XO6,.I(-WFSK"#O8Q-$/OT"WL
MCLFO:=Z0B'W_)Y[1P5RY5AY<D6/_]E_8_6"](R8X-H7)/P&=[3F&8X/X$*.Y
MMX./,L2-"#[^N.]K]DZ3 1$9J3S*F[>RO<\1%V#ED (&:.[CXGM?'I6-^+@'
M$7V MT\;3)1H;+@77M?6MH@)4*-):M+:,1](7^IC\&I)&O!>:YJC2SX:A.AB
M57-$N41:@]CT#'\(GJRO/_6S>#4O _A> U/H\9J8#K+?R'(PLDW#Y-W$+JF(
MZ#X&;SSX6RPV/"";/D%NW460Y^]LR>8.A*5+1DDXI@%.:)IJCR/8T9CG>,RF
M8YJL9B()XR(AL)&:#Y_%WJ3\3*K@R0BLXY]G:71)7VB2;>#0P;6K!L5XM5W'
M1O8:\( ,O%;L!MP00.3$/)H>M>1L?U*4".V8_:/^VY78-&UEDZ71.4WI*BX+
M\W8/MG.N';J73WD=#WOLK-XQLX?OX!U7^VN<^3@+9530H1=D5EO!>F 6AGD5
M) 7_7QK-XV 9)W$96P^V]B<>V?@:U2DCQY23[%,:1V,:9+C\ H3U@-EYI;)<
M<M9:,:=L@-?PWCMM=V,YVJ5@1_#-9=T!>N^F-0)DUUPX$4EJJA.=7YN,HG#?
M4VM',OY9U=@5NT^H6V*]&_S^VV*(N]2)9GL;'*Y3J4BA [=GW'QJY/,WJ?8T
MPSZS&IB\6]M8I/J2W*1$GOQ,.TN2[!6R=J^S_#*KEN6J2MAO6966>_9I>S^$
M?QYVZ:@]^+D]7_$^;@[>M.Y .P\@5+,L><PFXS>_<RD8WW"[25_8ZI+EW;G=
MA<%S,+$#?"!L**GQFF,78M>LFM\16Q.O<^ <UQ?$?H]35,#])R= B==Z5'A=
MRQ'5)TJZWF1YP.PGBE>,FSF>&$WH,Z3&NK9:$GLUH2W O2;$*8][60;RI?HN
MR_1B[-H1S[YB2YM@(67P1@+.=/@MB1)QNJ2;G(9Q'=Z=K;.\C/_<NMUD\9A=
MA?C8K(QKH&GGXB8!RRNT.Z'O&J;*P;VN0.'!-,4IK820%]O:*P46'&:](7Y/
M$Z%;LRQS8S\S%GN="EP[T(4J?G"'\&M!]S1['LA [W*Z">)Z:S3..#5>_X9I
M:<ZP47883\,@S:#]G](H$-O8IFM\<8C9\[K=TZ"!]=K B<7,)J'&$<96H/(=
MT&.] ;IL]S_NK>T1X=GN!ALW8'U6_A.PP2'L)[T5AMNGP@NN@Y"NNS@3I]=-
MLKTIO3MFG0V+38Z'W#7%AI $-24^$[RESOEXG-2KD2E@>ZV*T2&/PK0(3;G-
M>@3&N^&(8K8,/]RY2T,V.W/3;OXL'5&9BS<KKRG43$D>RJ"L(*;=\K,!9^FE
M/7_CF*9ZD.Y1;7RO'\ VQQZB<=UQ!3)XG8:58":Q*,\,0VPI!&,=9-!..DNC
M.?MHTM!8=^RCI2 8*$--=!@*-A$G8NP#\/7<94;.0Z%@B@F8,2W.2$IY[*FV
M\3T9MF4K9FG)=1#GO*[*+/JC*DI3Y',\^]&V8!,:U6R_1O!BL<J)N+OF"*2B
MJ"8)6F+O$^H5V_R%95/57ZX0G8%GO#9P]097>1A#O>BL(2/$,J3W_YFC%L@X
M4"=ME<#8\S>P#)\#MT^;]2T%++P/--L,DN4T?DJW.J6.X91Q,'*)'):&P)-Q
M;;*#1S,D"ML@V*T9YDC>AN;K((7 \AXC>>/\F>XVY'8QYY>4LQ>:BY61EQ9G
MO\;;-5@=EM@)LGU[0I.[8\A-&BT8B_T?HE%:6&@Q%W?<@7&?/M9N8^$F+1G*
M>)F83UJF2,%FWX8FCK5D1<0IVJP.7T]=;2C\VJ,X+LHK^G6SBT%NB\%FD:9&
MCC5)5<8IVJ0!O^4HD-&0:N-_+VIIV,4S9!3=I%=I .')21%RFPP$[G!_\QR<
M8+, +":["W@MB8(3%R1.>5":N0,(SJP'&C;]2'L?@A'9]\0#\=VEGMA(F'Z<
M+B3 Z'A!>+!N.:L:ZJ0NM1>+-D,VFNDVJ0_;>QPZ:^_'JGNNS2D@EMHOHXO;
M8:EE-ZYTW0E4JAM=F&YA*$J'IB:=,C""=9SR&?22%F$>;PQ1*V<N3U-67Q,L
M4Y>)!8VMN>$T9#7(N!&)6N(#[<%=#CG8'R^J$BY8_RM;%L93LQUE'6TWOFMS
MFRWY5$'>;7,?Z$V!S">V).?\W?0JC6"/SE;?D/'S?(8_LB7_#^_SI4O#=]\'
M[?TKV(Z.=]PA[?D3WL?48=OED(-\AJFR\T/X3*,JH8O5/4U@1K@+\O*=/^(7
MA("[.'_?^J7GX8.)LH[Z1-<NS=UZEVN*(#2VOPMZO8 NIR.<D"@RT+R]8&GC
M?. %AF&V8UJN:R-4(QWB06./CD!'F-X<T0,-=WFVHD7!< 7)-;6F#>MD1WZ0
MV BR\_[P%@T:^[$ ,]R2+*J$AP=6U/_:"Y61P66O[Q"KH\#2T'Z6XS[<,0Q^
M^^$..ST:.W( J=M4(>J0U5>\22YGI0UP>3>R=JE_H$^0L')/-U"Z(WVZ25=9
MON;.Z?F[_-'-O1LAR8]S-[JI9M?.60P: YZ.7<MTE9+@-H,D)XTPHD@[(\OW
MA@*+R]?3^B&WSXWUJ'8]HC%;ANS A\=RW<%JIMIGGLZNX$%]]Q>:5O2:_1$*
M->3,2?TU+I\OJJ+,UC2_>@N3*H+J-@5;/PH>9C"[\Z/%?/OEN/=P:5[0OK/!
M79I@NJB;"WF>],I+N8'O:3ZT57[^]C.:@69"U>U:3D,VG(C\"$=I/WF?TI6:
M%(9[49;&#C$=<QIW:X!J0/T<1[6H%YHOL_ZQ[836GE2R:F^P,9>#!GF:56TU
MF[@_%>N@1YYL5J-%J>8]FL\Y=;HC#WL')?6B-"=P.J1E'#@N$9=S2P70]M<C
MKW0.76W 9EK"Y#7X_<RRMH-C-IK8JEJ<4^87T=H&^/7FD<4^ITHZWJ'Q3DUM
MCXPGB?&^R.^.W>9<UW=ER-7YS>/E#/ML\ ]<?J\!F6DND,EP/\Z'YH+CK7<.
M2QV^J=<&T'!MAM-Y7N-J&$+]@QZ&0G8L!V-,^K$=I+7[Q1KH?8MQM=XDV3NM
M,U8A$FR^,W[+=!H4S[;,@M%BCIHR,K&16SDA(V5X7Q=W!*[-U>)74ARH'(#-
MC7NC804I*P]T$XBL0WYB870"K+3'<\4&X+;.EH70N]FXH-,S0B4Y*1IZ)(\)
MGU=%G-*B8(:^E!FNRIM5\K#+9%%3!!QS3AO?,'4V<^?V;I"3(?>]5;87X[1,
M6<SQW="\?(=#5?9%_K3VKWE<TL5J91IL_?1'F[I<8#?35Q^Q=XMQ1=@UD)I%
MG&W73.05N$BV6GF?S"#S,@0SMY7UV=J^=,:/*_,Q)[%Q#5(G,#=.[Z8X":ZQ
M A/17:XF[:+,V&X.[1)\6ZV7-%^LFHM*,KYB6W%[Z(]IFX.P57.T$J.QP"&$
MFK_/Z>%<(FLNF!6"Q;M%/53+@LW/#,K5RU &CY'TJ*D,/6"W4A<,=&BLIP><
M-ELUI(33XDF0V6[#?"@IQDKNT7HTT#T6-,>7\-(/<-B2YHA2G#N-&;[5VL?@
MT:0&[K+:J;&:U? -5L6P'&^P'E =EW19WJ1%F5?K86U8B?$=NP]#U5_<6_I4
M"-\VWF8,<QQ!G:< LK*ND^!)V_V:B+Y%67BT[F??XKUJ/;/N0:@'=HFD)9*8
M /7??/3^??8>).7[/0UI_-)UE,P4N/K=!D^[QB/HV ZN)O32WY<Q \#&)B2.
M9DGV!*\:?*'@^&L=;R?%I8%!G-JLPQF(P@%GTG\COPNN8R?0\D8\T#RFQ?GC
M:W:7RWNX/ A06)0S0(]+0VY@]:0,X"+GGWXF#1L1?%Y5=9$$13%S4U,/+2X5
M#0/5DAJ!@\QPZ>8N?@L2FM-_4C;9/H<!9 ;9YK<>6ERZ&0:JQ;4E!VE9_$]Q
M>C.^/LSF\PMG]:CDV#5DP.JB),9&&)_?^4W6@VCRFQ>KNC0$'*V(G&4E#UJ?
M]$8*P*7+B>A=<[Z;5]?XD9/W!'#1Y&R]SM*O:5Q:U[$N!3*=6>#I]UB!CG!"
MSV.,KK,O3/7/=S';$-AG01LALO[O1ZF/C9I\ ^1GWJ>\AS(+O]\4146CRRIG
M&^([YGMF$1_^UUE^2\L'6I8)?Y*=30+WM&1;"/B/Q0J.FLMW?KXWTZH0[ETX
M+K4?H&7Z"V3L$R3FWR 1_PA4%F)?D5/J*LOY>V1%\R4^L^;-M_A%&_XU>: :
M\.]YV7U;.DPXSH<RM&G23\+2=FK:"%,KQ,[FM&SMIO4K'VGXG$*D@SD8]K5F
MD .933C"U?1\HWK<*J?W=4B8ZA=:/F?13?I"Y>LK5XPO6\=AG4JN:<Z1#Y?^
MQH'6,E#%,!/L1.$GM0!22_ R_!:K51S2ATT0TD5*+2/.1(1+23T(M8N4G)1P
M6L*(O8ZD\R#\3M/HFNH'"NU/N+I:P]7M8$D 99V\F/0L#&&IR]+%ZCI.H<IC
M7Q2@EQI7S[M U7.+)0]_"5=PJ?MX/QI2KCHR+XAGOV:K%40PEB6X3X#2?#W!
MG169[L;BUA2I".#N',_^_<1DB'#-LN0^(=<O3Z_THMF;E)D;<RDOJ?C?FY09
M(!1 +NZ"=SA-M)4F&\^-2[]3H!N>7^"\3)OR'S%3M11#-D+.=DDS/$K.V79$
M'!ZS644IV^:F9!OW"2AY +JKDD$,R6LY6U7L<"GY/$NK@K<4PI0QK_0X0LM&
M]A-1<Q_V47I>"D%<RV$KRHNB+X+BF<U1(@@A_0K' Q173ESJ'0M;"PO#;=.-
M$*!Z59:3$C]*O?_\2//U/ O2V5-.>=3'%KJWDB)3VQ!.34_WGPEP$& A#8_7
M_1XOY@4&)!*Q: 35U^IF::KII<:E'1>HYLIF_/)V+KD(]!4IGRDI07,):"[@
M+VAXG!OCZ*YY), R":HDN!1CQ6>9UN)(>1+!3^[?5G[NUPVSI+2\IK1'"<,L
MN)3BC->8B1PWG*3:K( 58BVXU 9!H"L>)7)6FXD%L]IZ\ ZI;<E8B8R1^=8;
M#S^G0?*UH _9JGP-<EL8V$J)2TM#,(V5;Q@]80RDYO#J)7R)TWA=K6%&/@\2
M<"[Y6;6F$ L=+G7T@^PJ0U(+KV IZ,41NI](99I602)!R8*YOS$G?Y'JVNBA
MQ:618:!:\)%SD+54CJST2]X9$\E27*IY?,V<5<-H3T,U+= QJBE?,V\G,!6-
MMLN/&6HF#!(C4\XP4M/Q"P1\XNWJ:G5HSXMV#/5JH/YWG#ZQQL.S+'#E2AQ4
MY#EDA_+SZCK?5+QGN%A96)C-UJ^L+5:=D(H>\/<'!9=E>>\'[0Q7 H+H9(V(
M_;N6#_]L/T "!10)FXQBL7&'$)F5,V^QF2I-^SG?.*@VVOPO/:!ZK __A8Q?
M;[4O4V^S\?R$A"$PEY;)^RS*-B6-Y/$DY"CF&1MTC)ECN\N2.'Q_I&_E>9*%
MWS4;G28&E\7MU ;]X3LAC$AII!5'MN61WX5$ B()E^EE>VEU,I]S0QY2+S4N
MO;I '>4_ Q^JS<TUZS1G#0'Q:2A(03I&/RO&ADL]\8O[  +B$U%/BW24>AB;
MIV.;B#(*YQ/07G)<*G+"JA_M<"9TIZ%MW'RQ EALN0PIC8JO!8VNLURIBZKI
MS)T5E_Y&X]:NXS8"P-N$DU)^2+J1<MA?@I*\PGW="FYVP%T0( I:P7YFS,TF
MB9FK!2^VW[%>?0X*.C0N'7AP*=<=L#:-"D["64G-BV280NC^(LG8-NEI:V]E
MG4[[R'%IS FK\:1<<I$M-O^W0T?H:8 >EZ+<P)KORN%3E8S"R=1@33/;/^-2
MA!&;=NM)QO%DSK+O%+CAS#>,)F^#UY_GYG>AV').W=QME%W? W'8N?:I NY
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M+'V"Q/6;%!#&+_0NL>;M3Y2#2Y6[-:*KZ9__\^=_$,E-@/T3OP70"" @P6\
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M09Z&XF)#X2@P?9+97$:'12-"--CLV+03GIJ2U*2^^USDQ<VSHK_76S*,_6Y
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M*UU43DDL/JT_X"&MA3WCZ[ %D?]2DCB/ISZLQK\O@KWEL?MBAR]S\&8%.>7
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MT(RU'X0?61TH1UUX)."G(DH0\'GBS[8@NM15H:QUX9RH>98E@02?O%2_"H9
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M\S5$'SOSI@GM0&YX"U"FN[Y:VX MN.5H[8JPD\#R0>?/ZII0E>CZ-FT#*B%
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MT[M"XI9P[OM^8GGYMQ?DA?C9*\LS7X2UM 84;^3-N5(.%,SY5X)E?=6Z]FO
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M"B3ET6\)-$"!$H[V;@V$+H5'BPM5)?0(VP8(@0'3UAE\2&PWHAW\2"Q:>O-
MP@T)8>0 ZZ*'PS7 D19,+5&UI.KAN-8\">UG"[RV4E1"/XIM8H4% J:MV66W
M\USB]*.(Q'K4@&JB'SHT,>/ (6IKZ)#PA5K7"#AF1*71G=5-#!8Y%"T1H#7I
M7SC9_]A:4%T#\+<[R3<06F 'VRSR@?5NPC["T)4ZP:25S/"B:+G"I/*@I[T4
M]$Z5^U)1S0R: .H'XZJA=)@-G$-%\6R]M#RB]$]RBF+G]P*I6HD0H<2-VK:(
MV-]M@I?O'>)F--!_G-"G/_P^(1O+&]$1'^\%UHN6JA0R8QC K!6O_X448EV
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MN;8\V722WLY55,).G*!GUF 07/6(2Z^"%O*84W B=@4^920]?LP$$H\\> M
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MA?V_)RLB]#?_%U!+ 0(4 Q0    ( .6*>5KXG[1Z.9\  %SI!P +
M      "  0    !E>#$P+3$Y+FAT;5!+ 0(4 Q0    ( .6*>5JW<,%>31D
M %9O 0 +              "  6*?  !E>#$P+3(P+FAT;5!+ 0(4 Q0    (
M .6*>5HJT5&=/P(  "P5   *              "  =BX  !E>#$Y+3$N:'1M
M4$L! A0#%     @ Y8IY6LZDPT"$!0  O2(   H              ( !/[L
M &5X,C$M,2YH=&U02P$"% ,4    " #EBGE:D;:SP.@"   A#@  "@
M        @ 'KP   97@R,RTQ+FAT;5!+ 0(4 Q0    ( .6*>5K>W9)?<@@
M &8]   *              "  ?O#  !E>#,Q+3$N:'1M4$L! A0#%     @
MY8IY6A(=X%&F"   2$@   H              ( !E<P  &5X,S$M,BYH=&U0
M2P$"% ,4    " #EBGE:Y=%22;<%  #Q'   "@              @ %CU0
M97@S,BTQ+FAT;5!+ 0(4 Q0    ( .6*>5H?DQO3R@4  +D=   *
M      "  4+;  !E>#,R+3(N:'1M4$L! A0#%     @ Y8IY6I"J>,.:(P,
M\6T8  P              ( !-.$  &9O<FTQ,"UK+FAT;5!+ 0(4 Q0    (
M .6*>5IW8<Y+'Q8  (CQ   1              "  ?@$! !S;71I+3(P,C0Q
M,C,Q+GAS9%!+ 0(4 Q0    ( .6*>5K\K"\*&AX  $F' 0 5
M  "  48;! !S;71I+3(P,C0Q,C,Q7V-A;"YX;6Q02P$"% ,4    " #EBGE:
M3;V_U&9"  #+) 0 %0              @ &3.00 <VUT:2TR,#(T,3(S,5]D
M968N>&UL4$L! A0#%     @ Y8IY6O]1X2B$FP  >R4) !4
M ( !+'P$ '-M=&DM,C R-#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( .6*>5K/
MH2W'EFT  - B!P 5              "  >,7!0!S;71I+3(P,C0Q,C,Q7W!R
;92YX;6Q02P4&      \ #P!_ P  K(4%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:SMTI="http://sanaramedtech.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="smti-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="AsOf2025-03-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
        </entity>
        <period>
            <instant>2025-03-18</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-04-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SMTI:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SMTI:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SoftTissueRepairProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SMTI:SoftTissueRepairProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SoftTissueRepairProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SMTI:SoftTissueRepairProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BoneFusionProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SMTI:BoneFusionProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BoneFusionProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SMTI:BoneFusionProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_InternalUseSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SMTI:InternalUseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_InternalUseSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SMTI:InternalUseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_InternalUseSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SMTI:InternalUseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:AppliedAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember_custom_CashClosingConsiderationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">SMTI:CashClosingConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:AppliedAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember_custom_StockClosingConsiderationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">SMTI:StockClosingConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:AppliedAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-01_custom_AppliedAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:AppliedAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="From2024-08-012024-08-31_custom_AppliedAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:AppliedAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AppliedAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:AppliedAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AppliedAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SMTI:AppliedAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_us-gaap_ConvertibleDebtMember_us-gaap_ExtendedMaturityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LoanRestructuringModificationAxis">us-gaap:ExtendedMaturityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-01_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-01</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CustomerRelationshipsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">SMTI:CustomerRelationshipsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CustomerRelationshipsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">SMTI:CustomerRelationshipsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AmortizableIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">SMTI:AmortizableIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AmortizableIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">SMTI:AmortizableIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-07-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SMTI:SeriesBTwoPreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="From2020-07-012020-07-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SMTI:SeriesBTwoPreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember32609109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SMTI:SeriesBTwoPreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SMTI:SeriesBTwoPreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-03-012022-03-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SMTI:SeriesBTwoPreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_DirectDermatologyIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_ClassAPreferredSharesMember_custom_PixalereHealthcareIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SMTI:ClassAPreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:PixalereHealthcareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-06-012021-06-30_custom_ClassAPreferredSharesMember_custom_PixalereHealthcareIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SMTI:ClassAPreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:PixalereHealthcareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_PixalereHealthcareUSALLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">SMTI:PixalereHealthcareUSALLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2024-09-012024-09-30_custom_CommonUnitsMember_custom_ChemoMouthPieceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SMTI:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_CommonUnitsMember_custom_ChemoMouthPieceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SMTI:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_ChemoMouthPieceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ChemoMouthPieceLLCMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ChemoMouthPieceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ChemoMouthPieceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SIHealthcareTechnologiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:SIHealthcareTechnologiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SIHealthcareTechnologiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:SIHealthcareTechnologiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_DirectDermatologyIncMember32609359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_DirectDermatologyIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:DirectDermatologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PixalereHealthcareIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:PixalereHealthcareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PixalereHealthcareIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:PixalereHealthcareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ChemoMouthPieceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ChemoMouthPieceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:ChemoMouthPieceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SIHealthcareTechnologiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:SIHealthcareTechnologiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SIHealthcareTechnologiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:SIHealthcareTechnologiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OfficeSpaceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SMTI:OfficeSpaceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OfficeSpaceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SMTI:OfficeSpaceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-04-17_custom_CRGTermLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-17</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CRGTermLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CRGTermLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-04_custom_CRGTermLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-04</instant>
        </period>
    </context>
    <context id="From2024-09-042024-09-04_custom_CRGTermLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-04</startDate>
            <endDate>2024-09-04</endDate>
        </period>
    </context>
    <context id="From2024-04-172024-04-17_custom_CRGTermLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-17</startDate>
            <endDate>2024-04-17</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CRGTermLoanAgreementMember_custom_BackendFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:BackendFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-01_custom_CadenceTermLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CadenceTermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CadenceTermLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CadenceTermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CadenceTermLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CadenceTermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CRGTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:CRGTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CadenceTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:CadenceTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CRGTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:CRGTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PaidInKindInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:PaidInKindInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PaidInKindInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:PaidInKindInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_BackendFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:BackendFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_BackendFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:BackendFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CadenceTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:CadenceTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CadenceTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SMTI:CadenceTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2018-08-262018-08-27_custom_SubLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:SubLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-26</startDate>
            <endDate>2018-08-27</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-07-31_custom_BIAKOSLicenseAgreementMember_custom_RochalIndustriesLLCMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:BIAKOSLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:RochalIndustriesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-07-31_custom_BIAKOSLicenseAgreementMember_custom_RochalIndustriesLLCMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:BIAKOSLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:RochalIndustriesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_BIAKOSLicenseAgreementMember_custom_RochalIndustriesLLCMember_srt_MaximumMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:BIAKOSLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:RochalIndustriesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-07-31_custom_BIAKOSAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:BIAKOSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BIAKOSLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:BIAKOSLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BIAKOSLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:BIAKOSLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ABFLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ABFLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ABFLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MaximumMember_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ABFLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-05-31_custom_RochalMember_custom_DebriderLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SMTI:RochalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:DebriderLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:DebriderLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:DebriderLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:DebriderLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:PrecisionHealingMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember_custom_AccreditedInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SMTI:AccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:PrecisionHealingMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-04_custom_PrecisionHealingMergerAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:PrecisionHealingMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-04</instant>
        </period>
    </context>
    <context id="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:PrecisionHealingMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_custom_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SMTI:WarrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:PrecisionHealingMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:PrecisionHealingMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="From2022-07-012022-07-31_custom_ScendiaPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ScendiaPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_ScendiaPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ScendiaPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2023-08-012023-08-31_custom_ScendiaPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ScendiaPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-10-31_custom_ScendiaPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ScendiaPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2023-08-012023-08-01_custom_ServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="From2023-12-202023-12-20_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-20</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <context id="From2023-12-202023-12-20_custom_LicenseAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-20</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <context id="From2023-12-202023-12-20_custom_LicenseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-20</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-01_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-01_custom_LicenseAgreementMember_us-gaap_RoyaltyAgreementTermsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-12_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SMTI:TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-12</instant>
        </period>
    </context>
    <context id="From2024-12-312024-12-31_custom_TwoThousandFourteenOmnibusLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SMTI:TwoThousandFourteenOmnibusLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-12-312024-12-31_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SMTI:TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SMTI:TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-02-012023-02-28_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SalesAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_PrecisionHealingIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">SMTI:PrecisionHealingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_AccreditedInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SMTI:AccreditedInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_PrecisionHealingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:PrecisionHealingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-04_custom_NonaccreditedInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SMTI:NonaccreditedInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-04</instant>
        </period>
    </context>
    <context id="From2022-04-012022-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="AsOf2022-04-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="AsOf2022-04-30_custom_PrecisionHealingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SMTI:PrecisionHealingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandFourteenOmnibusLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SMTI:TwoThousandFourteenOmnibusLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SMTI:TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SMTI:NoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SMTI:NoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SMTI:NoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SMTI:NoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2017-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="From2021-07-012021-07-31_custom_ConsultingAgreementMember_custom_MsSalamoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SMTI:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SMTI:MsSalamoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:ServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SanaraSurgicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SMTI:SanaraSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_THPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SMTI:THPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SanaraSurgicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SMTI:SanaraSurgicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_THPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SMTI:THPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-162025-01-16_us-gaap_SubsequentEventMember_custom_SubscriptionAndShareholdersAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:SubscriptionAndShareholdersAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-16</startDate>
            <endDate>2025-01-16</endDate>
        </period>
    </context>
    <context id="From2025-01-162025-01-16_us-gaap_SubsequentEventMember_custom_SubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-16</startDate>
            <endDate>2025-01-16</endDate>
        </period>
    </context>
    <context id="From2025-03-192025-03-19_us-gaap_SubsequentEventMember_custom_CRGTermLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000714256</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SMTI:CRGTermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-19</startDate>
            <endDate>2025-03-19</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Integer">
        <measure>SMTI:Integer</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000005">0000714256</dei:EntityCentralIndexKey>
    <SMTI:RoyaltyReceivable
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0076"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0083"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0139"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0169"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0170"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOther
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0369"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <SMTI:BackendFee
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaidInKindInterest
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <SMTI:AccruedInterestIncomeExpense
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireLoansReceivable
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0569"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_us-gaap_RoyaltyMember"
      id="xdx2ixbrl0590"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MinimumMember"
      id="xdx2ixbrl0628">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_InternalUseSoftwareMember"
      id="xdx2ixbrl0662"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0688"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0690"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0792"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0798"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2023-12-31_custom_ChemoMouthPieceLLCMember"
      id="xdx2ixbrl0902"
      unitRef="USD"
      xsi:nil="true"/>
    <SMTI:EquityMethodInvestmentsEconomicInterest
      contextRef="AsOf2023-12-31_custom_ChemoMouthPieceLLCMember"
      id="xdx2ixbrl0904"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2023-12-31_custom_SIHealthcareTechnologiesLLCMember"
      id="xdx2ixbrl0910"
      unitRef="USD"
      xsi:nil="true"/>
    <SMTI:EquityMethodInvestmentsEconomicInterest
      contextRef="AsOf2023-12-31_custom_SIHealthcareTechnologiesLLCMember"
      id="xdx2ixbrl0912"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0916"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2023-01-012023-12-31_custom_ChemoMouthPieceLLCMember"
      id="xdx2ixbrl0935"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2023-01-012023-12-31_custom_SIHealthcareTechnologiesLLCMember"
      id="xdx2ixbrl0938"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0941"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0944"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-12-31_custom_CRGTermLoanMember"
      id="xdx2ixbrl1055"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-12-31_custom_PaidInKindInterestMember"
      id="xdx2ixbrl1058"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-12-31_custom_BackendFeeMember"
      id="xdx2ixbrl1061"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-12-31_custom_CadenceTermLoanMember"
      id="xdx2ixbrl1063"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1075"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1083"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1085"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1087"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1089"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1093"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1307"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1309"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1315"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1317"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1319"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1321"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1345"
      unitRef="Shares"
      xsi:nil="true"/>
    <SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1347"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1351"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1353"
      unitRef="Shares"
      xsi:nil="true"/>
    <SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1355"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1357"
      unitRef="Shares"
      xsi:nil="true"/>
    <SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1359"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1361"
      unitRef="Shares"
      xsi:nil="true"/>
    <SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1363"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <SMTI:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1365"
      xsi:nil="true"/>
    <SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1367"
      unitRef="Shares"
      xsi:nil="true"/>
    <SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1369"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <SMTI:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1371"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1447"
      unitRef="USD"
      xsi:nil="true"/>
    <SMTI:IncomeTaxReconciliationIncomeTaxExpenseIntangibles
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      id="xdx2ixbrl1505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      id="xdx2ixbrl1512"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseOther
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      id="xdx2ixbrl1547"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseOther
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      id="xdx2ixbrl1550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      id="xdx2ixbrl1577"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      id="xdx2ixbrl1580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      id="xdx2ixbrl1584"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOther
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      id="xdx2ixbrl1586"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOther
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      id="xdx2ixbrl1587"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOther
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1588"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      id="xdx2ixbrl1612"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      id="xdx2ixbrl1614"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      id="xdx2ixbrl1615"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1616"
      unitRef="USD"
      xsi:nil="true"/>
    <SMTI:ExecutiveSeparationCosts
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      id="xdx2ixbrl1619"
      unitRef="USD"
      xsi:nil="true"/>
    <SMTI:ExecutiveSeparationCosts
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      id="xdx2ixbrl1621"
      unitRef="USD"
      xsi:nil="true"/>
    <SMTI:ExecutiveSeparationCosts
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      id="xdx2ixbrl1622"
      unitRef="USD"
      xsi:nil="true"/>
    <SMTI:ExecutiveSeparationCosts
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1623"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      id="xdx2ixbrl1629"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000012">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000013">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000014">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000015">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000016">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000018">001-39678</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000019">SANARA MEDTECH INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000020">TX</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000021">59-2219994</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000022">1200     Summit Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-12-31" id="Fact000023">Suite 414</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000024">Fort Worth</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000025">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000026">76102</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000027">(817)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000028">529-2300</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-12-31" id="Fact000029">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-12-31" id="Fact000030">SMTI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-12-31" id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000032">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000033">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000034">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000035">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000036">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000037">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000038">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000039">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000040">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000041">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-28"
      decimals="0"
      id="Fact000042"
      unitRef="USD">118175765</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-18"
      decimals="INF"
      id="Fact000043"
      unitRef="Shares">8901903</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityListingParValuePerShare
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000044"
      unitRef="USDPShares">0.001</dei:EntityListingParValuePerShare>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000046">The
information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated by reference
to the registrant&#x2019;s Definitive Proxy Statement on Schedule 14A relating to the 2025 Annual Meeting of Shareholders which will be
filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Annual Report on Form
10-K relates.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000050">We recognize the critical importance of cybersecurity
in safeguarding sensitive information and maintaining operational resilience. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zgAXqd46XXQb"&gt;We have processes for assessing, identifying and managing
cybersecurity risks, which are built into our information technology function and are designed to help protect our information assets
and operations from internal and external cyber threats, protect employee and customer information from unauthorized access or attack,
as well as secure our networks and systems&lt;/span&gt;.&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zKuu0cmyEY71"&gt;The audit committee of the board of directors (the
&#x201c;Audit Committee&#x201d;) is responsible for overseeing cybersecurity risk and periodically updates our board of directors on such
matters. The Audit Committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates
regarding any significant new cybersecurity threats or incidents.&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a company, we leverage the National Institute
of Standards and Technology (NIST) Cybersecurity Framework to align with industry best practices and to develop policies and procedures,
which include a Cybersecurity Response Plan focusing on detection, validation, mitigation, recovery, and refinement. In addition to the
Cybersecurity Response Plan, we provide cybersecurity awareness training to our employees, including training on social engineering,
phishing, password protection, confidential data protection, mobile security, and incident reporting, to help prevent and reduce the
impact of potential cybersecurity events.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have strategically invested resources and tools
to combat the ever-changing cyber threat landscape. These investments include growing our internal technology team headcount and bolstering
our partnerships with entities with external expertise, resulting in increased protection, monitoring, and response capabilities. We
have also made investments to carry cybersecurity insurance that provides additional protection and resources to reduce a cybersecurity
event&#x2019;s impact and potential losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our technology and management teams meet regularly
with key internal and external stakeholders to review cybersecurity concerns and areas for continued focus and improvement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

We face risks from cybersecurity threats that could
have a material adverse effect on our business, financial condition, results of operations, cash flows or reputation. To date, we have
not experienced any risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially
affected or are reasonably likely to materially affect our business strategy, financial condition, results of operations, or cash flows.
See &#x201c;Risk Factors &#x2013; Risks Related to Our Business &#x2013; Security breaches and other disruptions could compromise our information
and expose us to liability, which would cause our business and reputation to suffer.&#x201d;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000051">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000052">The audit committee of the board of directors (the
&#x201c;Audit Committee&#x201d;) is responsible for overseeing cybersecurity risk and periodically updates our board of directors on such
matters. The Audit Committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates
regarding any significant new cybersecurity threats or incidents.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000053">410</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000054">The critical audit matter communicated below
is a matter arising from the current period audit of the financial statements that were communicated or required to be communicated to
the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our
especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion
on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate
opinion on the critical audit matter or on the accounts or disclosures to which it relates.</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000055">Weaver and Tidwell, L.L.P</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000056">Austin, Texas</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000064"
      unitRef="USD">15878295</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000065"
      unitRef="USD">5147216</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000067"
      unitRef="USD">12408819</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000068"
      unitRef="USD">8474965</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000070"
      unitRef="USD">40566</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000071"
      unitRef="USD">8400</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000073"
      unitRef="USD">40566</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000074"
      unitRef="USD">8400</us-gaap:AccountsReceivableNetCurrent>
    <SMTI:RoyaltyReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">49344</SMTI:RoyaltyReceivable>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">2753032</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">4717533</us-gaap:InventoryNet>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">1101478</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000085"
      unitRef="USD">1123798</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">608411</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000088"
      unitRef="USD">33305988</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">19005869</us-gaap:AssetsCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000094"
      unitRef="USD">41006776</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000095"
      unitRef="USD">44926061</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">3601781</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">3601781</us-gaap:Goodwill>
    <us-gaap:LongTermInvestments
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000100"
      unitRef="USD">8297223</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">3084278</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">1447907</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">1995204</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000106"
      unitRef="USD">432317</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">1257956</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">54786004</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">54865280</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000112"
      unitRef="USD">88091992</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000113"
      unitRef="USD">73871149</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000121"
      unitRef="USD">1499764</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000122"
      unitRef="USD">1924082</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000124"
      unitRef="USD">30913</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000125"
      unitRef="USD">77805</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000127"
      unitRef="USD">30913</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000128"
      unitRef="USD">77805</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000130"
      unitRef="USD">10778840</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000131"
      unitRef="USD">7676770</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000133"
      unitRef="USD">2621867</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000134"
      unitRef="USD">2047678</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000137"
      unitRef="USD">1100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000140"
      unitRef="USD">580357</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000142"
      unitRef="USD">358687</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000143"
      unitRef="USD">361185</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000145"
      unitRef="USD">15290071</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000146"
      unitRef="USD">13767877</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000151"
      unitRef="USD">30689290</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000152"
      unitRef="USD">9113123</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000154"
      unitRef="USD">748001</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000155"
      unitRef="USD">2723001</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000157"
      unitRef="USD">1237051</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000158"
      unitRef="USD">1737445</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000160"
      unitRef="USD">1215617</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000161"
      unitRef="USD">1941686</us-gaap:OtherLongTermDebt>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000163"
      unitRef="USD">33889959</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000164"
      unitRef="USD">15515255</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">49180030</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000167"
      unitRef="USD">29283132</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000178"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000180"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000182"
      unitRef="Shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000184"
      unitRef="Shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000186"
      unitRef="Shares">8753773</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000188"
      unitRef="Shares">8753773</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000190"
      unitRef="Shares">8535239</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000192"
      unitRef="Shares">8535239</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000175"
      unitRef="USD">8754</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000176"
      unitRef="USD">8535</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000194"
      unitRef="USD">77179211</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">72860556</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">-37784392</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">-28036814</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000200"
      unitRef="USD">39403573</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">44832277</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000203"
      unitRef="USD">-491611</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">-244260</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000206"
      unitRef="USD">38911962</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">44588017</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000209"
      unitRef="USD">88091992</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">73871149</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000212"
      unitRef="USD">86672425</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000213"
      unitRef="USD">64989842</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000215"
      unitRef="USD">8139901</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">7852686</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000218"
      unitRef="USD">78532524</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">57137156</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000224"
      unitRef="USD">76559863</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000225"
      unitRef="USD">56994753</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">5703362</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000228"
      unitRef="USD">4132425</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000230"
      unitRef="USD">4923224</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000231"
      unitRef="USD">3675026</us-gaap:DepreciationAndAmortization>
    <SMTI:ChangeInFairValueOfDeferredAndEarnoutLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000233"
      unitRef="USD">1938451</SMTI:ChangeInFairValueOfDeferredAndEarnoutLiabilities>
    <SMTI:ChangeInFairValueOfDeferredAndEarnoutLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000234"
      unitRef="USD">3449895</SMTI:ChangeInFairValueOfDeferredAndEarnoutLiabilities>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000236"
      unitRef="USD">85247998</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">61352309</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000239"
      unitRef="USD">-6715474</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000240"
      unitRef="USD">-4215153</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000245"
      unitRef="USD">3128395</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">475783</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000248"
      unitRef="USD">-90007</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000251"
      unitRef="USD">21978</us-gaap:InterestIncomeOther>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000255"
      unitRef="USD">251034</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000257"
      unitRef="USD">-3196424</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000258"
      unitRef="USD">-224749</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000260"
      unitRef="USD">-9911898</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000261"
      unitRef="USD">-4439902</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000263"
      unitRef="USD">-247351</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000264"
      unitRef="USD">-136705</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000266"
      unitRef="USD">-9664547</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000267"
      unitRef="USD">-4303197</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000269"
      unitRef="USDPShares">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000271"
      unitRef="USDPShares">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000273"
      unitRef="USDPShares">-0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000275"
      unitRef="USDPShares">-0.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000277"
      unitRef="Shares">8484224</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000279"
      unitRef="Shares">8484224</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000281"
      unitRef="Shares">8278949</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000283"
      unitRef="Shares">8278949</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">8299957</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000285"
      unitRef="USD">8300</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000286"
      unitRef="USD">65213987</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000287"
      unitRef="USD">-23394757</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000288"
      unitRef="USD">-107555</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000289"
      unitRef="USD">41719975</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000299"
      unitRef="Shares">100829</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000293"
      unitRef="USD">100</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000294"
      unitRef="USD">3442622</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000297"
      unitRef="USD">3442722</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <SMTI:StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000307"
      unitRef="Shares">34501</SMTI:StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards>
    <SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000301"
      unitRef="USD">35</SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards>
    <SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000302"
      unitRef="USD">203031</SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards>
    <SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000303"
      unitRef="USD">-338860</SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards>
    <SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000305"
      unitRef="USD">-135794</SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000315"
      unitRef="Shares">73809</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000309"
      unitRef="USD">74</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000310"
      unitRef="USD">3089571</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000313"
      unitRef="USD">3089645</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000323"
      unitRef="Shares">26143</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000317"
      unitRef="USD">26</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000318"
      unitRef="USD">911345</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000321"
      unitRef="USD">911371</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000327"
      unitRef="USD">-4303197</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000328"
      unitRef="USD">-136705</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000329"
      unitRef="USD">-4439902</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000337"
      unitRef="Shares">8535239</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000331"
      unitRef="USD">8535</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000332"
      unitRef="USD">72860556</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000333"
      unitRef="USD">-28036814</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000334"
      unitRef="USD">-244260</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000335"
      unitRef="USD">44588017</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000345"
      unitRef="Shares">8535239</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">8535</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000340"
      unitRef="USD">72860556</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000341"
      unitRef="USD">-28036814</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000342"
      unitRef="USD">-244260</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000343"
      unitRef="USD">44588017</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000353"
      unitRef="Shares">164451</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000347"
      unitRef="USD">165</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000348"
      unitRef="USD">4435883</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000351"
      unitRef="USD">4436048</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <SMTI:StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000361"
      unitRef="Shares">54083</SMTI:StockIssuedDuringPeriodSharesForNetSettlementAndRetirementOfEquityBasedAwards>
    <SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">54</SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards>
    <SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000356"
      unitRef="USD">-42228</SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards>
    <SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000357"
      unitRef="USD">-83031</SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards>
    <SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000359"
      unitRef="USD">-125205</SMTI:StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000364"
      unitRef="USD">-75000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000367"
      unitRef="USD">-75000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">-9664547</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000374"
      unitRef="USD">-247351</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000375"
      unitRef="USD">-9911898</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000383"
      unitRef="Shares">8753773</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000377"
      unitRef="USD">8754</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000378"
      unitRef="USD">77179211</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000379"
      unitRef="USD">-37784392</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000380"
      unitRef="USD">-491611</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000381"
      unitRef="USD">38911962</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000391"
      unitRef="Shares">8753773</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000385"
      unitRef="USD">8754</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000386"
      unitRef="USD">77179211</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000387"
      unitRef="USD">-37784392</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000388"
      unitRef="USD">-491611</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000389"
      unitRef="USD">38911962</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000396"
      unitRef="USD">-9911898</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000397"
      unitRef="USD">-4439902</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000402"
      unitRef="USD">4923224</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000403"
      unitRef="USD">3675026</us-gaap:DepreciationAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000405"
      unitRef="USD">624448</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000406"
      unitRef="USD">202941</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryWriteDown
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000408"
      unitRef="USD">521757</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000409"
      unitRef="USD">406812</us-gaap:InventoryWriteDown>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000411"
      unitRef="USD">4436048</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000412"
      unitRef="USD">3442722</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000414"
      unitRef="USD">547297</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000415"
      unitRef="USD">342972</us-gaap:OtherNoncashExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000417"
      unitRef="USD">-90007</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000421"
      unitRef="USD">251034</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <SMTI:BackendFee
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000423"
      unitRef="USD">358086</SMTI:BackendFee>
    <us-gaap:PaidInKindInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000426"
      unitRef="USD">838965</us-gaap:PaidInKindInterest>
    <SMTI:AccretionOfFinanceLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000429"
      unitRef="USD">210931</SMTI:AccretionOfFinanceLiabilities>
    <SMTI:AccretionOfFinanceLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000430"
      unitRef="USD">98926</SMTI:AccretionOfFinanceLiabilities>
    <SMTI:AmortizationAndWriteoffOfDebtIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000432"
      unitRef="USD">209499</SMTI:AmortizationAndWriteoffOfDebtIssuanceCosts>
    <SMTI:AmortizationAndWriteoffOfDebtIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000433"
      unitRef="USD">5138</SMTI:AmortizationAndWriteoffOfDebtIssuanceCosts>
    <SMTI:ChangeInFairValueOfDeferredAndEarnoutLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000435"
      unitRef="USD">1938451</SMTI:ChangeInFairValueOfDeferredAndEarnoutLiabilities>
    <SMTI:ChangeInFairValueOfDeferredAndEarnoutLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000436"
      unitRef="USD">3449895</SMTI:ChangeInFairValueOfDeferredAndEarnoutLiabilities>
    <SMTI:AccruedInterestIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000438"
      unitRef="USD">-21978</SMTI:AccruedInterestIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000444"
      unitRef="USD">4508958</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000445"
      unitRef="USD">1821895</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000447"
      unitRef="USD">32166</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000448"
      unitRef="USD">-90148</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000450"
      unitRef="USD">-1442744</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000451"
      unitRef="USD">1545339</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000453"
      unitRef="USD">515496</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000454"
      unitRef="USD">-496200</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000456"
      unitRef="USD">-424318</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000457"
      unitRef="USD">531380</us-gaap:IncreaseDecreaseInAccountsPayable>
    <SMTI:IncreaseDecreaseInAccountsPayableRelatedParty
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000459"
      unitRef="USD">-46891</SMTI:IncreaseDecreaseInAccountsPayableRelatedParty>
    <SMTI:IncreaseDecreaseInAccountsPayableRelatedParty
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000460"
      unitRef="USD">43768</SMTI:IncreaseDecreaseInAccountsPayableRelatedParty>
    <SMTI:IncreaseDecreaseInAccruedRoyaltiesAndExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000462"
      unitRef="USD">574189</SMTI:IncreaseDecreaseInAccruedRoyaltiesAndExpenses>
    <SMTI:IncreaseDecreaseInAccruedRoyaltiesAndExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000463"
      unitRef="USD">-739645</SMTI:IncreaseDecreaseInAccruedRoyaltiesAndExpenses>
    <SMTI:IncreaseDecreaseInAccruedBonusesAndCommissions
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000465"
      unitRef="USD">3102069</SMTI:IncreaseDecreaseInAccruedBonusesAndCommissions>
    <SMTI:IncreaseDecreaseInAccruedBonusesAndCommissions
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000466"
      unitRef="USD">-81513</SMTI:IncreaseDecreaseInAccruedBonusesAndCommissions>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000468"
      unitRef="USD">-502892</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000469"
      unitRef="USD">-252366</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000471"
      unitRef="USD">-23784</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000472"
      unitRef="USD">-3245556</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000477"
      unitRef="USD">205848</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000478"
      unitRef="USD">265246</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000480"
      unitRef="USD">23452</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000484"
      unitRef="USD">650</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000486"
      unitRef="USD">5302952</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireLoansReceivable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000489"
      unitRef="USD">1079391</us-gaap:PaymentsToAcquireLoansReceivable>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000493"
      unitRef="USD">9942750</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000495"
      unitRef="USD">-6611643</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000496"
      unitRef="USD">-10207346</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000504"
      unitRef="USD">1160740</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000506"
      unitRef="USD">61658</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000501"
      unitRef="USD">29339260</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000502"
      unitRef="USD">9688341</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000508"
      unitRef="USD">9750000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000511"
      unitRef="USD">-75000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000512"
      unitRef="USD">911371</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000514"
      unitRef="USD">-125205</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000515"
      unitRef="USD">-135794</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <SMTI:CashPaymentOfFinanceAndEarnoutLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000517"
      unitRef="USD">2022549</SMTI:CashPaymentOfFinanceAndEarnoutLiabilities>
    <SMTI:CashPaymentOfFinanceAndEarnoutLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000518"
      unitRef="USD">822795</SMTI:CashPaymentOfFinanceAndEarnoutLiabilities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000520"
      unitRef="USD">17366506</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000521"
      unitRef="USD">9641123</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000523"
      unitRef="USD">10731079</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000524"
      unitRef="USD">-3811779</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000526"
      unitRef="USD">5147216</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000527"
      unitRef="USD">8958995</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000529"
      unitRef="USD">15878295</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000530"
      unitRef="USD">5147216</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000535"
      unitRef="USD">1580984</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000536"
      unitRef="USD">283948</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000542"
      unitRef="USD">1531773</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000545"
      unitRef="USD">3089645</us-gaap:StockIssued1>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000548"
      unitRef="USD">3759642</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <us-gaap:NatureOfOperations contextRef="From2024-01-01to2024-12-31" id="Fact000550">&lt;p id="xdx_804_eus-gaap--NatureOfOperations_zwh5tnIBXdx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 1 &#x2013; &lt;span id="xdx_824_zju88NUxA3Dg"&gt;NATURE OF BUSINESS AND BACKGROUND&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Sanara MedTech Inc. (together with its wholly owned
and majority owned subsidiaries on a consolidated basis, the &#x201c;Company&#x201d;) is a medical technology company focused on developing
and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic
wound and skincare markets. Each of the Company&#x2019;s products, services and technologies are designed to achieve the Company&#x2019;s
goal of providing better clinical outcomes at a lower overall cost for patients, regardless of where they receive care. Through its two
operating segments, Sanara Surgical and Tissue Health Plus (&#x201c;THP&#x201d;), the Company strives to be one of the most innovative
and comprehensive providers of effective surgical, wound and skincare solutions and is continually seeking to expand its offerings for
patients requiring treatments across the entire continuum of care in the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As further discussed in Note 14, the Company historically managed its business on the basis of one operating
and reportable segment. During the second quarter of 2024, the Company changed its
reportable segments to reflect a change in the manner in which the business is managed. Based on the growing importance of the value-based
wound care program to the Company&#x2019;s future outlook and how the Company&#x2019;s chief operating decision maker, the Chief Executive
Officer, reviews operating results and makes decisions about resource allocation, the Company now has &lt;span id="xdx_906_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240401__20240630_zaB4xXkgHaC4" title="Number of reportable segment"&gt;two&lt;/span&gt; reportable segments: Sanara
Surgical and THP.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Sanara Surgical &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Sanara Surgical segment primarily markets and
sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Sanara Surgical&#x2019;s
soft tissue repair products include, among other products, the Company&#x2019;s lead product, CellerateRX Surgical Activated Collagen
(&#x201c;CellerateRX Surgical&#x201d;), a hydrolyzed collagen that provides a moist environment for surgical sites to aid in the natural
wound healing process, and BIASURGE Advanced Surgical Solution, a sterile no-rinse, advanced surgical solution used for wound irrigation.
Sanara Surgical&#x2019;s bone fusion products include, among other products, BiFORM, an osteoconductive, bioactive, porous implant that
allows for bony ingrowth across the graft site, and ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor
cells and conformable bone fibers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Sanara Surgical also includes an in-house research
and development team, Rochal Technologies, with an extensive pipeline of innovative products under development.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Tissue Health Plus &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Through the Company&#x2019;s subsidiary, Tissue Health
Plus (formerly known as &#x201c;WounDerm&#x201d; and &#x201c;United Wound and Skin Solutions, LLC&#x201d;), the Company is seeking to simplify
skin health, starting with wound care through a refined business plan. Through THP, the Company plans to offer a first of its kind value-based
wound care program to payers and risk-bearing entities such as accountable care organizations and value-based primary care companies,
with Medicare Advantage payers as the initial target market for this program. The THP segment is focused on value-based wound care services.
Through THP, the Company plans to offer a first of its kind value-based wound care program to payers and risk-bearing entities such as
accountable care organizations and value-based primary care companies, with Medicare Advantage payers as the initial target market for
this program.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;THP&#x2019;s programs are expected to enable payers
to divest wound care spend risk, reduce wound related hospitalizations and improve patient quality of life. THP plans to coordinate delivery
of community and home-based wound care for its managed patients. Community-based care spans a variety of settings including physician
offices, skilled nursing facilities, assisted living facilities and senior living facilities. THP&#x2019;s programs are intended to integrate
science and evidence-based medicine protocols to standardize wound prevention and treatment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a result of the change in reportable segments,
certain prior period amounts have been recast to conform to the current period presentation. Throughout this Annual Report on Form 10-K,
unless otherwise indicated, amounts and activity reflect reclassifications related to the Company&#x2019;s change in reportable segments.
The change in reportable segments had no impact on the Company&#x2019;s previously reported Consolidated Balance Sheets, Consolidated
Statements of Operations, Consolidated Statements of Cash Flows or Consolidated Statements of Shareholders&#x2019; Equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000552"
      unitRef="Integer">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000554">&lt;p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zQ5sa65pzRFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 2 &#x2014; &lt;span id="xdx_829_zELV8x07mAM8"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_zWgD8C7GaIkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_z5VScNKQbWcd"&gt;Principles of Consolidation and Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the accounts of Sanara MedTech Inc. and its wholly owned and majority-owned subsidiaries, as well as other entities in which
the Company has a controlling financial interest. All significant intercompany profits, losses, transactions and balances have been eliminated
in consolidation. Certain prior year amounts have been reclassified to conform to the current year presentation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--UseOfEstimates_zX6nXHAESdFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zeobAQWcjXK5"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity
with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and
the reported revenue and expenses during the reporting period. However, actual results could differ from those estimates and there may
be changes to the Company&#x2019;s estimates in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zVH5nCCKGtJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zgPXxcOOsSHg"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid investments
purchased with an original maturity of three months or less to be cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zpLuYGKBoAuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_z2p7h9RuBYk4"&gt;Income/Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company computes income/loss per share in accordance
with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 260, Earnings per Share, which requires the Company to present basic
and diluted income per share when the effect is dilutive. Basic income/loss per share is computed by dividing income/loss attributable
to common shareholders by the weighted average number of shares of common stock outstanding. Diluted income/loss per share is computed
similarly to basic income/loss per share, except that the denominator is increased to include the number of additional shares of common
stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common
stock were dilutive. All common stock equivalents were excluded from the calculations for the periods presented as their inclusion would
have been anti-dilutive during the years ended December&#160;31, 2024 and 2023 due to the Company&#x2019;s net loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWXU0FDCQDwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes the shares of common
stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the years ended December&#160;31,
2024 and 2023 as such shares would have had an anti-dilutive effect:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zf7w48RRD9A9" style="display: none"&gt;SCHEDULE
OF COMPUTATION OF DILUTED NET LOSS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_z2Dd1IDQxPbb" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_zfZm4fFZ5OOc" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zDvw2srqeA2d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left; padding-left: 0pt"&gt;&lt;span style="font-size: 10pt"&gt;Stock options&lt;sup id="xdx_F4C_zmB7sEMtIBwj"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;31,013&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;93,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKD4QRq4eUl3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;sup id="xdx_F48_zFdIWwfer048"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0569"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,725&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zsbhPOlzXXF3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Unvested restricted stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;202,787&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z6ObFpoJjSwj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Anti-dilutive
    securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;202,787&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;144,211&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td id="xdx_F0E_zLw243GCkSl4" style="width: 0.25in"&gt;(a)&lt;/td&gt;&lt;td id="xdx_F1D_zQ2VZuA9Ai1g"&gt;Shares underlying stock options assumed pursuant to the merger agreement
                                            with Precision Healing, Inc. (&#x201c;Precision Healing&#x201d;) in April 2022.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td id="xdx_F0F_zRE6wyIXY6d7" style="width: 0.25in"&gt;(b)&lt;/td&gt;&lt;td id="xdx_F1E_zt5c7r2IXmL5"&gt;Shares underlying warrants assumed pursuant to the merger agreement
                                            with Precision Healing in April 2022.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AE_zKpKnX5IfzJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zvpssZlOVqdl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zBN1XGdmgHGh"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes revenue in accordance with
ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Revenues are recognized when a purchase order is received
from the customer and control of the promised goods or services is transferred to the customer in an amount that reflects the consideration
the Company expects to be entitled to receive in exchange for transferring those goods or services. Revenue is recognized based on the
following five-step model:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: -9pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;-&lt;/td&gt;&lt;td style="text-align: justify"&gt;Identification of the contract with a customer&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;-&lt;/td&gt;&lt;td style="text-align: justify"&gt;Identification of the performance obligations
                                            in the contract&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;-&lt;/td&gt;&lt;td style="text-align: justify"&gt;Determination of the transaction price&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;-&lt;/td&gt;&lt;td style="text-align: justify"&gt;Allocation of the transaction price to the performance
                                            obligations in the contract&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;-&lt;/td&gt;&lt;td style="text-align: justify"&gt;Recognition of revenue when, or as, the Company
                                            satisfies a performance obligation&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Details of this five-step process are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Identification of the contract with a customer&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Customer purchase orders are generally considered
to be contracts under ASC 606. Purchase orders typically identify the specific terms of products to be delivered, create the enforceable
rights and obligations of both parties and result in commercial substance. No other forms of contract revenue recognition, such as the
completed contract or percentage of completion methods, were utilized by the Company in either 2024 or 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Performance obligations&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s performance obligation is generally
limited to delivery of the requested items to its customers at the agreed upon quantities and prices.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Determination and allocation of the transaction price&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has established prices for its products.
These prices are effectively agreed to when customers place purchase orders with the Company. Rebates and discounts, if any, are recognized
in full at the time of sale as a reduction of net revenue. Allocation of transaction prices is not necessary where only one performance
obligation exists. For certain sales transactions, we incur group purchasing organization fees that are based on a contractual percentage
of applicable sales and are recorded as a reduction of the revenue for those transactions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Recognition of revenue as performance obligations are satisfied&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Product revenues are recognized when a purchase order
is received from the customer, the products are delivered, and control of the goods and services passes to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Disaggregation of Revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zydaPT1G4ZKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue streams from product sales and royalties
are summarized below for the years ended December&#160;31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z9Njba69Dhx4" style="display: none"&gt;SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231_z9BTxnEdZ442" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_ztPw1I3NSwZa" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SoftTissueRepairProductsMember_zneCjYnaFoe7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left; padding-left: 0pt"&gt;Soft tissue repair products&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;76,125,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;54,836,410&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--BoneFusionProductsMember_zl6rE4Y3bJA6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Bone fusion products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,547,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,952,432&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zaDbFNK5EtN" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Royalty revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0590"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;201,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zKdc18lqmb9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Total Net Revenue&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;86,672,425&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;64,989,842&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zaRG0x0BD4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended December 31, 2024 and
2023, all of the Company&#x2019;s net revenue was generated from Sanara Surgical. The Company is preparing to launch the first THP
pilot program with a wound care provider group during the second quarter of 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--CreditLossFinancialInstrumentPolicyTextBlock_zau6cFpP84v6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zkO6xtwjAUph"&gt;Accounts Receivable Allowances&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable are typically due within 30
days of invoicing. The Company establishes an allowance for credit losses to provide for an estimate of accounts receivable which
are not expected to be collectible. The Company bases the allowance on an assessment of customer creditworthiness, historical
payment experience, the age of outstanding receivables and other information as applicable and will record its allowance based on
the estimated credit losses. The Company&#x2019;s accounts receivable balance, net was $&lt;span id="xdx_90D_eus-gaap--AccountsReceivableNetCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zzTaJygWj6v1" title="Accounts receivable"&gt;12,408,819&lt;/span&gt;, $&lt;span id="xdx_906_eus-gaap--AccountsReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zoxigWdgakN6" title="Accounts receivable"&gt;8,474,965&lt;/span&gt;, and $&lt;span id="xdx_90B_eus-gaap--AccountsReceivableNetCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zBusyyYA3Bsj" title="Accounts receivable"&gt;6,805,761&lt;/span&gt; as of December
31, 2024, December 31, 2023, and December 31, 2022, respectively. The Company recorded credit loss expense of $&lt;span id="xdx_90B_eus-gaap--ProvisionForDoubtfulAccounts_c20240101__20241231_zl7NwK9XaDN7" title="Bad debt expense"&gt;624,448&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--ProvisionForDoubtfulAccounts_c20230101__20231231_zLbUbIGGyrgl" title="Bad debt expense"&gt;202,941&lt;/span&gt;
during the years ended December&#160;31, 2024 and 2023, respectively. The allowance for credit losses was $&lt;span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20241231_zLMuSoGtDiEd" title="Allowance for credit losses"&gt;1,173,441&lt;/span&gt;
at December&#160;31, 2024 and $&lt;span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zboG2jZNi8lk" title="Allowance for credit losses"&gt;528,030&lt;/span&gt;
at December&#160;31, 2023. Credit loss reserves are maintained based on a variety of factors, including the length of time
receivables are past due and a detailed review of certain individual customer accounts. The Company also establishes other
allowances to provide for estimated customer rebates and other expected customer deductions. These allowances totaled $&lt;span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_c20241231_ztbX3Z9Q2YI1" title="Allowance for customer rebates and deductions"&gt;4,897&lt;/span&gt;
at December&#160;31, 2024 and $&lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_c20231231_zYAfTFwYXIgb" title="Allowance for customer rebates and deductions"&gt;3,820&lt;/span&gt;
at December&#160;31, 2023. If circumstances related to customers change, estimates of the recoverability of receivables would be
further adjusted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_zuU61DQo9Vdk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zateYLuhUsxd"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventories are stated at the lower of cost or net
realizable value, with cost computed on a first-in, first-out basis. Inventories consist primarily of finished goods, and also include
an immaterial amount of raw materials and related packaging components. The Company recorded inventory obsolescence expense of $&lt;span id="xdx_901_eus-gaap--InventoryWriteDown_c20240101__20241231_zCTwYKZUNe6f" title="Inventory obsolescence expense"&gt;521,757&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--InventoryWriteDown_c20230101__20231231_zovbIFGgdTr1" title="Inventory obsolescence expense"&gt;406,812&lt;/span&gt; during the years ended December&#160;31, 2024 and 2023, respectively. The allowance for obsolete and slow-moving inventory
had a balance of $&lt;span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_c20241231_zc074IrXpNph" title="Allowance for obsolete and slow-moving inventory"&gt;534,549&lt;/span&gt; at December&#160;31, 2024 and $&lt;span id="xdx_902_eus-gaap--InventoryValuationReserves_iI_c20231231_zyOJP02HiKF4" title="Allowance for obsolete and slow-moving inventory"&gt;446,917&lt;/span&gt; at December&#160;31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zH8nmSqF4w6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zb79f3OI2Ddf"&gt;Property and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment are stated at cost, less accumulated
depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the related assets, ranging
from &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember_zP6XLLBlsNy2" title="Estimated useful lives::XDX::P2Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0628"&gt;two&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_c20241231__srt--RangeAxis__srt--MaximumMember_zZiC3dzkTRu6" title="Estimated useful lives"&gt;ten years&lt;/span&gt;. Below is a summary of property and equipment for the periods presented:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zqRliQNnUB1d" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zQKNzkO8FU9g" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Useful&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_zjuto5QPegHf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zwcZH3iFbWbi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVlyBmKFNc29" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; padding-left: 0pt"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center; padding-left: 0pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zpfitIsrj9Ak" title="Useful Life"&gt;3&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zuDth0z9viv1" title="Useful Life"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;295,963&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;194,788&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zrthfTCFxxhk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zs8CneFLDiB6" title="Useful Life"&gt;3&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_z2kIMVBvCVw2" title="Useful Life"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;216,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;201,785&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zJ56vuocB1Ih" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zeQhlRy083Za" title="Useful Life"&gt;5&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zbWxC8rWUL7c" title="Useful Life"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;346,508&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zLVSo8nF94k1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_z3ksmxolhQ3c" title="Useful Life"&gt;2&lt;/span&gt;-&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zfSPGPNrx4ye" title="Useful Life"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;181,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134,170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zkzxzTMzV3c3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Internal use software&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 0pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_ztngxXxxLfR" title="Useful life"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0662"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,618,999&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz6Up_znA7HeNhBpG8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,040,930&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,454,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz6Up_z5x7dqCdRrr7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(608,613&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,196,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz6Up_zph1Y9kIAJq5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;432,317&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,257,956&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zm4xRmkwAxS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation expense related to property and equipment
was $&lt;span id="xdx_906_eus-gaap--Depreciation_c20240101__20241231_zjo3LfxdWLG2" title="Depreciation"&gt;1,031,487&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--Depreciation_c20230101__20231231_z0BnoG2WACQ3" title="Depreciation"&gt;456,138&lt;/span&gt; during the year ended December&#160;31, 2024 and 2023, respectively. Depreciation expense for the year ended
December&#160;31, 2024 included a non-cash charge of $&lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_z8IlaiQpIepi" title="Depreciation"&gt;506,836&lt;/span&gt; to write-off the remaining net book value of certain internal use software
assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--InternalUseSoftwarePolicy_zrF1Mx2vgan" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zIKZP3FaoK1g"&gt;Internal Use Software&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounted for costs incurred to develop
or acquire computer software for internal use in accordance with ASC Topic 350-40, Intangibles &#x2013; Goodwill and Other. The Company
capitalized the costs incurred during the application development stage, which generally included third-party developer fees to design
the software configuration and interfaces, coding, installation and testing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company began capitalization of qualifying costs
when both the preliminary project stage was completed and management authorized further funding for the completion of the project. Costs
incurred during the preliminary project stage along with post implementation stages of internal-use computer software was expensed as
incurred. The Company also capitalized costs related to specific upgrades and enhancements when it was probable the expenditures would
result in additional functionality. Capitalized development costs were classified as &#x201c;Property and equipment, net&#x201d; in the
Consolidated Balance Sheets and were depreciated over the estimated useful life of the software, which was generally &lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_c20241231_zEG0ftpJryRl" title="Software, estimated useful life"&gt;five years&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z1WdfEV3R3Rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zJk3m1hNnfCe"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The excess of purchase price over the fair value
of identifiable net assets acquired in business combinations is recorded as goodwill. As of December&#160;31, 2024 and December&#160;31,
2023, all of the Company&#x2019;s goodwill relates to the acquisition of Scendia Biologics, LLC (&#x201c;Scendia&#x201d;), which is included
in the Sanara Surgical segment. Goodwill has an indefinite useful life and is not amortized. Goodwill is tested annually as of December&#160;31
for impairment, or more frequently if circumstances indicate impairment may have occurred. The Company may first perform a qualitative
assessment to determine if it is more likely than not that the fair value of the reporting unit is less than the respective carrying
value. If it is determined that it is more likely than not that a reporting unit&#x2019;s fair value is less than its carrying value,
then the Company will determine the fair value of the reporting unit and record an impairment charge for the difference between fair
value and carrying value (not to exceed the carrying amount of goodwill). &lt;span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_dxL_c20240101__20241231_zf8A9BY2laia" title="Impairment of goodwill::XDX::-"&gt;&lt;span id="xdx_902_eus-gaap--GoodwillImpairmentLoss_dxL_c20230101__20231231_zSP9gN96Qp8" title="Impairment of goodwill::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0688"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0690"&gt;No&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; impairment was recorded during the year ended December&#160;31,
2024 or 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_z0H17BQcYr0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zesGLPv7Z3n7"&gt;Intangible Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Intangible assets are stated at cost of acquisition
less accumulated amortization and impairment loss, if any. Cost of acquisition includes the purchase price and any cost directly attributable
to bringing the asset to its working condition for the intended use. The Company amortizes its finite-lived intangible assets on a straight-line
basis over the estimated useful life of the respective assets which is generally the life of the related patents or licenses, seven years
for customer relationships and five years for assembled workforces. See Note 5 for more information on intangible assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQQvnP4shxjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zbyigOjCH2M9"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Long-lived assets, including certain identifiable
intangibles held and to be used by the Company, are reviewed for impairment whenever events or changes in circumstances indicate that
the carrying amount of such assets may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets
based on estimated future cash flows and the estimated liquidation value of such long-lived assets and provides for impairment if such
undiscounted cash flows are insufficient to recover the carrying amount of the long-lived assets. If impairment exists, an adjustment
is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value.
Fair values are determined based on quoted market values, undiscounted cash flows or internal and external appraisals, as applicable.
Assets to be disposed of are carried at the lower of carrying value or estimated fair value less cost to sell. A $&lt;span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn5n6_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zFeTMhSeGVo3" title="Depreciation"&gt;0.5&lt;/span&gt; million non-cash
charge to write-off the remaining net book value of certain THP internal use software assets was recorded during the year ended December&#160;31,
2024. &lt;span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20230101__20231231_z0RhOg8Dufg1" title="Impairment of long-lived assets"&gt;No&lt;/span&gt; impairment was recorded during the year ended December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--EquityMethodInvestmentsPolicy_zCGU5SwufEW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_ztdSbWsdtScl"&gt;Investments in Equity Securities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s equity investments consist of
nonmarketable equity securities in privately held companies without readily determinable fair values. Unless accounted for under the
equity method of accounting, the investments are reported at cost minus impairment, if any, plus or minus changes resulting from observable
price changes in orderly transactions for the identical or similar investment in the same issuer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company applies the equity method of accounting
to investments when it has significant influence, but not controlling interest, in the investee. Judgment regarding the level of influence
over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors,
participation in policy-making decisions and material intercompany transactions. As discussed further in Note 6 as of December&#160;31,
2024, the Company had two investments that are recorded applying the equity method of accounting. The Company&#x2019;s proportionate share
of the net income (loss) resulting from these investments is reported under the line item captioned &#x201c;Share of losses from equity
method investments&#x201d; in the Company&#x2019;s Consolidated Statements of Operations. The Company&#x2019;s equity method investments
are adjusted each period for the Company&#x2019;s share of the investee&#x2019;s income or loss and dividend paid, if any. The Company
classifies distributions received from its equity method investments using the cumulative earnings approach in the Company&#x2019;s Consolidated
Statements of Cash Flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has reviewed the carrying value of its
investments and has determined there was no impairment or observable price changes as of or for the year ended December&#160;31, 2024
and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z8rBtA5vItM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zccdqe3IkqB9"&gt;Fair Value Measurement&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As defined in ASC Topic 820, Fair Value Measurement
(&#x201c;ASC 820&#x201d;), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market
participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the
valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair
value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted
prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level
3 measurement). This fair value measurement framework applies at both the initial and subsequent measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The three levels of the fair value hierarchy defined
by ASC 820 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 &#x2013; Quoted prices are available in active
markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or
liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of
financial instruments such as exchange-traded derivatives, marketable securities and listed equities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 &#x2013; Pricing inputs are other than quoted
prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes
those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard
models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current
market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these
assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are
supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include
nonexchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 &#x2013; Pricing inputs include significant
inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that
result in management&#x2019;s best estimate of fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying amounts of cash, accounts receivable,
accounts payable and accrued expenses, other than acquisition-related expenses, approximate fair value because of the short-term nature
of these instruments. The fair value of acquisition-related accrued expenses is categorized as Level 2 of the fair value hierarchy. The
value of these instruments has been estimated using discounted cash flow analysis based on the Company&#x2019;s incremental borrowing
rate. The carrying value of the Company&#x2019;s CRG Term Loan (defined below), which has a fixed interest rate approximates fair value
based on instruments with similar terms (Level 2 inputs). The fair value of the contingent earnout consideration and the acquisition
date fair value of goodwill and intangibles related to the acquisitions discussed in Notes 3 and 5 are based on Level 3 inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Liabilities for contingent consideration for the
Precision Healing merger, acquisition of Scendia and Applied Asset Purchase (defined below) (see Note 3 for more information) are measured
at fair value each reporting period, with the acquisition-date fair value included as part of the consideration transferred. The contingent
consideration for the Scendia acquisition was settled as of September 30, 2024, and the final earnout payment of approximately $1.1 million
was paid in cash in October 2024. The Precision Healing contingent consideration is classified as a liability at its fair value at each
reporting period due to the fact that the monetary value of the shares to be issued is predominantly dependent on the exercise contingency
(i.e., revenue targets). Subsequent changes in fair value of contingent consideration related to the Precision Healing merger are reported
under the line item captioned &#x201c;Change in fair value of earnout liabilities&#x201d; in the Company&#x2019;s Consolidated Statements
of Operations. The Company reviewed the thresholds necessary to trigger a payment on the Precision Healing earnout as of December 31,
2024 and deemed the thresholds to be unachievable by the sellers, therefore, the remaining fair value on the earnout was reduced to zero.
Due to the Applied Asset Purchase being accounted for as an asset acquisition and given that the transaction did not include contingent
shares, subsequent revaluations of contingent consideration for the Applied Asset Purchase results in an adjustment to the contingent
consideration liability and the intellectual property intangible asset with a cumulative catch-up amortization adjustment. The current
year change in fair value of earnout liability below is as a result of a net decrease in the estimated fair value of the earnout liability
established at the time of the Company&#x2019;s Precision Healing merger. The current year revaluation of earnout liability below is a
result of a decrease in the estimated value of the earnout liability established at the time of the Applied Asset Purchase. The following
table sets forth a summary of the changes in fair value for the Level 3 contingent earnout considerations.&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zyMX4K6dm2g4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zlfDaPl3CVAl" style="display: none"&gt;SCHEDULE
OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_495_20240101__20241231_zGPyhUGHNZDf" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_zZYTfAj7HLie" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; padding-left: 0pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,823,001&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_zooAX9QzVyf6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 9pt; padding-left: 0pt"&gt;Change in fair value of earnout liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,938,451&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability_zNjJ5pGNlySg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 9pt; padding-left: 0pt"&gt;Revaluation of earnout liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(51,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements_zETuDA62VB44" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt"&gt;Settlements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,085,549&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_zbXliTDqnde7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;748,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zR31WoaaVx26" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zXVrVoI0j0v" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zQLkHdchx9E3"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Income taxes are accounted for under the asset and
liability method, whereby deferred income taxes are recorded for temporary differences between financial statement carrying amounts and
the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years
in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all the
deferred tax asset will not be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zW7kGy8BeOM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z2uC0X764h8d"&gt;Share-based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for share-based compensation
to employees and nonemployees in accordance with ASC Topic 718, Compensation &#x2013; Stock Compensation. Share-based compensation is
measured at the grant date, based on the fair value of the award, and is recognized as expense over the stipulated vesting period, if
any. The Company estimates the fair value of share-based payments using the Black-Scholes option-pricing model for common stock options
and warrants, and the closing price of the Company&#x2019;s common stock for grants of common stock, including restricted stock awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zsaYDcSy2eR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zmgxSQsBIQN5"&gt;Research and Development Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;)
expenses consist of personnel-related expenses, including salaries, share-based compensation and benefits for all personnel directly
engaged in R&amp;amp;D activities, contracted services, materials, prototype expenses and allocated overhead, which is comprised of compensation
and benefits, lease expense and other facilities-related costs. R&amp;amp;D expenses include costs related to enhancements to the Company&#x2019;s
currently available products and additional investments in the product and platform development pipeline. The Company expenses R&amp;amp;D
costs as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_z7hRzsnmClZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z1yk2PchwuZ1"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2016, the Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, Financial Instruments - Credit Losses (Topic
326). This update amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate
credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The Company
adopted the new guidance effective January 1, 2023. The adoption did not have a material impact on the Company&#x2019;s consolidated financial
position, results of operations or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2023, FASB issued ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;), which requires disclosure of incremental
segment information on an annual and interim basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and
interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company adopted the new guidance
effective December 31, 2024. The adoption did not have a material impact on the Company&#x2019;s consolidated financial position, results
of operations or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3IibpPc84ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z4TJcBV8RiWa"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, FASB issued ASU 2023-09, Income
Taxes (Topic 740): Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;), which expands the disclosure required for income
taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the effect of this pronouncement on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2024, FASB issued ASU 2024-03, Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,
which requires new disclosures providing further detail of a company&#x2019;s income statement expense line items. ASU 2024-03 is effective
for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is
permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.&lt;/p&gt;

&lt;p id="xdx_853_zuGP1w71ll1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000556">&lt;p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_zWgD8C7GaIkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_z5VScNKQbWcd"&gt;Principles of Consolidation and Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the accounts of Sanara MedTech Inc. and its wholly owned and majority-owned subsidiaries, as well as other entities in which
the Company has a controlling financial interest. All significant intercompany profits, losses, transactions and balances have been eliminated
in consolidation. Certain prior year amounts have been reclassified to conform to the current year presentation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000558">&lt;p id="xdx_840_eus-gaap--UseOfEstimates_zX6nXHAESdFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zeobAQWcjXK5"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity
with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and
the reported revenue and expenses during the reporting period. However, actual results could differ from those estimates and there may
be changes to the Company&#x2019;s estimates in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000560">&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zVH5nCCKGtJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zgPXxcOOsSHg"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid investments
purchased with an original maturity of three months or less to be cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000562">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zpLuYGKBoAuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_z2p7h9RuBYk4"&gt;Income/Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company computes income/loss per share in accordance
with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 260, Earnings per Share, which requires the Company to present basic
and diluted income per share when the effect is dilutive. Basic income/loss per share is computed by dividing income/loss attributable
to common shareholders by the weighted average number of shares of common stock outstanding. Diluted income/loss per share is computed
similarly to basic income/loss per share, except that the denominator is increased to include the number of additional shares of common
stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common
stock were dilutive. All common stock equivalents were excluded from the calculations for the periods presented as their inclusion would
have been anti-dilutive during the years ended December&#160;31, 2024 and 2023 due to the Company&#x2019;s net loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWXU0FDCQDwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes the shares of common
stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the years ended December&#160;31,
2024 and 2023 as such shares would have had an anti-dilutive effect:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zf7w48RRD9A9" style="display: none"&gt;SCHEDULE
OF COMPUTATION OF DILUTED NET LOSS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_z2Dd1IDQxPbb" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_zfZm4fFZ5OOc" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zDvw2srqeA2d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left; padding-left: 0pt"&gt;&lt;span style="font-size: 10pt"&gt;Stock options&lt;sup id="xdx_F4C_zmB7sEMtIBwj"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;31,013&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;93,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKD4QRq4eUl3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;sup id="xdx_F48_zFdIWwfer048"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0569"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,725&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zsbhPOlzXXF3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Unvested restricted stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;202,787&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z6ObFpoJjSwj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Anti-dilutive
    securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;202,787&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;144,211&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td id="xdx_F0E_zLw243GCkSl4" style="width: 0.25in"&gt;(a)&lt;/td&gt;&lt;td id="xdx_F1D_zQ2VZuA9Ai1g"&gt;Shares underlying stock options assumed pursuant to the merger agreement
                                            with Precision Healing, Inc. (&#x201c;Precision Healing&#x201d;) in April 2022.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td id="xdx_F0F_zRE6wyIXY6d7" style="width: 0.25in"&gt;(b)&lt;/td&gt;&lt;td id="xdx_F1E_zt5c7r2IXmL5"&gt;Shares underlying warrants assumed pursuant to the merger agreement
                                            with Precision Healing in April 2022.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AE_zKpKnX5IfzJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000564">&lt;p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWXU0FDCQDwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes the shares of common
stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the years ended December&#160;31,
2024 and 2023 as such shares would have had an anti-dilutive effect:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zf7w48RRD9A9" style="display: none"&gt;SCHEDULE
OF COMPUTATION OF DILUTED NET LOSS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_z2Dd1IDQxPbb" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_zfZm4fFZ5OOc" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zDvw2srqeA2d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left; padding-left: 0pt"&gt;&lt;span style="font-size: 10pt"&gt;Stock options&lt;sup id="xdx_F4C_zmB7sEMtIBwj"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;31,013&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;93,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKD4QRq4eUl3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;sup id="xdx_F48_zFdIWwfer048"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0569"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,725&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_zsbhPOlzXXF3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Unvested restricted stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;202,787&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedStockMember_z6ObFpoJjSwj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Anti-dilutive
    securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;202,787&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;144,211&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td id="xdx_F0E_zLw243GCkSl4" style="width: 0.25in"&gt;(a)&lt;/td&gt;&lt;td id="xdx_F1D_zQ2VZuA9Ai1g"&gt;Shares underlying stock options assumed pursuant to the merger agreement
                                            with Precision Healing, Inc. (&#x201c;Precision Healing&#x201d;) in April 2022.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td id="xdx_F0F_zRE6wyIXY6d7" style="width: 0.25in"&gt;(b)&lt;/td&gt;&lt;td id="xdx_F1E_zt5c7r2IXmL5"&gt;Shares underlying warrants assumed pursuant to the merger agreement
                                            with Precision Healing in April 2022.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000566"
      unitRef="Shares">31013</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000567"
      unitRef="Shares">93892</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000570"
      unitRef="Shares">16725</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_UnvestedRestrictedStockMember"
      decimals="INF"
      id="Fact000572"
      unitRef="Shares">202787</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_UnvestedRestrictedStockMember"
      decimals="INF"
      id="Fact000573"
      unitRef="Shares">144211</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_UnvestedRestrictedStockMember"
      decimals="INF"
      id="Fact000575"
      unitRef="Shares">202787</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_UnvestedRestrictedStockMember"
      decimals="INF"
      id="Fact000576"
      unitRef="Shares">144211</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000580">&lt;p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zvpssZlOVqdl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zBN1XGdmgHGh"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes revenue in accordance with
ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Revenues are recognized when a purchase order is received
from the customer and control of the promised goods or services is transferred to the customer in an amount that reflects the consideration
the Company expects to be entitled to receive in exchange for transferring those goods or services. Revenue is recognized based on the
following five-step model:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: -9pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;-&lt;/td&gt;&lt;td style="text-align: justify"&gt;Identification of the contract with a customer&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;-&lt;/td&gt;&lt;td style="text-align: justify"&gt;Identification of the performance obligations
                                            in the contract&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;-&lt;/td&gt;&lt;td style="text-align: justify"&gt;Determination of the transaction price&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;-&lt;/td&gt;&lt;td style="text-align: justify"&gt;Allocation of the transaction price to the performance
                                            obligations in the contract&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;-&lt;/td&gt;&lt;td style="text-align: justify"&gt;Recognition of revenue when, or as, the Company
                                            satisfies a performance obligation&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Details of this five-step process are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Identification of the contract with a customer&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Customer purchase orders are generally considered
to be contracts under ASC 606. Purchase orders typically identify the specific terms of products to be delivered, create the enforceable
rights and obligations of both parties and result in commercial substance. No other forms of contract revenue recognition, such as the
completed contract or percentage of completion methods, were utilized by the Company in either 2024 or 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Performance obligations&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s performance obligation is generally
limited to delivery of the requested items to its customers at the agreed upon quantities and prices.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Determination and allocation of the transaction price&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has established prices for its products.
These prices are effectively agreed to when customers place purchase orders with the Company. Rebates and discounts, if any, are recognized
in full at the time of sale as a reduction of net revenue. Allocation of transaction prices is not necessary where only one performance
obligation exists. For certain sales transactions, we incur group purchasing organization fees that are based on a contractual percentage
of applicable sales and are recorded as a reduction of the revenue for those transactions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Recognition of revenue as performance obligations are satisfied&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Product revenues are recognized when a purchase order
is received from the customer, the products are delivered, and control of the goods and services passes to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Disaggregation of Revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zydaPT1G4ZKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue streams from product sales and royalties
are summarized below for the years ended December&#160;31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z9Njba69Dhx4" style="display: none"&gt;SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231_z9BTxnEdZ442" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_ztPw1I3NSwZa" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SoftTissueRepairProductsMember_zneCjYnaFoe7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left; padding-left: 0pt"&gt;Soft tissue repair products&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;76,125,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;54,836,410&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--BoneFusionProductsMember_zl6rE4Y3bJA6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Bone fusion products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,547,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,952,432&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zaDbFNK5EtN" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Royalty revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0590"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;201,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zKdc18lqmb9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Total Net Revenue&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;86,672,425&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;64,989,842&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zaRG0x0BD4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended December 31, 2024 and
2023, all of the Company&#x2019;s net revenue was generated from Sanara Surgical. The Company is preparing to launch the first THP
pilot program with a wound care provider group during the second quarter of 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000582">&lt;p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zydaPT1G4ZKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue streams from product sales and royalties
are summarized below for the years ended December&#160;31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z9Njba69Dhx4" style="display: none"&gt;SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231_z9BTxnEdZ442" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_ztPw1I3NSwZa" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SoftTissueRepairProductsMember_zneCjYnaFoe7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left; padding-left: 0pt"&gt;Soft tissue repair products&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;76,125,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;54,836,410&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--BoneFusionProductsMember_zl6rE4Y3bJA6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Bone fusion products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,547,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,952,432&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_zaDbFNK5EtN" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Royalty revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0590"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;201,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zKdc18lqmb9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Total Net Revenue&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;86,672,425&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;64,989,842&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_SoftTissueRepairProductsMember"
      decimals="0"
      id="Fact000584"
      unitRef="USD">76125012</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_SoftTissueRepairProductsMember"
      decimals="0"
      id="Fact000585"
      unitRef="USD">54836410</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_BoneFusionProductsMember"
      decimals="0"
      id="Fact000587"
      unitRef="USD">10547413</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_BoneFusionProductsMember"
      decimals="0"
      id="Fact000588"
      unitRef="USD">9952432</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_us-gaap_RoyaltyMember"
      decimals="0"
      id="Fact000591"
      unitRef="USD">201000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000593"
      unitRef="USD">86672425</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000594"
      unitRef="USD">64989842</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000596">&lt;p id="xdx_84C_eus-gaap--CreditLossFinancialInstrumentPolicyTextBlock_zau6cFpP84v6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zkO6xtwjAUph"&gt;Accounts Receivable Allowances&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable are typically due within 30
days of invoicing. The Company establishes an allowance for credit losses to provide for an estimate of accounts receivable which
are not expected to be collectible. The Company bases the allowance on an assessment of customer creditworthiness, historical
payment experience, the age of outstanding receivables and other information as applicable and will record its allowance based on
the estimated credit losses. The Company&#x2019;s accounts receivable balance, net was $&lt;span id="xdx_90D_eus-gaap--AccountsReceivableNetCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zzTaJygWj6v1" title="Accounts receivable"&gt;12,408,819&lt;/span&gt;, $&lt;span id="xdx_906_eus-gaap--AccountsReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zoxigWdgakN6" title="Accounts receivable"&gt;8,474,965&lt;/span&gt;, and $&lt;span id="xdx_90B_eus-gaap--AccountsReceivableNetCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zBusyyYA3Bsj" title="Accounts receivable"&gt;6,805,761&lt;/span&gt; as of December
31, 2024, December 31, 2023, and December 31, 2022, respectively. The Company recorded credit loss expense of $&lt;span id="xdx_90B_eus-gaap--ProvisionForDoubtfulAccounts_c20240101__20241231_zl7NwK9XaDN7" title="Bad debt expense"&gt;624,448&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--ProvisionForDoubtfulAccounts_c20230101__20231231_zLbUbIGGyrgl" title="Bad debt expense"&gt;202,941&lt;/span&gt;
during the years ended December&#160;31, 2024 and 2023, respectively. The allowance for credit losses was $&lt;span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20241231_zLMuSoGtDiEd" title="Allowance for credit losses"&gt;1,173,441&lt;/span&gt;
at December&#160;31, 2024 and $&lt;span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zboG2jZNi8lk" title="Allowance for credit losses"&gt;528,030&lt;/span&gt;
at December&#160;31, 2023. Credit loss reserves are maintained based on a variety of factors, including the length of time
receivables are past due and a detailed review of certain individual customer accounts. The Company also establishes other
allowances to provide for estimated customer rebates and other expected customer deductions. These allowances totaled $&lt;span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_c20241231_ztbX3Z9Q2YI1" title="Allowance for customer rebates and deductions"&gt;4,897&lt;/span&gt;
at December&#160;31, 2024 and $&lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_c20231231_zYAfTFwYXIgb" title="Allowance for customer rebates and deductions"&gt;3,820&lt;/span&gt;
at December&#160;31, 2023. If circumstances related to customers change, estimates of the recoverability of receivables would be
further adjusted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000598"
      unitRef="USD">12408819</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000600"
      unitRef="USD">8474965</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000602"
      unitRef="USD">6805761</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000604"
      unitRef="USD">624448</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000606"
      unitRef="USD">202941</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000608"
      unitRef="USD">1173441</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000610"
      unitRef="USD">528030</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000612"
      unitRef="USD">4897</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000614"
      unitRef="USD">3820</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000616">&lt;p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_zuU61DQo9Vdk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zateYLuhUsxd"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventories are stated at the lower of cost or net
realizable value, with cost computed on a first-in, first-out basis. Inventories consist primarily of finished goods, and also include
an immaterial amount of raw materials and related packaging components. The Company recorded inventory obsolescence expense of $&lt;span id="xdx_901_eus-gaap--InventoryWriteDown_c20240101__20241231_zCTwYKZUNe6f" title="Inventory obsolescence expense"&gt;521,757&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--InventoryWriteDown_c20230101__20231231_zovbIFGgdTr1" title="Inventory obsolescence expense"&gt;406,812&lt;/span&gt; during the years ended December&#160;31, 2024 and 2023, respectively. The allowance for obsolete and slow-moving inventory
had a balance of $&lt;span id="xdx_901_eus-gaap--InventoryValuationReserves_iI_c20241231_zc074IrXpNph" title="Allowance for obsolete and slow-moving inventory"&gt;534,549&lt;/span&gt; at December&#160;31, 2024 and $&lt;span id="xdx_902_eus-gaap--InventoryValuationReserves_iI_c20231231_zyOJP02HiKF4" title="Allowance for obsolete and slow-moving inventory"&gt;446,917&lt;/span&gt; at December&#160;31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000618"
      unitRef="USD">521757</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000620"
      unitRef="USD">406812</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000622"
      unitRef="USD">534549</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000624"
      unitRef="USD">446917</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000626">&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zH8nmSqF4w6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zb79f3OI2Ddf"&gt;Property and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment are stated at cost, less accumulated
depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the related assets, ranging
from &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember_zP6XLLBlsNy2" title="Estimated useful lives::XDX::P2Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0628"&gt;two&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_c20241231__srt--RangeAxis__srt--MaximumMember_zZiC3dzkTRu6" title="Estimated useful lives"&gt;ten years&lt;/span&gt;. Below is a summary of property and equipment for the periods presented:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zqRliQNnUB1d" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zQKNzkO8FU9g" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Useful&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_zjuto5QPegHf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zwcZH3iFbWbi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVlyBmKFNc29" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; padding-left: 0pt"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center; padding-left: 0pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zpfitIsrj9Ak" title="Useful Life"&gt;3&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zuDth0z9viv1" title="Useful Life"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;295,963&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;194,788&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zrthfTCFxxhk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zs8CneFLDiB6" title="Useful Life"&gt;3&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_z2kIMVBvCVw2" title="Useful Life"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;216,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;201,785&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zJ56vuocB1Ih" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zeQhlRy083Za" title="Useful Life"&gt;5&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zbWxC8rWUL7c" title="Useful Life"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;346,508&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zLVSo8nF94k1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_z3ksmxolhQ3c" title="Useful Life"&gt;2&lt;/span&gt;-&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zfSPGPNrx4ye" title="Useful Life"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;181,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134,170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zkzxzTMzV3c3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Internal use software&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 0pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_ztngxXxxLfR" title="Useful life"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0662"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,618,999&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz6Up_znA7HeNhBpG8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,040,930&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,454,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz6Up_z5x7dqCdRrr7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(608,613&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,196,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz6Up_zph1Y9kIAJq5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;432,317&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,257,956&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zm4xRmkwAxS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation expense related to property and equipment
was $&lt;span id="xdx_906_eus-gaap--Depreciation_c20240101__20241231_zjo3LfxdWLG2" title="Depreciation"&gt;1,031,487&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--Depreciation_c20230101__20231231_z0BnoG2WACQ3" title="Depreciation"&gt;456,138&lt;/span&gt; during the year ended December&#160;31, 2024 and 2023, respectively. Depreciation expense for the year ended
December&#160;31, 2024 included a non-cash charge of $&lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_z8IlaiQpIepi" title="Depreciation"&gt;506,836&lt;/span&gt; to write-off the remaining net book value of certain internal use software
assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      id="Fact000630">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000632">&lt;p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zqRliQNnUB1d" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zQKNzkO8FU9g" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Useful&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_zjuto5QPegHf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zwcZH3iFbWbi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zVlyBmKFNc29" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; padding-left: 0pt"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center; padding-left: 0pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zpfitIsrj9Ak" title="Useful Life"&gt;3&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zuDth0z9viv1" title="Useful Life"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;295,963&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;194,788&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zrthfTCFxxhk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zs8CneFLDiB6" title="Useful Life"&gt;3&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_z2kIMVBvCVw2" title="Useful Life"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;216,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;201,785&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zJ56vuocB1Ih" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zeQhlRy083Za" title="Useful Life"&gt;5&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zbWxC8rWUL7c" title="Useful Life"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;346,508&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zLVSo8nF94k1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_z3ksmxolhQ3c" title="Useful Life"&gt;2&lt;/span&gt;-&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zfSPGPNrx4ye" title="Useful Life"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;181,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134,170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zkzxzTMzV3c3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Internal use software&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 0pt"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_ztngxXxxLfR" title="Useful life"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0662"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,618,999&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz6Up_znA7HeNhBpG8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,040,930&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,454,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz6Up_z5x7dqCdRrr7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(608,613&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,196,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz6Up_zph1Y9kIAJq5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;432,317&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,257,956&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember"
      id="Fact000637">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember"
      id="Fact000639">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="Fact000634"
      unitRef="USD">295963</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="Fact000635"
      unitRef="USD">194788</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember"
      id="Fact000644">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember"
      id="Fact000646">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="Fact000641"
      unitRef="USD">216491</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="Fact000642"
      unitRef="USD">201785</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember"
      id="Fact000651">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember"
      id="Fact000653">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000648"
      unitRef="USD">346508</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000649"
      unitRef="USD">304338</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember"
      id="Fact000658">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember"
      id="Fact000660">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000655"
      unitRef="USD">181968</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000656"
      unitRef="USD">134170</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_InternalUseSoftwareMember"
      id="Fact000665">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_InternalUseSoftwareMember"
      decimals="0"
      id="Fact000663"
      unitRef="USD">1618999</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000667"
      unitRef="USD">1040930</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000668"
      unitRef="USD">2454080</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000670"
      unitRef="USD">608613</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000671"
      unitRef="USD">1196124</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000673"
      unitRef="USD">432317</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000674"
      unitRef="USD">1257956</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000676"
      unitRef="USD">1031487</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000678"
      unitRef="USD">456138</us-gaap:Depreciation>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2024-01-012024-12-31_custom_InternalUseSoftwareMember"
      decimals="0"
      id="Fact000680"
      unitRef="USD">506836</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:InternalUseSoftwarePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000682">&lt;p id="xdx_849_eus-gaap--InternalUseSoftwarePolicy_zrF1Mx2vgan" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zIKZP3FaoK1g"&gt;Internal Use Software&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounted for costs incurred to develop
or acquire computer software for internal use in accordance with ASC Topic 350-40, Intangibles &#x2013; Goodwill and Other. The Company
capitalized the costs incurred during the application development stage, which generally included third-party developer fees to design
the software configuration and interfaces, coding, installation and testing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company began capitalization of qualifying costs
when both the preliminary project stage was completed and management authorized further funding for the completion of the project. Costs
incurred during the preliminary project stage along with post implementation stages of internal-use computer software was expensed as
incurred. The Company also capitalized costs related to specific upgrades and enhancements when it was probable the expenditures would
result in additional functionality. Capitalized development costs were classified as &#x201c;Property and equipment, net&#x201d; in the
Consolidated Balance Sheets and were depreciated over the estimated useful life of the software, which was generally &lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_c20241231_zEG0ftpJryRl" title="Software, estimated useful life"&gt;five years&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="AsOf2024-12-31" id="Fact000684">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000686">&lt;p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z1WdfEV3R3Rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zJk3m1hNnfCe"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The excess of purchase price over the fair value
of identifiable net assets acquired in business combinations is recorded as goodwill. As of December&#160;31, 2024 and December&#160;31,
2023, all of the Company&#x2019;s goodwill relates to the acquisition of Scendia Biologics, LLC (&#x201c;Scendia&#x201d;), which is included
in the Sanara Surgical segment. Goodwill has an indefinite useful life and is not amortized. Goodwill is tested annually as of December&#160;31
for impairment, or more frequently if circumstances indicate impairment may have occurred. The Company may first perform a qualitative
assessment to determine if it is more likely than not that the fair value of the reporting unit is less than the respective carrying
value. If it is determined that it is more likely than not that a reporting unit&#x2019;s fair value is less than its carrying value,
then the Company will determine the fair value of the reporting unit and record an impairment charge for the difference between fair
value and carrying value (not to exceed the carrying amount of goodwill). &lt;span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_dxL_c20240101__20241231_zf8A9BY2laia" title="Impairment of goodwill::XDX::-"&gt;&lt;span id="xdx_902_eus-gaap--GoodwillImpairmentLoss_dxL_c20230101__20231231_zSP9gN96Qp8" title="Impairment of goodwill::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0688"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0690"&gt;No&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; impairment was recorded during the year ended December&#160;31,
2024 or 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000692">&lt;p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_z0H17BQcYr0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zesGLPv7Z3n7"&gt;Intangible Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Intangible assets are stated at cost of acquisition
less accumulated amortization and impairment loss, if any. Cost of acquisition includes the purchase price and any cost directly attributable
to bringing the asset to its working condition for the intended use. The Company amortizes its finite-lived intangible assets on a straight-line
basis over the estimated useful life of the respective assets which is generally the life of the related patents or licenses, seven years
for customer relationships and five years for assembled workforces. See Note 5 for more information on intangible assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000694">&lt;p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQQvnP4shxjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zbyigOjCH2M9"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Long-lived assets, including certain identifiable
intangibles held and to be used by the Company, are reviewed for impairment whenever events or changes in circumstances indicate that
the carrying amount of such assets may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets
based on estimated future cash flows and the estimated liquidation value of such long-lived assets and provides for impairment if such
undiscounted cash flows are insufficient to recover the carrying amount of the long-lived assets. If impairment exists, an adjustment
is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value.
Fair values are determined based on quoted market values, undiscounted cash flows or internal and external appraisals, as applicable.
Assets to be disposed of are carried at the lower of carrying value or estimated fair value less cost to sell. A $&lt;span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn5n6_c20240101__20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--InternalUseSoftwareMember_zFeTMhSeGVo3" title="Depreciation"&gt;0.5&lt;/span&gt; million non-cash
charge to write-off the remaining net book value of certain THP internal use software assets was recorded during the year ended December&#160;31,
2024. &lt;span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20230101__20231231_z0RhOg8Dufg1" title="Impairment of long-lived assets"&gt;No&lt;/span&gt; impairment was recorded during the year ended December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2024-01-012024-12-31_custom_InternalUseSoftwareMember"
      decimals="-5"
      id="Fact000696"
      unitRef="USD">500000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000698"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000700">&lt;p id="xdx_84B_eus-gaap--EquityMethodInvestmentsPolicy_zCGU5SwufEW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_ztdSbWsdtScl"&gt;Investments in Equity Securities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s equity investments consist of
nonmarketable equity securities in privately held companies without readily determinable fair values. Unless accounted for under the
equity method of accounting, the investments are reported at cost minus impairment, if any, plus or minus changes resulting from observable
price changes in orderly transactions for the identical or similar investment in the same issuer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company applies the equity method of accounting
to investments when it has significant influence, but not controlling interest, in the investee. Judgment regarding the level of influence
over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors,
participation in policy-making decisions and material intercompany transactions. As discussed further in Note 6 as of December&#160;31,
2024, the Company had two investments that are recorded applying the equity method of accounting. The Company&#x2019;s proportionate share
of the net income (loss) resulting from these investments is reported under the line item captioned &#x201c;Share of losses from equity
method investments&#x201d; in the Company&#x2019;s Consolidated Statements of Operations. The Company&#x2019;s equity method investments
are adjusted each period for the Company&#x2019;s share of the investee&#x2019;s income or loss and dividend paid, if any. The Company
classifies distributions received from its equity method investments using the cumulative earnings approach in the Company&#x2019;s Consolidated
Statements of Cash Flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has reviewed the carrying value of its
investments and has determined there was no impairment or observable price changes as of or for the year ended December&#160;31, 2024
and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000702">&lt;p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z8rBtA5vItM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zccdqe3IkqB9"&gt;Fair Value Measurement&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As defined in ASC Topic 820, Fair Value Measurement
(&#x201c;ASC 820&#x201d;), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market
participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the
valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair
value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted
prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level
3 measurement). This fair value measurement framework applies at both the initial and subsequent measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The three levels of the fair value hierarchy defined
by ASC 820 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 &#x2013; Quoted prices are available in active
markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or
liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of
financial instruments such as exchange-traded derivatives, marketable securities and listed equities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 &#x2013; Pricing inputs are other than quoted
prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes
those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard
models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current
market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these
assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are
supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include
nonexchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 &#x2013; Pricing inputs include significant
inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that
result in management&#x2019;s best estimate of fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying amounts of cash, accounts receivable,
accounts payable and accrued expenses, other than acquisition-related expenses, approximate fair value because of the short-term nature
of these instruments. The fair value of acquisition-related accrued expenses is categorized as Level 2 of the fair value hierarchy. The
value of these instruments has been estimated using discounted cash flow analysis based on the Company&#x2019;s incremental borrowing
rate. The carrying value of the Company&#x2019;s CRG Term Loan (defined below), which has a fixed interest rate approximates fair value
based on instruments with similar terms (Level 2 inputs). The fair value of the contingent earnout consideration and the acquisition
date fair value of goodwill and intangibles related to the acquisitions discussed in Notes 3 and 5 are based on Level 3 inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Liabilities for contingent consideration for the
Precision Healing merger, acquisition of Scendia and Applied Asset Purchase (defined below) (see Note 3 for more information) are measured
at fair value each reporting period, with the acquisition-date fair value included as part of the consideration transferred. The contingent
consideration for the Scendia acquisition was settled as of September 30, 2024, and the final earnout payment of approximately $1.1 million
was paid in cash in October 2024. The Precision Healing contingent consideration is classified as a liability at its fair value at each
reporting period due to the fact that the monetary value of the shares to be issued is predominantly dependent on the exercise contingency
(i.e., revenue targets). Subsequent changes in fair value of contingent consideration related to the Precision Healing merger are reported
under the line item captioned &#x201c;Change in fair value of earnout liabilities&#x201d; in the Company&#x2019;s Consolidated Statements
of Operations. The Company reviewed the thresholds necessary to trigger a payment on the Precision Healing earnout as of December 31,
2024 and deemed the thresholds to be unachievable by the sellers, therefore, the remaining fair value on the earnout was reduced to zero.
Due to the Applied Asset Purchase being accounted for as an asset acquisition and given that the transaction did not include contingent
shares, subsequent revaluations of contingent consideration for the Applied Asset Purchase results in an adjustment to the contingent
consideration liability and the intellectual property intangible asset with a cumulative catch-up amortization adjustment. The current
year change in fair value of earnout liability below is as a result of a net decrease in the estimated fair value of the earnout liability
established at the time of the Company&#x2019;s Precision Healing merger. The current year revaluation of earnout liability below is a
result of a decrease in the estimated value of the earnout liability established at the time of the Applied Asset Purchase. The following
table sets forth a summary of the changes in fair value for the Level 3 contingent earnout considerations.&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zyMX4K6dm2g4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zlfDaPl3CVAl" style="display: none"&gt;SCHEDULE
OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_495_20240101__20241231_zGPyhUGHNZDf" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_zZYTfAj7HLie" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; padding-left: 0pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,823,001&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_zooAX9QzVyf6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 9pt; padding-left: 0pt"&gt;Change in fair value of earnout liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,938,451&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability_zNjJ5pGNlySg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 9pt; padding-left: 0pt"&gt;Revaluation of earnout liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(51,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements_zETuDA62VB44" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt"&gt;Settlements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,085,549&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_zbXliTDqnde7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;748,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zR31WoaaVx26" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000704">&lt;p id="xdx_898_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zyMX4K6dm2g4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zlfDaPl3CVAl" style="display: none"&gt;SCHEDULE
OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_495_20240101__20241231_zGPyhUGHNZDf" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_zZYTfAj7HLie" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; padding-left: 0pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,823,001&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_zooAX9QzVyf6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 9pt; padding-left: 0pt"&gt;Change in fair value of earnout liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,938,451&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability_zNjJ5pGNlySg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 9pt; padding-left: 0pt"&gt;Revaluation of earnout liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(51,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements_zETuDA62VB44" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt"&gt;Settlements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,085,549&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_zbXliTDqnde7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;748,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000706"
      unitRef="USD">3823001</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000708"
      unitRef="USD">-1938451</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <SMTI:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000710"
      unitRef="USD">-51000</SMTI:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability>
    <SMTI:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000712"
      unitRef="USD">-1085549</SMTI:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000714"
      unitRef="USD">748001</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000716">&lt;p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zXVrVoI0j0v" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zQLkHdchx9E3"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Income taxes are accounted for under the asset and
liability method, whereby deferred income taxes are recorded for temporary differences between financial statement carrying amounts and
the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years
in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all the
deferred tax asset will not be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000718">&lt;p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zW7kGy8BeOM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z2uC0X764h8d"&gt;Share-based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for share-based compensation
to employees and nonemployees in accordance with ASC Topic 718, Compensation &#x2013; Stock Compensation. Share-based compensation is
measured at the grant date, based on the fair value of the award, and is recognized as expense over the stipulated vesting period, if
any. The Company estimates the fair value of share-based payments using the Black-Scholes option-pricing model for common stock options
and warrants, and the closing price of the Company&#x2019;s common stock for grants of common stock, including restricted stock awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000720">&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zsaYDcSy2eR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zmgxSQsBIQN5"&gt;Research and Development Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;)
expenses consist of personnel-related expenses, including salaries, share-based compensation and benefits for all personnel directly
engaged in R&amp;amp;D activities, contracted services, materials, prototype expenses and allocated overhead, which is comprised of compensation
and benefits, lease expense and other facilities-related costs. R&amp;amp;D expenses include costs related to enhancements to the Company&#x2019;s
currently available products and additional investments in the product and platform development pipeline. The Company expenses R&amp;amp;D
costs as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <SMTI:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000722">&lt;p id="xdx_84A_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_z7hRzsnmClZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z1yk2PchwuZ1"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2016, the Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, Financial Instruments - Credit Losses (Topic
326). This update amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate
credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The Company
adopted the new guidance effective January 1, 2023. The adoption did not have a material impact on the Company&#x2019;s consolidated financial
position, results of operations or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2023, FASB issued ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;), which requires disclosure of incremental
segment information on an annual and interim basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and
interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company adopted the new guidance
effective December 31, 2024. The adoption did not have a material impact on the Company&#x2019;s consolidated financial position, results
of operations or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</SMTI:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000724">&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3IibpPc84ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z4TJcBV8RiWa"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, FASB issued ASU 2023-09, Income
Taxes (Topic 740): Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;), which expands the disclosure required for income
taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the effect of this pronouncement on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2024, FASB issued ASU 2024-03, Income
Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,
which requires new disclosures providing further detail of a company&#x2019;s income statement expense line items. ASU 2024-03 is effective
for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is
permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AssetAcquisitionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000726">&lt;p id="xdx_80F_eus-gaap--AssetAcquisitionTextBlock_zg4P3jX7T053" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 3 &#x2013; &lt;span id="xdx_82E_zib08xopEAP5"&gt;APPLIED ASSET PURCHASE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 1, 2023, the Company entered into
an Asset Purchase Agreement (the &#x201c;Applied Purchase Agreement&#x201d;) by and among the Company, as guarantor, Sanara MedTech Applied
Technologies, LLC, a Texas limited liability company and wholly owned subsidiary of the Company (&#x201c;SMAT&#x201d;), The Hymed Group
Corporation, a Delaware corporation (&#x201c;Hymed&#x201d;), Applied Nutritionals, LLC, a Delaware limited liability company (&#x201c;Applied&#x201d;,
and together with Hymed, the &#x201c;Sellers&#x201d;), and Dr. George D. Petito (the &#x201c;Owner&#x201d;), pursuant to which SMAT acquired
certain assets of the Sellers and the Owner, including, among others, the Sellers&#x2019; and Owner&#x2019;s inventory, intellectual property,
manufacturing and related equipment, goodwill, rights and claims, other than certain excluded assets, all as more specifically set forth
in the Applied Purchase Agreement (collectively, the &#x201c;Applied Purchased Assets&#x201d;), and assumed certain Assumed Liabilities
(as defined in the Applied Purchase Agreement), upon the terms and subject to the conditions set forth in the Applied Purchase Agreement
(such transaction, the &#x201c;Applied Asset Purchase&#x201d;). The Applied Purchased Assets include the underlying intellectual property
of, as well as the rights to manufacture and sell, certain hydrolyzed collagen products, including CellerateRX Surgical, for human wound
care use.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Applied Purchased Assets were purchased for an
initial aggregate purchase price of $&lt;span id="xdx_90E_eus-gaap--PaymentsToAcquireProductiveAssets_pn4n6_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zB9Il9w4xY8j" title="Assets purchase price"&gt;15.25&lt;/span&gt; million, consisting of (i) $&lt;span id="xdx_905_eus-gaap--AssetAcquisitionConsiderationTransferredOtherAssets_pn4n6_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--CashClosingConsiderationMember_zUdzufzCtdKj" title="Cash consideration paid"&gt;9.75&lt;/span&gt; million in cash (the &#x201c;Cash Closing Consideration&#x201d;),
(ii) &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--StockClosingConsiderationMember_zDXhqTuf55Ll" title="Shares issued as consideration"&gt;73,809&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;Stock Closing Consideration&#x201d;) with an agreed upon value of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_pn5n6_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--StockClosingConsiderationMember_zt97hdZrMyoi" title="Value of shares issued as consideration"&gt;3.0&lt;/span&gt;
million and (iii) $&lt;span id="xdx_909_eus-gaap--OtherLoansPayable_iI_pn5n6_c20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_z1OsLdc0mT1k" title="Installment payable"&gt;2.5&lt;/span&gt; million in cash (the &#x201c;Installment Payments&#x201d;), to be paid in four equal installments on each of the
next four anniversaries of the closing of the Applied Asset Purchase (the &#x201c;Closing&#x201d;). The first Installment Payment of $&lt;span id="xdx_900_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zyabbarSrsZg" title="Payment of installment"&gt;625,000&lt;/span&gt;
was made in August 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the Closing, the Company licensed certain
of its products from Applied through a sublicense agreement (the &#x201c;Sublicense Agreement&#x201d;) with CGI Cellerate RX, LLC (&#x201c;CGI
Cellerate RX&#x201d;), a related party (see Note 13 for additional information regarding transactions with related parties). Pursuant
to the Sublicense Agreement, the Company had an exclusive, world-wide sublicense to distribute certain hydrolyzed collagen products,
including CellerateRX Surgical, into the surgical and wound care markets. In connection with the Applied Asset Purchase, Applied assigned
its license agreement with CGI Cellerate RX to SMAT (the &#x201c;License Agreement&#x201d;), and on October 10, 2024, the License Agreement
and the Sublicense Agreement were terminated for no additional consideration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition to the Cash Closing Consideration, Stock
Closing Consideration and Installment Payments, the Applied Purchase Agreement provides that the Sellers are entitled to receive up to
an additional $&lt;span id="xdx_90B_ecustom--EarnoutPayable_iI_pn5n6_c20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zHnd4Q7GIKOi" title="Earnout payable"&gt;10.0&lt;/span&gt; million (the &#x201c;Applied Earnout&#x201d;), which is payable to the Sellers in cash, upon the achievement of certain
performance thresholds relating to SMAT&#x2019;s collections from net sales of a collagen-based product currently under development. Upon
expiration of the seventh anniversary of the Closing, to the extent the Sellers have not earned the entirety of the Applied Earnout,
SMAT shall pay the Sellers a pro-rata amount of the Applied Earnout based on collections from net sales of the product, with such amount
to be due credited against any Applied Earnout payments already made by SMAT (the &#x201c;True-Up Payment&#x201d;). The Applied Earnout,
minus the True-Up Payment and any Applied Earnout payments already made by SMAT, may be earned at any point in the future, including
after the True-Up Payment is made.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the Applied Asset Purchase and
pursuant to the Applied Purchase Agreement, effective August 1, 2023, the Company entered into a professional services agreement (the
&#x201c;Petito Services Agreement&#x201d;) with the Owner, pursuant to which the Owner, as an independent contractor, agreed to provide
certain services to the Company, including, among other things, assisting with the development of products already in development and
assisting with research, development, formulation, invention and manufacturing of any future products (the &#x201c;Petito Services&#x201d;).
&lt;span id="xdx_90C_ecustom--PurchaseAgreementDescription_c20240101__20241231_zDR5wgh9ebt9" title="Purchase agreement description"&gt;As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of
the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain
products the Owner develops or co-develops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first
$50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%)
on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv)
$500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in
cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described
in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Petito Services Agreement has an initial term
of three years and is subject to automatic successive one-month renewals unless earlier terminated in accordance with its terms. The
Petito Services Agreement may be terminated upon the Owner&#x2019;s death or disability or by the Company or the Owner &#x201c;For Cause&#x201d;
(as defined in the Petito Services Agreement); provided, however, that the base salary described in (i) of the foregoing paragraph shall
survive termination through the three-year initial term and the royalty payments and incentive payments described in (ii)-(v) of the
foregoing paragraph shall survive termination of the Petito Services Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As the contingent consideration was negotiated as
part of the transfer of assets, the contingent obligation was measured at fair value and included in the total purchase consideration
transferred. Accordingly, since the Applied Asset Purchase was accounted for as an asset acquisition and did not include contingent shares,
the contingent consideration is classified as a liability at its estimated fair value at each reporting period with subsequent revaluations
recognized as an adjustment to the intellectual property intangible asset and the earnout liability with a cumulative catch-up amortization
adjustment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--AssetAcquisitionTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zxJytX6QcDnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The total purchase consideration for the Applied
Asset Purchase as determined by the Company was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_ztC3meezwqk9" style="display: none"&gt;SCHEDULE
OF ASSET PURCHASE CONSIDERATIONS&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 92%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Consideration&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Equity Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_z2dmqgq7z4L2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Dollar Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AssetAcquisitionConsiderationTransferredOtherAssets_maAACTzk9b_zza98cZNX7N" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left; padding-left: 0pt"&gt;Cash Closing Consideration&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;9,750,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_maAACTzk9b_zwYdNodpNAke" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Fair value of Stock Closing Consideration&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zXDdhJapU3eg" title="Equity Shares"&gt;73,809&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,089,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments_maAACTzk9b_zw7h3kxU9WI3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;Fair value of Installment Payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,040,808&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AssetAcquisitionConsiderationTransferredCashPaidForInventory_maAACTzk9b_zkrHiYSUkVof" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Cash paid for inventory&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments_maAACTzk9b_zPlGwUIoSCx1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Fair value of Petito Services Agreement defined payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;825,834&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_maAACTzk9b_zN89THawGPna" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Fair value of Petito Services Agreement contingent consideration&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;893,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_maAACTzk9b_zktigTQotIah" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Direct transaction costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;162,743&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferred_iT_mtAACTzk9b_znTrnBD5j554" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 9pt; padding-left: 0pt"&gt;Total purchase consideration&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;16,792,037&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zuJeAk47Ts45" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Based on guidance provided by ASC 805, Business Combinations
(&#x201c;ASC 805&#x201d;), the Company recorded the Applied Asset Purchase as an asset acquisition due to the determination that substantially
all the fair value of the assets acquired was concentrated in a group of similar identifiable assets. The Company believes the &#x201c;substantially
all&#x201d; criterion was met with respect to the acquired intellectual property being the only significant asset acquired. Accordingly,
the Company accounted for the transaction as an asset acquisition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The purchase consideration, plus transaction costs,
was allocated to the individual assets according to their fair values as a percentage of the total fair value of the assets purchased,
with no goodwill recognized. Based on the estimated fair value of the gross assets acquired, the total fair value of the net assets acquired
was primarily attributable to, and classified as, finite-lived intellectual property in the fourth quarter of 2023. The total purchase
consideration was allocated based on the relative estimated fair value of such assets as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zRoZpPa3rsZ2" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_z7wHAGAOoyk" style="display: none"&gt;SCHEDULE
OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231__us-gaap--BusinessAcquisitionAxis__custom--AppliedAssetPurchaseAgreementMember_zc9DgPk03U69" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_maBCRIAz5eD_zp9BIsLjBOi7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; padding-left: 0pt"&gt;Inventory&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;30,007&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment_iI_maBCRIAz5eD_z3Yc4pd783Ae" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,062&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty_iI_maBCRIAz5eD_zN0Sy7fTNyt3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Intellectual property&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;16,728,968&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iTI_mtBCRIAz5eD_zuI1kuvDP4p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 9pt; padding-left: 0pt"&gt;Net assets acquired&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;16,792,037&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zovDFZZpCEz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember"
      decimals="-4"
      id="Fact000728"
      unitRef="USD">15250000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember_custom_CashClosingConsiderationMember"
      decimals="-4"
      id="Fact000730"
      unitRef="USD">9750000</us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember_custom_StockClosingConsiderationMember"
      decimals="INF"
      id="Fact000732"
      unitRef="Shares">73809</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember_custom_StockClosingConsiderationMember"
      decimals="-5"
      id="Fact000734"
      unitRef="USD">3000000.0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:OtherLoansPayable
      contextRef="AsOf2023-08-01_custom_AppliedAssetPurchaseAgreementMember"
      decimals="-5"
      id="Fact000736"
      unitRef="USD">2500000</us-gaap:OtherLoansPayable>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="From2024-08-012024-08-31_custom_AppliedAssetPurchaseAgreementMember"
      decimals="0"
      id="Fact000738"
      unitRef="USD">625000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <SMTI:EarnoutPayable
      contextRef="AsOf2023-08-01_custom_AppliedAssetPurchaseAgreementMember"
      decimals="-5"
      id="Fact000740"
      unitRef="USD">10000000.0</SMTI:EarnoutPayable>
    <SMTI:PurchaseAgreementDescription contextRef="From2024-01-01to2024-12-31" id="Fact000742">As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of
the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain
products the Owner develops or co-develops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first
$50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%)
on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv)
$500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in
cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described
in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.</SMTI:PurchaseAgreementDescription>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="From2024-01-012024-12-31_custom_AppliedAssetPurchaseAgreementMember"
      id="Fact000744">&lt;p id="xdx_898_eus-gaap--AssetAcquisitionTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zxJytX6QcDnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The total purchase consideration for the Applied
Asset Purchase as determined by the Company was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_ztC3meezwqk9" style="display: none"&gt;SCHEDULE
OF ASSET PURCHASE CONSIDERATIONS&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 92%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Consideration&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Equity Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_z2dmqgq7z4L2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Dollar Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AssetAcquisitionConsiderationTransferredOtherAssets_maAACTzk9b_zza98cZNX7N" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left; padding-left: 0pt"&gt;Cash Closing Consideration&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;9,750,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_maAACTzk9b_zwYdNodpNAke" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Fair value of Stock Closing Consideration&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zXDdhJapU3eg" title="Equity Shares"&gt;73,809&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,089,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments_maAACTzk9b_zw7h3kxU9WI3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;Fair value of Installment Payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,040,808&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AssetAcquisitionConsiderationTransferredCashPaidForInventory_maAACTzk9b_zkrHiYSUkVof" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Cash paid for inventory&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments_maAACTzk9b_zPlGwUIoSCx1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Fair value of Petito Services Agreement defined payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;825,834&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_maAACTzk9b_zN89THawGPna" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Fair value of Petito Services Agreement contingent consideration&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;893,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetAcquisitionConsiderationTransferredTransactionCost_maAACTzk9b_zktigTQotIah" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Direct transaction costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;162,743&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferred_iT_mtAACTzk9b_znTrnBD5j554" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 9pt; padding-left: 0pt"&gt;Total purchase consideration&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;16,792,037&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember"
      decimals="0"
      id="Fact000746"
      unitRef="USD">9750000</us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember"
      decimals="INF"
      id="Fact000750"
      unitRef="Shares">73809</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember"
      decimals="0"
      id="Fact000748"
      unitRef="USD">3089645</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <SMTI:AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember"
      decimals="0"
      id="Fact000752"
      unitRef="USD">2040808</SMTI:AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments>
    <SMTI:AssetAcquisitionConsiderationTransferredCashPaidForInventory
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember"
      decimals="0"
      id="Fact000754"
      unitRef="USD">30007</SMTI:AssetAcquisitionConsiderationTransferredCashPaidForInventory>
    <SMTI:AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember"
      decimals="0"
      id="Fact000756"
      unitRef="USD">825834</SMTI:AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember"
      decimals="0"
      id="Fact000758"
      unitRef="USD">893000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember"
      decimals="0"
      id="Fact000760"
      unitRef="USD">162743</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember"
      decimals="0"
      id="Fact000762"
      unitRef="USD">16792037</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="From2024-01-012024-12-31_custom_AppliedAssetPurchaseAgreementMember"
      id="Fact000764">&lt;p id="xdx_892_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hus-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zRoZpPa3rsZ2" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_z7wHAGAOoyk" style="display: none"&gt;SCHEDULE
OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231__us-gaap--BusinessAcquisitionAxis__custom--AppliedAssetPurchaseAgreementMember_zc9DgPk03U69" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_maBCRIAz5eD_zp9BIsLjBOi7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; padding-left: 0pt"&gt;Inventory&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;30,007&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment_iI_maBCRIAz5eD_z3Yc4pd783Ae" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,062&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty_iI_maBCRIAz5eD_zN0Sy7fTNyt3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Intellectual property&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;16,728,968&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iTI_mtBCRIAz5eD_zuI1kuvDP4p" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 9pt; padding-left: 0pt"&gt;Net assets acquired&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;16,792,037&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="AsOf2024-12-31_custom_AppliedAssetPurchaseAgreementMember"
      decimals="0"
      id="Fact000766"
      unitRef="USD">30007</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment
      contextRef="AsOf2024-12-31_custom_AppliedAssetPurchaseAgreementMember"
      decimals="0"
      id="Fact000768"
      unitRef="USD">33062</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment>
    <SMTI:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty
      contextRef="AsOf2024-12-31_custom_AppliedAssetPurchaseAgreementMember"
      decimals="0"
      id="Fact000770"
      unitRef="USD">16728968</SMTI:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntellectualProperty>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="AsOf2024-12-31_custom_AppliedAssetPurchaseAgreementMember"
      decimals="0"
      id="Fact000772"
      unitRef="USD">16792037</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000774">&lt;p id="xdx_800_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zUMiHlNSvxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 4 &#x2013; &lt;span id="xdx_829_z6hnJIGhED54"&gt;CONVERTIBLE LOAN RECEIVABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with a potential equity investment
in an unaffiliated entity engaged in the development of certain surgical technologies, the Company entered into a convertible loan agreement
in July 2024 pursuant to which the Company loaned $&lt;span id="xdx_908_eus-gaap--AccountsNotesAndLoansReceivableNetCurrent_iI_c20240731__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z6tWJaLouo96" title="Accounts and financing receivable, after allowance for credit loss, current"&gt;1,079,391&lt;/span&gt; to the unaffiliated entity. The loan was initially set to be repaid on &lt;span id="xdx_907_eus-gaap--LoansHeldForSaleMaturityDate_iI_dd_c20240731__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zrz2NeNAiX9c" title="Maturity date"&gt;October 1, 2024&lt;/span&gt;. However, the Company extended the repayment date to &lt;span id="xdx_906_eus-gaap--LoansHeldForSaleMaturityDate_iI_dd_c20240731__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--LoanRestructuringModificationAxis__us-gaap--ExtendedMaturityMember_zyHUucI2h076" title="Extended maturity date"&gt;January 15, 2025&lt;/span&gt;. On October&#160;1, 2024, the Company began accruing
interest at &lt;span id="xdx_902_eus-gaap--LoansReceivableBasisSpreadOnVariableRate_iI_pid_dp_c20241001__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z8y8lKaCuoBh" title="Accruing interest"&gt;8&lt;/span&gt;% per annum. Pursuant to the convertible loan agreement, the Company had the option to convert the outstanding balance of
the loan into noncontrolling equity interests of the unaffiliated entity upon satisfactory completion of certain due diligence activities.
As of December&#160;31, 2024, the loan balance was $&lt;span id="xdx_90A_eus-gaap--OtherReceivablesNetCurrent_iI_c20241231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zHqtcgoRbx4j" title="Loan receivable"&gt;1,101,478&lt;/span&gt; including accrued interest and is recorded under the caption &#x201c;Convertible
loan receivable&#x201d; in the Company&#x2019;s Consolidated Balance Sheets. As of January 16, 2025, the loan was converted into equity
of the unaffiliated entity (see Note 15 for additional information).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="AsOf2024-07-31_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="Fact000776"
      unitRef="USD">1079391</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:LoansHeldForSaleMaturityDate
      contextRef="AsOf2024-07-31_us-gaap_ConvertibleDebtMember"
      id="Fact000778">2024-10-01</us-gaap:LoansHeldForSaleMaturityDate>
    <us-gaap:LoansHeldForSaleMaturityDate
      contextRef="AsOf2024-07-31_us-gaap_ConvertibleDebtMember_us-gaap_ExtendedMaturityMember"
      id="Fact000780">2025-01-15</us-gaap:LoansHeldForSaleMaturityDate>
    <us-gaap:LoansReceivableBasisSpreadOnVariableRate
      contextRef="AsOf2024-10-01_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="Fact000782"
      unitRef="Pure">0.08</us-gaap:LoansReceivableBasisSpreadOnVariableRate>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-12-31_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="Fact000784"
      unitRef="USD">1101478</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000786">&lt;p id="xdx_805_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zhNJtyzKTZYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 5 &#x2013; &lt;span id="xdx_827_z6JXM58yrwO8"&gt;GOODWILL AND INTANGIBLES, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfGoodwillTextBlock_zTGXs8g4Fheh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The changes in the carrying amount of the Company&#x2019;s
goodwill were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zI1uAHA97Hv3" style="display: none"&gt;SCHEDULE
OF CHANGES IN  CARRYING AMOUNT OF  GOODWILL&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BD_zKF7tAVcgPsd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43B_c20230101__20231231_eus-gaap--Goodwill_iS_zvp0tyZIiUJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; padding-left: 0pt"&gt;Balance as of December 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,601,781&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--GoodwillAcquiredDuringPeriod_zPUBBkKxaUY5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt"&gt;Acquisitions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43F_c20240101__20241231_eus-gaap--Goodwill_iS_zUmw9polaCCc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,601,781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_433_c20240101__20241231_eus-gaap--Goodwill_iS_zpjNYIFHzTXg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,601,781&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--GoodwillAcquiredDuringPeriod_zUREqh5ZTQYg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0pt"&gt;Acquisitions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0798"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43E_c20240101__20241231_eus-gaap--Goodwill_iE_zVslytut81yk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,601,781&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_433_c20240101__20241231_eus-gaap--Goodwill_iE_zC3jJ0CYOgQ3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,601,781&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A9_z8FhhmKtk4Xg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the change in reportable operating
segments, the Company reassessed goodwill with respect to the change in reportable operating segments as they are presented in this report.
Goodwill was recorded in connection with the acquisition of Scendia and is included entirely within the Sanara Surgical segment. The
Company&#x2019;s assessment determined that these changes, or any other matters noted, did not alter the Company&#x2019;s conclusion that
goodwill is not impaired as of December&#160;31, 2024 or 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zKnw0olVTIA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying values of the Company&#x2019;s intangible
assets were as follows for the periods presented:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zSbQCCzgJQoe" style="display: none"&gt;SCHEDULE
OF CARRYING VALUE OF INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Accumulated &lt;br/&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Accumulated &lt;br/&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-left: 0pt"&gt;Amortizable Intangible Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 22%; text-align: left; text-indent: 9pt; padding-left: 0pt"&gt;Patents and Other IP&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzacLpJoCB4f" style="width: 10%; text-align: right"&gt;38,009,240&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z34r0mrsgYCd" style="width: 10%; text-align: right"&gt;(5,008,856&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGD09bO2Heu8" style="width: 10%; text-align: right"&gt;33,000,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zU3Xvw5YNoJ4" style="width: 10%; text-align: right"&gt;38,570,549&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znSiCMFdFlF4" style="width: 10%; text-align: right"&gt;(3,181,186&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z9DMfstX9qC1" style="width: 10%; text-align: right"&gt;35,389,363&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Customer relationships and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_z0Q7LkAuznS4" style="text-align: right"&gt;7,948,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zboaEJaqV0w2" style="text-align: right"&gt;(3,007,118&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zTRhoMuzUnFb" style="text-align: right"&gt;4,941,181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zUufLULozobf" style="text-align: right"&gt;7,947,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zxdi5Ww7uDTg" style="text-align: right"&gt;(1,861,887&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zK66QEFscaT5" style="text-align: right"&gt;6,085,445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt"&gt;Product Licenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zIplH3ty2SOe" style="border-bottom: Black 1pt solid; text-align: right" title="Cost"&gt;4,793,879&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zGkzAqnxsnfa" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization"&gt;(1,728,668&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zeLKiobF3Wui" style="border-bottom: Black 1pt solid; text-align: right" title="Net"&gt;3,065,211&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zZszQyhQUOU4" style="border-bottom: Black 1pt solid; text-align: right" title="Cost"&gt;4,793,879&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zE5FhTtwgnV" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization"&gt;(1,342,626&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zKQICmYYa6Ek" style="border-bottom: Black 1pt solid; text-align: right" title="Net"&gt;3,451,253&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zTACvoj38QJd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;50,751,418&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z6bzJ0qtxY25" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;(9,744,642&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zXE2wVpemuB2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;41,006,776&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z0U8AtRQIQoj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;51,311,760&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zKA4Nl2Kmlci" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;(6,385,699&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z4lHAjeII1H" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;44,926,061&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z3qnmUBw0ZR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December&#160;31, 2024, the weighted-average
amortization period for finite-lived intangible assets was &lt;span id="xdx_904_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20240101__20241231_zeH8Z3WgqU0c" title="Weighted-average amortization period"&gt;14.6&lt;/span&gt; years. Amortization expense related to intangible assets was $&lt;span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_zPOYtVhC5IWc" title="Amortization of intangible assets"&gt;3,891,737&lt;/span&gt;
and $&lt;span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zOJ0pn353DX" title="Amortization of intangible assets"&gt;3,218,888&lt;/span&gt; for the year ended December&#160;31, 2024 and 2023, respectively. The estimated remaining amortization expense as of December&#160;31,
2024 for finite-lived intangible assets is as follows:&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zr0bTaT8mq06" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zKy7TUmt7uU5" style="display: none"&gt;SCHEDULE
OF FUTURE AMORTIZATION EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_498_20241231_zrea05s5Vkt1" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz6Rp_zPVZR6GPUrB6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 87%; text-align: left; padding-left: 0pt"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,894,221&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz6Rp_zqfIUhTZ1ei5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,876,965&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz6Rp_z1z70AMge649" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,763,113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz6Rp_zsA2WMrUjKS1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,722,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz6Rp_zdTCe818pr8e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,722,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANz6Rp_zb2hTvQcaMx2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;22,028,369&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz6Rp_z3mOAudjHYph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;41,006,776&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zbkNOpHLMLhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has reviewed the carrying value of intangible
assets and has determined there was no impairment during the year ended December&#160;31, 2024 or 2023.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000788">&lt;p id="xdx_89F_eus-gaap--ScheduleOfGoodwillTextBlock_zTGXs8g4Fheh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The changes in the carrying amount of the Company&#x2019;s
goodwill were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zI1uAHA97Hv3" style="display: none"&gt;SCHEDULE
OF CHANGES IN  CARRYING AMOUNT OF  GOODWILL&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BD_zKF7tAVcgPsd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43B_c20230101__20231231_eus-gaap--Goodwill_iS_zvp0tyZIiUJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; padding-left: 0pt"&gt;Balance as of December 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,601,781&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--GoodwillAcquiredDuringPeriod_zPUBBkKxaUY5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt"&gt;Acquisitions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43F_c20240101__20241231_eus-gaap--Goodwill_iS_zUmw9polaCCc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,601,781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_433_c20240101__20241231_eus-gaap--Goodwill_iS_zpjNYIFHzTXg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,601,781&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--GoodwillAcquiredDuringPeriod_zUREqh5ZTQYg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0pt"&gt;Acquisitions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0798"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43E_c20240101__20241231_eus-gaap--Goodwill_iE_zVslytut81yk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,601,781&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_433_c20240101__20241231_eus-gaap--Goodwill_iE_zC3jJ0CYOgQ3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,601,781&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000790"
      unitRef="USD">3601781</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000794"
      unitRef="USD">3601781</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000796"
      unitRef="USD">3601781</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000800"
      unitRef="USD">3601781</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000802"
      unitRef="USD">3601781</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000804">&lt;p id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zKnw0olVTIA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying values of the Company&#x2019;s intangible
assets were as follows for the periods presented:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zSbQCCzgJQoe" style="display: none"&gt;SCHEDULE
OF CARRYING VALUE OF INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Accumulated &lt;br/&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Accumulated &lt;br/&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-left: 0pt"&gt;Amortizable Intangible Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 22%; text-align: left; text-indent: 9pt; padding-left: 0pt"&gt;Patents and Other IP&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzacLpJoCB4f" style="width: 10%; text-align: right"&gt;38,009,240&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z34r0mrsgYCd" style="width: 10%; text-align: right"&gt;(5,008,856&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGD09bO2Heu8" style="width: 10%; text-align: right"&gt;33,000,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zU3Xvw5YNoJ4" style="width: 10%; text-align: right"&gt;38,570,549&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znSiCMFdFlF4" style="width: 10%; text-align: right"&gt;(3,181,186&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z9DMfstX9qC1" style="width: 10%; text-align: right"&gt;35,389,363&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Customer relationships and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_z0Q7LkAuznS4" style="text-align: right"&gt;7,948,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zboaEJaqV0w2" style="text-align: right"&gt;(3,007,118&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zTRhoMuzUnFb" style="text-align: right"&gt;4,941,181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zUufLULozobf" style="text-align: right"&gt;7,947,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zxdi5Ww7uDTg" style="text-align: right"&gt;(1,861,887&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsAndOtherMember_zK66QEFscaT5" style="text-align: right"&gt;6,085,445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt; padding-left: 0pt"&gt;Product Licenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zIplH3ty2SOe" style="border-bottom: Black 1pt solid; text-align: right" title="Cost"&gt;4,793,879&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zGkzAqnxsnfa" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization"&gt;(1,728,668&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zeLKiobF3Wui" style="border-bottom: Black 1pt solid; text-align: right" title="Net"&gt;3,065,211&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zZszQyhQUOU4" style="border-bottom: Black 1pt solid; text-align: right" title="Cost"&gt;4,793,879&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zE5FhTtwgnV" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization"&gt;(1,342,626&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zKQICmYYa6Ek" style="border-bottom: Black 1pt solid; text-align: right" title="Net"&gt;3,451,253&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zTACvoj38QJd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;50,751,418&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z6bzJ0qtxY25" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;(9,744,642&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zXE2wVpemuB2" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;41,006,776&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z0U8AtRQIQoj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;51,311,760&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_zKA4Nl2Kmlci" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;(6,385,699&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AmortizableIntangibleAssetsMember_z4lHAjeII1H" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;44,926,061&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="AsOf2024-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000805"
      unitRef="USD">38009240</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000806"
      unitRef="USD">-5008856</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000807"
      unitRef="USD">33000384</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000808"
      unitRef="USD">38570549</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000809"
      unitRef="USD">-3181186</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000810"
      unitRef="USD">35389363</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="AsOf2024-12-31_custom_CustomerRelationshipsAndOtherMember"
      decimals="0"
      id="Fact000811"
      unitRef="USD">7948299</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_custom_CustomerRelationshipsAndOtherMember"
      decimals="0"
      id="Fact000812"
      unitRef="USD">-3007118</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31_custom_CustomerRelationshipsAndOtherMember"
      decimals="0"
      id="Fact000813"
      unitRef="USD">4941181</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="AsOf2023-12-31_custom_CustomerRelationshipsAndOtherMember"
      decimals="0"
      id="Fact000814"
      unitRef="USD">7947332</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_custom_CustomerRelationshipsAndOtherMember"
      decimals="0"
      id="Fact000815"
      unitRef="USD">-1861887</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31_custom_CustomerRelationshipsAndOtherMember"
      decimals="0"
      id="Fact000816"
      unitRef="USD">6085445</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="AsOf2024-12-31_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact000818"
      unitRef="USD">4793879</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact000820"
      unitRef="USD">-1728668</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact000822"
      unitRef="USD">3065211</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="AsOf2023-12-31_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact000824"
      unitRef="USD">4793879</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact000826"
      unitRef="USD">-1342626</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31_us-gaap_LicensingAgreementsMember"
      decimals="0"
      id="Fact000828"
      unitRef="USD">3451253</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="AsOf2024-12-31_custom_AmortizableIntangibleAssetsMember"
      decimals="0"
      id="Fact000829"
      unitRef="USD">50751418</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_custom_AmortizableIntangibleAssetsMember"
      decimals="0"
      id="Fact000830"
      unitRef="USD">-9744642</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31_custom_AmortizableIntangibleAssetsMember"
      decimals="0"
      id="Fact000831"
      unitRef="USD">41006776</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="AsOf2023-12-31_custom_AmortizableIntangibleAssetsMember"
      decimals="0"
      id="Fact000832"
      unitRef="USD">51311760</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_custom_AmortizableIntangibleAssetsMember"
      decimals="0"
      id="Fact000833"
      unitRef="USD">-6385699</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31_custom_AmortizableIntangibleAssetsMember"
      decimals="0"
      id="Fact000834"
      unitRef="USD">44926061</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="From2024-01-01to2024-12-31" id="Fact000836">P14Y7M6D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000838"
      unitRef="USD">3891737</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000840"
      unitRef="USD">3218888</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000842">&lt;p id="xdx_89C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zr0bTaT8mq06" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zKy7TUmt7uU5" style="display: none"&gt;SCHEDULE
OF FUTURE AMORTIZATION EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_498_20241231_zrea05s5Vkt1" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz6Rp_zPVZR6GPUrB6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 87%; text-align: left; padding-left: 0pt"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,894,221&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz6Rp_zqfIUhTZ1ei5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,876,965&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz6Rp_z1z70AMge649" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,763,113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz6Rp_zsA2WMrUjKS1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,722,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz6Rp_zdTCe818pr8e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,722,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANz6Rp_zb2hTvQcaMx2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;22,028,369&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz6Rp_z3mOAudjHYph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;41,006,776&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000844"
      unitRef="USD">3894221</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000846"
      unitRef="USD">3876965</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000848"
      unitRef="USD">3763113</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000850"
      unitRef="USD">3722054</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000852"
      unitRef="USD">3722054</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000854"
      unitRef="USD">22028369</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000856"
      unitRef="USD">41006776</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:InvestmentHoldingsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000858">&lt;p id="xdx_800_eus-gaap--InvestmentHoldingsTextBlock_zhHL8Ob4jeL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 6 &#x2013; &lt;span id="xdx_823_zmKO8uNoPkod"&gt;INVESTMENTS IN EQUITY SECURITIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s equity investments consist of
nonmarketable equity securities in privately held companies without readily determinable fair values. Unless accounted for under the
equity method of accounting, the investments are reported at cost minus impairment, if any, plus or minus changes resulting from observable
price changes in orderly transactions for the identical or similar investment of the same issuer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;DirectDerm &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2020, the Company made a $&lt;span id="xdx_905_eus-gaap--LongTermInvestments_iI_c20200731__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_zwgzQ4yKNTQg" title="Long term investments"&gt;500,000&lt;/span&gt; long-term
investment to purchase certain nonmarketable securities consisting of &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20200731__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_z2rlGR01R9v5" title="Number of shares for purchase"&gt;7,142,857&lt;/span&gt; Series B-2 Preferred Shares of Direct Dermatology Inc.
(&#x201c;DirectDerm&#x201d;), representing approximately &lt;span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200731__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_zfbGfDRkcHK4" title="Ownership percentage"&gt;2.9&lt;/span&gt;% ownership of DirectDerm at that time. Through this investment, the Company
received exclusive rights to utilize DirectDerm&#x2019;s technology in all acute and post-acute care settings such as skilled nursing
facilities, home health and wound clinics. In 2021, the Company purchased an additional &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_zhPkgESnUPe8" title="Purchase of additional shares"&gt;3,571,430&lt;/span&gt; shares of DirectDerm&#x2019;s Series
B-2 Preferred for $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_z9H4fpGbWvyg" title="Value of shares purchased"&gt;250,000&lt;/span&gt;. In March 2022, the Company purchased an additional &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220301__20220331__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_z7AUOXUn29Fg" title="Purchase of additional shares"&gt;3,571,429&lt;/span&gt; shares of DirectDerm&#x2019;s Series B-2 Preferred
for $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220301__20220331__dei--LegalEntityAxis__custom--DirectDermatologyIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBTwoPreferredSharesMember_zh3ALofMorD7" title="Value of shares purchased"&gt;250,000&lt;/span&gt;. The Company&#x2019;s ownership of DirectDerm was approximately &lt;span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DirectDermatologyIncMember_zfVKIsJHOgV8" title="Ownership percentage"&gt;8.1&lt;/span&gt;% as of December&#160;31, 2024. The Company does not have
the ability to exercise significant influence over DirectDerm&#x2019;s operating and financial activities. In accordance with ASC Topic
321, Investments - Equity Securities (&#x201c;ASC 321&#x201d;), this investment was reported at cost as of December&#160;31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Pixalere&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2021, the Company invested $&lt;span id="xdx_90E_eus-gaap--Investments_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredSharesMember__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zSxCHf3lF808" title="Investments"&gt;2,084,278&lt;/span&gt; to
purchase &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210601__20210630__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredSharesMember__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zXATieq1zkif" title="Purchase of additional shares"&gt;278,587&lt;/span&gt; Class A Preferred Shares (the &#x201c;Pixalere Shares&#x201d;) of Canada based Pixalere Healthcare Inc. (&#x201c;Pixalere&#x201d;).
The Pixalere Shares are convertible into approximately &lt;span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210601__20210630__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredSharesMember__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zSBlA6Gygs02" title="Conversion rate"&gt;27.3&lt;/span&gt;% of the outstanding equity of Pixalere. Pixalere provides a cloud-based wound
care software tool that empowers nurses, specialists and administrators to deliver better care for patients. In connection with the Company&#x2019;s
purchase of the Pixalere Shares, Pixalere granted Pixalere Healthcare USA, LLC (&#x201c;Pixalere USA&#x201d;), a subsidiary of the Company,
a royalty-free exclusive license to use the Pixalere software and platform in the United States. In conjunction with the grant of the
license, the Company issued Pixalere a &lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PixalereHealthcareUSALLCMember_zaXt0zVypam9" title="Ownership interest"&gt;27.3&lt;/span&gt;% equity ownership interest in Pixalere USA valued at $&lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentAggregateCost_iI_c20210630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PixalereHealthcareUSALLCMember_zMHfkG0axJO5" title="Ownership value"&gt;93,879&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reviewed the characteristics of the Pixalere
Shares in accordance with ASC Topic 323, Investments &#x2013; Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Due to the substantive
liquidation preferences of the Pixalere Shares over Pixalere&#x2019;s common stock, the Pixalere Shares are not &#x201c;in-substance&#x201d;
common stock, and therefore, the Company does not utilize the equity method of accounting for this investment. In accordance with ASC
321, this investment was reported at cost as of December&#160;31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;ChemoMouthpiece &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2024, the Company, through its wholly
owned subsidiary, Sanara CMP LLC (&#x201c;Sanara CMP&#x201d;), entered into a Unit Purchase Agreement (the &#x201c;Unit Purchase Agreement&#x201d;)
with ChemoMouthpiece, LLC (&#x201c;CMp&#x201d;), pursuant to which Sanara CMP purchased &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240901__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonUnitsMember__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_z1eBwKcIz7c9" title="Number of shares purchased"&gt;100,674.72&lt;/span&gt; common units in CMp for an aggregate
purchase price of $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240901__20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonUnitsMember__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zmaR5vSiQZqd" title="Purchase of shares, value"&gt;5.0&lt;/span&gt; million, or $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__custom--CommonUnitsMember__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zwPOeEwhgTM3" title="Share price per unit"&gt;49.6649&lt;/span&gt; per unit, which represented approximately &lt;span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20240930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ChemoMouthPieceLLCMember_zMkguyl4WCBk" title="Ownership interest"&gt;6.64&lt;/span&gt;% of the issued and outstanding membership
interest of CMp immediately following such purchase. Subsequent to the Company&#x2019;s initial investment in CMp, units of CMp were sold
to other investors, thereby decreasing the Company&#x2019;s ownership of CMp to &lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ChemoMouthPieceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z8zEBmhITRD1" title="Ownership interest"&gt;6.59&lt;/span&gt;% as of December&#160;31, 2024. CMp is a privately
held medical device company that develops and commercializes propriety oral cryotherapy products for cancer patients, including, among
other things, CMp&#x2019;s Chemo Mouthpiece oral cryotherapy device, which is a 510(k) cleared cryotherapy device designed to reduce the
incidence and severity of chemotherapy induced oral mucositis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has reviewed the characteristics of Sanara
CMP&#x2019;s investment in CMp in accordance with ASC 323 and determined that Sanara CMP made a non-controlling investment in a limited
liability company. According to the guidance provided in ASC 323-30-S99-1, investments in limited liability companies whereby an investor
holds more than a 3% to 5% ownership interest would generally be accounted for under the equity method of accounting. Therefore, the
Company utilized the equity method of accounting for this investment and recorded its initial investment at cost plus transaction costs.
Sanara CMP&#x2019;s share of the earnings or losses of CMp is recorded in the Company&#x2019;s Consolidated Statements of Operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;SI Technologies &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2022, the Company established a 50/50
joint venture, SI Healthcare Technologies, LLC (&#x201c;SI Technologies&#x201d;) (formerly known as SI Wound Care, LLC), with InfuSystem
Holdings, Inc. (&#x201c;InfuSystem&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the Unit Purchase Agreement with
CMp, the Company, CMp, certain subsidiaries of CMp, InfuSystem and SI Technologies, entered into an Exclusive Distribution Agreement
(the &#x201c;Distribution Agreement&#x201d;) pursuant to which SI Technologies was appointed as the sole and exclusive U.S. distributor
of CMp&#x2019;s Standard Chemo Regiment Kits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The parties to the Distribution Agreement also entered
into an Intellectual Property Rights Agreement, pursuant to which SI Technologies was granted the exclusive right to use CMp&#x2019;s
intellectual property rights to permit resale and use of the CMp Product in the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has reviewed the characteristics the
Company&#x2019;s investment in SI Technologies in accordance with ASC 323 and determined that the Company made a non-controlling investment
in a limited liability company. According to the guidance provided in ASC 323-30-S99-1, investments in limited liability companies whereby
an investor holds more than a 3% to 5% ownership interest would generally be accounted for under the equity method of accounting. Therefore,
the Company utilized the equity method of accounting for this investment and recorded its initial investment at cost. The Company&#x2019;s
share of the earnings or losses of SI Technologies is recorded in the Company&#x2019;s Consolidated Statements of Operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--EquityMethodInvestmentsTextBlock_zMAOGUcywrpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes the Company&#x2019;s
investments for the periods presented:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B1_zCcxAJwBrCR7" style="display: none"&gt;SCHEDULE
OF INVESTMENTS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Carrying Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Economic Interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Carrying Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Economic Interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; padding-left: 0pt"&gt;Equity Method Investments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left; padding-left: 0pt"&gt;ChemoMouthpiece, LLC&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EquityMethodInvestments_iI_c20241231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zcpoyufaA91d" style="width: 12%; text-align: right" title="Equity method investment"&gt;5,172,242&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20241231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zFILfgArJySa" style="width: 12%; text-align: right" title="Economic interest"&gt;6.59&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EquityMethodInvestments_iI_c20231231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zTWjiExoXqZ2" style="width: 12%; text-align: right" title="Equity method investment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0902"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20231231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zvaLSPsMIXFd" style="width: 12%; text-align: right" title="Economic interest"&gt;&lt;span style="font-size: 10pt"&gt;	&lt;span style="-sec-ix-hidden: xdx2ixbrl0904"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;SI Healthcare Technologies, LLC&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EquityMethodInvestments_iI_c20241231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zsKNjv2gy1n" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment"&gt;40,703&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20241231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zsacXtxDj3Vk" style="text-align: right" title="Economic interest"&gt;50.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EquityMethodInvestments_iI_c20231231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zyubXmNPqhuf" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0910"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20231231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zZSYDhwoUL77" style="text-align: right" title="Economic interest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt"&gt;Total Equity Method Investments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EquityMethodInvestments_iI_c20241231_z2mR1u00kUL9" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment"&gt;5,212,945&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EquityMethodInvestments_iI_c20231231_zeTm9EaiIrS2" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; padding-left: 0pt"&gt;Cost Method Investments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Direct Dermatology, Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember_zajuHWuZ0d86" style="text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember_zYF0psdqkmd2" style="text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Pixalere Healthcare Inc.&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zccDcGcAE01" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment"&gt;2,084,278&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zpkcWZajaP9" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment"&gt;2,084,278&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt"&gt;Total Cost Method Investments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231_zx4UnM7vPRyg" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment"&gt;3,084,278&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231_zMWJbmdCEJ8b" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment"&gt;3,084,278&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 12pt"&gt;Total Investments&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--Investments_iI_c20241231_zYIgxxc9imw9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Investments"&gt;8,297,223&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Investments_iI_c20231231_zJIX2dufIDGk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Investments"&gt;3,084,278&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_z3WmyT2ZRFLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--GainLossOnInvestmentsTextBlock_zPv5lPsfHCz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes the Company&#x2019;s
share of losses from equity method investments reflected in the Company&#x2019;s Consolidated Statements of Operations for the periods
presented:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zHAhEl1usZHf" style="display: none"&gt;SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zehAYE0OgDLd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zjVewtCWnOHg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Year
                                            Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; padding-left: 0pt"&gt;Investments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeLossFromEquityMethodInvestments_hdei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zpUm7WViBV5g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: left; padding-left: 0pt"&gt;ChemoMouthpiece, LLC&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(105,710&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0935"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeLossFromEquityMethodInvestments_hdei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zLNnrROfrmJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;SI Healthcare Technologies, LLC&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,703&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0938"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeLossFromEquityMethodInvestments_zULRmngvImI6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 12pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;(90,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0941"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeLossFromEquityMethodInvestments_zkslVPI9vICb" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 12pt"&gt;Loss from equity method investment&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;(90,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0944"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_znq0kSjxirih" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:InvestmentHoldingsTextBlock>
    <us-gaap:LongTermInvestments
      contextRef="AsOf2020-07-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember"
      decimals="0"
      id="Fact000860"
      unitRef="USD">500000</us-gaap:LongTermInvestments>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-07-012020-07-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember"
      decimals="INF"
      id="Fact000862"
      unitRef="Shares">7142857</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-07-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember32609109"
      decimals="INF"
      id="Fact000864"
      unitRef="Pure">0.029</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember"
      decimals="INF"
      id="Fact000866"
      unitRef="Shares">3571430</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember"
      decimals="0"
      id="Fact000868"
      unitRef="USD">250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-03-012022-03-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember"
      decimals="INF"
      id="Fact000870"
      unitRef="Shares">3571429</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-03-012022-03-31_custom_DirectDermatologyIncMember_custom_SeriesBTwoPreferredSharesMember"
      decimals="0"
      id="Fact000872"
      unitRef="USD">250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_DirectDermatologyIncMember"
      decimals="INF"
      id="Fact000874"
      unitRef="Pure">0.081</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:Investments
      contextRef="AsOf2021-06-30_custom_ClassAPreferredSharesMember_custom_PixalereHealthcareIncMember"
      decimals="0"
      id="Fact000876"
      unitRef="USD">2084278</us-gaap:Investments>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-06-012021-06-30_custom_ClassAPreferredSharesMember_custom_PixalereHealthcareIncMember"
      decimals="INF"
      id="Fact000878"
      unitRef="Shares">278587</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2021-06-012021-06-30_custom_ClassAPreferredSharesMember_custom_PixalereHealthcareIncMember"
      decimals="INF"
      id="Fact000880"
      unitRef="Pure">0.273</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-06-30_custom_PixalereHealthcareUSALLCMember"
      decimals="INF"
      id="Fact000882"
      unitRef="Pure">0.273</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="AsOf2021-06-30_custom_PixalereHealthcareUSALLCMember"
      decimals="0"
      id="Fact000884"
      unitRef="USD">93879</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-09-012024-09-30_custom_CommonUnitsMember_custom_ChemoMouthPieceLLCMember"
      decimals="INF"
      id="Fact000886"
      unitRef="Shares">100674.72</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-09-012024-09-30_custom_CommonUnitsMember_custom_ChemoMouthPieceLLCMember"
      decimals="-5"
      id="Fact000888"
      unitRef="USD">5000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-09-30_custom_CommonUnitsMember_custom_ChemoMouthPieceLLCMember"
      decimals="INF"
      id="Fact000890"
      unitRef="USDPShares">49.6649</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-09-30_custom_ChemoMouthPieceLLCMember"
      decimals="INF"
      id="Fact000892"
      unitRef="Pure">0.0664</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_ChemoMouthPieceLLCMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000894"
      unitRef="Pure">0.0659</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000896">&lt;p id="xdx_89C_eus-gaap--EquityMethodInvestmentsTextBlock_zMAOGUcywrpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes the Company&#x2019;s
investments for the periods presented:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B1_zCcxAJwBrCR7" style="display: none"&gt;SCHEDULE
OF INVESTMENTS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Carrying Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Economic Interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Carrying Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Economic Interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; padding-left: 0pt"&gt;Equity Method Investments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left; padding-left: 0pt"&gt;ChemoMouthpiece, LLC&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EquityMethodInvestments_iI_c20241231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zcpoyufaA91d" style="width: 12%; text-align: right" title="Equity method investment"&gt;5,172,242&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20241231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zFILfgArJySa" style="width: 12%; text-align: right" title="Economic interest"&gt;6.59&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EquityMethodInvestments_iI_c20231231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zTWjiExoXqZ2" style="width: 12%; text-align: right" title="Equity method investment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0902"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20231231__dei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zvaLSPsMIXFd" style="width: 12%; text-align: right" title="Economic interest"&gt;&lt;span style="font-size: 10pt"&gt;	&lt;span style="-sec-ix-hidden: xdx2ixbrl0904"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;SI Healthcare Technologies, LLC&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EquityMethodInvestments_iI_c20241231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zsKNjv2gy1n" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment"&gt;40,703&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20241231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zsacXtxDj3Vk" style="text-align: right" title="Economic interest"&gt;50.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EquityMethodInvestments_iI_c20231231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zyubXmNPqhuf" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0910"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--EquityMethodInvestmentsEconomicInterest_iI_pid_dp_uPure_c20231231__dei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zZSYDhwoUL77" style="text-align: right" title="Economic interest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt"&gt;Total Equity Method Investments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EquityMethodInvestments_iI_c20241231_z2mR1u00kUL9" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment"&gt;5,212,945&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EquityMethodInvestments_iI_c20231231_zeTm9EaiIrS2" style="border-bottom: Black 1pt solid; text-align: right" title="Equity method investment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; padding-left: 0pt"&gt;Cost Method Investments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Direct Dermatology, Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember_zajuHWuZ0d86" style="text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231__dei--LegalEntityAxis__custom--DirectDermatologyIncMember_zYF0psdqkmd2" style="text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Pixalere Healthcare Inc.&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zccDcGcAE01" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment"&gt;2,084,278&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231__dei--LegalEntityAxis__custom--PixalereHealthcareIncMember_zpkcWZajaP9" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment"&gt;2,084,278&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt"&gt;Total Cost Method Investments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20241231_zx4UnM7vPRyg" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment"&gt;3,084,278&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OtherInvestmentsAndSecuritiesAtCost_iI_c20231231_zMWJbmdCEJ8b" style="border-bottom: Black 1pt solid; text-align: right" title="Cost method investment"&gt;3,084,278&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 12pt"&gt;Total Investments&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--Investments_iI_c20241231_zYIgxxc9imw9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Investments"&gt;8,297,223&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Investments_iI_c20231231_zJIX2dufIDGk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total Investments"&gt;3,084,278&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2024-12-31_custom_ChemoMouthPieceLLCMember"
      decimals="0"
      id="Fact000898"
      unitRef="USD">5172242</us-gaap:EquityMethodInvestments>
    <SMTI:EquityMethodInvestmentsEconomicInterest
      contextRef="AsOf2024-12-31_custom_ChemoMouthPieceLLCMember"
      decimals="INF"
      id="Fact000900"
      unitRef="Pure">0.0659</SMTI:EquityMethodInvestmentsEconomicInterest>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2024-12-31_custom_SIHealthcareTechnologiesLLCMember"
      decimals="0"
      id="Fact000906"
      unitRef="USD">40703</us-gaap:EquityMethodInvestments>
    <SMTI:EquityMethodInvestmentsEconomicInterest
      contextRef="AsOf2024-12-31_custom_SIHealthcareTechnologiesLLCMember"
      decimals="INF"
      id="Fact000908"
      unitRef="Pure">0.5000</SMTI:EquityMethodInvestmentsEconomicInterest>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000914"
      unitRef="USD">5212945</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherInvestmentsAndSecuritiesAtCost
      contextRef="AsOf2024-12-31_custom_DirectDermatologyIncMember32609359"
      decimals="0"
      id="Fact000917"
      unitRef="USD">1000000</us-gaap:OtherInvestmentsAndSecuritiesAtCost>
    <us-gaap:OtherInvestmentsAndSecuritiesAtCost
      contextRef="AsOf2023-12-31_custom_DirectDermatologyIncMember"
      decimals="0"
      id="Fact000918"
      unitRef="USD">1000000</us-gaap:OtherInvestmentsAndSecuritiesAtCost>
    <us-gaap:OtherInvestmentsAndSecuritiesAtCost
      contextRef="AsOf2024-12-31_custom_PixalereHealthcareIncMember"
      decimals="0"
      id="Fact000920"
      unitRef="USD">2084278</us-gaap:OtherInvestmentsAndSecuritiesAtCost>
    <us-gaap:OtherInvestmentsAndSecuritiesAtCost
      contextRef="AsOf2023-12-31_custom_PixalereHealthcareIncMember"
      decimals="0"
      id="Fact000922"
      unitRef="USD">2084278</us-gaap:OtherInvestmentsAndSecuritiesAtCost>
    <us-gaap:OtherInvestmentsAndSecuritiesAtCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000924"
      unitRef="USD">3084278</us-gaap:OtherInvestmentsAndSecuritiesAtCost>
    <us-gaap:OtherInvestmentsAndSecuritiesAtCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000926"
      unitRef="USD">3084278</us-gaap:OtherInvestmentsAndSecuritiesAtCost>
    <us-gaap:Investments
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000928"
      unitRef="USD">8297223</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000930"
      unitRef="USD">3084278</us-gaap:Investments>
    <us-gaap:GainLossOnInvestmentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000932">&lt;p id="xdx_894_eus-gaap--GainLossOnInvestmentsTextBlock_zPv5lPsfHCz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes the Company&#x2019;s
share of losses from equity method investments reflected in the Company&#x2019;s Consolidated Statements of Operations for the periods
presented:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zHAhEl1usZHf" style="display: none"&gt;SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zehAYE0OgDLd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zjVewtCWnOHg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Year
                                            Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; padding-left: 0pt"&gt;Investments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeLossFromEquityMethodInvestments_hdei--LegalEntityAxis__custom--ChemoMouthPieceLLCMember_zpUm7WViBV5g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; text-align: left; padding-left: 0pt"&gt;ChemoMouthpiece, LLC&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(105,710&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0935"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeLossFromEquityMethodInvestments_hdei--LegalEntityAxis__custom--SIHealthcareTechnologiesLLCMember_zLNnrROfrmJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;SI Healthcare Technologies, LLC&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,703&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0938"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeLossFromEquityMethodInvestments_zULRmngvImI6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 12pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;(90,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0941"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeLossFromEquityMethodInvestments_zkslVPI9vICb" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 12pt"&gt;Loss from equity method investment&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;(90,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0944"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2024-01-012024-12-31_custom_ChemoMouthPieceLLCMember"
      decimals="0"
      id="Fact000934"
      unitRef="USD">-105710</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2024-01-012024-12-31_custom_SIHealthcareTechnologiesLLCMember"
      decimals="0"
      id="Fact000937"
      unitRef="USD">15703</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000940"
      unitRef="USD">-90007</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000943"
      unitRef="USD">-90007</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000946">&lt;p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_z8YUS1o7i6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 7 &#x2013; &lt;span id="xdx_82A_ziwQd4pvaMO8"&gt;OPERATING LEASES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company periodically enters operating lease contracts
for office space and equipment. Arrangements are evaluated at inception to determine whether such arrangements constitute a lease. Right
of use assets (&#x201c;ROU assets&#x201d;) represent the right to use an underlying asset for the lease term, and lease liabilities represent
the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized on the transition
date based on the present value of lease payments over the respective lease term, with the office space ROU asset adjusted for deferred
rent liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2024, the Company had two material
operating leases for office space. In March and September of 2023, the Company amended its primary office lease to obtain additional
space, as well as extend the term. The leases had remaining lease terms of &lt;span id="xdx_906_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceOneMember_zvaoNF3TiIL8" title="Remaining lease term"&gt;72&lt;/span&gt; and &lt;span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dt_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeSpaceTwoMember_zL9BumQvplok" title="Remaining lease term"&gt;eight months&lt;/span&gt; as of December 31, 2024. The Company is
evaluating its renewal options for the lease expiring in eight months. For practical expediency, the Company has elected to not recognize
ROU assets and lease liabilities related to short-term leases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC Topic 842, Leases, the Company
has recorded ROU assets of $&lt;span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20241231_zSGWkqdJYgjh" title="Operating lease right of use assets"&gt;1,447,907&lt;/span&gt; and a related lease liability of $&lt;span id="xdx_904_eus-gaap--OperatingLeaseLiability_iI_c20241231_z0mFIu2M0Rs4" title="Operating lease liability"&gt;1,595,738&lt;/span&gt; as of December&#160;31, 2024. The Company recorded
lease expense of $&lt;span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20240101__20241231_z9YOUM9yJMHi" title="Operating lease expenses"&gt;555,192&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OperatingLeaseExpense_c20230101__20231231_zLoWAdiNqQB8" title="Operating lease expenses"&gt;434,066&lt;/span&gt; for the year ended December&#160;31, 2024 and 2023, respectively. Cash paid for amounts included
in the measurement of operating lease liabilities was $&lt;span id="xdx_902_eus-gaap--OperatingLeasePayments_c20240101__20241231_zUbsUiKKUoJ4" title="Operating lease payments"&gt;505,017&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--OperatingLeasePayments_c20230101__20231231_zKIMHXQWlVb9" title="Operating lease payments"&gt;380,576&lt;/span&gt; for the year ended December&#160;31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The present value of the Company&#x2019;s operating
lease liabilities as of December&#160;31, 2024 is shown below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z6SrZdDpjvZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Maturity of Operating Lease Liabilities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B2_zVpEBCFbTnD9" style="display: none"&gt;SCHEDULE OF OPERATING LEASE LIABILITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_zoNBxnuX22O6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
    2024&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzW5D_zjc5xaOe24Ce" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; text-align: left; padding-left: 0pt"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;466,800&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzW5D_zpdsmcKdg2H2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300,369&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzW5D_zX1Mw46DoAX5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;291,220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzW5D_z6CxGiouOPN8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;295,689&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzW5D_zmtdZPUWLlMd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzW5D_z6aPHovppDxa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;303,891&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzW5D_zujVdPcAhTD3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,958,127&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zh2CjtCVwjI7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(362,389&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_z36I6Zs5X84b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Present Value of Lease Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,595,738&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zO1XIQtOKK91" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Operating lease liabilities &#x2013; current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;358,687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zWHH6k26Z8ol" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Operating lease liabilities &#x2013; long-term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,237,051&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zGC1yUjJxZz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December&#160;31, 2024, the Company&#x2019;s
operating leases had a weighted average remaining lease term of &lt;span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zbwSh6gGgX2d" title="Weighted average remaining lease term"&gt;5.5&lt;/span&gt; years and a weighted average discount rate of &lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zRYLzp9Bg5Ih" title="Weighted average discount rate"&gt;7.8&lt;/span&gt;%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2024-12-31_custom_OfficeSpaceOneMember"
      id="Fact000948">P72M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2024-12-31_custom_OfficeSpaceTwoMember"
      id="Fact000950">P8M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000952"
      unitRef="USD">1447907</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000954"
      unitRef="USD">1595738</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000956"
      unitRef="USD">555192</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000958"
      unitRef="USD">434066</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000960"
      unitRef="USD">505017</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000962"
      unitRef="USD">380576</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000964">&lt;p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z6SrZdDpjvZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Maturity of Operating Lease Liabilities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B2_zVpEBCFbTnD9" style="display: none"&gt;SCHEDULE OF OPERATING LEASE LIABILITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_zoNBxnuX22O6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
    2024&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzW5D_zjc5xaOe24Ce" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; text-align: left; padding-left: 0pt"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;466,800&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzW5D_zpdsmcKdg2H2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300,369&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzW5D_zX1Mw46DoAX5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;291,220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzW5D_z6CxGiouOPN8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;295,689&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzW5D_zmtdZPUWLlMd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzW5D_z6aPHovppDxa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;303,891&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzW5D_zujVdPcAhTD3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,958,127&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zh2CjtCVwjI7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(362,389&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_z36I6Zs5X84b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Present Value of Lease Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,595,738&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zO1XIQtOKK91" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Operating lease liabilities &#x2013; current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;358,687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zWHH6k26Z8ol" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Operating lease liabilities &#x2013; long-term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,237,051&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000966"
      unitRef="USD">466800</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000968"
      unitRef="USD">300369</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000970"
      unitRef="USD">291220</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000972"
      unitRef="USD">295689</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000974"
      unitRef="USD">300158</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000976"
      unitRef="USD">303891</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000978"
      unitRef="USD">1958127</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000980"
      unitRef="USD">362389</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000982"
      unitRef="USD">1595738</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000984"
      unitRef="USD">358687</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000986"
      unitRef="USD">1237051</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact000988">P5Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000990"
      unitRef="Pure">0.078</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000992">&lt;p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_zTK1cGuLprgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 8 &#x2013; &lt;span id="xdx_821_z1V9SP76OE92"&gt;DEBT AND CREDIT FACILITIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;CRG Term Loan Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April&#160;17, 2024 (the &#x201c;Closing Date&#x201d;),
the Company entered into a term loan agreement, by and among the Company, as borrower, the subsidiary guarantors party thereto from time
to time (collectively, the &#x201c;Guarantors&#x201d;), CRG Servicing LLC as administrative agent and collateral agent (the &#x201c;Agent&#x201d;),
and the lenders party thereto from time to time (the &#x201c;CRG Term Loan Agreement&#x201d;), providing for a senior secured term loan
of up to $&lt;span id="xdx_903_eus-gaap--SecuredDebt_iI_pn5n6_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zkyXn7Lb45Fd" title="Secured term loan"&gt;55.0&lt;/span&gt; million (the &#x201c;CRG Term Loan&#x201d;). As of December 31, 2024, the CRG Term Loan Agreement provided for (i) $&lt;span id="xdx_900_ecustom--GrossCashReceivedFromTermLoan_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_z2u5D3iR4xS5" title="Loans borrowed"&gt;15.0&lt;/span&gt; million of the CRG Term
Loan that was borrowed on the Closing Date (the &#x201c;First Borrowing&#x201d;) and (ii) up to an aggregate of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentUnusedBorrowingCapacityAmount_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_z87NT3YY1d25" title="Remaining amount available for borrowing"&gt;40.0&lt;/span&gt; million available
for borrowing in two subsequent borrowings, provided that &lt;span id="xdx_907_eus-gaap--DebtInstrumentDescription_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zEF4Wk4NbXV7" title="Borrowing capacity description"&gt;each such borrowing was required to be at least $5.0 million and occur between the Closing
Date and June 30, 2025,&lt;/span&gt; subject to the satisfaction of certain conditions, including the Agent having received certain fees. The Company used a portion of the initial proceeds of the First Borrowing under the CRG Term
Loan to extinguish the Cadence Term Loan described further below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 4, 2024, the Company, pursuant
to its option under the CRG Term Loan Agreement, borrowed an additional $&lt;span id="xdx_901_ecustom--GrossCashReceivedFromTermLoan_iI_pn5n6_c20240904__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zEwZVLQ5Nemb" title="Loans borrowed"&gt;15.5&lt;/span&gt; million under the CRG Term Loan Agreement (the &#x201c;Second
Borrowing&#x201d;). The Company used $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_pn5n6_c20240904__20240904__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_z25cvTlIG6Ef" title="Proceeds from loans used for investment"&gt;5.0&lt;/span&gt; million of the proceeds of the Second Borrowing for its investment in CMp.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The First Borrowing, Second Borrowing and any additional
borrowings under the CRG Term Loan are due and payable on &lt;span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20240904__20240904__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zLycjQHvx4Nc" title="Debt maturity date"&gt;March 30, 2029&lt;/span&gt; (the &#x201c;Maturity Date&#x201d;), absent any acceleration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The CRG Term Loan bears interest at a per annum rate
equal to &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20240417__20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zSKYLcZj6iCj" title="Interest rate per annum"&gt;13.25&lt;/span&gt;% (subject to a &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_uPure_c20240417__20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zwFCbP73kcle" title="Incremental increase during an event of default"&gt;4.0&lt;/span&gt;% increase during an event of default), of which &lt;span id="xdx_902_ecustom--CashPaidPercentage_iI_dp_uPure_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zbepd7w9vhDc" title="Cash paid percentage"&gt;8.00&lt;/span&gt;% must be paid in cash and &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zcvjZo14WRYb" title="Paid-in-kind and aggregate principal loan amount, percentage"&gt;5.25&lt;/span&gt;% may, at the election
of the Company, be deferred through the 19&lt;sup&gt;th&lt;/sup&gt; quarterly Payment Date (defined below) by adding such amount to the aggregate
principal loan amount, so long as no default or event of default under the CRG Term Loan Agreement has occurred and is continuing. The
Company is required to make quarterly interest payments on the final business day of each calendar quarter following the Closing Date,
commencing on the first such date to occur at least 30 days after the Closing Date (each, a &#x201c;Payment Date&#x201d;). Interest is
payable on each Payment Date in arrears with respect to the time between each Payment Date and upon the payment or prepayment of the
CRG Term Loan, ending on the Maturity Date. In addition, the Company is required to pay an upfront fee of &lt;span id="xdx_901_ecustom--DebtInstrumentUpFrontFeePercentage_iI_dp_uPure_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zqb33vD88gO7" title="Debt upfront fee percentage"&gt;1.50&lt;/span&gt;% of the principal amount
of the CRG Term Loan, which is payable as amounts are advanced under the CRG Term Loan on a pro rata basis. The Company is also required
to pay a back-end fee equal to &lt;span id="xdx_908_ecustom--DebtInstrumentBackEndFeePercentage_iI_dp_uPure_c20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_ziD61m5HNzIh" title="Debt instrument back-end fee percentage"&gt;7.00&lt;/span&gt;% of the aggregate principal amount advanced under the CRG Term Loan Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the year ended December&#160;31, 2024, the Company
paid $&lt;span id="xdx_903_eus-gaap--InterestPaid_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zhncjVlXJBR6" title="Interest paid"&gt;1,278,424&lt;/span&gt; of interest in cash and recorded $&lt;span id="xdx_900_eus-gaap--PaidInKindInterest_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zxdhlurrsHLh" title="Interest paid-in-kind"&gt;838,965&lt;/span&gt; of interest paid-in-kind related to the CRG Term Loan. The paid-in-kind interest
was applied to the principal balance of the CRG Term Loan. The Company recorded $&lt;span id="xdx_90C_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember__us-gaap--DebtInstrumentAxis__custom--BackendFeeMember_z36IRGzRIpk6" title="Interest expense related to back-end fee"&gt;358,086&lt;/span&gt; for the year ended December&#160;31, 2024 to
interest expense related to the back-end fee. The back-end fee is accreted and amortized to interest expense over the term of the CRG
Term Loan. Paid-in-kind interest and the accreted back-end fee are included in &#x201c;Long-term debt, net of current portion&#x201d; in
the Consolidated Balance Sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Subject to certain exceptions, the Company is required
to make mandatory prepayments of the CRG Term Loan with the proceeds of certain assets sales and in the event of a change of control
of the Company. In addition, the Company may make a voluntary prepayment of the CRG Term Loan, in whole or in part, at any time. All
mandatory and voluntary prepayments of the CRG Term Loan are subject to the payment of prepayment premiums as follows: &lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateTerms_dp_uPure_c20240417__20240417__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zERu6NtwjzYk" title="Debt instrument rate description"&gt;(i) if prepayment
occurs on or prior to the date that is one year following the applicable borrowing (the &#x201c;Borrowing Date&#x201d;), an amount equal
to 10.0% of the aggregate outstanding principal amount of the CRG Term Loan being prepaid and (ii) if prepayment occurs one year after
the applicable Borrowing Date and on or prior to two years following the applicable Borrowing Date, an amount equal to 5.0% of the aggregate
outstanding principal amount of the CRG Term Loan being prepaid.&lt;/span&gt; No prepayment premium is due on any principal prepaid if prepayment
occurs two years or more after the applicable Borrowing Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain of the Company&#x2019;s current and future
subsidiaries, including the Guarantors, are guaranteeing the obligations of the Company under the CRG Term Loan Agreement. As security
for their obligations under the CRG Term Loan Agreement, on the Closing Date, the Company and the Guarantors entered into a security
agreement with the Agent pursuant to which the Company and the Guarantors granted to the Agent, as collateral agent for the lenders,
a lien on substantially all of the Company&#x2019;s and the Guarantors&#x2019; assets, including intellectual property (subject to certain
exceptions).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The CRG Term Loan Agreement contains affirmative
and negative covenants customary for financings of this type, including limitations on the Company&#x2019;s and the Guarantors&#x2019;
abilities, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions above certain
thresholds, merge or consolidate with others, dispose of assets, pay dividends and distributions and enter into affiliate transactions,
in each case, subject to certain exceptions. In addition, the CRG Term Loan Agreement contains the following financial covenants requiring
the Company and the Guarantors in the aggregate to maintain:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;liquidity in an amount which shall
                                            exceed the greater of: (i) $&lt;span id="xdx_907_ecustom--MinimumCashBalanceValue_iI_pn5n6_c20241231_zChe9SW0Jrqh" title="Minimum cash balance"&gt;3.0&lt;/span&gt; million and (ii) to the extent the Company has incurred certain
                                            permitted debt, the minimum cash balance, if any, required of the Company by the creditors
                                            of such permitted debt; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;annual minimum revenue of at least:
                                            (i) $&lt;span id="xdx_90F_ecustom--AnnualMinimumRevenueYearOne_pn5n6_c20240101__20241231_zJhAc9AV4VWi" title="Annual minimum revenue, year one"&gt;60.0&lt;/span&gt; million for the twelve-month period beginning on January 1, 2024 and ending on
                                            December&#160;31, 2024, (ii) $&lt;span id="xdx_902_ecustom--AnnualMinimumRevenueYearTwo_pn5n6_c20240101__20241231_zOdXSo4iE0D1" title="Annual minimum revenue, year two"&gt;75.0&lt;/span&gt; million for the twelve-month period beginning on January
                                            1, 2025 and ending on December 31, 2025, (iii) $&lt;span id="xdx_906_ecustom--AnnualMinimumRevenueYearThree_pn5n6_c20240101__20241231_zMSDUbJdoShb" title="Annual minimum revenue, year three"&gt;85.0&lt;/span&gt; million for the twelve-month period
                                            beginning on January 1, 2026 and ending on December 31, 2026, (iv) $&lt;span id="xdx_90B_ecustom--AnnualMinimumRevenueYearFour_pn5n6_c20240101__20241231_zhspa9GlKpB6" title="Annual minimum revenue, year four"&gt;95.0&lt;/span&gt; million for the
                                            twelve-month period beginning on January 1, 2027 and ending on December 31, 2027, and (v)
                                            $&lt;span id="xdx_90B_ecustom--AnnualMinimumRevenueYearFive_pn5n6_c20240101__20241231_z9TKPx1cYZmk" title="Annual minimum revenue, year five"&gt;105.0&lt;/span&gt; million during each twelve-month period beginning on January 1 of a given year thereafter.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The CRG Term Loan Agreement contains representations
and warranties of the Company and the Guarantors customary for financings of this type, and also includes events of default customary
for financings of this type, including, among other things, non-payment, inaccuracy of representations and warranties, covenant breaches,
a material adverse change, bankruptcy and insolvency, material judgments and a change of control, in certain cases subject to customary
periods to cure. The occurrence and continuance of an event of default could result in the acceleration of the obligations under the
CRG Term Loan Agreement. As of December 31, 2024, the Company was in compliance with all debt covenants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cadence
Term Loan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the entry into the Applied Purchase Agreement, on August&#160;1, 2023, SMAT, as borrower, and the Company, as guarantor,
entered into a loan agreement (the &#x201c;Cadence Loan Agreement&#x201d;) with Cadence Bank (the &#x201c;Bank&#x201d;) providing for, among
other things, an advancing term loan in the aggregate principal amount of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230801__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zHZDNOKo9JLl" title="Principal amount"&gt;12.0&lt;/span&gt; million (the &#x201c;Cadence Term Loan&#x201d;), which
was evidenced by an advancing promissory note. Pursuant to the Cadence Loan Agreement, the Bank agreed to make, at any time and from
time to time prior to February 1, 2024, one or more advances to SMAT.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
proceeds of the advances under the Cadence Loan Agreement were used for working capital and for purposes of financing up to one hundred
percent (&lt;span id="xdx_90D_ecustom--PercentageOfLoanProceedsUsedForAcquisition_iI_pid_dp_uPure_c20230801__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zj5ur4hsgQ87" title="Loan percentage used for acquisition"&gt;100%&lt;/span&gt;) of the Cash Closing Consideration and Installment Payments for the Applied Asset Purchase and related fees and expenses,
including any subsequent payments that were due to the Sellers after the Closing. On August 1, 2023, the Bank, at the request of SMAT,
made an advance for $&lt;span id="xdx_90A_eus-gaap--FederalHomeLoanBankAdvances_iI_pn4n6_c20230801__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zrYouzh5dNT" title="Loan bank advance"&gt;9.75&lt;/span&gt; million. The proceeds from the advance were used to fund the Cash Closing Consideration for the Applied Asset
Purchase.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unpaid principal balance of outstanding advances bore interest, subject to certain conditions, at the lesser of the Maximum Rate (as
defined in the Cadence Loan Agreement) or the Base Rate, which was for any day, a rate per annum equal to the term secured overnight
financing rate (Term SOFR) (as administered by the Federal Reserve Bank of New York) for a one-month tenor in effect on such day plus
three percent (&lt;span id="xdx_908_eus-gaap--FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate_iI_pid_dp_uPure_c20230801__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zza0MZCyOXT" title="Bank, interest rate"&gt;3.0&lt;/span&gt;%). As of December&#160;31, 2023, the interest rate on the advance under the Cadence Term Loan was &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_z4Wz2wRpl15e" title="Interest rate on advances"&gt;8.3&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
the Closing Date of the CRG Term Loan Agreement, the Cadence Loan Agreement was terminated and all outstanding amounts under the Cadence
Term Loan were repaid in full and all security interest and other liens granted to or held by Cadence were terminated and released. In
addition, unamortized debt issuance costs as of the termination date of $&lt;span id="xdx_909_eus-gaap--InterestExpenseOther_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CadenceTermLoanAgreementMember_zsszZEWqhMe4" title="Interest expense"&gt;53,438&lt;/span&gt; were included in &#x201c;Interest expense&#x201d; in the
Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfDebtTableTextBlock_zIsg681yAnZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below presents the components of the Company&#x2019;s outstanding debt for the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B6_zmrsJBFytyAk" style="display: none"&gt;SCHEDULE
OF LONG-TERM DEBT&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_zNFyPgSXxZgf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_z9l8Zt0EA1H7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--CRGTermLoanMember_zeqhzEqyaw2e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;CRG Term Loan&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;30,500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1055"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--PaidInKindInterestMember_zUfuoig8Q83b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Paid-in-kind interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;838,965&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1058"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--BackendFeeMember_z5aVyIYzPYHd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Back-end fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;358,086&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1061"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--CadenceTermLoanMember_zaVWB1qZMKy8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Cadence Term Loan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1063"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,750,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzYHB_zZEHdl4obr0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,697,051&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,750,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredFinanceCostsNet_iNI_di_msLTDzYHB_zk74bRzhcld3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: unamortized debt issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,007,761&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(56,520&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebt_iTI_mtLTDzYHB_zv5L08O0fdk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Debt, net of debt issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,689,290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,693,480&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LongTermDebtCurrent_iI_ztnJ6x50cnlj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Current portion of debt&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;580,357&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LongTermDebtNoncurrent_iI_zklisHAOfnf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Long-term debt, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;30,689,290&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,113,123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zMeBdRXHZnV2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zgsCXX4dXIna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below presents the aggregate maturities of the Company&#x2019;s outstanding debt as of December&#160;31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zEexwUetOxof" style="display: none"&gt;SCHEDULE
OF MATURITIES OUTSTANDING&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zxaa3sEEE7y8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maDICAzHTB_z4EjHutIBkMa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1083"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maDICAzHTB_zss0VSJhmmm9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maDICAzHTB_zosy1ThNwxbc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1087"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maDICAzHTB_zTKab2wyicN7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1089"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_maDICAzHTB_zJCOJs4T6aTk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2029&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;31,697,051&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_iI_maDICAzHTB_z4VsxxZuRpOd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1093"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DebtInstrumentCarryingAmount_iTI_mtDICAzHTB_zJlKfsFP7l6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total debt&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;31,697,051&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zVDT02dSa9Ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the CRG Term Loan, the Company incurred $&lt;span id="xdx_90A_eus-gaap--DeferredFinanceCostsGross_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--CRGTermLoanMember_zyuyKfnj7jP1" title="Debt issuance costs"&gt;1,160,740&lt;/span&gt; in debt issuance costs during the year ended December&#160;31, 2024.
Debt issuance costs are amortized to &#x201c;Interest expense&#x201d; in the Consolidated Statements of Operations over the life of the
debt to which they pertain. The total unamortized debt issuance costs were $&lt;span id="xdx_904_eus-gaap--DeferredFinanceCostsNet_iI_c20241231_zYQlxfSwzekk" title="Unamortized debt issuance costs"&gt;1,007,761&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--DeferredFinanceCostsNet_iI_c20231231_z7zEIB6Yu1lj" title="Unamortized debt issuance costs"&gt;56,520&lt;/span&gt; as of December&#160;31, 2024 and December&#160;31,
2023, respectively. Debt issuance costs are included in &#x201c;Long-term debt, net of current portion&#x201d; in the Consolidated Balance
Sheets. Amortization expense related to debt issuance costs was $&lt;span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_c20240101__20241231_zq5OSL6zmSUb"&gt;209,499&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--AmortizationOfFinancingCosts_dc_c20230101__20231231_zQnBTZgFXudf" title="Amortization expense of debt issuance costs"&gt;5,138&lt;/span&gt; for the year ended December&#160;31, 2024 and 2023,
respectively. Amortization for the year ended December&#160;31, 2024 includes the write-off of debt issuance costs of $&lt;span id="xdx_90B_eus-gaap--WriteOffOfDeferredDebtIssuanceCost_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--CadenceTermLoanMember_zLu9QJ4wHVtk" title="Write-off of debt issuance costs"&gt;56,520&lt;/span&gt; related
to the termination of Cadence Term Loan. The fair value of the Company&#x2019;s long-term debt approximated its carrying value as December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:SecuredDebt
      contextRef="AsOf2024-04-17_custom_CRGTermLoanAgreementMember"
      decimals="-5"
      id="Fact000994"
      unitRef="USD">55000000.0</us-gaap:SecuredDebt>
    <SMTI:GrossCashReceivedFromTermLoan
      contextRef="AsOf2024-12-31_custom_CRGTermLoanAgreementMember"
      decimals="-5"
      id="Fact000996"
      unitRef="USD">15000000.0</SMTI:GrossCashReceivedFromTermLoan>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="AsOf2024-12-31_custom_CRGTermLoanAgreementMember"
      decimals="-5"
      id="Fact000998"
      unitRef="USD">40000000.0</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2024-01-012024-12-31_custom_CRGTermLoanAgreementMember"
      id="Fact001000">each such borrowing was required to be at least $5.0 million and occur between the Closing
Date and June 30, 2025,</us-gaap:DebtInstrumentDescription>
    <SMTI:GrossCashReceivedFromTermLoan
      contextRef="AsOf2024-09-04_custom_CRGTermLoanAgreementMember"
      decimals="-5"
      id="Fact001002"
      unitRef="USD">15500000</SMTI:GrossCashReceivedFromTermLoan>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="From2024-09-042024-09-04_custom_CRGTermLoanAgreementMember"
      decimals="-5"
      id="Fact001004"
      unitRef="USD">5000000.0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-09-042024-09-04_custom_CRGTermLoanAgreementMember"
      id="Fact001006">2029-03-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2024-04-172024-04-17_custom_CRGTermLoanAgreementMember"
      decimals="INF"
      id="Fact001008"
      unitRef="Pure">0.1325</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2024-04-172024-04-17_custom_CRGTermLoanAgreementMember"
      decimals="INF"
      id="Fact001010"
      unitRef="Pure">0.040</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <SMTI:CashPaidPercentage
      contextRef="AsOf2024-04-17_custom_CRGTermLoanAgreementMember"
      decimals="INF"
      id="Fact001012"
      unitRef="Pure">0.0800</SMTI:CashPaidPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2024-04-17_custom_CRGTermLoanAgreementMember"
      decimals="INF"
      id="Fact001014"
      unitRef="Pure">0.0525</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <SMTI:DebtInstrumentUpFrontFeePercentage
      contextRef="AsOf2024-04-17_custom_CRGTermLoanAgreementMember"
      decimals="INF"
      id="Fact001016"
      unitRef="Pure">0.0150</SMTI:DebtInstrumentUpFrontFeePercentage>
    <SMTI:DebtInstrumentBackEndFeePercentage
      contextRef="AsOf2024-04-17_custom_CRGTermLoanAgreementMember"
      decimals="INF"
      id="Fact001018"
      unitRef="Pure">0.0700</SMTI:DebtInstrumentBackEndFeePercentage>
    <us-gaap:InterestPaid
      contextRef="From2024-01-012024-12-31_custom_CRGTermLoanAgreementMember"
      decimals="0"
      id="Fact001020"
      unitRef="USD">1278424</us-gaap:InterestPaid>
    <us-gaap:PaidInKindInterest
      contextRef="From2024-01-012024-12-31_custom_CRGTermLoanAgreementMember"
      decimals="0"
      id="Fact001022"
      unitRef="USD">838965</us-gaap:PaidInKindInterest>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31_custom_CRGTermLoanAgreementMember_custom_BackendFeeMember"
      decimals="0"
      id="Fact001024"
      unitRef="USD">358086</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentInterestRateTerms
      contextRef="From2024-04-172024-04-17_custom_CRGTermLoanAgreementMember"
      id="Fact001026">(i) if prepayment
occurs on or prior to the date that is one year following the applicable borrowing (the &#x201c;Borrowing Date&#x201d;), an amount equal
to 10.0% of the aggregate outstanding principal amount of the CRG Term Loan being prepaid and (ii) if prepayment occurs one year after
the applicable Borrowing Date and on or prior to two years following the applicable Borrowing Date, an amount equal to 5.0% of the aggregate
outstanding principal amount of the CRG Term Loan being prepaid.</us-gaap:DebtInstrumentInterestRateTerms>
    <SMTI:MinimumCashBalanceValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001028"
      unitRef="USD">3000000.0</SMTI:MinimumCashBalanceValue>
    <SMTI:AnnualMinimumRevenueYearOne
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001030"
      unitRef="USD">60000000.0</SMTI:AnnualMinimumRevenueYearOne>
    <SMTI:AnnualMinimumRevenueYearTwo
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001032"
      unitRef="USD">75000000.0</SMTI:AnnualMinimumRevenueYearTwo>
    <SMTI:AnnualMinimumRevenueYearThree
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001034"
      unitRef="USD">85000000.0</SMTI:AnnualMinimumRevenueYearThree>
    <SMTI:AnnualMinimumRevenueYearFour
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001036"
      unitRef="USD">95000000.0</SMTI:AnnualMinimumRevenueYearFour>
    <SMTI:AnnualMinimumRevenueYearFive
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001038"
      unitRef="USD">105000000.0</SMTI:AnnualMinimumRevenueYearFive>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-08-01_custom_CadenceTermLoanAgreementMember"
      decimals="-5"
      id="Fact001040"
      unitRef="USD">12000000.0</us-gaap:DebtInstrumentFaceAmount>
    <SMTI:PercentageOfLoanProceedsUsedForAcquisition
      contextRef="AsOf2023-08-01_custom_CadenceTermLoanAgreementMember"
      decimals="INF"
      id="Fact001042"
      unitRef="Pure">1</SMTI:PercentageOfLoanProceedsUsedForAcquisition>
    <us-gaap:FederalHomeLoanBankAdvances
      contextRef="AsOf2023-08-01_custom_CadenceTermLoanAgreementMember"
      decimals="-4"
      id="Fact001044"
      unitRef="USD">9750000</us-gaap:FederalHomeLoanBankAdvances>
    <us-gaap:FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate
      contextRef="AsOf2023-08-01_custom_CadenceTermLoanAgreementMember"
      decimals="INF"
      id="Fact001046"
      unitRef="Pure">0.030</us-gaap:FederalHomeLoanBankAdvancesBranchOfFHLBBankInterestRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-12-31_custom_CadenceTermLoanAgreementMember"
      decimals="INF"
      id="Fact001048"
      unitRef="Pure">0.083</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseOther
      contextRef="From2024-01-012024-12-31_custom_CadenceTermLoanAgreementMember"
      decimals="0"
      id="Fact001050"
      unitRef="USD">53438</us-gaap:InterestExpenseOther>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001052">&lt;p id="xdx_89A_eus-gaap--ScheduleOfDebtTableTextBlock_zIsg681yAnZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below presents the components of the Company&#x2019;s outstanding debt for the periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B6_zmrsJBFytyAk" style="display: none"&gt;SCHEDULE
OF LONG-TERM DEBT&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_zNFyPgSXxZgf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_z9l8Zt0EA1H7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--CRGTermLoanMember_zeqhzEqyaw2e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;CRG Term Loan&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;30,500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1055"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--PaidInKindInterestMember_zUfuoig8Q83b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Paid-in-kind interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;838,965&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1058"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--BackendFeeMember_z5aVyIYzPYHd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Back-end fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;358,086&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1061"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--CadenceTermLoanMember_zaVWB1qZMKy8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Cadence Term Loan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1063"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,750,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzYHB_zZEHdl4obr0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,697,051&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,750,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredFinanceCostsNet_iNI_di_msLTDzYHB_zk74bRzhcld3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: unamortized debt issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,007,761&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(56,520&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebt_iTI_mtLTDzYHB_zv5L08O0fdk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Debt, net of debt issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,689,290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,693,480&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LongTermDebtCurrent_iI_ztnJ6x50cnlj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Current portion of debt&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;580,357&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LongTermDebtNoncurrent_iI_zklisHAOfnf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Long-term debt, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;30,689,290&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,113,123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-12-31_custom_CRGTermLoanMember"
      decimals="0"
      id="Fact001054"
      unitRef="USD">30500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-12-31_custom_PaidInKindInterestMember"
      decimals="0"
      id="Fact001057"
      unitRef="USD">838965</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-12-31_custom_BackendFeeMember"
      decimals="0"
      id="Fact001060"
      unitRef="USD">358086</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-12-31_custom_CadenceTermLoanMember"
      decimals="0"
      id="Fact001064"
      unitRef="USD">9750000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001066"
      unitRef="USD">31697051</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001067"
      unitRef="USD">9750000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001069"
      unitRef="USD">1007761</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001070"
      unitRef="USD">56520</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001072"
      unitRef="USD">30689290</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001073"
      unitRef="USD">9693480</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001076"
      unitRef="USD">580357</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001078"
      unitRef="USD">30689290</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001079"
      unitRef="USD">9113123</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001081">&lt;p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zgsCXX4dXIna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below presents the aggregate maturities of the Company&#x2019;s outstanding debt as of December&#160;31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zEexwUetOxof" style="display: none"&gt;SCHEDULE
OF MATURITIES OUTSTANDING&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zxaa3sEEE7y8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maDICAzHTB_z4EjHutIBkMa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1083"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maDICAzHTB_zss0VSJhmmm9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maDICAzHTB_zosy1ThNwxbc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1087"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maDICAzHTB_zTKab2wyicN7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1089"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_maDICAzHTB_zJCOJs4T6aTk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2029&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;31,697,051&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_iI_maDICAzHTB_z4VsxxZuRpOd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1093"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DebtInstrumentCarryingAmount_iTI_mtDICAzHTB_zJlKfsFP7l6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total debt&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;31,697,051&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001091"
      unitRef="USD">31697051</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001095"
      unitRef="USD">31697051</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="AsOf2024-12-31_custom_CRGTermLoanMember"
      decimals="0"
      id="Fact001097"
      unitRef="USD">1160740</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001099"
      unitRef="USD">1007761</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001101"
      unitRef="USD">56520</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001102"
      unitRef="USD">209499</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001104"
      unitRef="USD">5138</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="From2024-01-012024-12-31_custom_CadenceTermLoanMember"
      decimals="0"
      id="Fact001106"
      unitRef="USD">56520</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001108">&lt;p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zyn7a0RhC1ta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="Section42"&gt;&lt;/span&gt;NOTE
9 - &lt;span id="xdx_823_z1Qc7X96lzrf"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;License
Agreements and Royalties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;CellerateRX
Surgical&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--LicenseAgreementAndRoyaltiesDescription_c20180826__20180827__us-gaap--TypeOfArrangementAxis__custom--SubLicenseAgreementMember_z1wiiKLFpLik" title="License agreement and royalties description"&gt;In
August 2018, the Company entered an exclusive, world-wide sublicense agreement with CGI Cellerate RX to distribute certain hydrolyzed
collagen products, including CellerateRX Surgical, into the surgical and wound care markets. Pursuant to the Sublicense Agreement, the
Company paid royalties of 3-5% of annual collected net sales of these products.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
discussed further in Note 3, on August 1, 2023, the Company purchased certain assets from Applied, including the rights to manufacture
and sell certain hydrolyzed collagen products, including CellerateRX Surgical, for use in the human wound care market. In connection
with the Applied Asset Purchase, Applied assigned the License Agreement with CGI Cellerate RX to SMAT, and on October 10, 2024, the License
Agreement and Sublicense Agreement were terminated for no additional consideration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the Sublicense Agreement, royalty expense, which was recorded in &#x201c;Cost of goods sold&#x201d; in the accompanying Consolidated Statements
of Operations, totaled &lt;span id="xdx_904_eus-gaap--RoyaltyExpense_dc_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zg9pirJt6j03" title="Payment for additional royalties"&gt;zero&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--RoyaltyExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zjYQogUF8Igd" title="Payment for additional royalties"&gt;991,099&lt;/span&gt;, respectively, for the year ended December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;BIASURGE
Advanced Surgical Solution, BIAK&#x14c;S Antimicrobial Wound Gel and BIAK&#x14c;S Antimicrobial Skin and Wound Cleanser&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2019, the Company executed a license agreement with Rochal Industries, LLC (&#x201c;Rochal&#x201d;), a related party, pursuant to
which the Company acquired an exclusive world-wide license to market, sell and further develop antimicrobial products for the prevention
and treatment of microbes on the human body utilizing certain Rochal patents and pending patent applications (the &#x201c;BIAK&#x14c;S
License Agreement&#x201d;). Currently, the products covered by the BIAK&#x14c;S License Agreement are BIASURGE Advanced Surgical Solution,
BIAK&#x14c;S Antimicrobial Wound Gel, BIAK&#x14c;S Antimicrobial Skin and Wound Cleanser. All three products are 510(k) cleared.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
commitments under the terms of the BIAK&#x14c;S License Agreement include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Company pays Rochal a royalty of &lt;span id="xdx_901_ecustom--RoyaltyPercentage_pid_dp_uPure_c20190701__20190731__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember__dei--LegalEntityAxis__custom--RochalIndustriesLLCMember__srt--RangeAxis__srt--MinimumMember_z1GljJ0oTp5h"&gt;2&lt;/span&gt;-&lt;span id="xdx_900_ecustom--RoyaltyPercentage_pid_dp_uPure_c20190701__20190731__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember__dei--LegalEntityAxis__custom--RochalIndustriesLLCMember__srt--RangeAxis__srt--MaximumMember_zwPN1bjo2Vak"&gt;4&lt;/span&gt;% of net sales. The minimum annual royalty due to Rochal
                                            will increase to a maximum amount of $&lt;span id="xdx_909_eus-gaap--PaymentsForRoyalties_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember__dei--LegalEntityAxis__custom--RochalIndustriesLLCMember__srt--RangeAxis__srt--MaximumMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zAQaEqol1ZZe" title="Payments for royalties"&gt;150,000&lt;/span&gt; in 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Company may pay additional royalties annually based on specific net profit targets from sales
                                            of the licensed products, subject to a maximum of $&lt;span id="xdx_90A_eus-gaap--RoyaltyExpense_c20190701__20190731__us-gaap--TypeOfArrangementAxis__custom--BIAKOSAgreementMember__srt--RangeAxis__srt--MaximumMember_zw7ai2w07Ee5" title="Payment for additional royalties"&gt;1,000,000&lt;/span&gt; during any calendar year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unless
previously terminated by the parties, the BIAK&#x14c;S License Agreement expires with the related patents in December 2031.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
this agreement, royalty expense, which is recorded in &#x201c;Cost of goods sold&#x201d; in the accompanying Consolidated Statements of
Operations, was $&lt;span id="xdx_908_eus-gaap--RoyaltyExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember_ztxKteX7hEnh" title="Royalty expense"&gt;177,005&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--RoyaltyExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--BIAKOSLicenseAgreementMember_zlO37oX9lW14" title="Royalty expense"&gt;130,000&lt;/span&gt; for the year ended December&#160;31, 2024 and 2023, respectively. The Company&#x2019;s Executive
Chairman and Chief Executive Officer is a director of Rochal, and indirectly a significant shareholder of Rochal, and through the potential
exercise of warrants, a majority shareholder of Rochal. Another one of the Company&#x2019;s directors is also a director and significant
shareholder of Rochal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;CuraShield
Antimicrobial Barrier Film and No Sting Skin Protectant&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2019, the Company executed a license agreement with Rochal pursuant to which the Company acquired an exclusive world-wide license
to market, sell and further develop certain antimicrobial barrier film and skin protectant products for use in the human health care
market utilizing certain Rochal patents and pending patent applications (the &#x201c;ABF License Agreement&#x201d;). Currently, the products
covered by the ABF License Agreement are CuraShield Antimicrobial Barrier Film and a no sting skin protectant product.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
commitments under the terms of the ABF License Agreement include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Company will pay Rochal a royalty of &lt;span id="xdx_90E_ecustom--RoyaltyPercentage_pid_dp_uPure_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zjsB3QQfie63" title="Royalty percentage"&gt;2&lt;/span&gt;-&lt;span id="xdx_904_ecustom--RoyaltyPercentage_pid_dp_uPure_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zIShVvIq8KB8" title="Royalty percentage"&gt;4&lt;/span&gt;% of net sales. The minimum annual royalty due to
                                            Rochal will be $&lt;span id="xdx_906_eus-gaap--RoyaltyExpense_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zClDPwa1y06k" title="Payments for royalty"&gt;50,000&lt;/span&gt; beginning with the first full calendar year following the year in
                                            which first commercial sales of the products occur. The annual minimum royalty will increase
                                            by &lt;span id="xdx_90D_ecustom--IncreaseInRoyaltyAnnualPercentage_pid_dp_uPure_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember_zTZDzuYBd0Ub" title="Increase in royalty annual percentage"&gt;10&lt;/span&gt;% each subsequent calendar year up to a maximum amount of $&lt;span id="xdx_900_eus-gaap--RoyaltyExpense_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zWWWoVEq5YD1" title="Maximum amount of royalty"&gt;75,000&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Company will pay additional royalties annually based on specific net profit targets from
                                            sales of the licensed products, subject to a maximum of $&lt;span id="xdx_908_eus-gaap--RoyaltyExpense_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--ABFLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember_zJiaB7wATsw4" title="Payment for additional royalties"&gt;500,000&lt;/span&gt; during any calendar year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unless
previously terminated or extended by the parties, the ABF License Agreement will terminate upon expiration of the last U.S. patent in
October 2033. No commercial sales or royalties have been recognized under this agreement as of December&#160;31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Debrider
License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2020, the Company executed a product license agreement with Rochal, pursuant to which the Company acquired an exclusive world-wide
license to market, sell and further develop a debrider for human medical use to enhance skin condition or treat or relieve skin disorders,
excluding uses primarily for beauty, cosmetic, or toiletry purposes (the &#x201c;Debrider License Agreement&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
commitments under the terms of the Debrider License Agreement include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
                                            FDA clearance of the licensed products, the Company will pay Rochal $&lt;span id="xdx_90F_eus-gaap--Cash_iI_c20200531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RochalMember__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember_zs3SfXcyEcD1" title="Payment in cash"&gt;500,000&lt;/span&gt; in cash and
                                            an additional $&lt;span id="xdx_90C_eus-gaap--PaymentsToAcquireBusinessesGross_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember_zTLIS1IQVXIa" title="Payment of cash"&gt;1,000,000&lt;/span&gt;, which at the Company&#x2019;s option may be paid in any combination
                                            of cash and its common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Company will pay Rochal a royalty of &lt;span id="xdx_90B_ecustom--RoyaltyPercentage_pid_dp_uPure_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zX5t1WBrt2c3" title="Royalty percentage"&gt;2&lt;/span&gt;-&lt;span id="xdx_908_ecustom--RoyaltyPercentage_pid_dp_uPure_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zDvPKxsHK4qh" title="Royalty percentage"&gt;4&lt;/span&gt;% of net sales. The minimum annual royalty due to
                                            Rochal will be $&lt;span id="xdx_908_eus-gaap--PaymentsForRoyalties_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zfcSCwc0e2y" title="Payments for royalty"&gt;100,000&lt;/span&gt; beginning with the first full calendar year following the year in
                                            which first commercial sales of the licensed products occur and increase by &lt;span id="xdx_90D_ecustom--IncreaseInRoyaltyAnnualPercentage_pid_dp_uPure_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember_zITPScHQdDGh" title="Increase in royalty annual percentage"&gt;10&lt;/span&gt;% each subsequent
                                            calendar year up to a maximum amount of $&lt;span id="xdx_90E_eus-gaap--PaymentsForRoyalties_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zhX2ywq8eWV2" title="Annual royalty"&gt;150,000&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Company will pay additional royalty annually based on specific net profit targets from sales
                                            of the licensed products, subject to a maximum of $&lt;span id="xdx_909_ecustom--PaymentsForAdditionalRoyalties_c20200501__20200531__us-gaap--TypeOfArrangementAxis__custom--DebriderLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zCOqqwqHkHbi" title="Payment for additional royalties"&gt;1,000,000&lt;/span&gt; during any calendar year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unless
previously terminated or extended by the parties, the Debrider License Agreement will expire in October 2034. No commercial sales or
royalties have been recognized under this agreement as of December&#160;31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Acquisitions&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Rochal
Asset Acquisition&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an asset purchase agreement with Rochal effective July 1, 2021, pursuant to which the Company purchased certain
assets of Rochal. Pursuant to the asset purchase agreement, for the three-year period after the effective date, Rochal was entitled to
receive consideration for any new product relating to the business that is directly and primarily based on an invention conceived and
reduced to practice by a member or members of Rochal&#x2019;s science team. For the three-year period after the effective date, Rochal
was also entitled to receive an amount in cash equal to twenty-five percent of the proceeds received for any Grant (as defined in the
asset purchase agreement) by either the Company or Rochal. In addition, the Company agreed to use commercially reasonable efforts to
perform Minimum Development Efforts (as defined in the asset purchase agreement) with respect to certain products under development,
which if obtained, will entitle the Company to intellectual property rights from Rochal in respect of such products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Precision
Healing Merger Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2022, the Company closed a merger transaction with Precision Healing pursuant to which Precision Healing became a wholly owned
subsidiary of the Company. Pursuant to the terms of the merger agreement, holders of Precision Healing common stock and preferred stock,
other than the Company, were entitled to receive closing consideration, consisting of $&lt;span id="xdx_906_eus-gaap--AssetAcquisitionConsiderationTransferred_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zUlp44IKFAe9" title="Cash consideration"&gt;125,966&lt;/span&gt; in cash consideration, which was paid
to stockholders who were not accredited investors, &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zIqg208eqk1" title="Issuance of shares"&gt;165,738&lt;/span&gt; shares of the Company&#x2019;s common stock, which was paid only to accredited
investors, and the payment in cash of approximately $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zUeMrfm2EID4" title="Payment in cash"&gt;0.6&lt;/span&gt; million of transaction expenses of Precision Healing. The Company recorded the
issuance of the &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zmpKxc1ygb6c" title="Issuance of shares"&gt;165,738&lt;/span&gt; shares to accredited investors and cash payments to nonaccredited investors based on the closing price per share
of the Company&#x2019;s common stock on April&#160;4, 2022, which was $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20220404__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zfnHf1QNgh35" title="Share price"&gt;30.75&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the closing of the merger, the Precision Healing outstanding options previously granted under the Precision Healing Plan converted, pursuant
to their terms, into options to acquire an aggregate of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zXBcNOx8uZr7" title="Options to acquire shares"&gt;144,191&lt;/span&gt; shares of Company common stock with a weighted average exercise price
of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zFjXhuGyRW39" title="Weighted exercise price"&gt;10.71&lt;/span&gt; per share. These options expire between August 2030 and April 2031. In addition, outstanding and unexercised Precision Healing
warrants converted into rights to receive warrants to purchase (i) &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCnnojVU6PD2" title="Warrants to purchase shares"&gt;4,424&lt;/span&gt; shares of the Company&#x2019;s common stock with an initial exercise
price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvBLCTopRBC2" title="Exercise price"&gt;7.32&lt;/span&gt; per share and an expiration date of&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCKf6TKnFxRg" title="Expiration date"&gt; April 22, 2031&lt;/span&gt;, and (ii) &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zSrwplEvgvfb" title="Warrants to purchase shares"&gt;12,301&lt;/span&gt; shares of the Company&#x2019;s common stock with
an initial exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zLlC6zn1gDJd" title="Exercise price"&gt;12.05&lt;/span&gt; per share and an expiration date of &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zbFxlszRdG9j" title="Expiration date"&gt;August 10, 2030&lt;/span&gt;. Concurrent with the assumption of the Precision
Healing Plan, the Company terminated the ability to offer future awards under the Precision Healing Plan. As of December 31, 2024, all
warrants to purchase shares of the Company&#x2019;s common stock pursuant to the transaction with Precision Healing were exercised and
there were &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_zLWpwM8Hpiv8" title="Options remaining to be exercised"&gt;31,013&lt;/span&gt; share options remaining to be exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the merger agreement, upon the achievement of certain performance thresholds, the securityholders of Precision Healing, including
the holders of options and warrants to purchase Precision Healing common stock and certain persons promised options to purchase Precision
Healing common stock, was also entitled to receive payments of up to $&lt;span id="xdx_90D_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_pn5n6_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_z7sUU9ygK3Gg" title="Contingent consideration payments receivable"&gt;10.0&lt;/span&gt; million, which was accounted for as contingent consideration
pursuant to ASC 805. The earnout consideration was payable in cash or, at the Company&#x2019;s election, was payable to accredited investors
in shares of Company common stock at a price per share equal to the greater of (i) $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--PrecisionHealingMergerAgreementMember_zV1gW8aK2Zah" title="Share price"&gt;27.13&lt;/span&gt; or (ii) the average closing price of Company
common stock for the 20 trading days prior to the date such earnout consideration was due and payable. Pursuant to the merger agreement,
a minimum percentage of the earnout consideration may be required to be issued to accredited investors in shares of Company common stock
for tax purposes. The amount and composition of the portion of earnout consideration payable was subject to adjustment and offsets as
set forth in the merger agreement. The Company reviewed the performance thresholds necessary to trigger an earnout payment as of December
31, 2024 and deemed the performance thresholds to be unachievable. Therefore, the remaining fair value of the earnout consideration was
reduced to zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Scendia
Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2022, the Company closed the Scendia acquisition pursuant to which Scendia became a wholly owned subsidiary of the Company. Pursuant
to the purchase agreement, the aggregate consideration for the acquisition at closing was approximately $&lt;span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zEcE7fYkqTYa" title="Acquisition consideration transferred"&gt;7.6&lt;/span&gt; million, subject to customary
post-closing adjustments. The consideration consisted of (i) approximately $&lt;span id="xdx_90C_eus-gaap--Cash_iI_pn5n6_c20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zXBSrZacQPIb" title="Cash"&gt;1.6&lt;/span&gt; million of cash, subject to certain adjustments, and
(ii) &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zTfNhl8NjtJh" title="Issuance of common stock for purchase of assets"&gt;291,686&lt;/span&gt; shares of common stock of the Company. Pursuant to the purchase agreement, at closing, the Company withheld &lt;span id="xdx_909_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zfdgusQS7Isc" title="Number of shares withheld"&gt;94,798&lt;/span&gt; Indemnity
Holdback Shares, which such Indemnity Holdback Shares were withheld to the extent provided in the purchase agreement to satisfy Ryan
Phillips&#x2019; (&#x201c;Phillips&#x201d;) indemnification obligations and subsequently issued and released to Phillips in July 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to the cash consideration and the stock consideration, the purchase agreement provides that Phillips was entitled to receive
two potential earnout payments, payable on an annual basis, not to exceed $&lt;span id="xdx_900_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_pn5n6_c20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_z3XdyLaK1EF7" title="Earnout consideration"&gt;10.0&lt;/span&gt; million in the aggregate, which was accounted for as
contingent consideration pursuant to ASC 805. The earnout consideration was payable to Phillips in cash or, at the Company&#x2019;s election,
in up to &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zALt5ZMGHmMi" title="Number of shares issuable"&gt;486,145&lt;/span&gt; shares of the Company&#x2019;s common stock upon the achievement of certain performance thresholds relating to net revenue
attributable to sales of Scendia products during the two-year period following the closing. The Company made the first earnout payment
of approximately $&lt;span id="xdx_904_ecustom--EarnoutPayment_c20230801__20230831__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zyBy2wRYzpEc" title="Earnout payment"&gt;693,000&lt;/span&gt; in cash in August 2023 and the second and final earnout payment of approximately $&lt;span id="xdx_906_ecustom--EarnoutPayment_pn5n6_c20241001__20241031__us-gaap--TypeOfArrangementAxis__custom--ScendiaPurchaseAgreementMember_zsMlBoJNXpCe" title="Earnout payment"&gt;1.1&lt;/span&gt; million in cash in October
2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Applied
Asset Purchase&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August&#160;1, 2023, the Company closed the Applied Asset Purchase. The Applied Purchased Assets were purchased for an initial aggregate
purchase price of $&lt;span id="xdx_907_eus-gaap--PaymentsToAcquireProductiveAssets_pn4n6_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zNAQ2FIbS5o9" title="Assets purchase price"&gt;15.25&lt;/span&gt; million, consisting of (i) the Cash Closing Consideration, (ii) the Stock Closing Consideration and (iii) the
Installment Payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to the Cash Closing Consideration, Stock Closing Consideration and Installment Payments, the Applied Purchase Agreement provides
that the Sellers are entitled to receive the Applied Earnout, which is payable to the Sellers in cash, upon the achievement of certain
performance thresholds relating to SMAT&#x2019;s collections from net sales of a collagen-based product currently under development. Upon
expiration of the seventh anniversary of the Closing, to the extent the Sellers have not earned the entirety of the Applied Earnout,
SMAT shall pay the Sellers the True-Up Payment. The Applied Earnout, minus the True-Up Payment and any Applied Earnout payments already
made by SMAT, may be earned at any point in the future, including after the True-Up Payment is made. The first Installment Payment of
$&lt;span id="xdx_90F_eus-gaap--PaymentsToAcquireOtherProductiveAssets_c20240801__20240831__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember_zpLFHtKRplv" title="Assets purchase price"&gt;625,000&lt;/span&gt; was made in August 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Applied Asset Purchase and pursuant to the Applied Purchase Agreement, effective August 1, 2023, the Company entered
into the Petito Services Agreement with the Owner, pursuant to which the Owner, as an independent contractor, agreed to provide the Petito
Services. &lt;span id="xdx_90F_ecustom--PurchaseAgreementDescription_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_ziOZVaacqzij" title="Purchase agreement description"&gt;As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the
term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of
certain products the Owner develops or codevelops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for
the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half
percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0
million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0
million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments
described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Petito Services Agreement has an initial term of three years and is subject to automatic successive one-month renewals unless earlier
terminated in accordance with its terms. The Petito Services Agreement may be terminated upon the Owner&#x2019;s death or disability or
by the Company or the Owner &#x201c;For Cause&#x201d; (as defined in the Petito Services Agreement); provided, however, that the base salary
described in (i) of the foregoing paragraph shall survive termination through the three-year initial term and the royalty payments and
incentive payments described in (ii)-(v) of the foregoing paragraph shall survive termination of the Petito Services Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other
Commitments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December&#160;20, 2023, the Company signed an exclusive license agreement with Tufts University (&#x201c;Tufts&#x201d;) to develop and
commercialize patented technology covering 18 unique collagen peptides. As part of this agreement, the Company formed a new subsidiary,
Sanara Collagen Peptides, LLC (&#x201c;SCP&#x201d;) and issued &lt;span id="xdx_903_ecustom--OutstandingUnitsPercentage_pid_dp_uPure_c20231220__20231220__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zSDmp5LMjP4a" title="Outstanding units percentage"&gt;10&lt;/span&gt;% of SCP&#x2019;s outstanding units to Tufts. SCP has exclusive rights
to develop and commercialize new products based on the licensed patents and patents pending. SCP will pay royalties to Tufts based on
net sales of licensed products and technologies. Under the exclusive license agreement, royalties will be calculated at a rate of &lt;span id="xdx_909_ecustom--RoyaltyExpensePercentage_dp_uPure_c20231220__20231220__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zDpCnc6Xc9o7"&gt;1.5&lt;/span&gt;%
or &lt;span id="xdx_90C_ecustom--RoyaltyExpensePercentage_dp_uPure_c20231220__20231220__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zNOUdJgpOwv" title="Royalty expense percentage"&gt;3&lt;/span&gt;%, depending on the type of product or technology developed. SCP will pay Tufts a minimum annual royalty of $&lt;span id="xdx_90D_eus-gaap--RoyaltyExpense_c20240101__20240101__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zdb49u65JHIj"&gt;50,000&lt;/span&gt; on January 1
of the year following the first anniversary of the first commercial sale of the licensed products or technologies. SCP will pay Tufts
a $&lt;span id="xdx_900_eus-gaap--RoyaltyExpense_c20240101__20240101__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--RoyaltyAgreementTermsMember_zmM8L5EZFZTb"&gt;100,000&lt;/span&gt; minimum annual royalty on January&#160;1 of each subsequent year during the royalty term specified in the exclusive license
agreement. There have been no material accounting impacts related to this arrangement as of December&#160;31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <SMTI:LicenseAgreementAndRoyaltiesDescription
      contextRef="From2018-08-262018-08-27_custom_SubLicenseAgreementMember"
      id="Fact001110">In
August 2018, the Company entered an exclusive, world-wide sublicense agreement with CGI Cellerate RX to distribute certain hydrolyzed
collagen products, including CellerateRX Surgical, into the surgical and wound care markets. Pursuant to the Sublicense Agreement, the
Company paid royalties of 3-5% of annual collected net sales of these products.</SMTI:LicenseAgreementAndRoyaltiesDescription>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-01-012024-12-31_us-gaap_CostOfSalesMember"
      decimals="0"
      id="Fact001112"
      unitRef="USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2023-01-012023-12-31_us-gaap_CostOfSalesMember"
      decimals="0"
      id="Fact001114"
      unitRef="USD">991099</us-gaap:RoyaltyExpense>
    <SMTI:RoyaltyPercentage
      contextRef="From2019-07-012019-07-31_custom_BIAKOSLicenseAgreementMember_custom_RochalIndustriesLLCMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001115"
      unitRef="Pure">0.02</SMTI:RoyaltyPercentage>
    <SMTI:RoyaltyPercentage
      contextRef="From2019-07-012019-07-31_custom_BIAKOSLicenseAgreementMember_custom_RochalIndustriesLLCMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001116"
      unitRef="Pure">0.04</SMTI:RoyaltyPercentage>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2025-01-012025-12-31_custom_BIAKOSLicenseAgreementMember_custom_RochalIndustriesLLCMember_srt_MaximumMember_srt_ScenarioForecastMember"
      decimals="0"
      id="Fact001118"
      unitRef="USD">150000</us-gaap:PaymentsForRoyalties>
    <us-gaap:RoyaltyExpense
      contextRef="From2019-07-012019-07-31_custom_BIAKOSAgreementMember_srt_MaximumMember"
      decimals="0"
      id="Fact001120"
      unitRef="USD">1000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-01-012024-12-31_custom_BIAKOSLicenseAgreementMember"
      decimals="0"
      id="Fact001122"
      unitRef="USD">177005</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2023-01-012023-12-31_custom_BIAKOSLicenseAgreementMember"
      decimals="0"
      id="Fact001124"
      unitRef="USD">130000</us-gaap:RoyaltyExpense>
    <SMTI:RoyaltyPercentage
      contextRef="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001126"
      unitRef="Pure">0.02</SMTI:RoyaltyPercentage>
    <SMTI:RoyaltyPercentage
      contextRef="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001128"
      unitRef="Pure">0.04</SMTI:RoyaltyPercentage>
    <us-gaap:RoyaltyExpense
      contextRef="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MinimumMember"
      decimals="0"
      id="Fact001130"
      unitRef="USD">50000</us-gaap:RoyaltyExpense>
    <SMTI:IncreaseInRoyaltyAnnualPercentage
      contextRef="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember"
      decimals="INF"
      id="Fact001132"
      unitRef="Pure">0.10</SMTI:IncreaseInRoyaltyAnnualPercentage>
    <us-gaap:RoyaltyExpense
      contextRef="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MaximumMember"
      decimals="0"
      id="Fact001134"
      unitRef="USD">75000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2019-10-012019-10-31_custom_ABFLicenseAgreementMember_srt_MaximumMember_us-gaap_ProductAndServiceOtherMember"
      decimals="0"
      id="Fact001136"
      unitRef="USD">500000</us-gaap:RoyaltyExpense>
    <us-gaap:Cash
      contextRef="AsOf2020-05-31_custom_RochalMember_custom_DebriderLicenseAgreementMember"
      decimals="0"
      id="Fact001138"
      unitRef="USD">500000</us-gaap:Cash>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember"
      decimals="0"
      id="Fact001140"
      unitRef="USD">1000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <SMTI:RoyaltyPercentage
      contextRef="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001142"
      unitRef="Pure">0.02</SMTI:RoyaltyPercentage>
    <SMTI:RoyaltyPercentage
      contextRef="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001144"
      unitRef="Pure">0.04</SMTI:RoyaltyPercentage>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember_srt_MinimumMember"
      decimals="0"
      id="Fact001146"
      unitRef="USD">100000</us-gaap:PaymentsForRoyalties>
    <SMTI:IncreaseInRoyaltyAnnualPercentage
      contextRef="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember"
      decimals="INF"
      id="Fact001148"
      unitRef="Pure">0.10</SMTI:IncreaseInRoyaltyAnnualPercentage>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember_srt_MaximumMember"
      decimals="0"
      id="Fact001150"
      unitRef="USD">150000</us-gaap:PaymentsForRoyalties>
    <SMTI:PaymentsForAdditionalRoyalties
      contextRef="From2020-05-012020-05-31_custom_DebriderLicenseAgreementMember_srt_MaximumMember"
      decimals="0"
      id="Fact001152"
      unitRef="USD">1000000</SMTI:PaymentsForAdditionalRoyalties>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember"
      decimals="0"
      id="Fact001154"
      unitRef="USD">125966</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember_custom_AccreditedInvestorsMember"
      decimals="INF"
      id="Fact001156"
      unitRef="Shares">165738</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember"
      decimals="-5"
      id="Fact001158"
      unitRef="USD">600000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember_custom_AccreditedInvestorsMember"
      decimals="INF"
      id="Fact001160"
      unitRef="Shares">165738</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-04-04_custom_PrecisionHealingMergerAgreementMember"
      decimals="INF"
      id="Fact001162"
      unitRef="USDPShares">30.75</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember"
      decimals="INF"
      id="Fact001164"
      unitRef="Shares">144191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember"
      decimals="INF"
      id="Fact001166"
      unitRef="USDPShares">10.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001168"
      unitRef="Shares">4424</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001170"
      unitRef="USDPShares">7.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_us-gaap_WarrantMember"
      id="Fact001172">2031-04-22</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_custom_WarrantOneMember"
      decimals="INF"
      id="Fact001174"
      unitRef="Shares">12301</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_custom_WarrantOneMember"
      decimals="INF"
      id="Fact001176"
      unitRef="USDPShares">12.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember_custom_WarrantOneMember"
      id="Fact001178">2030-08-10</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001180"
      unitRef="Shares">31013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMergerAgreementMember"
      decimals="-5"
      id="Fact001182"
      unitRef="USD">10000000.0</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:SharePrice
      contextRef="AsOf2022-04-30_custom_PrecisionHealingMergerAgreementMember"
      decimals="INF"
      id="Fact001184"
      unitRef="USDPShares">27.13</us-gaap:SharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-07-012022-07-31_custom_ScendiaPurchaseAgreementMember"
      decimals="-5"
      id="Fact001186"
      unitRef="USD">7600000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:Cash
      contextRef="AsOf2022-07-31_custom_ScendiaPurchaseAgreementMember"
      decimals="-5"
      id="Fact001188"
      unitRef="USD">1600000</us-gaap:Cash>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2022-07-012022-07-31_custom_ScendiaPurchaseAgreementMember"
      decimals="INF"
      id="Fact001190"
      unitRef="Shares">291686</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="From2022-07-012022-07-31_custom_ScendiaPurchaseAgreementMember"
      decimals="INF"
      id="Fact001192"
      unitRef="Shares">94798</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationAsset
      contextRef="AsOf2022-07-31_custom_ScendiaPurchaseAgreementMember"
      decimals="-5"
      id="Fact001194"
      unitRef="USD">10000000.0</us-gaap:BusinessCombinationContingentConsiderationAsset>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-07-012022-07-31_custom_ScendiaPurchaseAgreementMember"
      decimals="INF"
      id="Fact001196"
      unitRef="Shares">486145</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <SMTI:EarnoutPayment
      contextRef="From2023-08-012023-08-31_custom_ScendiaPurchaseAgreementMember"
      decimals="0"
      id="Fact001198"
      unitRef="USD">693000</SMTI:EarnoutPayment>
    <SMTI:EarnoutPayment
      contextRef="From2024-10-012024-10-31_custom_ScendiaPurchaseAgreementMember"
      decimals="-5"
      id="Fact001200"
      unitRef="USD">1100000</SMTI:EarnoutPayment>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember"
      decimals="-4"
      id="Fact001202"
      unitRef="USD">15250000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="From2024-08-012024-08-31_custom_AppliedAssetPurchaseAgreementMember"
      decimals="0"
      id="Fact001204"
      unitRef="USD">625000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <SMTI:PurchaseAgreementDescription
      contextRef="From2023-08-012023-08-01_custom_ServicesAgreementMember"
      id="Fact001206">As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the
term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of
certain products the Owner develops or codevelops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for
the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half
percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0
million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0
million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments
described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.</SMTI:PurchaseAgreementDescription>
    <SMTI:OutstandingUnitsPercentage
      contextRef="From2023-12-202023-12-20_custom_LicenseAgreementMember"
      decimals="INF"
      id="Fact001208"
      unitRef="Pure">0.10</SMTI:OutstandingUnitsPercentage>
    <SMTI:RoyaltyExpensePercentage
      contextRef="From2023-12-202023-12-20_custom_LicenseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001209"
      unitRef="Pure">0.015</SMTI:RoyaltyExpensePercentage>
    <SMTI:RoyaltyExpensePercentage
      contextRef="From2023-12-202023-12-20_custom_LicenseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001211"
      unitRef="Pure">0.03</SMTI:RoyaltyExpensePercentage>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-01-012024-01-01_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact001212"
      unitRef="USD">50000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-01-012024-01-01_custom_LicenseAgreementMember_us-gaap_RoyaltyAgreementTermsMember"
      decimals="0"
      id="Fact001213"
      unitRef="USD">100000</us-gaap:RoyaltyExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001215">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zzHl05Rhnwe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="Section43"&gt;&lt;/span&gt;NOTE
10 &#x2013; &lt;span id="xdx_825_zHGBAGgWsh4"&gt;SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the Company&#x2019;s Annual Meeting of Shareholders held in July 2020, the Company approved the Restated 2014 Omnibus Long Term Incentive
Plan (the &#x201c;2014 LTIP&#x201d;) in which the Company&#x2019;s directors, officers, employees and consultants are eligible to participate.
The 2014 LTIP terminated on September 3, 2024, and no future awards may be granted pursuant to the 2014 LTIP. Previously granted awards
under the 2014 LTIP will remain outstanding until they expire by their terms or under the terms of the 2014 LTIP.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 12, 2024, the Company&#x2019;s shareholders approved the 2024 Omnibus Long-Term Incentive Plan (the &#x201c;2024 LTIP&#x201d;),
which went into effect upon shareholder approval. The maximum number of shares of the Company&#x2019;s common stock that may be delivered
pursuant to awards granted under the 2024 LTIP is &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240612__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_z5A725WRvSX6" title="Maximum number of shares available for grant"&gt;1,000,000&lt;/span&gt;, subject to increase by any awards under the 2014 LTIP (i) that were outstanding
on or after June 12, 2024, and that, on or after such date, are forfeited, expire or are canceled, and (ii) any shares subject to awards
relating to common stock under the 2014 LTIP that are settled in cash on or after June&#160;12, 2024 (the &#x201c;Prior LTIP Awards&#x201d;).
The 2024 LTIP also provides that, to the extent an award under the 2024 LTIP or a Prior LTIP Award is forfeited, expires or is canceled,
in whole or in part, the shares subject to such forfeited, expired or canceled award may again be awarded under the 2024 LTIP. As of
December&#160;31, 2024, a total of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20241231__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFourteenOmnibusLongTermIncentivePlanMember_zv1qPBD64qN1" title="Number of shares issued"&gt;742,405&lt;/span&gt; shares had been issued under the 2014 LTIP, &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20241231__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_zuEzD7RHw9kl" title="Number of shares issued"&gt;2,543&lt;/span&gt; shares had been issued under the 2024 LTIP
and &lt;span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_zvgy4Y23GsMe" title="Number of shares available for issuance"&gt;1,000,137&lt;/span&gt; were available for issuance under the 2024 LTIP.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 1, 2023, the Company closed the Applied Asset Purchase. Included in the purchase price was &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20230801__20230801__us-gaap--TypeOfArrangementAxis__custom--AppliedAssetPurchaseAgreementMember__us-gaap--ContingentConsiderationByTypeAxis__custom--StockClosingConsiderationMember_zJSCfIgzhMUc" title="Shares issued as consideration"&gt;73,809&lt;/span&gt; shares of the Company&#x2019;s
common stock. See Note 3 for more information regarding the acquisition of Applied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2023, the Company entered into a Controlled Equity Offering&lt;sup&gt;SM&lt;/sup&gt; Sales Agreement (the &#x201c;Sales Agreement&#x201d;)
with Cantor Fitzgerald &amp;amp; Co., as sales agent (&#x201c;Cantor&#x201d;), pursuant to which the Company could offer and sell from time
to time, to or through Cantor, shares of the Company&#x2019;s common stock having an aggregate offering price of up to $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230201__20230228__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zzrhENfLwR51" title="Aggregate offering price"&gt;75,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales
of the shares were made in sales deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) promulgated under
the Securities Act of 1933, as amended. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement,
Cantor agreed to use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal
law, rules and regulations and the rules of The Nasdaq Capital Market to sell the shares from time to time based upon the Company&#x2019;s
instructions, including any price, time period or size limits specified by the Company. The Company had no obligation to sell any of
the shares under the Sales Agreement and could suspend or terminate the offering of its common stock pursuant to the Sales Agreement
upon notice to Cantor and subject to other conditions. Cantor&#x2019;s obligations to sell the shares under the Sales Agreement were subject
to satisfaction of certain conditions, including customary closing conditions. Pursuant to the Sales Agreement, the Company paid Cantor
a commission of 3.0% of the aggregate gross proceeds from each sale of the shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2023, the Company sold an aggregate of &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdzEWMdigE0j" title="Sale of stock"&gt;26,143&lt;/span&gt; shares of common stock for gross proceeds of approximately $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaHOdqJVwKN2" title="Number of shares issued, value"&gt;1.1&lt;/span&gt; million and net proceeds
of approximately $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQuxBPvHxXk7" title="Net proceeds"&gt;0.9&lt;/span&gt; million pursuant to the Sales Agreement. The Company paused the offering at the end of the first quarter of 2023
and did not reactivate it during the remainder of 2023. The Form S-3 registration statement for this offering expired at the beginning
of 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2022, the Company closed a merger transaction with Precision Healing pursuant to which Precision Healing became a wholly owned
subsidiary of the Company. Pursuant to the terms of the merger agreement, holders of Precision Healing common stock and preferred stock,
other than the Company, were entitled to receive closing consideration, consisting of $&lt;span id="xdx_90C_eus-gaap--AssetAcquisitionConsiderationTransferred_c20220401__20220430__us-gaap--AssetAcquisitionAxis__custom--PrecisionHealingIncMember_zwhML6wBZdj9" title="Cash consideration"&gt;125,966&lt;/span&gt; in cash consideration, which was paid
to stockholders who were not accredited investors, &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220401__20220430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zLsZtY9QlFIc" title="Issuance of shares"&gt;165,738&lt;/span&gt; shares of the Company&#x2019;s common stock, which was paid only to accredited
investors, and the payment in cash of approximately $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20220401__20220430__dei--LegalEntityAxis__custom--PrecisionHealingMember_zBMCHZboTBF2" title="Payment in cash"&gt;0.6 &lt;/span&gt;million of transaction expenses of Precision Healing. The Company recorded the
issuance of the &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220401__20220430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zaAH9tR5uvqg" title="Issuance of shares"&gt;165,738&lt;/span&gt; shares to accredited investors and cash payments to nonaccredited investors based on the closing price per share
of the Company&#x2019;s common stock on April&#160;4, 2022, which was $&lt;span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20220404__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonaccreditedInvestorsMember_zjH9EOTBmCMa" title="Share price"&gt;30.75&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the closing of the merger, the Precision Healing outstanding options previously granted under the Precision Healing Plan converted, pursuant
to their terms, into options to acquire an aggregate of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220430_zPwPWdh8zcTc" title="Options to acquire shares"&gt;144,191&lt;/span&gt; shares of Company common stock with a weighted average exercise price
of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_c20220401__20220430_ziKZdQAmjdad" title="Weighted exercise price"&gt;10.71&lt;/span&gt; per share. These options expire between August 2030 and April 2031. In addition, outstanding and unexercised Precision Healing
warrants converted into rights to receive warrants to purchase (i) &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220430_zjPLfVYARmHl" title="Warrants to purchase shares"&gt;4,424&lt;/span&gt; shares of the Company&#x2019;s common stock with an initial exercise
price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430_zBosu5CtKrV9" title="Exercise price"&gt;7.32&lt;/span&gt; per share and an expiration date of &lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220430_zQ3CcwYs1cK8" title="Expiration date"&gt;April 22, 2031&lt;/span&gt;, and (ii) &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdDOrW58Omsj" title="Warrants to purchase shares"&gt;12,301&lt;/span&gt; shares of the Company&#x2019;s common stock with
an initial exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMe6HaJSlRP" title="Exercise price"&gt;12.05&lt;/span&gt; per share and an expiration date of &lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6e5k5ATMWL5" title="Expiration date"&gt;August 10, 2030&lt;/span&gt;. Concurrent with the assumption of the Precision
Healing Plan, the Company terminated the ability to offer future awards under the Precision Healing Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the merger agreement, upon the achievement of certain performance thresholds, the securityholders of Precision Healing, including
the holders of options and warrants to purchase Precision Healing common stock and certain persons promised options to purchase Precision
Healing common stock, were entitled to receive payments of up to $&lt;span id="xdx_90C_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_pn5n6_c20220401__20220430__us-gaap--AssetAcquisitionAxis__custom--PrecisionHealingIncMember_zCACVhMdvcQa" title="Payment of contingent consideration"&gt;10.0&lt;/span&gt; million, which was accounted for as contingent consideration pursuant
to ASC 805. The earnout consideration was payable in cash or, at the Company&#x2019;s election, payable to accredited investors in shares
of Company common stock at a price per share equal to the greater of (i) $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_c20220430__dei--LegalEntityAxis__custom--PrecisionHealingMember_zJ5q7Efnnppj" title="Share price"&gt;27.13&lt;/span&gt; or (ii) the average closing price of Company common stock
for the 20 trading days prior to the date such earnout consideration is due and payable. The Company reviewed the performance thresholds
necessary to trigger an earnout payment as of December 31, 2024 and deemed the performance thresholds to be unachievable. Therefore,
no earnout consideration is expected to be paid to the securityholders of Precision Healing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Restricted
Stock Awards&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December&#160;31, 2024, the Company issued restricted stock awards under the 2014 LTIP which are subject to certain vesting
provisions and other terms and conditions set forth in each recipient&#x2019;s respective restricted stock agreement. The Company issued
&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFourteenOmnibusLongTermIncentivePlanMember_zXiF5hjxZOqb" title="Stock granted and issued"&gt;161,908&lt;/span&gt; shares, net of forfeitures, under the 2014 LTIP and &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember_zDsNimRzcPnk" title="Stock granted and issued"&gt;2,543&lt;/span&gt; shares under the 2024 LTIP, of restricted common stock to employees,
directors, and certain advisors of the Company during the year ended December&#160;31, 2024. The fair value of these awards was $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20240101__20241231_zZ9s6JBATeyd" title="Restricted stock award, gross"&gt;5,747,656&lt;/span&gt;
based on the closing price of the Company&#x2019;s common stock on the respective grant dates, which will be recognized as compensation
expense on a straight-line basis over the vesting period of the awards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based
compensation expense of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_c20240101__20241231_zb95tl8U7sGk" title="Share-based compensation"&gt;4,436,048&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_c20230101__20231231_zrnrlLmS0BMk" title="Share-based compensation"&gt;3,442,722&lt;/span&gt; was recognized in &#x201c;Operating expenses&#x201d; in the accompanying Consolidated
Statements of Operations during the year ended December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December&#160;31, 2024, there was $&lt;span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231_z9u25RmlQmIg" title="Unrecognized share-based compensation expense"&gt;4,189,272&lt;/span&gt; of total unrecognized share-based compensation expense related to unvested share-based equity
awards. Unrecognized share-based compensation expense is expected to be recognized over a weighted-average period of &lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zbCvWw0vAFsa" title="Unrecognized share-based compensation expense period for recognition"&gt;1.5&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z6qxkf0tNoYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Below
is a summary of restricted stock activity for the year ended December&#160;31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_z5VFOABi92Zf" style="display: none"&gt;SUMMARY
OF RESTRICTED STOCK ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Grant Date Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Nonvested at beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231_z5JCnPbMX14f" style="width: 16%; text-align: right" title="Non-vested shares, beginning"&gt;144,211&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20241231_zc17mwwoYVK3" style="width: 16%; text-align: right" title="Weighted average grant date fair value, beginning"&gt;34.07&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231_zHscIUeYGuuk" style="text-align: right" title="Granted"&gt;192,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zZJy94IlE743" style="text-align: right" title="Weighted average grant date fair value, granted"&gt;35.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231_zBmNK5U67uGd" style="text-align: right" title="Vested"&gt;(105,875&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zlU9B1uuFNVe" style="text-align: right" title="Weighted average grant date fair value, vested"&gt;34.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231_zTROEIFXHzi7" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited"&gt;(28,332&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231_zyRmcP01KWC7" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, forfeited"&gt;35.31&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231_zP8FFn04tnwd" style="border-bottom: Black 2.5pt double; text-align: right" title="Non-vested shares, ending"&gt;202,787&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20241231_z0QSPV0TdEpk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending"&gt;34.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zFloXdegGY51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuHi6wwNrXq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the status of outstanding stock options at December&#160;31, 2024 and changes during the year then ended is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zE4SbhyEYz85" style="display: none"&gt;SCHEDULE OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contract Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding at beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zwAgg9EoMw7d" style="width: 12%; text-align: right" title="Options outstanding, beginning"&gt;93,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zVhLNEojQcmk" style="width: 12%; text-align: right" title="Weighted average exercise price outstanding, beginning"&gt;10.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted or assumed&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z8zVkBqcLNB3" style="text-align: right" title="Options, Granted or assumed"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1307"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zAqi3k5Q8F38" style="text-align: right" title="Weighted average exercise price, Granted or assumed"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1309"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231_zBCSDARL6fZ5" style="text-align: right" title="Options, Exercised"&gt;(62,879&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zfLKWGHwa5fk" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;10.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zexCYAjPo6xb" style="text-align: right" title="Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1315"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zpi1qmxtYm18" style="text-align: right" title="Weighted average exercise price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1317"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20240101__20241231_zYGDoAXqFEoc" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1319"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zCLZsMlDuWRd" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1321"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_znAeFCWTCglb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending"&gt;31,013&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zzP5xdnTMCJg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price outstanding, ending"&gt;10.57&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_znfZyXZKxqqb" title="Weighted average remaining contract life outstanding"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp2d_c20241231_zkHVSzUHGD37" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, ending"&gt;701,975.3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zz8wTmwNLtc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, ending"&gt;31,013&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zOCGiwedUe12" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price exercisable, ending"&gt;10.57&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_znRXA31fwum8" title="Weighted average remaining contract life exercisable"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp2d_c20241231_z5IkBBHzKxu8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, exercisable"&gt;701,975.3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zssu9gzM2B6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zM6bs8p5qup9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the status of outstanding warrants to purchase common stock at December&#160;31, 2024 and changes during the year then ended
is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_z14rStEIKokj" style="display: none"&gt;SCHEDULE
OF WARRANTS TO PURCHASE COMMON STOCK&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contract Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding at beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231_zqetGtIzzIk5" style="width: 12%; text-align: right" title="Number of warrants outstanding, beginning"&gt;16,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zfXL4f4sqUm4" style="width: 12%; text-align: right" title="Weighted average exercise price outstanding, beginning"&gt;10.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted or assumed&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231_z69vSccbr4Yh" style="text-align: right" title="Number of warrants, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1345"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20240101__20241231_zwwFylDLrnl1" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1347"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231_zKtUIXzWQ24d" style="text-align: right" title="Number of warrants, exercised"&gt;(16,725&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_c20240101__20241231_z2tIDvFibrQl" style="text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1351"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20240101__20241231_zIGqfTSyRcwg" style="text-align: right" title="Number of warrants, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1353"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice_c20240101__20241231_zOLXnJANg3M7" style="text-align: right" title="Weighted average exercise price, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1355"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20240101__20241231_zYGAHTGZfZvi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1357"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20240101__20241231_z5poFFZx1aHe" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1359"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231_zQx2MccL41C5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1361"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zqUbQCKgYu72" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price outstanding, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1363"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_c20240101__20241231_z75lDqKTVcl7" title="Weighted average remaining contract life outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1365"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20240101__20241231_zsFFs2LbWIvf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants exercisable, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1367"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zjxITHyaQFs6" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, exercisable, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1369"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_c20240101__20241231_zllBN8SiQ0I3" title="Weighted average remaining contract life exercisable, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1371"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zgzGAXVlsqv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-06-12_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact001217"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="From2024-12-312024-12-31_custom_TwoThousandFourteenOmnibusLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact001219"
      unitRef="Shares">742405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="From2024-12-312024-12-31_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact001221"
      unitRef="Shares">2543</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact001223"
      unitRef="Shares">1000137</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2023-08-012023-08-01_custom_AppliedAssetPurchaseAgreementMember_custom_StockClosingConsiderationMember"
      decimals="INF"
      id="Fact001225"
      unitRef="Shares">73809</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-02-012023-02-28_custom_SalesAgreementMember"
      decimals="0"
      id="Fact001227"
      unitRef="USD">75000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_custom_SalesAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001229"
      unitRef="Shares">26143</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_custom_SalesAgreementMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001231"
      unitRef="USD">1100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31_custom_SalesAgreementMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001233"
      unitRef="USD">900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="From2022-04-012022-04-30_custom_PrecisionHealingIncMember"
      decimals="0"
      id="Fact001235"
      unitRef="USD">125966</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-04-012022-04-30_custom_AccreditedInvestorsMember"
      decimals="INF"
      id="Fact001237"
      unitRef="Shares">165738</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-04-012022-04-30_custom_PrecisionHealingMember"
      decimals="-5"
      id="Fact001239"
      unitRef="USD">600000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-04-012022-04-30_custom_AccreditedInvestorsMember"
      decimals="INF"
      id="Fact001241"
      unitRef="Shares">165738</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:SharePrice
      contextRef="AsOf2022-04-04_custom_NonaccreditedInvestorsMember"
      decimals="INF"
      id="Fact001243"
      unitRef="USDPShares">30.75</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-04-012022-04-30"
      decimals="INF"
      id="Fact001245"
      unitRef="Shares">144191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="From2022-04-012022-04-30"
      decimals="INF"
      id="Fact001247"
      unitRef="USDPShares">10.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-30"
      decimals="INF"
      id="Fact001249"
      unitRef="Shares">4424</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-30"
      decimals="INF"
      id="Fact001251"
      unitRef="USDPShares">7.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2022-04-30" id="Fact001253">2031-04-22</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001255"
      unitRef="Shares">12301</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001257"
      unitRef="USDPShares">12.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2022-04-30_us-gaap_CommonStockMember"
      id="Fact001259">2030-08-10</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="From2022-04-012022-04-30_custom_PrecisionHealingIncMember"
      decimals="-5"
      id="Fact001261"
      unitRef="USD">10000000.0</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:SharePrice
      contextRef="AsOf2022-04-30_custom_PrecisionHealingMember"
      decimals="INF"
      id="Fact001263"
      unitRef="USDPShares">27.13</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_custom_TwoThousandFourteenOmnibusLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact001265"
      unitRef="Shares">161908</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyFourOmnibusLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact001267"
      unitRef="Shares">2543</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001269"
      unitRef="USD">5747656</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001271"
      unitRef="USD">4436048</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001273"
      unitRef="USD">3442722</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001275"
      unitRef="USD">4189272</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2024-01-01to2024-12-31" id="Fact001277">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001279">&lt;p id="xdx_89D_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z6qxkf0tNoYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Below
is a summary of restricted stock activity for the year ended December&#160;31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_z5VFOABi92Zf" style="display: none"&gt;SUMMARY
OF RESTRICTED STOCK ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Grant Date Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Nonvested at beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231_z5JCnPbMX14f" style="width: 16%; text-align: right" title="Non-vested shares, beginning"&gt;144,211&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240101__20241231_zc17mwwoYVK3" style="width: 16%; text-align: right" title="Weighted average grant date fair value, beginning"&gt;34.07&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231_zHscIUeYGuuk" style="text-align: right" title="Granted"&gt;192,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zZJy94IlE743" style="text-align: right" title="Weighted average grant date fair value, granted"&gt;35.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231_zBmNK5U67uGd" style="text-align: right" title="Vested"&gt;(105,875&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zlU9B1uuFNVe" style="text-align: right" title="Weighted average grant date fair value, vested"&gt;34.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20241231_zTROEIFXHzi7" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited"&gt;(28,332&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231_zyRmcP01KWC7" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, forfeited"&gt;35.31&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231_zP8FFn04tnwd" style="border-bottom: Black 2.5pt double; text-align: right" title="Non-vested shares, ending"&gt;202,787&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20241231_z0QSPV0TdEpk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending"&gt;34.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001281"
      unitRef="Shares">144211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001283"
      unitRef="USDPShares">34.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001285"
      unitRef="Shares">192783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001287"
      unitRef="USDPShares">35.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001289"
      unitRef="Shares">105875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001291"
      unitRef="USDPShares">34.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001293"
      unitRef="Shares">28332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001295"
      unitRef="USDPShares">35.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001297"
      unitRef="Shares">202787</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001299"
      unitRef="USDPShares">34.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001301">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuHi6wwNrXq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the status of outstanding stock options at December&#160;31, 2024 and changes during the year then ended is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zE4SbhyEYz85" style="display: none"&gt;SCHEDULE OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contract Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding at beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zwAgg9EoMw7d" style="width: 12%; text-align: right" title="Options outstanding, beginning"&gt;93,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zVhLNEojQcmk" style="width: 12%; text-align: right" title="Weighted average exercise price outstanding, beginning"&gt;10.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted or assumed&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z8zVkBqcLNB3" style="text-align: right" title="Options, Granted or assumed"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1307"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zAqi3k5Q8F38" style="text-align: right" title="Weighted average exercise price, Granted or assumed"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1309"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231_zBCSDARL6fZ5" style="text-align: right" title="Options, Exercised"&gt;(62,879&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zfLKWGHwa5fk" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;10.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zexCYAjPo6xb" style="text-align: right" title="Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1315"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zpi1qmxtYm18" style="text-align: right" title="Weighted average exercise price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1317"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20240101__20241231_zYGDoAXqFEoc" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1319"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zCLZsMlDuWRd" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1321"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_znAeFCWTCglb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending"&gt;31,013&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zzP5xdnTMCJg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price outstanding, ending"&gt;10.57&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_znfZyXZKxqqb" title="Weighted average remaining contract life outstanding"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp2d_c20241231_zkHVSzUHGD37" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, ending"&gt;701,975.3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zz8wTmwNLtc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, ending"&gt;31,013&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zOCGiwedUe12" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price exercisable, ending"&gt;10.57&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_znRXA31fwum8" title="Weighted average remaining contract life exercisable"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp2d_c20241231_z5IkBBHzKxu8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, exercisable"&gt;701,975.3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001303"
      unitRef="Shares">93892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001305"
      unitRef="USDPShares">10.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001311"
      unitRef="Shares">62879</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001313"
      unitRef="USDPShares">10.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001323"
      unitRef="Shares">31013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001325"
      unitRef="USDPShares">10.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-01-01to2024-12-31" id="Fact001327">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31"
      decimals="2"
      id="Fact001329"
      unitRef="USD">701975.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001331"
      unitRef="Shares">31013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001333"
      unitRef="USDPShares">10.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-01to2024-12-31" id="Fact001335">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-12-31"
      decimals="2"
      id="Fact001337"
      unitRef="USD">701975.3</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001339">&lt;p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zM6bs8p5qup9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the status of outstanding warrants to purchase common stock at December&#160;31, 2024 and changes during the year then ended
is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_z14rStEIKokj" style="display: none"&gt;SCHEDULE
OF WARRANTS TO PURCHASE COMMON STOCK&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contract Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding at beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231_zqetGtIzzIk5" style="width: 12%; text-align: right" title="Number of warrants outstanding, beginning"&gt;16,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zfXL4f4sqUm4" style="width: 12%; text-align: right" title="Weighted average exercise price outstanding, beginning"&gt;10.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted or assumed&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231_z69vSccbr4Yh" style="text-align: right" title="Number of warrants, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1345"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20240101__20241231_zwwFylDLrnl1" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1347"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231_zKtUIXzWQ24d" style="text-align: right" title="Number of warrants, exercised"&gt;(16,725&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_c20240101__20241231_z2tIDvFibrQl" style="text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1351"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20240101__20241231_zIGqfTSyRcwg" style="text-align: right" title="Number of warrants, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1353"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice_c20240101__20241231_zOLXnJANg3M7" style="text-align: right" title="Weighted average exercise price, forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1355"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20240101__20241231_zYGAHTGZfZvi" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1357"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20240101__20241231_z5poFFZx1aHe" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1359"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231_zQx2MccL41C5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1361"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zqUbQCKgYu72" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price outstanding, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1363"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_c20240101__20241231_z75lDqKTVcl7" title="Weighted average remaining contract life outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1365"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20240101__20241231_zsFFs2LbWIvf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants exercisable, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1367"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zjxITHyaQFs6" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, exercisable, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1369"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1_c20240101__20241231_zllBN8SiQ0I3" title="Weighted average remaining contract life exercisable, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1371"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001341"
      unitRef="Shares">16725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001343"
      unitRef="USDPShares">10.80</SMTI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001349"
      unitRef="Shares">16725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001373">&lt;p id="xdx_80F_eus-gaap--ConcentrationRiskDisclosureTextBlock_zcoCAlUg23A5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="Section44"&gt;&lt;/span&gt;NOTE
11 &#x2013; &lt;span id="xdx_82C_zmqHOHzS9loj"&gt;CUSTOMERS AND SUPPLIERS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had no customers in 2024 that accounted for at least &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomersMember_zgRDknZhGJT7" title="Concentration risk percentage"&gt;10&lt;/span&gt;% of the Company&#x2019;s annual sales or whose accounts receivable balance
exceeded &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomersMember_zLmGSm7jZNla" title="Concentration risk percentage"&gt;10&lt;/span&gt;% of the year-end balance. The Company had no customers in 2023 that accounted for at least &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomersMember_z0dbiuCTnwq7" title="Concentration risk percentage"&gt;10&lt;/span&gt;% of Company&#x2019;s annual
sales and whose accounts receivable exceeded &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomersMember_zikBQbSRy7Of" title="Concentration risk percentage"&gt;10&lt;/span&gt;% of the year-end balance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s principal revenue producing products are purchased from one manufacturer. If this supplier became unable to provide finished
goods inventory in a timely manner, the Company&#x2019;s business, operating results, and financial condition could be materially adversely
affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember"
      decimals="INF"
      id="Fact001375"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember"
      decimals="INF"
      id="Fact001377"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember"
      decimals="INF"
      id="Fact001379"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomersMember"
      decimals="INF"
      id="Fact001381"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001383">&lt;p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_zW8PLiy5wfUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="Section45"&gt;&lt;/span&gt;NOTE
12 &#x2013; &lt;span id="xdx_823_zIUDeJqnjdEk"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC Topic No. 740, Income Taxes. This standard requires the Company to provide a
net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book
and tax accounting and any available operating loss or tax credit carry forwards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;After
applying the provisions of Section 382 of the Internal Revenue Code, the unexpired net operating loss (&#x201c;NOL&#x201d;) carryforward
at December&#160;31, 2024 was approximately $&lt;span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231_zQBjEGhaq3vd" title="Operating loss carryforwards"&gt;57.5&lt;/span&gt; million, of which, approximately $&lt;span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20171231_z0uewXasegQl" title="Operating loss carryforwards"&gt;26.5&lt;/span&gt; million, generated in 2017 and prior, will &lt;span id="xdx_90D_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231_zt580QlQAC7c" title="Expiration description"&gt;expire
between 2024 and 2037&lt;/span&gt;. Under the Tax Cuts and Jobs Act, the NOL generated from 2018 through 2024, of approximately $&lt;span id="xdx_908_ecustom--EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount_pn5n6_c20240101__20241231_zhsv7fEpDm0j" title="NOL generated under tax cuts and job cuts"&gt;30.9&lt;/span&gt; million, will
have an indefinite carryforward period but can generally only be used to offset 80% of taxable income in any particular year. The Company
may be subject to certain limitations in its annual utilization of NOL carry forwards to off-set future taxable income pursuant to Section
382 of the Internal Revenue Code, which could result in NOLs expiring unused.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zDexFok1wvv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of the deferred income tax assets and liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zO4X4e74S19e" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20241231_zXqFpu9ozH0h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_z0YMB7w7Jg67" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzdlW_zV5wMbphzigk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 68%; text-align: left"&gt;Net operating loss carry forwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;12,907,965&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;12,467,570&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzdlW_zmCHALkULCMl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,006,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,119,193&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzdlW_zm7Fd6nPHNvf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;789,373&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;711,598&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzdlW_zpqRpfmiqg91" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;528,148&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DeferredTaxAssetsLeaseLiability_iI_maDTAGzdlW_zebjHgLkZGt" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;389,882&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;512,668&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_iI_maDTAGzdlW_zfa1QhIUKbt9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Contingent liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;221,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;221,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsAcquistionLiability_iI_maDTAGzdlW_zqJnSsTsgC0d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Acquisition liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;176,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTAGzdlW_zSbk2Pu5oAtk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Bad debt and other reserves&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;287,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129,924&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsInventory_iI_maDTAGzdlW_zXfhbudQYQph" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Inventory reserves&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;130,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzdlW_z79OxiHDkbYa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other temporary differences&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,049,365&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;203,340&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzdlW_maDTANzNjR_zLoRnjRL8Er5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,902,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,179,274&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxLiabilitiesDepreciationAndAmortization_iNI_di_msDTANzNjR_z73LmKXbJo68" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,683,259&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,180,688&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_msDTANzNjR_z0d3cnWqMnp4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Right of Use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(353,763&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(487,402&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_msDTANzNjR_zYFFete0AkP1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1434"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(424,423&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxLiabilitiesContingentLiability_iNI_di_msDTANzNjR_zpkI1SPUqglg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Contingent liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(38,308&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(130,802&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredTaxLiabilitiesOtherTemporaryDifferences_iNI_di_msDTANzNjR_zreAXdMSzRvb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other temporary differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(294,608&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(166,712&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzNjR_zMVXwnPkmLI2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,532,298&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,789,247&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzNjR_zRS3W84wCb1g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1446"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1447"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zvTC5MNUeP1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
&lt;span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20240101__20241231_zGxppO0kIGJ6" title="Valuation allowance, percentage"&gt;100&lt;/span&gt;% valuation allowance has been provided for all deferred tax assets, as the ability of the Company to generate sufficient taxable
income in the future is uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reconciliations
of the expected federal income tax expense (benefit) based on the statutory income tax rate of 21% to the actual benefit for the years ended December&#160;31,
2024 and 2023 are listed below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zR9sd5vFkOF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_ziiFgjcbV2wl" style="display: none"&gt;SCHEDULE
OF INCOME TAX EXPENSE (BENEFIT)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_zdUv5yhISozk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zeFeZkvncMS4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_maITEBzW13_zpcDyM73dcw7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Expected federal income tax benefit&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(2,019,060&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(903,220&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_maITEBzW13_zWii2kQ3ybA4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State and local taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(338,138&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(226,714&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationFairValueAdjustments_iN_di_maITEBzW13_zgMNASbh1fuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fair value adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(497,373&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(819,270&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_iN_di_maITEBzW13_zkh70zPU45Sj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(237,838&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(557,168&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_iN_di_maITEBzW13_zb6ZtLsiEPNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199,857&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118,765&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration_iN_di_maITEBzW13_zo5BoJh5RUWa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;NOL carryover adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,806&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,148,128&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--IncomeTaxReconciliationIncomeTaxExpenseIntangibles_iN_di_maITEBzW13_zKyrGAhfc6s6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Intangibles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1471"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(720,407&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps_iN_di_maITEBzW13_zJ9hso5GDaU9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other true ups&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,343&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(230,474&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_iN_di_maITEBzW13_zeNrwgUE2PZg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Changes in tax rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,732&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;673,449&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_maITEBzW13_zW1lPccamP2k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,743,051&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,813,167&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzW13_zCHKSOxvgkM2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;48,380&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1484"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zgCOT5GQuJwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
tax years starting with 2021 are open for examination. The Company&#x2019;s 2022 federal tax return was under audit as of March 24, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001385"
      unitRef="USD">57500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2017-12-31"
      decimals="-5"
      id="Fact001387"
      unitRef="USD">26500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxExaminationDescription contextRef="From2024-01-01to2024-12-31" id="Fact001389">expire
between 2024 and 2037</us-gaap:IncomeTaxExaminationDescription>
    <SMTI:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact001391"
      unitRef="USD">30900000</SMTI:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001393">&lt;p id="xdx_891_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zDexFok1wvv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of the deferred income tax assets and liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zO4X4e74S19e" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20241231_zXqFpu9ozH0h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_z0YMB7w7Jg67" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzdlW_zV5wMbphzigk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 68%; text-align: left"&gt;Net operating loss carry forwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;12,907,965&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;12,467,570&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzdlW_zmCHALkULCMl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,006,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,119,193&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzdlW_zm7Fd6nPHNvf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;789,373&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;711,598&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_maDTAGzdlW_zpqRpfmiqg91" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;528,148&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DeferredTaxAssetsLeaseLiability_iI_maDTAGzdlW_zebjHgLkZGt" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;389,882&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;512,668&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_iI_maDTAGzdlW_zfa1QhIUKbt9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Contingent liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;221,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;221,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsAcquistionLiability_iI_maDTAGzdlW_zqJnSsTsgC0d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Acquisition liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;176,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTAGzdlW_zSbk2Pu5oAtk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Bad debt and other reserves&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;287,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129,924&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsInventory_iI_maDTAGzdlW_zXfhbudQYQph" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Inventory reserves&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;130,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzdlW_z79OxiHDkbYa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other temporary differences&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,049,365&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;203,340&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzdlW_maDTANzNjR_zLoRnjRL8Er5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,902,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,179,274&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxLiabilitiesDepreciationAndAmortization_iNI_di_msDTANzNjR_z73LmKXbJo68" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,683,259&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,180,688&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_msDTANzNjR_z0d3cnWqMnp4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Right of Use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(353,763&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(487,402&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_msDTANzNjR_zYFFete0AkP1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1434"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(424,423&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxLiabilitiesContingentLiability_iNI_di_msDTANzNjR_zpkI1SPUqglg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Contingent liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(38,308&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(130,802&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredTaxLiabilitiesOtherTemporaryDifferences_iNI_di_msDTANzNjR_zreAXdMSzRvb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other temporary differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(294,608&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(166,712&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzNjR_zMVXwnPkmLI2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,532,298&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,789,247&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzNjR_zRS3W84wCb1g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1446"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1447"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001395"
      unitRef="USD">12907965</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001396"
      unitRef="USD">12467570</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001398"
      unitRef="USD">3006029</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001399"
      unitRef="USD">2119193</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001401"
      unitRef="USD">789373</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001402"
      unitRef="USD">711598</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001404"
      unitRef="USD">7330</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001405"
      unitRef="USD">528148</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <SMTI:DeferredTaxAssetsLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001407"
      unitRef="USD">389882</SMTI:DeferredTaxAssetsLeaseLiability>
    <SMTI:DeferredTaxAssetsLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001408"
      unitRef="USD">512668</SMTI:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001410"
      unitRef="USD">221065</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001411"
      unitRef="USD">221028</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <SMTI:DeferredTaxAssetsAcquistionLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001413"
      unitRef="USD">112722</SMTI:DeferredTaxAssetsAcquistionLiability>
    <SMTI:DeferredTaxAssetsAcquistionLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001414"
      unitRef="USD">176629</SMTI:DeferredTaxAssetsAcquistionLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001416"
      unitRef="USD">287900</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001417"
      unitRef="USD">129924</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001419"
      unitRef="USD">130605</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001420"
      unitRef="USD">109176</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001422"
      unitRef="USD">1049365</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001423"
      unitRef="USD">203340</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001425"
      unitRef="USD">18902236</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001426"
      unitRef="USD">17179274</us-gaap:DeferredTaxAssetsGross>
    <SMTI:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001428"
      unitRef="USD">5683259</SMTI:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <SMTI:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001429"
      unitRef="USD">6180688</SMTI:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001431"
      unitRef="USD">353763</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001432"
      unitRef="USD">487402</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001435"
      unitRef="USD">424423</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <SMTI:DeferredTaxLiabilitiesContingentLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001437"
      unitRef="USD">38308</SMTI:DeferredTaxLiabilitiesContingentLiability>
    <SMTI:DeferredTaxLiabilitiesContingentLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001438"
      unitRef="USD">130802</SMTI:DeferredTaxLiabilitiesContingentLiability>
    <SMTI:DeferredTaxLiabilitiesOtherTemporaryDifferences
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001440"
      unitRef="USD">294608</SMTI:DeferredTaxLiabilitiesOtherTemporaryDifferences>
    <SMTI:DeferredTaxLiabilitiesOtherTemporaryDifferences
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001441"
      unitRef="USD">166712</SMTI:DeferredTaxLiabilitiesOtherTemporaryDifferences>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001443"
      unitRef="USD">12532298</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001444"
      unitRef="USD">9789247</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001449"
      unitRef="Pure">1</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001451">&lt;p id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zR9sd5vFkOF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_ziiFgjcbV2wl" style="display: none"&gt;SCHEDULE
OF INCOME TAX EXPENSE (BENEFIT)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_zdUv5yhISozk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zeFeZkvncMS4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_iN_di_maITEBzW13_zpcDyM73dcw7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Expected federal income tax benefit&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(2,019,060&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(903,220&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_iN_di_maITEBzW13_zWii2kQ3ybA4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State and local taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(338,138&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(226,714&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationFairValueAdjustments_iN_di_maITEBzW13_zgMNASbh1fuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fair value adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(497,373&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(819,270&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_iN_di_maITEBzW13_zkh70zPU45Sj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(237,838&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(557,168&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_iN_di_maITEBzW13_zb6ZtLsiEPNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199,857&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118,765&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration_iN_di_maITEBzW13_zo5BoJh5RUWa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;NOL carryover adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,806&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,148,128&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--IncomeTaxReconciliationIncomeTaxExpenseIntangibles_iN_di_maITEBzW13_zKyrGAhfc6s6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Intangibles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1471"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(720,407&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps_iN_di_maITEBzW13_zJ9hso5GDaU9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other true ups&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,343&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(230,474&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_iN_di_maITEBzW13_zeNrwgUE2PZg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Changes in tax rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,732&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;673,449&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_iN_di_maITEBzW13_zW1lPccamP2k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,743,051&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,813,167&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzW13_zCHKSOxvgkM2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;48,380&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1484"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001453"
      unitRef="USD">2019060</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001454"
      unitRef="USD">903220</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001456"
      unitRef="USD">338138</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001457"
      unitRef="USD">226714</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <SMTI:IncomeTaxReconciliationFairValueAdjustments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001459"
      unitRef="USD">497373</SMTI:IncomeTaxReconciliationFairValueAdjustments>
    <SMTI:IncomeTaxReconciliationFairValueAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001460"
      unitRef="USD">819270</SMTI:IncomeTaxReconciliationFairValueAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001462"
      unitRef="USD">237838</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001463"
      unitRef="USD">557168</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001465"
      unitRef="USD">-199857</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001466"
      unitRef="USD">-118765</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <SMTI:IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001468"
      unitRef="USD">-97806</SMTI:IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration>
    <SMTI:IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001469"
      unitRef="USD">5148128</SMTI:IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration>
    <SMTI:IncomeTaxReconciliationIncomeTaxExpenseIntangibles
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001472"
      unitRef="USD">720407</SMTI:IncomeTaxReconciliationIncomeTaxExpenseIntangibles>
    <SMTI:IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001474"
      unitRef="USD">-90343</SMTI:IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps>
    <SMTI:IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001475"
      unitRef="USD">230474</SMTI:IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001477"
      unitRef="USD">-9732</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001478"
      unitRef="USD">-673449</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001480"
      unitRef="USD">-2743051</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001481"
      unitRef="USD">-7813167</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001483"
      unitRef="USD">-48380</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001486">&lt;p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zt0nVz9F1OD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="Section46"&gt;&lt;/span&gt;NOTE
13 &#x2013; &lt;span id="xdx_826_zbDYVFpMrdX8"&gt;RELATED PARTIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;CellerateRX
Sublicense Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had an exclusive, world-wide sublicense to distribute certain hydrolyzed collagen products, including CellerateRX Surgical into
the surgical and wound care markets from an affiliate of The Catalyst Group, Inc. (&#x201c;Catalyst&#x201d;), CGI Cellerate RX, which licensed
the rights to these products from Applied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
discussed further in Note 3, on August 1, 2023, the Company purchased certain assets from Applied, including the underlying intellectual
property of, as well as the rights to manufacture and sell certain hydrolyzed collagen products, including CellerateRX Surgical. In connection
with the Applied Asset Purchase, Applied assigned the License Agreement with CGI Cellerate RX to SMAT, and on October 10, 2024, the License
Agreement and Sublicense Agreement were terminated for no additional consideration. Ronald T. Nixon, the Company&#x2019;s Chief Executive
Officer and Executive Chairman, is the founder and managing partner of Catalyst.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Product
License Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2019, the Company executed a license agreement with Rochal, a related party, whereby the Company acquired an exclusive world-wide
license to market, sell and further develop antimicrobial products for the prevention and treatment of microbes on the human body utilizing
certain Rochal patents and pending patent applications. Currently, the products covered by the BIAK&#x14c;S License Agreement are BIASURGE
Advanced Surgical Solution, BIAK&#x14c;S Antimicrobial Wound Gel and BIAK&#x14c;S Antimicrobial Skin and Wound Cleanser. Each of these
products are 510(k) cleared. Mr. Nixon is a director of Rochal, and indirectly a significant shareholder of Rochal, and through the potential
exercise of warrants, a majority shareholder of Rochal. Another one of the Company&#x2019;s directors is also a director and significant
shareholder of Rochal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2019, the Company executed the ABF License Agreement with Rochal whereby the Company acquired an exclusive world-wide license
to market, sell and further develop certain antimicrobial barrier film and skin protectant products for use in the human health care
market utilizing certain Rochal patents and pending patent applications. Currently, the products covered by the ABF License Agreement
are CuraShield Antimicrobial Barrier Film and a no sting skin protectant product.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2020, the Company executed a product license agreement with Rochal, whereby the Company acquired an exclusive world-wide license
to market, sell and further develop a debrider for human medical use to enhance skin condition or treat or relieve skin disorders, excluding
uses primarily for beauty, cosmetic, or toiletry purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 9 for more information on these product license agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Consulting
Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Concurrent
with the Rochal asset purchase, in July 2021, the Company entered into a consulting agreement with Ann Beal Salamone pursuant to which
Ms. Salamone agreed to provide the Company with consulting services with respect to, among other things, writing new patents, conducting
patent intelligence, and participating in certain grant and contract reporting. In consideration for the consulting services to be provided
to the Company, Ms. Salamone is entitled to receive an annual consulting fee of $&lt;span id="xdx_903_eus-gaap--ProfessionalFees_c20210701__20210731__us-gaap--PlanNameAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSalamoneMember_zQU0p1QfVNAl" title="Consulting fee"&gt;177,697&lt;/span&gt;, with payments to be paid once per month. The
consulting agreement had an initial term of three years, unless earlier terminated by the Company, and was subject to renewal. Effective
July 13, 2024, the consulting agreement with Ms. Salamone was amended to provide that the initial term shall be automatically renewed
for successive one-year terms for up to three successive years unless earlier terminated by either party without cause at any time, provided
that the terminating party provides 90 days advance written notice of termination. Ms. Salamone is a director of the Company and is a
significant shareholder and the current Chair of the board of directors of Rochal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Catalyst
Transaction Advisory Services Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2023, the Company entered into a Transaction Advisory Services Agreement (the &#x201c;Catalyst Services Agreement&#x201d;) effective
March 1, 2023 with Catalyst, a related party. Pursuant to the Catalyst Services Agreement, Catalyst, by and through its directors, officers,
employees and affiliates that are not simultaneously serving as directors, officers or employees of the Company (collectively, the &#x201c;Covered
Persons&#x201d;), agreed to perform certain transaction advisory, business and organizational strategy, finance, marketing, operational
and strategic planning, relationship access and corporate development services for the Company in connection with any merger, acquisition,
recapitalization, divestiture, financing, refinancing, or other similar transaction in which the Company may be, or may consider becoming,
involved, and any such additional services as mutually agreed upon in writing by and between Catalyst and the Company (the &#x201c;Catalyst
Services&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Catalyst Services Agreement, the Company agreed to reimburse Catalyst for (i) compensation actually paid by Catalyst to any of
the Covered Persons at a rate no more than a rate consistent with industry practice for the performance of services similar to the Catalyst
Services, as documented in reasonably sufficient detail, and (ii) all reasonable out-of-pocket costs and expenses payable to unaffiliated
third parties, as documented in customary expense reports, as each of (i) and (ii) is incurred in connection with the Catalyst Services
rendered under the Catalyst Services Agreement, with all reimbursements being contingent upon the prior approval of the Audit Committee
of the Company&#x2019;s Board of Directors. The Company incurred costs pursuant to the Catalyst Services Agreement of $&lt;span id="xdx_90A_eus-gaap--CostsAndExpensesRelatedParty_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_ziRcprlXAmHd" title="Cost and expenses related party"&gt;288,594&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--CostsAndExpensesRelatedParty_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_zqcawDISSKx7" title="Cost and expenses related party"&gt;174,486&lt;/span&gt;
in the year ended December&#160;31, 2024 and 2023, respectively, and is recorded in &#x201c;Selling, general and administrative&#x201d;
in the accompanying Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ProfessionalFees
      contextRef="From2021-07-012021-07-31_custom_ConsultingAgreementMember_custom_MsSalamoneMember"
      decimals="0"
      id="Fact001488"
      unitRef="USD">177697</us-gaap:ProfessionalFees>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="From2024-01-012024-12-31_custom_ServicesAgreementMember"
      decimals="0"
      id="Fact001490"
      unitRef="USD">288594</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="From2023-01-012023-12-31_custom_ServicesAgreementMember"
      decimals="0"
      id="Fact001492"
      unitRef="USD">174486</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001494">&lt;p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_z9lcO0Mpn5v7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="Section47"&gt;&lt;/span&gt;NOTE
14 &#x2013; &lt;span id="xdx_82B_z5uIoq8pO2La"&gt;SEGMENT REPORTING&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
discussed in Note 1, the Company historically managed its business as &lt;span id="xdx_908_eus-gaap--NumberOfOperatingSegments_dc_uInteger_c20240101__20241231_zxyyxpfKK3Y5" title="Number of operating segment"&gt;&lt;span id="xdx_903_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240101__20241231_zfj3ZpGgI3Kk" title="Number of reportable segment"&gt;one&lt;/span&gt;&lt;/span&gt; operating and reportable segment. During the second quarter
of 2024, the Company changed its reportable segments to reflect a change in the manner in which the business is managed. Based on the
growing importance of the value-based wound care program to the Company&#x2019;s future outlook and how the Company&#x2019;s chief operating
decision maker (&#x201c;CODM&#x201d;), the Chief Executive Officer, reviews operating results and makes decisions about resource allocation,
the Company has &lt;span id="xdx_902_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240401__20240630_z67SpXJ8aYbh" title="Number of reportable segment"&gt;two&lt;/span&gt; reportable segments: Sanara Surgical and THP.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Segment
Adjusted EBITDA is the primary profitability measure used by the CODM for purposes of assessing financial performance and resource
allocation. The Company defines Segment Adjusted EBITDA for the reportable segments as net income (loss) excluding interest
expense/income, provision/benefit for income taxes, depreciation and amortization, non-cash share-based compensation expense, change
in fair value of earnout liabilities, share of losses from equity method investments, executive separation costs, legal and
diligence expenses related to acquisitions, and gains/losses on disposal of property and equipment, as each are applicable to the
periods presented. The Company has historically presented this profitability measure as Segment EBITDA and, starting with the fourth
quarter ended December 31, 2024, is presenting it as Segment Adjusted EBITDA. The definition and methodology for calculating this
measure has remained unchanged. Segment Adjusted EBITDA, as it relates to the Company&#x2019;s reportable segments, is presented in
conformity with ASC 280, Segment Reporting, and is excluded from the definition of non-GAAP financial measures under the Securities
and Exchange Commission&#x2019;s Regulation G and Item 10(e) of Regulation S-K. Segment Adjusted EBITDA may not be comparable to
similarly titled measures reported by other companies. The CODM also reviews budget-to-actual variances for expenses on a monthly
basis when making decisions about allocating resources to the segments. The Company has not included any disclosure regarding total
segment assets, as no segment level asset information is regularly provided to the CODM.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Sanara
Surgical&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other
sterile environments. Sanara Surgical&#x2019;s soft tissue repair products include, among other products, the Company&#x2019;s lead product,
CellerateRX Surgical, and BIASURGE Advanced Surgical Solution, which is a sterile no-rinse, advanced surgical solution used for wound
irrigation. Sanara Surgical&#x2019;s bone fusion products include, among other products, BiFORM, which is an osteoconductive, bioactive,
porous implant that allows for bony ingrowth across the graft site, and ALLOCYTE Plus, which is a human allograft cellular bone matrix
containing bone-derived progenitor cells and conformable bone fibers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sanara
Surgical also includes an in-house research and development team (Rochal Technologies) with an extensive pipeline of innovative products
under development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Tissue
Health Plus&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
THP segment is focused on value-based wound care services. Through THP, the Company plans to offer a first of its kind value-based wound
care program to payers and risk-bearing entities such as accountable care organizations and value-based primary care companies, with
Medicare Advantage payers as the initial target market for this program.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;THP&#x2019;s
programs are expected to enable payers to divest wound care spend risk, reduce wound related hospitalizations and improve patient quality
of life. THP plans to coordinate delivery of community and home-based wound care for its managed patients. Community based care spans
a variety of settings including physician offices, skilled nursing facilities, assisted living facilities and senior living facilities.
THP programs are intended to integrate science and evidence-based medicine protocols to standardize wound prevention and treatment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Currently,
there are no allocated costs included in the THP segment. All corporate and overhead expenses are included in the Sanara Surgical segment,
as substantially all of those costs relate to supporting the operations and activities of the Sanara Surgical segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the change in reportable segments, certain prior period amounts have been recast to conform to the current period presentation.
Throughout this Annual Report on Form 10-K, unless otherwise indicated, amounts and activity reflect reclassifications related to the
Company&#x2019;s change in reportable segments. The change in reportable segments had no impact on the Company&#x2019;s previously reported
Consolidated Balance Sheets, Consolidated Statements of Operations, Consolidated Statements of Cash Flows or Consolidated Statements
of Shareholders&#x2019; Equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z5lKpvEEPshb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table reflects results of operations including significant segment expenses that are regularly provided to the CODM for
the Company&#x2019;s reportable segments and Segment Adjusted EBITDA for the periods indicated below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zeVqkUwBWXb4" style="display: none"&gt;SCHEDULE
OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zLIukRbgfhrf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zkIysJvU6A6a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zRBwLO7WudVg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_z5jVy3pkifS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zXfWfYRJGQm7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zKvlVpSKttwl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zmmvrvDfHeIf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Net revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;86,672,425&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1505"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;86,672,425&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;64,987,112&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;2,730&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;64,989,842&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--GrossProfit_pp0p0_zqxfeJsKF5k5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gross profit (loss)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78,532,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1512"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78,532,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,143,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,235&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,137,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pp0p0_z5CtTRvdihJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Selling, general and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,673,642&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,886,221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,559,863&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,826,852&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,167,901&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,994,753&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_zYg7XUlNl2A2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,828,663&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,874,699&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,703,362&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;902,782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,229,643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,132,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DepreciationAndAmortization_i01_pp0p0_zx27jzi1oRNf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,785,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,137,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,923,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,046,859&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,628,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,675,026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesFairValueAdjustment_zj2C1Ekwg4Fi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of earnout liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,451&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,924,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,938,451&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,298,336&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,151,559&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,449,895&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InterestExpenseOther_i01_pp0p0_zYKipiwKsQsf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,196,424&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1547"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,196,424&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;224,749&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1550"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;224,749&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ProfitLoss_pp0p0_zrla761eanxa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net income (loss)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,937,583&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(7,974,315&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9,911,898&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;440,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4,880,387&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4,439,902&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--EarningsBeforeInterestTaxesDepreciationAndAmortization_pp0p0_z7OnNybafWI5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Segment Adjusted EBITDA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,148,722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,457,415&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,691,307&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,289,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,162,387&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;127,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zbhZYin5XBLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zqzR2pBSdqxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a reconciliation of net income (loss) to Segment Adjusted EBITDA for the Company&#x2019;s reportable segments
for the periods indicated below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zALkQpjlbLGj" style="display: none"&gt;SCHEDULE
OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zClfXTIsfWx9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_z2XqVdMcKLB6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zVNTBgAcyH0h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zSO6NUbYJ963" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zZGSpCyt7khd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20231231_z4lguIpRj1df" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProfitLoss_pp0p0_zezQ8oQ9pkV2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Net Income (Loss)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;(1,937,583&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;(7,974,315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;(9,911,898&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;440,485&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;(4,880,387&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;(4,439,902&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Adjustments:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InterestExpense_zAkGGoh0AeZg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,128,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1577"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,128,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;475,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1580"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;475,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestIncomeOther_iN_di_zzIY6DT7ud64" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,978&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1584"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,978&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1586"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1587"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1588"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DepreciationAndAmortization_i01_pp0p0_zHBp3n4G8a86" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation and amortization &lt;sup id="xdx_F4C_z1FJsCFRwQfh"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,785,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,137,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,923,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,046,859&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,628,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,675,026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_zPTZHXKFCrW8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Noncash share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,969,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;138,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,107,253&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,201,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241,392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,442,722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesFairValueAdjustment_zCl9HrZ6nePb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of earnout liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,451&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,924,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,938,451&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,298,336&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,151,559&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,449,895&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromEquityMethodInvestments_iN_di_z3253TAfteya" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Share of losses from equity method investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1612"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1614"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1615"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1616"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ExecutiveSeparationCosts_z5MSPLDWS9Tj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Executive separation costs &lt;sup id="xdx_F4E_zRPyIqyrxbCd"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;964,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1619"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;964,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1621"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1622"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1623"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_znqTCNw4Wcpk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition costs &lt;sup id="xdx_F44_zbrOTqNsjIR3"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;185,029&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,165,260&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,350,289&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;423,513&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;423,513&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--EarningsBeforeInterestTaxesDepreciationAndAmortization_pp0p0_z6Q6PSNNOfwh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Segment Adjusted EBITDA&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,148,722&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(6,457,415&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,691,307&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,289,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,162,387&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;127,247&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F01_z0uipYDTBTz6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_zWCjaXeLHmF2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Includes
                                            a $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--PropertyAndEquipmentWriteOff_iI_c20241231_zJC0st7jzVq4" title="Property and equipment write off"&gt;506,836&lt;/span&gt; non-cash charge during the fourth quarter of 2024 to write-off the remaining net
                                            book value of certain THP internal use software assets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0F_zwCBMaXL2AO" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_z6XS7fBBbkn5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Includes
                                            $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231_zJKt3Xeqlclc" title="Share based compensation related to executive separation costs"&gt;328,795&lt;/span&gt; of share-based compensation related to executive separation costs for the twelve
                                            months ended December&#160;31, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0E_zMpKyZU4yTwh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F16_zC2lTmDvtW5h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition
                                            costs include legal, tax and accounting services related to prospective acquisitions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AB_zJY6ME8hV3Sf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001496"
      unitRef="Integer">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001498"
      unitRef="Integer">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact001500"
      unitRef="Integer">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001502">&lt;p id="xdx_894_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z5lKpvEEPshb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table reflects results of operations including significant segment expenses that are regularly provided to the CODM for
the Company&#x2019;s reportable segments and Segment Adjusted EBITDA for the periods indicated below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zeVqkUwBWXb4" style="display: none"&gt;SCHEDULE
OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zLIukRbgfhrf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zkIysJvU6A6a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zRBwLO7WudVg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_z5jVy3pkifS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zXfWfYRJGQm7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zKvlVpSKttwl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zmmvrvDfHeIf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Net revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;86,672,425&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1505"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;86,672,425&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;64,987,112&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;2,730&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;64,989,842&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--GrossProfit_pp0p0_zqxfeJsKF5k5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gross profit (loss)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78,532,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1512"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78,532,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,143,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,235&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,137,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pp0p0_z5CtTRvdihJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Selling, general and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,673,642&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,886,221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,559,863&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,826,852&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,167,901&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,994,753&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_zYg7XUlNl2A2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,828,663&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,874,699&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,703,362&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;902,782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,229,643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,132,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DepreciationAndAmortization_i01_pp0p0_zx27jzi1oRNf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,785,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,137,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,923,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,046,859&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,628,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,675,026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesFairValueAdjustment_zj2C1Ekwg4Fi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of earnout liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,451&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,924,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,938,451&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,298,336&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,151,559&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,449,895&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InterestExpenseOther_i01_pp0p0_zYKipiwKsQsf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,196,424&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1547"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,196,424&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;224,749&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1550"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;224,749&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ProfitLoss_pp0p0_zrla761eanxa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net income (loss)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,937,583&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(7,974,315&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9,911,898&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;440,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4,880,387&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4,439,902&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--EarningsBeforeInterestTaxesDepreciationAndAmortization_pp0p0_z7OnNybafWI5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Segment Adjusted EBITDA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,148,722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,457,415&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,691,307&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,289,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,162,387&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;127,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001504"
      unitRef="USD">86672425</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001506"
      unitRef="USD">86672425</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001507"
      unitRef="USD">64987112</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      decimals="0"
      id="Fact001508"
      unitRef="USD">2730</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001509"
      unitRef="USD">64989842</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001511"
      unitRef="USD">78532524</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001513"
      unitRef="USD">78532524</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001514"
      unitRef="USD">57143391</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      decimals="0"
      id="Fact001515"
      unitRef="USD">-6235</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001516"
      unitRef="USD">57137156</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001518"
      unitRef="USD">71673642</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      decimals="0"
      id="Fact001519"
      unitRef="USD">4886221</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001520"
      unitRef="USD">76559863</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001521"
      unitRef="USD">54826852</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      decimals="0"
      id="Fact001522"
      unitRef="USD">2167901</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001523"
      unitRef="USD">56994753</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001525"
      unitRef="USD">2828663</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      decimals="0"
      id="Fact001526"
      unitRef="USD">2874699</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001527"
      unitRef="USD">5703362</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001528"
      unitRef="USD">902782</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      decimals="0"
      id="Fact001529"
      unitRef="USD">3229643</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001530"
      unitRef="USD">4132425</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001532"
      unitRef="USD">2785829</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      decimals="0"
      id="Fact001533"
      unitRef="USD">2137395</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001534"
      unitRef="USD">4923224</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001535"
      unitRef="USD">2046859</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      decimals="0"
      id="Fact001536"
      unitRef="USD">1628167</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001537"
      unitRef="USD">3675026</us-gaap:DepreciationAndAmortization>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001539"
      unitRef="USD">-14451</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      decimals="0"
      id="Fact001540"
      unitRef="USD">-1924000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001541"
      unitRef="USD">-1938451</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001542"
      unitRef="USD">-1298336</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      decimals="0"
      id="Fact001543"
      unitRef="USD">-2151559</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001544"
      unitRef="USD">-3449895</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:InterestExpenseOther
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001546"
      unitRef="USD">3196424</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001548"
      unitRef="USD">3196424</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001549"
      unitRef="USD">224749</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001551"
      unitRef="USD">224749</us-gaap:InterestExpenseOther>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001553"
      unitRef="USD">-1937583</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      decimals="0"
      id="Fact001554"
      unitRef="USD">-7974315</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001555"
      unitRef="USD">-9911898</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001556"
      unitRef="USD">440485</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      decimals="0"
      id="Fact001557"
      unitRef="USD">-4880387</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001558"
      unitRef="USD">-4439902</us-gaap:ProfitLoss>
    <SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001560"
      unitRef="USD">9148722</SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      decimals="0"
      id="Fact001561"
      unitRef="USD">-6457415</SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001562"
      unitRef="USD">2691307</SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001563"
      unitRef="USD">5289634</SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      decimals="0"
      id="Fact001564"
      unitRef="USD">-5162387</SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001565"
      unitRef="USD">127247</SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001567">&lt;p id="xdx_890_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zqzR2pBSdqxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a reconciliation of net income (loss) to Segment Adjusted EBITDA for the Company&#x2019;s reportable segments
for the periods indicated below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zALkQpjlbLGj" style="display: none"&gt;SCHEDULE
OF RECONCILIATION OF NET INCOME (LOSS) TO SEGMENT EBITDA FOR REPORTABLE SEGMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zClfXTIsfWx9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_z2XqVdMcKLB6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zVNTBgAcyH0h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--SanaraSurgicalMember_zSO6NUbYJ963" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--THPMember_zZGSpCyt7khd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20231231_z4lguIpRj1df" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Sanara Surgical&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;THP&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProfitLoss_pp0p0_zezQ8oQ9pkV2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Net Income (Loss)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;(1,937,583&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;(7,974,315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;(9,911,898&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;440,485&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;(4,880,387&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;(4,439,902&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Adjustments:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InterestExpense_zAkGGoh0AeZg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,128,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1577"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,128,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;475,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1580"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;475,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestIncomeOther_iN_di_zzIY6DT7ud64" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,978&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1584"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,978&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1586"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1587"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1588"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DepreciationAndAmortization_i01_pp0p0_zHBp3n4G8a86" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation and amortization &lt;sup id="xdx_F4C_z1FJsCFRwQfh"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,785,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,137,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,923,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,046,859&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,628,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,675,026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_zPTZHXKFCrW8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Noncash share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,969,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;138,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,107,253&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,201,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241,392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,442,722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesFairValueAdjustment_zCl9HrZ6nePb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of earnout liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,451&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,924,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,938,451&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,298,336&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,151,559&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,449,895&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromEquityMethodInvestments_iN_di_z3253TAfteya" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Share of losses from equity method investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1612"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1614"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1615"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1616"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ExecutiveSeparationCosts_z5MSPLDWS9Tj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Executive separation costs &lt;sup id="xdx_F4E_zRPyIqyrxbCd"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;964,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1619"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;964,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1621"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1622"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1623"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_znqTCNw4Wcpk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition costs &lt;sup id="xdx_F44_zbrOTqNsjIR3"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;185,029&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,165,260&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,350,289&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;423,513&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;423,513&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--EarningsBeforeInterestTaxesDepreciationAndAmortization_pp0p0_z6Q6PSNNOfwh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Segment Adjusted EBITDA&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,148,722&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(6,457,415&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,691,307&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,289,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,162,387&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;127,247&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F01_z0uipYDTBTz6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_zWCjaXeLHmF2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Includes
                                            a $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--PropertyAndEquipmentWriteOff_iI_c20241231_zJC0st7jzVq4" title="Property and equipment write off"&gt;506,836&lt;/span&gt; non-cash charge during the fourth quarter of 2024 to write-off the remaining net
                                            book value of certain THP internal use software assets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0F_zwCBMaXL2AO" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_z6XS7fBBbkn5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Includes
                                            $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231_zJKt3Xeqlclc" title="Share based compensation related to executive separation costs"&gt;328,795&lt;/span&gt; of share-based compensation related to executive separation costs for the twelve
                                            months ended December&#160;31, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -13.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0E_zMpKyZU4yTwh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F16_zC2lTmDvtW5h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition
                                            costs include legal, tax and accounting services related to prospective acquisitions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001569"
      unitRef="USD">-1937583</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      decimals="0"
      id="Fact001570"
      unitRef="USD">-7974315</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001571"
      unitRef="USD">-9911898</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001572"
      unitRef="USD">440485</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      decimals="0"
      id="Fact001573"
      unitRef="USD">-4880387</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001574"
      unitRef="USD">-4439902</us-gaap:ProfitLoss>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001576"
      unitRef="USD">3128395</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001578"
      unitRef="USD">3128395</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001579"
      unitRef="USD">475783</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001581"
      unitRef="USD">475783</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001583"
      unitRef="USD">21978</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001585"
      unitRef="USD">21978</us-gaap:InterestIncomeOther>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001590"
      unitRef="USD">2785829</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      decimals="0"
      id="Fact001591"
      unitRef="USD">2137395</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001592"
      unitRef="USD">4923224</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001593"
      unitRef="USD">2046859</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      decimals="0"
      id="Fact001594"
      unitRef="USD">1628167</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001595"
      unitRef="USD">3675026</us-gaap:DepreciationAndAmortization>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001597"
      unitRef="USD">3969008</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      decimals="0"
      id="Fact001598"
      unitRef="USD">138245</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001599"
      unitRef="USD">4107253</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001600"
      unitRef="USD">3201330</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      decimals="0"
      id="Fact001601"
      unitRef="USD">241392</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001602"
      unitRef="USD">3442722</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001604"
      unitRef="USD">-14451</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      decimals="0"
      id="Fact001605"
      unitRef="USD">-1924000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001606"
      unitRef="USD">-1938451</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001607"
      unitRef="USD">-1298336</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      decimals="0"
      id="Fact001608"
      unitRef="USD">-2151559</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001609"
      unitRef="USD">-3449895</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001611"
      unitRef="USD">-90007</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001613"
      unitRef="USD">-90007</us-gaap:IncomeLossFromEquityMethodInvestments>
    <SMTI:ExecutiveSeparationCosts
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001618"
      unitRef="USD">964466</SMTI:ExecutiveSeparationCosts>
    <SMTI:ExecutiveSeparationCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001620"
      unitRef="USD">964466</SMTI:ExecutiveSeparationCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001625"
      unitRef="USD">185029</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      decimals="0"
      id="Fact001626"
      unitRef="USD">1165260</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001627"
      unitRef="USD">1350289</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001628"
      unitRef="USD">423513</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001630"
      unitRef="USD">423513</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="From2024-01-012024-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001632"
      unitRef="USD">9148722</SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="From2024-01-012024-12-31_custom_THPMember"
      decimals="0"
      id="Fact001633"
      unitRef="USD">-6457415</SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001634"
      unitRef="USD">2691307</SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="From2023-01-012023-12-31_custom_SanaraSurgicalMember"
      decimals="0"
      id="Fact001635"
      unitRef="USD">5289634</SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="From2023-01-012023-12-31_custom_THPMember"
      decimals="0"
      id="Fact001636"
      unitRef="USD">-5162387</SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001637"
      unitRef="USD">127247</SMTI:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <SMTI:PropertyAndEquipmentWriteOff
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001640"
      unitRef="USD">506836</SMTI:PropertyAndEquipmentWriteOff>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001643"
      unitRef="USD">328795</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001646">&lt;p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_ztNHvCG7OWL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
15 &#x2013; &lt;span id="xdx_82C_z8ySwQNbRevf"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Exclusive
License and Distribution Agreement With, and Minority Investment in, Biomimetic Innovations Ltd&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Licensing
and Distribution Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 16, 2025 (the &#x201c;Execution Date&#x201d;), the Company entered into a Licensing and Distribution Agreement (the &#x201c;License
Agreement&#x201d;), by and between the Company and Biomimetic Innovation Limited, a privately-held medical device company headquartered
in Shannon, Co. Clare Ireland (&#x201c;BMI&#x201d;), pursuant to which the Company acquired the exclusive U.S. marketing, sales and distribution
rights to OsStic&#xae; Synthetic Injectable Structural Bio-Adhesive Bone Void Filler (&#x201c;OsStic&#x201d;), as well as an adjunctive
internal fixation technology featuring novel delivery to promote targeted application of OsStic (&#x201c;ARC&#x201d; and together with
OsStic, the &#x201c;Products&#x201d;), for use in the treatment of a wound or injury caused by a traumatic incident.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the License Agreement, the Company was appointed by BMI as the exclusive distributor to promote, market, offer to sell, transfer,
distribute and sell the Products for trauma indications inside the United States and its territories for an initial five-year term, which
term may be automatically renewed for successive two-year periods at the Company&#x2019;s discretion, provided that the Company is in
compliance with its obligations thereunder (the &#x201c;Term&#x201d;). From the Execution Date until October 13, 2025, the Company has
an exclusive option to negotiate exclusive distribution rights for the Products in additional fields and/or additional territories on
substantially the same terms as those set forth in the License Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
License Agreement requires that the Company pay BMI quarterly royalties (the &#x201c;Quarterly Royalties&#x201d;) based on a percentage
of the Net Sales Value (as defined in the License Agreement) of the Products during the Term, with the applicable percentage of the Net
Sales Value for OsStic being in the mid-single digit range. Pursuant to the License Agreement, the Company and BMI agreed to negotiate
the applicable percentage of the Net Sales Value for ARC at a future date. The License Agreement also requires that the Company pay BMI
minimum royalty payments being in the low to mid six figure range for the first, second and third years, respectively, following the
receipt of first regulatory approval for the marketing and sale of a Product.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Subscription
and Shareholders&#x2019; Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the License Agreement, on the Execution Date, the Company entered into a Share Subscription and Shareholders&#x2019; Agreement
(the &#x201c;Subscription Agreement&#x201d;), by and among the Company,&lt;span id="xdx_905_eus-gaap--SubsequentEventDescription_c20250116__20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAndShareholdersAgreementMember_zsBN6v56KJOj" title="Subsequent description"&gt; The Russell Revocable Living Trust, BMI and the existing shareholders
of BMI, pursuant to which the Company agreed to contribute up to approximately &#x20ac;8.0 million to BMI through a series of capital contributions
in exchange for an aggregate of 16,460 ordinary shares of BMI, constituting approximately 12.5% of the outstanding equity of BMI as of
the Execution Date. The Company made an initial cash investment totaling approximately &#x20ac;3.0 million on the Execution Date, and the
Company&#x2019;s previously announced convertible loan to BMI was converted into &#x20ac;1.0 million of equity in BMI. Pursuant to the Subscription
Agreement, the remaining &#x20ac;4.0 million contribution is due upon the achievement of certain development, clinical and regulatory milestones&lt;/span&gt;
(the &#x201c;Milestones&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Subscription Agreement, so long as the Company holds a five percent ownership interest or greater in BMI, the Company is entitled
to have one person appointed to BMI&#x2019;s board of directors. &lt;span id="xdx_908_eus-gaap--SubsequentEventDescription_c20250116__20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zIPXR1KYGaPf" title="Subsequent description"&gt;The Company&#x2019;s initial investment of approximately &#x20ac;4.0 million
caused the Company to exceed the five percent ownership interest threshold in BMI, and as a result the Company&#x2019;s Chief Corporate
Development &amp;amp; Strategy Officer, Tyler Palmer, has been nominated and appointed to BMI&#x2019;s board of directors.&lt;/span&gt; In addition, the
Company has the right to send one non-voting observer to attend meetings of the BMI board of directors, regardless of the Company&#x2019;s
ownership interest level. The Company&#x2019;s capital contributions must be used to fund the development and commercialization of the
Products, and the Company has certain veto and consent rights to further protect the Company&#x2019;s investment in BMI and to support
its ability to successfully market and sell the Products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;CRG Term Loan Amendment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;On [&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March
19, 2025&lt;/span&gt;], the Company and the Guarantors entered into the First Amendment to Term Loan Agreement with the Agent and the lenders
party thereto from time to time, which amended the CRG Term Loan Agreement to, among other things, &lt;span id="xdx_90C_eus-gaap--DebtInstrumentDescription_c20250319__20250319__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--CRGTermLoanAgreementMember_zkx7qtxFiz0a" title="Debt description"&gt;(i) entitle the Company to two additional
borrowings following the Second Borrowing, which borrowings must occur on or prior to December 31, 2025, if at all, and (ii) remove the
requirement that any borrowing be in whole multiples of $5.0 million.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SubsequentEventDescription
      contextRef="From2025-01-162025-01-16_us-gaap_SubsequentEventMember_custom_SubscriptionAndShareholdersAgreementMember"
      id="Fact001648">The Russell Revocable Living Trust, BMI and the existing shareholders
of BMI, pursuant to which the Company agreed to contribute up to approximately &#x20ac;8.0 million to BMI through a series of capital contributions
in exchange for an aggregate of 16,460 ordinary shares of BMI, constituting approximately 12.5% of the outstanding equity of BMI as of
the Execution Date. The Company made an initial cash investment totaling approximately &#x20ac;3.0 million on the Execution Date, and the
Company&#x2019;s previously announced convertible loan to BMI was converted into &#x20ac;1.0 million of equity in BMI. Pursuant to the Subscription
Agreement, the remaining &#x20ac;4.0 million contribution is due upon the achievement of certain development, clinical and regulatory milestones</us-gaap:SubsequentEventDescription>
    <us-gaap:SubsequentEventDescription
      contextRef="From2025-01-162025-01-16_us-gaap_SubsequentEventMember_custom_SubscriptionAgreementMember"
      id="Fact001650">The Company&#x2019;s initial investment of approximately &#x20ac;4.0 million
caused the Company to exceed the five percent ownership interest threshold in BMI, and as a result the Company&#x2019;s Chief Corporate
Development &amp; Strategy Officer, Tyler Palmer, has been nominated and appointed to BMI&#x2019;s board of directors.</us-gaap:SubsequentEventDescription>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2025-03-192025-03-19_us-gaap_SubsequentEventMember_custom_CRGTermLoanAgreementMember"
      id="Fact001652">(i) entitle the Company to two additional
borrowings following the Second Borrowing, which borrowings must occur on or prior to December 31, 2025, if at all, and (ii) remove the
requirement that any borrowing be in whole multiples of $5.0 million.</us-gaap:DebtInstrumentDescription>
    <SMTI:NoInsiderTradingFlag contextRef="From2024-01-01to2024-12-31" id="Fact001654">true</SMTI:NoInsiderTradingFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000566"
          xlink:label="Fact000566"
          xlink:type="locator"/>
        <link:footnote id="Footnote000577" xlink:label="Footnote000577" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Shares underlying stock options assumed pursuant to the merger agreement
                                            with Precision Healing, Inc. (&#x201c;Precision Healing&#x201d;) in April 2022.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000566"
          xlink:to="Footnote000577"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000567"
          xlink:label="Fact000567"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000567"
          xlink:to="Footnote000577"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0569"
          xlink:label="xdx2ixbrl0569"
          xlink:type="locator"/>
        <link:footnote id="Footnote000578" xlink:label="Footnote000578" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Shares underlying warrants assumed pursuant to the merger agreement
                                            with Precision Healing in April 2022.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0569"
          xlink:to="Footnote000578"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000570"
          xlink:label="Fact000570"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000570"
          xlink:to="Footnote000578"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001590"
          xlink:label="Fact001590"
          xlink:type="locator"/>
        <link:footnote id="Footnote001638" xlink:label="Footnote001638" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes
                                            a $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90F_ecustom--PropertyAndEquipmentWriteOff_iI_c20241231_zJC0st7jzVq4"
  title="Property and equipment write off">506,836</xhtml:span> non-cash charge during the fourth quarter of 2024 to write-off the remaining net
                                            book value of certain THP internal use software assets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001590"
          xlink:to="Footnote001638"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001591"
          xlink:label="Fact001591"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001591"
          xlink:to="Footnote001638"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001592"
          xlink:label="Fact001592"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001592"
          xlink:to="Footnote001638"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001593"
          xlink:label="Fact001593"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001593"
          xlink:to="Footnote001638"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001594"
          xlink:label="Fact001594"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001594"
          xlink:to="Footnote001638"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001595"
          xlink:label="Fact001595"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001595"
          xlink:to="Footnote001638"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001618"
          xlink:label="Fact001618"
          xlink:type="locator"/>
        <link:footnote id="Footnote001641" xlink:label="Footnote001641" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes
                                            $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09OQ0lMSUFUSU9OIE9GIE5FVCBJTkNPTUUgKExPU1MpIFRPIFNFR01FTlQgRUJJVERBIEZPUiBSRVBPUlRBQkxFIFNFR01FTlRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231_zJKt3Xeqlclc"
  title="Share based compensation related to executive separation costs">328,795</xhtml:span> of share-based compensation related to executive separation costs for the twelve
                                            months ended December&#160;31, 2024.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001618"
          xlink:to="Footnote001641"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1619"
          xlink:label="xdx2ixbrl1619"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1619"
          xlink:to="Footnote001641"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001620"
          xlink:label="Fact001620"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001620"
          xlink:to="Footnote001641"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1621"
          xlink:label="xdx2ixbrl1621"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1621"
          xlink:to="Footnote001641"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1622"
          xlink:label="xdx2ixbrl1622"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1622"
          xlink:to="Footnote001641"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1623"
          xlink:label="xdx2ixbrl1623"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1623"
          xlink:to="Footnote001641"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001625"
          xlink:label="Fact001625"
          xlink:type="locator"/>
        <link:footnote id="Footnote001644" xlink:label="Footnote001644" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Acquisition
                                            costs include legal, tax and accounting services related to prospective acquisitions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001625"
          xlink:to="Footnote001644"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001626"
          xlink:label="Fact001626"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001626"
          xlink:to="Footnote001644"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001627"
          xlink:label="Fact001627"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001627"
          xlink:to="Footnote001644"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001628"
          xlink:label="Fact001628"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001628"
          xlink:to="Footnote001644"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1629"
          xlink:label="xdx2ixbrl1629"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1629"
          xlink:to="Footnote001644"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001630"
          xlink:label="Fact001630"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001630"
          xlink:to="Footnote001644"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
